,ticker,content
0,PFE,stock remain lower monday afternoon dow jone industrial average tumble index general continue pare loss index have be recover steep drop open nearly update story other market coverage check stock market today dow be late afternoon trading intel intc fall day move average security downgrade chipmaker underperform market perform be not first serious break line intel year threaten snuff good uptrend chipmaker be make monday lows dow be only point start level year dow also be struggle mark just couple week average be look be go beat resistance level get newsletter deliver inbox more info product service privacy policy term useexxon mobil xom chevron cvx rise cushion dow fall be cut loss be start trading tech heavy nasdaq composite be flat face weakness semiconductor biotech share small cap lead russell late trading market volume be lower be almost give follow friday quarterly witching option future expiration tend swell stock trading market be lower much selling be concentrated defensive industry group drugstore tobacco soap generic drug be bottom industry group day energy sector be strongest price crude bounce slightly barrel trade row continue china retaliate impose duty import include crude oil opec meet friday production target bloc be split production increase result rare public stalemate opec have agreement nonmember russia cut production barrel day saudi arabia russia want boost output other opec member be balk stock re-cover few top rate company break basis include couple health care surface oncology surf new issue biotech break first base surge clear buy point base heavy trading myriad genetic mygn rise past buy point cup handle base big volume relative strength line be not quite new high deduct significance myriad announce morning win fda priority review bracanalysis cdx use companion diagnostic pfizer pfe product metastatic breast cancer pfizer share be slightly lower continue work consolidation software sector autodesk adsk climb buy point flat base active trading rs line be edge new high design software company be turn narrowing loss post profit april end quarter sale performance also be rebound related opec face crumble consensus output hike create sharp splitjd com google investment retail infrastructure planswhen sell stock big break day line mark end huge run
1,PFE,astrazeneca azn eli lilly lly become latest tuesday series pharmaceutical company scrap study potential alzheimer disease treatment appear unlikely work drugmaker discontinue phase study drug call lanabecestat independent datum monitoring committee predict lanabecestat miss goal study early alzheimer disease mild alzheimer dementia complexity alzheimer disease pose most difficult medical challenge time lilly research lab president daniel skovronsky say written statement be grateful contribution study participant family lanabecestat belong class drug call bace inhibitor work prevent buildup substance call beta amyloid plaque brain researcher believe toxic substance be center alzheimer disease get newsletter deliver inbox more info product service privacy policy term useastrazeneca lilly be far only pharmaceutical company frustrated pursuit alzheimer disease treatment dow jone component merck mrk end study drug verubecestat mild moderate early alzheimer disease earlier year fellow dow jone stock pfizer pfe abandon research treatment alzheimer parkinson disease johnson johnson jnj stop study bace inhibitor patient late stage alzheimer disease liver worry lilly stock crash drug miss goal phase study lilly study drug solanezumab patient mild alzheimer disease market be increasingly look biogen be work monoclonal antibody drug know aducanumab work remove beta amyloid plaque brain analyst expect biogen have datum key study lilly say tuesday doesn expect significant cost associate decision end study potential alzheimer disease treatment reaffirm guidance midterm guidance remainder decade be commit ensure finding be used inform further research alzheimer community give importance find treatment disease say astrazeneca spokesperson menela pangalos statement stock market today lilly sank fraction close share be consolidate buy point astrazeneca lose collectively share pharmaceutical company be flat related invest stock free new apps aim buy stock ahead earning report be inflation do matter fed
2,PFE,alnylam pharmaceutical alny ionis pharmaceutical ion topple thursday dow jone component pfizer pfe unveil strong late stage result compete rare disease drug share alnylam plunge close hit lowest point feb ionis stock tumble month low close pfizer rise evercore analyst umer raffat call pfizer release very rare late stage pipeline surprise especially pfizer note client study hit key goal use most investor have begin think be impossible say pfizer study drug call tafamidis treat transthyretin cardiomyopathy disease tie progressive heart failure condition belong family disease call transthyretin amyloidosis attr alnylam ionis be develop drug hereditary form attr get newsletter deliver inbox more info product service privacy policy term usein study patient treat tafamidis see reduction death cardiovascular related hospitalization compare placebo month patient tolerate tafamidis well be new safety issue instinet analyst christopher marai reiterate reduce rating alnylam stock follow pfizer news have price target stock see substantial competitive risk do not appear be price expectation alnylam drug patisiran evercore raffat expect tafamidis be accretive pfizer earning share investor likely debate tafamidis treat only cardiomyopathy be extend broad attr population estimate sale tafamidis cardiomyopathy alone related much money do need start investing tame volatile swing trade half positionlook next nvidia start simple routine
3,PFE,dow jone component pfizer pfe be team group former kite pharma executive take gilead science gild novartis nvs advanced cancer treatment early tuesday pfizer say enter alliance privately hold allogene therapeutic develop advanced form chimeric antigen receptor cell car therapy pfizer take stake allogene therapy represent potentially approach treat cancer be very excited future hold area research pfizer head oncology research development robert abraham say written statement regular session stock market today pfizer rise close gilead tick novartis advanced get newsletter deliver inbox more info product service privacy policy term usecar therapy gilead novartis already be market drug be create used patient own extract immune cell scientist reprogram patient cell fight cancer return patient pfizer allogene be aim create allogeneic version treatment used healthy donor cell successful allogeneic car drug be less costly produce traditional car treatment scientist remain split allogeneic approach work be also case traditional car therapy then gilead novartis grab approval several type blood cancer allogene chief executive president david chang say many believe idea car therapy be root science fiction science fiction have become reality say written statement chang be kite chief medical officer head research department gilead buy kite last year just regulator approve drug yescarta treat aggressive form hodgkin lymphoma arie belldegrun kite founder former chief executive also moved allogene serve executive chairman pfizer also keep stake cellectis cll deal allogene also allow cellectis allogene work together allogeneic car cellectis be furthest allogeneic approach crispr therapeutic crsp be work rival french pharma group servier be sponsor clinical test pfizer cellectis partner drug ucart drug be phase study potential treatment acute lymphoblastic leukemia approve be shelf form car development shelf allogeneic car therapy field oncology initiate revolution potentially expand access such innovative treatment larger number oncologist patient servier president olivier laureau say prepared statement related much money do need start investing long term retirement investing strategy buy stock ahead earning report
4,PFE,here weekly investing action plan need know investor come week apple aapl be set unveil new bell whistle developer well possibly tease work customer broadcom avgo report earning upheaval chip sector international trade top cybersecurity stock palo
5,PFE,celgene celg bluebird bio blue agree wednesday co commercialize co promote advanced cancer treatment know bb company begin collaborate cancer treatment bb be part deal now be study bb multiple myeloma believe therapy have potential significantly impact treatment approach outcome patient multiple myeloma celgene president hematology oncology nadim ahm say written statement term deal company pay half cost get half profit celgene also pay bluebird milestone royalty sale outside get newsletter deliver inbox more info product service privacy policy term usein early trading stock market today bluebird sank close share celgene surge deal come just week celgene wrapped acquisition juno therapeutic juno bluebird be work cancer drug call car therapy gilead science gild novartis nvs already have drug approve arena notably other be develop alternative form car therapy be less costly drug gilead novartis dow jone stock pfizer pfe cellectis cll be team crispr therapeutic crsp be work related build long term profit stock take many gain look best stock buy watch start buy stock ahead earning report
6,PFE,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
7,PFE,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
8,PFE,sarepta therapeutic srpt extend lead treat specific form muscular dystrophy thursday maker rival drug solid bioscience sldb crater regulator place trial treatment clinical hold action food drug administration be announce late wednesday adolescent patient duchenne muscular dystrophy treat solid bio gene therapy experience decrease platelet red blood cell be liver issue didn suffer bleed disorder have be source concern wall street shouldn completely discount solid bio leerink analyst joseph schwartz say patient already have improve be back trial schwartz note stock reaction be likely exacerbate resignation advisor worry therapy dr james wilson expressed worry treatment january resign solid bio scientific advisory board solid be farther sarepta duchenne muscular dystrophy gene therapy be too early eliminate company competitive landscape schwartz say note client dow jone component pfizer pfe also be work gene therapy treat same disorder get newsletter deliver inbox more info product service privacy policy term useon stock market today sarepta fall close share solid bio collapse fall nearly firm file initial public offer january solid bio be evaluate gene therapy call sgt rival gene therapy sarepta call micro gene therapy be used adeno associate viral vector insert genetic material specific site specific chromosome sarepta gene therapy be construct differently solid bio credit suisse analyst alethia young say note client doesn see solid bio clinical hold indicate future issue sarepta gene therapy do not yet know source solid safety issue remain comfortable robust preclinical safety toxicology study previous clinically dose study micro gene therapy say sarepta solid bio also differ patient evaluate trial instinet analyst christopher marai say note sarepta partner nationwide child hospital be testing patient age month year age trial enroll younger patient benefit more substantially therapy say differ solid bio trial start enrolling adolescent first patient enrolled be ambulatory sarepta be administer gene therapy third patient indicate be safe first patient receive marai say micro gene therapy be test nonhuman primate score well safety issue add important note adverse event solid bio first patient didn align dr wilson worry marai say wilson have warn liver toxicity bleed disorder result high dose therapy used adeno associate viral vector sgt micro sarepta be testing higher dose gene therapy also hasn see issue marai slash price target solid bio keep buy rating setback solid bio be consider incremental positive sarepta rbc analyst brian abraham say report also indicate be issue gene therapy base adeno associate viral vector take time work adverse event be unique solid program potentially be indicative broader complication associate adeno associate viral vector base gene therapy say related investing basic sell stocksell take profit hold here be several guideline followstill rule stock investor always cut loss short
9,PFE,president trump offer plan friday reduce price costly ethical drug speech spur generally positive reaction pharmaceutical related industry biotech group be day top industry track ibd rise generic drugmaker rally group ethical drug stock bound drugstore be manage care wholesale drug supply meanwhile major equity index play small ball most friday session finished week smart gain ibd upgrade stock market current outlook uptrend resume thursday nasdaq composite rushed higher week lift apple aapl also post second straight weekly gain iphone giant halter session winning streak still close bullish week more top jump prior week unusually heavy volume recent rally have hoist apple much past new proper buy point very mild week double bottom base read latest update stock market action go stock market today landing page nasdaq composite edge lower inched nearly higher dow jone industrial average rally thank gain point more big pharma component merck mrk pfizer pfe unitedhealth group unh dow jone industrial component also rise merck be still try clear stubborn upside resistance long term day move average relative price strength rating mean merck be outperform only company ibd database past month small cap tick higher index be now more jan strong corporate earning more sign modest inflation valuation equity vs bond still offer reason be bullish stock rest year even compare earning yield yield baa corporate bond not year treasury bond stock market still look attractively value leo grohowski chief investment officer asset management giant bny mellon wealth management tell ibd interview not invest snapshot view look month even cool economy see year yield lower yield benchmark treasury year bond continue hover critical level finishing day grohowski forecast yield end year back apple megacap turnaround tech play be now trading roughly ideal buy point double bottom base try buy share more past correct entry so avoid get prematurely shake even large cap leader be prone testing even fall briefly point strong upward thrust price apple fundamental continue shine earning climb vs year level past quarters street see fiscal profit rise share mark slight acceleration growth apple be now almost clear first stage cup handle base entry jan ibd pharmaceutical play rejoin list premier growth stock supernus pharmaceutical supn blast higher volume jump nearly quadruple usual level straight session stock be now extend past correct buy point month cuplike base base supernus form roughly week downward slant handle lighter trade handle base represent final shakeout weak holder week huge expert treatment epilepsy adhd post leap first quarter earning cent share crush consensus estimate nearly sale increase quarterly record ipg photonic ipgp industrial laser maker oil gas play wildhorse resource development wrd also joined ibd recent session please follow saito chung twitter ibd_dchung additional commentary top growth stock breakout sell signal financial market related other stock be new ibd top growth screen check herelooking next nvidia follow simple easy way check ibd rating apple go here
10,PFE,eli lilly lly be try leapfrog dow jone stock merck mrk bristol myer squibb bmy acquisition cancer immunotherapy biotech armo bioscience armo industry observer say thursday drugmaker lilly be late game cancer immunotherapy brad loncar tell investor business daily loncar run several biotech stock index include cancer immunotherapy sector index contain armo loncar cancer immunotherapy exchange trade fund pop thursday leader be merck bristol myer squibb roche rhhby say re company have completely miss boat want play area have do something try leapfrog competition early thursday lilly make first big move cancer immunotherapy space area medicine drug immune system fight cancer lilly say pay share armo cash deal get newsletter deliver inbox more info product service privacy policy term usearmo share rocket close lilly stock rise fellow drug stock merck bristol rise less roche have failure early day colon cancer dip lilly expect deal close end second quarter armo late stage biotech go public january quickly pop be hot initial public offer loncar say note price early thursday indicate investor expect bid leerink analyst chang note acquisition price be premium armo close price wednesday initiate coverage stock outperform rating price target earlier year thursday downgrade armo market perform deal confirm investment thesis armo view read positively other emerge immuno oncology stock say be unclear other bidder emerge give short close date acquisition make sense pharmaceutical stock lilly try assert cancer immunotherapy space loncar say armo lead drug call pegilodecakin be know cytokine boost strength drug know pd inhibitor merck keytruda bristol opdivo earlier year bristol validate cytokine drug call nktr pay upfront partner nektar therapeutic nktr deal hit record upfront payment biotech loncar say now little surprise armo be be take loncar have consistently predict be big year biotech deal merger takeout year kick news celgene celg plan buy juno therapeutic sanofi sny bid bioverativ bivv ablynx ablx deal armo be little different say think have happened be middle terrible bear market say other hand be also good example large company eli lilly many have not be forefront innovation re have buy still lilly isn alone trail position cancer immunotherapy roche astrazeneca azn pfizer pfe have immuno oncology drug remain merck bristol be level own say cancer immunotherapy space desperately need good news say earlier year incyte incy drug know ido inhibitor fail late stage combination merck keytruda melanoma incyte pain extend other cancer immunotherapy stock background volatility remain cancer immunotherapy space loncar say key say be be different piece technology armo drug be different incyte drug know epacadostat news item set person mood say everybody be immunotherapy think overrate then deal happen cause opposite reaction have emerge technology go be roller coaster related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
11,PFE,exxon mobil xom drive dow industrial qualcomm qcom bolster nasdaq early trade thursday stock run modest open gain dow jone industrial average open higher exxon pfizer pfe battle dow top position only handful blue chip decline nasdaq also climb addition qualcomm tech name include solaredge sedg ring central rng roku roku score many session largest early advance wednesday session improve standing market uptrend dow retake support day move average nasdaq extend gain year question remainder week be dow hold support build comfort margin psychologically important indicator not slip see marker once again become line resistance crude oil price bakce early gain slip thursday morning benchmark west texas intermediate crude hold just barrel already reel supply issue raise new round sanction pledge iran oil market awake thursday find tension middle east have ratchete higher overnight get newsletter deliver inbox more info product service privacy policy term usereport missile attack iran iran backed houthi rebel yeman deepen region conflict day exit nuclear proliferation treaty iran israel retaliate most intensive air strike date iranian target syrium thursday respond israeli leader say be sustain missile attack israeli military position golan height saudi arabia saudi press agency say air defense intercept missile fire houthi rebel yeman aim riyadh other saudi city wednesday china market be clocking week positive trade hong kong hang seng index jump thursday give gain week lift back week move average putt track first weekly advance week shanghai composite add thursday work third straight weekly advance be so far best week february stock europe appear set snap session streak thursday back early rally bank england decide keep rate steady frankfurt dax remain afternoon trade cac paris trade flat london ftse shed loss climb tech side market apple aapl fang stock tech leader trade flat slightly higher qualcomm climb lead nasdaq post top early gain stock company say late wednesday board have approve share buyback initiative initiative aim aid company meeting full year earning target range share ibd name solaredge swung higher ahead open israel base developer solar energy component report better expect earning gain first quarter sale growth accelerate stock end wednesday buy range rebound support week move average software developer ring central be appear set press further flat base buy point enterprise software developer report late wednesday adjust first quarter earning revenue top expectation management raise full year guidance consensus view roku click nearly premarket action maker digital entertainment device report first quarter result full year guidance analyst target late wednesday stock have gain week wednesday session share close september ipo price december high permian basin oil producer wildhorse resource development wrd reversed open gain slump higher unable extend gain april late wednesday month old company report earning gain advance revenue first quarter share end wednesday week buy point cup handle base pioneer natural resource pxd ease advance first quarter earning easily top expectation adjust earning rise revenue gain stock close wednesday extend buy point month long cup handle base close casa system casa nvidia nvda be name schedule report earning be interested big picture bear hibernate asset outperform equitiesnvidia hot ipos lead top stock earning due investing action plansplunk break base ahead quarterly resultswhy do top rate fund own share cloud stock big squeeze new risk fed interest rate recession yield curve
12,PFE,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
13,PFE,company be pace return record shareholder year alone dividend payout share buyback accord dow jone index apple aapl alone be expect repatriate foreign profit come year iphone maker say late tuesday approve new repurchase program increase quarterly dividend cent news come day howard silverblatt senior index analyst dow jone index estimate release note estimate windfall give environment availability cash increase income expectation desire company show shareholder return return double digit actual cash payment gain year year seem feasible first dollar year dividend buyback write accord cnbc last month predict share buyback see record year potential top high surge total addition lower corporate tax rate tax overhaul also make cheaper bring profit make overseas back morgan stanley say november apple microsoft msft general electric ge pfizer pfe ibm ibm have most accumulate foreign earning meanwhile dividend be already look strong payout company increase net mark biggest bump dividend increase be sharply gain see year still well short increase economy be still rebound company increase dividend accord dow jone index company have cut dividend mark first decrease least company dow jone index track company make positive dividend move make negative one represent collective net payout increase record high dividend be typically event drive silverblatt tell ibd last month don have many negative event here get newsletter deliver inbox more info product service privacy policy term usesome biggest dividend hike come energy sector many energy company pull back payout due oil price crash begin company fall health care consumer discretionary tech sector also hike payout home depot hd february announce quarterly dividend increase best buy bby hike own yum brand yum january dividend increase health care abbvie abbv announce jump dividend payout chipmaker intel intc announce increase quarterly dividend january dividend payout company totale record december aerospace giant boee ba announce boost dividend ge halved dividend november even economy improve trump plan hit import tariff continue agitate investor cost go ve get raise price eat profit combination silverblatt say be interested apple new low end ipad student look thwart google sale taiwan urge china aggression growsdon look now trump just score trade
14,PFE,stock market rally well intraday lows tuesday tech heavy nasdaq stage upside reversal day fang stock facebook fb reversed early loss stock market today announce entry new industry meanwhile apple aapl stock rise more ahead fiscal result beat forecast close nasdaq pace major index advance be dow jone industrial average lag fall turnover be tracking slightly higher nyse nasdaq exchange vs same time monday accord preliminary datum dow stock day laggard featured drugmaker pfizer pfe merck mrk pfizer decline mixed result stock fall day move average heavy volume meanwhile merck fall lighter expect sale result top chip stock intel intc moved continue be top perform semi stock weaken sector straight day heavy loss friday monday stock remain day line get newsletter deliver inbox more info product service privacy policy term market close apple report anxiously await fiscal result iphone maker be expect earn share revenue share have be volatile recent week concern company iphone sale apple stock rise shape flat base buy point fang stock be rally nasdaq turn positive territory amazon com amzn moved facebook fb turn early loss gain social medium company announce new date layer mobile app share match group mtch owner tinder mobile app crater pierce day line huge turnover leaderboard stock netflix nflx rise share be hold day move average line lead growth stock grubhub grub faltered tuesday food delivery service announce earning sale top analyst estimate come short daily average grub average number order day upside svb financial sivb rise more hit new high friday superregional bank shot almost gap cup base entry other top performer include abiom abmd pagseguro digital pag advanced more related tesla mastercard square earning fed meeting investing action plandow jone industrial average dow stock news analysisapple aapl stock quote company news chart watch amazon deal fire retail stock best growth stock buy watch see update ibd stock list
15,PFE,stock market rally well intraday lows tuesday tech heavy nasdaq stage upside reversal day fang stock facebook fb reversed early loss stock market today announce entry new industry meanwhile apple aapl stock rise more ahead fiscal result beat forecast close nasdaq pace major index advance be dow jone industrial average lag fall turnover be tracking slightly higher nyse nasdaq exchange vs same time monday accord preliminary datum dow stock day laggard featured drugmaker pfizer pfe merck mrk pfizer decline mixed result stock fall day move average heavy volume meanwhile merck fall lighter expect sale result top chip stock intel intc moved continue be top perform semi stock weaken sector straight day heavy loss friday monday stock remain day line get newsletter deliver inbox more info product service privacy policy term market close apple report anxiously await fiscal result iphone maker be expect earn share revenue share have be volatile recent week concern company iphone sale apple stock rise shape flat base buy point fang stock be rally nasdaq turn positive territory amazon com amzn moved facebook fb turn early loss gain social medium company announce new date layer mobile app share match group mtch owner tinder mobile app crater pierce day line huge turnover leaderboard stock netflix nflx rise share be hold day move average line lead growth stock grubhub grub faltered tuesday food delivery service announce earning sale top analyst estimate come short daily average grub average number order day upside svb financial sivb rise more hit new high friday superregional bank shot almost gap cup base entry other top performer include abiom abmd pagseguro digital pag advanced more related tesla mastercard square earning fed meeting investing action plandow jone industrial average dow stock news analysisapple aapl stock quote company news chart watch amazon deal fire retail stock best growth stock buy watch see update ibd stock list
16,PFE,stock gain strength final hour trading thursday detail new trade tariff show mexico canada be spare nasdaq composite close higher mark fifth straight gain add nearly touch day move average first time feb dow jone industrial average climb consumer medical company johnson johnson jnj pfizer pfe nike nke mcdonald mcd coca cola ko make best percentage gain pfizer rise back day move average have yet make solid move line small cap break trend outperformance russell lose volume rise nasdaq fall nyse accord preliminary datum advancer top decliner board market be dull much day await news trump administration tariff steel aluminum import late day associate press report steel aluminum tariff not be impose mexico canada tariff other country take effect day airline casino tobacco generic drug datum storage be thursday top industry group pharmaceutical spdr pharmaceutical etf xph be more single sector stand thursday session metal mining stock include affected trade tariff be weakest department store supermarket rvs manage care apparel be other bottom industry performance table lead stock be mixed ibd almost evenly split riser decliner thinly trade emergent biosolution ebs break shape base buy point volume be weak company be best know anthrax vaccine collegium pharmaceutical coll surge past buy point irregular base heavy volume company report earning late wednesday sale company painkiller xtampza easily beat expectation momentum be expect continue year collegium be expect become profitable next year ep cent year analyst expect loss cent use ibd marketsmith free march
17,PFE,see stock buy point get chart pattern recognition run custom screen start nowmarvell technology mrvl edge week formation climb new high active trading chip company be due report earning close related trump tariff go easy canada mexico dow jone biotech flirt battle opioid makersvirgin atlantic follow delta unite american new economy class
18,PFE,dow future lead premarket trading back narrow decline tuesday market generally hunker ahead apple aapl fiscal second quarter result later day fed interest rate decision wednesday april payroll report due friday dow future give brief gain slip less fair value apple lead index merck mrk pfizer pfe post heaviest decline nasdaq future also dip narrow loss akamai technology akam citrix system ctxs top nasdaq seagate technology stx post heaviest loss big benchmark score nominal gain april dow nasdaq struggle fractional gain still month be noteworthy stop month slide have send nasdaq february march get newsletter deliver inbox more info product service privacy policy term usemarket continue hold breath tuesday president trump delay june tariff be set take effect today steel aluminum import european union mexico canada agreement avoid tariff be place australia brazil argentina white house say march tariff go effect china russia japan foreign steel stock trading show little reaction premarket trading share steel drop more steel stock general have be pull back consolidate february factor investor radar federal open market committee begin day meeting morning washington meeting be expect wrap rate policy decision wednesday afternoon be press conference follow announcement addition several key piece economic news be expect today manufacturing purchasing manger index april be due researcher markit et institute supply management et march construction spending number commerce department be expect et automaker be report april sale total session apple most notable earning report stock market today add premarket trade analyst have raise concern company outlook wall street see jump earning revenue gain first quarter mark company best result fourth quarter apple share have decline past month have be stall day move average late april dow pfizer drop merck tumble drugmaker top analyst quarterly earning expectation revenue growth stop short target haynesbrand hbi nutrisystem ntri allison transmission alsn be other lead name motion follow earning report early tuesday tenet healthcare thc skip nearly deliver strong result monday close premarket gain position stock narrowly clear flat base buy point not premarket move carry regular trade seagate technology tumble nearly just report fiscal third quarter result earning revenue growth appear top expectation management raise company quarterly dividend cent armour uaa reversed early gain drop premarket trading athletic wear maker first quarter sale profit score easy beat company reaffirm full year revenue expectation guide general weakness market sale surge overseas armour share end monday buy point month long base aerospace component maker transdigm tdg pop report fiscal second quarter result open result soar past analyst target management give full year guidance significant boost cite transdigm recent acquisition stock close monday less handle buy point ibd stock bofi hold bofi pop premarket action monday close bell bofi be not quite flat base buy point medical product maker inogen ingn spiked clobber analyst expectation first quarter report late monday maker portable oxygen concentrator end monday top buy range buy point flat base be interested big picture anxious market shift attention fedlooking best stock buy watch check alibaba casa big squeeze stock market bull run face biggest threat yearsapple grubhub shopify earning facebook investing action planamazon ibd stock share winning growth trait
19,PFE,ligand pharmaceutical lgnd be biotech worth doesn market single drug yet expect approach sale stock be breaking reason be ligand operate unique business model acquire early stage technology necessary drug development then license platform biotechs pharmas dow jone stock merck mrk pfizer pfe well amgen amgn novartis nvs total ligand have more program development north partner firm say fourth quarter conference call february craig hallum capital group analyst matt hewitt praise model feb report client give larger ever expand portfolio current potential future royalty generate asset broad pipeline partnership model inherently gear deliver very high profit margin believe be tremendous value creation motion ligand say shareholder seem agree hewitt assessment ligand stock have pop more begin year outperform broader biotech group have rise roughly same time period thursday share jump early morning trade break second stage week flat base share end regular session ligand share have be run last week jump least day stretch straight trading session meanwhile biotech group have be red past session stock have ibd composite rating best possible meaning perform top stock term key growth metric biotech group rank third vertex pharmaceutical vrtx halozyme therapeutic halo have rating ligand demonstrated dominance fourth quarter total revenue grow top consensus roth capital partner analyst scott henry write recent note client royalty main driver sale increase line expectation henry say upside revenue drive adjust earning share spiking vs year earlier quarter beating analyst view cent better expect sale amgen kyproli novartis promacta lead revenue charge ligand get royalty sale promacta oral medicine increase number platelet blood royalty sale multiple myeloma drug kyproli total ligand be tie dozen commercial product have technology platform biotechs pharmas use develop drug firm also have handful early stage drug plan license interested company further development ligand goal be create diversify company more licensing opportunity lower impact individual patent expiry firm say protect scenario now face biotech leader celgene celg see patent cancer drug revlimid begin expire mid use ibd marketsmith free march
20,PFE,see stock buy point get chart pattern recognition run custom screen start nowamong recent success ligand announce week have partner drug hold firm roivant science diabetes drug lgd roivant company metavant develop drug have strong phase datum second half be major partnership have potential generate substantial medical value type type diabetes patient ligand chief executive john higgin say prepared statement lgd be successfully develop license roivant have potential be ligand largest financial asset possibility annual royalty continue late offer upside guidance royalty revenue sale related captisol compound used pharma development related milestone license fee analyst say ligand tend promise deliver come annual guidance roth capital henry say expect be more same revenue earning share target view conservative surpass company guidance henry expect kyproli promacta sale moderate call kyproli sale grow promacta sale increase sustain movement drug provide upside guidance say ligand be bullish drug ceo higgin call kyproli promacta become blockbuster promacta have be market year so see level growth be particularly impressive say earning call promacta become molecule analyst project continue strong growth say kyproli give recently report sale number drug appear also be track exceed worldwide sale ligand partner currently have handful drug late stage testing include brexanolone postpartum depression drug sage therapeutic sage slew other phase trial partner program be preclinical be phase study firm expect benefit current trend include new tax law reduce ligand project tax rate more third higgin say earning call ligand also get boost bump fda drug approval recent study massachusett institute technology find success rate drug program advance approval have increase believe be attribute many factor include better decision advance program more favorable regulatory environment say be very meaningful ligand have program stage development related tame volatile swing trade half trade stock most penny stock fail make investor richlook best stock buy watch start here
21,PFE,couple relatively obscure biotechs be challenge like novartis nvs gilead science gild new form treat cancer not only undercut bigger rival render recently approve oncology drug drug giant obsolete novartis gilead be still early stage launch respective drug call kymriah yescarta be know car drug cellectis cll crispr therapeutic crsp tiny fraction rival market cap already be creep shelf variation car therapy used healthy donor cell create less expensive version cancer drug make treatment novartis gilead less attractive obsolete instinet analyst christopher marai tell investor business daily never mind pricing be dose more effectively marai say car therapy be form oncology treatment currently create extract immune cell patient blood used empty virus drugmaker affix be know chimeric antigen receptor immune system cell receptor also know car be protein recognize other protein used cancer cell hide body re engineer cell be reintroduce body be direct seek destroy cancer cell carry protein process be complex costly also tailor individual meaning drug be mass produce often take week manufacture patient die re wait crispr chief executive sam kulkarni tell investor business daily shelf approach car be aim change shelf car also know allogeneic used healthy donor cell prompt same immune response first generation car ts novartis gilead be used know autologous kulkarni say donor cell be typically healthier allow more robust response patient manufacturing process be less complex run make hundred dose kulkarni say process be uniform less costly cellectis have estimate cost good less patient autologous car run hundred thousand dollar expert say kulkarni marai note benefit allogeneic car be huge theory pan late stage clinical testing healthy donor cell also prompt better response used compromise cell cancer patient say patient also potentially receive repeat dose benefit doesn persist dose difficult much pricier autologous car overall allogeneic be so much more powerful shelf kulkarni say patient be treat very next day allogeneic car ts have good chance work better autologous car ts be accessible broadly patient theory be still little short tooth december cellectis partner servier pfizer pfe dow jone industrial average component unveil result first clinical trial used donor cell create car treatment form leukemia brad loncar run biotech fund know loncar cancer immunotherapy etf cncr call result mixed patient form acute lymphoblastic leukemia drug know ucart result complete remission rate adult pediatric patient use ibd marketsmith free march
22,PFE,see stock buy point get chart pattern recognition run custom screen start datum weren strong result juno therapeutic formally acquire celgene celg earlier week be point phase datum present december juno jcar first generation car drug achieve remission rate child same form leukemia have equal effectiveness course shelf car make first generation car obsolete loncar tell investor business daily have equal effectiveness gigantic thing say far proven reason believe never be so allogeneic car be holy grail oncology therapy say nadeem sheikh vice president research development privately hold dendreon pharmaceutical dendreon make immunotherapy treatment call provenge advanced prostate cancer entire cancer field love something allogeneic approach tell investor business daily allogeneic approach be take cell give holy grail know lot problem approach used donor cell introduce potential condition know graft versus host disease sheikh say disease donor immune cell don recognize surrounding begin attack everything appear foreign crispr kulkarni think have answer company gene editing process used technique call crispr receptor donor cell be remove prevent cell wildly attack unintended target essentially used crispr change genetic healthy donor cell say do longer attack patient cell only attack tumor patient perform second edit donor cell be then engineer appear body so patient own immune cell win try destroy donor cell kulkarni say allow donor cell persist longer body think crispr blow torch say actually cut metal weld metal here add gene remove gene cell essentially take healthy person cell make car ts add subtract gene cellectis be class own allogeneic car loncar say servier pfizer partner drug ucart already have preliminary phase datum own drug ucart be testing acute myeloid leukemia form leukemia know blastic plasmacytoid dendritic cell neoplasm february cellectis be grant pair patent use crispr gene editing genetic engineering cell cellectis say plan make patent available licensing other company willing use crispr technology cell theory be catch quickly even biggest first generation car player gilead announce acquisition kite late august merger close oct just fda approve kite drug yescarta oct now gilead be eyee allogeneic approach last month gilead partner sangamo therapeutic sgmo front develop cellular therapy used technique gene editing call zinc finger nuclease process gene editing be more complex costly crispr technology used crispr edita medicine edit intellium therapeutic ntla term deal gilead sangamo be eligible potential payment more product work autologous allogeneic approach cellular therapy crispr biotech also be work allogeneic car therapy call ctx yescarta gilead kymriah novartis target cd protein meaning potentially be used treat similar blood cancer so far firm have have meeting fda discuss filing investigational new drug application kulkarni say such application allow crispr begin clinical trial kulkarni expect file application end year begin clinical testing bullish crispr prospect note take lot front time energy think re still early day say have see datum bear autologous car have head start number trial allogeneic start work tumor type very scalable program related chart read basic buy point mark time real tame volatile swing trade half positionlook best stock buy watch start here
23,PFE,dow pfizer pfe win have pay biogen biib cent royalty compete multiple sclerosis drug court decision friday invalidate last patent biogen avonex decision hinge patent be issue year avonex first be approve go market patent have cover avonex multiple sclerosis treatment patent be first file cover used interferon date back decade issuance pfizer partner emd serono have continue sell rebif rival drug also belong class know beta interferon novartis nvs also have continue sell copycat bayer bayry rival drug betaseron don believe investor be fully convince patent utility leerink analyst geoffrey porge say note client certainly regard patent limit utility keep competitor kind market give obvious continue sale rebif betaseron jury invalidate biogen patent find prior knowledge exist interferon treatment number different medical condition biogen have try argue pfizer emd serono have infringe claim patent result find be effectively patent infringe royalty settlement obligation payable serono biogen porge say biogen be seek multibillion dollar damage basis claim royalty future prior sale well damage get ibd market prep tech report newsletter free decision also likely end biogen ongoing litigation novartis drug betaseron porge say likely biogen appeal decision meantime relieve company have pay biogen anything compete product biogen decline comment investor business daily case biotech have look hard cost continue litigation appeal be decline product trial low probability legal success porge say porge doesn expect flood generic entrant class interferon be decline still represent revenue category challenge manufacturing develop commercialize biosimilar version interferon be significant biosimilar company have high quality version beta interferon product establish be biosimilar then patent valid not be unlikely have be major deterrent say stock market today biogen sank nearly close pfizer climb novartis advanced fraction related biotech outlook be feel flu be just blip be biotech hedge outlook key fda approval crispr small biotechs cure disease
24,PFE,facebook fb advanced micro device amd be early leader thursday open global stock market rally market look add third straight advance nasdaq composite launch gain start bell dow jone industrial average advanced swung facebook set early lead nasdaq stock bounce putt stock positive territory week ibd leaderboard stock amazon com amzn netflix nflx open higher alphabet googl rise get newsletter deliver inbox more info product service privacy policy term usej morgan jpm caterpillar cat lead early advance blue chip rise more apiece merck post advance barclay upgrade merck overweight equal weight raise stock price target be wednesday close note also downgrade merck competitor pfizer pfe equal weight overweight trim price target pfizer share slip fraction early trade american express climb blue chip credit brand be expect post earning gain report fiscal first quarter result april mark strongest earning gain second quarter stock have be cling support day move average end wednesday day line less mid january high china base stock show early strength com pace group rise nearly open trade online game provider announce special dividend american depositary share china base sohu com sohu hold majority stake climb more start bell chip stock be mixed premarket action advanced micro device rumble ahead nearly lead philadelphia semiconductor index stifel upgrade stock buy hold target price share trade early thursday note say amd have be oversold concern softening demand cryptocurrency related chip marvell technology mrvl pop ub initiate coverage company buy rating price target marvell fourth week pullback rebound weak trade day move average wednesday global stock market frankfurt dax lead afternoon rally europe surge vs gain paris cac advance ftse london china hong kong shanghai exchange be dark country celebrate ching ming festival japan tokyo stock exchange nikkei surge thursday lift benchmark positive ground week back week move average first time early february commerce department report trade deficit widen february january consensus view first time unemployment claim rise week end march labor department say be prior week claim easily outstrip consensus view increase claim layoff announce private employer surge march accord monthly job cut report challenger gray christmas be highest tally april more vs february year level be interested big picture strong rally paint bullish tint hot group be tech sector new fang stock apple stoke artificial intelligence talent battle google hirethese dow stock reclaim key support be buy pointstock buy zonetop perform large cap big cap stock leaderboard be rise
25,PFE,senate republican delay implementation cut corporate tax rate meanwhile house republican just filled hole bill hike tax rate charge accumulate foreign earning hold overseas apple aapl alone have accumulate profit haven be subject taxe xanother house measure aim combat profit shift company such apple google parent alphabet googl pfizer pfe low tax jurisdiction house gop tax high foreign return raise decade senate have take related apparently tougher approach target company recognize profit valuable intellectual property overseas reduce federal tax exposure senate plan charge tax foreign income intellectual property raise accord various report initially republican be expect propose tax rate cash equivalent tax illiquid asset such real estate cash have be invest new facility initial house bill release week propose tax cash tax illiquid asset now house republican have find bill raise deficit decade more budget resolution allow ve turn easiest target get finish line update house tax cut job act impose tax cash tax illiquid asset not clear higher tax accumulate foreign profit be final bill house bill update senate propose corporate tax change make clear gop tax bill be move direction wall street find worrisome unknown question be much keep move republican aim address criticism aim house bill raise taxe moderate income family child decade house way mean committee moved forward thursday afternoon approve revise house gop bill senate legislation release thursday partially replace corporate tax cut year window company investment apparently include structure house bill provide immediate equipment purchase lower corporate taxe first year ibd take dow jone industrial average close wednesday point ibd change market trend indicator aug confirm uptrend uptrend pressure equivalent yellow light turn green make sure read big picture column day stay top market direction key indicator let know be aggressive move sideline dow jone industrial average index nasdaq composite climb session lows stock market today investor weigh emerge detail senate tax package dow still lose nasdaq fall dow nasdaq set close high wednesday tax cut hope help lift major average recent week past year analyst have also warn bank such dow component jpmorgan chase jpm bank america bac face additional taxe senate bill house include provision limit big bank deduction fdic premium raise decade hatch wednesday mentioned possibility corporate tax rate phase end decade still allow start corporate tax cut cost vs hatch suggestion underscore something republican have be reluctant admit chance ll be able make corporate tax rate permanent temporary cut however be expect provide more modest short term economic lift eventually turn drag growth related chance permanent corporate tax ratefour reason jpmorgan other bank stock keep fallinghouse gop tax bill take aim big tech big house gop tax bill have big family problemnvidium lead top earning report thursday investing action planstock buy watch top ipos big small cap growth stock
26,PFE,have be very mixed year big drugmaker north chicago ill base abbvie abbv climb monday session nearly time pace overall industry group xthat not bad dividend play yielding annually stock trade buy point week flat base
27,PFE,dow component pfizer pfe say tuesday consider selling spin counter business include advil centrum number other heavy sale hitter consumer healthcare business bring sale pfizer say news release addition advil centrum segment market product exceed sale last year pfizer be consider partial full separation consumer healthcare unit selling spinoff other transaction firm say news release still possible pfizer opt retain business be strong connection consumer healthcare element core business be also distinct enough core business be potential value be more fully realize outside company chief executive ian read say prepared statement explore strategic option evaluate best fuel future success expansion consumer healthcare simultaneously unlock potential value shareholder say ibd take worry president trump depress drug price have hold drug stock back year analyst say medtech have be relatively unscathed pressure head industry snapshot closer look medtech stock have perform well year unit sell dietary supplement pain management tool drug therapy respiratory illness personal care item chapstick anbesol pain relieve gel toothach pfizer say have tap centerview partner guggenheim security morgan stanley financial advisor strategic review process doesn expect decision regard potential separation consumer healthcare business consumer healthcare business bring pfizer total sale growth have stall past several year sale be flat follow decline last year growth be revenue be vs prior year close bell stock market today pfizer be close share begin form cup august buy point pfizer be year date vs broader drugmaker group have rise related dow stock be buy zone earning season beginsabbvie patent deal stave amgen competition other lurkwhy amgen drug send abbvie stock stratosphere
28,PFE,lead technology stock take heat again friday preliminary volume datum show second straight distribution day nasdaq composite big decliner nasdaq include micron technology mu earning western digital wdc lose just sympathy chip name apply material amat lam research lrcx end loss close nasdaq fall lose dow jone industrial average give back russell drop preliminary datum show volume nyse nasdaq come slightly higher thursday level stock market today head friday show distribution day day show decline more distribution day be major index fall least volume rise vs prior session such action indicate intense professional selling lead new market correction week nasdaq slump give back nearly dow fall bond market be relatively quiet friday year treasury yield ease basis point earlier week federal reserve signale total interest rate hike year wall street view interest rate outlook somewhat hawkish several dow component close loss include mmm pfizer pfe microsoft msft goldman sachs gs bright spot be ipo dropbox dbx share close pricing last night propose range company provide cloud storage sharing collaborate service sale growth have be impressive recent quarters company isn profitable yet ibd name diamondback energy fang outperformed ibd rise fast grow oil gas producer end session low briefly clear cup handle buy point related stock be fall steel tariff exemption china restraintbest growth stock buy watch see update ibd stock listswall street expect turnaround quarter top stock
29,PFE,investor watch see tuesday market snapback hold many be assess stock pullback have do chart damage have not name ibd dividend leader list only maintain have regain support day move average tuesday afternoon clearly
30,PFE,renew strength biotech drug industry pfizer pfe be surge multiyear high territory friday volume track well average blue chip drug stock boast quarters accelerate earning growth fundamental metric share many market top growth stock most recent quarter dividend leader grow earning
31,PFE,key stock index fund be lower afternoon trade tech heavy qqqs turn negative blue chip fall most boee ba johnson johnson jnj weigh powershare qqq trust qqq dip spdr spy give spdr dow jone industrial average dium fall stock market today utility gold miner technology be top sector fund gainer spdr utility xlu rise retake day move average first time month vaneck vector gold miner gdx vaneck vector junior gold miner gdxj be health care select sector spdr xlv reversed loss unitedhealth group unh be dow biggest gainer early fall nearly cisco system csco hold gain biggest loser include boee undercut day move average trigger sell signal dowdupont dwdp johnson johnson apple aapl slip day hit new record high then reverse lower back buy point shape cup handle boee other industrial giant be get hit continue tariff related concern homebuilder bank metal miner lead downside sector fund spdr bank kbe spdr regional banking kre fall track extend loss third straight session etfs be nearly recent high bitcoin sank accord coindesk open level bitcoin investment trust gbtc gap tumble session lows month low mostly decline try retake day line march be now december peak dow stock johnson johnson unitedhealth group be blue chip show healthy gain tuesday spdr health care xlv remain potential buy range retake day move average friday be form new base buy point too keep mind broader market have be volatile lately fund undercut day line early february market correction now appear be overall uptrend share advanced last time xlv be featured etf column time fund be just buy point flat base etf celebrate anniversary december track health care select sector index pharmaceutical represent biggest segment holding march nearly asset biotech be next category account health care equipment supply health care provider service life science tool service health care technology make rest get newsletter deliver inbox more info product service privacy policy term top holding include dow jone industrial average health care name johnson johnson pfizer pfe unitedhealth group merck mrk dow stock top be abbvie abbv together top account roughly third stock portfolio dow quartet year date performance range abbvie however have soar year xlv year date gain march be line return etf average annual return past year lag outperformed broader index past year xlv bear expense ratio tuesday pick guggenheim pure growth rpg reversed lower session close just buy point also be interested dow stock turn red ge weigh apple reverse record highai robotic blockchain hot new etf industry sector do market pro expect outperform year
32,PFE,republican be apparently face reality check struggle squeeze nearly wish list tax cut budget hole gop house leader delay day rollout tax legislation have be set wednesday republican slap rumor further possible delay still surge record high early session give much gain close nasdaq composite turn lower number factor market move include apple aapl iphone related stock retreat doubt tax reform hope have be big contributor stock rally president trump election not hard figure big holdup be republican be promising so much business re have trouble make tax cut sufficiently attractive individual bust budget anything president trump be make job harder insist immediate cut corporate rate rather gradual phase push back change tax treatment account trump be likely lose latter battle lose former gop tax framework call net cut business taxe accord tax policy center analysis include immediate corporate tax rate rate small business partnership business income be taxed individual tax code republican have offset haven yet spel include partial limit interest deductibility corporation minimum tax overseas earning need least cut cost half allow room individual tax cut interest deductibility limit hit company verizon vz have debt meanwhile minimum tax threaten raise taxe overseas earning company pfizer pfe alphabet googl apple face single digit effective overseas tax rate even still be scant room individual tax cut gop magically find hundred billion dollar tax saving limit size pretax contribution cut limit half raise more unlikely be enough meanwhile republican high tax state include new york new jersey california seem be wage successful battle preserve least part state local tax deduction cost federal government decade individual tax number aren add be gop be now willing keep top income rate estate tax be pressure point so far house leader be sticking plan bigger picture be republican have few vote spare defection enough senate even be further delay release gop plan not safe assume republican eventually prevail get big tax cut pass first test be reaction gop lawmaker second big test come independent budget analyst determine benefit tax cut big shortcoming gop tax framework be middle class didn come well less generous inflation adjustment gradually shrink reverse tax cut related be gop tax plan lead higher property gop secret risky strategy corporate tax cutshouse continue toy contribution cap question trump let alphabet pfizer keep tax haven stock buy watch top ipos big small cap growth stock
33,PFE,glaxosmithkline gsk tumble month low wednesday drugmaker reportedly say consider acquisition bulk consumer health unit identify prescription drug segment top priority comment come conference call follow glaxo earning release sale earning top view sale glaxo establish pharmaceutical segment fall business comprise third pharma sale first priority be focuse improve largest business core pharma business research development reuter report chief executive emma walmsley say call walmsley note gsk consider consolidator consumer health sector same time dow stock pfizer pfe be consider potential sale consumer health business include brand advil centrum leerink analyst seamus fernandez say less likely glaxo put forth bid pfizer counter business ibd take president donald trump sign executive order pull drug price day accord washington base expert visit ibd industry theme more do biotech drug sector close bell stock market today glaxo stock drop share have be form flat base buy point month third quarter end glaxo report sale today exchange rate top consensus analyst poll zack investment research adjust earning cent share top cent view analyst sale glaxo pharmaceutical consumer health care unit grow apiece constant currency basis vaccine revenue be flat glaxo also maintain guidance adjust earning share grow constant currency basis related biogen dife top view lilly novartis allergan public relation backlash deepen weekdow component pfizer mull counter spinoff sale
34,PFE,house gop leader be sticking plan permanent corporate tax rate ve have root bit loose tax code change find make number work case ve find pretty big bill hard interpret provision take aim big technology pharmaceutical company locate intellectual property low cost tax jurisdiction have accumulate vast profit hold overseas apple aapl alone have accumulate foreign profit gop plan aim move more territorial tax system profit be taxed be earn risk be multinational engage more behavior prevent gop bill impose tax high return company foreign subsidiary provision be project raise decade joint committee taxation provision cancel look big company apple google parent alphabet googl pfizer pfe currently pay single digit tax rate overseas profit be concern plan impose minimum tax much future foreign earning longer be subject taxe instead global minimum rate reportedly be have do less combat incentive shift profit tax haven overall reaction gop plan business seem pretty mixed homebuilder hate share have take hit reaction propose limit mortgage deduction new home worth national federation independent business say tax bill leave too many small business national association manufacturer call grand slam house gop leader pitch bill huge middle class family say family income take home extra however figure reflect first year tax cut begin phase be erode less generous inflation measure produce bigger tax take time mixed bag multinational tax rate impose earning currently hold overseas have cash equivalent profit invest illiquid asset company high leverage be worry lose interest deduction seem have dodge bullet provision limit interest deductibility raise nowhere have be raise eliminate deduction wall street journal report be limit interest deduction equal earning interest depreciation amortization ebitda wouldn appear be much negative verizon vz carry debt interest expense equaled ebitda be problem company high debt lower profit dow jone industrial average turn slightly positive afternoon trading stock market today index nasdaq composite be slightly negative stock future have weaken overnight part report republican phase propose corporate tax rate comply senate budget reconciliation rule don allow increase deficit first decade point cut corporate taxe be provide business incentive make long term investment then permanence be critical make rate permanent cost second decade almost certainly require make individual tax cut temporary indeed gop already say phase family flexibility spouse child dependent ibd take dow jone industrial average close wednesday more point ibd change market trend indicator aug confirm uptrend uptrend pressure equivalent yellow light turn green make sure read big picture column day stay top market direction key indicator let know be aggressive move sideline house republican cave pressure drop idea limit pretax contribution have give hundred billion extra fund work first decade lower tax receipt budget window original house plan have generate more border adjustment tax import be quash outcry wal mart wmt other big retailer have give such big revenue booster grease skid tax cut public find irresistible trick gop be make individual tax cut sufficiently attractive preliminary tax policy center analysis find business tax cut include cut small business partnership income be taxed individual basis cost net house bill have cut cost more half provide room individual cut further gop gradually unwind individual tax cut adopt less generous inflation gauge adjust tax bracket size new standard deduction tax policy center find taxpayer income face tax hike related gop plan cut mortgage interest deduction slam housing tax reform bill leave generous contribution cap be gop tax plan lead higher property gop secret risky strategy corporate tax cutsstock buy watch top ipos big small cap growth stock
35,PFE,share dow component johnson johnson jnj topple early tuesday appeal court upheld ruling invalidate patent blockbuster arthritis drug remicade just week lose blockbuster patent decision limit ability seek damage fellow dow stock pfizer pfe launch remicade biosimilar inflectra late accord court appeal federal circuit antibody cover be disclose earlier patent bloomberg report stock dip much news come time fourth quarter earning report close bell stock market today tumble finish just last week nation top patent court invalidate patent cover blockbuster cancer drug zytiga quarter sale remicade fall worldwide steepest decline international sale vs year earlier period remicade be part immunology unit grow say remicade face increase discount rebate biosimilar competition evercore analyst umer raffat say pfizer inflectra compete directly remicade didn get much traction fourth quarter pfizer contend court complaint have block access overwhelming share consumer biosimilar readiness plan seem be protect volume engage proactive rebate basically limit uptake biosimilar raffat say note client late tuesday pfizer issue prepared statement be good day patient battle chronic disease court have rule key patent have assert block access inflectra be invalid however continue use scheme exclusionary contract maintain remicade monopoly position prevent patient payer provider opportunity benefit inflectra respond say be disappoint court ruling believe intellectual property protection such patent datum protection enable invest discovery development tomorrow life change life save new medicine re proud impact remicade have make improve health life more person worldwide be commit help ensure remicade remain accessible affordable patient meanwhile new tax rate corporation help issue street top profit guidance rbc analyst glenn novarro say bellwether health giant beat fourth quarter sale earning expectation full year revenue forecast lag analyst collective view drug acquire takeover actelion pharma miss novarro expectation call sale adjust income share revenue guidance lag consensus analyst poll zack investment research adjust earning forecast crushed view share ibd take biotechs be poise surprise upside fourth quarter other be still struggle competition take edge key product analyst say preview earning season see other scheme crop visit ibd industry theme novarro be less bullish have predict sale adjust profit share believe higher revenue guidance be combination better pharmaceutical performance currency lower tax rate be partially responsible higher earning share guidance say note client fourth quarter dow stock report adjust income share sale grow respective year year consensus be adjust profit share sale worldwide pharmaceutical sale narrowly beat analyst collective view novarro say organically sale growth be constant currency basis sale anticoagulant xarelto schizophrenia drug top expectation say cancer drug imbruvica darzalex be line plaque psoriasis crohn disease drug stelara miss drug buy acquisition actelion pharma broadly miss novarro forecast more important brand opsumit uptravi bring line sale medical device sale top novarro estimate revenue consumer segment meet novarro view related biotech merger spigot turn juno bioverativ biotech stock surprise upside earning biotech stock rocket rumor biogen buy
36,PFE,major average close heavy loss market slide come important test dow jone industrial average lead loss nearly point lose nearly point earlier index lose index fall day move average bounce line be positive sign index fall much day line market have even further drop nasdaq composite be day line composite have better performance dow hot january market rally volume be higher same time friday market breadth continue deteriorate decline stock lead advancer nearly nyse nasdaq exxon mobil xom chevron cvx pressured dow industrial again oil company sell friday earning report exxon mobil drilled nearly pierce day move average chevron lose be january high certainly aren alone spdr energy etf xle be prior high also fall day line industry group energy build health care banking sector be weakest today market johnson johnson jnj pfizer pfe dow component also have be selling report earning be more fall day line pfizer violate day average most ibd stock be lower also be hold day line be trading day move average grubhub grub fall day line monday raymond james cut rating market perform outperform earning be due thursday open average ibd stock be more week high average have be skewer lower big decliner such petm express pet daqo new energy dq note oppenheimer holding opy briefly clear buy point cup handle base volume be more double average relative strength line make new high share fall back entry point market plunge related dow suffer worst point drop ever percentage loss not historichere spot major stock market top easy wayit time review stock selling smartsexxon mobil miss forecast badly chevron profit weakdow topple judge toss patent blockbuster drug
37,PFE,eli lilly lly issue strong guidance early wednesday follow footstep abbvie abbv dow pfizer pfe improve tax rate earning expectation fourth quarter beat lilly call tax rate result lilly now see adjust income share grow vs sale be expect be lilly cite tax legislation improve tax rate outlook adjust earning sale guidance top view respectively lilly stock drop close stock market today collectively drug stock tumble day amazon amzn berkshire hathaway brka jpmorgan chase jpm pledge cut health care cost evercore analyst umer raffat note lilly animal health business disappoint sale food animal product decline widely miss expectation say report client miss stem lilly be face competitive pressure product used cattle milk supplement call posilac nonsteroidal growth stimulant call optaflexx ibd take lilly have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup look other strong drug performer milk have be oversupplied market depress price raffat say production have be strong many customer be forgo posilac optaflexx be likely suffering rule china export trade deal meat contain optaflexx say outside animal health be very few miss leerink analyst seamus fernandez say note client sale plaque psoriasis drug taltz diabetes med humulin erectile dysfunction drug ciali lag consensus still total sale grow year year beat consensus adjust earning share increase top analyst view related dow pfizer tumble drug sector beat raiseamazon health care disruption fear clash realitygilead stock break abbvie earning here valeant climb month make sense biotech stock top bigger rival prevent migraine
38,PFE,seller be stock market again tuesday dow nasdaq hold stiff loss less hour remain tuesday session dow take biggest hit fall hurt weakness pfizer pfe unitedhealth group unh pfizer earning disappoint fuel loss stock unitedhealth group give back news amazon com amzn berkshire hathway brka jpmorgan chase jpm be collaborate way offer health care employee more transparency lower cost provider pharmacy benefit management service fall hard news express script esrx crater be well session lows touch day move average cvs health cvs slump amazon buck trend rise ahead earning report thursday close leaderboard name have be standout performer buy point lose nasdaq composite ease volume nyse nasdaq be tracking higher monday level stock market today more so nyse nasdaq suffer distribution day monday loss higher volume distribution day be sign institutional selling workday wday be bright spot nasdaq rise nearly weekly chart show conventional entry daily show earlier cup handle entry meanwhile day fed meeting get underway today decision interest rate be due wednesday et market be not expect rate hike time chance march meeting be pretty good accord cme group fedwatch market see chance quarter point hike range march year treasury yield add basis point ahead friday job report economist expect nonfarm payroll rise unemployment rate hold steady ibd align technology algn company invisalign brace re-cover lows quick test day move average share align be still ahead earning report close ibd name grubhub grub gap fall nearly barclay downgrade share equal weight overweight price target stock be flat base clear last week earning be due feb open growth stock be weak again name ibd be more late trading related workday rise veeva upgrade margin hubspot downgrade health care stock tumble amazon berkshire jpmorgan allianceamazon score price target increase ahead fourth quarter reportalibaba likely show strongest revenue growth quarters
39,PFE,stock index fund be mixed pare early loss tech stock lead upside apple aapl intel intc advanced dow jone industrial average mcdonald mcd boee ba weigh heavily powershare qqq trust qqq be spdr spy be spdr dow jone industrial average dium fall stock market today small cap rally ishare core small cap ijr ishare russell iwm qqq be show relative strength find support day move average biotech oil explorer semiconductor be biggest sector fund gainer health care stock include pfizer pfe merck mrk johnson johnson jnj advanced dow jone industrial ishare nasdaq biotechnology ibb exchange trade fund reversed sharply higher gain also blue chip apple aapl reversed early loss slight gain be flat line continue hold day line be new record intraday high earlier week spdr gold share gld ishare gold trust iau be gold price rise ounce etfs be try hold support day line utility real estate industrial underperform technology wasn spare thursday stock market sell lead etf top like apple microsoft msft facebook fb be hold better most spdr technology xlk extend loss third straight session get close test day move average however didn breach line way many other etfs do friday do be find support line stage solid rebound line set new chance add buy share early december bounce day yielded gain jan high be featured etf column dec say buy be riskier market uptrend be pressure so crucial keep close eye xlk broader market be fare make purchase etf suffer steep drop late january high feb low so condition haven be exactly ideal fund track technology select sector index marked anniversary december software account biggest chunk asset feb just internet software service weigh tech hardware storage peripheral service semiconductor chip equipment be next xlk top holding be apple microsoft facebook class share alphabet googl represent stock portfolio apple have see bullish news week warren buffett say monday buy more share iphone maker other stock past year other report show apple take smartphone industry profit grab lead wearable device market apple stock be high be hold day line sign free ibd newsletter market prep tech fund year date gain feb lead return accord morningstar direct average annual return past year also outperformed period xlk carry expense ratio thursday pick spdr gold share gld ishare gold trust iau fall sharply day pare loss close respective day line also be interested apple intel dive dow trump tariff take stock marketstock sell dow apple boee reverse celgene divesdow apple intel hold steady stock sell bitcoin gain
40,PFE,key stock index fund extend loss friday follow cautious remark fed chairman jerome powell apple aapl intel intc be dow few gainer spdr spy fall spdr dow jone industrial average dium slide powershare qqq trust qqq drop stock market today foreign stock lag ishare msci emerge market eem ishare msci eafe efa respectively sector fund be lower board semiconductor telecom financial decline least vaneck vector semiconductor smh pull back ishare phlx semiconductor soxx slide etfs hit new high intraday ve re-cover loss steep pullback day move average early month intel lead upside dow industrial chip giant surge respective friday monday be trading highest level citi research tuesday affirm buy rating name intel top pick also dow apple hold fractional gain climb new record high earlier session share rise monday warren buffett say buy more iphone maker stock anything else past year apple be berkshire hathaway brkb second biggest hold gold real estate homebuilder be biggest sector loser spdr gold share gld ishare gold trust iau lose etfs tumble day line first time more month gold future fall ounce bitcoin climb accord coindesk earlier high bitcoin investment trust gbtc add track third straight advance still day line top rate stock such apple jpmorgan jpm microsoft msft be pack punch price performance dividend be top holding ishare core dividend growth dgro be potential buy zone advance day move average broader market endure sharp sell day line earlier month come back retake day line not best type pullback use new buy share rise early september bounce day line jan peak fund track morningstar dividend growth index mark fourth anniversary june name imply target stock have track record consistent dividend growth feb financial represent biggest chunk asset nearly information technology be next then health care industrial consumer staple top holding include microsoft jpmorgan apple pfizer pfe johnson johnson jnj account total asset broadly diversify portfolio contain stock microsoft gain year date monday close jpmorgan be apple advanced apple rise monday boost bullish comment billionaire investor warren buffett say buy more iphone maker share other stock past year stock close just shy record high apple offer annualize dividend yield microsoft pay jpmorgan yield overall dgro month dividend be average payout track top stock market trend free ibd buffett name dgro top holding include coca cola ko well fargo wfc johnson johnson jnj procter gamble pg etf year date gain friday be slightly ahead return accord morningstar direct average annual return past year also outpace benchmark index gain dgro expense ratio be diversify etfs mentioned monday column powershare qqq trust qqq be now extend bounce day line first trust dorsey dynamic focus fvc be nearly buy range rebound support line related dow lead buffett drive apple stock new record high cat lead dow apple pare gain chance buy buffett stocksdoe make sense invest coal day
41,PFE,major stock index be poise end week high note wall street find much intel intc earning report dow jone industrial average component gap open recently trade high chip bellwether be several large cap tech name have be force pivot new market growth easy task company intel market capitalization highlight intel report be sale datum center business rise make nearly third total sale quarter late afternoon trading nasdaq composite be add dow jone industrial average gain be set notch weekly gain past week volume nyse be tracking lower thursday level stock market today nasdaq volume be pace be touch higher pfizer pfe be strong gainer dow time high ahead tuesday earning report read more pfizer ibd income investor feature top gainer nasdaq include chip firm maxim integrate product mxim share jump more share pull back other chip stock thursday fall revisit buy point flat base serve part base base chart pattern leaderboard name jd com jd also do well nasdaq rise nearly clear cup handle base week buy point economic news first estimate gdp growth come little consensus estimate headline miss consumer spending business investment still rise nicely thor industry tho winnebago industry wgo lead rv maker fall sharply second straight session northcoast research downgrade neutral buy stock plunge week move average line week heavy volume unequivocal sell signal buy stock break basis september dell technology dvmt also lag badly plunge report company be consider public share offer perhaps possible transaction cloud compute visualization software maker vmware vmw dell be majority owner vmware vmware be session high still soar ibd small cap mimedx mdxg extend gain big way thursday cup handle buy point share jump more hit intraday high related cryptocurrency theft fear japan exchange halt altcoin tradesjd com vault record high plan expansion fundraisingbest stock buy invest stock market used simple routine
42,PFE,valeant pharmaceutical vrx have climb hit low share tumble wednesday analyst suggest rise past month make sense believe movement be confluence factor have little do underlie factor have much more do perception surround liquidity bankruptcy risk piper jaffray analyst christopher raymond say note client short underlie dynamic mean valeant be still trouble say close bell stock market today valeant topple finish share have be run breaking cup handle base buy point late november month alone valeant be tuesday close short interest now stand compare high say be related fact valeant also have long term debt maturity have maturity respectively liquidity risk be likely table now say however do not mean dynamic surround business have change prescription volume valeant dermatology brand eye care legacy segment show decline respectively vs raymond say unit be face payer pressure loss exclusivity key drug further appear antibacterial xifaxan be mature say xifaxan be approve treat traveler diarrhea irritable bowel syndrome diarrhea hepatic encephalopathy condition occur patient liver dysfunction ibd take valeant have ibd composite rating best possible meaning outperform more stock term key growth metric still lag leader abbvie cr head ibd stock checkup look other top rate drug stock xifaxan account sale third quarter be likely earning interest taxe depreciation amortization raymond say mean gross margin be likely range pressure be xifaxan be most important revenue driver valeant raymond say require only small specialty salesforce reach community hospital setting such be topline driver continue demonstrate steady track record order anxiety regard liquidity bankruptcy risk not reemerge say xifaxan be also soon face competition cosmo pharmaceutical aemcolo cosmo be aim file approval aemcolo traveler diarrhea term enter market end year new launch valeant be enter glaucoma space vyzulta rival aerie pharmaceutical aeri rhopressa other player include dow stock pfizer pfe allergan agn novartis nvs competition be likely result wide spread gross net sale vyzulta valeant be also launch siliq treat plaque psoriasis physician feedback suggest go treatment drug class be novartis cosentyx eli lilly lly taltz do not believe be opportunity be significant enough drive sustainable ebitda growth say quite contrary continue believe loss exclusivity payer pressure continue be headwind raymond reiterate underperform rating price target valeant related novartis top high crush fourth quarter earningsabbott spike record top quarterly expectationswhy biotech stock outperform peer
43,PFE,teva pharmaceutical teva mylan myl be group generic drug maker hit thursday consortium hospital say make medicine circumvent rise drug price estimate hospital group be involved effort create nonprofit company provide generic medicine hospital accord new york time goal be avoid rise drug price medicine shortage stock market today generic stock collectively dip fall earlier trade share teva fall close mylan lose other tumble include lannett lci close aclaris therapeutic acrs dip ani pharmaceutical anip dove nearly hospital have struggle shortage drug morphine sodium bicarbonate saline last april department justice serve subpoena number firm include pfizer pfe baxter bax relate saline shortage drugmaker have be political hook rise price particularly older patent drug martin shkreli former head turing pharmaceutical draw ire buy drug used aids patient spiking price tablet ibd take ani pharma lead company generic drug industry group ibd composite rating best possible mean outperform most stock term key growth metric head ibd stock checkup look other strongly rate drug stock valeant pharmaceutical vrx become wall street superstar crash burn early buy older drug then raise price valeant stock be nearly hit bottom april share dip thursday number generic drug maker become subject antitrust investigation price antibiotic diabetes medicine related beware price war big pharma biotech company horizongeneric drug maker face pricing issue other pharmas don twill trump break republican push major drug price reform
44,PFE,year be shape be boisterous biotech acquisition celgene celg sanofi sny matter day announce plan spend north take company analyst say celgene sanofi particular be face challenge area insurance company be push back payment rheumatology diabetes also leave like novartis nvo eli lilly lly trouble say brad loncar manage immunotherapy base fund company have buy growth loncar tell investor business daily ve be grow revenue do artificial thing drug price increase tax inversion kind other type financial engineering thing be go away be spend biotech deal mizuho analyst salim sy tell ibd year so far celgene have say spend buy remainder juno therapeutic juno doesn already own sanofi be spending acquire bioverativ bivv ablynx ablx company haven buy anything just matter opportunity sy say buy spree kick august gilead science gild announce plan acquire cancer play kite pharma gilead have be suffering major slowdown hepatitis drug sale high cure rate saturation europe celgene sanofi announce plan acquire juno bioverativ same day january day later sanofi say buy rare disease drugmaker ablynx celgene acquisition follow disappointing third quarter sale psoriatic arthritis plaque psoriasis drug otezla widely miss expectation biotech also cut guidance otezla shortfall terminate several trial crohn disease loncar describe celgene long term growth prospect time bleak picture also face patent cliff mid cancer drug revlimid ibd take challenge hold stock market correction decline help share form new potential base be still possible capture big gain head investor corner tip make gain correction so really couldn afford say sanofi other hand be skunked twice try acquire medivation actelion pharma dow component pfizer pfe beat sanofi medivation dow johnson johnson jnj be able acquire actelion sanofi roy behren fund manager capital management say sanofi commit acquisition make hostile bid medivation go back initially higher bid actelion filing show hostile approach be generally unsuccessful space fact scientist be such important part value equation tell ibd case sanofi medivation couldn arrive price be friendly be very difficult complete acquisition high profile acquisition late early acquirer have suffer pressure sale key moneymaker tax reform allow company pay less corporate taxe repatriate cash lower rate prime pump acquisition strong believer be go be huge year acquisition loncar say larger company growth be slow tax reform deal add fuel fire make easier do deal nordisk lose ablynx sanofi now loncar expect nordisk go other asset contend deep exposure diabetes market lilly too be see challenge diabetes meanwhile amgen amgn older drug be face new competition big company really need do say be outlier mizuho analyst sy say biogen biib instance guide flat sale multiple sclerosis unit include impact royalty get revenue roche rhhby new drug ocrevus perception franchise be dwindle say argument investor make lot guy biogen amgen base business be go away not necessarily case biogen be stable still flat sale win be enough pique investor interest biogen aducanumab potential treatment alzheimer disease be carrot investor clinical trial datum be available end early long carrot be become really difficult hedge fund community short stock say aducanumab produce return work large cap biotechs typically don see behren note biotechs seem be fairly interested immunotherapy oncology include gilead acquisition kite celgene plan acquire juno be work drug know car therapy immune system identify fight cancer have be lot activity oncology space term immunotherapy say larger company be try gobble promising technology still affordable be also see quite few testing company be acquire celgene acquisition juno follow common storyline behren say celgene invest juno create immunotherapy cancer autoimmune disease duo be furthest jcar potential treatment hodgkin lymphoma celgene pull trigger juno jan make sense be premium juno close price prior trading day biotechs even more high tech tend come significant premium trading price say re somewhat risky be huge payoff event re successful nektar therapeutic nktr bristol myer squibb bmy be similar plot september duo pair test nektar drug call nktr bristol opdivo patient melanoma kidney cancer lung cancer november nektar present strong early datum combo loncar peg nektar potential takeover target call nktr revolutionary day later bristol announce pay nektar upfront comprise cash purchase share test nktr opdivo opdivo yervoy deal allow bristol remain leader immuno oncology immuno oncology combination risk bid nektar evercore analyst umer raffat say feb note client have doubt nektar phone have be ring hook november datum be so interesting loncar say someone be bold enough buy put acquirer class own immuno oncology drug call parp inhibitor also look interesting loncar say clovis oncology clvs tesaro tsro have drug approve class be small enough acquire astrazeneca azn also work space sarepta therapeutic srpt neurocrine bioscience nbix biomarin pharmaceutical bmrn have also have successful launch recently company want revenue growth buy rare disease drug say have best sale ramp think type company be really interesting right now wouldn be surprised get buy related biotech investor flee drove market correction rock groupthese biotechs spring back market correction analystwhy biotech stock outperform peer
45,PFE,drugmaker pfizer pfe be approach potential buy point tuesday most recent quarter dow stock year year earning growth come first double digit gain revenue rise vs year period snap quarter streak decline sale company continue see weakness
46,PFE,mile white be name ceo abbott laboratory be youngest head major health care company today longest serve chief health care have make reputation master strategist know make bold move abbott none be more dramatic spun research base pharmaceutical half firm abbvie abbv abbott have market capitalization half industry leader pfizer pfe merck mrk seem crazy many white perceive develop new drug have completely different business rhythm new abbott now focus device diagnostic nutritional product brand generic drug result abbott stock have rise share share give market cap abbvie share increase share share give value approach creation combine be now worth far more pfizer merck white have be rank barron world best ceo straight year keep company current relevant white tell ibd continually shape business ensure re need opportunity be future instance recent acquisition st jude medical make leader range grow medical device category new technology make huge difference patient investor white grow la vegas earn bachelor science mechanical engineering stanford mba year later joined mckinsey co chicago consultant feel work be fascinating project client come go white say want something feel connect longer term be more fulfill white be hire abbott base north chicago suburb abbott park ill director sale diagnostic year later be offer chance head division grow asia pacific region prestigious position year old turn meant move japan wife want open child bookstore white say be big believer work life balance be confident other opportunity advancement come way indeed year later be choose be new ceo follow year add title chairman board wife run bookstore year selling abbott have rarely do acquisition divestiture founding whirlwind change follow white take helm include be dramatic traumatic abbott acquire kos pharmaceutical maker cardiovascular drug cash deal sell core laboratory point care diagnostic division general electric ge fall white decide revive challenged division instead investing research development streamline operation reorganize product service new diagnostic division august begin launch family next generation instrument informatic service common software hardware platform design be easy use more efficient white call game changer industry other acquisition abbott paid pharmaceutical unit belgium base solvay expand presence emerge market same year plan be announce purchase unit piramal healthcare make abbott biggest pharmaceutical company india success company acquisition largely depend ability anticipate consumer medical need understand practice medicine be head aggressively position company benefit internal external investment not just acquire company white say do do more business make better improve exist operation ve develop very discipline integration process learn best bring new asset abbott help expand reach potential faster better have more be just preliminary spin half company abbott take third quarter charge abbvie be officially list new york stock exchange jan make white such savvy deal maker ask jim cramer mad money show cnbc november have real talent anticipate consumer future medical need then aggressively position company benefit year become ceo abbott release humira go treat form arthritis plaque psoriasis crohn disease other ailment now part abbvie make sale make best selling drug world white have foresight spin part company ahead explosion debate drug price guide global enterprise massive change result mistake abbott biggest occur midst drama lead split october abbott be fine marketing depakote brand valproic acid world most widely prescribe epileptic drug condition not approve food drug administration part settlement cost total company agree strengthen internal control separate abbvie january new abbott emerge focus not only diagnostic product service medical device nutritional line brand generic medicine latter be establish pharmaceutical division sell develop market brand name be trust more unknown due high quality efficacy standard doesn have high cost base pharma division now offer more product development acquire cfr pharmaceutical more double latin american brand generic pharmaceutical presence abbott be also world leader adult nutritional product include ensure zoneperfect well leader baby nutrition similac other line special dietary need glucerna juven company be also leader diabetes care introduce revolutionary continuous glucose monitoring device freestylelibre september company purchase st jude medical cash stock establish abbott leader medical device arena also close alere make leader point care diagnostic market ve reinvent company multiple time past year white say continuous process shape company future work very deliberately ensure remain relevant current person serve change take place environment re several different business today be decade be choose specifically relevance science be go demographic socioeconomic factor be go customer be go re still grow strong stock be time high today abbott employ worker country revenue be net income be ceo chairman abbott laboratory global leader medical device diagnostic nutritional product brand generic medicine overcome fail sale challenged diagnostic business turn investing innovation become highly profitable consistent grower company lesson envision long term big goal work detailed step get even mean defy industry consensus need continually ask be better way answer be always yes even exactly not yet be apparent more leader success pam nicholson drife global growth enterprise holdingstaco bell founder change america fast food menumeet man hire take amazonphil knight clear hurdle make nike merchandising champion
47,PFE,pressure president trump dividend leader list member pfizer pfe announce defer drug price increase await president blueprint drug pricing dividend rich stock be move right side potential base be just away set record high stock market today xnew york base pfizer develop brand prescription drug latest report quarter earning growth measure double digit third straight quarter vs year period revenue perked full year analyst expect earning growth share late fda approve pfizer xeljanz first oral medicine treatment chronic ulcerative colitis drug be expect earn sale get newsletter deliver inbox more info product service privacy policy term useaccord credit suisse pfizer recent restructure signal begin new era growth start company organize business analyst have neutral rating stock price target dividend stock leader yield disburse next quarterly cash payout cent share dividend be greater year period pfizer stock be near record high move striking distance buy point buy point be result month consolidation process accord ibd stock checkup stock accumulation distribution rating be solid accumulation distribution rating measure institutional demand last quarter downside relative price strength rating be dismal be expect stock have be base late january meanwhile stock relative strength line paint blue marketsmith chart be steadily rebound remain old high related pfizer opt defer price hike trump scrutiny so next dow jone industrial average dow stock news analysisbiotech stock watch pharma industry newsdelta earning consumer price index oil report investing action plan
48,PFE,share dow jone component pfizer pfe climb wednesday food drug administration approve blockbuster xeljanz chronic ulcerative colitis treatment stock market today pfizer lift close share other pharmaceutical company advanced pfizer stock be consolidate buy point meanwhile dow jone industrial average rise xeljanz gain approval treat patient moderate severe form ulcerative colitis chronic inflammatory bowel disease affect colon physician already use drug treat rheumatoid arthritis psoriatic arthritis other ulcerative colitis treatment be administer intravenous infusion injection fda say news release expand approval xeljanz open new possibility patient say julie beitz fda spokesperson get newsletter deliver inbox more info product service privacy policy term usexeljanz be first oral medicine grab approval treat chronic ulcerative colitis new treatment be need patient moderately severely active ulcerative colitis beitz say prepared statement today approval provide alternative therapy debilitating disease limit treatment option xeljanz bring sale rise year year xeljanz be pfizer second biggest inflammation immunology drug enbrel enbrel treat several form arthritis psoriasis account sale last year analyst poll thomson reuter expect generate accord reuter related do spot major market top easy look heavy best stock buy watch start basic analyze stock cup handle
49,PFE,count pfizer best dividend stock stock market not only stout dividend yield also strong performance new drug best dividend stock often show consistent track record dividend payout pfizer pfe certainly pass muster here earlier month company declare quarterly dividend cent share dividend be payable june shareholder record pfizer consecutive quarterly dividend long know blockbuster drug lipitor viagra xanax pfizer fourth quarter earning report show strong performance other drug company innovate health unit strength be drive ibrance eliquis xeljanz drug show sale increase respectively ibrance be breast cancer treatment eliquis be used prevent stroke blood clot person irregular heartbeat xeljanz be rheumatoid arthritis treatment innovative health deliver total sale make total sale get newsletter deliver inbox more info product service privacy policy term usepfizer have see plenty interest consumer health business include brand advil chapstick procter gamble pg be talk pfizer buy unit couldn agree price pfizer make headline earlier month inked accord privately hold allogene therapeutic partnership help pfizer compete gilead science gild novartis nvs advanced cancer treatment used car therapy car therapy be patient own immune cell be used treat cancer pfizer allogen aim create allogenic version car therapy used healthy donor cell earning pfizer be due open related biotech pharma industry stock newsbest income stock buy watch
50,PFE,plunge share teva pharmaceutical teva weigh generic drug stock thursday sale profit continue drop offer weak guidance top word potential delay key migraine drug fourth quarter teva bring adjust profit cent share sale decline respectively sale multiple sclerosis drug copaxone decline grow generic competition year teva see adjust profit share sale lag consensus respectively teva outlook reflect likelihood increase challenge management note roughly half decline reflect impact loss exclusivity copaxone milligram piper jaffray analyst david amsellem say note client significant chunk decline also not surprisingly reflect continue pressure generic business close bell stock market today teva plunge close earlier fall much generic drug stock collectively dip analyst say rival mylan myl new copaxone generic be price discount teva brand drug dr reddy laboratory rdy be delay momenta pharmaceutical mnta novartis nvs unit sandoz have milligram generic market year pfizer pfe manufacturing facility pass re inspection generic drug sale fall year year teva record goodwill impairment related generic business pricing pressure government regulation accelerate generic approval delay launch continue be challenge sale be teva profit revenue top consensus analyst poll zack investment research adjust profit cent share sale copaxone sale also beat consensus view mizuho analyst irina koffler say note client still expect generic entrant mid ibd take teva relative strength rating have be rise month now have rs rating best possible see go rating visit ibd datum story further teva say manufacturer active pharmaceutical ingredient used migraine drug fremanezumab receive warning letter food drug administration regard fill finish part facility mean fremanezumab be delay fremanezumab be currently set go fda june drug belong class know cgrps aim prevent migraine aldr amgen amgn eli lilly lly be work drug class be source anxiety surround business simply afford have additional misstep particularly context highly competitive cgrp migraine space amsellem say related sanofi regeneron dip eczema drug dupixent lag crispr small biotechs cure disease biotechs spring back market correction analyst
51,PFE,index other major average have first week be worst show year apple aapl guide lower many suspect amazon amzn boee ba deliver strong result facebook fb tout strong ad rate alibaba baba miss earning paypal pypl crash former parent ebay ebay moved cut ty move amazon jpmorgan chase jpm berkshire hathaway brkb team tackle health care cost hit insurer pharmacy benefit manager bitcoin meltdown continuedx hot start major average suffer worst weekly loss year dow nasdaq rise bond yield worldwide pressured stock unitedhealth unh cvs health cvs many other insurer fall amazon jpmorgan berkshire health care joint venture amazon boee facebook be earning winner alibaba be notable loser apple aapl do bitcoin plummet loss accelerate facebook joined chorus regulator worldwide crack cryptocurrency apple aapl earning share rise year year sale fiscal first quarter narrowly beat expectation apple sell iphone vs consensus unit average selling price due new iphone iphone model fuel overall result march quarter apple expect sale base midpoint guidance official estimate share fall friday new month low commerce leader report adjust earning share smash consensus big benefit tax cut help revenue rise also beating revenue amazon web service rise sale echo line smart speaker far exceed expectation amazon amzn say share gain hit new high intraday facebook fb report robust earning revenue growth top forecast user growth cool user time spend facebook fall even latest big news feed change executive say conference call ad rate be soar ease analyst revenue fear share hit record high thursday alphabet googl share fall google parent report adjust earning be share year earlier miss view traffic acquisition cost google pay partner website carry ad soar google expect rise tac moderate google rise tac have be link contract renewal apple well internet search shift mobile phone revenue rise top consensus adjust ep exclude impact tax reform result additional expense amazon jeff bezos jpmorgan jamie dimon berkshire warren buffett say new nonprofit company be aim reduce cost employee be successful own firm think be expand service corporate america health insurer pharmacy benefit manager sell unitedhealth largest health insurer also pbm sank drugstore pbm cvs health cvs be buy insurer aetna aet lose pure play pbm express script esrx retreat paypal pypl report strong earning line guidance former parent ebay ebay report line earning stronger expect gross merchandise volume real news be ebay stunned wall street news replace paypal handle payment own site partnership adyen move add revenue stream share ebay soar nearly thursday paypal lose week close buy point day line chinese commerce giant revenue soar best gain least quarters beating view earning share climb slightly miss forecast alibaba buy stake ant financial former unit run payment service alipay replace deal alibaba get ant financial pretax profit alibaba provide intellectual property not cash move clear hurdle possible ant financial ipo alibaba share week tumble recent buy point add job january better expect average hourly wage surge vs year earlier far view best ism manufacturing index continue point raid employment gain fast growth wage gain be good news spur federal reserve raise rate more aggressively year software leader report adjust earning share cent year year sale fiscal second quarter analyst expect cent microsoft get lift cloud compute business include azure office dynamic current quarter microsoft guide earning share cent sale view share hit record high intraday thursday amd amd broadcom avgo qorvo qrvo offer investor positive financial news amd beat wall street target december quarter guide estimate higher current quarter broadcom give preliminary sale earning guidance fiscal first quarter top view qorvo rocket disclose big contract major customer apple aapl next generation iphone qorvo deliver better expect result fiscal guide well wall street target current quarter boee ba report ep share exclude share benefit tax cut way boee beat analyst view revenue climb also top view boee also guide ep revenue forecast higher tax cut spur more investment make case new midmarket jet more compelling boee also get missile defense contract pentagon up up order new jet give venerable jumbo jet new lifeline meanwhile lockheed martin lmt ep jump revenue rise defense giant guide ep view higher boee share rise week lockheed hit new high video game publisher electronic art ea see stock surge record high report big gain online service associate sport game franchise fifa madden nfl boost live service be reveal part ea line december quarter earning report video game hardware software firm nintendo ntdoy post better expect december quarter result thank continue success switch console related software take interactive software announce major delay highly anticipate wild west action game red dead redemption now set release oct instead spring visa mastercard top analyst forecast person break plastic more often spend holiday visa also buyback follow american express axp just suspend buyback visa also hike quarterly cash dividend cent share homebuilder stock continue struggle even big builder report better expect earning prior week surprise miss nvr nvr housing demand price be strong concern be grow rise labor material cost mortgage rate low be rise america largest homebuilder horton dhi beat ep revenue wednesday share meet resistance day line pultegroup phm stock keep fall slide gross margin even earning sale top view smaller meritage home mth also beat smaller home mho holding mdc miss ep slew biotechs drugmaker report earning include pfizer pfe eli lilly lly vertex pharmaceutical vrtx astrazeneca azn merck mrk top wall street fourth quarter earning expectation pfizer come sale adjust profit cent share lilly total sale grow firm bring adjust income share vertex report sale adjust profit cent share astrazeneca report core earning share sale merck result be mixed top line miss view adjust income cent share beat cent amgen amgn report sale adjust earning share lag consensus merger news sanofi sny announce acquire ablynx ablx exxon mobil xom fall well short consensus fellow dow industrial component chevron cvx also miss ep view share plunge day line chevron undercut recent buy point separately crude production continue hit fresh longtime high crude supply rise first time week crude future remain year high ferrari race gap buy zone report strong earning thursday meanwhile auto sale slump january big decline ford fiat chrysler fcau gm gm sale edge higher miss view toyota tm sale sky-rocket strong truck sale
52,PFE,agreement dow jone component pfizer pfe defer drug price increase effort play nice president donald trump lead analyst wednesday question fallout drug giant action be industry analyst wonder other pharmaceutical company follow pfizer example notably celgene celg be still go ahead increase blockbuster cancer drug revlimid pomalyst rbc capital market analyst brian abraham say report pfizer unprecedented reversal early july price increase mark tangible administrative influence morgan stanley analyst david risinger say report client note pfizer be await more detail so call blueprint tug drug price late tuesday pfizer say chief executive ian read have extensive discussion trump lead company back price increase drug have be effective july earlier week trump attack pfizer other raise drug price reason get newsletter deliver inbox more info product service privacy policy term use pfizer share president concern patient commitment provide affordable access medicine need read say written statement also note pfizer have commit capital expand manufacturing not everyone jived pfizer trump announcement sen ron wyden ore call pfizer trump administration reveal detail arrangement lead pfizer back drug price increase secret sweetheart arrangement big pharma company be exactly america drug pricing system be break tweet trump admin be busy try score cheap pr point pharma company continue raise price double digit pfizer stock dip close broadly share pharmaceutical company fall same amount stock market today trump renew pledge lower cost prescription medicine time analyst largely say propose blueprint appear be more rhetoric reform morgan stanley risinger believe pfizer price increase reversal have slightly negative implication second quarter earning season note pfizer update guidance commentary be key later month addition news put term damper future price increase action other pharma bio company say pfizer indicated action be temporary only commit keep price unchanged end other pharmaceutical company also rethink guidance say manufacturer limit price increase year hold entirely customary january increase be key swing factor earning think be underestimated market say even celgene price increase revlimid pomalyst remain line medical inflation rbc abraham say be also historical increase meanwhile gilead science gild joined pfizer walk back plan price increase note see more re-serve price increase increase transparency potentially temper headline risk public scrutiny have be experience pfizer line view company self polouse price increase much larger degree now say also wednesday pfizer announce split business distinct unit contend loom loss exclusivity restructure pfizer innovative medicine division include biosimilar infection drug sterile injectable establish medicine unit include patent brand generic drug finally company consumer healthcare branch hold counter medicine innovative medicine run current innovative health business well new hospital medicine business unit pfizer also incorporate biosimilar portfolio oncology inflammation immunology unit establish medicine hold majority pfizer patent drug include lyrica cholesterol drug lipitor high blood pressure drug norvasc erectile dysfunction drug viagra business run globally unit be meant operate true stand alone business pfizer company say news release have own manufacturing marketing regulatory exception enable function consumer healthcare other hand differ pfizer prescription medicine business pfizer say firm confirm still mull strategic alternative unit expect make decision end year trend consumerism increase focus stay healthy be cause consumer seek easily accessible health wellness solution firm say company believe business be well position continue growth get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing trade stock most penny stock fail make investor richnew option strategy limit risk earning
53,PFE,solid bioscience sldb plunge wednesday high volume rival sarepta therapeutic srpt report strong datum duchenne muscular dystrophy treatment stock market today solid bioscience crash close sarepta unveil strong result gene therapy muscular dystrophy tuesday see stock pop biotech stock collectively rise less biotech company be work treatment duchenne muscular dystrophy muscle wasting disease genetic component condition be tie mutation gene make protein related muscle fiber function solid bioscience plummet wednesday analyst say smaller biotech actually have better duchenne muscular dystrophy treatment instinet analyst christopher marai attribute way solid bioscience construct drug sgt get newsletter deliver inbox more info product service privacy policy term use recommend accumulate solid bioscience duchenne muscular dystrophy gene therapy field become increasingly risk see potential upside sgt become best class differentiate formula say note marai keep buy rating price target solid bioscience earlier week food drug administration lift clinical hold keep biotech company enrolling patient study likely solid bioscience report datum study earlier guidance second half marai say solid bioscience be compete sarepta dow jone component pfizer pfe market support say view duchenne muscular dystrophy market be large enough support multiple gene therapy solution say chardan analyst gbola amusa similarly see sarepta report tuesday have positive impact solid bioscience solid stock sky-rocket tuesday sarepta share ramp close record high see positive read solid base similarity approach be superior element solid microdystrophin construct amusa say report client further possible sgt demonstrate even more effectiveness be see tuesday sarepta amusa say keep buy rating price target solid share related much money do need start investing long term retirement investing strategy etfssell take profit hold here be several guideline follow
54,PFE,gene therapy company sarepta therapeutic srpt bluebird bio blue be race bring gene therapy solution grow list rare disease same gene therapy company face daunting list hurdle include price have range high patient last month sarepta present strong result gene therapy
55,PFE,kris bakowski be diagnosed alzheimer disease georgia resident feel relieve finally put name fog be slowly envelop brain even be viable alzheimer treatment month forget own phone number have trouble colleague name mapping route home work become chore day find alone mall recollection be get biopharma company believe be able help soon analyst say biogen biib be first crack code disease modify alzheimer treatment slow disease progression indeed biogen tokyo base eisai announce late thursday phase test alzheimer drug slow progression disease month news send biogen stock soar more point friday novartis nvs roche rhhby amgen amgn other also be develop potential alzheimer drug number development stage biotech company victory be not certain number big pharma company include merck mrk eli lilly lly johnson johnson jnj have be road abandon plan alzheimer treatment least expert see success next decade wouldn come too soon bakowski other alzheimer patient get newsletter deliver inbox more info product service privacy policy term usebakowski now have be blog alzheimer experience year blog post alzheimer association describe month testing lead diagnosis subsequent relief hopeful cure son lifetime family isn so optimistic husband liken titanic ship be sink son be go survive wasn write son reflect be mother be death row innocent crime potential alzheimer market be massive estimate american be live alzheimer other form dementia way intervene alzheimer association expect cost care person disease hit today dollar be estimate bakowski many expert be hopeful privately hold proclara bioscience be cadre biotech company aim develop alzheimer treatment chief medical officer david michelson call field pretty vibrant michelson have hold position merck lilly say steady drumbeat bad news alzheimer treatment reflect not so much failure affect specific target brain issue such side effect specific test recently speak webinar host endpoint news lot really tremendous work ongoing enable new approach be become possible generate promising new target say be actually very hopeful optimistic next year hold research alzheimer several drug have be approve treat dementia alzheimer type include eisai namenda allergan agn treat symptom alzheimer disease neither cure disease elliot goldstein chief executive promis neurosciences count type treatment hand none slow progression disease tell investor business daily promis be also work alzheimer treatment trade toronto stock exchange doesn have sale earning yet goldstein previously work novartis be also develop alzheimer drug biogen strongest hope be drug now dub aducanumab goldstein predict drug come market aducanumab have high potential approval have show small improvement decline patient alzheimer symptom say biogen do not respond request comment article visit ibd stock checkup see biogen rate now key fundamental technical metric total biogen have potential alzheimer treatment pipeline aducanumab be farthest late stage study likely have datum analyst say biogen eisai thursday announcement involved drug know ban test involved patient diagnosed early alzheimer company say drug antibody achieve statistical significance key predefined endpoint evaluate effectiveness month biogen stock jump close have surge intraday high gain point still messy field biogen stock plunge valentine day year add new patient ongoing study aducanumab move catch investor guard also week merck scrap late stage alzheimer treatment study risk look likely outweigh benefit be volatile area canaccord analyst sumant kulkarni tell investor business daily have be very spectacular failure past component investor think next work help stock point view then again say nothing else have work past trouble alzheimer treatment research be scientist aren exactly sure cause disease prevailing theory ty disease buildup toxic plaque brain happen protein call beta amyloid structurally change beta amyloid be sticky clump together become plaque pharmaceutical company be look approach beta amyloid essentially boil remove prevent bace inhibitor work prevent buildup monoclonal antibody biogen aducanumab aim remove promis goldstein note adverse event also be sidestep alzheimer treatment come side effect know amyloid related imaging abnormality aria refer swell brain goldstein say promis alzheimer treatment set begin clinical study doesn cause mizuho analyst salim sy say possible help patient get past aria common idiom industry be don get aria be really treat plaque tell ibd then trouble determine study be design well proclara michelson say first evidence show drug engage intend target beta amyloid second patient be proven actually have alzheimer third study be big appropriate duration turn look back history aren many study many drug have be study way really fulfill element say argue only study have hit design goal be merck now fail bace inhibitor know verubecestat biogen aducanumab february merck scrap study alzheimer treatment patient prodromal very early stage alzheimer disease year earlier say same drug have virtually chance find positive effect patient mild moderate form disease meanwhile field be thin stop midstage test bace inhibitor group patient liver safety concern january pfizer pfe stop research alzheimer parkinson disease lilly alzheimer treatment failure late be acutely painful company monoclonal antibody call solanezumab lose late stage study last study be patient mild form alzheimer promis alzheimer treatment bound several toxic misfold protein cause alzheimer goldstein say function theory be other target alzheimer disease outside beta amyloid drug be also testing theory tangle protein call tau be root cause privately hold unite neurosciences hope come vaccine alzheimer goal be use drug treatment early alzheimer preventive measure physician administer drug too late rescue brain unite neurosciences chief medical officer ajay verma tell investor business daily verma background be biogen direct development drug include aducanumab be merck novartis verma expect aducanumab get approval several sell side analyst model likelihood aducanumab appease food drug administration verma see possibility aducanumab be expensive be first treatment slow progression alzheimer disease think challenge be be solution just rich say verma ultimately expect solution treat alzheimer disease lie combination drug be key treat cancer hiv cardiovascular disease metabolic disease high cholesterol say intervention number alzheimer patient triple james hendrix say endpoint news webinar hendrix be director global science initiative alzheimer association need better therapy need sooner rather later hendrix say alzheimer treatment study be tricky unite neurosciences verma say barrier blood brain make get drug brain difficult animal model aren particularly predictive study run long period time further complicate matter science isn sure stage be best treat reason be center approval rate fda alzheimer treatment accord paper present hendrix industry average be research be improve hendrix say scientist be aware potential impact beta amyloid tau well number approach target different stage end be enough alzheimer treatment just delay begin disease several year say be possible delay onset die something else say also stock market forecast next month build long term profit stock take gain robotic surgery revolution be just get term retirement investing strategy etfsnew option strategy limit risk earning
56,PFE,stock fought positive finish wednesday health care construction stock book day widest loss video game stock notch bevy breakout dow jone industrial average lead end boost boee ba monster advance heel glow result nasdaq composite rise struggle fractional gain market drop sharply fed et announcement committee hold target interest rate unchanged offer slightly more wary tone inflation day other economic news be positive early datum adp show january hire slip less expect december pending home sale chicago region manufacturing january gauge easily top expectation dow be hold back medical component merck mrk johnson johnson jnj pfizer pfe drop more drugmaker eli lilly lly tumble follow generally positive fourth quarter report drug sector investor be apparently still react tuesday news innovative health care partnership amazon com amzn berkshire hathaway brka jpmorgan jpm amazon advanced putt past buy point profit take zone other fang stock tech leader lose ground netflix nflx fall furthest nearly still extend early january tesla tsla rise average trade third gain session share be now more november low back support week move average climb right side possible month base pattern video game trade be day winner ninetendo ntdoy take interactive electronic art ea clear buy point add entry ninetendo trim gain afternoon trade remain just buy range cup base buy point electronic art pare advance hold buy range top buy point also cup base take chalk surge end very top buy range cup base buy point concrete aggregate supplier take session worst performance industry concrete uscr tumble more eagle material exp martin marietta mlm vulcan material vmc fall apiece eagle material post mixed fourth quarter report open reaction also have be link public private infrastructure cost sharing question raise president trump state union address ibd name telecom software developer casa system casa gain more soft trade stock be attempt start right side first base end jan high december ipo price argentina base bank grupo servielle supv also ibd name jump almost nearly average trade move technically place stock buy range rebound support week move average volume need kick next day so order confirm buy opportunity bottom ibd list mimedx group mdxg daqo new energy dq shed other important market news wednesday bring game apple amazon alphabet report action planbiggest homebuilder hit resistance earning sell don freeze double digit gain stock shrink fastlooking stock nvidia start list
57,PFE,major market average carry more loss early trade tuesday amazon com amzn remain steady stock market today major index tech heavy nasdaq composite dow jone industrial average decline dow jone industrial mcdonald mcd pfizer pfe trade lower report earning early tuesday mcdonald top earning estimate strong same store sale growth share fall remain day line meanwhile pfizer drop beating top bottom line estimate share be back buy range cup handle buy point share surge multus year high friday elsewhere dow apple aapl recent free fall continue tuesday decline share have fall last day hit new high jan stock be near loss cut level flat base entry ahead thursday earning release fang stock amazon com announce new partnership berkshire hathaway brkb jpmorgan jpm center provide health care employee amazon fall remain well extend buy point company report earning polaris industry pii crumble pierce day line heavy volume stock have be battle stay flat base entry jan have trouble clear resistance area meanwhile homebuilder pultegroup phm barely beat street earning sale target stock fall further day line drop chip leader apply material amat nvidia nvda fall apply be search support day line etch handle cup formation graphic chip maker nvidia remain extend cup shape base buy point chinese leader be move lower overnight weakness shanghai composite hang seng index commerce giant alibaba baba jd com jd fall nearly apiece be fall back buy range recent buy point alibaba be cup shape base entry leaderboard name jd be cup handle entry ibd only handful name be trading positive territory market sell day loser be grubhub grub food delivery service drop just day breaking flat base entry share look support day line related apple stock chart be tell go earning iphone ea report more medical earning investing action sell don freeze double digit gain stock shrink fastlooking stock nvidia start list
58,PFE,sell health stock tuesday joint venture amazon com amzn jpmorgan chase jpm berkshire hathaway brkb wring cost saving health care system appear very unlikely impact industry earning next couple year accord analyst figure rein health cost participation big health care player look impossible task needham analyst kevin caliendo say note cost implement system adjudicate patient datum partner hospital doctor pharmacy national basis be onerous caliendo add scale big new partner wouldn be big enough squeeze discount provider steering patient way compare purchasing power unitedhealth unh cvs health cvs aetna aet anthem antm new company have align other provider way provide best care employee caliendo conclude fact caliendo give cvs big vote confidence earlier tuesday say plan combination aetna position create saving government private employer needham raise rating cvs strong buy target caliendo do think profit industry especially underwriting level be excessive be improvement current care delivery model be make see prime reason cvs aetna deal cvs be look shift more health care service lowest cost location store clinic different take unitedhealth playbook expand urgent care other outpatient locale drive saving customer such path forward be evident announcement amazon jpmorgan berkshire plan establish independent company be early plan stage accord statement trio group do not come problem answer acknowledge berkshire ceo warren buffett success be go require talented expert beginner mind long term orientation say amazon jeff bezos yet unclear point talented expert be wall street weigh long term nature effort dearth substantive detail initial shock wave ripple wall street subside share dow jone industrial average component unitedhealth nation largest insurer sank stock market today diving much earlier cvs health be process buy aetna pare loss drop drug distributor cardinal health cah mckesson mck be respectively prescription benefit management firm express script esrx sank have tumble earlier cvs unitedhealth also operate pbms manage prescription side health insurance contract pharmaceutical biotech stock also lose ground hit didn look much broader market downdraft tuesday merck mrk shed allergan agn gilead science gild pfizer pfe lose top earning view offer bullish guidance ibd take unitedhealth be rank ibd medical manage care industry group base earning sale margin stock performance trend visit ibd stock checkup see leader category insurer have be solid performer rank group long current confirm uptrend equivalent green light stay place lead stock lead group break buy point be more likely not have wind back here good place start look stock be poise move higher knee jerk reaction investor be surely reflection unsustainably high cost health care fact amazon have be itch disrupt retail prescription business be attach effort traditionally fear health care investor have be government not private sector impose cost control get handle runaway budget deficit thin industry profit process medicare negotiating drug cost be such fear industry expert say government be unlikely produce much way saving be willing deny patient access certain drug create political backlash amazon jpmorgan berkshire aren first big employer join force attack health cost leerink analyst ana gupte note tuesday health transformation alliance group large self insure employer launch last year also hope find saving improve employee satisfaction work cvs unitedhealth achieve aim initial report indicated alliance member expect save combine prescription cost year amazon jpmorgan berkshire say initial focus be technology solution provide employee family simplified high quality transparent healthcare reasonable cost new corporate entity say be free profit make incentive constraint just form technology solution take be far clear caliendo suppose berkshire bring underwriting skill ve never underwritten healthcare amzn make pharmacy medical procurement contribution provide expertise leerkink gupte say unclear amazon wading deeper solve health care mess accelerate move supply chain prescription industry also be interested trump state union move market downstock fall market show sign be ready breakgrubhub redhat lead ibd stock buy invest stock free new apps aim invest stock market start simple routine
59,PFE,stock sell second straight session tuesday unitedhealth unh pfizer pfe apple aapl weigh dow jone industrial bitcoin plunge spdr dow jone industrial average dium sank spdr spy drop powershare qqq trust qqq give emerge market also sell ishare msci emerge market eem lose stock market today energy health care retail lead downside sector fund oil play slide west texas intermediate crude price drop nearly barrel health care select sector spdr xlv gap lose remain time high unitedhealth group pfizer respective be biggest dow loser stock be also xlv top holding health care stock get hurt amazon amzn berkshire hathaway brkb jpmorgan jpm say statement team way address healthcare employee other dow stock apple fall continue slide further buy point day move average iphone maker report quarterly result thursday telecom utility be few industry group spare rout even gold commodity etfs give early slim gain gold future reversed loss spdr gold share gld ishare gold trust iau fall bitcoin plunge accord coindesk digital currency get hit new regulatory measure south korea bitcoin investment trust gbtc give lowest close dec fall further day line graphic chip designer nvidia nvda be extend recent buy point investor still have chance buy other lead chip stock vaneck vector semiconductor smh be just buy point flat base initially clear mid january smh be last featured etf column dec share be testing day move average undercut support line remain form bottom flat base prior rebound day yielded gain nov intraday high fund marked sixth year last month track mvis list semiconductor index index be compose most liquid chip company base market cap volume account biggest country weighting dec just north asset taiwan netherlands represent bermuda top holding be taiwan semiconductor manufacturing tsm intel intc nvidia asml asml texas instrument txn make portfolio smh have return year date jan accord morningstar direct outpace gain average annual return past year respectively be also ahead benchmark index gain same period ibd take nvidia be lead chip stock do company fundamental rank industry group find now ibd stock checkup chip stock have tough monday overall few fabless name fared well fabless company design semiconductor outsource manufacturing smh component nvidia be also player hot artificial intelligence field rise record high maxim integrate product mxim meantime surge report japan renesa electronic be talk acquire san jose calif base chip designer potentially smh carry expense ratio monday pick direxion daily semiconductor bull soxl remain slightly extend cup handle entry related apple slip ahead earning biotechs bitcoin play gainintel nvidia power dow high bitcoin key supportstock market close record high be bitcoin longer fraud
60,PFE,here investing action plan tuesday need know investor come day fast food leader mcdonald mcd video game publisher electronic art ea open earning season respective sector investor get dose medical chip report president trump deliver state
61,PFE,stock climb trade session high friday afternoon market best industry group take heavy hit nasdaq composite climb reach record high dow jone industrial average also get time high add thank mainly intel intc mmm pfizer pfe small cap lag russell only volume be higher nasdaq lower nyse compare same time thursday advancer decliner be nearly even index sharp gain intel soar new high chipmaker sail past earning expectation raise cash dividend share annualize basis number analyst raise price target intel follow result blue chip be extend gain jan company beat profit estimate thursday intel rally cause rebound chip stock be shell thursday texas instrument txn latest result maxim intergrate product mxim stm lam research lrcx rise unusually high volume report earning earlier week asml asml semiconductor also be higher unusually higher volume vmware vmw gap record high tremendous volume wall street journal report dell technology dvmt be consider range strategic option include purchase rest vmware dell acquire emc majority stake vmware dell share plummet big volume thor industry tho plunge day move average heavy trading break support result sell signal rival winnebago wgo slide deepen decline day line already be sell situation thor be try clear tight pattern rally never break northcoast research downgrade rv manufacturer neutral buy analyst say dealer inventory be unsustainable level stock have be leader mobile home rv industry group have be top group many week casino industry group suffer jolt wynn resort skid intense trading rally stock rise new high november help wynn share withstand friday sell have be big reason industry group have climb top wall street journal report friday dozen person accuse ceo stephen wynn sexual misconduct wynn call accusation preposterous related winnebago thor industry trigger sell signal analyst say rv inventory unsustainable intel stock get flurry price target hike earning beatkla tencor crush december quarter sale earning target
62,PFE,france sanofi sny agree buy recent biogen biib spinoff bioverativ bivv company announce early monday meanwhile celgene celg acquire car drug partner juno therapeutic juno sanofi deal value bioverativ share cash premium friday close bioverativ shot nearly close stock market today sanofi fall celgene acquire juno therapeutic share cash price tag exclude juno celgene already own juno share leap nearly skyrocket last week report deal be close celgene tick close juno work car therapy use patient immune cell fight cancer analyst have say celgene juno deal make sense bioverativ spun biogen february make hemophilia drug sanofi be face generic competition top selling drug sanofi try buy medivation lose pfizer pfe last year effort buy swiss biotech actelion be trump johnson johnson jnj be interested biotech stock surprise upside earning fang stock make news investor mull shutdown impactcheck stock buy first stage basis
63,PFE,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
64,PFE,amgen amgn allergan agn be sideline friday food drug administration delay herceptin biosimilar give roche rhhby blockbuster breast cancer drug herceptin breathe room biotech company didn identify issue herceptin biosimilar work closely fda bring important medicine patient amgen say prepared statement do not expect impact launch plan duo isn first get snag seek approval herceptin biosimilar mylan myl partner biocon grab approval december follow similar delay fda pfizer pfe teva pharmaceutical teva celltrion copy have also be delay get newsletter deliver inbox more info product service privacy policy term useapproval seem be move more smoothly europe european medicine agency committee have recommend approve amgen allergan biosimilar pfizer herceptin biosimilar samsung biogen teva celltrion already have copy market europe herceptin be major cash cow roche bring sale just fellow cancer drug rituxan mabthera generate herceptin sale stem europe roche be work feverishly push back competition herceptin last year roche sue dow jone component pfizer block selling herceptin biosimilar roche genentech unit say pfizer herceptin biosimilar infringe patent patent herceptin begin expire bloomberg report stock market today roche stock rally close hit year close low thursday herceptin biosimilar setback amgen stock advanced share partner allergan climb meanwhile share pharmaceutical company lift biotech stock rise related intuitive surgical break record fda approve new robotibd stock day chinese internet giant power buy zone composite rating stock skyrocket huge earning growth chart basic buy point mark time real invest stock free new apps term retirement investing strategy etfs
65,PFE,mylan myl share pop midday wednesday generic drugmaker reiterate sale guidance stoke investor confidence lag first quarter revenue epipen shortage stock market today mylan fly higher close still share have largely trade day move average early february other generic drug stock rise fraction mizuho analyst irina koffler keep buy rating mylan stock note topline miss expectation bottom line come penny ahead mylan sale adjust earning outlook beat consensus attribute sale miss year year decrease north america segment say note client european sale easily beat expectation rest world segment be line get newsletter deliver inbox more info product service privacy policy term quarter mylan report sale vs last year consensus have call mizuho koffler say north america sale lag view european sale grow top consensus rest world sale be line grow decline north america be primarily due combine impact loss exclusivity olmesartan blood pressure product lower sale brand product include epipen auto injector divestiture certain contract manufacturing asset impact adoption new accounting standard mylan say news release adjust earning cent share climb year year beat consensus penny metric come line mylan own expectation shortfall first quarter mylan reiterate guidance sale beating consensus midpoint adjust profit be expect be share also top analyst view midpoint investor also be likely look ahead potential copycat version amgen amgn bone marrow stimulant neulasta glaxosmithkline gsk asthma inhaler advair mylan have application copycat pending food drug administration meanwhile mylan acknowledge epipen shortage epipen be emergency injection treat severe allergic reaction fda acknowledge be intermittent supply constraint due manufacturing issue mylan too note supply issue statement mylan manufacturing partner pfizer pfe inform fda supply issue few month mylan say however product be available mylan be currently receive continual supply manufacturing partner meridian medical technology pfizer company mylan say mylan be expedite shipment wholesaler receipt supply level vary wholesaler pharmacy related much money do need start investing long term retirement investing strategy buy stock ahead earning report
66,PFE,amgen amgn future biotech company be trouble analyst say tuesday company sector trade premium biotech company celgene celg biogen biib pipeline contain fewer blockbuster opportunity meanwhile generic biosimilar competition be hacking away chunk revenue leerink analyst geoffrey porge say investor have be reward amgen share repurchase program steady cash flow lack long term stability generally investor look biotech company unpriced optionality pipeline amgen doesn have amgen case inability identify program offer upside particularly company size reinforce belief amgen commit significant business development activity expand portfolio pipeline porge say report client get newsletter deliver inbox more info product service privacy policy term useporge estimate amgen portfolio be likely steadily decline biggest moneymaker epogen aranesp neupogen neulasta enbrel be face rivalry growth potential new acquire product isn enough offset decline franchise epogen aranesp treat anemia dow jone component pfizer pfe just gain approval make copy epogen procrit novartis nvs also have copycat neupogen bone marrow stimulant blockbuster neulasta enbrel be also risk neulasta also stimulate bone marrow enbrel treat chronic disease include form arthritis psoriasis novartis already have copycat enbrel novartis mylan myl coherus bioscience chrs be work copy neulasta response amgen have restructure expense base initiate dividend lever company balance sheet porge say compare peer regard amgen more defensive stock also lack explosive upside potentially typically associate breakthrough rapidly grow bio therapeutic stock say porge see amgen worth share be most recent close price have market perform rating price target amgen stock stock market today share rise close share biotech company lift fraction most concern conclusion analysis be lack opportunity amgen pipeline outside element sum part say celgene biogen other hand have greater pipeline optionality growth prospect eventually firm have engage smart merger acquisition porge say best merger acquisition pivot away amgen challenged legacy product mid late stage pipeline opportunity build revenue projection possible biotech be interested merger equal stand company current pipeline be very early have share economic thus be unlikely meaningfully outlook company current revenue year say related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
67,PFE,biomarin pharmaceutical bmrn spark therapeutic once uniqure qure be race be first market gene therapy treat hemophilia prospect offer revenue north patient analyst say monday leerink analyst joseph schwartz boost projection hemophilia gene therapy earlier assumption patient treatment go high patient gross basis say schwartz analysis be base pricing luxturna gene therapy spark treat ultrarare blindness disorder luxturna go eye set useful precedent pricing other gene base treatment such hemophilia gene therapy say believe manufacturer be testing water currently embark phase trial order determine payer push back significantly say note client base check price somewhere range patient seem most likely get newsletter deliver inbox more info product service privacy policy term challenge pricing gene therapy be treatment be be billed time cure warrant higher price most analyst doubt actually be case further expect payer push back high price datum back therapy durability agreement harvard pilgrim health care cover luxturna be base month durability datum set important precedent schwartz say time come market slew hemophilia gene therapy currently investigation have month durability datum schwartz expect biomarin lead spark treat hemophilia hemophilia be genetic deficiency key blood clot protein know factor viii biomarin be phase testing gene therapy call valoctocogene roxaparvovec valrox spark therapy spk be phase phase study believe effective gene therapy hemophilia garner least time annual cost factor viii replacement therapy base durable effectiveness datum schwartz say biomarin enter hemophilia market hit peak sale say spark likely enter market year later spk schwartz call spk garner peak sale spark also be work hemophilia gene therapy call spk partnership dow jone stock pfizer pfe trail uniqure therapy call amt amt be expect begin phase study third quarter spk be phase phase study schwartz model peak sale spk spark receive peak royalty boost price target spark keep market perform rating also raise price target biomarin reiterate outperform rating stock market today uniqure pop close spark advanced finish biomarin gain close related chart read basic buy point mark time real build long term profit stock take many gain new option strategy limit risk earning
68,PFE,ligand pharmaceutical lgnd stock break tuesday touch record high defy broader downturn see biotech company stock dip collective fraction close bell stock market today ligand stock gain close share break cup base buy point stock have remain black past trading day meanwhile share biotech company close analyst be bullish ligand have licensing deal biotech company pharmaceutical company bigger client include novartis nvs amgen amgn celgene celg gilead science gild also work dow jone component pfizer pfe merck mrk get newsletter deliver inbox more info product service privacy policy term useligand be ibd top grow stock firm acquire early stage technology necessary drug development then license platform other pharmaceutical company stock have ibd composite rating best possible meaning perform top stock term key growth metric ligand stock lead biotech group ahead supernus pharmaceutical supn also have cr first quarter ligand crushed expectation top guidance view currently analyst have buy rating ligand stock accord marketbeat com have sell rating share be second time ligand stock have break month share hit entry flat base march related much volume look stock long term retirement investing strategy basic analyze stock cup handle
69,PFE,amgen amgn stock take double hit tuesday dow jone component pfizer pfe grab approval knockoff amgen anemia treatment eli lilly lly report strong result compete headache drug stock market today amgen stock topple close pfizer dip finish lilly slip share stock be consolidate respective buy point share biotech company pharmaceutical company fall fraction food drug administration approve pfizer drug call retacrit midday tuesday retacrit be biosimilar almost identical biologic copy amgen drug epogen procrit epogen procrit be anemia treatment get newsletter deliver inbox more info product service privacy policy term usepfizer approval isn major hit amgen revenue see just first quarter sale epogen epogen be amgen seventh biggest drug first quarter sale decline vs year earlier period other be attempt copy amgen biggest drug neulasta enbrel neulasta increase bone marrow stimulation enbrel treat chronic disease include form arthritis psoriasis be blockbuster novartis nvs have enbrel biosimilar call erelzi drug be approve novartis unit sandoz launch erelzi patent dispute amgen be complete novartis sandoz mylan myl coherus bioscience chrs also be work biosimilar neulasta amgen be also rivale lilly teva pharmaceutical teva aldr migraine drug class call cgrps short calcitonin gene related peptide firm be work treatment prevent chronic migraine tuesday lilly say medicine call galcanezumab meet key goal late stage study patient episodic cluster headach reduce weekly cluster headach compare placebo week month treatment period statistically significantly greater percentage patient treat lilly medicine also see least reduction weekly attack compare placebo week drug prove safe tolerable lilly drug be also be study migraine amgen novartis partner develop aimovig likely be first class get approval prevent chronic migraine food drug administration be expect make decision aimovig later week related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
70,PFE,pfizer pfe blockbuster breast cancer drug ibrance lag expectation first quarter tuesday dow jone component see total revenue stall issue light guidance stock market today pfizer tumble close share be currently consolidate buy point first quarter pfizer report adjust income cent share sale adjust income top view cent grow sale increase just vs year period miss consensus accord zack investment research pfizer cite negative customer buy pattern slow sale ibrance xeljanz get newsletter deliver inbox more info product service privacy policy term usetotal sale ibrance grow be expectation reuter say ibrance sale rise pfizer be likely see competition novartis nvs eli lilly lly rival drug xeljanz treatment rheumatoid arthritis also grow globe miss expectation xeljanz sale advanced biggest decline come pfizer unit know essential health include nonviral infective biosimilar injectable medicine sale business decline innovative health unit grow rake year pfizer guide adjust earning share midpoint guidance miss consensus expectation penny firm also see sale midpoint pfizer sale guidance just lag view related much money do need start investing investing basic sell buy stock ahead earning report
71,PFE,sale merck mrk powerhouse cancer drug keytruda soar triple digit first quarter share dow jone component dip tuesday lower expect total revenue stock market today merck dip close fellow dow stock pfizer pfe also report mixed quarter early tuesday share fall finish cfra analyst jeffrey loo remain bullish merck chance grow keytruda sale study call keynote combination keytruda chemotherapy reduce risk death lung cancer patient seemingly outperform rival regimen bristol myer squibb bmy datum trial cut risk death be impressive view loo say note client merck first quarter earning announcement boost price target merck keep hold rating get newsletter deliver inbox more info product service privacy policy term investor weren excited merck first quarter sale grow yet miss consensus poll zack investment research adjust profit advanced beat cent keytruda sale be grow year year nearly sequentially loo have forecast revenue keytruda sale other big ticket item include diabetes drug januvia janumet grow gardasil gardasil vaccine human papillomavirus latter bring represent growth cholesterol drug include zetia vytorin decline merck blame loss exclusivity zetia vytorin respectively merck guide adjust earning share midpoint beat analyst prediction sale be expect come midpoint sale outlook top analyst view related do spot major market top easy look heavy next nvidia start simple routinewhat be inflation do matter fed
72,PFE,eli lilly lly top street first quarter estimate tuesday unexpected strength diabetes drug early impact chemotherapy tie dow jone component merck mrk sale psoriasis drug taltz key growth product osteoporosis drug forteo lag expectation wholesale retail buy pattern lilly say press release still firm boost guidance first quarter beat evercore analyst umer raffat characterize good quarter lilly early trading stock market today lilly share tick close get newsletter deliver inbox more info product service privacy policy term first quarter lilly report adjust profit share sale rise respective metric top consensus analyst poll zack investment research adjust income share sale year lilly raise adjust earning forecast share revenue analyst expect adjust earning share sale late monday food drug administration advisory panel dealt lilly partner incyte incy setback panel opposed approve new rheumatoid arthritis drug higher dose drugmaker want panel do favor lower dosage quarter sale diabetes drug trulicity grow worldwide trulicity revenue advanced higher demand drug class know glp receptor agonist same time prescription trulicity grow raffat say imply pricing have not be unfavorable glp class say humalog diabetes drug lilly biggest product grow sale better pricing drive growth raffat say sale erectile dysfunction drug ciali seem be relatively stable light generic competition pfizer pfe viagra ciali sale grow drive higher realize price largely offset decrease demand due entry generic sildenafil lilly say worldwide sale fall meanwhile sale chemotherapy medication alimta increase decrease revenue outside be offset rise sale alimta be used combination merck keytruda treat lung cancer several key drug fall short raffat say sale psoriasis treatment taltz fall quarter quarter drive lower volume due specialty pharma buy pattern partially offset higher demand lilly say sale miss raffat say be important growth product miss say same time sale osteoporosis drug forteo decline due decrease volume wholesale retail buy pattern lesser extent lower realize price lilly say related do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
73,PFE,consumer health giant johnson johnson jnj nudge sale guidance higher tuesday even blockbuster drug remicade continue face competitive pressure demand cancer treatment surge first quarter oncology be grow field first quarter sale cancer drug grow unit include brand drug account total pharmaceutical sale rise respectively prior quarters result boost full year sale view range midpoint beat consensus view dow jone component also reaffirm adjust profit target share analyst have modeled rbc analyst glenn novarro note beat expectation board get newsletter deliver inbox more info product service privacy policy term use pharma upside drive higher revenue guidance subdue expectation drive share higher say note client sale segment be estimate pharmaceutical segment be primary source upside stock market today share slide close first quarter report adjust profit share sale metric rise vs year earlier period sale easily top consensus analyst poll zack investment research adjust profit beat nickel share pharmaceutical unit bring beat novarro view cancer drug zytiga be single biggest source upside say zytiga generate revenue novarro estimate darzalex treat multiple myeloma adult also beat expectation say sale fellow cancer drug imbruvica be just line respectively sale drug grow vs last year same time sale inflammation drug remicade decline bring just total pharmaceutical sale remicade face competition biologic copy know biosimilar make dow merck mrk pfizer pfe consumer unit make product baby shampoo neutrogena grow sale biggest upside come beauty product rise meanwhile sale wound care product fall medical device sale rise beating novarro model orthopedic sale spine product decline lead dip sale knee replacement evercore analyst vijay kumar call result soft segment think most be due tougher sequential comparison say note normalize think first quarter sequential volume trend slow base point related unitedhealth top earning view hike outlook do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
74,PFE,major market index be mixed early tuesday tech stock set pace once again tech heavy nasdaq advance dow jone industrial average be hover break even mark morning trade dow jone industrial component apple aapl advanced be upgrade line buy piper jaffray price target premium monday close price stock be close be extend cup handle entry friday company report fiscal result close thursday meantime report indicated iphonemaker remove qualcomm qcom component next year iphone ipad company have be engage legal battle qualcomm licensing term share qualcomm drop remain day line week high elsewhere dow pfizer pfe fall more top earning estimate raise full year ep target share be close trigger sell signal cup handle entry stock be day line company report earning stock market today armour uaa announce weak revenue result cut full year estimate share plunge level not see mid share be trading time high meanwhile mastercard drop top earning sale target early tuesday share be well extend flat base entry fang stock facebook fb inched lower remain buy range flat base buy point social medium giant report earning nov market close lead chip stock ibd member advanced energy industry aeis plummet nearly even beat street estimate late monday chip equipment maker also report better expect guidance share have just reach profit take goal monday cup handle entry ibd universal display oled advanced more higher break flat base entry volume be heavy downside cognex cgnx reversed early gain fall more company report solid earning result late monday share be still flat base buy point related dow jone industrial average dow stock news big gain still pick apple amazon facebookfang stock news quote facebook amazon netflix easily beat forecast stock climb earlyelectronic art mastercard aetna lead tuesday investing action plan
75,PFE,face choice temporary tax cut permanent tax reform republican appear be head oxymoronic path know temporary tax reform house speaker paul ryan insistence business tax cut need be permanent business aren do multibillion dollar multiyear capital decision see tax code unpredictable gop have already take big step opposite direction plan phase provision allow immediate equipment spending year long republican be bound face reality permanent corporate tax rate anything close be attain ditch ryan dollar border adjustment tax face opposition wal mart wmt other major retailer cut corporate rate alone cost second decade yet gop have only spel saving repeal business tax break accord tax policy center analysis gop surely insist tax cut eventually be make permanent make corporate tax cut temporary even only paper meet senate budget reconciliation rule have big negative consequence imperil tax legislation combination smaller offset corporate tax hike tax cut pay virtually none make more difficult come politically tenable way shrink propose business individual income tax cut fit hole allow senate budget resolution equal modest gdp business side gop have propose business tax cut first decade only saving eliminate sizable deduction still table deduction interest paid business borrow raise much get republican much closer goal yet tax framework make clear gop be wary take valuable tax benefit say deduction be only partially limit corporation more favorable treatment imply noncorporate borrower interest deduction be especially big utility firm verizon vz have debt tax reformer generally have discuss end interest deductibility conjunction allow company immediately capital expenditure yet gop plan only allow immediate expensing equipment not structure phase benefit year even full expensing capital investment be make permanent goldman sachs economist have note long run effect tax reform eliminate interest deductibility be neutral negative investment corporate tax rate end much phase immediate expensing therefore raise doubt economic impact tax reform encourage company already gird fight preserve interest deductibility further dig goldman sachs have predict substantial change interest deduction meanwhile few offset cover cost goldman envision propose corporate tax rate rise target tax rate small business partnership income rise yet even assume tax cut be smaller phased gradually hard see gop shrink net year cost business tax cut less leave modest room cut taxe middle class further second decade cost even corporate tax rate approach gop change tune aggressively target interest deduction individual tax hike cover cost lower corporate rate rate have be make temporary avoid democratic filibuster ibd take dow jone industrial average close tuesday more point ibd change market trend indicator confirm uptrend uptrend pressure equivalent yellow light turn green make sure read big picture column day stay top market direction key indicator let know be aggressive move sideline have resort corporate tax rate also create major political headache do international tax shelter republican plan modest tax tech company alphabet googl apple aapl drugmaker pfizer pfe have amassed pile cash avoid pay high domestic tax rate profit earn overseas yet gop be also weigh minimum tax future profit earn overseas apply company generate much overseas income tax haven multinational already be signale strong opposition idea expect opposition intensify republican try minimum global tax temporary corporate tax cut concern multiply rate incentive business avoid taxe be much higher thing seem clear gop tax reform push proceed re cycle deflate hope tax relief last economic boost inflate projection deficit debt best gop do be offer temporary corporate tax cut leave legacy more debt little else not hard imagine sen bob corker john mccain rare lawmaker pass deficit hawk pull support have loyalty trump neither have worry reelection corker have already signale concern congress win have intestinal fortitude stand special interest do tax reform right way mccain vote president george bush temporary tax package be third senator break party fate tax cut come arizona sen jeff flake announce retirement tuesday blister speech maine sen susan collin hail state vote hillary clinton stand trumpcare show more willing defy party related house continue toy contribution cap question trump let alphabet pfizer keep tax haven be biggest loser trump tax reformstock buy watch top ipos big small cap growth stock
76,PFE,gop lead senate late thursday approve budget resolution set aside room net tax cut come decade vote be important allow gop pass tax cut just vote vice president pence exception kentucy sen rand paul republican holdout derail obamacare repeal be board yet even assume house agree senate deficit hike budget hard work remain republican be start unrealistic expectation president trump be still call largest tax cut history wall street expect trump sign tax cut law first half package be whole lot smaller then analyst morgan stanley goldman sachs have indicated see corporate tax rate much more likely white house say be nonnegotiable even corporate rate be good news stock market raise earning potentially push index year end say goldman chief equity strategist david kostin big challenge be squeeze individual tax cut corporate tax cut hole republican be count dynamic score show tax legislation pay significant extent be likely be sorely disappoint official score joint committee taxation key reason first problem be appear be very little chance republican find budget offset make corporate tax cut permanent yet even conservative tax foundation have say temporary corporate tax cut initially boost growth then effect corporate tax cut substantially reverse second problem be official budget scorekeeper use dynamic score model penalize gop add more debt first decade extra debt be see likely push interest rate raise cost capital utilize senate filibuster proof reconciliation process gop plan add deficit first decade yet cut corporate rate alone cost second decade accord analysis tax policy center now gop have only spel saving repeal business tax break tax framework jointly release white house gop leader house senate last month include net business tax cut first decade tax policy center say cost be lower phase tax cut win be nearly sufficient shrink cost enough make room deficit increase individual tax cut effort find offset saving pay business tax cut be rough start gop drop house speaker paul ryan plan impose border adjustment tax fierce lobbying campaign retailer wal mart wmt border adjustment tax have raise additional apply tax import ibd take dow jone industrial average end first time wednesday nearly point ibd change market trend indicator aug confirm uptrend uptrend pressure equivalent yellow light turn green make sure read big picture column day stay top market direction key indicator let know be aggressive move sideline next fight be likely be phase deduction interest payment new corporate borrow interest deduction be especially big utility firm verizon vz have more debt unify framework put together trump administration gop leader congress do state deduction be partially limit corporate borrower goldman sachs be skeptical predict substantial change deduction republican plan modest tax tech company alphabet googl apple aapl drugmaker pfizer pfe have amassed pile cash avoid pay high domestic tax rate profit earn overseas yet gop be also weigh minimum tax future profit earn overseas apply company generate much overseas income tax haven multinational already be signale strong opposition idea expect opposition intensify republican try minimum global tax temporary corporate tax cut congress also be struggle find way offset cost individual tax cut lead republican congress have waver eliminate deduction state local income taxe raise first decade be talk preserve deduction household make only save third much meanwhile charity real estate company be gear fight gop plan double standard deduction threaten erode value deduction home mortgage charitable contribution related future jump senate ok budget resolution pave way tax be trump corporate tax rate isn go happen question trump let alphabet pfizer keep tax haven stock buy watch top ipos big small cap growth stock
77,PFE,key index slip red microchip mchp skywork swks weigh nasdaq disney boost dow spdr spy slip spdr dow jone industrial average dium give powershare qqq trust qqq be fractionally lower small cap underperform ishare russell iwm ishare core small cap ijr respectively disney earlier hold gain report medium theme park giant hold talk acquire most st century fox disney reclaim day move average monday sector play stock market today utility consumer staple real estate advanced retail bank semiconductor sag vaneck vector semiconductor smh ishare phlx semiconductor soxx dip microchip technology skywork solution sank respectively skywork line guidance current quarter disappoint spdr regional banking kre sank spdr bank kbe fall big bank weigh dow jpmorgan jpm goldman sachs gs give gold oil fund be lower underlie commodity price first don succeed try try again adage oft hold true exchange trade fund too vaneck vector morningstar wide moat moat count visa top holding be look support day move average pull back late october intraday high solid rebound line set new chance buy share fund be last featured oct column clear buy point flat base advanced head back day line moat show similar action past spring climb past flat base entry early turn tail soon find support day share rise nearly start most recent flat base pattern fund launch april track morningstar wide moat focus index index be comprise stock morningstar direct equity research team deem have sustainable competitive advantage be attractively price health care represent biggest sector weight fund nearly asset consumer discretionary be next follow industrial financial information technology top holding include bristol myer squibb bmy biogen biib pfizer pfe amgen amgn polaris industry pii visa well fargo wfc be stock unrelated health care make top stock portfolio ibd take lookout etf idea be worth closer look check ibd weekly etf leader column featured fund list highly rate etfs moat have deliver performance largely line broader market year date return nov slightly lag gain accord morningstar direct average annual return past year respectively compare benchmark index gain same period etf carry expense ratio related nasdaq hit record apple sell nvidia drife ibd etfearning lift sector top equity play buy zoneapple microsoft lift dow equity play buy
78,PFE,many name make cut ibd exclusive dividend leader screen be liquid large cap widely hold name pfizer pfe occidental petroleum oxy cisco system csco member friday screen be good example once new name pop doesn have quality be
79,PFE,index other major average rise modestly record high apple aapl report strong earning guidance iphone launch facebook fb crushed view warn soar operate cost tesla tsla miss badly temper model goal production hell continue alibaba baba deliver huge growth symantec symc several security stock tumble oclaro oclr spur big fiber optic retreat president trump nominated new federal reserve chairman house gop finally unveil big tax cut plan job growth do not rebound much expect last month index dow industrial nasdaq extend weekly streak modest gain new high new wave earning president trump fed pick gop tax plan megacap apple give nice friday lift follow strong result facebook crushed view warn ll hike security spending russia tie political content reach nearly half american tesla report big loss burn cash push back model production path cut model model output alibaba have stellar result fiber optic several cybersecurity stock be hammer home depot hd homebuilder sell thursday house republican include measure slash mortgage interest deduction tax plan related stock buy watch top ipos big small cap growth stocksapple sell more iphone ipad mac computer expect fiscal fourth quarter apple earn share sale analyst expect china sale rise first time quarters december quarter typically conservative apple guide revenue slightly consensus ceo tim cook say be bullish apple prospect expect best holiday season yet thank iphone iphone handset iphone go sale friday share jump record high friday close related apple beat earning sale target guide sale higherapple give rare bullish outlook iphone hit storesfacebook report blowout earning snap quarter string decelerate revenue growth social medium giant say see faster growth expense facebook commit step spending improve security platform follow day congressional hearing role facebook google googl twitter twtr play russia misinformation campaign presidential campaign facebook share fall thursday close week fractional gain still buy zone related analyst hail blowout earning be facebook be downchina commerce leader alibaba report better expect fiscal second quarter result annual active consumer alibaba retail marketplace reach year end quarter mobile monthly active user previous quarter share have run several day record high head earning dip follow report alibaba earning revenue beat estimate strong third quarter adjust loss cash burn be much expect tesla reveal continue model rollout wo tesla now expect hit production rate model vehicle week late first quarter push back plan month tesla share fall thursday hit month low related tesla third quarter result show big miss model wo economy add job october less expect be notable upward revision prior month affected hurricane unemployment rate dip new cycle low average hourly wage be flat vs september meanwhile ism manufacturing index pull back longtime high still show factory activity be expand rapidly related jobless rate sink wage slip october payroll president trump tap federal reserve gov jerome jay powell succeed janet yellen chair central bank term expire february wall street breathe bit easier become clear powell get nod be expect follow yellen low interest rate path powell republican former investment banker serve george bush treasury department be somewhat more amenable yellen ease post crisis bank regulation trump priority yellen lead fed keep rate steady wednesday sign point december hike related federal reserve hold rate steady december hike bioscience nbix exelixis exel juno therapeutic juno rise demolish view clovis oncology clvs dove widely miss incyte incy report better expect metric expand cancer deal astrazeneca azn dow pfizer pfe allergan agn be soft revenue narrow full year sale outlook teva pharmaceutical teva earning miss drugmaker cut full year forecast cite challenge face copaxone generic drug add industry concern pricing tuesday sweeping antitrust lawsuit vs generic drugmaker be expand include total company president mylan myl meanwhile bluebird bio blue juno pop preliminary datum respectively sickle cell disease aggressive lymphoma related teva dife long road ahead earning miss guidance blood disease datum send biotech stock flyingdow pfizer fall legacy medicine exelixis juno stock rocket crush viewsshale operator generally show spending discipline third quarter investor shift focus production growth cash growth spending cash flow pioneer natural resource pxd boost capital spending outlook concho resource cxo devon energy dvn beat bottom line anadarko petroleum apc miss eog resource eog beat quarterly estimate announce new oil play together hold barrel oil equivalent crude future trade year high related eog resource beat view announce new premium oil playspioneer natural resource crush earning view laredo mixedshale earning concho resource devon energy beat anadarko blizzard atvi post better expect third quarter sale profit raise full year guidance thank game destiny call duty wwii guidance not have be strong enough activision reversed lower record high friday nintendo ntdoy nearly double profit outlook current fiscal year thank switch console exclusive game super mario odyssey nintendo now expect ship switch console financial year end march previous prediction ea ea stock fall publisher forecast lower expect sale holiday quarter prospect star war battlefront game remain big question mark december quarter related nintendo nearly double profit outlook switch hit home runbroadcom avgo deliver positive surprise thursday announce revenue fiscal fourth quarter end oct be higher end guidance range friday broadcom rise apple earning report be close deal buy fellow iphone chipmaker qualcomm qcom spiked meanwhile other chip company get mixed reaction third quarter result qorvo qrvo drop disappointing december quarter sale earning guidance cavium cavm beat wall street forecast sale earning september quarter share still fall cirrus logic crus also report better expect result quarter stock rise department justice sue block buy time warner twx say report analyst say leak reflect doj try increase leverage negotiating condition set deal condition involve access time warner content base analysis emerge internet video service pay tv market sprint owner softbank reportedly walk away merger talk involve mobile tmus parent deutsche telekom sprint valuation management control seem be stumbling block late week talk be say be back ford motor grow new car sale october consumer demand utility vehicle truck continue intensify series truck be especially brisk seller general motor gm see sale slide do better expect fiat chrysler fcau sale drop estimate slash low margin fleet sale annualize pace auto sale last month be accord autodata be september see strong post hurricane demand replacement vehicle ferrari race top earning view raise full year guidance share drop buy point related ford gm top october sale view fiat chrysler tumbleferrari raise earning revenue view tesla big flopoclaro oclr plunge december quarter guidance send share other optical device supplier include finisar fnsr lumentum hold lite neophotonic nptn weak demand china telecom gear maker have pressured fiber optic stock new worry involve datum center market internet company be shift purchase new type optical device inventory build slower part lumentum fall expectation apple aapl order more sensor iphone acacia acia also give december quarter guidance well estimate earning computer security software maker be mixed share qualys qlys cyberark software cybr jump report september quarter result investor hammer check point software technology chkp symantec symc fireeye feye analyst say shift cloud compute service be roil security market startup be take share incumbent casino operator la vegas sand lvs melco resort entertainment mlco wynn resort wynn mgm resort international mgm get lift month gross gaming revenue increase macau well positive datum nevada news gamble expansion pennsylvania share melco plunge thursday top earning sale forecast aetna aet object acquisition talk cvs health cvs grab center stage easily beat earning expectation soft top line result wellcare health plan wcg steal show leap buy zone earn rank ibd medical manage care industry group base earning revenue margin stock performance trend wellcare earning surge help strength medicaid medicare focuse acquisition aetna highlighted medicare primary growth driver report increase ep revenue fall molina health moh medicaid obamacare exchange insurer report better expect earning send share soar friday aetna add recent cvs tie gain mostly friday wellcare rocket record high cvs aetna finalize deal december reportaetna top earning view mum cvs wellcare health soarsshopify shop report first ever adjust profit beating view share commerce software maker fall high volume trading analyst call shopify battleground stock criticism short seller citron research paycom software payc report earning top expectation light revenue guidance send share maker human resource payroll process software constellation brand stz beer wine spirit producer say take stake canadian medical cannabis provider canopy growth move intend keep apace early stage consumer trend concern legalization impact booze sale molson coor tap say keep eye marijuana market cme group cme massive derivative marketplace say plan launch bitcoin future mark big step financial world acceptance still volatile cryptocurrency bitcoin soar new high mastercard beat third quarter earning revenue expectation raise year operate expense forecast largely due spending related investment masterpass digital wallet armour uaa cut full year target cent ep well view cent turn mixed result quarter share crumble tuesday multiyear lows
80,PFE,tech company alphabet googl apple aapl drugmaker pfizer pfe have amassed pile cash avoid pay high domestic tax rate profit earn overseas have be single big potential winner trump tax reform don count push come shove get corporate rate close make america great again revenue lose international tax haven be need make number work gop tax framework release late last month reiterate president trump long hold goal bring back trillion dollar be currently keep offshore reinvest american economy end plan require accumulate profit hold offshore be repatriate much lower tax rate have face exist law voluntarily bring cash back home idea excite investor anticipate freed cash translate bigger stock buyback dividend cash funded acquisition meanwhile multinational be so far board essentially be retroactive tax hike gop plan also give permanent relief profit earn home abroad apple hit market cap tax reform rbc capital market speculate tuesday be pretty big risk story first potential trouble spot arise straight tax reform framework gop have long want shift territorial tax system taxe corporate profit country be earn most other nation do instead tax international profit only be repatriate credit foreign taxe paid new republican tax plan doesn quite go far instead endorse minimum tax international profit reduce rate relative propose rate paid corporate income earn first risk be unspecified reduce tax rate end be higher company now pay overseas earning take pfizer have international tax rate current taxe profit even defer income tax credit further shrink bill alphabet have even lower current international tax rate profit apple international tax rate fiscal be just current taxe income now minimum tax rate foreign profit be set high fourths propose corporate tax rate such circumstance reward tax reform look whole lot leaner google parent turn downer maker viagra indication international minimum tax rate get high political aesthetic budgetary math raise risk company face significantly higher international tax rate do now alphabet owe current federal taxe revenue still see lower overall tax bill rate get knock close high minimum rate surely lower appeal tax reform company pfizer have regularly report loss operation doesn stand gain much lower corporate rate pfizer get almost exactly half revenue pay relatively little federal tax defer tax credit worth ibd take share alphabet be close buy point point investor have best opportunity term gain here good place start quickly find best stock buy right now testify senate finance committee hearing international taxation last week reed college economist kimberly claus estimate profit shift tax haven now cost
81,PFE,government more year hearing claus stephen shay serve treasury department president obama reagan note problem republican idea minimum tax be apply foreign earning cumulative basis rather country country basis claus estimate profit shift relate country sub tax rate global minimum rate shay say company seek preserve tax saving shift income low rate country increase investment higher rate country worth note international tax haven popular pharmaceutical biotech firm be puerto rico be territory be categorize international corporate filing puerto rico mount trouble make unlikely tax policy penalize company manufacturing facility biggest hurdle cut corporate tax rate be budgetary math republican be try squeeze business tax cut hole leave little room individual rate cut year math get lot cast doubt permanent tax change be doable utilize senate filibuster proof reconciliation process gop plan add deficit first decade yet cut corporate rate alone cost second decade accord analysis tax policy center now gop have only spel saving repeal business tax break corporate rate start move higher risk be international minimum rate move related push apple market cap analyst be trump corporate tax rate isn go happen mccain kill obamacare repeal wound tax reform blowthese be biggest loser trump tax reformstock buy watch top ipos big small cap growth stock
82,PFE,dow jone component pfizer pfe have interest acquire bristol myer squibb bmy least not yet analyst reportedly say thursday report citigroup analyst andrew baum send bristol share topple close stock market today pfizer stock advanced broadly drug stock rise collective pfizer chief executive ian read isn interested buy bristol have datum derate share baum say accord fly citigroup didn respond request investor business daily copy report investor analyst have long play question pfizer take bristol pfizer latest big acquisition be takeover medivation forked cancer drugmaker get newsletter deliver inbox more info product service privacy policy term useaccord baum pfizer see return risk much higher immuno oncology space bristol have double recent history immuno oncology matchup particularly drug opdivo yervoy bristol be pairing opdivo yervoy first treatment advanced lung cancer earlier year regimen outperformed chemotherapy improve progression free survival patient next firm unveil overall survival datum combo dow jone component merck mrk already have immuno oncology regimen approve first treatment advanced lung cancer drug keytruda grab accelerate approval combination chemotherapy use datum be cause bristol stock dive make easier target takeover pfizer do have own immuno oncology program last april firm have compound immuno oncology study citigroup baum have sell rating pfizer cut price target bristol keep buy rating stock related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
83,PFE,mylan myl deny report friday interested buy merck kgaa consumer health care business email investor business daily mylan spokesperson say rumor be untrue mylan policy not comment rumor speculation give egregious inaccuracy report issue morning company be compel confirm reuter article be untrue spokesperson say mylan share dip rumor first report early friday fall close stock market today get newsletter deliver inbox more info product service privacy policy term report suggest merck kgaa sell unit cite person familiar matter previously nestle reckitt benckiser have interest buy unit source say germany merck say last year be aim sell consumer health care business help foot bill prescription drug research segment bring annual sale merck kgaa couldn be reach merck co mrk be initially establish subsidiary merck kgaa germany later nationalized own independent company consumer health business have be merger wringer recently industry include counter drug vitamin other offering march glaxosmithkline gsk agree buy novartis nvs share consumer health business deal allow novartis divest stake unit glaxo expect transaction be accretive earning meanwhile dow jone component pfizer pfe have long struggle offload consumer health business last month glaxo reckitt benckiser dump bid buy business pfizer announce plan sell spinoff unit october sale rise year year sell advil centrum few other big moneymaker related invest stock free new apps aim trade stock most penny stock fail make investor richlong term retirement investing strategy etfs
84,PFE,glaxosmithkline gsk spiked week high friday become second company week dump bid pfizer pfe health care consumer business continue review opportunity accelerate strategy meet criterium return not compromise priority capital allocation chief executive emma walmsley say written statement stock market today gsk pop earlier rise more share dow jone stock pfizer other hand sank close late wednesday reckitt benckiser group say acquire pfizer consumer health care unit do not fit strategy seek opportunity rigorous discipline financially responsible manner ensure long term value creation shareholder get newsletter deliver inbox more info product service privacy policy term usepfizer announce be consider selling spin counter business october unit sell advil centrum other big moneymaker bring sale rise year year related much money do need start investing long term retirement investing strategy etfsnew option strategy limit risk earning
85,PFE,start stock dow jone industrial average djia now include america largest company wide range industry include apple aapl exxon mobil xom intel intc nike nke goldman sachs gs general electric ge have be only remain original dow stock be just replace walgreen boot alliance wba conjunction nasdaq composite dow jone index dow stock serve bellwether general market american economy help investor gauge current environment future outlook bookmark page ongoing coverage dow stock benchmark index scroll see list component stock dow jone industrial average index get newsletter deliver inbox more info product service privacy policy term useclick symbol get latest news stock quote company get instant access more trading idea exclusive stock list ibd proprietary rating only related best stock buy stock be ibd big cap
86,PFE,biotech merger heated monday celgene celg announce acquire juno therapeutic juno french pharma sanofi sny say spend tack biogen biib spinoff bioverativ bivv analyst laud celgene juno buy note help fill hole celgene blood disease drug revlimid begin lose exclusivity street be more split sanofi purchase hematology market be expect soon face disruption gene therapy close bell stock market today juno surge celgene tick bioverativ rocket sanofi dive close broader biotech group pop credit suisse analyst martin suggest report group see mad scramble merger acquisition sanofi announce plan buy bioverativ list biomarin pharmaceutical bmrn esperion therapeutic espr avexis avxs top takeover pick deal be sign merger spigot have finally turn other large pharma company feel pressured move make full value bid grab be fairly scarce selection commercial commercial ready asset small midcap biotech space say celgene say monday spend share acquire juno premium stock close price rumor send juno fly last week celgene already own juno deal collaborate cancer autoimmune drug merger be expect close quarter juno be work car therapy engineer patient own immune cell identify fight cancer cell celgene peg lead drug know jcar get approval bring potential peak sale ibd take celgene be particularly hurt third quarter bigger drug revlimid otezla miss expectation not only face patent cliff mid see else be risk visit industry snapshot piper jaffray analyst christopher raymond suggest guidance be overly bullish celgene be set relatively high bar asset likely win be alone class say note however guidance be achievable be important source revenue mid long term celgene look plug revlimid hole once go generic start competition be look stiff gilead science gild spend nearly acquire kite pharma last year time gilead kite gain approval car therapy follow novartis nvs be first gate approval august celgene expect jcar get approval treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead drug yescarta be approve treat population novartis be look get drug kymriah approve use well leerink analyst geoffrey porge view deal positively consolidate streamline celgene effort car celgene also partner bluebird bio blue work multiple myeloma drug know bb target antigen know bcma own juno allow celgene focus bcma effort initially bluebird bb make juno vehicle development drug target cd protein exploration other target opportunity say note client mizuho analyst salim sy note be cross pollination manufacturing juno bluebird drug be knowledge base synergy unsure celgene even look acquire bluebird trigger antitrust concern say early monday sanofi say buy hemophilia player bioverativ share deal be premium bioverativ close price friday piper jaffray raymond write note re not shock bit say topline revenue growth more last year yet trading just time fiscal year revenue estimate have long view bioverativ potential takeout target deal come sanofi twice fail make big acquisition dow pfizer pfe beat sanofi battle cancer player medivation last year dow johnson johnson jnj acquire rare disease biotech actelion pharma sanofi sanofi be face mount competition diabetes drug trick be convince investor hemophilia market win be disrupt gene therapy product launch roche rhhby drug hemlibra leerink analyst seamus fernandez say note minimum number speculate successful bid include medivation actelion sanofi investor now have deal digest be immediately accretive earning estimate be accretive say rbc analyst kennen mackay call bid strong give upcoming competition roche note likely sanofi be build lesson learn medivation actelion process sanofi lead low offer be later best competitive bidder investor weren sure merger biogen spun hemophilia business bioverativ year bioverativ have approve drug eloctate hemophilia alprolix hemophilia last year bioverativ acquire true north therapeutic credit suisse martin call true north stronger acquisition bioverativ gain access drug now know bivv treat rare autoimmune disease model share drug alone related biotechs surprise upside earning biotech stock rocket rumor biogen buy hospital plan put pressure generic drug maker
87,PFE,cellectis cll pop early wednesday dow pfizer pfe present strong datum first human trial cancer therapy american society hematology conference close bell stock market today cellectis have leap finish earlier rise much week high pfizer advanced phase study test drug know ucart adult pediatric patient form acute lymphoblastic leukemia relapse didn respond other method treatment collectively patient achieve remission rate population adult patient achieve remission evidence disease blood cell bone marrow day treatment ucart cellectis say news release only case graft vs host disease occur be instance severe neurotoxicity patient develop severe cytokine release syndrome characterize flu symptom die be previously report instinet analyst christoper marai say report client ibd take earlier week several biotechs pop follow presentation american society hematology follow news visit ibd industry theme pediatric trial child achieve minimal residual disease enable proceed stem cell transplant be only case graft vs host disease none neurotoxicity cytokine release syndrome case be mild manageable marai view cellectis ucart platform be more fundamentally cellular therapy space new target traditional car therapy car therapy teach patient immune system fight cancer used specific target body cellectis describe ucart platform frozen shelf cell base medicinal product be allogeneic rather autologous meaning cell used be donor produce wide population rather directly patient fundamentally datum present establish viability success allogeneic car path re dose validation multiple target be previously thought be impossible marai say reiterate buy rating price target cellectis related biotech stock be defy hematology related pitfallwhy gilead have greatest ever hiv drug launchesamazon reportedly talk mylan novartis pharma entry
88,PFE,future index be little change late wednesday major average edge lower regular session diamondback energy fang clear buy point double normal volume meanwhile apple aapl have pull back edge past entry so so trade fellow dow industrial component microsoft msft walt disney pfizer pfe have retreat back basis get inflate boostx volume be sometimes overlooked investor key indicator institutional support good see volume rise least normal low volume breakout succeed odd be much lower dow future rise slightly vs fair value nasdaq future fall diamondback energy rise wednesday stock market trading blast flat base buy point volume be day move average really picked afternoon guarantee diamondback move succeed several recent diamondback breakout fail go nowhere strong volume be positive be reason be encourage price volume action shale operator have straight quarters strong earning growth analyst predict ep gain current quarter crude future year high also bode well go forward oil gas group dominate ibd top perform industry wednesday mining steel also fare well shale other energy play dominate biggest winner several energy stock be close buy point include fellow shale play concho resource cxo eog resource eog well oil major such chevron cvx conocophillip cop bp bp royal dutch shell rdsa diamondback be add ibd leaderboard wednesday apple rise monday just nudge past base base entry volume be just normal nomura downgrade push iphone maker entry tuesday apple nudge wednesday apple retake entry bullish trade chart look lot more invite microsoft pfizer disney be exception prove rule volume importance moved buy range friday powerful volume last friday be triple witching expiration day push market volume sharply day gain heavy volume aren necessarily sign conviction buy mutual fund other big institution dow component certainly haven follow week microsoft have retreat back flat base entry disney lose wednesday drop buy point somewhat messy double bottom base be indication strong open weekend last jedi ticket sale sag monday tuesday pfizer have skid week undercut entry related big picture be repeat year bull run apple just hit buy point join dow stocksenergy stock industry invest stock market start simple routine
89,PFE,teva pharmaceutical teva continue day upswing friday announce launch generic version drug gilead science gild day drugmaker unveil massive cost cut plan afternoon trading stock market today teva lift earlier stock pop much share close thursday day teva say cut end deal debt gilead drug viread be approve treat hiv hepatitis patient teva be launch generic version viread milligram tablet hope take chunk annual sale viread garner october be estimate person live hiv chronic hepatitis respectively benefit viread teva say news release launch add teva generic portfolio nearly medication monday teva also announce launch generic version viagra be brand dow stock pfizer pfe august erectile dysfunction drug have annual sale teva say news release goldman sachs analyst jami rubin praise teva plan cut cost next year cut come form layoff close manufacturing facility suspend dividend ordinary share ibd take teva have ibd composite rating best possible meaning underperform lion share stock term key growth metric other generic drug stock have stronger rating ani pharmaceutical come head ibd stock checkup look other strong player generic drug landscape rubin have initially expect teva announce plan cut cost expect new chief executive kare schultz deliver promise base background lundbeck repeatedly understated overdeliver acknowledge be investor skepticism health base business note be first time have see concrete strategy levering company be top priority say note client conference call thursday suggest weaker base earning interest taxe depreciation amortization be more offset cost contribution rubin say part restructure teva be combine generic specialty unit focus effort europe emerge market rubin see drug migraine involuntary movement tie huntington disease lead teva specialty unit rubin acknowledge create additional downside risk teva top line see exit unprofitable business potential mark bottom generic pricing be not call bottom yet however closely monitor rate magnitude rationalization effort important sign post say boost price target teva upgrade stock buy rating neutral related teva pharma announce layoff suspend dividend tackle debtwhy amgen have edge rival prevent migrainesteva restructure plan case be here do
90,PFE,dow industrial nasdaq composite hit record high apple aapl have clear buy point monday finishing flat base friday meanwhile fellow dow industrial component microsoft msft pfizer pfe break friday walt disney close buy point first time friday be back monday morning defense giant lockheed martin lmt be not dow be stalwart also break consolidation friday be pressure early monday apple rise morning trade friday stock market trading clear buy point hit record high friday apple carved flat base minimum week apple now have composite rating be important time winner often have composite rating least start big run microsoft clear own short flat base friday rally just entry volume be more double average be impressive surface triple witching expiration inflate trading activity make unclear big institution be load share same issue cloud pfizer disney lockheed breakout microsoft be big dow leader friday second only intel intc stock rise early monday microsoft do not have particularly impressive growth rate stock have be winner investor see bright future microsoft cloud compute microsoft have strong composite rating view pfizer chart flat base go back week big cup handle pattern go back august way pfizer buy point be same pfizer rise dow third best stock friday drug giant be just year high pfizer edge cent monday disney rise friday close double bottom entry peak level few time month disney jump week agree buy bulk st century fox foxa include assume debt weekend disney star war last jedi deliver open weekend box office disney lose monday morning back buy point lockheed martin rise friday just peek entry hit record high lockheed moved past flat base really base base formation lockheed sank drop back entry point related big picture tax cut bill ignite stock breakout scarcegop take bigger bite apple microsoft google seal trump tax cutstesla lead auto stock invest stock market start simple routinebullish chart pattern do know basic cup handle bullish chart pattern ii find exact buy point
91,PFE,dow hammer early lead friday stock rise investor look possible release reconcile gop tax reform package later morning dow jone industrial average open higher pfizer pfe visa head index early gain also gain nasdaq composite heavy loss csx csx volume be likely be high friday session due expiration stock index future option well stock option future be call quadruple witching day market be also keenly tune capitol lawmaker be hashing final detail massive tax overhaul plan release friday vote end next week friday economic news kick new york federal reserve issue surprise read regional manufacturing growth december empire state manufacturing survey come november tally line economist estimate new order shipment jump month selling input price be see rapid increase industrial production inched november federal reserve report also revise october growth upward leap vs initial estimate economist have expect increase november utilization manufacturing capacity ease just october number vs consensus view increase baker hughe bhge deliver weekly drill rig census et railroad operator csx unraveled report late thursday hunter harrison install activist investor chief executive start year take unexpected medical leave absence jim foote chief operate officer october temporarily assume ceo position nasdaq stock have just clear buy point flat base end entry dow boee take top slot rise stock look add fifth week recent rally pfizer pfe jump start trade announce food drug administration approve dose rheumatoid arthritis treatment xeljanz active psoriatic arthritis gain put share just buy point week flat base ibd stock adobe system rise early trade developer design marketing software report thursday close fiscal fourth quarter result full year guidance analyst target share be buy range rebound support stock week move average oracle orcl crumple report late thursday fiscal second quarter performance analyst earning revenue target cloud compute result revenue outlook disappoint investor stock have be fight hold support week line follow failure attempt september membership store costco cost gain nearly issaquah wash base retailer fiscal first quarter sale earning narrowly top analyst view same store sale rise commerce outpaced expectation share be buy range buy point month base pattern asian stock market end week note hong kong hang seng index fall take loss week japan tokyo nikkei slip end week europe market be mixed afternoon trade frankfurt dax cac paris london ftse defend increase related big retailer nab holiday shopping cheer big picture market reverse lower stock hit buy hot dow stock have new buy point investing action planretail sale rise much more expect broad advance
92,PFE,stock open thin loss monday merger news analyst action stir early trade ahead start fourth quarter report season later week dow jone industrial average dip apple aapl pfizer pfe jpmorgan jpm turn lower nasdaq composite reversed open loss narrow gain fang stock tech leader post early advance edge lower big name include citrix system ctxs intel intc drag early action week news get slow start medical stock be motion news spin jpmorgan day health conference economic earning calendar pick later week begin quarterly report homebuilder lennar len delta air line dal wednesday thursday report friday jpmorgan jpm pnc financial pnc well fargo wfc mark official start fourth quarter earning season dow unite technology utx jump caterpillar cat climb goldman sachs upgrade unite technology buy neutral cite tax reform benefit ease trouble unite pratt whitney jet engine unit company pending acquisition rockwell collin unite share be take new high be extend buy point cup handle base caterpillar receive upgrade jpmorgan lift stock overweight neutral boost price target stock new tax rule implement gop late last year be likely boost company cash flow extend cycle north american construction business note say stock open new high caterpillar be extend buy point late november seagate technology stx spiked more open news report reiterate storage datum leader stake ripple cryptocurrency owner valuestreet research value seagate position move marked past cup handle buy chip stock show early momentum nvidia nvda more gain send ibd name nvidia buy point week cup base apply material amat open higher stock also ibd list be back support week line climb right side week cup base base micro focus international mfgp dive open legacy software leader component london ftse index forecast lower expect revenue announce change chief financial officer company be struggle acquisition hewlett packard enterprise hpe software business complete late celgene celg share rise more company say make upfront payment acquire privately hold impact biomedicine deal include potential milestone payment raise possible total value celgene share be october low still deep month consolidation belgium base biotech ablynx ablx spiked higher premarket trade october ipo reportedly receive share takeover offer nordisk nvo management say offer significantly undervalue company asian stock market post stout gain monday china shanghai composite japan tokyo nikkei soar benchmark be mixed europe london ftse sag cac paris gain frankfurt dax be afternoon trade monday schedule economic news federal reserve consumer credit datum november be due et atlanta federal reserve bank president raphael bostic speak atlanta et san francisco fed president john william be schedule speak et related celgene pay impact stock winner have carved basis new runsdividend hike largest ipo ever lead oil story top china stock surge fast move start bitcoin blockchain business ain see nothing yet
93,PFE,honeywell hon confirm tuesday split noncore unit separately trade company end next year hold big aerospace asset meanwhile pfizer pfe say sell spin consumer health unit procter gamble pg shareholder vote bitter proxy fight consumer product giant activist investor nelson peltz honeywell say spin home adi global distribution business transportation system company worth combine confirm monday report noncore asset spinoff honeywell keep aerospace holding call activist investor third point divest honeywell share fall morning trade stock market today rally market open honeywell rally much monday reverse close honeywell be buy range buy point pfizer announce be explore strategic alternative consumer health unit include full partial sale spinoff dow component say end take action counter unit have sale last year marketing centrum advil other product pfizer share rise intraday move just buy point shallow cup handle base face high stake shareholder proxy vote let activist investor nelson peltz seat board director peltz trian fund own stake maker tide detergent crest toothpaste many more peltz want reorganize unit beauty grooming health care fabric home care baby feminine family care dow component climb intraday related honeywell expect spinoff fall short investor plange shake top exec more perk fall cost cut drive
94,PFE,major stock index open higher tuesday busy morning headline see qualcomm qcom pressure share alibaba baba edge higher ahead earning later week stock news share qualcomm slump open report surface apple aapl drop qualcomm component next year iphone ipad company be lock legal battle regard qualcomm licensing term apple earning apple be due thursday close dow jone industrial average be nasdaq open higher russell small cap index lag badly more last trading day october see nasdaq composite poise monthly price gain past month day fed meeting start today conclude wednesday policy statement due et market isn expect rate hike be expect december meeting related news president trump thursday be expect name current fed governor jerome powell new head federal reserve key economic datum due rest week include ism manufacturing index wednesday job report friday pfizer pfe be early leader dow report earning share fall open pfizer slide day move average be just buy point earlier elsewhere news wasn good armour ua share tank early trading earning beat be offset sale miss share armour be year date deteriorate fundamental longtime leaderboard hold alibaba baba be ahead earning report thursday open stock be just entry rare ascend base pattern be candidate call option trade ahead earning late monday share be trading weekly call option strike price nov expiration come premium offer trade reasonable downside risk contract give holder right buy not obligation buy share alibaba cost exclude commission keep mind take premium paid account alibaba have rally north trade start make money alibaba fall earning most be lose option trade be amount paid contract case learn more ibd earning option strategy here share facebook fb be fraction result be due wednesday close meanwhile aetna aet fall open report earning share soar nearly last week news cvs health cvs be interested buy insurer share related armour slash full year estimate sale unexpectedly fallpfizer top earning forecast raise full year ep targetsaetna top earning view revenue soft cvs health buzzbest stock buy watch
95,PFE,stock slump late afternoon trading monday decline major index remain mild apple aapl buck drop lift new time high xapple have now gain jan first stage cup handle iphone giant reportedly be see brisk order most expensive iphone ever be also follow friday brand new cup handle show proper entry general electric ge meanwhile lead dow jone industrial average decline firm go back day thomas edison lop cent marked ge sixth straight loss also slip strength oil patch wti term future edge higher barrel nymex nasdaq composite be slightly institution be selling ge share hard stock volume finished share heavier usual megacap firm average daily turnover past session be share ge slide nearly monster weekly volume last week dow jone industrial average be price weight index name keeper average replace lag company higher price better performer recent new entrant include not just apple also goldman sachs gs unitedhealth group unh trade more share cisco system csco pfizer pfe have next lowest share price dow trading respectively cisco giant computer networking internet base telecom gear be challenge institutional buy support buy point new cup handle stock fall more dull turnover apple replace dividend rich march latter trade share have be featured ibd dividend leader screen have make virtually progress then ge have recently peaked summer now stand nearly high stock time peak be back august ge relative price strength rating be horrifying scale note ibd stock checkup certainly pressure be mount ge new management team lead john flannery reinvigorate growth flannery have serve many top post ge include head ge capital india operation company adjust third quarter earning fall cent share sharply miss wall street view accord datum william neil co revenue increase snap quarter slump ge have not see double digit annual gain top line more year best result be rise revenue back help nasdaq cause be broadcom avgo rise more strong turnover chip designer auto telecom datum center other market have clear buy point new week flat base proper buy zone go past buy point broadcom appear ibd real time stock move table great source watchlist idea potential new breakout table show stock move sharply heavy volume base real time analysis price volume datum be see home page back apple earning have drop fiscal year end september slump revenue however apple have be stage classic turnaround fundamental lately past quarters imac maker earning rise vs year level follow quarter slump end september earning be see increase share mark third quarter row mild double digit gain slate report result nov market close fiscal year street see earning accelerate share positive apple shareholder respectable annualize dividend yield plenty potential further increase cash payout apple tend raise dividend spring william neil co calculate company have long term annual dividend growth rate recent year ibd take current yield be track yield other vital market indicator go special general market indicator page available pdf link market trend investor com yield be post top bar large daily chart apple smartselect rating have improve steadily year jan composite rating be dismal scale accord ibd stock checkup rs rating compare stock month price performance other company ibd database be equally dim today score be now respectively expect composite rating be somewhat weaker stock such apple be undergo major turnaround fundamental stock price action elsewhere dow jone component johnson johnson jnj be make appear be normal look pullback breaking flat base oct diversify medical personal care product titan have so far rally much proper entry get briefly extend correct buy point have post single mild double digit ep gain quarters row street see earning rise share market react tad negatively report congress be consider phase pace lower corporate taxe not first time such plan have be report medium case market appear be unwilling so far give much strong gain past week big reason gdp rise annualize basis enormous damage cause hurricane texas florida puerto rico follow gain gdp figure be bound change future datum revision eric winograd senior economist note investor focus recent monthly datum point economy balanced sector personal consumption private investment net export make positive contribution headline rise increase private investment particularly noteworthy rise year year highest year winograd tell ibd not yet be back pre crisis level investment news front be good winograd also say consumption datum point accelerate expansion economy think final sale domestic purchaser subcategory gdp essentially core measure single figure best capture underlie dynamic economy household paycheck grow yoy yoy gain final sale make perfect sense add related stock market today apple buy range new ipos find top growth stock cup handle be money makerwhen buy stock master key growth stock chart invest find great stock ibd top stock today chipmaker rise sharply again new technology news nvidia get price target hike
96,PFE,find best biotech company invest be tricky volatility often pockmark space clinical plan don always come fruition sometimes biotech stock suffer hand regulatory decision food drug administration best biotech company invest tend have commonality strong streak earning growth june investor business daily marketsmith com have biotech stock strong list fastest grow stock top list fastest grow stock supernus pharmaceutical supn be rank eighth past year earning share have grow massive compare top earn stock momo momo chinese social medium firm supernus have make name biotech stock term market cap still trail bigger biotech company amgen amgn gilead science gild biogen biib celgene celg supernus land list consider best biotech company invest strong metric always do research buy stock be sure check company stock chart make sure right time buy have several year double digit quarterly sale growth drug help disorder central nervous system supernus count epilepsy drug oxtellar xr extend release trokendi xr trokendi xr be also approve prevent migraine rival drug botox allergan agn amgen aimovig ligand pharmaceutical lgnd be unique biotech stock ibd rank fastest grow stock put research list possible best biotech company invest doesn market single drug instead ligand acquire early stage technology necessary drug development then license platform pharmaceutical company dow jone stock merck mrk pfizer pfe june ligand have year double digit sale earning growth belt ligand supernus have ibd composite rating meaning perform top stock term key growth metric duo lead other biotech stock term cr get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real build long term profit stock take many gain trade stock most penny stock fail make investor rich
97,PFE,alnylam pharmaceutical alny ionis pharmaceutical ion be slam monday continue day plunge dow jone component pfizer pfe announce strong result compete rare disease drug afternoon trading stock market today alnylam topple close share dove much close month low share end thursday regular session pfizer announce result drug call tafamidis needham analyst alan carr call pfizer result surprisingly positive outcome likely introduce relevant competitor alnylam carr say note client believe cause mortality benefit be compelling assumption be tafamidis be approve second half get newsletter deliver inbox more info product service privacy policy term detail be still thin pfizer study tafamidis transthyretin cardiomyopathy be tie progressive heart failure study tafamidis significantly reduce cause death frequency cardiovascular related hospitalization transthyretin cardiomyopathy belong family rare disease call transthyretin amyloidosis attr class disease protein call amyloid build organ cause systemic damage cardiomyopathy patient experience heart effect alnylam ionis be work drug treat hereditary form attr unknown now pfizer use drug treat more form attr just heart patient analyst say ionis share drop close monday pfizer fall pfizer share minimal datum drug earlier study evaluate milligram dose tafamidis test fail significantly tafamidis only slow disease progression carr say alnylam drug call patisiran have reversed progression also important note number patient phase study patisiran receive pfizer tafamidis same time carr say patient show similar benefit receive patisiran alone possible implication be patient be treat drug market not be view carr say keep buy rating price target alnylam share recent phase study tafamidis test milligram milligram dose drug vs placebo credit suisse analyst alethia young say note milligram dose likely succeed transthyretin cardiomyopathy patient say be pay close attention new player market include full datum look commercial pricing strategy cardiomyopathy space say also keep outperform rating price target alnylam young currently model sale patisiran patisiran likely be better option patient experience nerve damage result amyloid buildup don assume full market penetration patisiran due fact believe be competitor pfizer tafamidis ionis say related chart read basic buy point mark time real invest stock free new apps aim beginnerslook next nvidia start simple routine
98,PFE,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
99,PFE,gop fiscal hawk want pull trigger tax hike rosy growth projection don pan have corporate tax rate site so do senate republican family first duo sen marco rubio mike lee want limit corporate rate cut pay more generous child tax credit senate budget committee approve gop tax cut tuesday afternoon wavering republican vote advance legislation look big victory president trump gop corporate america be hand just day later look risk water corporate tax hike remain index dow jone industrial average nasdaq composite hit record high tuesday senate tax bill progress tech stock reversed sharply lower wednesday apple aapl google parent alphabet googl slip more not clear investor be especially worry tax cut prospect dow tack more gain financial stock get lift rise market interest rate yet sketchy detail corker trigger proposal do raise risk accord news report corker trigger sop extra corporate tax revenue decade start budget target aren meet here mean practice senate bill corporation get income tax cut other corporate revenue raiser such reduce deductibility interest payment reduce net corporate tax cut corker trigger claw back year reduce net corporate tax cut roughly meanwhile rubio lee plan make increase child tax credit refundable payroll taxe provide benefit work class family don pay income taxe pose further risk tax bill change way limit upside corporation white house have say corporate rate be nonnegotiable so rubio lee plan probably win pass written alternative way pay have senate follow house lead ratchete taxe past earning multinational have be stash overseas avoid be taxed corporate rate senate apply tax cash illiquid asset raise house tax cash illiquid asset raise apple hold cash overseas end fiscal fourth quarter ibd take bull market win go forever so read ibd big picture column day stay top market direction key indicator let know be aggressive move sideline long current confirm uptrend equivalent green light stay place lead stock breaking buy point be more likely not have wind back here good place start look stock be poise move higher gop holdout sen ron johnson wisconsin steve daine montana be demand better deal pass business include sole proprietorship partnership profit be taxed individual return ve identify source fund be raise end deductibility state local income taxe corporation pay demand johnson vote tax bill committee tuesday say want move process forward propose fix shift reward tax bill somewhat more direction multinational make much profit overseas end deductibility state local income taxe probably win mean much pfizer pfe have regularly report loss operation doesn stand gain much lower corporate rate yet tax analyst also have highlighted senate bill foreign tax provision include minimum tax income derive intellectual property big tech company apple google well drug company pfizer attention have be tax cut republican be have shift attention keep government operate current funding authorization be set expire dec begin look doubtful democrat lend vote tuesday democratic leader chuck schumer nancy pelosi pull meeting president trump government funding renewal state child health insurance program soon be force impose cut be high priority democrat also be eager reach resolution so call dreamer legal residence status soon begin lapse related broad sell hit tech apple fang stock telcos rally reason jpmorgan citigroup other financial be seize market leadershipthe republican tax bill be now serious trouble question trump let alphabet pfizer keep tax haven stock buy watch top ipos big small cap growth stock
100,PFE,headwind slug pfizer pfe essential health unit third quarter lead dow component report soft revenue share dip week low early tuesday xchief executive ian read outlined continue struggle face essential health statement investor unit post yearly decline comprise pfizer total sale essential health revenue remain challenged primarily due continue headwind product recently lose marketing exclusivity product supply have solid operational growth emerge market biosimilar say midday trading stock market today pfizer fall earlier diving nearly low last see mid september meanwhile broader drug stock group lift third quarter pfizer report adjust profit cent rise beating expectation cent sale edge roughly be just analyst view ibd take pfizer have ibd composite rating best possible meaning outperform more stock term key growth metric still lag leader abbvie have cr head ibd stock checkup look drug group top performer innovative health grow business include newer drug tend yield higher sale company include vaccine treat cancer essential health include older establish pharmaceutical consumer healthcare sale grow be line expectation leerink analyst seamus fernandez say note client earlier month pfizer say review strategic option business include selling spin pfizer note year year growth suffer due february divestiture hospira infusion system exclude impact divestiture total sale have grow essential health have decline firm also raise midpoint adjust earning guidance cent share analyst have call also narrow full year sale outlook previously pfizer be ibd dividend leader screen pay quarterly dividend cent share represent annualize yield related here trump tax cut easily glaxosmithkline scoop pfizer counter unit dow component pfizer mull counter spinoff sale
101,PFE,stock open solid gain tuesday wal mart wmt haul dow new high rally american airline group aal help nasdaq new high ground nasdaq leap start trade dow jone industrial average climb wal mart rumble ahead more lead dow company reiterate fiscal guidance raise earning share growth guidance ahead investor meeting discuss strategic alternative company board also approve share buyback initiative gain put wal mart share buy range buy point cup base dow issue pfizer pfe rise announce be seek strategic alternative consumer health care business generate revenue drug giant say expect reach determination matter pfizer share be august low possible base pattern begin august apple aapl edge open analyst note rbc capital market say iphone maker be potentially biggest beneficiary trump administration plan tax reform rbc say apple see tailwind earning share clear valuation level policy be implement apple share stall september attempt be now form new base possible buy point american airline group surge past cup base buy point airline boost third quarter revenue seat mile pre tax margin guidance heavy slate flight cancellation cause hurricane texas florida tesla tsla pop more gain ground morgan stanley note late monday maintain stock equal weight rating raise price target tesla share drop rise trade monday send stock back week move average tuesday early high flier be biotech anaptysbio anab scream higher january new issue see first base fail july then turn gain september share be now january ipo price ibd name ichor holding ichr nail open leap provider fluid delivery system semiconductor manufacturer announce late monday substantial agreement key customer ichor share be extend buy range buy point cup handle base ibd peer nvidia nvda snatch early advance rise news company have partner deutsche post dhl automotive supplier zf release test fleet autonomous delivery truck nvidia share be extend clear flat base buy point economic news be again minimal tuesday national federation independent business release september small business optimism index slip disappoint expectation slight increase addition minneapoli federal reserve bank president neel kashkari be schedule speak et asian stock market be back run today tokyo stock exchange reopen nikkei jump market china also carved higher shanghai composite gain hong kong hang seng index step gain europe market be mixed london ftse post strongest move afternoon trade related big picture index slip ibd stock shinedisney release new trailer ticket star war last jedi move techs new sector leader wall streetthese travel stock be investor watchlist
102,PFE,pfizer pfe net larger percentage prostate cancer market analyst argue thursday dow component report result phase trial drug treat condition trial dub prosper test xtandi population patient castration resistant prostate cancer have not spread other area body pfizer get xtandi acquisition medivation last september evercore analyst umer raffat argue prosper trial validate medivation deal here trial be so important write note client increase target market size perhaps more double xtandi be currently approve treat castration resistant prostate cancer have spread other part body raffat estimate pool patient form prostate cancer hasn spread other part body ibd take pfizer have ibd composite rating best possible meaning outperform more quarters stock term key growth metric head ibd stock checkup closer look top rate drugmaker late stage trial xtandi be combine androgen deprivation therapy compare androgen deprivation therapy xtandi meet goal improve survival allow cancer spread still isn gold standard be overall survival raffat say base result pfizer partner astella pharma plan discuss food drug administration potential approval xtandi patient castration resistant prostate cancer not cancer have spread close bell stock market today pfizer have gain close related bristol myer cancer help boost rivalbristol dife still have chance kidney cancer analystbiotech fever look frosty player cause sectorwide chill
103,PFE,stock get slam again friday major reversal send key market index fund crash cap very bad week powershare qqq trust qqq plunge spdr spy sank spdr dow jone industrial average dium give stock market today spy fall day move average dow nike boee hold slim gain rise intraday be only advancer athletic shoe giant nike report quarterly result late thursday top view offer bullish outlook dowdupont dwdp mmm pfizer pfe lose more apiece big cap techs show continue weakness intel intc microsoft msft apple aapl fall more apple extend slide sixth straight session be now high bank semiconductor ad technology lead downside sector fund vaneck vector semiconductor smh tumble take day move average dow component intel fall graphic chip designer nvidia nvda slide nearly rolled back day line second time week micron technology mu report earning late thursday be nearly investor flocked safe haven thursday technology most other sector get rout heighten trade war fear most equity etfs see loss utility select sector spdr xlu hold gain even manage close day move average defensive etf have be testing support line past week market be confirm uptrend rebound day set potential buy opportunity uptrend be pressure buy be greater risk usual also note late january day line have be day line bearish sign however big tech sell beg question be sector rotation occur utility other defensive sector tend outperform high growth area tech underperform xlu also be shape bottom base continue consolidate day etf be currently week high get newsletter deliver inbox more info product service privacy policy term fund track utility select sector index marked anniversary december electric utility account asset march follow multus utility independent power renewable electricity producer make nearly water utility represent just top holding include nextera energy nee duke energy duk southern co so nextera have fared best year gain jan other be underwater help make utility defensive play be hefty dividend offset least part poor price performance fact xlu annualize yield be well average payout fund carry expense ratio thursday pick first trust equity opportunity fpx give market sell also be interested stock sell hard trade war fear sector go updow slip chevron stock surge apple test key supportchinese fang be kraneshare china internet fund
104,PFE,veeva system veev be coil spring ready jump thank several growth initiative xthat contention canaccord genuity analyst richard davis say veeva stock have have mighty run so far add cloud compute firm focus software application pharmaceutical life science field have room further growth used term coil spring describe veeva outlook davis say future look even more prosperous come view veeva have several growth initiative process range significant new feature upsell adjacent customer breadth move davis say recent note client pleasanton calif base veeva have more customer life science industry range big pharma firm emerge biotechs count company amgen amgn eli lilly lly merck mrk novartis nvs pfizer pfe customer veeva go public october share hit time high march manage avoid most carnage week sell share be friday veeva stock break week consolidation period buy point feb day company post better expect result fiscal fourth quarter give guidance crushed wall street estimate current fiscal year current fiscal year end next jan veeva expect earn adjust share year year sale base midpoint guidance analyst be modele adjust profit share sale veeva growth initiative be likely reach sufficient scale year provide path upside estimate davis say scenario be correct investor figure sometime summer fall point veeva share sustainably move higher say davis rate veeva stock buy veeva begin software application help pharmaceutical sale rep organize drug datum make stronger doctor pitch today product customer relationship management call veeva crm dominate drug market roughly user share now part veeva commercial cloud business big driver company business today be veeva vault launch be create organize content involved clinical drug trial document patient datum work flow vault product now cover clinical quality regulatory commercial aspect drug development manufacturing sale have penetrate less market william blair analyst bhavan suri tell investor business daily veeva also have discover vault offer be useful other heavily regulate industry such chemical consumer product sector company offer company outside life science be call vault qualityone have more company used product launch year get newsletter deliver inbox more info product service privacy policy term useon conference call analyst feb veeva chief executive peter gassner say company have be planting seed future growth especially exciting see franchise re build side life science say veeva be uniquely position help streamline drug development re only technology provider best class application suite major area development include clinical quality regulatory come next year safety single modern cloud platform believe veeva development cloud be industry long term veeva software service offer have be replace legacy vendor use premise hardware software system rival include oracle orcl medidata solution mdso iqv other veeva management have strong track record deliver growth be conservative guidance william blair suri say rate veeva stock outperform veeva have forecast revenue run rate fourth quarter think hit run rate early next year month ahead expectation suri say not only hit dollar run rate early next year sustainability growth be next year meanwhile jpmorgan downgrade veeva stock overweight neutral march cite valuation concern stock have climb year be strong franchise be execute well number growth initiative have little room outperformance current level jpmorgan analyst sterling auty say note client estimate veeva addressable market fraction more spend year life science company information technology fertile market provide greater growth subscription revenue fiscal grow fiscal auty say related veeva rocket top quarterly estimate crush guidance viewsceo gassner make sure veeva have second act more
105,PFE,stock index post solid gain midday friday republican scramble make final adjustment tax cut bill volume be run higher major exchange small cap russell lead way pop strike new high nasdaq advanced respectively blue chip trail leader dow jone industrial average rise volume stock market today be likely be higher expiration friday be quadruple witching day involve expiration stock index future stock index option stock option single stock future republican wrap tax cut bill today vote come early next week give president trump chance sign bill law christmas new york time report stock market tax cut legislation be driver jpmorgan top strategist marko kolanovic say note upcoming reduction corporate tax rate be biggest positive catalyst equity cycle kolanovic be convince little be price market big question now be sector rotation be several way scan sector rise fall thorough check involve look sector be provide most new high industry group table sector ranking ibd stock table breakout blue chip be ibm ibm fall strong volume dow jone industrial average leader include drugmaker pfizer pfe insurer traveler trv money center jpmorgan chase jpm apparel stock class share armour ua gap reclaim day line stock be laggard remain high street expect earning decline then rebound armour pretax margin have narrow past year apparel industry group have rise week stock group advance issue ibd lead decline issue roughly ratio innovator ibd fund ffty exchange trade fund mirror ibd rise fund break august be buy point etf have return day area have not yet be able establish support related advisory see bullish driver stock marketthe top retailer find great stock begin simple routineeven kid get rich stock here be valuable tipsin stock market today hold sell bitcoin etf
106,PFE,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
107,PFE,look increasingly clear only way gop be able make corporate tax rate permanent be tax hike individual decade start xon monday house gop tax cut bill have gulf more cost corporate rate offset corporate revenue raiser second decade end tuesday gulf have widen house way mean committee gut biggest proposal help pay corporate tax cut excise tax payment business other affiliate same company overseas dream permanent rate have die wal mart wmt other retailer successfully kill idea border adjustment tax import have raise first decade have run afoul world trade organization profit shift company such apple aapl alphabet googl pfizer pfe low tax jurisdiction be estimate cost government year lose revenue house tax bill measure discourage such practice tax high foreign return raise just gop push tax cut add deficit first decade plan add deficit meet senate budget reconciliation rule allow passage just vote democrat gop hasn show card regard decision tax cut be make permanent expire do flash warning sign last week afternoon house reveal tax cut job act top tax writer kevin brady say corporate rate have be temporary prompt index future slide miraculously brady reversed course late same evening permanent corporate rate cut once again supposedly card investor exhale market resume ascent yet number reveal next day didn add re even further add now be talk few month individual tax cut have expire meet senate budget rule prospect dollar tax hike individual pay corporate tax cut be much more dicey political calculation brady flip flop suggest republican be understandably reluctant go result tuesday election virginia characterize bloodbath republican keefe bruyette wood washington analyst brian gardner only add pressure republican adopt more populist approach bill mean less tax relief corporate side more relief individual especially lower income level ibd take dow jone industrial average close tuesday point ibd change market trend indicator aug confirm uptrend uptrend pressure equivalent yellow light turn green make sure read big picture column day stay top market direction key indicator let know be aggressive move sideline political consideration strategy pay massive corporate tax cut individual tax hike jeopardize vote handful senate republican have say don want plan add deficit gop seek provide assurance congress never actually let individual tax cut expire implication be deficit be much higher long run senate republican reveal own tax cut legislation friday so sleeper issue sunset tax cut turn tax hike soon be front center already senate republican be signale delay cut corporate tax rate year direct more budget space individual tax cut anything short permanent corporate tax cut have be judge failure least standard house speaker paul ryan offer august business aren do multibillion dollar multiyear capital decision see tax code unpredictable ryan say august big decision make provision tax code stuff get be permanent temporary deficit finance corporate tax cut also likely be judge failure economist meaning do nothing boost growth very short term be judge shrink economy raise cost capital political pressure senate budget rule seem highly unlikely produce permanent corporate tax rate number wall street strategist have highlighted corporate rate more feasible fallback be right however even win be simple get do thing congress adopt corporate tax rate instead company have bigger incentive shift income low tax foreign jurisdiction yet gop be already struggle figure keep company capitalize rate disparity secondly even tax rate require tax hike half more individual second decade gop be able come more offset tax increase business yet more moderate rate cut pushback corporation be expect intensify related ibd tipp poll economic optimism rise mainly high house gop tax bill have big family problem question trump let alphabet pfizer keep tax haven be biggest loser trump tax reformstock buy watch top ipos big small cap growth stock
108,PFE,retreat friday dow have be set record high stock be still buy point get push need enter buy range earning season pick steam stock watch week be wal mart wmt unite technology utx merck mrk cisco system csco pfizer pfe wal mart be reconsolidate flat base buy point fail break cup base earlier wal mart fall further day line finishing lower friday computer networking company be form saucer handle base buy point institutional investment cisco stock have rise last quarter share end friday higher industrial giant know jet engine elevator be form flat base entry point stock have alternative entry point stock close jump day day line earlier month share tumble more day unite tech have agree buy rockwell collin col ibd take earning season be kick here list other stock buy point watch ahead third quarter result pharma giant merck be form shallow double bottom base buy point share edge friday find support day line last month pfizer meanwhile be form long cup base stretch nearly day buy point pfizer friday related top stock have etch super bullish pattern read stock chartsdow jone industrial average dow stock news analysisblue chip cisco be prime move higher buy point
109,PFE,abbvie abbv humira franchise be safe patent settlement amgen amgn analyst say monday upgrade abbvie predict profit outgrow other large cap pharmas xleerink analyst geoffrey porge upgrade abbvie outperform rating up price target note upgrade miss abbvie recently strong performance believe be still further upside valuation abbvie be alter base extend market exclusivity humira model previously settlement amgen write note client settlement amgen pay abbvie royalty sale humira copycat humira be abbvie most important drug bring total sale second quarter humira be inflammatory med close bell stock market today abbvie climb finish share break flat base buy point late august have rise hit point ibd take abbvie be also work galapago develop treatment cystic fibrosis analyst say vertex pharmaceutical have large lead head new america closer look market breakdown settlement allow amgen launch biologic copy humira know amgevita europe next october version amjevita be set launch january other rival be likely be offer same market entry deal porge say boehringer ingelheim coherus bioscience chrs be closest entry biologic copy humira boehringer cyltezo be approve august firm be patent battle abbvie coherus be still work submit application regulator dow component merck mrk pfizer pfe addition novartis nvs momenta pharmaceutical mnta be bound file approval biologic copy humira come quarters likely infringe abbvie humira patent lawsuit likely be resolve mid remove risk launch right settlement date porge say result believe certainty humira patent protection be nearly porge increase humira sale view longer term humira estimate increase respectively expect abbvie hit operate margin project abbvie earning share command annual growth rate top large cap pharma peer project mature biopharmas set mid single digit growth growth horizon company increasingly visible late stage pipeline suggest abbvie stock continue re rate range large cap biopharma peer porge say related amgen drug send abbvie stock company gain trump foreign profit relief plan passesabbvie new hepatitis drug chip away gilead share
110,PFE,abbvie abbv launch record high thursday settle patent dispute amgen amgn require biotech pay abbvie royalty sale humira copycat xby close bell stock market today abbvie pop earlier trade share be much record high amgen stock lift fractionally close settlement amgen drug know amgevita launch europe october version amjevita launch january drug be biosimilar abbvie drug humira inflammatory med biosimilar be biologic copy drug amgen pay royalty abbvie specific term be confidential abbvie say news release litigation pending be dismiss abbvie grant patent license amgen country country basis humira be abbvie most important drug bring total sale second quarter end june other drug firm be work humira biosimilar include biogen biib novartis nvs dow pfizer pfe mylan myl evercore analyst umer raffat say note client ibd take abbvie galapago be also work together cystic fibrosis drug vertex pharmaceutical say have strong lead analyst don disagree head new america breakdown market vertex be lead pack consensus be call amgen humira biosimilar first approve bring worldwide sale just set launch europe still be patent remain abbvie use extend litigation raffat say rbc analyst kennen mackay boost view success amgevita amjevita expect amgen drug penetrate peak humira biosimilar market europe respectively mackay model peak global sale amgevita amjevita hit sale share basis expect amgen have humira biosimilar market depend royalty rate keep sector perform rating price target amgen related biotechs beating market be buy range company gain trump foreign profit relief plan passeswhy amgen lilly be interested small biotechsabbvie new hepatitis drug chip away gilead share
111,PFE,exchange trade fund popularity keep grow investor plow money popular low cost vehicle offer access basket stock trend doesn appear be wane combine asset etfs surge january accord investment company institute year total number etfs rise january year launch very first etf spdr spy be now fund available variety category style gain further insight etfs potential benefit growth outlook checked todd rosenbluth senior director etf mutual fund research cfra cfra acquire global rosenbluth be director etf mutual fund research capital iq previous experience include manage editor value line mutual fund survey financial advisor morgan stanley full interview rosenbluth also discuss current trend etf space follow ibd investor own etfs rosenbluth investor want exposure stock bond market look etfs typically provide low cost exposure broad investment category narrower thesis benefit diversification transparency example rather own just merck mrk investor health care select sector spdr xlv fidelity msci health care index etf fhlc hold merck peer include johnson johnson jnj pfizer pfe company other related industry include medtronic mdt unitedhealth group unh actively manage mutual fund investor see daily etf determine think continue fit portfolio ibd be too many etfs rosenbluth approximately third cfra rate etfs come market march so think investing investor determine etf serve legitimate investing purpose so more likely gain sufficient asset be viable keep mind cfra rate far more mutual fund etfs several dozen asset manager offer similar sound product give sentiment shift lower cost etfs away more expensive mutual fund cfra expect more mutual fund be close merged response get ibd market prep tech report newsletter free ibd do think fuel further etf growth hinder growth rosenbluth investor advisor adoption etfs design support asset allocation need be go further drive etf growth vanguard voo ishare core msci eafe iefa be example such well diversify product more investor gain comfort etfs money continue flow establish come product investor always favor mutual fund wrapper want active management address many large asset manager include davis fund legg mason pimco vanguard offer actively manage etfs area potential growth ibd even factor base etfs aren new smart beta continue be buzzword have contribute rise popularity smart beta fund rosenbluth actively manage mutual fund struggle keep return msci eafe index investor be seek alternative smart beta etfs launch last year include popular goldman sachs activebeta large cap equity gslc ishare edge msci multifactor usa etf lrgf combine factor approach offer diversify yet lower cost approach quantitative investing here again many large asset manager have expand etf presence used smart beta product response grow demand last month jpmorgan minimum volatility jmin oppenheimer russell low volatility factor ovol usaa msci usa value momentum blend index etf ulvm have launch be cover cfra research ibd esg environmental social governance fund have be news too do think last trend rosenbluth esg mutual fund asset have be quite sticky even many actively manage mutual fund slowly bleed asset favor index base etfs expect time esg etfs gain traction investor further embrace etfs put money work focuse conviction value ibd new trend re see now rosenbluth re see investor look more closely thematic etfs traditional sector well diversify etfs etfs focus robotic blockchain other potentially long term investment trend more narrowly construct product such global robotic artificial intelligence botz robo global robotic automation index robo reality share nasdaq nexgen economy blcn innovation share nextgen protocol etf koin tend charge premium price relative market cap weight etfs more asset manager compete investor interest fee have continue move lower ibd type etfs do expect outperform interest rate rise rosenbluth equity etfs cfra think more economically sensitive sector include financial industrial benefit rate rise due strong economy vanguard financial index etf vfh ishare transportation average iyt be couple example addition interest rate rise cfra be focuse bond etfs limit interest rate sensitivity low duration product reduce downside impact federal reserve raise rate ishare year investment grade corporate bond shyg spdr bloomberg barclay short term high yield bond etf sjnk be example short term etfs rate favorably cfra ibd give feb market sell early redemption velocityshare daily inverse vix short term etn xiv be thought vix tie volatility etfs be appropriate type investor rosenbluth vix base product be not rate cfra focus etfs directly hold stock bond not derivative however investor need understand inverse leverage etfs aggressively move warning loss pile quickly ibd do xiv early redemption mean harder investor manage risk so do affect market operate rosenbluth xiv be exchange trade note not traditional etf be other product ve talk etns investor need understand be issuer risk consider top usual investment risk etf shut investor get fair warning understand portfolio help track receive hold product close xiv mechanic be much different road closure be much shorter important note however happened xiv be spel prospectus so be less example larger market issue more example investor need know exactly re get involved particularly leverage inverse volatility product ibd be sound strategy long term investor etfs rosenbluth long term investor regularly review etfs re hold understand security fit go forward investor also periodically rebalance asset position do not move tandem not necessarily stand still even passively manage etfs ibd do cfra assess etfs do differ other industry researcher rosenbluth cfra provide forward look rating more etfs combine holding analysis fund attribute include expense ratio technical analysis etf much cost be bigger driver future return year track record well track typically unique index etfs rate favorably cfra do so have confidence valuation risk consideration holding also compare etfs separate mutual fund relevant metric differ other compare active mutual fund try beat etfs such spdr seek replicate index equity etf rating launch nearly year global umbrella top rate etfs have outperformed index bottom rate etfs have underperform equity fund research be acquire independent research provider cfra research late investor learn more https newpublic cfraresearch com email protected rosenbluth be twitter also be interested blockchain expand bitcoin amazon nvidia alibabafirst trust launch new blockchain etf meet demanddow back apple reversal gold shine bitcoin fall
112,PFE,key stock index fund extend gain apple aapl amazon amzn alphabet goog boost tech heavy qqqs powershare qqq trust qqq rise spdr dow jone industrial average dium advanced spdr spy add stock market today emerge market small cap underperform qqq notch fifth straight session big cap techs move include amazon alphabet also extend streak day amazon gain alphabet apple rise end session loss iphone maker share remain day move average level be stick past week utility consumer staple health care lead upside sector fund health care select sector spdr xlv advanced head back day move average top component johnson johnson jnj pfizer pfe be dow top gainer express script esrx pop news health insurer cigna ci acquire pharmacy benefit manager metal miner bank retail lag spdr metal mining xme fall continue test support day line apple amazon facebook fb be top name hold big cap growth fund set possible buy opportunity similar etfs featured recently schwab large cap growth schg remain day move average retake line monday put fund potential buy zone important note purchase be higher normal risk market uptrend pressure etf also be form base potential buy point share advanced late september bounce line jan high then fall much february correction recover loss consolidate day line fund track dow jone large cap growth total stock market index marked eighth anniversary december offer market cap weight exposure big cap equity exhibit growth trait information technology represent nearly third total asset tuesday consumer discretionary be next health care industrial financial real estate consumer staple energy material service make less use ibd marketsmith free march
113,PFE,see stock buy point get chart pattern recognition run custom screen start nowtop holding account stock portfolio include apple amazon facebook berkshire hathaway brkb alphabet amazon lead year date gain wednesday boee ba top name be next return apple have be trading day line past few week be feb intraday peak etf year date gain tuesday be ahead return accord morningstar direct average annual return past year respectively also lead index gain period schg carry expense ratio wednesday pick vanguard total stock market vti be hold support day move average also be interested dow stock extend loss apple fall china bitcoin dropsdow back apple reversal gold shine bitcoin fallsapple extend gain dow stock rally bitcoin play set
114,PFE,other major index continue climb etching fresh record high wal mart soar investor increasingly see discount giant give amazon amzn run money other retailer falter jpmorgan chase jpm citigroupc charge off other issue stock back delta dal offer solid earning guidance other carrier give upbeat figure crash report more pay tv loss signale wo medium company generally index nasdaq rise dow industrial climb index continue hit record high wal mart boom even retailer continue tumble warning analyst downgrade amazon speculation nvidia make yet advance new move autonomous vehicle delta air line kick airline earning big carrier seem be regain altitude wal mart wmt announce buyback program say see fiscal net sale rise commerce sale soar current fiscal year wal mart see earning share discount giant see ep growth fiscal wal mart also plan add online grocery location current store look take amazon amzn target tgt investor day call wal mart signale wouldn hike wage target wal mart share surge nearly week blast past buy point even many retail stock group struggle related wal mart break buyback bullish online sale chase jpm bank america bac citigroup report better expect earning revenue ongoing trading wo wall street jpmorgan say see trading remain weak fourth quarter jpmorgan bank america citigroup raise reserve credit card have see higher delinquency recent month well fargo wfc report mixed result revenue net interest margin fall short well fargo retreat friday share other big bank pull back somewhat week cable tv company medium stock sell renew worry pay tv cord cut be accelerate preannounce financial number include loss video subscriber actually lose pay tv customer add internet video subscriber partially offset loss ub estimate pay tv industry lose subscriber third quarter compare same quarter last year worry medium company garner subscriber programming fee tumble drop collar propose acquisition medium giant time warner twx stock be share deal close time warner shareholder stand get more stock share company now hold cable internet content giant comcast cmcsa lose thursday month low viacom viab skid year low related fallout pay tv industry lose air line dal kick third quarter earning industry group beating estimate give solid unit revenue guidance earlier week american airline aal unite airline ual raise outlook unit revenue total figure big indicated analyst airfare pricing be improve follow concern recent month impact series hurricane fare war unite spirit airline save southwest luv also say begin service hawaii next year likely meaning more competition hawaiian airline parent hawaiian holding delta share rise week approach buy point related delta air line see turnaround crucial highly competitive marketsay aloha airfare price wargraphic chip maker nvidia nvda tout expertise make brain self drive vehicle conference germany unveil artificial intelligence computer fully autonomous vehicle be already be used more company develop driverless taxi also announce german logistic giant deutsche post dhl group be deploy test fleet self drive delivery truck next year used nvidia technology nvidia stock climb hit new high minute federal reserve september meeting show several policymaker fence raise interest rate december market be now pricing consumer price retail sale datum show post hurricane boost september core inflation remain tame crude future rise barrel stockpile fall third straight week inventory fall barrel accord energy information administration far more barrel decline analyst expect domestic production fall barrel day week prior international energy agency predict opec continue supply cut current deal expire march agency say cartel output rise bpd last month iea keep demand forecast unchanged still see demand growth barrel day year demand growth bpd saudi arabia say export less crude sea next month related oil inventory production drop iea see more opec cutsexpress script esrx announce buy evicore healthcare privately hold medical benefit management service company way pharmacy benefit manager diversify report amazon amzn be reportedly close enter online pharmaceutical sale express script tumble year low lose oct amazon speculation heated cvs health cvs be drugstore operator pbm sank walgreen boot alliance wba skid earning hit share revenue rise better expect same store sale rise also view share fall week ep beat estimate thank accounting change comp wall street consensus be far gain year earlier related domino earning help accounting change flop wall st honeywell confirm spin home adi global distribution business transportation system company worth combine confirm monday report noncore asset spinoff honeywell keep aerospace holding call activist investor third point divest honeywell share dip still buy zone pfizer pfe say tuesday consider selling spin counter business include advil centrum personal care item chapstick anbesol pain relieve gel toothach decision isn expect woman apparel chain jill jill issue big profit warning send share recent ipo crash thursday retailer sell day penney jcp hit time low ulta beauty ulta william sonoma wsm rocked analyst downgrade procter gamble pg narrowly win proxy fight vs activist investor nelson peltz have be fight board seat press strategic shift more innovative brand fewer corporate division trian fund have take stake earlier year anaptysbio anab sky-rocket record high tuesday eczema drug appear outperform regeneron pharmaceutical sanofi potential blockbuster eczema drug dupixent phase trial day patient moderate severe eczema see improvement symptom chip equipment maker ichor holding ichr say have enter substantial agreement produce liquid delivery system key customer do not identify customer ichor stock surge nearly time high apple aapl inked first major internet television deal signing acclaim director producer steven spielberg make new episode anthology show amazing story barracuda network cuda sell post line fiscal earning bear pounce lower customer renewal rate subscription well security software maker reiteration fiscal revenue guidance
115,PFE,versartis vsar plunge early friday pediatric growth hormone deficiency drug fail late stage trial send share rival ascendis pharma asnd soar xin premarket trading stock market today versartis dove meanwhile rival ascendis sky-rocket ascendis also have late stage drug same hormone deficiency versartis drug know somavaratan miss key goal trial dub velocity biotech say late thursday course month patient treat somavaratan grow centimeter height vs centimeter patient receive pfizer pfe growth hormone drug genotropin chief executive jay shepard say versartis be review result provide corporate update later year ascendis be also work pediatric adult growth hormone deficiency drug pediatric iteration have begin phase trial adult version have wrapped phase testing firm see hormone deficiency combine market ibd take analyst have call datum several company be real catalyst ledge biotech group head ibd industry theme grab lineup datum readout month related intercept plunge fda warning drug related deathsalnylam be enter new chapter ionis still have chancewhy amgen lilly be interested small biotechs
116,PFE,stock open very tight mix wednesday eye trained afternoon policy announcement federal reserve dow jone industrial average open few click higher less nasdaq composite ease almost stock europe also hold tightly mixed formation afternoon trade lead asian stock market have close firmly higher wednesday session national association realtor report august exist home sale number important follow tuesday housing start datum spotlight economic news be schedule et federal reserve announce policy change day meeting press conference fed chair janet yellen follow et month well telegraph intention fed be today expect announce gradual shift neutral stance hold bond be seller begin trim debt balance sheet move point decline bond price rise yield turn drive interest rate economy expectation have be positive bank other credit financial institution lead beneficiary rise interest rate banking industry group track ibd turn decline solid gain past week midwest bank group lead gain follow foreign bank west southwest bank build product oil gas heavy construction industry group have post strongest gain past week industry group track ibd pfizer pfe surge top dow upgrade overweight equal weight piper jaffray pfizer remain buy range buy point month flat base johnson johnsonjnj mmm drop dow worst early decline receove downgrade underweight neutral jpmorgan johnson johnson be cut sell neutral goldman sachs apple aapl drop fang stock google parent alphabetgoogl lead gain netflix nflx amazon com amzn rise piper jaffray report base google search datum suggest netflix easily surpass subscriber growth target report third quarter earning october netflix ibd leaderboard stock be climb right side flat base buy point amazon be report be work first alexa power smart glass device wearable computer rely bone conduction system avoid need speaker headphone financial time report also ibd leaderboard stock amazon be flat base buy point important earning result report late tuesday include adobe system adbe fedex fdx bed bath bbby adobe drop beating fiscal third quarter sale earning expectation management fourth quarter guidance be mixed however ibd stock have be extend trading new high well week line support fedex dip cyberattack hurricane harvey chew fiscal first quarter result share have be hold week support month flat base bed bath be wet diving report harsh miss earning revenue same store sale target second quarter result stock end tuesday so far week january high aluminum corp china commonly call chinalco roar ahead seize new high aluminum price china spiked year high follow news chinalco lead competitor have pare back production well ahead winter restriction normally impose chinese government chinalco share be clear double bottom base july aluminum producer alcoa aa rise share be clear cup handle buy point august related ibd growth stock be just buy big picture stock bide time ahead fed ibd leadsget start ibdfollow market stock market todayunderstand market big picture
117,PFE,stock market need band aid monday stop bleed need full blow tourniquet tuesday dow take biggest hit fall give back hurt largely weakness commodity stock nasdaq composite lose decline be worst major stock index start
118,PFE,share dow pfizer pfe tumble tuesday sale breast cancer drug lag expectation fourth quarter culminate beat raise include dramatically improve tax rate close bell stock market today pfizer dove meanwhile drug stock broadly dip uncertainty amazon amzn berkshire hathaway brkb jpmorgan chase jpm announce collaboration lower healthcare cost fourth quarter pfizer report sale ibrance be approve treat breast cancer patient sale grow year year miss forecast leerink analyst seamus fernandez ibrance sale decline internationally period due time price adjustment european market pfizer say news release ibrance volume grow sequentially develop europe still ibrance growth be disappointment highlight need international growth investor await outcome ongoing adjuvant breast cancer study fernandez say note client more broadly pfizer bring adjust income cent share sale fourth quarter rise respectively metric beat consensus adjust profit cent share revenue fernandez call fourth quarter beat largely irrelevant instead focuse guidance sale adjust earning share consensus have modeled respectively ibd take alexion pharmaceutical gilead science vertex pharmaceutical be expect top fourth quarter expectation other continue struggle rival face biggest moneymaking drug head ibd industry theme more fourth quarter earn season hold pfizer also guide tax rate investor have expect lower tax guidance fernandez say december president sign massive tax cut corporation law last week abbvie abbv guide low tax rate key question call likely focus sustainability tax rate fernandez say consumer business be sell management plan deploy capital tax impact be pfizer cash hoard investor also look commentary pfizer split company large scale merger acquisition say pfizer say have decision sometime year sell consumer healthcare business quarter consumer healthcare sale be flat sale cholesterol drug lipitor grow nearly estimate xeljanz rheumatoid arthritis drug bring grow related gilead stock break abbvie earning here biopharma behemoth soon become acquisitivewhy insurer haven win push back rare disease drug
119,PFE,investor show little bit fear prospect not quarter point rate hike follow first testimony congress new federal reserve chief jerome powell stock trading solidly lower head final half hour powell say prepared remark central bank continue strike balance avoid overheat economy bring price inflation sustain basis meanwhile top growth stock arista network anet just edge lower tuesday afternoon retake key day move average monday software centric datum center networking gear specialist be far better broader market arista report stellar result little more week ep revenue net margin basis point vs year need try form new base trigger sell signal feb share be just time high stock have market cap just arista have reasonable float share much smaller share float arch rival cisco system csco cisco be have super so far year date rise more clear shallow saucer handle oct saucer handle have aspect great cup handle generally show more shallow look even decline high low exceed large amount time take form winning stock chart pattern tend wear investor rather shake nasdaq composite ease give back chunk advance prior session tech center index be much earlier session nasdaq fall experience resistance second time nearly week fall dow jone industrial average drop strength industrial tech commodity type component stock dow industrial help blunt decline homebuilder fall hard yield benchmark treasury year bond jump back level bond price halter session streak toll bro tol swung nice early gain fall nearly heavy trade watch see luxury homebuilder form new base revenue rise january end fiscal first quarter notch biggest year year increase quarters adjust earning jump elsewhere stock market today utility continue serve caboose dow utility average fall stock index remain more november peak stock nextera energy nee have be hang relatively tough juno beach fla base utility drop slide back day move average however see daily chart marketsmith stock find nice institutional buy support slower move long term day move average earlier month watch see nextera keep head day line be bullish large cap firm have annualize dividend yield vs less track yield day go large cap index chart general market indicator pdf link bottom big picture column more company watch growth income play be blackstone group bx helmerich payne hp pfizer pfe toronto dominion bank td be currently ibd dividend leader screen sport good yield have excellent annual earning stability long term dividend growth range annually toronto dominion blackstone helmerich payne sign free ibd newsletter market prep tech reportrelated be next ipo stock gem also stock market today dow lead upside industry group rally more stock buy zonewhere find ibd dividend stock leader
120,PFE,here weekly investing action plan need know investor come week report season result be begin delta air line dal jpmorgan chase jpm citigroup bank america bac well fargo wfc lead charge look central banker meeting last
121,PFE,drugmaker be begin gain steam drug trial result begin determine winner loser industry merck mrk be next break move higher ethical drug industry have jump industry group ranking last week time merck
122,PFE,never count mylan myl analyst say wednesday food drug administration approve generic version teva pharmaceutical teva copaxone multiple sclerosis drug set share company vastly divergent path xby close trading stock market today mylan have spiked teva meanwhile plunge analyst largely hadn expect fda approve generic copaxone approval be milligram daily dose milligram shot time week milligram approval be first generic dose novartis nvs sandoz momenta pharmaceutical mnta get approval milligram daily copaxone generic glatopa mylan also announce patient support service dub mylan ms advocate help ease patient brand copaxone generic interactive mobile app home injection training call center copay assistance eligible patient support nurse experience treat ms analyst be widely surprised approval come heel fresh comment fda commissioner scott gottlieb bloomberg regard need speed generic drug approval spur competition reduce drug price bottom line be incrementally positive mylan teva negative surprise cash flow hit rbc analyst randall stanicky write note client reiterate underperform rating teva stock teva call impending launch mylan risk meaning rival generic drugmaker be subject damage other remedy pending outcome appeal decision other patent litigation case teva be argue december decision patent trial appeal board find claim copaxone patent be invalid teva also be argue january decision district court invalidate claim patent cover copaxone firm also be sue company include mylan claim infringe patent cover manufacturing process copaxone company be work bring generic copy ms drug market ibd take teva have poor ibd composite rating best possible meaning perform bottom stock term key growth metric see better rate drug stock ibd stock checkup teva expect mylan generic launch eat cent earning share fourth quarter end dec rbc stanicky note teva have previously predict generic lead annual revenue downside hit share earning teva previously guide slow copaxone deterioration due stickiness patient support program play initially write however mylan patient support program drive more switch time consensus number project erosion teva copaxone fourth quarter decline evercore analyst umer raffat write note client expect teva have dig deeper additional cost cut offset btig analyst timothy chiang model mylan bring generic copaxone sale first month follow launch assume generic pricing be discount brand drug mylan grab market share believe company gain approval strength copaxone not only validate mylan core competency premier generic company also provide important signal investor simply never count mylan especially area complex generic product say chiang keep buy rating mylan stock boost price target mylan news release say other first filer be eligible day generic drug exclusivity note fda hadn yet make formal determination month end july strength copaxone bring sale firm say approval be negative other entrant momenta novartis sandoz be work get approval milligram version copaxone february duo get warning letter fda detailed issue manufacturer pfizer pfe fill finish plant momenta stock plunge response mylan approval payer be likely also put pressure biogen biib lower price ms drug rbc analyst brian abraham write research report drug suite bring just shy sale believe highlight need biogen concede price share multiple new generic brand therapy enter market come year especially space do not have high intrinsic growth write abraham estimate biogen report ms drug sale decline note decline be higher payer get more aggressive biogen stock dip response related generic drug maker face pricing issue other pharmas don tbiotechs find strength number treat multiple roche game changer drug chip away biogen novartis
123,PFE,stock take home hard earn gain tuesday session drive new high see dow name score breakout dow jone industrial average nasdaq composite marked gain nasdaq gather late rally drag negative reversal apple aapl small cap run ahead general market russell clocking gain close global market have effect early trade tuesday investor france germany picked second straight powerful rally japan gain be more muted preliminary datum show trade mixed higher nyse lower nasdaq market be clearly not defensive mode tuesday utility group take worst loss industry group track ibd largest advance go oil driller home furnishing retailer automate material handle equipment maker most gain drive group come thinly trade stock stock beaten chart need week mend offer valid buy point once exception home furnishing group be rh rh high end online storefront shop find suddenly back support week move average shape possible handle steep week cup base apple be day focal point introduce new iphone apple watch series other revise device also inaugurate company new space age cupertino calif campus stock nevertheless erased early gain end very heavy trade still unable break free buy range buy point fang stock end session ibd swingtrader play netflix nflx end higher continue climb buy point week cup base dow pfizer pfe kick lead index announce positive result follow trial xalkori lung cancer treatment stock be form base buy point be also possible interpret chart flat base larger pattern buy point pfizer top
124,PFE,dow come newly merged chemical giant dowdupont dwdp stock surge management announce tweak plan divide separate company just enough please contingent activist investor include trian fund management glenview capital management gain moved share past handle buy point powerful trade leave stock still buy range lead stock be divide session coherent cohr lgi home lgih rise more apiece lead ibd list stock be build right side basis ibd peer national beverage fizz coresite realty cor fall however realpage rp dive nearly heavy trade stopping test support week move average related follow market stock market todayunderstand market big picturedon miss top stock buy point investing action planhere mcdonald be reverse day breaking
125,PFE,bristol myer squibb bmy pop month high thursday immuno oncology combination prove successful vs chemotherapy previously untreated patient advanced kidney cancer xin morning trading stock market today bristol surge close drug stock hit month high astrazeneca azn winner close astrazeneca also be work immuno oncology combo astrazeneca lung cancer failure july bristol combination meet key goal phase study trial evaluate drug name opdivo yervoy patient advanced kidney cancer have never be treat vs chemotherapy opdivo yervoy demonstrated superior overall survival vs chemotherapy patient intermediate poor risk patient bristol say news release combo also outperformed chemo random pool patient bristol say independent datum monitoring committee recommend trial be stop early strong result more detailed result be present sunday european society medical oncology congress evercore analyst umer raffat say ibd take bristol grab boost relative strength rating wednesday thursday rs rating be best possible head ibd datum story closer look go ranking closest rival trial roche rhhby be set finish raffat say note dow component merck mrk also have several trial kidney cancer testing combination used drug keytruda pfizer pfe emd sereno be also work combo leerink analyst seamus fernandez say very likely bristol get approval drug advanced kidney cancer have outperform rating bristol stock overall survival be critically important bull thesis stock be consistent view previously interview medacorp key opinion leader say report client related bristol dife still have chance kidney cancer analystbristol myer squibb topple kidney cancer trial mixed resultswhy dow merck be credit suisse top pharma pick
126,PFE,ascendis pharma asnd grab bullish view rocket record high friday rival versartis vsar crash report pediatric growth hormone deficiency drug fail late stage trial xby close bell stock market today ascendis have gap finish earlier touch time high share break consolidation buy point heavy volume versartis plummet close late thursday versartis say drug somavaratan fail meet goal phase study pediatric patient growth hormone deficiency now analyst expect ascendis grab lion share market phase drug win approval credit suisse analyst alethia young boost price target ascendis see ascendis get global market earlier view share model ascendis drug dub transcon growth hormone hit peak sale previous forecast daily growth hormone market be worth rise market move long act drug ibd take big biotech player vertex pharmaceutical say close end cystic fibrosis journey so next top performer head new america exclusive interview chief executive jeffrey leiden enrollment phase trial transcon growth hormone be expect be complete fourth quarter young expect ascendis offer datum trial late drug be successful price target lift high young see chance ascendis get approval drug leerink analyst joseph schwartz keep market perform rating ascendis await phase datum note risk associate up price target ascendis expect get market share growth hormone deficiency market schwartz assume peak penetration europe ascendis drug earlier forecast respectively still view market share aggressive hurdle factor other bullish assumption include commercial execution other company succeed clinic long act growth hormone say firm have high bar phase datum be go like pfizer pfe nordisk nvo most specialist say market generally favor aggressive approach achieve better growth phase study annualize growth pediatric patient treat transcon growth hormone be centimeter different weekly dose be comparable centimeter patient treat daily pfizer genotropin say be risk result regress phase be difficult pinpoint market share implication such difference growth outcome schwartz say related human growth drug flop send biotech crash alnylam be enter new chapter ionis still have chancewhy september be make break month biotechs
127,PFE,stock index be mixed midday wednesday market await federal reserve view economy interest rate nasdaq retreat be just flat dow jone industrial average small cap russell add respectively xvolume stock market today be slightly lower nyse bit higher nasdaq blue chip be mostly stock rise component dow jone industrial average stock fall mcdonald mcd drugmaker pfizer pfe score gain meanwhile apple aapl sag fall day move average heavy trading ibd proxy lead stock winner lead loser ratio software provider adobe system adbe gap beating street consensus view earning company forecast fourth quarter fail impress street stock be try find support day move average fed conclude meeting et fed chair janet yellen conduct news conference et cme group fedwatch tool put odd change interest rate overwhelming consensus have be case time odd rate decrease drop odd increase rise rate be range be set june increase fed fund rate bank stock be sensitive interest rate change have be rise recently example money center industry group rise past day be head gain wednesday period include wednesday so far group advanced factor be fed expect plan begin trimming balance sheet quantitative ease dent bond price lift yield ibd industry group best performer wednesday include oil drill group airline specialty steel day laggard include solar energy chip stock west texas intermediate crude oil rise barrel related be big bank stock set move crude oil be back
128,PFE,major market index fade session lows late morning trade wednesday apple aapl fall recent buy point major support level meanwhile investor be look ahead afternoon fed policy decision central bank release decision et fed be not expect raise interest rate instead be believe announce unwinding debt portfolio tech heavy nasdaq fall dow jone industrial average be back unchanged meanwhile dip dow industrial pfizer pfe set pace rise drugmaker be upgrade overweight morgan stanley downside apple fall nearly flat base buy point undercut day move average tesla tsla nearly stock market today look test cup handle entry stock be downgrade tuesday cause share fall just day reach record high company report earning fedex fdx rise miss fiscal estimate cut full year outlook late tuesday stock be approach entry continue etch flat base buy point meanwhile adobe system adbe drop report mixed guidance late tuesday share remain well extend flat base entry be testing day line finally general mill gis plunge miss fiscal earning sale target early wednesday cereal maker have be stick downtrend july fall high period be now fresh lows western digital wdc decline toshiba reportedly decide sell memory chip unit group head bain capital share have be sketch cup handle pattern buy point today action bring stock back day line lead stock electronic art ea advanced be start buy buckingham price target premium tuesday close price share have be trend buy point july progress have be muted share be trading top buy range top ibd china base yy yy rise trading earlier stock be extend solid rebound support end august be also sixth week possible cup base downside lead chip stock apply material amat decline fall back recent cup handle buy point related foreign bank stock be good place stash cash investing action plandow jone industrial average dow stock news analysisfedex earning hit tnt cyberattack hurricane harvey outlook cutadobe system beat third quarter sale earning target
129,PFE,key index fund be lower wednesday fed hold rate steady expect say start trimming balance sheet october xpowershare qqq trust qqq sank spdr spy fall spdr dow jone industrial average dium give apple aapl weigh drop put iphone maker back buy point breach day move average oil fund lead upside west texas intermediate crude price surge barrel spdr oil gas exploration production xop rise vaneck vector oil service oih add unite state oil uso powershare db oil dbo rise nearly apiece gold play sag vaneck vector junior gold miner gdxj vaneck vector gold miner gdx fall more apiece spdr gold share gld ishare gold trust iau fall gold future dip ounce chip homebuilder utility also underperform stock market today exist home sale august fall seasonally adjust rate view vaneck vector semiconductor smh fall remain buy range flat base entry ishare phlx semiconductor soxx be still buy zone handle entry component stock apply material amat lose nearly slip cup handle buy point doesn extra income dividend fund have break stock market trade time high vanguard dividend appreciation vig dip early tuesday clear flat base buy point monday fund be more july be featured column seek support day move average share take slight dip rise shape right side flat base set new potential buy opportunity fund track nasdaq dividend achiever select index marked anniversary april index include stock history increase dividend least year row exclude be less likely raise payout industrial account vig biggest sector weighting aug asset consumer service weigh health care consumer good financial technology respectively microsoft msft johnson johnson jnj pepsico pep be top holding microsoft be buy range recently clear base base entry maker xbox surface pay annualize dividend late tuesday redmond wash base company announce hike quarterly payout cent share name pepsico pep cfo hugh johnston board director fund have slightly underperform year date return accord morningstar direct vs benchmark index gain vig annualize yield be ahead payout etf expense ratio be ishare core high dividend hdv be buy range breaking tuesday past flat base entry etf be last featured june clear prior flat base start just complete pattern fund track morningstar dividend yield focus index launch march hdv provide access dividend pay stock have be screen financial health top sector weighting be consumer defensive energy communication service health care exxon mobil xom pfizer pfe be top name hdv have return year date average annual return trail past year offer annualize dividend yield vig carry expense ratio tuesday pick midcap dividend don schwab mid cap schm be still just shy respective buy point related big bank lift dow high long term winner break hot chip stock soar dow hit new high be japan back dow keep hit new high top chip stock break
130,PFE,investor drive stock positive finish friday dow jone industrial seize new high ground nasdaq composite close just fraction record territory nasdaq dow jone industrial average rise grab gain small cap outpaced slightly overall action leave russell ahead preliminary datum show volume rise sharply nasdaq nyse exchange subway terror attack london north korean missile fire japan stir uncertainty early session prove unable phase market optimism final week federal open market committee highly anticipate meeting start tuesday economic news be also potential stumbling block trade friday disappointing retail sale industrial production number august sharp slowdown new york region manufacturing september bright spot be consumer sentiment university michigan report weaken less expect preliminary estimate september lead index nonetheless power third gain week leave nasdaq gain dow jone industrial average head shoulder group gain strongest advance week end dec boee ba easily outstrode dow rise breaking flat base buy point left stock well buy range extend dow peer verizon vz apple aapl intel intc also logged gain more dow list pfizer pfe backed hold flat base buy point have clear fast trade tuesday fang stock post comparatively mild session facebook fb rise amazon com amzn netflix nflx alphabet googl lose ground nividianvda buzz more heavy volume evercore isi boost price target stock maintain outperform rating nvidia remain buy range first solar fslr also crack buy point bolt higher deutsche bank upgrade solar component maker system installer buy hold stock remain buy range narrowly entry injured list oracle orcl collapse nearly friday fiscal first quarter late thursday raise question sustainability growth nascent cloud compute business sell breach stock week move average weighty trade send sell signal stop short loss buy point have trigger automatic sell rule related fed adobe fedex defense giant lead investing action planfollow market stock market todayunderstand market big picturecan make big stock profit small cash yes here be way
131,PFE,theravance biopharma tbph exelixis exel tick most acquisition box big pharma overview biotech merger picture analyst say friday acquisition biotech company pharma be important theme space needham analyst alan carr say note client believe late development stage commercial stage biotech company be particularly attractive acquisition target part due reduce risk company carr cover theravance attract big pharmas amgen amgn eli lilly lly teva pharmaceutical teva total carr count company be interested buy theravance base research area business development interest past acquisition theravance have approve drug antibiotic hard treat infection exelixis agio pharmaceutical agio bavarian nordic pharmaceutical bhvn progenic pharmaceutical pgnx be attract interest pharmaceutical apiece abbvie astrazeneca azn novartis nvs roche rhhby dow stock pfizer pfe johnson johnson jnj be most acquisitive base carr criterium have least potential target biotechs stand better chance be acquire vs other carr say january have be acquisition public biotech company involve payment more upfront more half already have approve drug have least phase datum carr write oncology be key target japanese pharmas rare disease play be likely be acquire later stage ibd take last month potential acquisition target jump ibd relative strength rating best possible today still have rating head ibd datum story closer look stock catalyst rare disease tend be interest mid specialty pharmas biotechs traditional drugmaker be likely avoid drug pricing controversy january only rare disease firm snatch be actelion pharmaceutical european pharma acquire more later stage biotechs vs less risk adverse japanese pharmas allergan agn big area interest include central nervous system rare disease oncology account acquisition respectively january have be new chemical entry approval food drug administration small midsize biotechs gain type approval have be acquire already have drug market time acquisition many oncology company few rare disease company be acquire say gilead science gild acquisition kite pharma kite break approval rule gilead announce plan spend buy kite month ahead expect approval date first drug blood cancer novartis rival treatment be approve day later related small biotech launch month high today here whyexelixi recover bristol inspire pitfall kidney cancerbristol dife still have chance kidney cancer analyst
132,PFE,key index be higher friday dow jone industrial average knock new high extend streak xpowershare qqq trust qqq lead gain spdr dow jone industrial average dium gain spdr spy be emerge market outperformed ishare msci emerge market eem rise sector fund chip telecom retail lead upside stock market today gold energy health care lag vaneck vector semiconductor smh ishare phlx semiconductor soxx advanced more be buy range respective entry component stock nvidia nvda surge break flat base graphic chipmaker be ibd stock vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx give spdr gold share gld ishare gold trust iau dip apiece gold future be ounce dow jone industrial average close fresh record high thursday thank big gain unite technology utx pfizer pfe merck mrk keep give produce double digit return year continue offer new chance buy spdr dow jone industrial average dium climb past flat base entry thursday remain buy range last set buy opportunity rebound day move average mid august right time be featured etf column share have now advanced nearly bounce line back early june break past flat base buy point rise aug high etf track price weight blue chip index mark anniversary january biggest holding include boee ba goldman sachs gs apple aapl accord morningstar direct top name account asset dium year date return be just ahead gain long haul fund performance be roughly line benchmark index instance dium have post average annual return past year qqq carry expense ratio ibd take boee be time high be worthy watch list find top rate stock industry group ibd stock checkup guggenheim equal weight rsp be shape right side flat base get close buy point fund be spotlight june etf column hold buy range earlier climb entry left side high current pattern fund launch april track equal weight index total return name indicate much more diversify dium biggest sector weighting be consumer cyclical financial service industrial health care technology order top holding include nrg energy nrg alexion pharmaceutical alxn ralph lauren rl rsp ytd return lag lead past year average annual return vs benchmark index gain etf bear expense ratio thursday pick ishare edge msci multifactor usa lrgf take buy point be still buy range powershare russell equal weight portfolio eqal be still trading just entry related dow lead big name gain equity play set upapple dow top loser dow stock be buy range apple gain launch event kick dividend play watch
133,PFE,major stock index end mixed thursday selling focuse nasdaq composite loss be tame preliminary datum show volume exchange come lower wednesday level friday turnover be likely jump weekly monthly stock index option expire nasdaq lose even chip equipment stock outperformed ease dow jone industrial average hold well rise component dow industrial score record close high help strength unite technology utx pfizer pfe merck mrk consumer price come bit hotter expect august rise vs expectation gain core rate exclude food energy price rise line expectation wall street have more economic datum ponder friday release august retail sale datum empire state manufacturing index latest read consumer confidence university michigan last week ibd tipp economic optimism index reach month high straight optimistic read oracle orcl do well thursday hour session report earning share rise end regular session unchanged highlight total cloud revenue jump stock market today tesla tsla continue attract buyer ceo elon musk say unveil semi truck offer be october tesla clear cup handle base buy point rise average turnover other breakout include leaderboard name square sq have be solid performer ipo november share rise still buy range buy point square be high pe stock deservedly so annual earning expect surge year ibd take focuse newer company innovative product drive growth be good way achieve big profit stock market learn more new be so important check lesson ibd university semiconductor space apply material amat be top gainer ibd rise chip equipment firm be work later stage base buy point group peer brook automation brk be also set base buy point share rise same ultra clean holding uctt be just buy point share jump related oil stock buy zone crude retake investing action planapple kick augment reality era new buy stock sell stock success read investor corner
134,PFE,citigroup thursday initiate coverage electric car maker tesla tsla neutral high risk wall street analyst also give commerce leader amazon com amzn price target hike upgrade pc printer maker hp hpq athletic apparel vendor nike nke downgrade drugmaker pfizer pfe xcitigroup analyst itay michaeli set price target tesla say be fundamentally bullish tesla bull bear case stock have merit marketwatch report re positive tesla position car future leader view upside case still be significant however prefer better entry point say michaeli see tesla have stronger balance sheet want see sign production ramp model car minimal cannibalization model sale tesla stock rise stock market today morgan stanley analyst brian nowak reiterate overweight rating amazon com raise price target amazon stock rise hit new time high intraday rbc capital market upgrade hp outperform sector perform raise price target hp stock be morgan stanley upgrade nike stock overweight equal weight raise price target nike be top buy point credit suisse lower rating pfizer stock neutral pfizer share be stock have be consolidate last week buy point
135,PFE,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
136,PFE,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
137,PFE,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
138,PFE,major market index rally modestly dow jone industrial average hit fresh time high earlier index advanced tech heavy nasdaq climb briefly turn negative xamong dow industrial financial component jp morgan jpm goldman sachs gs set pace rise more downside pfizer pfe decline report mixed result tuesday drugmaker top earning estimate fall short revenue side share have be consolidate mid thirty year longtime lead stock fang member amazon amzn advanced early trade attempt recapture day line be lose monday heavy volume armour uaa beat top bottom line estimate early tuesday disappoint investor lower full year guidance newly announce restructure cut workforce share fall nearly have languish price level late january stock have fall high september other apparel retailer also feel burn foot locker fl ralph lauren rl decline respectively stock be trading day line other company report earning leader be breaking stock market today cognex cgnx be breaking cup shape base stock market today rise blast buy point machine vision system maker beat estimate raise revenue forecast meanwhile shopify shop jump session high buy point finally investor turn attention apple aapl close release earning analyst expect iphone maker earn share revenue year year increase respectively share edge higher analyst action regeneron pharmaceutical regn fall monday decline early tuesday robert baird downgrade biotech underperform neutral share fall day line first time ibd essent group esnt advanced cautiously approach flat base entry downside china base yirendai yrd plunge result thin stock be still cup base entry related apple tesla need know investor next armour top view cut guidance announce jone industrial average dow stock news stock news quote facebook amazon netflix google
139,PFE,stock open sharply higher second straight session tuesday earning trigger number powerful early breakout dow jone industrial average jump start trade add nasdaq composite also advanced apple aapl fang stock trade higher amazon com amzn lead group open gain apple rise market look fiscal third quarter earning report due close early economic news commerce department show june personal income flat well increase miss expectation gain june spending eke line tally economist consensus view construction spending datum manufacturing index markit institute supply management be due later morning dow pfizer pfe slip report mixed second quarter result goldman sachs gs knock index strongest open move caterpillar cat dased news chief financial officer brad halverson retire next year company say launch external search successor american airline group aal pop buoy upgrade overweight neutral jpmorgan gain create buy opportunity rebound support stock week move average mid july high lumber liquidator ll drilled gain company shift profit second quarter earning revenue same store sale top analyst expectation wide margin gap gain left share buy range buy point month cup base shopify shop spiked early action developer cloud base small business commerce platform report strong second quarter result raise full year revenue guidance analyst expectation surge send share buy range buy point week cup handle base cognex cgnx jetted report broad second quarter raise guidance ibd stock gap move left share extend past buy point month flat base ibd peer ichor holding ichr drop premarket trade company launch offer share hold shareholder stock be eighth week cup base royal caribbean cruise rcl steam ahead take new high board beat second quarter result miami base cruise line have stage multiple test week line have not pause long enough build proper base long cup handle base january automaker take hard early hit july sale report show sharp fall demand month general motor gm shed report july sale decline year year ford also drop report sale month share fiat chrysler fcau hold narrow gain drop july sale related big picture wrong tech stock likely benefit apple iphone upgrade supercycleapple headline busy week earning potential option tradesapple earning consensus just get withapple lead top stock earning tuesday action planchip stock watch semiconductor industry news
140,PFE,key index fund be mixed midday thursday dow jone industrial average lead big gain boee ba pfizer pfe xspdr dow jone industrial average dium be spdr spy be flat powershare qqq trust qqq be energy gold telecom be biggest gainer stock market today retail biotech homebuilder underperform vaneck vector oil service oih spdr oil gas exploration production xop surge west texas intermediate crude price rise barrel unite state oil uso powershare db oil dbo gain respectively spdr gold share gld ishare gold trust iau climb apiece gold future be slightly higher ounce stock market have be set more potential buy opportunity rise record high territory powershare russell equal weight portfolio eqal be build right side flat base potential buy point close wednesday less entry prior flat base breakout june january yielded respective gain fund track russell equal weight index be launch december index be equally weight sector group stock sector also equally weight fund index get rebalance quarterly basis traditional market cap weight approach give more clout bigger cap stock equal weight help limit impact single stock eqal biggest sector weighting be information technology industrial health care consumer staple energy accounting just top holding include dowdupont dwdp nrg energy nrg pilgrim pride ppc respective asset fund year date return lag gain accord morningstar direct eqal cary expense ratio let revisit ishare edge msci multifactor usa lrgf be featured etf column fund be poise break flat base clear buy point june advanced nearly pause form current flat base pattern lrgf close wednesday nickel shy entry ibd take apply material be hot chipmaker be worthy watch list find top rate stock industry group ibd stock checkup fund launch april be bit younger eqal lrgf track msci usa diversify multiple factor index focus financially healthy firm stock be inexpensive smaller company trend stock accord ishare information technology account biggest sector weighting financial make health care industrial top holding include accenture acn general motor gm apply material amat lrgf trail ytd gain vs benchmark index return outpaced past year vs gain expense ratio be wednesday pick material select sector spdr xlb vanguard material index fund vaw ease slightly remain buy range respective flat base buy point related apple dow top loser dow stock be buy range apple gain launch event kick dividend play watch hot biotech play reach be apple still buy range
141,PFE,stock slip start bell monday quickly improve mixed trade earning season tapered finish number china name picked boost trade overseas dow jone industrial average nasdaq composite open fractional loss nasdaq re-cover narrow gain first minute trade economic calendar get quiet start monday week highlighted new exist home sale number july kansa city federal reserve international economic policy symposium launch jackson hole wyo friday earning season be wind chipmaker cree cree broadcom avgo marvel technology mrvl expect report week other significant name include salesforce com crm toll brother tol hp hpq apple aapl edge fraction netflix nflx rise lead fang stock apple continue hover buy range cup base buy point trading be generally quiet dow nike nke be lead exception early action move undercut stock day move average heavy trade signal breakdown institutional support stock dive more heavy trade test support line friday cisco system csco rise dow strongest early move company announce acquire software developer springpath cash overseas china market post positive session monday momentum appear carry trade name china wuba open nation equivalent craigslist report sunday second quarter earning top analyst expectation wide margin revenue growth stop short estimate gross margin decline vs year stock be extend trading new new high flat base buy point baidu bidu open higher search engine giant have be look enough lift power brief consolidation just aug high extend flat base buy point china unicom chu drive ahead more telecom provider boast subscriber announce be prepare stock offer part effort restructure ownership trading be shut shanghai exchange stock hit upward limit shanghai composite last week rise best weekly gain early april china name dominate ibd list early trade yy yy rise more sina sina rise alibaba group holding baba rise nearly commodity trade generally higher oil gold less copper post early advance pound europe market be mixed mid session london ftse cling fractional gain frankfurt dax cac paris fall related big pic stock reverse sign hint bottomset watch list top stock buy pointsfed top rate stock report investing action plan
142,PFE,key index fund be board stock market today overseas market stay ahead xishare msci eafe efa ishare msci emerge market eem rise spdr dow jone industrial average dium spdr spy lead index fund gain apiece powershare qqq trust qqq add energy retail bank be biggest gainer sector fund gold telecom utility underperform spdr gold share gld ishare gold trust iau give vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx lose gold future dip ounce spdr retail xrt advanced retake day move average first time nearly month component stock kohl kss jump department store operator say open amazon amzn shop store oil play advanced boost rise west texas intermediate crude price barrel spdr oil gas exploration production xop vaneck vector oil service oih surge nearly unite state oil uso powershare db oil dbo add apiece health care exchange trade fund be just respective buy point pull back time high spdr health care xlv ease second straight session tuesday close slightly buy point flat base etf advanced nearly early june prior flat base start most recent pattern fund mark anniversary december have attract asset track health care select sector index be comprise health care name pharmaceutical account biggest chunk asset nearly biotech weigh health care provider service health care equipment supply contribute respectively top holding include johnson johnson jnj pfizer pfe unitedhealth group unh biotechs score big gain last week also make top list amgen amgn gilead science gild celgene celg biotech industry track ibd surge last week spur part gilead acquisition kite pharma kite gilead share soar kite rocket week xlv have outperformed year date gain accord morningstar direct also outpaced benchmark index past year respective return vs gain same period etf carry expense ratio ibd take biotech be rank base fundamental technical metric track ibd find now ibd stock checkup vanguard health care index fund vht be also trading slightly flat base buy point case be fund launch january track msci investable market health care index pharma make biggest sector weighting july asset biotech health care equipment manage health care follow respective weighting top holding include many same name xlv johnson johnson pfizer unitedhealth amgen celgene gilead vht have return year date past year respectively expense ratio be tuesday etf pick first trust equity opportunity fpx ishare russell midcap growth iwp close respective flat base buy point related think miss big biotech rally check playsgold oil rally stock sell long term winner buygilead kite deal boost biotech etf clear buy pointbiotech extend gain breakout put apple amazon focus
143,PFE,here weekly investing action plan need know investor come week xapple aapl tesla tsla square sq grubhub grub headline busy week earning top shale producer weigh sign slow activity oil patch fresh set
144,PFE,exelixis exel be hot streak south san francisco base biotech have notch series achievement recent month post first time operate profit confirm effectiveness compound treat kidney cancer retire nearly debt couple improve fundamental short term market share growth potential have propel exelixis complete transformation development stage company commercially viable drugmaker have plan keep grow partnership like bristol myer squibb bmy roche hold rhhby exelixis chief executive michael morrissey say email interview investor business daily real game changer company come food drug administration april approval cabometyx second drug exelixis be selling used compound know cabozantinib make tablet form first only single agent therapy patient have already undergo treatment advanced renal cell carcinoma demonstrate clinically meaningful improvement parameter measure survival rate response medication put path re now able grow organization cash generate operation execute plan create new generation exelixis medicine morrissey say initial collaboration really want cabozantinib become backbone choice immunotherapy combination so be interested evaluate many promising immuno oncology agent possible provide clear clinical rationale do so be hard pressed find someone organization hasn have close personal experience disease own life love friend morrissey say commitment patient drive do everything bring new therapy forward make sure re accessible inform everything do clinic field office echo investor nod approval increase stock value analyst hold consensus rating outperform accord june report research drive investing exelixis share now be flirt buy territory high not see nearly year have top buy point cup base several time recent trading session cowen co analyst eric schmidt say email exelixis share be best performer biotech be continue outdo sector year share be roughly year date overall sector be successful launch cabozantinib renal cell carcinoma be responsible stock performance exelixis growth say schmidt maintain outperform rating exelixis base long term growth potential thank company clinical initiative partnership balance sheet upside schmidt say be pharmaceutical biotech competitor exelixis be largely immune concern lower drug price speculative effect propose health care legislation trump governmental issue be not concern business cancer drug pricing be quite secure schmidt say oppenheimer co inc analyst leah cann give stock perform rating expectation company ability grow unit sale product estimate exelixis total revenue grow compound annual growth rate next year increase cann say founder publicly trade exelixis first start used cabozantinib medication know cometriq be capsule used treat thyroid cancer have find limit market compare cabometyx exelixis third product cotellic be formulation compound know cobimetinib market collaboration genentech exelixis revenue be first quarter end march sale jump year period turn profit first time fourth quarter company continue black first quarter net income cent share reverse year loss cent share ibd take june exelixis go fall next day have flirted level several time have yet stay consistently stock be rank eighth ibd medical biom biotech group celgene spot exelixis further flout balance sheet fundamental announce repayment deerfield note year ahead schedule saving approximately interest expense past year exelixis retire total debt morrissey say company use free cash invest additional clinical trial product pipeline resume internal discovery effort pursue licensing opportunity many biotech company exelixis have have debt book much history importance financial flexibility be understated morrissey say allow further goal deliver new treatment option patient need also fuel stock run be company june announcement independent panel find trial cabozantinib significantly improve progression free survival compare pfizer pfe sutent used patient previously untreated advanced renal cell carcinoma give scarcity active differentiate asset industry see cabozantinib franchise extremely valuable say william blair analyst andy hsieh june research report hsieh note cabometyx launch second line renal market contribute significantly revenue shareholder return ongoing clinical regulatory initiative materially increase total addressable market cabozantinib say exelixis remain track complete supplemental new drug application cabozantinib first line advanced renal cancer treatment third quarter company not comment possible sale analyst say exelixis be ultimately court larger company say cowen schmidt nothing have be publicly disclose be shock exelixis be be acquisition target
145,PFE,biotech stock celgene celg bluebird bio blue regeneron regn biogen biib spinoff bioverativ bivv move cancer treatment developer exelixis exel be poise pop new buy zone exelixis share price have soar week follow confirmation positive result phase trial so call cabosun trial compare cabozantinib exelixis used
146,PFE,xmajor stock index show modest gain afternoon trading thursday wall street digest strong earning oracle orcl health care stock outperformed gop release new version obamacare repeal bill stock market today oracle orcl gap flat base entry rise strong earning be catalyst buy stock gap buy point important buy close open price possible oracle open share be recently trading nasdaq composite lead way rally dow jone industrial average picked small cap outperformed russell volume nyse nasdaq be tracking slightly lower wednesday level health care related industry group outperformed few retail group lag outperformer dow include unitedhealth unh johnson johnson jnj pfizer pfe merck mrk meanwhile china stock be pressured chinese regulator ask weibo wb stop audio video stream service share weibo lose be session lows chinese government have be step effort stop political speech social medium site sina sina alibaba baba have ownership stake weibo share sina be well session lows still fall alibaba ease american airline aal picked be well session high news qatar airline be consider stake company american be still buy range handle entry tesla tsla gain time high company reportedly reach agreement city shanghai explore build production facility related weibo ibd chinese internet stock be selling offunitedhealth hca merck rally senate trumpcare bill pare term cutstesla get closer big manufacturing expansion china
147,PFE,sell wednesday bristol myer squibb bmy be overdo analyst say bristol fail meet key benchmark kidney cancer trial prompt rival exelixis exel pop nearly xbristol still have chance treat advanced kidney cancer patient combination immuno oncology drug opdivo yervoy ub analyst marc goodman say note client follow bristol late tuesday announcement opdivo yervoy be compare chemotherapy know sunitinib previously untreated advanced kidney cancer patient combo improve progression free survival month median wasn statistically significant vs month chemo patient combo experience tumor shrinkage vs patient chemo trial continue second half bristol be expect have datum overall survival say bristol fail secure filing first treatment renal cell carcinoma current datum bristol be year roche rhhby pfizer pfe assume have positive datum goodman say ibd take bristol have ibd composite rating best possible lag nordisk lead specialty drug stock cr head ibd stock checkup look other top rate drug stock bristol be expect discuss result food drug administration narrow miss progression free survival fda not require overall survival datum approval leerink analyst seamus fernandez write note client progression free survival datum show notable trend favor combo appear datum have achieve statistical significance have be sole primary endpoint say roche be work phase trial immuno oncology drug tecentriq cancer drug avastin advanced kidney cancer expect read early dow component pfizer have late stage trial drug bavencio inlyta advanced kidney cancer expect mid bristol late tuesday announcement also benefit exelixis see share pop much early trade be just fraction midday stock market today bristol meanwhile slip close roche gain penny pfizer lose cent exelixis drug cabometyx be approve second third treatment kidney cancer investor have be worry number ongoing combination trial combo bristol look most promising leerink analyst michael schmidt say news raise regulatory bar potential term competitor first treatment renal cell carcinoma write note client also help push enrollment partner trial advanced kidney cancer bristol exelixis related bristol myer squibb topple kidney cancer trial resultswhy dow merck be credit suisse top pharma pickwill pfizer cancer drug help grow merger
148,PFE,stock index padded cushion day move average midday thursday heavy construction stock rumble group eighth daily gain row nasdaq small cap russell lead gain respectively midday add blue chip dow jone industrial average claw higher volume stock market today be run higher major exchange compare same time wednesday price gain accompany rise volume be consider more bullish advance fading volume heavy construction space granite construction gva jump build right side consolidation granite construction be expect grow earning year analyst expect earning growth heavy construction group be market laggard rise past session group include potential player post harvey storm recovery contractor quanta service pwr tack stock approach buy point cup handle base company be expect grow ep year next year meanwhile construction mining equipment group rise third consecutive day group score new high caterpillar cat notch week high then retreat cat relative strength line be high bullish sign mean stock be outperform go thursday session equipment group be industry group so call fang stock facebook fb amazon com amzn netflix nflx alphabet googl be exception apple aapl be not fang stock major tech company be head fifth daily gain row blue chip be mostly component dow jone industrial average pfizer pfe lead pop related amazon rival be ready break stock benefit post storm recovery
149,PFE,puma biotechnology pbyi portola pharmaceutical ptla alnylam pharmaceutical alny lead deluge loss thursday see sector slide week low ibd company biotech industry group slip spot rank xin midday trading stock market today biotechs overall lose touch low last see june biotech industry group be now rank sixth group ibd track fourth last week biotech stock hit month high july ride wave ahead second quarter earning wednesday close sector have fall high earning season come close wednesday portola puma alnylam offer report alnylam sale miss expectation adjust loss be deeper expect prod share drop leerink analyst paul matteis remain bullish alnylam keep market perform rating price target see ideal opportunity alnylam treat acute hepatic porphyrium drug givosiran disorder involve buildup chemical body alnylam drug class use rna interference silence specific gene ibd take biotech fever look have chill late july long term view remain cloudy follow number biotechs beat second quarter expectation raise guidance get detail ibd industry theme think acute hepatic porphyrium represent ideal indication rna interference medicine basis be underserved orphan disease drive single target matteis write research report alnylam be also aim file application patisiran year end patisiran be be develop treat rare condition know hereditary attr amyloidosis abnormal protein build multiple organ damage impede puma dove announce late wednesday european approval breast cancer drug nerlynx have be push back least first quarter earlier view third quarter nerlynx be likely be biggest driver share term rbc analyst matthew eckler tell client note also potential lack thereof partner merger acquisition say firm also report loss share widening share year earlier quarter miss analyst view share loss adjust loss share widen cent analyst view be not immediately available late wednesday portola say work manufacturing process change push launch bevyxxa first quarter biotech reiterate plan launch sometime september november credit suisse analyst vamil divan say bevyxxa be treatment prevent blood clot hospitalize patient risk due moderate several mobility restriction drug be portola first only approve pipeline include anticoagulant blood cancer drug inflammatory drug european regulator be expect issue opinion bevyxxa late early second quarter portola report collaboration license revenue dip year earlier period lag model loss share grow cent be wider consensus view cent loss revenue stem agreement dow component pfizer pfe johnson johnson jnj janssen unit well bristol myer squibb bmy bayer bayry daiichi sankyo portola topple related alnylam report lag sale wider expect lossesperrigo beat raise lift generic drug buck teva mylan trendcan generic drug stock catch break mylan crash
150,PFE,stock index post small move be mostly blue chip dow jone industrial average scratch slim gain nasdaq trim lose small cap russell also subtract dow jone industrial average be just little bit flat dow be head seventh day outperformance vs major index volume midday thursday be run higher major exchange stock market today winner hold slight advantage vs loser dow jone industrial average drugmaker pfizer pfe surge mega cap stock retook day line stock have composite rating be roughly middle pack rating downside intel intc drop chipmaker appear poise end session streak recent earning report boost intel earning increase best increase late intel have composite rating stock be chip peer stock checkup investor com intel be not fast growth story stock also serve dividend play annualize dividend yield be dividend growth rate be accord william neil co datum intel be shape double bottom base buy point ibd list best stock fundamental technical stagger lower wednesday thursday advancer lead decline stock ratio ibd china base stock ibd rise solid price gainer include sina sina light volume yy yy average volume momo momo be internet group marathon oil mro jump heavy volume company report quarterly result wednesday close earning fall short expectation revenue beat consensus view related stock breaking stock approach buy point
151,PFE,merck mrk keytruda continue gain share immuno oncology drug bristol myer squibb bmy roche rhhby approval keytruda chemotherapy combination overall immuno oncology drug sale grow month month datum symphony health show merck keytruda be gain share expense bristol opdivo yervoy leerink analyst seamus fernandez say keytruda share increase percentage point opdivo yervoy share fall respectively combine end roche drug tecentriq remain steady share year market tecentriq differ keytruda opdivo target pd protein vs pd protein target merck bristol drug pfizer pfe bavencio astrazeneca azn imfinzi be also pd antibody bavencio imfinzi be newest market have achieve only nominal share third first month respectively follow approval fernandez write note client ibd take other immuno oncology news kite pharma kite bluebird bio blue stock have rocket month follow american society clinical oncology meeting chicago head industry snapshot deep dive fernandez expect keytruda keep gain share follow approval advanced lung cancer combination alimta eli lilly lly keytruda also receive recent approval bladder cancer tumor evercore analyst umer raffat say keytruda be tracking analyst projection sale second quarter june sale be month month keytruda be likely beat expectation raffat write note client stock market today merck component dow jone industrial average be close share bristol rise roche stock lift related tesaro overcome clovis lead combo merck co biotech fly nearly strong trial be drug better dow merck pause cancer trial investigate keytruda tie death
152,PFE,xstock trek lower tuesday give back only piece ground gain monday nasdaq take hardest hit fall drop dow jone industrial average drift preliminary datum show volume exchange come higher monday level west texas intermediate crude drop just barrel oil slough undercut low settle lowest point november move ve send oil related stock crowd lowest slot dow barely even register chevron cvx exxon mobil xom drop less oil stock post only day worst loss stock general electric ge be dow worst performer weak trade apple aapl tumble fang stock end lower price target increase netflix nflx medical drugmaker biotechs post strong session merck mrk pfizer pfe easily top dow industrial respectively ibd stock regeneron pharmaceutical regn alexion pharmaceutical alxn lead nasdaq biotechs drugmaker take day top gain nasdaq stock regeneron surge reach month high novartis nvs report rth macular degeneration drug have outperformed regeneron eylea head head clinical trial regeneron be clear month cup base novartis share rise tuesday alexion jump regulatory filing show ceo ludwig hanson make purchase company share worth ibd leaderboard stock floor decor fnd end higher back early high gain left share buy range buy point settle april ipo price retail be tuesday worst perform industry dd penney jcp drop ross store rost shed almost worst decline nasdaq stock several big name be schedule roll earning report close adobe system adbe fedex fdx red hat rht top list related biotechs be lead industry month highamazon get rating upgrade whole food buy be grubhub next
153,PFE,clovis oncology clvs tesaro tsro deliver blockbuster ovarian cancer drug grab takeover interest analyst say friday ahead key trial clovis expect later month duo rival bigger astrazeneca azn market cap be more time clovis tesaro combine clovis tesaro joined astrazeneca parp inhibitor market last year parp inhibitor work block family enzyme cancer cell use proliferate pfizer pfe abbvie abbv be also work parp inhibitor credit suisse analyst alethia young see class drug also have impact prostate breast lung cancer think parp inhibitor market be big enough clovis have blockbuster product well write strongly believe company be likely attractive target large global biopharma company later month clovis be expect unveil result phase trial dub ariel drug rubraca tesaro previously set high bar trial drug zejula have benefit patient regardless specific genetic top line basis think ariel work group focus be potential commercial difference use biomarker safety write note client young expect tesaro stock be volatile follow clovis trial note lift overhang share have outperform rating tesaro clovis stock rate tesaro stock price target clovis price target stock market today clovis stock rise tesaro stock gain astrazeneca pfizer abbvie stock be respectively ibd take american society clinical oncology layer battlefield fight cancer company merck bristol myer squibb incyte roche be work combine drug immuno oncology spectrum get more ibd industry theme share fellow cancer biotech incyte incy topple sustain price target cut leerink analyst michael schmidt trim price target incyte stock incyte eli lilly lly rheumatoid arthritis treatment be delay april food drug administration delay approval drug call baricitinib instead ask more information trial now schmidt say expect sale see drug launch schmidt be bullish seattle genetic sgen stock small biotech bristol myer squibb bmy unveil strong datum combination drug adcetris opdivo classical hodgkin lymphoma sign cancer disappear patient series trial combination potentially provide chemotherapy free treatment option patient hodgkin lymphoma relapse be treat surgery schmidt have outperform rating seattle genetic bristol myer stock related tesaro crash beating astrazeneca stronger databristol incyte match beat dow merck combination spotlight drug giant donnybrook cancer treatment
154,PFE,johnson johnson jnj diabetes drug invokana cut cardiovascular event long term study eli lilly lly stand benefit most doctor steer clear medication worry increase risk amputation study dub canvas be present late monday dow stock johnson johnson say invokana reduce risk cardiovascular death nonfatal heart attack nonfatal stroke vs drug placebo additional analysis show invokana lower risk hospitalization heart failure invokana also delay progression albuminurium presence specific chemical urine indicate kidney disease rbc analyst glenn novarro say canvas study be unlikely reverse negative trajectory invokana sale first quarter invokana invokamet sale drop year year novarro forecast dip sale eli lilly other hand benefit johnson johnson study merck mrk trail analyst say lilly jardiance be sglt inhibitor work help kidney lower blood glucose level merck januvia be dpp block glucagon release trigger insulin secretion validate cardiovascular benefit boost sglt class credit suisse analyst vamil divan write similar study lilly jardiance also show benefit cardiovascular outcome jardiance also cut risk cardiovascular death mortality even canvas study lilly be poise grab chunk invokana sale food drug administration require johnson johnson physician potential amputation associate invokana invokana double risk amputation recent study expert cite leerink analyst seamus fernandez say amputation worry be biggest differentiate factor physician decision prescribe jardiance invokana show similar cardiovascular benefit diabetes patient close stock market today johnson johnson stock tick finish regular trading session lilly stock add share diabetes drugmaker merck dip end day ibd take johnson johnson stock have ibd composite rating meaning outperform more quarters stock term key growth metric more ibd rating visit ibd stock checkup meanwhile dpp class diabetes drug include merck januvia face incremental pressure credit suisse divan say time however expect enthusiastic response canvas efficacy datum drive use sglt class earlier course treatment concurrently push dpp further back say note client merck pfizer pfe dow stock be jointly work sglt inhibitor call ertugliflozin regulator approve drug december win have datum cardiovascular outcome several year pfizer take chunk sale meaning shift januvia ertugliflozin be net negative merck related lilly grab diabetes share dow amputation woesabbvie expect rival chip away biggest drug franchisedow pfizer face challenge roche lilly loom
155,PFE,biotech stock celgene celg regeneron regn biogen biib spinoff bioverativ bivv move cancer drug developer exelixis exel be track new several day big gain biotech sector regeneron bluebird bio blue pull back friday celgene bioverativ continue climb afternoon trading friday stock
156,PFE,major market average erased early gain stock market today nasdaq composite turn lower nasdaq fall dow jone industrial average advanced less supreme court lift ban president trump travel ban order foreigner majority muslim nation unclear move have impact open weak durable good order have little impact durable good order fall vs expect decline dow industrial financial component goldman sachs gs american express axp lead way rise respectively apple aapl moved more intraday trade late morning action iphone maker be attempt recapture day line downside performer be limit exxon mobil xom pfizer pfe fall micron technology mu jump freeport mcmoran fcx rise well session high martin marietta material mlm advanced graphic chip maker nvidia nvda reversed trade move lower be incyte incy humana hum qorvo qrvo
157,PFE,analyst action stock market today ibd stock regeneron pharmaceutical regn grubhub grub find downgrade early monday red hot biotech trade be moved market perform outperform sanford bernstein share food deliverer fall nearly morgan stanley downgrade firm equal weight increase competition ubereat grubhub be now well buy point
158,PFE,meanwhile retailer coach coh costco cost be upgrade coach be upgrade buy neutral buckingham research costco be moved outperform market perform raymond james share coach rise costco advanced be try end deep slide
159,PFE,fang stock be motion early monday lead early advance also late morning retreat facebook fb fall hit record high intraday netflix nflx sank amazon amzn google parent alphabet googl lose respectively
160,PFE,alphabet waymo announce deal monday rental car giant avis car avis manage waymo fleet autonomous vehicle avis share rise more
161,PFE,ibd chip stock macom technology solution mtsi ichor holding ichr jump respectively well session high macom be extend ichor be rise sharp pullback week average china education stock tal education tal follow rise be rise support again day line
162,PFE,downside medidata solution mdso fall veeva system veev decline be extend most recent entry
163,PFE,related
164,PFE,durable good order fall business investment weak
165,PFE,costco upgrade grubhub downgrade amazon effect paypal pt hike
166,PFE,dow jone industrial average dow stock news analysis
167,PFE,fang stock news quote facebook amazon netflix google
168,PFE,analyst action stock market today ibd stock regeneron pharmaceutical regn grubhub grub find downgrade early monday red hot biotech trade be moved market perform outperform sanford bernstein share food deliverer fall nearly morgan stanley downgrade firm equal weight increase competition ubereat grubhub be now well buy point meanwhile retailer coach coh costco cost be upgrade coach be upgrade buy neutral buckingham research costco be moved outperform market perform raymond james share coach rise costco advanced be try end deep slide fang stock be motion early monday lead early advance also late morning retreat facebook fb fall hit record high intraday netflix nflx sank amazon amzn google parent alphabet googl lose respectively alphabet waymo announce deal monday rental car giant avis car avis manage waymo fleet autonomous vehicle avis share rise more ibd chip stock macom technology solution mtsi ichor holding ichr jump respectively well session high macom be extend ichor be rise sharp pullback week average china education stock tal education tal follow rise be rise support again day line downside medidata solution mdso fall veeva system veev decline be extend most recent entry related durable good order fall business investment weakcostco upgrade grubhub downgrade amazon effect paypal pt hikeddow jone industrial average dow stock news stock news quote facebook amazon netflix google
169,PFE,spark therapeutic once therapeutic cort defy downtrend biotech sector wednesday instead rocket fresh high strong second quarter report stock market today spark top year high rise share touch high last see april pop earlier rise first time initial public offer broader biotech sector third straight session ibd company biotech industry group recent stock market darling hit month high july slip sixth group track last week be rank fifth second quarter end june spark report sale adjust loss share revenue grow top expectation loss widen loss share year earlier period miss consensus loss share spark also report initial datum patient form hemophilia bleed disorder cause miss defective clot protein know factor viii participant treat drug dub spk achieve stable factor viii average north spontaneous bleed ibd take biotech fever be cool second quarter earning season wind long term view look weak uncertain head ibd industry theme deep dive late tuesday report sale adjust income cent share respective vs year earlier period analyst have call sale adjust income expectation be not immediately available income share cent beat analyst view cent be continue enroll phase trial drug treat cush syndrome result body be expose high level hormone cortisol long time symptom include abdominal obesity high blood pressure stretch mark weak muscle bone acne also have cortisol modulator enter phase trial future be combine xtandi drug pfizer pfe acquire buy medivation last year population patient prostate cancer enrollment be also ongoing phase phase trial drug combine celgene celg abraxane treat patient solid tumor cancer related small biotech launch month high today here sanofi earning spook regeneron share week lowbiotech gain last week keep go
170,PFE,generic competition chip away pfizer pfe depression drug pristiq contribute revenue miss second quarter analyst say tuesday dow component report earning xon stock market today pfizer sank pfizer be consolidation go back exactly year stock recently retake day day move average second quarter pfizer report adjust income cent share sale adjust earning grow nearly top consensus analyst poll zack investment research cent sale miss view fall evercore analyst umer raffat note pristiq sale lag consensus drug lose market exclusivity march drop be very rapid say note client contribute year year decline pfizer essential health unit house legacy drug sale prevnar pneumonia drug decline miss analyst prediction raffat say decline be due timing center disease control prevention purchase pediatric patient international market grow pfizer oncology unit appear be stabilize raffat say worldwide ibrance sale rocket vs year earlier quarter obliterate consensus view ibrance be used treat specific population patient advanced breast cancer ibd take pfizer have ibd composite rating meaning perform bottom half stock term key growth metric head ibd stock checkup look drugmaker strongest rating sale enbrel struggle quarter revenue drug plunge outside canada beat consensus raffat say pfizer cite competition biosimilar europe decline pfizer raise full year adjust income guidance share cent midpoint reaffirm sale guidance pfizer be member dow jone industrial average last week fellow dow drug giant merck mrk report better expect earning strong sale immuno oncology drug keytruda related clovis regeneron be lead biotech deluge todayhow dow merck be benefit back astrazeneca bristoldow merck crushed keytruda sale view astrazeneca keep clovis tesaro unveil blockbuster drug
171,PFE,stock be lower afternoon trading thursday earning report spark major move nasdaq fall unsteady direction session dow fared better rise pfizer pfe help dow rise drugmaker work long pattern otherwise industrial be make unimpressive move small cap russell be well volume be higher nyse lower nasdaq compare same time wednesday day leadership be spread eclectic mix automaker video gaming internet drill software other industry group be more same be worst perform bracket include medical energy technology other assorted group be more automaker be top group today session due tesla tsla share leap nearly heavy volume electric car company beat expectation quarterly result tesla climb back day move average few top rate stock come heavy selling earning report molina healthcare moh gap nearly have erased gain early molina report loss share cite loss obamacare exchange business molina exit wisconsin utah market scale back presence washington state plan sharp premium increase remain market sierra wireless swir gap loss stock be work new base now be buy point june sierra beat profit view midpoint guidance sale earning be view motley fool report sierra wireless also announce be acquire numerex nmrx stock deal value combine company develop internet thing product numerex share fall ibd member masimo masi slide roil base have be form medical technology company fall beating sale profit estimate raise guidance couple software stock break basis qualys qlys clear flat base share surge past buy point big volume stock gap sale earning beat expectation management raise full year revenue profit forecast jpmorgan upgrade stock today overweight neutral tableau software datum rise more time average volume top buy point publisher datum analysis software earn cent share second quarter expectation improvement year loss cent share royal bank canada raise target price ubiquiti network ubnt break cup type base buy point maker wireless networking gear top earning revenue estimate also guide current quarter earning higher most salient characteristic base be big gap side start pattern today relative price strength accumulation distribution rating be weak ubiquiti improve today gap related aetna trounce expectation big obamacare insurer crashesthese top stock be soar buy zone earningshere analyst don tesla earningsnetwork stock soar buy zone earning guidance
172,PFE,nasdaq reversed lower touch time friday semiconductor stock take heat financial outperformed again strong show thursday fuel news house pass bill seek undo dodd frank financial reform pass dow jone industrial average edge higher help strength chevron cvx pfizer pfe goldman sachs gs jpmorgan jpm also outperformed selling nasdaq weigh dow component apple aapl microsoft msft show loss nearly lose nasdaq composite slump distribution day be work nasdaq volume be tracking higher thursday level nvidia nvda reversed spectacular fashion hurt negative comment short seller citron research rise intraday share be afternoon trading nvidia be several growth name ibd hit hard other decliner include macom mtsi lumentum lite nasdaq chip name micron mu kla tencor klac apply material amat show loss financial remain bright spot california base east west bancorp ewbc extend gain rise share be nearly so far week still buy range buy point be low volume so far stock market today digital realty trust dlr real estate investment trust operate datum center announce plan buy smaller competitor dupont fabro technology dft share digital realty fall news seek support day move average dupont fabro jump nearly benchmark crude oil july delivery be recently trading barrel year treasury yield add basis point related red hot reit expand presence boom datum center marketalibaba score price target hike stock climb new high
173,PFE,xtenet healthcare thc other hospital lead broad advance health care stock thursday senate republican unveil own version trumpcare short takeaway courtesy mizuho analyst sheryl skolnick be senate bill be lot less short term lot more long term comparison house version particular medicaid spending suffer smaller hit term face even bigger long term cut hospital group hca healthcare hca rise tenet healthcare jump universal health service uhs gain stock performance have even take management surprise politico publish letter tenet send employee ask rally opposition trumpcare investor have good reason focus more intermediate term always possible big year cut be interrupt delay democrat make comeback example other hand sharp eventual spending cut relative obamacare threaten support moderate gop senator nbc news be report gop senator plan voice opposition new legislation enough deny passage manage care company also be solidly higher thursday centene cnc molina moh big player obamacare exchange medicaid expansion be better performer centene climb molina anthem antm biggest obamacare exchange insurer rise anthem say wednesday pull obamacare marketplace indiana wisconsin centene be rare company make profit exchange medicaid be big profit driver industry include unitedhealth group unh dow jone industrial average component insurer stand benefit gop plan tax health insurance plan unitedhealth rise record high aetna aet gain humana hum advanced skolnick message investor buy unh hca prospect more modest health spending cut fear assume trumpcare even pass also lift share drugmaker biotechs dow component merck mrk rise pfizer pfe johnson johnson jnj notch record high johnson johnson also stand benefit repeal obamacare tax medical device merck have be rally good news immuno oncology treatment keytruda crossed aggressive entry near conventional buy point
174,PFE,stock market close mixed thursday late wave selling erased much day work nasdaq have be close less higher wipe modest gain close fraction lower dow jone industrial average fall less medical company merck mrk johnson johnson jnj pfizer pfe unitedhealth unh be best dow component small cap perform better russell climb downward reversal certainly be not encourage volume be lower board accord preliminary datum suggest institutional investor do not sell massive quantity also negative reversal be not severe scale senate republican unveil own version legislation replace obamacare investor seem mean health care sector medical software drug wholesaler manage care several other medical sector industry group be day best perform rise healthsouth hls break base base pattern close buy point volume be average dampen otherwise bullish move share rise hologic holx break flat base rise past buy point also suffer weak volume relative strength line be new high back day company say win fda approval aptima herpes treatment bankrate rate have better volume break pattern buy point volume be average stock add downside taylor morrison home tmhc gap loss sec filing company say price offer share do not specify price also say filing average sale community month end be home month vs same period net sale order same month rise expect home closing quarter end june be related unitedhealth hca merck rally senate trumpcare bill pare term cut key stock index play buy range biotechs surge again
175,PFE,roche rhhby displace dow pfizer pfe segment lung cancer market analyst say wednesday american society clinical oncology meeting highlighted additional challenge pfizer stock market today pfizer fall roche late tuesday roche present datum head head trial drug alecensa vs pfizer xalkori xalkori be approve treat patient advanced lung cancer specific genetic defect alecensa be approve lung cancer patient progressed be intolerant xalkori class drug call alk inhibitor month follow patient treat alecensa survive median month disease progress vs month patient treat xalkori presenter call roche result remarkable outstanding declare alecensa be now optimal alk inhibitor first line set credit suisse analyst vamil divan say note client first line treatment be first defense disease lung cancer doctor have breakfast yesterday also acknowledge xalkori be relatively weak alk inhibitor be likely change practice pattern base trial write divan note pfizer be work next generation alk inhibitor help soften blow lose xalkori sale also lung cancer pfizer be develop second generation drug target specific receptor know egfr inhibitor ibd take biogen biib spinoff bioverativ bivv be near stock announce plan beef pipeline acquisition true north therapeutic head ibd stock analysis closer look bioverativ setup pfizer be still struggle vs newer therapy particularly be consider immuno oncology drug class aim block certain interaction involve protein enzyme immune system prevent immune response pfizer drug bavencio be approve treat rare aggressive skin cancer bavencio have show strong result liver cancer combine inlyta pfizer liver cancer drug help slow decline revenue inlyta divan say class breast cancer drug know cdk inhibitor be get more crowd pfizer ibrance continue dominate divan say acknowledge novartis nvs kisqali eli lilly lly abemaciclib have show strong trial result prostate cancer johnson johnson jnj zytiga put pressure xtandi similar drug pfizer acquire buy medivation related regeneron cholesterol buster get boot amgen battle tesaro crash beating astrazeneca stronger clovis astrazeneca muddy potential deal tesaro
176,PFE,regeneron pharmaceutical regn go heart debate tuesday question validity amgen amgn patent ldl cholesterol bust drug repatha analyst say follow court hearing wall street be split wednesday appeal court process land analyst investment bank evercore expect regeneron sanofi sny triumph counterpart mizuho say chance amgen succeed stock market today regeneron rise amgen climb share regeneron partner sanofi be tuesday regeneron amgen battle minute appeal court hearing stake be fate regeneron sanofi drug praluent judge previously side amgen say regeneron sanofi praluent infringe amgen patent drug repatha judge stay injunction praluent pending appeal court process be likely end line appeal court side amgen mizuho analyst salim sy say note client supreme court take very few patent case decision have broad implication future patent struggle evercore analyst umer raffat say audio record follow meeting amgen patent cover entire antigen describe bound regeneron say be too broad regeneron do be go heart debate say know patent shouldn be valid begin say regeneron be say be amgen patent focus invention be not do amgen say praluent be too similar drug repatha antibody patent be circumvent tweak amino acid then point investing drug development return win be realize sy say ibd take bioverativ bivv biogen biib spinoff have year average return growth rate see be smart investment visit ibd stock analysis regeneron note dow pfizer pfe time try unsuccessfully develop similar drug also belong pcsk inhibitor class pfizer hold intellectual property pcsk inhibitor neither repatha praluent exist example illustrate even similar antibody be different sy say raffat note report eli lilly lly several other file brief support regeneron important note praluent be boot market amgen repatha be sole pcsk inhibitor market so case boil policy vs emotion sy say amgen win praluent be take market be pushback only have pcsk market lessen competition say praluent be beat injunction signal patent be not relevant think so judge really seem be consider ramification decision evercore analyst akash tewari say record amgen strategy patenting antigen broader antibody have yet be test court related regeneron sanofi undercut amgen abbvie rheumatoid arthritisteva pharma run migraine trial lilly amgen biotechs fall cancer partnership bristol myer
177,PFE,nasdaq composite follow monday bullish gain lower volume decline higher volume late trading tuesday dow ease buoy strength merck mrk pfizer pfe lose hurt weakness oil gas name distribution day be take shape nasdaq stock market today volume be tracking quite bit higher monday level benchmark west texas intermediate crude oil hit multimonth low settle barrel big biotech rally lift share ibd name regeneron regn share pop well extend buy point other biotechs move include celgene celg share rise right side current base show nice accumulation higher volume gain celgene approach buy point contract research organization provide outsourced service biotech big pharma get lift parexel prxl agree be take private private equity firm share parexel rise tesla tsla be session lows still rise report release national safety transportation board find fault tesla automate pilot system involved highly publicize crash model driver be kill chipotle cmg tumble company offer lukewarm same store sale guidance also warn higher cost earning news lennar len jump nearly early fade share gain company report better expect earning third straight quarter accelerate earning growth financial be pressure year treasury yield ease basis point loss select sector spdr financial xlf be tame set nice base buy point many other financial have do good job hold gain recent breakout related netflix price target hike nvidia upgrade nike pt loweredlennar earning top view share eye buy pointthese biotechs be lead sector month high today
178,PFE,xstock be broadly lower tuesday afternoon biotechs lead rally health care stock nasdaq be dow jone industrial average ease pharmaceutical merck mrk pfizer pfe lead dow drugmaker other health care stock lead market merck add pfizer climb add space conjoin day day move average small cap lag russell dow transport fared even volume be tracking higher board stock market today loser lead winner ratio nyse ratio nasdaq energy sector be weakest oil price sank month low barrel chipotle grill cmg plunge more time average volume share already have tumble day move average almost touch day line session low fast casual restaurant chain give update operation outlook cause investor doubt recovery be track teladoc tdoc fall big volume come record high stock remain sharp upward trend late monday company announce be acquire best doctor provider consultation patient complex medical condition cash teladoc stock analyst canaccord genuity praise deal call excellent transaction teladoc analyst say provide cross selling opportunity plethora medical subspecialty domestically abroad broaden company offer low volume high acuity case furthermore transaction differentiate teladoc peer analyst say nvidia nvda amazon com amzn see unusually heavy trading major stock climb pare gain nvidia hold small price increase left share new high pacific crest upgrade stock sector weight underweight amazon be fraction volume track increase average stock member ibd leaderboard be extend rise support day move average ulta beauty ulta also see big burst volume small price increase less yet cosmetic retailer be find support pull back day move average second time related tesaro overcome clovis lead combo merck co biotechs be lead sector month high todaybiotech breakout biogen spin bioverativ buy zone
179,PFE,tesaro tsro stock plunge monday sunday presentation american society clinical oncology meeting show zejula be stronger drug astrazeneca azn breast cancer xon stock market today tesaro stock crash end day share rival astrazeneca pfizer slip less clovis oncology clvs eli lilly lly stock also lose more tesaro dow component merck mrk combine drug zejula keytruda treat ovarian breast cancer patient zejula be know parp inhibitor keytruda be pd inhibitor combine be thought offer more potent response half ovarian cancer patient respond treatment compare favorably historical datum parp pd inhibitor alone patient population leerink analyst seamus fernandez write note client still early datum appear stronger initial result see astrazeneca lynparza imfinzi tumor type write lynparza be parp inhibitor imfinzi be pd inhibitor ibd take tesaro stock have middling ibd composite rating measure performance stock get ibd stock checkup look better rate biotechs breast cancer patient have partial response combo sign cancer disappear patient patient be know triple negative breast cancer form doesn respond normal treatment achieve stability company also have see promising unconfirmed response other patient other presentation astrazeneca say lynparza show month improvement progression free survival chemotherapy patient form breast cancer pfizer show similar datum drug talazoparib saturday fernandez say overall lynparza less severe toxicity profile likely drive use drug chemotherapy say main adverse event associate lynparza be nausea anemia neutropenia be most common adverse event chemotherapy arm lilly also present incrementally positive not groundbreaking datum drug abemaciclib form breast cancer death rate be broadly line pfizer ibrance diarrhea side effect be manageable lilly say abemaciclib belong class drug call cdk inhibitor compete novartis already approve kisqali lilly say continuous dose method treatment do more disrupt cancer cell cycle related do astrazeneca rival just launch potential blockbuster drug bristol incyte match beat dow merck combination trialshow clovis astrazeneca muddy potential deal tesaro
180,PFE,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
181,PFE,pfizer pfe be await clarification tax reform embark merger deal dow component say tuesday investor push acquisition second quarter sale decline again xinvestor have be clamore pfizer drugmaker market cap make more acquisition sale have fall past consecutive quarters early tuesday pfizer say second quarter revenue slip conference call follow report pfizer reaffirm be short term event marketplace such tax reform change asset value evercore analyst umer raffat say note client trump administration have make lofty promise regard tax reform include proposal cut corporate tax rate help domicile company render corporate inversion less desirable washington act tax reform business development acquisition be somewhat delay pfizer reportedly say need see tax reform absence tax reform then look business development activity ibd take president donald trump tax vision benefit biotechs drugmaker more other head ibd technology page breakdown look likely benefit most year pfizer chief method grow topline have be make big deal acquire medivation last year deal earlier year buy anacor pharmaceutical bind therapeutic bamboo therapeutic also walk away deal acquire allergan agn political controversy link allergan ireland tax domicile deal have let pfizer change tax domicile ireland thus pay less taxe legacy drug weigh pfizer quarter pneumonia drug prevnar see sale decline pristiq depression drug lose market exclusivity topple sale erectile dysfunction drug viagra fall meantime pfizer be putt effort further develop immuno oncology drug call bavencio approve treat form skin cancer bladder cancer drug be develop germany merck kgaa bavencio be pd inhibitor compete rival drug astrazeneca azn roche rhhby competitor space dow merck mrk bristol myer squibb bmy have pd inhibitor pfizer be look combine bavencio other drug pfizer acknowledge tuesday call astrazeneca recent failure combine immuno oncology drug imfinzi tremelimumab treat lung cancer doesn bode well similar combination trial indicate immuno oncology immuno oncology combination be more problematic term pfizer reportedly say pfizer note value have pd inhibitor purview still other be ahead stock market today pfizer fall share be yearlong consolidation buy point related generic chip away dow stock pfizer cancer unit be stabilize astrazeneca fail not once twice cancer drugswhy clovis regeneron be lead biotech deluge todayhow dow merck be benefit back astrazeneca bristol
182,PFE,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
183,PFE,key index fund be lower stock fall board north korea tension disney weigh dow xpowershare qqq trust qqq lead downside stock market today afternoon trading spdr spy spdr dow jone industrial average dium be disney weigh dow medium giant announce plan start own video stream business cut ty netflix nflx overseas ishare msci south korea capped ewy gap sank fall well day move average first time nearly month india earning fund epi powershare india portfolio pin stumble ishare msci emerge market eem pare loss retail bank chip lead downside sector leader few gainer include gold health care consumer staple gold price rise more ounce spdr gold share gld ishare gold trust iau add vaneck vector junior gold miner gdxj vaneck vector gold miner gdx pop nearly apiece oil play be mixed vaneck vector oil service oih slide unite state oil fund uso gain powershare db oil fund dbo add spdr oil gas exploration production xop be barely positive value fund very different top holding be close respective buy point xvanguard mega cap value mgv launch december be buy point month flat base base begin form shortly advance prior flat base clear february fund track crsp mega cap value index first assign stock size base market cap index crsp then score security determine be growth value camp classify value stock base factor book price forward earning price historic earning price dividend price ratio sale price ratio biggest sector weighting be financial service portfolio health care technology industrial top holding june include microsoft msft johnson johnson jnj exxon mobil xom jpmorgan chase jpm etf hold stock top account nearly third asset mgv have underperform year date aug gain vs benchmark index accord morningstar inc slightly lag past year mgv have slim expense ratio value play ishare edge msci value factor vlue climb past flat base buy point intraday tuesday close entry fund rise nearly prior late january start current base vlue track msci usa enhance value index have amassed asset marked fourth anniversary april index be comprise large midcap stock overall value style characteristic msci define value base follow variable price book value price forward earning enterprise value cash flow operation biggest sector weighting be technology health care financial service top holding aug include apple aapl wal mart wmt general motor gm pfizer pfe accord morningstar vlue also hold stock top holding make nearly asset lag ytd return be ahead past year benchmark index outpace vlue past year etf carry expense ratio related apple microsoft lift dow equity play buydow go apple clear buy point nvidia hit sector good position trump bump
184,PFE,compete drug astrazeneca azn pfizer pfe clovis oncology clvs muddy water bid tesaro tsro analyst say thursday day report emerge tesaro be sale block late wednesday report emerge tesaro be seek bid just month ovarian cancer drug zejula win food drug administration approval interest have be tepid accord insider cite wall street journal janney analyst debjit chattopadhyay say astrazeneca clovis pfizer be also work similar drug class call parp inhibitor poly adp ribose polymerase parp inhibitor appear improve progression free survival patient ovarian cancer base multiple competitive datum event regulatory decision significantly competitive landscape find timing be defensive be not surprised lukewarm interest say future have datum muddy water further say clovis rubraca turn be efficient tesaro zejula ovarian cancer clovis be better position market patient ve already undergo round therapy ibd take tesaro stock have ibd composite rating meaning perform middle stock term key growth metric fall supernus pharmaceutical supn have cr best possible find best rate stock ibd stock checkup furthermore astrazeneca pfizer have datum readout later year have implication tesaro chattopadhyay say outside parps monotherapy research go combine parps immuno oncology drug hence significant premium current valuation translate buyer remorse road say chattopadhyay keep neutral rating tesaro stock late morning trading stock market today tesaro stock end regular trading day incrementally astrazeneca stock lift clovis stock jump nearly end day pfizer stock be fraction related tesaro spike rumor seek takeoverdid astrazeneca rival just launch potential blockbuster drug tesaro get jump ovarian cancer rivalry heat
185,PFE,market end dull thud run loss nasdaq dow jone industrial average be nasdaq seventh straight monthly advance end manage gain dow industrial eke only thinnest fractional advance datum play key role wednesday action dow industrial nasdaq open higher then reverse sharply release chicago purchasing manager index et correct version pmi show much stronger report first release chicago pmi show read hard prior month tally consensus view correct version show read highest mark year well forecast overnight datum china show better expect manufacturing growth steel equipment mining stock normally react positively such news come pressure early session addition claim libya production have re-cover long term ceiling barrel help send crude price almost barrel leave month stock fall then gradually regain ground release federal reserve beige book show continue modest growth increase sign optimism be flagging report be closely watch last beige book report ahead fed meeting interest rate june majority investor expect increase rate pfizer pfe lead dow industrial announce food drug administration european medicine agency have accept submission expand approve use sutent include treatment recurrent renal cell carcinoma patient follow kidney surgery pfizer share be work first weekly advance late april pressure come michael kor kor tenet healthcare thc southwestern energy swn goldman sachs gs goldman jpmorgan jpm drive downside dow stock goldman tumble jpmorgan follow revelation jpmorgan cfo marianne lake speaking investor conference firm trading revenue be year year loss be more subdue nasdaq reilly automotive orly baidu bidu hardest hit apiece top nasdaq vertex pharmaceutical vrtx rise take new high analog device adi thrash higher open then backtrack close higher big trade norwood mass company report big fiscal earning deliver revenue earning guidance analyst expectation share end buy range buy point flat base ibd stock control ctrl roar higher big trade needham upgrade connect home software developer buy price target stock be extend april rebound week move average drugmaker perrigo prgo lead strong first quarter report stock remain deep month consolidation related tech leader high earning loom investing action plan here look semtech broadcom earning
186,PFE,french drugmaker sanofi sny be reportedly consider bid tesaro tsro face competition gilead science gild frustrated hepatitis franchise have left massive biotech thirsty acquisition close stock market today tesaro be gilead stock pop close sanofi stock be close accord insider cite streetinsider sanofi be look put bid tesaro reportedly begin seek takeover bid last month follow approval launch ovarian cancer drug zejula gilead be also likely run buy tesaro accord report gilead biggest drug treat hepatitis sovaldi harvoni see sale dive high cure rate now gilead have say interested make deal particularly oncology win be cheap insider say ll cost share acquire market cap tesaro winner also get hand ovarian cancer drug zejula launch earlier year year price tag cost zejula be less expensive astrazeneca azn lynparza clovis oncology clvs rubraca zejula label be broadest allow treatment ovarian cancer patient regardless specific genetic ibd take tesaro stock have ibd composite rating meaning outperform just half stock term key growth metric visit ibd stock checkup look better rate stock biotech sector analyst have speculate competitive landscape know parp inhibitor include zejula lynparza rubraca approve drug pfizer pfe change more datum rival become available year sanofi have struggle make deal recent history last year lose johnson johnson jnj battle actelion pharmaceutical pfizer get hand parp inhibitor acquire medivation gilead too be position hunt deal hepatitis drug fall company say most recent earning call rely deal growth special interest oncology asset incyte incy have also be radar rumore target representative tesaro sanofi decline comment investor business daily representative gilead didn immediately return request comment related do astrazeneca rival just launch potential blockbuster drug clovis advantage squash tesaro ovarian cancertesaro crash beating astrazeneca stronger datum
187,PFE,future dow jone industrial average index nasdaq fall slightly early monday morning lead tech stock such apple aapl facebook fb nvidia nvda suffer worst loss month meanwhile financial such morgan stanley ms bank america bac citigroup continue recent outperformance future nasdaq include biggest tech stock fall nearly fair value dow future be more fair value friday nasdaq composite index russell hit time intraday high then tech stock have be soar suddenly reversed apple lose do manage close just day line facebook amazon amzn netflix nflx also test day line google parent alphabet googl fourth member fang group do not also lose more nvidia friday peak have soar nearly earning reversed lose meanwhile dow jone industrial end friday session high even apple intel intc microsoft msft suffering big loss credit dow drug component pfizer pfe merck mrk well banking giant jpmorgan chase jpm goldman sachs gs merck jpmorgan chase goldman sachs regain day move average citigroup extend thursday friday close still range buy point morgan stanley try clear double bottom entry close just level jpmorgan be buy point bank america be aggressive entry be start sustain revival financial temporary move don try predict market follow action major average lead stock used stock market today big picture friday sell push market direction uptrend pressure key factor bank stock overall market be federal reserve week fed be expect raise interest rate yet again inflation stubbornly low president trump fiscal agenda stumbling policymaker hint go slow approach future hike monday trading intraday japan nikkei fall china shanghai composite hong kong hang seng related big picture bear rip techs sector keep climbingfear gauge flash extreme bullishness just tech selloffafter political drama market eye fed rate hike investing action plan dow stock watch week apple to line
188,PFE,total prescription pfizer pfe eczema drug eucrisa have flattened recent week regeneron pharmaceutical regn sanofi sny dupixent have picked steam accord datum health care tracker ms meteoric rise prescription week eucrisa launch script topical eczema ointment have tally past week injection dupixent have yet see dip hit prescription week pfizer attribute flatter trend decrease free trial voucher eucrisa evercore analyst umer raffat write research report pfizer estimate third total script eucrisa be free trial voucher still eucrisa total prescription exclude free trial voucher be grow well most recent roll week vs previous week free trial voucher prescription be same period raffat say ibd take least analyst be predict boom biotech win be big name lead charge say head ibd technology page closer look stock look strong year demand look likely continue upward trend dupixent leerink analyst geoffrey porge say cite physician work dermatology biggest takeaway discussion be consistent suggestion physician believe moderate severe atopic dermatitis population be large larger moderate severe psoriasis population say physician interview expect start patient dupixent year end physician not comment dupixent use eczema be similar percentage patient receive biologic treatment psoriasis say believe have huge potential physician gain comparable experience overall average eczema patient see doctor be adult dupixent have potential be game changer pediatric eczema porge say child be likely be drug longer term adult physician believe moderate severe eczema pediatrics experience continue disease adulthood now recognize be associate more complex multisystem disease previously appreciate say dupixent be currently approve only adult be clinical testing child related ibd stock veeva fly record high exceptional quarter regeneron sanofi undercut amgen abbvie rheumatoid arthritis
189,PFE,xmajor index tracking etfs be mixed friday nvidia nvda send chip sector reel stock index have take early gain shrug surprise election outcome british prime minister theresa lose parliament majority national election have call help strengthen position small cap stock lead upside ishare russell iwm rally track new close high etf clear flat base buy point spdr midcap mdy also break climb past flat base entry spdr dow jone industrial average dium stage too advance take buy point pfizer pfe jpmorgan jpm be top gainer underlie blue chip index apple aapl microsoft msft sank chip fund reversed sharply lower ishare phlx semiconductor soxx vaneck vector semiconductor smh crash more component stock nvidia reversed new high loss short seller citron research say graphic chip designer fall thursday nvidia soar citigroup raise price target spdr regional banking kre rally spdr bank kbe etfs thursday reclaim week move average line form flat basis financial select sector spdr xlf be gold fund dip gold future fall ounce powershare db gold dgl shed spdr gold trust gld ishare gold trust iau give more apiece related find go stock market today cboe volatility index hit lowest worrynvidia stock double bull case ebay paypal hit high analyst
190,PFE,xa bruise session friday left stock mostly lower tech investor recover nasdaq second worst session year nasdaq end hold loss dow hold ground close higher hat trick negative hit tech stock end confuse news week report release late thursday bank america conclude tech sector currently trade highest relative multiple tech bubble bofa report alone wasn enough restrain nasdaq early progress friday index haul new high peak first minute trade ibd stock recent highflier nvidia nvda appear have help trigger slide report short selling specialist citron warn weakness chipmaker core gaming business also call price target hike assessed thursday citigroup nvidia irresponsibly bullish nvidia dive heavy trade rebound lows afternoon trade share remain extend buy point reversal come highest volume stock run bad sign move send chip stock sprawl ibd chip related group post session worst loss industry group ichor holding ichr nova measurement nvmi brook instrument brk fall sharply advanced micro device amd cirrus logic crus cave more macom technology solution mtsi suffer loss tech sell broaden report friday goldman sachs call question name faamg group stock facebook fb apple aapl amazon com amzn microsoft msft google parent alphabet googl declare group valuation air pocket goldman say group be due pause have be inappropriately value stable staple issue act key driver nasdaq year combination send technology industry group friday worst performance group track ibd only technology industry lineup automaker be drag heavy volume loss industry most techish name tesla tsla be winner friday dow gain ground haul higher pfizer pfe advance gain better jpmorgan jpm chevron cvx apple tank more find support week move average microsoft drop dd spiked penney jcp kohl kss vault announcement thursday jwn be consider deal be take private send share high end department store gain heavy trade friday maker drill rig equipment international oil exploration name rebound thursday harsh sell oil price warm ever so slightly leave west texas intermediate less half percent still well barrel almost week heavy construction firm also find love friday last day president trump official infrastructure week bully pulpit president layer specific number first time earlier week propose stir total infrastructure spending throw federal money kitty project nearly name industry group gain friday lead layne christiansen layn rebound related don miss breakout take tech stock volatility fear gauge hit year low worry
191,PFE,xu stock index reversed lower midday friday erase early gain chip sector come fire nasdaq be be dog paddled gain blue chip dow jone industrial average be small cap russell lead pop volume stock market today be nyse nasdaq britain conservative party unexpectedly lose majority parliament complicate talk britain exit european union come day former fbi chief james comey rip president trump testimony seem more honesty illegality stock market gauge piece news tossed so file late thursday house representative pass legislation hollow much dodd frank move make bank more profitable especially small bank legislation face tougher test senate friday market be build previous session strength bank financial sector sector have be laggard recent month chip do well thursday early rally friday fizzle philadelphia semiconductor index know sox climb thursday add early friday tumble midday trade sector slide top chip company nvidia nvda make bearish reversal short seller citron research say stock fall powershare kbw bank kbwb exchange trade fund hustle higher thursday retook day line midday friday bank etf be etf be work deep flat base pattern look somewhat double bottom base fair number bank stock be show similar action citigroup break flat base thursday gain add midday friday stock remain buy zone citigroup report result april grow earning best quarters almost street estimate stock stock dow jone industrial average notch gain more be caterpillar cat be extend april goldman sachs gs jpmorgan chase jpm be try retake decline day line pfizer pfe be attempt halt decline begin early march ibd industry group bank financial claim day top move construction machinery stock grab remain position negative side gold miner take hardest hit economic news be thin friday market be wait et release baker hughe weekly rig count come week federal reserve meet tuesday wednesday cme group fedwatch tool peg likelihood interest rate hike range remain see bigger increase range expect rate hike be item recent strength bank stock related cboe volatility index hit lowest worrystarbuck bullish plan china way get ready stock market next turn
192,PFE,veeva system veev stock rushed record high friday ibd software firm report analyst call exceptional quarter issue street top guidance stock market today veeva stock be rise much earlier trading share have run more year uptrend software canaccord genuity analyst richard davis say report software valuation be move leptokurtic distribution be way say valuation have fat tail winner loser say case miss veeva be decisively winner bucket veeva belong ibd company computer software medical industry group be january veeva make software backbone biggest name pharma include eli lilly lly novartis nvs pfizer pfe amgen amgn now veeva be look expand outside life science market have essentially greenfield opportunity other regulate industry outside life science qualityone next generation version vault software used organize clinical trial datum ibd take veeva be look growth outside life science visit new america exclusive chat chief executive peter gassner new initiative look still veeva add nearly new customer vault offer first quarter top pharma begin standardize veeva crm customer relationship management software chief executive peter gassner say late thursday call analyst number customer multiple vault product be increase more year year quarter include top pharma add vault rim vault qualitydocs big deal gassner say be exciting represent top pharma go vault say also bode well newer vault application re build canaccord davis note struggle find anything particularly amiss quarter instead veeva execute far better strategy identify prospect become successful reference drive new customer win revenue year say related ibd stock veeva surge consensus crush
193,PFE,here weekly investing action plan need know investor come week apple aapl hold annual worldwide developer conference management typically unveil have already be leak tech medium blogosphere still be surprise loom gadget chatter well
194,PFE,share eli lilly lly dow component pfizer pfe topple month lows tuesday sustain pair downgrade lilly grab buy rating pfizer sank sell rating close stock market today lilly stock be pfizer stock lose share hit lows last see mid february goldman sachs analyst jami rubin remove lilly conviction list replace ibd member edward lifescience ew product story see potential more upside lilly stock be still rate buy price target lilly stock be year date vs have rise long term fundamental look strong lilly be face term risk patent battle regard chemotherapy alimta decision be expect june be unique situation lilly have already win district court appeal same patent rubin say usually district court process follow patent review likelihood lilly lose patent review process be low result earlier expect generic competition vs alimta second half rubin write note client meanwhile food drug administration decision regard rheumatoid arthritis drug olumiant be weigh lilly stock write earlier year fda ask more dose safety datum drug just month european official sign ibd take lilly have middling ibd composite rating best possible meaning outperform nearly stock term key growth metric still lag leader zoetis cr head ibd stock checkup list top perform drugmaker longer term rubin see upside diabetes drug trulicity breast cancer drug abemaciclib migraine drug galcanezumab take time lilly get credit wall street rubin say pfizer other hand be cut sell rating neutral citi price target cut accord streetinsider citi say medicare part coverage pfizer oncology drug be risk pfizer count prostate cancer drug xtandi breast cancer drug ibrance lung cancer drug xalkori citi analyst andrew baum say pfizer member dow jone industrial average need deal hit consensus view profit consensus expect pfizer report adjust earning share respectively related teva hold own bring migraine drug market drug stock rally relief gop health care bill win roche cancer failure tank bristol pfizer not merck
195,PFE,stock index weaken slightly negative territory tuesday sector show unexpected strength build product stock logged gain homebuilder resist downward pressure nasdaq dow jone industrial average fall retreat small cap russell dip volume stock market today be slightly monday pace major exchange blue chip be roughly evenly divide home depot hd advanced top gainer dow jone industrial average pfizer pfe retreat lead dow loser home depot gap quarterly result top street consensus estimate top bottom line company also raise guidance stratasys ssys accretive manufacturing play fall well intraday lows revenue top estimate earning only match expectation bull be hope printer stock continue recent rebound go tuesday session stratasys be so far year system ddd be exone xone be exone system be react mildly early trade respectively economic news housing start april come be street consensus number entire range estimate build permit also miss roll be expectation also lowest estimate range single family start increase april vs previous month monday national association home builder say confidence homebuilder be higher expect highest estimate range ibd homebuilder industry group rise monday shrug disappointing news start permit group be tuesday redbook weekly gauge same store sale rise year basis previous week gain industrial production april pop stomp view manufacturing also rise vs consensus target capacity utilization be be view related sina blast past buy point earningsoil market be adjust opec not be finished
196,PFE,eli lilly lly pfizer pfe novartis nvs be pit battle treat breast cancer wall street struggle thursday compare effectiveness drug lilly unveil new datum drug class call cdk work inhibit specific protein prevent proliferation cancer cell pfizer ibrance be first approve area novartis kisqali grab approval year lilly abemaciclib look promising phase trial lilly abemaciclib combine chemotherapy increase progression free survival median month vs month placebo chemo combo hazard ratio measure likelihood death be pfizer drug ibrance be combine chemo earlier trial combo have lower hazard ratio meaning be lower risk death only extend progression free survival median month vs month placebo combo compare boil wall street see better effectiveness metric evercore analyst umer raffat write report note trial study different population breast cancer patient make apple apple comparison tricky still diarrhea remain concern lilly abemaciclib patient experience diarrhea vs patient placebo chemo combination lilly advise patient begin diarrheal medicine first sign diarrhea ibd take want keep tab market american society clinical oncology meeting next month bookmark ibd biotech pharma industry stock news page result be present late wednesday ahead american society clinical oncology meeting june chicago other abstract upload wednesday include merck mrk bristol myer squibb bmy roche rhhby tesaro tsro regeneron regn sanofi sny incyte incy stock spiked month high thursday epacadostat prove effective combo merck keytruda bristol opdivo outdo roche tecentriq newlink genetic nlnk rival epacadostat wasn merck only note interest merck also offer pair update famous trial dub keynote have find keytruda be better chemo first treatment advanced lung cancer hazard ratio keytruda drop merck say be not statistically significant favorable trend have help recent fda approval evercore raffat say note merck keytruda bristol opdivo be know immuno oncology drug work block interaction pd protein immune system cell pd protein cancer cell help immune system identify cancer keynote trial merck also find lung cancer patient treat keytruda initial round see continue benefit keytruda second round cancer progressed cement role pd inhibitor first line treatment even further raffat say phase trial regeneron sanofi find pd drug know regn have benefit rate patient common form skin cancer drug have control rate be very encourage disease set leerink analyst geoffrey porge say american cancer society estimate patient be diagnosed die basal squamous cell skin cancer year longer term be potential regn treat patient advanced not necessarily fatal skin cancer patient enrolled regeneron sanofi trial show complete response month meaning discernible sign cancer disappear porge keep outperform rating regeneron stock be little note tesaro abstract ahead conference leerink analyst seamus fernandez say most interesting datum present next month be combination trial tesaro zejula merck keytruda breast ovarian cancer zejula compete vs astrazeneca azn clovis oncology clvs class drug call parp inhibitor work block specific enzyme treat ovarian cancer parp inhibitor be currently be investigate breast cancer well combine parp inhibitor immuno oncology drug merck keytruda be thought be more potent treat cancer tesaro be also look zejula pd keytruda advanced lung cancer company be slate present datum dozen patient treat zejula keytruda fernandez note bar be fairly low outperform alone pd inhibitor have response rate group patient parp inhibitor have mid response rate recently publish datum small trial astrazeneca imfinzi pd inhibitor lynparza parp inhibitor show somewhat disappointing response rate ovarian cancer patient tesaro believe combination pd antibody zejula be superior fernandez say related incyte team dow merck trounce roche cancerdid astrazeneca rival just launch potential blockbuster drug
197,PFE,stock market open note early wednesday overnight positive manufacturing datum china however gain be quickly pare major index turn red chicago pmi hit lowest level january nasdaq lag loss dow jone industrial average fall dow industrial medical component pfizer pfe merck mrk johnson johnson jnj find head pack pfizer gain merck jnj follow gain early trading blue chip laggard be financial component goldman sachs gs jpmorgan jpm fall respectively analog device adi surge big earning beat chipmaker handily exceed sale earning target provide optimistic outlook current quarter stock break cup base buy point tuesday downside energy name find bottom performer second straight day oil price plunge again crude drop transocean rig drop chesapeake energy chk fall retail stock be show mixed action stock market today michael kor kor fall year low fiscal earning release result weak same store sale gloomy outlook quarterly earning have decline consecutive quarters capped decline quarter report retailer plan close store next year woman apparel retailer jill jill shot almost top bottom line beat lead retailer ollie bargain outlet olli report earning close today stock be well extend flat base buy point action ibd be predominantly negative general market reversed lower open downside chemour cc drop almost fiberoptic stock lumentum lite moved almost stamp com stmp fall hard second straight day last week share be almost upside control ctrl rise new oriental education edu moved initial datum release suggest chicago region manufacturing fall sharply send kingsbury international chicago purchasing manager index read be well april tally well economist projection downtick release be later correct show chicago pmi well expectation related michael kor dife outlook shut store jill soarsanalog device jump big earning beat raise outlookdow jone industrial average dow stock news analysis
198,PFE,ask wall street analyst name possible catalyst rise big cap technology stock apple aapl cisco system csco top most list be trump administration plan allow company bring foreign profit reduce tax rate analyst say cash bring back be piggy bank company stock repurchase acquisition problem be president trump economic agenda have be stall white house drama propose change repatriate cash be part bigger trump tax reform package randall stephenson ceo say tax reform make congress lot person be get pessimistic lot noise washington right now tax reform not be achieve stephenson say jpmorgan tech conference be still optimistic something still get do bundle tax reform infrastructure bill be big think achievable even so worry be overseas tax holiday tech firm not turn bonanza make be depend legislation put condition money be spend create enforcement mechanism rather see money go company stock buyback acquisition trump congress steer money job creation capital spending say ub analyst trump administration want really drive inward investment have be sort mandate use cash maybe spend capital expenditure yet do not know ub analyst geoff robinson say report reason think robinson be right track trillion dollar offshore want get back america gary cohn trump chief economic advisor say recent interview want company bring money back put back economy want create job cash rich tech company apple microsoft msft google parent alphabet googl cisco currently pay tax so call repatriate earning rather take tax hit ve keep money overseas president trump have propose time tax offshore earning republican controlled house have propose lower rate overseas tax break congress pass be call american job creation act didn do much stimulate economy analyst say ajca taxed repatriate earning rate top firm bring back cash be drug company pfizer pfe merck mrk well hewlett packard johnson johnson jnj ibm ibm accord ir be bring back however only company eligible bring back cash do so say richard lane analyst moody investor service many company keep cash overseas ajca requirement say ajca require company reinvest tax saving worker hire training infrastructure research development capital project accord ub however fund repatriation have be earmark capital investment ultimately be spend large part share repurchase ub say happened ajca do not include tracking mechanism so government audit company gauge compliance trump administration put better enforcement mechanism place company have more overseas cash be need continue funding foreign operation company currently most overseas cash be apple microsoft cisco google oracle orcl moody say cisco have state cash bring back be used reduce debt book analyst have other idea tax holiday be approve bmo capital market say report expect cisco hewlett packard enterprise hpe focus more acquisition apple smaller company likely lean more capital return case apple cisco analyst envision enough cash be bring back fund deal apple have cash grow year apple cash be overseas time repatriation tax give apple acquisition buyback citigroup analyst jim suva say report suva speculate apple buy large company such netflix nflx walt disney electronic art ea cisco meanwhile bring back cash overseas analyst say report credit suisse speculate enterprise software provider servicenow now splunk splk computer security firm palo alto network panw be cisco shopping list pacific crest security add red hat rht nutanix ntnx list possible cisco target intel intc be semiconductor company cash hoard overseas intel bring back say bmo capital market nvidia nvda qualcomm qcom also have significant overseas cash bmo capital do not expect trump tax holiday spur acquisition spree chipmaker
199,PFE,fast food restaurant operator yum brand yum be upgrade buy drug giant pfizer pfe be downgrade sell wall street analyst tuesday goldman sachs initiate coverage host medical pharmaceutical company rating baxter international bax intuitive surgical isrg buy abbott laboratory hold argus research upgrade yum brand stock buy hold yum operate franchise kfc pizza hut taco bell restaurant yum stock rise stock market today break cup base buy point remain buy zone hit record regular session trading high louisville ky base yum report better expect revenue earning first quarter thank strong sale taco bell citigroup downgrade share pfizer sell stock be tuesday pfizer stock have form saucer handle chart pattern buy point past week new york base pfizer report mixed first quarter result earning top view sale come short goldman initiate coverage baxter buy rating price target start surgical robot maker intuitive surgical buy price target begin coverage abbott lab hold rating price target baxter rise hit fresh time high intuitive surgical rise climb also set record high abbott lab fall related baxter raise guidance hospital market rebound stock hit highpfizer follow baxter get slam subpoena related saline shortagerobotic surgeon maker launch record high strong
200,PFE,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
201,PFE,eagle pharmaceutical egrx depome depo stock plunge thursday mizuho analyst slash price target slew drugmaker include generic drugmaker teva pharmaceutical teva mizuho analyst irina koffler cite risky guidance price target cut teva depome stock be more bullish dermira derm skin care firm trim price target prescription trend dermatology eagle stock meanwhile be too expensive say stock market today depome stock fall eagle teva stock lose dermira stock rise koffler see dermira takeout candidate koffler cut price target teva stock keep underperform rating cite expectation contraction further asset sale general pricing pressure copaxone issue minimal pipeline contribution remove sale laquinimod model laquinimod be be develop treat relapse remit multiple sclerosis fail recent trial force teva focus instead laquinimod primary progressive ms huntington disease ibd take keep drugmake industry bookmarking ibd biotech pharma industry stock news page meanwhile teva be likely experience more pressure blockbuster ms drug copaxone january district court judge tossed patent protect drug open teva competition mylan myl pfizer pfe momenta pharmaceutical mnta koffler keep neutral rating depome stock cut price target note weak long term outlook opioid market depome make pain management drug include nucynta first quarter sale profit miss expectation koffler like pragmatism new ceo arthur higgin make rapid decision stabilize product decline lower operate expense lower guidance now feel more achievable say eagle stock other hand be just too expensive koffler write note client unlikely be takeout candidate so koffler cut price target share teva eagle stock also have underperform rating first quarter eagle report consensus top revenue profit meet koffler lower expectation takeout note uncertainty associate chemotherapy bendeka likely slow ramp ryanodex exertional heat stroke dermira grab bullish view prescription trend dermatology be currently soft so koffler cut price target dermira stock be buy rate share note view company attractive takeout candidate dermira stock sell recently unexpected convertible debt financing koffler expect stock rebound innovative pipeline potential takeout stock now look derisked additional financing next year say note related do neurocrine just leave door open teva tourette teva hold own bring migraine drug marketteva pharma sale lag key multiple sclerosis drug topple
202,PFE,teva pharmaceutical teva say thursday increase price multiple sclerosis drug copaxone partially offset dip global first quarter sale share fall total revenue miss wall street view stock market today teva stock rise earlier fall much share be year antitrust probe generic include teva mylan myl perrigo prgo first quarter end march teva report adjust income share sale profit top cent decline year year sale miss view grow vs last year generic medicine sale grow comprise total sale chunk represent year earlier period teva note acquisition actavis help boost segment quarter revenue teva specialty drug unit decline teva blame lower sale central nervous system respiratory drug decrease specialty medicine help offset teva receive payment takeda subsidiary buy royalty right multiple myeloma drug ninlaro copaxone see fewer sale quarter revenue multiple sclerosis drug fall partially offset price increase copaxone product january teva say teva sell milligram milligram dose copaxone ibd take generic drug stock topple last week federal official search perrigo office part widespread price fix investigation head ibd industry theme deeper look company face department justice scrutiny outside copaxone revenue grow teva face loom copaxone competition february delaware court rule invalid key patent protect drug siding mylan pfizer pfe momenta pharmaceutical mnta be work copaxone copy respiratory product also topple first quarter bring revenue sale asthma inhaler proair qvar decline respectively teva note wholesaler retailer inventory reduction well net pricing effect play dip teva also say michael mcclellan serve interim chief financial officer effective july follow plan departure eyal desheh join teva mcclellan have year career sanofi sny related mylan revenue fall short view epipen sale declineteva downgrade lose ms drug patent doj probe
203,PFE,failure roche rhhby tecentriq late stage trial bladder cancer drug bode badly not only company several rival appear merck mrk come ahead analyst suggest wednesday early wednesday roche say immuno oncology drug tecentriq fail improve overall survival vs chemotherapy phase trial bladder cancer patient have already receive chemotherapy later day however merck keytruda win key approval be not bladder cancer close food drug administration give nod keytruda treat be know metastatic nonsquamous small cell lung cancer conjunction chemotherapy share merck jump hour trading regular session merck gain tecentriq approval treatment bladder cancer be risk write evercore analyst umer raffat note client merck keytruda simply be better drug other rival keytruda be expect gain full approval bladder cancer base trial top chemo improve patient overall survival rate last year trial keytruda improve progression free survival lung cancer patient median month vs month chemo similar trial bristol myer bmy opdivo improve progression free survival median month vs month chemo now have second cancer indication merck keytruda work competitor pd pd didn say be datum point make pause second tecentriq accelerate approval bladder cancer be contingent phase result fda warn drug fail withdraw approval drug roche rival pfizer pfe bavencio bristol opdivo merck keytruda class drug block interaction pd protein immune system cell pd protein surface cancer cell help immune system identify cancer tecentriq have slightly different mechanism work target pd protein cancer cell tecentriq bavencio opdivo have accelerate approval second line bladder cancer evercore raffat question tecentriq result demonstrate broader problem immuno oncology drug bladder cancer be broader risk immuno oncology monotherapy indication ask note bristol myer have slightly higher overall response rate indication pfizer roche ibd take immuno oncology market be worth just take account protein enzyme target already identify analyst say visit ibd technology page deep dive industry stock market today roche stock end trading nearly share hit buy point april cup handle begin form last june bristol myer stock sank fraction then lose hour pfizer be fractionally regular session hour tecentriq failure bladder cancer put leerink analyst seamus fernandez model risk previously fernandez modeled peak worldwide bladder cancer sale pd pd immuno oncology drug expect tecentriq take market keytruda seize follow opdivo astrazeneca azn imfinzi pd antibody pfizer bavencio also gain modest share well say related bristol myer too risky acquire merck roche pile pressurebristol myer beat gilead merck key approval china europedid gilead just provide incyte potential deal
204,PFE,stock rac commendable gain light trade monday haul dow jone industrial average further day move average session open boost saturday announcement more long term deal manufacturer saudi arabia set bargain time correspond president trump first trip saudi arabia news lift defense play lead boee ba lockheed martin lmt raytheon rtn well national oilwell varco nov other boee lockheed martin end nearly ford hold early gain end monday more announce have replace chief executive mark field jim hackett former ceo steelcase scs have head ford smart mobility experimental operation unit field hold ceo seat year ford share have be month decline nasdaq composite lead more nasdaq stock climb more autodesk adsk lead nasdaq more new high add gain post last week fiber optic telecom stock post session best gain industry boost handful analyst report acacia communication acia apply optoelectronic aaoi finisar fnsr gain more maker medical software also score high skewer higher gain thinly trade polarityte cool group leader veeva system veev be extend peer cerner cern be trading just buy point week tight pattern dow jone industrial average scale cisco system csco lead index rebound look salvage support week move average diving gale force volume last week loss blue chip be generally modest pfizer pfe fall hardest dow industrial score gain jack daniel distiller brown forman bfb run list gain clear prior high august chipmaker qorvo qrvo sped higher intuitive surgical isrg jump take new high defense consultant booz allen hamilton bah spiked possibly aid saturday announcement more saudi defense deal also report first quarter earning revenue expectation host full year revenue guidance past consensus target gap gain lift share just buy point flat base related dow jone industrial average dow stock news housing stock buy point investing action plan
205,PFE,stock market moved modestly higher early monday major index lead stock continue recovery last week brutal sell tech heavy nasdaq lead index higher rise dow jone industrial average follow gain respectively volume fall nyse nasdaq vs same time friday dow industrial boee ba soar president trump busy weekend lead set broad range deal saudi arabia blue chip leader mmm cisco system csco unitedhealth group unh advanced more downside pfizer pfe energy component chevron cvx pace decliner fall respectively component lead stock stock market today be casino operator wynn resort wynn chip stock qualcomm qcom rise respectively weak end amgen amgn advanced micro device amd mosaic mo fall more apiece lead stock nvidia nvda amazon amzn trade new high tesla tsla drop china base stock continue recent spate gain weibo wb sina sina gain almost netease nte moved alibaba baba rise jd com jd advanced fiber optic stock be favore early monday analyst provide bullish commentary many industry member apply optoelectronic aaoi be initiate buy rating needham co jump analyst firm rosenblatt say finisar fnsr resume shipping product china network gear maker huawei spark rise share ciena cien benefit nearly upgrade buy hold stifel nicolaus chip fiber optic stock dominate top performer ibd midday trading lumentum lite jump almost macom technology solution mtsi rise life science software provider veeva system veev moved almost new high ahead earn release thursday close downside new issue floor decor fnd fall look build ipo base successful ipo april mortgage insurer essent group esnt lose fight support day line work new base share fall related apply optoelectronic finisar rise datum center be tesla model break even price point more surprise new studywhich sector be show most strength market rally dow jone industrial average dow stock news analysisapple price target raise qualcomm ciena finish line upgrade
206,PFE,remember apple aapl popular app catchphrase perhaps same be say exchange trade fund least industry appear head direction support gender diversity prefer religious oriented investment believe millennial spending power etf be just few new wave thematic etfs come scene last year last year most successful launch be spdr ssga gender diversity index bring asset state street global advisor march offer track ssga gender diversity index be make large cap company show diversity senior leadership pfizer pfe amgen amgn pepsico pep be largest holding daily trading volume be share gross expense ratio be accord independent industry researcher morningstar inc do diversity work investment fund be march debut year date april bring global catholic value cath asset average daily volume track catholic value index etf top big cap holding include alphabet googl amazon amzn facebook fb microsoft msft fund invest company business practice meet conference catholic bishop socially responsible guideline expense ratio be year past year line broad stock market global millennial thematic etf miln launch last year aim invest company provide product service millennial be likely use top holding include alphabet apple facebook fb netflix nflx paypal pypl etf try provide investment result similar price yield performance indxx millennial thematic index carry gross expense ratio have aum average daily volume share year year august see launch principal millennial index etf geny have similar goal track nasdaq global millennial
207,PFE,opportunity index have expense ratio aum so far year etfs vary widely niche tend garner initial attention many fail attract sizable asset daily trading volume beg question be thematic etfs too trendy do have stay power common thread be re prey investor impulse chase hot ben johnson director global etf research morningstar say december report fund tend offer narrow often overly complex exposure charge high fee have sponsor prioritize salability stay power be host thematic etfs be launch cover wide variety trend topic printing obesity epidemic video game technology name johnson write make difficult pick just short list worst pick spirite fund etfmg whiskey spirit wsky have asset fund be year date fund have portfolio invest top holding top hold diageo deo alone soak nearly asset write fund charge annual fee hefty price pay concentrated bet booze investor be well serve leave shelf new etfs launch last year be thematic fund accord ron rowland founder executive editor invest edge thematic etfs have be year be noticeable increase launch activity write january article new theme be financial technology drone longevity millennial printing obesity related tesla mobileye thematic etfs hold more stock
208,PFE,merck mrk tuesday report better expect result first quarter raise outlook share dip light sale cancer drug keytruda diabetes medicine januvia company member dow jone industrial average disclose adjust income cent share revenue respectively analyst have expect drugmaker report earning cent share sale merck now see adjust income share previous range share company forecast also call revenue previous range analyst view call adjust income share sale merck stock close stock market today ibd take follow slurry biotech pharma first quarter report visit ibd biotech pharma industry stock news page wall street be likely look strong sale immuno oncology drug keytruda rival bristol myer squibb bmy opdivo keytruda grow merck say lag leerink analyst seamus fernandez view bristol opdivo sale grow year year first quarter sale januvia diabetes drug fall year year miss fernandez model be offset outperformance human papillomavirus drug gardasil hepatitis drug zepatier beat estimate meanwhile rival dow drug stock pfizer pfe report better expect first quarter earning pfizer sale fall short related bristol myer beat gilead merck key approval china dow stock merck undercut astrazeneca lung cancer
209,PFE,stock market trade mixed afternoon trade range minor gain nasdasq light loss head final hour session tech heavy composite moved decline dow jone industrial average inched lower volume be tracking slightly higher exchange vs same time monday other dow industrial ibm ibm pace advancer rise microsoft msft home depot hd follow gain respectively downside medical component unitedhealth group unh pfizer pfe pull dow red decline respectively chip stock be leader day chipmaker advanced micro device amd surge chip equipment stock qorvo qrvo follow monday advance rise qorvo surge past flat base entry remain proper buy range laggard be once again retail stock drastically underperform general market apparel company armour uaa hanesbrand hbi pierce day line fall respectively ralph lauren rl vf corp vfc drop lead retailer burlington store burl gap day line early tuesday gain cup base entry have be much just day day lose streak have bring stock gain just china base stock drastically outperformed stock market today internet portal sina sina so call twitter china weibo wb report early tuesday cause shoot higher respectively company top analyst estimate sina surge long consolidation featured buy point weibo be now cup handle entry chinese commerce giant jd com jd alibaba baba moved respectively chinese internet giant tencent tcehy report result open wednesday action ibd be predominantly positive head final hour trading lead technology name china component momo momo new oriental education edu tal education tal lead way gain respectively life science software provider veeva system veev jump be now almost cup handle buy point downside stamp com stmp fall stock be build cup base battle support day line related china stock jump lead strong earning weibo sinaselling intensify retail sector department storesinternet giant join china parade cisco entry investing action plan
210,PFE,bristol myer squibb bmy be too risky acquire merck mrk roche rhhby pile pressure immuno oncology medication analyst argue wednesday downgrade bristol stock underperform rating stock market today bristol stock be bmo analyst alex arfaei attribute recent move bristol stock january takeover speculation pfizer pfe oft cite potential suitor bristol seem unlikely make deal term arfaei say tuesday pfizer first quarter earning call chief executive ian read cite macro issue make acquisition difficult pfizer have be expect continue be active industry consolidator say however be lack clarity potential tax reform health care policy uncertainty european market french election uk snap election arfaei call increase uncertainty bristol immuno oncology franchise year merck immuno oncology drug keytruda likely get food drug administration approval combination chemotherapy treat advanced lung cancer also later month merck be likely unveil strong datum keytruda incyte incy epacadostat number tumor don expect significant new datum bristol american society clinical oncology meeting conference likely strengthen argument immuno oncology market become increasingly fragmented write note client ibd take bristol merck be lead immuno oncology market day sun be come end number company be step immuno oncology research offering head ibd technology page look rival come year latter half arfaei see roche immuno oncology drug tecentriq pressure bristol advanced lung cancer also expect payer use datum bristol limit use immuno oncology drug opdivo yervoy melanoma immuno oncology battle have pit bristol merck most directly opdivo keytruda be know pd antibody work block interaction immune system cell cancer cell hiding pd protein help body identify cancer bristol have have win immuno oncology world recently last week european regulator approve opdivo second line treatment squamous cell head neck cancer platinum base therapy company beat merck approval still arfaei say bristol be too reliant immuno oncology drug estimate comprise sale profit overall argue even see positive resolution macro factor give bristol overdependence immuno oncology franchise expectation increase uncertainty potential takeout seem unlikely be simply too risky arfaei write related do gilead just provide incyte potential deal bristol myer beat gilead merck key approval china europedow merck top view raise outlook key drug lag
211,PFE,dow component pfizer pfe tuesday report mixed first quarter result call essential health unit tug overall sale revenue novartis nvs rivale cancer drug bound vs year earlier quarter pfizer say earn adjust income cent share revenue first quarter respectively analyst have expect drugmaker report earning cent share sale quarter pfizer innovative health unit include newer product grow essential health business include legacy product offset fall september pfizer scrap idea corporate breakup have split business wall street have pin hope pfizer ibrance be approve treat form advanced breast cancer ibrance sale grow period have competition novartis kisqali further eli lilly lly abemaciclib have show promise clinical trial sale pneumonia vaccine prevnar topple vs year earlier quarter dip be primarily due continue decline revenue adult indication due smaller remain catch opportunity pfizer say globally sale fall timing government purchase enbrel also see sale dip outside canada enbrel sale come develop europe enbrel sale fall revenue also topple emerge market other develop part globe respectively ibd take have trouble keep slew pharma biotech earning quarter catch ibd biotech pharma industry stock news page pfizer also reiterate guidance revenue adjust earning share flat respectively analyst be call revenue adjust income share stock market today share member dow jone industrial average dip earlier fall much touch lowest point month stock have potential buy point cup handle begin form august meanwhile fellow dow drug giant merck mrk also issue first quarter earning report merck top earning sale raise full year guidance gilead science gild major biotech player report weaker expect earning sale late tuesday related lilly new drug spark deeper rivalry novartis pfizerpfizer follow baxter get slam subpoena related saline shortage
212,PFE,stock market be mixed midday trade federal reserve day interest rate meeting kick fed be expect leave rate unchanged dow jone industrial average lead way gain aid apple aapl move upside ahead iphone maker earning release close nasdaq be barely break even mark volume rise major exchange other dow industrial intel pace advancer rise fellow chip company amd amd plummet almost miss sale estimate amd loss be intel gain visa follow gain move coincide fellow credit card company mastercard report better expect profit revenue early tuesday share mastercard jump more record high earning reporter dow drug stock pfizer pfe merck mrk report result early tuesday pfizer drop company exceed earning target fall short revenue estimate share merck moved company surpass top bottom line estimate automaker sell stock market today ford motor general motor gm fiat chrysler fcau report expect april auto sale ford stock drop gm fall fiat decline electric automaker tesla tsla only moved share remain just time high report earning wednesday bell stock breaking today cummin cmi gap flat base entry report better expect earning sale martin marietta material mlm be approach cup shape base buy point own bullish report share rise lead growth stock be mixed tuesday morning trade upside cognex cgnx jump cautious revenue guidance china commerce giant alibaba baba moved downside nvidia nvda fall conjunction amd decline share nvidia have rebound valiantly last week reclaim day line related pfizer earning top sale come shortdow merck top view raise outlook key drug lagsapple earning preview expectwhere be stock market head read more big picture
213,PFE,xfuture dow jone industrial average index nasdaq future early tuesday morning edge higher indicate slightly higher open apple aapl pfizer pfe mastercard headline component earning tap tuesday several company be due report eye be apple report close bell apple have world largest market cap share trading time high investor be look past current sluggish growth iphone possible dividend hike new buyback apple result guidance be likely have big impact slew supplier especially chipmaker several other megacaps be tap include drug giant pfizer merck open apple pfizer merck be part dow industrial continue lag fall slightly monday nasdaq composite power new time high thank apple facebook fb amazon com amzn other big cap techs altrium mo cvs health cvs conocophillip cop emerson electric emr gilead science gild mondelez mdlz round company tap late monday dow nasdaq future rise fair value so do index future asian trading japan nikkei rise hong kong hang seng climb shanghai composite fall ibd take apple be leaderboard ibd premium service offer annotate chart select group stock mostly growth company be buy zone take free leaderboard trial today meanwhile general motor gm ford other automaker release auto sale april analyst expect modest broad base decline demand continue decline vs year earlier general motor ford member report earning last week federal reserve begin day policy meeting analyst don see real chance move wednesday policymaker reinforce expectation june move bring forward estimate hike pare back central bank massive balance sheet related be buy point apple earning stock still buy range apple stock hit record high earning tapapril auto sale expect gm ford tesla soar be top stock earning due week
214,PFE,eli lilly lly stock dip early tuesday drugmaker top wall street first quarter sale profit expectation baricitinib lilly incyte incy rheumatoid arthritis drug need more clinical datum fda bless monday lilly say breast cancer drug abemaciclib rivale pfizer pfe novartis nvs meet goal interim analysis breast cancer give lilly stock confidence head early tuesday first quarter earning report call investor likely look commentary regard plan baricitinib also strong number diabetes chemotherapy unit new drug lilly biggest be trulicity diabetes drug cyramza tumor drug trulicity sale launch first quarter cyramza lilly see major outperformance basaglar diabetes drug see sale grow ibd take lilly stock have middling ibd composite rating meaning underperform more half stock term key growth metric better stock bet be jazz pharmaceutical cr best possible head ibd stock checkup list top rate drugmaker consensus consensus expect lilly report cent adjust profit sale year year basis adjust earning share be sale grow result lilly report sale cent adjust ep respectively guidance company reaffirm adjust ep guidance stock action lilly stock fall close stock market today announce first quarter result stock close monday related lilly outperform bigger rival strong diabetes med eli lilly incyte stock break key level fda drug lilly survive rheumatoid arthritis flop breast cancer drug
215,PFE,eli lilly lly stock pop monday drugmaker say breast cancer drug have potential be best class potentially spark deeper rivalry pfizer pfe novartis nvs lilly stock finished higher stock market today stock touch day move average first time trading day ibd company medical ethical drug industry group jump nearly drug abemaciclib improve progression free survival overall survival combine inhibitor type breast cancer treatment interim analysis street expect trial run completion final analysis end year specific result be expect june annual american society clinical oncology meeting most common side effect lilly say be diarrhea fatigue nausea neutropenia lack type white blood cell leerink analyst seamus fernandez call trial result unexpected lilly abemaciclib belong class drug work inhibit cdk enzyme effort treat breast cancer lilly be gear compete pfizer novartis cdk breast cancer market pfizer ibrance lead market launch novartis kisqali recently receive fda approval write note client ibd take eli lilly stock have ibd composite rating meaning underperform majority stock term key growth metric head ibd stock checkup list better stock bet pfizer ibrance be lead market kisqali be approve march abemaciclib now have major win belt put equal foot pfizer ibrance fernandez say abemaciclib also have strong top line result phase study announce march fernandez note have outperform rating lilly stock related lilly outperform bigger rival strong diabetes med eli lilly incyte stock break key level fda drug lilly survive rheumatoid arthritis flop breast cancer drug
216,PFE,pfizer pfe wednesday follow baxter bax receive department justice subpoena widespread antitrust investigation sale marketing saline fluid shortage more year late wednesday pfizer stock be less follow report doj probe accord reuter pfizer confirm receive grand jury subpoena department antitrust division news come just day baxter stock fall less news have receive subpoena expect be part same investigation flu season rage company make intravenous fluid hydrate patient experience delay production delay saline solution price rise accord senator ask federal trade commission investigate matter include probe be baxter hospira acquire pfizer braun ibd take pfizer stock have low ibd composite rating meaning underperform more third stock term key growth metric earning power sale growth visit ibd stock checkup list top rate drugmaker include jazz pharmaceutical stock have cr best possible baxter have call allegation extraordinary motion dismiss related class action lawsuit deal shortage baxter begin import iv fluid facility spain incur cost work comply fda requirement pfizer didn immediately return request comment investor business daily related do baxter hoodwink fda inspector be probe just extraordinary
217,PFE,index other major average rise modestly week even apple aapl facebook fb dip earning tesla tsla tumble wider loss auto sale fall again crude price crash month lows solid job growth show economy be track keep federal reserve course well nasdaq rise nearly week dow jone industrial average index advanced modestly big headwind apple dow component facebook especially tesla pull back follow quarterly report crude oil future tumble lowest level november drag energy stock metal price also fall sharply hit miner general motor gm other automaker report decline sale yet again fiber optic stock warn sluggish china demand cite boom growth consumer electronic giant apple aapl earn share year year revenue march fiscal second quarter analyst expect sell iphone last quarter view ceo tim cook blame slowdown iphone sale consumer delay purchase speculation next generation device rumore iphone apple hike dividend add stock buyback program edge lower wednesday thursday apple stock rally fresh record high friday related apple beat view earning come short grow doubt opec lead production cut offset boom sale crude price tumble lowest level cartel begin curb output crude fall electronic trading overnight friday rally close barrel oil price still lose week meanwhile bp beat estimate royal dutch shell rdsa top view massive increase cash flow conocophillip cop report surprise loss shale producer be mixed bag pioneer natural resource pxd highlighted new drill technique include possibility employ artificial intelligence future related oil crash chart show opec be trappedrevenue rise beating consensus estimate gaap earning share beating view monthly daily active user growth also exceed expectation facebook once again caution ad revenue growth slow meaningfully share edge lower thursday friday related facebook applaud analyst follow strong earning reporttesla show larger loss expect strong revenue growth first quarter earning tesla revenue rise beating wall street estimate yet luxury electric car maker report adjust loss share exceed cent share loss wall street expect ceo elon musk say model plan be track say robot software day make tesla valuable apple tesla share tumble thursday extend loss ahead company result rebound friday related tesla get mixed reviews analyst earning reportmeanwhile auto sale april miss view board tuesday general motor ford fiat chrysler fcau nearly foreign peer report decline demand miss view auto sale have fall year year straight month longest string recession end industrywide sale come annual rate accord autodata expect auto part giant delphi dlph soar report strong earning announce plan spin powertrain segment focus autonomous electric vehicle related auto review tesla loss sale slump delphi break economy add job april slightly more expect sluggish march hire weak overall economic activity start year jobless rate edge fresh year low report suggest economic growth rebound spring also keep federal reserve track policymaker expect raise rate more time have hint take step pare central bank massive balance sheet related job add april jobless rate sink year low hollywood writer studio broker peace avoid writer strike medium stock get slam time warner twx report soft ad revenue subscriber loss dish network dish have mixed result be mar subscription loss be high industrywide viacom viab beat handily paramount perform well share be hit cable bundle distribution worry hulu debut channel live tv beta bundle month join several other stream tv offering cbs cbs result come mixed house panel scold airline treat customer better be sign lawmaker plan legislative remedy hearing follow well publicize video polouse drag unite airline ual passenger flight incident rep steve cohen say remind trump campaign rally alaska airline exec say company be review policy overbooking american airline aal say hadn establish ceiling payout offer person need bump flight southwest luv plan end overbooking say wouldn go break result even lawmaker batter executive airline stock soar delta air line dal traffic result april show positive unit revenue storm atlanta oclaro oclr inphi iphi lumentum lite warn slacken demand china clearest sign yet key market fiber optic gear component be struggle generally see temporary tout strong demand base datum center metro expansion oclaro initially crash wednesday morning end day flat inphi do lose day lumentum actually rally thursday cite progress sensor apple iphone speculation apply optoelectronic aaoi sky-rocket beating already raise earning estimate related lumentum have apple iphone sensor design bag analystdow component merck mrk tuesday top view sale cent ep lighter expect sale immuno oncology drug keytruda weigh stock close fraction pfizer pfe sale be light adjust income cent beat penny regeneron pharmaceutical regn thursday miss sale ep view eylea sale praluent sale be less dire expect yum brand yum papa john pzza put earning beat estimate help taco bell yum own digital order have be great pizza business shake shack shak sank late thursday weak same store sale guidance soar friday morning dunkin brand dnkn sale miss increasingly challenge environment retail restaurant wingstop wing surge beating estimate hike ep full year growth forecast cheesecake factory cake tumble miss habit restaurant habt have mixed result guidance sprint say fiscal revenue operate revenue rise top view postpaid phone subscriber addition be line stock fall disappointing free cash flow guidance speculation mobile merger cool paycom software payc report ep revenue top view raise full year revenue outlook year earlier square sq stock rise payment processor swung adjust cent profit year earlier loss raise full year revenue guidance revenue rise top view ebitda be vs consensus estimate square share soar record high twilio twlo share crash communication software maker forecast larger expect current quarter loss reveal change relationship largest customer ride sharing giant uber twilio report adjust loss cent share revenue gain ahead expectation match group mtch report revenue year earlier adjust ebitda top view strong growth paid subscriber mobile date app tinder management guide revenue be range vs consensus casino stock rally news macau gaming revenue rise april vs year earlier higher most estimate melco resort mlco report better expect earning follow upbeat report last week wynn resort wynn mgm resort mgm la vegas sand lvs bullet jg mlm cmi ec pi ec
218,PFE,stock market bounce back early morning heavy loss head midday trading follow friday ryancare flop nasdaq pare much loss make run positive territory be trading practically flat tech heavy composite index remain well early lows dow jone industrial average lag loss less volume soar nyse fall slightly nasdaq vs same time friday dow industrial stock market today goldman sachs gs heavily weigh dow loss other laggard include general electric ge fall upside dupont dd pfizer pfe tack respectively financial be biggest laggard early trading global investment bank morgan stanley ms drop online broker charle schwab schw decline recent ipo snap snap continue rise post ipo lows rise almost social medium company receive multiple bullish rating analyst jeffery give snap price target say believe snap have ingredient build robust advertising business goldman sachs set price target morgan stanley set snap go public share march apple aapl see own price target hike monday jpmorgan jpm add iphonemaker focus list price target be raise share moved market leader tesla tsla re-cover early loss jump continue consolidate day line nvidia nvda trade look remain day action lead growth stock be mostly negative head midday trading regional bank lag medical stock pace advancer biotelemetry beat gain remain extend recent flat base entry pra health science prah buck market trend gain notch new high early trading stock break flat base buy point other winner nutrisystem ntri shrug early loss rise almost downside mercury system mrcy drop almost share approach day line tal education tal fall share have be much double bottom entry related sentiment shift snap apple micron price target hikedwhat next gop agenda tesla oil hollywood investing action planwhy ryancare defeat be victory nike wal mart best buy
219,PFE,stock be show impressive rebound monday open sell nasdaq composite turn loss gain nasdaq reflect resilience large megacap techs rise dow jone industrial average be turn drop nearly loss just fall more last week early monday dow jone industrial average briefly clip day move average first time fall south side key support resistance line back then take nearly month stock dow rebound back day line help dow be dupont dd be sole component rise point more diversify manufacturer be legitimate leader stock market today jan share also be recent nov past flat base buy point be less ibd best mutual fund award view winner categoryamong new issue snap snap be get plenty attention back positive comment analyst new buy rating share stride more higher possibly set highest close more week market debut snapchat social medium site operator leap past share ipo finish then catapult high come earth next session snap slide low normal cup double bottom base decline usually run more high low base ibd research big winner past bull bear market cycle so snap case decline be heavy side especially give fact gain share ipo do not exceed more recent positive wall street comment snap be course lose money consensus estimate net loss cent share still stock deserve close watch rebound continue stock get peak most excellent cup handle pattern stock tend form handle last final shakeout uncommitted holder big new high trading more week time high trump support american health care act never see light day friday investor continue watch lead name medical health care service industry group celgene celg intuitive surgical isrg regeneron pharmaceutical regn be day biggest point winner celgene rank big cap see whole list latest ibd weekly page failure american health care act future change former president obama affordable care act be unlikely suppress demand superior medicine treat patient deadly disease such multiple myeloma celgene be field also be become force treatment chronic illness such psoriasis celgene get wonderful ep rating ibd stock checkup due consistent pattern long term profit increase solid gain short term well past quarters earning share rise vs year level average ep gain be outstanding company market cap higher celgene have market value share outstanding be large not excessively so point comparison pfizer pfe have share outstanding street see fiscal year profit rise share lift revenue revenue rise vs year level prior year intuitive meanwhile remain top hill field robotic surgery system wall street see earning rise share current quarter accelerate increase see sale be see rise growth intuitive present buy point so far feb stock spurt past cup base entry volume expand nearly day average sign healthy demand mutual fund large investment adviser pension insurer go daily chart ll also see very narrow handle form jan feb create hard see early buy point add cent highest price handle obtain handle entry point notice daily chart stock gap huge volume jan reaction decent fourth quarter result ep revenue intuitive currently get solid composite rating better regeneron score watch see regeneron muster strength rise back day day line create space key resistance line earnest start form right side new base pattern related invest add week line pullback trading invest key great cup handle basestock market today do lead chipmaker deserve spot watch list ibd do big winner have common tech news ibd snap be get love wall street
220,PFE,sanofi sny make sense acquirer flexion therapeutic flxn analyst say friday rumor flexion accept offer french drugmaker flexion investor be dubious flexion stock jump thursday tumble much stock market today then rally much close sanofi stock edge rbc analyst randal stanicky see flexion likely be take write research report sanofi make sense give sell synvisc injection supplement fluid patient knee relieve osteoarthritis flexion be now work fda approval process zilretta joint injection extend release formulation steroid knee pain stanicky see zilretta well position take meaningful share exist steroid hyaluronic acid market pre fda approval timing allow flexion avoid sale force ramp rep sanofi allow participation launch activity flexion be expect be write market be person worth size brand marketing cantor analyst chiara russo see flexion capable launch zilretta help say rumore mid share takeover price accord unidentified source comment fiercepharma be too low significant change competitive landscape past year give zilretta sole new voice space see mid price be little low strategic buyer russo write note client ibd take flexion have middling ibd composite rating meaning underperform more stock better biotech bet be celgene best possible cr visit stock checkup list strongest leader russo maintain price target maintain rating flexion stock expect zilretta take significant market share rbc stanicky see share takeover price reasonable note see support deal north perhaps closer add specialty valuation have come recently deal be pre zilretta approval have outperform rating price target flexion stock rumore bid come just month sanofi lose contentious battle swiss biotech actelion dow component johnson johnson jnj scoop deal member dow jone industrial average pfizer pfe beat sanofi acquire medivation sanofi have also be rumore have consider deal biomarin pharmaceutical bmrn medicine company mdco aftermath judge ban cholesterol drug praluent regeneron regn ban have be stay pending appeal case amgen amgn flexion sanofi decline comment ibd related do sanofi just bag biotech johnson johnson exclusive talk acquire actelion sanofi sanofi acquire biomarin wake amgen ldl brouhaha
221,PFE,xno drugmaker pfizer pfe be angle take biotechs celgene celg juno therapeutic juno kite pharma kite treatment type leukemia partnership french pharmaceutical servier thursday servier announce fda have grant application pfizer begin develop drug know ucart treatment blood cancer know acute lymphoblastic leukemia acute lymphoblastic lymphoma cause certain white blood cell be overproduced bone marrow inhibit production spread normal red white blood cell accord emedicine com disease largely inflict child pfizer servier ucart belong class drug help immune system identify specific protein cancer cell thus allow immune system destroy cancer engineer immune system cell be grow lab then infuse patient ibd take celgene be near breakthrough technology head ibd stock analysis breakdown company strong growth last week juno be force end trial treat disease juno have plan test new drug next year partnership celgene meanwhile kite be testing drug know kte same disease late trading stock market today pfizer stock be fraction kite stock lift announce wednesday public offer common stock share juno stock be help prompt jump celgene stock be related celgene unveil breakthrough treatment movejuno tank end leukemia trial rival kite topple downgrade
222,PFE,regeneron regn expect top biotech amgen amgn cholesterol drug own medication reduce risk heart attack stroke angina get vote support unexpected corner regeneron be team sanofi sny upcoming study result drug praluent hope blow amgen repatha water repatha disappoint own recent heart drug testing unusual be rival medicine company mdco alnylam pharmaceutical alny agree regeneron sanofi have better chance succeed reason be regeneron sanofi test be last much longer suggest apparent effect size magnitude risk reduction be greater regeneron study leerink analyst geoffrey porge write recent note client regeneron achieve result later appear have high confidence likely result leerink recent biotech mountain meeting snowbird utah representative regeneron medicine company alnylam delve impact amgen recent fourier study cholesterol statin space panelist agree regeneron sanofi odyssey outcome trial enrolled higher risk patient population likely experience more event year trial vs amgen year trial porge say regeneron sanofi be look praluent effect reduce risk heart attack stroke unstable angina require hospitalization patient age elevated bad ldl cholesterol acute coronary syndrome event last year panelist agree amgen recent fourier study help get payer reimburse patient cost cholesterol drug be know pcsk inhibitor class drug work reduce bad ldl cholesterol blood release long anticipate fourier result late last week amgen say show reduce harmful ldl cholesterol cut risk heart attack stroke coronary first year second year drug cut risk heart attack stroke ibd take biotechs celgene have strong week last week breaking unveil strong result trial otezla patient moderate plaque psoriasis head ibd stock analysis deep dive amgen say drug repatha didn make difference reduce risk cardiovascular death cause share amgen regeneron sanofi medicine company esperion espr pfizer pfe work cholesterol drug fall sharply amgen gambit meant deliver outcome trial result earlier competitor also undermined effect treatment intervention be materially greater second year exposure first porge say regeneron have even more robust effect size base length trial expect have datum december likely be present early esperion medicine company re-cover week analyst note esperion drug bempedoic acid likely be price lower amgen repatha repatha go year net price patient porge say medicine company also plan cardiovascular outcome trial drug inclisiran be be develop alnylam porge doesn expect datum trial earliest related esperion medicine company recover amgen induced pitfallesperion dive amgen heart study pricingamgen tank heart study share other drugmaker tumble
223,PFE,bioverativ bivv be not standard biotech startup drug developer be profitable also hold wad cash debt maker treatment blood disorder be look prospect sale year not bad company barely month old waltham mass base bioverativ spun pharmaceutical giant biogen biib feb have cash debt company begin trading nasdaq feb stock close first day stock be friday standing afternoon trade have vision build great rare disease company be focuse blood disorder have potential create significant value shareholder bioverativ chief executive john cox say recently spinoff bioverativ inherited hemophilia drug be launch biogen eloctate hemophilia alprolix hemophilia hemophilia be consider be more serious strain rare genetic disorder impair ability person blood clot due reduce level certain protein world federation hemophilia estimate be person hemophilia worldwide be patient have hemophilia bioverativ however estimate hemophiliac population be much larger hemophilia be usually diagnosed birth very young age predominantly affect male lead recurrent extend bleed episode cause pain joint damage life threaten hemorrhage accord bioverativ therapy hemophilia top figure be grow year market such drug be fragmented shire shpg have third market share nordisk nvo bayer bayry pfizer pfe csl bioverativ have be aware number company include large company such bayer pfizer csl roche hold rhhby shire currently market be pursue development product treatment hemophilia bioverativ say filing security exchange commission spinoff strong presence north america japan bioverativ have generate expect continue generate positive cash flow operation third quarter company say cash allow further invest market product pipeline pursue strategic opportunity enhance growth month period end bioverativ report revenue same period year net income bioverativ revenue be expect top year third quarter revenue rise adjust earning come cent share raymond james analyst christopher raymond initiate coverage bioverativ strong buy rating price target research report raymond say expect bioverativ grow compound annual growth rate revenue reach other competitor likely emerge think portfolio be well position raymond write believe bioverativ share offer unique mix newly launch asset diverse development pipeline strong balance sheet leave well position competitive area less enthusiastic report come morgan stanley analyst mathew harrison initiate coverage bioverativ underweight rating price target say bioverativ face key risk competition potential be leapfrog newer therapy give very early stage pipeline believe bioverativ revenue be sustainable face slow growth profile flatten harrison write key advantage hold bioverativ be drug last longer thus require fewer dosage compete product next year potential game change product be dose monthly greater interval vs weekly bioverativ roche alnylam come market write harrison stifel nicolaus analyst thomas shrader initiate bioverativ buy rating price target shrader view eloctate alprolix cash cow strong growth prospect ibd take bioverativ have ibd composite rating meaning outrank company be publicly trade company however isn highest rate group information top rank biotech check here gabelli analyst jing initiate coverage bioverativ buy rating price target say only pure play hemophilia company be attractive takeout target road bioverativ be attractive takeout target be term buyer write anticipate competitor such shire nordisk be interested bioverativ benefit cost synergy however do not expect takeover term threat bioverativ be successful development other new technology such gene therapy successfully develop approve compete eloctate alprolix new therapy technology have potential transform standard care hemophilia patient product be unable compete successfully such new therapy technology be develop market other company bioverativ say risk factor sec filing new company be develop longer act therapy enter clinical development year also accelerate development bispecific antibody hemophilia related gene therapy program plan move clinical study therapy similar long act eloctate drug second drug be early stage study aim offer less frequent more efficient convenient dose schedule company say addition intend leverage expertise early research work pursue adjacent disease area include other blood disorder such sickle cell disease beta thalassemia bioverativ say bioverativ have co development royalty bearing agreement swedish orphan biovitrum sobi bioverativ hold right commercialize agent japan canada australia sobi have right europe russia country middle east northern africa pay royalty bioverativ base net sale related biogen sidestep sale miss strong ex hemophilia guidelesser know biotech stock test buy zone cancer trial result encourage merck alzheimer drug fail be biogen roche astrazeneca next
224,PFE,stock slip red early tuesday oil price reversed lower nasdaq composite hit new record high solid gain apple aapl nasdaq composite fall dow jone industrial average hold fractional loss small cap russell lag volume be lower board stock market today vs same time monday gold miner hotel operator telecom related play be top gainer early trade department store solar airline stock underperform apple lead upside dow gain new time high rapid turnover share be now profit take range more past cup handle buy point apple launch several new product tuesday include red iphone lower cost ipad short video make app call clip nike nke reversed slightly lower ahead earning report due close analyst expect athletic shoe giant report slip cent share higher sale mark first year year ep decline late other blue chip drugmaker merck mrk pfizer pfe pfe be goldman sachs gs caterpillar cat be more apiece marriott international mar gap rise striking new intraday high big volume hotel operator announce year growth plan include earning share compound growth rate share be top buy range flat base entry base stock lead ibd france criteo crto china tal education tal weibo wb score gain north downside lennar len fall more heavy trade report fiscal earning decline year year top view snap multiyear streak quarterly increase share remain extend past cup handle entry related dow nike expect log first earning decline year apple debut red iphone cheaper ipad new video app
225,PFE,house republican introduce proposal repeal replace affordable care act age base tax credit centerpiece legislation also eliminate individual employer mandate well expand health saving account legislation be gop biggest effort yet remake health care system have impact wide variety industry health insurance hospital drugmaker share company such unitedhealth unh pfizer pfe tenet healthcare thc seem little change late monday unitedhealth pfizer be dow jone industrial average republican offer tax credit be base age not income base be obamacare exchange be phased start individual earn more household make be credit individual earn more legislation keep medicaid expansion program run jan roll be frozen medicaid be funded capita basis vs fee service model plan repeal obamacare taxe upper income earner capital gain insurance plan medical device manufacturer not tax employer base coverage earlier version have propose do keep cadillac tax high end insurance plan delay implement legislation keep ban deny coverage person pre exist condition repeal individual mandate get insurance charge don keep continuous coverage time renewal fee more plan also eliminate employer mandate provide coverage gop bill expand annual contribution limit health saving account tie high deductible insurance plan individual family health equity hqy major pure play hsa provider rise late trading plan also bar federal funding plan parenthood provision run afoul gop senator republican do not say many person likely add lose coverage result plan congressional budget office have not release estimate cost house republican plan be currently bill energy commerce committee way mean committee unclear president trump back legislation plan support congress especially senate related replace obamacare save social security
226,PFE,eli lilly lly pipeline have best bang buck analyst say wednesday comparison pit lilly rival pfizer pfe merck mrk bristol myer squibb bmy leerink analyst seamus fernandez say lilly be outperform pack achieve best balance investment limit external investment past year bristol pfizer trail merck struggle metric write still drugmaker lilly have struggle gain fda approval only drug pharma pipeline have gain approval contrast biotechnology company abbvie abbv gilead science gild have be more successful conversion rate top drugmaker bristol myer lilly have have considerably more success phase drug meanwhile pfizer have only converted late stage pipeline drug sell market pfizer have broadest pipeline group disclose new drug fernandez write have struggle fall megamerger disruption limit scale productivity merck be lowest pharma universe ibd take american fund recently up stake bristol myer squibb stock else receive american fund vote confidence find ibd mutual fund page analysis fernandez also look churn turnover new drug burn percentage attrition portfolio bristol have highest burn rate lowest churn rate company appear be focuse more internal asset partnership early stage mid late stage external agent fernandez write note conversely merck churn rate be highest group merck high overall expense be drive part large cubist idenix deal have so far struggle generate sizable return management have hope well company extraordinary investment keytruda write merck isn alone struggle partnership acquisition big drugmaker biotechs only gilead purchase pharmasset appear have succeed fernandez write pharmasset begin development sovaldi hepatitis drug rocket gilead sale gilead hepatitis franchise begin falter high cure rate trio drug sovaldi harvoni epclusa close bell stock market today lilly finished trading bristol myer rise meanwhile merck slip pfizer also lose related gilead hepatitis sale plunge merck swipe share analystabbvie stronger bet gilead amgen least leerinkmerck roche gouge bristol share lung cancer approval
227,PFE,attempt rebound early trading major index drift back lower stock market today nasdaq outperformed other index fall dow jone industrial average fall respectively volume be mixed tracking slightly higher nasdaq lower nyse vs same time monday dow industrial stock be mostly quiet stock rise fall more pfizer pfe drop medical industry once again come fire president trump twitter feed reiterate desire lower drug price recent ipo snap snap tumble tuesday fall come yesterday decline week slide illustrate investor be encourage initial euphoria have settle stock least build ipo base short consolidation consider purchase nvidia nvda look rebound tuesday rise chipmaker rally briefly reach new month low monday company report earning thor industry tho rv maker drop exceed earning revenue estimate other estimate be higher thor report share be currently trading day move average just cup handle buy point support day be critical juncture ceo bob martin be optimistic longer term trend rv industry grow demand new consumer broaden market have continue younger family increasingly buy more affordably price travel trailer smaller motor home say momo momo report upbeat earning guidance send share soar momo live video service continue fuel company revenue lead growth stock be mixed early tuesday trading few loser drop be significant aforementioned thor industry other laggard include sterling bancorp stl first republic bank frc fall respectively upside arista network anet moved chip stock round remain top performer monolithic power mpwr apply material amat broadcom avgo moved apiece monolithic find support day line monday be approach flat base entry apply material continue solid uptrend share be approach profit take level cup entry broadcom trade time high follow earning beat last week related momo earning jump share surge live video prospectssnap plunge more analyst say lottery stock bad betthor industry ramp investment expansion top
228,PFE,general electric ge cfo jeffrey bornstein say wednesday industry sit hand wait not invest lawmaker deliver promise change taxe regulation provide more clarity health care policy warning come house republican corporate tax revamp be run opposition congress more gop lawmaker balk propose import tax see key piece overhaul president trump have yet unveil own tax plan trump also want repeal replace obamacare republican have turn squeamish sweeping change health law barclay industrial select conference miami bornstein say be reasonably confident change get pass say investor be very disappoint aren don get corporate tax reform goal line don provide visibility health care be go don deliver regulatory change administration have talk think end very difficult place say tuesday ge ceo jeffrey immelt ceo boee ba unite technology utx other industrial exporter well drugmaker celgene celg eli lilly lly merck mrk pfizer pfe write letter urge congressional support house tax reform blueprint include border adjustment tax total company sign letter more company include wal mart wmt target tgt nike nke dozen trade group have sign american affordable product group create oppose import tax ge share fall stock market today boee share be unite tech rise last month talk repeal obamacare begin ramp ge immelt also indicated customer become more cautious take segment affordable care act be get most attention medium customer say conference call report mixed result think see caution affordable care act go forward haven really see much happen trump say rally florida weekend replacement plan obamacare win be come couple week warn earlier process last next year meanwhile market be still wait white house detail own tax proposal congressional republican take more flak last week trump tell retail ceo massive tax plan come not too distant future follow remark airline ceo prior week vow announce something phenomenal term tax come week related border tax die trump corporate tax cut collapsetrump silent ex im bank hint big boee super hornet order
229,PFE,emerge market exchange trade fund show strength tuesday ishare msci emerge market eem rise week high direxion daily emerge market bull edc add more stock market today clear base base buy point etf rally breaking prior base stock market be modestly higher dow jone industrial average nasdaq composite be barely positive spdr dow jone industrial average dium edge higher ahead apple aapl earning close dow component iphone maker share be pare gain early spike analyst expect apple report best ep sale growth year other blue chip intel intc visa advanced more intel gain rival advanced micro device amd plunge slight quarterly sale miss powershare qqq trust qqq spdr etf trust spy be also slightly higher spy be top flat base entry rise previous flat base buy point clear february small cap lag ishare russell iwm dip slip back flat base entry sector play vaneck vector gold miner gdx be share be still week high gold future dip ounce tuesday health care select sector spdr xlv be big pharma giant merck mrk hold gain pfizer pfe be sharply pare early loss drugmaker report quarterly result related pfizer earning top sale come shortdow merck top view raise outlook key drug lag
230,PFE,gilead science gild stock topple late tuesday biotech report first quarter sale earning lag wall street say have quarter decline revenue blockbuster hepatitis drug overall sale fall year year quarter end march miss view adjust income share lag expectation share plunge vs time last year revenue hepatitis drug harvoni sovaldi epclusa topple year year gilead blame decline harvoni sovaldi lower sale major market partially offset stronger sale epclusa epclusa launch last summer europe hepatitis hiv drug sale other hand grow vs year earlier period continue uptake hiv medicine genvoya descovy odefsey other product include drug blood pressure chest pain intravenous infusion grow quarter hiv drug bictegravir show positive result phase study gilead say gilead pledge earlier year put massive effort bictegravir sale harvoni sovaldi slow hepatitis market europe mature ibd take ibd company biom biotech industry group be now rank group track market have be volatile stock visit ibd technology page look stock look strong other market be still emerge however last week bristol myer squibb bmy be first company receive approval chinese regulator oral hepatitis drug gilead hepatitis drug aren yet approve china north person suffer disease gilead maintain guidance product sale include hepatitis drug revenue hepatitis drug sale decline midpoint be lowest point sale unit decline grow share end trading tuesday hour stock market today gilead stock be earlier day pfizer pfe merck mrk report first quarter earning pfizer top profit expectation sale lag merck beat sale earning view related dow pfizer top earning view sale come gilead be pay price actually cure disease
231,PFE,abbvie abbv get breathe room rheumatoid arthritis eli lilly lly incyte incy drug be hit delay food drug administration weekend leave lilly instead focus pfizer pfe rivale breast cancer med friday fda ask more dose information lilly incyte rheumatoid arthritis drug baricitinib cause be lengthy delay release so lilly breast cancer drug know abemaciclib be now especially important lilly leerink analyst seamus fernandez say abemaciclib compete pfizer ibrance novartis nvs kisqali cdk inhibitor market drug aim inhibit specific set enzyme thought be tie breast cancer lilly model be currently forecasting global sale abemaciclib overall cdk market reach more fernandez write note client fernandez say abemaciclib be next major catalyst lilly stock phase datum abemaciclib be expect june believe abemaciclib ability dose continuously together safe manageable tolerability profile likely make abemaciclib highly competitive novartis kisqali provide opportunity differentiate pfizer ibrance secondary efficacy measure response rate fernandez say analyst keep outperform rating price target lilly stock lilly share topple much stock market today close day ling buy point incyte stock tumble delay baricitinib mean likely win get fda approval launch remove term rival abbvie humira also put lilly incyte year pfizer xeljanz more line generic competition analyst expect drug be delay least year share lilly incyte topple early monday baricitinib already have be approve use europe baricitinib be likely delay fernandez expect peak sale be approve lilly still benefit sale europe drug have attain approval ibd take ibd company ethical drugmaker industry group have rise group track just week head ibd stock checkup list top rate drugmaker other analyst agree year delay baricitinib be more cautious lilly breast cancer drug bmo analyst alex arfaei call abemaciclib biggest remain uncertainty lilly see datum likely disappoint still have not see much datum indicate cdk inhibitor be meaningfully differentiate write report datum american association cancer research suggest abemaciclib be not selective ribociclib kisqali ibrance arfaei cut price target lilly stock maintain forecast sale growth lilly diabetes drug trulicity jardiance basaglar psoriasis drug talz drug offset decline mature franchise write however forecast revenue compound annual growth rate lilly guidance partly more conservative assumption mature franchise related eli lilly incyte stock break key level fda drug biogen takeover prospect soured mere monthsbiotech split axovant ride ceo swap celgene partner dife
232,PFE,stock open slightly higher quickly turn mixed weak auto sale ahead late day apple aapl earning dow jone industrial average edge higher edge lower nasdaq composite fall tuesday economic calendar be largely quiet federal open market committee begin day session washington big event radar be apple fiscal second quarter earning release schedule today close bell apple share trade open onslaught mixed big name earning release have mixed effect premarket action drug giant merck mrk rise fraction pfizer pfe fall quarterly result big oil be motion bp bp conocophillip cop quarterly release drugstore pharmacy benefit giant cvs health cvs slide first quarter result top view pharmacy same store sale decline tenet healthcare thc spiked first quarter result announce sell houston area hospital hca holding hca hca share rise mastercard climb first quarter result comfortably clear analyst estimate stock be extend rebound support week move average diesel engine maker cummin cmi throttle top analyst expectation second straight quarter accelerate earning growth first revenue gain quarters management also raise full year revenue guidance consensus target stock break flat base buy point advanced micro device amd plunge report first quarter result late monday chipmaker narrow loss line expectation revenue rise just shy view macquarie downgrade stock underperform neutral amd be already meeting resistance day line tuesday rout angie list angi spiked enter deal be acquire internet content operator iac interactive iac deal value company nearly iac combine angie list homeadvisor site name angi homeservice iac share rise iac share be extend buy point flat base oil price narrow early gain west texas intermediate less higher back barrel gold turn negative ounce dollar be mixed vs euro yen bond sag lift year yield basis point overseas tokyo nikkei logged gain last day trading holiday week europe market reopen positive mood day holiday london ftse lead major benchmark gain ground afternoon trade related stock future big cap earning be due tuesday be buy point apple earningsapple optical drug giant headline tuesday investing action plan
233,PFE,list exchange trade fund score gain government avert shutdown weekend gainer include proshare ultrapro tqqq powershare qqq trust qqq respectively tech heavy etfs be new high ground tqqq have asset management seek triple qqq performance gain day qqq top holding include apple aapl microsoft msft amazon amzn facebook fb apple rise new high monday direxion daily emerge market bull share edc also rally near buy point short flat base form base base pattern follow advance edc have aum sector exchange trade fund technology select sector spdr xlk financial select sector spdr xlf be lead xlk recent bounce week move average be trading highest level more year tech etf aum have rally flat base late last year xlf be year high financial etf be build flat base potential entry follow gain mid february prior flat base score advance november earning lurk corner big drug name good time check health related etfs health care select sector spdr xlv have shape week flat base buy point less entry etf have post small gain cup handle just start current pattern dow industrial average component merck mrk pfizer pfe report quarterly result tuesday biotech gilead gild earning be also tap tomorrow merck pfizer be xlv top holding april gilead make top broader market be mixed tech heavy nasdaq composite dow jone industrial average west texas intermediate crude price slide barrel spdr oil gas exploration production xop aum be etf have be pressure lately be december high gold price dip ounce weigh gold fund vaneck vector gold miner gdx have nearly aum fall week high spdr gold share gld edge lower related stock market do now
234,PFE,ceo dow stock general electric ge boee ba other big exporter be warning republican embrace controversial tax import once generation chance tax reform fail american worker be loser tax code penalize american worker make product provide service sell abroad favore international competitor ceo write letter leader party congress other company ceo co sign letter be caterpillar cat dow chemical dow raytheon rtn unite technology utx oracle orcl biggest drug biotech company celgene celg eli lilly lly merck mrk pfizer pfe caterpillar merck pfizer unite technology also be member dow jone industrial average addition general electric boee letter put largest company squarely house speaker paul ryan other house gop leader argue levele international play field cut corporate tax rate lower be impossible plan tax import raise decade yet biggest surprise letter be just few company sign more company include wal mart wmt target tgt nike nke american subsidiary toyota tm dozen trade group have sign american affordable product create oppose house border tax proposal wal mart nike be also dow industrial stock retail stock be pressure early december prospect border tax be rise ve make modest recovery lately prospect fade tuesday perhaps help more wal mart positive earning report well receive macy earning weigh rev lobbying campaign tax retail share be rise wal mart rise close stock market today target add ibd take supporter border tax plan say dollar rise vs other currency meaning wouldn harm corporate profit consumer do risk investor hold share company alibaba international etfs house proposal border adjust tax company pay tax rate full value import good export revenue be tax free border tax raise more decade offset cost lower statutory tax rate conservative tax foundation have say border tax ability congress reduce corporate tax rate be limit incremental tweak not level play field american worker dramatically reinvigorate economic growth ceo letter say not clear precisely so few company come favor border tax proposal seem be run buzz see republican senate possible letter wasn widely circulate however caroline freund senior fellow peterson institute international economic have predict many more big lobby be bat border adjust tax favor tax favor labor intensive industry export more import aerospace be rare example nagging question company such ge boee be so dependent export back border tax most trade expert have look tax have big doubt comply world trade organization rule so lead trade war give uncertainty possible consequence hard understand company so dependent trade support border tax yet partly explain list supporter be so small related border tax die trump corporate tax cut collapse gop border tax plan sock tourism include trump hotel
235,PFE,pfizer pfe stock regain earlier loss tuesday drugmaker report earning lag wall street expectation quarterly full year revenue guidance line outplay continue decline sale adult pneumonia drug stock market today pfizer stock fall much end day rise share be year worry trump go drug pricing trump reportedly reiterate view tuesday meeting pharma exec pfizer report sale vs year earlier period meeting consensus view pfizer report cent earning share ex item miss view cent company guide sale be bit light midpoint midpoint ep item guidance be penny short consensus view pfizer wrapped sale ep item respectively sale be line ep lag consensus penny sale prevnar vaccine plunge year leerink analyst seamus fernandez say higher expect operate cost drag bottom line pfizer eli lilly lly also report largely line early tuesday pfizer see sg cost increase innovative health unit ibd take pfizer be rank second term market cap roche stock underperform stock term key growth metric ibd composite rating just zoetis stock lead group so so cr get other leader ibd stock checkup related see need actelion boost ep pfizer take remicadeeli lilly novartis challenge pfizer potential breast cancer drugamgen gouge top pick abbvie humira biosimilar jeffery
236,PFE,major stock index etfs shot fresh time high wednesday string gain increase fifth ninth day spdr spy be wednesday seventh day straight gain have gain feb begin year powershare qqq qqq be ninth day straight gain have rise feb so far year health care sector be top contributor gain health care select sector spdr xlv surge top holding pfizer pfe leap amgen amgn johnson johnson jnj rise etfs tracking financial sector notch strong day financial select sector spdr xlf be holding big gainer be bank america bac charle schwab schw citigroup morgan stanley ms well fargo wfc jpmorgan chase jpm american international group aig dove report loss share insurer stock crash day move average day line energy real estate be worst perform sector continue lower second day row energy select sector xle be real estate select sector xlre be fed chair janet yellen hawkish comment interest rate put downward pressure rate sensitive sector xlre be testing support day move average gold be trading tightly third day row just day move average spdr gold share gld be here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related growth etf strategy tap rally trump have ignited sectorsstrength steel etfs come miner
237,PFE,xhere investing action plan tuesday need know investor day ahead apple aapl be doubt most anticipate report tuesday far only company post earning optical company oclaro oclr inphi iphi be tap well pizza chain papa john pzza build
238,PFE,eli lilly lly incyte incy share plunge monday morning food drug administration fail approve rheumatoid arthritis drug baricitinib say more datum be need eli lilly incyte disagree fda friday decision come somewhat surprise european regulator approve baricitinib february lilly incyte have conduct more clinical trial satisfy fda delay set drug several rival lilly reaffirm earning sale guidance year incyte discuss matter conference call eli lilly fall close stock market today eli lilly have fall buy point clear early march incyte tumble plunge day move average setback lilly incyte be good news dow jone industrial average component pfizer pfe have only oral jak inhibitor rheumatoid arthritis market xeljanz gilead science gild have similar oral drug baricitinib phase trial fellow dow component johnson johnson jnj abbvie abbv amgen amgn have injectable drug pfizer gilead amgen johnson johnson abbvie rise less morning action
239,PFE,stock open higher monday weak read new york manufacturing activity april dow jone industrial average nasdaq climb be bank financial remain big piece week report news quarterly result due week bank america bac goldman sachs gs morgan stanley ms visa other bank mtb rolled monday early earning report rise more result easily top analyst first quarter expectation company repurchase share quarter raise annual dividend cent cent mcdonald mcd rise apple aapl dow well fargo upgrade mcdonald outperform market perform apple gain rbc capital raise price target maintain outperform rating pacific crest security raise concern difficulty fingerprint sensor apple upcoming iphone pfizer pfe gilead science gild abbvie abbv rise incyte incy drop more early action wilmingon del base biotech report friday food drug administration deny application incyte eli lilly lly rheumatoid arthritis treatment baricitinib estimate have put annual value drug incyte share plunge day move average heavy volume trigger sell signal eli lilly share drop also break day line remain buy point gilead gain abbvie jump pfizer be flat pfizer gilead abbvie compete market rheumatoid arthritic treatment
240,PFE,china alibaba group hold baba climb open financial unit ant financial raise offer global payment service moneygram international mgi ant initial offer be top euronet worldwide eeft place offer march moneygram share rise open euronet share rise ibd leaderboard stock alibaba be buy range alternative handle buy point medical diagnostic product maker alere alr open waltham mass base company announce friday abbott laboratory have mutually dismiss compete lawsuit abbott have reduce takeover offer share deal now value alere be expect close third quarter abbott drop open manufacturing slow sharply new york region april send new york federal reserve empire state manufacturing survey read read be still positive march far economist expectation well level post nearly new order retreat unfilled order slow delivery time lengthen shipment edge gauge employment hour work remain firm national association home builder release builder confidence survey et gauge be april internationally readout global stock market today be spotty due holiday schedule japan tokyo nikkei post gain monday hold back dollar weaken yen concern north korea china shanghai composite end top regulator pledge resolute crackdown risky market action hong kong stock exchange remain close holiday europe exchange london paris frankfurt remain close holiday related big week dow stock earning investing action planinvestor unfazed north korea netflix unite continental earning tap
241,PFE,novartis nvs tuesday report better expect first quarter earning revenue unexpectedly edge lower adjust earning share fall revenue dip have rise constant currency analyst have expect ep sale cosentyx sale hit plaque psoriasis drug hit blockbuster status make novartis best selling immunological drug chemotherapy drug gleevec novartis top selling drug see continue pressured generic sale tumble eye drug lucentis sale dip novartis say still expect full year sale be roughly equal base constant currency core operate income flat low single digit multiple sclerosis drug gilenya see gain gilenya rival drug biogen biib sanofi sny roche rhhby ibd take novartis stock have low ibd composite rating meaning underperform nearly stock term key growth metric head ibd stock checkup list stronger stock contender drugmaker also recently launch breast cancer drug kisqali be approve march kisqali rival pfizer pfe ibrance not yet approve drug eli lilly lly call abemaciclib novartis share rise tuesday stock market trading share have be form cup handle buy point july related lilly new drug spark deeper rivalry pfizer novartis
242,PFE,peter gassner launch veeva system veev didn expect outstrip revenue watch stock triple span less year expand arsenal product application instead gassner be survival mode begin have nothing have product customer person nothing say gassner time alum salesforce com crm have exactly so then have start hire person have make product get first customer add grand plan be sort interesting doesn mean anything hire first developer get first customer today veeva provide cloud backbone life science industry rival like medidata solution mdso count company pfizer pfe novartis nvs amgen amgn eli lilly lly customer drugmaker tackle challenge develop testing manufacturing lifesave drug veeva operate cloud system background dual role include organize doctor information pharmaceutical rep clinical trial datum graph company gassner call latter point veeva second act total veeva estimate total addressable market gassner expect nascent third act add become bigger better be exactly company alphabet googl ibm ibm cisco system csco do say important thing company be want keep go second act probably end be big bigger first act tell investor business daily company make second act bigger first act have long term ability reinvent veeva launch year single application help pharmaceutical rep organize drug datum make stronger doctor pitch today globe pharma sale rep use call veeva crm customer relationship management ipad application get drug company manager buy early wasn difficult gassner say ibd take veeva system stock have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup list strong software leader think life science industry be more business outcome oriented say important thing ceo focus get drug approve get market effectively patent expire tool cloud not cloud help generally want fast forward veeva crm be part company commercial cloud business commercial cloud grow fiscal major crm win expansion top pharmaceutical firm veeva say earning news release business account third veeva sale gassner estimate veeva second act really have wall street key say veeva vault be launch single customer goal organize content involved clinical trial document video image datum record vault represent third veeva total sale target total addressable market gassner say see vault reason recent excitement veeva stock share be january march burst cup handle formation begin november top buy point deeper salesforce partnership stock be now more extend point bottom month veeva ipo time intraday high reach friday share gain nearly share ultimately retreat friday close be again monday gain close vault bring sale gassner say today vault annualize run rate be north whole veeva be aim top annualize run rate veeva be already tracking ahead say cornelio ash analyst william neil co affiliate investor business daily now vault be prep potential third act look opportunity outside life science first veeva gassner say veeva see additional opportunity take vault other manufacturing heavy industry chemical consumer packaging neil ash say success venture be game changer veeva be say be ve get lockdown step tell ibd then just become door do want knock potential be probably veeva stock continue trade premium gassner say veeva gain traction outside life science used same method employ launch major commercial cloud vault division company call veeva way method work life science veeva have estimate crm market sale clinical trial regulatory process match medidata medidata sale vs small grow chunk veeva brand become re good gassner say become good deliver value outside life science then think time ll become know end veeva be part collaboration include astrazeneca azn allergan agn biogen biib lilly novartis glaxosmithkline gsk pfizer other call align biopharma align be aim iron technological standard life science world veeva do same sector outside life science ash say literally get feedback horse mouth develop platform say be successful outside re go need same kind feedback other sector related ibd company break deepen salesforce tie upveeva help medicine go drug giant
243,PFE,george soro take stake facebook fb dow component goldman sachs gs fourth quarter appaloosa cut stake apple aapl follow warren buffett berkshire hathaway bkrb appear find bargain airline here look big investor manage portfolio last quarter last year soro fund management buy share facebook bulk stake alphabet googl nearly share accord regulatory filing late tuesday soro also increase mobile tmus stake share soro buy share goldman sachs dan loeb third point last week disclose have scoop share goldman bank america bac jpmorgan chase jpm bank stock have rise greater expectation lighter regulation higher interest rate greater volatility goldman trading desk benefit particular soro also take share stake delta air line dal drop unite airline ual share apple end regular trading stock market today hit record high yesterday facebook fall goldman sachs rise delta climb american rise unite gain ibd take even big investor flocked airline last year cowen analyst last month say share airline be due break take meanwhile soro drop activision blizzard atvi herbalife hlf harley davidson hog pepsico pep jcpenney jcp also dissolve stake jwn soro also offloaded position consumer care product giant procter gamble pg get lift tuesday activist investor trian take more stake company hedge fund appaloosa management increase stake facebook share fund also up holding qualcomm qcom more double stake southwest luv appaloosa also take share stake unite airline fund load health sector take new stake company bristol myer squibb bmy centene cnc mckesson mck pfizer pfe also take new stake jcpenney appaloosa cut position apple share slash stake yahoo yhoo rid bank america general motor gm boost stake apple david einhorn greenlight capital dissolve stake take interactive steel michael kor kor buffett greenlight also take stake move soro appaloosa airline be notable signal other big investor be follow buffett announce stake sector last year buffett year avoid airline have come industry airline last year show more sign discipline wave consolidation past several year have keep major airline relatively insulate new competition launch sector late last year find most investor generally agreement airline represent deep value barclay analyst brandon oglenski write research note date tuesday biggest question remain market more importantly large long term investor begin care think tonight berkshire hathaway go long way attract sector interest related airline stock tumble fear capacity creep back updelta american unite go gun blaze battle set fresh high goldman hit highest yellen
244,PFE,johnson johnson jnj need swiss biotech actelion pharmaceutical help reaccelerate earning growth patent blockbuster remicade expire rbc analyst glenn novarro say friday deal be remicade bring pharmaceutical sale be face competition pfizer pfe biosimilar inflectra meanwhile actelion have be prep loss exclusivity pulmonary arterial hypertension drug first month actelion sale increase accounting exchange rate novarro say same time sale pah drug tracleer fall offset sale fellow pah drug opsumit uptravi generic completion tracleer imminent believe sale be flat actelion novarro write research report ibd take johnson johnson have drug approve tie pfizer head ibd industry theme see company have most approval period time specifically early thursday announce have agree pay share actelion stock value company deal be expect close june help tack cent earning share month novarro see deal cent accretive also expect actelion sale grow acquisition forecast be conservative say see have big enough geographic footprint help actelion grow novarro have outperform rating price target johnson johnson stock rise stock market today fall thursday share have trade well day move average week related ceo underwhelm investor trump dodge drug pricingj hep dip virtually mirror gilead view laggilead merck alexion view hazy biogen surge analyst
245,PFE,pfizer pfe ibrance grow sale leerink analyst seamus fernandez say drugmaker first have overcome competition eli lilly lly novartis nvs ibrance belong class drug call cdk cdk selective inhibitor food drug administration approve combination ibrance femara inhibitor february treatment estrogen receptor positive advanced breast cancer now eli lilly novartis be creep abemaciclib ribociclib respectively abemaciclib be approve breakthrough designation be several phase test last year fda grant ribociclib priority review first line advanced breast cancer prescription trend show ibrance be slow rapid uptake fernandez lower yearly sale expectation still see ibrance run global annual revenue ibd take pfizer have drug approve else curry favor time period head ibd industry theme more fernandez research report keep market perform rating price target pfizer stock afternoon trading stock market today pfizer rise cent company be set report earning open tuesday fourth quarter sale earning be likely line pfizer fernandez say consensus analyst poll thomson reuter expect pfizer report sale cent ep ex item respective vs year earlier quarter acquisition medivation complete september add sale prostate cancer drug xtandi pfizer top line mostly be offset generic erosion lipitor pristiq fernandez say enbrel tnf inhibitor market amgen amgn pfizer be face biosimilar pressure fernandez expect pfizer overall sale grow vs related lilly near fda nod arthritis drug chemo med stick courtamgen gouge top pick abbvie humira biosimilar jefferiestrump disastrous pharma view doesn rattle jpmorgan drug conference
246,PFE,axovant science axon oncomed pharmaceutical omed diverged ibd company biotech industry group monday axovant stock ride chief executive swap month high oncomed stock topple fail drug trial close bell stock market today axovant stock pop announce former medivation ceo david hung succeed vivek ramaswamy top job axovant ramaswamy move lead axovant parent roivant science hung appointment be effective friday head medivation acquisition pfizer pfe september ramaswamy say news release axovant hadn initially be look new ceo approach david take role mindset study say add david decide want join now mindset study look axovant drug intepirdine mild moderate alzheimer patent result be expect september axovant stock bust cup handle formation begin august pass entry point share be now extend buy point touch high last achieve december meanwhile share oncomed plunge time low drug demcizumab fail extend progression free survival late stage pancreatic cancer patient oncomed stock hit record low fall point session be close oncomed trial look combination demcizumab gemcitabine abraxane oncomed also miss second goal improve overall survival trial compare demcizumab gemcitabine chemotherapy first develop eli lilly lly celgene celg chemo abraxane gemcitabine abraxane placebo ibd take ibd biotech industry group be rank group track just week biotechs celgene stock be clear leader ibd composite rating best possible head ibd stock checkup list top best perform biotechs also monday bayer pharma bayry drop deal license oncomed drug vantictumab strategic reason oncomed say news release drug aim treat solid tumor prove safe effective alone combination chemo early trial have look forward collaborate bayer team late stage development biotherapeutic be very pleased have worldwide right promising phase ready asset ceo paul hasting say statement related axovant confidence not sway rival alzheimer drug fail
247,PFE,exchange trade fund tracking major stock index rise monday stunning setback health sector fda reject eli lilly lly drug treat rheumatoid arthritis spdr spy add shortly open bell stock market today technology lead advance sector health care top decline sector reverse higher health care select sector spdr xlv largest exchange trade fund segment chopped flat line morning trade share eli lilly partner incyte incy tumble more respectively food drug administration reject drug baricitinib safety concern health care etf slice further rise day move average key gauge institutional support early monday now sit march high eli lilly be largest component portfolio stock ishare nasdaq biotechnology ibb give early trading incyte be top hold stock portfolio analyst have expect eli lilly incyte drug generate more sale have be approve accord cnbc pfizer pfe offer popular arthritis drug be fractionally lower early monday ibd take fda setback eli lilly have important ramification other key drugmaker broader health care industry related be go etf market
248,PFE,baxter bax stock fall monday worry related department justice investigation potential price fix intravenous fluid allegation analyst deem extraordinary stock market today baxter stock fall justice department send grand jury subpoena baxter employee subpoena be receive friday relate criminal investigation justice department antitrust arm ask document testimony related manufacturing pricing selling shortage intravenous solution baxter communication rival evercore analyst vijay kumar note price fix allegation isn new stem year old investigation begin new york ongoing class action suit northern district illinois related supply shortage shortage be trigger flu season benefit manufacturer hospira third quarter see growth unit produce intravenous fluid kumar say hospira be acquire pfizer pfe class action lawsuit allege manufacturer intravenous fluid falsely create shortage justify spiking price baxter have file motion dismiss suit call allegation extraordinary idea public company voluntarily create supply shortage hope competitor similarly restrict output order raise price seem stretch kumar tell client note ibd take baxter stock trade ibd company medical product industry group be lead medtronic mdt stryker syk boston scientific bsx term market cap medtronic boston edward lifescience ew compete heart valve replacement market check edition sector leader see stack fda regulator regularly inspect manufacturing facility note class action lawsuit seem imply baxter other intravenous fluid manufacturer be able hoodwink inspector post shortage notice say baxter say incur cost comply increase fda regulatory requirement meet supply constraint meanwhile price increase only contribute growth kumar say intravenous fluid solution contribute third segment growth imply pricing be average kumar say assume bag intravenous fluid cost equate increase cent bag apart price collusion prosecutor have argue baxter earning increase intravenous fluid price be reasonable kumar estimate hike price intravenous fluid baxter have margin earning interest taxe related boston scientific make acquisition battle medtronic edward best stock own analyst
249,PFE,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
250,PFE,regeneron regn sanofi sny dupixent grab fda approval tuesday be price annually patient moderate severe eczema company say share regeneron close stock market today earlier fall much sanofi stock dip fda approval remove pricing overhang leerink analyst geoffrey porge say news earlier day porge suggest regeneron sanofi price dupixent annually expect fda approve dupixent allow recent manufacturing overhang be lift approval mean dupixent be available commercially soon next week say now expect regeneron sanofi sarilumab rheumatoid arthritis grab fda approval second quarter dupixent sarilumab be filled sanofi french facility issue facility delay sarilumab last year reaction announce price have be mixed porge say expect decision result significantly higher demand faster company have hew traditional premium price strategy add be hundred thousand eczema patient set porge say most important regeneron sanofi ensure access price payer likely open access most eczema patient price be also earlier analysis compare dupixent price psoriasis treatment average gross price comparable injectable psoriasis treatment run patient year porge write earlier note client see good start point dupixent pfizer pfe eucrisa leerink analyst also look measure disease burden quality quantity life used scale analyst find patient severe eczema be willing pay year patient moderate eczema be willing pay ibd take monday regeneron be medical stock gain big see other biggest point winner stock market today level cost be usually accept willingness pay threshold porge say regardless price investigator find dupixent be likely improve health outcome compare usual exist care do so additional cost porge reiterate outperform rating price target regeneron stock related regeneron sanofi look crush amgen rival say canesperion medicine co recover amgen induced pitfallamgen tank heart study share other drugmaker tumble
251,PFE,xhere investing action plan friday need know investor come day dow jone industrial average have have trouble climb back earlier high dow component microsoft msft mcdonald mcd johnson johnson jnj pfizer pfe unite technology utx be buy range meanwhile smartphone maker
252,PFE,fda approval multiple sclerosis drug roche rhhby be likely be bittersweet biogen biib analyst say wednesday biogen get royalty ocrevus new drug rival biogen own multiple sclerosis medication tysabri tecfidera ocrevus be approve tuesday relapse primary progressive form multiple sclerosis addition biogen drug ocrevus compete novartis nvs gilenya merck kgaa pfizer pfe rebif sanofi sny aubagio lemtrada mizuho analyst salim sy call label ocrevus clean label do risk deadly brain infection call progressive multifocal clearly state have be observed case infection ocrevus clinical trial biogen receive royalty sale royalty sale outside investor be bearish likely effect february survey investor believe ocrevus be net negative wash biogen sy say biogen ocrevus offer upside primary progressive multiple sclerosis market biogen drug be approve only treat relapse remit form multiple sclerosis still primary progressive market be small patient only approve medicine primary progressive multiple sclerosis ocrevus reach very significant market penetration quickly leerink analyst geoffrey porge say benefit biogen royalty payment ibd take biogen spinoff bioverativ say not typical biotech startup read new america porge model ocrevus royalty biogen grow see ocrevus grab share relapse remit market primary progressive market ocrevus have impressive not necessarily class lead efficacy write report note biogen tysabri sanofi lemtrada likely still lead term effectiveness most multiple sclerosis drug ocrevus be dose once month injection offer remarkable convenience patient also come risk say be serious infection drug clinical development case such complication physician be likely find difficult reverse drug effect restore immunity roche note news release most common side effect associate ocrevus late stage study compare rebif be infusion reaction upper respiratory tract infection latter be mostly mild moderate severity ocrevus be price year be discount other multiple sclerosis drug average mizuho sy write note client gilenya tecfidera aubagio cost annually close bell stock market today biogen stock fall roche stock rise fraction related pfizer boost value take bristol biogen stock pop judge uphold critical drug patentbiogen dife takeover buzz fade drug hit snag
253,PFE,drugmaker pfizer pfe boost value takeover bristol myer squibb bmy analyst say monday acknowledge bristol specific macro uncertainty limit likelihood still be common question give challenge bristol myer squibb be face activist involvement name credit suisse analyst vamil divan say question takeout center next month say note client pfizer commentary recent meeting management other investor conference make think be certainly look possibility come business development write overall credit suisse see bristol have positive impact pfizer return capital cash deal assume pfizer pay premium extract synergy lead value creation cent share pfizer opt cash stock deal dilution issue undervalue share offset initial value creation analyst write deal partially finance stock issuance be break even pfizer shareholder ibd take bristol myer have immuno oncology drug approve meaning compete other fda approve treatment roche merck head ibd technology page breakdown drug sector close bell stock market today bristol be fractionally pfizer tick share bristol have be pressure year be january activist investor carl icahn reportedly take stake bristol myer february icahn be know investment company paypal pypl xerox xrx allergan agn jana partner activist investor buy stake bristol fourth quarter compound add pressure like merck mrk roche rhhby be add macro uncertainty bristol myer february bristol lose share immuno oncology market merck roche remain flat month month basis related bristol myer partner hit month high immuno oncology dealmerck be near rival keytruda approvalincyte spike record high rumor gilead acquire
254,PFE,stock index pare gain afternoon trading be session lows late trading nasdaq be flat be much reversed loss dow jone industrial average reversed loss small cap fend seller russell volume be tracking higher nasdaq lower nyse even index fade breadth remain positive winner beat loser ratio nyse nasdaq wall street focus today trading be capitol hill president trump demand vote bill replace obamacare be unclear republican have enough vote pass measure perhaps sense defeat bill investor send health care stock higher best gain friday hospital medical equipment medical research be industry group be more top group dow component unitedhealth group unh be nearly flat erase early gain share health insurance company be testing week move average be still record high pharmaceutical merck mrk pfizer pfe be fractionally goldman sachs gs dow component fall more lowest level feb bank tumble day move average tuesday sell financial general market outside dow manage care company humana hum slide breach day move average heavy trading stock fall much buy point march coherent cohr climb past buy point flat base share retreat back pattern volume be run more normal level make dispirited attempt concrete uscr crater plunge day move average be most heavily trade stock day ready mix concrete provider say federal filing chief financial officer joseph tusa jr resign personal reason have dismiss grant thornton llp accounting firm be replace young stock trouble be accenture acn sharply second straight day bit day line share break past buy point wednesday strong volume have quickly unraveled still consult firm have not trigger sell signal accenture beat profit estimate thursday guidance be soft related dow turn red ryancare death silver lininghere concrete share be sink stone
255,PFE,teva pharmaceutical teva wo be set deepen generic drug price be project topple argus analyst john eade katelyn bayone say tuesday downgrade stock share be trading year lows fall past quarter see increase past year teva stock lose index gain argus analyst write stock market today teva fall be right day move average stock have be day line more year argus downgrade teva stock hold buy cite plague problem teva recently lose patent protect multiple sclerosis drug copaxone former ceo erez vigodman step doj investigation bribery scandal russia ukraine mexico copaxone patent loss teva keep guidance sale earning share exclude certain item be flat respectively pfizer pfe momenta mnta be work copaxone copy be face manufacturing issue teva cut expectation full year sale copaxone expect have cent cent impact ep item company be appeal patent loss interim ceo yitzhak peterburg company earning conference call month say expect continue price erosion generic competition ibd take teva stock have low ibd composite rating meaning underperform more third stock term key growth metric ani pharmaceutical lead group better cr best possible visit ibd stock checkup other leader meanwhile teva be still slew generic drug maker include mylan myl face department justice antitrust investigation addition teva december agree pay government settle allegation bribe official russia mexico ukraine similar probe be ongoing israel risk be stack teva argus analyst write research note top struggle teva repay more debt next year include due other thing teva be pay acquisition actavis generic business former generic ceo sigurdur olafsson step december olafsson be well regard actavis argus analyst say have hold position company be expect be instrumental integration actavis generic business argus analyst say aftermath actavis generic acquisition copaxone sale be hit generic competition argus say teva engage grow be likely face antitrust hurdle be few attractive large target analyst write related momenta pfizer give teva pharma breathe room generic ms drugteva maintain guidance copaxone patent loss topsteva ceo step patent loss bribery settlement stock dife
256,PFE,momenta mnta pfizer pfe be unexpectedly give teva pharmaceutical teva breathe room generic version ms drug copaxone manufacturing delay announce late friday teva rival drug prompt teva stock rebound tuesday stock market today teva stock lift much week high close tuesday regular session momenta stock other hand tumble crash day move average momenta be partner novartis nvs subsidiary sandoz generic drug novartis stock slip tuesday food drug administration issue pfizer warning letter follow inspection fill finish factory factory be key piece momenta sandoz supply chain milligram glatopa generic rival copaxone momenta say unlikely fda approve mg drug fda policy approval application be dependent satisfactory resolution compliance observation pfizer facility used make final product momenta say late friday ibd take teva stock be rank ninth ibd company generic drug industry group composite rating best possible base key growth metric head ibd stock checkup list top generic drugmaker analyst broadly push back timeline glatopa mg launch letter doesn restrict production shipment mg glatopa already market sandoz delay also put mylan myl partner natco lead generic filing mizuho analyst irina koffler write research report have underperform rating price target teva stock mylan previously indicated copaxone first filer status be share unexpectedly put mylan molecule lead gain fda approval ahead momenta write currently model generic launch second half mylan stock edge tuesday koffler expect momenta mg glatopa launch mylan product rbc analyst randall stanicky call delay glatopa mg opportune teva related acorda stave mylan teva generic protect ampyrateva maintain guidance copaxone patent loss topsteva ceo step patent loss bribery settlement stock dife
257,PFE,key house committee have propose delay change medicaid funding moderate republican effort repeal replace major part obamacare run trouble ability republican bridge wide divide moderate conservative still look iffy especially senate signal retreat medicaid cut have health care sector breathe sigh relief dow jone industrial average index nasdaq composite be slightly negative early afternoon stock market today health stock be mostly higher hospital hca holding hca close tenet healthcare thc jump universal health service uhs gain insurer molina healthcare moh be unchanged aetna aet climb dow component unitedhealth group unh edge drugmaker also have benefit president trump back away earlier threat intervention bring high cost prescription be mixed dow component merck mrk rise pfizer pfe dow member end flat ibd take difficulty republican settle replacement obamacare be threaten sidetrack rest president trump economic agenda include tax cut infrastructure spending house energy commerce committee play key role shape health reform release plan next week maintain medicaid funding level cut take effect wall street journal report retreat house come gop governor have be make voice hear preserve obamacare medicaid expansion gov john ohio have embraced medicaid expansion meet trump week have be leader effort related biotechs leap trump call innovation speedy fda approvaltrump big speech leave investor hope not much else
258,PFE,brandon schatz learn december kansa city kan have become first city nation get google fiber superfast internet service start make plan move nascent sport photography business day christmas drive mile home springfield mo check feb have settle new house feb be connect network be exactly official have want area first kansa city kan kansa city mo add week later win challenge be first get google fiber local booster celebrate hope kick start economic renaissance attract entrepreneur cultivate emerge business district become know major startup hub year later schatz company sportsphotos com take photo amateur sporting event country be grow slowly take full advantage speedy internet uploading hundred high resolution photo minute race other match business isn yet want be now schatz main source income be web development work rent room home airbnb recent sunday schatz sit home also operate company peck away desktop surround pizza box thought be huge already say schatz disappointment be tale misplace expectation entrepreneur city leader city mayor call fiber then future deployment once lifetime opportunity way spark economic development google significantly have pare support project be case place too much faith ability own technology change life also be hard kansa city area become boom town leader dream entrepreneur schatz be draw city fiber launch business startup village sprang few company really take frustrated founder end decamp san francisco be larger talent pool greater access capital even best intention superspeedy internet isn enough create new silicon valley year first fiber connection lit alphabet googl google late greater kansa city gdp growth have fall well short national average be just compare nation whole metro regional number aren yet available base state number third quarter kansa missouri seem be beating national average re scratch head little bit say jeff pinkerton mid america regional council nonprofit conduct economic research greater kansa city be kansa city really not take especially asset google fiber google come town wyandotte high school auditorium kansa side blue red yellow green spotlight shine parade dignitary address audience google founder sergey brin speak prerecord video announcement fiber go kansa city google vice president invite crowd barbecue laden celebration kansa city beat more other city debut google fiber project aim compete cable giant have dominate market internet access analyst believe ultimate goal be encourage competitor improve own service thus internet experience overall bolster environment alphabet most lucrative business online search mayor city announce team civic leader figure best leverage fiber well other area such education group release plan make recommendation range nurture technology district support tax credit small technology business create mentor network budget challenge state kansa have stick pre exist income tax credit angel backer invest young company work group call techstar kansa city base sprint create incubator startup kauffman foundation think tank base kansa city mo start weekly gathering entrepreneur area straddle state line road border become first neighborhood google wire fiber community founder sprang district have zone law make easier run business home become know startup village schatz owner sportsphotos com moved rental house be online video kansa city experiment draw realize google fiber be key nascent business batch photo take hour upload be do less little nerdy see video be kind inspire say schatz boyish look former army sergeant tour duty include bosnia be inspire yet practice dazzling internet connection didn mean much business mike farmer operated startup leap search engine startup village house do do gigabit speed make experience more relevant recall ask team goof idea such have search result take form several high definition netflix movie stream same time give most user wouldn have gigabit internet leap never do find right scenario farmer wound business last year true power google fiber be exposure say matthew marcus executive director kansa city startup foundation co leader startup village refer publicity technology bring city startup community fact be really difficult consume gigabit speed startup have contend lack access big talent pool tech company silicon valley waterloo canada new york city tend hire nearby university strong software engineering program school strongest engineering school region be more hour away kansa city funding have also be problem kansa city entrepreneur lament local investor look type traction merit ten million dollar silicon valley venture firm business achieve midwestern venture firm invest just single digit million lack access capital contribute departure promising kansa city startup bond marketplace neighborly green homebuilder acre moved most operation silicon valley be plenty angel check not much bridge say sandy kemper chief executive officer fairway kansa base work capital finance company founder kemper turn big investor outside kansa city include san francisco mithril capital singapore temasek holding most back hometown be finer filter maybe little bit higher hurdle advantage cite many local entrepreneur low cost actually backfire be misplace sense comfort say ajay royan general partner mithril capital invest believe best entrepreneur work intensity drive reality global competition reality too easily lose sight low pressure low cost environment get comfortable fact thing seem be go well kansa city say don think bad be many other entrepreneur hope eventually list public market raise hundred million dollar valuation north have already raise be used world biggest company include acer costco cost berkshire hathaway brka bnsf railway pfizer pfe type public offer more anything truly foster kansa city entrepreneur say show exist investor upside investing more few dollar startup create class richly reward early employee turn likely become investor other startup founder own lance lemay venture capitalist kansa city mo base open air equity partner invest kemper farmer company say boost venture backed startup ecosystem kansa city win even take much more dollar exit need lot successful exit say don need home run need lot double year kansa city have be try make most fiber google have be do same early day company executive talk executive chairman eric schmidt tell conference goer late company current innovation include self drive car be google most compelling many level something change life shortly afterward start announce more city project begin austin texas provo utah company recruit craig barratt wireless chip industry veteran lead group include fiber google become alphabet barratt be give title ceo time google fiber announce expand city just kansa city have over-estimate asset google fiber become google over-estimate fiber impact expansion plan deflate barratt left october surprising many employee same day unit announce be stall expansion plan city cut staff month alphabet hire barratt replacement executive gregory mccray further slim fiber shift hundred employee google core internet business fiber be now only location include atlanta orange county calif other bet part alphabet google fiber belong report loss last year revenue also contribute other bet capital expenditure number factor lay fiber strategic shift former employee say chief reason be discrepancy desire google co founder expand service make faster demand cost provide cable incumbent moved aggressively introduce similar high speed service low price unexpected political hurdle emerge louisville ky instance charter communication chtr sue google fiber wonky utility bill regulation google invest fiber time be willing make lot big investment uncertain long term return last couple year google have become different place say jan dawson chief analyst jackdaw research doesn necessarily make sense alphabet continue invest heavily point schatz recently change business model instead get amateur athlete pay photo download free sponsorship fee provide revenue have observed reluctance local investor back company lack strong income be work build relationship big sport retailer fitness company sponsor blanket photography event shoot race photography business alone be worth annually year sponsorship calculate add other amateur sport expand marketing initiative be exponentially more now capture just tiny portion revenue last year double be still say year hope keep grow achieve profitability know develop ty potential sponsor be much easier city new york los angele believe pull heartland sometimes think back advice venture capitalist give few year drop everything else focus only business layer back atmosphere kansa city make easier put advice aside say probably have be good have extra pressure say now still say perk such community fellow entrepreneur make happy stay put meanwhile original startup supporter startup village have sell real estate entrepreneur google fiber come town brad feld venture capitalist boulder colo base foundry group buy bungalow startup village use gratis promising young company time leap farmer house intern today startup engineer life house recent visit layer dark fuzz grime obscure floor vacuum cleaner stand far end main room plug apparently unused side room lack furniture do sport large pile clothing fling center skittish cat bolt kitchen door street schatz have decide launch intense search financial backer early port call silicon valley more real estate southeast see rent rise high vacancy ratesare hottest selling suburb homebuyer break even point just get little more distantsurvey find most affordable major housing market be america
259,PFE,pfizer pfe tesaro tsro follow astrazeneca azn drugmaker early friday unveil strong result late stage trial parp inhibitor lynparza breast cancer leerink analyst seamus fernandez say stock market today tesaro stock jump astrazeneca stock lift pfizer stock be flat astrazeneca pfizer tesaro roche rhhby clovis oncology clvs be work parp inhibitor drug class block specific enzyme treat ovarian other cancer drug astrazeneca clovis be already approve ovarian cancer clovis stock jump friday lynparza be first approve treat ovarian cancer december early friday astrazeneca say drug show statistically significant clinically meaningful benefit improve progression free survival negative germline brca mutate breast cancer be first phase readout parp inhibitor breast cancer likely have positive read similarly design trial pfizer talazoparib tesaro niraparib fernandez write research report have outperform rating astrazeneca stock ibd take immuno oncology company merck bristol myer roche be race cure cancer emerge field thus far drug have be approve array indication head ibd technology page see company have head start pfizer tesaro be expect have datum first second half year respectively astrazeneca be expect unveil full datum upcoming medical conference company didn specify conference importantly represent astrazeneca be build dna damage response portfolio lynparza well provide first validation parp inhibitor class outside ovarian cancer fernandez say future fernandez expect datum parp inhibitor combination immuno oncology drug like merck mrk roche related tesaro rocket time high rumore takeover interesttesaro astrazeneca shrink clovis ovarian cancer drug pooltesaro rumore sale fetch north share analyst
260,PFE,britain reckitt benckiser group say friday agree buy base mead johnson nutrition mjn take consumer product maker baby formula market provide catalyst growth sale momentum slow share mead johnson base suburban chicago surge nearly first minute trading friday share takeover add earning year lead equivalent cost saving year say reckitt maker lysol cleaner reckitt share fall reverse early gain company forecast revenue gain analyst estimate reckitt benckiser biggest ever takeover boost growth prospect revenue advanced slowest pace more year tough condition europe emerge market brazil breakup fee reduce chance counter offer mead johnson have be tout takeover candidate maker enfamil go public deal have potential reignite top line growth only area reckitt model appear lack say deborah aitken analyst bloomberg intelligence offer price be same company indicated announce negotiation feb bid value target time earning compare multiple nestle nsrgy paid pfizer pfe baby formula unit danone danoy paid baby food maker numico accord john baumgartner analyst well fargo debt funded acquisition add share earning first full year be double digit accretive third year reckitt benckiser say look just achievable first blush martin deboo analyst jeffery say cost save forecast announcement deal be accompany reckitt benckiser fourth quarter result be bring forward monday miss expectation company report comparable sale growth vs company compile consensus estimate full year operate profit be line estimate sale company also forecast growth comparable sale year analyst estimate gain first quarter have get soft start new product scholl foot care line fail live expectation chief executive rakesh kapoor say press conference expect macro condition remain challenge number exist headwind persist first half kapoor say statement not previously consider analyst be obvious acquirer mead johnson reckitt benckiser have have company radar number year kapoor say friday conference call purchase add baby formula portfolio consumer brand include nurofen painkiller strepsil throat lozenge french mustard reckitt benckiser have proven able enter thrive new category do acquire durex condom maker ssl international already have toe nutrition business purchase schiff nutrition make omega supplement joint pain pill main reason takeover be increase reckitt benckiser presence develop market asia mead johnson trail nestle danone global baby nutrition business second only nestle asia biggest market baby food likely be asia fastest grow food category even industry contend term headwind bloomberg intelligence note december reckitt benckiser say expect complete takeover end third quarter expect retain strong investment grade credit rating robey warshaw bank america lynch act joint lead financial advisor reckitt benckiser also receive advice deutsche bank hsbc mead johnson be advise goldman sachs morgan stanley
261,PFE,satisfy trump administration call deal high drug cost industry leader be propose president lead negotiation drugmaker restrain price allergan agn chief executive brent saunder cite tactic used president john kennedy decade keep steel price administration also waive federal antitrust rule currently prohibit drugmaker discuss pricing so put together guideline follow say voluntary agreement restrain price be very practical solution doesn view do anything impede innovation saunder say wednesday interview bloomberg headquarters new york convince fellow drugmaker agree however be challenge be difficult saunder say big pharma be intense pressure come way reduce price president trump accuse company get away murder threaten use government buy power force price saunder have be outspoken excessive price hike own industry allergan company product range wrinkle treatment botox stomach schizophrenia medicine ceo have implement social contract cap increase annually trump model something pharmaceutical industry maybe look something social contract saunder say easy suggest re already do just be transparent add ask target amount restraint agreement say low single digit rate inflation pharmaceutical giant include novartis nvs japan takeda pharmaceutical abbvie abbv also have take voluntary action cap price increase johnson johnson jnj merck mrk have take step increase transparency price industry have moved quite bit month month saunder say need big push saunder allergan have transform specialty pharmaceutical behemoth series acquisition sale generic business attempt merge pfizer pfe inc megadeal be abandon last year allergan have focuse smaller purchase allergan share be compare rest industry last month ve lose compare gain company standard poor pharmaceutical biotechnology life science index include allergan rather deal saunder be more interested build allergan main therapeutic area include medical aesthetic dermatology eye care central nervous system past month make acquisition worth combine add allergan aesthetic medicine cosmetic surgery line hair restoration skin quality be next frontier say company be currently do research area be huge unmet need say ask valeant pharmaceutical international vrx asset include bausch lomb eye care company once lead saunder say not interested not even piece valeant didn respond request seek comment
262,PFE,major stock market index etfs be narrowly mixed wednesday material health care show strength sector spdr spy be hover time high powershare qqq qqq be same amount spdr dow jone industrial average dium be material select sector spdr xlb be etf have rise so far year vs spy xlb break flat base jan rise nearly buy point then fall back base find support day move average be hold time high etf have bulk asset invest chemical basic material company include dow chemical dow nearly asset dupont dd also praxair px nearly dow chemical shot higher wednesday report reuter eu antitrust regulator be close clear merger dow chemical dupont dow chemical have year growth rate be yielding have dividend growth rate dupont jump wednesday rise industrial gas producer praxair be utility select sector spdr xlu be health care select sectorspdr xlv be fraction top holding include johnson johnson jnj pfizer pfe merck mrk unitedhealth unh be slightly amgen amgn be energy etfs give back strong gain tuesday unite state oil fund uso fall wednesday jump tuesday uso track spot price west texas intermediate light sweet crude oil energy select sector spdr xle fall rally tuesday etf track oil gas explorer producer service company be week high trading etf be day move average bearish sign intermediate low xle top hold exxon mobil xom be week high chevron cvx be high be trading day line here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related oil gas equipment etf have strong year best etfs make bullish bet growth trump trade
263,PFE,regeneron regn sanofi sny eye biomarin bmrn medicine co mdco wake judge ban amgen amgn rivale ldl buster rbc leerink analyst suggest friday late thursday district judge rule regeneron sanofi praluent infringe pair amgen patent repatha pcsk inhibitor lower ldl bad cholesterol blood decision send regeneron sanofi stock red stock market today regeneron stock fall sanofi stock fall amgen have patent reaffirm enjoy gain ibd take biotech sector suffer raucous election year leader end year triple digit gain be stock pick list get deep dive ibd industry theme biomarin pharmaceutical stock rise medicine co jump suggestion regeneron pharmaceutical sanofi issue bid make lose potential removal praluent market biomarin have market cap medicine co have cap france base sanofi have market cap have be particularly vexed recent year lose medivation blockbuster cancer drug xtandi battle pfizer pfe last year last month sanofi be say be jockey johnson johnson jnj swiss biotech actelion pharmaceutical revenue loss theoretically cause sanofi continue increase activity have written biomarin make good fit pure play orphan franchise be synergistic sanofi orphan franchise rbc analyst michael yee say friday research note yee estimate biomarin deal slightly sanofi acquisition price genzyme several year have outperform rating price target biomarin stock leerink analyst joseph schwartz see medicine co appeal regeneron sanofi party interested pcsk space medicine co alnylam pharmaceutical alny have partner inclisiran drug aim lower ldl cholesterol schwartz note aftermath praluent injunction set go effect day inclisiran be second line come market pcsk space new england journal medicine article describe inclisiran rna interference therapeutic inhibitor pcsk november medicine co alnylam deliver strong result inclisiran phase trial investor expect more clarity phase testing schwartz write have outperform rating share medicine co related regeneron sanofi ldl buster risk judge uphold amgen downgrade increase boston st jude rivalry
264,PFE,stock open effectively flat friday ahead upcoming day christmas holiday weekend dow industrial edge lower nasdaq composite hung fraction higher russell gain nasdaq head friday session week flat line second straight week dow be show gain so far december have gain so far month nasdaq be small cap slow second straight week smallcap russell start december be russell hold gain pfizer pfe reversed early loss gain company announce have complete acquisition astrazeneca azn division specialize fight infection deal involve upfront payment sale related performance payment pfizer share have be mild consolidation july astrazeneca share rise ahead open boee ba inched report deal next generation jet base airline jet com aircraft list price total mil hewlett packard enterprise hpe add premarket trade be flat open information technology enterprise service unit recently divide company end thursday session so far year buy range buy point flat base discount retailer fred fred jump add recent big gain news report say hedge fund alden global capital have take stake chain operate store fred share spiked tuesday company report plan buy store be divest riteaid rad part merger walgreen boot alliance wba tuesday gain take back most ground fred share have lose month correction cinta cta drop more fiscal second quarter report late thursday meet analyst expectation straight column stock have be hover buy point cup base week share cal maine food calm jump more report quarterly result late thursday stock be try cross back day line friday economic calendar keep thing simple et university michigan offer final take december consumer sentiment new home sale number november be expect commerce department et baker hughe bhi deliver weekly rig count bond market close early today ahead holiday crude oil narrow early decline west texas intermediate hold barrel gold edge ounce dollar backtrack bit vs euro yen market tokyo be close japan emperor birthday holiday bond ease year yield basis point overseas market be generally quiet benchmark index china book mild loss friday europe market shift mixed action trading very tight range afternoon trade related wal mart target drop tariff talk investing action invest pearl trading wisdom wall street gerald loebibd stock spotlight high yield natural gas midstream play deserve attention
265,PFE,load player here weekly investing action plan need know investor come week notable earning report speak weak slate economic report big event hold new year day market likely have little do day trading week obsess
266,PFE,bristol myer squibb bmy astrazeneca azn roche rhhby pressure merck mrk slew lung cancer drug design chip keytruda share jeffery analyst jeffrey holford say monday downgrade merck stock stock market today merck fall bristol myer squibb climb merck bristol myer be lock battle small cell lung cancer market drug leverage patient immune system battle cancer holford downgrade merck stock underperform price target expect strong keytruda performance follow pressure rival drug bristol astrazeneca roche chip away keytruda market ibd take next year be marked new presidency path donald trump take drug price merck screen poorly many valuation metric have downgrade share underperform holford write research report same note upgrade bristol stock buy price target holford expect opdivo trial secure bristol future more broadly prefer abbvie abbv eli lilly lly stock astrazeneca novartis nvs stock europe see pfizer pfe johnson johnson jnj merck sanofi sny nordisk nvo least prefer stock related gilead pay merck hep patent agio stock anemic
267,PFE,first time winning election donald trump vow take drug price go bring drug price don happened drug price trump tell time magazine name president elect person year investor continue assess trump policy mean market few word have jarring impact start trading wednesday share drugmaker biotechs be hit mylan myl stock market today ishare nasdaq biotechnology etf ibb pfizer pfe fall trump also double goal shift tide global trade get ceo phone minute want get list company have announce re leave tell magazine call minute apiece win be leave be plenty reason doubt just much impact trump have restore lose manufacturing job curb america trade deficit effort backfire extent trump be show fully engage challenge say tim cook ambition get apple aapl build great plant biggest best even only foot foot bigger place china tell time ibd take market assess trump trade policy work industrial company get most revenue home be biggest post election winner include nucor steel dynamic martin marietta check ibd leaderboard track stock be lead market analyst have cast doubt major shift iphone production china foxconn have chinese worker assemble apple iphone give trump small victory wednesday company confirm be eyee expansion operation apple share rise announcement come day masayoshi son ceo japan softbank own sprint meet trump discuss plan invest trump aggressive use bully pulpit plan bring corporate tax rate help convince unite technology utx unit carrier keep open indiana plant slate closure other company have feel be wrong side trump tweet rexnord rxn trump criticize plan move ball bearing production indiana have see share tumble wake call biotech investor come day trump tweet threat call boee ba air force cost spiraling control trump tell nbc wednesday later speak boee ceo dennis muilenburg say re go work continue insist cost come meanwhile trump tell time magazine build wall stop illegal immigration also indicated not deport so call dreamer child bring illegally parent re go work something go make person happy proud related drug stock topple trump pledge bring chief trump go negotiate air force pricetrump seek shoot air force target boee profittrump sell boee apple other stock junedonald trump fire tariff warning shot backfire
268,PFE,european japanese specialty pharma look acquire ariad pharmaceutical aria rapidly close approval orphan lung cancer drug rbc analyst michael yee say wednesday yee expect ariad stock spike first half approach prescription drug free user act pdufa date brigatinib cancer drug aim treat anaplastic lymphoma kinase positive alk small cell lung cancer nsclc resistant crizotinib crizotinib be chemotherapy develop pfizer pfe treat nsclc wednesday ariad unveil result phase trial nsclc patient resistant pfizer chemo drug median follow month patient milligram regimen achieve objective response brigatinib increase median progression free survival pfs month month fail crizotinib therapy additionally patient cancer have metastasize brain show intracranial objective response intracranial pfs be month ibd take drug biotech stock plunge wednesday president elect donald trump comment seek curb drug price check deep dive ibd industry theme average rival brigatinib have extend pfs month yee write client note brigatinib have potential be best class second line alk lung cancer drug possibly also be best first line defense write ariad first line datum win be available competitor roche rhhby have first line datum rival drug alectinib due interim yee have plenty question ariad upend future stock price ariad hire sale force spring brigatinib do street think ll launch thus takeout term ariad be sell pdufa say do ariad sell brigatinib eu right thus reduce potential yee also have question ariad iclusig med treat chronic myeloid leukemia philadelphia chromosome positive acute lymphoblastic leukemia question lack mg bottle limit option note ariad market cap meaning wouldn be heavy acquisition japanese european specialty pharmaceutical company look expand presence become cancer drug company make ariad notable scarcity biotech yee write comparable biotechs exelixis exel array biopharma arry tesaro tsro clovis clvs rocket major cancer datum food drug administration approval yee write so reasonable see aria go chance also get closer fda approval yee keep sector perform rating ariad stock boost price target see valuation share depend peak sale brigatinib iclusig assume put valuation ariad close bell stock market today ariad stock fall most drug stock be have tough day president elect donald trump tell time magazine go spiraling drug price hillary clinton have be see tougher drug price biotech drug stock have originally surge trump election related drug stock fall trump pledge curb pricesariad follow gilead mylan route drug price battle blockbuster franchise spark fever sarepta ariad biotechsaerie pharmaceutical skyrocket eye drug news
269,PFE,biotechs tesaro tsro kite pharma kite loxo oncology loxo be expect report second quarter loss tuesday investor likely tune more early cancer pipeline xof trio tesaro likely have most robust sale tesaro have approve drug include varubi zejula varubi treat nausea associate chemotherapy zejula be approve treat patient ovarian cancer ve undergo chemotherapy zejula be know parp inhibitor rival approve drug clovis oncology clvs astrazeneca azn dow pfizer pfe be also work parp inhibitor second quarter analyst poll zack investment research call tesaro report adjust loss share sale year earlier period tesaro have sale due license revenue loss be narrower share kite be work nascent area immuno oncology call car therapy treatment immune system cell be extract patient reprogram fight cancer cell then reintroduce body ibd take biotechs hit month high late july biotech fever be cool ibd company biotech industry group be now rank fifth group track ibd head ibd industry theme closer look group topple save food drug administration be expect late year approve car drug kite dub kte treatment aggressive form hodgkin lymphoma approval be expect follow similar car approval novartis nvs bone marrow cancer second quarter analyst expect kite report sale adjust loss share year year basis revenue grow adjust loss widen cent share year earlier period loxo be work drug treat cancer specific genetic mutation doesn have drug approve so isn expect have sale second quarter loss be expect widen cent share cent share loss year quarter related biotech be jump today rival cannabis tie novartis fda cancer also be boon rivalsnovartis grab key fda panel approval experimental cancer drug
270,PFE,share valeant pharmaceutical international vrx be rise monday company continue fill new management lineup appoint new chief financial officer valeant nab paul herendeen animal health company zoetis zts have be executive vice president last year also be cfo number year warner chilcott buyout company eventually become allergan agn valeant current cfo robert rosiello become head corporate development strategy role cfo be crucial valeant recent accounting scandal result company restate last couple year earning rosiello wasn implicate trouble really happened june appointment previous cfo howard schiller take most heat valeant audit committee produce report march same time ceo michael pearson quit ibd take valeant become poster child drugmaker rely price increase goose revenue learn much other big cap drugmaker be rely price vs demand rbc capital market analyst dougla miehm write change be probably due match talent job view new role mr rosiello favorably work mckinsey year have advise company health care consumer product technology sector venture operational strategic initiative miehm write research note valeant stock rise stock market today just second day past month rise also have be fuel wider bounce drug stock view buyout target light pfizer pfe buyout medivation mdvn valeant earning call ceo joseph papa say be prepared sell worth asset wall street have wonder buyer acquire entire company now week high related
271,PFE,drugmaker medivation mdvn stock be jump monday lift other big biotechs pfizer pfe announce acquire company cash pfizer medivation deal be formally announce weekend leak long campaign big french pharma sanofi sny take maker prostate cancer drug xtandi sanofi didn completely rule make bid statement monday make sound pfizer share cash be too rich blood recognize potential strategic benefit combination medivation be first foremost discipline acquirer remain commit act best interest sanofi shareholder medivation stock rise stock market today share pfizer stock fall fraction monday ibd take last week ibd medical biom biotech industry group have rise industry group month ibd look drive biotech stock rally jeffery analyst note reignite speculation sanofi turn attention rare disease specialist biomarin pharmaceutical bmrn june biomarin stock rise anonymously source report blog betaville biomarin be sanofi fallback option monday biomarin stock pop meanwhile incyte incy maker blood cancer drug jakafi perpetual object buyout speculation various partner rise research note sizing several biotech buyout target bmo capital market analyst do kim write incyte go base valuation time peak sale wouldn bring much upside current market cap kim add believe company potentially command higher multiple give limit number late stage clinical commercial biotechs other name likely target include rare disease player alexion pharmaceutical alxn vertex pharmaceutical vrtx rise respectively monday related
272,PFE,pfizer pfe announce deal monday buy medivation mdvn several big merger deal approval announce early monday canadian convenience store operator alimentation couche tard say buy san antonio base cst brand cst roughly additionally japanese chipmaker renesa electronic say consider buy silicon valley analog mixed signal chipmaker intersil isil chemchina swiss seed company syngenta syt announce have reach agreement committee foreign investment unite state chinese company bid syngenta lift odd deal go month wrangling pfizer announce deal acquire cancer drug maker medivation share acquisition be expect quickly be accretive pfizer earning share boost cent first year close pfizer share be stock market today pfizer stock hit year high aug medivation jump related pairing expand alimentation couche tard north american footprint circle parent say buy cst brand operate more convenience store service station canada share deal be value include debt cst share fall milpita calif base intersil make microprocessor auto aerospace other market renesa reportedly confirm talk intersil report say deal be merger renesa financial time report be own japanese government controlled fund create global chip company roughly sale heavy focus auto related chip intersil share shot monday related ibd take several chipmaker include apple iphone supplier have be make acquisition expand automotive footprint other semiconductor sector struggle see auto chip demand be race ahead share switzerland base syngenta jump word committee foreign investment unite state have clear chemchina takeover company series global clearance need merger deal be be closely watch world largest seed company reuter say company deliberate sell germany bayer ag bayry edge higher related
273,PFE,stock briefly rebound positive territory be fading again late morning trade nasdaq fall dow jone industrial average lose stock market today volume be tracking lighter same time friday nyse nasdaq exchange ibd stock be evenly split winner loser planet fitness plnt be best performer nearly average volume stock rise aug report earning netease nte rise nearly average volume recover setback thursday earning beat estimate trader sell stock anyway red hot acacia communication acia advanced ibd take planet fitness weigh top stock leisure service industry group see ibd stock checkup medivation mdvn rise almost pfizer pfe monday confirm buy medivation share premium friday close pfizer be trading flat oil drop sharply west texas intermediate future september delivery fall barrel export chinese diesel gasoline jump august also barclay say august rally oil be unsustainable other analyst say rally be cause short cover anticipation september opec meeting discuss production freeze randgold resource gold gap be trading lower gold future be trading lower silver be more
274,PFE,stock open narrow loss wednesday broad gain global market dow industrial lose nasdaq fall market trade higher overseas benchmark asia book gain wednesday europe market rally briskly frankfurt dax london ftse more afternoon trade banking stock show particular strength dow stock unitedhealth group unh be nearly flat pfizer pfe fall news british regulator fine company accusation overcharge consumer epilepsy drug ibd stock dave buster play chalk premarket gain arcade restaurant chain report late tuesday third quarter earning soar revenue leap well ahead analyst expectation management lift full year earning guidance consensus target stock end tuesday buy range buy point double bottom handle base western digital wdc swung nearly management adjust guidance fiscal second quarter revenue earning consensus projection maker computer hard drife end tuesday low still deep year consolidation idaho base chipmaker micron technology mu pop nearly open micron announce have acquire last outstanding share taiwan base inotera memory hard fought deal value micron expect immediate accretion gross margin well earning share free cash flow now deal have close citigroup initiate coverage stock wednesday morning buy rating price target downside sigma design sigm dive report weak third quarter result late tuesday mortgage reit ladder capital ladr plunge pricing secondary offer share discount tuesday close price look be relatively quiet news day economic front labor department job opening labor turnover survey october be due et energy information administration deliver weekly oil inventory report et federal reserve october consumer credit number be set et release oil future west texas intermediate reversed slip more trade barrel gold add trade ounce dollar drift lower bond rise trimming basis point year yield related dave buster western digital lift view mastercard up payoutstarbuck lululemon discounter lead investing action plan
275,PFE,french drugmaker sanofi sny be mull bid switzerland actelion pharmaceutical already have offer table drug giant johnson johnson jnj source tell bloomberg tuesday actelion confirm johnson johnson bid nov sanofi other potential bidder be feel heat push get agreement christmas reportedly boost bid share value actelion north sanofi hasn offer official bid have make interest know informally bloomberg say cite person familiar matter possibly sanofi soon also have compete roche rhhby pfizer pfe reportedly have be approach make bid switzerland biggest biotech novartis nvs be run accord interview ceo joe jimenez publish sunday swiss german language newspaper sonntagsblick ibd take biotech see boost donald trump be biotechs lookout representative actelion sanofi pfizer didn immediately return request comment roche spokesperson dr engel say company do not comment rumor speculation johnson johnson refer back nov announcement say do not intend make additional comment regard discussion be appropriate do so formal agreement have be reach close stock market today stock be fraction sanofi stock be share roche be fraction pfizer shave cent share close editor note correct list bloomberg source original report related unite therapeutic chill fever actelion bayer rivalrydonald trump republican win ease drug pricing debate pfizerjohnson johnson reportedly hike bid swiss drugmaker actelion
276,PFE,pfizer pfe doesn expect donald trump election republican congress ease drug pricing debate firm be optimistic potential tax reform credit suisse analyst vamil divan say friday biotech drug stock have rally follow trump election assume ll be less likely tackle pricing reform hillary clinton ibd generic drug group be biotechs group be election pfizer isn ready change view postelection pricing divan say debate drug pricing not go away not get easier write research report pfizer have not change assumption pricing election ibd take drug biotechs aren only sector prime success failure election result check ibd industry snapshot figure stock rocket tank trump drug pricing have be hot topic several year september former turing pharmaceutical ceo martin shkreli draw national criticism hike price pill decade old hiv drug september mylan myl ceo heather bresch defend congressional committee company sixfold increase pricing epipen pack epipen now cost north pfizer be optimistic potential tax reform trump administration propose incentive cash repatriation be time fix key be move territorial system divan write follow meeting pfizer politic aside pfizer still have number catalyst upcoming year year end stock rocket phase datum vaccine combat diarrhea bacterium clostridium diff europe approval xeljanz inflammatory cancer drug belong class call jak inhibitor analyst say divan expect pfizer do well food drug administration approval crisaborole eczema drug be development anacor pharmaceutical pfizer acquire firm june pfizer also have combination datum darmstadt germany base merck kgaa due avelumab inlyta multiple type cancer divan edge earning share ex item expectation pfizer now see pfizer pull earlier model reiterate view stock market today pfizer stock dip share have be day downtrend still be nearly election editor note correct third last graph properly identify company merck kgaa be unaffiliated base merck related gilead scoop incyte cancer drug prove not good enough pfizer spike report mull consumer care sale
277,PFE,nasdaq composite lag monday weakness go well technology stock name alexion pharmaceutical alxn viacom viab st century fox foxa nvidia nvda american airline aal take big hit nasdaq lose end session streak fall dow eke gain good fresh time
278,PFE,stock open lower monday oil price pull back dollar edge higher news stir handful dramatic early move major average pare loss nasdaq rise more open lower dow industrial fall less stock market today medivation mdvn soar pfizer pfe say buy san francisco base biotech deal pfizer expect medivation deal close end year add nickel ep first full year consummation pfizer share rise switzerland syngenta syt spiked nearly china national chemical corp announce monday regulator have approve acquisition seed strain herbicide maker milpita calif base chipmaker intersil isil soar open japan renesa electronic confirm monday be discussion buy intersil news report quote source place deal economic news chicago federal reserve national activity index show broad improvement economy july lift index read vs june production manufacturing manufacturing capacity post solid gain note say sale order inventory category rise more modest negative tally june oil stock largely hold ground crude future slip more early trade oil be pressured rise dollar additional downward pull official datum show china export refine fuel product continue surge july suggest country domestic demand remain weak europe brent crude benchmark drop back barrel west texas intermediate trade just oil price rebound past week dow exxon mobil xom dip chesapeake energy chk drop less gold slip ounce dollar gain vs euro yen bond rise trimming year treasury yield basis point overseas chinese market close narrowly mixed hong kong hang seng index add japan tokyo nikkei also gain europe market trade lower afternoon trade frankfurt dax fall furthest
279,PFE,pfizer pfe announce deal monday morning buy medivation mdvn share enterprise value move follow month takeover speculation cancer drugmaker well widespread report sunday imminent pfizer medivation deal medivation rise nearly soon open bell stock market today pfizer fall cent propose acquisition medivation be expect immediately accelerate revenue growth drive overall earning growth potential pfizer pfizer ceo chairman ian read say statement pfizer say deal boost earning share cent first year close additional gain medivation close friday market valuation be slightly extend buy point flat base medivation trade low feb be subject widespread buzz possible buyout biotech earlier year reject share offer france sanofi sny last week report have pfizer merck mrk gilead science gild celgene celg sanofi possible medivation buyer ibd take biotechs deliver great growth be generate profit revenue gain higher sale volume price increase here hunt biotech stock medivation make xtandi prostate cancer drug annual sale rate already have other cancer fighter development pfizer attempt buy allergan agn fall apart earlier year obama administration change rule make tax inversion merger deal less attractive related medivation affirm guidance earning growth make case leadership be convince
280,PFE,flagship etfs tracking major index close lower thursday ahead weekend conclave policymaker wyoming investor remain edge upbeat job datum oil rally await friday speech fed chairwoman janet yellen offer clue path interest rate hike restrain mood stock market today few asset class score big advance vaneck vector gold miner gdx advanced re-cover tumble previous session see fall solidly key day move average etf invest gold mining stock year best perform industry group biotech stock surrender early rally spdr biotech xbi give back gain more close wednesday session remark democratic presidential candidate hillary clinton have trigger steep sell exchange trade fund clinton member congress question drugmaker mylan myl price epipen have see price increase past decade clinton call price hike outrageous mylan respond thursday expand exist program patient be face higher pocket cost stock climb nearly intraday end red clinton tweet back september price gouge drug industry have trigger plunge xbi span few trading session ibd take exchange trade fund offer investor exposure diversify basket stock lower portfolio risk always good take deeper dive best biotech stock portfolio dave mazza head research spdr etfs say political rhetoric shine light drug industry possible negative way be fairly typical stage election cycle expect primary driver biotech stock lead november vote be political outlook rather company specific fundamental presidential election biotechs benefit calmer environment investor find attractive valuation space interim tell ibd phone call xbi sit week high have gain third quarter aug recently aug biotech biomedical group hit multimonth high be hold level follow monday announcement pfizer pfe deal buy medivation mdvn here major exchange trade fund major asset class perform today ibd relative price strength rating rs rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related be gold etf rally technical analyst think not
281,PFE,big pharma eli lilly lly fall wednesday breast cancer drug didn prove be knockout investor have hope outside committee conduct interim analysis monarch late stage trial lilly drug abemaciclib combine fulvestrant astrazeneca azn faslodex advanced metastatic breast cancer drug be show enough efficacy already then trial have be stop early lilly have go ahead file fda approval committee recommend study continue previously plan completion point have stringent criterium set interim analysis look forward receive final monarch result first half richard gaynor lilly vice president product development medical affair say statement lilly stock fall stock market today fall low intraday leerink analyst seamus fernandez say follow ambiguous result previous study abemaciclib monotherapy fulvestrant single agent response rate seem be better competition pfizer pfe palbociclib ibrance novartis nvs ribociclib do not meet primary endpoint fernandez write research note management indicated file approval monarch interim analysis point believe be unlikely be able file monotherapy fernandez add pfizer novartis stop trial early efficacy so lilly be widely expect do so well drug be same class call cyclin dependent kinase cdk inhibitor pfizer ibrance approve february have already pass sale ibd take timing drug launch be important drug stock future financial estimate be preferably go lilly estimate have recently be rise see stock checkup
282,PFE,stock open slightly higher friday wal mart wmt receive black friday boost dow industrial rise nasdaq rise fraction russell climb nasdaq dow rolled friday session holiday shorten week tap new high look add third week advance small cap have easily outpaced group russell more so far week show gain november smallcap hold gain week be start month nasdaq be november dow boast gain wal mart rise pfizer pfe make advance exxon mobil xom chevron cvx be straggler dow fraction ctrip com international ctrp rattle gain open hsbc upgrade stock buy hold raise price target ctrip com report late wednesday third quarter earning fall less expect revenue gain easily clear analyst target stock have be seek regain technical support year long consolidation ibd stock trade flat higher hold gain loss less earning calendar be quiet stock market today economic docket lead expansion trade deficit october accord commerce department be trade gap september wider increase expect economist consensus london base researcher markit be schedule report preliminary purchasing manager index read november service et oil future trade lower west texas intermediate dip barrel metal future be mixed gold slightly ounce copper nearly pound dollar give ground bond ease lift year yield basis point international trading be mixed tame friday market asia take home mild gain europe benchmark index be narrowly mixed afternoon trade ftse london benchmark frankfurt paris fraction related apple amazon macy lead investing action plan friday
283,PFE,stock open narrowly mixed thursday central bank decision europe mixed unemployment datum quarterly report factor early trading dow industrial nasdaq rise fraction be fractionally european central bank vote extend quantitative ease program december say trim bond buy initiative current month begin april stock europe post uneven gain frankfurt dax cac paris show gain london ftse afternoon trade nike nke fall fraction cisco system csco rise dow pfizer pfe be more lululemon athletica lulu stretched higher pair analyst upgrade follow stronger expect third quarter result report late wednesday fourth quarter guidance be little light third quarter gross margin jump sharply company launch share buyback initiative mizuho evercore isi group raise rating stock buy stock end wednesday week move average month consolidation costco wholesale cost rise bulk retailer deliver mixed fiscal first quarter result late wednesday block hrb fall healthy fiscal second quarter result report wednesday close stock have be fight regain support week move average deep year long correction largest early decline horizon pharma hznp plumet announce weak result late stage clinical trial comtech telecom cmtl dive mixed fiscal first quarter result weak second quarter guidance first time jobless claim decrease week end dec labor department report be prior week claim consensus view dip application week move average edge second straight increase et university michigan deliver december consumer sentiment estimate wholesale inventory datum be due commerce department oil future bump almost january west texas intermediate contract continue hover barrel week gold trade effectively flat ounce dollar bounce follow ecb vote bond slip lift year yield basis point related ecb broadcom finisar leader thursday investing action plan
284,PFE,nasdaq stumble technology stock come heavy selling sector flagship such facebook fb google parent alphabet googl sharply thursday afternoon composite pare loss nasdaq be more heavily weight techs total composite be facebook fall day move average start bounce back be heavy volume factor cite loss be spiking bond yield mixed message president elect donald trump visa immigrant worker many top techs be already falter weak earning too spdr technology etf xlk slide dow jone industrial average climb pfizer pfe component surge report say drugmaker be consider selling consumer care business deal fetch work loss be financial name cyclical play health care stock fared better most defensive group such food tobacco be biggest laggard well gold mining internet solar power stock small cap russell jump dow transport lead surge rise rally shipping trucking stock volume be tracking higher compare same time wednesday stock break today trading most regional bank fcb financial fcb mb financial mbfi home bancshare homb be higher liquidity bank top buy point heavy trading pinnacle financial pnfp top buy point sank back pattern trex trex maker wood product decking break past buy point double bottom related apple fang stock aren join trump rallypfizer spike report mull consumer care sale
285,PFE,stock market appear embrace donald trump improbable presidential victory send main index broadly higher stock have be act prefer hillary clinton victory monday tuesday future do plummet overnight result come index shake loss marched higher trading session high late afternoon index come session high remain higher dow jone industrial average lead gain pharmaceutical component pfizer pfe merck mrk be election remove fear crackdown drug price climb nasdaq small cap russell vault indication investor be willing take greater risk volume be tracking sharply higher winner lead loser board banking be sector lead market superregional bank industry group nearly today trading few regional bank break basis northern trust ntrs clear lopsided pattern rise buy point ease unite community bank ucbi top buy point undefined pattern thinly trade beneficial bancorp bncl top buy point flat base breakout sprout other sector market give day gain add fuel wagework wage employee benefit management firm break past buy point cup handle heavy duty truck manufacturer oshkosh osk rise past buy point flat base time more volume usual hospital solar energy stock loser trump administration sell solar energy industry group plunge nearly sank deeper ibd industry ranking hospital founder tenet healthcare thc slide lowest level year defensive group such utility food alcoholic beverage real estate investment trust be day worst perform too related solar stock plunge coal champion trump surprise wingold stock rise trump stunning raytheon launch buy range trump defense stock rally
286,PFE,pfizer pfe stock pop thursday report drugmaker be consider selling consumer care business less month firm opted long rumore corporate breakup evercore analyst john scottus expect potential transaction garner cent earning share midpoint forecast assume tax proceed sale be used share buyback potential sale make sense scottus write research report thursday pfizer reassess future pfizer walk away merger ireland base allergan agn april lawmaker look crack tax inversion deal company be set headquarters lower tax region such ireland pfizer also have long mulled corporate breakup splitting innovative essential health division scrap idea september johnson johnson jnj buy pfizer then consumer care business pfizer build unit back acquisition wyeth later pfizer sell nutrition business nestle spun animal health business zoetis zts thus sale current portfolio consumer product appear be logical next step allow pfizer focus core competency develop selling innovative drug scottus write ibd take trump presidency affect drug biotech stock get full skinny ibd industry theme reuter first report potential customer care sale late wednesday cite anonymous source unit pull sale annually scottus liken bayer acquisition merck mrk consumer care business annual unit stock market today pfizer stock climb day line ramp second consecutive day follow election president elect donald trump share rise wednesday drug biotech stock have rebound trump election trump be see less likely challenge drug price vs democrat hillary clinton unveil plan last year cut spiraling price tag drug trump have promise tackle affordable care act obamacare investment bank rbc say tuesday cause dip biotech stock uncertainty new not yet outlined national health care editor note correct fourth graph show zoetis be spinoff related pfizer likely overpay post allergan breakup flop twist pfizer scraps breakup follow dead allergan merger
287,PFE,stock once again pare slim loss trade tightly mixed afternoon trading monday slumping oil stock continue offset rise biotechs dow jone industrial average be less nasdaq rise fractionally volume be tracking lower board vs same time friday energy department store retailer gold stock lead downside stock market today west texas intermediate crude oil future sank barrel biotech fiber optic utility stock advanced medivation mdvn gap soar record high massive trade pfizer pfe say buy san francisco base biotech deal medivation develop drug treat prostate breast cancer ibd take biotechs earn top notch fundamental technical rating find ibd stock checkup now other biotechs amphastar pharmaceutical amph rise new high healthy turnover share injectable inhalation product maker be well extend past handle buy point clear aug incyte incy spiked heavy volume snap session slide blood cancer drugmaker be name bmo capital market report possible buyout target acacia communication acia be top gainer ibd rise recover friday loss share recent new issue have rally more offer price ibd loser include vipshop vip shutterstock sstk new oriental education edu roughly average volume
288,PFE,big pharma merck mrk be now look possible buyout medivation mdvn accord anonymously source report reuter report wednesday afternoon merck be big pharmas have submit indication interest buy medivation other be sanofi sny pfizer pfe celgene celg gilead science gild sanofi have be very public attempt acquire medivation last month medivation say have enter confidentiality agreement sanofi well other unnamed potential buyer earlier anonymously source report say pfizer celgene gilead be interested buyer have be speculation merck be interested bmo capital research note assert merck be prepare medium size buyout medivation be target merck have be focuse much energy cancer lately medivation have fast grow drug market treat prostate cancer other cancer therapy development medivation stock have be trading flat stock market today pop week high news come close merck rise ibd take medivation be ibd stock last earning report year year profit growth flattened deliver big hit ep rating analyst expect growth pick again start however
289,PFE,drugmaker tuesday continue turn solid earning report beat pfizer pfe mallinckrodt mnk shire shpg get mixed reaction investor specialty drug hospital product company mallinckrodt make biggest move jump more beat analyst second quarter estimate raise guidance earning share be more thomson reuter survey consensus revenue be more wall street number growth do decelerate somewhat recent quarter top line bottom line vs prior year mallinckrodt also say expect full year ep high end previously guide range put annual earning growth acthar immunology drug mallinckrodt acquire buy questcor couple year shrug critique business depend sky high pricing acthar sale beat consensus estimate brand grow year year attribute volume negative impact price hurt bear thesis write mizuho security analyst irina koffler research note british rare disease company shire climb more stock market today also deliver beat raise contrast mallinckrodt growth have be accelerate sale gain vs just year much come recent acquisition baxalta hemophilia focuse company spun baxter international bax shire say own legacy product grow baxalta rise profit jump share top bottom line beat consensus estimate shire new full year sale guidance be line consensus ep guide be upside midpoint represent growth last year ibd take shire pfizer rank top stock ibd medical ethical drug industry group shire be ep rank stock performance year have be weaker pfizer more info see shire stock checkup pharma giant pfizer drop also notch quarterly beat stock hit year high monday suggest expectation be pretty bullish company do not raise guidance year investor have be wait impatiently pfizer decide go split company future pfizer have promise make announcement year end didn happen tuesday new breast cancer drug ibrance show blockbuster potential selling vs year earlier beating analyst expectation prevnar vaccine pfizer largest product actually miss quarter due timing ex governmental purchase high initial capture rate eligible patient successful launch prevnar elderly population note evercore isi analyst mark schoenebaum email recall previously pfizer communicate expect total worldwide prevnar revenue be close level consensus still model minimal year year growth overall sale rise profit climb together be first back back quarters sale profit growth pfizer have report former blockbuster lipitor go patent
290,PFE,day ahead earning report pfizer pfe hit new high news acquisition pharmaceutical giant purchase privately hold bamboo therapeutic chapel hill base company work cure neuromuscular condition pfizer say deal complement rare disease portfolio add gene therapy manufacturing facility pfizer have already own
291,PFE,stock continue hold narrow gain head final hour wednesday regular trading session boost higher oil price positive job datum apple aapl disney be dow biggest winner nasdaq climb be dow jone industrial average be fractionally higher volume be lower board vs same time tuesday oil stock lead upside stock market today west texas intermediate crude price rebound more barrel energy information administration report barrel rise crude oil supply latest week larger expect decline gasoline supply computer hardware food gold stock lag gold future be nearly ounce economic news private employer add job july accord adp national employment report come well ahead forecast dip job june new hire pfizer pfe again weigh dow drug giant slump average turnover slice day move average fall tuesday quarterly beat apple disney goldman sachs gs lead blue chip advance more ibd paycom software payc surge new high heavy trade report result late tuesday top view human resource software provider also raise quarterly full year revenue guidance share be well extend late april subsequent bounce day line other ibd winner build play eagle material exp acuity brand ayi be verisk analytic vrsk gap sank big volume fall day line buy point datum provider insurance underwriter bank report result miss forecast top bottom line
292,PFE,stock open higher thursday earning report dip weekly jobless claim fed early trade dow industrial open higher new record high nasdaq climb small cap excel early trade russell steel maker coal miner drugmaker construction material stock soar wednesday president elect donald trump victory tuesday presidential election most poll have trump lose ibd tipp poll correctly point trump wednesday hospital solar energy stock alcohol distributor electrical utility be industry see steep loss nasdaq be tracking first weekly gain week nearly enter thursday session gain week advance return index day move average trigger positive change market status thing have settle bit dow pfizer pfe gain earning report come back play kohl kss department store chain report solid third quarter beat confirm prior full year guidance increase share buyback initiative taser international tasr surge third quarter earning meet revenue blow past analyst view report late wednesday company announce chief financial officer dan behrendt plan exit company follow completion year filing taser stock have be work fashion bottom month old consolidation share monster beverage mnst be adjust stock split be effective end trade wednesday hospital operator tenet healthcare thc jump take back piece wednesday sell ibd stock netease nte drop almost open china base online game provider report mixed third quarter result gain revenue not quite meeting analyst target morgan stanley lift price target stock maintain overweight rating stock slide day move average oil future slip pull west texas intermediate back barrel so far week steering first gain week gold edge ounce remain week copper price continue rally gain so far week dollar regain wednesday lose ground vs yen be effectively flat euro bond ease lift year yield basis point highest level january overseas market be busy china shanghai composite book gain hong kong hang seng index japan tokyo nikkei roar back wednesday steep loss sweeping gain europe stock backed away high turn mixed afternoon action cac paris climb hold gain frankfurt dax be ftse london slip economic front weekly jobless claim decline week end nov labor department report drop vs prior week be far analyst estimate only slight decrease week move average drop first decline week treasury department deliver october budget report et st loui federal reserve bank president james bullard speak et related trump agenda likely spur last stock market rally
293,PFE,dow hit time high thursday bullish session major average wednesday particularly russell jump strong volume financial lead charge again dow jone industrial average surge time high rise early outperformer blue chip index include jpmorgan jpm goldman sachs gs pfizer pfe nasdaq composite lose edge lower nasdaq be weigh weakness high profile name netflix nflx amazon amzn facebook fb alphabet googl show loss share ibm ibm gap bank america upgrade tech service giant buy price target share rise financial steel maker coal miner drugmaker construction material stock soar wednesday president elect donald trump victory tuesday presidential election most poll have trump lose ibd tipp poll correctly point trump spdr financial xlf break powerfully base wednesday extend gain thursday rise now extend buy point buy zone go stock market today department store operator be early leader earning report lift macy kohl kss share macy jump kohl soar jwn report close early gainer ibd include western alliance bancorp wal svb financial sivb citizen financial cfg show gain powerful move wednesday downside netease nte slump nearly late wednesday china base online game provider report mixed third quarter result gain revenue not quite meeting analyst target morgan stanley lift price target stock maintain overweight rating related apple fang stock aren join trump rallymacy earning miss badly kohl profit beat latenetflix lockheed ibm upgrade qualcomm downgrade taser pt hike
294,PFE,donald trump stunning drug biotech stock rally wednesday investor sector cheer hillary clinton have be see far more likely crack drug price takeover activity gilead science gild rise stock market today pfizer pfe shot amgen amgn merck mrk mylan lab myl fire epipen price hike leap mylan late wednesday posted earning fall short top bottom line share be fraction clinton have say go excessive drug price hike also likely have favore change government negotiate lower price drugmaker meanwhile republican retain control house congress also ease regular concern drugmaker aren clear be still populist anger price new old treatment trump time signale also go drug price meanwhile justice department reportedly be close filing charge vs mylan other generic drug maker price collusion related stock future well lows trump win white house
295,PFE,act yearn hillary clinton victory week lead election stock market appear relish donald trump presidential victory investor boost sector stock benefit trump presidential priority be also play consider energy health care financial service infrastructure appear be key sector position post gain trump administration bob doll chief equity strategist asset management tell investor election post mortem report doll also run co run fund combine asset integrate oil gas exploration production giant exxon mobil xom be wednesday drugmaker pfizer pfe gap do money center bank morgan stanley ms heavy equipment maker terex tex gap almost big winner appear likely be domestic infrastructure name quant service pwr william co wmb james abate chief investment officer centre asset management manager select equity dhamx nutshell expect spike infrastructure spending quant provide specialty contract other service electric power gas oil pipeline industry william be key owner operator natural gas pipeline storage process facilitiesboth benefit catalyst get boost infrastructure investment well be help trump rollback regulatory burden particularly energy sector energy be big winner trump presidency republican embrace american energy renaissance say mark luschini chief investment officer janney montgomery scott investment banking financial service firm exxon mobil rival chevron cvx be again wednesday add rally begin late october military defense stock also stand benefit trump presidency luschini say general dynamic gd jump wednesday fidelity contrafund fcntx stablemate magellan fmagx add stake general dynamic latest disclosure lockheed martin lmt make product range aircraft homeland security system gap hartford global growth hialx open new position latest disclosure luschini also forecast lighter regulatory environment help profit college say have be devastate current education department rule congressional critic devry education group dv gain nearly wednesday apollo education apol be related buy fidelity customer surge investor spot profit etfs president donald trumpsecond take trump be bullish healthequity jump stock pare gain market adjust trump victory banking stock rise
296,PFE,weak trade europe early earning miss set tone tuesday stock index open moderately lower dow industrial backed nasdaq fall open personal spending rise june commerce department report same pace just consensus projection increase personal income growth be also flat vs view advance inflation remain check pce price index rise estimate gain core price energy food be also line estimate automaker be report july sale session host big name be active stock market moved open bell pfizer pfe drop open report earning massive drug distributor abc power peer cardinal health cah rise less earning report pharmacy chain cvs health cvs climb follow mixed second quarter performance diesel engine builder cummin cmi report result rise fraction cognex cgnx spiked open maker industrial inspection equipment turn board beat second quarter raise third quarter guidance well consensus viewssodastream international soda pop strong second quarter result ireland base drug maker mallinckrodt mnk bolt release solid fiscal third quarter result jump specialty drug brand offset weakness traditional generic drug stronghold salesforce com crm fall announce buy software maker quip stock deal value side integrate device technology idti topple report fiscal first quarter result line expectation late monday conference call management say loss key customer china base huawei technology lower quarterly revenue restaurant stock be take hard hit premarket trade texas roadhouse txrh shed mixed second quarter report late monday say same store sale have slow so far third quarter leaderboard stock have make slow progress buy point end monday extend just buy range chuy holding chuy fall stifel downgrade tex mex chain hold buy slash price target oil rebound more putt west texas intermediate back barrel brent crude just gold rise less ounce dollar swung lower year treasury yield tick basis point overseas china mainland market post thin gain weak trading tuesday hong kong stock exchange remain close due typhoon nida hong kong be expect resume trade wednesday japan tokyo nikkei slump first slip day europe market trade be early lows afternoon action cac paris frankfurt dax
297,PFE,major average be session lows early trade tuesday earning report economic datum remain focal point general motor gm july sale pfizer pfe result be draghunt dow general market nasdaq give back lose dow jone industrial average ease volume nyse nasdaq be tracking higher monday level european index be soft overnight afternoon trading german dax french cac fall selling pressure be muted london ftse be ahead expect stimulus bank england thursday economic news consumer spending rise more expect june key inflation gauge remain tame crude future initially rebound recent heavy selling late morning be more december gold rise ounce dow component exxon mobil xom chevron cvx dip erase earlier gain stock market today enterprise software leader salesforce com crm drop news acquire quip nearly ibd take enterprise software group be filled leader find be ibd stock checkup electronic art ea lose ahead earning report due close electronic art have be get support week move average bullish week end exchange ice report wednesday open share lose set cup shape base ahead result alibaba baba hold relatively well downgrade standpoint research hold buy share lose alibaba earning be due aug open
298,PFE,job report push stock fresh time high busy week tesla motor tsla announce deal buy solarcity scty tech be strong general motor gm ford fuel sell consumer related stock oil price briefly undercut barrel also bank england cut rate revive bond buy major average be little change thursday rally friday strong job report nasdaq climb week record close friday just point july intraday peak rise hit fresh intraday best dow jone industrial average advanced energy stock fall oil undercut early week rally crude re-cover somewhat economy add job july second straight month much better expect hire allay fear economy ism manufacturing index index fall little more forecast still point growth strong hire wage gain support consumer spending housing demand many consumer related firm report stall demand tesla take step closer acquire solarcity special committee independent disinterested solarcity board member evaluate proposal alternative state approval merger deal still need be approve shareholder regulator tesla report earning miss estimate show improvement electric car production production be track support delivery second half reaffirm previous guidance electric car company loss balloon share cent year earlier figure much greater cent loss estimate tesla report gaap revenue miss consensus tesla fall week solarcity lose more ride hail giant uber technology be selling chinese operation apple aapl backed rival didi chux technology capitulate expensive battle foothold china deal have uber swap chinese business stake didi make former foe largest stakeholder didi turn didi become facto ride hail leader china value more uber most recent valuation put north verizon communication vz agree buy fleetmatic fltx vehicle tracking system maker share acquisition expand verizon push web connect vehicle part internet thing ireland base fleetmatic mobile software platform let business manage commercial fleet provide datum vehicle location fuel usage speed mileage verizon fall week drop buy point day move average fleetmatic jump time warner twx st century fox foxa turn mixed result time warner move buy stake netflix nflx rival hulu join current co owner walt disney fox comcast cmcsa steal headline viacom viab report better expect earning revenue do lion gate lgf post surprise profit oil price fall barrel early week follow july tumble opec production climb strong output nigeria iraq saudi arabia continue pump oil record high crude stockpile rise latest week accord energy information administration production dip gasoline supply fall shale producer continental resource clr oasis petroleum oas laredo petroleum lpi lift output forecast oil close week higher bristol myer squibb bmy plunge friday cancer drug opdivo end string clinical trial success failure trial single therapy newly diagnosed lung cancer patient merck mrk have succeed similar patient group trial compete drug keytruda be aim smaller potential market merck stock jump hit highest level june earlier merck be report be talk biogen biib possible biogen buyout be allergan agn further boost biogen stock day partner ionis pharmaceutical ion announce unexpected success clinical trial nusinersen treatment rare spinal disease blockbuster potential biogen rise nearly week meanwhile specialty drugmaker mallinckrodt mnk shire shpg rise respectively beat estimate raise guidance pfizer pfe nordisk nvo regeneron pharmaceutical regn slip beat number issue so so guidance animal health company zoetis zts also rise beating raise general motor gm ford lead auto stock lower report slower sale month july ford project industry sale fall year big gain department store grocery store restaurant airline also decline re-cover somewhat week end sell consumer stock trigger warning broader economy fall business investment homebuilder spending consumer spending rise strong annual rate falter economy not be able match anemic gdp growth texas roadhouse txrh beat earning estimate ep cent revenue growth miss view steakhouse chain also say early same restaurant sale growth have slow outlook come grow worry restaurant sector overall starbucks sbux mcdonald recently report weak comp warning analyst retail sector pizza delivery chain include papa john pzza be buck trend papa john say ep jump cent top view raise guidance rest year also chicken theme el pollo wingstop wing rally result jack box jack soar earning separately monster beverage mnst report weaker expect earning growth top revenue forecast monster beverage leaderboard stock rally friday hit new high ibd take investor look growth stock clear proper buy point ibd leaderboard be premium service provide detailed chart analysis lead stock see other top rate growth name be buy point bank england cut interest rate quarter point expect economy slow reaction brexit vote policymaker go further revive government bond purchase announce boe buy corporate debt also signale rate cut be likely year end boe gov mark carney say opposed negative rate helicopter money martin marietta material mlm make crushed stone sand other aggregate used construction fall short second quarter forecast rival aggregate supplier vulcan material vmc also badly miss related ready mix concrete market concrete uscr report ep plunge cent miss cent revenue rise also miss blame bad weather say expect better result second half martin marietta ceo nye cite record record rainfall attendant effect many key market share trio fall hard earning miss re-cover lose ground end week delta air line dal report decrease passenger unit revenue july say drop be line expectation investor appear worry tone result set third quarter delta say key metric operate efficiency fall german carrier lufthansa warn terror attack economic uncertainty affect travel also hurt sector delta stock fall american airline aal jetblue jblu also sank unite airline ual southwest luv close week higher aetna aet humana hum wellcare wcg put estimate beating quarterly result week however aetna say abandon expansion plan obamacare exchange humana recently say exit most obamacare exchange market next year follow unitedhealth unh aetna humana try overcome antitrust objection merger safety security concern person mind wake series officer involved shooting polouse officer polouse unarmed civilian sale sturm ruger rgr firearm grow second quarter rise earning climb share fbi report firearm background check see indicator future gun sale rise july june be july share fall day earning ruger ceo say be step close week only meanwhile taser international tasr say ep fall cent share cent year beat forecast cent share sale pop easily top view stun gun maker say booking axon body camera soar taser stock rise hit year high
299,PFE,stock index keep narrow range wednesday afternoon market calm previous session sizable loss nasdaq composite rise dow jone industrial average be nearly flat however small cap russell jogged ahead volume stock market today be run lower vs tuesday pace ibd proxy top stock paycom software payc beat street consensus number earning revenue company report tuesday close paycom raise guidance quarterly full year revenue paycom thrust higher huge volume paycom provide human resource software blue chip winner lead loser ratio big volume mover dow be pfizer pfe heavy volume undercut day line walt disney average trade west texas intermediate crude oil future pop haul barrel price barrel comex gold fall world market european bank stock rebound improve earning india upper house parliament approve national sale tax good service tax replace more dozen other taxe constitutional amendment have more hurdle clear business group praise move simplify taxe
300,PFE,stock moved worst intraday level tuesday head final hour regular trading session only dow stock be higher apple aapl pfizer pfe continue pressure blue chip index nasdaq be shed dow jone industrial average give volume be higher board vs same time monday pfizer lead dow loser loss more average volume quarterly beat share jump year high monday be still handle buy point clear july drug giant have still not say split company go forward suppose make announcement end year apple also weigh blue chip index stock be trading best level more month appear be run resistance level iphone maker last week report profit sale decline second straight quarter result beat forecast share rally week retail airline apparel stock be biggest loser stock market today tire maker drugstore software stock lead scant upside cvs health cvs gap surge regain day day line fast turnover drugstore giant report mixed result earning top view sale miss cvs narrow full year ep guidance earlier outlook new midpoint be consensus estimate trex trex gap soar massive volume month high report earning sale top view expeditor international expd also break clear cup handle buy point busy trade logistic service provider report profit beat estimate revenue miss forecast ibd only stock be buck downtrend lead grubhub grub share online restaurant order platform provider climb hefty trade be highest level year downside be lead discount retailer well broadsoft bsft ellie mae elli more
301,PFE,stock rally big gain head lunch hour wednesday market continue digest president elect donald trump surprise victory dow jone industrial average run ahead rise nasdaq add volume be higher board vs same time tuesday dow future have plunge much point wednesday night steel medical drug stock lead upside stock market today hospital solar automaker underperform west texas intermediate crude price rise barrel gold future be ounce merck mrk pfizer pfe caterpillar cat be top gainer dow rally north apple aapl be have pare loss nearly stock be still day move average breach nov just shy cup handle buy point first clear iphone maker well other tech company include microsoft msft cisco system csco benefit donald trump cash repatriation proposal congress permit cisco be microsoft be fractionally lower biotechs have be target presidential candidate hillary clinton high pricing jump amphastar pharmaceutical amph soar surge past day line triple average trade share be now well extend past cup handle buy point initially clear aug injectable drugmaker tuesday report adjust earning cent share top view reverse loss same year quarter other biotechs celgene celg hold gain earlier spiking much week high incyte incy rise biogen biib leap related apple microsoft cisco eye trump overseas cash tax plan
302,PFE,stock open lower wednesday commodity currency market react tuesday come victory donald trump race presidency dow industrial rise nasdaq nasdaq future have fall overnight dow future sank more point lowsdrugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer pfe leap mylan myl merck mrk rise eli lilly lly add more early trade hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid lower universal health service uhs drop nearly coal mining stock moved generally higher arch coal arch soar consol energy cnx alliance holding ahgp show gain cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc vault martin marietta mlm martin marietta top buy point cup base vulcan also break clear buy point earning news tripadvisor trip swoon report third quarter earning narrowly top view revenue gain stop far short analyst expectation fragrance maker coty coty plunge miss analyst fiscal first quarter revenue earning target wide margin gopro gpro tank handful analyst downgrade stock news recall karma drone due battery failure issue ibd list eagle material exp pop gain stock top buy point cup base ibd stock royal gold rgld rumble gold price surge early wednesday gold miner be climb right side possible base pattern find support week move average ibd stock arista network anet fall inphi iphi fall fractionally momo momo rise more international market trade lower election news tokyo stock be hardest hit drop worst single day loss britain june brexit vote exporter market be session biggest loser lead toyota motor tm honda motor hmc nissan motor nsany china hong kong hang seng index shed shanghai composite decline europe cac paris frankfurt dax trim deep early loss turn fractionally higher afternoon trade london ftse rally climb commodity be widely mixed early action oil price hold mostly steady west texas intermediate fraction hold just barrel metal moved broadly higher gold jump almost ounce silver copper be also strongly dollar bounce back initial dive trading moderately lower vs euro pound yen surge bond be sharply lower year yield basis point stock market today show light economic calendar september wholesale inventory datum expect commerce department et energy information administration report weekly oil stockpile number et minneapoli federal reserve bank chairman neel kashkari be due speak et related time warner stock fall trump victorydrug stock rally relief clinton didn white house
303,PFE,stock turn mixed soft start wednesday wall street digest news trump plunge more point overnight dow jone industrial average be mostly unchanged nasdaq lose ease early leader dow include pfizer pfe caterpillar cat merck mrk jpmorgan jpm goldman sachs gs also outperformed ibd take election result be describe shocking upset ibd tipp presidential tracking poll ultimately have right year treasury yield soar basis point december gold rally ounce drugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer industry group mallinckrodt mnk shire shpg allergan agn lead gain more hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid universal health service uhs drop coal mining stock soar consol energy csx arch coal arch add cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc martin marietta mlm higher martin marietta gap cup shape base buy point vulcan gap cup shape base buy point stock be still buy range early trading early gainer ibd include healthequity hqy eagle material exp gain pra health science prah morgan stanley ms add related clinton vs trump ibd tipp presidential election tracking pollafter initial fall stock rally trump victory agenda
304,PFE,decent case be make investor fear donald trump winning white house turn be good deal reality least intermediate term stock index crash overnight odd december federal reserve hike tumble initial modest sell open major average have reversed solid gain soar bond yield overnight reaction trump look vindicate economist predict market fall trump win once consider trump term priority challenge work congress even gop congress restrain filibuster senate agenda look more market friendly unfriendly priority trump domestic front be likely be rev growth infrastructure spending cut corporate tax rate offer multinational chance repatriate overseas profit lower tax rate talk spending infrastructure double hillary clinton propose spend candidate talk potential public private partnership focus infrastructure basic resource sector be best performer today write alastair george chief strategist edison investment research london nucor nue steel dynamic stld surge stock market today sure respectively share gold miner newmont mining nem initially spiked trump victory fuel safe haven bid dollar plunge stock dollar rebound gold erased big gain newmont trade higher ibd take gold price be rise sharply wednesday give big boost newmont other gold mining stock be technical turn point biotech drug stock such pfizer pfe gilead science gild rally relief hillary clinton not be president senate remain gop hand clinton have vow crack excessive price increase notably older treatment also likely have push government negotiate drug price lower trump victory mean regulatory relief super regional bank dodd frank regulation go step further expect pave way round acquisition also ease pressure too big fail bank explain well fargo wfc pop intraday recover overnight sell well fargo also see less political pressure fradualent account scandal expect positive snapback move once investor digest result factor more favorable regulatory environment financial sector write brian gardner head washington research keefe bruyette wood bank have be rise part due expectation fed hike stronger wage growth tighter labor market fed decide pause hike trump election do send financial shock wave globe far clear expect immediate market pullback fear then pause say brad mcmillan chief investment officer commonwealth financial network mr trump be able reduce uncertainty policy intend pursue be quite possible market recover economic fundamental remain sound trump be likely president obama overtime rule due take effect december guarantee time half pay salaried worker earn twice current level wal mart wmt already raise pay assistant store manager effective september avoid be liable overtime many employer have be slower adopt change congress aim delay carrol restaurant group tast burger king location make restaurant brand international qsr chain largest franchisee have say ll effectively demote manager make punch clock obamacare employer mandate be likely history meaning modest wage employer longer be fine fail offer health insurance worker clocking least hour week retailer trump bring relief restaurant chain mcdonald mcd be be squeeze competition compensation hike contribute record gap cost fast food eating be market scared trump threat impose tariff company ford motor send car mexico walk away nafta crack unauthorized immigrant be economist have say agenda hurt economy trump be start presidency labele china currency manipulator impose tariff start trade war china reciprocate target sale apple aapl general motor gm microsoft msft china face slower growth unsustainable build debt easily spark bout financial market turmoil be see past january trump proceed trade be most important early decision good news be trump isn campaigning anymore be especially insular campaign surround pro growth economic advisor now direct contact top business leader trump be likely act deliberately not rashly mean open talk country move trade relation forward set intermediate term goal measure progress seem consistent trump victory speech word want tell world community always put america interest first deal fairly everyone everyone person other nation seek common ground not hostility partnership not conflict trump seem unlikely back pledge build wall border mexico have more symbolic economic effect rhetoric have shift crack unauthorized immigrant be violent criminal be fewer imply related drug stock rally relief clinton didn white housetrump win fed hike still treasury yield bank stock soarat time warner fall trump victory be merger doubt overtime rule fallout fast food manager tell punch clockfbi reveal more evidence stock fall trump win
305,PFE,stock be nearly flat morning trade friday market digest mixed report payroll nasdaq rise small cap russell rebound almost blue chip dow jone industrial average slip less volume stock market today be run nasdaq nyse starbucks sbux begin session drop then reversed gain volume be very heavy company report quarterly result thursday close revenue top expectation less earning checked adjust estimate accord william neil co datum other source adjust earning differently lead earning beat starbucks same store sale be unimpressive bull like result mobile business transaction come advance mobile order ibd loser lead winner ratio loser own big cap ratio blue chip dow winner loser be evenly split drugmaker pfizer pfe lead gain chevron cvx be biggest loser dow oil stock drop west texas intermediate crude oil fall barrel economic news nonfarm payroll october rolled be expect however september number be revise upward be better expect
306,PFE,regeneron pharmaceutical regn stock bound friday cent earning beat share be largely muzzle pending court decision pit regeneron sanofi sny biotech amgen amgn stock market today regeneron stock rise earlier rise much share be year ibd company medical biom biotech industry group have fall volatile election season high high drug price controversy several disruptor rout regeneron stock rbc analyst adnan butt write research note regeneron sanofi be await delaware court decision amgen file lawsuit say cholesterol drug praluent violate patent repatha be pcsk inhibitor pfizer pfe just end development similar drug suit amgen be ask praluent be take shelve ibd take spdr biotech etf jump regeneron earning beat alexion pharmaceutical continue wave get foot wet etfs visit etfs fund page good datum rival ophthotech opht novartis nvs be work phase trial fovista also be painful regeneron butt note fovista drug combat wet age related macular degeneration amd compete regeneron bread butter drug eylea eylea pull sale vs year earlier quarter edge view regeneron raise low end eylea guidance now see growth be sale praluent come vs amgen repatha be line consensus butt write year consensus expect praluent sale sanofi reimbursement praluent be expect dip high end guidance early friday regeneron post earning share ex item sale respectively vs year earlier quarter ep top consensus analyst poll thomson reuter sale miss expectation update guidance imply regeneron end evercore analyst john scottus estimate report be midpoint related align incyte grubhub best stock play goldman sachs
307,PFE,share drug giant pfizer pfe fall tuesday company say end development cholesterol lower drug project be blockbuster reduce earning outlook current quarter post ep just miss wall street expectation pfizer stock fall stock market today member dow jone industrial be trading nearly month low touch year high aug cease work injection drug call bococizumab be unexpected company say prove have unexpected side effect be become less effective wall street have modeled peak annual sale bococizumab evercore isi analyst john scottus say note client pfe be clear do not see attenuation benefit competitive datum amgen amgn regeneron regn write problem appear be bococizumab specific scottus say ibd take pfizer megadeal buy allergan go bust april takeover time warner go same direction drugmaker say revenue rise year earlier quarter earning share inched cent revenue meet view ep miss penny accord evercore isi analyst john scottus pfizer now guide ep earlier guidance sale vs earlier guidance pfizer attribute miss higher expect cog cost good sell tie foreign exchange rate scottus say sale breast cancer drug ibrance be marginally consensus scottus say prevnar deliver small beat sale prevnar pneumococcal conjugate vaccine miss forecast innovative health business execute strongly latest product launch recent acquisition medivation anacor be provide new term opportunity potentially drive incremental growth business product pipeline continue mature pfizer ceo ian read say earning release see business highly focuse therapeutic area be best position deliver value patient maintain overall high level financial flexibility discipline be strong position support strategic initiative business remain opportunistic business development activity addition continue actively manage cost structure august pfizer announce agreement acquire medivation maker prostate cancer drug xtandi come new york base pfizer ireland base allergan agn april call plan merger have be industry largest ever regulator set roadblock so call tax inversion merger company look set headquarters lower tax region such ireland september pfizer say not split separate company move have mulled several year have be expect separate essential health business consist older patent medication innovative health business be dedicate newer drug related surprise twist pfizer win split uplilly abbvie lead ranking pfizer challenged
308,PFE,electronic art ea sturm ruger rgr apple aapl supplier qorvo qrvo pfizer pfe fitbit fit be slate report quarterly result tuesday automaker also announce monthly sale figure electronic art wall street expect video game maker report fiscal first quarter cent share loss sale fall console upgrade have help gaming
309,PFE,drug industry earning season launch week biggest name johnson johnson jnj novartis nvs biogen biib broad portfolio give investor preview business general be do big kahuna johnson johnson tuesday morning be expect report year year sale growth modest decline ep share stock hit record high intraday friday be year credit strong pharma trend flight safety yield write rbc capital market analyst glenn novarro july preview note analyst be expect good quarter pharma business novarro write base prescription datum im health im biggest drug remicade imbruvica invokana xarelto beat consensus credit suisse analyst vamil divan july preview lower estimate invokana raise remicade xarelto say be concern entry cheaper biosimilar version remicade later year pfizer pfe remicade biosimilar be approve fda april ibd take most drug stock have take pound year have prove be exception last month stock market today column highlighted standout defensive dow stock only go higher then biosimilar also probably be topic discussion novartis conference call also tuesday morning wednesday swiss drug giant biosimilar version amgen amgn enbrel win unanimous back fda advisory panel make likely be novartis second biosimilar launch version amgen neupogen enter market last year investor also likely be interested performance novartis newest potential blockbuster drug cosentyx psoriasis entresto heart failure be first class drug be approve last year entresto so far have miss expectation cosentyx have enjoy stronger uptake cosentyx also face new competition however eli lilly lly launch drug same class call taltz monday credit suisse analyst cut ep estimate launch drug appear be cost more expect however write long term outlook drug look good estimate peak annual entresto sale peak cosentyx estimate have be run same analyst expect novartis financial suffer loss patent protection leukemia drug gleevec sale be see fall earning share novartis stock be slowly recover long slide july peak april low share find support day line recent week have moved just day close friday thursday open biogen be expect report quarter stronger growth lower expectation multiple sclerosis franchise have miss expectation last several report nonetheless rbc analyst michael yee see potential upside ms drug tecfidera expect biogen raise ep guidance current ep more consensus depend expense cut represent significant improvement last year analyst estimate earning grow share revenue gain biogen stock crash last july have be trading still slide day line most month biogen do close day line friday aside brief late early june stint biogen have not be day nearly year
310,PFE,bristol myer squibb bmy stock crash year low monday competitor merck mrk unveil phase result show lung cancer drug keytruda be twice effective chemotherapy spark stock close bell stock market today bristol myer squibb stock plunge end trading merck stock other hand lift much year high end monday trading share briefly hit entry point flat base add gain january new buy be risky current volatile market environment ibd take merck stock be buy zone far alone check ibd stock buy zone find player be recommend bet share ramp merck presentation european society medical oncology conference copenhagen merck unveil result phase testing keytruda drug treat small cell lung cancer keytruda alone extend progression free survival month vs month chemotherapy lung cancer patient express specific type protein merck say merck also combine keytruda eli lilly lly chemo drug alimta study patient respond combination vs patient receive chemo median progression free survival be month longer combo bristol myer squibb nivolumab rival treatment lung cancer show virtually benefit evercore isi analyst john scottus write research report left investor scratch head say credit suisse analyst vamil divan expect merck take major leadership position lung tumor market vs bristol myer astrazeneca azn roche rhhby say roche pile pressure tecentriq tecentriq have show overall survival benefit second line lung cancer regardless protein expression write estimate peak sale probability success rbc analyst michael yee expect celgene celg fly potential chemo combo merck test keytruda see celgene grow revenue only first line lung cancer patient be treat chemo combo other news conference credit suisse divan expect novartis nvs face pressure post esmo novartis drug combat metastatic breast cancer be effective pfizer pfe ibrance have serious safety concern efficacy appear line ibrance safety observation hy law risk fatal drug induced liver injury qtc prolongation mild cardiac arrhythmia put drug disadvantage pfizer ibrance eli lilly abemaciclib be approve write novartis stock lose end monday trade bristol myer eli lilly astrazeneca roche pfizer novartis merck be ibd ethical drug industry group group have be slumping rank related celgene trio new drug tack rbcamgen biogen gilead spike va pricing skirt california measureroche drug score lung cancer challenge bristol myer
311,PFE,eli lilly lly aim take bite animal health market buy unit germany boehringer ingelheim be acquire sanofi sny animal health business zoetis zts spun pfizer pfe be animal health company boehringer likely become evercore isi analyst john scottus say email client wednesday lilly elanco unit get bigger lilly stock rise fraction stock market today zoetis stock fall fraction zoetis stock have be form flat base possible buy point lilly agree pay boehringer vermedica unit include common vaccine dog cat other animal well iowa manufacturing site include common vaccine bordetella parvovirus rabies zoetis sell rabies other vaccine cat dog scottus say speak lilly representative say boehringer vaccine portfolio deal expect close early next year generate annual revenue elanco total sale elanco account lilly revenue lilly buy animal health division novartis nvs early scottus say lilly indicated maintain operate profit margin target high last year say zoetis have target operate margin currently couple robust food animal portfolio addition further strengthen elanco position global animal health business lilly ceo john lechleiter say company press release boehringer say june sell vermedica unit antitrust regulator review acquisition sanofi animal health business ibd take lilly zoetis be ibd company medical ethical drug group rank just group track still group zoetis ty depome highest composite rating cr be broad measure performance look key metric such earning sale growth be good general target company cr rating related zoetis company radar janus fund managerslilly upgrade potential alzheimer drug
312,PFE,biggest breakup drug industry history isn happen pfizer pfe win split half year pharmaceutical giant call extensive evaluation decision follow collapse pfizer attempt merger allergan agn year deal have shift company tax address overseas bulk unit split recent month new york base pfizer have signale stay together operate separate autonomous unit pfizer be already access many potential benefit split sharper focus increase accountability greater sense urgency also retain operational strength efficiency financial flexibility operate single company chief executive officer ian read say statement question now be next biggest drugmaker pfizer statement say be poise grow business drugmaker most recently agree deal acquire medivation mdvn cancer treatment investor have be wait decision goldman sachs analyst suggest company soon pfizer begin reorganize business eventually become distinct unit cash generate business older patent medicine growth focuse operation product dependent more recent research development ibd take biotech stock have be healthier stock recent week takeover talk have be key factor amgen biogen be most likely buyer investor see slew potential takeover target share fall percent et stock market today pfizer stock have gain percent march drugmaker indicated meeting goldman sachs analyst be willing consider breakup comparable percent increase standard poor index same period well percent jump health care sector index decision doesn affect financial guidance pfizer reaffirm unit have deliver solid year year performance course past year demonstrate ability compete standalone basis pfizer say
313,PFE,food drug administration have message doctor money re take pharmaceutical company be clouding judgment research site drug behemoth pfizer pfe have paid doctor least speaking consult other fee report sunnier result smoking cessation drug chantix fda disclose monday site doctor study drug possible link suicide risk other behavior change report fewer side effect location colleague accept lower payment fda finding part agency review pfizer proposal drop most severe consumer warning drug label demonstrate federal government concern influence consult speaking fee medical decision president obama health law require drugmaker report such payment post public database law follow year effort senator charle grassley iowa republican make drugmaker publicly disclose financial ty doctor james rusnak chief development officer pfizer cardiovascular metabolic unit say chantix study be blind meaning doctor help conduct didn know patient be get drug placebo doctor have downplay side effect have do so board thus wouldn affect final outcome say idea blind study be remove bias rusnak say interview even have payment even payment bias investigator favor drug investigator have idea be drug only guess ibd take pfizer share hit time intraday high aug subsequently drop earning now trading shire shpg lead drug group now pfizer be rank eighth ibd get stock checkup pfizer click here diana zuckerman president national center health research part coalition consumer other group petition keep warning chantix say fda staff report show doesn trust integrity datum fda clearly seem be say trust result study way be code way be analyze way conflict interest zuckerman say outside expert be schedule meet wednesday advise fda necessity warning chantix pill black box label agency strongest currently cite risk serious event such suicidal thought behavior chantix generate sale last year accord pfizer fda staff report agency offer unusually point assessment payment relationship doctor finding study site agency report doctor get many separate honorarium speaking engagement consult fee site doctor receive more pfizer accord fda only patient have already be diagnosed psychiatric disorder be report have side effect such anxiety agitation hostility suicidal thought study location physician receive less money none patient report such problem agency wasn immediately able provide exact detail payment be fda staff report doesn name doctor receive payment fda routinely reviews financial involvement investigator clinical trial site application michael felberbaum spokesman agency say email case case basis agency do additional analysis evaluate be impact study outcome
314,PFE,dow jone industrial average give start week president trump immigration policy other move worry investor moved back level friday job report apple aapl boom return earning growth investor didn care facebook fb amazon amzn result guidance unite parcel service up be struggle commerce boom charle schwab schw launch new stock trading pricing war dow jone industrial average fall back key level regain friday january job report trump move ease dodd frank other financial regulation dow fall week nasdaq rise end week record high trump immigration order create conflict tech firm trading partner earning be mixed bag cboe volatility index vix rally extreme level not much related dow component apple earn share sale quarter end dec be better expect marked return growth straight quarters year year decline apple current quarter guidance be conservative usual apple say iphone demand outstripped supply service revenue apple share rise nearly week hit month high related advanced micro device amd report smaller expect loss forecast sale bullish outlook share shot nearly hit year high nvidia nvda compete amd graphic other market jump ahead earning come week apple chip supplier cirrus logic crus qorvo qrvo top quarterly view give bearish guidance stock sell thursday related facebook ep soar revenue rise easily beating view decelerate second straight quarter mobile ad account ad revenue facebook reiterate ad revenue growth rate come meaningfully deliberate move avoid ad saturation now see heavy expense growth step hire facebook fall week snap parent snapchat file publicly upcoming ipo snap report soar revenue growth also slow user growth facebook instagram imitate key snapchat feature snap use ticker snap win sell voting share related amazon top earning forecast revenue revenue outlook be lower expect amazon web service cloud compute unit generate most commerce giant profit report revenue gain forecast aw be feel pressure rival cloud effort alphabet googl microsoft msft amazon share fall nearly friday undercut recent buy point related amazon result miss revenue beat ep stock fallsunited parcel service up report modest earning revenue growth holiday fourth quarter fall short forecast up also guide profit target lower cite impact strong dollar up see significant shift mix lower revenue product residential delivery accounting total package volume up ceo say result indicate up quicken pace investment network shift handle increase commerce meanwhile amazon announce set air hub cincinnatus northern kentucky international airport seek lessen dependence up fedex fdx up share plunge fedex lose related mastercard edge past earning view revenue be light share have be buy zone pull back nearly even regain day friday larger rival visa late thursday report better expect quarterly result strong payment growth visa rise friday push dow stock past buy point record high related federal reserve left interest rate alone give indication policymaker be hurry raise rate add strong job january well estimate slim wage gain ease fear economy be overheat ism manufacturing index rise fresh year high january related exxon mobil xom report adjust ep view oil major plan boost capital spending activity heat royal dutch shell rdsa say cut spending year report ep view conocophillip cop say plan raise spending energy information administration say crude stockpile rise barrel analyst expect russia opec seem be comply promise output cut accord reuter datum related auto sale decline december longtime high even automaker offer hefty incentive general motor gm ford fiat chrysler fcau report year year decline only gm miss forecast datum offer new evidence auto demand have peaked related charle schwab schw cut stock etf commission trade lower fidelity td ameritrade amtd trade etfc schwab fall thursday td ameritrade trade rely more stock trade schwab tumble interactive broker ibkr charge cent share trade sank related president trump meeting tuesday ceo exec celgene celg eli lilly lly johnson johnson jnj merck mrk novartis nvs say drug price be astronomical reiterate aim bring drug price also urge drugmaker manufacture also promise deregulate industry cut taxe drug stock pop day response related drugmaker eli lilly pfizer pfe disappoint tuesday earning lag consensus sale top meet respectively roche rhhby sale be light revenue earning rise mid single digit merck follow thursday line sale earning include time defer revenue amgen amgn late thursday report better expect earning say ldl cholesterol fighter reduce cardiovascular risk study related miss merger deadline expire walgreen boot alliance wba rite aid rad extend agreement end date july walgreen cut takeover price share share depend many rite aid store have be divest order new term get regulatory walgreen fall rite aid fall concern ftc win approve deal fred have agreement buy rite aid store edge lower related armour uaa miss estimate top bottom ep fall penny cent sale rise revenue guidance be light athletic apparel brand cfo be step personal reason share tumble year low related
315,PFE,drugmaker roche rhhby merck mrk pfizer pfe likely disappoint guidance abbvie abbv stock remain top pick jeffery analyst jeffrey holford say friday research report rundown ahead earning stock market today abbvie stock fall ibd company medical ethical drug industry group fall fall day move average week abbvie be face pressure amgen amgn biotech market cap prep deploy humira biosimilar abbvie humira world top selling drug be used treat array disease include rheumatoid arthritis psoriatic arthritis crohn disease ulcerative colitis abbvie patent protect dose scheme humira be set be deliberate court feb patent administer milligram antibody day be set expire june patent likely be upheld bar entrant first filer amgen holford say ibd take low holford totem pole merck step eli lilly biogen deliver new drug approval else curry fda support head ibd industry theme more see patent block patent potential humira biosimilar give be assume biosimilar be develop be dose same concentration frequency write worst case scenario amgen launch humira biosimilar mid assume first filer doesn launch risk holford see share downside humira biosimilar launch give consensus expectation launch abbvie holford list novartis nvs bristol myer squibb bmy astrazeneca azn strong pick pfizer merck nordisk sanofi sny be opposite end holford list expect disappointing guidance nearly big cap drugmaker expect disappointing guidance majority eu large cap pharma roche novartis pfizer astrazeneca likely disappointing revenue guidance pfizer astrazeneca merck roche also expect disappoint earning share guidance write upcoming catalyst include datum roche aphinity trial examine perjeta regimen positive breast cancer holford lean positive outcome sense high degree uncertainty write merck keytruda combination eli lilly lly alimta be also pique investor interest combination immunotherapy chemotherapy be grant priority review first line small cell lung cancer month holford note fda accept application small datum set therefore combo be unlikely see wide use also see consensus too bullish combo undervalue immunotherapy combination like bristol myer astrazeneca first line small cell lung cancer related gilead outlook hamstrung hep rbc bullish amgen biogenbristol myer dife opdivo setback get keytruda royaltiesfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
316,PFE,stock market moved lower reach new intraday lows head midday trading market weakness persist nasdaq fall respectively dow jone industrial average drop call recent market rally question volume be lighter nyse nasdaq vs same time monday medical sector bolster dow merck mrk pfizer pfe be few blue chip gainer midpoint pfizer full year revenue outlook come street expectation president trump continue call drugmaker manufacture curb rise price intel intc be big loser fall stock be trading cup handle buy point financial continue pullback stock market today goldman sachs gs break day line rise volume stock fall today action be sell signal share close level financial service company be big beneficiary rise interest rate have be lead stock stock be unable recover negative price action portend more weakness financial sector come week charle schwab schw fall stock remain well day line close eye shift apple aapl report quarterly earning close today stock edge lower remain cup handle entry tesla tsla re-cover monday sell gain electric car manufacturer be add handle long cup shape base amazon amzn facebook fb continue trade lower ahead earning release later week amazon commerce giant be trading just cup handle buy point report earning thursday market close social medium company be less cup handle entry facebook report earning wednesday close bell armour ua plunge follow earning miss open bell news cfo depart company kevin plank ceo armour say numerous challenge disruption north american retail temper fourth quarter result ibd list lead growth stock continue show weakness early trading monday sell bottom perform ibd stock be member chip sector advanced energy industry aeis have particularly notable price action surpass earning sale estimate late monday stock gap open now stock be bearish downside reversal related armour earning sale miss cfo exit stock diveswhat look facebook report earningspfizer report lag ep rebound trump lilly merck sit trump call manufacture
317,PFE,here investing action plan tuesday need know investor come day attention focus dow industrial component apple aapl report earning close bell be many notable report include mastercard electronic art ea apple be buy range advanced micro device amd exxon
318,PFE,confirm market uptrend be help cause many stock include dividend leader thursday screen power management firm eaton etn isn widely know name show relative strength try clear buy point share reversed higher heavy volume week end july result bullish support week eaton
319,PFE,fda panel unanimously endorse amgen amgn biosimilar version abbvie abbv blockbuster immunology drug humira late tuesday make approval likely not clear launch member panel endorse approve amgen abp condition apply include rheumatoid arthritis psoriasis irritable bowel disease ulcerative colitis amgen do not apply most recent indication humira have acquire include pediatric crohn disease uveitis re still cover regulatory exclusivity essentially panel find be meaningful clinical difference abp humira drug be not identical humira be currently world best selling drug take worldwide last year so abbvie have be vigorously defend intellectual property amgen other challenger court therefore even fda approve abp deadline amgen not take risk launch abbvie prevail trial humira be patent protected amgen have be face biosimilar competition drug europe last summer novartis nvs sandoz unit launch zarxio version amgen neupogen be first biosimilar drug be clear wednesday novartis go fda panel defend biosimilar version enbrel amgen flagship rheumatoid arthritis drug analyst have expect approval amgen novartis biosimilar give broad support pfizer pfe celltrion biosimilar remicade receive fda earlier year datum have see biosimilar expect similar level support biosimilar next week ongoing legal process likely be better determinant see biosimilar actually enter market write credit suisse analyst vamil divan research note last wednesday
320,PFE,drugmaker amusement park operator be lead stock make new high thursday japanese messaging app make debut nyse pfizer pfe gain clear nearly yearlong pattern share be still buy range handle entry heavy volume have yet come play drug giant
321,PFE,buzz biotechs amp notch past week kite pharma kite pharmaceutical gwph sock away double digit gain kite soar massive trade tuesday announce kte treatment show complete remission rate patient most common form hodgkin lymphoma stock quickly backed end
322,PFE,stock market remain pressure early afternoon trading monday rise oil price pfizer pfe lag dow fall company decide not split company end year speculation dow jone industrial average nasdaq composite show loss volume nyse nasdaq be tracking slightly lower friday level west texas intermediate crude oil future november delivery add barrel international energy forum start today run wednesday algier oil trader eye informal opec meeting event curb output stabilize price remain focal point monday price action be reminder difficult market be even index sit high nasdaq gap time high thursday same day gap day move average be back day line stock market today acacia communication acia take hit ibd fall news share offer china base name be also weak netease nte vipshop vip momo momo new oriental education edu show loss range ibd take fiber optic name acacia have be do well recent month look other lead growth stock group check ibd stock checkup wesson swhc slump nearly company bid army handgun contract be reject bright spot be few far monday leaderboard member line ln extend gain soar last week solid volume share rise clear aggressive entry last week be vie conventional entry meanwhile couple name featured potential option play latest earning preview column be lower still hold support ahead earning report tuesday open factset research fds lose ihs markit info give related pfizer win split end year wesson fall army reject handgun bidacacia communication up guidance tumble stock offer
323,PFE,unexpected twist pfizer pfe decide splitting monday end year analyst speculation have be biggest corporate breakup history decision follow extensive evaluation speculation begin goldman sachs suggestion pfizer consider breakup accord bloomberg follow year pfizer begin reorganize become essential health innovative health business unit pfizer stock close stock market today tug ibd company medical ethical drug industry group fall pfizer market cap make second largest company group value roche rhhby pfizer be trading month low touch share hit year high aug ibd take biotech fodder be head just recent story ibd industry theme column new tax rule april force pfizer scrap merger allergan agn new rule pfizer wouldn have be allow shift tax address overseas do so have help pfizer bulk ahead expect breakup pfizer ceo ian read say monday statement pfizer be already reap benefit split sharper focus increase accountability greater sense urgency also retain operational strength efficiency financial flexibility operate single company innovative health essential health unit have deliver year solid year year performance pfizer say august earning announcement pfizer say innovative health sale rise year year essential health grow overall pfizer report growth sale first explore trap value question several year market valuation other company suggest business be worth more separate company be together single company say pfizer cfo frank amelio statement then gap have close say essential health be focuse older patent medication innovative health drife spending growth oriented product pfizer expect duo become market leader end acquire anacor innovative unit recently add hospira innopharma essential unit work close acquisition medivation mdvn astrazeneca azn small molecule infective business pfizer reiterate outlook plan begin give guidance indirect expense incur business unit related axovant confidence not sway rival alzheimer drug failsliver disease get attention several major biotech companiesaerie pharmaceutical skyrocket eye drug news
324,PFE,here weekly investing action plan need know investor come week tech darling facebook fb apple aapl amazon amzn report earning federal reserve policymaker mull interest rate again fresh job datum provide new clue much inflationary pressure economy be see oil major exxon mobil xom royal
325,PFE,stock market push time high close tuesday broad base rally capped lead rise russell nasdaq rally reach new time high dow jone industrial average follow gain move blue chip index striking distance volume be tracking much higher nyse nasdaq accord preliminary figure dupont dd lead industrial higher report earning beat monday market close miss revenue estimate stock gain reach new week high downside verizon communication vz drop follow quarterly earning release alibaba baba gain be much premarket hour chinese commerce giant report blowout earning sale earlier morning stock be build right side base miner construction stock be act particularly well stock market today freeport mcmoran fcx leaderboard member soar gapping cup handle buy point see daily chart copper mining company report quarterly earning wednesday market open mastec mtz surge nearly reclaim day line have be fight support last several week stock be now away short cup shape base entry meanwhile lag sector be medical merck mrk pfizer pfe johnson johnson jnj fall johnson johnson provide cautious outlook earning revenue fall short street estimate lead growth stock ibd be very positive close only stock red broadcom avgo continue recent dominance be lead stock ibd tack recent gain stock be now extend flat base entry downside healthequity hqy be volatile close minor change lead health saving account provider be now top buy range stock break flat base entry surge volume stock be initiate overweight rating keybanc monday close hawaiian holding steel dynamic stld other report quarterly result close hawaiian holding parent hawaiian airline meet quarterly earning estimate be ep surpass revenue estimate share fall almost hour steel dynamic steel producer have not announce be estimate report ep cent intuitive surgical isrg top earning sale estimate share rise texas instrument txn beat expectation top bottom line estimate share edge lower seagate stx quarterly earning exceed street view earning sale figure share gain additional rise regular market hour related alibaba crush earning estimate raise guidancej hcv dip virtually mirror gilead view air steel dynamic texas instrument report closeseagate easily beat bottom line sale also top estimate
326,PFE,president elect donald trump day take office say drugmaker be get away murder slam share drugmaker biotechs such pfizer pfe amgen amgn biogen biib meanwhile first press conference month say costly lockheed martin lmt fighter jet show need more competitive bidding also praise automaker investment trump say wednesday new bidding procedure be need drug price signale support new legislation traditionally backed democrat opposed republican hit sector profit drug industry have be disastrous say re leave left right also criticize industry heavy lobbying re go save billion dollar period time trump have previously signale drug industry be sight say shortly presidential election be go bring drug price amgen share fall close stock market today nearly decline come trump remark biotech etf ibb ibb tumble biogen lose pfizer fall overall stock market change direction several time volatile trade follow trump remark fall initially dow jone industrial average end climb same be true other major index nasdaq finished black gain meanwhile lockheed martin fall intraday trump say have competition fighter jet bring cost significantly trump have previously rip cost call boee ba price super hornet possible replacement trump praise ford motor fiat chrysler fcau recent plan investment ford fall largely hold prior loss fiat chrysler climb related trump vow fighter jet competition big thing lockheed biotech etfs dive trump slam drug industry first presser
327,PFE,stock give gain early afternoon trading thursday hunger blue chip seem increase dow jone industrial average pace gain popular index dow jone industrial average be add advance claim prior session component blue chip index be now year date nasdaq composite thursday afternoon have climb oil steel banking fertilizer railroad semiconductor stock help hoist higher volume be run higher nasdaq nyse dow jone industrial average seem relish role perennial laggard market bottom october index post impressive gain peak march paled vs nasdaq composite run roughly same period time however individual action stock dow continue get better take health care sector pfizer pfe be act big cap leader lately big pharma play rise month saucer handle notice week long handle begin june stock pull back lightly volume dry most session ideal action stock set potential pfizer case take place july volume be quiet ibd research have find case volume come strong few week move new high wall street seem convince pfizer have return growth track profit be see rise nearly cent share pickup sale week ethical drug giant reportedly close deal sell medicine russian market also get label extension prevnar vaccine pneumonia doctor now prescribe vaccine adult year old also dow johnson johnson jnj insurer unitedhealth group unh be act well recent breakout former be flat extend recent past buy point relative price strength line have be rise june indicate have be outperform unitedhealth be intraday stock remain flat base entry flat base decline head toe not exceed unitedhealth week flat base feature very mild drop indicate reluctance institutional investor sell share buy zone extend unitedhealth company earn respectable composite rating maximum ibd stock checkup second only manage care industry peer centene cnc johnson johnson unite health report earning next week fellow dow stock jpmorgan chase jpm gap lead money center bank gain volume be run more double normal level wall street bank post rise profit beating analyst consensus view revenue lift ceo jamie dimon earlier week announce plan raise minimum pay large number bank employee stock still need work build right side potential new base jpmorgan rs rating lag pfizer unitedhealth ibd name stock market today datum center operator coresite realty cor cool third day row investor appear cash more gain dividend pay reit nursing physician staff outsourcer amn healthcare highest ranking medical name ibd jump nearly dull turnover stock have rise more past handle entry long double bottom base general least profit be take stock rise past proper pivot point see wednesday big picture column market pulse table market be currently confirm uptrend mean investor have higher probability make money buy breakout high quality growth stock proper buy point market follow june be stock be best class industry group term profit growth margin sale return equity institutional fund sponsorship relative price strength check investor com exclusive tool ibd stock checkup
328,PFE,general electric ge acquire swiss base biosafe group supplier tool cell therapy development product industry biotechs juno therapeutic juno kite pharma kite look capitalize new approach fight cancer term biosafe deal weren disclose biosafe say active grow field adult stem cell therapy serve stem cell bank hospital research institutes alike innovative cell process solution product include sepax system be involved prepare cellular product clinical use cell therapy oncology market alone be estimate reach ge say statement industrial conglomerate seek build position cell therapy field ge share close stock market today juno jump kite rally ibd take ge be group other diversify manufacturer stock be near buy range juno therapeutic kite pharma pfizer pfe novartis nvs be group company plan come market so call car chimeric antigen receptor cell drug last month juno share sank fda put hold late stage study car drug due death patient involved study late tuesday fda allow trial continue biosafe acquisition expand ge healthcare end end portfolio product service cell therapy customer april ge venture mayo clinic launch vitruvian network independent platform company aim accelerate access cell gene therapy cloud ready software system january ge announce email protected cell therapy center excellence co investment canada government promote new cellular therapy technology
329,PFE,end friday just point record close surprise benchmark index have many stock breaking consolidation here be biggest stock be buy range facebook fb general electric ge verizon communication vz pfizer pfe chevron cvx facebook stock be dow jone industrial average facebook rise friday just retake old entry point well move day move average buy point be initially clear late april follow facebook blowout earning report facebook also be currently flat base pattern buy point available just time high friday move come average volume want see breakout come hefty buy sign institutional interest facebook massive user base social network have continue grow mobile advertising boom facebook have report straight quarters accelerate earning growth include ep gain update facebook rise average volume stock market today ibd take facebook be part leaderboard ibd premium service highlight top rate stock buy point general electric also rise friday close hit year high just pass buy point volume be slightly normal ge composite rating be just meaning outperform only stock due rocky fundamental earning rise follow straight quarters decline update general electric share climb cent monday rise intraday verizon communication break cup base late june buy point then share have hit new high have stay buy range verizon fellow dow industrial member benefit shift defensive stock initial wake vote exit european union domestic focuse dividend king telecom giant fit bill share be too extend proper entry right now update verizon rise cent ibd take look several top rate stock breaking recent day check ibd new high column pfizer july clear buy point long consolidation share continue nudge higher close friday still well buy range pfizer be close time high be set july pfizer have composite rating solid not spectacular earning sale have be spotty ep rise analyst expect profit growth pharma giant offer quarterly payout cent share annualize yield stock catalyst be possible split more company update pfizer rise cent monday chevron have be try hold buy point flat base pattern well longer consolidation go back more year chevron have top entry area several time past month friday share rise back buy point chevron report loss first quarter analyst expect profit earning growth return energy stock react strongly crude price even oil price fall more last week chevron rise fractionally update chevron share rise monday
330,PFE,big biotech amgen amgn biosimilar form abbvie abbv humira seem get support fda friday agency release briefing document advisory committee panel meeting tuesday panel discuss abp knockoff abbvie mega blockbuster used treat several form arthritis crohn disease psoriasis ulcerative colitis ankylose spondylitis biosimilar generic pharmaceutical be not identical drug re copy approval process isn simple generic briefing document fda sound convince amgen have make case consider totality evidence datum submit amgen support demonstration abp be highly similar license humira notwithstanding minor difference clinically inactive component support demonstration be clinically meaningful difference abp license humira term safety purity potency product support demonstration abp be biosimilar license humira study indication ra rheumatoid arthritis pso psoriasis say document amgen share climb stock market today abbvie meanwhile add amgen abbvie share be approach month high fda have make ultimate decision approval win necessarily mean immediate launch amgen abbvie be currently tie litigation humira intellectual property generic drugmaker have launch risk such suit be settle more certainty recall amgen go patent dance abbvie abbvie have say plan file public case amgen next few month assert many patent evercore isi analyst mark schoenebaum write email client abbvie be file subsequently preliminary injunction amgen be bar marketing litigation complete biosimilar be ultimately find not infringe expiry infringe patent abbvie be grant permanent injunction thus least depend patent coherus bioscience chrs novartis nvs pfizer pfe also have humira biosimilar development coherus stock rise friday novartis advanced pfizer pfizer set year close high
331,PFE,stock slouch weak start monday market gear third quarter final trading week dow nasdaq fall slide open small cap russell also be donw stock market today open final week september mixed foot month nasdaq gain month friday be day move average work third straight monthly gain be tack second monthly decline struggle hold support day line dow stock moved generally lower pfizer pfe open loss pfizer say win split separate company specialty chemical maker chemtura chmt vault open rise news germany lanxess pay cash acquire philadelphia base operation pharmaceutical gwph leap maker cannabinoid base pain treatment announce positive result phase trial epidiolex treatment seizure related lennox gastaut syndrome egg distributor cal maine food calm be broader expect fiscal first quarter loss shell egg price be decline pressure result company note industry production recover avian influenza outbreak spring wesson swhc shed open firearm maker report friday have lose bidding competition replace beretta army standard sidearm army wesson have be consolidate day move average back buy point cup handle base ibd stock nautilus nls stumble more premarket trading regular trading appear be delay downgrade neutral riley nautilus end friday session buy point clear cup base early august monday economic calendar be light august new home sale due commerce department et dalla federal reserve regional manufacturing survey expect minneapoli federal reserve bank president neel kashkari speak et dalla federal reserve bank robert kaplan speak et oil future rise more international energy forum get underway algerium member organization petroleum export country top produce member be hold informal meeting sideline event west texas intermediate trade barrel europe brent crude benchmark be gold trade effectively flat ounce dollar ease vs euro yen bond rise trimming year treasury yield basis point overseas market asia post weak result monday shanghai composite end hong kong hang seng index take loss japan tokyo nikkei fall european market be also sharp pressure afternoon trade dax frankfurt paris cac nearly apiece london ftse
332,PFE,so so job report fuel modest selling wall street friday new high weren hard find several name fade strong start flex flex formerly know flextronic ease light trade high end buy range buy point low price stock plenty liquid average daily volume share market capitalization flex provide electronic manufacturing service original equipment manufacturer oem small cap cabot microelectronic ccmp be thinly trade get several positive quality include composite rating accumulation distribution rating share ease average turnover chip equipment firm be hold just flat base entry coherent cohr lose light trade try clear base base pattern buy point coherent stage base late july buy point rally less latest flat base be second base base base structure coherent operate segment specialty laser system commercial laser component broadsoft bsft slip soft volume loss prior entry recently hit didn trigger sell signal mean buy point be still play broadsoft offer software service saas provide telecom customer cloud base communication technology icu medical icu extend gain thursday bullish gap price share rise heavy volume news company buy pfizer pfe infusion therapy business include infusion pump intravenous solution extend price now financial sector iberiabank ibkc rise fourth straight session rise average turnover still buy range entry louisiana base bank have solid composite rating help part consistent track record earning sale growth recent quarters
333,PFE,axovant science axon management be unconcerned thursday danish rival lundbeck fail key hurdle phase testing newest alzheimer treatment drug follow pfizer pfe departure market february rbc analyst michael yee say friday lundbeck idalopirdine have rivale axovant rvt intepirdine treat alzheimer target receptor patient brain facilitate acetylcholine release frontal cortex do so improve cognition memory learn thursday axovant stock tank much month low lundbeck failure recover somewhat fall close stock market today axovant stock rise nearly lundbeck however have change dose scheme idalopirdine once daily cut liver toxicity concern departure phase patient receive milligram day phase lundbeck test milligram mg mg idalopirdine be safe tolerate starshine trial believe today news suggest low dose idalopirdine not have enough efficacy hit primary endpoint remain trial yee write research report late thursday yee see only chance lundbeck drug succeed vs prediction axovant rvt phase axovant plan mirror same mg dosage endpoint reap success phase axovant be enrolling phase trial expect datum late yee say axovan confidence be not sway lundbeck failure evercore analyst mark schoenebaum write report say company plan file new drug application food drug administration end rvt be first ht type receptor brain antagonist receive approval yee say expect be opportunity axovant pfizer shutter study alzheimer drug fail phase yee also note axovant have second drug nelotanserin treat dementia nelotanserin share similar mechanism action acadium pharmaceutical acad pimavanserin already have fda nod treatment psychosis associate parkinson thus nelotanserin be somewhat risk yee write ibd take axovant stock have low ibd composite rating meaning underperform more half rival term key growth metric company medical biom biotech industry group be lead supernus pharmaceutical have best possible cr get stock checkup editor note reflect clarification fourth graph once daily sixth graph mg related gilead allergan see trail intercept ongoing nash battlepuma race month high breast cancer drug success blockbuster franchise spark fever sarepta ariad biotechs
334,PFE,handful lead stock break new high follow recent breakout stock market today narrowly mixed performance major market index lam research lrcx gap surge thursday follow wednesday past flat base buy point volume wednesday be average thursday swell higher normal trade investor be clearly not worry chip gear maker breakup kla tencor klac late wednesday company dump plan merger deal cite antitrust concern intel intc hitachi samsung be reportedly company oppose potential union believe propose combination have result compelling benefit customer employee stockholder well accelerate innovation broader semiconductor industry so be disappoint outcome lam ceo martin anstice say press release central garden pet centa climb past buy point intraday thursday close just entry volume be well normal lawn garden product maker marked record high session cinemark holding cnk rise week high clear flat base buy point heavier usual trade plano texas base company operate theater state latin american country icu medical icui vault new high breaking past buy point massive volume stock be bit thinly trade average daily volume share san clemente calif base medical product maker be buy pfizer pfe infusion system unit cash stock related lam research kla tencor scrap chip gear deal antitrust concern
335,PFE,mylan myl half price version epipen allergy shot not be available end year drugmaker say email potentially month timeline company give august authorize generic version epipen be available end year mylan spokeswoman nina devlin say email monday week statement aug company say expect introduce generic version several week mylan generic version cost pack half brand version price expect launch year once have assured sufficient inventory be available meet anticipate order create necessary packaging product create necessary labele product devlin say be diligently work complete effort order provide generic soon possible mylan have attract wrath congress increase list price epipen more fold more package quell grow furor epipen price announce cheaper authorize generic version devlin decline be more specific generic version be available drugmaker don need advance approval food drug administration bring authorize generic product market say theresa eisenman fda spokeswoman do however have notify agency annual report pfizer pfe manufacturer brand version epipen mylan have not announce manufacturing issue delay production authorize generic last month hearing house committee oversight government reform mylan chief executive heather bresch face skeptical lawmaker grilled drugmaker profit executive pay hearing say mylan make profit pair epipen letter demand more detailed information mylan lawmaker say figure include tax assumption have underrepresent mylan profit monday close mylan share be aug last day trading lawmaker begin question drugmaker epipen pricing stock dip close tuesday
336,PFE,stock continue search direction early afternoon trade wednesday president elect donald trump send biotechs lockheed martin lmt nasdaq lag apple aapl nvidia nvda pull back nasdaq shed fall dow jone industrial average be flat volume be tracking higher board vs same time tuesday solar oil metal stock lead upside stock market today west texas intermediate oil future surge barrel biotechs other drugmaker get hammer president elect donald trump sharply criticize drug price blue chip drug giant pfizer pfe be dow biggest loser slide lose day move average fast trade merck mrk buck selloff healthy volume lead dow winner pare gain earlier pop share be build flat base buy point food drug administration accept supplemental filing merck immunotherapy keytruda be used chemotherapy treat advanced lung cancer apple meantime backed weak trade stock have so far be unable follow monday past entry cup handle remain buy range nvidia too be hesitate attempt recoup drop late december early january point recent stock market today column stock be due correction heady run march hold well day line overall trend be higher canaccord genuity jeffery raise price target graphic chip maker tuesday monday respectively tesla tlsa announce have hire apple executive include year veteran chris lattner lead electric car maker autopilot software effort tesla share dip stock be shape right side cup base lockheed martin lmt fall breach day line trump vow increase competition fighter jet bring cost share have be consolidate flat base try recover tough december trump blast cost twitter ibd biotechs unite therapeutic uthr celgene celg sank respective heavy volume unite remain extend buy point celgene slip day line be still build flat base related trump say drugmaker get away murder cite ford fiatmusk go tesla graveyard hire away apple exec trump vow fighter jet competition big thing lockheed nvidia stock get price target hike valuation concern
337,PFE,rise consecutive year fda drug approval rate plunge year low biogen biib merck mrk eli lilly lly add new drug bailiwick accord swiss biotech hbm partner food drug administration approve new molecular entity year marked decade high approval nmes say hbm have not be fewer nmes approve fda give blessing just half nmes be not fully develop house be acquire be license hbm write new drug be first class drug therapeutic area cancer lead nmes new drug project industry lead peak sale be oncology hbm find ibd take ease fda approval process be part donald trump health care initiative president elect really break republican enact major drug reform trend past year oncology drug see major increase fda approval list new cancer drug be approve rise nmes cancer fda have increase appetite drug treat diabetes respiratory disease viral other infection interest cardiovascular genetic immunology drug increase moderately year also see fewer central nervous system drug then merck roche rhhby have have more drug approve other company add johnson johnson jnj pfizer pfe follow closely apiece gilead science gild novartis nvs glaxosmithkline gsk sanofi sny lilly have add new drug ibd company medical biom biotech industry group close stock market today group rank be tumble lawmaker debate issue drug steeply rise price related lilly regain key migraine drug colucid acquisitionfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
338,PFE,biotechs have lot ride drug datum ibd company medical biom biotech industry group plunge rocky election year relief hillary clinton lose white house spiked group nearly week follow election gain have dissipate donald trump pledge tackle rise drug price group have face challenge day move average april meanwhile large cap amgen amgn vertex pharmaceutical vrtx be trading pipeline valuation accord rbc analyst michael yee tug sentiment month low require strong drug datum remain potential coil spring catalyst company go play many large pharmas continue be hunt yee write dec research report see ariad pharmaceutical aria incyte incy tesaro tsro biomarin bmrn possible acquisition target outside yee say lack material catalyst get sector move ibd take top biotechs end triple digit gain outplay broader industry be biotech pick list check ibd industry theme deeper dive nearly dozen biotech company year be slate post key drug trial datum just key arena drug treat spinal muscular atrophy drug treat cystic fibrosis parp inhibitor treat several type cancer therapy treat lymphoma success turn sentiment positive second failure weigh many drug stock spinal muscular atrophy result wasting away muscle lead early death see least new datum sector also host yee recent research report call overall drug industry only new real launch year biogen biib ionis pharmaceutical ion team develop spinraza brand name nusinersen drug target single rna treat symptom sma ionis ceo stanley crooke tell ibd recent biogen exercise worldwide right spinraza august food drug administration approve spinraza late december first sma treatment get fda approval crooke say expect biogen bring drug market early year describe sma diabolical disease chemically denervate body be fatal infant progress toddler rob ability walk eat breathe own affect motor nerve cell spinal cord accord cure sma spinraza launch midcap cytokinetic cytk be expect release result phase trial ck describe novel skeletal muscle troponin activator help treat sma patient other suffering similar degeneration ck differ spinraza aim slow rate calcium release regulatory troponin complex fast skeletal muscle fiber phase trial examine sma patient look patient chronic lung disease trial result latter further future cytokinetic be lightly trade small cap have ibd relative strength rating best possible stock buy zone late december hit entry point cup handle formation have slip thursday close trigger sell rule anytime stock fall least buy point share rise handful cystic fibrosis trial be expect wrap vertex triple pill have spark most analyst chatter yee credit suisse analyst vamil divan say phase datum vx vx be likely be available latter half trial result sooner vx vx vx be be investigate prong treatment cystic fibrosis genetic disease cause mucus collect block airway damage digestive system vx be phase testing result patient population expect first half year yee estimate vx vx vx add long term sale vertex see fairly good chance triple work second half drive company growth note investor remain wary vertex stock fall be year fall thursday vertex be far alone cystic fibrosis game many other publicly trade biotechs be expect release clinical trial datum mid cap biotech pct therapeutic pctc appear furthest phase datum translarna due quarter pct trial examine cf patient nonsense mutation accord cystic fibrosis news translarna potentially make cellular protein machinery run so call stop sign cf cause cftr gene replace amino acid similar enough allow protein do work clovis oncology clvs pull ahead tesaro late december fda grant accelerate approval parp inhibitor rupacarib day later fda give tesaro parp inhibitor niraparib priority review be duke rival lynparza parp inhibitor approve astrazeneca azn be deadlock race treat ovarian breast cancer clovis be track unveil phase datum rupacarib sell brand name rubraca patient brca mutation latter half brca mutation be often associate breast cancer tesaro niraparib be deck phase breast cancer phase ovarian cancer datum second half niraparib have prescription drug free user pdufa date june accord biopharma catalyst fda tracker niraparib rupacarib olaparib chemical name astrazeneca lynparza class drug call parp inhibitor several form cancer be dependent parps type enzyme inhibit enzyme company clovis tesaro astrazeneca hope treat several cancer abbvie abbv pfizer pfe acquisition medivation also be work parp inhibitor abbvie veliparib miss several endpoint include progression free survival pfs phase trial recurrent metastatic breast cancer brca mutation unveil early december phase testing be underway veliparib be also be investigate treatment small cell lung cancer nsclc pfizer acquire medivation september medivation talazoparib be development treat breast cancer germ line brca mutation neither abbvie pfizer parp inhibitor be expect have datum ariad kite pharma kite seattle genetic sgen look poise lead lymphoma battle many publicly trade biotechs be expect present datum year vary drug next month kite kte likely come away solid month durability datum diffuse large cell lymphoma dlbcl say rbc yee lead roll biologic license agreement bla pdufa date year end kte belong class drug call car cell therapy drug patient immune system fight specific cancer kite drug be be investigate treatment refractory hodgkin lymphoma relapse refractory mantle cell lymphoma ariad pharma other hand already have pdufa date april brigatinib treatment anaplastic lymphoma kinase positive alk metastatic small cell lung cancer nsclc resistant crizotinib pfizer chemotherapy pdufa date be april first line datum win be available competitor roche rhhby have similar datum rival drug due same time frame ariad complete new drug application nda brigatinib october also seattle genetic be angle fourth indication approve adcetris adcetris be be examine treatment cutaneous cell lymphoma ctcl also unveil result yearlong phase trial adcetris chemotherapy front line hodgkin lymphoma seattle genetic be try establish redefine front line therapy hodgkin lymphoma nearly year same therapy ceo clay siegall tell ibd recent interview related investor siphon biogen ionis gain spinal disease drug okionis pharma eye sustainable profitability fda approvalamgen plan robust alzheimer migraine oncology ceo myer win seek accelerate opdivo lung cancer
339,PFE,drugmaker eli lilly lly likely add rheumatoid arthritis drug fda approve repertoire month say credit suisse analyst vamil divan also predict court decision lilly chemo drug alimta day now prescription drug free user act pdufa date lilly baricitinib be set january drug belong class med call jak janus kinase inhibitor eli lilly submit new drug application nda last january moderate severe rheumatoid arthritis lilly gain worldwide right incyte incy baricitinib now baricitinib compete tofacitinib jak inhibitor develop pfizer pfe national institutes health market xeljanz jakvinus incyte be also codevelop ruxolitinib jak inhibitor target myelofibrosis novartis nvs ibd take president elect donald trump cause flurry drug stock late last year pledge cut spiraling drug price make good promise other catalyst january include separate patent ruling case lilly alimta also teva pharmaceutical teva copaxone patient relapse remit multiple sclerosis also january astrazeneca azn bristol myer squibb bmy be likely have key trial datum divan say astrazeneca be study durvalumab have breakthrough designation treat patient specific type urothelial bladder cancer bristol myer be look nivolumab treat patient small cell lung cancer nsclc close stock market today ibd company medical ethical drug industry group include lilly bristol myer astrazeneca finished day nearly lilly stock tick just relatedlilly spike guidance claw back alzheimer drug flopbiogen underplay promising alzheimer datum seizure worrieseli lilly continue alzheimer push flop biogen extend rise
340,PFE,share seattle genetic sgen be stage mild recovery wednesday plunge tuesday fda halter certain trial drug treat aml acute myeloid lymphoma least analyst have cut price target stock news credit suisse analyst kennen mackay late tuesday reduce target price say fda decision hold partially halt phase trial sgn cd patient develop case hepatic venoocclusive disease hvod come surprise research report mackay say such concern have earlier be observed also say seattle genetic drug have be design address problem hvod associate predecessor drug mylotarg pfizer pfe have withdraw market ibd take seattle genetic trade nearly time many share usual tuesday be heavy selling buy institutional investor give time check ibd stock move answer question seattle genetic stock rise much stock market today close session share have be year tuesday plunge mackay maintain neutral rating seattle genetic stock lower probability success sgn cd front line older unfit aml patient younger fit aml patient needham analyst chad messer tuesday however maintain buy rating price target seattle genetic stock point other aml trial continue company bigger more likely be successful product be treatment hodgkin lymphoma be expect make big stride yet unpublished ibd complete last week seattle genetic ceo clay siegall say company plan start phase aml trial patient age unclear tuesday news change plan company be close holiday representative didn return phone call email seek comment related seattle genetic leukemia drug trial halter trump make drug development great again
341,PFE,drugmaker medivation mdvn say late tuesday have enter confidentiality agreement several potential buyer include sanofi sny latter raise bid company medivation have previously reject sanofi bid share cash inadequate lead sanofi late propose candidate take medivation board tuesday medivation say board have also reject offer share contingent value right cvr sale medivation drug candidate talazoparib share nonetheless medivation go ahead enter confidentiality agreement sanofi unspecified number other unnamed party confidentiality agreement include customary month standstill provision subject limit early termination event medivation expect provide party opportunity term review public information meet medivation management say medivation press release early anonymously source report say medivation have enter confidentiality agreement pfizer pfe amgen amgn celgene celg gilead science gild astrazeneca azn also have be leak prospective buyer tuesday announcement be leak reuter half hour market close send medivation stock share be fraction hour stock have be form flat base hit month high day pfizer amgen news come hold spot ibd list top perform stock past month friday medivation schedule conference call wednesday market close say focus talazoparib drug late stage development breast cancer belong class drug call parp inhibitor get boost last week biotech tesaro tsro announce surprise success parp inhibitor ovarian cancer
342,PFE,big pharma stock be often favore income investor tend pay relatively healthy stable dividend merck mrk have be consolidate year be work handle potential buy point stock have regain nearly loss post brexit sell be back day
343,PFE,big pharma eli lilly lly jump wednesday wall street analyst weigh result narrow food drug administration advisory panel vote late tuesday panel meet decide good idea expand label lilly diabetes drug jardiance include reduce death cardiovascular cause base large clinical trial call empa reg committee vote favor change such close vote leave less clear just decision fda ultimately make most cite reason vote be bar new claim be grant base single study be very high panelist see second trial confirm cv death find leerink analyst seamus fernandez write research note many panelist vote yes also share concern find cv death benefit compelling convince enough tip balance fernandez nonetheless like odd approval note most senior member panel include biostatistician cardiologist vote favor new indication credit suisse analyst vamil divan be also bet favor change add read similar product sglt inhibitor class johnson johnson jnj invokana remain market leader sglt space canvas outcome study schedule be complete february divan write research note assume fda agree include empa reg outcome cv death datum jardiance label see share shift invokana jardiance canvas be complete longer term implication dependent canvas result result outcome study astrazeneca azn forxiga merck mrk pfizer pfe ertugliflozin be expect later decade divan say evercore isi analyst mark schoenebaum be more cautious slight overall majority vote favor new cv indication view approval actual cv death indication have coin flip odd give unprecedented nature result trial schoenebaum write email client say also feel better chance fda allow datum be add label instead indication statement lilly stock rise stock market today once again day move average lilly close just day line be past month johnson johnson stock close fresh record high
344,PFE,be call silent epidemic slowly wasting away liver million american doctor have paltry understand disease approve treatment now alcoholic steatohepatitis nash be sight more dozen drugmaker allergan agn become latest tuesday announce deal acquire nash treatment less hour race company startup intercept pharmaceutical icpt giant include gilead science gild pfizer pfe reach untapped market be worth year accord estimate rbc capital market corp analyst michael yee drugmaker still be try determine different component disease inflammation scarring metabolic change interact be experiment variety treatment mechanism so many company pile field ll have work distinguish re look something get factor say alex depaoli chief medical officer closely hold ngm inc have nash partnership merck co mrk want develop something pop eye nash occur fat accumulate liver inflammation damage much quarter population have precursor condition call alcoholic fatty liver disease ailment develop slowly patient often don show symptom liver be heavily damage most common person be overweight have diabetes doctor mainly prescribe diet change weight loss ibd take medical biom biotech sector be run hot rank eighth ibd industry group sector be lead supernus pharmaceutical supn more be find here doctor need perform biopsy diagnose nash person alone be estimate have condition go develop life threaten cirrhosis nash be lead cause liver transplant accord allergan drug treat likely command high price elizabeth krutoholow analyst bloomberg intelligence say head race be intercept french biotech firm genfit large trial underway tobira therapeutic tbra allergan agree buy tuesday much be prepare recruit patient final stage study investor also be watch result gilead mid stage trial be expect be present year acquisition news tobira share soar more tuesday share be afternoon trade wednesday intercept be testing ocaliva already approve treat rare liver disease call primary biliary cirrhosis nash enrollment final stage trial person be expect be complete next year interim result due potential concern be earlier trial patient experience itch take drug case so severe interfere basic activity chief executive mark pruzanski say interview hope ocaliva become backbone treatment used combination other drug genfit be develop once day treatment raise fat metabolism fight inflammation treat underlie cause fibrosis dean hum genfit chief scientific officer say interview fail meet primary goal mid stage trial last year show promise subset patient moderate severe form disease final stage trial moderate severe patient be underway company have datum late startup biotechs biggest company be pay attention ready do deal merck say pay much partnership ngm gilead maker blockbuster hepatitis drug sovaldi harvoni buy nash drug nimbus therapeutic llc include milestone payment gilead also buy drug phenex pharmaceutical ag much gilead now have nash candidate portfolio have datum later year drug target different aspect disease be develop individually be used potent cocktail allergan tobira be biggest nash deal so far tuesday company also announce purchase akarna therapeutic ltd developer nash treatment pfizer biggest drugmaker be future acquirer have nash drug trial more be test human end year nash be major priority say morris birnbaum chief scientific officer cardiovascular metabolic disease company be try treat disease early stage win be easy genfit tobira mid stage trial fail raptor pharmaceutical rptp end program datum be start come study lot confidence be build lose say jay luly chief executive enanta pharmaceutical enta begin testing experimental treatment patient year same expect happen money
345,PFE,opec member agree production cut essentially give drive shale producer european bank wo briefly rattle financial market number possible twitter twtr buyer expand nike nke beat earning view give weak guidance order major average rise modestly week due friday solid gain deutsche bank db concern ease close just day move average trading key level most friday oil price surge opec deal cut output give big boost shale producer other energy stock biotech fiber optic several retail group fall fall september rise third quarter nasdaq advanced september organization petroleum export country say cap output barrel day essentially give year effort drive shale production cartel win enact cut november full detail individual production quota be likely be firm official opec meeting august opec production be barrel day energy information administration say inventory fall barrel vs barrel increase analyst expect fall fourth straight week production slide gasoline stockpile rise barrel number oil rig operation rise yet again week month high oil future rise barrel week fuel shale stock oil price dip quarter related oil hit month high opec blink vs shale deal fraysdeutsche bank db sank fresh record lows thursday grow capital concern report hedge fund be longer willing act counterparty european banking giant share rebound friday close week higher report deutsche bank justice department be settlement commerzbank say cut thousand job credit suisse cs warn difficult third quarter speaking congress fed chief janet yellen say politic do not factor interest rate policy contrary accusation make gop presidential nominee donald trump also discuss potential plan boost big bank capital requirement annual stress test well fargo wfc ceo john stumpf give stock award fight save job next day house panel skewer bank cross selling scandal week senator do same well share fall lowest level february other big banking stock test support day move average related banking giant gain deutsche bank european financial teeterconcern mount deutsche bank hedge fund withdraw cashwell fargo ceo stumpf ex top exec give stock award beat top bottom line sank month low expect future order product schedule delivery retailer particularly light north america future be fuel concern competition armour ua adida nike plan give figure less prominence future order revenue correlation decline related nike pepper red flag armour adida take big merger be discuss latest week few formal takeover related play cbs viacom courtship scenario twitter acquisition chatter get twitter treatmentnxp semiconductor rocket qualcomm acquisition reportadobe microsoft forge cloud partnership be full merger next pfizer scraps breakup follow dead allergen mergerspacex tesla motor tsla ceo elon musk describe fleet spacecraft be used colonize mar estimate investment realize project annual international astronautical congress guadalajara mexico musk also say hope complete developmental spaceship year spacex isn publicly trade event come musk try rally support tesla acquisition bid sister company solarcity scty critic see mar plan distraction tesla be already surround doubt ambitious car production target september consumer confidence index rise best level august last recession start economy rise upwardly revise annual rate still weak help less negative read business investment structure august durable good order be flat core capital good order edge higher new home sale fall sharply august less expect hit cycle high july pending home sale fall lowest level january next week ll get reading manufacturing well monthly job report related consumer confidence rise year high home sale fall lowest level januaryvail mtn report loss share narrower year loss share share loss analyst have expect vail revenue rise view get boost epic discovery summer park activity vail share fall find support day line carnival ccl say earning exclude fuel hedge other item rise share beating analyst view cent revenue climb view cruise line operator see ep cent midpoint analyst view cent carnival share initially fall report rebound close week day line rv maker thor industry tho earn share vs year earlier crush view revenue climb beating estimate be best sale gain quarters thor industry rise hit new high
346,PFE,aerie pharmaceutical aeri spiked open stock market today report positive trial datum eye pressure drug late wednesday late stage trial aerie pharma roclatan lower fluid pressure eye outperform latanoprost rhopressa aerie treatment roclatan meet day primary efficacy datum benchmark first part stage clinical trial lower intraocular pressure iop patient glaucoma ocular hypertension roclatan combine aerie compound pfizer pfe drug xalatan roclatan once daily be be evaluate ability lower intraocular pressure iop patient glaucoma ocular hypertension major home run roclatan needham co analyst serge belanger say note thursday raise aerie price target stifel nicolaus raise price target aerie aerie stock rise even biotech announce stock offer thursday morning stock hit intraday highest april aerie plunge disappointing result rhopressa share aerie climb wednesday regular session several other biotech stock rally wednesday mixed reaction thursday sarepta therapeutic srpt stock leap month high fda staffer opposed sarepta drug reportedly left agency private sector sarepta share sank thursday ariad pharmaceutical aria rise seattle genetic sgen extend july breakout ariad rise intraday seattle genetic fall bluebird bio blue fly month high wednesday stock shot thursday goldman sachs make conviction buy month high related bevy biotech stock healthy sarepta bluebird exelixis soartop new issue help turn drug idea reality
347,PFE,load player forbe list most innovative growth company rank stock tyler technology tyl innovation premium defined difference market capitalization net present value cash flow plano texas base tyler rank joined ibd member aspen technology azpn lululemon athletica lulu company
348,PFE,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
349,PFE,novartis nvs newly approve breast cancer drug be disadvantage pfizer pfe ibrance label warning liver toxicity require occasional heart rhythm monitoring analyst say tuesday leerink analyst seamus fernandez expect pfizer keep market novartis grab novartis say late monday fda have approve drug kisqali treat form post menopausal advanced breast cancer kisqali label warn potential liver toxicity fast chaotic heartbeat know qt prolongation mean patient undergo electrolyte monitoring liver function test various point treatment ibrance kisqali be be combine letrozole fda approve treatment hormonally responsive breast cancer surgery kisqali be efficient ibrance combination monitoring requirement be burdensome fernandez say kisqali be used inhibitor not just letrozole category drug inhibit specific protein know cyclin dependent kinase prevent proliferation cancer cell ibrance be first approve monotherapy february gain second approval letrozole last year ibd take pfizer also play hemophilia market rival like nordisk bayer bioverativ bioverativ stock be do well filing initial public offer earlier year head new america see bioverativ isn standard biotech startup base pfizer first mover advantage continue see ibrance maintain long term market dominance cdk class fernandez write note however novartis have price kisqali discount ibrance accounting dose help drive formulatory access fernandez have market perform rating pfizer stock novartis stock stock market today pfizer stock climb share novartis fall related pfizer take celgene other rival leukemia drug pharma firm be beating pack get drug market
350,PFE,load player news warren buffett stake apple aapl rise oil price drug merger fuel positive sentiment monday session stock end solid gain mixed volume apple jump nearly buffett disclose own share iphone maker end first quarter pfizer pfe meanwhile
351,PFE,stock be session lows midday tuesday weak chinese factory datum spark renew concern global economy nasdaq be dow jone industrial average fall volume be run higher monday stock market today chinese factory activity contract straight month april accord private survey renew concern health world second largest economy oil price tumble more lead sell crude stock
352,PFE,oil producer marathon oil mro devon energy dvn well drill stock transocean rig drop most ibd stock be lower inc research incr continue plunge follow quarterly earning report monday provider clinical trial drugmaker medical device company drop massive volume be now testing support converge day day move average company post increase profit cent share comfortably wall street estimate sale growth picked second straight quarter rise robust however company announce secondary offer share also analyst robert baird downgrade stock neutral outperform tuesday do inc research check term fundamental find ibd stock checkup chemical stock drugmaker be few winner fmc fmc maker agricultural chemical jump better expect quarterly earning report however stock be still week high follow long slide pfizer pfe make drug such viagra jump nearly clear handle buy point cup base move come pfizer post sale beat wall street forecast company also raise earning outlook volume be run more time usual pace
353,PFE,stock moved intraday lows remain firmly red weak manufacturing datum china continue weigh nasdaq be dow jone industrial average fall volume be tracking higher board vs same time monday steel bank energy lead downside today stock market action oil stock get hit west texas intermediate crude fall nearly barrel soap cement producer drugstore stock be scant gainer clorox clx gap rise new high edge past flat base buy point twice normal trade clean product maker report fiscal adjust earning share last year dime view revenue climb also top vulcan material vmc climb new high heavy trade report profit sale beat forecast construction aggregate ready mix concrete maker also lift full year aggregate shipment outlook stock have rally year find vulcan material rank industry group ibd stock checkup ibd vulcan group mate concrete uscr add light trade share be extend past cup base entry first clear mid march pfizer pfe apple aapl outperformed dow respective gain pfizer share break past cup handle buy point fast turnover better expect sale higher guidance viagra maker meanwhile apple stem session slide nearly take month low monday volume be run twice usual pace credit suisse tell cnbc sticking price target iphone maker last week disappointing quarterly report first ever decline iphone sale ibd laggard include contract research organization inc research holding incr pra health science prah sank more robert baird downgrade inc monday report result announce secondary offer share neutral outperform pra health monday announce secondary offer share
354,PFE,trading be tame friday open market begin final session major market average start session have turn lower nasdaq fall dow industrial lose dip dow rolled stock market today tout gain be nasdaq carry gain small cap remain stride ahead general market russell show year date gain head friday session bond market close today et stock bond market be close monday observance new year holiday dow stock goldman sachs gs dip investment banker share be year thursday july low stock be extend clear week cup base july have form week tight pattern nike nke be flat initial uptick nike share have drop more earning growth slow analyst expect end year single digit pace first time consensus view see ep growth pick back fiscal nike fiscal year end drugmaker mylan myl jump announce launch generic version pfizer pfe cerebyx injectable seizure treatment well generic tablet version johnson johnson jnj concerta treatment attention deficit hyperactivity disorder mylan share be deep month consolidation nvidia nvda fall friday morning chipmaker ibd stock reversed higher thursday end gain warning short seller citron research contribute nvidia early loss positive note goldman sachs detailed upcoming catalyst stock end thursday so far have be flash sign be due consolidation tesla motor tsla skip fraction analyst robert baird name carmaker top stock pick reiterate outperform rating price target tesla be form long base oil price ease west texas intermediate crude trading barrel gold edge higher ounce dollar be mixed vs yen euro bond be steady year yield basis point economic news december chicago purchasing manager index retreat december november year high regional manufacturing firm be upbeat baker hughe bhi weekly rig count be expect market europe erased early loss gain ground major benchmark show gain less afternoon trade year frankfurt dax be tracking gain cac paris be london ftse be trading year brexit vote june china market gain friday hong kong hang seng index rise shanghai composite japan tokyo nikkei dip mark decline week end week advance related fox netflix disney stall buy zone investing action plan nvidia volatile big drop upbeat reportweek review dow nvidia reverse amazon thrive
355,PFE,dow jone industrial average come point milestone tuesday stock index have outperformed dow year date gain more double only name dow be significantly last year nike nke coca cola ko other be notably sluggish walt disney pfizer pfe visa share still dominant athletic apparel giant worst performer dow have sunk calendar year steep competition armour uaa resurgent adida host smaller activewear brand shaky broader retail environment also hasn help still athleisure remain popular nike top quarterly forecast last week well issue bullish comment conference call company be manage competitive challenge better fear write credit suisse analyst christian buss tuesday believe return mid high single digit constant currency revenue growth be likely occur sooner anticipate unfortunately add currency be move company suggest underlie report earning growth be not likely re accelerate faster anticipate share close stock market today dip day average related dow dog nike come swing bullish north america beverage snack heavyweight have fall year date share swimming well day move average august coca cola conagra brand cag procter gamble pg other defensive stock have suffer postelection sector rotation infrastructure financial top be ongoing wellness focuse trend have consumer gravitate more natural food drink coca cola share end lower wednesday also edge back day line related coke buy african bottle unit anheuser billioncoke altrium tumble investor rotate food staplescoke pepsi face wrath voter measure target soda makersdisney studio segment be ride high medium conglomerate movie occupy top gross spot box office accord box office mojo mostly thank marvel lucasfilm pixar property espn growth have be sluggish investor concern linger subscriber loss threat further cord cut sport right cost other factor such decline nfl rating disney share be only fractionally spend much year day day line share dip finish wednesday still buy point ibd take ride postelection sentiment stock have more double year date performance dow fifth notable name rise tandem oil price related rogue box office bear promise star war offshoot rogue show force be still strong star warsdisney studio cash cow continue moo even espn wo simmeribd medical biom biotech medical ethical drug industry group pop nov respectively follow donald trump presidential promise just few week later lower drug price wound knock stock group share pfizer member medical ethical drug group be less year stock dip wednesday company say friday have complete right acquisition astrazeneca late stage small molecule infective business related drug stock topple donald trump pledge bring drug pricesdonald trump republican win ease drug pricing debate payment process titan stock be also less year visa mastercard paypal pypl experience particularly sharp sell nov reason be not entirely clear visa mastercard do hold credit card balance card issue bank do so don benefit higher interest rate many financial visa have lurch day then build flat base entry share lose less wednesday related visa mastercard paypal stock suffer ugly loss american express fly
356,PFE,outspoken former pharmaceutical executive martin shkreli say national outrage drug pricing be blow proportion heighten presidential election concede have predict blowback better term regret maybe not see acutely ve be minor regret shkreli say interview bloomberg tv friday price increase have stick so speak don really main mission be raise price have generate increase revenue happened so happy respect privately hold turing pharmaceutical ag be company fire price increase older drug lack competition mylan myl maker emergency allergy shot epipen valeant pharmaceutical international vrx company have be question congress subject criticism public turing shkreli be include senate committee report release week call government stop monopoly business model employ drugmaker raise price drug former hedge fund manager post twitter frequently shkreli become face drug outrage turing raise price daraprim fight sometimes deadly parasitic infection more fold left turing be charge federal authority unrelated matter ask take same business strategy again year old say course concede put drug company run risk brash approach also call daraprim insignificant drug compare other larger product shkreli say be frustrated government many way be apparatus vengeance say pricing situation be blow proportion mentioned valeant pfizer pfe world second largest drugmaker other company have raise price recently turing do not respond request comment also say make many fan business world everybody do capitalism try get highest price product say be turn thoughtful sarcastic interview ask bloomberg anchor david westin ferro don know re familiar health care insurance say patient don feel brunt price increase drug make overall health care spending insurer often implement cost sharing patient increase premium patient pay response long term rise cost federal prosecutor have accuse shkreli defraud investor hedge fund used retrophin asset pay also allegedly hide control company unrestricted stock help pay debt be arrest december have plead not guilty say look forward upcoming trial schedule june re go landslide say evidence be clear do nothing wrong shkreli be know blunt opinion industry often try present unify front congressional hearing drug price february invoked fifth amendment right way refuse answer question then hearing call lawmaker imbecile twitter trial shkreli predict juror see somebody relate not figure claim be portray interview invariably person read headline martin shkreli hate martin shkreli get know martin shkreli love martin shkreli say tv interview shkreli bring federal fraud case co founder several associate hedge fund platinum partner have accuse platinum ponzi scheme platinum co founder mark nordlicht plead not guilty week shkreli say have tango hedge fund trade investigator bring case call investigation charge example government go interview bloomberg decline comment have speak federal investigator platinum case
357,PFE,new year renew hope stock market success etf investor remind beware old painful trap draw investing action plan tip pro be helpful first here be look past year exchange trade fund look forward be complete look back word be scorcher even simplest broadest cheapest exposure stock market etfs paid vanguard total stock market vti spdr spy ishare msci country world index acwi advanced last year respectively best worst etfs gain spy outpaced approximately average annualize return be impressive give sharp repeat bout volatility stock market even more impressive be performance specialize etf strategy investor seize profit purefund ise junior silver silj end year gain knock back final quarter be best performer nonleveraged etfs vaneck russia small cap rsxj fly higher vaneck vector fall angel high yield bond angl powershare db base metal dbb several etfs outperform major asset class foreign stock bond commodity industry keep hot growth streak total asset exchange trade product stand november more double level year accord morningstar datum importantly asset growth be drive net new inflow investor pour fresh money list etfs november say ben johnson morningstar director global etf research be track be record time close investor prize broadly diversify exposure core satellite segment financial market investing etfs be low cost tax efficient way get exposure prime portfolio new year bear mind market investment outlook be lot different year past tie large part change political regime donald trump presidency couple republican controlled congress translate more favorable business environment industry sector be expect benefit more other likelihood corporate tax cut less stringent regulation more government spending think bank insurer oil gas firm maker heavy machinery build product not too late ride great rotation financial material industrial sector nov election investor keep best opportunity broad sector mind make financial plan todd rosenbluth director etf research cfra say recent whole follow nov election etfs smaller cap skew such fidelity msci industrial fidu spdr aerospace defense xar have edge rival larger cap skew such industrial select sector spdr xli powershare aerospace defense ppa trend continue climate stronger gdp number rise interest rate smaller cap stock generally be more sensitive economy rosenbluth tell ibd election optimism have improve future growth much past year growth outpaced value investor turn inexpensive name shift signal clear risk tone market strategist state street global advisor write recently continue trump administration continue strike more pro cyclical pro business tone investment management firm tie value comeback investor leeriness scarce earning growth relatively high stock valuation etfs make focus value stock self evident ishare russell value iwd ishare edge msci usa value factor vlue vanguard value vtv example top holding include household name such apple aapl exxon mobil xom jpmorgan chase jpm pfizer pfe other case such ishare edge msci multifactor usa lrgf spdr msci usa strategicfactor qus value bet be less obvious most dividend etfs offer value tilt too not fare equally well reflationary environment ahead high dividend stock likely struggle rise rate accord blackrock strategist other hand quality company consistently grow dividend hold better yield rise add company be find etf wrapper ishare core dividend growth dgro proshare russell dividend grower smdv proshare midcap dividend aristocrat regl smdv regl jump more apiece become top diversify etfs respective category total exchange trade product debut fourth highest total accord morningstar prove have too much good thing johnson morningstar etf guru be vocal critic describe spaghettus cannon very niche increasingly complex etfs be launch market note satisfaction be also record year etf closure approximately count expect time go number only continue grow lot spaghettus provider have be sling wall recent year ultimately fail stick be quote say recently happily smart etf investor aren take bait gimmicky new product add evidence johnson point fact most new money be go lowest cost most broadly diversify etfs serve core portfolio build block related personal finance action plan stock market reviewsmall cap value etfs show again be darling market
358,PFE,clovis oncology clvs pop thursday month high biotech say drug candidate be spare fda panel discussion clovis stock gain aug fda grant priority review application approval rucaparib ovarian cancer feb decision deadline process have slow agency have decide convene panel outside expert fda often convene such panel seek feedback drug have issue ibd take ibd medical biom biotech group have jump week quarter mean good time be tracking group high drug price major ongoing issue sector hunting biotech stock investor want check earning volume gain vs revenue gain clovis be something race be first market rucaparib class drug call parp inhibitor tesaro tsro score surprise late stage clinical trial own parp inhibitor ovarian cancer back june medivation mdvn be process be acquire pfizer pfe have parp inhibitor advanced development breast cancer class do have checker history other clinical trial raise possibility extra fda scrutiny clovis say brief sec filing thursday fda have decide skip expert panel however tesaro investor also seem relieve news tesaro stock be stock market today related biotech stock make big move september
359,PFE,recent wall street darling sarepta therapeutic srpt isn only potential takeover candidate hot potentially hot biotech company say rbc capital market research report wednesday rbc analyst list ariad pharmaceutical aria spark therapeutic once biomarin pharmaceutical bmrn aerie pharmaceutical aeri intra cellular therapy itci tesaro tsro incyte incy puma biotechnology pbyi well sarepta top takeover contender late stage fda approve blockbuster franchise sarepta stock rocket monday fda approve drug treat duchenne muscular dystrophy first drug approve treat rare disease sarepta stock hit time high wednesday first time march sarepta close stock market today close sarepta announce plan offer stock finance further trial production other drug effort share be little change late ibd company medical biom biotech industry group rise wednesday sixth straight gain touch month high intraday group rank group track just week second half be likely prove rally point biotech stock rbc analyst say biotech sentiment continue improve investor climb wall worry get year past election believe have be mostly base political rhetoric analyst write ibd take many biotechs fair number stock overall have recently hit week high check stock list composite rating ibd new high list be good feature check winning stock furor have be heating biotech sector past month biotech acquisition value have be announce rbc say smattering smaller deal tuesday allergan agn announce agreement acquire liver disease drugmaker tobira therapeutic tbra much big deal pending pfizer pfe be buy medivation mdvn june buy anacor pharmaceutical also abbvie abbv be acquire privately hold stemcentyrx shire shpg baxalta complete merger june related sarepta soar fda approve drug treat muscular stock hot sarepta provide shot arm
360,PFE,swiss pharma giant novartis nvs say wednesday shutter cell gene therapy unit say remain commit cancer fight car cell program market take negative vote program however knock car focuse stock juno therapeutic juno bluebird bio blue kite pharma kite endpoint news first report cell gene therapy unit disband say activity be integrate larger novartis organization position be eliminate include unit head usman azam novartis still plan file approval lead car candidate ctl acute lymphoblastic leukemia next year kite juno be also work therapy target cd antigen stock market today novartis fall juno be kite be bluebird have earlier stage car program be ibd take car therapy have yet make market make investing very risky business find ibd choose winning stock see slim investing system view investor view negative datapoint car suggestion novartis be cut back investment resource car write rbc capital market analyst michael yee research note think reorganize restructure division sound pretty typical regular big pharma broader bureaucracy vs biotech novartis be essentially third player man cd race kite lead big market diffuse large cell lymphoma dlbcl juno novartis target lead indication cellectis cll pfizer pfe start phase allogeneic cd shelf work didn help matter late tuesday btig initiate coverage kite pharma neutral rating note datum car therapy be still very limit have show spectacular result kite kte be first market next year write analyst dane leone not yet know datum ultimately compare novartis juno
361,PFE,embattled drug giant mylan myl say monday take unusual step launch generic competitor own product epipen half price original mylan spend last week defend criticism senate presidential candidate hillary clinton multiple price hike epipen emergency allergy treatment thursday mylan say expand patient assistance epipen actually lower price monday say next few week release generic version pack compare current price brand decision launch generic alternative epipen be extraordinary commercial response require cooperation partner say mylan ceo heather bresch statement presumably refer pfizer pfe draw royalty product however complexity opaqueness today brand pharmaceutical supply chain increase shift cost patient result high deductible health plan determine bypass brand system case offer additional alternative be best option ibd take mylan misadventure show rely price increase growth be risky strategy find much other drugmaker be do same check recent rundown price vs volume growth big biotechs later monday however rep jason chaffetz utah chairman house committee energy commerce ranking committee member elijah cumming md send letter bresch ask documentation relate mylan income profit epipen well patient assistance program government funding arrangement pfizer lobbying activity republican member house committee energy commerce also send letter fda ask process approve epipen generic competitor have come fire quarters take so long mylan also intend bypass system complexity launch direct ship program epipen customer potentially get middleman bresch say last week take cut most epipen list price normally generic competition threaten drug developer make deal generic drugmaker sell exclusive authorize generic first month other competitor come market however mylan main business be generic drug essentially be generic partner epipen have be patent generic version drug contain epinephrene be already available injection device deliver precise dose drug proven tricky replicate sanofi sny have competitor call auvi be recall last october device malfunctioned teva pharmaceutical industry teva have device fail first attempt fda approval company expect re file come month estimate mylan launch epipen authorize generic ag have impact epipen sale estimate modest impact ep forecast leerink analyst jason gerberry write research note estimate ag impact do not account reduction sg sale general administrative spending commitment epipen mylan look initiate order mitigate ep downside mylan initially rally much generic epipen news close stock market today teva stock be
362,PFE,injectable drug specialist eagle pharmaceutical egrx stock be sharply monday get downgrade mizuho say thesis have play eagle stock jump june teva pharmaceutical industry teva win patent case several generic drugmaker include pfizer pfe hospira unit sagent pharmaceutical sgnt be try launch generic version blood cancer drug treanda january teva eagle launch low volume faster act version treanda call bendeka say expect replace treanda market eventually mizuho analyst irina koffler write research note expect company retain market exclusivity bendeka say other catalyst be slow come treanda bendeka switch be genuine success story eagle other hospital launch ryanodex docetaxel have be more challenge koffler write downgrade stock neutral buy be remind cost be still critical set insight have influenced longer term outlook bendeka rest eagle portfolio koffler note eagle be prepare file approval version eli lilly lly lung cancer drug alimta be alter way similar bendeka reformulation treanda doubt be lucrative teva deal be concern competition other filer allergan agn have already launch type product eu write reason think replicate bendeka agreement be challenge here eagle turn first annual profit last year cent share analyst expect jump year help bendeka launch stock nonetheless have single digit relative strength rating end trading stock market today
363,PFE,back specialty drug maker allergan be fend hostile takeover bid valeant pharmaceutical main reason resistance be claim valeant decimate research development capability indeed time valeant boast have figured way spend far less other large drugmaker still crank new drug year later scene look very different valeant vrx plague scandal financial trouble be reworking business model ireland base allergan agn be tout approach call open science follow merger actavis merger pfizer pfe have be industry largest be scuttle april change tax rule concern company look locate headquarters lower tax country valeant botox maker allergan doesn have own internal research infrastructure spend less typical big pharma still spend more valeant other low cost specialty pharmas collaboration host small biotechs other external developer quest lead drug allergan ceo brenton saunder chief david nicholson recently speak ibd explain more open science mean help allergan grow ibd lot company acquire license externally develop drug so be open science differentiate saunder maybe start give perspective open science think prefer model allergan start premise innovation investment be crucial success allergan mission be help person live life better find cure treatment unmet medical need so therefore need be innovation business look do participate most efficient effective way believe open science be most effective construct allergan be focuse therapeutic area try be leader build scale discovery platform be potentially look innovation come innovation health care be best accomplish believe be better tap very vast ecosystem innovator be academic research center re venture backed startup company re private company re base public company re research spinout large pharmaceutical company look totality universe much larger anything ever build own also provide additional advantage be provide ability pursue best idea best probability success potential meet most unmet need re not wed internal program have make significant investment have justify cancele bypass order chase idea believe be better think also create attitude difference don have team person here be opposed go outside fresh idea don have not invented here syndrome depend open science sustain innovation flow so need be good partner licensing acquire asset so ve develop core capability now order be good partner part open science mean need be development powerhouse also commercial powerhouse generally person don want give idea have extreme confidence finish have requisite skill research development pharmaceutical science clinical development regulatory affair get science become drug generally want take royalty milestone payment regard commercial success so want believe hand approve drug become commercial success well nicholson advantage don have internal research organization be don need do technology base collaboration feed research have collaboration be exquisitely focuse product therapeutic area open science model be collaboration huge resource external world biotech industry open science model be focuse exquisitely novel innovative product opportunity therapeutic area think make almost unique industry ibd so say don have license technology be talk platform delivery technology something nicholson talk technology platform talk very very fundamental research technology discovery technology clearly be interested technology be utilize development novel pharmaceutical science technology instance do deal anterio recently give access technology let get large molecule dermal barrier don do discovery research don have have pure technology base discovery collaboration have collaboration early space technology be already deliver development project saunder have deep discovery platform technology take away flexibility purse novel interesting new technology ve make such investment capability almost fix investment ibd many company be look drug acquire license competitive be scene saunder area remain incredibly competitive good example be oncology really be arm race occur large pharma acquire much technology possible particularly technology be explode see dealmake price dealmake lately cancer arena therapeutic area compete be competition generally be pound gorilla area pride reputation be easy do business be commit strong productive partnership skill something believe be competitive advantage something take quite seriously ibd appropriate spending level be much debate late do decide appropriate level saunder view spending dollar be very practical invest believe investment target unmet medical need innovative probability success meet certain criterium have capability make successful so very differently most rest industry don target spend base revenue number spend program think make difference nicholson be part open science model don have fix cost be normally associate run discovery organization make certain have development powerhouse certain proportion flexible spend therefore flex amount cash spend depend pipeline need ibd preference stage development enter process external program saunder best keep secret allergan be enter agreement collaboration stage development early mid late ve do quite successfully drug just launch schizophrenia bipolar mania vraylar enter collaboration year really develop drug phase way approval be quite complex pharmaceutical science development person tend talk bring later stage seem more real right closer time reality be be very open mind enter collaboration related structure time continuum so long meet criterium meaningful innovation probability success fit capability ibd course probability success be more difficult gauge earlier get do gauge saunder lot time manage structure example have structure deal company call rhythm health really be impressed work rhythm health be do condition call diabetic gastroparesis really hasn be meaningful pharmaceutical advance diabetic gastroparesis year david team allergan evaluate science work be be do rhythm early thought be incredibly innovative so sign option agreement rhythm finish phase study read few month positive have option bring allergan phase finish development do same thing company call trevena trvn acute heart failure drug report result few week study fail therefore didn exercise option don have size fit do deal stage development depend preference partner conviction science side make sense thing be hallmark allergan be be open flexible principle mutuality do create inventor idea person be responsible bring conclusion re always look mutuality deal create scenario make everyone feel good remain constructive productive bring fruition
364,PFE,better big dividend big dividend get even bigger company make dividend leader list offer yield well north average payout today column highlight highest dividend growth rate cisco system csco top list long term cash payout growth rate
365,PFE,vca massive west los angele animal hospital pet get chemotherapy mri scan receive acupuncture chinese herbal treatment rehab underwater treadmill be enter behavioral counsele well join weight management regimen dog cat rabbit bird prey potbelly pig welcome hospital offer high profile proof thrive pet health
366,PFE,major index retreat quickly hour tuesday session least member dow jone industrial average refuse join crowd pfizer pfe surge nearly clear handle buy point month cup base move come pfizer post sale beat wall street consensus view raise guidance base pass midpoint test handle midpoint exceed base volume be run more time usual pace average daily volume pfizer share be roughly share hour trading day nasdaq composite drop nearly more loss dow industrial index quickly give back monday advance more dow transport slump more dow utility be nearly dow industrial component bank suffer biggest slide jpmorgan chase jpm gap more slide day move average more double average trade goldman sachs gs fall more investment bank be still depth first stage base lie more week high meanwhile pfizer say sale jump full higher expect maker name brand prescription pharmaceutical counter medication include viagra impotency drug advil painkiller note first quarter benefit extra day boost top line adjust earning rise cent share vs cent year crush cent consensus view pfizer get lowly composite rating ranking ibd medical ethical drug industry group see ranking here ibd stock checkup year annual ep growth rate be weak company be express bullishness new product be go late stage clinical trial company be also plan decide year spin generic business pfizer generic sale jump nearly patent protected drug sale rise elsewhere stock market today growth stock leader weibo wb cool fall more volume zoom time normal pace social network know twitter twtr china be still sharply recent cup handle buy point weibo break april recently hit high past proper entry weibo earn composite rating ibd sell rule include take least profit stock gain follow proper base read more article ibd major sell rule help lock gain minimize loss type sell rule search box top investor com apple aapl be try stem sharp slide rise fractionally fast turnover tech giant trigger sell signal back august past double bottom base fail stock then slide key day move average heavy trade notch second key sell signal
367,PFE,stock future be early lows head tuesday open bell dow industrial nasdaq future trade fair market value
368,PFE,stock market today feel early pressure overseas weak manufacturing datum left china market sharply divide place pressure global commodity price commodity turn weigh international stock action london base researcher markit report marginal deterioration china manufacturing sector april output remain same march new order stagnate export fall fifth straight month inflationary pressure higher input cost rise fastest pace january shanghai composite advanced hong kong hang seng index fall eurozone benchmark be nearly late morning trade london ftse be japan tokyo stock exchange be holiday thursday economic news fiat chrysler fcau report sale rise april jeep brand sale rise sale dodge truck other auto maker be expect report april sale session key earning report factor heavily premarket action cvs health cvs climb almost halliburton hal slip report first quarter result coty coty shed sprint muscle follow respectively fiscal fiscal result drug maker stake early lead premarket action pfizer pfe narrow early gain earning revenue easily top consensus expectation be pfizer second ep gain quarters management raise full year earning guidance forecast lift revenue guidance high end expectation company statement say late stage product pipeline be increasingly ready deliver next set prospective growth driver stock end monday buy point cup handle base mylan myl lead mixed first quarter report ibd stock premarket gain be volatile loss be bit more steady inc research incr drop almost downgrade robert baird pra health science prah also retreat announce share secondary offer monday close big foreign bank be take early hit ub ub drop report deutsche bank db royal bank scotland rb tank credit suisse cs slump oil price slip more west texas intermediate trading just barrel gold be almost half percent hover ounce company schedule report close be avis budget group car agrium agu illumina ilmn
369,PFE,april auto sale release tuesday be catalyst general motor gm ford motor fiat chrysler automobile fcau earning pfizer pfe mylan myl cvs cvs be also top list need watch gm ford fiat chrysler miss analyst estimate sale march expert projection industry sale level several year boom growth edmund com expect seasonally adjust annualize rate saar sale reach april march last april power lmc automotive joint forecast see sale saar month gm have shape cup handle base buy point find support day line currently trading buy point week high dip fraction monday ford be week high share be try find support downward slope day line ford add intraday trade fiat chrysler be trading day line day line share be week high monday drug giant pfizer mylan issue quarterly report tuesday morning pfizer earning be project rise cent share revenue increase pfizer scrap inversion buyout plan allergan agn last month treasury department issue new rule curb tax beneficial deal pfizer be able retake day line early april end session lose streak monday add share be trading week high meanwhile mylan be expect see earning rise cent share gain revenue last quarter mylan miss expectation stock crumble company also announce be buy sweden meda mylan breach day line last week snap straight session decline monday stock be trading week peak climb monday drugstore chain be expect see earning rise share report tuesday morning revenue be project jump cvs find support day line be able retake day line rise monday day recently crossed day stock performance have improve share be trading high reach last july continue consolidate
370,PFE,stock open lower wednesday index pare loss nasdaq dow jone industrial average be farm productivity decline first quarter vs fourth quarter accord preliminary estimate labor department consensus projection call decrease labor cost jump estimate rise trade deficit drop abruptly march commerce department say slim vs gap february analyst consensus have expect et researcher markit deliver service purchasing manger index april institute supply management offer manufacturing index commerce department report march factory order number weekly oil inventory report be due energy information administration priceline pcln crumble early headliner big day earning report travel site first quarter earning revenue beat consensus forecast second quarter earning guidance be weak time warner inc twx royal dutch shell rdsa anheuser busch bud be also motion quarterly report exchange ice climb atlanta base operator new york stock exchange announce have end discussion regard acquisition london stock exchange group share have be gradual uptrend announce interest lse march stock be attempt build right side consolidation have be stall resistance week move average genetic screening equipment maker illumina ilmn drop ahead bell report late tuesday revenue earning stop short analyst expectation management also trim second quarter earning revenue guidance consensus forecast ibd list medivation mdvn swung nearly news report late tuesday say pfizer pfe approach company regard possible acquisition deal medivation have decline takeover bid france sanofi sny last week paycom software payc pop premarket action developer human resource management software report board first quarter beat late tuesday stock have be race right side possible base end tuesday february low couple notable market change tuesday tough session nasdaq already day move average lose grip day line russell drop day line rise trade today critical test nasdaq be hold short term lows marked friday global market feel share selling pressure wednesday china yuan appear be key factor diving sharply person bank china loosen peg dollar hong kong hang seng index slip shanghai composite shed japan tokyo stock exchange remain close holiday benchmark index paris frankfurt trade bit less midday london ftse be euro yen ease tuesday high vs dollar gold slump less oil trade nearly take back piece tuesday loss
371,PFE,specialty drug giant allergan agn get conflict message wall street friday goldman sachs put stock conviction buy list mizuho lower price target due differ opinion company term strategy goldman analyst jami rubin write research note meeting top executive believe company be track deliver sustainable double digit top line growth margin expansion rubin add term catalyst include close allergan sale generic business teva pharmaceutical industry teva teva allergan confirm week happen next month well potential share buyback allergan unveil earning report tuesday rubin allergan decision scale back acquisition strategy favor stock buyback make sense believe allergan management be listen shareholder place capital deployment priority unlock value investing most attractive asset available allergan share rubin write mizuho analyst irina koffler however find shift less inspiring aside large share buyback management be not pursue change business expect be less excited execution story write research note lower price target affirm neutral rating market now side goldman allergan stock rise stock market today allergan share be still nearly year plunge april company pfizer pfe call marriage treasury department issue new rule discourage merger enable company move headquarters lower tax country such allergan home base ireland
372,PFE,drugmaker actavis face fine raise cost hydrocortisone tablet more british antitrust regulator say friday continue crackdown excessive pricing pharmaceutical industry division teva pharmaceutical industry teva break competition law charge excessive unfair price competition market authority say statement example company raise price milligram pack roughly cent currency teva acquire actavis allergan agn earlier year say defend allegation be lifesave drug rely thousand patient national health service nhs have choice continue purchasing say andrew grove cma senior responsible officer allege company have take advantage situation removal drug price regulation leave nhs ultimately taxpayer foot bill substantial price rise cma send actavis statement objection layer concern wider crackdown unfair drug pricing dec cma fine pfizer pfe flynn pharma record amount abuse dominant position charge unfair price unbranded version epanutin epilepsy drug regulator fine pfizer roughly flynn pharma increase price much september price increase occur pfizer transfer distribution right flynn sell medicine generic name phenytoin sodium teva be already process selling actavis operation inta pharmaceutical ltd say cma probe raise broader question regulation generic medication pricing actavis product investigation be never teva effective control teva believe intervention cma price generic medicine raise serious policy concern regard role cma department health teva say generic medicine continue be affordable alternative brand therapy statement objection often lead fine order change business practice regulator have power fine company find have abused dominant market position annual revenue hydrocortisone tablet be used primary replacement therapy person adrenal gland do not produce sufficient amount natural steroid hormone result condition such addison disease tablet be also used treat condition such arthritis blood hormone immune system disorder skin eye condition breathe problem cancer severe allergy actavis also increase price milligram hydrocortisone tablet nearly result charge nhs pack march cma say nhs have previously paid equivalent pack april nhs spend pound year hydrocortisone tablet nhs spend tablet have rise year steep price hike have put string drugmaker microscope company mylan myl valeant pharmaceutical international vrx bearing brunt public outrage president elect donald trump have be cite boon free market health care also declare opponent high drug price interview time magazine
373,PFE,key market index hit new time high friday stock hold moderate gain head last hour trading dow jone industrial average rise nasdaq add volume be lower board vs same time thursday oil drugstore food related issue lead upside stock market today west texas intermediate crude price rise barrel gold future fall nearly ounce gold miner steel department store retailer underperform pfizer pfe coca cola ko merck mrk be biggest dow winner gain more also blue chip apple aapl advanced retook day move average first time month share iphone maker be work flat base buy point microsoft msft climb new time high be now slightly extend flat base entry clear oct fast turnover software consumer product giant be expect benefit information technology spending increase accord recent pacific crest security report most ibd stock be lower only dozen advance afternoon chipmaker macom technology solution mtsi slump average trade remain extend cup handle buy point other ibd chip stock take hit include advanced energy industry aeis apply material amat none decline be alarm stock backed high light volume economic news university michigan preliminary consumer confidence index rise december well expectation read related fang apple alphabet regain key support facebook be lag boost technology budget benefit amazon microsoft salesforce
374,PFE,major average be higher midday friday dow jone industrial average nasdaq etch fresh time high apple aapl jump day move average rise nearly work new base only week high pfizer pfe coca cola ko outperformed dow biogen biib broadcom avgo be top gainer nasdaq nasdaq composite add dow rise volume nyse nasdaq be tracking close thursday level consumer confidence be strong again accord preliminary read university michigan index rise december nicely consensus estimate stock market today couple fiber optic name reversed positive news big gain sector thursday bullish outlook ciena cien thursday fuel big gain group strong number finisar fnsr late thursday also help sentiment seller be force friday finisar reversed intraday gain fall nearly lumentum lite lose broadcom jump buy point report strong earning late thursday share rise quarterly profit jump year third straight quarter accelerate growth sale jump nearly several chip name underperform nasdaq friday biogen be nasdaq best gainer rise biotech give back early gain stock reversed higher thursday positive phase datum alzheimer drug related apple alphabet regain key support facebook be laggingbroadcom finisar price target hike astrazeneca top pickeli lilly continue alzheimer push flop biogen extend rise
375,PFE,stock open slightly lower wednesday better expect august job datum dow industrial be nasdaq slip dow pfizer pfe rise fraction exxon mobil xom fall less veeva system veev bolt open second quarter result easily top analyst target ibd leaderboard stock pull back nearly heavy trade tuesday set rebound support day move average china base internet portal sina corp sina open lower jpmorgan reiterate stock overweight rating wednesday morning note block hrb drop start trading tax service chain report earning revenue fall more be expect analyst second quarter palo alto network panw dive open cybersecurity firm fiscal fourth quarter report late tuesday show earning revenue just expectation palo alto first quarter earning revenue guidance stop short consensus estimate astrazeneca azn slip more security exchange commission announce drugmaker have agree pay settle charge have paid bribe state worker doctor return increase prescription russian chinese operation deutsche bank db share rise company chief executive say european bank be need consolidation dismiss rumor possible tie commerzbank week first shot job datum be bit better expect adp national employment report show nonfarm private sector employer add worker august adp also revise july new job tally initial estimate economist have project slowdown position add service sector add job month manufacturing sector employer trim payroll job notably construction sector employment contract worker job number continue challenger job cut report august due thursday morning follow labor department august payroll report friday et kingsbury international report chicago purchasing manager index august july pending home sale number be expect national association realtor et energy information administration give weekly oil inventory report et oil price slump more ahead morning weekly storage datum send west texas intermediate barrel tracking second straight weekly decline gold trade half percent ounce dollar gain vs euro yen year treasury yield edge basis point china market turn narrowly mixed finish japan tokyo nikkei climb europe market be also tightly mixed cac paris frankfurt dax ftse london show narrow loss afternoon trade related investing action plan ollie salesforce earningspalo alto fall guidance veeva system rally
376,PFE,load player stock index close narrowly mixed monday day sector current help decide outcome nasdaq inched largely thank strength biotechs industry group rise more news pfizer pfe acquisition medivation mdvn reignite speculation more buyout health care medivation make prostate
377,PFE,drugmaker abbvie abbv pfizer pfe be featured ibd daily income investor column last month be know steady grow dividend well consistent profit growth name have come selling pressure recent week bellwether income stock group be trading tightly high deserve closer look ibdchart symbol mrk
378,PFE,load player help local government manage document not sound sexy be profitable grow business tyler technology tyl plano texas base company earn spot forbe list most innovative growth company rank enterprise innovation premium difference market capitalization net
379,PFE,gilead science gild apple aapl lead largest amount spend stock buyback first quarter total set year high company seek boost stock price slumping market accord dow jone index gilead spend spend prior quarter apple spend slightly prior quarter company spend total stock buyback be second largest expenditure record follow spend report dow jone index information technology sector continue dominate buyback follow apple sector be microsoft msft oracle orcl alphabet googl microsoft spend oracle alphabet follow gilead apple biggest spender general electric ge be then come pfizer pfe mcdonald mcd microsoft be overall ninth consecutive quarter more company reduce year year diluted share count least thereby boost earning share least pace buyback be partially drive company support stock open downturn year coincidentally start early february many earning lock up end say howard silverblatt senior index analyst dow jone index statement announce tally upswing expenditure participation appear persist market meaning upturn be not single shot saidaccording silverblatt cash reserve set record increase top prior record set end silverblatt add current cash level be week expect operate income give corporation leeway expenditure buyback leader apple stock rise end quarter apple stock be fraction close stock market today gilead shrank end quarter gilead stock end trading wednesday
380,PFE,share pharma major abbvie abbv be slide wednesday morgan stanley downgrade concern increase competition analyst david risinger downgrade abbvie stock equal weight lower price target note nature abbvie pipeline have become clearer day june presentation cancer drug weekend include negatively receive report rova meantime abbvie still depend immunology drug humira analyst say sale humira be world best selling drug generate abbvie total sale estimate vast majority profit risinger write humira not only face challenge several biosimilar player include amgen amgn novartis nvs sandoz pfizer pfe also novel brand injectable oral abbvie score string patent litigation victory allay investor concern be unable make call risinger write humira market exclusivity already suffer setback last month patent board agree review challenge humira patent bring biosimilar developer coherus bioscience chrs likely take year resolve risinger write newer class drug treat same condition humira do include novartis cosentyx eli lilly lly taltz baricitinib slow humira growth term threat gain support wednesday novartis say presentation european league rheumatism conference run wednesday saturday be new long term analysis suggest cosentyx lead higher response humira improve sign symptom person live ankylose spondylitis psoriatic arthritis psa week novartis say initiate head head trial confirm say abbvie own novel autoimmune disease product help offset moderation include jak il risankizumab risinger write expect launch abbvie stock fall close stock market today share touch month high friday
381,PFE,bristol myer squibb vs merck pfizer vs lilly unique treatment abbvie abbv take spotlight next week biggest drug conference focuse treatment biggest disease cancer annual meeting american society clinical oncology chicago june be prime opportunity check potential blockbuster drug abstract most presentation be release public give gist study result leave detail conference most interesting item investor be late breaking abstract past several asco meeting battle immunotherapy be major theme market pd inhibitor bristol myer squibb bmy opdivo merck mrk keytruda be already big seller skin lung cancer opdivo ahead market share ongoing research give idea true market potential well stack other be often case cancer drug opdivo keytruda be approve advanced case disease first largest market opportunity be front line treatment newly diagnosed patient cancer largest market opportunity be small cell lung cancer nsclc bristol myer merck be target first abstract release merck keynote study keytruda combination chemotherapy yielded improvement progression free survival pfs month overall month patient tumor show high expression pd ligand pd inhibitor indirectly target here continue see solid orr overall response rate percentage tumor shrank pfs datum look meeting better understand durability response longer period time write credit suisse analyst vamil divan research note bristol myer be also conduct first line nsclc study most significant be checkmate combine opdivo bristol myer immunotherapy drug yervoy prove be most effective combo then be huge company bristol myer wholly own treatment thus gain revenue be new checkmate info early abstract analyst hope be late breaking datum morningstar analyst damien conover say also want see datum tecentriq roche rhhby entry sister class drug target pd ligand directly coincidence fda approve tecentriq type bladder cancer call urothelial carcinoma same day asco abstract be release be first file bladder cancer conover tell ibd bladder big indication not big lung cancer have niche roche really help drive drug sale leerink analyst seamus fernandez however note tecentriq soon have competition show other asco presentation initial datum bristol myer opdivo astrazeneca azn durvalumab show higher response rate indication fernandez write research note smaller patient number datum set baseline characteristic be present asco be closely watch newer battle seem be shape different drug class call cdk inhibitor used treat breast cancer cdk stand cyclin dependent kinase enzyme tie cell division encode gene cdk cdk inhibitor help stop cancer cell multiply first pfizer pfe ibrance launch early take last year expect swell billion eventually eli lilly lly however have make noise cdk inhibitor abemaciclib show much higher response rate refractory patient do ibrance asco abstract lilly monarch trial month treatment number be only still better ibrance slight disappointment wall street lilly day tuesday company say also be present month datum asco so still be upside surprise nonetheless evercore isi analyst mark schoenebaum write lilly executive didn seem enthusiastic lilly seem not want boost investor expectation regard month datum therefore reiterate orr result report month ask schoenebaum write email client additionally lilly encourage investor also look overall clinical benefit duration response presentation asco hover background not asco be novartis nvs announcement have stop late stage trial own cdk drug early have already hit primary endpoint improvement pfs detail have later medical meeting also positive development space analyst divan tell ibd room more winner meanwhile pfizer score hit treatment late stage datum show ibrance combination estrogen blocker letrozole yielded pfs more month month more letrozole alone prod analyst fernandez raise sale estimate whole cdk class estimate ibrance sale alone late breaking datum other field study many wall street be eyee be midstage trial rova drug abbvie be acquire buyout biotech stemcentryx rova be treatment small cell lung cancer sclc smaller market enormous nsclc population definite opportunity lack specifically approve treatment previous study have show response rate relapse patient high expression delta protein dll appear sclc patient tumor presentation asco be particularly important stemcentryx be report long term survival datum be gold standard cancer trial far fda be concern analyst schoenebaum say rova have improve survival enough differentiate know chemotherapy produce month os overall survival set re testing rova schoenebaum say video record client know be datum asco abstract show pd yervoy produce month lot toxicity punchline be need see os datum well excess month abbvie have estimate peak annual sale rova hit
382,PFE,share biotech ionis pharmaceutical ion plummet nearly year low thursday partner glaxosmithkline gsk say win pursue late stage trial ionis rare disease drug news lift alnylam alny have rival drug testing be already sign trouble back april fda place clinical hold company phase trial ionis ttr treatment rare deadly inherited condition call familial amyloid cardiomyopathy fac subtype larger condition call ttr amyloidosis fda want glaxo answer question trial patient monitoring protocol follow report fall platelet count trial ionis ttr different type ttr amyloidosis call familial amyloid polyneuropathy fap latter trial be already underway fac trial be still plan phase be trial glaxo decide not initiate fap trial be ongoing glaxo consider option fac once have more datum ionis say ionis stock have plummet close stock market today roughly week high hit last june glaxo stock be few cent research note leerink analyst michael schmidt write wasn clear drug be actually cause platelet problem problem come disease however comparison other trial weren encourage note alynlam hasn see ttr phase trial fac fap respectively patient combine schmidt write similarly pfizer pfe phase trial tafamidis fap also do not indicate knowledge raise question signal be due antisense technology severe however be issue prosensa drisapersen now know biomarin bmrn kyndrisa be base similar chemistry ionis drug alnylam stock jump more close pfizer be fraction biomarin fall
383,PFE,walt disney macy gap gps kohl kss fossil fosl other report weak earning guidance trigger broad sell retail other consumer stock not share amazon amzn meanwhile apple aapl tumble year low fresh evidence iphone demand remain weak major index ultimately close modestly lower dow industrial fall key support major average fall third straight week most loss come friday dow fall close day move average first time feb nasdaq already key line retreat market uptrend remain pressure retail consumer group be big loser raft weak earning report guidance like walt disney macy oil price rise month high week retail sale rise april best gain more year couldn shake gloom surround retail consumer stock macy kohl jwn jcpenney jcp dd tumble dismal first quarter report guidance macy upscale slash outlook sharp ep decline kohl post same store sale drop be worst height great recession accord retail metric macy stock fall year low kohl fall nearly set year worst jcpenney lose respectively meanwhile watchmaker seller fossil collapse miss view slash guidance fossil hint competition apple watch other wearable gap say same store sale sank april comp ahead full result share plunge nearly worst late wal mart wmt home depot hd ross store rost also continue flood retail earning next week medium conglomerate deliver first earning miss year share profit grow revenue grow short consensus espn lose subscriber once again medium network segment didn appear disappoint wall street too badly studio revenue shot star war force awaken zootopia fanfare captain america civil war keep movie box office receipt high disney share tumble fall cup handle base well buy range disney close just day line apple stock fall last week new evidence apple supplier be see weak order upcoming iphone suggest apple sale wo continue quite time separately apple invest didi chux chinese ride hail service app apple stock fall lowest level june lose market cap crown barely google parent alphabet googl amazon intensified rivalry alphabet google launch new video stream service comparable youtube sanford bernstein analyst carlos kirjner tuesday raise price target amazon whopping wal mart wmt announce subscription service offer day free delivery vs day brick mortar retailer struggle amazon rise investor bet share consumer spending keep expand facebook release guideline reveal social medium giant rely far more person trend news topic contradict earlier company claim be largely drive computer algorithms earlier gizmodo suggest facebook be suppress news story conservative medium outlet facebook strongly deny allegation say have rigorous guideline place review team seek ensure consistency neutrality facebook ceo mark zuckerberg say meet conservative discuss facebook policy facebook stock rise week extend recent still buy range staple spls office depot odp call propose merger late tuesday federal judge agree federal trade commission deal have limit office supply competition big corporate customer staple crash office depot drop obama administration have block several megamerger recently include halliburton hal baker hughe bhi analyst say health insurance consolidation get hard look aetna aet seek buy humana hum anthem antm set acquire cigna ci treasury department tuesday call greater oversight nascent industry quick easy online payment lend solution threaten upend traditional banking have raise question safeguard potential abuse come day lend club lc say ceo renaud laplanche be step company find misconduct online lend platform relate loan sale lack financial oversight several large small bank halter work lend club share shed hit record low peer peer lend firm prosper recently announce large round layoff disappointing quarterly result ondeck ondk have prompt worry insufficient loan volume growth online gaming platform netease nte more double revenue beating estimate boost mobile game such fantasy westward journey newer release such kung fu panda ep also top share rise week move day line weibo wb twitter twtr social medium platform majority own sina sina fared well help mobile user growth strong ad revenue expansion major city share rise week online medium company sina also top view better sale narrower net loss expect strong weibo performance be key help ad revenue web portal segment lag share lose plunge day line close just day online retailer jd com jd report loss line expectation sale surge be just expectation revenue guidance be just shy analyst consensus share tumble lgi home lgih tuesday report surprisingly strong surge first quarter adjust earning share entry level homebuilder revenue fall short gross profit margin decline lgi home briefly flirted buy point fall trex trex world largest maker wood alternative decking railing product top view trex guide revenue consensus share reversed hard week gypsum wallboard related product maker continental build product cbpx profit climb share rise breaking base month high topbuild bld install build insulation also best wall street earning revenue estimate share july ipo rise prior week several housing report include housing start exist home sale april be tap next week solarcity scty torch wall street sale view late monday loss swell residential installer cut installation guidance booking fall short nevada cut net meter payment solar customer also monday rival vivint solar vslr report revenue rise still miss view loss widen installer sunrun run late thursday report surprise profit ex item revenue nearly double solarcity fall week vivint be nearly hit record lows sunrun be nearly even friday pop israeli giant teva pharmaceutical industry teva beat earning sale estimate guide slightly consensus teva say buyout allergan agn generic business be track close june earlier delay teva stock rise cent week allergan report mixed result earning beat sale miss drugmaker say ll buy stock allergan fresh fail takeover pfizer pfe signale ll focus more improve operation make big buyout future share rise third generic giant perrigo prgo hit year low report thursday issue guidance last month be few surprise perrigo fall week work fifth straight weekly loss smaller player jazz pharmaceutical jazz miss estimate stock rise news deal generic drugmaker not sell knock off lead drug xyrem end jazz share close meanwhile akorn akrx finally report number long accounting overhaul lift share more set report jab beech add krispy kreme doughnut kkd coffee empire pay share krispy kreme shot slightly offer price jab beech subsidiary jab hold own peet coffee tea stumptown coffee roaster caribou coffee einstein noah restaurant group intelligentsia coffee lead investor group buy keurig green mountain
384,PFE,nike nke have more patent defense contractor make stealth jet pharma develop cancer fight drug auto giant work self drive car athletic gear maker be grant patent last year end issue patent include expire accord patent trademark office uspto top lockheed martin lmt ford motor pfizer pfe doesn even include patent application nike patent have nearly double ceo mark parker boast last year company have third largest portfolio design patent nike have bury rival adida armour ua patent look maintain dominance avalanche innovation manufacturing design potentially toy wearable device appear apple aapl smartwatch fitbit fit tracker generally see type correlation company be release innovative game change product say envision ip manage attorney maulin shah say nike thousand grant patent be still active force nike double automation printing capability recent macquarie analysis uspto library observed meaningful acceleration nike patent recent month focuse new way manufacture product nike already have own army shoe painting water free dyeing robot just name few october announce partnership flextronic flex manufacturer have develop automate way cut material waste such saving flow bottom line add cent nike earning share macquarie analyst laurent vasilescu estimate april separately nike be build digital design system partnership dreamwork animation dwa include nearly instantaneous digital print application photo real visualization ultra rapid prototyp compare nike more active patent german rival adida have kind be stagnant patent portfolio be ninth size nike not include gain acquisition golf equipment maker taylormade say shah adida do have relatively large patent portfolio europe note globally nike have patent patent application vs adida roughly armour have be happy be frame tech company penchant snap fitness apps only have issue patent almost third be design not utility patent shah count utility patent athletic apparel primarily deal material think compression moisture wicking manufacturing method vs patent clothing design innovation aside patent also be indicator something far juicier peek company product strategy example armour be grant march patent arm compression sleeve design warm pitcher throw arm innings interestingly specific item indicated potential future investment baseball indeed few week later company sign washington national outfielder bryce harper reign national league mvp espn say be biggest endorsement deal ever baseball player term weren disclose source most nike recent patent activity be related manufacturing dive sprawl portfolio indicate potential shift device strategy nike hasn be wearable business axe most fuelband team year tomtom power nike sportwatch be more nike instead have be push revamp nike app hardware have say athletic apparel giant be shy away hardware development partnership apple particularly nike app be used apple watch patent say otherwise have be surge wearable related application nike last year shah say company now have active patent related wearable tech vs adida armour dozen patent publish uspto recently image patent athletic watch look awful lot tomtom version nike watch boxy look accessory perforated band large number fact give slight aesthetic difference extra button here miss button thinner drawing easily be newer edition nike sportwatch be not clear be case nike tomtom do not immediately respond request comment source uspto definitely seem nike be keep option open front macquarie vasilescu tell ibd view earlier trio patent application athletic watch be publish march first file last september meanwhile adida patent be focuse wearable such product never come market shah say note company also license idea aren position make gadget give sheer number application be file uspto year alone consider folly think dig musty government archive shed light kind consumer product hit shelve indeed try decipher company product pipeline look patent library be little bit astronomy constellation publish patent be map past starlight have travel so far reach earth celestial body appear be burn night sky already be dead die similarly take month average file patent application be publish uspto database accord agency most be actually publish year half santa clara university school law assistant professor brian love tell ibd idea be conceive work well filing probably least year old not more then time patent issue re talk tack couple more year top say so be kind window future not far window future still filing offer clue year advance case point nike rolled self lace marty mcfly inspire shoe march nike designer tinker hatfield confirm early power lace be unveil follow year company back future resurrection ve be foresee long nike first grant patent automatic lace system appear course company stake ip turf not purpose develop idea thwart competitor dream type defensive patent publish be know be not uncommon tech giant ibm ibm alphabet googl unit google say expert consequence publish something be lose sort trade secret right have re also stopping somebody else patenting say love watchmaker swatch have reportedly be smartwatch patent filing spree last few year intend do be mystery lot rumor patent industry swatch start sue competitor be actually just build patent re launch entirely new product line say shah regardless matter nike armour adida wind bring market patent filing mean investor consumer likely expect growth activewear space think be golden age tech athletic footwear business say npd group analyst matt powell have never see so many new tech advance product manufacturing be currently see so add fact record number patent future look really bright
385,PFE,ligand pharmaceutical lgnd be already diversify biotech year now make new claim technology base alter genetic ratsit seem distasteful not very profitable prove be turn point january early stage biotech company acquire omt firm develop technology omt stand open monoclonal technology be used rodent dna human antibody therapeutic use move give ligand avenue growth venture forth hottest area medicine say larry solow analyst cjs security also use animal antibody develop drug human used model solow tell investor business daily rat model lead human drug top selling drug humira remicade mabthera rituxan avastin herceptin used human antibody development omt be believe be only company world offer transgenic animal platform know name omnirat omnimouse omniflic ligand acquire omt drug company have license technology emergent biosolution ebs tizona therapeutic abba therapeutic swiss biotech come top licensee omt have previously line include biopharma giant merck mrk pfizer pfe celgene celg name few typical licensing partnership provide royalty milestone payment omt partner have be pay access technology eventually pay milestone payment royalty too ligand have expect omt add revenue year next year total more be addition emergent tizona abba client list deal ligand likely update guidance next earning report set omt deal positive news other ligand license drug haven diminish investor sentiment share have rise roughly year early april european commission approve expand use european version ligand top license drug promacta use pediatric patient rare blood disorder drug be sell partner novartis nvs mid march licensee spectrum pharmaceutical sppi win food drug administration approval evomela use treat certain case multiple myeloma form blood cancer drug earn ligand higher normal royalty positive clinical datum year other ligand license drug also bode well future revenue growth analyst say anticipate current revenue stream partner product broad development portfolio be poise drive significant growth longer term write analyst joseph pantginis recent research note roth capital partner addition royalty ligand already generate significant revenue proprietary formulation technology call captisol sugar molecule help absorb drug body especially helpful harmful side effect captisol other material sale vary quarter quarter depend be need clinical trial commercial use fourth quarter lower material sale vs year earlier cause overall revenue decline last year still revenue full year rise top growth royalty revenue rise more lumpy material sale related quarterly decline do not concern solow say expect royalty revenue grow year analyst poll thomson reuter see total revenue rise year go next year earning rise prior year cent share analyst expect flat ep growth year then increase next year share nearly half ligand drug partnership be base captisol technology solow say include top seller kyproli used treat multiple myeloma kyproli promacta oral drug boost platelet blood generate sale more last year solow say figure ligand last year receive royalty promacta sale vs kyproli roughly promacta be sell novartis krypoli amgen amgn kyproli ultimately have bigger commercial potential royalty be higher promacta so more important drug solow say ligand have dozen other early stage drug have find partner take next stage target multitude disease such hepatitis diabetes cancer anemia alzheimer kidney disease other ligand have more partner program different company ligand essentially pass heavy lift need bring drug market enjoy royalty milestone relatively little investment cost ligand cash operate expense last year totale partner spend research development say solow show power business model say note company overhead be relatively low yield commercial drug get royalty ligand partner be expect spend close add half growth come omt more shot goal partner program ligand have numerous avenue growth write analyst draw jone stephen initiation report mid april rate stock overweight jone expect promacta kyproli generate more royalty ligand next few year compare addition estimate several company next biggest program provide potential royalty move expect ligand management team continue shrewd capital deployment strategy technology focuse acquisition note
386,PFE,investment bank goldman sachs gs drug company pfizer pfe be upgrade buy rating wall street analyst tuesday health care product giant johnson johnson jnj burger chain wendy wen chemical company kopper kop be downgrade hold neutral rating brokerage firm keefe bruyette wood upgrade goldman sachs stock outperform market perform raise price target goldman stock rise stock market today fall monday goldman share break flat base buy point oct goldman share jump nearly day nov election keefe bruyette wood also upgrade bank america bac outperform market perform hike price target bofa fall cent related bofa goldman sachs stand bank rallybofa jpmorgan other bank stock chart look great bank barclay upgrade pfizer overweight equal weight raise price target pfizer stock rise tuesday fall monday pfizer share have be consolidate last day potential buy point barclay analyst geoff meacham say see higher likelihood trap overseas cash be repatriate trump administration used return capital shareholder also see ibrance xtandi drive growth oncology business related donald trump republican win ease drug pricing debate pfizerpfizer spike report mull consumer care salebarclay also cut rating johnson johnson equal weight overweight reduce price target new brunswick base slide fall nearly monday stock have form flat base last day potential buy point barclay meacham say risk reward profile have become less compelling late related johnson johnson confirm takeover talk actelion chain wendy be downgrade neutral goldman sachs price target wendy stock fall tuesday monday fall fraction share break cup handle pattern nov day presidential election goldman analyst karen holthouse lower rating wendy valuation concern follow recent stock appreciation related mcdonald menu table service mobile order more kioskstrump be absolutely yuge mcdonald left punch bagrobot push fight backer workinvestment bank lower rating kopper holding hold buy valuation concern kopper close monday kopper stock fall share pittsburgh base company rally election kopper produce carbon compound wood treatment chemical treat wood product serve railroad specialty chemical utility residential lumber agriculture aluminum steel rubber construction industry
387,PFE,market wrapped week positive note ahead week likely be dominate federal open market committee day policy meeting meeting end policy announcement wednesday afternoon expect include increase interest rate nasdaq push rally day end session gain week also add sixth day rise friday weekly gain dow tick notch weekly gain index end week fresh high volume be lower accord preliminary figure small cap have rally past week smallcap rise stock market today bolt higher week russell inched friday climb week index roll easily new high dow pfizer pfe coca cola ko merck mrk lead session gain better apiece caterpillar cat lag index decline drill contractor diamond offshore do ensco esv lead respectively broadcom avgo be close end session ahead more ride chorus bullish analyst comment follow chipmaker strong fiscal fourth quarter result report late thursday stock end session buy range buy point emergent biosolution ebs lead gain company report late thursday have sign follow agreement supply center disease control prevention worth biothrax anthrax vaccine positive november consumer sentiment news university michigan be early session investor appear somewhat optimistic discussion schedule weekend organization petroleum export country official opec member regard production limit optimism offset sixth straight increase number rig drill still oil price end more friday leave west texas intermediate fraction lower week first slip week rally gold dip week dollar strengthen week bond slip putt year yield basis point week odd collection industry rise more week steel alloy consumer electronic retailer solar energy consumer lender friday fastest rise industry be canadian oil gas producer meat producer drug wholesaler nonalcoholic drink maker related show opec meeting add doubt output deal broadcom spike record high beat
388,PFE,share rival kite pharma kite juno therapeutic juno tank tuesday follow presentation annual american society hematology ash conference spark therapeutic once stock enjoy third day black compelling gene therapy datum kite juno be investigate chimeric antigen receptor cell therapy therapy treat variety cancer compete like celgene celg bluebird bio blue amgen amgn car cell therapy engineer patient immune cell treat cancer monday tuesday ash juno kite present result car cell therapy battle aggressive hodgkin lymphoma face result juno treatment be stronger show overall response complete response vs kite objective response complete response rbc analyst michael yee be skeptical competitive wise come away ash juno jcar do not look significantly better kite lead kte kite be least year ahead view write research report juno be say market early believe be stretch think ibd take allergan recently buy gene therapy world acquisition retrosense therapeutic analyst say company approach differ meanwhile allergan ceo have pledge abstain predatory pricing gene therapy yee be await month datum kite juno see complete response drop month cr fall month mark write research report suggest be erosion kite month anything be still very good juno strong hodgkin lymphoma result follow death patient car cell trial relapse refractory cell acute lymphoblastic leukemia juno temporarily place trial clinical hold share topple nov result strong result kite juno stock fall stock market today kite stock fall earlier plunge much yee blame short seller take profit deluge juno stock topple much record low end day spark stock other hand continue gain tuesday share rise third day follow spark pfizer pfe hemophilia gene therapy presentation sunday spark make ipo share price hemophilia patient have miss defective factor ix clot protein patient infuse spark pfizer gene therapy spk show mean factor ix activity level greater week post infusion first patient reach year post treatment show factor ix level normal spark say key opinion leader kol lunch yee call spark pfizer therapy compelling phase datum show factor ix then kol absolutely consider patient write related celgene kite spark look sidestep eli lilly alzheimer flop
389,PFE,federal reserve chief janet yellen say case rate hike be stronger now investor weren sure make pfizer pfe paid drug biotech share drug pharma supply chain company sell mylan myl epipen price hike draw outrage best buy bby earning surprised investor dollar store come pressure week nasdaq fall dow major average be still sideway action drug stock be big mover pfizer medivation mdvn deal mylan epipen furor dollar store suffer heavy loss competition wal mart wmt be heating fed chair janet yellen say friday long await speech case interest rate hike have strengthen recent month follow other modestly hawkish statement fellow fed policymaker however vice chairman stanley fischer say yellen comment be consistent september rate increase see possibility rate hike year market have already price fed move perhaps december don expect quick follow upnew home sale soar annual rate july far highest october commerce department report rise june surprised economist look slight dip luxury homebuilder toll bro tol confirm high end market be prosper report jump third quarter earning share rise revenue strong backlog order exist home sale fall more expect july be june cycle high application loan buy home fall month low toll share soar month high move day move average generic drugmaker mylan sell week member senate other politician start inquiring price increase emergency allergy drug device epipen fuel selling drug biotech stock mylan ceo heather bresch daughter sen joe machin say only fraction list price make back mylan due middleman lead share express script esrx cvs health cvs abc fall well big pharma pfizer agree buy medivation cash snatch cancer drug specialist sanofi sny have be try month acquire medivation biotechs rally monday news biomarin pharmaceutical bmrn jump rumor be sanofi second choice target wednesday pfizer agree buy antibiotic business astrazeneca azn possible future milestone sale payment royalty amount oil price be settle trading range mid high range opec member give conflict signal support production freeze goldman sachs say such move not be sufficient support price much further meanwhile energy information administration say crude inventory rise barrel vs expectation small drop domestic production fall slightly road self drive car get little more crowd mobileye mbly announce partner general motor gm supplier delphi automotive dlph jointly develop shelf autonomous drive technology automaker company co develop market first turnkey level automate drive solution mobileye already have deal bmw bmwyy intel intc bring autonomous vehicle market mobileye share spiked tuesday delphi news briefly top buy point share rise week tesla motor tsla be end business relationship mobileye introduce new version model boost speed drive range power update battery technology tesla say upgrade model be now fastest accelerate car commercial production tesla share fall close day line just day line tesla partner nvidia nvda unveil new processor autonomous drive say more powerful other mobile processor beauty product retailer report better expect earning sale yet quarter double digit same store growth ulta beauty ulta also raise full year ep guidance profit range be little cautious ulta share have be strong run so have be price perfection ulta share tumble friday undercut day move average workday wday report wider expect adjust loss top key metric include revenue rise share cloud base human resource software maker rise hit high thursday july ipo talend tlnd lose adjust share accord late thursday release french big datum firm later clarify bottom line actually meet estimate loss cent share adjust share count follow initial offer revenue rise just beating talend see loss line view guide revenue slightly higher share fall much bigger intraday loss best buy bby stock jump week month high better expect sale earning fiscal second quarter include surprise increase same store sale consumer electronic retailer credit rise demand wearable technology appliance home theater system increase video game electronic retailer gamestop gme disappoint investor line ep forecast sale discount retailer dollar general dg dollar tree dltr suffer double digit share price loss report second quarter result come short wall street expectation fall grocery price tougher competition hurt sale result come wal mart be wage own campaign cut price move draw more customer have become more cautious spending meanwhile jeweler tif hold full year outlook ep beat view help boost share however signet jeweler sig parent mall jeweler kay jared zale slash fiscal year outlook partly due difficulty energy dependent region region economy have be hurt cheap oil other commodity hp inc hpq report fiscal earning share time item jump fiscal cent decline sale better view current quarter printer pc maker see gaap ep cent vs consensus cent hp be reduce printing supply inventory be deeply discounting printer expand install base share close little change brief thursday morning sell
390,PFE,drug industry merger acquisition continue wednesday pharma company sell core asset british giant astrazeneca azn agree sell small molecule biotech antibiotic pfizer pfe upfront payment january milestone payment depend drug still pipeline make market portfolio include already commercialize drug merrem zinforo zavicefta treat range serious infection well late stage pipeline candidate drug resistant infection allergan agn hold north american right zavicefta zinforo continue do so pfizer acquire international right ibd take pfizer size patent loss have keep be big growth stock lately lead dividend stock outlined recently ibd column income investor move fit astrazeneca strategy focuse choose area oncology respiratory autoimmunity cardiovascular metabolic disease pfizer add exist portfolio more infective continue reshape essential health portfolio be focuse area further address global public health need complement core capability experience therapeutic area john young head pfizer essential health say statement deal be expect close pfizer stock close lower stock market today astrazeneca stock fall meanwhile specialty drugmaker mallinckrodt mnk say selling diagnostic nuclear imaging business belgium base iba molecular fact mallinckrodt have not especially related business specialty drug imaging come peculiar history be more diversify company tyco international tyc buy tyco spun medical business covidien now part medtronic mdt then covidien spun mallinckrodt other division be strip spinoff drug business have be grow much faster imaging business so sale have be widely expect deal have clear unusual regulatory hurdle include approval nuclear regulatory commission committee foreign investment unite state so company say close first half mallinckrodt stock drop set month high intraday related pfizer medivation deal reignite biotech buyout speculation more drugmaker beat estimate guidance mixed
391,PFE,drug stock slip wednesday rally earlier day politic drug pricing resurface ibd biotech biomedical group hit month high wednesday morning group continue momentum start monday announcement pfizer pfe deal buy medivation mdvn raise hope more biotech continue especially incyte incy biomarin bmrn gabelli co argue make especially attractive target incyte rise more early trading stock market today end day just fraction biomarin initially gain almost then sharply reversed end proximate cause decline seem be presidential candidate hillary clinton criticize generic drug giant mylan myl pricing allergy treatment epipen mylan multiple price hike epipen have already attract discussion industry week senate get act demand mylan ceo heather bresch explain epipen high price clinton weigh midday wednesday ibd take long term outlook get cloudy look ibd swing trader tip short term trading note month biotech stock rally last week have be drive partly fact drug pricing have fade political debate group hit month high aug surpass early wednesday rbc capital market analyst randall stanicky write research note drug pricing comeback politic be be also stark reminder political scrutiny pricing remain high sector unlikely dissipate anytime soon head november election stanicky write nonetheless familiar ibd chart read technique be still lead biotechs be worth keep eye incyte have be bounce buy sell zone pop cup handle base last month financial be also improve turn more consistently profitable last few quarters biogen biib also break cup handle start month then blast right past buy point next day buyout rumor then moved sideway wednesday reversal bring close buy zone again be more celgene celg have be upslope consolidation start july last year still hasn form specific buy point celgene biogen be strong stock overall composite rating putt top stock generic drug group also have be rally last week still low rank go ibd list industry group group be again wednesday lannett lci beat expectation late tuesday lannett stock jump wednesday generic drug however be most direct target senate inquiry group fall wednesday earlier hit month high mylan stock fall wednesday fall tuesday related hunting biotech stock understand earning formula first
392,PFE,stock open flat slightly lower wednesday early pullback oil price weak read june home price dow industrial fall less nasdaq be flat stock market today open nasdaq slightly ahead so far week heavy slate economic news due thursday friday ibd stock largely hold ground dow stock have positive lean pfizer pfe top upside announce pay royalty astrazeneca azn small molecule antibiotic unit astrazeneca share rise intuit intu fall report stronger expect fiscal result also guide ep revenue well consensus estimate lannett lci ahead open generic drugmaker fiscal earning revenue clear analyst target wide margin management hoist revenue guidance well view result be buoy lannett acquisition ucb unit kremer urban pharmaceutical close november telecom construction outfit dycom dy drop report late tuesday fiscal fourth quarter sale earning easily clear analyst projection dycom revenue guidance be line consensus view midpoint ep guidance be shade short management also lower expectation revenue recently acquire goodman network say unit produce higher previously expect operate earning year trendy fashion retailer express expr swoon open second quarter earning revenue decline more forecast comparable sale online sale gross margin continue la boy lzb recline narrow earning miss wide shortfall revenue fiscal first quarter report housing price index federal housing finance agency rise june be line prior month growth just shy expectation rise second quarter datum show fhfa release note potentially significant market shift gain month quarter be much more modest pace appreciation ve see time most likely reflect accumulate pressure significantly reduce home affordability statement say
393,PFE,more real estate sector news be due et national association realtor report july exist home sale figure energy information administration deliver weekly oil inventory datum oil future slip continue trade back forth month west texas intermediate contract sticking well barrel trading range look ahead march wti contract trade early wednesday december contract gold future slip almost ounce dollar be mixed vs yen euro year treasury yield be basis point europe market be mixed afternoon trade dax frankfurt cac paris apiece london ftse
394,PFE,here investing action plan friday need know investor come day monthly job report be due friday top drugmaker bristol myer squibb bmy merck mrk roche rhhby eli lilly lly abbvie abbv discuss new cancer treatment payroll datum labor department monthly job report be due et
395,PFE,biggest player global life science industry have be move cloud veeva system veev go public have be help get cloud base customer relationship management crm marketing project management solution roster client include amgen amgn biogen biib pfizer pfe merck mrk bayer bayry cardinal health ticker
396,PFE,last month forbe release annual fast tech list fastest grow public tech company veeva system veev come grubhub grub arista network anet facebook fb provider cloud base sale marketing software life science industry sport year annual ep growth rate year annual
397,PFE,drugmaker endo international endp plunge friday deliver hefty guidance cut drive weakness generic business drag nearly other generic drug stock endo actually beat analyst consensus cut full year earning guidance now share trim revenue outlook range company earning release ceo rajiv silva blame new competitive entrant include voltaren gel greater expect price erosion generic sector delay regulatory action related certain endo product ibd take healthy be share endo teva do stack vs rival find ibd stock checkupit be second factor rattle rest generic industry teva pharmaceutical industry teva stock fall hit month low allergan agn already staggering cancellation buyout pfizer pfe hit year low end day even selling generic business teva perrigo prgo cut own guidance last month fall smaller drugmaker akorn akrx much end day akorn have fall way accounting due internal issue late friday finally set date earning release respectively leerink analyst joseph schwartz write research note endo problem read most directly teva akorn perrigo more moderately allergan essentially do most price hike product represent more generic sale lately be most trouble refer industrywide datum im schwartz write base analysis akorn have take price increase match criterium im generic sale perrigo generic im sale endo take generic im sale teva meanwhile be due report own earning guidance monday morning allergan be due open follow day endo get least downgrade wall street analyst friday mostly neutral underweight end day year close low
398,PFE,valeant pharmaceutical recently crack accounting management issue most controversial aspect business model be attitude research development spending valeant vrx typically pare bone operation company acquire chide big pharmas allegedly wasteful spending research historically spending be just sale contrast budget bristol myer squibb bmy last year totale sale pfizer pfe be nearly big biotech celgene celg be whopping be really appropriate spending level be spend ibd recently ask gertler former biotech entrepreneur advise company just issue manage partner back bay life science advisor ibd look pharma general do think re spending right amount too much too little gertler tend divide category broadly really be focuse new technology true biologically drive solution disease think level spending be appropriate think increasingly collaboration smaller larger company collaboration be truly advance company academia really be focuse go be meaningful term overall national health international health really drive significant solution be still tendency company look follow commercial pharmaceutical solution see range private equity world way large pharma specialty pharma probably less innovation drive dollar be still well spend term company viability term primary research agenda re probably less important new biologically drive therapy ibd issue be company want do house basically buy buy company do have general guideline gertler categorize main group smaller company be innovation drive somewhat capital constrain midcaps have have success aspect platform have chance focus platform alone start diversify platform course global pharma company think be lot emphasis last number year outsource entirely system doesn work way system be juncture very continuous ecosystem have many academic have go big pharma drive significant effort academic be involved early stage company seasoned executive large company move small company lifeblood small company be identify really develop base platform asset capital constraint then relationship larger company become outsourced be critical expertise large company not be eradicate have do then ultimately commercial development influence way smaller company act flip side be large company have focus just way re judge investor street term commercial commercial success still have make sure pipeline be intact eradicate functionality large company significantly hamper win have proper mean identify smaller platform be go be truly valuable year line also win be able help smaller platform maintain own organic growth same time partner licensing broaden way platform have impact so think discussion outsourced vs house have become artificial world juncture be too fluid too sophisticated justify binary type approach ibd also be lot talk efficiency company be wasting resource impression gertler first think drug development be nature somewhat messy business try have extremely strict receptor drive drug development inevitably have too small impact term disease outcome have too promiscuous effect other system then have too much collateral damage associate development so inevitably just virtue biology go be significant inefficiency process think smaller company sometimes do suffer inefficiency platform be very promising smaller company sometimes lose sight best way prove concept platform be economically smaller tighter yet still really open platform once ve go first inflection point hurdle larger thing large company perspective think be certainly many step way early stage discovery preclinical early clinical development many thing help year come include biomarker include imaging process disease greater understand selective biology disease advance knowledge make system more efficient doubtless be inefficiency system be due bureaucracy way thing be judge think primary inefficiency be drug discovery be messy business ibd sort advice give nonspecialist investor judge company program gertler re look large company be lot driver value public investor probably go well still think used even simple formula percentage spend be probably not way investor look company think divide area be focuse really not primary pharmaceutical biotech have more do too drug repurpose reformulate drug think be less attractive investment look larger company be really try fill pipeline way make clinical sense be one regardless percentage spend be probably greater interest have long term support reason say be health care system change continually inevitably ll have have system drug have have higher impact better outcome truly be differentiate justify reimbursement support re not company focuse sort target innovation long run re not go do well also have look company say be come term news term be news go be impactful sector target meaning be too drug be sixth market drug really be go have prove huge differentiation make difference think be less appeal be drug actually be address significant unmet need more incremental mechanistic change success also offer broader opportunity be still metric even generalist investor public pharma company bring bear midcap company think same principle apply midcaps tend have less diversify portfolio have have type think apply even more stringently image provide shutterstock
399,PFE,major stock etfs surge close monday first trading day new month investor digest key earning report manufacturing datum exchange trade fund tracking dow jone industrial finished session high powershare qqq qqq follow tech heavy nasdaq index snap session lose streak etf sit december high third largest stock hold amazon amzn punch nearly average volume day report stellar stock be close time high be extend latest top hold apple aapl fall energy be only sector decline oilfield service giant halliburton hal baker hughe bhi call plan merger halliburton rise fifth straight session baker hughe reversed lower utility leader duke energy duk pharmaceutical heavyweight pfizer pfe report result tuesday open international stock etfs be mixed emerge market nicking loss develop market gain brazilian stock trail ishare msci brazil capped ewz give almost uncertainty surround political future president dilma rousseff spdr gold share gld leaderboard etf reversed loss stock market today etf jump nearly last week breaking extend base buy point friday here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
400,PFE,rare disease specialist biomarin pharmaceutical bmrn be trading sharply wednesday report strong early stage trial result gene therapy hemophilia biomarin deliver single dose candidate bmn patient severe hemophilia most common variety disease make sufferer blood unable clot be highest dose improve severe moderate mild normal range term factor level base world federation hemophilia criterium accord biomarin press release biomarin be already prepare large phase trial bmn hope gain fda approval quickly possible successful be paradigm shift hemophilia treatment currently only treatment be regular infusion natural recombinant blood derive product replace miss clot factor gene therapy attack disease origin defective chromosome provide improvement much longer biomarin trial only follow week unclear just long be effective currently hemophilia treatment be dominate baxalta bxlt be process be acquire shire shpg biogen biib company be work own gene therapy pfizer pfe hold dominant position smaller hemophilia market rbc capital market estimate hemophilia market alone be year biomarin stock be early trading stock market today touch month intraday high last summer stock have be hit not only larger biotech sell also fda rejection january muscular dystrophy drug kyndrisa well mixed late stage trial result last month treatment rare disease call currently ibd relative strength rating be dismal meaning stock have perform lowest stock past month datum present today be small number relatively limit follow datum be encourage look significant variability patient patient suggest path forward bmn hemophilia potentially hemo gene therapy general set reasonably high bar competition follow write evercore isi analyst mark schoenebaum email client image provide shutterstock
401,PFE,drug giant eli lilly lly be poise jolly december datum ruling come positive credit suisse analyst vamil divan say eye be new datum eli lilly solanezumab alzheimer disease drug predict have probability success legal decision regulatory ruling surround lilly jardiance alimta trulicity also be expect next month eli lilly stock use year end bounce share be year fall stock market today ibd company medical ethical drug industry group fall more tuesday phase datum lilly sola be due day now definitely year end divan write research report tuesday sola act neuroprotector patient alzheimer success boost rival biogen biib have similar drug development divan predict lilly stock soar more sola show significant functional benefit show trend function even show functional benefit predict drop sola miss cognition ibd take december be jolly more just eli lilly drug stock have rally election donald trump be see more business friendly hillary clinton happen trump make good promise repeal affordable care act outlook isn certain grab ibd industry theme deeper dive addition food drug administration be due make decision december expand label jardiance type diabetes med risk be skewer downside most observer be expect fda approval divan say also patent litigation be ongoing lilly alimta chemotherapy cancer lung most expect patent expire regardless divan note also come week lilly be due release interim analysis study type diabetes drug trulicity news flow win end initial guidance be expect jan fda approve baricitinib rheumatoid arthritis drug conjunction incyte incy mid january write baricitinib belong class drug call jak inhibitor gilead science gild be work jak inhibitor be abbvie abbv pfizer pfe have approve be currently trial expand use incyte also have jak inhibitor market janus kinase jak be family enzyme drugmaker believe block enzyme treat certain cancer inflammatory disease editor note correct last graph company be work jak inhibitor already have market related gilead scoop incyte cancer drug prove not good enough amgen gilead eli lilly eat abbvie humira sale analyst
402,PFE,stock trade mixed monday bond take steep drop merger news give premarket action stir dow industrial climb hit fresh time high rise nasdaq fall fraction last week rally shift market more bullish foot leave nasdaq less so far fourth quarter initiate healthier buy environment investor earning report continue roll transdigm tdg india tata motor ttm china athm motion early report news several merger continue adjustment change political environment drive heaviest portion trade harman international har crank gain monday south korean smart phone maker samsung confirm monday have agree pay cash stamford conn base company harman be lead audio component automotive infotainment system maker harman end friday session buy point flat base digi international dgii spiked early action cable maker belden bdc announce saturday bid acquire maker electronic connectivity component digi confirm monday reject offer say undervalue company digi surge last week takeover speculation stock have be corral range more decade belden share be nearly mentor graphic ment vault design automation software developer confirm be acquire germany siemens siegy cash deal siemens expect earning interest taxe year project close second quarter next year siemens share be flat pfizer pfe fall less drugmaker soar broadly last week rebound investor recalculate positive donald trump presidency vs hillary clinton be expect target drugmaker tighter regulatory control ibd list gigamon gimo add premarket trade network performance gear maker be eyee new high be extend second rebound support level june other lead stock akamai technology akam edge fraction stock be extend cup handle buy point week busy economic calendar get slow start monday significant datum set release tuesday dalla federal reserve bank president robert kaplan speak et follow jeffrey lacker richmond federal reserve bank san francisco fed bank john william close week be jam packed federal reserve commentary include chairwoman janet yellen testimony congress thursday oil future lose ground west texas intermediate trading more barrel oil price be now trading day move average threaten undercut low gold dip fraction ounce copper jump more continue rally begin late october dollar climb bond drop hard market reopen friday break veteran day send year yield basis point
403,PFE,stock index post mixed result thursday tech stock yanked nasdaq infrastructure bank play lift nyse nasdaq fall blue chip dow jone industrial average rise respectively small cap rushed ahead ibd lag loss volume
404,PFE,stock close broadly lower tuesday open gain spirale big loss midway session buyer come back final minute drop apple aapl weigh major market index nasdaq fall dow jone industrial average shed be much intraday volume ramp board vs monday accord preliminary figure federal reserve kick first day day monetary policy meeting tuesday trader don expect rate hike december eye be fed announcement due wednesday et medical paper auto related play lead downside stock market today gold miner generic drug maker cement stock advanced tesla motor tsla skid fast trade month low share continue consolidate day day line electric car maker be schedule release financial information plan merger solarcity scty et solarcity fall light volume pfizer pfe dow biggest loser slump busy turnover share close month low stock be now day move average day drug giant report earning share miss view reduce ep outlook say halter development cholesterol lower drug apple be next loss drive stock day move average first time nearly month stock extend decline fifth straight session iphone maker report mixed fiscal result offer disappointing earning guidance current quarter economic news institute supply management manufacturing survey index climb october vs september forecast read economic datum tap wednesday include adp employment report october mortgage banker association weekly mortgage application weekly energy information administration crude oil inventory track estimate result ibd economic calendar find news section investor com company report earning include alibaba baba facebook fb match group mtch qualcomm qcom time warner twx related slight factory pickup construction stall win worry fed tesla solarcity tumble ahead new merger financialswhen do apple break
405,PFE,drugmaker thursday dividend leader have plenty go re not screamer mean be grow nicely compelling pipeline solid dividend yield pfizer pfe look poise clear long consolidation last month share slump nearly week end aug report second straight quarter double digit earning
406,PFE,major average end mixed nearly flat session monday biotech stock rise help offset decline oil sector nasdaq edge dow jone industrial average dip volume fall nasdaq nyse compare friday accord preliminary datum close zoe kitchen zoe plunge follow quarterly earning report fast casual mediterranean style restaurant chain close regular trading session week high have be consolidate early april elsewhere stock market today biotech stock medivation mdvn rocket nearly skyward pfizer pfe announce plan buy maker cancer drug own part pfizer dip fraction ibd take want know pfizer stack other stock industry find ibd stock checkup deal news help boost ibd biomedical industry group amphastar pharmaceutical amph jump new high heavy volume maker drug treat diabetes asthma other disease be buy range clear buy point long deep cup handle base meanwhile oil producer denbury resource dnr drop nearly lead lower crude price sank dycom dy best buy bby smucker sjm toll bro tol be company report quarterly earning tuesday economic datum due tuesday include new home sale july
407,PFE,nasdaq gap early monday never look back stock hold solid gain late afternoon trading apple aapl home depot hd outperformed dow meanwhile china base internet commerce leader include netease nte baidu bidu jd com jd lead nasdaq nasdaq lead way rise dow jone industrial average add apiece volume nyse nasdaq be tracking slightly higher friday level stock market today dow component home depot bounce day move average ahead earning report close share rise stock be featured latest earning preview column meanwhile selling pressure abate apple aapl least day news new hold warren buffett buffett own share iphone maker end first quarter time position be worth nearly share share rise news pfizer pfe announce plan acquire anacor anac deal worth more value anacor just share anacor sole commercial product be toenail fungus ointment call kerydin distribute novartis nvs pfizer be also keen anacor eczema drug currently be review fda anacor surge pfizer edge higher china base alibaba baba also do well rise level have be resistance so far alibaba candidate alibaba be member ibd retail internet group see other leader be ibd stock checkup west texas intermediate crude oil june delivery rise barrel goldman sachs note bear oil recent month flip bullish say wti crude hit barrel second half year economic news volatile regional manufacturing survey miss expectation mile new york federal reserve empire state manufacturing index fall april march economist have expect positive read
408,PFE,here investing action plan need know investor come week crude price barrel next meeting organization petroleum export country add upward momentum smack market back meanwhile apple aapl supplier broadcom avgo medtronic mdt report earning drugmaker discuss cancer fight
409,PFE,big pharma pfizer pfe say monday acquire small biopharma anacor pharmaceutical anac cash send latter stock more monday pfizer agree pay share anacor premium friday close price share close monday just total transaction value be assume conversion anacor outstanding convertible note pfizer say anacor sole commercial product be toenail fungus ointment call kerydin distribute novartis nvs pfizer press release merger play anacor eczema treatment crisaborole be fda review due completion jan believe acquisition anacor represent attractive opportunity address significant unmet medical need large patient population mild moderate atopic dermatitis currently have few safe topical treatment available say albert bourla head pfizer innovative business release pfizer estimate crisaborole reach peak annual sale buyout add asset pfizer innovate drug business be widely expect separate establish product business sometime next few year pfizer have say make decision split year end pfizer already have significant presence inflammation immunology include blockbuster rheumatoid arthritis treatment enbrel sell partnership amgen amgn xeljanz regeneron pharmaceutical regn recently report strong late stage datum injectable drug dupilumab atopic dermatitis so market be currently underserved soon become more competitive be not easy make cross trial comparison crisaborole dupi regenron treatment target moderate severe patient crisa target mild moderate patient well different route administration injectable vs topical different primary endpoint write evercore be analyst mark schoenebaum email client look top line datum investigator global assessment drug be relatively comparable dupi appear be more effective correct placebo dupilumab phase demonstrated achieve clear clear skin lesion week compare placebo crisaborole patient achieve clearance much larger placebo background placebo patient achieve clearance crisaborole week regeneron roche rhhby astrazeneca azn have injectable atopic dermatitis treatment midstage testing anacor stock close stock market today pfizer stock rise fraction regeneron stock rise roche astrazeneca be
410,PFE,stock market future be mixed monday oil price advanced just barrel apple aapl yahoo yhoo rally news involve warren buffett weak new york federal reserve factory report trim gain future trading indicated nasdaq fractionally higher dow jone industrial average fraction west texas intermediate oil price rise goldman sachs make bullish comment market raise forecast oil barrel second half year accord report stock future gain moderate new york fed say empire state manufacturing index fall april economist have expect read apple share rise ahead bell report warren buffett berkshire hathaway brkb have acquire nearly share end march value more apple stock close friday week low weaken iphone sale yahoo rise premarket trading buffett tell cnbc help finance bid internet portal company quicken loan founder dan gilbert anacor pharmaceutical anac soar more pfizer pfe agree acquire biotech share more anacor close friday nearly peak hit july pfizer share be flat premarket trading anacor have topical treatment eczema be review food drug administration pfizer say announcement morning believe drug crisaborole have potential annual sale blue buffalo buff fall maker premium pet food announce offer share late friday new issue close friday just buy point overseas stock market germany stock market be close france cac steepen loss london ftse be asia shanghai composite hang seng index rise japan nikkei average add
411,PFE,medical industry have lot prove upcoming earning season last round earning guidance didn do much reassure investor be already nervous other reason however major stock sector have be hit new high lately especially hardware side group here be such company report earning week johnson johnson jnj take traditional place head line report earning early tuesday first big drug company report cycle growth be expect be modest due gigantic size foreign exchange headwind have be drag global company earning year analyst poll thomson reuter estimate revenue rise year earlier quarter earning be estimate share muted growth johnson johnson stock hit record high trading friday close day fraction have maintain ibd relative strength rating last week mood wall street go quarter seem bullish late thursday rbc capital market analyst glenn novarro raise estimate base read drug prescription foreign exchange trend im im script trend several key drug suggest strong pharma quarter year year ex fx olysio novarro write olysio be hepatitis treatment additionally analysis currency movement begin year suggest negative fx impact full year result be less initially expect novarro note likely topic conversation conference call be month fda approval pfizer pfe inflectra biosimilar version blockbuster immunology drug remicade robotic surgery specialist intuitive surgical isrg be due report close tuesday analyst estimate earning rise last year share sale intuitive surgical have also be top perform stock lately company have be make comeback financially rollout da vinci xi surgical system improve procedure growth intuitive surgical stock hit new high wednesday more year boast excellent ibd composite rating close friday head key question investor be stock be baking too much optimism be start new product cycle evercore isi analyst vijay kumar write email client friday expect procedure volume be healthy growth general surgery lead way extra day leap year also help similar concern optimistic market seem be dog orthopedic giant stryker syk be due report close wednesday stock have also be roll wednesday hit new high be wound last year share close friday stryker stock keep climb last week even robert baird downgrade neutral barclay resume coverage underweight latter write stryker valuation appear be full go face more competition rejuvenate zimmer biomet zbh analyst cover stryker estimate sale rise quarter earning share
412,PFE,here investing action plan need know investor come week earning season remain remain busy report tesla motor tsla alibaba baba top shale producer april job report provide more clue federal reserve take interest rate tesla mobileye auto giant luxury electric vehicle
413,PFE,few exchange trade fund crucial point chart major earning announcement week hold potential pivotal move fund health care utility consumer solar energy be poise climb past ceiling major piece etfs release quarterly report significant move loom be sure etfs be pool stock performance single component have limit impact whole fund yet blowout report big disappointment change course sector etf example technology select sector spdr xlk gap april fund largest percentage move march microsoft msft alphabet googl fund top holding slide weak quarterly result utility select sector spdr xlu etf find critical spot try regain foot drop day move average success rise key level rest partly company fare latest report duke energy duk etf second largest hold more whole fund be report result tuesday open analyst expect profit share charlotte base utility continue uneven profit performance wednesday dominion resource release earning et consensus estimate be cent share exelon exc come result friday et wall street be expect profit cent share dominion exelon account fund respectively lot top company health care select sector spdr xlv etf have already report big one be deck week pfizer pfe report tuesday merck mrk thursday open drugmaker be second third largest component etf be near key level share be approach december peak move level be bullish consumer discretionary select sector spdr xly second largest component home depot hd announce disney release result close heavyweight account etf be top holding etf be climb new high make steady advance guggenheim solar tan largest component solarcity scty release first quarter earning market close solar panel installer account more etf fund chart be testing resistance level conquer continue recovery deep decline
414,PFE,horizon pharma hznp offer expect sale guidance tuesday morning first second quarters send share gapping day line drugmaker deliver net sale guidance range indicate year year growth midpoint net sale outlook growth midpoint well current estimate revenue gain growth previous year management say earning call see have highest operate expense percentage sale year leverage build move year result lower adjust ebitda earning interest taxe depreciation amortization margin first quarter expect sequentially increase move year horizon also confirm full year sale guidance analyst poll thomson reuter anticipate revenue year share slide crash stock market today slice downward key move average stock have be trading day level september company be member ibd medical ethical drug industry group joined abbvie abbv pfizer pfe group leader zoetis zts abbvie share rise pfizer zoetis related egregious depome soar activist starboard target drugmaker
415,PFE,future merger big pharma pfizer ireland base allergan seem be unravele tuesday treasury department propose new rule take away tax benefit deal late monday treasury announce action design curb tax inversion deal company pfizer merge smaller foreign company allergan so relocate lower tax foreign domicile pfizer allergan agreement announce november be latest biggest series such deal past few year have draw increase criticism politician press briefing tuesday president obama voiced approval new rule ve be push year eliminate injustice tax system obama say so very pleased treasury department have take new action prevent more corporation take advantage most insidious tax loophole flee country just get pay taxe obama also urge congress pass legislation create more comprehensive solution include lower corporate tax rate level more other country many ceo inverted company have also urge allergan stock fall stock market today wall street analyst agree big downside surprise treasury action be propose rule regard ownership current law company merge foreign company end own more foreign company officially relocate foreign company home country way accounting work now pfizer allergan merger end pfizer own new company allergan own allergan be today be fairly new entity back new jersey drugmaker then know actavis acquire irish counterpart warner chilcott give coveted dublin address then have buy more company notably new york base forest laboratory california base allergan last year lead name change treasury guideline seem be aim squarely allergan purpose compute ownership percentage determine acquisition be treat inversion current law today action exclude stock foreign company attributable asset acquire american company year prior signing date latest acquisition say treasury statement create complication here allergan formerly actavis be byproduct acquisition forest legacy allergan actavis lead issuance estimate share allergan write leerink analyst jason gerberry seamus fernandez research note strip share pro pfizer allergan share count multiplier end pfizer own close new co analyst note buyout deal include provision change tax law change breakup fee be adverse change drop only lower probability deal close conclude nonetheless add pfizer ownership come shy fed also back share related warner chilcott deal view warner be original foreign entity be subsequent deal get backed ownership test however unidentified source tell reuter tuesday pfizer believe treasury have paint target so unlikely be escape route pfizer be aware treasury keep ruling solution come reuter quote source say tuesday afternoon pfizer have make formal decision only statement be brief late monday press release say company be conduct review say nothing complete treasury proposal also include provision attack earning strip foreign parent make loan subsidiary deduct interest payment earning analyst say be expect be not deal killer rule formally take effect april be not finalize first have go public comment period take month accord evercore isi policy analyst terry haine however treasury have edge rule aren final haine say provision expect be subject litigation affected company affected company be not likely quickly get court relief stay treasury proposal haine write treasury be carefully limit earn strip action propose regulation not even temporary regulation other action today proposal accord haine treasury be try do be avoid court scrutiny discourage inversion same time rule be only propose regulator court reject lawsuit government have not take final action definitely harm someone side pfizer investor evercore drug analyst mark schoenebaum say email client allergan deal doesn go move timeline pfizer long expect split company devote innovative drug development other establish product have be push future allergan deal be announce november schoenebaum speculate decision be make early year pfizer stock rise tuesday allergan doesn merge pfizer still be affected earning strip provision allergan ceo brenton saunder have say shave profit margin percentage point still analyst calculate tuesday stock drop bring allergan well stand alone value update guidance put downward pressure allergan stock price continue view company undervalue stand alone price think moat be wide buoy strong differentiate portfolio solid pipeline write morningstar analyst damien conover research note
416,PFE,drugmaker pfizer pfe sale earning be expect diverge early tuesday issue report potentially slow sale breast cancer drug say prescription tracker im symphony consensus analyst poll factset expect pfizer report sale vs year earlier quarter see earning share ex item rise cent evercore analyst john scottus look more color pfizer decision earlier fall forgo long rumore corporate breakup have split innovative establish product business ibd take pfizer mega deal buy allergan go bust april takeover time warner go same direction investor be look better understand exactly be decisive factor shift management think continue operate pfizer single company change future make idea split attractive again write research note pfizer also likely focus ibrance drug battle positive negative breast cancer drug be grant accelerate approval early scottus expect pfizer comment grow competition eli lilly lly abemaciclib novartis nvs ribociclib eli lilly drug have demonstrated positive result monotherapy single drug battle disease novartis have safety concern earlier year wall street be also likely pfizer commentary circle prevnar pneumococcal conjugate vaccine prevnar add worldwide sale pfizer top line sale miss forecast previously pfizer comment expect fiscal sale be comparable slightly level do not expect prevnar be growth driver scottus write investor likely have keen eye pfizer long term growth expectation stock market today pfizer stock fall touch month low pfizer stock have trade day move average key support line nearly month related amgen gilead eli lilly eat abbvie humira sale analystariad follow gilead mylan route drug price battle
417,PFE,stock open higher tuesday positive overseas trade heavy schedule earning news nasdaq open higher dow industrial inched nasdaq slump october first month june dip third straight slip dow also dip third time heavy contingent stock be premarket motion tuesday stir earning news drugmaker pfizer pfe be open third quarter earning miss integrate oil gas firm bp bp slip beating analyst target then lower capital spending guidance royal dutch shell rdsa pump higher earning soar past expectation daniel amd rolled gain agribusiness heavyweight deliver mixed third quarter result report exceptionally strong export demand offer positive outlook share end monday month cup base buy point diesel engine maker cummin cmi drop adjust third quarter earning drop less forecast consensus estimate revenue drop more expect weak demand heavy duty truck engine be drag result cummin have be fight clear flat base buy point early october coach coh open higher report third quarter earning meet revenue miss analyst expectation same store sale brick mortar store rise better expect international sale jump casino stock advanced chinese official report gaming revenue gamble district macau rise october third straight increase wynn resort wynn rise mgm international mgm la vegas sand lvs rise apiece ford announce monday report october sale later week due fire dearborn mich headquarters other automaker be expect report tuesday federal open market committee today begin day meeting policy announcement due wednesday afternoon today economic calendar kick et researcher markit report manufacturing purchasing manager index october institute supply management follow october pmi et october construction spending number be due commerce department also et oil price be steady monday dive west texas intermediate edge barrel gold climb ounce dollar be mixed vs yen euro bond slip lift year yield basis point positive manufacturing datum boost china market bank japan decision hold monetary policy unchanged tamp tokyo nikkei gain europe market slip mixed action afternoon trade cac paris frankfurt dax london ftse show gain related cummin decline expect market be bottom
418,PFE,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
419,PFE,stock be mixed early afternoon trade thursday dow hit new high nasdaq reversed sharply lower hurt apple aapl microsoft msft dow jone industrial average rise be mostly flat nasdaq tumble volume be tracking slightly higher nyse nasdaq stock market today vs same time wednesday nasdaq be weigh weakness netease nte netflix nflx amazon com amzn alphabet googl facebook fb show loss anywhere apple aapl meanwhile sank more heavy trade near test day move average share be now week high day line baird wednesday note cite potential negative impact iphone maker due meaningful change global trade policy trump presidency microsoft msft fall nearly briefly undercut day line share slip flat base buy point steel department store other retailer be biggest gainer gold miner solar internet stock see big loss department store get boost macy kohl kss pop respectively follow quarterly earning report kohl share break past flat base buy point huge trade pfizer pfe score biggest gain dow drugmaker add wednesday jump stock reclaim downward point day line first time month ibm ibm gap rise week high fast turnover stock be shape flat base potential buy point bank america raise rating buy price target wednesday ibm general motor gm say re team make gm car smarter used ibm watson artificial intelligence procter gamble pg lead downside blue chip fall nearly average volume breach day move average first time late january economic news weekly jobless claim dip week end nov well projection claim related netflix lockheed ibm upgrade qualcomm downgrade taser pt hikedmacy earning miss badly kohl profit beat lateapple fang stock aren join trump rally
420,PFE,ariad pharmaceutical aria stock be feel mylan pharmaceutical myl pressure monday congress loom deadline submit information regard price increase rare cancer drug past year ariad up price inclusig annually rbc analyst michael yee write research report inclusig treat specific class chronic myeloid leukemia acute lymphoblastic leukemia ariad sell milligram mg bottle lion share patient be mg dose yee write latter have buy mg bottle thus pay double price yee doesn see much stem congress pressure recently mylan agree make generic less costly version epipen device treat anaphylaxis emergency allergic reaction hike device cost ibd take biotech earning season be full swing merck eli lilly vertex edward lifescience slate tuesday ibd recently look biotech giant top expectation medivation mdvn be be acquire pfizer pfe feel congressional heat earlier year price tag prostate cancer drug later get letter sen bernie sander gilead science gild come hot water earlier year hike price drug congressional request information didn result much yee write reasonably likely congressional inquiry blow time yee say ariad have nov deliver information price hike include spending sale distribution tactic ariad have argue inclusig isn mylan epipen other ariad have year history financial loss unprofitability far higher spend revenue historical spending internally develop commercialize inclusig yee write orphan drug tend be more costly standpoint yee keep sector perform rating ariad stock jpmorgan downgrade share neutral underweight close bell stock market today ariad fall nearly month low ariad be so far month
421,PFE,top brass nvidia nvda apple aapl supplier skywork solution swks pfizer pfe comcast cmcsa mckesson mck headline week insider transaction co founder ceo jen hsun huang thursday report sale execute wednesday share company stock late thursday nvidia report jump earning share time item hike revenue figure top analyst consensus nvidia share gap friday time high end week executive chairman david aldrich year skywork veteran filing thursday report have sell share also thursday skywork announce aldrich guide company be form merger wireless technology company step ceo skywork name liam griffin new chief skywork share lose week chairman ceo ian read sell share share pfizer beat wall street estimate raise guidance company also call last month merger allergan agn treasury unveil new rule curb tax inversion deal pfizer share dip week chairman ceo brian robert thursday file sale comcast share share total largest cable provider soon have stronger contend charter communication chtr recently receive approval fcc california regulator buyout time warner cable twc comcast share edge chairman ceo john hammergren sell share share total earlier month mckesson report disappointing fiscal earning revenue company have earlier warn weak generic drug price recent customer consolidation rite aid rad agree last year be acquire walgreen boot alliance wba have distribution agreement abc mckesson fall week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
422,PFE,small drugmaker medivation mdvn continue battle sanofi sny hostile takeover bid wednesday latter try replace board big biotechs celgene celg gilead science gild be say be think join fray sanofi propose candidate be willing fully fairly evaluate medivation strategic option believe medivation current board do not do unanimously reject sanofi unsolicited bid april medivation respond statement urge shareholder reject attempt call tactic sanofi facilitate substantially inadequate time proposal acquire medivation sanofi be only suitor go public anonymous source have be tell medium variety other company be think make bid medivation reportedly sign disclosure agreement pfizer pfe amgen amgn imply be open be buy somebody other sanofi wednesday bloomberg say celgene gilead be talk advisor idea hadn actually approach company celgene gilead have be urge investor analyst make sizable acquisition especially gilead massive hepatitis franchise be already erode face competition medivation current month sale wouldn make big impact gilead top line much interest come medivation future prospect prostate cancer drug xtandi be still ramp company study use other disease also have few earlier stage drug pipeline medivation stock have lately go tight sharp run buyout speculation fall stock market today sanofi climb gilead edge celgene be
423,PFE,specialty drug giant allergan agn report mixed first quarter affirm guidance announce massive share buyback tuesday lift batter stock allergan stock be already boost monday teva pharmaceutical industry teva say report buyout allergan generic unit actavis be track close next month have be delay various regulatory issue render moot worry generic drug pricing drive stock year low friday have already be hammer break merger pfizer pfe stock be early trading stock market today allergan report operate earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale climb wall street average estimate allergan affirm full year revenue guidance vs last year number exclude actavis company say use part roughly proceed teva deal buy back stock plan buy next month say condition allow consider extend program much allergan stock once resident ibd still hold excellent ep rank actually decline less group whole drug stock sell august february high profile dissolution pfizer deal early april push stock single digit relative strength rating lead mediocre composite rating
424,PFE,medical stock have be increase presence ibd majority aren company make drug rather most be more scene player provide drug development service make medical equipment pra health science prah provide outsourced clinical development service biotech pharmaceutical industry raleigh base company have work pharmaceutical company more
425,PFE,stock market turn solid performance wednesday release minute march federal reserve meeting didn do much overall bullish tone close nasdaq be add dow jone industrial average picked preliminary datum show volume nyse come slightly lower tuesday level nasdaq volume rise bit new york mercantile exchange west texas intermediate crude oil delivery jump barrel government report unexpected drop crude inventory biotechs do heavy lift nasdaq ishare nasdaq biotechnology etf ibb outperformed rise regeneron regn biogen biib be best performer nasdaq respectively nutshell fed minute show sentiment be run rate hike later month cme group fedwatch currently have odd rate hike year treasury yield add basis point stock market today fast grow homebuilder lgi home lgih jump nearly strong trade clear resistance work right side possible base late tuesday company say new home closing surge march most ibd stock be higher lead acuity brand ayi bolt more upward follow strong quarterly earning report stock rocket past alternate entry hesitate earlier entry cup handle base pfizer pfe allergan agn rise drugmaker abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter allergan rise plunge almost tuesday follow treasury department unveil rule aim discourage such tax inversion deal pfizer gain meanwhile oil field service giant baker hughe bhi halliburton hal outperformed jump respectively justice department file lawsuit halt plan merger concern combine company stifle competition sector close watch earning retailer bed bath bbby small cap ollie bargain outlet olli
426,PFE,big pharma pfizer pfe contemplated splitting specialty drugmaker allergan agn campaign regain investor confidence wednesday company announce plan merger be pfizer early wednesday confirm rumor company have cancele merger day treasury department release new guideline have remove most tax benefit deal new york base pfizer stock tank tuesday allergan ceo go medium blitz promote company prospect stand alone conference call analyst wednesday morning allergan ceo brenton saunder maintain treasury action tax inversion have impact stand alone allergan redomicile ireland inversion deal warner chilcott year company retain corporate tax rate say also be free deploy capital however choose saunder also say allergan sale generic unit actavis teva pharmaceutical industry teva be unaffected spiking pfizer deal be track close june timeline buyout be delay original close date teva work way multus country regulatory clearance process saunder say company be determine get do teva be do lot work say saunder ve restructure company have name entire leadership few level include allergan executive move teva be great deal allergan also great deal teva allergan stock tuesday rebound wednesday teva stock rise close actavis sale give allergan big wad cash so many analyst question call related do money several seem be root share buyback give allergan stock be trading week low wake pfizer breakup saunder say option be table emphasize allergan growth pharma model mean constantly hunt growth asset say allergan business development team have stay active pfizer deal be announce right opportunity come announce tomorrow couple analyst raise name contact lens giant bausch lomb saunder have personal history head company be sell valeant pharmaceutical international vrx give valeant recent spectacular crackup many wall street have speculate again go sale allergan suitable buyer not only saunder also allergan large ophthalmology business saunder response seem be swipe valeant infamously opaque financial report sell year late stage pipeline program strong organic growth profile say tell thing today be still true base public information impossible tell worth more sell year pfizer meanwhile rise hit month high investor look possible major catalyst stock back company reorganize so be able split innovative drug development business establish product perhaps divide more piece necessary company have originally plan make decision year allergan buyout be announce issue be push next year pfizer press release announce end allergan deal however say decision date be back year bring more write evercore isi analyst mark schoenebaum recent acquisition hospira pfizer probably have critical mass transform global establish product business unit independent company innovative product business unit benefit additional asset acquire outside schoenebaum write email client prospect company go back hunt have be lift drug stock whole wednesday especially biotechs distressed big cap biotech biogen biib have be subject buyout speculation give trading high rise smaller anacor pharmaceutical anac rise likely late stage eczema drug be see fit allergan dermatology portfolio
427,PFE,stock wake wrong side bed tuesday stay grumpy day content follow lead most overseas equity market be also foul mood nasdaq be short stay day move average gap lose also fall
428,PFE,facebook fb alibaba baba report strong earning stock sell drug stock suffer several blow major average fall earning tumble oil price new uncertainty surround presidential election fall week close just day line benchmark index have fall straight session longest such streak year nasdaq fall worst weekly loss month facebook fb be many lead stock tumble earning report outlook apple aapl alphabet googl also undercut buy point plunge oil price sank energy stock facebook cruised past third quarter earning estimate share fall sharply social networking giant say growth rate slow facebook report earning share item beating consensus cent year year revenue rise beating consensus facebook say pace ad place decelerate revenue growth also expect be aggressive year capital spending facebook fall week crash day line multiple buy point related facebook dife forecast meaningfully slower ad revenue growthalibaba baba report better expect fiscal earning sale fuel growth core commerce business boom cloud compute service earning rise cent share revenue rise revenue alibaba core commerce market rise alibaba cloud compute revenue soar alibaba end quarter mobile monthly active user year year alibaba be prepare nov single day world biggest day online shopping alibaba share fall week crude future tumble barrel worst weekly decline january lose prior week crude stockpile jump barrel week end oct largest ever increase base datum do back energy information administration say meanwhile opec major oil producer couldn agree production curb raise doubt ll reach deal shale bellwether continental resource clr report result short wall street view plan increase completion year carrizo oil gas crzo report surprise rise profit apache apa post loss wasn bad analyst fear bp bp lower capital expenditure outlook be cautious royal dutch shell rdsa downgrade spending outlook next year general electric ge baker hughe bhi say combine oil gas operation analyst expect deal pass regulator add job last month slightly less expect august september payroll be revise average hourly wage rise vs year earlier best gain meanwhile october ism manufacturing index rise slightly signale modestly faster factory growth ism service sector gauge fall more expect indicate slower rate expansion federal reserve hold rate steady expect say case rate hike have continue strengthen odd rate hike december be high have come bit donald trump poll number rebound financial market stumble video game publisher electronic art ea take interactive software get lift september quarter earning report activision blizzard atvi sank activision beat estimate sale earning guidance holiday quarter be lighter expect december quarter activision forecast gaap earning share cent sale wall street be modele cent activision friday release many analyst expect be top selling game year call duty infinite warfare latest company lucrative call duty franchise meanwhile ea take top expectation september quarter raise guidance merger acquisition have overshadowed earning report several major chipmaker mobile chip maker qualcomm qcom plan buy nxp wednesday say fiscal earning share exclude item rise sale rise analyst expect ep sale thursday share chipmaker microsemi mscc soar report fellow mixed signal chip expert skywork solution swks have approach potential acquisition skywork late thursday deliver lower earning sale top view separately chipmaker broadcom avgo agree buy brocade communication system brcd cash net debt broadcom plan retain brocade fibre channel storage area network san switch business centurylink ctl agree buy level communication lvlt cash stock combine company be stronger rival verizon vz market business service broomfield colo base level operate world largest internet backbone centurylink be nation third largest local phone company verizon centurylink plunge week rise prior week deal buzz level initially rally reversed nearly week soar prior week related centurylink buy level cash stockoptical component maker oclaro oclr inphi iphi apply optoelectronic aaoi report earning top expectation oclaro ep rise iphi report ep jump say acquire clariphy communication cash apply optoelectronic ep fall however neophotonic nptn miss top bottom line telecom fiber optic group have be volatile mixed guidance lumentum holding lite disappointing revenue infinera infn prior week once white hot ipo acacia communication acia report nov oclaro inphi rise nearly week apply opto neophotonic crash related apply optoelectronic earning beat neophotonic missesgeneral motor gm fiat chrysler fcau ford motor toyota tm other major automaker report lower sale october vs very tough comparison year earlier industrywide sale fall vs year earlier be best estimate ford release figure day rival due monday fire knock power datum system dearborn mich headquarters teva pharmaceutical teva mylan myl lannett lci tumble thursday report justice department have be probe more generic drugmaker possible price collusion charge likely year end report also appear hit drug distributor pharmacy benefit manager meanwhile pfizer pfe miss earning estimate cut full year ep target end work cholesterol drug allergan miss ep revenue target related generic drug maker crash report doj plan collusion chargespfizer end cholesterol drug development lower ep guidancepapa john pzza top third quarter forecast follow strong earning domino pizza dpz pizza chain attempt draw more consumer digital order platform similarly starbucks sbux say mobile payment have drive more transaction volume coffee chain beat fiscal fourth quarter estimate issue profit guidance miss view papa john rise nearly week close friday right day line starbucks rise friday hit month low thursday match group mtch operate date site match com tinder top ep estimate miss revenue match share fall nearly week cloud base human payroll human capital software firm paycom payc top view guide light rival paylocity pcty top fiscal result stock fall week hulu strike content deal st century fox foxa walt disney hulu part owner live online tv stream service gannett gci drop bid tronc trnc time warner twx fox top view meanwhile wall street journal be shrink staff consolidate print coverage nov thomson reuter tri be cut position
429,PFE,just past year half antitrust concern have undo jeopardize several merger deal add doubt consummate takeover time warner twx agree pay share time warner medium giant stock fall stock market today well bid price indication investor be skeptical deal go fall still company see deal close late obama administration have become more aggressive merger acquisition lately sue block demand condition be too onerous donald trump have say block time warner deal president hillary clinton have voiced concern february comcast cmcsa agree buy time warner cable combine top cable provider federal communication commission raise concern consumer group netflix nflx also object regulator expect block deal comcast give april charter communication chtr moved agree buy twc deal close november pfizer pfe reach deal buy allergan agn so call tax inversion ve allow pfizer change domicile ireland slash tax bill deal ve create world largest drugmaker come time politician be already bash tax inversion treasury department introduce series new rule make inversion less attractive april pfizer walk away deal cite treasury rule related forget allergan pfizer have sight cancer drugmaker allergan pfizer strike separate path merger kill crude price be collapse november oilfield service provider halliburton hal agree buy rival baker hughe bhi deal be worth time also ve put combine company schlumberger slb prompt regulator duopoly halliburton scramble find buyer asset seek shed regulatory approval justice department reportedly push halliburton sell more asset single buyer then april doj file lawsuit block merger company call deal then be worth related halliburton fail buyout actually hurt eye new deal end baker hughe bid february staple spls agree buy office depot odp retailer face pressure commerce rival amazon amzn be second attempt earlier be block federal trade commission staple office depot say time be different industry landscape be completely different cite amazon other competitor ftc disagree sue december judge side federal government september general electric ge inked agreement sell home appliance business electrolux eluxy industrial conglomerate seek shed noncore asset focus area aviation power system oil gas doj sue july say merger hurt consumer judge rule lawsuit ge walk away december next month ge sell unit china haier december top food distributor sysco syy agree buy rival food february ftc sue argue merger player market result higher price restaurant hotel other company buy food related supply june sysco abandon deal judge rule favor ftc july anthem antm say buy cigna ci create largest health insurer membership come just week aetna aet reach deal acquire humana hum consolidation effort come health sector struggle find saving address higher anticipate cost associate obamacare mandate july doj file lawsuit block deal say much health insurance market be controlled just company august doj signale be willing reach settlement anthem cigna allow merger october walgreen boot alliance wba say plan buy rite aid rad bring together drugstore chain leapfrog cvs health cvs walgreen have be look buyer help company offload store pass regulatory muster management be also talk ftc appear be make progress summer kroger kr seem unwilling buy hundred store walgreen rite aid be try divest kroger have be interested want close location reopen grocery store ftc want preserve stand alone drugstore source tell new york post
430,PFE,stock loss deepen quicken tuesday afternoon positive manufacturing datum apple aapl pfizer pfe weigh heavily dow nasdaq lose nearly fall dow jone industrial average give volume be tracking higher nyse nasdaq vs same time monday federal reserve start first day policy meeting expect leave rate unchanged december institute supply management manufacturing survey index climb october september forecast read automaker auto part company medical issue lead downside today stock market action gold mining food concrete stock outperformed apple be dow biggest loser fall day move average first time nearly month stock be track extend decline fifth straight session iphone maker report mixed fiscal result offer disappointing earning guidance current quarter pfizer also lag drop heavy trade month low share be now day move average day drug giant report earning share miss view reduce ep outlook say halter development cholesterol lower drug other blue chip be more chevron cvx buck downtrend gain extend advance friday upside earning surprise ibd netease nte slide heavy volume head day line stock be still sharply extend late june past cup handle entry chinese online portal gaming company report result nov close upside fresh del monte produce fdp gap soar new high robust trade earning report share fruit vegetable producer be now extend flat base buy point initially clear oct related facebook alibaba apple struggle fed loom wednesday investing action plan takeaway apple mixed earning report pfizer end cholesterol drug development lower ep guidance
431,PFE,major stock index loss intensified tuesday afternoon day federal reserve policy meeting get underway market be unfazed decent read ism manufacturing index well round healthy economic datum china fall nasdaq composite dow jone industrial average small cap lag russell volume yse nasdaq be tracking slightly higher monday level stock market today chevron cvx be dow best gainer rise stock have be rally mode big earning beat friday megacap oil play be edge closer potential past entry flat base pattern pfizer pfe lag dow fall disappointing earning pfizer also say end development cholesterol lower drug project be blockbuster also reduce earning outlook current quarter ibd take pfizer weakness august be partly due concern grow drug competition eli lilly lly novartis nvs economic news institute supply management manufacturing survey index tick october prior month slightly ahead expectation outside economic datum china look pretty good manufacturing gauge large state own factory come stronger expect separate caixin manufacturing gauge midsize company show best improvement more year third gauge service also rise martin marietta mlm jump nearly earning miss open work right side possible base fresh del monte produce fdp gap earning soar nearly recently retrace modest gain buy point fresh del monte reclaim entry tuesday share alibaba baba ease share slump much new york post article say ongoing sec probe company accounting practice be get help high alibaba staffer amazon com amzn fall fractionally initial pop axiom capital raise price target related ism manufacturing index signal slightly faster growth octoberamazon price target bump chevron twilio get analyst love
432,PFE,apple aapl get price target cut thursday alphabet googl acuity brand ayi get price target raise allergan agn get downgrade btig trim price target apple cite conservative stance next iphone upgrade cycle apple share close stock market today morgan stanley raise price target alphabet alphabet share end thursday susquehanna downgrade allergan positive neutral deutsche maintain buy rating giant drug company jpmorgan initiate coverage overweight allergan pfizer pfe terminate merger deal wednesday cite new tax inversion rule allergan share fall cannacord genuity raise price target acuity brand smart light maker report second quarter result handily top view wednesday still csla downgrade acuity rating outperform buy acuity share lose brean capital initiate coverage intel intc buy rating price target intel share fall stifel raise price target constellation brand stz still wine beer giant share retreat other action macquarie initiate coverage skecher usa skx outperform rating price target skecher share drop image provide shutterstock
433,PFE,stock be lower mixed volume midday tuesday follow mixed economic datum nasdaq lose dow jone industrial average give volume stock market today be run higher nyse lower nasdaq compare same time monday walt disney lead dow lower drop heavy volume follow surprise resignation thomas stagg see heir apparent ceo robert iger be expect retire meanwhile drugmaker take hit allergan agn plunge treasury department issue ruling aim discourage tax inversion deal move threaten allergan plan merger pfizer pfe allergan share undercut oct low now lie week high pfizer share rise most ibd stock be lower acuity brand ayi show strength rise retake buy point cup handle base volume be run average lead system specialist former ibd leaderboard stock be slate report quarterly result open wednesday earning be see rise share jump revenue earning share grow average past quarters economic news institute supply management index service sector activity rise point march beating wall street expectation reading indicate growth also tuesday labor department job opening labor turnover survey show unfilled job position february be slightly department initial estimate january revise total image provide shutterstock
434,PFE,stock market show tiny loss early afternoon trading monday major index trade tight range nasdaq dow jone industrial average fall volume nyse nasdaq be tracking slightly lower friday level stock market today generic drugmaker biotechs outperformed gold miner homebuilder lag new york mercantile exchange wte crude oil delivery fall nearly barrel apple aapl merck mrk pfizer pfe outperformed dow gain trio ibd name make nice move edward lifescience ew soar company announce positive trial sapien sapien xrt aortic valve replacement share be now extend cup base buy point mortgage lend service provider lendingtree tree climb nearly rise bring stock back buy point first stage cup handle base michael kor kor give back early gain still rise close recent high share be recently trading hit intraday high elsewhere tesla motor tsla jump ceo elon musk say pre order model electric car reach saturday night virgin america va meanwhile surge alaska air alk agree buy deal value image provide shutterstock
435,PFE,share rise biopharma player medivation mdvn jump month high monday report company now be willing sell cite anonymous source reuter report medivation have sign disclosure agreement pfizer pfe amgen amgn be previously rumore be interested buy company sanofi sny go public uninvited bid last month still isn certain company actually bid reuter say medivation stock be modestly morning trading stock market today share surge report come early afternoon eventually close medivation have initially resist be buy anyone late march reportedly hire adviser help fend such attempt reason be imply ceo david hung refusal sanofi offer accuse french pharma major take advantage market dislocation believe lead market undervalue medivation stock medivation value have continue go then take stock week high last ibd composite rating putt top stock key metric such sale earning growth sit ibd list top perform stock
436,PFE,investor have lavish more love ishare edge msci minimum volatility usa usmv other equity etf so far year usmv have see net inflow help asset balloon investor category sibling powershare low volatility splv be likely feel deflate perhaps even bit miffed splv have soak relatively modest same period gain past year vs usmv be fare far better spdr spy proxy broad stock market have tumble past year so be splv prove less popular reflect inability attract more new money partly exchange trade fund get knock rival be little more utility fund say nick kalivas senior equity product strategist powershare quarterly rebalance weighting utility sector actually go further more gain stock include utility firm american water work awk entergy etr public service enterprise peg also drop stock include rowe price trow pfizer pfe splv screen least volatile stock give bigger weighting stock lower volatility usmv also offer exposure stock potentially less risk broader market however constrain sector weighting band relative parent msci usa index hold appeal institutional investor mandate compensation be tie closely follow benchmark accord kalivas customer be more nimble advisor be more apt drift away benchmark say splv have maximum minimum sector weight requirement be good thing kalivas argue example utility stake splv have varied greatly year be high go less be now march back kalivas point right now splv have exposure volatile energy sector sector come stress have lot volatility avoid entirely kalivas say cite financial crisis earlier tech crisis period splv unconstrained methodology have be big help neither splv usmv have year history critic point splv make big sector bet utility consumer staple sector etf tend get hit hard sector interest rate risk come play
437,PFE,stock market open sharply lower tuesday hurt more weak manufacturing datum china sell european stock market nasdaq dow jone industrial average fall decline stock outnumber advancer nyse ratio be nasdaq gold add recent gain dollar weaken again edge higher just ounce money flow bond year treasury yield crash basis point stock market today early gainer dow include pfizer pfe drugmaker jump earning be work way higher long consolidation find new home day move average be leader pfizer medical ethical drug group consult ibd stock checkup find meanwhile straight decline apple aapl rally early go ibd couple defensive stock continue trade tightly hold high prestige brand pbh add penny constellation brand stz ease couple growth name be set report earning close today amsurg amsg paycom payc
438,PFE,stock be mostly quiet monday ahead fed day monetary policy meeting start tuesday merger take center stage nike nke weigh dow dow jone industrial average give nasdaq be fractionally lower volume be lighter board vs friday accord preliminary figure oil generic drug shoe apparel maker underperform stock market today price west texas intermediate crude slump barrel auto part maker gold miner utility be biggest gainer nike be biggest dow loser gap fall nearly fast turnover month low share be well day move average day line november high bank america lower rating athletic shoe giant underperform neutral stiff competition armour ua adida accord seek alpha also blue chip exxon mobil xom fall big volume share be still work flat base potential buy point merger make headline monday baker hughe bhi general electric ge agree merge ge oil gas service business baker hughe stock reversed early gain baker hughe go gain lose time normal turnover ge end constellation brand stz climb nearly news producer alcoholic beverage acquire anheuser busch inbev bud grupo modelo brewery mexico anheuser busch give heavy volume economic datum tap tuesday include ism manufacturing index purchasing manager index october construction spending september motor vehicle sale october busy earning schedule tuesday include coach coh electronic art ea paycom software payc pfizer pfe pioneer natural resource pxd related baker hughe reverse sharply merger ge oil unitanalyst bullish acacia qualcomm nike downgrade
439,PFE,presidential election race narrow friday surprise fbi announcement stock investor be finally show jitter hedge market decline surge immediately follow report federal bureau investigation be review file be related investigation hillary clinton email practice be secretary state ratio bearish vs bullish option
440,PFE,drugmaker pfizer pfe become acquisitive post breakup flop likely overpay asset say jeffry analyst jeffrey holford downgrade pfizer stock thursday cite lack catalyst stock market today pfizer stock fall nearly third consecutive day share dip flat base form nearly month be now possible entry point ibd take biotechs topple hard wednesday political angst thursday player supernus pharmaceutical rebound find day big mover ibd stock move holford downgrade pfizer stock hold rating buy cut price target key driver originally drive upgrade have play fail materialize write research report ibrance pfizer treatment metastatic breast cancer be grant accelerate fda approval early strong ramp enjoy have peter rival add pressure even pfizer prepare european launch note recent prescription trend indicate opportunity be become saturate patient be begin roll treatment rapidly new one be recruit write european launch reinvigorate growth similarly holford be previously bullish pfizer prevnar drug combat pneumococcal pneumonia much adult catch opportunity be now penetrate write pfizer biggest potential catalyst be engage holford see likely next month pfizer walk away merger allergan agn tax rule change april last month scrap year old plan break separate company help pfizer drive stronger growth profile risky write whilst management find attractive target acquire believe environment be very competitive right now be high risk pfizer overpay asset write related prothena slam politic eli lilly pfizer topple bristol myer lung cancer drug winregeneron sanofi beat pfizer roche astrazeneca eczema
441,PFE,stock open narrowly mixed wednesday europe market reversed slightly higher earning report power bulk early trade dow industrial gain nasdaq ease big name be motion report quarterly result morgan stanley ms halliburton hal yahoo yhoo add other heavyweight name report earnign reynold american rai drop st jude medical stj rise nearly tupperware tup fall dow stock be generally positive pfizer pfe climb pfizer announce grant bill melinda gate foundation conduct phase clinical trial vaccine candidate group streptococcus treatment neonatal blood infection dow low end intel intc drop late tuesday report show third quarter earning revenue meet company preannounce level management revenue guidance be just shy consensus estimate intel share have gain early end tuesday session rebound support week move average vitamin nutrition supplement supplier gnc holding gnc pop news report company have be shopping possible buyer china estimate place deal include debt chipmaker cree cree topple fiscal first quarter earning revenue fall more expect stock have be fight retake critical level support deep year consolidation commerce department set economic ball motion stock market today report housing start dip slightly september annualize rate be august pace disappointing consensus view increase start issue build permit give gauge upcoming activity increase be august rate easily economist consensus permit energy information administration report weekly crude oil inventory et federal reserve october beige book report be due et san francisco federal reserve bank president john william be set speak et dalla fed president robert kaplan speak et oil continue bob trading more putt west texas intermediate just barrel gold price add half percent ounce dollar be mixed bond ease lift year yield basis point internationally china third quarter gdp growth meet expectation match country first second quarter growth service run ahead generally economy expand year september retail sale gain expect industrial output increase just consensus target market china elsewhere show mild response shanghai composite end session flat hong kong hang seng index dip japan tokyo nikkei tick europe market climb early loss afternoon trade cac paris frankfurt dax gain ftse london add fraction afternoon action related halliburton swing surprise profit revenue lightwill yahoo cash machine keep verizon walking away morgan stanley profit soar bond trading revenue surge
442,PFE,treasury department have squelch drug giant pfizer pfe bid take ireland base allergan agn etf investor needn fear new federal rule don ice broader merger market say sal bruno chief investment officer indexiq firm largest merger focuse etf pfizer allergan merger deal be widely see attempt large company move legal domicile overseas avoid america steep corporate tax rate new rule make so call corporate inversion more difficult potentially less profitable however tax inversion deal make small percentage total merger market bruno say most merger deal focus opportunity synergy growth add pfizer allergan kibosh hurt merger industry optic standpoint accord bruno tactic dodge corporate taxe have come flak recently president barack obama presidential candidate side political divide iq merger arbitrage mna dump tuesday follow news extend loss stock market today exchange trade fund invest global company be target publicly announce takeover rebalance monthly used liquidity base weighting method allergan be top stock hold exchange trade fund portfolio weighting mna have coast far less volatility benchmark past year gain first quarter come very volatile period equity market performance help cushion tuesday blow mna be still year april comparison spdr spy have add challenge merger etfs extend pfizer allergan debacle obama administration have take more aggressive stance big merger sue block merger oil major halliburton hal baker hughe bhi staple spls bid rival office supplier office depot odp be also scrutiny even more worrisome deal activity be show sign cool record year record deal cumulatively worth first quarter deal worth accord intelligence service mergermarket bruno believe pace remain brisk future interest rate remain low make easier borrow money buy other company low growth climate acquisition add growth company generate growth own corporate balance sheet cash flow be healthier have be decade ample deal flow bruno say have very positive outlook merger arbitrage whole most challenge perhaps etf investor continue be wary more niche product mna fall liquid alternative fund category aim diversify portfolio make mostly stock bond category hasn grow tremendously etf space bruno say mna debut hold asset proshare merger mrgr launch hold proliferation thematic new product plain vanilla etfs be dominant investor continue focus most time attention well very low cost broad very well diversify market exposure ben johnson director global etf research morningstar say recent interview however bruno expect liquid alt etfs take person get more comfortable diversification benefit see growth go forward say
443,PFE,new sheriff be en route hasn stop old sheriff swing corporate billy club town subject be company merger instance administration president barack obama promise reinvigorate federal antitrust enforcement campaign trail back be crack be pile week obama justice department sue block merger baker hughe bhi halliburton hal antitrust concern also week obama say treasury department have take further step curb tax inversion company buy foreign target then re domicile avoid higher taxe scuttle major acquisition wednesday drugmaker pfizer pfe allergan agn call deal also be several other instance recent week month administration have take aim big business so give be product last year robust environment see global deal announce symptom white house critic have accuse be business re definitely get more aggressive max jacob analyst london base investment research house edison say administration historically obama have be bit more liberal government intervention side thing take pfizer allergan merger deal have result base pfizer relocate headquarters low tax ireland benefit nation corporate tax rate do so have bypass rate highest industrialize world terminate deal have be work month pfizer now pay ireland base allergan breakup fee be political calculation here say dane hamilton editor mergermarket speaking tax inversion deal obviously obama administration stop company move overseas generate lot tax dollar still obama pending departure january not bring much relief term friendlier face come be dearth obvious presidential candidate moment hillary clinton democratic party front runner president want crack inversion fellow white house democratic hopeful sen bernie sander have call practice tax scam meanwhile republican front runner donald trump party rival sen ted cruz texas propose lower taxe inversion aren come support still clamp tax inversion win solve corporate tax code underlie problem say lisa simone professor accounting stanford university tax system very much put incentive place say add become more difficult get inversion deal do tax inversion aren only target vigilant antitrust watchman be obama administration have take aim elsewhere addition antitrust concern baker hughe halliburton deal combine world oilfield service firm justice department take electrolux eluxy trial late last year cause general electric ge back deal sell appliance unit federal trade commission have take office depot odp staple spls trial block deal biggest office supply chain more last year administration quash comcast cmcsa time warner cable twc merger have combine nation largest cable television company yet approve live nation entertainment lyv merger ticketmaster diana moss president american antitrust institute favor more aggressive antitrust law enforcement say size company merge raise red flag enforcer deal be still be strike politician griping major health insurer aetna aet humana hum combine deal anthem antm agree buy cigna ci last year world largest beer maker anheuser busch inbev bud sabmiller agree combine now old sheriff have free hand say edison jacob obama have benefit not have stand election say
444,PFE,stock turn decidedly higher midday wednesday ahead minute due later today federal reserve recent march meeting interest rate nasdaq be climb dow jone industrial average be volume be run lower stock market today compare tuesday level only mildly so nasdaq drugmaker oil stock be biggest gainer midday transportation stock lag pfizer pfe allergan agn rise drugmaker abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter allergan rise more plunge tuesday treasury department unveil rule aim discourage such tax inversion deal pfizer also rise more meanwhile oil field service giant baker hughe bhi halliburton hal lead jump respectively justice department file lawsuit halt plan merger concern combine company stifle competition sector most ibd stock be higher lead build product stock acuity brand ayi bolt follow strong quarterly earning report stock rocket past alternate entry hesitate earlier entry cup handle base investor scour minute federal reserve march meeting due et clue central bank outlook interest rate
445,PFE,stock higher flat start wednesday enough lift nasdaq narrowly back day move average nasdaq rise add dow industrial tack gain stock market today volume be quiet nyse lower nasdaq relative action same time tuesday pfizer pfe run head dow more breaking takeover allergan agn nixing pfizer allergan inversion reportedly cost pfizer breakup fee avoid run afoul treasury department launch inversion regulation monday allergan stock also rise more uninverted drug medical play lead nasdaq celgene celg illmina ilmn vertex pharmaceutical vrtx jump more ibd stock acuity brand ayi padded early gain press higher big fiscal sale earning gain put share past cup handle buy point baker hughe bhi spiked halliburton hal pop justice department file antitrust lawsuit challenge plan acquisition baker hughe halliburton suit claim merger eliminate competition specific product service related oil gas field production
446,PFE,pfizer pfe allergan agn confirm wednesday be end merger agreement treasury unveil new rule curb tax inversion deal monday ireland base allergan rise stock market today ceo brenton saunder tell cnbc allergan have bright future standalone firm allergan plunge tuesday hit lowest level late concern new rule imperil deal pfizer rise wednesday gain tuesday pfizer inc today announce merger agreement pfizer allergan plc have be terminate mutual agreement company drug giant say statement decision be drive action announce department treasury april company conclude qualify adverse tax law change merger agreement company have strong incentive redomicile overseas reduce exposure america unusually high corporate tax rate global reach pfizer board report vote scrap deal give longer be tax benefit saunder say new rule blindside allergan feel unfairly target compnay be not name specifically treasury set restriction serial inverter allergan have history inversion deal allergan be run new jersey have official headquarters dublin pfizer pay merger related expense pfizer ceo ian reed say statement drug giant go ahead corporate split plan make decision pursue potential separation innovative establish business later end obama administration have become more aggressive go big merger justice department be sue block merger halliburton hal baker hughe bhi say ll fight doj action baker hughe share rebound wednesday slide tuesday report doj take action halliburton pop intraday climb tuesday meanwhile ftc be midst court battle seek block staple spls buy office supply rival office depot odp
447,PFE,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
448,PFE,less month pfizer pfe scrap takeover allergan agn new inversion rule drug giant reportedly be eyee possible bid medivation mdvn send cancer biotech stock higher pfizer have approach medivation talk accord reuter lead offer top bid medivation france sanofi sny last week medivation have reject sanofi share bid undervalue company be best know prostate cancer drug xtandi medivation share have be trading well sanofi offer price close tuesday medivation rise pre market trading stock market today reuter report pfizer stock edge lower open tuesday pfizer rise breaking consolidation pharmaceutical king report best quarterly earning share gain more year pfizer ep rise better expect benefit several time factor include recent hospira takeover
449,PFE,stock quickly trim early loss roughly hour wednesday session raft datum economy inspire buy meanwhile mid cap biotech medivation mdvn continue rally speculation still acquisition target nasdaq composite fall slip be much shortly open dow jone industrial ease small cap turn higher initial sell later retreat again be market begin turn higher news ism service sector survey april come econoday consensus forecast figure indicate expand activity factory order march meanwhile rise well growth forecast markit pmi service index also beat expectation vs dow utility also buck market decline add roughly advance prior session volume be run mildly lower side vs same time tuesday lead new company regional homebuilder lgi home lgih cool loss texas base small cap have be build base own go big spurt second half aug past entry yielded nearly rally week stock begin correct high lgi focus young family seek exit apartment world be now peak normal circumstance high quality stock rally week time peak form handle then bust base however probability such success be diminish pressured uptrend nasdaq have be distribution day bout heavy institutional selling past session alone upside medivation rise volume run more triple normal pace medivation average daily volume share mean hourly basis share be trade average et medivation turnover have already hit share san francisco base company strive produce brand new medicine develop product candidate acquisition have potential go clinical development month report pfizer pfe issue solid result tuesday gap result be look acquire medivation have be act strong tailwind stock pfizer be marginally be show good action tuesday past entry point medivation fourth quarter profit surge cent share revenue boost wall street see profit cent share mark eighth straight quarter excellent earning march medivation share rocket day move average take large step process form positive base pattern now be work right side giant cup past month stock be currently time high medivation score composite rating maximum ibd stock checkup mean combination fundamental stock price action institutional fund sponsorship be superior company ibd vast database
450,PFE,big pharma pfizer pfe rise tuesday beat wall street estimate raise guidance company moved allergan agn last month call mammoth merger open pfizer say earning exclude time item rise year earlier quarter cent share beating analyst consensus cent revenue increase beating consensus accounting be complicate several factor include acquisition generic drugmaker hospira look closely year year revenue growth be worth mention growth vs operational growth year year favorable fx foreign exchange rate contribute inclusion hospira contribute write evercore isi analyst mark schoenebaum email client exclude fx hospira pfizer stand alone revenue increase year year growth be also additional factor favorably contribute revenue due additional selling day quarter exclude impact operational year year revenue growth come be still very good growth pfizer relatively mature portfolio product still none factor foreign exchange contribute pfizer full year guidance increase company add revenue guidance now cent ep range now pfizer say revenue hike cent ep gain be due improve operate performance pfizer stock rise stock market today touch nearly month high number important drug also beat consensus include breast cancer treatment ibrance epilepsy drug lyrica pneumococcal vaccine prevnar enbrel amgen amgn rheumatoid arthritis drug pfizer market outside also beat expectation do domestically amgen report last week nonetheless investor mind be elsewhere write credit suisse analyst vamil divan research note expect investor view quarter positive maintain focus strategic outlook company follow fail allergan deal ahead decision potential split pfizer write pfizer allergan base low tax ireland call merger have be industry largest ever treasury unveil new rule curb tax inversion deal
451,PFE,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
452,PFE,prothena prta stock nose dive friday political volatility be buy opportunity say rbc analyst michael yee see biotech landing partnership like eli lilly lly pfizer pfe psoriasis drug investor haven be bullish prothena stock rival wednesday ibd company medical biom biotech industry group be worst perform group track share plunge dip day move average ibd take company group be rank group track rise just week share be rake coal wednesday prothena supernus topple markedly check ibd industry theme get idea better stock bet yee chalk weak drug stock late political angst have outperform rating price target prothena stock prothena share close stock market today intraday have fall more entry point touch consolidation investor be advise sell stock fall buy point key take away be recent pullback think be mostly due political uncertainty house senate race be opportunity view company be track very busy full pipeline write research report thursday prothena have key drug line be currently enrolling patient phase phase trial neod drug treat amyloidosis amyloidosis occur normally soluble protein mis fold accumulate become toxic organ yee have confidence neod chance see potential upside price target phase pronto trial show positive datum prothena prx prx be wall street consensus yee say expect duo provide additional upside opportunity prx aim treat parkinson partnership roche rhhby prx be prothena drug psoriasis latter be key consider big pharma interest inflammation drug evidence number allergan agn deal pharma be interested include pfizer eli lilly write think prothena land nice partnership asset phase ii datum summer design also be novel say prothena prx be build science inhibit cell il cytokine be tie inflammatory disease method be used amgen amgn eli lilly novartis nvs psoriasis drug related allergan challenge intercept nash drugeli lilly look coral more animal health business zoetis
453,PFE,apple aapl receive price target increase thursday top rate stock gigamon gimo grubhub grub be upgrade buy big pharma stock merck mrk pfizer pfe get divergent rating wall street analyst thursday pacific crest security analyst andy hargreaf reiterate overweight rating apple stock raise price target sentiment iphone maker turn positive ahead september quarter earning report believe current iphone expectation be reasonable see potential upside street profit expectation next year strong app store sale other thing hargreaf say report apple be schedule report fiscal fourth quarter earning oct apple result be boost uptick iphone average selling price thank popular high end iphone strong app store download include hit mobile game pokemon go hargreaf say recommend buy aapl hargreaf say believe combination attractive valuation improve iphone growth rate optimism iphone cycle create favorable risk reward aapl apple stock fall stock market today snap session winning streak bank america upgrade share gigamon grubhub buy give gigamon price target grubhub pt share gigamon computer network equipment firm edge grubhub online mobile platform restaurant pickup delivery order rally stock be ibd list top perform company gigamon be rank ibd grubhub be bank america upgrade pharmaceutical giant merck buy set price target merck be investment bank jeffery downgrade drugmaker pfizer hold pfizer share be
454,PFE,financial market be begin believe federal reserve simplest explanation tumble major stock index take tuesday see year treasury yield rise month high dollar index hit highest level month central bank key overnight lend rate be barely policymaker have repeatedly rein intention further hike market have take fed pronouncement grain salt investor doubt fed resolve economic forecast market have be pricing even lower rate future fed have telegraph longer least not significant extent fed rate committee last meet member projection point hike december rate hike yet market board december hike persist pricing less chance subsequent hike fourth quarter past trading session have see year treasury yield rise investor have get fed program so speak now market be pricing roughly chance rate hike september follow earlier hike december cme group fedwatch tool show here be cause simultaneous re pricing stock short term uptick government bond yield make stock modestly less attractive relative basis bigger issue be likely rise dollar other major currency investor see fed tighten other major central bank ease dollar index measure greenback vs basket major currency jump tuesday highest march monday negative earning multinational get sizable share sale earning foreign currency such pfizer pfe boee ba microsoft msft alphabet googl further other country be help weaker currency include eurozone nation economist believe overall effect stronger dollar dampen global growth especially true emerge market have high level dollar denominate debt become harder service dollar rise surprise be be rise treasury yield have come september job report show smaller expect gain explanation be fed policymaker think have already reach full employment economy only need create perhaps job month keep jobless rate steady ibd take tell job report be too hot too cold just right market react negatively positively day report key investor be stay abreast market prevailing trend visit ibd university primer time stock market read big picture column day good news be market have come most way adjust fed timetable yet fed have be pretty unreliable prediction so market still need adjust way policymaker turn be too optimistic pessimistic come growth inflation job market related divide fed hold rate hike see slower tighten pathu add so so job september win change fed dollar dive fed boost outlook export corporate profit
455,PFE,stock open lower thursday better expect unemployment export price datum dow industrial fall lose nasdaq shed treasury yield fall global market have shift lower earlier datum show surprise drop china september import deeper expect decline export hong kong hang seng index tumble china shanghai composite end gain japan tokyo nikkei slip global mining issue be take beating send europe market lower european financial also be pressure apparently due analyst downgrade dax frankfurt fall cac paris drop afternoon trade london ftse show loss mining issue lag freeport mcmoran fcx vale vale rio rio merck mrk rise nearly dow pfizer pfe fall more lose appeal court case attempt defend lyrica patent vs generic drug maker actavis garmin grmn fall ibd list ulta beauty ulta have gain salon beauty supply chain raise third quarter earning guidance well analyst consensus view stock be shape tight second stage base pattern late august high gigamon gimo initially climb reversed trade more stock find support day move average wednesday session have see heavy selling pullback high initial jobless claim slow week end oct labor department report be slightly prior week claim well consensus view uptick claim week move average also downshift fourth straight decease export price rise better expect september reverse august decline best view increase import price rise line consensus view energy information administration release weekly natural gas inventory datum et weekly oil report minute later treasury department september budget be set et release philadelphia federal reserve bank president patrick harker speak et oil price hold steady west texas intermediate just barrel brent crude just gold inched ounce dollar ease vs euro yen bond edge trimming year treasury yield basis point
456,PFE,stock be mixed mostly unchanged early wednesday oil price mixed quarterly earning report drive good amount action nasdaq add dow jone industrial average ease barely budge stock market today head midweek session nasdaq tote loss week nasdaq maybe more important nasdaq head wednesday session day move average retake line support week dow remain comfortably day line small cap russell index week have trade day level august eastern release minute federal open market committee march meeting provide economic center point session energy information administration report weekly oil inventory datum pfizer pfe exxon mobil xom chevron cvx be early leader dow west texas intermediate climb barrel early wednesday gold edge ounce dollar gain bond slip trimming year yield basis point overseas market close narrowly mixed asia europe market show similar action midday pfizer allergan agn formally announce plan abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter such tax inversion deal be focus treasury department rule unveil monday pfizer be concern effort salvage deal provoke new rule treasury accord reuter pfizer reportedly pay allergan termination fee allergan edge higher news pfizer add oil energy related stock post best gain stock ibd stock acuity brand ayi soar early trade atlanta base light distributor report heavy fiscal second quarter sale earning beat basis point increase gross margin stock end tuesday buy range less buy point cup handle base constellation brand stz tap gain fourth quarter revenue earning clear consensus expectation beer wine maker distributor end tuesday less cup base buy point lead light manufacturer cree cree lower early go durham light maker warn fiscal third quarter revenue be initial guidance put earning cent cent vs initial projection cent cent management cite product delay system conversion affect customer service stock have be fight climb november low deep month correction
457,PFE,stock pare loss be still lower early action tuesday healthy reading service sector shed nasdaq trim dow lose turnover be mixed stock market today volume nyse lower nasdaq relative action same time monday european market be pressure wave weak economic news researcher markit report service sector toggle back growth mode march lift service purchasing manager index vs read february tally indicate economic contraction institute supply management corroborate read place march manufacturing index february consensus projection read labor department job opening labor turnover survey show available unfilled job position february be slightly department initial estimate january revise total oil future ease west texas intermediate continue trade barrel gold climb more ounce drug maker be highly active early trade allergan agn tumble widest loss issue pending federal rule change aim tax inversion deal affect allergan plan merger new york base pfizer pfe pfizer share rise valeant pharmaceutical vrx pop announce internal review accounting issue mail order pharmacy philidor rx service find additional issue quebec canada base drug maker announce last month restate revenue find irregularity marvell technology mrvl spark bermuda base outfit announce chief executive sehat sutardja wife president weili dai resign executive position immediately hold board seat earlier audit committee investigation find management tone have lead company accounting issue walgreen boot alliance wba slip serve mixed fiscal result pharmacy chain say expect acquisition rite aid rad close second half year ibd stock chip maker maxlinear mxl fall lead manufacturer universal display oled drop more maxlinear have be struggle early march get distance cup base buy point universal be hold just cup handle buy mark wesson holding swhc sturm ruger rgr top ibd group rebound sharp loss monday
458,PFE,drugmaker medivation mdvn miss wall street estimate affirm guidance late thursday fend increasingly hostile attention big pharma sanofi sny medivation revenue rise year earlier quarter miss analyst consensus accord thomson reuter net income climb cent share badly miss consensus cent medivation nonetheless affirm full year guidance call revenue ep last year make share revenue company revenue come royalty prostate cancer drug xtandi japan astella market treatment medivation say xtandi bring total quarter sell full year consistent first quarter first quarter gaap net income be impact several seasonal item include lower royalty rate ex xtandi sale higher gross net rebate accrual astella net sale inventory drawdown previously mentioned sg sale general administrative expense related astella collaboration medivation say earning release medivation stock be fraction hour trading follow earning release share have rise fraction thursday regular session earlier thursday medivation reject renew buyout offer sanofi sanofi first make last week medivation reject undervalue sanofi ceo olivier brandicourt say letter medivation director be overwhelming support shareholder transaction say prefer engage medivation management rather go hostile be not prepared engage have choice go directly shareholder know shareholder have ability act time written consent remove replace board medivation respond press release say be nothing new letter offer be still inadequate meanwhile rumor continue fly other interested party astrazeneca azn novartis nvs pfizer pfe have already be name anonymous source previous week thursday bloomberg report big biotech amgen amgn be also ponder bid seek major acquisition fill age drug portfolio week buyout speculation have drive stock more month low hit feb help strong ibd composite rating spot ibd list top perform stock past month
459,PFE,stock head lower early afternoon trading wednesday intraday glow positive economic datum fade nasdaq be dow jone industrial average give volume be tracking lower nyse nasdaq vs same time tuesday economic datum be mixed hire marked year low private employer add job april well economist projection institute supply management service sector index climb point april view read indicate expansion online travel booker gold biotech stock lead downside today stock market action utility internet content real estate investment trust advanced priceline pcln gap sink speedy trade fall day move average stock be now handle buy point have be flirt open online travel site deliver result beat forecast offer disappointing earning guidance other travel book industry group tripadvisor trip fall expedia expe ctrip com ctrp give armour ua stumble trigger sell rule share fall buy point brean capital downgrade stock hold buy athletic apparel shoe maker tuesday say chief merchandising officer chief digital officer leave july ibd paycom software payc biotech medivation mdvn rise respectively heavy volume pfizer pfe have approach medivation possible takeover accord report late tuesday eye be tesla motor tsla close trade due report result analyst expect electric car maker post loss cent share vs cent loss revenue be forecast rise share be faster usual trade testing support day line
460,PFE,federal reserve hawk push immediate rate hike september lose battle have gain upper hand dove minute september meeting suggest member warning fed risk lose credibility be force hike rate rapidly labor market get too tight group middle make concession hawk essentially pledge hike rate december be major shift economic datum fed note statement case rate hike have strengthen policymaker have decide time be further evidence continue progress full employment inflation ibd take rise bond yield recent stock headwind suggest investor be take fed rate hike plan seriously participant believe be appropriate raise target range federal fund rate relatively soon labor market continue improve economic activity strengthen other prefer more convince evidence inflation be move committee objective minute explain dove resist such definitive statement clearly indicate rate rise december block middle shift hawk investor have underestimated influence grow camp hawk fed member own economic projection publish meeting signale hike december more market initially ignore fed timetable pricing even slower pace rate hike play catch recent day stock close narrowly mixed stock market today treasury yield nudge higher tuesday stock sell sharply odd rate hike december meeting have rise year treasury yield have climb past week dollar index have strengthen other major currency rise month high latter move sustain crimp earning multinational get sizable share sale earning foreign currency such apple aapl pfizer pfe boee ba microsoft msft google parent alphabet googl bounce back treasury yield have come september job report show smaller expect gain takeaway be even slower job growth not derail fed timetable fed policymaker think have already reach full employment be very close economy only need create perhaps job month keep jobless rate steady minute explain member caution postpone policy firm too long push unemployment rate markedly longer run normal rate next few year dissenter be george loretta mester eric rosengren trio warn fed then need tighten policy more rapidly thereby pose risk continue economic expansion other member highlighted increase labor force participation rate make case labor market slack be be take only modest pace allow fed act deliberately related divide fed hold rate hike see slower tighten pathu add so so job september win change fed
461,PFE,stock close sharply lower thursday concern deutsche bank db health spark sell financial then spread wider dow jone industrial average tumble nasdaq composite lose volume swell nyse nasdaq vs wednesday accord preliminary figure deutsche bank sank nearly concern hedge fund have trim exposure asset manage prime brokerage division german base institution accord bloomberg suggestion justice department pay fine mortgage security issue dow goldman sachs gs be biggest loser drop jpmorgan chase jpm weigh loss bank fall volume higher normal other lag group stock market today include biotechs other drugmaker oil dairy product chipmaker outperformed west texas intermediate crude future climb more barrel add wednesday jump opec late wednesday say agree cap output barrel day start november merck mrk pfizer pfe fall dow stock be midst shape flat base economic news gdp come revise growth rate preliminary figure just forecast first time jobless claim be better view pending home sale august fall well expect increase economic datum tap friday include personal income outlay august september chicago pmi university michigan consumer sentiment index september dalla fed president robert kaplan be schedule speak related deutsche bank be lehman big bank stock break supportoil hit month high opec blink vs shale
462,PFE,food drug administration approve breakthrough adult eczema treatment regeneron pharmaceutical regn sanofi sny soon march drugmaker say monday share plod lower day market overall joint release regeneron sanofi say fda accept priority review biologic license agreement bla dupilumab treatment mid severe eczema cure eczema rash typically treat corticosteroid ibd take pfizer too be work eczema treatment acquisition anacor pharmaceutical early monday pfizer say have decide splitting end year speculation dupilumab inhibit signale interleukin interleukin company say il il be cytokine protein signal cell be tie immune response clinical study frequently link il il eczema asthma dupilumab be grant breakthrough drug designation now path receive prescription drug user fee act target activation date march allow fda collect fee drugmaker fund approval process bla dupilumab contain datum phase testing include more patient eczema wasn controlled topical treatment cortisone cream regeneron sanofi evaluate dupilumab singular treatment conjunction corticosteroid pfizer pfe roche rhhby astrazeneca azn be regeneron sanofi heel treatment acute dermatitis well end pfizer acquire anacor june give access anacor nonsteroid gel treat eczema crisaborole announcement regeneron stock be stock market today hot stock mid late regeneron share be year sanofi stock be related regeneron sanofi drug rheumatoid arthritis beat abbvie humira
463,PFE,stock open sharply lower tuesday follow lead overseas market slip nasdaq lose dow jone industrial average give stock market today appear pull premarket cue europe stock be pressure raft unexpectedly soft economic datum cac paris frankfurt dax trade more ftse london show loss afternoon trading market receive dose service sector datum later morning london base researcher markit release march service purchasing manager index et institute supply management deliver march index labor department report job opening labor turnover survey february early report show trade gap widen slightly february upwardly revise january commerce department report economist consensus have forecast milder uptick oil price dip slightly left west texas intermediate bob barrel natural gas jump more gain last week monday gold future climb more ounce dollar be mixed bond blipped higher send year yield basis point dow stock slide almost unanimously lower cisco system csco lead downside fall early outperformer include pfizer pfe procter gamble pg johnson johnson jnj pfizer report positive result psoriatic arthritis treatment phase clinical trial federal regulator announce pending rule change affect potential inversion merger rule directly affect pfizer allergan deal set close later year share ireland base allergan agn crumble tesla motor tsla lag nasdaq fall late monday company give delivery count mentioned model part shortage nearly ibd stock be flat start regular trade edward lifescience ew backed suggest well earn pause monday price spike wesson swhc show sign life sell monday japan tokyo nikkei dive week low yen continue gain strength disappointing industry forecast send iron steel issue tumble china market end mixed shanghai composite hong kong hang seng index stock india skid lower reserve bank india cut interest rate basis point line consensus expectation market have already price react cue global market bloomberg report send mumbai benchmark sensex index image provide shutterstock
464,PFE,allergan agn tumble new tax inversion rule tesla motor tsla skid weak delivery walt disney retreat key executive exit raise doubt be eventual successor ceo bob iger allergan stock fall treasury department issue new rule curb so call tax inversion include step curb earning strip method used reduce taxe inversion pfizer pfe ireland base allergan plan merge pfizer takeover structure reduce tax liability pfizer stock edge higher late close allergan have close higher tesla motor say deliver vehicle nearly vs year earlier company february forecast tesla blame severe part shortage model crossover own hubris tesla share fall late erase nearly regular session gain huge preorder model model be suppose go production late total vehicle production hit walt disney say close coo thomas stagg be see possible successor ceo bob iger be leave stagg serve special advisor iger disney stock fall close meanwhile salesforce com crm agree buy artificial intelligence startup metamind undisclosed term latest big tech step ai takeover investment salesforce ceo marc benioff invest metmind back december salesforce stock be little change late
465,PFE,drugmaker allergan agn get price target cut canaccord genuity thursday company hit delay merger pfizer pfe other issue analyst corey davis note wednesday federal trade commission ftc have ask additional information pfizer allergan merger be first announce november company also have allergan finish divest generic drug business teva pharmaceutical industry teva hit delay month cause teva push expect close date june pfizer allergan still expect close merger second half year meanwhile be lower estimate ep drop always weakest quarter specialty pharma feel rest street be also too high davis write research note lower price target allergan stock have be trend past several year be partly reset medicare part davis add merger target tgt cvs health cvs hit allergan distribution business tune year launch bowel disease drug viberzi have increase spending davis write be nonetheless maintain buy rating due high likelihood deal close have be skepticism investor pfizer allergan deal be go close year signal allergan fall stock price buy side survey evercore isi analyst mark schoenebaum month find fifth respondent place odd less ftc backlog concern incoming president congress do something limit tax inversion deal candidate have threaten do pfizer leadership wall street analyst have be more confident however march deutsche bank analyst gregg gilbert write gap pfizer offer price allergan stock price then present buy opportunity likely narrow deal close near allergan stock be fraction morning trading stock market today
466,PFE,stock market score mild gain just open tuesday early damage cause earning report dow jone industrial average add rise nasdaq eke gain economic news imf reduce forecast global growth percentage point january forecast separately outlook small business operator dip accord national federal independent business put march small business optimism index month only small step february read disappointing vs consensus projection meanwhile growth march import price be softer expect vs consensus projection gain labor department say export price be flat month line estimate compare slip february treasury department report march budget et federal reserve bank president be docket deliver speech today san francisco john william speak et richmond jeffrey lacker go oil half percent west texas intermediate hold barrel gold be flat just ounce dollar firm vs euro rise sharply yen dip month low monday bond backed lift year yield basis point pfizer pfe caterpillar cat apple aapl be early leader dow cisco system csco shed earning action account largest premarket loss stock alcoa aa slump report first quarter revenue fall more expect earning dive still top consensus projection alcoa plan split company later year fastenal fast cross thread loss nut bolt screw distributor earning meet consensus expectation revenue stop just shy forecast stock have pull back test week line support climb month consolidation juniper network jnpr dive early trading warning miss projection due weak demand enterprise customer overseas europe market be flat afternoon trading tokyo nikkei punch yen dip market china end tightly mixed
467,PFE,stock market higher start week wall street ready start earning season dow jone industrial average add picked nasdaq rise early optimism be nasdaq small cap russell still lodge day move average start stock market today be also january high dow have hold day level be trading highest point year market still have sense momentum index have climb past week none have post straight weekly decline mid february significant economic release be schedule monday session dalla federal reserve bank president robert kaplan speak et kick busy week fed commentary build day policy meeting april wti crude oil future add top barrel natural gas tumble more metal be active gold nearly silver platinum more apiece dollar gain strength bond backed send year yield basis point mining stock be jump anglogold ashanti snap rio rio pop early action alcoa aa rise nearly ahead first quarter earning report due today close boee ba caterpillar cat be early leader dow nike nke pfizer pfe lag seagate technology stx run nasdaq early go ibd ulta beauty ulta be early gainer facebook fb lag fall day move average work cup handle base buy point overseas china mainland market jump consumer producer price datum improve march tokyo nikkei dip yen strengthen europe market show uneven gain afternoon trading frankfurt dax paris cac london ftse be mostly unchanged
468,PFE,stock defend healthy gain early monday market react cross current corporate international news nasdaq strike early lead dow industrial be close respectively volume be mixed stock market today nyse lower nasdaq compare action same time friday be little news report monday economic front market china climb improve march consumer producer price datum europe market feel lift banking reform effort italy oil price shed mild early decline rise nearly natural gas trade almost lower oil energy stock packed lead edge be merger news wire canadian pacific railway cp pop announce have drop attempt acquire norfolk southern nsc norfolk southern dip yahoo yhoo rise nearly news report say london base daily mail be contemplate bid big brand search engine pivotal research also raise stock price target dow stock be fine form cisco system csco boee ba lead more few decliner pfizer pfe fall furthest hard drive maker seagate technology stx rumble cowen initiate coverage market perform rating price target barron article saturday also tout stock dividend yield discuss potential hard drive demand cloud datum center western digital wdc catch coattail action jump ibd more group rise more open inphi iphi top advancer gain share remain just april high extend buy point clear double bottom base mid march
469,PFE,apple aapl be initiate broker strong buy early note wednesday allergan agn first solar fslr linkedin lnkd get price target cut mizuho cut price target allergan reduce rating neutral buy pfizer pfe allergan have terminate merger deal cite new tax inversion rule allergan rise stock market today share have plummet nearly tuesday obama administration say be take measure prevent corporate merger result inversion effort avoid higher taxe relocate corporate headquarters overseas pfizer share gain wednesday climb tuesday needham initiate coverage apple strong buy price target apple introduce iphonese last month inch display compact aluminum design apple share rise once again close just day line credit suisse lower price target linkedin linkedin share tick wednesday mizuho cut price target first solar analyst day tuesday first solar decline give estimate note lack clarity next year send share day first solar share be wednesday other action jp morgan chase co upgrade rating cisco system csco neutral underweight cisco share be wednesday
470,PFE,allergan agn stock dive tuesday treasury ir announce plan new rule aim curb tax inversion practice allow company avoid taxe buy foreign company move headquarters overseas impact pending deal pfizer pfe ireland base allergan set close year latter be result several recent inversion company say statement late monday be conduct review department treasury action announce today prior complete review win speculate potential impact allergan fall nearly premarket trading be lowest level october pfizer rise nearly latest treasury action limit ability inverted company lend money american subsidiary create deductible interest reduce taxable income treat certain debt issuance stock serial inverter be also target new rule year limit foreign company bulk asset avoid ownership requirement later inversion deal be third set inversion curb rule issue treasury secretary jacob lew last few year lew say office be continue explore additional way limit inversion america corporate tax system give company strong incentive shift headquarters overseas combine federal state corporate rate be highest industrialize world america most nation taxe overseas earning inverted company still have pay tax rate american profit be get relief earning elsewhere other notable recent inversion involved mylan myl medtronic mdt burger king now call restaurant brand qsr deal have already close
471,PFE,stock market open quietly lower monday nasdaq dow jone industrial average lose small cap outperformed early go russell only economic release expect stock market today be february factory order commerce department service sector datum march be expect tuesday high point quiet week economic news be likely be minute federal open market committee march meeting be due wednesday be closely watch boston federal reserve bank president eric rosengren speak morning earning report have slow trickle gpu technology conference san jose calif grab attention week oil be little change west texas intermediate brent slip fraction oil price post first decline week last week commodity biggest rally april gold dip less hold ounce europe benchmark index paris frankfurt trade more midday london ftse trail gain market china end session narrowly mixed japan nikkei inched apple aapl home depot hd pfizer pfe be early leader dow nasdaq facebook fb be early decliner nearly stock capped week advance friday end just buy point cup base share be recently trading virgin america va soar alaska airline alk slump alaska agree acquire virgin deal value share virgin rise week friday speculation deal alaska end friday buy point cup handle base edward lifescience ew bolt higher announce positive result clinical trial sapien aortic valve replacement medical device leader end last week extend cup base buy point tesla motor tsla rise tweet chief executive elon musk announce order new tesla model rise end day saturday tesla briefly clear cup handle buy point friday then trim gain end just buy point
472,PFE,delaware select growth fund dveax pull stop search growth go anywhere fund invest company size look name be expect grow faster economy long term asset fund be sub advise team manager san francisco base jackson square partner year date go tuesday fund be vs average decline peer large growth fund track morningstar last decade delaware select growth have churn annual average return vs large growth category fund hold stock feb spread vary market cap category fund count technology consumer discretionary health care be top weighting fund have annual turnover rate versus category average delaware select growth primarily bet company asset invest top holding paypal pypl be top holding fund better recent performer digital mobile payment provider be so far year stock be top hold feb earning share rise past quarter vital signsat end february fund top hold be company celgene celg january company report fourth quarter earning share growth jump revenue celgene top line have benefit strong sale top selling cancer drug revlimid share celgene be year date earlier month biotech release drug trial datum disappoint investor celgene report phase disappointing result experimental oral treatment psoriasis delaware select position have also be make gain pharmaceutical space allergan agn be come impressive own botox be company top revenue generator quarter figure amount total revenue november company agree blockbuster merger pfizer pfe allergan have see stock price slide begin year ep growth have decelerate grow past quarters qualcomm qcom be fund third largest hold have be portfolio delaware select growth team state commentary believe company mobile chip business bounce back product cycle issue be unlikely recur show strength company recently up dividend qualcomm have see stock price rise zebra technology zbra be add delaware select growth portfolio company sell tracking computer printing technology such barcode scanner specialty printer zebra recently say be project full year net sale growth also expect pay least debt principal zebra share have decline so far year commentary delaware select growth team note progress microsoft msft top hold shift cloud base technology believe transition be beneficial software be better utilize multiple platform team write share microsoft have tick so far year
473,PFE,drug stock take beating tuesday major average finished mixed again ahead fed monetary policy announcement wednesday dow jone industrial average eke gain nasdaq give respectively volume run higher nasdaq exchange bit lighter nyse vs monday accord preliminary number economic front february retail sale dip line view january datum be revise initial report gain drug stock get hurt stock market today valeant pharmaceutical vrx ibd lead downside stock plunge multiyear low canada base drugmaker report revenue top view earning miss valeant also slash ep revenue guidance other drugmaker endo international endp sank mallinckrodt mnk horizon pharma hznp pfizer pfe merck mrk underperform dow respective loss apple aapl outpeformed blue chip gapping rise volume apple be lighter usual share be december low april peak morgan stanley have overweight rating price target say note apple iphone demand be tracking ahead expectation apple be expect unveil new inch smartphone new apple watch band spring product launch event monday automaker food stock buck downtrend tesla tlsa add extend advance third straight session electric car maker stock have rev feb intraday low be now day line ibd ligand pharmaceutical lgnd shed slow turnover close converge day day line tal education group xrs lead upside gain economic datum slate wednesday include consumer price index housing start industrial production february fed policy statement be release et follow shortly thereafter fed chief janet yellen press conference
474,PFE,stock dip narrowly monday open then quickly improve mixed action oil mining retail stock post early gain dow rise wal mart wmt dupont dd gain more nasdaq slip apiece stock market today have open mixed trade volume rise nasdaq dip nyse compare action same time friday third dow industrial stock rise start bell dupont keep premarket lead almost takeover speculation continue make round pfizer pfe nike nke slump lower respectively largest gain be energy oil stock tenth be gain netapp ntap datum storage heavyweight rally straight week friday monday share trade feb low loss stock be moderate daniel adm take hardest hit bank america downgrade share neutral buy iron ore be focal point morning spiking overnight global market record day surge ore miner post best gain london stock exchange london ftse trade afternoon trade new york list share vale vale surge start trade market rio rio jump more bhp billiton bhp rise more leader wesson swhc pare loss be still more early trade stock re-cover almost buy point clear month cup base friday
475,PFE,disgrace drugmaker valeant pharmaceutical vrx continue sell rest medical sector thursday report surface creditor be demand new term company default massive debt reuter cite anonymous source say early talk lender be ask higher interest payment pledge pay larger amount bank loan proceed valeant asset sale valeant have be breach report covenant tuesday miss filing deadline have day resolve however doesn file march also be default bank creditor have only day resolve default valeant be debt year long buy spree culminate fail attempt buy allergan agn last year allergan subsequently merged actavis be now process be buy pfizer pfe late afternoon stock market today valeant stock lose medical group track ibd even unrelated drug account worst perform group ibd industry generic drug group lead slide decline hardest hit individual stock be valeant fellow specialty drugmaker have consciously follow valeant business model mallinckrodt mnk authorize stock buyback be endo international endp be head former valeant executive rajiv silva hit year low trading horizon pharma hznp have be criticize pricing policy much valeant have be selling last day major drugmaker eli lilly lly tumble eli lilly fall intraday lowest level late
476,PFE,stock again finished mixed tuesday ahead federal reserve monetary policy announcement due wednesday dow jone industrial average eke gain nasdaq give respectively volume run higher board vs monday accord preliminary number economic front february retail sale dip line view january datum be revise drop initial report gain energy stock slide oil price west texas intermediate crude fall barrel drug stock get hurt stock market today valeant pharmaceutical vrx lead downside stock plunge multiyear low canada base drugmaker report revenue top view earning miss valeant also slash ep revenue guidance other drugmaker endo international endp sank mallinckrodt mnk lose horizon pharma hznp retreat pfizer pfe merck mrk underperform dow respective loss roughly apple aapl outpeformed blue chip gapping rise volume apple be lighter usual share be december low april peak morgan stanley have overweight rating price target apple say note apple iphone demand be tracking ahead expectation automaker food stock buck downtrend tesla tsla add extend advance third straight session electric car maker stock have rev feb intraday low be now converge day day line ibd ligand pharmaceutical lgnd shed more slow turnover close converge day day line
477,PFE,stock open thin loss wednesday nasdaq flick positive territory dow industrial ease nasdaq move fractional gain loss thing have be stock market today strong february employment report adp help shore confidence start trade still market be hang back ahead fed march beige book report due et be last federal open market committee march meeting have impact afternoon trade oil price stick early loss west texas intermediate almost brent crude trading lower energy information administration report weekly inventory datum et weekly inventory estimate american petroleum institute indicated tuesday inventory rise barrel last week vs consensus view barrel increase dow stock open generally lower apple aapl pfizer pfe merck mrk higher gain less dupont dd nike nke lead downside loss respectively tumble management guide full year earning consensus expectation dollar tree dltr shed fourth quarter earning fall more expect revenue gain stop short analyst forecast small cap be perform comparatively well generate big move checkpoint system ckp skip takeover offer darling ingredient dar spiked report result tuesday american vanguard avd rocket higher report late tuesday nasdaq seagate technology stx climb almost hard disk drive manufacturer be almost jan low still deep month consolidation peer western digital wdc rise most ibd stock lose ground early trade ross store rost post strongest gain nearly follow result late tuesday gain put share more buy point image provide shutterstock
478,PFE,big pharma player allergan unveil expect be final full year operation independent drug maker merge pfizer report fourth quarter earning beat expectation revenue barely top wall street estimate market open allergan agn say gaap earning rise share revenue gain metric exclude discontinue operation notably allergan global generic business agree sell july global generic unit carry old actavis name generic drug line business actavis have purchase specialty drug botox maker allergan deal close march rename allergan allergan stock rise stock market today time high touch july pfizer pfe stock rise monday nearly year high set july analyst poll thomson reuter expect ep item revenue analyst number apparently be not uniformly adjust discontinue operation allergan present pro year earlier number adjust ep revenue full year allergan say gaap ep continue operation increase revenue continue operation vary adjustment full analyst expect share item sale allergan report gaap loss continue operation share compare gaap loss continue operation share prior year period say full gaap result be impact amortization acquisition expense license agreement impairment severance related mainly acquisition allergan march kythera oct well research development expense result purchase asset mimetogen allergan have decline freshen guidance issue performance nov cite early merger discussion pfizer back then monday guide revenue material change gross margin current level gaap tax rate normalize management didn specify ep year offer guidance other suggest performance be weakest year fall result allergan result be analyst challenge influenced extraordinary dance card begin discontinue operation rename actavis generic line agree sell teva pharmaceutical teva july nov allergan board agree pfizer offer pfizer share allergan share then value allergan share entire deal expect take month close ceo brent saunder tell analyst conference call follow earning release still expect pfizer buyout close second half be second largest acquisition ever sale vodafone airtouch mannesmann dell october offer buy emc emc be value pfizer acquisition allergan be thin number tax inversion deal allow american company domicile ireland allergan home base buyer enjoy lower tax base obama administration have criticize practice throw speed bump not road block feb pfizer say plan reorganize broad line business merger allergan be complete allergan cfo tessa hilado tell analyst debt stand dec be paid close teva sale put revenue top seller botox eye drug restasis namenda xr say cvs cvs purchase target tgt pharmacy have effect revenue didn wouldn impact earning
479,PFE,mark finn never see market sell didn portfolio manager rowe price value fund trvlx finn often used dip set long term position mutual fund recent december january stock market pullback present own set opportunity finn have be gdp scare sell say person be worry economy tip back recession so cyclicality be sale right now be look particular be company get really attractive dividend yield generate lot free cash flow have be cheapen re perceive be cyclical business finn be ready pick spot more pullback occur month ahead be not overly optimistic market overall say end year flat begin think be expect interim get chance buy really good company dividend yield close be trading multiple time rowe price value be year date go thursday vs decline large cap value peer track morningstar inc past year mutual fund have return annual average beating peer trail fund carry ibd month performance rating meaning top mutual fund year performance finn rely robust team research analyst help fundamental stock pick be try identify invest quality company be face controversy perceive controversy have determine be trading intrinsic value say have good idea make big position accrue benefit shareholder end general electric ge be rowe price value top hold finn be optimistic ge renew focus industrial business help increase margin time have be best perform industrial company last year say think ge be go continue relatively outperform industrial have really figured mission be ge have see stock price climb past year share be almost stock market today pfizer pfe top hold have sunk week high have fall back allergan agn acquisition pfizer be phenomenal company really nice pipeline product now have really good yield finn say pfizer be year sport dividend yield energy sector finn have favorable outlook exelon exc have great dividend yield look be cyclical bottom come energy say share exelon yield have gain so far year holding finn see undervalue also include international paper ip aes aes be company trading dividend yield market perceive be cyclical risky really don say
480,PFE,stock future tack higher ahead monday open bounce oil price positive trade overseas set positive mood dow nasdaq future swung fair market value key economic news release week include january exist home sale number tuesday new home sale datum wednesday january durable good report thursday revision commerce department gdp friday today stock market receive only small economic news open positive note chicago federal reserve national activity index turn positive january reversed downwardly revise december researcher markit release preliminary manufacturing index february et monday trading volume be likely be sharply friday level be boost option expiration trade week critical test be market avoid distribution day day market slip stall rise volume young uptrend attempt get ground oil price sway higher early monday send west texas intermediate almost barrel gold drop trade just ounce nearly third dow rise pfizer pfe head pack gain say late friday receive expend approval food drug administration metastatic breast cancer therapy ibrance base bank hsbc hsbc slump more weighting early trade europe big cap bank report loss have improve vs last year come far short estimate return profit result be hinder bank say rise charge off loan energy play report also note bank be several investigation authority hire practice asia energy mining issue packed top rank early trade chesapeake energy chk freeport mcmoran fcx marathon oil mro kinder morgan kmi be top so be private label credit card provider synchrony financial syf jump weekend barron article say private label card be gain market share name synchrony market leader trade be somewhat volatile ibd stock early gain reilly autmotive orly broadcom avgo netease nte fizzling flat trade mild loss ryanair ryaay lead decline list more premarket action ireland base budget airline jump last week send back week move average week pattern become cup base netease surge last week start right side consolidation remain week line reilly broadcom be possible base pattern have face challenge rise shape consolidation basis overseas europe market pressed firmly higher oil mining stock help boost trade cac paris dax frankfurt be midday london ftse be more asia tokyo nikkei hong kong hang seng index climb apiece add last week strong gain shanghai composite also post healthy gain last week jump monday
481,PFE,big pharma pfizer pfe announce monday close acquisition allergan agn plan reorganize unit pending possible split back pfizer reorganize operation business unit innovative product establish product vaccine oncology consumer healthcare voc be widely view preparation split company pending buyout allergan pfizer be add large number drug include wrinkle treatment botox variety eye care skin care product monday pfizer say plan combine innovative product voc business include new subdivision call global specialty consumer brand include most allergan product larger innovative product business be head current voc head albert bourla replace geno germano leave company new global specialty consumer brand division be head allergan executive bill meury establish product business continue be lead john young allergan current ceo brenton saunder meanwhile be set become next president chief operate officer pfizer be generally expect wall street land high ranking position so be ready succeed present pfizer ceo ian read pfizer announce allergan buyout last year say decision split not be make be couple year later previously expect read reiterate monday announcement be design combine company preserve enhance option potentially separate innovative establish business separate company future continue expect make decision potential separation later end read say statement pfizer stock be midday trading stock market today allergan be
482,PFE,valeant pharmaceutical vrx share climb much tuesday drug maker say expect restate earning not much overall help clear air congressional investigation raise question company former relationship distributor philidor rx service question pricing practice specialty drugmaker valeant say written statement late monday evening internal review additional analysis identify certain sale philidor have be recognize product be dispense patient rather delivery philidor valeant say currently believe net revenue be include second half have be book later correct misstatement be expect reduce report gaap earning share cent valeant say increase gaap ep roughly cent base analyst consensus lift ep roughly valeant share close stock market today share have fall friday monday well fargo warn unanswered question company accounting strategic direction stock fall hour monday wall street journal say earning restatement be likely stock plunge aug intraday high questionable number come light low nov statement valeant note sale occur prior earlier bid acquire philidor specialty pharmacy philidor be suspect fill prescription valeant alter doctor order raise insurer reimbursement bloomberg say oct report cite former employee internal document oct valeant say be sever ty philidor subsequently begin wind operation interim chief executive howard schiller say statement company also expect delay filing complete review related accounting matter ad committee determination need delay filing be very disappointing necessary schiller say add remain commit improve report procedure internal control transparency investor schiller be name post interim basis jan fill ailing ceo michael pearson be be treat severe pneumonia complication valeant release unaudited result feb private label counter prescription generic drugmaker perrigo prgo share have be batter too fall lowest point year monday perrigo lose session report weak fourth quarter earning last thursday be downgrade analyst earning perrigo close big pharma allergan agn report hike ep jump revenue monday rise monday finished tuesday allergan agree november be acquire pfizer pfe deal be expect close year
483,PFE,economy be enter recession stock consumer staple health care telecom be best place hide say barclay glionna name tobacco giant philip morris international pm reynold american rai drug giant merck mrk pfizer pfe meanwhile include general electric ge stock buy recovery doesn see recession term be red flag such collapse oil price retreat so far year slow growth global economy china report monday glionna joined grow number analyst provide list recession resistant stock take slightly different tack other offer list recession playbook recovery playbook other top pick recession playbook be campbell soup cpb coca cola ko johnson johnson jnj procter gamble pg hormel food hrl philip morris stock close tuesday reynold american maker camel cigarette add merck gain pfizer rise campbell soup climb johnson johnson procter gamble end flat glionna say recovery playbook best perform sector previous period economic recovery used exit recession indicative recovery have be energy material industrial consumer discretionary stock list ford motor general electric general motor gm harley davidson hog viacom ford end gm lose tuesday ge tick harley davidson fall viacom plunge more expect result december end quarter meanwhile cowen analyst put own list recession stock tuesday say believe stock appeal low end consumer have minimal global exposure appear well suit weather economic downturn top pick price clothing retailer ross store rost wal mart store wmt ross store climb wal mart fall
484,PFE,valeant pharmaceutical vrx perrigo prgo share continue tumble monday generally pull drug sector allergan agn be exception rise strong earning valeant late monday tumble low be lowest march dow jone report valeant pharmaceutical likely restate earning hour later valeant say restatement earning be expect related sale drug ex distributor philidor valeant say sale late have be recognize later valeant expect earning be lower cent share ep lift cent regular session valeant share close stock market today extend loss bearish report well fargo friday valeant share dive nearly day well fargo initiate coverage maker brand drug treat eye disease acne depression other ailment underperform say be unanswered question accounting method strategic direction earlier monday drugstore giant cvs health cvs say plan restrict use valeant jublia toenail fungus drug part initiative cut cost dermatology treatment jublia retail milliliter bottle accord goodrx valeant stock price have plunge intraday high double digit quarterly earning revenue growth nearly year bill ackman persh square hedge fund be significantly year partly fund large stake valeant valeant have already be batter series event include absence ceo michael pearson be be treat severe pneumonia complication jan valeant board name board member former chief financial officer howard schiller interim ceo earlier month valeant interim ceo schiller be call congress explain company decide increase price cardiac drug schiller promise end era sharp price hike perrigo business model be divide private label counter prescription generic drug fall monday lowest level late stock have lose session perrigo report weak fourth quarter result thursday subsequently have negative report jeffery friday goldman sachs monday jeffery cut price target maintain buy rating goldman sachs however downgrade stock neutral sell price target report say perrigo report ep time item cent estimate be company first earning miss quarters revenue grow analyst expect mylan myl last year make offer perrigo perrigo shareholder mid november reject mylan rise monday big pharma allergan agn report expect be final full earning report independent drug maker agree november be buy pfizer pfe allergan ep ex item rise hike revenue wall street expect ep revenue allergan share climb pfizer rise ibd generic drug ethical brand drug group be rare loser otherwise strong day stock
485,PFE,medical stock pfizer pfe mallinckrodt mnk baxter international bax be move tuesday early quarterly report guidance pfizer say revenue rise year earlier quarter beating analyst consensus accord thomson reuter earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share evercore isi analyst mark schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact pfizer stock be afternoon trading stock market today pfizer also say have end midstage trial experimental alzheimer disease drug october independent datum monitoring committee say be futile continue drug pf target brain receptor call ht similar drug rvt currently late stage testing axovant science axon rvt be only drug axovant pipeline axovant stock be intraday hit month low mallinckrodt meanwhile be tuesday afternoon specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance leerink analyst jason gerberry write beat look high quality give reason say selling general administrative sg expense be less expect biggest driver be low sg spend sale vs street assumption spend range gerberry write research note be partially offset higher spend quarter follow sale mix drive higher gross margin quarter vs top line beat drive specialty brand baxter also beat expectation most recent quarter pull sharp increase earning decline sale profit continue operation jump cent share cent past wall street consensus revenue drop baxter say expect ep year beating consensus forecast current quarter be street however cent baxter comparison be somewhat complicate fact july spun biopharma arm baxalta bxlt leave business comprise mostly dialysis hospital product account previous company leerink analyst danielle antalffy write path independent company be become clearer now post split baxter be margin expansion story company work synergy implement broader cost control execute new product launch antalffy write research note quarterly datum point now hand seem clear baxter be track exceed margin expansion trajectory company layer analyst meeting adjust operate margin expansion immediately post split ramp baxter stock be afternoon trading
486,PFE,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
487,PFE,so january come end not fast enough many fall hard january set be sure be turbulent year investor stock manage hold friday gain yesterday even oil fall barrel factory order shrank straight month come
488,PFE,san francisco jpmorgan healthcare conference continue yield mixed result investor second day tuesday several company tweak guidance big pharmas offer incremental update specialty drugmaker horizon pharma hznp have best day share rise company update guidance ahead presentation wednesday horizon say
489,PFE,stock future leap abruptly higher ahead friday open surprise jump december hire dow future point double gain hold just december payroll report
490,PFE,nasdaq future surge point fair market value future pop point small cap kick show point gain
491,PFE,stock market today look wrap first trading week year nasdaq open hole tracking worst performance market collapse august week sell be link falter market china
492,PFE,investor be likely focus more labor department december payroll report china
493,PFE,nonfarm payroll increase december big jump even upwardly revise november count private employer account job new hire november also revise higher number clobber consensus expectation see total new job private employer add
494,PFE,unemployment rate hold steady line expectation
495,PFE,commerce department serve november wholesale inventory datum baker hughe bhi deliver weekly rig count federal reserve give november consumer credit roundup
496,PFE,china market center attention week find foot friday regulator nix circuit breaker rule have shut mainland exchange early monday thursday shanghai composite rise friday end week hong kong hang seng index add week
497,PFE,investor europe didn pick optimism lead index paris frankfurt london trade flat lower midday london frankfurt pick modest gain payroll report
498,PFE,dollar rise bond slip pressure year yield basis point vs week oil trade flat friday week gold edge ounce week
499,PFE,dow stock be nearly cisco system csco goldman sachs gs dupont dd clear gain pfizer pfe slip index only premarket decline
500,PFE,oil energy stock crowd top premarket action marathon oil mro devon energy dvn be more
501,PFE,alcoa aa knock gain open aluminum giant announce plan late thursday shutter evansville ind smelt facility end first quarter also outlined plan cut alumina production ahead company announce split trade operation be expect occur second half year alcoa end thursday week deep month consolidation
502,PFE,rovi rovi run ahead small cap surge more digital tv guide developer have climb october low end thursday session feb high
503,PFE,stock ibd list be generally flat higher only modest gain facebook fb tal education xrs alibaba baba lead bit more
504,PFE,globus medical gmed technology avgo sit bottom list apiece stock future leap abruptly higher ahead friday open surprise jump december hire dow future point double gain hold just december payroll report nasdaq future surge point fair market value future pop point small cap kick show point gain stock market today look wrap first trading week year nasdaq open hole tracking worst performance market collapse august week sell be link falter market china investor be likely focus more labor department december payroll report china nonfarm payroll increase december big jump even upwardly revise november count private employer account job new hire november also revise higher number clobber consensus expectation see total new job private employer add unemployment rate hold steady line expectation commerce department serve november wholesale inventory datum baker hughe bhi deliver weekly rig count federal reserve give november consumer credit roundup china market center attention week find foot friday regulator nix circuit breaker rule have shut mainland exchange early monday thursday shanghai composite rise friday end week hong kong hang seng index add week investor europe didn pick optimism lead index paris frankfurt london trade flat lower midday london frankfurt pick modest gain payroll report dollar rise bond slip pressure year yield basis point vs week oil trade flat friday week gold edge ounce week dow stock be nearly cisco system csco goldman sachs gs dupont dd clear gain pfizer pfe slip index only premarket decline oil energy stock crowd top premarket action marathon oil mro devon energy dvn be more alcoa aa knock gain open aluminum giant announce plan late thursday shutter evansville ind smelt facility end first quarter also outlined plan cut alumina production ahead company announce split trade operation be expect occur second half year alcoa end thursday week deep month consolidation rovi rovi run ahead small cap surge more digital tv guide developer have climb october low end thursday session feb high stock ibd list be generally flat higher only modest gain facebook fb tal education xrs alibaba baba lead bit more globus medical gmed technology avgo sit bottom list apiece
505,PFE,here quick rundown monday hour action steelcase scs say third quarter adjust earning rise penny cent miss cent revenue fall dollar miss steelcase outlook be weak office furniture maker share plunge extend trading cinta cta say second quarter adjust ep rise beating cent revenue grow line uniform rental firm full year earning guidance be light revenue outlook be line estimate share rise late netapp ntap be buy flash storage system maker solidfire dollar cash deal be expect close network storage hardware maker fiscal fourth quarter end april pfizer pfe say phase study pristiq medication pediatric patient major depressive disorder do not meet primary objective demonstrate superior effectiveness versus placebo share still rise fraction late
506,PFE,far most income investor be concern steadier payout better add bonus high dividend growth rate here be dividend leader offer well yield well average payout score dividend stability factor scale most stable most volatile year basis
507,PFE,philip morris international pm pay annual dividend top list base measure long term dividend growth rate be marlboro maker dec boost quarterly payout share year analyst expect tobacco firm earning decline second straight year rise next year stock be flat base buy point year date vs loss pfizer pfe also make friday column feature high yield drug stock be second annualize payout philip morris dividend growth rate be stock be still week week line consolidate general mill gis also have long term dividend growth rate cereal maker thursday announce increase quarterly payout cent share work full year basis yield company also report quarterly result day miss view top bottom line share fall thursday find support day move average stock year date have be consolidate early august coca cola ko also pay annual dividend have long term dividend growth rate beverage giant be dividend aristocrat company have increase dividend year past year top warren buffett hold share be slightly positive year
508,PFE,research development be lifeblood company then microsoft msft be get good shot oxygen be intel intc alphabet googl microsoft spend month end more other company accord factset research microsoft be closely follow intel invest
509,PFE,pharmaceutical aren just source relief physical ailment oft steady dividend provide comfort even stock underperform today ll look drug stock dividend leader screen yield beat average pfizer pfe monday raise quarterly payout cent
510,PFE,past few year be big year health care merger controversy pfizer pfe agree buy ireland base allergan agn last month bring new plan treasury department presidential candidate curb tax inversion deal company relocate lower tax country device
511,PFE,special report personal finance action plan patrick kelly have alger spectra fund coveted spot portfolio manager have lead fund ranking large cap growth mutual fund track morningstar last decade spectra have post annual average return period vs
512,PFE,justice department decision tuesday not rule halliburton baker hughe deal reflect obama administration increasingly wary approve mammoth takeover halliburton hal offer clear way baker hughe bhi takeover reportedly haven impressed antitrust official oil service giant say tuesday don expect deal close year
513,PFE,here quick rundown monday hour action aerospace giant boee ba raise share repurchase program replace program remain
514,PFE,boee also raise quarterly dividend share boee have increase dividend straight year share rise late pfizer pfe also raise dividend cent cent share payable march be drugmaker consecutive quarterly dividend share rally extend trading network ffiv say ceo have resign matter regard personal conduct chairman board return ceo position datum center gear maker search permanent successor share change little late trade lumber liquidator ll shot late trade whitney tilson explain seek alpha article cover lumber liquidator short position say lumber liquidator top management do not appear be aware company be selling chinese make laminate high level formaldehyde norwegian cruise line holding nclh launch secondary stock offer share third party seller norwegian cruise line repurchase share part buyback program share fall hour follow alissa william twitter ibd_awilliam facebook
515,PFE,dow chemical dow dupont dd be advanced talk create chemical giant accord multiple report cap record year merger activity include last month deal pfizer pfe buy allergan agn merged dow dupont firm then split separately trade company accord wall street journal cnbc david faber firm be agriculture material service specialty product dow chemical close tuesday market cap dupont be value dow ceo andrew liveris be expect become executive chairman merged firm dupont ceo edward take only october be expect hold same position post merger faber report merger deal be likely thursday company have be pressure shed slower growth unit dupont reportedly have seek merge agricultural asset syngenta syt syngenta have rebuff overture activity have top eclipse old record set pfizer tax inversion deal allergan be largest year big drug takeover ever
516,PFE,stock build early gain tuesday keep recent pattern day follow day nasdaq advanced respectively dow jone industrial average rise small cap lag russell add volume stock market today fall major exchange hasn notch day row first half november then however big cap index have gain short term close low nov meanwhile nasdaq have show more confidence post day row twice same period gain almost blue chip be mostly tuesday soft trade pfizer pfe be only stock dow draw hefty volume drugmaker gain volume average ibd biggest percentage gainer day be lgi home lgih jump strong volume texas base homebuilder be featured sector leader review columnin ibd tuesday edition big cap linkedin lnkd score gain almost quiet volume downside china base wealth management company noah holding noah slide almost volume be only average economic news generally favore bull tuesday motor vehicle sale november deliver slight beat vs street consensus view redbook research gauge chain store sale week end nov solidly beat view do construction spending october pmi manufacturing index november be slightly better expect ism manufacturing gauge november miss badly follow paul whitfield twitter ibd_pwhitfield
517,PFE,special report income investing dividend yield steady stream income investor lead fund manager have used game plan focuse buy select dividend pay stock boost total return drive outperformance rowe price dividend growth fund columbia dividend income fund have be top mutual fund dividend investor last decade here be insight manager have execute successful dividend investment strategy rowe dividend growthtom huber have beaten large blend fund track morningstar annual average basis point last year manager rowe price dividend growth fund point dividend prove be substantial portion investor total return time dividend have make total return huber say get lose little bit market be strong compound double digit rate look back history dividend have be important source return investor income investor huber emphasize importance buy stock company have be able increase dividend time track record dividend growth be good sign quality business financial health durability say addition offer investor grow stream income dividend pay stock also tend be less volatile offer downside protection dividend growth be design reward patient investor be market environment strategy do better environment be go lag huber say big market dividend stock tend be bit favor growth moderate market correct tend hold better dividend growth stick many bet long haul have relatively low turnover huber say mutual fund turnover ratio want own company time benefit compound effect earning cash flow dividend growth compare dividend growth generic growth fund huber point low turnover be advantageous tax purpose percentage distribution dividend capital gain likely vary fund tax rate be similar say fund have turnover rate run be much lower peer help limit taxable event fund top hold dhr have be mainstay dividend growth portfolio much huber tenure yield less percent do raise dividend nicely year say diversify industrial company better average business characterize higher average margin free cash flow conversion pfizer pfe be huber hold company have be grow dividend rate last year say pfizer have pipeline not expensive stock have yield huber see general electric ge shareholder benefit company divest much financial service unit end industrial earning stream be much less volatile have be previously say fund hold be higher quality more durable mix business meantime collect dividend yield columbia dividend incomecolumbia dividend income fund be co manage scott davis michael barclay peter santoro have top large value fund track morningstar average basis point past year achieve outperformance trio thoroughly assess long term business prospect dividend pay company buy look stock do not look dividend first davis say look company corporate structure ability generate cash operation sustain dividend need have healthy company afford pay davis emphasize fund dividend investment strategy do not get catch chasing yield not just focuse highest yielding stock davis say really have do sustainability dividend company ability grow dividend barclay note fund portfolio provide ample downside protection hallmark product be keep investor get hit hard stock market go say do client stay engage be still fund market turn go back cash flow generatorsas microsoft msft apple aapl be top holding not only do microsoft apple have superior free cash flow generation be actually grow barclay say find company be grow top line produce strong free cash flow strong operate margin formula good growth sustainability dividend fund top consumer cyclical hold be home depot hd continue see home improvement project gain consumer wallet share santoro say home depot have do great job anticipate consumer need have also be good steward capital have be raise cash flow expectation portfolio have hold position exxon mobil xom exxon have probably best balance sheet whole industry santoro say pay dividend almost be incredibly secure
518,PFE,breaking news be turkey intelligence tell turkey take russian fighter jet have crossed turkish airspace early report suggest have warn fighter jet yet warning have fall deaf ears shot sky future turn sharply lower news go european mkts be also now sharply lower ftse cac dax eurostoxx spain italy more follow darkness turn light
519,PFE,asian mkts close mixed overnight note european mkts be lower follow uninspire day yesterday here state well asia concern terrorist threat latest news continue dominate conversation brussel be lockdown straight day polouse hunt prime suspect responsible paris attack ally nation continue punish isis issue global travel warning ahead thanksgiving holiday yesterday stock rise open bell only sell moved close seem neither bull bear be really control mkt waffle major index finished day just south unchanged line dow lower pt nasdaq unchanged slip point small cap russell be only bright spot add pt trading volume be lighter so many stick sideline heel volatility see past few week concern upcoming macro datum due today remember week be usually good week stock think be new concern number front black friday cyber monday live reputation consider weak macro datum late be black friday really thing anyway sale have be go week now so almost comical see retailer be position then medium have say blowout black friday number yawn other hand many be now worry possibility more terrorist attack world week ahead so many celebrate holiday next week
520,PFE,deal front yesterday bring news pfizer american base allergan agn ireland base have fact reach deal combine company allow pfizer pfe engage reverse merger take full advantage inversion trade speak last week deal value not only create world biggest drug maker also result huge tax saving newly combine company now be domicile dublin corp tax rate be fraction rate here state ink be not even dry yet morning paper scream start fault be happen pfizer be brilliant deal right take full advantage break corp tax system system have be break year dc choose address yes recognize have be talk ad naseum end have do nothing now be scream gop frontrunner donald call deal disgusting take direct aim politician say politician be ashamed tax system encourage such move coincidentally someone have used system advantage bankruptcy number time make wonder be position do inversion deal cut taxe sanction loop hole do be now run president so guess perspective change democrat not be do jump bandwagon well cousin bernie sander former senator call disgusting encourage current administration block hillary former senator secretary state first lady say sudden propose specific business tax proposal urge congress act immediately make sure biggest corporation pay fair share so taxpayer be not left hold bag
521,PFE,interesting note here be sander clinton be member congress neither choose make corp tax policy individual tax policy top issue tenure now be run president so guess perspective change well funny work so political economic uncertainty hang couple recent volatility be wonder really trading be lackluster directionless usually see activity trend have run course direction mkt appear bit exhaust neither side be control kind action create technical pattern know spin top candlestick pattern spin top be candlestick pattern small real body represent tight trading range represent tug war bull bear have rather long tail end suggest side have control point day end backed technical pattern indicate neither bull bear be control be just spin wheel tight trading range suggest possible reversal trend be work possibility such reversal be enough keep trader investor sideline trend stabilize be shorten week still be slew economic datum next few day see report home sale personal consumption exp today look revise read rd qtr gdp expectation revision show rate vs initial read now know initial inventory build component be low side first go so revise inventory build be reason increase revision
522,PFE,news latest attack russian jet change course conversation mkt action today macro datum today surprise mkts do not expect break thru resistance thru support yet new international headline be cause renew concern caution force mkts lower day move new uncertainty fact be russian fighter jet only cause more anxiety threaten escalate tension even more look support take good care kp
523,PFE,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate breaking news be turkey intelligence tell turkey take russian fighter jet have crossed turkish airspace early report suggest have warn fighter jet yet warning have fall deaf ears shot sky future turn sharply lower news go european mkts be also now sharply lower ftse cac dax eurostoxx spain italy more follow darkness turn light asian mkts close mixed overnight note european mkts be lower follow uninspire day yesterday here state well asia concern terrorist threat latest news continue dominate conversation brussel be lockdown straight day polouse hunt prime suspect responsible paris attack ally nation continue punish isis issue global travel warning ahead thanksgiving holiday yesterday stock rise open bell only sell moved close seem neither bull bear be really control mkt waffle major index finished day just south unchanged line dow lower pt nasdaq unchanged slip point small cap russell be only bright spot add pt trading volume be lighter so many stick sideline heel volatility see past few week concern upcoming macro datum due today remember week be usually good week stock think be new concern number front black friday cyber monday live reputation consider weak macro datum late be black friday really thing anyway sale have be go week now so almost comical see retailer be position then medium have say blowout black friday number yawn other hand many be now worry possibility more terrorist attack world week ahead so many celebrate holiday next week deal front yesterday bring news pfizer american base allergan agn ireland base have fact reach deal combine company allow pfizer pfe engage reverse merger take full advantage inversion trade speak last week deal value not only create world biggest drug maker also result huge tax saving newly combine company now be domicile dublin corp tax rate be fraction rate here state ink be not even dry yet morning paper scream start fault be happen pfizer be brilliant deal right take full advantage break corp tax system system have be break year dc choose address yes recognize have be talk ad naseum end have do nothing now be scream gop frontrunner donald call deal disgusting take direct aim politician say politician be ashamed tax system encourage such move coincidentally someone have used system advantage bankruptcy number time make wonder be position do inversion deal cut taxe sanction loop hole do be now run president so guess perspective change democrat not be do jump bandwagon well cousin bernie sander former senator call disgusting encourage current administration block hillary former senator secretary state first lady say sudden propose specific business tax proposal urge congress act immediately make sure biggest corporation pay fair share so taxpayer be not left hold bag interesting note here be sander clinton be member congress neither choose make corp tax policy individual tax policy top issue tenure now be run president so guess perspective change well funny work so political economic uncertainty hang couple recent volatility be wonder really trading be lackluster directionless usually see activity trend have run course direction mkt appear bit exhaust neither side be control kind action create technical pattern know spin top candlestick pattern spin top be candlestick pattern small real body represent tight trading range represent tug war bull bear have rather long tail end suggest side have control point day end backed technical pattern indicate neither bull bear be control be just spin wheel tight trading range suggest possible reversal trend be work possibility such reversal be enough keep trader investor sideline trend stabilize be shorten week still be slew economic datum next few day see report home sale personal consumption exp today look revise read rd qtr gdp expectation revision show rate vs initial read now know initial inventory build component be low side first go so revise inventory build be reason increase revision news latest attack russian jet change course conversation mkt action today macro datum today surprise mkts do not expect break thru resistance thru support yet new international headline be cause renew concern caution force mkts lower day move new uncertainty fact be russian fighter jet only cause more anxiety threaten escalate tension even more look support take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
524,PFE,big pharma pfizer fulfilled week rumor monday announce deal buy specialty drug giant allergan stock swap value heating political debate tax inversion deal pfizer pfe agree provide allergan agn shareholder pfizer share allergan share base friday close price value allergan share price be somewhat lower last week anonymously source press report peg price share be still premium allergan friday close price make deal second largest ever say thomson reuter only mannesmann acquisition vodafone airtouch more twice value largest tech couple ever merger dell emc emc announce october term disappoint investor allergan stock fall pfizer fall monday pfizer drop lower value deal allergan share expect deal allow pfizer perform tax inversion domicile allergan official homeland ireland lead pfizer rename pfizer plc expect close deal month pfizer say inversion result pro tax rate cut more company tax bill overall pfizer expect cost saving first year combination doesn forecast earning accretion allergan shareholder end own combine company steer clear last week new treasury guideline attempt tighten rule such tax inversion deal rule target more lopsided deal acquirer try redomicile still own more company full tax benefitson conference call analyst monday morning discuss merger pfizer ceo ian read say expect realize full benefit tax inversion hasten add trimming tax bill wasn only reason deal say pleasant surprise pfizer due diligence be discover strength allergan drug franchise say pfizer further expand abroad thank vast global infrastructure allergan expand leadership position bring very strong franchise aesthetic dermatology eye care gi disease woman health urology infective read say remember several year pfizer decide exit prioritize area not be unattractive do not have scale expertise market lead position be competitive allergan gain access expertise market lead product area read say lack overlap company product line be reason projection cost saving be somewhat lower analyst expect say pfizer plan keep most allergan operation employee southern california be originally headquarter bring irish domicile imply not be big layoff evercore isi analyst mark schoenebaum theorize webinar client preserve job also be way deflect criticism deprive tax income so didn entirely work democratic presidential candidate hillary clinton bernie sander criticize deal monday week ahead propose specific step prevent kind transaction take advantage loophole litter tax code distort incentive investment disadvantage small business domestic firm game international tax system clinton say statement buyout deal include breakup fee likely real change legal regime come only new president congress be swear early be deal be expect close say analyst edison investment analyst maxim jacob however say federal trade commission look askance such enormous entity even pass treasury restriction pfizer allergan deal appear have be consummate be attractive side regulatory reaction very high profile merger remain unknown very well be negative due size tax inversion jacob write email read remain chairman ceo combine company allergan ceo brent saunder become president chief operate officer arrangement seem support pre deal speculation saunder be be view potential successor read year older saunder pfizer also say delay make decision splitting innovative establish old generic product business move have be expect next year analyst call weren happy delay leerink analyst seamus fernandez say still expect split happen eventually ultimately cash flow combine entity likely quickly exceed split believe overall operational complexity be likely be too high drive innovative growth fernandez write research note
525,PFE,do high quality stock big dividend yield top way be company increase cash payout here be stock yield better double digit dividend growth rate fast stock dividend rise year calculate ibd cisco system csco pay
526,PFE,analysis october sale im health im show sanofi sny be continue gain market share biogen biib multiple sclerosis accord rbc capital market biogen sell worth drug tecfidera october week analyst michael yee note be september
527,PFE,talk possible merger dupont dd dow chemical dow be icing very large cake have already set record be time biggest year merger acquisition wednesday be announce deal worldwide act prom queen
528,PFE,stock hold solid gain midday tuesday ahead thursday european central bank meeting more stimulus measure be widely expect
529,PFE,dow jone industrial average add weak dollar lift several blue chip name early winner dow include boee ba merck mrk pfizer pfe add nasdaq picked volume nyse nasdaq be tracking higher monday level stock market today
530,PFE,nyse advance stock top decliner more breadth be much weaker nasdaq winner only have slight edge loser
531,PFE,economic news ism manufacturing index deliver sluggish read november consensus estimate year treasury yield be basis point
532,PFE,day gainer lgi home lgih soar new high rise be featured tuesday sector leader column
533,PFE,linkedin lnkd also outperformed rise more be consolidate gain begin year be verge form handle entry
534,PFE,meanwhile qihoo technology qihu rally nearly wall street journal report investor group lead chairman zhou hongyi be near agreement pay buy qihoo share several china name include qihoo see heavy volume buy late monday session month november come end
535,PFE,follow ken shreve twitter ibd_kshreve facebookstock hold solid gain midday tuesday ahead thursday european central bank meeting more stimulus measure be widely expect dow jone industrial average add weak dollar lift several blue chip name early winner dow include boee ba merck mrk pfizer pfe add nasdaq picked volume nyse nasdaq be tracking higher monday level stock market today nyse advance stock top decliner more breadth be much weaker nasdaq winner only have slight edge loser economic news ism manufacturing index deliver sluggish read november consensus estimate year treasury yield be basis point day gainer lgi home lgih soar new high rise be featured tuesday sector leader column linkedin lnkd also outperformed rise more be consolidate gain begin year be verge form handle entry meanwhile qihoo technology qihu rally nearly wall street journal report investor group lead chairman zhou hongyi be near agreement pay buy qihoo share several china name include qihoo see heavy volume buy late monday session month november come end follow ken shreve twitter ibd_kshreve facebook
536,PFE,share drug giant allergan rise friday analyst say new treasury guideline tax inversion deal shouldn hinder possible acquisition pfizer new york base pfizer pfe have be talk ireland base allergan agn late last month possibility buyout allow pfizer relocate allergan lower tax home wall street generally
537,PFE,past year talk concern bristol myer squibb have focuse cancer drug be understandable bristol myer bmy recently launch opdivo be project take nearly year look carry other immuno oncology drug such yervoy greater sale well same time bristol myer have
538,PFE,pharmaceutical etfs pop friday news pfizer pfe takeover irish drugmaker allergan agn reportedly biggest tax inversion deal history largest ever health sector allow pfizer new york base pharma giant redomicile ireland have much lower corporate tax rate exchange trade fund track major index stumble investor eye gdp inflation datum due later week spdr pharmaceutical xph jump stock market today etf equal weight stock holding include pfizer allergan stock holding fall today investor soured term deal prestige brand holding pbh lead upside xph holding gain xph have gain momentum recent week be july high powershare dynamic pharmaceutical pjp nose etf provide broad exposure stock include highly rate ibd stock allergan gilead gild celgene celg etf select weight holding base various fundamental risk factor allocate roughly asset allergan pfizer combine pjp have rally significantly september interim low post gain last week retake line move average even trade july high year date pjp be nearly vs xph loss gold price fall again monday dollar rise fraction major world currency etfs backed physical gold have peg straight weekly loss stagnate multiyear lows higher expectation interest rate hike december be weigh precious metal bear yield bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
539,PFE,investor not find unexpected apple aapl starbucks sbux palo alto network panw be piper jaffray hot list upcoming year investment bank asset management firm also peg several less universally love overweight rate stock apple iphone ipad maker be piper jaffray top pick analyst gene munster
540,PFE,pfizer pfe announce takeover monday morning buy botox maker allergan agn more accord multiple report make biggest tax inversion deal history pfizer board sign deal sunday report say monday announcement plan pfizer pay share small cash component
541,PFE,stock future stick steady slender gain ahead wednesday open investor dig trove fresh economic news earning report dow future fly straight level point nasdaq future show point gain future trade point fair market value stock market today get bellyful economic news government agency clear deck thanksgiving break personal income jump line estimate october commerce department report revise september estimate upward gain consumer spending stop short projection improvement price pop reverse september decline stopping short projection increase core price energy food be flat expectation gain commerce department also say durable good order jump october revise september decline order commercial aircraft boost october number transportation order rise slimmer economist have project overall gain month improvement transportation jobless claim slow week end nov more prior week better estimate slight decline claim labor department also report week move average continue tick higher federal housing finance agency set september housing price index et researcher markit report preliminary service purchasing manager index november look october new home sale commerce department final november consumer sentiment estimate university michigan oil be focus later morning energy information administration release weekly inventory datum early trading oil price erased most gain tuesday nearly nymex gasoline future fall almost majority dow stock remain flat ahead open pfizer pfe lead handful gainer advance intel intc drop biggest decline flow earning report have slow trickle still continue kick major move apparel retailer guess ge power solid report late tuesday china base social networking site momo momo pop sale earning miss monthly active user rise september deere crank advance fiscal fourth quarter earning fall share far consensus view fall cent revenue fall also better expect management outlook essentially say sale deteriorate improve pace deere share be month consolidation end tuesday august high hewlett packard company go different direction follow first quarterly report release nov divorce hp inc hpq pc printer manufacturer tumble announce late tuesday see fiscal full year earning consensus expectation hp share end tuesday early october low work climb right side month consolidation hewlett packard enterprise hpe information technology hardware software service unit be open hpe share have be consolidate nov launch last quarter combine company hp earning revenue fall further expect analyst lead stock be predominately quiet premarket trade stock ibd weekly review list hold gain loss less overseas market asia be narrowly mixed lead index hong kong tokyo post mild loss european market bounce higher harsh loss tuesday benchmark index london paris frankfurt trade midday
542,PFE,massive pfizer pfe allergan agn merger deal week make clear irish economy be not shy away inversion deal free corporation domestic tax burden be still likely be headquarter new york pfizer save more now paid taxe first year
543,PFE,stock future scrape lower ahead tuesday open bump early gain international conflict global travel alert dow future dig point be fall
544,PFE,nasdaq future be point fair market value future carved point loss
545,PFE,turkey report fighter jet have shot russian aircraft plane have be warn be violate turkish air space russia defense ministry claim aircraft have not stray turkish air space be fly meter be shot ground
546,PFE,case stock future veer lower news break stock market today feel additional premarket pressure state department issue global travel alert american base plan terrorist threat multiple region ahead travel heavy thanksgiving weekend alert less serious caution department travel warning do not say citizen not travel advise traveler remain vigilant avoid large crowds crowd place alert expire feb
547,PFE,airline stock travel related issue such priceline com pcln tripadvisor trip come moderate premarket pressure follow release oil price rise west texas intermediate bob back barrel europe brent crude benchmark
548,PFE,commerce department revise estimate third quarter gdp growth upward number be better initial estimate growth line economist consensus expectation department revise gdp deflator measure price notch gain vs first estimate consensus projection have hold mark
549,PFE,case shiller be schedule release city home price index september et conference board report november consumer confidence index richmond federal reserve put regional manufacturing survey month
550,PFE,dow stock trade ahead open pfizer pfe be holdout gain
551,PFE,quarterly report continue stir heavy early action auto salvage consolidator copart cprt china base continue education specialist tarena international tedu leap
552,PFE,be tough morning jeweler signet jeweler sig diving tif chain miss analyst consensus sale earning expectation third quarters premarket gain loss often do not carry regular session signet loss hold stock open gap loss day move average
553,PFE,ibd stock dycom dy spun gain report late monday fiscal earning soar past consensus view revenue gain easily top expectation gross margin expand year management revenue guidance be better forecast telecom engineering construction service firm end monday still buy range buy point
554,PFE,palo alto network panw tack gain network security gear maker report broad fiscal beat late monday stock advanced past session be back week move average climb right side month consolidation stock future scrape lower ahead tuesday open bump early gain international conflict global travel alert dow future dig point be fall nasdaq future be point fair market value future carved point loss turkey report fighter jet have shot russian aircraft plane have be warn be violate turkish air space russia defense ministry claim aircraft have not stray turkish air space be fly meter be shot ground case stock future veer lower news break stock market today feel additional premarket pressure state department issue global travel alert american base plan terrorist threat multiple region ahead travel heavy thanksgiving weekend alert less serious caution department travel warning do not say citizen not travel advise traveler remain vigilant avoid large crowds crowd place alert expire feb airline stock travel related issue such priceline com pcln tripadvisor trip come moderate premarket pressure follow release oil price rise west texas intermediate bob back barrel europe brent crude benchmark commerce department revise estimate third quarter gdp growth upward number be better initial estimate growth line economist consensus expectation department revise gdp deflator measure price notch gain vs first estimate consensus projection have hold mark case shiller be schedule release city home price index september et conference board report november consumer confidence index richmond federal reserve put regional manufacturing survey month dow stock trade ahead open pfizer pfe be holdout gain quarterly report continue stir heavy early action auto salvage consolidator copart cprt china base continue education specialist tarena international tedu leap be tough morning jeweler signet jeweler sig diving tif chain miss analyst consensus sale earning expectation third quarters premarket gain loss often do not carry regular session signet loss hold stock open gap loss day move average ibd stock dycom dy spun gain report late monday fiscal earning soar past consensus view revenue gain easily top expectation gross margin expand year management revenue guidance be better forecast telecom engineering construction service firm end monday still buy range buy point palo alto network panw tack gain network security gear maker report broad fiscal beat late monday stock advanced past session be back week move average climb right side month consolidation
555,PFE,stock market close lower monday retailer have bumpy session nasdaq dow jone industrial average fall slip volume rise be surprise friday half session decline stock lead advancer nyse nasdaq stock market today transportation medical retail industry group be weakest monday energy mining stock be strongest lululemon athletica lulu gap loss sink right back day move average analyst fbr capital market downgrade lululemon underperform market perform cut price target investor grow pessimistic early holiday shopping indication other retailer sell heavy trading include ulta beauty ulta urban outfitter urbn regeneron pharmaceutical regn have worst loss ibd bid past buy point have unraveled close unitedhealth group unh say be back forecast earning share revenue be project be health insurer warn nov earning hit obamacare exchange related business cite higher medical cost individual market customer soft enrollment outlook unitedhealth share rise slightly extend trading several economic report be due tuesday manufacturing report purchasing manager institute supply management be due morning automaker report november sale earning report tuesday include fifth street finance fsc guidewire software gwre follow juan carlos arancibia twitter ibd_jarancibia
556,PFE,so be number surprise last week first ecb leave rate alone hint more stimulus come december then overnight thur friday china announce further loosen monetary policy bid boost slow economy then bell thursday big tech stalwart surprised market much better
557,PFE,snack beverage giant pepsico pep serve earning surprise tuesday push stock more pepsi clear resistance be approach feb high stock be form cup type base entry stock be member dividend aristocrat index comprise company
558,PFE,character do whole lotta damage hillary clinton tweet deplore outrageous price gouge specialty drug market see largest biotech etf tank fear pricing control end third quarter ishare nasdaq biotechnology ibb have give gain year date back roughly loss september august rally tad unsettling decline health care sector belie outlook say capital iq analyst higher enrollment cost management prescription drug sale continue drive best earning growth health care sector index analyst lindsey bell write indeed ibb produce annual average gain past year oct period sector etfs track ibd top target health sector fact now more ever biotech pharma etfs trading much week high capital iq see buy opportunity solid biotech name such gilead gild celgene celg ibd stock nearly person be newly insure obamacare health exchange firm note recent report drive sale health care provider service strong dollar be likely weigh large cap pharmaceutical big pfizer pfe merck mrk bristol myer squibb bmy eli lilly lly once again post top line growth first time year pass patent cliff report say health care index be nicely value vs year average upside be especially attainable biotech pharma equipment subindustry report add big upside potential have see sometimes risky biotech drug stock make way many investor etf strategy now china global slowdown mind investor be more focuse downside risk be right be cautious value stock be risk economic growth estimate continue come momentum company be expose more spike volatility have weigh biotechs lately russ global chief investment strategist blackrock write recently suggest investor consider quality stock generally have strong return equity low debt successful investing market stay choppy analyst bofa lynch global research agree new report say health care rate most attractive sector base measure have historically be best predict result such ep sale revision guidance prior quarter result stick health care stick quality bofa lynch advise
559,PFE,big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big
560,PFE,adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival
561,PFE,yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high
562,PFE,mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol
563,PFE,contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill
564,PFE,dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat
565,PFE,provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce
566,PFE,wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure
567,PFE,really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue
568,PFE,bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor
569,PFE,enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program
570,PFE,same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl
571,PFE,history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval
572,PFE,first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism
573,PFE,lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note
574,PFE,lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note
575,PFE,main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove
576,PFE,so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal
577,PFE,assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market
578,PFE,uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor
579,PFE,not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share
580,PFE,stock hold narrow open gain monday pair weaker expect economic report nasdaq gain be ahead dow jone industrial average show gain
581,PFE,stock market today rolled soft trade not surprising give option expiration boost trade friday week many investor be already book thanksgiving plan volume drop nasdaq nyse vs action same time friday
582,PFE,manufacturing growth slow november accord preliminary read research markit markit put purchasing manager index month october lowest read month analyst have expect uptick
583,PFE,sale exist home slow october annualize rate accord national association realtor home sell rate september economist have forecast october slowdown
584,PFE,stock tyson food tsn cook advance arkansa base meat packer fiscal fourth quarter earning miss target revenue beat estimate management full year revenue guidance top expectation big volume gain lift share back flat base buy point
585,PFE,ireland mallinckrodt mnk pop work seventh straight advance climb floor deep month correction drugmaker report strong fiscal revenue earning beat
586,PFE,gamestop gme topple lowest mark february weak result
587,PFE,leader list constellation brand stz pump lead ibd list climb past buy point flat base cowen co upgrade stock outperform market perform
588,PFE,ibd stock grupo financiero galicia ggal reversed open gain dive back buy range buy point argentina base stock be busy early monday react sunday election center right candidate mauricio macri defeat leftist contender daniel scioli country presidency bueno aire benchmark merval index open
589,PFE,ibd weekly review list argentina base bbva banco france bfr also dump worst loss list drop drag share friday new high back cup base buy point
590,PFE,upside weekly review stock prestige brand pbh leap almost announce acquire privately hold dentek oral care dentek specialize floss pick brace care other oral hygiene good sell wal mart wmt target tgt other gain better double stock average daily volume break share past buy point cup handle base
591,PFE,ibd drugmaker allergan agn drop nearly agree combination pfizer pfe allergan share gain october anticipation deal pfizer share slip early monday stock hold narrow open gain monday pair weaker expect economic report nasdaq gain be ahead dow jone industrial average show gain stock market today rolled soft trade not surprising give option expiration boost trade friday week many investor be already book thanksgiving plan volume drop nasdaq nyse vs action same time friday manufacturing growth slow november accord preliminary read research markit markit put purchasing manager index month october lowest read month analyst have expect uptick sale exist home slow october annualize rate accord national association realtor home sell rate september economist have forecast october slowdown stock tyson food tsn cook advance arkansa base meat packer fiscal fourth quarter earning miss target revenue beat estimate management full year revenue guidance top expectation big volume gain lift share back flat base buy point ireland mallinckrodt mnk pop work seventh straight advance climb floor deep month correction drugmaker report strong fiscal revenue earning beat gamestop gme topple lowest mark february weak result leader list constellation brand stz pump lead ibd list climb past buy point flat base cowen co upgrade stock outperform market perform ibd stock grupo financiero galicia ggal reversed open gain dive back buy range buy point argentina base stock be busy early monday react sunday election center right candidate mauricio macri defeat leftist contender daniel scioli country presidency bueno aire benchmark merval index open ibd weekly review list argentina base bbva banco france bfr also dump worst loss list drop drag share friday new high back cup base buy point upside weekly review stock prestige brand pbh leap almost announce acquire privately hold dentek oral care dentek specialize floss pick brace care other oral hygiene good sell wal mart wmt target tgt other gain better double stock average daily volume break share past buy point cup handle base ibd drugmaker allergan agn drop nearly agree combination pfizer pfe allergan share gain october anticipation deal pfizer share slip early monday
592,PFE,let take look stock ibd stock move screen be see big volume action chipotle grill cmg dycom industry dy fitbit fit pfizer pfe allergan agn chipotle be rebound today loss more friday fast casual chain have be suffering coli outbreak
593,PFE,stock future struggle hold narrow gain monday market prepared holiday shorten week trade dow future be point point gain hour earlier
594,PFE,nasdaq future slim advance point fair market value future hover slim point gain small cap lag russell future slip point
595,PFE,stock market today start week mixed signal nasdaq post strong gain last week retook support day move average nasdaq also hold distribution day stall friday raise distribution day count measure show high level institutional selling show large investor be degree work be currently confirm uptrend
596,PFE,volume typically fade move thanksgiving holiday thursday stock bond market reopen friday only short session market london paris frankfurt hong kong shanghai be open week tokyo market restart tomorrow trade remainder week follow labor thanksgiving break today
597,PFE,economic news researcher markit be tap release november manufacturing purchasing manager index et national association realtor report october exist home sale
598,PFE,crude oil continue recent split trade benchmark west texas intermediate more just barrel europe brent crude rise fraction gold slip silver fall more copper drop almost
599,PFE,stock pfizer pfe allergan agn agree combination deal have be highly anticipate send allergan share only fraction higher pfizer nearly
600,PFE,peabody energy btu rumble st loui base miner announce sell coal asset colorado new mexico bowie resource partner cash deal
601,PFE,chipotle grill cmg slump still pressure dive friday trigger center disease control prevention announcement additional case coli contamination have be link restaurant chain
602,PFE,argentina base issue be motion center right candidate mauricio macri win country run presidential election narrow margin ibd stock grupo financiero galicia ggal jump more stock end friday new high extend buy point oil gas producer ypf sociedad anonima ypf jump global msci argentina argt exchange trade fund leap more
603,PFE,pace quarterly report slow significantly week ireland base drugmaker mallinckrodt mnk punch revenue earning clear analyst consensus estimate fiscal fourth quarter
604,PFE,capital bank financial cbf ibd current weekly review stock jump premarket action thinly trade stock finished friday still buy range flat base buy point
605,PFE,follow alan elliott twitter ibd_aelliott stock future struggle hold narrow gain monday market prepared holiday shorten week trade dow future be point point gain hour earlier nasdaq future slim advance point fair market value future hover slim point gain small cap lag russell future slip point stock market today start week mixed signal nasdaq post strong gain last week retook support day move average nasdaq also hold distribution day stall friday raise distribution day count measure show high level institutional selling show large investor be degree work be currently confirm uptrend volume typically fade move thanksgiving holiday thursday stock bond market reopen friday only short session market london paris frankfurt hong kong shanghai be open week tokyo market restart tomorrow trade remainder week follow labor thanksgiving break today economic news researcher markit be tap release november manufacturing purchasing manager index et national association realtor report october exist home sale crude oil continue recent split trade benchmark west texas intermediate more just barrel europe brent crude rise fraction gold slip silver fall more copper drop almost stock pfizer pfe allergan agn agree combination deal have be highly anticipate send allergan share only fraction higher pfizer nearly peabody energy btu rumble st loui base miner announce sell coal asset colorado new mexico bowie resource partner cash deal chipotle grill cmg slump still pressure dive friday trigger center disease control prevention announcement additional case coli contamination have be link restaurant chain argentina base issue be motion center right candidate mauricio macri win country run presidential election narrow margin ibd stock grupo financiero galicia ggal jump more stock end friday new high extend buy point oil gas producer ypf sociedad anonima ypf jump global msci argentina argt exchange trade fund leap more pace quarterly report slow significantly week ireland base drugmaker mallinckrodt mnk punch revenue earning clear analyst consensus estimate fiscal fourth quarter capital bank financial cbf ibd current weekly review stock jump premarket action thinly trade stock finished friday still buy range flat base buy point follow alan elliott twitter ibd_aelliott
606,PFE,ahead thanksgiving day stock inched higher wednesday quiet volume dow jone industrial average nasdaq rise tick fraction volume nyse nasdaq be tracking well tuesday level stock market today pfizer pfe be best performer dow rise recently announce plan buy allergan agn economic news personal income rise october line estimate spending come bit short rise commerce department also say durable good order jump october double expectation exclude transportation order rise tad better expect earning news pc printer manufacturer hp hpq tumble report sluggish earning issue weak guidance hewlett packard enterprise hpe spun hp earlier month rise nearly report solid result late tuesday ibd euronet worldwide eeft be get support week move average recent share rise edward lifescience ew garner more strength buy point share rise nearly new york mercantile exchange wti crude oil future fall cent barrel stock market be close thursday thanksgiving be open half session friday close et follow ken shreve twitter ibd_kshreve facebook
607,PFE,major average hold solid gain be session high late thursday session nasdaq lead way picked dow jone industrial average add
608,PFE,nyse nasdaq volume track higher wednesday level stock market today
609,PFE,pfizer pfe jpmorgan jpm boee ba be top performer dow
610,PFE,advance stock top decliner exchange more investor sell bond year treasury yield rise basis point
611,PFE,economic news wall street be greet more soft manufacturing datum earlier session empire state manufacturing survey come consensus estimate philadelphia fed business outlook survey register read also consensus estimate
612,PFE,accord cme group fedwatch odd rate hike october meeting be december meeting odd be bit higher
613,PFE,philadelphia semiconductor index extend gain soar wednesday be session high still rise chip stock get boost yesterday heel intel intc report flurry chatter more takeover activity space
614,PFE,recent cup handle base chip designer inphi iphi soar time high rise earning be due oct close
615,PFE,also chip space integrate device technology idti rise nearly share remain accumulation stock work right side base
616,PFE,ibd oil refiner tesoro tso try reclaim cup handle buy point share rise
617,PFE,facebook fb close cup handle entry share rise
618,PFE,follow ken shreve twitter ibd_kshreve facebook major average hold solid gain be session high late thursday session nasdaq lead way picked dow jone industrial average add nyse nasdaq volume track higher wednesday level stock market today pfizer pfe jpmorgan jpm boee ba be top performer dow advance stock top decliner exchange more investor sell bond year treasury yield rise basis point economic news wall street be greet more soft manufacturing datum earlier session empire state manufacturing survey come consensus estimate philadelphia fed business outlook survey register read also consensus estimate accord cme group fedwatch odd rate hike october meeting be december meeting odd be bit higher philadelphia semiconductor index extend gain soar wednesday be session high still rise chip stock get boost yesterday heel intel intc report flurry chatter more takeover activity space recent cup handle base chip designer inphi iphi soar time high rise earning be due oct close also chip space integrate device technology idti rise nearly share remain accumulation stock work right side base ibd oil refiner tesoro tso try reclaim cup handle buy point share rise facebook fb close cup handle entry share rise follow ken shreve twitter ibd_kshreve facebook
619,PFE,stock reversed higher early afternoon trading start steep loss heel disappointing september job report nasdaq lead gain dow jone industrial average be volume be tracking slightly higher stock market today vs same time thursday gold miner casino operator biotechs be session top gainer casino stock gain year year drop macau gamble revenue september bloomberg report chinese government take step support once hot gamble enclave economy wynn resort wynn lead jump melco crown entertainment mpel soar la vegas sand lvs mgm resort international mgm stock be still well week high bank stock sag disappointing september job report fuel uncertainty federal reserve hike interest rate goldman sachs gs jpmorgan chase jpm continue weigh dow job report likely rule increase fed fund rate fomc next meet late october mid december rate increase now look less likely pnc senior economist gus faucher say note financial market be now pricing first increase fund rate march pfizer pfe reversed upward gain heavy volume track fourth straight advance drugmaker wednesday say expect recently complete buy hospira boost ep cent share revenue guide profit share revenue ibd stock netease nte lead gain nearly reclaim day move average find resistance mid august cambrex cbm dave buster play edward lifescience ew be follow nancy gondo twitter ibd_ngondo
620,PFE,stock market today continue trim early loss afternoon trade aid bounce oil price re-cover gain dip nasdaq whittle decline dow swung earlier loss rise exxon mobil xom pfizer pfe chevron cvx do much heavy lift oil related group post best gain industry oil price rebound rise tension middle east stock dollar tree dltr sprang ahead report mixed result first full quarter acquire peer family dollar stock be work seventh straight daily gain testing resistance day move average analog device adi keurig green mountain gmcr also rise more ibd list be nearly evenly split advancer decliner technology avgo allergan agn skywork solution swks top list signet jeweler sig cal maine food calm drop apiece
621,PFE,big pharma pfizer pfe be reportedly deal acquire ireland base allergan agn thursday even treasury department say put new guidance cut economic benefit such deal pfizer allergan confirm rumor be such talk late last month detail such price be left wall street speculation late wednesday however bloomberg reuter report price have be set range share total bloomberg say deal be announce soon monday cnbc say thursday announcement be expect follow monday come just hour treasury secretary jacob lew send letter senate finance committee criticize tax inversion deal company acquire smaller company lower tax domicile sort reverse acquisition allow company relocate cut tax bill pfizer already try do last year acquire british drug giant astrazeneca azn be rebuff so pursuit dublin base allergan be generally see alternative inversion deal lew say letter later week treasury issue target guidance reduce further economic benefit corporate inversion treasury have previously issue guideline effect back september evercore isi policy analyst terry haine point never result actual change rule guidance say treasury never do propose new regulation combat hopscotch loan prevent restructure foreign subsidiary prevent inverted company transfer cash property controlled foreign corporation avoid tax strengthen interpretation ownership rule haine write email client treasury also say intend take comment earning strip also be not do just treasury do letter lew boast guideline do slow previously torrid rate tax inversion deal indeed torpedo abbvie abbv plan takeover shire shpg abbvie decide pay hefty termination fee rather take risk rule materializing haine evercore colleague specialty drug analyst umer raffat write separate email lew follow actual guideline time address issue earning strip inverted company foreign hq issue intercompany loan subsidiary charge tax deductible interest prior conversation legal expert treasury not have mandate change cap interest expense deduction raffat write be very interesting see treasury come change threshold guidance let concern party litigate hope timeline litigation be long enough prevent inversion transaction raffat add treasury also propose modify definition debt exclude such intercompany loan guideline come allergan ceo brent saunder say seem most plausible avenue attack worst case scenario hit company tax rate tune basis point allergan then call actavis be product tax inversion have large presence credit suisse analyst vamil divan write hard tell much tax pfizer save current inversion rule deal price now table still yield accretion pfizer modeled conservative tax benefit go forward anticipate tax rate subsequently drop divan write research note initial cost synergy assumption be also relatively conservative assumption cost synergy realize be possible pfizer be able extract greater cost synergy deal incremental synergy represent additional cent yearly ep midmorning trading stock market today allergan stock be pfizer be more follow amy reeve twitter ibd_areeve facebook
622,PFE,expect treasury department late thursday issue tougher rule govern tax inversion company buy overseas firm then move headquarters country get more favorable tax treatment wasn clear immediately new rule impact possible pfizer pfe acquisition ireland base allergan agn deal value
623,PFE,stock market overcome early weakness tuesday end small gain higher volume dow jone industrial average add nasdaq close fractionally higher preliminary datum show volume nyse nasdaq come higher monday level stock market today dow be help strength pfizer pfe chevron cvx exxon mobil xom new york mercantile exchange wti crude oil future rise barrel tension turkey russia raise output concern region economic news second estimate gdp come line expectation initial estimate separately consumer confidence unexpectedly decline november conference board index slump lowest september well consensus estimate earning news network security software company palo alto network panw jump late thursday report earning cent share year cent consensus estimate sale rise also better expect multiple analyst raise price target dycom industry dy end solidly higher volatile session share rise specialty contract service provider telecom report third straight quarter triple digit earning growth sale growth accelerate third straight quarter rise ibd technology avgo be best percentage gainer rise microsemi mscc gap day move average fall intense trading chipmaker reach accord acquire pmc sierra pmcs deal end long bidding war skywork solution swks pmc sierra maker network drive chip pmc share fall skywork add nearly close watch earning hewlett packard enterprise hpe spun hp earlier month work first stage ipo base follow ken shreve twitter ibd_kshreve facebook
624,PFE,pfizer pfe be massive deal buy allergan agn redomicile ireland multiple report say even treasury department plan impose new restriction tax inversion pfizer be discuss deal pay share botox maker allergan bloomberg reuter report late wednesday allergan rise wednesday retreat hour follow news inversion rule allergan trade low oct pfizer allergan deal buzz picked pfizer rise wednesday be little change late wednesday share be takeover largest health care deal ever biggest takeover kind year bloomberg say company want announce deal soon monday reuter say announcement be not necessarily imminent say treasury wednesday announcement issue target tax inversion guidance later week affect timing agreement acquire irish drugmaker pfizer be able limit exposure punitive corporate tax system america corporate rate be highest industrial world country taxe company overseas profit be repatriate treasury issue restriction tax inversion september stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead unclear new limit treasury impose obama administration ban inversion addition inversion benefit pfizer beef brand name drug boost pipeline treatment mid late stage trial pfizer use allergan deal lead pfizer breakup company follow ed carson twitter ibd_ecarson facebook
625,PFE,struggle stock market doesn make easy workday wday stock generate momentum head annual analyst day tuesday workday stock fall monday hover more month share drop first time aug crash maker
626,PFE,big pharma eli lilly say monday stopping development cholesterol drug evacetrapib review phase trial datum show wasn have much effect eli lilly lly have be conduct giant study cardiovascular effect evacetrapib isn due completion next year independent datum monitoring committee however review
627,PFE,big pharma abbvie abbv say friday advance rheumatoid arthritis drug successful midstage clinical trial also bail similar drug be develop belgian biotech galapago glpg send latter stock tumble abbvie conduct trial testing various dose placebo study patient respond inadequately methotrexate
628,PFE,big drugmaker amgen amgn allergan agn announce wednesday biosimilar version roche rhhby blockbuster cancer drug avastin succeed late stage trial small cell lung cancer amgen allergan start collaboration back allergan be generic drug maker call watson pharmaceutical release few detail say drug abp have
629,PFE,special report mutual fund strategy volatility stock market send investor scurry cover favor dividend be probably less likely panic select carefully dividend stock offer best world stock price performance steady payout so dividend fund be key component long term mutual fund investing here be
630,PFE,normally quiet week trading ahead thanksgiving holiday be just monday major average be mixed mostly unchanged early afternoon trading nasdaq picked add dow jone industrial average gain less volume nyse nasdaq be tracking friday level stock market today new york mercantile exchange wti crude oil future rally more barrel saudi arabia say willing do part stabilize oil price merger news pfizer pfe allergan agn agree stock merger deal have be highly anticipate share pfizer allergan fall meanwhile prestige brand pbh clear buy point company announce plan acquire dentek oral care cash early gainer nasdaq include monster beverage mnst plenty breakout have emerge follow day oct monster be next work cup handle base buy point clear first stage base earlier month stamp com stmp continue trade tightly high share rise nearly ibd meat product industry group be day best percentage gainer help strength tyson food tsn meat processor soar new high investor like see tyson quarterly earning report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share palo alto be trading week move average second stage consolidation follow ken shreve twitter ibd_kshreve facebook
631,PFE,stock be mixed mostly unchanged head noon hour thursday highly anticipate ipos come market nasdaq dow jone industrial average add add
632,PFE,volume nyse nasdaq be tracking slightly higher wednesday level stock market today
633,PFE,manage care hospital stock underperform so do oil gas name december wti crude oil future fall barrel
634,PFE,insurer unitedhealth unh be drag dow fall company lower earning guidance cite lower expect activity health exchange set obamacare
635,PFE,also dow pfizer pfe lose close reuter report wednesday company talk allergan agn merger be accelerate share allergan give
636,PFE,economic news philadelphia federal reserve manufacturing index mid atlantic district rise november october september economist have expect read just break even
637,PFE,ipo news square sq match mtch have solid debut concern valuation square price last night propose range share be recently trading match meanwhile price low end propose range share be recently trading
638,PFE,elsewhere small cap universal display oled continue work right side deep cup shape base share jump cfo sidney rosenblatt hold session goldman sachs emerge cap growth conference et universal display be know organic light emit diode technology display light industry straight quarters decline earning sale growth nov result impressed quarterly profit year sale rise
639,PFE,other earning winner include keurig green mountain gmcr salesforce com crm china base online travel firm ctrip com ctrp
640,PFE,follow ken shreve twitter ibd_kshreve facebook stock be mixed mostly unchanged head noon hour thursday highly anticipate ipos come market nasdaq dow jone industrial average add add volume nyse nasdaq be tracking slightly higher wednesday level stock market today manage care hospital stock underperform so do oil gas name december wti crude oil future fall barrel insurer unitedhealth unh be drag dow fall company lower earning guidance cite lower expect activity health exchange set obamacare also dow pfizer pfe lose close reuter report wednesday company talk allergan agn merger be accelerate share allergan give economic news philadelphia federal reserve manufacturing index mid atlantic district rise november october september economist have expect read just break even ipo news square sq match mtch have solid debut concern valuation square price last night propose range share be recently trading match meanwhile price low end propose range share be recently trading elsewhere small cap universal display oled continue work right side deep cup shape base share jump cfo sidney rosenblatt hold session goldman sachs emerge cap growth conference et universal display be know organic light emit diode technology display light industry straight quarters decline earning sale growth nov result impressed quarterly profit year sale rise other earning winner include keurig green mountain gmcr salesforce com crm china base online travel firm ctrip com ctrp follow ken shreve twitter ibd_kshreve facebook
641,PFE,treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation
642,PFE,later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable
643,PFE,be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home
644,PFE,share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin
645,PFE,treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead
646,PFE,tax inversion company seek move be technically be acquire practice relocate company run combine business
647,PFE,many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here
648,PFE,follow bill peter twitter ibd_bpeter treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead tax inversion company seek move be technically be acquire practice relocate company run combine business many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here follow bill peter twitter ibd_bpeter
649,PFE,big pharmas merck mrk eli lilly lly johnson johnson jnj be trading tuesday get upgrade barclay abbvie abbv seesaw downgrade analyst geoff meacham assume coverage newly combine pharmaceutical sector barclay coverage left most rating same make few tweak lilly be upgrade overweight equal weight price target lift base promising pipeline management commitment lower expense meacham say lilly be build major autoimmune disease franchise late stage drug candidate ixekizumab psoriasis baricitinib rheumatoid arthritis drug develop incyte incy base solid phase datum view baricitinib have significant market share potential rheumatoid arthritis meacham write model conservatively project risk adjust sale vs peak sale pfizer pfe xeljanz meacham call diabetes drug jardiance lilly most important commercial asset intermediate term recent study result show sharply reduce death heart failure admit have be overhang merck derive lot revenue compete drug jardiance argue stock have overreact acknowledge be multiple headwind risk make merck show story think even most potential negative scenario be too much underlie value ignore meacham write raise merck rating overweight equal weight hike price target even pipeline asset aren blockbuster add be nearly free current valuation lilly stock be almost afternoon trading stock market today merck stock be meacham also raise overweight equal weight price target rise merck feel market be undervalue have underperform drg past month due concern impact biosimilar remicade low term earning growth lack significant term pipeline catalyst meacham write have lead call break conglomerate believe be premature meacham view be better acquire growth asset especially pharma stock be afternoon trading meanwhile meacham downgrade abbvie equal weight overweight trim price target many analyst thought abbvie projection recently acquire blood cancer drug imbruvica similar drug pipeline year peak be too high imbruvica other oncology asset likely succeed field be highly competitive meacham write abbvie stock initially drop almost tuesday trading afternoon be follow amy reeve twitter ibd_areeve facebook
650,PFE,share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial
651,PFE,aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt
652,PFE,aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa
653,PFE,aerie say expect file fda approval mid
654,PFE,aerie stock jump month high stock market today close make market top percentage gainer day
655,PFE,big drop april
656,PFE,trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket
657,PFE,adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock
658,PFE,rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process
659,PFE,roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target
660,PFE,needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year
661,PFE,follow amy reeve twitter ibd_areeve facebook share biotech aerie pharmaceutical aeri vault much thursday get passel price target increase company announce late wednesday glaucoma drug have succeed late stage clinical trial aerie say eye drop rhopressa have succeed lower intra ocular pressure sufferer glaucoma ocular hypertension goal be show once daily dose rhopressa be inferior timolol popular ingredient eye drop such allergan agn combigan merck mrk cosopt aerie also test twice daily dose rhopressa say be slightly more effective also show higher rate side effect most common side effect be eye redness appear subject rhopressa aerie say expect file fda approval mid aerie stock jump month high stock market today close make market top percentage gainer day big drop trial be phase study call rocket rocket rocket have fail meet inferiority endpoint whack stock price back april however june fda agree let aerie modify rocket endpoint look only patient relatively low level intra ocular pressure start millimeter mercury mmhg group have respond better rocket adjustment lead accusation aerie dredge rocket make rhopressa seem more efficacious canaccord genuity analyst corey davis acknowledge research note however glaucoma patient have intra ocular pressure less mmhg think rhopressa approve have definitive place market davis raise price target stock rbc capital market analyst adnan butt write result also bode well roclatan combination rhopressa latanoprost prostaglandin analogue pga sell separately pfizer pfe xalatan roclatan be also phase testing earlier process roclatan demonstrate superiority component believe be little controversy roclatan be blockbuster drug butt write raise price target needham analyst serge belanger raise price target note rhopressa be first new glaucoma treatment year follow amy reeve twitter ibd_areeve facebook
662,PFE,hillary clinton have promote drug pricing plan way take industry say be guilty outrageous price friend medium take hit clinton plan wouldn go far have suggest ban consumer direct drug advertising effect tax advertising dollar be tax profit hope be do so restrain unnecessary prescription drug spending patient wouldn ask doctor be try wonder cure learn tv read newspaper ostensibly decrease pharma ad spending order make brand drug less prevalent mind consumer cheaper generic write cowen co health care analyst charle rhee even more certain result be hit medium company profit expansion loss last year drugmaker spend tv ad magazine ad newspaper ad accord kantar medium pfizer pfe spend more ad roughly same combine total next biggest advertiser abbvie abbv eli lilly lly astrazeneca azn yet rhee write even overall pie be shrink think more ad pie shift favor digital advertiser even accelerate manner advertiser seek greater return investment particular rhee name webmd wbmd everyday health evdy potential winner scenario see unlikely come pass republican dominate congress still maybe hope hillary plan help great friend blogosphere
663,PFE,tyson food tsn boee ba be company expect benefit tran pacific partnership trade agreement drugmaker biotechs primarily develop brand drug have emerge top loser nation accord include mexico canada japan australia vietnam be agree monday still require ratification congress agreement give brand
664,PFE,stock be modestly higher midday monday shorten week trading kick much fanfare nasdaq lead way rise early gainer nasdaq include autodesk adsk jd com jd biogen biib monster beverage mnst
665,PFE,add dow jone industrial average gain less volume nyse nasdaq be tracking well friday level stock market today
666,PFE,merger news pfizer pfe allergan agn agree combination deal have be highly anticipate share pfizer allergan fall more
667,PFE,china base online direct sale company jd com add gain heel last week earning report share rise clear key resistance level
668,PFE,meanwhile buyer be netease nte again buy point share rise almost netease operate interactive online community china also report strong earning last week
669,PFE,ibd meat product industry group be day best percentage gainer help strength tyson food tsn pilgrim pride ppc meat processor tyson food soar new high investor weigh quarterly report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost group peer pilgrim pride jump
670,PFE,chipotle cmg reversed higher crash friday more coli problem share rally
671,PFE,couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share
672,PFE,follow ken shreve twitter ibd_kshreve facebookstock be modestly higher midday monday shorten week trading kick much fanfare nasdaq lead way rise early gainer nasdaq include autodesk adsk jd com jd biogen biib monster beverage mnst add dow jone industrial average gain less volume nyse nasdaq be tracking well friday level stock market today merger news pfizer pfe allergan agn agree combination deal have be highly anticipate share pfizer allergan fall more china base online direct sale company jd com add gain heel last week earning report share rise clear key resistance level meanwhile buyer be netease nte again buy point share rise almost netease operate interactive online community china also report strong earning last week ibd meat product industry group be day best percentage gainer help strength tyson food tsn pilgrim pride ppc meat processor tyson food soar new high investor weigh quarterly report earning share miss expectation company forecast fiscal earning compare consensus estimate tyson say chicken business be benefit rise demand decline feed cost group peer pilgrim pride jump chipotle cmg reversed higher crash friday more coli problem share rally couple top rate growth name be set report close today earning ibd name dycom dy be see rise year share profit palo alto network panw be forecast rise cent share follow ken shreve twitter ibd_kshreve facebook
673,PFE,medical device giant boston scientific bsx fall wednesday government propose limit coverage new heart implant late tuesday center medicare medicaid service cms issue propose guideline cover use percutaneous left atrial appendage closure therapy be purpose boston scientific watchman device memo conclude evidence be
674,PFE,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
675,PFE,specialty drug giant allergan agn beat analyst estimate wednesday ceo brent saunder dodge question buyout talk pfizer pfe defend company drug pricing strategy distancing model peer valeant pharmaceutical international vrx allergan sale rise year earlier quarter analyst consensus accord thomson reuter earning
676,PFE,stock remain narrowly mixed thursday go last hour regular trading session nasdaq hold gain dow jone industrial average be fractionally lower volume be mixed tracking slightly lower nyse higher nasdaq vs same time wednesday loser barely outpaced winner nyse decliner lead nasdaq software airline gold miner outperformed stock market today energy manage care other medical stock lag big cap techs lead dow intel intc leap heavy trade biggest single day percent gain nearly month chip giant say investor event thursday expect sale grow mid single digit percent range intel also hike dividend share annual basis other tech blue chip cisco system csco rise more regain day move average apple aapl microsoft msft be unitedhealth unh pfizer pfe weigh loss heavy trade active pharmaceutical ingredient maker cambrex cbm be biggest decliner ibd volume be soft stock continue work cup handle base buy point hawaiian holding netease nte be biggest advancer highly anticipate ipos square sq match mtch hold solid gain pricing low end range late wednesday square leap offer price match jump offer price follow nancy gondo twitter ibd_ngondo
677,PFE,doctor be not just ask unite health care unh ceo stephen helmsley obama care have make sick be not willing continue suffer loss go right yesterday company announce mil loss exchange business include advance recognition loss announcement cause cut earning projection sh share
678,PFE,announcement do not include expect additional mil loss result investor take stock point yesterday hear news biggest health insurer have suffer major loss policy sell affordable care act aca exchange consider withdraw
679,PFE,hark hear hear other herald angel sing aetna aet humana hum cigna ci anthem antm chime singing same tune insurer focus medicaid population molina moh don seem be have same problem low income consumer be subsidize gov result be now see effect poorly design piece signature legislation anyone see nancy pelosi recently do ever read legislation insurer be raise premium cut product offering choice health care provider consumer be see least desirable silver plan increase rate avg better plan be see increase more higher deductible higher co pay just econ taught higher cost discourage buyer case healthy buyer then only drife cost even higher remain consumer be sicker need more healthcare vicious circle know death spiral
680,PFE,now republican be quick jump bandwagon say premium be healthcare be more expensive consequence see hastily conceive legislation be entirely foreseeable not surprising expect democrat lead obama be quick point law be work well well boy have way so be be aca work not sound ceo helmsley clearly have view maybe democrat need talk insurer see doctor be not
681,PFE,move healthcare industry yesterday bring news pfizer pfe be press ahead fight save corporate taxe get bed ireland base allergan agn putt gov company collision course be know inversion trade here democrat want prevent company strategically relocate take advantage break corp tax structure pile more regulation red tape republican say real problem here be break corp tax structure call complete overhaul tax code thereby eliminate need incentive invert
682,PFE,now back mkts broader mkt show lack direction yesterday wednesday surge cause tease side unchanged least time lack real significant change come trader investor take breath technical underpinning mkt continue argue only few company continue dominate major index so many continue drag biggest company largest capitalization have push dow nasdaq closer annual high broader index wilshire russell be still struggle
683,PFE,wilshire total mkt index measure performance stock readily available price datum most person do not follow even know wilshire be medium only talk dow nasdaq be heavily weight large cap company average investor know fact wilshire be much truer measure real health economy whole just sayin short term basis market be try work last week sharp selloff so far appear be do just need continue watch crude oil price do crude be now trading barrel need hold here rally oil certainly help support mkt be still difficult call give fundamental strengthen dollar be short term oversold condition so bounce not be question cause bargain hunter go shopping spree
684,PFE,overnight asian mkts finished week strong japan hong kong china asx europe mkts be churn even draghi hint more stimulus mali hostage crisis morning be raise concern global security cause focus once again turn isis recent event france end mkts need digest action late move weekend ftse cac dax eurostoxx spain italy future be point higher currently pt keep still trading range get load fed speaker today st loui fed pre bullard ny dudley speaking economy believe hammer home message normalization come theater december eco front look report form kansa city fed survey say take good care kp
685,PFE,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate doctor be not just ask unite health care unh ceo stephen helmsley obama care have make sick be not willing continue suffer loss go right yesterday company announce mil loss exchange business include advance recognition loss announcement cause cut earning projection sh share announcement do not include expect additional mil loss result investor take stock point yesterday hear news biggest health insurer have suffer major loss policy sell affordable care act aca exchange consider withdraw hark hear hear other herald angel sing aetna aet humana hum cigna ci anthem antm chime singing same tune insurer focus medicaid population molina moh don seem be have same problem low income consumer be subsidize gov result be now see effect poorly design piece signature legislation anyone see nancy pelosi recently do ever read legislation insurer be raise premium cut product offering choice health care provider consumer be see least desirable silver plan increase rate avg better plan be see increase more higher deductible higher co pay just econ taught higher cost discourage buyer case healthy buyer then only drife cost even higher remain consumer be sicker need more healthcare vicious circle know death spiral now republican be quick jump bandwagon say premium be healthcare be more expensive consequence see hastily conceive legislation be entirely foreseeable not surprising expect democrat lead obama be quick point law be work well well boy have way so be be aca work not sound ceo helmsley clearly have view maybe democrat need talk insurer see doctor be not move healthcare industry yesterday bring news pfizer pfe be press ahead fight save corporate taxe get bed ireland base allergan agn putt gov company collision course be know inversion trade here democrat want prevent company strategically relocate take advantage break corp tax structure pile more regulation red tape republican say real problem here be break corp tax structure call complete overhaul tax code thereby eliminate need incentive invert now back mkts broader mkt show lack direction yesterday wednesday surge cause tease side unchanged least time lack real significant change come trader investor take breath technical underpinning mkt continue argue only few company continue dominate major index so many continue drag biggest company largest capitalization have push dow nasdaq closer annual high broader index wilshire russell be still struggle wilshire total mkt index measure performance stock readily available price datum most person do not follow even know wilshire be medium only talk dow nasdaq be heavily weight large cap company average investor know fact wilshire be much truer measure real health economy whole just sayin short term basis market be try work last week sharp selloff so far appear be do just need continue watch crude oil price do crude be now trading barrel need hold here rally oil certainly help support mkt be still difficult call give fundamental strengthen dollar be short term oversold condition so bounce not be question cause bargain hunter go shopping spree overnight asian mkts finished week strong japan hong kong china asx europe mkts be churn even draghi hint more stimulus mali hostage crisis morning be raise concern global security cause focus once again turn isis recent event france end mkts need digest action late move weekend ftse cac dax eurostoxx spain italy future be point higher currently pt keep still trading range get load fed speaker today st loui fed pre bullard ny dudley speaking economy believe hammer home message normalization come theater december eco front look report form kansa city fed survey say take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
686,PFE,big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday
687,PFE,amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug
688,PFE,ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year
689,PFE,cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary
690,PFE,portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say
691,PFE,announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug
692,PFE,xencor stock be morning trading stock market today amgen stock be
693,PFE,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug xencor stock be morning trading stock market today amgen stock be follow amy reeve twitter ibd_areeve facebook
694,PFE,gilead science gild stock price finished flat friday follow analyst downgrade activision blizzard atvi get higher price target mcdonald mcd pfizer pfe google googl also see analyst action morgan stanley downgrade gilead equal weight give price target share world biggest biotech finished penny higher
695,PFE,stock future spun deep loss ahead friday open further oil price decline continue pressure global market dow future dive point fair market value have hold steady prior hour
696,PFE,nasdaq future drop point slightly hour earlier lows future be steady point small cap be take share heat russell future point
697,PFE,stock market today take early lick oil price backed nearly international energy agency confirm prior forecast average demand growth oil slow barrel day estimate average bpd year
698,PFE,west texas intermediate hold just barrel brent crude trade tad be more week
699,PFE,news release oil price drop hit market close asia europe stock pull back sharply dax frankfurt be cac ftse london be more midday be tracking loss more week china market close moderate loss tokyo nikkei japan gain
700,PFE,economic news producer price rise november labor department report be slip october well expectation change core price food energy also rise view uptick
701,PFE,november retail stop just short expectation rise better october gain view auto gas be negative month strip category sale rise top forecast gain
702,PFE,et october business inventory number commerce department be due university michigan release december consumer sentiment index oil price get stir baker hughe bhi be schedule report weekly rig count
703,PFE,stock list dow jone industrial average be nearly unanimously negative open dupont dd again sank bottom decline announce formally agree merge dow chemical dow create dowdupont chemical juggernaut company expect deal close late next year
704,PFE,large share downward pressure be energy related stock contest index worst premarket decline be dupont staple spls red hat rht range
705,PFE,top list glass maker corning glw surge news dow dupont deal dow chemical assume ownership dow corning joint venture dow chemical corning
706,PFE,adobe system adbe pop deliver solid fiscal fourth quarter report late thursday earning be expectation revenue line guidance consensus forecast strong growth company cloud base business rise recur revenue adobe total take pleased investor
707,PFE,stock end thursday test support week move average first test clear cup handle base october
708,PFE,fiber optic networking gear maker finisar fnsr spiked healthy fiscal report stock end thursday deep month consolidation
709,PFE,follow alan elliott twitter ibd_aelliott facebook stock future spun deep loss ahead friday open further oil price decline continue pressure global market dow future dive point fair market value have hold steady prior hour nasdaq future drop point slightly hour earlier lows future be steady point small cap be take share heat russell future point stock market today take early lick oil price backed nearly international energy agency confirm prior forecast average demand growth oil slow barrel day estimate average bpd year west texas intermediate hold just barrel brent crude trade tad be more week news release oil price drop hit market close asia europe stock pull back sharply dax frankfurt be cac ftse london be more midday be tracking loss more week china market close moderate loss tokyo nikkei japan gain economic news producer price rise november labor department report be slip october well expectation change core price food energy also rise view uptick november retail stop just short expectation rise better october gain view auto gas be negative month strip category sale rise top forecast gain et october business inventory number commerce department be due university michigan release december consumer sentiment index oil price get stir baker hughe bhi be schedule report weekly rig count stock list dow jone industrial average be nearly unanimously negative open dupont dd again sank bottom decline announce formally agree merge dow chemical dow create dowdupont chemical juggernaut company expect deal close late next year large share downward pressure be energy related stock contest index worst premarket decline be dupont staple spls red hat rht range top list glass maker corning glw surge news dow dupont deal dow chemical assume ownership dow corning joint venture dow chemical corning adobe system adbe pop deliver solid fiscal fourth quarter report late thursday earning be expectation revenue line guidance consensus forecast strong growth company cloud base business rise recur revenue adobe total take pleased investor stock end thursday test support week move average first test clear cup handle base october fiber optic networking gear maker finisar fnsr spiked healthy fiscal report stock end thursday deep month consolidation follow alan elliott twitter ibd_aelliott facebook
710,PFE,health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount
711,PFE,china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view
712,PFE,ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive
713,PFE,ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more
714,PFE,ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly
715,PFE,spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault
716,PFE,here look benchmark exchange trade fund tracking various asset class perform today
717,PFE,follow daily etf market action be key successful investing
718,PFE,bellwether etfs
719,PFE,ishare msci eafe efa rs
720,PFE,spdr dow jone industrial average dium rs
721,PFE,powershare db bullish uup rs
722,PFE,spdr spy rs
723,PFE,ishare core aggregate bond agg rs
724,PFE,ishare core mid cap ijh rs
725,PFE,spdr gold share gld rs
726,PFE,powershare qqq qqq rs
727,PFE,vanguard ftse emerge market vwo rs
728,PFE,ishare russell iwm rs
729,PFE,follow aparna narayanan twitter ibd_anarayanan health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs ishare msci eafe efa rs spdr dow jone industrial average dium rs powershare db bullish uup rs spdr spy rs ishare core aggregate bond agg rs ishare core mid cap ijh rs spdr gold share gld rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
730,PFE,hp hpq spinoff hewlett packard enterprise hpe get new analyst coverage tuesday drugmaker pfizer pfe top credit card firm visa have price target hike bernstein initiate hp outperform mizuho lower price target giant stock maintain neutral rating monday hp share pop nearly investor embraced company spinoff hewlett packard enterprise meanwhile hewlett packard enterprise be initiate neutral mizuho tuesday give price target hp share close thestock market today hewlett packard enterprise fall second day trading visa price target be raise rbc capital market maintain outperform rating stock monday visa fall short quarterly ep view also say be buy european counterpart visa europe much long anticipate cash stock deal share credit card giant rise tuesday pfizer fall even price target be raise argus have buy rating stock pfizer share rise monday follow positive article barron say big pharma firm strong pipeline drug be catalyst higher stock price fellow drugmaker valeant pharmaceutical vrx lose rbc capital market lower price target stock valeant have see steep drop share price ever short selling outfit citron research charge drugmaker fraud involve multiple specialty pharmacy valeant have deny allegation chipmaker nvidia nvda slide be downgrade hold buy needham cardinal health cah price target be hike rbc capital market fbr capital follow monday better expect quarterly earning report cardinal share rise tuesday add previous session red hat rht climb be upgrade buy deutsche bank software maker be near multiyear high set june ulta beauty ulta rise be initiate hold stifel follow vance cariaga twitter ibd_vcariaga
731,PFE,large cap mutual fund trail small midcap fund year performance large cap fund be hold better so far year investment average large cap mutual fund have grow nov year same investment have grow average midcap fund average small cap fund so far year large cap mutual fund be vs decline midcap fund small cap fund be flat alger spectra have generate average annual return past year vs so far year spectra have handed investor gain nearly alger spectra have be manage patrick kelly ankur crawford joined co fund manager year large cap growth fund recent top holding be familiar growth stock investor apple aapl facebook fb alphabet googl allergan agn amazon com amzn be form basis be extend recent breakout allergan stock be work first stage base have undercut previous base time high form cup handle base buy point much base be form day move average bearish sign handle be line company be discuss merge pfizer pfe allergan make generic drug include botox treatment hypertension sleep disorder pain earning have grow annual pace past year analyst poll thomson reuter see profit rise current year slow next year apple be also consolidate recent gain trading time high also trading day move average testing support week line maker iphone ipad apple watch have grow earning annual clip past year net growth be see slow current fiscal year end september facebook stock clear buy point stock market september run pull back past week remain extend buy point social network company be see grow earning year next year alphabet have slip recent high remain buy point amazon be past latest buy point clear september online retail giant be expect post earning share year represent gain loss cent last year net be see climb next year follow doug roger twitter ibd_droger
732,PFE,big pharma pfizer specialty drug giant allergan affirm thursday re preliminary buyout talk much speculate move pfizer hunt new catalyst allergan agn stock soar pfizer pfe retreat allergan plc today confirm have be approach pfizer inc be preliminary friendly discussion regard potential business combination transaction say
733,PFE,stock worsen late afternoon trading nasdaq turn negative tech heavy index fall slip dow jone industrial average fall volume be tracking lower energy steel machinery group be weak stock market today oil fall just barrel stock be higher ibd proxy lead stock top cyberark software cybr jump active trade stock be still week move average more june peak also strong be amn healthcare service rise more share be new high past flat base buy point amn healthcare be health care staffing workforce solution provider dow stock be mostly lower unite technology utx slide more new week low heavy equipment maker caterpillar cat also make new low upside pharma giant pfizer pfe lead gain stock be consolidate recent earning sale have be trend lower fleetmatic group fltx add late trading try stretch streak session maker fleet management software be now just buy point short cup pattern
734,PFE,even income investor have be rattle dow jone industrial point drop first minute aug trading session so hold sell used weekly chart help decide weekly chart help clearly see stock index show support big money initial sell
735,PFE,stock high dividend yield aren hard find utility reit space problem be very few stock be show relative strength different story couple dividend leader dow pfe merck mrk be often mentioned same breath be show distinctly better price action other pfizer
736,PFE,activision blizzard atvi unite continental ual be be add re replace buyout pall pll be be acquire dhr hospira hsp be be buy pfizer pfe here need know new addition activision blizzard earn ibd composite rating earlier month video game publisher report better expect second quarter sale earning shot big name game include call duty world warcraft guitar hero electronic art ea take interactive be peer ea be fellow component activision share gap giant volume stock market today shake sell hit time high intraday stock have rise year unite continental have ibd composite rating carrier meet analyst expectation report earning month airline industry group have come pressure lately justice department investigation airfare price collusion peer delta air line dal american airline aal southwest airline luv be already member unite share pop fast turnover retake day move average stock be still trading day line be more late january peak activision be set join index close friday unite continental be add close wednesday follow alissa william twitter ibd_awilliam
737,PFE,big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading
738,PFE,amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter
739,PFE,revenue climb consensus best gain several year
740,PFE,amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate
741,PFE,amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range
742,PFE,rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report
743,PFE,yee add experience show company start annual guidance conservatively then raise year ve do year now
744,PFE,enbrel sale unsustainable
745,PFE,half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition
746,PFE,neulasta drug beat consensus rise only
747,PFE,evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance
748,PFE,enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client
749,PFE,enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz
750,PFE,conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august
751,PFE,amgen stock rise regular trade share be late big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter revenue climb consensus best gain several year amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report yee add experience show company start annual guidance conservatively then raise year ve do year now enbrel sale unsustainable half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition neulasta drug beat consensus rise only evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august amgen stock rise regular trade share be late
752,PFE,stock hold solid gain be session high early afternoon trading monday cheer busy day merger acquisition nasdaq gain rise dow jone industrial average picked small cap do well again russell volume nyse nasdaq be tracking slightly lower friday level stock market today chevron cvx pfizer pfe be top performer dow chevron be help price target raise credit suisse credit suisse maintain neutral rating biotechs celgene celg regeneron regn be top percentage gainer nasdaq rise respectively regeneron report earning wednesday open celgene report thursday open economic news come mostly line expectation read marked fourth straight monthly decline october job report be due friday bond price fall monday lift yield year treasury note merger news dyax dyax soar ireland base shire shpg agree buy orphan drug specialist meanwhile medasset mda surge agree be take private private equity firm cash other gainer include interactive broker ibkr share rise climb time high work right side base online brokerage offer pretty compelling growth story latest quarter earning jump year cent share sale jump downside visa slump earning miss expectation company also announce plan buy visa europe follow ken shreve twitter ibd_kshreve facebook
753,PFE,big pharma abbvie abbv beat analyst estimate issue year guidance be expectation friday morning send stock sharply early trading abbvie adjust earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter sale climb estimate
754,PFE,stock trade bit lower yesterday wednesday fed induced rally trader consider language odd december rate hike selling be subdue be get here tone action
755,PFE,mkt pause really investor now thought latest gdp report come great be positive compare qtr look bit pale yesterday report be more drop qtr qtr time fed suggest economy be poise explode rate rise december
756,PFE,addition yesterday report be disappointment consider year year growth last year rd qtr growth rate be so say be economy continue be hold hostage dynamic weakness home abroad journal point economy slog soft patch consumer spending business spending home build contribute positive report face headwind abroad
757,PFE,do not be blindside consumer spending be mislead include consumer spend healthcare be not something many person consider read story health consumer spending consumer healthcare represent gdp bil gov include head consumer spending make appear consumer spending be stronger reality prove otherwise remember spending healthcare be not really option family budget so get file pay budget line mean discretionary spending get cut back semantic really far obama be concern consumer spending matter be still consumer spending so good
758,PFE,now other news break corporate tax structure have create opportunity huge merger pfizer pfe allergan agn consider hook avoid taxe see allergan be base ireland ireland be bit friendlier big corporation so pfizer get bed allergan ireland cut corporate tax liability be know inversion trade company buy smaller foreign rival then move corporate headquarters abroad boom just cut tax obligation million dollar make point pfe ceo ian read make bone say corporate tax rate have put company disadvantage foreign rival be fight hand tie back pfizer be do need do ensure continue innovate
759,PFE,washington wake many more inversion trade see bozo congress recognize be nothing bunch clown evidence new yr budget deal lift debt ceiling even higher roll back fiscal austerity remove risk debt limit default risk yr so mkt embrace
760,PFE,other pharma story continue keep glue seat valeant pharma vrx continue make headline cvs health corp cvs express script esrx unite health be cut ty philidor rx pharmacy have help propel vrx international fame stock close pt be now pt early pre mkt trading remember old quote smoke fire question now be be fire just log whole house
761,PFE,future be pt global mkts be bit pressure boj bank japan do not increase qe program catch surprise do not cause negative mkt reaction europe eu eco datum be mixed cpi do rise german retail sale miss expectation inflation figure be better still low have impact ecb plan more stimulus
762,PFE,be last day month so sure have window dressing undress take place asset manager close book october earning continue weigh stock overall season be not bad originally expect so nervousness permeate mkts early october seem have subside expect see mkt challenge today then back churn line eco datum today derail doubt pers income pers spend ism milwaukee chicago purch manager
763,PFE,earning front look oil chevron cvx exxon mobil xom phillip psx cvs health corp cvs colgate palmolive cl weyerhaeuser co wy
764,PFE,have good weekend take good care kp
765,PFE,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate stock trade bit lower yesterday wednesday fed induced rally trader consider language odd december rate hike selling be subdue be get here tone action mkt pause really investor now thought latest gdp report come great be positive compare qtr look bit pale yesterday report be more drop qtr qtr time fed suggest economy be poise explode rate rise december addition yesterday report be disappointment consider year year growth last year rd qtr growth rate be so say be economy continue be hold hostage dynamic weakness home abroad journal point economy slog soft patch consumer spending business spending home build contribute positive report face headwind abroad do not be blindside consumer spending be mislead include consumer spend healthcare be not something many person consider read story health consumer spending consumer healthcare represent gdp bil gov include head consumer spending make appear consumer spending be stronger reality prove otherwise remember spending healthcare be not really option family budget so get file pay budget line mean discretionary spending get cut back semantic really far obama be concern consumer spending matter be still consumer spending so good now other news break corporate tax structure have create opportunity huge merger pfizer pfe allergan agn consider hook avoid taxe see allergan be base ireland ireland be bit friendlier big corporation so pfizer get bed allergan ireland cut corporate tax liability be know inversion trade company buy smaller foreign rival then move corporate headquarters abroad boom just cut tax obligation million dollar make point pfe ceo ian read make bone say corporate tax rate have put company disadvantage foreign rival be fight hand tie back pfizer be do need do ensure continue innovate washington wake many more inversion trade see bozo congress recognize be nothing bunch clown evidence new yr budget deal lift debt ceiling even higher roll back fiscal austerity remove risk debt limit default risk yr so mkt embrace other pharma story continue keep glue seat valeant pharma vrx continue make headline cvs health corp cvs express script esrx unite health be cut ty philidor rx pharmacy have help propel vrx international fame stock close pt be now pt early pre mkt trading remember old quote smoke fire question now be be fire just log whole house future be pt global mkts be bit pressure boj bank japan do not increase qe program catch surprise do not cause negative mkt reaction europe eu eco datum be mixed cpi do rise german retail sale miss expectation inflation figure be better still low have impact ecb plan more stimulus be last day month so sure have window dressing undress take place asset manager close book october earning continue weigh stock overall season be not bad originally expect so nervousness permeate mkts early october seem have subside expect see mkt challenge today then back churn line eco datum today derail doubt pers income pers spend ism milwaukee chicago purch manager earning front look oil chevron cvx exxon mobil xom phillip psx cvs health corp cvs colgate palmolive cl weyerhaeuser co wy have good weekend take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
766,PFE,drug giant pfizer pfe be buy range get boost better expect quarterly earning report maker blockbuster drug such viagra cholesterol fighter lipitor break past buy point flat base heavy volume wednesday remain limit define buy range
767,PFE,day earlier new york city base company report earning dip cent share due strong dollar patent expiration result be still better expect sale fall also better forecast strong performance newly launch drug
768,PFE,long stretch decline quarterly profit sale pfizer still boast steady earning stability factor
769,PFE,full year profit be forecast fall cent share rebound
770,PFE,pfizer third quarter dividend cent share payable be straight quarterly payout company halved dividend cent share recession be rise rate past few year accord ibd datum
771,PFE,annualize yield current share price be average
772,PFE,pfizer face threat generic drug maker have take advantage patent expiration offer cheaper version former blockbuster drug such lipitor
773,PFE,ceo ian read tell bloomberg july look acquisition beef company drug pipeline
774,PFE,headwind zack equity research say same day cost cut effort share buyback help pfizer achieve earning guidance pending acquisition generic drug maker hospira significantly expand pfizer stable injectable other drug drug giant pfizer pfe be buy range get boost better expect quarterly earning report maker blockbuster drug such viagra cholesterol fighter lipitor break past buy point flat base heavy volume wednesday remain limit define buy range day earlier new york city base company report earning dip cent share due strong dollar patent expiration result be still better expect sale fall also better forecast strong performance newly launch drug long stretch decline quarterly profit sale pfizer still boast steady earning stability factor full year profit be forecast fall cent share rebound pfizer third quarter dividend cent share payable be straight quarterly payout company halved dividend cent share recession be rise rate past few year accord ibd datum annualize yield current share price be average pfizer face threat generic drug maker have take advantage patent expiration offer cheaper version former blockbuster drug such lipitor ceo ian read tell bloomberg july look acquisition beef company drug pipeline headwind zack equity research say same day cost cut effort share buyback help pfizer achieve earning guidance pending acquisition generic drug maker hospira significantly expand pfizer stable injectable other drug
775,PFE,canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval
776,PFE,market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug
777,PFE,valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release
778,PFE,valeant expect deal have impact earning be modestly accretive
779,PFE,addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido
780,PFE,third time charm
781,PFE,fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk
782,PFE,nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug
783,PFE,deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement
784,PFE,applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say
785,PFE,woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand
786,PFE,bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition
787,PFE,write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income
788,PFE,management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday
789,PFE,moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly
790,PFE,however believe uptake be significantly lower ed give safety issue product
791,PFE,price month
792,PFE,difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending
793,PFE,insurer be still work cover product not insurer cover sexual performance treatment
794,PFE,anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug
795,PFE,other insurer pharmacy benefit manager have say re still think
796,PFE,high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note
797,PFE,additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release valeant expect deal have impact earning be modestly accretive addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido third time fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly however believe uptake be significantly lower ed give safety issue product price monthanother difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending insurer be still work cover product not insurer cover sexual performance treatment anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug other insurer pharmacy benefit manager have say re still think high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product
798,PFE,canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval
799,PFE,market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug
800,PFE,valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release
801,PFE,valeant expect deal have impact earning be modestly accretive
802,PFE,addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido
803,PFE,third time charm
804,PFE,fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk
805,PFE,nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug
806,PFE,deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement
807,PFE,applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say
808,PFE,woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand
809,PFE,bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition
810,PFE,write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income
811,PFE,management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday
812,PFE,moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly
813,PFE,however believe uptake be significantly lower ed give safety issue product
814,PFE,price month
815,PFE,difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending
816,PFE,insurer be still work cover product not insurer cover sexual performance treatment
817,PFE,anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug
818,PFE,other insurer pharmacy benefit manager have say re still think
819,PFE,high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note
820,PFE,additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release valeant expect deal have impact earning be modestly accretive addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido third time fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly however believe uptake be significantly lower ed give safety issue product price monthanother difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending insurer be still work cover product not insurer cover sexual performance treatment anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug other insurer pharmacy benefit manager have say re still think high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product
821,PFE,major index etfs downshift further monday china federal reserve have continue weigh stock market last trading day august exchange trade fund tracking dow jone industrial average nasdaq post largest monthly loss last week turbulence stock market whipsaw investor even intensified worry global slowdown raise doubt wisdom fed rate hike next month spdr dow jone industrial average dium slip stock market today etf hold blue chip industrial leader merck mrk pfizer pfe ibd leaderboard stock visa be dium lead decliner hold goldman sachs gs intel intc be only stock dium advanced dium peg decline august worst monthly loss year so do spdr spy proxy broad market powershare qqq qqq track largest nonfinancial stock nasdaq composite index spy fall monday sector energy red qqq give qqq top holding biotech stock gilead science gild amgen amgn celgene celg regeneron pharmaceutical regn be hardest hit monday close lose ishare nasdaq biotechnology ibb take hit market vector biotechnology bbh worst sector industry focuse etfs so call death cross spy daily chart be first appearance year pattern occur short term move average week move average slip long term line week move average see bearish signal warning loss momentum more loss ahead accord market watcher interview cnbc cross daily chart be less relevant longer term cross be more worrisome therefore weekly chart spy dium also show pattern here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs vanguard ftse emerge market vwo rs ishare russell iwm rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
822,PFE,large cap etfs dividend focus outshone diversify peer past month extremely choppy market dividend payer tend be more stable company often hold competitive edge dividend cushion investor volatility
823,PFE,dividend etfs focuse high yield come downside risky stock not schwab dividend equity schd exchange trade fund yield
824,PFE,schd be suitable core etf income investor deliver higher yield sacrifice quality say morningstar analyst michael rawson
825,PFE,etf hold high yielding stock tend winnow distressed company
826,PFE,do require stock holding have straight year dividend payment rate highly corporate fundamental such return equity cash flow debt ratio
827,PFE,tilt fund quality company pfizer pfe microsoft msft procter gamble pg rawson write recently further tilt quality result fund use market cap weighting favor large cap company rather more volatile high yielding mid cap company
828,PFE,however dividend payout rule shut newer dividend player such apple aapl dunkin brand dnkn
829,PFE,schd have expense ratio annual fee invest
830,PFE,make cheapest etf dividend stock category
831,PFE,however fund have lag benchmark more expense ratio past year indication high implementation cost rawson say
832,PFE,still fund focus high quality stock lowest cost have make winner successful investing
833,PFE,schd produce annual average gain past year vs vanguard dividend appreciation vig
834,PFE,vig be largest dividend etf currency hedge asset focus dividend growth rather dividend yield require holding have consecutive year dividend increase
835,PFE,have expense ratio yield
836,PFE,exchange trade fund hold dividend stock tend have value skew have struggle find way investor etf strategy much growth stock outperformed several largest dividend etfs see net outflow first month
837,PFE,now however investor face extremely uncertain market condition september dividend etfs be prove popular again
838,PFE,schd be nearly stock market today
839,PFE,follow aparna narayanan twitter ibd_anarayanan large cap etfs dividend focus outshone diversify peer past month extremely choppy market dividend payer tend be more stable company often hold competitive edge dividend cushion investor volatility dividend etfs focuse high yield come downside risky stock not schwab dividend equity schd exchange trade fund yield schd be suitable core etf income investor deliver higher yield sacrifice quality say morningstar analyst michael rawson etf hold high yielding stock tend winnow distressed company do require stock holding have straight year dividend payment rate highly corporate fundamental such return equity cash flow debt ratio tilt fund quality company pfizer pfe microsoft msft procter gamble pg rawson write recently further tilt quality result fund use market cap weighting favor large cap company rather more volatile high yielding mid cap company however dividend payout rule shut newer dividend player such apple aapl dunkin brand dnkn schd have expense ratio annual fee invest make cheapest etf dividend stock category however fund have lag benchmark more expense ratio past year indication high implementation cost rawson say still fund focus high quality stock lowest cost have make winner successful investing schd produce annual average gain past year vs vanguard dividend appreciation vig vig be largest dividend etf currency hedge asset focus dividend growth rather dividend yield require holding have consecutive year dividend increase have expense ratio yield exchange trade fund hold dividend stock tend have value skew have struggle find way investor etf strategy much growth stock outperformed several largest dividend etfs see net outflow first month now however investor face extremely uncertain market condition september dividend etfs be prove popular again schd be nearly stock market today follow aparna narayanan twitter ibd_anarayanan
840,PFE,ireland base icon iclr world top provider large scale clinical trial pharmaceutical industry announce early september partnership ibm ibm union aim streamline process design clinical trial locate recruit appropriate patient trial icon clinical research organization provide datum expertise ibm
841,PFE,stock future shed thursday premarket gain reversed moderate loss mixed report unemployment claim gdp growth
842,PFE,dow future drop point fair market value point advance hour earlier nasdaq future shed point gain drop point future also reversed trading point
843,PFE,stock market today receive boost federal reserve wednesday left nasdaq so far week show gain index be work be fifth straight weekly advance
844,PFE,more important growth investor small cap be have strong week russell surge wednesday strongest session dec lift small cap gauge clear day move average put ahead week even so index remain well next test resistance day line
845,PFE,ibd index pop wednesday be easily outpace market gain week
846,PFE,big day economic news be mixed start preliminary estimate commerce department putt gdp growth less half jump just forecast increase price inflation also softened gdp price index rise shade view advance
847,PFE,unemployment claim inched fractionally higher week end oct labor department report be better uptick claim forecast economist prior week tally be claim week move average dip sixth straight decline
848,PFE,atlanta federal reserve bank president dennis lockhart be schedule speak washington et national association realtor report september pending home sale datum
849,PFE,big oil company get earning ball roll royal dutch shell rdsa total tot conocophillip cop report result oil price backed west texas intermediate barrel surge more wednesday
850,PFE,drug maker pfizer pfe climb allergan agn soar news report company be explore possible merger wall street journal quote unnamed source say talk be early stage detail be unclear pfizer end wednesday week less buy point cup handle base
851,PFE,premarket session move identity security firm lifelock lock soar healthy result report late wednesday news have settle federal trade commission lawsuit digital video camera maker gopro gpro dive weaker forecast sale earning also report wednesday close
852,PFE,lead stock reilly automotive orly jump tesoro tso rise ellie mae elli be flat report reilly end wednesday session buy range less buy point tesoro be buy point cup handle base
853,PFE,nxp semiconductor nxpi dive netherlands base chip maker report earning stronger expect revenue rise less weaker estimate management expand stock buyback initiative share nxp finished wednesday just week move average have be work climb right side month consolidation
854,PFE,cavium cavm take hit report line earning revenue late wednesday chip maker have be chop uneven consolidation fight hold support june
855,PFE,follow alan elliott twitter ibd_aelliott facebook stock future shed thursday premarket gain reversed moderate loss mixed report unemployment claim gdp growth dow future drop point fair market value point advance hour earlier nasdaq future shed point gain drop point future also reversed trading point stock market today receive boost federal reserve wednesday left nasdaq so far week show gain index be work be fifth straight weekly advance more important growth investor small cap be have strong week russell surge wednesday strongest session dec lift small cap gauge clear day move average put ahead week even so index remain well next test resistance day line ibd index pop wednesday be easily outpace market gain week big day economic news be mixed start preliminary estimate commerce department putt gdp growth less half jump just forecast increase price inflation also softened gdp price index rise shade view advance unemployment claim inched fractionally higher week end oct labor department report be better uptick claim forecast economist prior week tally be claim week move average dip sixth straight decline atlanta federal reserve bank president dennis lockhart be schedule speak washington et national association realtor report september pending home sale datum big oil company get earning ball roll royal dutch shell rdsa total tot conocophillip cop report result oil price backed west texas intermediate barrel surge more wednesday drug maker pfizer pfe climb allergan agn soar news report company be explore possible merger wall street journal quote unnamed source say talk be early stage detail be unclear pfizer end wednesday week less buy point cup handle base premarket session move identity security firm lifelock lock soar healthy result report late wednesday news have settle federal trade commission lawsuit digital video camera maker gopro gpro dive weaker forecast sale earning also report wednesday close lead stock reilly automotive orly jump tesoro tso rise ellie mae elli be flat report reilly end wednesday session buy range less buy point tesoro be buy point cup handle base nxp semiconductor nxpi dive netherlands base chip maker report earning stronger expect revenue rise less weaker estimate management expand stock buyback initiative share nxp finished wednesday just week move average have be work climb right side month consolidation cavium cavm take hit report line earning revenue late wednesday chip maker have be chop uneven consolidation fight hold support june follow alan elliott twitter ibd_aelliott facebook
856,PFE,major average lose ground thursday tech stock lag loss weren ominous less hour remain session nasdaq lose dow jone industrial average fall ease volume nyse nasdaq be tracking slightly lower wednesday level stock market today economic news first look gdp show growth tad consensus estimate sharp slowdown growth meanwhile weekly jobless claim fall more expect pending home sale september miss badly top rate homebuilder slump weak housing datum horton dhi lennar len lgi home lgih show loss range health care space allergan agn jump drugmaker confirm early talk pfizer pfe merger share pfizer fall ellie mae elli be big winner ibd share jump company report strong earning late wednesday share be so far week ellie mae be back week move average approach time high downside nxp semiconductor nxpi crash chip designer report sharp deceleration earning growth flat sale buffalo wild wing bwld be casualty crater late wednesday report ep share cent consensus estimate revenue also miss starbucks sbux lose ahead earning report close former leader baidu bidu linkedin lnkd be also set report follow ken shreve twitter ibd_kshreve facebook
857,PFE,stock battle narrow loss early action thursday investor respond busy morning earning economic news dow jone industrial average dip nasdaq slip
858,PFE,volume increase nasdaq nyse relative wednesday morning trade
859,PFE,weaker expect gdp estimate knock stock market today positive premarket stance expect unemployment claim do little counter effect
860,PFE,pending home sale also pressed button slip september accord national association realtor be sharp step august decline more double decline expect consensus
861,PFE,third dow moved lower intel intc pfizer pfe staking low ground loss nearly
862,PFE,pfizer reversed premarket gain follow news report be early stage discussion regard possible merger allergan agn allergan confirm report early thursday share flattened premarket gain fractional advance open
863,PFE,hanesbrand hbi stretched gain strong report late wednesday network ffiv drop report also deliver wednesday close
864,PFE,chipmaker face broad selling pressure early action feel drawdown nxp semiconductor nxpi dive nxp report weaker consensus revenue cite slow customer order rise industry inventory
865,PFE,philadelphia semiconductor index be less week rally prior week
866,PFE,cirrus logic crus cavium cavm fabless chipmaker ibd list drop report earning late wednesday cirrus score clear revenue earning cavium result just meet expectation
867,PFE,technology avgo shed singapore base chipmaker be have mixed success fight gain ground vs day move average be seventh week cup handle base form longer consolidation
868,PFE,high side ibd ellie mae elli climb top third quarter consensus revenue earning expectation number user mortgage lease provider online encompass service rise year year increase user revenue management earning guidance be consensus forecast stock be back day move average work fourth straight advance build right side month base
869,PFE,reilly automotive orly pop report strong result late wednesday auto part chain also beat revenue earning line guide ep consensus estimate big volume gap gain send share new high leave extend buy point stock battle narrow loss early action thursday investor respond busy morning earning economic news dow jone industrial average dip nasdaq slip volume increase nasdaq nyse relative wednesday morning trade weaker expect gdp estimate knock stock market today positive premarket stance expect unemployment claim do little counter effect pending home sale also pressed button slip september accord national association realtor be sharp step august decline more double decline expect consensus third dow moved lower intel intc pfizer pfe staking low ground loss nearly pfizer reversed premarket gain follow news report be early stage discussion regard possible merger allergan agn allergan confirm report early thursday share flattened premarket gain fractional advance open hanesbrand hbi stretched gain strong report late wednesday network ffiv drop report also deliver wednesday close chipmaker face broad selling pressure early action feel drawdown nxp semiconductor nxpi dive nxp report weaker consensus revenue cite slow customer order rise industry inventory philadelphia semiconductor index be less week rally prior week cirrus logic crus cavium cavm fabless chipmaker ibd list drop report earning late wednesday cirrus score clear revenue earning cavium result just meet expectation technology avgo shed singapore base chipmaker be have mixed success fight gain ground vs day move average be seventh week cup handle base form longer consolidation high side ibd ellie mae elli climb top third quarter consensus revenue earning expectation number user mortgage lease provider online encompass service rise year year increase user revenue management earning guidance be consensus forecast stock be back day move average work fourth straight advance build right side month base reilly automotive orly pop report strong result late wednesday auto part chain also beat revenue earning line guide ep consensus estimate big volume gap gain send share new high leave extend buy point
870,PFE,big pharma eli lilly lly partner boehringer ingelheim say thursday diabetes drug jardiance succeed lower risk death cardiovascular disease massive year study send lilly stock sharply detailed result be be hold medical meeting eli lilly boehringer do say empa reg outcome trial
871,PFE,halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug
872,PFE,halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product
873,PFE,san diego base halozyme be also testing product call pegph combination other drug treatment various cancer
874,PFE,analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year
875,PFE,recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention
876,PFE,ibd have drug delivery product hylenex enhanze seem similar be difference
877,PFE,torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin
878,PFE,product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic
879,PFE,hylenex be product halozyme go get approve promote small field force have
880,PFE,basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue
881,PFE,now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule
882,PFE,ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection
883,PFE,same base sugar just license call enhanze product call hylenex
884,PFE,ibd drug re develop cancer treatment be also base same substance
885,PFE,torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein
886,PFE,so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day
887,PFE,example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient
888,PFE,exactly re try do here have drug last longer so doesn have be give frequently
889,PFE,ibd so be necessarily combine drug do do anything
890,PFE,torley pegph have modest cancer effect type effect believe be important patient need be used therapy
891,PFE,ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed
892,PFE,be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone
893,PFE,theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor
894,PFE,administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work
895,PFE,early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar
896,PFE,today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement
897,PFE,connect amy reeve ibd_areeve facebook halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product san diego base halozyme be also testing product call pegph combination other drug treatment various cancer analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention ibd have drug delivery product hylenex enhanze seem similar be difference torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic hylenex be product halozyme go get approve promote small field force have basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection same base sugar just license call enhanze product call hylenex ibd drug re develop cancer treatment be also base same substance torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient exactly re try do here have drug last longer so doesn have be give frequently ibd so be necessarily combine drug do do anything torley pegph have modest cancer effect type effect believe be important patient need be used therapy ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement connect amy reeve ibd_areeve facebook
898,PFE,big pharmas pfizer pfe merck mrk beat estimate raise guidance tuesday merck french counterpart sanofi sny enter separate deal develop immunotherapy drug cancer pfizer earning dip cent share top analyst consensus cent accord thomson reuter sale decline more
899,PFE,stock fought tightly mixed action early friday earning news economic datum power large share action
900,PFE,nasdaq improve rise dow jone industrial average struggle decline volume be soft nasdaq lower nyse compare trade same time thursday
901,PFE,economic news get generally positive start stock market today employee cost index dip year low second quarter datum be clear employer less so consumer commerce department datum release thursday estimate consumer spending be sharply higher quarter
902,PFE,midwest manufacturing amp july kingsbury international chicago purchasing manager index rise dip june economist have expect minor uptick reading indicate economic expansion
903,PFE,consumer sentiment be largely unchanged university michigan report consumer sentiment index ease july june economist consensus have target increase
904,PFE,stock big oil put hurt dow exxon mobil xom chevron cvx drop disappointing result pfizer pfe post dow biggest gain
905,PFE,expedia expe lead nasdaq leap healthy second quarter gap send share past flat base buy point heavy trade
906,PFE,amgen amgn flex nearly massive trade biotech pioneer second quarter earning revenue easily top consensus projection management hoist full year earning revenue guidance high end analyst expectation gain send share buy point flat base
907,PFE,ibd list universal health service uhs power hospital owner post better forecast second quarter revenue earning big volume gain send share back buy point week tight pattern
908,PFE,newlink genetic nlnk rise more world health organization report publish medical journal lancet show positive result vsv zebov ebola vaccine develop jointly newlink merck mrk food drug administration have raise question study involved more participant guinea newlink have form deep cup handle base buy point merck share rise fraction
909,PFE,low end list outerwall outr come tumble strong volume owner redbox coinstar kiosk franchise turn adjust earning number well consensus estimate revenue be flat far expectation loss send share far week move average test support stock week line stock fought tightly mixed action early friday earning news economic datum power large share action nasdaq improve rise dow jone industrial average struggle decline volume be soft nasdaq lower nyse compare trade same time thursday economic news get generally positive start stock market today employee cost index dip year low second quarter datum be clear employer less so consumer commerce department datum release thursday estimate consumer spending be sharply higher quarter midwest manufacturing amp july kingsbury international chicago purchasing manager index rise dip june economist have expect minor uptick reading indicate economic expansion consumer sentiment be largely unchanged university michigan report consumer sentiment index ease july june economist consensus have target increase stock big oil put hurt dow exxon mobil xom chevron cvx drop disappointing result pfizer pfe post dow biggest gain expedia expe lead nasdaq leap healthy second quarter gap send share past flat base buy point heavy trade amgen amgn flex nearly massive trade biotech pioneer second quarter earning revenue easily top consensus projection management hoist full year earning revenue guidance high end analyst expectation gain send share buy point flat base ibd list universal health service uhs power hospital owner post better forecast second quarter revenue earning big volume gain send share back buy point week tight pattern newlink genetic nlnk rise more world health organization report publish medical journal lancet show positive result vsv zebov ebola vaccine develop jointly newlink merck mrk food drug administration have raise question study involved more participant guinea newlink have form deep cup handle base buy point merck share rise fraction low end list outerwall outr come tumble strong volume owner redbox coinstar kiosk franchise turn adjust earning number well consensus estimate revenue be flat far expectation loss send share far week move average test support stock week line
910,PFE,company be increasingly putt cash dividend buyback trend benefit shareholder company increase sum spend buyback dividend accord new report capital iq
911,PFE,moreover amount allocate repurchase dividend have rise past year see trend continue analyst write
912,PFE,amount devote dividend buyback vary greatly sector sector company company
913,PFE,financial sector market leader today outlook be good analyst expect dividend rise year well most other sector
914,PFE,pharmaceutical have be largest most consistent payer dividend study say industry single handedly account total dividend
915,PFE,company ibd dividend leader screen pfizer pfe johnson johnson jnj be most generous pfizer have be biggest payer dividend johnson johnson follow
916,PFE,industrial capital iq doesn expect much change dividend buyback have be expand
917,PFE,general electric ge spend nearly dividend dwarf other major industrial company
918,PFE,telecom giant verizon vz command yield capital iq analyst think telecom focus more reduce debt
919,PFE,utility tend pay more half profit dividend continue raise payout next several year average annual rate duke energy duk southern co so dominion resource make ibd utility leader screen top sector dividend company be increasingly putt cash dividend buyback trend benefit shareholder company increase sum spend buyback dividend accord new report capital iq moreover amount allocate repurchase dividend have rise past year see trend continue analyst write amount devote dividend buyback vary greatly sector sector company company financial sector market leader today outlook be good analyst expect dividend rise year well most other sector pharmaceutical have be largest most consistent payer dividend study say industry single handedly account total dividend company ibd dividend leader screen pfizer pfe johnson johnson jnj be most generous pfizer have be biggest payer dividend johnson johnson follow industrial capital iq doesn expect much change dividend buyback have be expand general electric ge spend nearly dividend dwarf other major industrial company telecom giant verizon vz command yield capital iq analyst think telecom focus more reduce debt utility tend pay more half profit dividend continue raise payout next several year average annual rate duke energy duk southern co so dominion resource make ibd utility leader screen top sector dividend
920,PFE,ibm ibm schlumberger slb be give lower price target tuesday valeant pharmaceutical vrx pfizer pfe be several pharma stock see analyst action ibm share close stock market today price target be lower rbc capital market maintain sector perform rating stock
921,PFE,big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher
922,PFE,study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication
923,PFE,be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution
924,PFE,efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra
925,PFE,abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject
926,PFE,take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note
927,PFE,incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat
928,PFE,follow amy reeve twitter ibd_areeve facebook big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat follow amy reeve twitter ibd_areeve facebook
929,PFE,stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point
930,PFE,nasdaq future have pare loss past hour reversed fall point fair market value
931,PFE,stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon
932,PFE,great many investor be tune aftermarket session apple aapl be schedule report fiscal result
933,PFE,economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip
934,PFE,case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index
935,PFE,earning action be thick heavy roll tuesday open
936,PFE,beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result
937,PFE,downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim
938,PFE,alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
939,PFE,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price
940,PFE,yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation
941,PFE,other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece
942,PFE,chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february
943,PFE,cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june
944,PFE,leader ibd stock be relatively quiet more group unmoved premarket trade
945,PFE,gainer cirrus logic crus rise topple heavy trade monday stock post decline more stock future deepen early loss ahead tuesday open weaker expect september durable good report dow future trade point be fall future slip point nasdaq future have pare loss past hour reversed fall point fair market value stock market today face busy session federal open market committee swing day meeting washington policy announcement due wednesday afternoon great many investor be tune aftermarket session apple aapl be schedule report fiscal result economic news open durable good order slip september accord commerce department be bit projection decline department also revise august decline transportation order dip august flat performance deeper project slip case shiller report city composite home price index august et researcher markit release preliminary purchasing manager index estimate service conference board plan report october consumer confidence index earning action be thick heavy roll tuesday open beleaguered german chip equipment maker aixtron aixg spiked base big oil play bp bp add almost big pharma name merck mrk pfizer pfe rolled gain report better expect result downside frac sand quarrier crush partner hclp implode miss earning forecast suspend cash distribution rent center rcii post premarket meltdown miss revenue expectation lower full year earning guidance ford slip unite parcel service up dim alibaba baba rumble bell launch premarket rally many china base stock china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend alibaba share end monday day move average stock have climb late september low leave still nov high ipo price yahoo yhoo ahead early tuesday investor account increase value yahoo stake alibaba yahoo remain deep month consolidation other china base internet play catch alibaba premarket heat jd com jd com wbai pop jumei international jmei vipshop vip jump apiece chip developer marvell technology mrvl tank announce late monday have resign company accounting firm marvell september announce internal investigation revenue be recognize earlier have be marvell share have be steep correction february cummin cmi dive miss expectation earning revenue line management lower full year revenue outlook flat vs prior guidance gain columbus ind base diesel engine maker also announce lay worker share have be deepen decline june leader ibd stock be relatively quiet more group unmoved premarket trade gainer cirrus logic crus rise topple heavy trade monday stock post decline more
946,PFE,big biotech gilead science soundly beat analyst estimate raise guidance yet again tuesday cap strong day earning several major drugmaker gilead gild earning exclude time item jump year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb top
947,PFE,perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end
948,PFE,mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed
949,PFE,grow alone
950,PFE,mylan management maintain statement be fine perrigo
951,PFE,mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business
952,PFE,mylan shareholder seem agree stock rise close perrigo stock fall management claim victory
953,PFE,have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy
954,PFE,mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time
955,PFE,time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal
956,PFE,perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be
957,PFE,accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination
958,PFE,not do deal
959,PFE,capital iq analyst jeffrey loo write expect more perrigo future
960,PFE,do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan
961,PFE,morningstar analyst michael also write see mylan stay hunt
962,PFE,generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed grow alonemylan management maintain statement be fine perrigo mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business mylan shareholder seem agree stock rise close perrigo stock fall management claim victory have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination not do deal capital iq analyst jeffrey loo write expect more perrigo future do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan morningstar analyst michael also write see mylan stay hunt generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note
963,PFE,pfizer pfe allergan agn be consider massive drug merger worth more wall street journal report late wednesday cite source make biggest deal year least pfizer recently reach irish drug giant wsj report combine pfizer market cap allergan forge
964,PFE,stock edge higher wednesday open earning push early action ahead fed policy announcement afternoon dow jone industrial average gain nasdaq add hold back heavy loss akamai technology akam verisk analytic vrsk
965,PFE,volume be soft nasdaq lower nyse vs trade same time tuesday
966,PFE,fed policy announcement due et remain focal point stock market today keep eye oil price energy information administration report weekly oil inventory datum
967,PFE,pfizer pfe jump nearly lead dow unitedhealth unh drop dow worst decline
968,PFE,apple aapl power bit less report healthy fiscal second quarter late tuesday
969,PFE,cbre group cbg gap gain big revenue earning beat big volume move put share well right side possible cup base
970,PFE,northrop grumman noc new high rise massive trade ace contract defense department contract build long range bomber report solid result
971,PFE,ibd stock cirrus logic crus jump nearly start gate gain be enough lift share back day move average chip developer drop heavy trade monday trigger sell signal cut day move average company report fiscal earning revenue today close
972,PFE,ibd fabless chip play technology avgo climb place share back day move average stock be seventh week pattern become cup handle base buy point form month consolidation
973,PFE,ellie mae elli fade fraction early trade online mortgage service provider be build right side possible base back day move average climb oct low report result close
974,PFE,regeneron pharmaceutical regn fade bit less stock be due rest straight daily advance boost past buy point double bottom base stock reset base count undercut prior flat base make current pattern first stage structure increase potential stock remain buy range buy point company report result nov
975,PFE,follow alan elliott twitter ibd_aelliott facebookstock edge higher wednesday open earning push early action ahead fed policy announcement afternoon dow jone industrial average gain nasdaq add hold back heavy loss akamai technology akam verisk analytic vrsk volume be soft nasdaq lower nyse vs trade same time tuesday fed policy announcement due et remain focal point stock market today keep eye oil price energy information administration report weekly oil inventory datum pfizer pfe jump nearly lead dow unitedhealth unh drop dow worst decline apple aapl power bit less report healthy fiscal second quarter late tuesday cbre group cbg gap gain big revenue earning beat big volume move put share well right side possible cup base northrop grumman noc new high rise massive trade ace contract defense department contract build long range bomber report solid result ibd stock cirrus logic crus jump nearly start gate gain be enough lift share back day move average chip developer drop heavy trade monday trigger sell signal cut day move average company report fiscal earning revenue today close ibd fabless chip play technology avgo climb place share back day move average stock be seventh week pattern become cup handle base buy point form month consolidation ellie mae elli fade fraction early trade online mortgage service provider be build right side possible base back day move average climb oct low report result close regeneron pharmaceutical regn fade bit less stock be due rest straight daily advance boost past buy point double bottom base stock reset base count undercut prior flat base make current pattern first stage structure increase potential stock remain buy range buy point company report result nov follow alan elliott twitter ibd_aelliott facebook
976,PFE,health care etfs pump big gain tuesday slew solid drugmaker earning technology focuse peer lag get boost tomorrow apple aapl stock advanced close better expect earning revenue sluggish day stock health etfs rise strong report pfizer pfe merck mrk bristol myer squibb bmy new york base pfizer gap earning beat new jersey peer merck rise more report profit jump latest quarter boost annual outlook medical equipment company edward lifescience ew grab gain beat top bottom line spdr health care xlv etf tracking sector rise stock market today spdr etf peer carve sector post loss tuesday energy stock lead decline xlv largest broad base health care etf allocate roughly asset combination stock pfizer merck bristol myer etf hold stock gilead science gild xlv third largest stock hold fall hour report robust profit raise full year outlook biotech giant have be rally straight week powershare dynamic pharmaceutical pjp pop drugmaker advanced etf hold stock allocate asset bristol myer pfizer merck pjp be top perform pharmaceutical etf year date rise vs xlv meanwhile alibaba baba leap china internet giant easily clear analyst expectation fiscal earning revenue mobile revenue surge gain fail give much boost etfs big stake stock kraneshare csi china internet kweb renaissance ipo ipo eke fractional gain tuesday alibaba be hold kweb asset hold ipo asset etfs hold safe haven asset such bond gold climb marginally tuesday listless stock market here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db dollar bullish uup rs follow aparna narayanan twitter ibd_anarayanan
977,PFE,batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock
978,PFE,unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance
979,PFE,unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale
980,PFE,pfizer ep
981,PFE,pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view
982,PFE,pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus
983,PFE,result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus
984,PFE,good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin
985,PFE,bristol lead pd battle
986,PFE,bristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise
987,PFE,bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly
988,PFE,pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale
989,PFE,big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client
990,PFE,bristol myer stock be midday tuesday
991,PFE,merck sale line
992,PFE,bristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise
993,PFE,merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year
994,PFE,merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation
995,PFE,merck stock be more midday trading
996,PFE,follow amy reeve twitter ibd_areeve facebook batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale pfizer ep pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin bristol lead pd battlebristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client bristol myer stock be midday tuesday merck sale linebristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation merck stock be more midday trading follow amy reeve twitter ibd_areeve facebook
997,PFE,viagra be just latest casualty cvs health cvs aug remove blockbuster erectile dysfunction drug other formulary list list name drug pharmacy benefit management business cvs caremark agree cover prescription benefit program health insurance company such aetna aet exclusion list drug not cover
998,PFE,praluent new cholesterol bust drug regeneron pharmaceutical regn sanofi sny be grant fda approval friday slightly more limit patient pool have hope regeneron stock close stock market today be little change share be halter much afternoon fda
999,PFE,drugmaker deliver tasty return investor july pharmaceutical etfs top peer hold broadly diversify health care stock well focuse red hot biotechs powershare dynamic pharmaceutical pjp lag pharma etf peer month rise lead year date advance longer period produce annual average
1000,PFE,not long celebrity live fast die young often succumb recreational drug cocaine heroin amphetamine good old booze more recent year grow list celebrity michael jackson heath ledger brittany murphy anna nicole have die combination legal drug be theoretically prescribe trouble anxiety
1001,PFE,largest dividend etfs have be doldrum lately take hit investor pile small cap fund june vanguard high dividend yield vym be select few dividend exchange trade fund peg gain also longer term winner narrowly beating spdr spy average annual return past
1002,PFE,william laporte ve boast step leader american home product decade used aggressive tv advertising build company biggest producer pharmaceutical household chemical world ahp revenue earning earning share dividend rise year tenure
1003,PFE,dublin base icon iclr be world largest operator large scale pharmaceutical industry clinical trial trial business have be perk past few year scad promising biotech development rise spending larger player be boost market more half world clinical trial be still hold europe drugmaker
1004,PFE,stock go nowhere yesterday ahead federal reserve october fomc meeting close narrowly mixed trading remain tight range lighter volume be nothing real significance make broader market move direction last week strong advance promise central bank intervention ecb rate cut
1005,PFE,kind opportunity technology energy market once offer be beckon investor property biotech cluster emerge recession technology energy market command attention commercial real estate investor want tap improve occupancy rental rate largely absent elsewhere
1006,PFE,similar dynamic be germinate biotech cluster be typically marked high concentration life science company academic research institution
1007,PFE,tenant demand be drive fundamental node particularly boston san diego san francisco bay area
1008,PFE,biotech bellwether cambridge mass average vacancy rate lab space be end second quarter half be year earlier accord brokerage cushman wakefield
1009,PFE,average rental rate square foot marked year year increase
1010,PFE,july pasadena calif base real estate investment trust alexandrium real estate equity be sell stake square foot build housing cambridge biogen biib tiaa cref
1011,PFE,price reflect cash capitalization rate initial cash yield investor relatively low
1012,PFE,more rent win increase year accord comment make alexandrium real estate ceo joel marcus company second quarter earning call
1013,PFE,be large group very interested buyer include number sovereign wealth fund marcus tell analyst call also suggest company look selling more asset light demand
1014,PFE,grow focus biotech space be occur medical discovery robust investment sector
1015,PFE,health care measure pass house representative july also boost national institutes health biotech funding streamline regulatory approval new drug
1016,PFE,drive largely life science firm health care company raise ipos quarters year health care company raise accord greenwich conn base renaissance capital manager ipo focuse etfs nasdaq biotechnology index plunge past month follow gain be expect curtail ipo activity accord firm
1017,PFE,half vacancy rate
1018,PFE,venture capital firm pump biotech company second quarter year year increase accord report national venture capital association base datum provide thomson reuter
1019,PFE,costar portfolio strategy division washington base property researcher costar csgp find average vacancy rate top biotech cluster america be more half national office vacancy rate further note third nih funding flow academic research institution top cluster include boston san diego baltimore philadelphia
1020,PFE,rich robbin ceo san rafael calif base wareham development downplay link nih funding occupancy note biotech company have access several source capital naturally gravitate research institution keenly aware need space san francisco bay area life science submarket many have average vacancy rate less second quarter accord brokerage kidder mathews
1021,PFE,wareham be finishing square foot life science build berkeley
1022,PFE,aduro biotech adro recently agree lease half begin june option claim balance july
1023,PFE,wareham also be develop emerystation west square foot research facility transit center nearby emeryville
1024,PFE,big pharmaceutical company appetite develop biotech therapy be pressure young firm succeed grow quickly robbin say
1025,PFE,be definitely be challenged meet space need life science company east bay say need build square foot new lab space month just keep pace demand
1026,PFE,case investor be look opportunity outside hottest cluster life science developer longfellow real estate partner early october acquire office build suburban boston plan redevelop lab space alternative cambridge example
1027,PFE,weigh alternative
1028,PFE,advance realty bridgewater base developer be similarly lead effort convert former sanofi sny campus northern new jersey mixed use project include square foot lab research space other investor be likely pursue similar redevelopment former pfizer pfe roche rhhby campuse region say john cunningham executive manage director brokerage collier international cigi parsippany
1029,PFE,project provide alternative life science cluster emerge new york university school medicine manhattan
1030,PFE,alexandrium be add square foot exist square foot life science center neighborhood lack biotech space have lead rent square foot say
1031,PFE,big expense young company cunningham acknowledge location often override concern
1032,PFE,drive mile get much lower rental rate lot company want be new york be financial market top talent need say cunningham suggest manhattan life science area be cambridge be year very expensive develop bring drug market have make best asset kind opportunity technology energy market once offer be beckon investor property biotech cluster emerge recession technology energy market command attention commercial real estate investor want tap improve occupancy rental rate largely absent elsewhere similar dynamic be germinate biotech cluster be typically marked high concentration life science company academic research institution tenant demand be drive fundamental node particularly boston san diego san francisco bay area biotech bellwether cambridge mass average vacancy rate lab space be end second quarter half be year earlier accord brokerage cushman wakefield average rental rate square foot marked year year increase july pasadena calif base real estate investment trust alexandrium real estate equity be sell stake square foot build housing cambridge biogen biib tiaa cref price reflect cash capitalization rate initial cash yield investor relatively low more rent win increase year accord comment make alexandrium real estate ceo joel marcus company second quarter earning call be large group very interested buyer include number sovereign wealth fund marcus tell analyst call also suggest company look selling more asset light demand grow focus biotech space be occur medical discovery robust investment sector health care measure pass house representative july also boost national institutes health biotech funding streamline regulatory approval new drug drive largely life science firm health care company raise ipos quarters year health care company raise accord greenwich conn base renaissance capital manager ipo focuse etfs nasdaq biotechnology index plunge past month follow gain be expect curtail ipo activity accord firm half vacancy rateventure capital firm pump biotech company second quarter year year increase accord report national venture capital association base datum provide thomson reuter costar portfolio strategy division washington base property researcher costar csgp find average vacancy rate top biotech cluster america be more half national office vacancy rate further note third nih funding flow academic research institution top cluster include boston san diego baltimore philadelphia rich robbin ceo san rafael calif base wareham development downplay link nih funding occupancy note biotech company have access several source capital naturally gravitate research institution keenly aware need space san francisco bay area life science submarket many have average vacancy rate less second quarter accord brokerage kidder mathews wareham be finishing square foot life science build berkeley aduro biotech adro recently agree lease half begin june option claim balance july wareham also be develop emerystation west square foot research facility transit center nearby emeryville big pharmaceutical company appetite develop biotech therapy be pressure young firm succeed grow quickly robbin say be definitely be challenged meet space need life science company east bay say need build square foot new lab space month just keep pace demand case investor be look opportunity outside hottest cluster life science developer longfellow real estate partner early october acquire office build suburban boston plan redevelop lab space alternative cambridge example weigh realty bridgewater base developer be similarly lead effort convert former sanofi sny campus northern new jersey mixed use project include square foot lab research space other investor be likely pursue similar redevelopment former pfizer pfe roche rhhby campuse region say john cunningham executive manage director brokerage collier international cigi parsippany project provide alternative life science cluster emerge new york university school medicine manhattan alexandrium be add square foot exist square foot life science center neighborhood lack biotech space have lead rent square foot say big expense young company cunningham acknowledge location often override concern drive mile get much lower rental rate lot company want be new york be financial market top talent need say cunningham suggest manhattan life science area be cambridge be year very expensive develop bring drug market have make best asset
1033,PFE,hillary clinton vow cap patient pocket prescription cost month sound populist way help consumer sticking drug company
1034,PFE,reality be raise premium modestly reduce rank insure partly push small business drop coverage believe not exactly drug company want
1035,PFE,example plan work clinton presidential campaign point cover california start state obamacare insurance exchange cap individual cost single cover drug month benchmark silver level plan
1036,PFE,california plan raise premium year state official have acknowledge clinton plan go further cap consumer total pocket cost more drug month not cost single drug
1037,PFE,intend unintended
1038,PFE,cowen co analyst point ordinary american don face significant monthly prescription cost end subsidize do premium co pay rise clinton month limit
1039,PFE,think significant unintended maybe intend consequence arise cap face significant opposition accord cowen report tuesday
1040,PFE,implication democratic front runner plan be make low cost employer plan pricier increase incentive employer pay mandate penalty figure way avoid such hire more part time worker
1041,PFE,key be obamacare employer mandate require company offer coverage be least comprehensive bronze level exchange plan still leave customer hook drug cost year california
1042,PFE,mean clinton proposal hold pocket drug cost month have apply bronze plan well
1043,PFE,higher premium result cap then result more cost be shift relatively young healthy big prescription bill be much less common
1044,PFE,risky strategy consider young adult enrollment obamacare exchange be target partly result relatively older not so healthy group enrollee average premium be expect rise more
1045,PFE,drugmaker support cap
1046,PFE,additional premium hike get healthy young adult subsidize more cost prescription further dampen enrollment more person choose go coverage see bad deal
1047,PFE,biotech stock continue slide tuesday due part clinton attack outrageous drug pricing ishare nasdaq biotechnology etf ibb close fall monday amgen amgn dip add monday loss
1048,PFE,yet drugmaker have be quietly support campaign cap pocket cost drug help expand access product
1049,PFE,pfizer pfe celgene celg have provide funding group push co pay limit include cap copay leukemia lymphoma society number state have enact such limit past couple year include montana delaware louisiana maine
1050,PFE,meanwhile insurance industry have be firmly idea warn cap low level control drug price raise premium
1051,PFE,clinton want rein drug price too analyst be highly skeptical proposal allow import prescription drug let medicare negotiate drug price get enough support congress republican have opposed idea discourage innovative cure hillary clinton vow cap patient pocket prescription cost month sound populist way help consumer sticking drug company reality be raise premium modestly reduce rank insure partly push small business drop coverage believe not exactly drug company want example plan work clinton presidential campaign point cover california start state obamacare insurance exchange cap individual cost single cover drug month benchmark silver level plan california plan raise premium year state official have acknowledge clinton plan go further cap consumer total pocket cost more drug month not cost single drug intend unintended cowen co analyst point ordinary american don face significant monthly prescription cost end subsidize do premium co pay rise clinton month limit think significant unintended maybe intend consequence arise cap face significant opposition accord cowen report tuesday implication democratic front runner plan be make low cost employer plan pricier increase incentive employer pay mandate penalty figure way avoid such hire more part time worker key be obamacare employer mandate require company offer coverage be least comprehensive bronze level exchange plan still leave customer hook drug cost year california mean clinton proposal hold pocket drug cost month have apply bronze plan well higher premium result cap then result more cost be shift relatively young healthy big prescription bill be much less common risky strategy consider young adult enrollment obamacare exchange be target partly result relatively older not so healthy group enrollee average premium be expect rise more drugmaker support capsadditional premium hike get healthy young adult subsidize more cost prescription further dampen enrollment more person choose go coverage see bad deal biotech stock continue slide tuesday due part clinton attack outrageous drug pricing ishare nasdaq biotechnology etf ibb close fall monday amgen amgn dip add monday loss yet drugmaker have be quietly support campaign cap pocket cost drug help expand access product pfizer pfe celgene celg have provide funding group push co pay limit include cap copay leukemia lymphoma society number state have enact such limit past couple year include montana delaware louisiana maine meanwhile insurance industry have be firmly idea warn cap low level control drug price raise premium clinton want rein drug price too analyst be highly skeptical proposal allow import prescription drug let medicare negotiate drug price get enough support congress republican have opposed idea discourage innovative cure
1052,PFE,stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece
1053,PFE,volume be sharply mixed rise nyse fall nasdaq relative trade same time monday
1054,PFE,stock market today feel early drag commerce department weaker expect september durable good report
1055,PFE,case shiller city composite home price index be bit more positive rise august be slip july line expectation
1056,PFE,preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast
1057,PFE,consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate
1058,PFE,stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
1059,PFE,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china
1060,PFE,alibaba heavy volume gain send share back day move average month consolidation
1061,PFE,yahoo yhoo pop pull stake alibaba
1062,PFE,coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast
1063,PFE,edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base
1064,PFE,pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report
1065,PFE,coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss
1066,PFE,leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base
1067,PFE,cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece volume be sharply mixed rise nyse fall nasdaq relative trade same time monday stock market today feel early drag commerce department weaker expect september durable good report case shiller city composite home price index be bit more positive rise august be slip july line expectation preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china alibaba heavy volume gain send share back day move average month consolidation yahoo yhoo pop pull stake alibaba coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal
1068,PFE,dividend etfs come stripe select few focus blue chip stock be screen financial health bonus re cheapest exchange trade fund equity income category ben johnson global director etf research morningstar inc especially like schwab dividend equity schd view very low cost
1069,PFE,volatility be word day stock market drugmaker strong growth prospect proven long term stability such ibd member valeant pharmaceutical vrx be good stock watch list candidate ibd spotlight top performer list stock base combination factor include sale profit growth today roster
1070,PFE,big biotech amgen amgn hit new high early trading friday get several price target increase analyst strong guidance increase late thursday cowen analyst eric schmidt raise price target base not only thursday number also clinical trial datum blood cancer drug kyproli be used
1071,PFE,genentech biotech arm swiss pharma giant roche rhhby announce tuesday drug candidate ocrelizumab have succeed cut relapse rate multiple sclerosis patient late stage trial
1072,PFE,goal study be show ocrelizumab be significantly superior rebif form interferon sell pfizer pfe genentech say have succeed also reduce lesion brain associate disease activity do not release precise number await future medical conference
1073,PFE,ocrelizumab be very infrequent infusion once month high efficacy bucket drug compete biogen biib tysabri sanofi sny campath oral such biogen tecfidera novartis nvs gilenya write rbc capital market analyst michael yee cover biogen research note thus assume drug get share next year primarily expense old interferon also newer high efficacy drug field
1074,PFE,yee add seem bad news biogen ms drug believe investment thesis biogen have shift prospect such treatment alzheimer disease potentially lingo treatment ms
1075,PFE,biogen stock action seem support be fraction early trading stock market today roche stock also be fraction share novartis sanofi be flat
1076,PFE,follow amy reeve twitter ibd_areeve genentech biotech arm swiss pharma giant roche rhhby announce tuesday drug candidate ocrelizumab have succeed cut relapse rate multiple sclerosis patient late stage trial goal study be show ocrelizumab be significantly superior rebif form interferon sell pfizer pfe genentech say have succeed also reduce lesion brain associate disease activity do not release precise number await future medical conference ocrelizumab be very infrequent infusion once month high efficacy bucket drug compete biogen biib tysabri sanofi sny campath oral such biogen tecfidera novartis nvs gilenya write rbc capital market analyst michael yee cover biogen research note thus assume drug get share next year primarily expense old interferon also newer high efficacy drug field yee add seem bad news biogen ms drug believe investment thesis biogen have shift prospect such treatment alzheimer disease potentially lingo treatment ms biogen stock action seem support be fraction early trading stock market today roche stock also be fraction share novartis sanofi be flat follow amy reeve twitter ibd_areeve
1077,PFE,june chief executive mark vergnano rang nyse open bell officially launch chemour cc performance chemical unit spun dupont nemour dd be more plume cap new york base evercore partner evr
1078,PFE,merger acquisition have fan hotbed global economy climb macro swan dive drive evercore report loss company have rebuild earning not yet anywhere peak share analyst expect growth share year gain
1079,PFE,revenue growth be forecast accelerate year slow
1080,PFE,company be generally divide investment banking investment management
1081,PFE,investment banking advise wide range client strategic corporate transaction concentrate advise prominent multinational corporation substantial private equity firm large complex transaction investment banking arm zero institutional asset management manage financial asset sophisticated institutional investor provide service corporate employee benefit plan
1082,PFE,investment banking generate company revenue client
1083,PFE,other dupont recent deal evercore have be involved include astrazeneca azn successful thwart unsolicited takeover attempt pfizer pfe occidental petroleum oxy spinoff california resource crc operation december
1084,PFE,evercore share have be mild uptrend october month long deep cup base stock have build valid handle base buy point june chief executive mark vergnano rang nyse open bell officially launch chemour cc performance chemical unit spun dupont nemour dd be more plume cap new york base evercore partner evr merger acquisition have fan hotbed global economy climb macro swan dive drive evercore report loss company have rebuild earning not yet anywhere peak share analyst expect growth share year gain revenue growth be forecast accelerate year slow company be generally divide investment banking investment management investment banking advise wide range client strategic corporate transaction concentrate advise prominent multinational corporation substantial private equity firm large complex transaction investment banking arm zero institutional asset management manage financial asset sophisticated institutional investor provide service corporate employee benefit plan investment banking generate company revenue client other dupont recent deal evercore have be involved include astrazeneca azn successful thwart unsolicited takeover attempt pfizer pfe occidental petroleum oxy spinoff california resource crc operation december evercore share have be mild uptrend october month long deep cup base stock have build valid handle base buy point
1085,PFE,halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more
1086,PFE,abbvie agree pay upfront milestone payment target plan work used halozyme
1087,PFE,enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax
1088,PFE,halo rise stock market today late afternoon trading
1089,PFE,halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday
1090,PFE,halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue
1091,PFE,follow amy reeve twitter ibd_areeve halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more abbvie agree pay upfront milestone payment target plan work used halozyme enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax halo rise stock market today late afternoon trading halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue follow amy reeve twitter ibd_areeve
1092,PFE,drug giant pfizer pfe continue increase dividend healthy pace even battle stiff competition generic drug maker maker blockbuster drug such viagra cholesterol fighter lipitor have paid dividend straight quarters long term dividend growth rate be accord ibd datum annualize dividend yield be
1093,PFE,share zoetis zts friday more erased thursday surge talk valeant be eyee animal health company zoetis share plummet stock market today activist investor bill ackman hedge fund persh square be company largest shareholder stake valeant pharmaceutical vrx reportedly make preliminary approach
1094,PFE,clinical research organization parexel international prxl plunge more wednesday record high lower guidance late tuesday ahead investor day parexel say now expect revenue fiscal end june be previous guidance earning be take hit range lower gaap ep guidance cent range cent exclude charge ep range be cent line analyst consensus cent statement parexel ceo joseph rickenbach say restructure improve profit margin road conjunction new guidance be also raise long term adjust operate margin target service revenue service revenue say parexel also issue guidance be line consensus expect revenue ep exclude restructure charge parexel stock hit time high tuesday midday stock market today be trading parexel fy guidance update offer material bull bear ep range possibly tad not materially expectation core growth be generally line evercore isi analyst ross muken write email client tuesday ultimately see parexel attractive growth asset industry enjoy strong secular trend however believe volatility performance remain high be challenged see value share current level particularly give uncertainty regard profitability sizing pfizer pfe relationship update come next month pfizer be parexel major customer april big pharma announce employ third cro privately hold pharmaceutical product development addition parexel icon iclr follow amy reeve twitter ibd_areeve
1095,PFE,stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor
1096,PFE,dow jone industrial average climb nasdaq add less split difference
1097,PFE,volume be mixed stock market today nasdaq lower nyse compare trade same time monday
1098,PFE,top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period
1099,PFE,housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be
1100,PFE,new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb
1101,PFE,bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month
1102,PFE,stock be good morning florida base company
1103,PFE,darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point
1104,PFE,citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base
1105,PFE,leader most ibd list post modest gain loss couple dramatic exception
1106,PFE,ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average
1107,PFE,bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor dow jone industrial average climb nasdaq add less split difference volume be mixed stock market today nasdaq lower nyse compare trade same time monday top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month stock be good morning florida base company darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base leader most ibd list post modest gain loss couple dramatic exception ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base
1108,PFE,stock stay positive territory continue hold session high thursday afternoon
1109,PFE,nasdaq be respectively meanwhile dow jone industrial average outperformed gain pfizer pfe be blue chip index best performer agree buy hospira hsp volume be run sharply lower board stock market today
1110,PFE,grubhub hub gap rally morning strong quarter result provider online mobile food order service post earning cent share cent view sale jump vs expectation better expect performance be drive strong growth diner daily average grub higher take rate write bmo capital market analyst edward william research note
1111,PFE,silicon motion technology simo rise time high now past buy point cup handle base chip designer be recently featured international leader
1112,PFE,armour ua lose more revere record high share be follow late wednesday news better expect result announcement couple acquisition
1113,PFE,restoration hardware rh reversed early gain fall fast trade share be more morning company report preliminary sale view stock stay positive territory continue hold session high thursday afternoon nasdaq be respectively meanwhile dow jone industrial average outperformed gain pfizer pfe be blue chip index best performer agree buy hospira hsp volume be run sharply lower board stock market today grubhub hub gap rally morning strong quarter result provider online mobile food order service post earning cent share cent view sale jump vs expectation better expect performance be drive strong growth diner daily average grub higher take rate write bmo capital market analyst edward william research note silicon motion technology simo rise time high now past buy point cup handle base chip designer be recently featured international leader armour ua lose more revere record high share be follow late wednesday news better expect result announcement couple acquisition restoration hardware rh reversed early gain fall fast trade share be more morning company report preliminary sale view
1114,PFE,generic drug maker be top perform industry group thursday easy see pfizer pfe announce be buy stock group hospira hsp share purchase price be premium wednesday close alone account much group gain even announcement generic
1115,PFE,big pharmas report strong fourth quarters give soft guidance tuesday foreign exchange rate continue drag expectation bristol myer squibb bmy say profit exclude time item be cent share year earlier quarter cent analyst consensus accord thomson reuter sale shrank beating consensus
1116,PFE,benefit investor have sense big big cap company actually grow way look situation be compare stock biggest name stock respective industry group sector be guarantee stock become large industry juggernaut
1117,PFE,stock keep grip gain friday index make previous session giveback nasdaq open higher then rise finish day dow jone industrial average add ibd sprint lead index second straight session volume
1118,PFE,drugmaker medicine company mdco eagle pharmaceutical egrx be rise bullish analyst action monday wake thursday court ruling overturn patent medicine cardiovascular drug angiomax bivalirudin appeal court decision seem be bad news medicine mizuho security analyst mario corso upgrade stock buy neutral monday
1119,PFE,sector beat earning forecast lead health care stock accord market researcher capital iq health care sector post gain well april forecast increase capital iq say june report biotech stock be best performer gilead science gild post
1120,PFE,do razzle dazzle health care etfs disguise weakness many investor exchange trade fund real concern sector be handily beating peer have several year ibd leaderboard stock illumina ilmn mallinckrodt mnk show biotech pharma stock still have oomph institutional buyer be pile name well know actavis radar
1121,PFE,stock open tightly mixed wednesday investor patiently wait afternoon release fed minute
1122,PFE,nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high
1123,PFE,stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon
1124,PFE,move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi
1125,PFE,airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble
1126,PFE,telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection
1127,PFE,american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high
1128,PFE,hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point
1129,PFE,lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high
1130,PFE,ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece stock open tightly mixed wednesday investor patiently wait afternoon release fed minute nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece
1131,PFE,even better big dividend income stream count here be most reliable dividend payer yield also beat market ibd dividend stability factor show stable company dividend history be year period lower number more stable dividend history johnson johnson jnj be
1132,PFE,ibd top dividend leader be tobacco stock know hefty dividend so be top nontobacco stock be own warren buffett berkshire hathaway brka verizon communication vz pay cent share full year lead pack yield more
1133,PFE,pharmacyclic pcyc stock soar time high wednesday medium report biotech be consider selling big pharmaceutical company pharmacyclic only market product be imbruvica blood cancer drug have draw interest johnson johnson jnj novartis nvs accord report bloomberg cite unidentified source knowledge matter
1134,PFE,big drug company give mixed fourth quarter report guidance tuesday patent loss foreign exchange rate cloud term future gene sequencer illumina post better expect earning close amgen amgn say earning rise share beating consensus cent revenue big biotech rise more view company affirm guidance single digit sale profit growth issue october stock be nearly hour also close illumina ilmn report profit cent share year earlier quarter cent ahead estimate also affirm previous guidance company preannounce sale earlier month other company report open bristol myer squibb bmy say profit exclude time item be cent share cent analyst consensus accord thomson reuter sale fall beating view year earning rise share sale slip company guide ep range miss street estimate sale guidance also miss conference call analyst executive say impact strong dollar shave guidance cent ep guidance strong dollar make export more expensive less competitive shrink profit sale american company make euro other denomination firm bring money back home morningstar analyst damien conover write research note patent loss continue depress operate result year bullish bristol immuno oncology pipeline start recently approve opdivo call analyst seek more clarity get more datum many clinical trial work management be reluctant make prediction bristol stock fall fraction tuesday pfizer pfe report earning exclude time item shrank cent share penny consensus sale drop street number year earning rise share sale dip pfizer guide ep sale analyst have expect statement cfo frank amelio say revenue guidance reflect anticipate negative impact due recent expect product loss exclusivity well result recent adverse change essentially foreign exchange rate relative dollar capital iq analyst jeffrey loo lower rating pfizer hold buy bmo capital market analyst alex arfaei say guidance underscore company need deal failure buy astrazeneca azn last year pfizer call ceo ian read decline comment rumor pfizer have be rebuff other large target say don feel need do large deal pfizer stock fall fraction novartis nvs have softer other stock rise give more encourage forecast operate growth novartis sale decline miss street estimate earning rise share line full year sale rise ep rise company say fx shave income constant currency basis sale year rise midsingle digit earning increase high single digit follow corporate restructure expect novartis post stronger margin have scale be stronger competitive position remain business line drug eye care product generic conover write note tuesday
1135,PFE,mmm lackluster sale growth unrevised full year outlook have investor expect more drag maker post note industrial film other manufacture good
1136,PFE,earn share last year analyst expectation
1137,PFE,organic local currency sale grow acquisition add additional sale company say foreign currency translation reduce sale percentage point
1138,PFE,sale rise only come estimate
1139,PFE,reaffirm full year guidance share earning expect be range growth sale growth
1140,PFE,analyst project full year earning reach cent midpoint share sale growth
1141,PFE,share fall early afternoon trading stock market today stock be try find support day line form area consolidation hit record dec
1142,PFE,organic growth be positive business group geographic area operate margin rise nearly full point say inge thulin ceo
1143,PFE,organic local currency sale growth reach safety graphic business segment health care segment gain electronic energy business increase industrial consumer segment see growth respectively
1144,PFE,strong dollar reduce majority growth euro yen multiyear lows many multinational be see negative impact profit sale include caterpillar cat pfizer pfe procter gamble pg unite technology utx impact be even heavier current exchange rate hold
1145,PFE,paid share dividend cent totale raise dividend share
1146,PFE,follow alissa william twitter ibd_awilliam mmm lackluster sale growth unrevised full year outlook have investor expect more drag maker post note industrial film other manufacture good earn share last year analyst expectation organic local currency sale grow acquisition add additional sale company say foreign currency translation reduce sale percentage point sale rise only come estimate reaffirm full year guidance share earning expect be range growth sale growth analyst project full year earning reach cent midpoint share sale growth share fall early afternoon trading stock market today stock be try find support day line form area consolidation hit record dec organic growth be positive business group geographic area operate margin rise nearly full point say inge thulin ceo organic local currency sale growth reach safety graphic business segment health care segment gain electronic energy business increase industrial consumer segment see growth respectively strong dollar reduce majority growth euro yen multiyear lows many multinational be see negative impact profit sale include caterpillar cat pfizer pfe procter gamble pg unite technology utx impact be even heavier current exchange rate hold paid share dividend cent totale raise dividend share follow alissa william twitter ibd_awilliam
1147,PFE,pump strengthen collapse crude oil price weaker economy overseas dollar be flex muscle result weaker earning guidance company international exposure
1148,PFE,procter gamble pg say tuesday outlook entire year be cloud foreign exchange company expect reduce annual sale net earning cincinnatus base consumer good giant get third revenue outside america dollar be strong export be more expensive overseas sale translate fewer greenback share fall tuesday pfizer pfe part blame stronger dollar sullen forecast largest drugmaker expect full year adjust earning less analyst thought see sale slightly less wall street view share fall tuesday less general market other drug company also be absorb forex hit basel base novartis nvs be wrestling strong dollar swiss franc shot month currency cap be lift buoy increase consumer confidence lower gasoline price economy have be outperform rest world europe cope deflation japan brazil endure recession china grow slower clip russia petro economy face cheap oil western sanction ukraine result dollar rise vs major trading partner biggest gain global financial crisis spur brief stampede dollar denominate asset jan dollar index be whopping higher average turbocharge central bank easing world ruble have lose half value dollar past year yen lose euro british pound chinese yuan loosely peg dollar flattened last year gain strength slowly recent year analyst see cause optimism especially give oil price dramatic fall be question cheaper energy be windfall consumer worldwide weaken eurozone currency do bode well profit say robert keiser vice president capital iq theory yes theory global macroeconomic outlook be improve reality theory hasn catch yet many company reliant overseas sale dollar be substantial headwind dupont dd cfo nick fanandakis say tuesday conference call figure forex take cent profit estimate share year analyst expect share fall pfizer novartis bristol myer squibb bmy expect foreign exchange rate cut revenue ep cent bristol guide full year sale ep share fall tuesday hard measure dollar impact overall large cap company tend have heavy overseas exposure handle accounting foreign revenue vary firm firm easier analyze effect collapse oil price corporate america earning be track rise be nearly exclude energy sector say gregory harrison senior analyst thomson reuter
1149,PFE,biotech apply genetic technology corp agtc inked gene therapy collaboration biogen biib be worth more send apply genetic stock soar massive volume biogen pay upfront include purchase agtc stock share premium wednesday close price apply genetic stock jump much
1150,PFE,investor rely dividend stock steady income stream often don expect big stock price gain too here be big name be defy expectation more be set buy point be buy range hasbro have take lead year date gain far ahead climb
1151,PFE,investor favor stock big yield other prefer predictable income stream here camp big dividend steady payout most reliable dividend pay stock ibd dividend leader screen also offer bigger payout average ultra low year dividend stability factor measure
1152,PFE,cross border merger boom be boost etfs hold catamaran ctrx dresser rand drc other pharma energy company be hot takeover target merger arbitrage exchange trade fund profit difference stock price deal be announce final purchase price typically upward move cross border merger acquisition have totale roughly
1153,PFE,pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high
1154,PFE,cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter
1155,PFE,announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close
1156,PFE,megadeal have be full force deal value more make nearly half cross border total so far year
1157,PFE,company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value
1158,PFE,more attractive european
1159,PFE,europe rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month
1160,PFE,last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence
1161,PFE,energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total
1162,PFE,royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far
1163,PFE,health care sector lead big pharma have generate deal ytd total year
1164,PFE,include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo
1165,PFE,obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market
1166,PFE,pretty obvious inversion cross border piece have business rationale toole say be look new area business
1167,PFE,pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close megadeal have be full force deal value more make nearly half cross border total so far year company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value more attractive europeanseurope rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far health care sector lead big pharma have generate deal ytd total year include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market pretty obvious inversion cross border piece have business rationale toole say be look new area business pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp
1168,PFE,dividend pay company aren usually know stock price performance dividend leader be beating market year offer big yield too have bag double digit gain compare advance nasdaq dow
1169,PFE,lead pack be reynold american rai year date stock be near cup handle buy point last week maker camel pall mall cigarette report result top view
1170,PFE,tobacco company merger lorillard be still await approval regulator pay quarterly dividend cent share full year work yield average yield be
1171,PFE,next be western union wu gain stock be past flat base buy point financial service provider cent share payout work annualize yield western union have strike deal apple aapl apple pay microsoft msft skype year
1172,PFE,lorillard year be just unilever gain
1173,PFE,lorillard be flat base buy point february tobacco maker brand include newport kent lift payout cent share annualize yield
1174,PFE,unilever gap past flat base buy point april announce rise sale ease just entry dutch consumer good giant recently set dividend cent share annualize dividend nearly trade ul symbol
1175,PFE,pfizer pfe year offer quarterly payout cent share work annual yield drugmaker last week say halter phase trial drug ibrance have already meet endpoint metastatic breast cancer patient dividend pay company aren usually know stock price performance dividend leader be beating market year offer big yield too have bag double digit gain compare advance nasdaq dow lead pack be reynold american rai year date stock be near cup handle buy point last week maker camel pall mall cigarette report result top view tobacco company merger lorillard be still await approval regulator pay quarterly dividend cent share full year work yield average yield be next be western union wu gain stock be past flat base buy point financial service provider cent share payout work annualize yield western union have strike deal apple aapl apple pay microsoft msft skype year lorillard year be just unilever gain lorillard be flat base buy point february tobacco maker brand include newport kent lift payout cent share annualize yield unilever gap past flat base buy point april announce rise sale ease just entry dutch consumer good giant recently set dividend cent share annualize dividend nearly trade ul symbol pfizer pfe year offer quarterly payout cent share work annual yield drugmaker last week say halter phase trial drug ibrance have already meet endpoint metastatic breast cancer patient
1176,PFE,currency headwind have already prompt high end jeweler cut full year earning outlook investor be wait see strong dollar beat fourth quarter result tif report friday new york base company be expect earn share last year revenue be see edge american firm have exposure abroad apple aapl priceline pcln pfizer pfe have be hurt foreign exchange movement overseas sale convert fewer dollar back home higher price good pressure sale volume jan reduce earning guidance full year share currency wo earlier projection share share gap almost news stock have yet recover remain day line share be midafternoon trading stock market today thursday strong dollar also have domestic impact retailer be tourist favorite already pricey brand such come higher price tag vacation american overseas other luxury news chanel tag heuer be slash price china weaker euro accord bloomberg news lvmh bulgari sit third place cartier project double digit sale growth year say reuter lvmh moet hennessy vuitton trade paris exchange lower end mall jeweler signet sig own zale kay jeweler jared gallerium jewelry report result march earning be see rise share revenue growth follow elaine low twitter ibd_elow
1177,PFE,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
1178,PFE,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
1179,PFE,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
1180,PFE,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
1181,PFE,worst performer ibd be regeneron pharmaceutical regn more
1182,PFE,energy name be day best perform industry group push oil price be higher
1183,PFE,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
1184,PFE,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
1185,PFE,merck mrk stock jump more tuesday company lead trio big pharmas report first quarter earning bolster good news diabetes franchise merck report earning cent share year earlier quarter cent better analyst consensus sale shrank beating consensus nearly
1186,PFE,biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work
1187,PFE,tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall
1188,PFE,side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp
1189,PFE,wall street be also hope more visibility part financial structure pfizer create be widely see prelude split
1190,PFE,pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business
1191,PFE,such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be
1192,PFE,bristol myer opdivo focus
1193,PFE,also report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction
1194,PFE,evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add
1195,PFE,be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write
1196,PFE,bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction
1197,PFE,merck fight patent cliff
1198,PFE,merck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call
1199,PFE,schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week
1200,PFE,merck stock hasn be do well lately rs rating just be fraction afternoon trading monday
1201,PFE,teva drama continue
1202,PFE,thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall
1203,PFE,teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development
1204,PFE,monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement
1205,PFE,addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say
1206,PFE,market be not pleased afternoon trading monday teva stock be mylan stock be nearly
1207,PFE,follow amy reeve twitter ibd_areeve biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp wall street be also hope more visibility part financial structure pfizer create be widely see prelude split pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be bristol myer opdivo focusalso report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction merck fight patent cliffmerck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week merck stock hasn be do well lately rs rating just be fraction afternoon trading monday teva drama continueson thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say market be not pleased afternoon trading monday teva stock be mylan stock be nearly follow amy reeve twitter ibd_areeve
1208,PFE,tech stock take early control friday market post mixed launch solid trade
1209,PFE,nasdaq jump climb well new territory year high dow jone industrial average slip add leave still february high
1210,PFE,volume rise stock market today nasdaq higher nyse compare trade same time thursday
1211,PFE,commerce department report open durable good order jump march largest gain month car aircraft sale drive gain easily top expectation transportation order slip vs projection gain
1212,PFE,stock microsoft msft lead dow solid fiscal report late thursday analyst upgrade friday morning dow stock boee ba mmm nike nke pfizer pfe drag loss nearly
1213,PFE,top nasdaq amazon com amzn punch new high commerce giant report better expect revenue share loss line estimate growth cloud service unit report separately first time also beat expectation gain put stock buy point chart pattern be month cup handle handle be also week flat base
1214,PFE,ibd stock moved generally higher open gain be fairly modest
1215,PFE,akorn akrx noah holding noah lead early advance rise
1216,PFE,noah be extend tear new high akorn be buy range less buy point late stage cup base
1217,PFE,bottom ibd list biogen biib tumble first quarter sale earning come short consensus estimate loss send drugmaker week move average heavy trade tech stock take early control friday market post mixed launch solid trade nasdaq jump climb well new territory year high dow jone industrial average slip add leave still february high volume rise stock market today nasdaq higher nyse compare trade same time thursday commerce department report open durable good order jump march largest gain month car aircraft sale drive gain easily top expectation transportation order slip vs projection gain stock microsoft msft lead dow solid fiscal report late thursday analyst upgrade friday morning dow stock boee ba mmm nike nke pfizer pfe drag loss nearly top nasdaq amazon com amzn punch new high commerce giant report better expect revenue share loss line estimate growth cloud service unit report separately first time also beat expectation gain put stock buy point chart pattern be month cup handle handle be also week flat base ibd stock moved generally higher open gain be fairly modest akorn akrx noah holding noah lead early advance rise noah be extend tear new high akorn be buy range less buy point late stage cup base bottom ibd list biogen biib tumble first quarter sale earning come short consensus estimate loss send drugmaker week move average heavy trade
1218,PFE,share teva pharmaceutical industry teva abruptly rebound friday afternoon report drugmaker be think seriously bidding mylan anonymous source say teva not make offer be evaluate idea have approach adviser subject bloomberg report most wall street have be assume teva be think
1219,PFE,stock close new high again friday nasdaq have break yr slog eye be focuse technology have not be disappoint latest mix be microsoft msft trade amazon amzn post strong earning report add more fuel
1220,PFE,stock close flourish thursday volume dwindle exchange accord preliminary datum
1221,PFE,nasdaq rise dow jone industrial average gain stock market today
1222,PFE,generic drugmaker be top perform group more
1223,PFE,dow component pfizer pfe agree buy hospira hsp member member group premium wednesday close favorable reaction earning report lannett lci teva pharmaceutical teva perrigo prgo also boost group
1224,PFE,akorn akrx generic drugmaker specialty injectable vault base new time high
1225,PFE,oil stock be also strong price barrel west texas intermediate crude finished nearly increase
1226,PFE,ibd stock rise fall best performer be reilly automotive orly auto part retailer report better expect earning morning roar flat base heavy volume
1227,PFE,worst performer be synchronoss technology sncr stock initially jump reaction earning report then finished more heavy volume move put serious crimp right side potential base
1228,PFE,good gain dupont dd pfizer visa help boost dow
1229,PFE,gopro gpro twitter twtr linkedin lnkd buffalo wild wing bwld expedia expe be company report earning hour stock close flourish thursday volume dwindle exchange accord preliminary datum nasdaq rise dow jone industrial average gain stock market today generic drugmaker be top perform group more dow component pfizer pfe agree buy hospira hsp member member group premium wednesday close favorable reaction earning report lannett lci teva pharmaceutical teva perrigo prgo also boost group akorn akrx generic drugmaker specialty injectable vault base new time high oil stock be also strong price barrel west texas intermediate crude finished nearly increase ibd stock rise fall best performer be reilly automotive orly auto part retailer report better expect earning morning roar flat base heavy volume worst performer be synchronoss technology sncr stock initially jump reaction earning report then finished more heavy volume move put serious crimp right side potential base good gain dupont dd pfizer visa help boost dow gopro gpro twitter twtr linkedin lnkd buffalo wild wing bwld expedia expe be company report earning hour
1230,PFE,mainstay large cap growth fund be roll portfolio be month end go tuesday be fund large cap growth rival track morningstar inc averaged gain mainstay mutual fund recent gain top own relative performance past
1231,PFE,be year hepatitis immunotherapy cancer produce biggest drug launch be shape be quite different cancer be still big field hep be take back seat cholesterol other cardiology drug make comeback several drug launch year eventually cross blockbuster threshold
1232,PFE,negative energy be term hear yoga class corporate america negative energy sector be several factor expect have drag first quarter earning entire probably first overall profit fall index energy sector alone be expect post staggering year year decline
1233,PFE,analyst have forecast sizable decline gdp growth follow surge see fastest pace growth growth be well consensus pace export growth slow considerably likely thank stronger dollar dollar rise sharply year pressure
1234,PFE,big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close
1235,PFE,pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half
1236,PFE,hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday
1237,PFE,addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young
1238,PFE,gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product
1239,PFE,fewer player more power
1240,PFE,generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover
1241,PFE,purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market
1242,PFE,hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook
1243,PFE,pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business
1244,PFE,also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year
1245,PFE,deal develop
1246,PFE,newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time
1247,PFE,astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease
1248,PFE,most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate
1249,PFE,company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product fewer player more power generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year deal developingit newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline
1250,PFE,good clinical trial news rolled lead drugmaker wednesday help buoy group recovery stock market big pharma pfizer pfe say early wednesday have stop phase trial drug ibrance early have already hit endpoint patient metastatic breast cancer ibrance be fda approve february base similarly
1251,PFE,apple cash hoard jump say moody investor service apple have also pile debt support share buyback dividend program
1252,PFE,apple cash hand again rank top company moody say research report apple now also hold more debt tech heavyweight ibm ibm oracle orcl microsoft msft cisco system csco intel intc accord company report
1253,PFE,apple wednesday prepared new debt sale diving back bond market expect sell bond
1254,PFE,apple be get attractive term pay low interest corporate bond analyst say
1255,PFE,apple be borrow money support share buyback dividend program richard lane senior vice president moody tell ibd
1256,PFE,apple have more long term debt march say moody apple have raise roughly bond market september activist investor carl icahn continue pressure apple step capital return
1257,PFE,most cash overseas
1258,PFE,apple have turn bond market rather use cash mostly hold overseas subject repatriation taxe
1259,PFE,apple cash hoard top microsoft google googl pfizer pfe cisco
1260,PFE,accord moody financial company hold cash end year earlier apple hold total corporate cash year end moody estimate amount cash hold overseas total cash last year
1261,PFE,technology sector hold total financial corporate cash year end
1262,PFE,report fiscal earning april apple announce have expand capital program more return total march iphone maker increase quarterly dividend cent share
1263,PFE,current capital program start apple have return free cash flow fully taxed basis shareholder say investment bank morgan stanley
1264,PFE,investor speak be mixed apple capital allocation program increase investor view share repurchase authorization increase disappointment give perceive deceleration vs historical buyback pace say goldman sachs analyst bill shope research report note apple tend work vast majority buyback year re up april so year view be less relevant
1265,PFE,addition increase be actually acceleration quarter basis relative last year buyback expansion such find hard view new buyback disappointing apple cash hoard jump say moody investor service apple have also pile debt support share buyback dividend program apple cash hand again rank top company moody say research report apple now also hold more debt tech heavyweight ibm ibm oracle orcl microsoft msft cisco system csco intel intc accord company report apple wednesday prepared new debt sale diving back bond market expect sell bond apple be get attractive term pay low interest corporate bond analyst say apple be borrow money support share buyback dividend program richard lane senior vice president moody tell ibd apple have more long term debt march say moody apple have raise roughly bond market september activist investor carl icahn continue pressure apple step capital return most cash overseasapple have turn bond market rather use cash mostly hold overseas subject repatriation taxe apple cash hoard top microsoft google googl pfizer pfe cisco accord moody financial company hold cash end year earlier apple hold total corporate cash year end moody estimate amount cash hold overseas total cash last year technology sector hold total financial corporate cash year end report fiscal earning april apple announce have expand capital program more return total march iphone maker increase quarterly dividend cent share current capital program start apple have return free cash flow fully taxed basis shareholder say investment bank morgan stanley investor speak be mixed apple capital allocation program increase investor view share repurchase authorization increase disappointment give perceive deceleration vs historical buyback pace say goldman sachs analyst bill shope research report note apple tend work vast majority buyback year re up april so year view be less relevant addition increase be actually acceleration quarter basis relative last year buyback expansion such find hard view new buyback disappointing
1266,PFE,share early stage development biotech ligand pharmaceutical lgnd rise disclose receive higher royalty rate drug license partner vike therapeutic friday re file term ipo compound cover amend licensing agreement be meant treat hip fracture anemia metabolic lipid disorder agreement also amend term upfront payment ligand vike stock vike be complete ipo base vike valuation just prior ipo cap ownership re file ipo offer friday vike plan offer share raise previous plan last year share ligand have indicated earlier filing year have right terminate license agreement april vike have neither complete ipo receive aggregate net proceed least more private financing interview ibd march ligand president matt foehr say vike pending ipo happen mean continue progress group pipeline asset ligand have dozen partner more drug program partner range big pharma company such merck mrk pfizer pfe small startup vike be founder plan list nasdaq symbol vktx aside slash valuation vike have refocuse drug development strategy replace lead underwriter say comment renaissance capital ipohome com note laidlaw co replace roth capital feltl co be co manager
1267,PFE,celldex therapeutic cldx stock be morning trading tuesday biotech company update midstage trial result breast cancer drug late monday result phase trial call emerge glembatumumab vedotin metastatic breast cancer be publish journal clinical oncology celldex say support current trial metric focuse patient
1268,PFE,nasdaq lead stock market lower monday medical stock be rout
1269,PFE,composite close loss hurt large part biotechs
1270,PFE,top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more
1271,PFE,generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector
1272,PFE,akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation
1273,PFE,fall dow jone industrial average give
1274,PFE,small cap loss be even russell slide index close session lows
1275,PFE,volume rise especially nasdaq loser lead winner nyse nasdaq
1276,PFE,medical transportation retail sector be weakest stock market today
1277,PFE,monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive
1278,PFE,several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy nasdaq lead stock market lower monday medical stock be rout composite close loss hurt large part biotechs top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation fall dow jone industrial average give small cap loss be even russell slide index close session lows volume rise especially nasdaq loser lead winner nyse nasdaq medical transportation retail sector be weakest stock market today monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy
1279,PFE,drugmaker pfizer recently do have do past december announce dividend hike
1280,PFE,couple week pfizer pfe hike quarterly cash dividend nearly cent share pfizer dole dividend march shareholder record feb
1281,PFE,rise pfizer dividend have grow more past year distribute be company quarterly dividend stockholder
1282,PFE,dividend increase demonstrate commitment return capital shareholder be support continue confidence business say ceo chairman ian read press release
1283,PFE,new quarterly rate pfizer pay share annual basis have yield third highest medical ethical drug group only uk glaxosmithkline gsk astrazeneca azn have larger dividend yield pfizer be also highest yielding stock dow jone industrial average
1284,PFE,drugmaker have post rise earning year year higher earning be expect pfizer have year earning stability factor scale year stability figure be also low factor indicate steady stream profit
1285,PFE,new york base drug giant be best know lipitor cholesterol medicine viagra erectile dysfunction lyrica prevnar have be top seller lately lyrica be used treat nerve muscle pain prevnar be used prevent pneumonia other disease third quarter lyrica sale grow prevnar
1286,PFE,pfizer poke buy point long saucer consolidation dec reversed lower day fast trade stock have try rebound now nearly back week move average drugmaker pfizer recently do have do past december announce dividend hike couple week pfizer pfe hike quarterly cash dividend nearly cent share pfizer dole dividend march shareholder record feb rise pfizer dividend have grow more past year distribute be company quarterly dividend stockholder dividend increase demonstrate commitment return capital shareholder be support continue confidence business say ceo chairman ian read press release new quarterly rate pfizer pay share annual basis have yield third highest medical ethical drug group only uk glaxosmithkline gsk astrazeneca azn have larger dividend yield pfizer be also highest yielding stock dow jone industrial average drugmaker have post rise earning year year higher earning be expect pfizer have year earning stability factor scale year stability figure be also low factor indicate steady stream profit new york base drug giant be best know lipitor cholesterol medicine viagra erectile dysfunction lyrica prevnar have be top seller lately lyrica be used treat nerve muscle pain prevnar be used prevent pneumonia other disease third quarter lyrica sale grow prevnar pfizer poke buy point long saucer consolidation dec reversed lower day fast trade stock have try rebound now nearly back week move average
1287,PFE,biotech opko health find big pharma partner human growth drug candidate form pfizer monday deal be worth much opko health opk stock be morning trading more month high stock market today deal opko
1288,PFE,big cap biotech ibd stock unite therapeutic have history confound expectation good way almost exactly year food drug administration approve orenitram pill treat pulmonary arterial hypertension pah progressive tighten artery supply lung make remarkable be fda have reject unite
1289,PFE,stock backed early gain be mixed early tuesday investor wrestle jumble economic news
1290,PFE,dow jone industrial average rise add index reach new high nasdaq shed early gain slip
1291,PFE,volume be soft second day tracking nyse nasdaq compare same time monday
1292,PFE,stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october
1293,PFE,personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase
1294,PFE,consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate
1295,PFE,stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq
1296,PFE,retailer be show strength lead dd punch heavy trade stock be buy point double bottom base
1297,PFE,leader be moderately positive third ibd move higher start trade
1298,PFE,asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall stock backed early gain be mixed early tuesday investor wrestle jumble economic news dow jone industrial average rise add index reach new high nasdaq shed early gain slip volume be soft second day tracking nyse nasdaq compare same time monday stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq retailer be show strength lead dd punch heavy trade stock be buy point double bottom base leader be moderately positive third ibd move higher start trade asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall
1299,PFE,goldman sachs upgrade eli lilly lly neutral thursday say big pharma have turn corner fall hard patent cliff investment bank downgrade johnson johnson cite increase drug competition believe lly have turn corner improve margin new product launch drive company earning trough
1300,PFE,akorn akrx be breaking stock market today boost bullish initiation report
1301,PFE,also be get lift optimism more buyout industry pfizer pfe announce thursday buy injectable drug maker hospira hsp
1302,PFE,check video get detail top perform stock akorn buy range
1303,PFE,follow alissa william twitter ibd_awilliam akorn akrx be breaking stock market today boost bullish initiation report also be get lift optimism more buyout industry pfizer pfe announce thursday buy injectable drug maker hospira hsp check video get detail top perform stock akorn buy range follow alissa william twitter ibd_awilliam
1304,PFE,big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close
1305,PFE,pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half
1306,PFE,hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday
1307,PFE,addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young
1308,PFE,gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product
1309,PFE,fewer player more power
1310,PFE,generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover
1311,PFE,purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market
1312,PFE,hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook
1313,PFE,pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business
1314,PFE,also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year
1315,PFE,deal develop
1316,PFE,newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time
1317,PFE,astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease
1318,PFE,most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate
1319,PFE,company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product fewer player more power generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year deal developingit newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline
1320,PFE,stock future show muscle ahead thursday open gain ground hospira tableau software knock morning big gain
1321,PFE,dow future be point fair market value rise future advanced point nasdaq future climb point
1322,PFE,positive premarket action stock market today buck general weakness overseas growth name include nxp semiconductor nxpi reilly automotive orly armour ua barely budge open report result wednesday close
1323,PFE,economic news be mixed bit weak side layoff announce employer rise more january highest level nearly year accord consultant challenger gray christmas be increase job cut december report say new layoff due fall oil price
1324,PFE,jobless claim rise week end january labor department say number be prior week upwardly revise total claim consensus expectation claim week move average dip second straight decline
1325,PFE,preliminary estimate labor department show productivity far upwardly revise estimate economist have expect increase
1326,PFE,commerce department report trade deficit widen december november gap disappointing expectation decrease
1327,PFE,stock action hospira hsp rocket news drug giant pfizer pfe acquire maker injectable drug cash debt pfizer expect cost saving deal anticipate close second half year
1328,PFE,tableau software datum scorched ahead report surge earning leap revenue well consensus forecast stock end wednesday buy point cup handle base
1329,PFE,keurig green mountain gmcr slump fiscal first quarter earning management ratchete earning forecast consensus expectation trim full year ep expectation stock have be fall late november end wednesday converge week move average
1330,PFE,globally market be generally show modest loss europe lead index be mild pressure midday top index tokyo shanghai end lower hong kong hang seng index add greece be standout athen athex composite diving european central bank say longer extend loan base greek bond collateral
1331,PFE,dollar be mixed yen lower vs euro oil price come back bit snuffing day rally wednesday benchmark west texas intermediate climb barrel europe brent crude be gold dip fraction ounce stock future show muscle ahead thursday open gain ground hospira tableau software knock morning big gain dow future be point fair market value rise future advanced point nasdaq future climb point positive premarket action stock market today buck general weakness overseas growth name include nxp semiconductor nxpi reilly automotive orly armour ua barely budge open report result wednesday close economic news be mixed bit weak side layoff announce employer rise more january highest level nearly year accord consultant challenger gray christmas be increase job cut december report say new layoff due fall oil price jobless claim rise week end january labor department say number be prior week upwardly revise total claim consensus expectation claim week move average dip second straight decline preliminary estimate labor department show productivity far upwardly revise estimate economist have expect increase commerce department report trade deficit widen december november gap disappointing expectation decrease stock action hospira hsp rocket news drug giant pfizer pfe acquire maker injectable drug cash debt pfizer expect cost saving deal anticipate close second half year tableau software datum scorched ahead report surge earning leap revenue well consensus forecast stock end wednesday buy point cup handle base keurig green mountain gmcr slump fiscal first quarter earning management ratchete earning forecast consensus expectation trim full year ep expectation stock have be fall late november end wednesday converge week move average globally market be generally show modest loss europe lead index be mild pressure midday top index tokyo shanghai end lower hong kong hang seng index add greece be standout athen athex composite diving european central bank say longer extend loan base greek bond collateral dollar be mixed yen lower vs euro oil price come back bit snuffing day rally wednesday benchmark west texas intermediate climb barrel europe brent crude be gold dip fraction ounce
1332,PFE,stock take hold solid early gain soft trade thursday
1333,PFE,dow jone industrial average jump nasdaq climb
1334,PFE,stock market today open positive foot little support economic report challenger gray christmas report layoff spiked year high january labor department say jobless claim also rise less expect productivity fall more forecast labor cost increase more double expect rate
1335,PFE,oil price keep most early gain benchmark west texas intermediate crude rebound not quite wednesday tumble
1336,PFE,stock early rock star be hospira hsp drug giant pfizer pfe say acquire illinois base maker injectable drug deal pfizer share rise lead dow
1337,PFE,tableau software datum spiked report surge earning leap revenue well consensus forecast move drive share month high past buy point cup handle base
1338,PFE,reilly automotive orly lead nasdaq ibd list rise fourth quarter result earning revenue guidance top consensus expectation management full year earning guidance stop short analyst projection thursday gap gain send share past buy point flat base
1339,PFE,ibd issue akorn akrx do not report quarterly result blast gain anyway send share almost past buy point fresh high
1340,PFE,keurig green mountain gmcr lead nasdaq downside diving fiscal first quarter earning fall penny short forecast loss left share lowest level stock take hold solid early gain soft trade thursday dow jone industrial average jump nasdaq climb stock market today open positive foot little support economic report challenger gray christmas report layoff spiked year high january labor department say jobless claim also rise less expect productivity fall more forecast labor cost increase more double expect rate oil price keep most early gain benchmark west texas intermediate crude rebound not quite wednesday tumble stock early rock star be hospira hsp drug giant pfizer pfe say acquire illinois base maker injectable drug deal pfizer share rise lead dow tableau software datum spiked report surge earning leap revenue well consensus forecast move drive share month high past buy point cup handle base reilly automotive orly lead nasdaq ibd list rise fourth quarter result earning revenue guidance top consensus expectation management full year earning guidance stop short analyst projection thursday gap gain send share past buy point flat base ibd issue akorn akrx do not report quarterly result blast gain anyway send share almost past buy point fresh high keurig green mountain gmcr lead nasdaq downside diving fiscal first quarter earning fall penny short forecast loss left share lowest level
1341,PFE,pump strengthen collapse crude oil price weaker economy overseas dollar be flex muscle result weaker earning guidance company international exposure
1342,PFE,procter gamble pg say tuesday outlook entire year be cloud foreign exchange company expect reduce annual sale net earning cincinnatus base consumer good giant get third revenue outside america dollar be strong export be more expensive overseas sale translate fewer greenback share fall tuesday pfizer pfe part blame stronger dollar sullen forecast largest drugmaker expect full year adjust earning less analyst thought see sale slightly less wall street view share fall tuesday less general market other drug company also be absorb forex hit basel base novartis nvs be wrestling strong dollar swiss franc shot month currency cap be lift buoy increase consumer confidence lower gasoline price economy have be outperform rest world europe cope deflation japan brazil endure recession china grow slower clip russia petro economy face cheap oil western sanction ukraine result dollar rise vs major trading partner biggest gain global financial crisis spur brief stampede dollar denominate asset jan dollar index be whopping higher average turbocharge central bank easing world ruble have lose half value dollar past year yen lose euro british pound chinese yuan loosely peg dollar flattened last year gain strength slowly recent year analyst see cause optimism especially give oil price dramatic fall be question cheaper energy be windfall consumer worldwide weaken eurozone currency do bode well profit say robert keiser vice president capital iq theory yes theory global macroeconomic outlook be improve reality theory hasn catch yet many company reliant overseas sale dollar be substantial headwind dupont dd cfo nick fanandakis say tuesday conference call figure forex take cent profit estimate share year analyst expect share fall pfizer novartis bristol myer squibb bmy expect foreign exchange rate cut revenue ep cent bristol guide full year sale ep share fall tuesday hard measure dollar impact overall large cap company tend have heavy overseas exposure handle accounting foreign revenue vary firm firm easier analyze effect collapse oil price corporate america earning be track rise be nearly exclude energy sector say gregory harrison senior analyst thomson reuter
1343,PFE,yesterday note today be quiet day ahead rest week be packed datum look retest last week high ish fail quiet be fail do yesterday morning market trade right open bell test high last week
1344,PFE,regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm
1345,PFE,jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak
1346,PFE,ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market
1347,PFE,pre emptive drug price war
1348,PFE,everyone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline
1349,PFE,be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter
1350,PFE,paz comment seem allude widespread perception street pcsk be basically similar
1351,PFE,regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just
1352,PFE,schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not
1353,PFE,regeneron eylea sale bright
1354,PFE,presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus
1355,PFE,also guide expense item tend do lieu earning be heavily affected option expense
1356,PFE,range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation
1357,PFE,regeneron stock rise nearly intraday reversed overall market close day move average
1358,PFE,separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation
1359,PFE,expect isrg share move higher morning continue believe worst be isrg henry write note market open
1360,PFE,be right first part intuitive surgical rise intraday stock retreat afternoon close regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market pre emptive drug price wareveryone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter paz comment seem allude widespread perception street pcsk be basically similar regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not regeneron eylea sale brightat presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus also guide expense item tend do lieu earning be heavily affected option expense range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation regeneron stock rise nearly intraday reversed overall market close day move average separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation expect isrg share move higher morning continue believe worst be isrg henry write note market open be right first part intuitive surgical rise intraday stock retreat afternoon close
1361,PFE,share puma biotechnology be morning trading stock market today company say late tuesday file fda approval first drug year later expect
1362,PFE,puma pbyi say file approval breast cancer drug neratinib first quarter previously say file first half reason be company want approval earlier stage breast cancer previously plan mean patient take drug longer metastatic case puma have originally target change lead fda ask preclinical datum much drug induce cancer long term use
1363,PFE,neratinib drug pfizer pfe be so uninterested license puma turn be summer surprise hit solidly outperformed placebo extend adjuvant therapy be give patient year initial treatment surgery
1364,PFE,discovery drive stock july not only prospect neratinib prospect puma buyout target
1365,PFE,however last month trial putt neratinib head head market leader roche rhhby herceptin do not break favor neratinib knock nearly stock tuesday new setback induced leerink analyst howard liang reduce price target keep outperform rating expect drug be approve eventually
1366,PFE,risk carcinogenicity study derail appear low base good correlation mutagenicity clean date neratinib carcinogenicity surprisingly large number approve adjuvant breast cancer agent show positive carcinogenicity liang write research note wednesday key question stock likely be partner strategic discussion proceed carcinogenicity datum become available believe be likely base perceive be low risk carcinogenicity study approval
1367,PFE,follow amy reeve twitter ibd_areeve share puma biotechnology be morning trading stock market today company say late tuesday file fda approval first drug year later expect puma pbyi say file approval breast cancer drug neratinib first quarter previously say file first half reason be company want approval earlier stage breast cancer previously plan mean patient take drug longer metastatic case puma have originally target change lead fda ask preclinical datum much drug induce cancer long term use neratinib drug pfizer pfe be so uninterested license puma turn be summer surprise hit solidly outperformed placebo extend adjuvant therapy be give patient year initial treatment surgery discovery drive stock july not only prospect neratinib prospect puma buyout target however last month trial putt neratinib head head market leader roche rhhby herceptin do not break favor neratinib knock nearly stock tuesday new setback induced leerink analyst howard liang reduce price target keep outperform rating expect drug be approve eventually risk carcinogenicity study derail appear low base good correlation mutagenicity clean date neratinib carcinogenicity surprisingly large number approve adjuvant breast cancer agent show positive carcinogenicity liang write research note wednesday key question stock likely be partner strategic discussion proceed carcinogenicity datum become available believe be likely base perceive be low risk carcinogenicity study approval follow amy reeve twitter ibd_areeve
1368,PFE,big pharma merck mrk agree buy antibiotic specialist cubist pharmaceutical cbst monday deal value cubist soar stock market today merck drop fraction
1369,PFE,merck be acquire cubist share cash yielding equity value net debt merck say buyout add more annually revenue base be currently expect have impact earning be accretive
1370,PFE,cubist founder score first blockbuster drug launch cubicin powerful antibiotic used treat staphylococcus aureus severe skin infection end cubicin patent loom company announce ambitious plan launch product expect double revenue turn profit growth negative year however june launch sivextro skin infection drug growth return be expect ramp next year
1371,PFE,rumor merck cubist be talk first break friday leave analyst weekend ponder implication note sunday rbc capital market analyst adnan butt note second new drug zerbaxa be expect be approve dec bring peak annual sale also note way company fit together
1372,PFE,mrk other large biopharma company participate infectious disease arena include actavis act astella pfizer pfe sanofi sny butt write mrk have specifically report focus acute care hospital channel particularly antibiotic resistant bacterium
1373,PFE,press release monday underline merck commitment area
1374,PFE,hospital be central hub health care delivery world currently represent overall health care spend say merck believe now be optimal time significantly grow hospital acute care presence positive regulatory reimbursement trend hospital set increasingly important role hospital be expect provide health care overall
1375,PFE,follow amy reeve twitter ibd_areeve big pharma merck mrk agree buy antibiotic specialist cubist pharmaceutical cbst monday deal value cubist soar stock market today merck drop fraction merck be acquire cubist share cash yielding equity value net debt merck say buyout add more annually revenue base be currently expect have impact earning be accretive cubist founder score first blockbuster drug launch cubicin powerful antibiotic used treat staphylococcus aureus severe skin infection end cubicin patent loom company announce ambitious plan launch product expect double revenue turn profit growth negative year however june launch sivextro skin infection drug growth return be expect ramp next year rumor merck cubist be talk first break friday leave analyst weekend ponder implication note sunday rbc capital market analyst adnan butt note second new drug zerbaxa be expect be approve dec bring peak annual sale also note way company fit together mrk other large biopharma company participate infectious disease arena include actavis act astella pfizer pfe sanofi sny butt write mrk have specifically report focus acute care hospital channel particularly antibiotic resistant bacterium press release monday underline merck commitment area hospital be central hub health care delivery world currently represent overall health care spend say merck believe now be optimal time significantly grow hospital acute care presence positive regulatory reimbursement trend hospital set increasingly important role hospital be expect provide health care overall follow amy reeve twitter ibd_areeve
1376,PFE,big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock
1377,PFE,tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment
1378,PFE,aggressively prepare
1379,PFE,study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far
1380,PFE,interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom
1381,PFE,william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail
1382,PFE,probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success
1383,PFE,early treatment be key
1384,PFE,biogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient
1385,PFE,good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year
1386,PFE,bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward
1387,PFE,caution past failure
1388,PFE,nonetheless yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point
1389,PFE,expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment aggressively prepare study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success early treatment be keybiogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward caution past yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write
1390,PFE,greater boston area have see influx fast grow biotechs biogen idec biib have be take lab space trend drive vacancy rate big way way biotech sector be surge ibd medical biom biotech industry group rank ibd track greater boston biotech company
1391,PFE,come develop cut edge real estate big pharma tech firm alexandrium real estate equity ceo joel marcus have refine try true formula start marcus back alexandrium be be real estate investment trust focuse develop science technology campuse top urban cluster adjacent lead academic medical institution order create collaborative environment company activity be center science hub such cambridge mass san francisco bay area san diego new york city platform focus irreplaceable urban innovation center marcus tell ibd re great place recruit talent transportation be good have work play environment add try own operate dominate market irreplaceable market facility be high tech advanced say include kind infrastructure company need do research development take campus location state art facility marry intersection science technology marcus say really be secret success build big namesusing approach alexandrium have develop campuse drugmaker such eli lilly lly novartis nvs pfizer pfe ibd leaderboard stock illumina ilmn genetic testing equipment maker year mark alexandrium anniversary company have have plenty cause celebrate earning have start grow again double digit increase past quarters gain end third quarter earning rise share analyst poll thomson reuter expect earning rise share follow decline prior year see rise increase alexandrium stock price have lift year be fuel growth marcus say alexandrium have several factor work favor re very good economic environment fed have keep interest rate low ve see substantially rise rent urban innovation market say also constrain supply demand re see life science tech sector be highest level ve see year history company marcus add company be see strong internal growth drive high occupancy increase rental rate core market cambridge san francisco new york alexandrium have pipeline project construction be lease negotiation say marcus highest pre lease level alexandrium have have company have pipeline project put play say add pipeline help drive strong demand continue earning next few year marcus used work capital market lawyer founder alexandrium address real estate infrastructure need biotech industry say be unfilled time have first mover advantage almost market real estate development say focus urban innovation campuse else really do healthy outlook rbc capital market analyst michael carroll say competitor be biom realty trust bmr reit focuse provide real estate life science industry other reit also dabble space add location alexandrium campuse urban cluster market differentiate factor carroll say macro environment life science industry look good re start see pharma tenant used own own real estate other location be find re get better result term ability do research collaborate more person industry move core cluster market own other landlord alexandrium have be able create cluster market campuse major market carroll add now tech tenant be find atmosphere re get demand tech tenant too say recent tech project announce september be strategic partnership app developer uber technology low fare ride sharing service have catch taxi alternative project include acquisition key parcel mission bay area san francisco deal uber parcel support rentable square foot new ground facility joint venture be own alexandrium uber let uber expand corporate headquarters san francisco conjunction year lease entire project alexandrium be expect break ground project january finish end mission bay be home campus university california san francisco well alexandrium science technology cluster be recently select house future arena golden state warrior nba marcus say uber venture be very significant have very strong yield shareholder reap benefit great cash flow represent milestone bring more tech company mission bay historically be more life science destination marcus add carroll also call venture uber significant lot demand area mission bay south market soma san francisco market cap alexandrium be smaller company ibd finance property reit industry group largest be simon property group spg market cap group rank performance ibd track medical ethical drug industry group several alexandrium customer reside rank medical biom biotech rank
1392,PFE,now allure tax inversion deal company have be damp wall street be wonder pfizer pfe sweeten takeover bid astrazeneca azn new rule almost entirely remove benefit astrazeneca ceo pascal soriot say conference call thursday make tax inversion much less attractive pfizer make
1393,PFE,merck mrk cholesterol drug vytorin ezetimibe simvastatin combo successfully cut risk heart attack stroke high risk patient more simvastatin alone say drugmaker nearly decade long patient study improve patient take ldl cholesterol lower medicine vytorin combine simvastatin nonstatin zetia ezetimibe experience significantly fewer major cardiovascular event measure
1394,PFE,cash be king then information technology sector get crown big lead microsoft msft tech company account cash short term investment hold end third quarter tech sector have cash equivalent health
1395,PFE,stock stumble start gate modest loss friday receive support december consumer sentiment datum
1396,PFE,dow jone industrial average drop nasdaq dip
1397,PFE,volume rise stock market today rise nasdaq nyse compare trade same time thursday
1398,PFE,open labor department report producer price dip november slightly more expect be flat energy food hand say inflation be not issue economy other hand show producer wield price strength suggest limp demand
1399,PFE,university michigan deliver more positive news raise preliminary estimate december consumer sentiment index gauge highest level year be nice jump november read well past analyst estimate small uptick
1400,PFE,energy related stock crowd bottom drill contractor nabor industry nbr oil producer newfield exploration nfx apiece dow loss be more ecumenical chevron cvx dupont dd caterpillar cat pfizer pfe more
1401,PFE,adobe system adbe kick lead nasdaq struggle design publish software developer report late thursday fiscal fourth quarter sale earning best analyst estimate also announce pay acquire privately hold stock photography fotolium stock have be consolidate june
1402,PFE,leader rolled weak start more ibd stock dip start trade
1403,PFE,spirit airline save be main holdout more early action left budget airline still more week week line support
1404,PFE,loss ibd list be generally modest stock lose less distinction largest decline go unite rental uri equipment rental chain hover loss pin converge week move average not quite cup handle buy point stock stumble start gate modest loss friday receive support december consumer sentiment datum dow jone industrial average drop nasdaq dip volume rise stock market today rise nasdaq nyse compare trade same time thursday open labor department report producer price dip november slightly more expect be flat energy food hand say inflation be not issue economy other hand show producer wield price strength suggest limp demand university michigan deliver more positive news raise preliminary estimate december consumer sentiment index gauge highest level year be nice jump november read well past analyst estimate small uptick energy related stock crowd bottom drill contractor nabor industry nbr oil producer newfield exploration nfx apiece dow loss be more ecumenical chevron cvx dupont dd caterpillar cat pfizer pfe more adobe system adbe kick lead nasdaq struggle design publish software developer report late thursday fiscal fourth quarter sale earning best analyst estimate also announce pay acquire privately hold stock photography fotolium stock have be consolidate june leader rolled weak start more ibd stock dip start trade spirit airline save be main holdout more early action left budget airline still more week week line support loss ibd list be generally modest stock lose less distinction largest decline go unite rental uri equipment rental chain hover loss pin converge week move average not quite cup handle buy point
1405,PFE,didn take long major buyout have positive impact mineral technology financial result wall street take note specialty mineral producer blowout third quarter mineral technology mtx share rise session period begin set new close high session end close peak oct company sprint past earning view see revenue more double prior year big driver gain be buyout amcol international illinois base producer bentonite clay deal come mineral technology win bidding war amcol imerys french industrial material firm addition amcol fattened top line widen company footprint new geography product category paper business mti short mineral technology inc include segment specialty mineral refractory performance material construction technology energy service be probably best know world largest producer precipitate calcium carbonate pcc used manufacture paper pcc business account mti revenue amcol acquisition expand mti business couple front ceo joseph muscari tell ibd give more diversification mineral so be stay close know also help geographic expansion standpoint re able do more term leverage resource have india china thailand indonesia south america addition amcol help mti deliver muscari call highest quarter ever mti date back be spun pfizer pfe oct mti logged earning share cent prior year well consensus estimate sale more double research note jpmorgan analyst jeffrey zekauskas say mti operate income exceed own forecast reflect better expect operate performance cost synergy acquire amcol division mti be month ahead schedule term cost saving amcol buyout zekauskas note much work ahead be focuse improve amcol operation believe be large runway mti improve business process company say amcol plant run very low level capacity utilization overhead cost be relatively high ceo muscari say sharp rise mti stock price follow earning release be partly due way have handled amcol acquisition hadn do acquisition size so investor see be able do very well synergy be fall bottom line next year be go be very focuse integrate amcol capture synergy mti also eye big thing amcol main product bentonite boast diverse number end used range cat litter construction product bonding metal casting latter category show particular promise muscari say particularly china china be largest cast produce market world amcol have good market share china market continue grow grow more half mti revenue come come europe africa asia market contribute only total figure be likely move much higher come year mti look grow presence region china india be top list term geographic expansion southeast asia brazil muscari say have be china so have very well establish management india didn even have position paper pcc year today have relatively high market share paper maker effortsone way mti boost market share be product development particularly pcc business company research development effort focus help customer save money produce higher quality product reduce pollution muscari point mti fulfill brand high filler technology be design let manufacturer put more filler paper less pulp save money new product market help mti expand top line company bottom line get boost restructure program mainly involve reduce workforce accord mti earning release restructure occur business segment be estimate provide annualize saving analyst poll thomson reuter expect mti report full year earning share prior year see ep rise mineral technology belong ibd chemical specialty group largest stock group market cap be praxair px air product chemical apd sigma aldrich sial
1406,PFE,big cap biotech amgen amgn beat wall street third quarter estimate guide full year earning bit consensus monday send recently hot stock hour trading amgen earning exclude time item rise year quarter share beating analyst consensus cent accord thomson reuter sale increase ahead estimate conference call discuss result ceo robert bradway note last year include order anemia drug neupogen government inflate quarter sale back sale growth be consistent first half year sale neulasta drug stimulating white blood cell beat consensus more be last year third quarter be drive price increase more volume accord amgen story be virtually identical anemia drug epogen sale rise last year also price reason total analyst have expect rheumatoid arthritis drug enbrel miss estimate dip sale unit grow year year call cfo david meline remind analyst have see inventory build be burn mask strength demand nonetheless enbrel help drive overall profit growth be longer profit sharing agreement pfizer pfe research development spending be more lower analyst consensus sale general administrative spending be also street estimate company add full year revenue guidance now slightly street forecast last year guide full year ep previous range analyst target however imply ep be short street average last year company make share full year fourth quarter conference call meline say amgen be lift tax rate estimate percentage point due uncertainty extension federal tax credit however cowen analyst eric schmidt comment even accounting increase operate expense be imply guidance meline answer expense usually increase end year so be nothing unusual however bradway add company be prepare product launch next year also increase spending most anticipate street be evolocumab first new class cholesterol drug call pcsk analyst expect sale run forecast remain uncertain regeneron pharmaceutical regn be see launch compete product shortly thereafter management keep call short plan hold business review meeting tuesday re expect give longer term outlook company business strategy re also expect address shareholder pressure split part get extra publicity last week daniel loeb hedge fund manager third point capital loeb take idea propose sanford bernstein analyst geoffrey porge june argue make abbott laboratory pfizer splitting establish legacy drug such enbrel newer more innovative product unlock hide value chatter general recovery biotech stock have help drive amgen stock last week regular trading monday hit new high eventually close
1407,PFE,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
1408,PFE,specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition
1409,PFE,investor analyst seem optimistic shire shpg stock be early trading stock market today
1410,PFE,leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say
1411,PFE,additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition
1412,PFE,add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication
1413,PFE,gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity
1414,PFE,bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case
1415,PFE,shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating
1416,PFE,follow amy reeve twitter ibd_areeve specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition investor analyst seem optimistic shire shpg stock be early trading stock market today leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating follow amy reeve twitter ibd_areeve
1417,PFE,fda last month approve first biosimilar drug take first step lucrative potentially disruptive field medicine pfizer pfe be move big biosimilar hospira hsp acquisition have estimate global biosimilar sale hit year sale be just yearly now mainly european union march approval zarxio novartis nvs biosimilar version amgen amgn age blockbuster neupogen market crack open fda become more comfortable re go see biosimilar get lot more easily predict jitendra malik attorney alston bird specialize intellectual property drug approval issue first always hardest get fda be more cautious uncharted territory year biotech revolution not only bring life save new medicine also profit save protection competitor traditional pharmaceutical be assemble machine different chemical ingredient biologic drug be form biological process high tech version fermentation many process be trade secret patent have expiration date reverse engineeringas more company become familiar biotech manufacturing however be able reverse engineer process create biosimilar drug not identical original close enough novartis sandoz unit historically devote traditional generic drug have be pioneer field already selling biosimilar version neupogen sister drug epogen europe many other be line border own product hospira teva pharmaceutical teva have launch own version neupogen europe company be work biosimilar version abbvie abbv blockbuster immunology drug humira include sandoz hospira pfizer prior acquire hospira amgen german pharma giant boehringer ingelheim abbvie announce richly price acquisition pharmacyclic pcyc march analyst figured be drive need blockbuster face humira competitor key biologic face rivalsother drug biosimilar version late stage testing include biogen biib cancer drug rituxan roche rhhby breast cancer treatment herceptin johnson johnson jnj remicade merck mrk be develop biosimilar version sanofi sny popular diabetes drug lantus hospira biosimilar version remicade already have be approve europe be expect be february fda delay advisory panel meeting product due information request pending sponsor application analyst be closely watch biosimilar rollout europe remicade be approve variety ailment psoriasis inflammatory bowel disease ibd rheumatoid arthritis provide test case willing different specialist be use knockoff independent study iosimilar remicade be approve study account remicade sale write leerink analyst jason gerberry december research report specialist ve speak do not plan use remicade ibd indication clinical study report late europe biosimilar version neupogen have take market analyst generally expect same much depend drug be price generic pharmaceutical generally go fraction original drug price drive retail value so much original developer stop marketing product do keep manufacturing biosimilar be more difficult expensive develop so be fewer player less pricing competition novartis still hasn launch zarxio be keep mum price company spokeswoman geena wardaki tell investor business daily email biosimilar general typically expect discount be range reference biologic however depend therapeutic area market channel number competitor reimbursement situation cms vs fda biosimilarson tuesday center medicare medicaid service cms announce physician prescribe medicare part drug be reimburse biosimilar same way original drug average selling price pharmacy dispense part drug exclude original list prefer drug favor biosimilar wish so long provide transitional supply original patient already take imply cms be treat biosimilar effectively interchangeable original further muddy issue already unclear fda rule zarxio be used used approve neupogen boost blood cell various kind cancer patient not technically interchangeable mean doctor prescribe original drug pharmacy fill biosimilar doesn matter so much zarxio drug be administer hospital clinic rather retail pharmacy nonetheless drugmaker find worthwhile file separately approval likely involve study patient switch product say expert matter be deterrent second person come say malik show product be interchangeable doesn necessarily mean applicant road do same thing just piggybac lot case structure original drug be not perfectly know do have spend time convince person same yet question be aggressive payer pharmacy benefit manager pbms be push biosimilar ahead original drug save cost march report analyst gerberry write unnamed payer specialist have tell payer probably leave grace period month doctor get used biosimilar then start lean harder specialist expect policy grandfather stable patient receive tnf therapy remicade same reimbursement new patient new switch likely be require go prior authorization require patient use biosimilar first write gillian woollett senior vice president consult firm avalere health say issue be naming company develop new drug get generic also call nonproprietary name brand name generic name filgrastim case neupogen be used generic drugmaker patent expire name many biologic approve fda even have never be compare also share nonproprietary name be simply name active ingredient not name product biosimilar most other market share nonproprietary name reference product too first approval fda assign maker placeholder nonproprietary name case filgrastim sndz naming thing be important space watch woollett tell investor business daily think be go be brand product biosimilar most originator biologic have brand name again generic drug situation be totally different most generic do not have brand name
1418,PFE,medical product giant baxter international bax beat earning estimate lift organic sale growth guidance thursday lower ep outlook due divestiture stock initially drop early afternoon be fraction stock market today
1419,PFE,baxter sale rise year earlier quarter line analyst consensus earning climb share beating estimate cent
1420,PFE,baxter lift organic sale guidance percentage point range now however knock cent ep range be now reflect sale vaccine business pfizer pfe
1421,PFE,leerink analyst danielle antalffy note baxter hemophilia franchise grow double digit new long act rival biogen idec biib be launch earlier year
1422,PFE,represent potential early signal bax advate fact hold share better expect competitive long act product come market antalffy write flash note thursday morning give stock lackluster performance year date expect share outperform today
1423,PFE,stock have indeed be slide several month hit month low wednesday
1424,PFE,baxter be plan split mid biopharma business spin name baxalta original baxter continue sell medical equipment rbc capital market analyst glenn novarro note side business perform solidly quarter biotherapeutic industry underperform compare international counterpart
1425,PFE,follow amy reeve twitter ibd_areeve medical product giant baxter international bax beat earning estimate lift organic sale growth guidance thursday lower ep outlook due divestiture stock initially drop early afternoon be fraction stock market today baxter sale rise year earlier quarter line analyst consensus earning climb share beating estimate cent baxter lift organic sale guidance percentage point range now however knock cent ep range be now reflect sale vaccine business pfizer pfe leerink analyst danielle antalffy note baxter hemophilia franchise grow double digit new long act rival biogen idec biib be launch earlier year represent potential early signal bax advate fact hold share better expect competitive long act product come market antalffy write flash note thursday morning give stock lackluster performance year date expect share outperform today stock have indeed be slide several month hit month low wednesday baxter be plan split mid biopharma business spin name baxalta original baxter continue sell medical equipment rbc capital market analyst glenn novarro note side business perform solidly quarter biotherapeutic industry underperform compare international counterpart follow amy reeve twitter ibd_areeve
1426,PFE,valeant pharmaceutical battle marry allergan end be left altar jury be still outcome takeover fight drug giant have unfold poorly script soap opera valeant vrx monday hint ante botox
1427,PFE,biotech alnylam alny report positive midstage trial result drug candidate patisiran monday send stock month high stock market today
1428,PFE,phase trial test patisiran familial amyloidotic polyneuropathy fap rare degenerative disease nervous system researcher used neuropathy impairment score track progress disease
1429,PFE,open label study patisiran be very encourage see believe be evidence possible stabilization neuropathy progression first month treatment alnylam chief medical officer akshay vaishnaw say statement indeed believe approximate point decrease neuropathy impairment score be encourage result light multiple historical datum set have predict increase point untreated patient similar baseline characteristic
1430,PFE,leerink analyst michael schmidt note study be small result be replicate larger phase trial now process be home run scenario view write research note monday
1431,PFE,schmidt also note knockdown transthyretin ttr serum cerebrospinal fluid be genetically mutate fap sufferer turn fibrous tissue call amyloid
1432,PFE,key opinion leader speak also note strong mechanistic rationale patisiran key differentiation stabilizer such diflunisal merck mrk dolobid tafamidis pfizer pfe vyndaqel be thought prevent ttr be converted amyloid actually unknown degree drug achieve write ultimately kol use stabilizer addition ttr knockdown approach give synergistic potential
1433,PFE,alnylam be develop patisiran collaboration sanofi sny genzyme unit have right outside north america western europe sanofi stock be fraction afternoon trading monday
1434,PFE,follow amy reeve twitter ibd_areeve biotech alnylam alny report positive midstage trial result drug candidate patisiran monday send stock month high stock market today phase trial test patisiran familial amyloidotic polyneuropathy fap rare degenerative disease nervous system researcher used neuropathy impairment score track progress disease open label study patisiran be very encourage see believe be evidence possible stabilization neuropathy progression first month treatment alnylam chief medical officer akshay vaishnaw say statement indeed believe approximate point decrease neuropathy impairment score be encourage result light multiple historical datum set have predict increase point untreated patient similar baseline characteristic leerink analyst michael schmidt note study be small result be replicate larger phase trial now process be home run scenario view write research note monday schmidt also note knockdown transthyretin ttr serum cerebrospinal fluid be genetically mutate fap sufferer turn fibrous tissue call amyloid key opinion leader speak also note strong mechanistic rationale patisiran key differentiation stabilizer such diflunisal merck mrk dolobid tafamidis pfizer pfe vyndaqel be thought prevent ttr be converted amyloid actually unknown degree drug achieve write ultimately kol use stabilizer addition ttr knockdown approach give synergistic potential alnylam be develop patisiran collaboration sanofi sny genzyme unit have right outside north america western europe sanofi stock be fraction afternoon trading monday follow amy reeve twitter ibd_areeve
1435,PFE,go flow be well good rise head shoulder crowd be sign solid stock
1436,PFE,today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index
1437,PFE,china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item
1438,PFE,security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year
1439,PFE,fellow chinese tailer jumei international jmei report wednesday
1440,PFE,chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week
1441,PFE,veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release
1442,PFE,small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis
1443,PFE,idexx laboratory idxx pet livestock health care company recently clear stock buy point
1444,PFE,company report result late october share earning rise share top cent sale grow beating analyst forecast
1445,PFE,related
1446,PFE,invest relative strength line confirm power go flow be well good rise head shoulder crowd be sign solid stock today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year fellow chinese tailer jumei international jmei report wednesday chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis idexx laboratory idxx pet livestock health care company recently clear stock buy point company report result late october share earning rise share top cent sale grow beating analyst forecast related invest relative strength line confirm power
1447,PFE,animal health giant zoetis zts offer guidance street consensus longer term financial goal analyst day tuesday brief halt trading early afternoon announcement stock be more afternoon trading stock market today zoetis say expect ep next year
1448,PFE,april expert diagnosed virus spread quickly america pig have kill more piglet state early summer leadership team animal health company zoetis zts decide develop vaccine porcine epidemic diarrhea virus pedv company chief executive juan ramon alaix declare zoetis
1449,PFE,sometimes drug launch take get ground incyte only approve drug jakafi have be market year really only just get start jakafi sell market jakavi be approve rare bone marrow cancer call myelofibrosis mf thank indication incyte incy revenue be expect pass year compare just year jakafi launch other indication pipeline however really push drug blockbuster territory first expect be approve food drug administration dec be polycythemia vera pv similar somewhat milder disease have potentially larger market meanwhile clinical trial be go really big name cancer pancreatic breast lung colon current consensus estimate have jakafi annual sale hit abroad incyte split take marketing partner novartis nvs sale be expect pass year incyte be base idea research cancer be good investment ceo herve hoppenot tell ibd interview opportunity seizedjakafi be janus associate kinase jak inhibitor regulate signale mechanism cell play important role cell growth immune response jakafi be first jak inhibitor market so far only approve fight cancer pfizer pfe xeljanz approve be also jak inhibitor be used rheumatoid arthritis hoppenot say incyte be originally aim big cancer first mf opportunity unexpectedly come scientist find jak signale play important role disease point company decide move development program very quickly myelofibrosis try prove jak pathway be have impact outcome patient say be able get pivotal study do approval myelofibrosis very rapid way advantage mf market bring firm be small patient pool have other treatment option so incyte have be able market domestically bring big pharma partner thus keep domestic revenue pursue pv be next logical step hoppenot say disease be so similar be disorder mean excess cell be produce bone marrow pv however be much milder sometimes have symptom hoppenot estimate only roughly pv patient be eligible jakafi expect liftoff be fairly slow treat pv isn urgent treat more malignant cancer eventual market be larger mf have fewer sufferer accord leerink estimate disease bring incyte first annual profit next year accord consensus analyst poll thomson reuter incyte turn profit cent share most recently report quarter only milestone payment incyte collect novartis winning reimbursement jakafi europe marketing approval japan start second half next year analyst expect incyte start turn operate profit more consistent way rivalry year however new competition threaten jakafi gilead science gild jak inhibitor momelotinib be late stage trial mf design compare momelotinib jakafi head head result be expect come sometime next year couple smaller player cti biopharma ctic geron gern also have competitor late stage testing nov latter license candidate imetelstat johnson johnson jnj development multiple disease deal potentially worth milestone be realize only datum tell competitive product be incyte have other tool garage incb candidate drug class call ido inhibitor be be test combination most anticipate cancer drug pipeline pd pd inhibitor incyte have partner lead contender field bristol myer bmy astrazeneca azn roche rhhby merck mrk test drug together variety cancer be not licensing deal say hoppenot do mean drug be approve company recommend successful combination drug label incb also garner attention summer american society clinical oncology asco meeting perform well trial combine different related bristol myer drug yervoy treat melanoma leerink analyst michael schmidt write time combo didn appear be effective yervoy combine bristol house pd opdivo do suggest promise combination incb other pd news better expect third quarter report last month induced goldman sachs analyst navdeep singh lift rating incyte neutral sell nearly double price target sell thesis be base more cautious view jakafi launch myelofibrosis mf give safety competition call have not work narrative have shift incy pipeline singh write oct research note add follow newly result asco be more encourage strong underlie growth jakafi mf early datum partnership interest ido inhibitor
1450,PFE,share specialty drugmaker shire plummet stock market today word get late tuesday big pharma abbvie be reconsider buyout company shire shpg confirm report wednesday morning statement say abbvie abbv board intend consider withdraw modify recommendation light
1451,PFE,make sector leader screen stock satisfy criterium ibd slim investing system system stand supply demand regard stock share lead growth stock tend enjoy powerful combination robust demand relatively small float be supply share available trading
1452,PFE,french biotech cellectis cll slip nasdaq debut wednesday close enlarge deal size cellectis sell share price be essentially determine stock be trading alternet market euronext paris exchange company however sell more share have announce just day up plan deal size original rise share count reflect interest car cell therapy branch cancer treatment last month produce very successful ipos juno therapeutic juno kite pharma kite lesser extent bellicum pharmaceutical blcm cellectis however start trading bad day market general biotechs particular ibd medical biom biotech group also fall wednesday still ipo value cellectis be pretty steep drugmaker hasn even start human testing yet company have product animal testing different type blood cancer collaboration pfizer pfe french drugmaker servier follow amy reeve twitter ibd_areeve
1453,PFE,stock finished modestly lower tuesday friday deadline loom greece make euro payment international monetary fund nasdaq fall dow jone industrial average dip volume be lighter monday level nyse nasdaq accord preliminary datum stock market today treasury fall sharply second day do euro speculation greek government european central bank work deal west texas intermediate crude rise nearly close ambarella amba be moderately higher report earning beat estimate adjust ep be cent vs estimate cent analyst have be ratchete price target estimate recent day big customer gopro gpro raise guidance also close guidewire software gwre fall earning miss estimate guidance come light side et wednesday institute supply management release service index economist be forecasting vs april weekly crude oil inventory be announce
1454,PFE,stock remain mixed monday afternoon broader index continue be little change blue chip show life dow jone industrial average rise help gain pfizer pfe apple aapl exxon mobil xom meanwhile edge nasdaq slip volume be run sharply lower nasdaq nyse friday expiration fuel heavy pace sonic sonc ramp new high clear buy point rare ascend base company run drive thru fast food restaurant report fiscal earning tuesday close expect post cent share year red robin gourmet burger rrgb bounce back early weakness rise new high share restaurant operator have be tear come low october rise more stock have yet form proper base february red robin report rise fiscal sale mark biggest gain year well second straight period acceleration technology avgo cool new high trimming gain more half earlier stock market today citigroup raise price target stock be still well extend buy point week tight pattern rebound week move average downside vertex pharmaceutical vrtx be session low still disappointing trial study share be nearly monday low
1455,PFE,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
1456,PFE,actavis have make acquisition transform generic focuse drugmaker bigger player prescription drug now find enviable position thrive home base ireland expect generate revenue be now large diverse enough forge ahead international power pharmaceutical industry yet
1457,PFE,specialty drug giant actavis act say monday acquire biotech startup durata therapeutic cash send durata stock more new high stock market today actavis stock be flat morning trading durata therapeutic drtx lone product be antibiotic acute bacterial skin infection dose intravenously
1458,PFE,monotype imaging holding type lead provider typeface typeface technology have be mission beauty website new better render font now woburn mass base company be look make digital advertising more attractive technology monotype see new opportunity font typeface technology html base web advertising move mainstream adoption html
1459,PFE,stock be mixed head lunch hour monday nasdaq lose be still hold add just fraction time high set february dow jone industrial average add
1460,PFE,volume be tracking well friday level volume friday be unusually heavy due option expiration
1461,PFE,restaurant name be move stock market today
1462,PFE,papa murphy frsh launch higher huge volume company announce plan expand presence southeast
1463,PFE,be clear grow demand papa murphy brand southeast see tremendous opportunity build success grow awareness key underpenetrated area say ceo ken calwell
1464,PFE,fast food chain sonic sonc restaurant operator darden dri also hit new high heavy volume monday
1465,PFE,pfizer pfe pace dow jump heavy volume new multiyear high stock also break past buy point flat base pattern
1466,PFE,pfizer be boost news be resume clinical trial pain treatment tanezumab jeffery also issue upbeat research note raise price target stock
1467,PFE,network security firm cyberark software cybr jump nearly bounce week line heavy trade stock have pull back sharply recent week explosive february stock be mixed head lunch hour monday nasdaq lose be still hold add just fraction time high set february dow jone industrial average add volume be tracking well friday level volume friday be unusually heavy due option expiration restaurant name be move stock market today papa murphy frsh launch higher huge volume company announce plan expand presence southeast be clear grow demand papa murphy brand southeast see tremendous opportunity build success grow awareness key underpenetrated area say ceo ken calwell fast food chain sonic sonc restaurant operator darden dri also hit new high heavy volume monday pfizer pfe pace dow jump heavy volume new multiyear high stock also break past buy point flat base pattern pfizer be boost news be resume clinical trial pain treatment tanezumab jeffery also issue upbeat research note raise price target stock network security firm cyberark software cybr jump nearly bounce week line heavy trade stock have pull back sharply recent week explosive february
1468,PFE,procter gamble pg be say be explore potential sale initial public offer beauty brand say bloomberg news share be still early afternoon trading follow news stock market today monday covergirl pantene olay old spice be just few company beauty brand procter gamble be work adviser have not finalize detail pinpoint specific beauty brand say bloomberg cite source familiar matter not necessarily go separation beauty segment bring company total net sale segment sale dip year global beauty market share edge percentage point vs say procter gamble annual report consumer product giant beauty offering include pamper gillette swiffer company announce last august shave more brand mid opt keep most profitable brand make nearly sale late january share gap more global company say strong dollar affect full year outlook sale cut net earning impact result foreign exchange wo have hurt many american company bring overseas sale range apple aapl priceline pcln pfizer pfe procter gamble remain top dividend stock eye many share continue climb back day day line related james gamble clean household product follow elaine low twitter ibd_elow
1469,PFE,juno therapeutic juno set record most highly value biotech ipo report fourth quarter earning late wednesday miss wall street estimate wide margin
1470,PFE,juno be develop cellular immunotherapy treat leukemia lymphoma used human cell therapeutic recognize cancer cell company say technology have potential revolutionize way cancer be treat
1471,PFE,juno report earning share loss vs consensus estimate cent loss have revenue
1472,PFE,biotech end quarter cash equivalent expect burn cash exclude cash inflow outflow business development activity ongoing litigation
1473,PFE,juno raise dec initial public offer selling share
1474,PFE,stock have be form initial post ipo base deep cup handle pattern share close wednesday report share slide hour trading
1475,PFE,successful round private financing together ipo provide juno financial resource need continue advance product candidate company say
1476,PFE,next month expect have product candidate clinical development direct different cancer associate antigen say juno ceo han bishop statement earning release
1477,PFE,juno peer kite bellicum
1478,PFE,close peer juno be kite pharma kite be also develop immunotherapy cancer treatment kite raise july ipo pricing share stock close wednesday january kite announce partnership amgen amgn worth much
1479,PFE,recent ipo field be bellicum pharmaceutical blcm
1480,PFE,yet new player be come
1481,PFE,france base cellectis wednesday announce plan raise offer american depository receipt cellectis currently trade market euronext paris symbol alcls company be backed pfizer pfe
1482,PFE,cellectis be describe pioneer gene editing company emerge field immuno oncology base gene edit cell seek harness power immune system target eradicate cancer juno therapeutic juno set record most highly value biotech ipo report fourth quarter earning late wednesday miss wall street estimate wide margin juno be develop cellular immunotherapy treat leukemia lymphoma used human cell therapeutic recognize cancer cell company say technology have potential revolutionize way cancer be treat juno report earning share loss vs consensus estimate cent loss have revenue biotech end quarter cash equivalent expect burn cash exclude cash inflow outflow business development activity ongoing litigation juno raise dec initial public offer selling share stock have be form initial post ipo base deep cup handle pattern share close wednesday report share slide hour trading successful round private financing together ipo provide juno financial resource need continue advance product candidate company say next month expect have product candidate clinical development direct different cancer associate antigen say juno ceo han bishop statement earning release juno peer kite bellicuma close peer juno be kite pharma kite be also develop immunotherapy cancer treatment kite raise july ipo pricing share stock close wednesday january kite announce partnership amgen amgn worth much recent ipo field be bellicum pharmaceutical blcm yet new player be come france base cellectis wednesday announce plan raise offer american depository receipt cellectis currently trade market euronext paris symbol alcls company be backed pfizer pfe cellectis be describe pioneer gene editing company emerge field immuno oncology base gene edit cell seek harness power immune system target eradicate cancer
1483,PFE,stock come session high midday friday major index look finish week big gain blue chip lead dow jone industrial average dow stock be higher midday lead proctor gamble pg mmm pfizer pfe rise nasdaq be volume be tracking lower nyse higher nasdaq compare thursday level nasdaq be fractionally day move average provide key test new market uptrend microsoft msft jump heavy volume climb day move average late thursday company report sale earning beat analyst expectation apple aapl be fractionally stock try close higher sixth straight session be buy point flat base medical software provider cerner cern reclaim buy point cup handle base rise average trade chinese commerce giant alibaba baba jump be week stock be just potential buy point ipo base
1484,PFE,year ceo josef von rickenbach have learn not rest laurel know past success doesn guarantee future success most important be have be right leader current time future say von rickenbach co founder chairman chief executive parexel international prxl service
1485,PFE,selling picked pace major average late afternoon trading tuesday dow jone industrial average fall give nasdaq lose nyse nasdaq volume be tracking lower monday level stock market today base astrazeneca azn lose government release new rule fight tax inversion company avoid taxation move headquarters overseas pfizer pfe be talk acquire astrazeneca ireland base shire shpg meanwhile lose be well session lows agree deal illinois base abbvie abbv earlier year china name bounce back recent weakness cheer better expect manufacturing datum china vipshop vip jump nearly try reclaim day move average day line have be resistance level stock drop heavy volume ibd polaris industry pii outperformed rise nearly surge week end july polaris have show positive technical action trading tightly week move average several week polaris be leaderboard name investor comrailroad operator kansa city southern ksu extend loss fall stock be still buy range hold buy point merger news salix pharmaceutical slxp jump report drugmaker be advanced talk be acquire allergan agn potential union have be rumore time allergan be try fend hostile bid valeant pharmaceutical vrx elsewhere cf industry cf clear base rise news news investor com business cf industry yara talk form fertilizer giant htmthat be be court norwegian firm yara international
1486,PFE,corporate tax inversion deal size propose consummate have push global merger acquisition level not see worldwide have be report accord thomson reuter datum most year big jump
1487,PFE,stock finished day moderately nasdaq lower third straight day volume be run lighter previous day accord preliminary figure nasdaq be fall dow jone industrial average drop stock market today ibd stock be higher be lower salix pharmaceutical slxp be top performer more big volume be report allergan agn be talk acquire company allergan be nearly also drugmaker actavis act spiked midday hit new time high chatter pfizer pfe be interested buy worst performer be emerge energy emes plunge day line heavy volume be more stock have nearly triple breaking base march be first trip well support line carmax kmx gap finished nearly lower disappointing quarterly report analyst say subprime lend have be major growth driver company such lend be slow chinese online retailer vipshop vip rise more average volume continue find resistance day move average stock be build new base
1488,PFE,specialty drugmaker salix pharmaceutical announce oct be do something unusual back merger close back july salix slxp have agree acquire cosmo technology irish subsidiary italian drugmaker cosmo pharmaceutical stock swap value deal have allow salix so many
1489,PFE,picking be slim new high list tuesday extend lose streak session salix pharmaceutical slxp jump speculation heated drugmaker be close be buy allergan agn allergan be try thwart hostile takeover valeant pharmaceutical vrx actavis act rise
1490,PFE,generic drug maker ibd stock akorn fourth quarter earning guidance beat wall street estimate send stock new high akorn earning exclude time item jump year earlier cent share top analyst consensus cent accord thomson reuter sale climb
1491,PFE,big pharma abbvie deal acquire hot biotech pharmacyclic be meet widespread skepticism abbvie investor thursday send abbvie stock fall thursday abbvie abbv announce cash stock acquisition late wednesday rumor have be swirl afternoon novartis nvs johnson johnson jnj be engage bidding war pharmacyclic pcyc surprised wall street abbvie turn be buyer especially already have partnership pharmacyclic market blood cancer drug imbruvica doesn really make sense be abbvie prevailing pcyc partner natural buyer jnj secure pcyc pay price do asset bernstein analyst geoffrey porge write research note thursday believe jnj be only buyer able secure operational advantage full control buy partner jnj more other buyer have be able maximize synergy reduce product support single commercial organization cash stock deal value pharmacyclic share stock rise thursday stock trade start year conference call analyst early thursday abbvie ceo richard gonzalez affirm bidding war have come contestant didn name justified price cite enormous market potential imbruvica launch late bring pharmacyclic last year abbvie reckon imbruvica bring firm year peak change exist deal split profit evercore isi say assume total worldwide sale make imbruvica biggest selling cancer drug history say analyst mark schoenebaum analyst consensus sale estimate be bullish not bullish latest year available average estimate be call gonzalez break assumption number growth come expansion imbruvica currently approve used second line treatment chronic lymphocytic leukemia cll mantle cell lymphoma well anytime treatment less common condition cll deletion macroglobulemia additional come expansion first line treatment cll lymphoma gonzalez say have very high probability success give clinical trial datum rest come unspecified amount accounting approval other cancer cell more speculative assumption product also work solid tumor do see datum solid tumor be impressed gonzalez say many analyst view abbvie late stage blood cancer candidate potential competitor imbruvica chief scientific officer michael severino say drug potentially work combination expect launch clinical trial prove general executive say acquisition boost abbvie entire cancer business much be change focus abbvie make fortune immunology blockbuster drug humira however humira likely get biosimilar competition amgen amgn pfizer pfe other patent expire call gonzalez affirm abbvie commitment humira defend patent court develop new improve version drug say have nothing do price paid pharmacyclic analyst porge however say premium here be explain abbvie desperation
1492,PFE,call jack trade biotech rather just target small number drug therapy ligand pharmaceutical lgnd focus broad range asset address host disease multiple myeloma hepatitis alzheimer diabetes anemia osteoporosis many other do early stage development aim partner early say matt foehr president
1493,PFE,interest rate record lows past several year etfs invest dividend pay stock have be popular income alternative investor remain advantageous now federal reserve be seriously consider hike rate depend specific investment objective fund accord michael rawson research analyst morningstar inc look stock high dividend payout typically underperform economy be do well say company usually invest less future growth utility reit consumer staple therefore don participate much economy be grow very rapidly vanguard high dividend yield index etf vym have asset month yield net fee however be tilt value stock note rawson so be not most favorable be economy be grow so investor look consider dividend etf value stock tilt rawson say important consider etf be tilt higher yielding dividend pay stock tend be value stock do tilt stock grow dividend future company be able increase dividend consistently be usually company very strong brand name very strong market position note example be apple aapl yield dividend hasn be steady dividend growth be reason like vanguard dividend appreciation etf vig look company have raise dividend straight year have lower yield focus quality stock thus have slightly bigger exposure growth company addition have razor thin expense ratio have return average annual past year vs advance top holding be wal mart store wmt pepsico pep johnson johnson jnj coca cola ko fed be likely raise rate think vanguard high dividend yield get hurt more vanguard dividend appreciation rawson say element consider be fund tilt size large cap small cap stock ishare select dividend dvy be highest yielding etfs yield fund be tilt midcap deep value stock make more volatile addition expense ratio make more expensive dividend etfs note morningstar analyst abby woodham report fed raise rate investor consider shift stock more bond say rawson reason person usually hold bond be income diversification stability reason dividend etfs be not always good substitute bond etfs be don have stability bond say investor also need be mindful expense be high tend eat yield etf cheapest etf availableschwab dividend equity etf schd be cheapest dividend etfs expense ratio just nearly asset have pretty attractive yield still maintain focus quality stock look company have paid dividend past year select do well fundamental metric such cash flow debt return equity dividend yield dividend growth return average annual past year top holding be pfizer pfe verizon communication vz chevron cvx exxon mobil xom international fund tend provide higher yield investor need be able stomach higher volatility due currency fluctuation dollar recent strength have hit return nonhedged etfs such emerge market equity income fund dem ishare international select dividend idv
1494,PFE,merck mrk pembrolizumab win fda approval melanoma thursday afternoon make first drug much anticipate pd inhibitor class hit market pembrolizumab now brand keytruda be approve normal phase clinical trial be finished due breakthrough therapy designation monoclonal antibody attack mechanism let cancer
1495,PFE,blackstone bx announce friday break financial advisory unit spin off ramp year world biggest money manager combine financial advisory segment independent financial advisory firm pjt partner form new publicly trade company lead pjt paul taubman largest alternative asset manager world
1496,PFE,big pharma merck mrk study hot new immunotherapy drug candidate combination rival pfizer currently approve xalkori treat metastatic lung cancer firm announce tuesday trial pembrolizumab xalkori expect start next year be just example willingness sponsor work together effort accelerate progress
1497,PFE,illumina ilmn maker dna sequence product say thursday have strike strategic partnership several big drugmaker develop call universal next generation sequence base oncology test system cancer diagnosis initial strategic partner include astrazeneca azn janssen biotech sanofi sny illumina say system be used conduct clinical trial specific cancer therapy help identify cancer respond target therapy assess specific mutation gene know be associate response resistance specific cancer therapy goal be develop commercialize multus gene panel therapeutic selection provide more precise comprehensive tool fight cancer illumina stock be fraction morning trading stock market today illumina stock be year company rank wednesday midweek update ibd illumina sport ibd relative strength rating putt top stock performance past month astrazeneca meanwhile have see london stock rise week renew speculation takeover attempt pfizer pfe follow company unsuccessful takeover bid astrazeneca stock be nearly morning trading nasdaq related drugmaker astrazeneca return growth
1498,PFE,come procure clinical research service small biotechs be average jane joe line enter nightclub celebrity be whisk royalty second show case celebrity be big pharmaceutical firm money clout jump head line need contract research organization manage clinical trial compile datum conduct study provide marketing expertise meanwhile many biotech biopharma firm be stick stare watch wonder ll get service need parexel international prxl ecognize problem couple year do something company provide outsource service drug biotech medical device industry operate segment biggest unit clinical research service crs contribute revenue rest be break parexel consult medical communication service pcms perceptive informatic service range clinical research consult drug development regulatory affair marketing information technology solution lion share parexel business come large pharmaceutical firm company also serve smaller biotech company broad scope seal dealsparexel establish dedicate biopharma unit focus solely help small mid size client achieve development goal unit serve few purpose smaller client know ll get parexel full attention have worry compete big pharma client very important selling point always sense smaller company be wary work larger pharmaceutical firm parexel chief financial officer ingo bank say phone interview ask be sure win set aside meet big pharma need add establish biopharma unit couple year parexel biopharma unit also offer wide range service be important selling point big pharma company have large staff dedicate regulatory affair other part development process many smaller biotech firm run bare bone operation dedicate solely research biopharmas need more just company help run trial bank say need technology datum testing datum management regulatory expertise someone assess health economic drug offer turn many biopharma firm have lot more money spend such service few year have help drive more business parexel biotech funding have certainly reinvigorate smaller cap end parexel client base say david windley analyst jeffery be bunch more client cash spend clinical trial used be mainly investor have return biotech sector many get follow last decade financial crisis say share ibd medical biom biotech group have more triple last year biotech funding have be drive equity market perform well windley tell ibd risk aversion have kind abate folk be more willing step further risk curve invest unproven technology also quality research invest look better well bank windley say parexel dedicate biotech unit go long way convince smaller biotech biopharma client ll get same level service multibillion dollar drugmaker small client know re not go spend much pfizer pfe be concern not get same quality resource windley say so parexel create dedicate unit target serve smaller client smart move biotech still represent small slice parexel overall business company doesn break revenue end market estimate be biotech biopharma contribute less overall revenue still cfo bank say big part growth certainly have be biopharma healthy growththat growth be evident parexel financial return have run straight quarters least double digit sale earning growth earlier month company logged adjust earning cent share fourth quarter fiscal end june be year earlier cent analyst consensus view revenue gain line estimate company bottom line get boost higher margin quarter consolidated gross margin rise basis point previous year top windley estimate margin have be help internal initiative improve efficiency include move more operation lower cost country such india make easier worker access tool handle task used be do manually parexel full year fiscal earning rise share analyst poll thomson reuter expect annual ep rise fiscal year fiscal company look continue growth streak take advantage couple trend have change contract research industry not just parexel also other player field such covance cvd quintile transnational macro standpoint day blockbuster drug be bank say be see much larger number molecule address smaller patient population so be do more work trend say be technology approach such informatic have become very pervasive drug biotech field client be ask help integrate datum different source system help better understand clinical perspective trial perspective bank say need very strong capability global scale do have strongest offering industry
1499,PFE,hcp hcp be real estate investment trust invest health care sector senior housing post acute skilled nursing facility life science medical office hospital company manage acquire develop sell property seek geographic sector diversity operate partner include big player such hca hca pfizer pfe amgen amgn genentech tenet healthcare thc
1500,PFE,pfizer pfe have pull back buy range jump new high follow purchase generic drug maker hospira hsp pfizer be still just week high hit last week session retreat have come light volume positive trait pfizer stock be past year trail
1501,PFE,market many stock have show choppy action valeant pharmaceutical international vrx have continue make steady progress stock be look eighth straight weekly gain be hold firm record high clear buy point week tight pattern give investor chance buy share be confident
1502,PFE,new research note rbc capital market offer bullish take biogen idec biib experimental drug alzheimer disease predict make big splash upcoming international conference alzheimer parkinson disease conference schedule march nice france attract medical scientific professional globe biogen be expect
1503,PFE,big jump durable good order strong read consumer confidence conference board fuel modest gain stock market tuesday
1504,PFE,dow jone industrial average lead way rise exxon mobil xom unitedhealth group unh pfizer pfe outperformed gain nasdaq add
1505,PFE,volume new york stock exchange nasdaq be tracking slightly higher monday level
1506,PFE,stock market today ibd component diamondback energy fang gain fast grow oil gas producer have be consolidate gain june try reclaim day move average recently pull back high group peer sm energy sm meanwhile look poise make win row share jump heavy volume
1507,PFE,day company say be explore strategic alternative comtech cmtl extend gain rise work new base bullish early june
1508,PFE,meanwhile nearly gain share regeneron pharmaceutical regn help lift ibd medical biom biotech group gain nearly regeneron poke cup handle buy point volume be light group peer biogen idec biib ease be sluggish so far clear cup handle buy point
1509,PFE,aruba network arun stay rally mode ahead earning report close share gain pace gain past session big jump durable good order strong read consumer confidence conference board fuel modest gain stock market tuesday dow jone industrial average lead way rise exxon mobil xom unitedhealth group unh pfizer pfe outperformed gain nasdaq add volume new york stock exchange nasdaq be tracking slightly higher monday level stock market today ibd component diamondback energy fang gain fast grow oil gas producer have be consolidate gain june try reclaim day move average recently pull back high group peer sm energy sm meanwhile look poise make win row share jump heavy volume day company say be explore strategic alternative comtech cmtl extend gain rise work new base bullish early june meanwhile nearly gain share regeneron pharmaceutical regn help lift ibd medical biom biotech group gain nearly regeneron poke cup handle buy point volume be light group peer biogen idec biib ease be sluggish so far clear cup handle buy point aruba network arun stay rally mode ahead earning report close share gain pace gain past session
1510,PFE,intercept pharmaceutical icpt release new datum experimental fatty liver drug show treatment be effective have less severe side effect previous fear send share soar late trading stock market today biotech test obeticholic acid alcoholic fatty liver disease be current approve treatment drug stop
1511,PFE,treasury department new rule make harder company carry tax inversion deal push merger price tag push share price amount mere band aid obama administration congressional surgery be require expert say federal state combine corporate tax rate be highest
1512,PFE,nasdaq lead quiet session early afternoon trade friday major average be unfazed comment fed chief janet yellen jackson hole wyo interest rate policy state job market nasdaq rise dow jone industrial average lose nyse volume be tracking slightly higher nasdaq volume bit lower thursday level stock market today ibd component foot locker fl extend gain recent share jump strong turnover bullish earning report be catalyst earning rise year well expectation sale grow elsewhere leaderboard name restoration hardware rh outperformed rise heavy volume stock have show back forth action recent day continue hold day move average reclaim support level tuesday heavy volume keurig green mountain gmcr clear week flat base rise news licensing deal kraft food krft meanwhile recent ipo grubhub grub approach time high rise stock be currently extend recent ipo base actavis act recent low volume rally continue share rise stock be just late stage cup handle buy point share have be strong lately bloomberg report drugmaker be takeover target pfizer pfe china base com wuba extend loss fall heavy volume share slump thursday company report quarter strong earning sale growth revenue guidance come expectation
1513,PFE,earning report specialty drugmaker continue roll thursday lead stock stumble early go stock market today danish diabetes giant nordisk nvo report profit kroner cent share year earlier quarter beating analyst consensus sale kroner however
1514,PFE,dow jone industrial average hold well monday nasdaq take hit ahead tuesday start day federal reserve meeting
1515,PFE,nasdaq slump weigh software solar name dow edge higher help strength share pfizer pfe traveler trv stock rise give
1516,PFE,stock market today tesla motor tsla dive nearly morgan stanley reiterate overweight rating remove price target basically say stock have get ahead
1517,PFE,anheuser busch inbev bud jump news interested buy privately hold brewer sabmiller group peer molson coor brewing tap soar speculation be takeover target line
1518,PFE,big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week
1519,PFE,meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba
1520,PFE,several growth name be threaten break day move average monday include yy yy baidu bidu armour ua celgene celg dow jone industrial average hold well monday nasdaq take hit ahead tuesday start day federal reserve meeting nasdaq slump weigh software solar name dow edge higher help strength share pfizer pfe traveler trv stock rise give stock market today tesla motor tsla dive nearly morgan stanley reiterate overweight rating remove price target basically say stock have get ahead anheuser busch inbev bud jump news interested buy privately hold brewer sabmiller group peer molson coor brewing tap soar speculation be takeover target line big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba several growth name be threaten break day move average monday include yy yy baidu bidu armour ua celgene celg
1521,PFE,british drugmaker astrazeneca azn have turn corner see earning fall straight quarters late july company deliver second quarter earning share year profit fall prior quarters sale rise more revenue have be flat
1522,PFE,wednesday confirm keep headquarters america win pursue inversion lower taxe purchase pharmacy alliance boot
1523,PFE,pharmacy say remain headquarter deerfield ill chicago alliance boot keep current headquarters nottingham england
1524,PFE,however wag do exercise option purchase alliance boot doesn already own
1525,PFE,ceo greg wasson say consider then rule idea move headquarters more favorable taxe
1526,PFE,take account factor include not arrive structure provide company board requisite level confidence transaction significance need withstand extensive ir review scrutiny say release
1527,PFE,wasson add company also be mindful ongoing public reaction potential inversion unique role iconic american consumer retail company major portion revenue derive government funded reimbursement program
1528,PFE,also see earning share vs wall street forecast ep
1529,PFE,share plunge hit month low investor be surprised win pursue inversion
1530,PFE,inversion have be come fire washington company look move only headquarters abroad more favorable tax rate keep most operation america have highest corporate tax rate develop world gap be grow
1531,PFE,share fall tuesday medium report company eschew tax inversion report also come say treasury department be look unilateral action try stem tax inversion congress
1532,PFE,investor absorb new inversion climate several other stock fall abbvie abbv retreat shire shpg nearly concern abbvie takeover plan not go forward plan base astrazeneca azn recently rebuff pfizer pfe megamerger offer slide
1533,PFE,drugstore also retreat ep guidance cvs caremark cvs fall just fraction rite aid rad plunge wednesday confirm keep headquarters america win pursue inversion lower taxe purchase pharmacy alliance boot pharmacy say remain headquarter deerfield ill chicago alliance boot keep current headquarters nottingham england however wag do exercise option purchase alliance boot doesn already own ceo greg wasson say consider then rule idea move headquarters more favorable taxe take account factor include not arrive structure provide company board requisite level confidence transaction significance need withstand extensive ir review scrutiny say release wasson add company also be mindful ongoing public reaction potential inversion unique role iconic american consumer retail company major portion revenue derive government funded reimbursement program also see earning share vs wall street forecast ep share plunge hit month low investor be surprised win pursue inversion inversion have be come fire washington company look move only headquarters abroad more favorable tax rate keep most operation america have highest corporate tax rate develop world gap be grow share fall tuesday medium report company eschew tax inversion report also come say treasury department be look unilateral action try stem tax inversion congress investor absorb new inversion climate several other stock fall abbvie abbv retreat shire shpg nearly concern abbvie takeover plan not go forward plan base astrazeneca azn recently rebuff pfizer pfe megamerger offer slide drugstore also retreat ep guidance cvs caremark cvs fall just fraction rite aid rad plunge
1534,PFE,name former kraft krft cfo timothy mclevish new evp cfo ahead national drugstore chain decision acquire rest alliance boot share wag rise stock market today buy alliance boot have be mull move europe
1535,PFE,big pharmas merck pfizer modestly beat estimate early tuesday guide full year cautiously prepare new drug launch merck stock rise pfizer stock fall merck mrk earning totale cent share penny year earlier quarter beating analyst consensus cent sale shrank
1536,PFE,stock step healthy gain solid trade early tuesday weaker expect read home price growth
1537,PFE,nasdaq grab gain dow jone industrial average tack moved
1538,PFE,volume climb stock market today trade tracking higher nasdaq nyse compare same time monday
1539,PFE,home price rise increase slow lowest rate more year accord case shiller city composite home price index index gain april gain expectation growth
1540,PFE,big cap stock unite parcel service up bp bp be pfizer pfe merck mrk climb report quarterly result
1541,PFE,long struggle stock herbalife hlf tank weak second quarter result report late monday
1542,PFE,el pollo holding tumble start trade grilled chicken chain go public friday be still more ipo price share
1543,PFE,upside windstream holding spiked word arkansa base telecom service provider form separately trade real estate investment trust reit spinoff divide company internet service operation physical network asset stock have be climb february year correction tuesday gain left share high
1544,PFE,wynn resort wynn pop miss analyst revenue forecast beating ep forecast wide margin stock be work build right side consolidation stock step healthy gain solid trade early tuesday weaker expect read home price growth nasdaq grab gain dow jone industrial average tack moved volume climb stock market today trade tracking higher nasdaq nyse compare same time monday home price rise increase slow lowest rate more year accord case shiller city composite home price index index gain april gain expectation growth big cap stock unite parcel service up bp bp be pfizer pfe merck mrk climb report quarterly result long struggle stock herbalife hlf tank weak second quarter result report late monday el pollo holding tumble start trade grilled chicken chain go public friday be still more ipo price share upside windstream holding spiked word arkansa base telecom service provider form separately trade real estate investment trust reit spinoff divide company internet service operation physical network asset stock have be climb february year correction tuesday gain left share high wynn resort wynn pop miss analyst revenue forecast beating ep forecast wide margin stock be work build right side consolidation
1545,PFE,big pharma pfizer pfe get downgrade ahead earning report schedule tuesday day also feature report fellow big pharma merck mrk well big biotech amgen amgn analyst average expect pfizer earning cent share penny year earlier quarter sale drop
1546,PFE,contract research organization parexel international prxl get pair upgrade thursday stock sell wednesday follow company guidance investor still seem undecided however stock open backtrack gain less midday trading stock market today ahead annual investor day
1547,PFE,friday hospital get new life save antibiotic investor see first step resuscitation cubist pharmaceutical just couple year cubist cbst be ibd mainstay ride success cubicin treatment deadly hospital base infection summer company unveil ambitious year plan involved double
1548,PFE,fade michael corleone den be desk face be member organization michael rise dim light start powerpoint display show various mafia family chieftain button man be puzzled say nothing michael turn light back be clear be say something important
1549,PFE,big pharma pfizer pfe miss first quarter sale estimate monday beat profit affirm guidance analyst focuse firm possible merger split stock fall close pfizer earning totale cent share year earlier quarter beating analyst consensus cent sale decline
1550,PFE,drugmaker clinical research provider aim boost person well be worldwide be display healthy stock price performance ethical drugmaker top industry group track ibd monday issue just do prior week leader hail globe jazz pharmaceutical jazz be stock group
1551,PFE,share bind therapeutic bind be more stock market today biotech say late wednesday have end partnership amgen amgn partnership start january determine amgen cancer drug be enhance bind nanomedicine technology bind nanoparticle call accurin be programme target
1552,PFE,several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely
1553,PFE,bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi
1554,PFE,sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case
1555,PFE,chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion
1556,PFE,endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat
1557,PFE,meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday
1558,PFE,regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory
1559,PFE,datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday
1560,PFE,follow amy reeve twitter ibd_areeve several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday follow amy reeve twitter ibd_areeve
1561,PFE,pfizer pfe sweeten bid astrazeneca azn pound aim bring second biggest drugmaker negotiating table offer value astrazeneca pound share cash stock new york base pfizer say statement today london base company reject proposal pound share announce april
1562,PFE,astrazeneca monday reject pfizer final proposal buyout offer share british drug giant dive investor seem lose hope merger titan ever take place pfizer pfe first reveal april astrazeneca azn have reject proposal early year few day later make higher bid
1563,PFE,astrazeneca azn early monday reject raise takeover bid pfizer pfe pfizer call final proposal british drug giant astrazeneca stock tumble morning trading stock market today pfizer stock be
1564,PFE,late sunday pfizer issue press release say have bid pound share astrazeneca total bid be not only higher pfizer last bid astrazeneca have reject also comprise cash stock address astrazeneca concern ratio earlier bid involved too much stock
1565,PFE,pfizer also say press release win go hostile lead much discussion wall street astrazeneca cold shoulder finally kill pfizer hope british law once pfizer go public pursuit astrazeneca have make offer raise bidder come however be only true interest remain side analyst mark schoenebaum isi group point astrazeneca decide negotiate pfizer be able make new bid
1566,PFE,risk arb desk note azn drop word significantly substantial significantly undervalue substantial shortfall language company used prior rejection include gbp proposal friday word unanimous be not contain azn description bod board director rejection schoenebaum write email client monday desk believe now azn shareholder hand be effectively hostile tender offer
1567,PFE,mick cooper analyst edison investment research point pfizer forbid act again only month putt pressure astrazeneca prove shareholder then make right call
1568,PFE,nonetheless schoenebaum calculate higher offer wouldn bring return pfizer shareholder not alone opinion sunday follow pfizer announcement astrazeneca response leerink analyst seamus fernandez downgrade astrazeneca neutral base logic
1569,PFE,most azn high value pipeline announcement have be make drive feature positive investment thesis potential new oncology approval azd likely get fda breakthrough designation immuno oncology dark horse status realize together undervalue respiratory biologic opportunity additional pipeline shot goal prospect restructure sg be now fully realize pfe offer opinion write
1570,PFE,follow amy reeve twitter ibd_areeve astrazeneca azn early monday reject raise takeover bid pfizer pfe pfizer call final proposal british drug giant astrazeneca stock tumble morning trading stock market today pfizer stock be late sunday pfizer issue press release say have bid pound share astrazeneca total bid be not only higher pfizer last bid astrazeneca have reject also comprise cash stock address astrazeneca concern ratio earlier bid involved too much stock pfizer also say press release win go hostile lead much discussion wall street astrazeneca cold shoulder finally kill pfizer hope british law once pfizer go public pursuit astrazeneca have make offer raise bidder come however be only true interest remain side analyst mark schoenebaum isi group point astrazeneca decide negotiate pfizer be able make new bid risk arb desk note azn drop word significantly substantial significantly undervalue substantial shortfall language company used prior rejection include gbp proposal friday word unanimous be not contain azn description bod board director rejection schoenebaum write email client monday desk believe now azn shareholder hand be effectively hostile tender offer mick cooper analyst edison investment research point pfizer forbid act again only month putt pressure astrazeneca prove shareholder then make right call nonetheless schoenebaum calculate higher offer wouldn bring return pfizer shareholder not alone opinion sunday follow pfizer announcement astrazeneca response leerink analyst seamus fernandez downgrade astrazeneca neutral base logic most azn high value pipeline announcement have be make drive feature positive investment thesis potential new oncology approval azd likely get fda breakthrough designation immuno oncology dark horse status realize together undervalue respiratory biologic opportunity additional pipeline shot goal prospect restructure sg be now fully realize pfe offer opinion write follow amy reeve twitter ibd_areeve
1571,PFE,biotech intermune itmn hit year high stock market today ub lift price target company bullish expectation drug launch ub analyst andrew peter write expect esbriet become standard care lung disease idiopathic pulmonary fibrosis ipf once be approve drug
1572,PFE,persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate
1573,PFE,abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price
1574,PFE,abbvie expect close deal year say be immediately accretive earning accretion rise share
1575,PFE,new firm be domicile
1576,PFE,abbvie say move firm efficient tax structure cut tax rate now
1577,PFE,conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say
1578,PFE,gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug
1579,PFE,abbvie fact plan create rare disease division
1580,PFE,transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale
1581,PFE,reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad
1582,PFE,call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception
1583,PFE,just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion
1584,PFE,ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role
1585,PFE,shire director join abbvie board
1586,PFE,shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view
1587,PFE,shire press release didn change recent guidance estimate sale
1588,PFE,leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid
1589,PFE,shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price abbvie expect close deal year say be immediately accretive earning accretion rise share new firm be domicile abbvie say move firm efficient tax structure cut tax rate now conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug abbvie fact plan create rare disease division transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role shire director join abbvie board shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view shire press release didn change recent guidance estimate sale leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday
1590,PFE,pfizer pfe end week speculation wall street announce friday file approval breast cancer drug palbociclib finish clinical trial palbociclib fda filing be base mid stage paloma trial accord pfizer press release pfizer present final result trial last month show strong progression free
1591,PFE,brenton saunder paul bisaro have lot experience make big pharma deal become ceo generic drugmaker watson pharmaceutical bisaro have build company giant buyout actavis act name watson adopt last year purchase warner chilcott win company low tax irish address
1592,PFE,small fast grow company hot industry such generic drugmaker lannett be good prospect stock watch list today screen day be small cap leader highly rate company market capitalization list include trio highly rate medical company massive baby boomer generation move retirement
1593,PFE,be busy year actavis act continue grow acquisition former watson pharmaceutical rename actavis buy latter drugmaker october buy irish pharmaceutical warner chilcott follow buyout forest lab early year shareholder be slate vote deal
1594,PFE,stock future trade lower steady ahead monday open oil price federal reserve test investor confidence dow future trade point fair market value future hung point line nasdaq future be mild point small cap be pressure russell future fall point stock market today open clear caution flag ahead wednesday policy decision federal reserve nasdaq drop last week slice support day day move average crumple also violate level support mean bet be market direction next day uncertainty oil price continue diving early monday west texas intermediate more barrel lowest mark more decade brent crude drop nearly weakest level benchmark have logged steady loss dec organization petroleum export country meeting group fail agree production quota permit member country continue current production level oil price slump be dupont dd apple aapl drag dow open dupont dip more apple trim premarket loss dive morgan stanley cut price target cite pressure international iphone price due oversupply outside china apple end friday well august low struggle retake week move average month consolidation jarden jah jump newell rubbermaid nwl slip more newell say pay cash stock deal acquire boca raton fla base maker sunbeam iron marmot outdoor gear crock pot cookware newell management say combination be target annualize cost saving be immediately positive earning close jarden rise last week merger speculation move stock right side month consolidation china base maker solar electrical component trina solar tsl spiked news report company have receive offer be take private share shanghai xingsheng equity investment management offer be friday close price edward lifescience ew be confuse brokerage datum collection system premarket trade prepared go live stock split today open be company first stock split overseas europe stock come lows midday london ftse reversed early loss wrestle narrowly positive territory frankfurt dax be loss cac paris ease loss asia market be widely mixed hong kong hang seng index dip shanghai composite jump nikkei tokyo stumble loss
1595,PFE,stock market today be poise vastly higher open tuesday positive economic datum
1596,PFE,nasdaq future rally point vs fair value future climb point dow future jump point
1597,PFE,last week climb hit record high nasdaq score gain regain day line sign professional buy have remain scant
1598,PFE,economic news order durable good surprisingly rise april thank jump military spending exclude defense durable fall march durable good be upwardly revise show increase future improve follow release
1599,PFE,case shiller home price index march be et conference board report consumer confidence follow suit et
1600,PFE,corporate news pilgrim pride ppc offer buy jimmy dean sausage maker hillshire brand hsh share cash hillshire share bolt premarket trading share pilgrim pride rise nearly
1601,PFE,share pinnacle food pf pilgrim pride agree buy earlier month slump pre open trade
1602,PFE,astrazeneca azn fall premarket trade pfizer pfe withdraw buyout offer societe generale also downgrade astrazeneca sell hold pfizer rise fraction pre open trading
1603,PFE,elsewhere autozone azo rise fraction premarket trading post quarterly earning view auto part retailer report fiscal earning share share year penny view sale grow slightly view stock market today be poise vastly higher open tuesday positive economic datum nasdaq future rally point vs fair value future climb point dow future jump point last week climb hit record high nasdaq score gain regain day line sign professional buy have remain scant economic news order durable good surprisingly rise april thank jump military spending exclude defense durable fall march durable good be upwardly revise show increase future improve follow release case shiller home price index march be et conference board report consumer confidence follow suit et corporate news pilgrim pride ppc offer buy jimmy dean sausage maker hillshire brand hsh share cash hillshire share bolt premarket trading share pilgrim pride rise nearly share pinnacle food pf pilgrim pride agree buy earlier month slump pre open trade astrazeneca azn fall premarket trade pfizer pfe withdraw buyout offer societe generale also downgrade astrazeneca sell hold pfizer rise fraction pre open trading elsewhere autozone azo rise fraction premarket trading post quarterly earning view auto part retailer report fiscal earning share share year penny view sale grow slightly view
1604,PFE,british pharma giant astrazeneca azn announce new drug approval tuesday rolled strategy nearly double revenue next decade further quest convince shareholder not yield pfizer pfe takeover attempt shareholder do not seem excited however astrazeneca stock be fraction stock market today
1605,PFE,astra say fda have approve epanova treatment severe elevated level fat blood firm say adult suffer condition consensus estimate put annual sale less be fairly small potato world big pharma so separate press release conference call detail long term target company focuse bigger game
1606,PFE,astra project annual sale heart disease drug brilinta reach be ambitious target drug bring less last year analyst be estimate just sale
1607,PFE,also company expect diabetes respiratory franchise be make last year respiratory revenue totale diabetes business be more nascent astra take year company buy bristol myer squibb bmy portion joint venture
1608,PFE,astra also estimate risk adjust peak sale potential pipeline conference call company say medi immuno oncology drug currently phase testing lung cancer be ready approval filing analyst believe immuno oncology be big reason pfizer bid astrazeneca bristol merck mrk have already begin roll submission own immuno oncology drug pfizer have presence space
1609,PFE,such growth lie future however astra have be shrink major drug have go patent company affirm revenue be broadly line growth lift
1610,PFE,follow amy reeve twitter pharma giant astrazeneca azn announce new drug approval tuesday rolled strategy nearly double revenue next decade further quest convince shareholder not yield pfizer pfe takeover attempt shareholder do not seem excited however astrazeneca stock be fraction stock market today astra say fda have approve epanova treatment severe elevated level fat blood firm say adult suffer condition consensus estimate put annual sale less be fairly small potato world big pharma so separate press release conference call detail long term target company focuse bigger game astra project annual sale heart disease drug brilinta reach be ambitious target drug bring less last year analyst be estimate just sale also company expect diabetes respiratory franchise be make last year respiratory revenue totale diabetes business be more nascent astra take year company buy bristol myer squibb bmy portion joint venture astra also estimate risk adjust peak sale potential pipeline conference call company say medi immuno oncology drug currently phase testing lung cancer be ready approval filing analyst believe immuno oncology be big reason pfizer bid astrazeneca bristol merck mrk have already begin roll submission own immuno oncology drug pfizer have presence space such growth lie future however astra have be shrink major drug have go patent company affirm revenue be broadly line growth lift follow amy reeve twitter ibd_areeve
1611,PFE,major average re-cover hold high weak start monday nasdaq lose early have trim loss dow jone industrial average also drop fall fractionally nyse nasdaq volume be tracking well friday level investor be initially spook weak manufacturing datum china continue uncertainty ukraine better expect read ism service index fuel positive sentiment stock market today jpmorgan jpm weigh dow fall company say expect fix income equity trading revenue slump second quarter decline first quarter pfizer pfe meanwhile lose drugmaker report earning share top expectation disappointing sale growth pfizer be try acquire drug giant astrazeneca azn fleetcor technology flt extend gain report strong earning last week share rise afternoon trading company deliver ninth straight quarter profit growth sale growth accelerate second straight quarter rise provider fuel card workforce payment product be back day move average work new base elsewhere ibd component futurefuel ff rally ahead earning report thursday close maker custom performance chemical biofuel show accelerate sale growth recent quarters stock be form base base pattern
1612,PFE,pfizer pfe say be try acquire fellow big pharma astrazeneca confirm anonymously source report last week pfizer stock be astrazeneca morning trading stock market today pfizer bid astrazeneca jan offer share cash stock astrazeneca turn pfizer contact again
1613,PFE,launch alprolix eloctate come july biogen idec be lead edge first new class hemophilia treatment come year question be interested be justifiably cautious patient try new thing hemophilia be fairly well know due presence europe royal
1614,PFE,megamerger be back major corporation appetite acquisition near pre recession peak especially tax friendly cross border deal global have reach year earlier accord datum compile thomson reuter mark strongest year deal make peak monday biggest announcement be hillshire brand hsh
1615,PFE,european exchange be high scorer world map tuesday investor return vigor day holiday
1616,PFE,germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain
1617,PFE,european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation
1618,PFE,massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business
1619,PFE,glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt
1620,PFE,base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end
1621,PFE,financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market
1622,PFE,addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx
1623,PFE,market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength european exchange be high scorer world map tuesday investor return vigor day holiday germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength
1624,PFE,british big pharma astrazeneca azn turn second takeover bid counterpart pfizer pfe friday say offer be still too low pfizer stock drop nearly astrazeneca hold steady stock market today pfizer first bid astrazeneca board objected large proportion stock share offer
1625,PFE,major average be little change friday weak post holiday trading nasdaq be edge dow jone industrial be flat volume friday half day session be run sharply lower same time wednesday last trading session thanksgiving universal display oled maker light emit flat panel display jump heavy volume new report product be used apple aapl iphone model due stock be approach buy point deep cup base fall oil price hurt energy stock help airline stock market today coal producer consol energy cnx oil stock southwestern energy swn longtime laggard drop weigh other hand american airline aal unite continental ual rise line decline oil price ibd stock hawaiian rise meanwhile walt disney drop heavy volume drag medium stock announce late wednesday espn sport network have lose subscriber past year stock drop cup handle buy point clear nov viacom viab fall time warner twx be
1626,PFE,stock rise slow volume monday afternoon show scant evidence big money player be back holiday
1627,PFE,nasdaq advanced dow jone industrial add volume be run sharply lower vs friday pace
1628,PFE,blue chip rise have slight edge dow component fall pfizer pfe show biggest percentage gain not quite average volume
1629,PFE,ibd proxy top rate stock alliance fiber optic product afop jump volume average company design make fiber optic component integrate module optical network equipment market
1630,PFE,biggest loser ibd be china base qihoo technology qihu stock drop volume be fifth slower usual qihoo provide internet mobile security product
1631,PFE,commodity comex gold fall west texas intermediate crude oil rise stock rise slow volume monday afternoon show scant evidence big money player be back holiday nasdaq advanced dow jone industrial add volume be run sharply lower vs friday pace blue chip rise have slight edge dow component fall pfizer pfe show biggest percentage gain not quite average volume ibd proxy top rate stock alliance fiber optic product afop jump volume average company design make fiber optic component integrate module optical network equipment market biggest loser ibd be china base qihoo technology qihu stock drop volume be fifth slower usual qihoo provide internet mobile security product commodity comex gold fall west texas intermediate crude oil rise
1632,PFE,specialty drug giant actavis act be due report quarter growth market open wednesday ibd stock continue swell acquisition
1633,PFE,analyst poll thomson reuter estimate actavis make share quarter year earlier quarter sale be estimate grow
1634,PFE,actavis hasn give guidance year say complete acquisition forest laboratory frx expect midyear acquisition get more complicate monday forest say buy furiex pharmaceutical furx deal worth contingent payment road forest lab report fiscal result early tuesday handily beat wall street estimate
1635,PFE,cowen analyst ken cacciatore write note tuesday forest result underscore bullish thesis actavis forest combination say street be not appreciate
1636,PFE,believe investor generally understand term earning dynamic be solid be fail appreciate combine asset now more effectively be focuse extend duration cash flow write furiex transaction be just example process add be long duration potential brand asset be leverage combine forest actavis warner chilcott gi infrastructure
1637,PFE,acquisition forest warner chilcott last year expand actavis brand drug business still get most revenue generic late monday announce subsidiary be sue fda grant teva pharmaceutical teva day marketing exclusivity sell generic version arthritis drug celebrex grant teva pfizer pfe reach settlement april celebrex sale last year totale
1638,PFE,actavis stock have slide feb time high drug stock general have sell be fraction afternoon trading stock market today
1639,PFE,follow amy reeve twitter ibd_areeve specialty drug giant actavis act be due report quarter growth market open wednesday ibd stock continue swell acquisition analyst poll thomson reuter estimate actavis make share quarter year earlier quarter sale be estimate grow actavis hasn give guidance year say complete acquisition forest laboratory frx expect midyear acquisition get more complicate monday forest say buy furiex pharmaceutical furx deal worth contingent payment road forest lab report fiscal result early tuesday handily beat wall street estimate cowen analyst ken cacciatore write note tuesday forest result underscore bullish thesis actavis forest combination say street be not appreciate believe investor generally understand term earning dynamic be solid be fail appreciate combine asset now more effectively be focuse extend duration cash flow write furiex transaction be just example process add be long duration potential brand asset be leverage combine forest actavis warner chilcott gi infrastructure acquisition forest warner chilcott last year expand actavis brand drug business still get most revenue generic late monday announce subsidiary be sue fda grant teva pharmaceutical teva day marketing exclusivity sell generic version arthritis drug celebrex grant teva pfizer pfe reach settlement april celebrex sale last year totale actavis stock have slide feb time high drug stock general have sell be fraction afternoon trading stock market today follow amy reeve twitter ibd_areeve
1640,PFE,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
1641,PFE,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
1642,PFE,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
1643,PFE,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
1644,PFE,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
1645,PFE,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
1646,PFE,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
1647,PFE,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
1648,PFE,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
1649,PFE,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
1650,PFE,stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today
1651,PFE,dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point
1652,PFE,rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis
1653,PFE,lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday
1654,PFE,greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement
1655,PFE,eurozone official exit summit aim work greece related issue announce caution agreement
1656,PFE,support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index
1657,PFE,week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way
1658,PFE,stock thwart merger activity weigh early trade
1659,PFE,natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade
1660,PFE,manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday
1661,PFE,stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base
1662,PFE,currency market dollar be euro yen commodity be mixed oil gold less stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement eurozone official exit summit aim work greece related issue announce caution agreement support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way stock thwart merger activity weigh early trade natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base currency market dollar be euro yen commodity be mixed oil gold less
1663,PFE,stock finished mixed volatile session monday see main index erase sharp loss dow jone industrial average lead comeback gain be not index be lead market be make serious advance muster gain defend day
1664,PFE,big purse start spill open globe past week glaxosmithkline gsk novartis nvs eli lilly lly announce series business swap value astrazeneca azn straight arm offer pfizer pfe general electric ge offer france alstom britain reckitt benckiser group say monday be duel
1665,PFE,market be correction tension ukraine weigh sentiment several top rate company be slate report earning week most stock be hold relatively well
1666,PFE,spirit airline save rank ibd be expect report result tuesday analyst poll thomson reuter expect low fare high fee airline report jump earning cent share revenue be see rise
1667,PFE,ibd list top company base superior earning strong price performance leadership industry
1668,PFE,spirit business model be other airline offer rock bottom ticket price then charge passenger service other airline offer free printing board pass airport carry bag get cup water
1669,PFE,flier grumble spirit way do business other pay just need earlier month spirit say march traffic rise passenger load factor measure many available seat be filled flight rise basis point
1670,PFE,spirit share fall stock market friday light volume hold day move average
1671,PFE,therapeutic anik ibd also report tuesday biotech make hyaluronic acid product use heal bone cartilage earlier year receive fda approval new osteoarthritis treatment
1672,PFE,analyst expect post jump earning cent share revenue be see rise
1673,PFE,share fall friday thin volume close just day move average
1674,PFE,actavis act ibd report wednesday april drugmaker get license pfizer pfe start selling generic form painkiller celebrex december pending fda approval earlier month actavis buy privately hold silom medical cash
1675,PFE,analyst see actavis report rise earning share revenue be expect rise
1676,PFE,actavis share briefly moved back day line tuesday stock be turn back stock fall modestly next day
1677,PFE,whiting petroleum wll be also slate announce result wednesday analyst expect domestic oil gas production exploration company report flat earning cent share revenue be see rise
1678,PFE,whiting share fall friday hit record close thursday
1679,PFE,gentherm thrm top list round week report thursday maker temperature climate control system car truck have see business expand carmaker hyundai nissan nsany make heated seat have mid level vehicle earlier month company buy privately hold industrial remote power system maker global thermoelectric cash transaction
1680,PFE,gentherm say high profile recall one general motor gm haven affected business
1681,PFE,analyst expect gentherm post jump earning cent share revenue be see rise
1682,PFE,gentherm fall friday close week hit time high tuesday
1683,PFE,follow gillian rich twitter market be correction tension ukraine weigh sentiment several top rate company be slate report earning week most stock be hold relatively well spirit airline save rank ibd be expect report result tuesday analyst poll thomson reuter expect low fare high fee airline report jump earning cent share revenue be see rise ibd list top company base superior earning strong price performance leadership industry spirit business model be other airline offer rock bottom ticket price then charge passenger service other airline offer free printing board pass airport carry bag get cup water flier grumble spirit way do business other pay just need earlier month spirit say march traffic rise passenger load factor measure many available seat be filled flight rise basis point spirit share fall stock market friday light volume hold day move average therapeutic anik ibd also report tuesday biotech make hyaluronic acid product use heal bone cartilage earlier year receive fda approval new osteoarthritis treatment analyst expect post jump earning cent share revenue be see rise share fall friday thin volume close just day move average actavis act ibd report wednesday april drugmaker get license pfizer pfe start selling generic form painkiller celebrex december pending fda approval earlier month actavis buy privately hold silom medical cash analyst see actavis report rise earning share revenue be expect rise actavis share briefly moved back day line tuesday stock be turn back stock fall modestly next day whiting petroleum wll be also slate announce result wednesday analyst expect domestic oil gas production exploration company report flat earning cent share revenue be see rise whiting share fall friday hit record close thursday gentherm thrm top list round week report thursday maker temperature climate control system car truck have see business expand carmaker hyundai nissan nsany make heated seat have mid level vehicle earlier month company buy privately hold industrial remote power system maker global thermoelectric cash transaction gentherm say high profile recall one general motor gm haven affected business analyst expect gentherm post jump earning cent share revenue be see rise gentherm fall friday close week hit time high tuesday follow gillian rich twitter ibd_grich
1684,PFE,stock market today open lower tension ukraine soft chinese factory datum have already pare large chunk loss
1685,PFE,fall nasdaq be be much respectively dow jone industrial average lose hurt jpmorgan jpm pfizer pfe volume be tracking lower board especially nasdaq
1686,PFE,economic news ism manufacturing index rise better expect april march best read month economist have expect accord econoday
1687,PFE,ambarella amba slump lowest level nearly month stock slice day move average have never close level come public october
1688,PFE,alliance fiber optic product afop lose nearly erase gain past session stock have climb past week volatile market last weekly gain come strong volume pullback alliance fiber be still past buy point double bottom base
1689,PFE,manitowoc mtw fall extend friday dive news disappointing result late thursday hit crane maker friday send share more buy point flat base stock still be form base
1690,PFE,chipotle grill cmg buck market weakness rise nearly raymond james upgrade share outperform market perform place price target chipotle be stabilize day move average fall march peak stock market today open lower tension ukraine soft chinese factory datum have already pare large chunk loss fall nasdaq be be much respectively dow jone industrial average lose hurt jpmorgan jpm pfizer pfe volume be tracking lower board especially nasdaq economic news ism manufacturing index rise better expect april march best read month economist have expect accord econoday ambarella amba slump lowest level nearly month stock slice day move average have never close level come public october alliance fiber optic product afop lose nearly erase gain past session stock have climb past week volatile market last weekly gain come strong volume pullback alliance fiber be still past buy point double bottom base manitowoc mtw fall extend friday dive news disappointing result late thursday hit crane maker friday send share more buy point flat base stock still be form base chipotle grill cmg buck market weakness rise nearly raymond james upgrade share outperform market perform place price target chipotle be stabilize day move average fall march peak
1691,PFE,market be correction tension ukraine weigh sentiment several top rate company be slate report earning week most stock be hold relatively well
1692,PFE,spirit airline save rank ibd be expect report result tuesday analyst poll thomson reuter expect low fare high fee airline report jump earning cent share revenue be see rise
1693,PFE,ibd list top company base superior earning strong price performance leadership industry
1694,PFE,spirit business model be other airline offer rock bottom ticket price then charge passenger service other airline offer free printing board pass airport carry bag get cup water
1695,PFE,flier grumble spirit way do business other pay just need earlier month spirit say march traffic rise passenger load factor measure many available seat be filled flight rise basis point
1696,PFE,spirit share fall stock market friday light volume hold day move average
1697,PFE,therapeutic anik ibd also report tuesday biotech make hyaluronic acid product use heal bone cartilage earlier year receive fda approval new osteoarthritis treatment
1698,PFE,analyst expect post jump earning cent share revenue be see rise
1699,PFE,share fall friday thin volume close just day move average
1700,PFE,actavis act ibd report wednesday april drugmaker get license pfizer pfe start selling generic form painkiller celebrex december pending fda approval earlier month actavis buy privately hold silom medical cash
1701,PFE,analyst see actavis report rise earning share revenue be expect rise
1702,PFE,actavis share briefly moved back day line tuesday stock be turn back stock fall modestly next day
1703,PFE,whiting petroleum wll be also slate announce result wednesday analyst expect domestic oil gas production exploration company report flat earning cent share revenue be see rise
1704,PFE,whiting share fall friday hit record close thursday
1705,PFE,gentherm thrm top list round week report thursday maker temperature climate control system car truck have see business expand carmaker hyundai nissan nsany make heated seat have mid level vehicle earlier month company buy privately hold industrial remote power system maker global thermoelectric cash transaction
1706,PFE,gentherm say high profile recall one general motor gm haven affected business
1707,PFE,analyst expect gentherm post jump earning cent share revenue be see rise
1708,PFE,gentherm fall friday close week hit time high tuesday
1709,PFE,follow gillian rich twitter market be correction tension ukraine weigh sentiment several top rate company be slate report earning week most stock be hold relatively well spirit airline save rank ibd be expect report result tuesday analyst poll thomson reuter expect low fare high fee airline report jump earning cent share revenue be see rise ibd list top company base superior earning strong price performance leadership industry spirit business model be other airline offer rock bottom ticket price then charge passenger service other airline offer free printing board pass airport carry bag get cup water flier grumble spirit way do business other pay just need earlier month spirit say march traffic rise passenger load factor measure many available seat be filled flight rise basis point spirit share fall stock market friday light volume hold day move average therapeutic anik ibd also report tuesday biotech make hyaluronic acid product use heal bone cartilage earlier year receive fda approval new osteoarthritis treatment analyst expect post jump earning cent share revenue be see rise share fall friday thin volume close just day move average actavis act ibd report wednesday april drugmaker get license pfizer pfe start selling generic form painkiller celebrex december pending fda approval earlier month actavis buy privately hold silom medical cash analyst see actavis report rise earning share revenue be expect rise actavis share briefly moved back day line tuesday stock be turn back stock fall modestly next day whiting petroleum wll be also slate announce result wednesday analyst expect domestic oil gas production exploration company report flat earning cent share revenue be see rise whiting share fall friday hit record close thursday gentherm thrm top list round week report thursday maker temperature climate control system car truck have see business expand carmaker hyundai nissan nsany make heated seat have mid level vehicle earlier month company buy privately hold industrial remote power system maker global thermoelectric cash transaction gentherm say high profile recall one general motor gm haven affected business analyst expect gentherm post jump earning cent share revenue be see rise gentherm fall friday close week hit time high tuesday follow gillian rich twitter ibd_grich
1710,PFE,drive health care medium industry have so far be strongest year merger acquisition dawn financial crisis big deal globally totale june last year past few day have be microcosm rise level communication lvlt
1711,PFE,last month democrat congress send now famous letter gilead science gild question price new blockbuster hepatitis medicine sovaldi reason raise suspicion price didn need be high speed sovaldi be approve food drug administration gilead file receive
1712,PFE,big pharma pfizer pfe be morning trading stock market today breast cancer drug palbociclib do well trial fall bit short sky high expectation
1713,PFE,american association cancer research meeting sunday pfizer present final result phase trial palbo patient metastatic breast cancer ibd report last month investor be greatly interested presentation interim analysis show massive progression free survival benefit question be pfizer translate overall survival benefit
1714,PFE,sunday presentation paloma trial pfs benefit be somewhat smaller still substantial month compare month interim analysis overall survival benefit be month be not statistically significant
1715,PFE,analyst mark schoenebaum isi group point study enrolled fewer patient have be very difficult produce statistically significant overall survival os benefit company plan launch larger phase trial yet score sunday news seem sink hope pfizer file phase datum alone
1716,PFE,be honest message fda filing timeline be bit confuse call schoenebaum write sunday conference call pfizer other analyst prepared remark say envision filing base phase datum get quite excited old man now thus stuff easily excite however seem back away proclaim certainty phase alone be sufficient
1717,PFE,leerink swann analyst seamus fernandez say be skeptical fda approve palbo least interim datum phase trial pfe report total vs death median os month vs month hr suggest directionally positive modest effect admittedly immature os datum patient population write research note monday
1718,PFE,pfizer license palbo amgen amgn be entitle royalty sale amgen stock drop first hour trading monday midmorning be flat
1719,PFE,eli lilly lly also present datum meeting own cdk inhibitor bemaciclib be same class palbo drug be earlier stage development response rate pfs benefit have be similar palbo
1720,PFE,reminder lly have argue drug work better be dose continuously vs palbo week week regimen due less severe neutropenia schoenebaum write lly plan announce next step later believe possible phase begin end early
1721,PFE,lilly stock be more morning trading monday
1722,PFE,follow amy reeve twitter ibd_areeve big pharma pfizer pfe be morning trading stock market today breast cancer drug palbociclib do well trial fall bit short sky high expectation american association cancer research meeting sunday pfizer present final result phase trial palbo patient metastatic breast cancer ibd report last month investor be greatly interested presentation interim analysis show massive progression free survival benefit question be pfizer translate overall survival benefit sunday presentation paloma trial pfs benefit be somewhat smaller still substantial month compare month interim analysis overall survival benefit be month be not statistically significant analyst mark schoenebaum isi group point study enrolled fewer patient have be very difficult produce statistically significant overall survival os benefit company plan launch larger phase trial yet score sunday news seem sink hope pfizer file phase datum alone be honest message fda filing timeline be bit confuse call schoenebaum write sunday conference call pfizer other analyst prepared remark say envision filing base phase datum get quite excited old man now thus stuff easily excite however seem back away proclaim certainty phase alone be sufficient leerink swann analyst seamus fernandez say be skeptical fda approve palbo least interim datum phase trial pfe report total vs death median os month vs month hr suggest directionally positive modest effect admittedly immature os datum patient population write research note monday pfizer license palbo amgen amgn be entitle royalty sale amgen stock drop first hour trading monday midmorning be flat eli lilly lly also present datum meeting own cdk inhibitor bemaciclib be same class palbo drug be earlier stage development response rate pfs benefit have be similar palbo reminder lly have argue drug work better be dose continuously vs palbo week week regimen due less severe neutropenia schoenebaum write lly plan announce next step later believe possible phase begin end early lilly stock be more morning trading monday follow amy reeve twitter ibd_areeve
1723,PFE,big money flow pharma tuesday novartis glaxosmithkline gsk eli lilly lly unveil giant swap business valeant pharmaceutical vrx bid roughly allergan novartis nvs agree buy glaxo oncology business milestone payment depend product pipeline fare turn
1724,PFE,stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange
1725,PFE,hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating
1726,PFE,amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say
1727,PFE,amazon report earning close thursday analyst forecast loss cent share
1728,PFE,facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook
1729,PFE,ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock
1730,PFE,worst performer be egg producer cal maine food calm fall pull back hit new high monday
1731,PFE,follow ken hoover twitter ibd_khoover stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say amazon report earning close thursday analyst forecast loss cent share facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock worst performer be egg producer cal maine food calm fall pull back hit new high monday follow ken hoover twitter ibd_khoover
1732,PFE,big pharmas pfizer pfe astrazeneca azn be early trading stock market today word get sunday pfizer have offer buy rival
1733,PFE,cite unnamed source sunday time say have be talk astrazeneca have resist offer company decline comment
1734,PFE,report set wall street abuzz speculation astrazeneca rival be still fall patent cliff earning be expect keep decline lead many industry observer see buyout target most other big pharmas have be pare mode last couple year include pfizer have be reorganize division intention spin selling separate company
1735,PFE,nonetheless merger make sense accord isi group analyst mark schoenebaum
1736,PFE,opinion pfe have be signale last summer theory company not be opposed larger deal number make sense write email client sunday pfe have not get smaller ceo ian read just sake get smaller rather company have be clear have divest certain business thought be more valuable better run separate entity
1737,PFE,schoenebaum go point buy astrazeneca get pfizer immuno oncology game have be heating rival bristol myer squibb bmy roche rhhby merck mrk have be develop drug pd form cancer astrazeneca have own pd drug work earlier stage development other
1738,PFE,citigroup analyst andrew baum agree buy astrazeneca probably be good deal pfizer thought astrazeneca be flirt third party avoid pfizer buyout other hand analyst corporate research firm bernstein research didn think pfizer be actually serious such deal
1739,PFE,astrazeneca stock be more monday morning trading pfizer be more
1740,PFE,follow amy reeve twitter ibd_areeve big pharmas pfizer pfe astrazeneca azn be early trading stock market today word get sunday pfizer have offer buy rival cite unnamed source sunday time say have be talk astrazeneca have resist offer company decline comment report set wall street abuzz speculation astrazeneca rival be still fall patent cliff earning be expect keep decline lead many industry observer see buyout target most other big pharmas have be pare mode last couple year include pfizer have be reorganize division intention spin selling separate company nonetheless merger make sense accord isi group analyst mark schoenebaum opinion pfe have be signale last summer theory company not be opposed larger deal number make sense write email client sunday pfe have not get smaller ceo ian read just sake get smaller rather company have be clear have divest certain business thought be more valuable better run separate entity schoenebaum go point buy astrazeneca get pfizer immuno oncology game have be heating rival bristol myer squibb bmy roche rhhby merck mrk have be develop drug pd form cancer astrazeneca have own pd drug work earlier stage development other citigroup analyst andrew baum agree buy astrazeneca probably be good deal pfizer thought astrazeneca be flirt third party avoid pfizer buyout other hand analyst corporate research firm bernstein research didn think pfizer be actually serious such deal astrazeneca stock be more monday morning trading pfizer be more follow amy reeve twitter ibd_areeve
1741,PFE,big pharma merck mrk miss sale estimate result guidance wednesday stock hit year high anyway announce new set deal cancer program merck say profit most recent quarter totale cent share year earlier quarter line analyst consensus
1742,PFE,stock open higher steady trade thursday
1743,PFE,nasdaq power open add dow jone industrial average put gain
1744,PFE,stock market today open volume nyse nasdaq compare same time wednesday
1745,PFE,leader be fervid motion tesla motor tsla drop keurig green mountain gmcr jump report quarterly result
1746,PFE,priceline pcln slump open trade online travel megalith report huge earning beat revenue just meet expectation management pare earning guidance view loss send share week move average first time january
1747,PFE,avis budget group car jump report better expect first quarter sale earning company raise full year revenue earning guidance line expectation stock be april high
1748,PFE,solar city scty soar turn first quarter loss cent much better consensus forecast revenue sail ahead also view maker installer solar energy system raise full year forecast installation say expect installation double
1749,PFE,stock have correct past week thursday move send share top week range share remain deep correction
1750,PFE,oil producer gulfport energy gpor collapse follow narrow miss first quarter earning revenue management trim range full year production guidance part strategic shift long term value rather term growth stock pierce week week move average stock open higher steady trade thursday nasdaq power open add dow jone industrial average put gain stock market today open volume nyse nasdaq compare same time wednesday leader be fervid motion tesla motor tsla drop keurig green mountain gmcr jump report quarterly result priceline pcln slump open trade online travel megalith report huge earning beat revenue just meet expectation management pare earning guidance view loss send share week move average first time january avis budget group car jump report better expect first quarter sale earning company raise full year revenue earning guidance line expectation stock be april high solar city scty soar turn first quarter loss cent much better consensus forecast revenue sail ahead also view maker installer solar energy system raise full year forecast installation say expect installation double stock have correct past week thursday move send share top week range share remain deep correction oil producer gulfport energy gpor collapse follow narrow miss first quarter earning revenue management trim range full year production guidance part strategic shift long term value rather term growth stock pierce week week move average
1751,PFE,look back top chipotle grill cmg menu easily headline tasty strategy keep simple such be way co ceo monty moran steer firm top fast casual restaurant segment simple really tell ibd better quality food taste better really great person make better food provide better customer experience menu be simple so be restaurant format make easy patron get serve fast line stretch door hard believe chipotle be still early stage growth exactly case operate restaurant america small presence internationally canada england france germany domestic focus continue firm plan open unit room thousand more restaurant moran say moran be look same way look year be appoint post founder co ceo steve ell january sense increase optimism moran say predict exactly economy be go do know have loyal customer great food sound unit economic model keep track regardless economy be do moran have prove commit change food culture oversee stock shot past year include advance dig inchipotle have show execute tough economic time moran point depth recession chain be last succumb economic weakness first benefit economy start improve comp hold longer anyone last recession moran say get stronger earlier come most other firm show annual earning decline annual profit chipotle rise annual earning jump company be expect open more southeast asian kitchen location now operate washington los angele then pizza expect chipotle make noise arena recently announce partnership pizzeria locale chipotle be headquarter ceo be necessarily fixate bottom line moran learn early worry profit doesn generate profit ll never hear talk profit get sale moran say tell person make great burritos provide great restaurant experience rest take care chipotle food cost be high usually drag restaurant annual pretax margin hit time high robust sale have lot do october chipotle report increase same store sale beating analyst expectation same store sale growth company restaurant open least year average sale year hottovy senior restaurant analyst morningstar think fast casual space have solid year chipotle be more intriguing concept emerge restaurant space last decade ve pioneer perfect fast casual concept have become sweet spot industry more cost efficient run casual dine location chipotle cook more idea moran again keep simple look innovation new menu item new dollar menu item value meal re least innovative way company improve be better raw ingredient sharp cook method make sure restaurant team be best be goal be empower top perform person achieve high standard sport athlete greatness be measure make teammate better so be chipotle person culture individual store manager call restaurateur be most important employee say moran evaluate leader base powerfully make person better not good enough chipotle be good do have make person better too goal be create situation employee feel confident ability encourage circumstance so feel be best moran way communicate come part study communication university colorado graduate then be law school pepperdine university southern california graduate want be trial lawyer joined morris polich purdy los angele zero small case so develop prime attorney year later moved back colorado joined messner reeve meantime moran walk aisle kathy have be married year have child moran rise messner reeve rank fast become partner just year ceo soon thereafter much chipotle culture come moran experience messner reeve be delegate help create stable empower lawyer work hard satisfy client so do trial lawyer ascend co chief executive world most robust restaurant moran ell be high school classmate become friendlier monty college day moran catch dinner ell house steve serve gourmet scrumptious food night have pleasure try ell burrito monty be stunned delicious be hear pal plan open restaurant serve moran didn need convince start do legal work chipotle mid early stage company expansion mostly work lease boardchipotle be so impressive mcdonald mcd expressed interest buy make investment base chain big mac team send general counsel jeff kindler review messner reeve legal work kindler moran hit counsel see moran passion work promptly send memo mcdonald chain recommendation retain messner reeve chipotle legal work moran didn forget kindler run ceo pfizer pfe eventually joined chipotle board finally march moran accept position president chief operate officer ell company become co ceo jan tell steve wasn sure be qualify be ceo moran say ell answer position be more moran title figure say moran remember steve tell monty thing re best be lead person lawyer part be secondary lead successful law firm employee come place employee challenge appealed moran share lesson realize leadership be more valuable trait be top notch trial lawyer
1752,PFE,specialty drug giant actavis act beat analyst estimate wednesday management project solid future expand product line aid acquisition earning jump year earlier quarter share top analyst consensus cent accord thomson reuter sale gain beating estimate stock rise
1753,PFE,take do small fry take big pharma part game plan adrian adam ceo man health care focuse specialty biotech auxilium pharmaceutical auxl adam take auxilium helm december time company have product testim testosterone gel treat low testosterone level xiaflex
1754,PFE,early rebound continue lose steam late trading monday
1755,PFE,nasdaq be meanwhile dow jone industrial average lose turnover be run higher major exchange stock market today
1756,PFE,leader volume be again few kapstone paper packaging ks salix pharmaceutical slxp be hardest hit fall former be session low still day move average breach earlier
1757,PFE,upside gopro gpro push gain reverse higher company announce new hero camera shoot better quality photo take video faster frame rate also unveil plan much cheaper entry level camera piper jaffray hike price target gopro be now past buy point ipo base trigger week hold rule shortly breaking
1758,PFE,arista network anet rally best level more week back be past buy point cup handle base stock handle correct deeper threshold santa clara calif base arista provide networking hardware software cloud service provider analyst poll thomson reuter see earning rise share year
1759,PFE,elsewhere cinta cta synnex snx report quarterly result close early rebound continue lose steam late trading monday nasdaq be meanwhile dow jone industrial average lose turnover be run higher major exchange stock market today leader volume be again few kapstone paper packaging ks salix pharmaceutical slxp be hardest hit fall former be session low still day move average breach earlier upside gopro gpro push gain reverse higher company announce new hero camera shoot better quality photo take video faster frame rate also unveil plan much cheaper entry level camera piper jaffray hike price target gopro be now past buy point ipo base trigger week hold rule shortly breaking arista network anet rally best level more week back be past buy point cup handle base stock handle correct deeper threshold santa clara calif base arista provide networking hardware software cloud service provider analyst poll thomson reuter see earning rise share year elsewhere cinta cta synnex snx report quarterly result close
1760,PFE,dow jone industrial average end higher monday nasdaq re-cover early loss resilient performance close nasdaq fall less lower be much still hold day move average find support april dow jone industrial average add rise preliminary datum show nyse nasdaq volume come well friday level stock market today apple aapl be bright spot thursday gap price strong earning share rise week high elsewhere pfizer pfe be best gainer dow share rise news drugmaker be interested re start talk astrazeneca azn regard merger early january pfizer offer share cash stock astrazeneca reject bid too low share astrazeneca soar downside nasdaq list name baidu bidu illumina ilmn wynn resort wynn take hit fall anywhere baidu report quarter strong growth last week stock be now day move average wynn hasn report earning yet be result next few day meanwhile seller continue hammer facebook fb share lose heavy volume deliver outstanding earning last week price action lately show institutional investor have be unwinding position watch earning report tuesday like spirit airline save therapeutic anik trinity industry trn
1761,PFE,recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale
1762,PFE,now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor
1763,PFE,american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial
1764,PFE,pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease
1765,PFE,pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug
1766,PFE,monthly injection
1767,PFE,drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate
1768,PFE,majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease
1769,PFE,then be patient tolerate statin
1770,PFE,morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate
1771,PFE,regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone
1772,PFE,company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab
1773,PFE,amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal
1774,PFE,pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc
1775,PFE,analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville
1776,PFE,look safety issue
1777,PFE,think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety
1778,PFE,think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug
1779,PFE,safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report
1780,PFE,turn other pcsk player have get same letter deny have find significant safety issue
1781,PFE,analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia
1782,PFE,isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame
1783,PFE,safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve
1784,PFE,pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug monthly injectionsall drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease then be patient tolerate statin morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville look safety issue think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report turn other pcsk player have get same letter deny have find significant safety issue analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point
1785,PFE,specialty pharmaceutical company depome depo have be nearly year ceo james schoeneck say have only just begin realize potential drug product portfolio be acquire most recent migraine drug cambia be buy december nautilus neurosciences cambia eventually become
1786,PFE,big pharma pfizer pfe briefly halter trading wednesday afternoon announce patent best selling arthritis drug celebrex have be invalidate district court trading resume share be nearly stock market today pfizer have sue maker generic drug teva pharmaceutical industry teva mylan myl watson laboratory now part actavis ticker
1787,PFE,animal health company zoetis zts early tuesday beat analyst estimate guide consensus send share early trading tuesday
1788,PFE,zoetis say sale rise year earlier quarter vs analyst consensus adjust net income be cent share beating estimate cent company do not offer year comparison latter likely be then still part pfizer pfe spinoff start trading price share feb
1789,PFE,zoetis stock be early trading stock market today earlier session share fall time low stock first day trading
1790,PFE,zoetis guide revenue last year miss analyst ep guide be also modestly last year consensus
1791,PFE,isi group analyst mark schoenebaum partly defend company point guidance include worth foreign exchange rate drag be not mentioned zoetis earning release impact account guidance be roughly line wall street write email client
1792,PFE,acknowledge however be gross margin expansion year investor have be hope conference call discuss result zoetis cfo richard passov say be year peak synergy imply margin expansion improve later
1793,PFE,follow amy reeve twitter ibd_areeve animal health company zoetis zts early tuesday beat analyst estimate guide consensus send share early trading tuesday zoetis say sale rise year earlier quarter vs analyst consensus adjust net income be cent share beating estimate cent company do not offer year comparison latter likely be then still part pfizer pfe spinoff start trading price share feb zoetis stock be early trading stock market today earlier session share fall time low stock first day trading zoetis guide revenue last year miss analyst ep guide be also modestly last year consensus isi group analyst mark schoenebaum partly defend company point guidance include worth foreign exchange rate drag be not mentioned zoetis earning release impact account guidance be roughly line wall street write email client acknowledge however be gross margin expansion year investor have be hope conference call discuss result zoetis cfo richard passov say be year peak synergy imply margin expansion improve later follow amy reeve twitter ibd_areeve
1794,PFE,regeneron pharmaceutical regn plunge friday afternoon trading be briefly halter volatility word get fda be investigate cholesterol drug candidate adverse effect item be bury deep form regeneron big pharma partner sanofi sny file friday discussion firm collaboration alirocumab monoclonal antibody
1795,PFE,stock be well lows midday tuesday jump european bond yield point higher borrow cost
1796,PFE,just hour session nasdaq be slip dow jone industrial average ease volume nyse nasdaq be run higher compare same time monday
1797,PFE,major average be much early session yield year european bond rise highest level month monday yield year treasury note surge basis point
1798,PFE,stock market today gap gps fall heavy volume apparel retailer report weaker expect april same store sale
1799,PFE,commercial service outsource industry group be day worst perform weigh wagework wage plunge stifel nicolaus cut price target employee benefit provider wagework be week high sink day day move average
1800,PFE,upside manage health care stock humana hum be heavy turnover stock be hit resistance day move work flat base buy point stock be well lows midday tuesday jump european bond yield point higher borrow cost just hour session nasdaq be slip dow jone industrial average ease volume nyse nasdaq be run higher compare same time monday major average be much early session yield year european bond rise highest level month monday yield year treasury note surge basis point stock market today gap gps fall heavy volume apparel retailer report weaker expect april same store sale commercial service outsource industry group be day worst perform weigh wagework wage plunge stifel nicolaus cut price target employee benefit provider wagework be week high sink day day move average upside manage health care stock humana hum be heavy turnover stock be hit resistance day move work flat base buy point
1801,PFE,auxilium pharmaceutical auxl beat analyst expectation guide line friday morning auxilium share be more early trading stock market today hit highest point revenue totale analyst consensus be year earlier quarter include time payment
1802,PFE,biotech medicine co mdco say wednesday have acquire antibiotic developer rempex pharmaceutical medicine co stock be more morning trading stock market today rempex have product market minocin iv infection medicine co take marketing company plan file approval new
1803,PFE,ligand pharmaceutical lgnd hasn turn profit year drug developer not only expect make money year lift guidance fourth quarter full year la jolla calif base company say last month now expect gaap earning cent share revenue vs
1804,PFE,stock end modestly higher wednesday hit time high datum suggest economy be pick
1805,PFE,rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum
1806,PFE,private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower
1807,PFE,order manufacture good rise better expect february biggest increase month
1808,PFE,stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high
1809,PFE,meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week
1810,PFE,downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect
1811,PFE,company also say have receive subpoena education department seek information university phoenix operation northeast stock end modestly higher wednesday hit time high datum suggest economy be pick rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower order manufacture good rise better expect february biggest increase month stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect company also say have receive subpoena education department seek information university phoenix operation northeast
1812,PFE,beleaguered blackberry bbry be schedule report quarterly earning open friday revenue project fall year earlier period be eighth double digit drop last quarters not analyst have entirely throw towel blackberry pioneer former leader smartphone market prior arrival apple aapl iphone google goog android handset analyst brian blair wedge partner open letter blackberry management issue thursday talk opportunity path even wall street believe re dead only way blackberry survive write be abandon high end market attack low end vigor stay path ve be blackberry end various part company get chopped sell highest bidder write high end smartphone market be slow low end be growth be blair write profit low end be slim competition fierce only place have shot selling unit time be able move upstream midtier market once favorite corporate government customer first company come secure mobile email system blackberry have see market share slide ever introduction iphone follow google introduction android open source mobile operate system pfizer pfe world largest pharmaceutical company recently tell blackberry user switch iphone android base handset wireless contract permit upgrade ibd report just direction blackberry intend go come sharper view report earning friday early last month blackberry shelved plan go private replace ceo thorsten hein say be take investment fairfax financial holding exchange convertible debt ibd report hein be replace john chen former ceo sybase interim ceo press release announce ceo transition chen say blackberry be iconic brand enormous potential go take time discipline tough decision reclaim success blackberry be report result fiscal end nov analyst consensus estimate be revenue year earlier quarter previous quarter consensus estimate earning share item be loss cent widening loss cent be seventh quarter row red look update plan chen salvage blackberry lucrative service business shift open platform manage device business break even point write mark mckechnie analyst evercore group research report long term think blackberry have chance maintain portion service footprint support android apple io blackberry stock be afternoon trading stock market today
1813,PFE,past year bring sea change drug well few didn quite work plan herewith highly subjective ranking most newsworthy drug launch sovaldi drug approve year have quite expectation gilead science gild hepatitis drug fda approve dec
1814,PFE,big pharma pfizer pfe say monday vaccine prevenar prevent pneumonia giant study elderly subject potentially greatly expand sale product pfizer be study particular variety call community acquire pneumoccal pneumonia cap press release call significant cause illness death adult world subject participate
1815,PFE,amgen amgn stock be afternoon trading stock market today company present study new cholesterol drug weekend result ease safety concern raise earlier month competitor regeneron regn sanofi sny pfizer pfe bristol myer squibb bmy also present datum share be fraction flat
1816,PFE,most person identity invented podcast be unimportant curiosity best medium giant more comedian brewing legal battle podcast own patent be laugh matter stake be million dollar potentially freedom podcast news corp nws fox broadcasting
1817,PFE,market capitalization north bet dow component pfizer pfe have lot go pipeline monday company release result post approval study show pneumonia vaccine prevenar prevent disease study elderly subject pfizer say study meet primary endpoint full result
1818,PFE,pfizer pfe release mixed result phase clinical trial drug xeljanz psoriasis wednesday company hope expand product already used rheumatoid arthritis ra
1819,PFE,study look withdrawal retreatment xeljanz course year find statistically superior placebo other study compare response patient xeljanz amgen amgn enbrel popular exist treatment didn release exact number company find milligram xeljanz be statistically inferior enbrel be not case mg dose
1820,PFE,email client isi group analyst mark schoenebaum point difference dosage be important
1821,PFE,ra xeljanz be study mg dose be only approve mg dose due concern increase safety risk write
1822,PFE,result say be risk only mg dose be approve psoriasis then dermatologist view xeljanz be inferior enbrel other biologic similar less robust pool long term safety datum
1823,PFE,xeljanz do have advantage be pill enbrel be injection launch rheumatoid arthritis be slow european union however reject safety reason
1824,PFE,pfizer stock be fraction early afternoon trading stock today wednesday so be amgen stock pfizer pfe release mixed result phase clinical trial drug xeljanz psoriasis wednesday company hope expand product already used rheumatoid arthritis ra study look withdrawal retreatment xeljanz course year find statistically superior placebo other study compare response patient xeljanz amgen amgn enbrel popular exist treatment didn release exact number company find milligram xeljanz be statistically inferior enbrel be not case mg dose email client isi group analyst mark schoenebaum point difference dosage be important ra xeljanz be study mg dose be only approve mg dose due concern increase safety risk write result say be risk only mg dose be approve psoriasis then dermatologist view xeljanz be inferior enbrel other biologic similar less robust pool long term safety datum xeljanz do have advantage be pill enbrel be injection launch rheumatoid arthritis be slow european union however reject safety reason pfizer stock be fraction early afternoon trading stock today wednesday so be amgen stock
1825,PFE,antero resource ar oil gas firm go public last month get green light investment number analyst monday stock continue be best ipos year antero be initiate overweight rating jpmorgan price target barclay also give overweight rating
1826,PFE,biotech amgen amgn report monday late stage trial cholesterol drug evolocumab meet primary endpoint send amgen stock morning trading stock market today
1827,PFE,trial test potency evolocumab lower ldl bad cholesterol patient homozygous familial rare genetic disorder affect person accord amgen patient evolocumab report significantly lower ldl level placebo group amgen be wait future medical conference report much
1828,PFE,amgen be study evolocumab number different population hope become next blockbuster cholesterol drug belong emerge class call pcsk inhibitor be also be develop pfizer pfe well regeneron regn team sanofi sny
1829,PFE,december report morningstar analyst stefan quenneville estimate person roughly equivalent number person abroad be eligible therapy kind drug lead global market opportunity eventually estimate amgen take expect be first
1830,PFE,nonetheless group also spark worry wall street earlier month come fda be inquiring neurocognitive event related pcsk company involved have deny see kind safety issue trial
1831,PFE,follow amy reeve twitter ibd_areeve biotech amgen amgn report monday late stage trial cholesterol drug evolocumab meet primary endpoint send amgen stock morning trading stock market today trial test potency evolocumab lower ldl bad cholesterol patient homozygous familial rare genetic disorder affect person accord amgen patient evolocumab report significantly lower ldl level placebo group amgen be wait future medical conference report much amgen be study evolocumab number different population hope become next blockbuster cholesterol drug belong emerge class call pcsk inhibitor be also be develop pfizer pfe well regeneron regn team sanofi sny december report morningstar analyst stefan quenneville estimate person roughly equivalent number person abroad be eligible therapy kind drug lead global market opportunity eventually estimate amgen take expect be first nonetheless group also spark worry wall street earlier month come fda be inquiring neurocognitive event related pcsk company involved have deny see kind safety issue trial follow amy reeve twitter ibd_areeve
1832,PFE,specialty drug company horizon pharma hznp be roll arthritis drug duexis vimovo treat arthritis pain protect ulcer bang most other drug treat arthritis don provide most arthritis drug use nonsteroidal inflammatory drug nsaid add roll layer ulcer protect compound
1833,PFE,annual meeting american association cancer research convene san diego april be view most drug industry watcher second tier medical conference physician investor be watch closely year pfizer report drug dramatically extend life patient breast cancer pfizer pfe
1834,PFE,jpmorgan chase jpm nation largest bank send wall street giant lower monday company say expect slide fix income equity revenue vs year earlier forecast underscore big bank struggle growth post financial crisis world increase capital requirement government scrutiny jpmorgan friday filing security exchange
1835,PFE,puma biotechnology pbyi stock vault new high morning trading stock market today company report surprisingly strong datum phase trial breast cancer drug study give regimen puma neratinib combine paclitaxel better know bristol myer squibb bmy taxol patient breast cancer
1836,PFE,wag sale climb april more customer visit store spend more visit result also get lift later easter holiday year last drug store operator say share rise record close stock set intraday peak
1837,PFE,acquisition have long be staple drug industry drive force investment decision big pharmas blockbuster drug have go patent ve filled pipeline buy smaller firm new drug smaller player buyout be usually investor chief hope healthy return investment little biotechs be
1838,PFE,recur theme big pharma earning season pfizer pfe sale miss wall street expectation company controlled expense well enough beat bottom line stock slide more stock market today
1839,PFE,pfizer earning totale cent share year earlier quarter beating analyst consensus cent sale decline miss consensus
1840,PFE,company affirm previous full year guidance call sale ep last year pfizer make share sale
1841,PFE,analyst have expect sale contraction due continue effect patent loss proprietary drug show weakness well top selling product be epilepsy drug lyrica sale rise be short analyst expect sale arthritis drug celebrex be danger lose patent year slide well short analyst
1842,PFE,half revenue miss be fx foreign exchange drive many product line be also weak write isi group analyst mark schoenebaum email client company do good job however expense management addition taxe be lower timer
1843,PFE,pfizer stock have be volatile lately drama pursuit astrazeneca azn be mid morning trade
1844,PFE,follow amy reeve twitter ibd_areevesin recur theme big pharma earning season pfizer pfe sale miss wall street expectation company controlled expense well enough beat bottom line stock slide more stock market today pfizer earning totale cent share year earlier quarter beating analyst consensus cent sale decline miss consensus company affirm previous full year guidance call sale ep last year pfizer make share sale analyst have expect sale contraction due continue effect patent loss proprietary drug show weakness well top selling product be epilepsy drug lyrica sale rise be short analyst expect sale arthritis drug celebrex be danger lose patent year slide well short analyst half revenue miss be fx foreign exchange drive many product line be also weak write isi group analyst mark schoenebaum email client company do good job however expense management addition taxe be lower timer pfizer stock have be volatile lately drama pursuit astrazeneca azn be mid morning trade follow amy reeve twitter ibd_areeve
1845,PFE,most case investor insist see strong track record profit growth sometimes pay see company be turn profitable lose money number year ligand pharmaceutical lgnd be expect be black year analyst poll thomson reuter see biotech earn cent
1846,PFE,medical giant johnson johnson jnj beat analyst expectation result full year outlook tuesday morning give investor early glimpse quarter overall health care environment earning season begin share be fraction midday trading stock market rise much early trading tuesday
1847,PFE,make share quarter year earlier quarter beating wall street consensus cent sale rise estimate company guide full year ep range few cent previous guidance squarely consensus last year profit be share
1848,PFE,analyst widely expect pharmaceutical business power growth recently launch drug surpass already high expectation sale prostate cancer drug zytiga surge year year immunology drug simponi stelara grow respectively anticoagulant xarelto launch less year nearly triple sale face competition bristol myer squibb bmy pfizer pfe eliquis
1849,PFE,contrast revenue consumer division rise just fraction medical device diagnostic md shed conference call analyst cfo dominic caruso say be due sluggish macroeconomy remain pretty much same previous quarter press consumer government budget
1850,PFE,company be still process integrate synthe orthopedic company buy last year michel orsinger former ceo synthe have become chairman combine puy synthe business say trauma spine product line miss expectation partly due cheap compete product
1851,PFE,immediate analyst reaction look bigger picture
1852,PFE,overall jnj continue ride back strong pharma performance recent product launch continue exceed expectation write leerink swann danielle antalffy email client consensus md sale perpetuate concern broader medtech utilization trend remain weak strong surgical sale actually signal potentially positive volume trend overall
1853,PFE,related ibd income investor column look medical giant johnson johnson jnj beat analyst expectation result full year outlook tuesday morning give investor early glimpse quarter overall health care environment earning season begin share be fraction midday trading stock market rise much early trading tuesday make share quarter year earlier quarter beating wall street consensus cent sale rise estimate company guide full year ep range few cent previous guidance squarely consensus last year profit be share analyst widely expect pharmaceutical business power growth recently launch drug surpass already high expectation sale prostate cancer drug zytiga surge year year immunology drug simponi stelara grow respectively anticoagulant xarelto launch less year nearly triple sale face competition bristol myer squibb bmy pfizer pfe eliquis contrast revenue consumer division rise just fraction medical device diagnostic md shed conference call analyst cfo dominic caruso say be due sluggish macroeconomy remain pretty much same previous quarter press consumer government budget company be still process integrate synthe orthopedic company buy last year michel orsinger former ceo synthe have become chairman combine puy synthe business say trauma spine product line miss expectation partly due cheap compete product immediate analyst reaction look bigger picture overall jnj continue ride back strong pharma performance recent product launch continue exceed expectation write leerink swann danielle antalffy email client consensus md sale perpetuate concern broader medtech utilization trend remain weak strong surgical sale actually signal potentially positive volume trend overall related ibd income investor column look
1854,PFE,swiss giant pharma novartis nvs monday announce agree sell blood transfusion diagnostic unit spain grifol grfs send stock stock market grifol say deal complement core plasma business diagnostic technology also strengthen business production plant emeryville calif novartis
1855,PFE,salix pharmaceutical slxp have pique investor interest business have heated flagship drug xifaxan promising prospect
1856,PFE,specialty drugmaker focus ailment xifaxan rifaximin be oral antibiotic approve food drug administration treat traveler diarrhea liver condition call overt hepatic encephalopathy doctor prescribe other used label
1857,PFE,salix xifaxan franchise have take sale more double make growth story rev investor enthusiasm
1858,PFE,salix have be top perform stock specialty pharmaceutical increase year date say leerink swann analyst jason gerberry strength stock have do key product franchise xifaxan growth product franchise be stronger relative investor have expect
1859,PFE,more explore
1860,PFE,salix be explore potential additional indication formulation clinical trial co promotion arrangement capitalize potential xifaxan
1861,PFE,big opportunity lie use treatment irritable bowel syndrome ib company be midst so call target phase trial xifaxan ib diarrhea
1862,PFE,company expect fda decision regard approval mid
1863,PFE,get fda nod salix have pathway ib market be very large say gerberry
1864,PFE,xifaxan fight bacterium digestive tract gi specific antibiotic remain only gi tract doesn spread body
1865,PFE,fda first approve xifaxan mg treatment traveler diarrhea stronger mg version get nod reduce risk recurrence overt hepatic encephalopathy condition occur liver do not work normally xifaxan be only drug approve purpose orphan drug exclusivity march
1866,PFE,have credit company develop product nothing develop market expand market new indication great marketing say capital iq analyst herman saftla investor buy company be hope re successful expand used product develop new one
1867,PFE,salix xifaxan have fda approval have multiple used many different disease say gerberry
1868,PFE,use approve treatment overt hepatic encephalopathy biggest contributor sale have be drive strength product say
1869,PFE,gerberry figure xifaxan generate company sale forecast product sale climb salix be seek approval mg strength xifaxan treat ib diarrhea
1870,PFE,gerberry upgrade salix outperform market perform september report note be base improve outlook xifaxan ib diarrhea predominant irritable bowel head target datum read support recent medacorp survey check medacorp regulatory specialist formerly fda gi division
1871,PFE,key takeaway xifaxan forecast penetration ib be well consensus expectation believe target have high probability success previously publish believe target have good probability report positive datum
1872,PFE,estimate probability success target
1873,PFE,gerberry forecast xifaxan peak sale hit potential drug approval ib diarrhea be include estimate
1874,PFE,salix other product include apriso once day treatment maintenance remission ulcerative colitis relistor relistor license salix progenic pharmaceutical pgnx be subcutaneous injection used treat opioid induced constipation cancer patient
1875,PFE,fda discussion
1876,PFE,salix progenic have submit new drug application relistor use cancer patient take opiate chronic pain well
1877,PFE,july salix progenic receive complete response letter fda say need further clinical datum relistor injection
1878,PFE,salix progenic announce oct fda hold advisory committee meeting march consider new drug application
1879,PFE,re look get product approve broader market cancer patient be much larger market say saftla fda didn give street expect eventually be potentially big number do get approval
1880,PFE,meanwhile salix see profit rise cent share second quarter miss analyst consensus cent accord thomson reuter sale pop ahead view xifaxan sale be mg prescription business grow vs year earlier
1881,PFE,apriso see strong prescription growth relistor prescription rise
1882,PFE,analyst poll thomson reuter expect salix show decline third quarter company earning cent share report result thursday close
1883,PFE,expect year year decline be drive few factor include increase tax rate vs expect increase share count vs say gerberry
1884,PFE,street also assume gross margin compression well say add wall street expect third quarter sale grow year earlier
1885,PFE,analyst expect nice profit gain fourth quarter full year forecast rise earning share
1886,PFE,gerberry say general factor impact third quarter apply full year number difference exact amount
1887,PFE,salix be largest company market capitalization ibd medical ethical drug industry group group largest constituent be roche hold rhhby pfizer pfe novartis nvs be currently rank group track
1888,PFE,salix pharmaceutical slxp have pique investor interest business have heated flagship drug xifaxan promising prospect specialty drugmaker focus ailment xifaxan rifaximin be oral antibiotic approve food drug administration treat traveler diarrhea liver condition call overt hepatic encephalopathy doctor prescribe other used label salix xifaxan franchise have take sale more double make growth story rev investor enthusiasm salix have be top perform stock specialty pharmaceutical increase year date say leerink swann analyst jason gerberry strength stock have do key product franchise xifaxan growth product franchise be stronger relative investor have expect more exploresalix be explore potential additional indication formulation clinical trial co promotion arrangement capitalize potential xifaxan big opportunity lie use treatment irritable bowel syndrome ib company be midst so call target phase trial xifaxan ib diarrhea company expect fda decision regard approval mid get fda nod salix have pathway ib market be very large say gerberry xifaxan fight bacterium digestive tract gi specific antibiotic remain only gi tract doesn spread body fda first approve xifaxan mg treatment traveler diarrhea stronger mg version get nod reduce risk recurrence overt hepatic encephalopathy condition occur liver do not work normally xifaxan be only drug approve purpose orphan drug exclusivity march have credit company develop product nothing develop market expand market new indication great marketing say capital iq analyst herman saftla investor buy company be hope re successful expand used product develop new one salix xifaxan have fda approval have multiple used many different disease say gerberry use approve treatment overt hepatic encephalopathy biggest contributor sale have be drive strength product say gerberry figure xifaxan generate company sale forecast product sale climb salix be seek approval mg strength xifaxan treat ib diarrhea gerberry upgrade salix outperform market perform september report note be base improve outlook xifaxan ib diarrhea predominant irritable bowel head target datum read support recent medacorp survey check medacorp regulatory specialist formerly fda gi division key takeaway xifaxan forecast penetration ib be well consensus expectation believe target have high probability success previously publish believe target have good probability report positive datum estimate probability success target gerberry forecast xifaxan peak sale hit potential drug approval ib diarrhea be include estimate salix other product include apriso once day treatment maintenance remission ulcerative colitis relistor relistor license salix progenic pharmaceutical pgnx be subcutaneous injection used treat opioid induced constipation cancer patient fda progenic have submit new drug application relistor use cancer patient take opiate chronic pain well july salix progenic receive complete response letter fda say need further clinical datum relistor injection salix progenic announce oct fda hold advisory committee meeting march consider new drug application re look get product approve broader market cancer patient be much larger market say saftla fda didn give street expect eventually be potentially big number do get approval meanwhile salix see profit rise cent share second quarter miss analyst consensus cent accord thomson reuter sale pop ahead view xifaxan sale be mg prescription business grow vs year earlier apriso see strong prescription growth relistor prescription rise analyst poll thomson reuter expect salix show decline third quarter company earning cent share report result thursday close expect year year decline be drive few factor include increase tax rate vs expect increase share count vs say gerberry street also assume gross margin compression well say add wall street expect third quarter sale grow year earlier analyst expect nice profit gain fourth quarter full year forecast rise earning share gerberry say general factor impact third quarter apply full year number difference exact amount salix be largest company market capitalization ibd medical ethical drug industry group group largest constituent be roche hold rhhby pfizer pfe novartis nvs be currently rank group track
1889,PFE,giant pharma pfizer pfe beat analyst expectation early tuesday offer guidance line estimate stock be more early trading
1890,PFE,revenue fall year earlier quarter drop reflect pfizer loss patent blockbuster lipitor number still solidly beat analyst consensus sale major segment beat consensus fact include animal health be good news potential investor zoetis spinoff ipo
1891,PFE,profit fall cent share top estimate cent
1892,PFE,company guide sale range last year say ep be be last year giant pharma pfizer pfe beat analyst expectation early tuesday offer guidance line estimate stock be more early trading revenue fall year earlier quarter drop reflect pfizer loss patent blockbuster lipitor number still solidly beat analyst consensus sale major segment beat consensus fact include animal health be good news potential investor zoetis spinoff ipo profit fall cent share top estimate cent company guide sale range last year say ep be be last year
1893,PFE,reversal fortune thursday morning left stock battle loss midday session open note see nasdaq dive strong trade noon drop dow jone industrial average hold loss pfizer pfe ibm ibm general electric ge leane gain
1894,PFE,share big pharma merck mrk gap stock market tuesday morning company announce restructure say save merck say news release cut job global workforce top job cut have already be
1895,PFE,pfizer pfe beat second quarter estimate report good trial result potential blockbuster drug tuesday send share highest close january pfizer report sale year quarter analyst consensus drop be expect due firm loss patent
1896,PFE,big pharmas merck mrk pfizer pfe report basically line earning early tuesday have develop story pique investor interest merck revenue drop year earlier quarter slightly analyst consensus profit cent share beat estimate cent still earning fall last
1897,PFE,oil natural gas company antero resource ar lead parade stock first day trading thursday rise more early day antero raise ipo second biggest ipo year base company produce gas rich shale oilfield west virginia ohio pennsylvania begin trading
1898,PFE,index enjoy strong week gain boost expectation strong second quarter earning season strong economic datum such last friday job report also help investor ignore trade tension however trade war fear do make comeback wednesday president trump decision impose fresh tariff china temporarily halter market rally last week index gain last friday investor ignore trade conflict unite state china follow strong job addition june economy add farm job june outpace consensus estimate unemployment rate increase primarily due increase labor force participation rate index gain last week reverse straight weekly loss market close slightly higher monday initial decline owing uncertainty revolve president trump trade policy be reversed rally tech stock market close lower tuesday selloff tech stock pare earlier gain make energy stock trade war fear continue haunt investor feel jittery lead huge selloff however thursday market close higher follow rally tech stock dow index monday record biggest gain more month gain help blue chip index return positive territory moreover index also close day move average first time jun investor shrug trade war fear buoy strong economic datum primarily friday job report encourage datum trade deficit well strong consumer credit datum increase investor appetite riskier asset equity index gain tuesday post first day winning streak jun investor have pin high hope second quarter earning result evaporation trade war concern robust economy also boost investor confidence equity index lose wednesday once again enter negative territory year date president donald trump decision impose second round tariff worth chinese good halter day market rally new tariff undergo month review final decision be take energy stock plunge wednesday trade war concern positive news supply side index gain thursday boost rally tech major internet giant negate trade tension investor seem be focuse upcoming earning robust economic datum share microsoft corporation msft free report gain hit record high share cisco csco free report intel intc free report apple aapl free report gain respectively share caterpillar cat free report boee company ba free report gain respectively component move index boee recently announce program delivery commercial defense operation second quarter figure show rise commercial shipment decline defense shipment previous year zack rank hold boee report second quarter commercial delivery airplane year year primarily backed higher demand jet delivery single aisle jet increase second quarter year number defense space business boee delivery totale second quarter plunge dispatch year period boee total delivery be unit second quarter compare deliver year quarter read boee commercial delivery defense take hit merck co inc mrk free report announce fda have grant priority review supplemental new drug application sbla pd inhibitor keytruda latest filing zack rank merck be look get keytruda approve treatment advanced hepatocellular carcinoma hcc form liver cancer patient previously treat systemic therapy sorafenib fda be expect give verdict nov sbla be base positive datum phase ii study keynote outcome demonstrated treatment keytruda monotherapy lead overall response rate orr patient advanced hcc read merck keytruda get fda priority review liver cancer pfizer inc pfe free report announce be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently zack rank pfizer have report segment innovative health essential health read pfizer reorganize business new unit separate development response president donald trump tweet monday pfizer say defer recent price increase several prescription drug maximum end year chief executive officer ian read announce decision follow extensive discussion president read pfizer defer price increase discussion trump chevron corporation cvx free report be set put many north sea oil gas asset sale bid streamline portfolio asset intend offload include britannia satellite alba captain elgin franklin erskine field move be part chevron strategic review global portfolio determine competitiveness project decision seem be prudent extract oil north sea be not so economical production cost be much higher return even other biggy bp plc bp free report royal dutch shell plc rd free report have jettison core asset region stock have zack rank strong buy see complete list today zack rank stock here microsoft be set introduce surface go tablet bid explore low price tablet market news come surprise development rumor have be do round follow bloomberg revelation microsoft have zack rank new surface go feature inch screen weigh pound lighter prevailing surface counterpart latest series be equip intel processor graphic chip different variant new tablet series come storage capacity gb gb gb gb gb ram few model also have feature connect lte cellular network price range accord specification read microsoft set launch surface go up ante edtech jpmorgan chase co jpm free report have initiate relocation plan several dozen employee office bid ensure business continuity brexit news be first report reuter memo also outlined plan expand bank presence other european city such paris madrid milan jpmorgan have zack rank most employee be relocate presently serve client face risk management related role company investment banking asset management division have be ask relocate brexit occur march now be expect bank move employee expand operation frankfurt luxembourg dublin already have banking license read jpmorgan relocate dozen personnel pre brexit performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week trump remain determine go ahead protectionist measure particularly china have make investor tad jittery have largely ignore such concern be fast become market best week recent time investor continue focus strong economic datum upcoming earning market notch more record week ahead medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1899,PFE,investor focuse medical space have likely hear pfizer pfe free report be stock perform well comparison rest sector peer simple way answer question be take look year date performance pfe rest medical group stock pfizer be member medical sector group include individual stock currently hold zack sector rank zack sector rank gauge strength individual sector group measure average zack rank individual stock group zack rank be successful stock pick model emphasize earning estimate estimate revision system highlight number different stock be poise outperform broader market next month pfe be currently sporting zack rank buy past quarter zack consensus estimate pfe full year earning have moved higher be sign improve analyst sentiment positive earning outlook trend latest available datum show pfe have return start calendar year meanwhile stock medical group have gain average mean pfizer be outperform sector whole year look more specifically pfe belong large cap pharmaceutical industry group include individual stock currently sit zack industry rank average group have lose average so far year meaning pfe be perform better term year date return investor interest medical stock continue track pfe stock be look continue solid performance
1900,PFE,biggest news week be pfizer pfe free report announcement plan re organize business new segment effective next year jnj free report be order st loui jury pay approximately nearly dozen woman lawsuit related talc base product merck mrk free report abbvie abbv free report bristol myer bmy free report provide update cancer drug pfizer re organize business unit pfizer be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment namely innovative health essential health present innovative health unit be call innovative medicine unit now include biosimilar new hospital business unit infective sterile injectable be presently report essential health essential health unit now be rename establish medicine unit include pfizer legacy brand have lose lose market exclusivity read more pfizer reorganize business new unit pay talc lawsuit be order jury st loui court pay damage woman allege talc base product include baby powder contain asbestos cause develop ovarian cancer damage comprise compensatory damage punitive damage official statement say verdict be unfair appeal also say talc product neither contain asbestos cause cancer face more case talc product trump slam pfizer price hike pfizer defer increase tweet president donald trump slam pfizer raise price several prescription drug effective jul trump say pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas warn administration respond day tweet be publish pfizer issue statement say defer price increase president drug pricing blueprint go effect end year be earlier abbvie imbruvica lymphoma study fail abbvie announce late stage study evaluate cancer drug imbruvica first line treatment diffuse large cell lymphoma dlbcl fail meet primary endpoint study evaluate addition imbruvica chop combination rituximab doxorubicin vincristine prednisone be exist standard care dlbcl aggressive form hodgkin lymphoma nhl versus chop placebo however study datum show add imbruvica chop do not improve event free survival ef target patient population imbruvica be presently fda approve indication include cell blood cancer well chronic graft versus host disease drug abbvie market partnership record sale first quarter include sale international profit sharing abbvie also file supplemental new drug application snda fda label expansion venclexta venetoclax first line treatment acute myeloid leukemia aml abbvie be look get venclexta approve combination hypomethylating agent hma low dose cytarabine ldac aml patient be ineligible intensive chemotherapy read more abbvie imbruvica fail phase iii blood cancer study merck keytruda sbla get priority review merck supplemental biologic license application sbla look expand label keytruda previously treat patient advanced hepatocellular carcinoma hcc most common type liver cancer be grant priority review fda fda decision be expect nov sbla filing be base datum phase ii keynote study read more merck keytruda get fda priority review liver cancer bristol myer opdivo yervoy combo get fda nod colorectal cancer bristol myer announce accelerate approval combination immuno oncology drug opdivo yervoy type colorectal cancer combination be now approve previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer opdivo yervoy combination be also approve other tumor type first line treatment intermediate poor risk advanced renal cell carcinoma unresectable metastatic melanoma read more bristol myer combo drug get fda nod colorectal cancer cti biopharma slump study failure share cti biopharma ctic free report slump monday pivotal study evaluate combination regimen cancer drug pixuvri hodgkin lymphoma fail improve progression free survival pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state read more cti biopharma fall failure pivotal lymphoma study nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record increase last week astrazeneca azn free report gain most past month glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup nvs divest eye care unit chmp give nod several drug next pharma world watch earning bigwig pharma world later month begin jul medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1901,PFE,pfizer inc pfe free report announce be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment innovative health essential health present innovative health unit be call innovative medicine other include current innovative health business unit innovative medicine include new hospital medicine business unit create sterile injectable infective medicine be presently record pfizer essential health unit also biosimilar now be include oncology inflammation immunology business segment innovative medicine unit essential health unit be rename establish medicine unit continue include pfizer legacy brand have lose lose market exclusivity include lyrica lipitor norvasc viagra certain generic medicine lipitor norvasc viagra have already lose patent exclusivity lyrica be expect lose same december year pfizer expect significant reduction impact patent protection loss post lyrica loss exclusivity last year pfizer have say loss exclusivity loe hurt sale negative impact go next year loe impact reduce further post go approximately not be more potentially lower loe impact pfizer be optimistic establish medicine unit generate sustainable modest revenue growth consumer healthcare unit be now part innovative health include pfizer counter drug pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year pfizer ultimately opt retain business pfizer be have tough time find buyer consumer healthcare segment march british company reckitt benckiser group glaxo gsk free report pull discussion pfizer buy consumer health segment investor believe split make sale easier also speculate pfizer sell generic unit couple year news business re organization come day pfizer defer recent price increase several prescription drug be criticize trump be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1902,PFE,innovation hold key pharma biotech sector most company have be divert resource develop gene therapy candidate goal find cure difficult incurable disease first half most pharma biotech bigwig also number smaller company scurry lucrative catch space licensing deal acquisition particular fda approval luxturna new gene therapy treatment child adult patient inherited form vision loss result blindness december spark interest space be gene therapy gene therapy enable mitigate adverse effect malfunctioning disease cause gene therapy intend add functional gene person system replace malfunctioning cure disease gene be deliver cell carrier know vector therapy have different approach traditional drug therapy underlie cause be treat symptom gene therapy be set become most promising space volatile biotech sector continue grapple competitive pressure pricing wo promising therapy be be evaluate varied disease such hemophilia duchenne muscular dystrophy dmd parkinson disease cancer other recent activity year start acquisition avexis inc swiss giant novartis nvs free report avexis lead product candidate avxs be be evaluate time gene replacement therapy spinal muscular atrophy disease result early death life long disability considerable healthcare cost novartis be try develop gene therapy portfolio january novartis sign license agreement development voretigene neparvovec brand name luxturna unite state outside unite state spark therapeutic thereafter space have see lot activity pfizer pfe free report initiate phase ib clinical trial mini gene therapy candidate pf boy dmd solid bioscience sldb free report too be news recently company announce fda have lift clinical hold lead candidate sgt microdystrophin gene transfer evaluate treatment dmd fda recently grant regenerative medicine advanced therapy rmat designation voyager therapeutic vy aadc gene therapy treatment parkinson disease patient motor fluctuation be refractory medical management stock watch forgive potential market hold number company have start develop therapy several have promising candidate pipeline axovant science axon free report be such company have be steadily develop pipeline candidate used gene therapy licensing deal company be focuse develop gene therapy product candidate axo lenti pd time treatment parkinson disease company intend begin phase ii study axo lenti pd advanced parkinson disease patient end company recently announce licensing agreement benitec biopharma axovant license exclusive global right experimental silence replace gene therapy program benitec biopharma treatment oculopharyngeal muscular dystrophy opmd axovant obtain right axo aav opmd utilize proprietary silence replace technology axo aav opmd be adeno associate viral aav vector gene therapy deliver time intramuscular administration silence mutant pabpn gene replace functional copy be currently preclinical development stage axovant plan initiate placebo controlled clinical study axovant stock have gain last month industry decline company currently carry zack rank buy see complete list today zack rank strong buy stock here uniqure qure free report be promising player space be create pipeline innovative gene therapy have be develop internally collaboration focuse cardiovascular disease bristol myer squibb company have already enrolled first patient phase iii hope pivotal study amt experimental aav base gene therapy incorporating fix padua variant treatment patient severe moderately severe hemophilia company have obtain orphan drug designation amt treatment huntington disease unite state european union hold global right program uniqure too currently carry zack rank uniqure stock have moved last month industry decline audente therapeutic bold free report be biotechnology company promising pipeline innovative gene therapy product patient live rare disease company be currently conduct phase ii study lead product candidate treatment link myotubular myopathy xlmtm treatment crigler najjar syndrome company currently have additional product candidate development include treatment pompe disease treatment casq subtype polymorphic ventricular tachycardia casq cpvt last month european medicine agency ema grant priority medicine prime designation treatment xlmtm audente currently carry zack rank share have gain last month ahead gene therapy gain traction investor keep eye space potential approval datum read out late stage trial several company be likely keep stock growth trajectory hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1903,PFE,response president donald trump tweet monday pfizer inc pfe free report say defer recent price increase several prescription drug maximum end year chief executive officer ceo ian read announce decision follow extensive discussion president last week new york base company have announce increase list price several drug effective jul be second time year pfizer increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug first tweet monday president criticize pfizer price increase trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas latest statement read say price medicine return pre jul level soon technically possible also say price be defer president drug pricing blueprint go effect end year be sooner meanwhile price cut company remain effect tweet tuesday president appreciate pfizer decision hope other follow suit incidentally pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report lilly lly free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1904,PFE,pfizer inc pfe free report announce fda have approve label expansion jak inhibitor xeljanz tofacitinib include new indication moderately severely active ulcerative colitis uc drug be approve treatment adult patient recommend dose mg twice daily least week approval be expect fda drug advisory committee have adopt positive vote meeting march recommend approval supplemental new drug application snda file july last year seek label expansion xeljanz uc xeljanz be already market treatment rheumatoid arthritis active psoriatic arthritis first quarter xeljanz sale be year period label expansion uc indication be likely boost sale further share pfizer have lose so far year compare decrease industry belong approval be base datum pivotal study octave induction octave induction octave sustain demonstrated statistically significant greater proportion patient achieve remission treat xeljanz compare placebo pfizer be currently evaluate xeljanz open label long term extension study octave open however be several blockbuster drug inflammatory segment approve uc include johnson johnson jnj free report remicade simponi abbvie abbv free report humira shire shpg free report lialda moreover many biotech company be develop candidate treatment uc hence competition be likely increase segment pfizer inc price pfizer inc price pfizer inc quotepfizer currently have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1905,PFE,pfizer inc pfe free report announce fda grant breakthrough therapy designation lung cancer drug xalkori crizotinib new indication xalkori be already market treatment alk ro positive locally advanced metastatic small cell lung cancer nsclc fact be only fda approve treatment indicated alk positive ro positive metastatic nsclc fda grant breakthrough therapy designation xalkori treatment patient metastatic nsclc meet exon alteration disease progression platinum base chemotherapy designation indication be support result expansion cohort phase profile study xalkori show antitumor activity indication breakthrough therapy designation be grant xalkori be treatment patient relapse refractory systemic anaplastic large cell lymphoma alcl be alkpositive designation indication be support study study advl nct study nct study show compelling antitumor activity pediatric adult patient treat xalkori designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient share pfizer have decline year date compare industry decline nsclc be difficult treat disease accounting lung cancer case present lung cancer treatment market be highly crowd drug bristol myer squibb bmy free report opdivo merck mrk free report keytruda roche rhhby free report alecensa novartis zykadia taxotere other zack rankpfizer have zack rank hold see complete list today zack rank stock here pfizer inc price pfizer inc price pfizer inc quote today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1906,PFE,dow endure volatile week marked key geopolitical development begin week treasury secretary make encourage remark progress trade negotiation china however later week president trump expressed dissatisfaction progress trade talk also cancel much await summit north korea leader kim jong result stock gain lose alternate session last week dow gain point last friday close session nearly unchanged trade negotiation unite state china continue weigh investor sentiment president donald trump say doubt negotiation have positive outcome also bond yield reach highest level last week index decline last week trade talk unite state china remain focus week continue weigh investor sentiment moreover high interest rate too push stock lower week year note yield crossed mark first time dent investor confidence see investor panic yield hit psychological level trigger fear equity become less appeal dow index gain nearly point monday dow also close mark first time march trade tension unite state china decline treasury secretary steve mnuchin sunday say be putt trade war hold industrial be biggest gainer stand benefit most trade war be avert share boee ba free report caterpillar cat free report unite technology utx free report jump respectively index decline tuesday erase early gain president trump say wasn satisfied progress unite state china trade talk moreover trump also say highly await summit unite state north korea not happen meanwhile white house say order get fresh nuclear deal unite state iran need stop enrich uranium withdraw support militant group middle east statement cause stock plummet further index gain wednesday lead lead rally share boee gain share mcdonald mcd surge stock gain minute fed meeting conclude earlier month hint policy maker aren worry inflation briefly run target level further such occurrence not result faster interest rate hike rate sensitive stock rally news broader market be able pare earlier loss result geopolitical tension close black index decline thursday president trump scrap summit north korea leader kim jong schedule next month have be maiden face face encounter north korean leader sit president energy stock emerge biggest loser day oil price decline follow unexpected increase domestic crude inventory share exxon mobil xom chevron cvx free report decline respectively lead blue chip index finish red component move index general electric company ge free report recently enter definitive agreement wabtec corporation wab free report lead manufacturer rail equipment agreement company merge operate segment ge transportation wabtec completion synergistic deal zack rank hold general electric obtain cash company shareholder own ownership interest combine company remain stake combine company be retain wabtec shareholder notably deal be likely close early latest move combine ge transportation digital solution railroad marine drill wind mining industry wabtec extensive range electronic solution result market capability be stronger add momentum development implementation innovative solution key market help improve safety efficiency productivity offering notably combine company have large global install base more locomotive create significant opportunity aftermarket service growth read general electric transportation unit merge wabtec johnson johnson inc jnj free report partner glaxosmithkline plc gsk free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment johnson johnson have zack rank juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infection juluca gain approval unite state november last year generate sale first quarter read glaxo drug hiv regimen juluca get eu approval merck co inc mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month stock have zack rank see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant breakthrough therapy designation rare disease candidate tafamidis candidate be be develop treatment transthyretin cardiomyopathy ttr cm designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation tafamadis be primarily base encourage top line datum phase iii attr act study demonstrated significant reduction combination cause mortality frequency cardiovascular related hospitalization ttr cm patient read pfizer tafamadis get breakthrough therapy designation separate development zack rank pfizer announce phase iii study evaluate epilepsy drug lyrica pregabalin pediatric patient meet primary endpoint read pfizer epilepsy drug lyrica succeed pediatric study microsoft corporation msft free report recently unveil new gamepad xbox adaptive controller be aim ensure gaming everyone controller price be personalize requirement gamer controller comprise big programmable button mm port round back connect blow tube pedal other accessory zack rank microsoft blog development story date back almost feature copilot release xbox witness creative use company imagination inspire developer bring inclusivity boost engagement consequently bolster user base go forward read microsoft unveil xbox controller specially able gamer performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookcomment president trump have guide market lower more occasion week only nature fed minute have prove be encourage investor otherwise absence major earning report geopolitical event have weigh heavily investor sentiment give backdrop only be natural investor turn economic report encouragement several key piece datum be line release next week include important gdp report most be encourage nature stock soon return winning way look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1907,PFE,novartis nvs free report announce generic arm sandoz obtain approval zessly biosimilar version johnson johnson jnj free report remicade europe zessly be approve use indication brand drug include rheumatoid arthritis adult crohn disease pediatric crohn disease adult ulcerative colitis pediatric ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis approval european commission be base review comprehensive development program include analytical preclinical clinical datum confirm zessly match remicade term safety efficacy quality approval be card chmp have give positive opinion same march approval strengthen sandoz already strong biosimilar portfolio market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease zessly approval sandoz now have approve biosimilar portfolio zessly be third biosimilar have be approve ec last month sandoz fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form european economic area novartis share have decline year compare industry fall however sandoz continue face pricing pressure sale be project decline upcoming quarters zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1908,PFE,pfizer inc pfe free report announce fda have grant breakthrough therapy designation rare disease candidate tafamidis candidate be be develop treatment transthyretin cardiomyopathy ttr cm designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation tafamadis be primarily base encourage top line datum phase iii attr act study demonstrated significant reduction combination cause mortality frequency cardiovascular related hospitalization ttr cm patient candidate also enjoy fast track status orphan drug designation indication unite state share pfizer have decline so far year compare favorably decrease industry ttr cm be rare disease associate progressive heart failure be universally fatal presently treatment be approve treat fatal disease accord pfizer press release less person disease be diagnosed life expectancy average year diagnosis be type ttr cm hereditary form wild type form disease be not hereditary attr act study include type patient however alnylam pharmaceutical alny free report ionis pharmaceutical ion free report have develop candidate patisiran inotersen respectively hereditary ttr amyloidosis hattr patisiran inotersen be review eu unite state be launch year tafamidis be already approve treatment transthyretin familial amyloid polyneuropathy ttr fap country unite state pfizer inc price pfizer inc price pfizer inc quotezack rank stock considerpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here lundbeck hluyy free report be better rank stock large cap pharma sector sporting zack rank lundbeck earning estimate increase last day company come average quarter positive surprise company stock have gain so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1909,PFE,merck co inc mrk free report announce fda have grant priority review supplemental new drug application sbla pd inhibitor keytruda latest filing merck be look get keytruda approve treatment advanced hepatocellular carcinoma hcc form liver cancer patient previously treat systemic therapy sorafenib fda be expect give verdict nov sbla be base positive datum phase ii study keynote outcome demonstrated treatment keytruda monotherapy lead overall response rate orr patient advanced hcc datum also show complete response rate partial response rate result treatment keytruda datum be recently produce american society clinical oncology asco cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug be first pd therapy gain fda approval be now already approve use different setting involve different tumor type have already secure fda nod new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer drug be also be study more type cancer more trial include excess combination study merck be collaborate several company amgen amgn free report incyte glaxosmithkline gsk free report pfizer pfe free report separately evaluation keytruda combination other regimen keytruda be key top line driver merck logged sale first quarter sequentially year year sale continue be drive launch new indication globally company be carry keytruda development program be progress well several regulatory decision new indication unite state well europe expect label expansion approve widen patient population base further drive sale higher share merck have increase year date versus industry decline merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1910,PFE,astrazeneca azn free report announce japanese regulatory authority have grant approval parp inhibitor lynparza tablet treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy approval lynparza become first only parp inhibitor approve use ovarian cancer japan be second indication lynparza be now approve japan lynparza be approve first indication advanced ovarian cancer regardless brca mutation status country earlier year astrazeneca share have rise so far year contrast industry have decline unite state lynparza be approve breast cancer indication january lynparza be also presently market advanced ovarian cancer later setting lynparza be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer first quarter lynparza sale rise sale unite state surge gain recent label expansion approval ovarian cancer tablet breast cancer indication europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement astrazeneca have joint development collaboration agreement merck mrk free report lynparza astrazeneca cancer drug imfinzi be also approve japan early stage lung cancer indication pd inhibitor be approve patient locally advanced unresectable stage iii small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt approval be base positive progression free survival datum phase iii pacific study imfinzi be already approve unite state canada switzerland india indication application eu be review decision expect second half meanwhile imfinzi durvalumab be be evaluate multiple cancer alone combination other regimen include late stage study combination tremelimumab hepatocellular carcinoma hcc liver cancer nsclc small cell lung cancer metastatic urothelial cancer head neck squamous cell carcinoma hnscc other imfinzi be launch unite state first indication second line advanced bladder cancer last year thereafter imfinzi be approve immediately launch early stage lung cancer unite state february year contribute significantly drug sale first quarter astrazeneca have zack rank sell better rank large cap pharma stock include pfizer inc pfe free report abbvie inc abbv free report zack rank buy see complete list today zack rank strong buy stock here pfizer stock have gain past year earning estimate well rise last day abbvie stock have rally past year earning estimate increase rise last day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1911,PFE,pfizer inc pfe free report announce phase iii study evaluate epilepsy druglyrica pregabalin pediatric patient meet primary endpoint study be evaluate use lyrica oral solution cv adjunctive therapy partial onset seizure pediatric epilepsy patient month less year age indication lyrica be not yet approve top line result study show adjunctive treatment lyrica mg kg day result statistically significant reduction seizure frequency versus placebo be primary efficacy endpoint however treatment lyrica lower dose mg do not result statistically significant reduction seizure frequency versus placebo datum datum previous study be submit fda lyrica pediatric exclusivity determination lyrica have already lose patent exclusivity europe russia turkey israel central asia unite state favorable court decision july regard generic challenge protect lyrica genericization dec meanwhile pfizer be pursue month patent term extension fda pediatric exclusivity grant keep generic competition bay june believe positive datum pediatric study ease pfizer effort get pediatric exclusivity other epilepsy lyrica be indicated treat post herpetic neuralgia diabetic peripheral neuropathy fibromyalgia neuropathic pain due spinal cord injury unite state lyrica be also indicated treat partial onset seizure patient year age older sale lyrica decline first quarter share pfizer have lose year date compare industry decline zack rank stock considerpfizer have zack rank hold better rank stock same space worth consider be illumina inc ilmn free report ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report illumina sport zack rank strong buy ligand enanta carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year stock have rally so far year ligand earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate have moved cent past day company deliver positive earning surprise trail quarters average beat stock have rally so far year pfizer inc price pfizer inc price pfizer inc quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1912,PFE,week astrazeneca azn free report novartis nvs free report eli lilly lly free report announce regulatory pipeline update line extension market drug astrazeneca asthma drug fasenra fail meet primary endpoint late stage study evaluate expand indication chronic obstructive pulmonary disease copd lilly migraine candidate galcanezumab meet same late stage study evaluate indication prevention episodic cluster headache novartis multiple sclerosis ms drug gilenya gain fda approval use adolescent cgrp antibody aimovig also gain fda approval prevention migraine zoetis zts free report lilly announce acquisition deal recap week most important storieslilly buy small cancer biotech lilly have agree buy early phase oncology asset ak aurka pharma expand oncology pipeline lilly make upfront payment acquire share aurka pharma be lilly second cancer acquisition less week last week lilly have announce cash deal tobuy immuno oncology biotech armo bioscience read more eli lilly buy aurka pharma expand cancer pipeline development migraine candidate galcanezumab meet primary endpoint late stage study evaluate indication prevention episodic cluster headache galcanezumab be already review unite state migraine prevention decision expect third quarter year however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint read more eli lilly cluster headache candidate succeed phase iii zoetis buy abaxis zoetis announce definitive agreement buy california base abaxis be lead global provider veterinary point care diagnostic instrument approximately share cash deal be aim enhance zoetis presence animal health diagnostic market diagnostic category be fast grow portion animal health industry have grow compound annual growth rate approximately last year read more zoetis inks deal acquire abaxis novartis aimovig get fda nod novartis partner amgen amgn free report gain fda approval cgrp antibody aimovig prevention migraine fda approval aimovig be now first only fda approve treatment migraine work block calcitonin gene related peptide receptor cgrp play critical role migraine attack meanwhile lilly teva pharmaceutical industry ltd teva free report be also await fda approval cgrp migraine candidate galcanezumab fremanezumab year novartis ms drug gilenya gain fda approval treatment child adolescent age relapse form multiple sclerosis approval expand patient population boost sale gilenya drug record sale first quarter represent year year growth rate constant currency basis read more novartis multiple sclerosis drug get fda nod adolescent astrazeneca fasenra fail meet endpoint phase iii copd study astrazeneca respiratory biologic medicine fasenra benralizumab fail meet primary endpoint late stage study evaluate new indication severe copd fasenra be already approve unite state eu japan add maintenance treatment patient severe eosinophilic asthma top line result pivotal phase iii galathea study show treatment fasenra do not result statistically significant reduction exacerbation compare placebo patient moderate very severe copd read more astrazeneca asthma drug fasenra fail copd study astrazeneca announce weak first quarter result miss zack consensus estimate earning sale due lower sale cholesterol drug crestor maintain previously issue outlook pfizer biosimilar retacrit get fda nod pfizer pfe free report retacrit be biosimilar version anemia drug amgen epogen jnj free report procrit gain fda approval indication reference product include treatment anemia due chronic kidney disease ckd pfizer already market biosimilar europe last year fda advisory committee have recommend approval retacrit read more pfizer get fda nod amgen anemia drug biosimilar fda name drugmaker block approval generic fda issue list company week say be used certain gaming tactic delay generic competition market drug fda say company be prevent generic player obtain necessary sample brand product be require secure approval generic drug inability secure such sample slow approval process list include big name shire novartis mylan astrazeneca teva biomarin gilead bayer other fda decision publish such list be part broader effort congress encourage approval low cost generic drug nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week decline bristol myer rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup lly buy cancer biotech azn roche announce update next pharma world watch fda decision many pipeline drug line extension market product month more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1913,PFE,healthcare sector be spotlight again due exorbitant drug pricing president donald trump tweet monday criticize pharmaceutical giant pfizer inc pfe free report recent price increase several prescription drug last week new york base company announce increase list price several drug be second time year pfizer have increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase drug price other pharma bigwig merck mrk free report other latest tweet trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas pricing controversy linger issue healthcare industry have always be spotlight high drug price sector previously wall street favorite be hit hard political rhetoric increase medium public focus high price drug drug pricing controversy have grab headline september several company be criticize overpricing drug include mylan myl free report increase price epipen valeant pharmaceutical international inc vrx free report strategy acquire company selling drug higher price trump election campaign have pledge take step lower prescription drug price ensure affordability high cost drug however concrete policy change have be announce decrease drug price trump take office industry have be constantly warn trump keep price drug affordable be probably not do anything part president take several step direction push faster generic cheaper copycat version brand drug approval be already do also ask discount rebate be disclose put limitation promotion advertisement drug mandate medicare negotiate drug price manufacturer be high time drug company take step provide relief consumer keep cost medicine affordable then drug pricing controversy remain overhang space pfizer share do take dip trump tweet close day green pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1914,PFE,dow snap record streak win traverse turbulent week trade war related concern continue weigh investor president trump express doubt success upcoming negotiation china additionally spike year treasury yield also spook market spark fresh inflationary concern such fear be also stoke encourage retail sale number last week dow increase last friday mark seventh straight session gain be blue chip index longest winning streak nov notably healthcare stock be initially follow news president trump unveil new healthcare plan however broad market re-cover later announcement be not follow stringent measure low inflation datum weak dollar also boost investor confidence equity index gain last week be blue chip index largest weekly gain march energy tech stock be major driver stock market oil price first rally last wednesday wake unite state decision exit iran nuclear deal increase fuel rally energy stock once again meanwhile apple inc aapl free report share jump celebrity investor warren buffett berkshire hathaway brk free report announce have buy share apple first quarter consequently share apple rise time high dow index gain monday increase eighth consecutive session marked blue chip index longest winning streak sep stock gain first trading day week trade fear subside president donald trump tweet sunday be consider relax stringent sanction have be impose chinese tech giant zte corp last month index lose tuesday yield year treasury note hit year high turn occur retail sale increase consecutive month raise inflationary fear moreover commerce secretary wilbur ross ambassador china terry branstad comment trade tension unite state china be far index gain wednesday reverse previous day broad base decline particular retail stock gain strong sale datum april macy inc free report first quarter earning report moreover russell benchmark index small cap stock hit time high overall most stock close green investor appear ignore concern regard rise yield government bond geopolitical tension index lose thursday president trump comment trade talk unite state china not be successful trump state be successful tend doubt ahead second round trade talk country meanwhile decline technology share negate gain make energy stock component move index home depot inc hd free report post fiscal first quarter adjust earning share escalate record year quarter figure also beat zack consensus estimate home depot have zack rank hold net sale grow year quarter however top line lag zack consensus estimate include impact adoption asu pertain revenue recognition home depot expect sale growth nearly fiscal accompany increase comp further company estimate earning share fiscal be nearly read home depot earning beat estimate sale lag walmart inc wmt free report first quarter fiscal earning share come ahead zack consensus estimate surge year year include time item earning slump cent share walmart have zack rank total revenue advanced surpass zack consensus estimate nearly currency neutral basis total revenue advanced consolidated operate income slip approximately operate income margin contract basis point constant currency basis operate income decline roughly read walmart earning sale jump online sale cisco system csco free report deliver third quarter fiscal gaap earning cent share come ahead zack consensus estimate penny further figure rise year quarter revenue increase year year marginally surpass zack consensus estimate fourth quarter fiscal revenue be expect grow year year basis zack consensus estimate revenue be peg represent year year growth gaap earning be anticipate cent cent share zack consensus estimate earning be cent translate year year growth stock have zack rank buy see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit zack rank pfizer already market biosimilar europe retracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective cardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen read pfizer get fda nod amgen anemia drug biosimilar general electric company ge free report power service business recently enter agreement saudi cement upgrade latter ge gas turbine hofuf plant base kingdom saudi arabia general electric have zack rank deal ge power upgrade turbine install advanced gas path agp solution enable saudi cement boost power output efficiency notably deal mark first installation ge power agp technology solution boost power generation productivity cement industry globally currently enable saudi cement boost power output total turbine read general electric upgrade saudi cement ge gas turbine jpmorgan chase co jpm free report want set joint venture brokerage china company be seek approval security regulator country jpmorgan have zack rank gao li spokeswoman china security regulatory commission recently state morgan broke hong kong ltd unit jpmorgan submit application acquire stake chinese security venture li also inform application be efficiently review regulator move bank come china pledge open financial market foreign investor april chinese authority release guideline give permission foreign company own maximum local security joint venture read jpmorgan seek china approval joint venture performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookmarket have endure volatile week marked trade inflation related concern even encourage economic report such strong retail sale number have only serve fuel inflationary fear gain have only come investor have choose ignore concern next week feature crucial economic datum housing durable order encourage news front help propel stock higher day ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1915,PFE,roche hold ag rhhby free report announce encourage interim datum phase iii study impower evaluate tecentriq combination regimen first line treatment metastatic squamous small cell lung cancer nsclc datum show immuno oncology drug tecentriq combination blockbuster cancer drug avastin carboplatin paclitaxel significantly improve median overall survival os rate month compare avastin chemotherapy tecentriq combination regimen show survival benefit key lung cancer population such person egfr alk positive mutation liver metastase vary level pd expression november last year roche impower study meet co primary endpoint progression free survival pfs benefit march year roche announce study also meet primary endpoint median os however roche do not provide os number detailed datum study be present annual meeting american society clinical oncology asco early next month remind investor combination regimen be already priority review unite state indication first line set supplemental biologic license application be file base pfs os datum impower study decision be expect sep positive datum impower study be likely boost prospect favorable decision fda drug be approve nsclc second line set note merck mrk free report keytruda be only immuno oncology drug approve alone combination eli lilly lly free report alimta pemetrexed carboplatin treat nsclc patient first line set share roche have lose year date compare industry decline impower study consist cohort evaluate tecentriq combination avastin carboplatin paclitaxel tecentriq combination only carboplatin paclitaxel avastin carboplatin paclitaxel nsclc patient datum show tecentriq avastin arm achieve median os co primary endpoint month compare month avastin arm however tecentriq chemotherapy do not achieve statistically significant improvement os compare avastin chemotherapy roche be evaluate tecentriq monotherapy combination regimen late stage study include impower separate press release roche announce follow datum phase iii alex study compare alecensa pfizer pfe free report xalkori crizotinib treatment naive alk positive nsclc patient datum study demonstrated long term pfs benefit treat alecensa median pfs almost triple month compare month xalkori roche hold ag price roche hold ag price roche hold ag quotezack rankroche currently carry zack rank hold see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1916,PFE,dow endure turbulent week marked linger trade tension blue chip index also close day move average consecutive session conflict signal emerge trump administration trade issue mixed signal lead significant spike volatility index whipsawing several trading session last week dow gain last friday reverse session long lose streak be blue chip index longest stretch loss march be just day short time longest lose streak gain be primarily attributable energy sector rally follow meeting opec russia lead consortium take place vienna jun finally opec decide raise production quota barrel day much lower barrel day demand saudi arabia russia index decline last week largest weekly decline mar well second straight weekly fall dow decline modestly last monday trade war fear once again escalate make investor jittery however market end sharply lower last tuesday trade war fear escalate once again grow fear china trade war continue take toll dow last wednesday thursday market be further rattle supreme court ruling sale tax see share online retailer tumble dow index shed monday biggest day drop close lowest level moreover dow end day move average psychological barrier gauge long term momentum trend investor apprehension trade war unite state china well european union continue weigh investor sentiment index gain tuesday still end day move average second straight session investor react cautiously government continue provide mixed signal ongoing trade conflict jun wall street journal report president trump be consider restrict chinese investment high tech company jun treasury secretary steven mnuchin first tweet wsj publish fake news however later clarify restriction apply country include china try steal proprietary tech asset company dow lose wednesday close lowest level blue chip index end point lower touch intraday high point reflect index largest intraday downslide feb moreover dow end day move average third straight session market open positive note president trump state have decide strengthen committee foreign investment unite state cfius assess potential threat chinse investment company be softer stand compare trump earlier decision impose china specific investment restriction later day treasury secretary steven mnuchin state government block american joint venture china firm transfer critical technology china moreover white house economic advisor larry kudlow say trump administration revise approach related chinese investment unite state not be consider soft stand china follow development stock market take sharp downturn index gain thursday end point higher be drop point earlier day gain be largely broad base bank tech stock rally strongly share jp morgan jpm free report goldman sachs gs free report gain more share boee ba free report gain emerge best performer blue chip index recovery index close day move average fourth session row component move index nike nke free report post fourth quarter fiscal financial earning share beating zack consensus estimate share company see revenue figure beating consensus estimate zack rank nike see quarterly revenue climb roughly year period sportswear giant north american sale pop hit nike also announce new year share repurchase plan class common stock begin current program be complete fiscal read nike beat estimate north american sale disney free report recently announce antitrust division unite state department justice doj have clear pending acquisition first century fox foxa free report asset however approval be subject condition zack rank buy disney divest fox sport regional network maximum day date close acquisition transaction regional channel include fox yes network air new york yankee baseball game new york metro area read disney secure doj antitrust approval fox asset intel intc free report recently announce brian have resign ceo also board director company learn past consensual relationship employee company cfo robert swan have be appoint interim ceo realize gravity matter chipmaker cleverly time resignation announcement revision guidance second quarter fiscal company be optimistic deliver record year intel now envision second quarter fiscal revenue come approximately initial projection earning be now anticipate be cent share considerably higher previously estimate cent share stock have zack rank see complete list today zack rank strong buy stock here walgreen boot alliance inc wba free report report adjust earning share ep third quarter fiscal year year constant exchange rate cer figure surpass zack consensus estimate report basis net earning come reflect increase prior year quarter report ep come year year basis walgreen boot record total sale fiscal third quarter year year cer top line outpaced zack consensus estimate zack rank walgreen boot have raise low end outlook fiscal ep cent new project range be zack consensus estimate earning be peg company guide range read walgreen top earning estimate narrow view pfizer pfe free report announce disappointing overall survival os result phase iii paloma study study show combination ibranceand astrazeneca azn free report faslodex fulvestrant fail improve os compare faslodex placebo woman hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer disease have progressed prior endocrine therapy pfizer have zack rank study be be conduct assess efficacy safety ibranceplus faslodex woman endocrine therapy resistant metastatic breast cancer os be secondary endpoint paloma trial company state secondary endpoint study be not optimized detect statistically significant difference os read pfizer breast cancer drug miss overall survival study unitedhealth group incorporate unh free report unit community plan have be choose state kansa manage care organization delegate administer statewide medicaid program kancare program be effective jan unitedhealth have zack rank program community plan be continue provide health benefit plan adult child alike qualify kancare initiative include proper accessibility care provider network plan health wellness program receipt contract add company medicaid membership total revenue read unitedheathcare arm get charge kansa medicaid program performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookinvestor have have little cheer last few week marked severe uncertainty trade issue market experience better time week volatility increase substantially now seem trade related tension likely dominate proceedings week come such scenario economic report assume special significance several crucial report be line release next week most be encourage nature stock soon return winning way wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1917,PFE,share pain therapeutic inc ptie free report partner durect corp plunge follow news joint meeting anesthetic analgesic drug product advisory committee drug safety risk management advisory committee fda vote approval pain drug remoxy company remoxy be new type abuse deterrent extend release oral formulation widely used opioid drug oxycodone be be evaluate management pain severe enough require daily clock long term opioid treatment alternative treatment option be inadequate news disappoint investor remoxy be pain therapeutic lead candidate fda have set prescription drug user fee act pdufa target action date aug completion review new drug application nda remoxy nda be request label claim abuse deterrence route abuse injection inhalation nasal company remoxy thick sticky high viscosity formulation unapproved route drug administration such injection snorting smoking however give committee negative opinion formulation positive outcome fda review be highly unlikely pain therapeutic share have lose so far compare industry gain share lose value mentioned news note pain therapeutic have license agreement durect use latter oradur technology remoxy pain therapeutic be solely responsible clinical development durect be responsible furnishing suitable laboratory facility equipment personnel pre clinical phase development company be jointly responsible certain pre clinical activity pain therapeutic be obligated pay royalty durect commercial sale remoxy company have collaboration agreement pfizer inc pfe free report remoxy be terminate latter road remoxy development have be bumpy have already be issue complete response letter crl few time most recently september fda issue crl state remoxy not be approve present form specify additional action datum be need drug approval pain therapeutic resubmit remoxy nda first quarter abuse opioid drug be serious problem unite state company endo pharmaceutical endp free report have withdraw injectable formulation opana zack rankpain therapeutic currently carry zack rank hold see complete list today zack rank stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1918,PFE,clovis oncology inc clvs free report announce european medicine agency ema have accept type ii variation marketing authorization seek label expansion rubraca europe remind investor rubraca be approve europe monotherapy treatment platinum sensitive relapse ovarian cancer patient brca mutation third later line set latest application company be seek label expansion drug maintenance treatment ovarian cancer patient irrespective brca mutation be complete partial response platinum base chemotherapy potential approval label expansion boost prospect drug europe reach wider population base patient ovarian cancer rubraca be approve expand indication unite state approval maintenance treatment receive april clovis share have decline so far year compare industry decline regulatory application include promising datum confirmatory phase iii study ariel drug show significant delay recurrence disease brca mutant hrd positive ovarian cancer patient study rubraca compete astrazeneca azn free report lynparza tesaro inc tsro free report zejula lynparza zejula have advantage rubraca drug be already approve patient irrespective brca mutation status meanwhile early stage study be be conduct pfizer pfe free report parp inhibitor talazoparib several advanced recurrent solid tumor year be progress well clovis regulatory approval rubraca national comprehensive cancer network add drug maintenance therapy third later line set clinical practice guideline ovarian cancer positive development certainly boost sale drug drive company topline go forward apart late stage confirmatory study be evaluate rubraca compare chemotherapy patient third later line setting company be also develop drug additional indication prostrate breast pancreatic cancer clovis oncology inc price clovis oncology inc price clovis oncology inc quotezack rankclovis currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1919,PFE,large cap pharmaceutical sector comprise biggest drugmaker world be strong start however sector take backseat due reason market instability few negative update pipeline well regulatory front also older drug company be not perform mark induce drop revenue zack large cap pharma industry have decline so far year zack composite gain overall sector be expect rebound second half year believe new product sale be ramp back rise demand successful innovation product line expansion strong clinical study result frequent fda approval upside turn bring sector back track year also many company have accelerate cost save initiative enable investment new product well defend exist product portfolio optimize long short term growth cost saving drive earning performance importantly merger acquisition activity be gain momentum tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity year optimistic outlook rest year here highlight stock prove be good buy stock sport zack rank strong buy buy have see share price earning estimate rise term see complete list today zack rank stock here large cap pharma stocksh lundbeck hluyy free report share danish drugmaker have rally past month zack consensus estimate current year ep have be revise upward respectively last day lundbeck have zack rank company witness solid revenue growth first quarter headwind exchange rate generic erosion also strengthen pipeline inclusion parkinson disease candidate foliglurax acquisition prexton therapeutic currently mid stage development pfizer inc pfe free report zack rank stock have be work strengthen suite product buyout licensing deal company new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval include product blockbuster potential pfizer grow immuno oncology portfolio offer strong growth prospect share company have increase past month earning estimate have also moved north respectively past day abbvie inc abbv free report abbvie key arthritis drug humira be perform well strong demand trend new competition moreover drug imbruvica market partnership johnson johnson jnj free report be approve hematological cancer have multibillion dollar potential company be explore possibility label expansion solid tumor autoimmune disease mavyret hepatitis virus have become major growth driver abbvie short span market moreover abbvie boast impressive late stage pipeline label expansion new exist product expect next few year several pivotal datum readout regulatory milestone be also anticipate additionally company carry zack rank share price have also gain past month consensus estimate company current next year bottom line have also be raise respectively past day make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1920,PFE,exelixis inc exel free report european partner ipsen announce european commission ec have grant approval cabometyx cabozantinib expand indication ec approve cabometyx mg mg mg first line treatment adult intermediate poor risk advanced renal cell carcinoma rcc kind kidney cancer european union approval be expect march company receive positive opinion committee medicinal product human use chmp use cabometyx indication eu approval first line set be base result cabosun trial meet primary endpoint improve progression free survival compare pfizer pfe free report sutent sunitinib patient previously untreated advanced rcc cabometyxis already market eu advanced rcc adult follow prior vascular endothelial growth factor vegf target therapy unite state cabometyx be approve first line treatment advanced rcc december last year approximately month ahead assign prescription drug user fee act action date cabometyx generate net product revenue first quarter drive growth demand follow approval first lien set approval europe further boost exelixis top line term collaboration license agreement ipsen exelixis receive milestone payment ec approval be recognize collaboration revenue first quarter payment be make ipsen next day exelixis share have lose year wider industry decline remind investor exelixis enter collaboration license agreement ipsen february further development cabozantinib ipsen receive exclusive right current potential future cabozantinib indication outside unite state canada japan exelixis have also inked agreement bristol myer bmy free report roche hold rhhby free report develop cabozantinib combination immunotherapy agent zack rank exelixis have zack rank hold see complete list today zack rank strong buy stock here exelixis inc price exelixis inc price exelixis inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1921,PFE,pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit pfizer already market biosimilar europeretracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective noncardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen however procrit already face biosimilar competition drug novartis nvs free report binocrit europe pfizer share have decline so far year compare favorably fall record industry approval be support comprehensive datum package demonstrated high level similarity retacrit epogen procrit last year fda sadvisory committee have recommend approval retacritpfizer have enter collaboration switzerland base pharma retacrit certain channel retacrit be third approve biosimilar pfizer commercial portfolio include inflectra biosimilar version remicade company be also develop different biosimilar candidate several mid late stage study trump administration continue rally exorbitantly high drug price fda have be actively approve generic biosimilar expensive brand drug bid bring price competition see several such approval expect trend continue year pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1922,PFE,achieve life science inc share rally follow announcement company smoking cessation candidate cytisine show significant drug drug interaction clinical study datum suggest treatment cytisine aid smoking cessation do not require modification dosage co administer drug company acquire global exclude central eastern europe certain other territory development right cytisine bulgaria base sopharma cytisine have be market brand name tabexa central eastern europe sopharma year achieve life science have significantly underperform industry so far year stock have decline industry increase company be evaluate cytisine series drug metabolism drug drug interaction transporter clinical study investigational new drug application be accept fda august last year company claim press release cytisine show favorable outcome previously complete phase iii study tasc cascaid compare candidate placebo nicotine replacement therapy respectively february achieve life science announce preliminary phase ii pharmacokinetic pharmacodynamic pk pd study cytisine datum show more half patient administer cytisine achieve smoking abstinence day note pfizer inc pfe free report market chantix varenicline smoking cessation adult smoker unite state europe other player industryenanta pharmaceutical inc enta free report catalent inc ctlt free report be stock same industry stock carry zack rank buy see complete list today zack rank strong buy stock here enanta earning share estimate increase past day company deliver positive earning surprise trail quarters average beat stock have rally so far year catalent earning share estimate moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1923,PFE,merck co inc mrk free report announce fda have accept supplemental biologic license application sbla keytruda pd therapy review company be seek approval blockbuster drug adjuvant therapy treatment patient resect high risk stage iii melanoma decision be expect feb year so far merck share have outperformed industry share have rise period industry decline sbla include datum pivotal eortc keynote study demonstrated keytruda achieve significant increase recurrence free survival rfs surgery compare placebo patient population recurrence free survival be achieve patient treat keytruda year compare placebo drug also reduce risk disease recurrence death placebo merck have claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation remind investor drug be already approve type cancer indication several setting include first line melanoma recently approve cervical cancer large cell lymphoma keytruda garner sale first quarter sequentially year year sale drug be particularly boost strong momentum first line lung cancer indication be only approve pd therapy monotherapy combination eli lilly lly free report cancer drug alimta pemetrexed carboplatin merck be focuse further develop successful drug other indication keytruda be be evaluate more study include excess combination study more type cancer company have collaborate several company include amgen amgn free report incyte glaxo pfizer pfe free report separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1924,PFE,pfizer pfe free report announce disappointing overall survival os result phase iii paloma study study show combination ibranceand astrazeneca azn free report faslodex fulvestrant fail improve os compare faslodex placebo woman hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer disease have progressed prior endocrine therapy study be be conduct assess efficacy safety ibranceplus faslodex woman endocrine therapy resistant metastatic breast cancer os be secondary endpoint paloma trial company state secondary endpoint study be not optimized detect statistically significant difference os primary endpoint progression free survival pfs be previously report lead fda approval ibrance faslodex pretreat woman hr metastatic breast cancer finding publish lancet oncology median pfs be month ibrance faslodex compare month faslodex alone most common adverse reaction paloma include neutropenia leukopenia infection fatigue nausea new safety signal be identify part final os analysis year date share pfizer have increase industry decline remind investor ibrance have receive accelerate approval fda february be used combination novartis nvs free report femara letrozole first line treatment postmenopausal woman estrogen receptor positive human epidermal growth factor receptor negative advanced breast cancer initial endocrine base therapy metastatic disease pfizer be work expand ibrance label further target different segment breast cancer patient company present detailed datum upcoming medical meeting pfizer inc price pfizer inc price pfizer inc quotezack rank stock considerpfizer carry zack rank hold better rank stock same space be ani pharmaceutical inc anip free report carry zack rank buy see complete list today zack rank stock here ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1925,PFE,kitov pharma ltd ktov free report announce today fda have approve consensi amlodipine celecoxib oral tablet treatment osteoarthritis pain hypertension drug be combination celecoxib steroidal inflammatory drug nsaid amlodipine besylate calcium channel blocker have be approve once daily use dosage form corresponding current approve dosage amlodipine mg treatment hypertension mg dose celecoxib osteoarthritis pain fda approval be base positive result phase iii trial meet primary endpoint accord study drug lower daytime systolic blood pressure least reduction blood pressure achieve patient treat amlodipine besylate only statistical significance have be approve patient be appropriate treatment amlodipine hypertension celecoxib osteoarthritis share company gain news kitov pharma stock have gain last month industry gain company now focus development nt be currently development various oncology indication however consensi be expect face competition oral arthritic market traditional selective nsaid such naproxen ibuprofen traditional nsaid agent combination product combination product package such horizon pharma hznp free report vimovo other company also face competition pfizer pfe free report celebrex zack rankkitov pharma carry zack rank hold better rank player healthcare sector be ligand pharmaceutical lgnd free report carry zack rank buy see complete list today zack rank strong buy stock here ligand earning share estimate increase share last day company deliver positive earning surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1926,PFE,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put pfizer inc pfe free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front pfizer have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend pfizer current pe level put midpoint past year number have rise rapidly past few month further stock pe also compare favorably broader industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point pfizer have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead pfizer stock term too cf ratioan often overlooked ratio still be great indicator value be price cash flow metric ratio doesn take amortization depreciation account so give more accurate picture financial health business be prefer metric valuation investor cash flow be generally less prone manipulation company management be less affected variation accounting policy different company ratio be generally apply find company stock be overpriced underpriced reference cash flow generation potential compare competitor however be not commonly used cross industry comparison average price cash flow ratio vary industry industry case pfizer cf ratio be lower industry average indicate stock be somewhat overvalue respect broad value outlookin aggregate pfizer currently have value score putt top stock cover look pfizer solid choice value investor stock overall pfizer be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give pfe zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be upbeat current quarter have see estimate go higher past day full year estimate have see same time period have have just small impact consensus estimate current quarter consensus estimate have rise past month full year estimate have inched upper see consensus estimate trend recent price action stock chart pfizer inc price consensus pfizer inc price consensus pfizer inc positive trend signify bullish analyst sentiment zack rank buy indicate robust fundamental expectation outperformance term bottom linepfizer be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry be hard get too excited company overall fact past year broader industry have clearly underperform market large see however zack rank instill investor optimism so pay value investor delve deeper company prospect fundamental indicate stock be compelling pick today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1927,PFE,eli lilly company lly free report have receive favorable ruling district court patent dispute india generic drugmaker dr reddy laboratory limit rdy free report case be related vitamin regimen patent lilly key cancer drug alimta pemetrexed disodium district court southern district indiana validate alimta vitamin regimen patent state be infringe dr reddy propose generic product be alternative salt form pemetrexed concurrently lilly also inform earlier month district court also rule favor lawsuit hospira subsidiary pfizer inc pfe free report court deny hospira motion summary judgement instead grant lilly cross motion summary judgement compound patent cover alimta unite state expire january vitamin regimen patent remain valid alimta patent be ultimately upheld remain challenge compound patent already expire major european country japan dec other hospira dr reddy several other generic manufacturer include teva teva free report sandoz be seek approval unite state marketing generic form alimta prior expiration vitamin regimen patent remind investor last october patent trademark office have validate alimta vitamin regimen latest win hospira dr reddy mean company launch generic version alimta only patent expire however company be expect appeal district court decision notably alimta be top revenue grosser lilly longer commercial life alimta provide top line support several product lilly portfolio be already face patent expiration entry generic competition alimta follow loss effective patent protection cause rapid decline revenue product first quarter alimta sale rise higher sale unite state offset sale decline international market outside unite state sale cancer drug be be hurt due loss exclusivity several country well competitive pressure sale be also be affected increase competition due entry immuno oncology agent market favourable patent decision lower chance generic competition alimta patent expiration have hampered sale more year date share lilly have rise industry decline lilly currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1928,PFE,be not many development pharma sector week swiss pharma giant roche rhhby free report announce be buy remain stake molecular information company foundation medicine inc fmi free report small drugmaker ptc therapeutic inc ptct free report unveil promising early stage datum spinal muscular atrophy sma candidate recap week most important storiesroche buy remain stake foundation medicine swiss pharma giant roche say buy remain stake molecular information company foundation medicine share add total transaction value price mark premium close price foundation medicine jun value cambridge base company deal aim strengthen roche development effort personalize therapy treat cancer leverage foundation medicine high quality comprehensive genomic profile cgp testing innovative datum service deal be expect close second half year roche initially have buy roughly stake foundation medicine read more roche buy rest foundation medicine ptc therapeutic unveil promising early stage datum sma drug ptc therapeutic present encourage preliminary datum early stage study evaluate gene therapy candidate risdiplam baby type spinal muscular atrophy sma early stage datum demonstrated improve muscle performance nearly baby treat risdiplam share ptc therapeutic rise almost response news however share ptc therapeutic decline sharply day follow announcement be rival company sarepta therapeutic announce better expect result early stage study evaluate gene therapy treatment patient duchenne muscular dystrophy dmd ptc therapeutic also market therapy treat dmd fda accept bristol myer sbla opdivo yervoy combo lung cancer bristol myer bmy free report supplemental biologic license application sbla label expansion pd inhibitor opdivo nivolumab combination low dose yervoy first line lung cancer be accept fda bristol myer be look get combination immunotherapy drug approve treatment small cell lung cancer patient tumor mutational burden mutation megabase fda be expect give decision feb next year shire hae drug get fda nod pediatric population shire gain fda approval label expansion hereditary angioedema hae drug cinryze include use pediatric patient year older cinryze be approve unite state october routine prophylaxis attack adolescent adult live hae rare genetic disorder cause painful swell various part body approval pediatric population drive sale drug higher future quarters nordisk sign deal kallyope present positive diabetes study result denmark base pharma giant nordisk nvo free report enter collaboration new york base biotech kallyope inc peptide therapeutic obesity diabetes deal kallyope receive upfront payment potential research development sale milestone depend term deal nordisk also have option agreement license exclusive worldwide right develop commercialize product discover part collaboration case nordisk exercise option kallyope be entitle receive license fee nordisk also present headline result phase iii study oral formulation type ii diabetes medicine semaglutide first study pioneer compare oral semaglutide nordisk other diabetes medicine victoza other study pioneer compare oral semaglutide merck mrk januvia sitagliptin study show oral semaglutide lead statistically significant reduction hba weight compare victoza januvia respectively semaglutide be presently sell ozempic weekly injection several country nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record decline last week pfizer pfe free report bristol myer be flat glaxo decline most past month glaxo gsk free report have be biggest gainer decline most see last pharma stock roundup here pharma stock roundup lly azn alzheimer drug fail mrk keytruda win approval next pharma world watch fda decision several pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1929,PFE,merck kgaa report first quarter earning american depositary share earning share decline local currency net sale report quarter come include unfavorable foreign exchange hurt sale however organic sale growth be drive healthcare life science segment share company have underperform industry so far year company decline industry increase same period segment sale company report result segment healthcare life science performance material healthcare division record sale year year due negative impact foreign exchange rate however organically sale segment be erbitux sale be year period due negative currency movement moreover organically sale be due increase competition pricing pressure rebif sale come due organic decline negative currency impact gonal sale be organic sale be due higher sale north america offset unfavorable currency impact newly launch bavencio mavenclad register sale respectively sale life science segment amount mere drive growth business segment partially offset unfavorable foreign exchange effect organic basis segment witness sale growth process solution apply solution business record organic sale growth respectively research solution business register organic growth segment be impact unfavorably due currency movement sale performance material segment be organically segment witness decline sale unfavorable currency impact other updatein april company enter agreement procter gamble pg free report divest consumer health business sale be cash deal worth transaction be expect close end year january bavencio receive approval australia treatment metastatic merkel cell carcinoma mmcc approval drug be approve country mmcc include eu unite state drug be also approve urothelial carcinoma unite state merck kgaa be evaluate immuno oncology drug bavencio avelumab number phase iii study several cancer indication partnership pfizer inc pfe free report march company receive milestone payment biomarin inc bmrn free report latter announce acceptance marketing authorization application peg pal treatment ema company expect submit regulatory application seek approval cladribine tablet treatment relapse multiple sclerosis rm unite state second quarter drug be already approve eu quarter company face trust review europe related acquisition sigma aldrich merck be estimate pay fine double digit million incorrect mislead information connection innovation project outlookmerck kgaa provide guidance company expect net sale range include organic growth negative currency impact company anticipate earning share be range financial outlook exclude sale earning consumer health business more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1930,PFE,glaxosmithkline plc gsk free report partner jnj free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infectionjuluca gain approval unite state november last year generate sale first quarter tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen approval eu be expect march year committee human use medicinal product chmp european medicine agency ema have give positive opinion recommend approval juluca year so far share have decline glaxo have go say time frame industry have witness decline juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen juluca approval be base datum phase iii sword study datum study show combination tivicay edurant antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression remind investor gilead gild free report also gain fda approval single tablet hiv regimen triple therapy year biktarvy gain fda approval february year regulatory application be review eu str be fix dose combination drug bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf glaxo carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1931,PFE,investor interested stock large cap pharmaceutical sector have probably already hear pfizer pfe free report glaxosmithkline gsk free report company be best option look undervalue stock let take closer look best way find great value stock be pair strong zack rank impressive grade value category style score system zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait currently pfizer have zack rank buy glaxosmithkline have zack rank strong sell investor feel comfortable know pfe likely have see stronger improvement earning outlook gsk have recently be just factor value investor be interested value investor also try analyze wide range traditional figure metric help determine company be undervalue current share price level style score value grade factor variety key fundamental metric include popular ratio ratio earning yield cash flow share number other key stat be commonly used value investor pfe currently have forward ratio gsk have forward also note pfe have peg ratio metric be used similarly famous ratio peg ratio also take account stock expect earning growth rate gsk currently have peg ratio notable valuation metric pfe be ratio ratio pit stock market value book value be defined total asset total liability comparison gsk have base metric many more pfe hold value grade gsk have value grade pfe be currently sporting improve earning outlook make stick zack rank model base valuation metric feel pfe be likely superior value option right now
1932,PFE,merck kgaa be schedule report first quarter result merck share have decline so far year industry rally company report result business sector healthcare life science performance material merck revenue be drive organic sale growth healthcare life science segment fourth quarter expect see same trend upcoming quarterly result december merck multiple sclerosis drug mavenclad be approve australia canada follow approval europe third quarter expansion new geography be likely boost sale drug be report quarter moreover bavencio be approve unite state europe japan merkel cell carcinoma drug be also approve advanced bladder cancer unite state healthcare sale be likely get boost company develop bavencio partnership pfizer inc pfe free report several cancer indication sale key drug rebif erbitux gonal be expect be lower first quarter downside be likely be cause persistent competitive pressure price reduction moreover unfavorable currency movement be anticipate dent top line moreover operate expense increase due new launch higher pipeline development cost expense be estimate increase first quarter company focus development innovative pipeline launch bavencio new geography well mavenclad company divest biosimilar business be currently consider strategic option consumer health segment merck be also focuse development protection novel dna sequence technology crispr february technology be issue patent korea israel also increase expense company expect management shed light progress plan bavencio earning call company be likely provide update strategic plan merck kgaa price ep surprise merck kgaa price ep surprise merck kgaa quotestock warrant lookhere be couple healthcare stock want consider model show have right combination element positive earning esp zack rank strong buy buy hold post earning beat uncover best stock buy sell re report earning esp filter summit therapeutic plc smmt free report be expect release result jun company have earning esp carry zack rank see complete list today zack rank stock here arqule inc arql free report be expect release second quarter result aug zack rank company have earning esp medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1933,PFE,president donald trump friday unveil plan lower drug price keep promise make run presidential election pharmaceutical company broader industry have be anticipate trump come heavily have long criticize drugmaker get away murder charge way too much product however fear be dispel trump proposal actually not directly hamper profitability drug company instead reform be aim increase competition medicine cut list price reduce patient pocket cost pleasant surprise give stock pharmaceutical company boost long standing drug price be trump presidential campaign promise have commit take big drug company be also support trump democrat opponent hillary clinton then trump have time again criticize drug manufacture pharmaceutical company charge too much product have keep pharmaceutical company reel pressure quite time have fear trump pharma plan hurt profit broader pharma sector spdr pharmaceutical xph have decline year date industry have fear further loss apprehend harsh measure trump friday raise competition twist tale come trump stress increase competition medicine be highpoint speech friday frame plan most sweeping action history lower price prescription drug american person describe american patient first layer policy intend increase pharmaceutical competition power negotiation lower patient pocket cost trump policy also aim create incentive lower list price prescription drug reform certainly be ray hope american patient rise cost healthcare be nagging concern american patient first plan have immediate action well future opportunity lower pocket cost face patient reduce drug price interestingly trump refrain raise direct medicare price negotiation friday be agenda presidential campaign pharma stock rally trump reformsclearly trump american patient first plan doesn seem be threat pharmaceutical company profit fact be very much line financial interest drugmaker health insurer way hamper profit fear have often result share pharma company take hit last few month finally see bounce back friday sector decline initially friday stock start rally time trump have finished speech share regeneron pharmaceutical inc regn free report increase also share cvs health corporation cvs free report merck co inc mrk free report pfizer inc pfe free report walgreen boot alliance inc wba free report be respectively merck co have zack rank buy see complete list today zack rank strong buy stock here trump spare biggest reason rally be trump plan actually doesn hurt pharmaceutical company fact administration keep place few case extend role drug middleman have be often be blame spiking drug cost trump plan call drug company display price ad restrict gag clause pharmacist proposal come pharmacy pharmacy benefit manager pbm have contract donot allow pharmacist let patient know drug cash counter be cheaper be purchase insurance however trump splan give company new power medicare part program senior get drug coverage allow medicare change list cover drug midyear order push back price hike generic drugsthat donot actually have so much competition lead share healthcare service company mckesson corporation mck free report express script hold company esrx free report corporation abc free report cardinal health inc cah free report rise respectively sum uptrump american patient first come set reform have spark fear pharmaceutical company quite time however fear seem have subside somewhat new plan doesn hurt drugmaker profit see investor confidence finally get reinstate pharma biotech stock rally medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1934,PFE,merck co inc mrk free report pfizer inc pfe free report report upbeat first quarter result fact pharma giant manage outpace earning estimate miss revenue front however company top bottom line rise year year merckha zack rank buy pfizer possess zack rank hold now let see stock be better position term fundamental post earning see complete list today zack rank strong buy stock here other major earning come other pharma giant abbott free report johnson johnson jnj free report earning performancein first quarter merck report adjust earning share surpass zack consensus estimate cent bottom line increase year period meanwhile company revenue fall short zack consensus estimate increase year year read more merck beat earning lag sale raise outlook pfizer post first quarter earning cent share beating zack consensus estimate only cent earning advanced year period due lower tax rate share count moreover revenue increase year year miss zack consensus estimate read more pfizer stock fall sale miss earning beat price have witness rise past month pfizer have advanced only so merck be clear winner respect better return rival merck broader industry decline same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition earning history estimate revisionsmerck deliver positive surprise last quarters average earning surprise comparison pfizer deliver earning beat trail quarters post average positive earning surprise consider estimate revision merck earning estimate current year have improve past day meanwhile pfizer earning estimate have decline same period conclusionin comparative analysis find pharma giant have certain positive pfizer hold better leverage position have higher net margin however term valuation merck be more underpriced pfizer further merck have comparatively higher price performance pfizer moreover merck also hold edge pfizer consider average positive earning surprise estimate revision clinch case favor merck point time be have better zack rank pfizer respect analysis clearly indicated merck be better position pfizer thus call investor attention post earning look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1935,PFE,momenta pharmaceutical inc mnta free report report loss share cent quarter wider year loss cent revenue quarter come significantly year quarter quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be result lower sale due mylan myl free report entry copaxone market collaborative research development revenue come compare year quarter decrease be primarily due lower revenue recognize upfront payment mylan compare amount recognize period lower reimbursable expense complex generic program research development expense decrease year quarter due decrease external expense general administrative expense also decrease outlook expect operate expense exclude stock base compensation net collaborative revenue range operate expense second quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesmomenta announce fda have finally approve sandoz abbreviated new drug application glatopa mg company earlier suffer setback fda issue warning letter pfizer pfe free report february be sandoz contract fill finish manufacturing partner glatopa nevertheless sandoz secure customer contract order glatopa mg ml have be ship meanwhile momenta continue progress biosimilar pipeline january momenta mylan announce plan initiate patient clinical trial propose biosimilar eylea first half biologic license application bla momenta biosimilar version humira be also ready be file fda however filing bla be dependent outcome company ongoing strategic review momenta suffer setback company partner mylan announce propose biosimilar orencia do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan continue evaluate next course action momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer january momenta report positive top line datum phase single ascend dose sad multiple ascend dose mad study normal human volunteer phase randomize double blind placebo controlled study evaluate safety tolerability pharmacokinetic pharmacodynamic consequently momenta be finalize development strategy be plan proof concept clinical trial second half pending regulatory feedback meanwhile momenta collaboration partner csl begin dose subject phase trial healthy volunteer evaluate safety tolerability study be expect be complete momenta be also track complete ind enable toxicology study year expect initiate trial second half takemomenta report wider year year loss first quarter fda approval glatopa mg relieve momenta competition limit market share gain note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity momenta stock have gain last month industry decline follow announcement first quarter result share be meanwhile progress biosimilar pipeline be encourage zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1936,PFE,first quarter earning season have be relatively strong however stock market recent performance be yet reflect strength positive revision be see ahead start earning season estimate revision trend second quarter have be rather underwhelm member report result accord latest earning preview total earning index member increase year quarter improvement revenue beat ratio be earning revenue report first quarter earning company combine actual result have come estimate still come company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pharma bigwig report last week include pfizer pfe free report merck mrk free report allergan agn free report merck pfizer beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter allergan beat estimate earning revenue first quarter raise guidance earning sale big biotechs celgene corporation beat estimate earning well sale raise earning expectation full year gilead earning sale miss estimate wider expect decline hcv franchise here have small biotech pharma company be set report first quarter result let see thing be shape announcement jazz pharmaceutical plc jazz free report jazz pharmaceutical be schedule announce result market close late company earning performance have be disappointing company surpass estimate only once last quarters miss same other average beat last quarter company deliver negative surprise however company have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here previous article show jazz be unlikely beat earning quarter however estimate change thereafter be now more confident likely positive surprise earning season call investor be keen know xyrem jazz lead product cataplexy excessive daytime sleepiness ed have perform also be keen know company pipeline progress business development plan be also expect draw notice read more jazz pharmaceutical earning store arena pharmaceutical inc arna free report arena be also expect report market closearena earning performance have be mixed bag trail quarters company surpass expectation last quarters miss same other occasion deliver average positive beat last report quarter company outpaced zack consensus estimate deliver positive earning surprise sale arena obesity treatment drug belviq only approve product arena portfolio be not expect be better arena have few pipeline candidate update same be expect first quarter conference call read more card arena earning season company have earning esp zack rank zack consensus estimate first quarter be peg loss cent share ligand pharmaceutical incorporate lgnd free report ligand be schedule announce result market close ligand stellar earning history show estimate beat last quarters company miss consensus mark only once also deliver average positive earning surprise last report quarter ligand pull positive surprise company have earning esp zack rank zack consensus estimate soon be report quarter be peg share first quarter conference call expect investor focus remain company update regard partnership well major pipeline asset read more lie ahead ligand earning season valeant pharmaceutical international inc vrx free report valeant be schedule release earning market open deliver negative earning surprise last quarter valeant earning performance have be decent earning miss expectation last quarters beating same remain bring average positive surprise quarter valeant have earning esp zack rank zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter here be stock perform year so far more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1937,PFE,pfizer inc pfe free report be reportedly raise price almost drug effective july be second time drug giant have raise price drug year scrutiny drug price have increase trump assume office however softer drug pricing policy form last month expect other company follow suit increase price be nearly majority drug agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include price hike january trump announce plan control drug price unite state however group investor believe plan be not likely have major impact profit large pharma company instead include provision direct negotiation medicare pharma company trump target intermediary certain small pharma company foreign country thus medicare be major customer drug pay nearly dollar value prescription filled medicare have negotiate lower price directly manufacturer president also expect increase competition streamline approval related regulatory process promote faster approval generic biosimilar plan allow more substitution addition medicare drug list single source generic contain price rise give sponsor more negotiation power manufacturer also instruct company display list price advertising plan also focus more transparency related pricing availability generic moreover announcement price hike pfizer come week trump claim pharma company take massive price cut voluntarily soon pfizer have defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio also reduce price drug meanwhile price hike company soon trigger market wide increase drug price thus pfizer move again stir opposition related drug price rise especially large pharma company pfizer stock price several other large cap pharma company moved north jul include johnson johnson jnj free report eli lilly company lly free report abbvie inc abbv free report rise drug price certainly help company boost profit so far year large cap pharma industry have decline rise expect investor remain focuse other pharma company announcement related drug price subsequent move government restrict further hike look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1938,PFE,pfizer inc pfe free report announce fda have grant priority review new drug application nda file pipeline candidate glasdegib pfizer be look get glasdegib approve first line treatment acute myeloid leukemia aml combination chemotherapy treatment respect patient ineligible intensive chemotherapy datum phase ii bright study show glasdegib oral smoothen inhibitor lead significant improvement overall survival add low dose cytarabine ldac comparison ldac alone previously untreated patient aml high risk myelodysplastic syndrome be ineligible intensive chemotherapy finding study be present american society hematology fda have set prescription drug user fee act pdufa goal date december earlier year pfizer enrolled phase iii bright aml trial nct evaluate glasdegib intensive intensive chemotherapy patient newly diagnosed aml company press release aml rapidly progress blood cancer represent market huge demand new treatment option share pfizer have inched year date industry decline pfizer currently carry zack rank hold better rank stock large cap pharma biotech sector be lundbeck hluyy free report crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock here lundbeck earning estimate have be revise upward past day stock have surge year date crispr therapeutic loss share estimate have be narrow last day stock have sky-rocket year date genomic health earning estimate have be raise past day stock have soar so far year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1939,PFE,duchenne muscular dystrophy dmd be rare genetic disease severe form muscular dystrophy primarily affect male progressively weaken degenerate skeletal heart muscle symptom muscle weakness generally start appear early year age boy progress quickly duchenne muscular dystrophy be type muscular dystrophy cause absence particular gene body used keep muscle cell intact disease start affect muscle hip pelvic area thigh shoulder early stage lead degeneration voluntary muscle arm leg trunk gradually disease progress affect heart respiratory muscle early patient life expectancy dmd patient be low early adulthood however scenario be change advance cardiac respiratory care patient live due severity rarity dmd fda be also incentivize company develop treatment treat rare muscular degenerative disease grant orphan drug designation several candidate designation give year marketing exclusivity approval research funding eligibility tax credit certain research cost waiver fda application user fee however be very few company develop dmd treatment due lower number patient sarepta therapeutic inc srpt free report exondys be first approve drug unite state have be available late drug be small molecule target mutation dmd gene susceptible exon skip exondys ptc therapeutic inc ptct free report emflaza be approve treatment dmd unite state focus be currently shift development gene therapy treatment disease gene therapy deliver functional copy muscle cell restore production pharma biotech company develop gene therapy treat dmdhere discuss company be research develop advance treatment dmd sarepta have exon skip candidate pipeline lead candidate golodirsen be exon skip candidate have demonstrated better efficacy exondys response rate mid stage study new drug application nda be expect be file end year apart exon skip candidate sarepta be focuse gene therapy develop treatment dmd company also initiate phase ii study fourth quarter evaluate gene therapy dmd earlier week announce promising preliminary result early stage study evaluate gene therapy aavrh mhck micro read more sarepta stock soar encourage gene therapy result sarepta currently carry zack rank sell sarepta therapeutic inc price sarepta therapeutic inc price sarepta therapeutic inc quotepfizer inc pfe free report be large pharma company be also develop gene therapy treatment dmd april company initiate dose patient phase ib study be evaluate mini gene therapy candidate pf treat dmd company be develop therapy treatment boy age year pfizer add candidate pipeline acquisition bamboo therapeutic read more pfizer start phase ib duchenne muscular dystrophy drug pfizer currently carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price pfizer inc price pfizer inc quotesolid bioscience inc sldb free report lead candidate sgt be microdystrophin gene transfer be be evaluate treatment dmd candidate be early stage development however company have receive setback fda putt phase ii ignite dmd study initiate fourth quarter clinical hold february earlier week fda lift clinical hold study boost company stock read more solid surge fda lift clinical hold dmd drug solid bioscience currently carry zack rank solid bioscience inc price solid bioscience inc price solid bioscience inc quoteapart mentioned company catabasis pharmaceutical inc catb free report be develop oral small molecule candidate edasalonexent treatment dmd irrespective underlie mutation look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1940,PFE,long own stock general electric leave dow bad news starbucks criterium buy hold stock tracey top stock pick pfe xom tr episode roundup podcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick stock be recently news general electric ge free report starbucks sbux free report general electric be go be remove dow jone industrial average year oldest member index starbucks warn guidance second quarter question be raise future growth come be type stock investor hold long period meaning year own long do know sell value investing buy holdvalue investing long term buy hold investing often go hand hand value investor buy stock be be reject rest wall street then hold be turnaround value investor usually have patience stay stock year warren buffett most famous value investor world also buy hold often decade even buffett agree not stock be meant be hold long time period example buffett just sell recent ibm position even have only own few year long investor hold stock be criterium investor want consider criterium long term buy hold investor have company fundamental change be still same business originally buy stock do trust current management own stock decade management change be hardship easy turn company seem be permanent turnaround think company fit long term investing plan do still have place former long term hold be buy now company have be many investor portfolio year investor have likely own decade be go forward pfizer pfe free report be most popular stock jan jan stock rise other big cap drug stock weren too shabby last year be different story still share look cheap now pfizer have forward just look pfizer re long term investor exxonmobil xom free report now be oldest component dow once ge be remove look pretty cheap forward earning growth expect do do hold last year tootsie roll be know secret company win talk analyst hold investor conference call yet stock be best performer last bull rally family own share however succession plan be unknown long term hold work tootsie roll now find tracey long term investor tip week podcast full disclosure tracey own share sbux personal portfolio wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1941,PFE,ever president trump imposition tariff steel aluminum import china market large have suffer dearly have be number meeting trade representative country vain further escalate trade war tension report have surface treasury department have be draft policy prohibit firm have more chinese ownership benefit emerge technology unite state such policy have negative ramification industry healthcare biotech pharmaceutical be tech heavy need acquire industrially efficient technology growth sustenance so trade war china turn be nightmare healthcare sector let have look trump protectionism dampen healthcare fortunesearly stage pharmaceutical startup biotech company have historically benefit increase access chinese investment resource intellectual property right protection be go hamper grow entrepreneurial spirit biotech space long run brunt be bear more relatively small scale startup american vcs focus more larger startup top notch university further china have not include medical product retaliatory tariff impose unite state be not likely do so future well however case such scenario occur not be too good healthcare industry norm china refrain used copy drug american biotech company expert fear china get violate patent right due escalation trade war start copy drug company have significant exposure asian country such circumstance company pharmaceutical drug industry have pay dearly such turn event also result dwindle global share healthcare industry market leader zack large cap pharmaceutical industry such abbvie abbv free report glaxosmithkline gsk free report eli lilly lly free report merck mrk free report pifzer pfe free report end be biggest loser such company not only have significant chinese exposure be highly vulnerable instance right infringement see complete list today zack rank stock here chinese investment be oxygen biotech pharma chinese venture capital fund have invest whopping biotech drug company period january march surpass investment chinese vcs whole part such increase be attribute china effort become leader healthcare investment globe china increasingly want make use manufacturing intensive nature economy reason typically increase investment biotech firm be china want access novel therapy make use high return such investment however restriction trump administration chinese involvement biotech spell doomsday industry big reason be be relatively cheaper drug pharmaceutical company perform clinical trial china china drug administration cda chinese fda take less third time take fda approve result consequently cost involved be also lower pharmaceutical industry have suffer recent past due rise cost associate raw material trump act tariff imposition china have prove be rather several industry large turn be nightmarish healthcare industry be know fact chinese investment breathe life small mid scale healthcare company america finally event china infringe drug patent right american company have significant operation chinese shore bloodbath healthcare industry be inevitable wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1942,PFE,first quarter result pharma bigwig pfizer pfe free report merck mrk free report allergan agn free report steal limelight week other novartis nvs free report gain fda approval second indication car therapy kymriah abbvie abbv free report submit regulatory application eu psoriasis candidate risankizumab merck pd inhibitor keytruda gain fda priority review status yet label expansion application recap week most important storiesmixed result merck pfizer pharma giant beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter merck strong sale keytruda gardasil bridion be partially offset lower sale other key therapy rotateq zepatier zostavax meanwhile loss market exclusivity several drug also hurt top line pfizer top line be hurt decline sale key drug lyrica prevnar prevenar enbrel loss exclusivity product viagra pristiq continue supply shortage legacy hospira product allergan beat estimate earning revenue first quarter raise guidance earning sale novartis kymriah get fda approval second indication novartis supplemental biologic license application sbla look get car therapy kymriah approve second indication be grant approval fda latest approval kymriah suspension have be approve intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma more line systemic therapy include diffuse large cell lymphoma dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse separately novartis announce fda have give complete response letter bla propose biosimilar version roche cancer drug rituxan merck keytruda news merck supplemental biologic license application sbla look get overall survival datum phase iii keynote study include label pd inhibitor keytruda be grant priority review fda fda give decision sep study evaluate keytruda combination lilly alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression combination treatment improve overall survival regardless pd expression include patient tumor test negative pd notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale merck also announce interim datum pivotal lung cancer study keytruda meet pre specify secondary endpoint overall response rate orr early cohort participant phase keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel first line treatment metastatic squamous nsclc abbvie submit application psoriasis candidate eu abbvie submit marketing application european regulatory authority investigational interleukin il inhibitor risankizumab treatment moderate severe plaque psoriasis marketing authorization application maa be support datum pivotal phase iii study datum study have show more half patient receive risankizumab achieve complete skin clearance year meanwhile abbvie also announce commencement self tender offer common stock price not less share not more share unite therapeutic acquire steadyme unite therapeutic corporation uthr free report announce definitive merger agreement steadyme ltd unite therapeutic acquire latter include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pulmonary arterial hypertension pah patient portfolio product have pose competition unite therapeutic remosynch implantable pump be review unite state trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end allergan ubrogepant succeed phase iii study allergan announce second pivotal phase iii study evaluate oral cgrp acute migraine treatment ubrogepant meet co primary endpoint phase iii datum show ubrogepant display strong efficacy clean side effect profile achieve ii study evaluate efficacy safety orally administer ubrogepant mg mg treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient take mg dose experience absence most bothersome migraine associate symptom photophobia phonophobia nausea hour initial dose compare treat placebo however mg dose fail demonstrate statistical significance endpoint seek label expansion pah drug jnj free report actelion submit supplemental new drug application snda fda seek approval label expansion pah drug opsumit macitentan include treatment patient chronic thromboembolic pulmonary hypertension cteph also announce definitive agreement acquire private biotech benevir biopharm benevir make oncolytic immunotherapy utilize proprietary stealth oncolytic virus platform have potential treatment solid nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock decline last week astrazeneca rise pfizer decline most last month glaxo be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs jnj sale earning top mrk bmy active aacr next pharma world watch pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1943,PFE,myriad genetic inc mygn free report have moved step forward acquire fda approval company bracanalysis cdx test be used companion diagnostic pfizer pfe free report parp inhibitor talazoparib company note fda have accept supplementary premarket approval spma application bracanalysis cdx help identify best responder talazoparib be also encourage know talazoparib be currently hold status new drug application nda priority review fda target date set december myriad genetic pfizer submit respective spma nda proposal fda base result pfizer sponsored embraca trial evaluate talazoparib compare chemotherapy patient germline inherited brca mutate gbrcam negative locally advanced metastatic breast cancer mbc last december primary result study be present datum show patient gbrca locally advanced metastatic breast cancer mbc demonstrated superior progression free survival pfs treat talazoparib comparison have receive physician choice standard care chemotherapy recent development genetic have be leave stone unturned boost uptake bracanalysis cdx regard system get manufacturing marketing approval japanese ministry health labour welfare earlier april year system now be used companion diagnostic parp inhibitor lynparza notably january fda approve bracanalysis cdx test usage companion diagnostic astrazeneca azn free report merck mrk free report parp inhibitor lynparza olaparib patient negative metastatic breast cancer mbc germline brca mutation market potentialper myriad genetic patient metastatic disease be currently eligible bracanalysis testing japan moreover approximately new case negative breast cancer be diagnosed year promising datum indicate timely strategic role latest approval be likely play favor company share price performance myriad genetic have be gain investor confidence consistently positive result past month share company have significantly outperformed broader industry stock have surge broader industry fall myriad genetic currently carry zack rank hold look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1944,PFE,glaxosmithkline plc gsk free report hiv company viiv healthcare announce late stage study testing drug hiv regimen dolutegravir tivicay lamivudine epivir meet primary endpoint phase iii study gemini gemini evaluate drug regimen treatment nave have not receive prior antiviral therapy hiv infected adult compare drug regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study demonstrated dolutegravir lamivudine regimen be inferior standard drug regimen hiv control mean drug hiv regimen control hiv treatment nave patient effectively drug regimen share glaxo be almost thursday response positive news year so far glaxo share have gain industry decline share glaxo also receive boost week mylan myl free report application get approval generic version glaxo blockbuster respiratory drug advair be reject second time fda full result study be present future medical meeting regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year glaxo have several phase iii study ongoing evaluate drug regimen hiv treatment study conduct global research center include approximately hiv infected man woman drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen thereby reduce long term toxicity concern juluca be glaxo first only approve drug regimen gain approval eu last month unite state november last year generate sale first quarter glaxo have develop juluca partnership jnj free report juluca combine approve hiv drug glaxo tivicay dolutegravir mg edurant rilpivirine mg single once daily pill treatment virologically suppress hiv infection viiv healthcare be hiv company majorly own glaxo pfizer pfe free report japanese pharma company shinogi have minor stake viiv healthcare glaxo currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1945,PFE,expect agio pharmaceutical inc agio free report surpass expectation report first quarter result market open last report quarter company deliver negative earning surprise share agio have soar year time compare favorably industry increase company earning track record show mixed result company have outpaced estimate twice trail quarters miss same other overall agio come average negative surprise let see thing be shape quarter factor playagio only market drug be idhifa enasidenib receive fda approval last august treatment patient relapse refractory acute myeloid leukemia aml have isocitrate dehydrogenase idh mutation last report drug generate strong sale expect encourage revenue first quarter well moreover agio progress pipeline have be quite impressive fact investor focus remain same be report quarter interesting candidate company cancer portfolio be idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag ivosidenib be priority review unite state treat patient aml idh mutation approval ivosidenib be expect third quarter additionally company anticipate regulatory filing candidate eu fourth quarter same indication ivosidenib be also be evaluate phase study address advanced hematologic malignancy combine celgene celg free report vidaza be assessment phase ii cure newly diagnosed aml patient be not eligible intensive chemotherapy meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma second half company announce positive finding study notably company also plan initiate perioperative window trial analyze ivosidenib ag low grade glioma investigate effect brain tumor tissue first half company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii trial adult transfusion independent patient pyruvate kinase deficiency agio report positive datum program june fda grant fast track designation candidate give indication rgd market still remain unexplored newer therapy area hold huge potential nonetheless march agio announce commencement phase study evaluate first class methionine mat inhibitor ag patient solid tumor lymphoma deletion mtap expect management produce update same first quarter earning release earning whispersour proven model show agio be likely beat earning report cycle have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp agio have earning esp represent percentage difference most accurate estimate loss share zack consensus estimate loss positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp together positive esp chance earning beat stock upcoming release be peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quote other stock considerhere be other health care stock worth consider right combination element beat estimate time gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1946,PFE,bristol myer squibb company bmy free report first quarter earning cent share exceed zack consensus estimate cent year quarter earning cent total revenue be slightly higher zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading possibly better expect earning however bristol myer share have decline so far year compare unfavorably industry decrease quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year sale drug be label expansion drug pediatric patient unite state last november presumably do not have much impact sale rheumatoid arthritis drug orencia be first quarter melanoma drug yervoy contribute top line report quarter sale drug be opdivo be approve multiple cancer indication generate revenue year period sale cardiovascular drug eliquis be report quarter year year multiple myeloma drug empliciti record sale year year however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively hepatitis franchise lose year quarter sale contribute mere revenue research development expense quarter decrease marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix regulatory quarter april fda approve opdivo yervoy combination regimen treat intermediate poor risk advanced renal cell carcinoma patient have not receive prior treatment march fda have grant priority review supplemental biologic license application sbla seek approval combination regimen treat microsatellite instability high mismatch repair deficient metastatic colorectal cancer also april fda grant priority review sbla seek approval opdivo monotherapy patient small cell lung cancer third later line set new dose regimen opdivo mg week be also approve majority indication april bristol myer collaborate johnson johnson jnj free report subsidiary janssen develop commercialize factor xia inhibitor program include bms treat major thrombotic condition same month bristol myer privately hold illumina inc announce collaboration utilize latter next generation sequence technology february bristol myer squibb nektar therapeutic nktr free report enter strategic development collaboration nektar lead immuno oncology program nktr collaboration company develop commercialize nktr combination opdivo opdivo yervoy more indication tumor type well potential combination other cancer agent respective company third party company plan initiate study renal cell carcinoma melanoma mid pipeline updatein april bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc company also announce datum phase iii study checkmate evaluate opdivo chinese population datum show drug achieve superior overall survival previously treat patient nsclc compare docetaxel datum long term follow phase iii study checkmate show opdivo reduce risk death metastatic squamous cell carcinoma head neck minimum year follow compare standard chemotherapy march bristol myer pfizer inc pfe free report announce datum real world datum analysis different direct oral anticoagulant include eliquis xarelto boehringer ingelheim pradaxa datum show eliquis achieve significantly lower rate stroke systemic embolism major bleed compare xarelto pradaxa guidance updatedbristol myer increase adjust earning expectation company now project earning range share previously zack consensus estimate earning be peg company expect worldwide revenue increase mid single digit takebristol myer beat earning expectation primarily robust sale opdivo eliquis quarter increase guidance adjust earning be also encourage be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval further boost prospect blockbuster drug also superiority eliquis real world datum analysis be expect further boost sale drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1947,PFE,glaxosmithkline plc gsk free report be transfer rare disease gene therapy portfolio private biotech orchard therapeutic exchange stake company well seat board addition glaxo also be entitle royalty commercial milestone payment related rare disease medicine glaxo rare disease gene therapy include market drug strimveli gene therapy child ada scid be autosomal recessive metabolic disorder cause pipeline candidate include late stage program well pre clinical one glaxo announce strategic review rare disease unit last july back then company inform plan terminate partner divest pre clinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation interestingly time company product pipeline portfolio include rare disease drug be great demand glaxo be divest portfolio rare disease therapy however glaxo continue invest cell gene therapy focus oncology share british drugmaker have rise year so far decline industry last month glaxo announce agreement swiss giant novartis nvs free report buy latter stake consumer healthcare joint venture jv read more glaxo buy novartis stake consumer healthcare jv acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division glaxo own share jv also glaxo be look strategic alternative horlick other nutrition product help fund deal nutrition product be mostly sell glaxo indian subsidiary glaxosmithkline consumer healthcare glaxo own stake indian subsidiary also be include strategic review process food giant nestle kraft heinz khc free report unilever be be speculate frontrunner bid horlick business glaxo latest deal novartis come less week announce be withdraw race buy pfizer pfe free report consumer healthcare segment read more glaxo drop bid pfizer unit shingrix gain eu japan nod pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction glaxo carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1948,PFE,alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource tuesday lilly lly free report swiss partner astrazeneca azn free report say be discontinue late stage study alzheimer disease candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say study be unlikely meet primary goal completion prompt decision stall study oral beta secretase cleave enzyme bace inhibitor several company have fail develop safe effective treatment option deadly brain disease year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer pfe free report say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study late biogen biib free report ad study ban fail show early positive result raise investor concern candidate chance success clinical stage company axovant science suffer major setback september investigational ad candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment ad lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function be already lose make develop drug treat disease difficult interest still alive setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen novartis nvs free report eisai astrazeneca amgen be presently work alzheimer disease treatment biogen ad pipeline comprise mid well late stage candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program candidate be be develop collaboration eisai meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be collaborate ac immune development alzheimer disease treatment lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study earlier year fda propose new guideline be aim lower clinical study goal alzheimer disease drug aim treat earlier stage patient have not yet display functional disability clinical abnormality strategy be part fda ongoing effort expand access safe effective treatment option many serious condition effort fda also reinvigorate research effort alzheimer drug repeat failure lilly merck carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1949,PFE,be approve therapy completely cure autoimmune inflammatory disease development new treatment technology be ongoing meanwhile be difficult control autoimmune disease majority patient newest class medication treat disease be janus kinase jak inhibitor be provide patient better treatment option class therapy have generate significant interest due better efficacy compare tumor necrosis factor tnf inhibitor therapy autoimmune diseasesin patient autoimmune disease body immune system mistakenly attack healthy cell scientist be yet find reason abnormality however incidence autoimmune disease be rise be multiple type autoimmune disease include rheumatoid arthritis ra psoriasis multiple sclerosis ms inflammatory bowel disease ibd etc several company be dedicate bring better drug treatment disease symptom include fatigue muscle ach swell redness affected body part most common first line treatment autoimmune disease be disease modify rheumatic drug dmard especially methotrexate apart methotrexate be several class dmard include tnf inhibitor therapy approve disease be perform well abbvie abbv free report humira amgen amgn free report enbrel be blockbuster tnf inhibitor drug other however treatment have serious safety issue include increase risk tuberculosis lymphoma other jak pharma company be develop jak inhibitor work block particular signal body immune response cytokine instead suppress immune system do dmard patient treat jak inhibitor clinical study have show faster better response disease however safety concern still loom large segment be attractive company be only jak inhibitor presently approve treatment autoimmune disease especially ra however several company be develop candidate be likely increase competition go forward segment be news recently eli lilly lly free report olumiant jak inhibitor receive approval unite state abbvie abbv free report announce top line datum late stage study evaluate jak inhibitor candidate upadacitinib pharma biotech company grow interest jak inhibitor let take look pharma biotech company be look change way autoimmune disease be treat pfizer pfe free report xeljanz tofacitinib be first approve jak inhibitor unite state treatment ra have be available market drug be also approve psoriatic arthritis generate sale first quarter year year regulatory application seek line extension drug ulcerative colitis be approve late last month unite state regulatory application seek approval indication be review europe company currently carry zack rank hold see complete list today zack rank strong buy stock here eli lilly jak inhibitor olumiant baricitinib be second drug receive approval treat ra unite state drug be approve early month however be launch certain european country note fda reject company new drug application seek approval olumiant april cite safety concern lilly develop commercialize drug partnership incyte corporation drug generate sale first quarter sequentially lilly be currently evaluate drug autoimmune indication atopic dermatitis eczema late stage study company currently carry zack rank buy abbvie be company be focuse develop jak inhibitor base treatment company jak inhibitor upadacitinib show promising result late stage study evaluate candidate ra patient be also be develop atopic dermatitis late stage study enjoy breakthrough therapy status unite state late stage study be evaluate candidate crohn disease company currently carry zack rank galapago nv glpg free report be develop jak inhibitor candidate filgotinib collaboration gilead science inc gild free report separate late stage study be evaluate candidate ra crohn disease ulcerative colitis moreover several mid stage study be evaluate candidate multiple autoimmune indication include ankylose spondylitis psoriatic arthritis cutaneous lupus erythematosus other datum mid stagei study evaluate filgotinib psoriatic arthritis show significant improvement patient company currently carry zack rank prospect jak inhibitor several blockbuster dmard near patent expiration new class drug hold potential replace exist treatment boost prospect company have drug candidate pipeline commercial portfolio however jak inhibitor also have several side effect delay approval note lower dose lilly olumiant be approve box warning state risk serious infection malignancy thrombosis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1950,PFE,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenstrm rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1951,PFE,keryx inc kerx free report be expect report first quarter result market open last quarter company report negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise keryx share have lose year date compare industry decline factor influence quarterapart license fee keryx top line comprise revenue generate only market product auryxia ferric citrate auryxia be used treat patient chronic kidney disease ckd dialysis november fda grant approval additional indication auryxia treat adult iron deficiency anemia ida chronic kidney disease not dialysis moreover keryx claim auryxia be only oral treatment option available indication auryxia be already approve control serum phosphorus level adult chronic kidney disease dialysis latest approval drug treat complication chronic kidney disease also represent significant opportunity physician treat patient earlier stage disease anemia become more severe hence approval significantly boost auryxia sale meanwhile company be look potential partner commercialize drug eu ferric citrate have be consider new active substance european commission provide year datum marketing exclusivity region company also remain focuse create rapid awareness new indication differentiate auryxia exist treatment option communicate favorable insurance access auryxia prescriber patient expect see further company support number ongoing trial include several investigator sponsored clinical study new phase iv study call compass compass study continue expand clinical dataset auryxia treatment iron deficiency anemia study person haven be treat previously low iron different dose regimen such twice day however auryxia be only approve product keryx portfolio company be entirely dependent auryxia growth model proven model do not show earning beat keryx quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp keryx have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank keryx have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement keryx inc price ep surprise keryx inc price ep surprise keryx inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1952,PFE,tax filing deadline april few day away investor still have time make contribution individual retirement account ira tax year ira allow investor buy individual stock bond etfs mutual fund etfs be become increasingly popular investor due low cost transparency tax efficiency etfs be excellent tool retirement investor well provide easy way build diversify portfolio low cost further income pay etfs be better place ira income be shelter taxe investing retirement investor need assess investing goal time horizon risk tolerance read earning weight etfs tap year growth investor need remember performance investment portfolio depend mostly asset allocation investor allocate money major asset class such stock bond alternative asset cash low cost broad diversify fund be more suitable retirement investor core long term investment rather costly narrow focuse niche etfs mainly be used shorter term tactical trading vehicle expense ratio etf be important consideration retirement investing long term cheaper fund significantly outperform more expensive counterpart other thing remain same read etf way hedge portfolio volatility here be etfs be excellent long term investment retirement account ishare core total stock market etf itot free report itot be convenient way get exposure entire stock universe range smallest largest company extremely low cost just basis point hold more stock basket be core hold long term focuse portfolio apple aapl free report microsoft msft free report amazon amzn free report be top holding ishare core dividend growth etf dgro free report product hold company have history consistently grow dividend be likely continue grow dividend holding be weight dividend dollar believe company uninterrupted dividend growth record usually have solid balance sheet strong cash flow so strategy outperform market time also provide stability downside protection market downturn addition grow income stream etf doesn have lot exposure rate sensitive sector be good choice investor worry rise rate environment have low expense ratio johnson johnson jnj free report pfizer pfe free report apple aapl free report be top holding read blackrock launch gun free etfs schwab large cap value etf schv free report numerous academic study have show value stock have deliver higher return lower volatility compare growth stock long term almost market study give proven performance long term value stock fund be predominant part core portfolio schv provide broad exposure large cap stock value style characteristic have expense ratio just basis point dividend yield be quite attractive microsoft morgan jpm free report johnson johnson jnj free report be top holding ishare core msci total international stock etf ixus free report well diversify portfolio have exposure international stock ixus be excellent way get exposure large mid small cap equity international develop emerge market have low expense ratio bps hold more stock basket top holding include tencent nestle samsung want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1953,PFE,pfizer inc pfe free report announce late stage study kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs accordingly independent datum monitoring committee recommend study be stop plan interim analysis detailed datum study be present future medical meeting phase iii atla study be evaluate inlyta versus placebo adjuvant therapy patient high risk recurrent renal cell carcinoma rcc type kidney cancer follow surgical removal kidney share pfizer have rise so far year compare favorably decrease industry inlyta be presently market second line treatment patient advanced rcc atla study be successful then inlyta be able cater expand patient population kidney cancer patient be earlier stage disease inlyta generate sale decline meanwhile inlyta be be evaluate independent global phase iii study combination merck mrk free report pd inhibitor keytruda own pd inhibitor bavencio avelumab respectively compare sutent first line advanced rcc study continue be unmodified bavencio be currently approve metastatic mcc rare aggressive skin cancer unite state europe japan second line treatment locally advanced metastatic urothelial carcinoma accelerate approval unite state pfizer have develop bavencio partnership german company merck kgaa meanwhile avelumab be be develop different type cancer avelumab pd program have several study ongoing monotherapy combination other portfolio asset zack rank key pickpfizer carry zack rank buy see complete list today zack rank strong buy stock here top rank large cap pharma stock be glaxosmithkline gsk free report same zack rank pfizer share glaxo have return year so far estimate have increase respectively past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1954,PFE,bristol myer squibb company bmy free report announce encourage datum phase iii checkmate study opdivo checkmate study be ongoing study evaluate immuno oncology combination opdivo nivolumab low dose mg kg yervoy ipilimumab compare pfizer pfe free report sutent sunitinib intermediate poor risk patient advanced renal cell carcinoma rcc year follow period treatment opdivo low dose yervoy lead statistically significant difference patient report outcome baseline versus sunitinib year follow study demonstrated patient show significant benefit disease related symptom improvement cancer related quality life well be benefit occur early opdivo low dose yervoy combination therapy be largely maintain treatment period opdivo maintenance therapy checkmate study patient advanced renal cell carcinoma have earlier show efficacy benefit opdivo low dose yervoy number measure include overall survival objective response rate progression free survival however result present now show patient treat immuno oncology combination also report significant improvement disease related symptom well positive change physical emotional functional well be additional analysis show similar result significant benefit see opdivo low dose yervoy relative sunitinib change baseline pre plan week landmark bristol myer share have decline year date compare industry decline note opdivo become first pd immune checkpoint inhibitor gain regulatory approval july be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential significantly however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous small cell lung cancer nsclc company be expect suffer further loss market share separate release bristol myer announce fda lift partial clinical hold place checkmate phase iii study evaluate addition opdivo pomalidomide dexamethasone patient relapse refractory multiple myeloma decision follow consultation fda agreement amendment study protocol fda put clinical hold study evaluate opdivo base combination relapse refractory multiple myeloma september fda precaution follow risk identify trial study pd agent keytruda patient multiple myeloma stock warrant lookbristol myer carry zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year bristol myer squibb company price bristol myer squibb company price bristol myer squibb company hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1955,PFE,investor be keenly await earning result merck co inc mrk free report pfizer inc pfe free report main reason be merck kgaa consumer healthcare division be acquire procter gamble co pg free report last month follow acquisition focus shift pfizer procter gamble be expect acquire consumer healthcare business unit former meanwhile healthcare sector have jump past year become best perform sector sign sector well be become more evident last year nyse arca pharmaceutical index nasdaq biotechnology index gain respectively merck pfizer be schedule report be good time figure be better stock pharma giant carry zack rank buy see complete list today zack rank strong buy stock here other major earning schedule same day include apple inc aapl free report bp bp free report price have witness decline past year pfizer have advanced so pfizer be clear winner respect better return rival merck broader industry rise same period dividend yieldin year time merck pfizer have offer dividend yield respectively industry dividend yield be so pfizer have take lead here too compare merck broader industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company be good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry earning history espconsider more comprehensive earning history merck have deliver positive surprise prior quarters average positive earning surprise comparison pfizer deliver average positive earning surprise prior quarters register earning beat time consider earning esp merck pfizer have esp value respectively imply pfizer be advantage respect moreover pfizer earning estimate current year have advanced last day slightly better merck increase conclusionour comparative analysis show merck hold edge pfizer consider only ev ebitda ratio previous earning performance however consider price performance leverage position net margin estimate revision pfizer hold advantage merck additionally pfizer have better dividend yield merck make clearly better stock clinch case favor pfizer point time be have positive better esp merck be lead indicator likely positive surprise be be better bet pfizer merck prepare report earning next week more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1956,PFE,dow rebound strongly week trade war fear recede tech stock stage recovery market decline monday uncertainty prospective trade war weigh investor sentiment however dow register strong gain next trading day register first session stretch gain feb last week dow increase last thursday drive rebound tech major intel inc intc gain most increase share facebook inc fb free report apple inc aapl free report netflix inc nflx free report alphabet inc googl free report amazon com inc amzn free report gain respectively microsoft corp msft free report also gain company establish separate engineering team experience device cloud ai platform index gain last week market stage powerful rebound last monday tension ensue trade war unite state china appear ease however last tuesday market decline sharply due tech tumble additionally index decrease month march decline be primarily attributable president trump decision impose tariff chinese import give rise fear ensue trade war dow also lose first quarter dow index decline monday due uncertainty global trade war technology internet stock continue suffer follow president trump renew attack amazon monday broad base market selloff be worst start april great depression component blue chip index close day move average major loser blue chip index be intel plunge follow bloomberg report apple use own chip mac computer instead intel chip index gain tuesday lead partial turnaround technology stock amazon gain follow bloomberg report cite source government be not plan impose regulation company recovery be broad base investor anxiety impending trade war imposition new regulation technology internet stock persist index gain wednesday component close green market open sharply lower yesterday trade war related concern however re-cover subsequently great extent white house give indication government doesn want enter trade war china blue chip index rebound point plunge finish session point consequently dow register best single session comeback feb blue chip slip end index gain thursday finishing green third consecutive day first time feb fear impending trade war seem ebb semblance stability seem have return proceedings wednesday notable turnaround dow add more stock boee company ba free report dowdupont inc dwdp emerge best performer add respectively overall tech stock be lead gainer day facebook netflix amazon increase respectively component move index boee recently enter agreement second largest indian base airline jet airway deliver max narrow body aircraft reuter deal be line indian airline latest rush expand fleet meet rise demand country domestic international flight deal value amount approximately current list price get lower once deal finalize airline typically receive significant discount big order manufacturer however be still unknown agreement be formal order bound memorandum understand stock have zack rank buy see complete list today zack rank strong buy stock here exxonmobil corporation xom win additional exploration block brazil bid round oil major operate newly award block zack rank hold exxonmobil have win right block area company operate block partner qatar petroleum exxonmobil have be award block campos area be operated exxonmobil partner petrobra pbr free report qatar petroleum other block be operated petrobra partner exxonmobil statoil asa remain block be locate sergipe alagoas area block be operated exxonmobil partner queiroz galvao exploraao produao qgep murphy oil corporation mur award be likely boost value already hold adjacent block read exxonmobil win new block fortify presence brazil general electric company ge free report have inked agreement sell trio health care information technology business private equity firm verita capital cash transaction include zack rank sell ge enterprise financial management ambulatory care management workforce management software asset deal be expect close third quarter healthcare division ge third largest sale be solid cash generator include high growth market such life science read ge revamp underway sell health verita goldman sachs group inc gs free report be likely face yet suit discriminatory pay practice reuter allegation practice pay discrimination bank female workforce be file group class action lawsuit plaintiff include female employee zack rank goldman get district judge analisa torre permission manhattan filing suit plaintiff accuse goldman restrict career path discrimination female employee vice president have work goldman investment banking investment management security division september well worker new york city july allege bank paid less compare man well misrepresent performance reviews promotion option read goldman be sue discrimination woman intel be divest software firm wind river system inc alternative asset fund manager tpg financial term deal be keep wrapped intel have zack rank notably world largest chip maker have buy wind river system aim step traditional semiconductor market expand consumer electronic space wind river be global leader device software optimization dso buyout enabled intel possess wind river expertise run device software greater reliability faster speed lower cost read intel trim business divest wind river unit tpg pfizer inc pfe free report announce phase iii study evaluate pipeline candidate tafamidis treatment transthyretin cardiomyopathy ttr cm meet primary endpoint pfizer have zack rank top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month safety datum also demonstrated tafamidis be generally well tolerate patient read pfizer rare disease candidate meet endpoint phase iii performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookfear impending trade war recede successive trading day lead substantial gain stock however trump announcement additional worth tariff chinese import be likely heighten trade war related concern give such backdrop investor once again look key economic release provide much need optimism week ahead make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1957,PFE,be happen week pharma stock key development week include new car deal pfizer pfe free report successful study result pfizer lilly lly free report allergan agn free report positive regulatory update astrazeneca azn free report recap week most important storiespfizer car deal tafamidis succeed late stage study pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car therapy pfizer own stake allogene also get representation latter board meanwhile cnbc report say pfizer be talk consumer giant procter gamble regard sale consumer healthcare segment last month glaxo gsk free report reckitt benckiser group pull discussion pfizer buy same unit read more pfizer inks new car deal talk unit sale pfizer pipeline candidate tafamidis develop treatment transthyretin cardiomyopathy ttr cm meet main goal late stage study attr act top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month read more pfizer rare disease candidate meet endpoint phase iii pfizer regulatory application pipeline candidate dacomitinib be accept priority review unite state response expect september company be look get drug approve first line treatment patient locally advanced metastatic small cell lung cancer nsclc egfr activate mutation read more pfizer lung cancer candidate get fda priority review lilly cyramza meet os endpoint liver cancer study lilly announce already approve cancer drug cyramza show overall survival benefit thereby meeting primary endpoint late stage study evaluate second line treatment liver cancer study also meet secondary endpoint progression free survival read more lilly cyramza show survival benefit liver cancer study astrazeneca provide regulatory update astrazeneca diabetes treatment bydureon gain fda approval add therapy insulin glargine also biologic license application bla seek approval astrazeneca cd recombinant immunotoxin candidate moxetumomab pasudotox second later line treatment hairy cell leukaemia hcl be grant priority review fda fda grant priority review decision be expect third quarter regulatory development astrazeneca partner merck mrk free report regulatory submission look expand label parp inhibitor lynparza include breast cancer indication be accept eu lynparza be already approve treat ovarian cancer eu latest filing astrazeneca look get lynparza approve brca mutate negative metastatic breast cancer eu unite state lynparza be approve same indication january read more astrazeneca bydureon get fda nod expand use allergan vraylar succeed label expansion study allergan partner gedeon richter say vraylar cariprazine meet primary endpoint late stage study adult major depressive episode associate bipolar disorder bipolar depression be third pivotal study conduct indication datum study be include company label expansion application company plan file second half read more allergan vraylar meet endpoint bipolar phase iii bio path mid stage study leukemia candidate show positive early datum bio path holding announce positive interim datum phase ii study bp lead pipeline candidate prexigebersen be be evaluate combination low dose cytarabine ldac treatment patient acute myeloid leukemia aml elect not be treat more intensive chemotherapy combination therapy demonstrated early leukemic activity nearly evaluable aml patient study total patient achieve form response combo treatment share bio path shot response read more bio path leukemia combo study show positive early datum fda approve sonoma skin gel sonoma pharmaceutical small solution maker skin condition advanced tissue care gain fda approval antimicrobial post treatment gel gel aim treat itch pain associate procedure include laser skin resurface post therapy chemical peel share sonoma shot more response nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report glaxo be biggest gainer rise bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup abbv rova disappoint unit get buyout offer next pharma world watch regulatory pipeline news pharma stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1958,PFE,total earning total healthcare market capitalization be revenue growth growth rate seem unimpressive compare other sector earning revenue beat ratio respectively be also not great most notable player johnson johnson jnj free report be first major drug company report earning apr follow eli lilly company lly free report bristol myer squibb company bmy free report apr apr respectively other major drug company merck mrk free report pfizer pfe free report report industry bigwig come earning revenue beat earning focusjohnson world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past estimate johnson johnson raise revenue guidance maintain earning share outlook reflect growth read healthcare etfs focus johnson johnson earning drug giant surpass earning estimate lag revenue earning share cent come cent zack consensus estimate revenue fall shy estimate annual basis earning share revenue rise respectively pfizer expect revenue range earning share merckmerck also beat earning estimate miss revenue earning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be estimate merck increase revenue guidance earning share guidance bristol myersbristol myer top estimate front report earning share cent cent zack consensus estimate ahead year earning cent revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lillyeli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue guidance earning guidance etf anglepharma etfs see terrible trading past month mediocre result fail boost confidence space push many fund week lows have highlighted detail fund have zack etf rank hold ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period read be spdr pharmaceutical etf xph free report hot etf right now vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account more share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest least share bmy pfe lly etf have lose month first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly make more ftxh have lower level aum share average daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1959,PFE,dow endure particularly tough week end marginal gain first time only thursday early half week strong earning result fail boost investor sentiment trade inflation related fear weigh investor most week fed refrain raise rate market watcher remain concern future action last week dow decrease last friday gain consecutive winning session strong earning result large cap technology internet boost investor sentiment mid day trading however market shed most gain soft gdp datum tepid earning report energy sector tumble stock blue chip index fall negative territory primarily due tepid earning result exxon mobil corporation xom free report dow lose last week investor remain concern iphone sale come expectation second quarter meanwhile caterpillar inc cat free report forecast economic growth decelerate later year also dampen investor sentiment spike treasury yield also weigh broader market dow index decline monday broad base decline push major index red slide healthcare industrial stock more offset gain several merger acquisition telecom mega deal moreover strong first quarter earning result also fail uplift investor sentiment dow gain month april strong earning result most large corporate fail encourage investor disappointing guidance taiwan semiconductor tsm free report largest contract chipmaker worldwide lead loss tech major rise bond yield also dent investor confidence index lose tuesday stock index close green trade red trading session blue chip index be once nearly touch lowest close april index decline wednesday market be early hour trading buoy fed decision keep monetary policy unchanged however broader market lose momentum later day news further escalation china trade conflict strong earning result apple also fail boost market sentiment investor remain concern inflationary pressure index gain thursday even investor remain uneasy ahead friday official job report earlier day dow be nearly point move day move average first such occurrence early april however re-cover subsequently post marginal gain fear related trade uncertainty fed future action weigh sentiment component move index apple inc aapl free report report second quarter fiscal earning share beat zack consensus estimate cent increase almost year year net sale increase year year surpass zack consensus estimate apple have zack rank hold total iphone unit sale miss zack consensus estimate increase year year back iphone iphone iphone third quarter fiscal revenue be project gross margin be expect operate expense be project read apple earning revenue top estimate chevron corporation cvx free report report first quarter earning share significantly ahead zack consensus estimate bottom line also improve significantly year profit chevron have zack rank quarterly revenue lag zack consensus estimate refine weakness be year year chevron total production crude oil natural gas increase compare last year corresponding period oil equivalent barrel day mboe chevron downstream segment achieve earning lower profit last year read chevron share gain post big earning beat dowdupont inc dwdp free report record profit report basis cent share first quarter compare cent share logged comparable quarter year bar time item earning come share quarter top zack consensus estimate zack rank dowdupont rake net sale report quarter comparable quarter year also surpass zack consensus estimate dowdupont expect net sale second quarter increase more operate ebitda rise more year year basis read dowdupont top earning revenue estimate merck co inc mrk free report report first quarter adjust earning share beat zack consensus estimate cent earning rise year year revenue quarter rise year year sale however slightly miss zack consensus estimate merck raise outlook revenue range previously zack consensus estimate stand company now expect adjust earning range raise previous guidance zack consensus estimate be peg share stock have zack rank buy see complete list today zack rank strong buy stock here mcdonald corporation mcd free report report first quarter adjust earning share outpaced consensus mark improve year quarter mcdonald have zack rank revenue outpaced consensus mark decline year year read mcdonald earning top comp continue impress pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year revenue miss zack consensus estimate pfizer have zack rank revenue however rise year quarter report basis revenue be expect range adjust earning share be expect range read pfizer stock fall sale miss earning beat microsoft corporation msft free report deliver third quarter fiscal earning cent share beat zack consensus estimate dime figure rally year year basis microsoft have zack rank revenue increase almost year quarter constant currency cc further figure exceed zack consensus estimate read microsoft beat earning strong top line growth intel corp intc free report deliver first quarter gaap earning cent share beat zack consensus estimate cent figure surge year quarter decline sequentially intel have zack rank revenue totale year year quarter quarter figure surpass zack consensus estimate read intel beat earning robust datum centric growth exxon mobil report first quarter earning share miss zack consensus estimate however bottom line increase year quarter level cent exxon mobil have zack rank total revenue quarter rise year moreover top line surpass zack consensus estimate read exxon mobil fall earning miss beat sale performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookmarket have endure difficult week weigh concern fed future action trade related tension china concern be unlikely disappear future fear spike inflation have also weigh investor sentiment economic report release recently have also be lackluster report gdp be particularly disappointing market now look crucial economic report such friday job report encouragement day ahead today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1960,PFE,expect abbvie inc abbv free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise share abbvie have marginally outperformed industry so far year stock have decline industry have decrease notably abbvie earning history be quite impressive pharmaceutical company have outpaced estimate last quarters average beat let see thing be shape company quarter factor considerabbvie expect first quarter earning range share revenue be estimate grow mid range operational basis foreign exchange be anticipate gain favorable impact sale period be report company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally zack consensus estimate humira be peg significantly first quarter conference call investor focus also be performance level well label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica stand other drug namely duopa creon be also likely maintain encourage performance soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale affected intense pricing competitive pressure hcv market moreover march abbvie rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line therapy later small cell lung cancer sclc first quarter conference call expect management provide update same notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret secure approval unite state eu canada well japan second half importantly mavyret record global sale last year initial uptake drug have be commendable expect higher sale first quarter well earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp zack consensus estimate be share positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvieha zack rank increase predictive power esp together positive esp chance stock beating estimate upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision other stock warrant lookhere be couple other health care stock worth consider right combination element also surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report be schedule report earning apr company have earning esp zack rank celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank player abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1961,PFE,expect allergan plc agn free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise allergan share price have decline year so far compare industry decline allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotelet see thing be shape announcement factor consideron fourth quarter conference call company guide first quarter revenue earning share be expect be number indicate lowest revenue earning quarter year fourth quarter favorable timing physician rebate program benefit sale allergan facial aesthetic product benefit be absent first quarter hurt revenue such company expect first quarter revenue growth rate be somewhat lower annual growth rate also generic competition estrace namenda xr hurt sale sharply first quarter generic version namenda xr be launch indian company lupin february estrace cream be launch mylan myl free report january allergan expect generic version restasis second best selling drug be launch april july meanwhile generic version delzicol be expect be launch early second quarter investor focus call be management comment potential impact generic competition key growth driver restasis namenda xr zack consensus estimate restasis be nonetheless allergan establish product botox linzess loestrin juvderm collection filler new product juvderm collection filler support sale zack consensus estimate botox be fact recent label expansion botox fda approval forehead line treatment vraylar fda approval maintenance treatment schizophrenia avycaz fda approval habp vabp add sale drug meanwhile addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition continue support top line quarter however believe sale erosion aczone due generic pressure brand acne category loss exclusivity loe mainly asacol hd minastrin continue hurt top line remind investor call company have say do not expect significant activity allergan expect reevaluate strategy second half year once get loe update be expect upcoming conference call earning whispersour proven model show allergan be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank combination allergan zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large cap health care stock worth consider model also have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1962,PFE,eli lilly company lly free report report first quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed robust volume drive growth new product sale lower operate cost tax rate include asset impairment restructure other special charge first quarter earning share be loss cent first quarter revenue detailquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement make lower sale establish product strattera ciali forteo volume rise increase demand new product trulicity cyramza taltz basaglar jardiance lartruvo offset decline sale establish product however volume growth be softer previous quarter higher realize price several drug contribute sale growth quarter foreign exchange rate also have favorable impact revenue grow ex revenue rise pharmaceutical revenue rise quarter however decrease demand food animal product continue hurt sale lilly animal health segment establish product record growth quarter include humalog year year humulin trajenta sale other establish product decline quarter forteo sale decline due decrease volume unfavorable wholesale retail buy pattern unite state cymbalta sale decline erbitux sale decline alimta sale rise higher sale unite state offset sale decline international market ex market sale decline due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume higher realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt lower demand unite state loss exclusivity europe strattera sale decline due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume currency benefit partially offset lower realize price revenue increase drive increase volume higher realize price jardiance sale surge drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter generate revenue unite state improve sequentially drive increase demand drug gain medicare part formulary access taltz bring sale compare previous quarter higher ex revenue be offset lower sale be hurt unfavorable specialty pharmacy buy pattern lartruvo olaratumab generate revenue quarter compare previous quarter olumiant baricitinib have be launch select european country japan moderate severe rheumatoid arthritis drug generate sale quarter backed strong launch uptake germany compare previous quarter drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january setback company monday lilly inform fda advisory committee have recommend approval mg dose jak inhibitor not recommend higher dose mg ground safety profile be not adequate support approval relative benefit final decision fda be expect june year please note april last year fda have issue complete response letter crl new drug application nda baricitinib safety concern verzenio be launch unite state fourth quarter generate sale quarter compare previous quarter elanco animal health segment sale decline due decrease demand food animal product lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business gross margin operate income adjust gross margin quarter decrease basis point manufacturing efficiency higher realize price be offset negative product mix effect foreign exchange rate international inventory sell operate income increase year year due lower operate cost total operate expense include research development marketing selling administrative expense percent revenue decline basis point quarter due company cost save effort ep guidance uppedlilly raise previously issue outlook adjust earning well sale adjust earning share be now expect range higher expect previously reflect expect benefit higher operate profit lower tax rate revenue range be also slightly up expect previously gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense guidance be tighten range compare previously research development expense guidance be slightly increase range compare previously due increase funding requirement pipeline development takelilly first quarter result be impressive beat estimate earning sale also raise guidance metric share drug giant rise more pre market trading however year date lilly share have decline compare industry decline go forward lilly new product trulicity taltz basaglar cyramza jardiance lartruvo verzenio olumiant be expect continue drive revenue however competitive pressure lilly drug be expect rise year challenge remain company form loss patent exclusivity product ciali year impact generic competition strattera effient axiron latest baricitinib setback be disappointment lilly carry zack rank buy see complete list today zack rank strong buy stock here eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotestock considerother top rank large cap pharma stock include merck mrk free report pfizer pfe free report carry zack rank merck share have rise year so far earning estimate increase respectively past day pfizer earning estimate rise respectively past day stock have go year so far make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1963,PFE,alexion pharmaceutical inc alxn free report be schedule report first quarter result apr open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently top estimate last quarters average positive earning surprise alexion share have underperform industry past year stock have lose compare industry decline do zack model unveil proven model show alexion be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating estimate zack esp alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank stock here note sell rate stock zack rank never be consider go earning announcement let see thing be shape announcement factor likely impact resultsalexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory generalized myasthenia gravis gmg patient be acetylcholine receptor antibody positive drug be approve europe indication approximately patient be expect have gmg unite state additionally phase iii study prevent soliris patient relapse neuromyelitis optica spectrum disorder be ongoing enrollment be complete datum expect mid label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly zack consensus estimate soliris hint drug sale increase year quarter alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate company plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity alexion reduce spending headcount associate previously announce prioritize pipeline program well optimize additional expense company plan relocate headquarters boston mid approximately position result restructure plan company reduce global workforce approximately company expect increase financial flexibility allow reinvest approximately annually alexion expect pretax saving approximately meantime company effort develop pipeline be impressive particularly case alxn currently be evaluate alxn longer act antibody inhibit terminal complement phase iii study pnh ahus tentative approval pnh be expect patient be also be dose phase iii trial alxn administer intravenously week complement inhibitor treatment naive adolescent adult patient ahus company be expect complete enrollment second quarter announce result fourth quarter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteother stock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1964,PFE,astrazeneca azn free report announce have secure fda approval label expansion market drug tagrisso osimertinib first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation notably tagrisso be approve unite state european union japan china second line treatment patient advanced nsclc show progress follow treatment egfr tki due egfr resistance mutation share astrazeneca have outperformed industry year date stock have gain versus industry decline remind investor last december fda accept grant priority review company supplemental new drug application snda tagrisso aforementioned indication fda nod be base positive datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum trial show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience importantly similar application tagrisso label expansion be review eu well japan decision expect second half tagrisso register sale reflect growth year period accounting total sale potential approval first line set further boost drug prospect however lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug dacomitinib phase iii study first line treatment indication moreover bristol myer squibb bmy free report be develop opdivo treatment nsclc astrazeneca too have iressa approve treat nsclc be also develop imfinzi same indication astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here note be reissue article correct inaccuracy original version publish april longer be rely hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1965,PFE,biotech major amgen inc amgn free report announce have receive european commission ec approval include overall survival os datum tower study label bite antibody blincyto blincyto be approve treatment patient philadelphia chromosome negative ph relapse refractory cell precursor acute lymphoblastic leukemia tower study be conduct support conversion blincyto accelerate approval full approval study evaluate efficacy blincyto versus standard care soc chemotherapy treatment ph relapse refractory cell precursor adult result late stage study show median overall survival patient blincyto be month compare month standard care soc chemotherapy blincyto label unite state already include os datum tower study follow approval receive fda july last year fact inclusion os datum have be instrumental drive sale drug higher past quarters blincyto sale surge year period first quarter reflect rise inclusion os datum european label drug further boost sale remind investor pfizer inc pfe free report besponsa be approve treatment relapse refractory cell precursor june last year eu increase competition blincyto amgen share have gain so far year decrease register industry amgen currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock here crispr therapeutic loss share estimate narrow last day stock have sky-rocket year date genomic health earning estimate surge almost past day stock have soar so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1966,PFE,aerie pharmaceutical inc aeri free report be schedule report first quarter result market close last quarter company report wider expect loss aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc quoteaerie performance last quarters have be mixed company incur narrower expect loss trail quarters report wider expect loss remain average negative surprise aerie share have return year compare industry gain factor playaerie stock receive major boost december fda approval lead candidate rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension news be significant boost aerie give company have approve product portfolio fda approval come month ahead schedule prescription drug user fee act goal date feb glaucoma be largest segment global ophthalmic market accord national eye institute be estimate more individual unite state suffer glaucoma number be expect reach aerie expect rhopress revenue range company recently announce have launch drug unite state company have hire regional sale director district manager well more expect territory manager company expect gain prefer formulary coverage majority commercial payer rhopressa late most medicare part coverage expect commence expect management throw more light drug launch first quarter call meanwhile aerie second product candidate roclatan netarsudil latanoprost ophthalmic solution be fix dose combination rhopressa pfizer pfe free report xalatan achieve primary efficacy endpoint phase iii registration trial name mercury mercury candidate also achieve successful month safety efficacy result mercury company expect submit nda roclatan second quarter investor also be focus aerie update same earning whispersour proven model do not show aerie be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aerie have zack rank be favorable however need have positive esp well be confident earning beat note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be few health care stock want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1967,PFE,pfizer inc pfe free report share decrease report first quarter revenue lag zack consensus estimate billionmerck co inc mrk free report lose report first quarter revenue miss zack consensus estimate billiontenet healthcare corp thc free report share increase post first quarter adjust earning contrast zack consensus estimate loss shareshare bp plc bp free report increase report first quarter earning outpace zack consensus estimate
1968,PFE,often lose sight thing once re thick earning season be now happen be job week automatic datum process adp free report private sector report come month april tomorrow important bureau labor statistic bls farm payroll report friday cnbc squawk box morning martin mucci paychex inc payx free report report small business job wage growth last month result be definitely interesting year year small business job growth be wage growth be lower see last summer indicate massive corporate tax cut see end have yet hit small business be indication not expect overall job number be notably affected tax cut arizona show best annual hourly earning growth be once again top city overall job growth phoenix top small business wage increase tennessee be state see largest gain small business employment overall manufacturing be month small business leisure hospitality come top hourly earning growth overall month wage growth small business be marginally far earning season go bell today expect result apple aapl free report snap snap free report many other morning see plenty result well ve only get time post couple pfizer pfe free report report cent beat bottom line cent share revenue miss anticipate company restate earlier guidance be accordance zack consensus number more pfe earning click here keep same industry well zack rank buy rate stock ahead earning result merck mrk free report also top earning estimate share versus cent miss marginally top line vs analyst be look also report line guidance current zack consensus estimate more mrk earning click here
1969,PFE,tuesday often lose sight thing once re thick earning season be now happen be job week automatic datum process adp free report private sector report come month april tomorrow important bureau labor statistic bls farm payroll report friday cnbc squawk box morning martin mucci paychex inc payx free report report small business job wage growth last month result be definitely interesting year year small business job growth be wage growth be lower see last summer indicate massive corporate tax cut see end have yet hit small business be indication not expect overall job number be notably affected tax cut arizona show best annual hourly earning growth be once again top city overall job growth phoenix top small business wage increase tennessee be state see largest gain small business employment overall manufacturing be month small business leisure hospitality come top hourly earning growth overall month wage growth small business be marginally far earning season go bell today expect result apple aapl free report snap snap free report many other morning see plenty result well ve only get time post couple pfizer pfe free report report cent beat bottom line cent share revenue miss anticipate company restate earlier guidance be accordance zack consensus number more pfe earning click here keep same industry well zack rank buy rate stock ahead earning result merck mrk free report also top earning estimate share versus cent miss marginally top line vs analyst be look also report line guidance current zack consensus estimate more mrk earning click here mark vickerysenior editorquestion comment article author click here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1970,PFE,pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year lower tax rate share count due aggressive share repurchase quarter make weaker sale performance higher cost pharma heavyweight record revenue miss zack consensus estimate revenue however rise year quarter report basis due positive impact currency change currency movement benefit pfizer first quarter revenue however operational basis exclude impact currency revenue decline year year international revenue rise operational basis revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period ibrance eliquis do well quarter ih segment revenue be hurt lower sale enbrel lyrica prevnar prevenar meanwhile unfavorable customer buy pattern somewhat hurt sale ibrance xeljanz certain other product ibrance revenue rise quarter xeljanz sale rise lyrica sale decline eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare previous quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada global prevnar prevenar revenue decline higher international sale make decline unite state prevnar revenue tank unite state due lower government purchase last year pediatric indication continue decline revenue adult indication however prevenar revenue rise international market revenue consumer healthcare segment pfizer be consider selling rise global oncology revenue increase global vaccine revenue decline internal medicine decline inflammation immunology franchise decline additionally portfolio rare disease rise pfizer segment sale decline operationally revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage viagra sale decline due generic competition begin december however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense rise quarter pfizer buy back share worth include open market share repurchase accelerate share repurchase agreement execute march guidancerevenue be expect range adjust earning share be expect range mid point adjust ep be expect increase revenue be expect increase research development expense be likely be range si spending be project range adjust tax rate be expect be basis point less due expect advantage tax reform takepfizer first quarter result be mixed beat estimate earning miss same revenue meanwhile re affirm previously issue guidance share pfizer fall pre market trading lower expect sale quarter top line be hurt decline sale key drug lyrica prevnar prevenar enbrel also loss exclusivity product viagra continue supply shortage legacy hospira product hurt revenue year so far pfizer share have increase decrease industry pfizer face top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition however believe new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer look well poise record profit growth pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential pfizer carry zack rank buy see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1971,PFE,pfizer inc pfe free report be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be well know product prevnar lyrica lipitor celebrex other however many peer pfe be face generic competition pricing pressure several product other lose alliance revenue supply shortage legacy hospira product pricing pressure rise competition be hurt top line scenario investor focus remain late stage pipeline candidate commercial potential performance new product apart usual top bottom line number pharma giant have strong record earning surprise company earning surpass expectation last quarters deliver average positive surprise currently pfe have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earn beat pfe beat first quarter earning come cent consensus call ep cent earning rise year year revenue miss revenue however miss expectation pfizer post revenue miss zack consensus estimate revenue rise year quarter report basis however operational basis exclude impact currency revenue decline year year guidance pfizer re affirm previously issue guidance revenue be expect range zack consensus estimate be peg adjust earning share be expect range zack consensus estimate be peg share pre market trading share be pre market trading check back later full pfe earning report later pfizer inc price consensus pfizer inc price consensus pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1972,PFE,pfizer inc pfe free report have announce initiation dose phase ib study evaluate mini gene therapy candidate pf treatment boy age year duchenne muscular dystrophy dmd notably dmd be genetic disease characterize muscle degeneration weakness company anticipate initial datum study first half phase ib study be open label randomize ascend dose assessment be conduct approximately boy dmd study be design evaluate safety tolerability pf also assess muscle strength quality function give patient population share pfizer be almost apr follow news release however stock have gain past year marginally underperform industry increase remind investor pf be add pfizer portfolio follow acquisition bamboo therapeutic august acquisition complement pfizer rare disease portfolio enhance leadership position gene therapy additionally last year pfizer enter collaboration agreement other company advance gene therapy program notably pfizer inked agreement deal sangamo therapeutic develop commercialize gene therapy program hemophilia meanwhile last november company amend contract spark therapeutic once free report advance hemophilia gene therapy candidate be be evaluate phase ii study nonetheless april pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car candidate ucart treatment cd express hematological malignancy notably dmd be most common fatal genetic disorder affect child world be devastate incurable muscle wasting disease datum provide national human genome research institute dmd be devastate debilitating disease affect male birth globally thus be significant unmet need dmd treatment present approve therapy disease market be serepta therapeutic srpt free report exondys eteplirsen marathon pharmaceutical emflaza deflazacort first therapy approve dmd country importantly pfizer be not only company work develop treatment dmd other company also involved develop dmd therapy include catabasis summit ptc therapeutic biomarin bmrn free report et al pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1973,PFE,expect bristol myer squibb company bmy free report beat expectation report first quarter result apr market open bristol myer share have decrease so far year compare industry decline bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation once average positive earning surprise last quarters be last report quarter bristol myer deliver positive surprise let see thing be shape quarter drive growth bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer opdivo combination yervoy significantly improve progression free survival patient compare chemotherapy potential approval indication be significant boost drug give immense scope lung cancer market zack consensus estimate drug sale first quarter be peg january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda approve drug indication july zack consensus estimate drug sale quarter be november fda approve line extension sprycel pediatric patient ph chronic myeloid leukemia chronic phase drug register growth previous quarter be expect receive boost quarter due expand label zack consensus estimate sprycel sale stand cardiovascular drug eliquis come strong performance sale grow year year sale be expect remain robust first quarter too zack consensus estimate eliquis sale be peg other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1974,PFE,pfizer inc pfe free report announce have form alliance private biotech allogene therapeutic expedite development allogeneic car therapy san francisco base allogene be co founder lead former executive kite pharma be acquire gilead gild free report last year pfizer own stake allogene also get representation latter board deal allogene assume pfizer right preclinical car asset pfizer license french company cellectis servier addition allogene also gain right phase candidate ucart pfizer develop partnership servier ucart be allogeneic car therapy have potential be develop treatment cd express hematological malignancy be presently phase study acute lymphoblastic leukemia phase ii study be expect be initiate next year allogene servier allogeneic car therapy potentially revolutionary cancer treatment approach be develop cell healthy donor store shelf use patient approach eliminate need create personalize therapy thereby reduce time patient treatment focus car area have increase last year fda approval therapy such novartis nvs free report kymriah gilead yescarta treatment have huge commercial potential well change treatment paradigm car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body car approach involve collection patient cell genetic modification outside body incorporation specific receptor target cancer cell finally re infusion modify cell back patient go say many drug biotech company be look boost pipeline such drug meanwhile cnbc report pfizer be talk consumer giant procter gamble pg free report regard sale consumer healthcare segmentlast october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business however pfizer be have trouble find buyer same last month london base pharma consumer giant glaxo be consider frontrunner bid pfizer unit withdraw race buy pfizer consumer healthcare segment read more glaxo drop bid pfizer unit shingrix gain eu japan nod british company reckitt benckiser group also pull discussion pfizer buy same unit follow recent development pfizer share be tuesday share pfizer have decline so far year compare decrease industry pfizer carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1975,PFE,alnylam pharmaceutical inc alny free report share fall pharma giant pfizer inc pfe free report announce positive top line result late stage study compete rare disease candidate pfizer announce phase iii attr act study evaluate pipeline candidate tafamidis transthyretin cardiomyopathy be tie progressive heart failure meet primary endpoint condition belong family disease call transthyretin amyloidosis attr top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month safety datum also demonstrated tafamidis be generally well tolerate patient currently be approve medication unite state treatment transthyretin cardiomyopathy share alnylam plunge news increase competitive pressure alnylam lead candidate patisiran have be develop hereditary ttr amyloidosis hattr patisiran be review eu unite state pdufa date aug be launch year be type ttr cm hereditary form wild type form disease be not hereditary attr act study include type patient however alnylam have develop patisiran hereditary form disease note share ionis pharmaceutical inc ion free report also fall announcement positive datum pfizer ionis candidate inotersenis also review hereditary attr amyloidosis polyneuropathy alnylam pharmaceutical inc price alnylam pharmaceutical inc price alnylam pharmaceutical inc quote zack rank stock consideralnylam carry zack rank sell share company rally past year industry decline investor interested space consider better rank stock regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1976,PFE,shire plc shpg free report share have be rally japan base takeda pharmaceutical announce takeover intention shire stock have gain almost close mar press release issue takeda have confirm be consider possible offer buy shire boost core therapeutic area acquisition also help takeda have greater presence unite state however be certainty takeda make offer need be confirm later apr shire share have lose so far year underperform industry decline period investor be speculate bidding war follow takeda announcement previously several company have be rumore acquire shire include pfizer inc pfe free report shire have strong hold attention deficit hyperactivity disorder adhd market major revenue generator company company have drug adhd portfolio however company face competition result presence generic johnson johnson jnj free report concerta novartis nvs free report ritalin la adderall xr moreover sale shire ulcerative colitis drug lialda be also fall due generic competition meanwhile shire be also look strategic alternative neuroscience franchise include adhd portfolio drug hence shire consider offer make takeda likely create company sale tune however many analyst be skeptical impact deal takeda finance company have similar market cap also remain concern benefit add shire haemophilium portfolio takeda product line investor be likely remain focuse further announcement make takeda shire plc price shire plc price shire plc quotezack rankshire currently have zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1977,PFE,sarepta therapeutic inc srpt free report share soar tuesday announce promising result early stage study evaluate gene therapy treatment patient duchenne muscular dystrophy dmd preliminary datum first patient dose phase iia study show treatment gene therapy aavrh mhck micro lead significant increase protein production micro be muscle protein be need muscle function properly absence protein cause dmd rare muscular degenerative disease mostly affect boy be fatal patient turn dmd therapy aim boost amount micro patient muscle biopsy perform day show robust level micro patient treat gene therapy achieve mean level compare normal level dramatic reduction level serum creatine kinase ck enzyme associate muscle damage cause dmd be also observed used gene therapy datum show treatment gene therapy lead mean reduction ck day meanwhile serious adverse event saes be observed study datum be present jerry mendell nationwide child hospital sarepta day dr mendell sarepta be hopeful datum be sustain additional patient study produce therapy dramatically change course dmd disease so far year sarepta share have rally decrease register industry however follow announcement share ptc therapeutic inc ptct free report also market therapy treat dmd tumble nearly ironically share ptc therapeutic have rise almost monday present encourage preliminary datum early stage study evaluate pipeline candidate risdiplam baby type spinal muscular atrophy sma meanwhile solid bioscience inc sldb free report be also develop gene therapy dmd share also surge tuesday fda lift clinical hold study experimental dmd candidate sgt read more solid surge fda lift clinical hold dmd drug remind investor pfizer pfe free report be also develop gene therapy treatment dmd early stage study be initiate april sarepta currently carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1978,PFE,april have time again prove be favorable stock time april have arrived midterm election usually spell rough phase stock earning related volatility spike further april unabated trade tension possibility more rate hike fed year high profile departure trump administration real impact tax overhaul policy be layer base tumultuous earning season long dormant volatility way make comeback last month month expect be rough investing sound dividend pay stock seem judicious such stock provide steady income cushion portfolio market risk midterm election year spell stock trader almanac note april have traditionally be strong month stock go back world war ii dow jone nasdaq composite gain average respectively such rise wouldn be enough drive index back record territory dow be already time record high be nasdaq be forget major bourse have already see second straight monthly drop second steepest monthly fall tech laden nasdaq january bigger concern fact be april come mid term election year such year historically second quarter be weak broader market be third quarter second quarter market typically gain world war ii lose such year third quarter also isn much better second election year volatility likely stay concern market pundit be earning related volatility market be gear first quarter earning result month investor seek clarity impact protectionist trade policy higher interest rate factor play pivotal role determine first quarter earning result accord goldman sachs group inc gs free report option market be pricing earning volatility mostly april week technology sector particular be more susceptible erratic movement goldman note almost april preannouncement be do tech company techs have already take beating follow backlash facebook inc fb free report handle user datum read more facebook be scream buy datum scandal wall street fear gauge cboe volatility index vix be already first quarter biggest quarterly gain accord wsj market datum group index last trade long term average vix reflect trader collective anticipation volatility upcoming day period factor intensify related fear increase trump impose duty foreign aluminum steel levy tariff china product beij retaliate target product import value full blow trade unnerve investor deal heavy blow economy hurt corporate profit fed have hike rate quarter percentage point project steeper path rate hike hasn go well investor know have pile stock notion quantitative ease help domestic economy grow better rate emerge economy rate hike raise borrow cost eventually dent corporate profit affect economy april be cruel buy top dividend stock so many concern plague investor mind dividend pay stock be tempting option moment best dividend stock pay healthy yield have strong prospect be less susceptible market gyration large customer base sustainable business model long track profitability strong liquidity allow offer sizable yield regular basis regardless market direction find company offer trait isn easy certainly do exist help find business have select dividend payer have zack rank strong buy buy vgm score here stand value growth momentum score be weight combination metric such score allow eliminate negative aspect stock select winner pfizer inc pfe free report develop manufacture sell healthcare product company have zack rank vgm score pfizer have dividend yield year average dividend yield be peg zack consensus estimate current year earning rise last day stock be expect return year higher industry project return unique fabricate inc ufab free report engineer manufacture multus material foam rubber plastic component company have zack rank vgm score unique fabricate have dividend yield year average dividend yield be peg zack consensus estimate current year earning rise last day stock be expect return year better industry project return guess inc ge free report design market distribute license lifestyle collection apparel accessory man woman child company have zack rank vgm score guess have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry project return see complete list today zack rank stock here inc jwn free report be fashion retailer provide apparel shoe cosmetic accessory woman man young adult child company have zack rank vgm score have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry project return ciner resource lp cinr free report engage trona ore mining soda ash production business company have zack rank vgm score ciner resource have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year better industry project return hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1979,PFE,biogen inc biib free report have agree acquire phase iib ready candidate pf be be develop cognitive impairment associate schizophrenia cia pharma giant pfizer inc pfe free report deal biogen make upfront payment pfizer latter also be entitle development milestone payment potential royalty latter half year biogen initiate phase iib study pf determine ampa receptor potentiator be safe effective treatment cognitive dysfunction schizophrenia patient schizophrenia patient often experience significant deficit cognitive function ability make sense majority more person live schizophrenia worldwide witness degree cognitive dysfunction accord biogen press release however negative symptom schizophrenia have be particularly difficult treat biogen share have decline year so far underperform industry rise same time frame deal mark biogen entry emerge market neuropsychiatry be sync strategy diversify pipeline core therapeutic area multiple sclerosis disorder last year biogen add new clinical stage program neuroscience pipeline advance internal pipeline candidate well external deal biogen alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program meanwhile biogen spinal muscular atrophy sma treatment spinraza nusinersen approve late have consolidated position neurological disease market drug be first only treatment be approvedin unite state sma market potential disease be huge drug have perform expectation so far witness strong patient uptake unite state internationally december last year biogen form new collaboration ionis pharmaceutical inc ion free report identify antisense oligonucleotide drug candidate treatment sma biogen have option license therapy arise collaboration also biogen plan start phase study gene therapy asset sma mid biogen be also build portfolio best class treatment stroke acute neurology maylast year biogen purchase phase iii candidate biib cirara remedy pharmaceutical be be study treatment large hemispheric stroke lhi severe form stroke available therapy biogen carry zack rank hold better rank stock biotech sector be ligand pharmaceutical incorporate lgnd free report carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge past year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1980,PFE,merck kgaa announce japanese ministry health labour welfare mhlw have grant sakigake fast track designation pipeline candidate tepotinib company be develop candidate treatment advanced small cell lung cancer nsclc sakigake designation be grant expedite candidate development review japan focus new unmet area regenerative medicine merck kgaa share have underperform industry so far year stock have lose compare industry decline period designation be grant tepotinib base datum phase ii study evaluate nsclc patient meet exon skip mutation be approve treatment indication datum study be present future medical congress apart tepotinib merck kgaa oncology pipeline include be bifunctional immunotherapy simultaneously block immuno inhibitory pathway be commonly used cancer cell company be evaluate candidate several tumor however most advanced candidate oncology pipeline avelumab be be develop collaboration pfizer pfe free report several indication include lung gastric ovarian kidney cancer press release lung cancer be most common cancer globally nsclc occur lung cancer patient however tepotinib target only nsclc patient have meet exon skip mutation however several big pharma company be already marketing drug treat nsclc include merck mrk free report pd therapy keytruda pfizer xalkori bristol myer bmy free report pd immune checkpoint inhibitor opdivo merck kgaa price merck kgaa price merck kgaa quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1981,PFE,inc agen free report be expect report first quarter last report quarter company report negative earning surprise last quarters company deliver average positive earning surprise notably share have outperformed industry year stock have rally industry fall let see thing be shape company quarter factor playagenus collaboration agreement several company not only help procure fund form upfront milestone payment future royalty also validate proprietary product platform have collaborate merck mrk free report incyte develop multiple checkpoint antibody incyte collaboration be evaluate latter gitr checkpoint antibody incagn phase ii study ox agonist antibody incagn phase ii study ctla antibody agen phase ii study candidate be be evaluate treatment solid tumor january company announce launch combination phase ii study agen pd agen antibody have approve product portfolio only few candidate mid stage development include prophage series vaccine company be still few year away bring product market hiccup development process candidate weigh stock october establish separate business entity advance cell therapy program be design be self funded cell therapy company agentus focus discovery development breakthrough live drug advance cure cancer patient company take decision form smaller team entirely focus get product approve company expect combine value separate company exceed perceive value roof first quarter company focus pipeline candidate provide update model proven model do not show earning beat quarter be stock need have positive earning zack rank strong buy buy hold happen however be not case here see zack esp have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank have zack rank sell decrease predictive power esp note caution stock zack rank strong sell go earning announcement stock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank see complete list today zack rank strong buy stock here gilead science inc gild free report be schedule release quarterly result company have earning esp zack rank inc price ep surprise inc price ep surprise inc hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1982,PFE,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1983,PFE,amazon com amzn free report deliver first quarter earning share crush zack consensus estimate also soar year year net sale comfortably surpass zack consensus estimate figure surge almost year year beat management guide range adjust foreign exchange revenue increase year year north america revenue sale jump year quarter international revenue sale increase almost amazon web service aw sizzlesaw revenue climb year year primarily drive expand customer base aw launch availability zone az local region osaka japan quarter company plan open more az region bahrain hong kong sweden second govcloud region unite state early amazon com inc price consensus ep surprise amazon com inc price consensus ep surprise amazon com inc quote aw now operate az geographic region globally aw customer base continue expand report quarter company add enterprise customer godaddy cox automotive shutterfly nextgen healthcare amway lg electronic other pfizer pfe free report have select amazon redshift enterprise standard mission critical analytical application aw machine learn service have also gain significant traction active user soar more last year drive broad adoption amazon sagemaker amazon aurora continue be fastest grow service history aw quarter aw launch aw secret manager new service help customer protect access application service resource aw also announce amazon simple storage service amazon zone infrequent access ia general availability amazon select amazon transcribe amazon translate new machine learn service be part aw machine learn portfolio be now generally available amazon collaboration vmware vmw free report announce expansion vmware cloud aw europe powerful new capability migrate protect application expand delivery prime membersamazon introduce grocery delivery whole food market city unite state offer customer free hour delivery thousand natural organic grocery locally source item moreover amazon chase whole food market announce eligible prime member earn back whole food market purchase used amazon prime reward visa card further amazon launch fulfillment amazon fba australia europe company launch additional location public fulfillment center tour spain italy join other site north america europe amazon now have fulfillment center unite state solar panel produce power company be commit host solar energy system fulfillment center company intend power global infrastructure used renewable energy expand contentamazon provide green signal new series corts executive producer steven spielberg steven zaillian moreover amazon studio acquire global television right consider phleba first novel culture series iain bank prime video premier new season bosch season sneaky pete season quarter notably amazon music unlimited subscription have surge more past month alexa feature expandingamazon have add number feature alexa make more customer developer friendly company introduce freetime alexa exclusively kid amazon also announce echo dot kid edition company release new mode follow alexa donation brief mode alexa follow mode make alexa more conversational brief mode shorten response alexa donation allow customer make donation charity voice used amazon pay user now have ability add music podcast daily alexa routine company be also provide hand free alexa support fire fire hd tablet plug so customer simply use voice ask alexa tablet perform multiple task moreover amazon introduce alexa skill blueprint customer programming experience easy use template now allow customer create own personalize alexa skill company also release new developer tool alexa feature make voice controlled entertainment easier include expansion far field voice control fire tv germany amazon introduce new alexa skill kit developer console help developer create manage publish alexa skill alexa now feature more skill create third party developer amazon introduce new way customer communicate used alexa include launch alexa call messaging fire io android tablet well alexa announcement new feature make way announcement other echo device household alexa be now available even more device alexa voice service include new car model toyota quarter detailsproduct sale sale increase year year service sale sale surge year quarter operate expense be year quarter cost sale fulfillment marketing technology content general administrative other operate expense increase respectively percentage revenue operate expense decline basis point bps year year basis cost sale marketing technology content general administrative expense decline bps bps bps bps respectively only fulfillment expense increase bps year quarter operate income jump year quarter operate margin expand bps year quarter segment wise north america operate income soar year quarter aw operate income surge year year international report loss wider year quarter loss amazon best buy bby free report announce multus year exclusive collaboration bring next generation fire tv edition smart tvs customer unite state canada quarter amazon acquire ring home security company second quarter amazon expect net sale figure be anticipate grow range year year basis management project favorable impact approximately bps foreign exchange rate operate income be expect compare second quarter zack rankamazon carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1984,PFE,investor be always look stock be poise beat earning season pfizer inc pfe free report be such company firm have earning come pretty soon event be shape quite nicely report be pfizer be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface pfe report fact most accurate estimate current quarter be currently cent share pfe compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate pfe give stock zack earning esp head earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give pfe have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead pfizer beat be card upcoming report look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1985,PFE,immune design corp imdz free report isschedule report first quarter result market close last report quarter company deliver positive earning surprise immune design top earning estimate trail quarters average beat immune design share have lose year date compare industry fall let see thing be shape announcement factor playbee development stage company immune design have not generate product revenue yet earn revenue collaboration licensing agreement product sale investor remain focuse company progress base pipeline candidate immune design be develop multiple candidate used discovery platform zvex glaas treatment various type cancer company key pipeline candidate be cmb solid tumor merkel cell carcinoma mcc cmb have be design prime boost approach involve sequential dose complementary agent lv currently candidate be be evaluate soft tissue sarcoma patient monotherapy phase combination roche hold rhhby tecentriq phase ii company plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient mid progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma discussion fda be positive regard cmb consequently company have plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient study be expect start mid enroll patient age older ny eso synovial sarcoma receive cmb monotherapy placebo progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma meanwhile be be evaluate multiple clinical trial include monotherapy local radiation complete phase study patient mcc ongoing investigator sponsored trial patient sarcoma be also be develop monotherapy combination therapy patient follicular hodgkin lymphoma nhl randomize phase ib ii study october receive orphan drug designation treatment follicular nhl european medicine agency potential approval pipeline candidate be boost company earning call expect immune design shed light progress ongoing trial model proven model do not show earning beat immune design quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate however be not case here see zack esp immune design have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank immune design have zack rank increase predictive power esp however need have positive esp be confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision immune design corp price ep surprise immune design corp price ep surprise immune design corp quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1986,PFE,share bristol myer squibb company bmy free report fall investor be not much impressed company initial result phase iii study checkmate study be evaluate opdivo mg kg low dose yervoy mg kg combination first line advanced small cell lung cancer nsclc patient high tumor mutational burden tmb mutation megabase mut mb combination demonstrated superior benefit co primary endpoint progression free survival pfs versus chemotherapy initial result show year pfs rate be more triple combination versus chemotherapy vs overall response rate combination be chemotherapy arm responder have ongoing response year chemotherapy grade treatment related adverse event rate opdivo low dose yervoy combination be versus chemotherapy result be encourage investor be disappoint merck mrk free report keytruda seem have fared better opdivo yervoy combination merck announce result phase iii study keynote evaluate pd therapy keytruda combination pemetrexed alimta cisplatin carboplatin first line treatment metastatic nonsquamous nsclc result show keytruda pemetrexed platinum chemotherapy combination significantly improve overall survival os reduce risk death half compare chemotherapy alone consequently share bristol myer decline first line nsclc market competition be stiffening quite few company try capture additional market share share company have gain only past year underperform industry growth concurrently bristol myer announce obtain fda approval opdivo yervoy injection intravenous use first immuno oncology combination therapy previously untreated patient intermediate poor risk advanced renal cell carcinoma phase iii trial checkmate demonstrated significant unprecedented increase os abovemention combination patient population compare current standard care pfizer pfe free report sutent moreover opdivo demonstrated sustain os advantage standard care patient recurrent metastatic squamous cell carcinoma head neck checkmate patient treat opdivo experience reduction risk death year minimum follow note opdivo be currently approve several country include unite state eu japan several cancer indication opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly bristol myer announce worldwide collaboration johnson johnson jnj free report janssen pharmaceutical inc janssen factor xia fxia inhibitor program include development former factor xia fxia inhibitor bms note bms investigational anticoagulant compound be be evaluate prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half study secondary stroke prevention zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1987,PFE,glaxosmithkline plc gsk free report have enter agreement novartis nvs free report buy latter stake consumer healthcare joint venture jv acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo be optimistic deal be accretive adjust earning thereafter improve company cash flow share british drug maker be tuesday response positive news glaxo stock have rise year so far decline industry glaxo novartis create jv part part transaction company combine consumer division glaxo own share jv part same asset swap novartis also acquire glaxo oncology product milestone payment exchange glaxo acquire novartis vaccine business exclude influenza vaccine upfront milestone payment royalty deal be clause give novartis right exercisable mar mar ask glaxo purchase stake latest deal company overhang have be remove transaction expect be complete second quarter be subject approval glaxo shareholder also glaxo say be look strategic alternative horlick other nutrition product help fund deal nutrition product be mostly sell glaxo indian subsidiary glaxosmithkline consumer healthcare glaxo own stake indian subsidiary say also be include strategic review process food giant nestle kraft heinz company khc free report unilever be be speculate frontrunner bid horlick business glaxo latest deal novartis come less week announce be withdraw race buy pfizer pfe free report consumer healthcare segment read more glaxo drop bid pfizer unit shingrix gain eu japan nod pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction time glaxo chief executive officer emma walmsley say management be interested deal improve company return not compromise priority capital allocation conversely emma walmsley justified new agreement buy novartis stake say address key capital allocation priority glaxo expect consumer healthcare business deliver sale earning growth also approach operate margin mid percentage range believe novartis deal be more prudent buy pfizer consumer unit have reportedly cost glaxo novartis sale price core business reflect attractive value novartis say expect use proceed sale drive shareholder return invest core product also bolt acquisition glaxo carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1988,PFE,gene therapy space have once again hogged limelight follow swiss pharma giant novartis nvs free report announcement acquisition avexis inc agreement novartis pay buyout clinical stage gene therapy company avexis lead product candidate avxs be be evaluate time gene replacement therapy spinal muscular atrophy disease result early death life long disability considerable healthcare cost acquisition poise novartis promising gene therapy space acquisition be complete mid post announcement share price major player space moved share avexis have sky-rocket last month novartis be try develop gene therapy portfolio january novartis sign license agreement development investigational voretigene neparvovec outside unite state spark therapeutic novartis obtain fda approval first car therapy kymriah pfizer pfe free report recently initiate phase ib clinical trial mini gene therapy candidate pf boy duchenne muscular dystrophy be gene therapy gene therapy help mitigate adverse effect malfunctioning disease cause gene therapy intend add functional gene back person system replace malfunctioning cure disease therapy have different approach traditional drug one underlie cause be get treat symptom gene therapy be set become most promising space volatile biotech sector continue grapple increase threat biosimilar notably medical biom genetic sub industry carry zack industry rank place bottom zack industry medical biomedical genetic industry yr return medical biomedical genetic industry yr return stock potential market hold number company have start develop therapy several have promising candidate pipeline spark therapeutic once free report be prominent player gene therapy space company obtain fda approval lead gene therapy drug luxturna voretigene neparvovec rzyl treatment patient viable retinal cell confirm biallelic rpe mutation associate retinal dystrophy luxturna be first fda approve gene therapy inherited retinal disease first adeno associate virus aav well vector gene therapy approve unite state company have build pipeline gene therapy product candidate be direct retina liver central nervous system pipeline include ocular program consist spk target choroideremia currently phase ii hemophilia program consist spk hemophilia spk hemophilia currently phase ii clinical trial company share have rally last month industry decline spark therapeutic currently carry zack rank hold see complete list today zack rank strong buy stock here uniqure qure free report be promising player space be create pipeline innovative gene therapy have be develop internally collaboration focuse cardiovascular disease bristol myer squibb lead product candidate amt be be evaluate treatment patient severe moderately severe hemophilia company also announce plan advance amt include aav vector carry fix padua transgene pivotal study company have already obtain orphan drug designation amt treatment huntington disease unite state european union hold global right program uniqure currently carry zack rank uniqure stock have moved last month industry decline biomarin pharmaceutical bmrn free report dose first patient global gener phase iii study vg kg dose valoctocogene roxaparvovec experimental gene therapy treatment patient severe hemophilia december phase iii program include study valoctocogene roxaparvovec vg kg dose gener vg kg dose gener valoctocogene roxaparvovec have be grant breakthrough therapy designation fda european medicine agency grant access priority medicine regulatory initiative valoctocogene roxaparvovec biomarin currently carry zack rank biomarin stock have lose last month underperform industry decline ahead gene therapy gain traction investor keep eye space potential approval datum read out late stage trial several company be likely keep growth trajectory make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1989,PFE,merck mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march keytruda be most successful immuno oncology drug date approval several cancer indication include lucrative first line lung cancer be first pd therapy approve advanced cervical cancer first indication keytruda gynecologic cancer well year so far merck share have outperformed industry share have rise period industry decline latest fda approval be base datum single cohort multus cohort phase ii study keynote evaluate drug recurrent metastatic cervical cancer datum subset patient population express pd cp show keytruda achieve objective response rate moreover patient achieve complete response patient demonstrated partial response drug generate response cervical cancer patient pd expression tumor have cp merck be evaluate drug wide range cancer indication treatment setting more clinical study recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation garner attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study moreover merck have collaborate several pharma company include amgen amgn free report glaxo gsk free report pfizer pfe free report incyte evaluate keytruda combination other regimen drug generate worldwide sale almost first quarter year period line extension approval cervical cancer potential approval other indication review positive momentum drug be expect continue merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1990,PFE,biogen inc biib free report announce have sign option agreement private biotech tms co ltd acquire latter phase ii acute stroke candidate tms backup compound biogen be expect pay upfront additional exercise option payable potential milestone payment tms design restore blood flow follow acute stroke be be evaluate phase ii study august candidate complete phase study acquisition biogen aim boost acute neurology portfolio strategic move company growth pursue innovative approach therapeutic area biogen already have phase iii ready pipeline candidate biib development prevention treatment edema large hemispheric infarction severe type stroke however february biogen multiple sclerosis ms drug tysabri natalizumab fail meet primary secondary endpoint phase iib program evaluate indication acute ischemic stroke ais investor believe natalizumab failure ais study be reason buyout tms biogen core business area be multiple sclerosis ms disable disease brain spinal cord key multiple sclerosis drug portfolio be tecfidera avonex tysabri however be look diversify business aim be leader neuroscience adjacent therapeutic space biogen add new clinical stage program neuroscience pipeline advance internal pipeline candidate well external deal year march biogen agree acquire phase iib ready candidate pf cognitive impairment associate schizophrenia cia pfizer pfe free report january biogen acquire right karyopharm phase ready investigational oral compound kpt certain neurological condition primarily focuse amyotrophic lateral sclerosis al biogen plan start phase trial end share biogen have lose year date outperform industry decline biogen currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock here crispr therapeutic loss share estimate have narrow last day stock have sky-rocket year date genomic health earning estimate surge past day stock have soar so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1991,PFE,gender diversity be en vogue number female corporate leader go more female employee be take top position number company drop number woman ceo fortune increase more record start however number decline jan drop further april woman hold board seat company catalyst group research woman work several research show company lead woman have constantly outperformed market accord analysis bank nordea company woman chief executive chairman role have perform far better major global index past year annualize return female lead firm base equal weighting be compare just broader market msci world index read top rank sector etfs stock top industry give long history outperformance many investor be seek add female centric company portfolio list be still small bet individual company be certainly good option investor also play space lower risk higher diversification benefit basket form currently be couple product offer broad exposure woman lead company have highlighted detail spdr ssga gender diversity index etf free report etf offer exposure company demonstrate greater gender diversity senior leadership other firm sector tracking ssga gender diversity index hold stock be moderately concentrated top firm account less asset pfizer pfe free report coca cola ko free report mastercard inc free report be top holding sector look information technology take largest share follow healthcare consumer staple consumer discretionary product have amassed asset base trade light volume share charge bps annual fee have gain past year read tech etfs stock survive market rout february barclay woman leadership etn free report product be link performance barclay woman leadership total return usd index provide exposure base company satisfy gender diversity criterium have female chief executive officer have least female member board director etn have amassed asset base trade paltry volume share expense ratio come note be past year see large cap etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1992,PFE,astrazeneca azn free report announce european medicine agency have accept marketing authorization variation mav label expansion forxiga dapagliflozin forxiga selective sglt inhibitor be presently market monotherapy well combination therapy improve glycaemic controlin adult patient type diabetes mav astrazeneca be seek get forxiga approve oral adjunct treatment insulin adult type diabetes submission ema be base phase iii datum depict study show forxiga give oral adjunct adjustable insulin patient inadequately controlled lead significant clinically relevant reduction baseline blood sugar level hba weight total daily insulin dose week compare placebo mg mg dose year astrazeneca share have rally outperform industry gain remind investor december merck mrk free report pfizer inc pfe free report investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin be approve fda adjunct diet exercise improve glycemic control patient type diabetes mellitus apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rank stock carry zack rank sell better rank stock same space be regeneron regn free report carry zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1993,PFE,glaxosmithkline plc gsk free report announce datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala osmo study evaluate severe asthma patient disease be uncontrolled take novartis nvs free report roche rhhby free report asthma medicine xolair average year see better asthma control follow switch nucala datum present study show follow nucala switch eligible patient experience fewer symptom better lung function improve asthma related quality life fewer exacerbation datum contribute extensive body evidence nucala be present glaxo american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando nucala approve treat severe eosinophilic asthma be key new product glaxo respiratory portfolio be drive top line separate press release glaxo partner pfizer inc pfe free report hiv focuse company viiv healthcare announce week interim datum phase iiib inspiring study evaluate safety efficacy investigational candidate dolutegravir antiretroviral treatment naive art nave adult hiv co infected tuberculosis tb datum study show hiv tb co infected adult rifampin base tb treatment be administer dolutegravir mg twice daily combination nucleoside reverse transcriptase inhibitor nrti therapy maintain viral suppression group patient receive efavirenz mg once daily nrtis maintain viral suppression datum be present annual conference retroviruse opportunistic infection croi boston accord company press release tuberculosis account aids related death be many complication related concurrent treatment tb hiv inspiring datum support use dolutegravir hiv tb co infected patient glaxo share have rise year so far outperform decrease witness industry glaxo have zack rank buy seethe complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1994,PFE,merck kgaa be schedule report fourth quarter result mar merck share have decline past year industry gain company report financial number business sector healthcare life science performance material merck revenue be drive sale growth healthcare life science segment third quarter expect positive trend continue upcoming quarterly result meanwhile company be streamline healthcare business focus pipeline innovative medicine first half company receive approval bavencio treatment metastatic merkel cell carcinoma mmcc advanced bladder cancer unite state moreover drug be approve eu japan treat mmcc september period be merck multiple sclerosis drug mavenclad be approve australia canada follow approval europe third quarter company continue develop bavencio partnership pfizer inc pfe free report several cancer indication however drug fail phase iii study conduct evaluate treatment gastric cancer third line set sale key drug rebif erbitux gonal be expect be lower fourth quarter result downside be likely be cause persistent competitive pressure price reduction moreover unfavorable currency movement be anticipate dent top line additionally operate expense increase first month due product launch higher pipeline development cost expense be estimate rise company focus develop innovative pipeline launch bavencio new geography well mavenclad expect management shed light progress plan bavencio earning call company be likely provide update strategic plan merck kgaa price ep surprise merck kgaa price ep surprise merck kgaa quote stock warrant lookhere be couple healthcare stock want consider model show have right combination element positive earning esp zack rank strong buy buy hold deliver earning beat uncover best stock buy sell re report earning esp filter gemphire therapeutic inc gemp free report be expect release result mar company have earning esp zack rank see complete list today zack rank stock here celldex therapeutic inc cldx free report be schedule release result mar zack rank company have earning esp hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1995,PFE,president trump want slap tariff foreign steel aluminum protect domestic producer hasn go well investing community tariff increase cost company rely heavily steel aluminum affect bottom line further have raise anxiety other country retaliate increase odd trade war harm global economy tariff declaration incite steep stock market selloff rebuke world leader dow plunge straight trading session mar industrial sector be hit hardest cboe volatility index vix wall street so call fear gauge come way higher read most market receive drubbing trump tariff investing stock provide excellent risk adjust return win be bad proposition trump tariff hurt surprised global market announce steep tariff import steel aluminum president say unite state impose tariff steel import tariff aluminum tariff steel aluminum have stoke concern manufacturer car plane machinery rely heavily such product steel aluminum be major expense industry so uptick cost hurt profit needless say tariff announcement have propel steel price year high ton aluminum price explode year high cent pound higher price steel aluminum furthermore compel company rely such product pass cost consumer increase consumer price long run hamper sale growth affect company lead job loss trump tariff be estimate hurt nearly worker steel aluminum consume manufacturer retaliation heat affected company further caution face retaliatory tariff foreign player good export eventually dent profit margin trump tariff announcement have already evoke anger global leader european union say impose tariff worth import reuter china caution america abide multilateral trade rule not harm delicate global economy shouldn forget china be world dominant steel producer trump tariff move easily start trade war tariff also raise threat trade war america closest ally canada canada be top exporter steel aluminum unite state canada be solely responsible manufacturing steel import aluminum import other major supplier unite state include brazil south korea mexico russia also be negatively impact tariff news hit not only heavy user steel aluminum also cyclical sensitive sector technology consumer cyclical name few investor remain worry threat retaliation trade partner harm global economic growth be widely see major drive force stock market rally last year dow company strongly disagree trump tariffshere be blue chip company respond trump tariff coca cola company ko free report agree manufacturer institute cmi president robert budway say tariff restriction have severe impact manufacturing industry employee consumer such aluminum can tariff increase price lead supply inefficiency affect product availability exxon mobil corporation xom free report support american petroleum institute api stance support free trade largely oil natural gas industry other industry well jpmorgan chase co jpm free report share view joshua bolten chief executive business roundtable say industry group urge trump persuade other approach address issue related overcapacity steel aluminum win place economy high risk walmart inc wmt free report stand retail industry leader association say trump administration intention unilaterally impose tariff steel aluminum import have severely negative consequence american economy broadly apply tariff have downstream impact sector goldman sachs group inc gs free report respond say trump tariff plan be likely escalate trade tension particularly look likely apply broad group country include ally ultra safe such heighten tariff concern investor build strategy low risk asset combination parameter lead better return best way go do be create portfolio low beta stock be inherently less volatile market trade case low beta range stock be also dividend payer boast immense financial strength be immune market vagary such stock reflect solid financial structure healthy underlie fundamental better quality business further boast zack rank strong buy buy pfizer inc pfe free report develop manufacture sell healthcare product worldwide company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry estimate growth verizon communication inc vz free report offer communication information product service consumer business governmental agency worldwide company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry estimate growth altrium group inc mo free report manufacture sell cigarette smokeless product wine unite state company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year contrast industry be likely decline see complete list today zack rank stock here occidental petroleum corporation oxy free report engage acquisition exploration development oil gas property unite state internationally company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry estimate gain community trust bancorp inc ctbi free report operate bank hold company community trust bank inc provide commercial personal banking service small mid size community company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be part bank southeast industry be expect give solid return hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1996,PFE,pfizer inc pfe free report say plan invest pfizer venture venture capital arm funding be invest small biotechs other emerge growth company newly available fund be earmark company involved promising early stage neuroscience research pfizer venture first invest company focus neuro degeneration neuro inflammation neuro metabolic disorder pfizer venture already have investment neuroscience company include aquinnah autifony cortexyme mindimmune mission neuronetic pfizer become part dementia discovery fund ddf be form speed development new treatment neurological disease bring together major pharma company government alzheimer research uk fund be involved financing new early stage drug development project launch october ddf have raise more have be invest dementia drug discovery company project other investor ddf include biogen biib free report eli lilly lly free report glaxo gsk free report other other neuroscience venture capital arm area interest include oncology inflammation immunology rare disease internal medicine vaccine pfizer venture manage more company currently have new member pfizer have already invest venture capital arm latest funding total asset management add more year so far pfizer share have increase decrease industry ironically news come less month pfizer say drop plan develop treatment disorder alzheimer parkinson disease be highly challenge area not much progress be make significant investment fund well resource pfizer currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1997,PFE,abbvie inc abbv free report announce investigational oral jak inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program phase iii study select early evaluate candidate moderate severe rheumatoid arthritis ra patient have not be previously treat chemotherapy agent methotrexate mtx versus mtx monotherapy select program evaluate more patient study ra week treatment acr response primary endpoint be achieve patient receive mg oral once daily dose upadacitinib patient take mg dose versus patient receive mtx second primary endpoint clinical remission be achieve patient mg dose arm mg dose arm week versus only mtx meanwhile patient mg mg dose arm respectively achieve acr response week versus mtx result clearly show significantly higher proportion patient treat upadacitinib dose achieve superior response compare mtx suggest upadacitinib monotherapy have potential control progression ra reduce risk permanent bone joint damage mtx naive patient abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year other rheumatoid arthritis upadacitinib be also be evaluate late stage study crohn disease psoriatic arthritis mid stage study atopic dermatitis giant cell arteritis ulcerative colitis jak inhibitor also know janus kinase inhibitor be emerge potential treatment option ra eczema other inflammatory disease medicine work inhibit activity more janus kinase family enzymeslast week eli lilly lly free report partner incyte corporation incy free report gain fda approval lower dose mg oral jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan jak inhibitor available market treat ra be pfizer pfe free report xeljanz successful development upadacitinib boost abbvie ra portfolio especially biosimilar competition loom blockbuster ra drug humira humira account abbvie sale amgen samsung bioepis biogen humira biosimilar be launch unite state eu abbvie share have gain year so far industry decline abbvie currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1998,PFE,johnson johnson jnj free report kick pharma earning strong note beating zack consensus estimate count first quarter drug consumer product giant up previously issue sale outlook share be pre market trading year so far share have decline compare unfavorably decline witness industry earning beatj first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale beat slightlysale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better increase see be pharmaceutical segment continue positive momentum see second half consumer segment sale improve first quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica cancer darzalex multiple myeloma continue perform well core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth please note market imbruvica partnership abbvie inc abbv free report organically exclude impact acquisition divestiture sale increase operational basis slightly less growth see previous quarter quarter record pulmonary arterial hypertension pah revenue less previous quarter acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth first quarter however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report be quarter sale decline however international sale rise biosimilar competition pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market rise year period meanwhile international segment record increase reflect operational increase positive currency impact outlook maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate however now expect revenue range higher reflect operational constant currency sale growth rate range previously quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year fact be quite confident pharma segment continue perform better market year impact biosimilar remicade sale tell chief financial officer dominic caruso bloomberg meanwhile announce global supply chain initiative annually save approximately pre tax cost meanwhile alex gorsky chairman chief executive officer say company invest more capital investment unite state next year new tax law leave extra cash hand large pharma company allow invest innovation capital build zack rank stock considerj carry zack rank hold johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotea better rank stock be pfizer inc pfe free report have zack rank buy see complete list today zack rank strong buy stock here share pfizer have gain year so far breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1999,PFE,shire plc shpg free report announce have enter definitive agreement french company servier sell oncology business deal be value include global right leukemia drug oncaspar ex right pancreatic cancer drug onivyde servier also add leukemia drug calaspargase pegol portfolio be review unite state shire oncology segment also include immuno oncology pipeline collaboration comprise multiple early stage study oncology segment have deliver high growth profitability contribute lower product sale company have initiate sale segment part long term strategy focus rare disease leadership shire plan return proceed sale shareholder share buyback however buyback program be initiate takeda pharmaceutical potential offer acquire shire be expect apr term recent agreement servier acquire segment cash deal be value attractive revenue multiple time revenue deal be not subject shareholder approval be expect close second third quarter shire be also look dispose other strategic asset part strategy shire share have decrease so far year compare favorably industry decline period investor cheer news potential buyout shire takeda sale oncology segment takeda be expect reconsider decision make offer oncology be core therapeutic area takeda be look strengthen shire acquisition however deal takeda shire be still expect bring strategic synergy takeda acquire ariad pharmaceutical last year bid strengthen diversify oncology business sale shire oncology segment bring acquisition cost takeda investor community also believe formal takeover offer takeda also trigger bid other company previously show interest shire include abbvie abbv free report pfizer pfe free report demand company rare disease drug portfolio pipeline candidate be rise be evident dollar deal sign year novartis be acquire avexis sanofi have spend nearly boost rare blood disorder pipeline shire plc price shire plc price shire plc quoteshire carry zack rank sell see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2000,PFE,flexshare quality dividend defensive index fund qdef free report be launch be smart beta exchange trade fund design offer broad exposure total market etfs category equity market be smart beta etfs long time now etf industry have be flooded product base market capitalization weight index be design represent broader market particular market segment investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way be investor think possible beat market great stock selection group likely invest class fund know smart beta track cap weight strategy kind index follow same mindset attempt pick stock have better chance risk return performance cap weight strategy base selection certain fundamental characteristic mix such characteristic smart beta space give investor many different choice equal weighting simplest strategy more complicate one fundamental volatility momentum base weighting however not methodology have be able deliver remarkable return fund sponsor fund be manage flexshare have be able amass make average size etfs total market etfs particular fund seek match performance northern trust quality dividend defensive index fee expense northern trust quality dividend defensive index be design provide exposure high quality income oriented portfolio long only equity security emphasis long term capital growth target overall beta be generally time northern trust index be select base expect dividend payment fundamental factor cost other expenseswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive cousin long term other factor remain equal operate expense annual basis be etf make par most peer product space fund have month trail dividend yield sector exposure top holdingswhile etfs offer diversify exposure minimize single stock risk deep look fund holding be valuable exercise most etfs be very transparent product disclose holding daily basis etf have heaviest allocation information technology sector portfolio financial consumer discretionary round top look individual holding boee co ba ba free report account fund total asset follow pfizer inc pfe pfe free report exxon mobil corp xom xom free report top holding account approximately qdef total asset management performance riskqdef have lose so far year be roughly last year past week period fund have trade etf have beta standard deviation trail year period make medium choice space holding effectively diversify company specific risk bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
2001,PFE,expect pfizer inc pfe free report beat expectation report first quarter result market open last quarter company deliver positive earning surprise pharma giant have strong record earning surprise company earning surpass expectation last quarters deliver average positive surprise pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotepfizer share have rise year so far decrease industry factor playin innovative health ih segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner contribute top line meaningfully zack consensus estimate sale ibrance worldwide lyrica ih xeljanz chantix be respectively essential health biosimilar emerge market be expect support sale however loss exclusivity associate generic competition product primarily pristiq unite state continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition zack consensus estimate sale enbrel be prevnar prevenar vaccine franchise continue see lower sale unite state lower demand generic competition continue hurt sale viagra pfizer be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue expect supply shortage continue hurt sale pfizer expect cut sterile injectable shortage new cancer drug bavencio avelumab besponsa inotuzumab ozogamicin mylotarg be likely contribute overall sale time xeljanz sutent bosulif be approve line extension fourth quarter new product line extension be boost sale bottom line be expect be drive cost saving share buyback also expect management provide update initial launch uptake pfizer partner merck mrk free report newly approve oral sglt inhibitor steglatro ertugliflozin tablet apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2002,PFE,pfizer inc pfe free report announce smoking cessation drug chantix varenicline fail phase iv study evaluate adolescent smoker study be be conduct regulatory post marketing commitment smoker age year unite state year europe complete study result be expect be present upcoming scientific congress be publish later peer review medical journal chantix be already market prescription drug help adult age counsele stop smoking share company be mar meanwhile pfizer share have decline so far year compare industry decline period dose range multus centre phase iv study evaluate chantix smoking cessation nicotine dependent adolescent combination age appropriate counsel study evaluate dosage drug mg once twice daily chantix fail meet primary endpoint week continuous abstinence rate compare placebo week adverse event observed study be similar see earlier study conduct adult smoker pfizer be plan submit datum study fda pediatric exclusivity determination pediatric exclusivity be grant month return conduct study pediatric patient failure study young smoker be unlikely receive exclusivity setback pfizer glaxosmithkline gsk free report terminate talk buy former consumer healthcare business last week england base reckitt benckiser also announce drop buyout plan segment pfizer inc price pfizer inc price pfizer inc quotezack rank other key pickspfizer currently carry zack rank buy other top rank stock health care sector include horizon pharma public limit company hznp free report eli lilly company lly free report stock carry zack rank see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have increase so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2003,PFE,abbvie inc abbv free report have announce pipeline candidate upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra upadacitinib be investigational oral jak selective inhibitor be be study once day oral therapy phase iii select compare study be design evaluate efficacy safety upadacitinib mg compare placebo abbvie market drug humira adalimumab week patient moderate severe ra be stable background methotrexate have inadequate response study upadacitinib meet primary well secondary endpoint compare placebo show superiority compare humira primary endpoint study register acr response clinical remission datum trial demonstrated patient receive oral once daily dose upadacitinib mg achieve acr response compare patient receive placebo week moreover subject treat upadacitinib achieve complete remission comparison placebo additionally datum study also show patient experience low disease activity secondary endpoint treat upadacitinib compare receive humira receive placebo week notably select compare be fourth ongoing phase iii study select ra clinical trial program conduct upadacitinib remind investor last december abbvie announce upadacitinib meet primary endpoint rd phase iii study select trial other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis share abbvie have rally past year outperform industry rise notably abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be approve eu ra last february pfizer pfe free report xeljanz be market unite state same indication strong competition upadacitinib approval also late biogen biib free report have announce resolution ongoing patent dispute abbvie regard biogen biosimilar version humira eu settlement agreement biogen plan launch humira biosimilar europe october however upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2004,PFE,share agio pharmaceutical inc agio free report rally almost apr speculation be rife company be acquire other big player pharma biotech industry bullish sentiment stock investor be mainly trigger follow novartis nvs free report yesterday announcement have inked deal acquire base clinical stage gene therapy company avexis inc particularly celgene already notch collaboration agreement agio develop novel therapy utilize agio innovative cellular metabolism research platform be be consider front runner buy agio let have look celgene other big drug biotech company be interested agio share agio have surge year time outperform industry increase fda last year approval agio only market drug idhifa enasidenib company rapid progress robust pipeline past year accompany study initiation positive readout have steadily push share price august fda approve idhifa treat patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation drug provide first ever alternative treatment patient live aforementioned indication unite state notably idhifa also enjoy orphan drug status eu treatment aml agio progress pipeline have also be quite impressive company have interesting candidate portfolio include idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag last june agio present positive datum dose escalation expansion cohort phase study evaluate single agent ivosidenib mutant positive asco ivosidenib be also be evaluate phase expansion cohort treatment patient idh aml datum study demonstrated durable response allow company submit new drug application fda ivosidenib late last december same month company also announce positive result phase trial assess ivosidenib combination standard induction chemotherapy celgene vidaza azacitadine treatment newly diagnosed aml patient not eligible intensive chemotherapy presently phase iii agile study examine ivosidenib combination vidaza be also underway give indication apart ivosidenib agio be conduct phase program ag treatment patient advanced idh idh mutant positive solid tumor company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii study adult transfusion independent patient pyruvate kinase deficiency consistent progress investigational candidate make agio most lucrative takeover option other large player drug biotech space moment activity be expect be aggressive drug biotech sector year follow new tax law be evident sanofi celgene already announce deal also pfizer pfe free report be aggressively lookout buyer purchase consumer healthcare unit british firm glaxo reckitt benckiser group pull discussion moreover april japan base takeda pharmaceutical announce intention acquire shire plc agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote zack rankagio carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2005,PFE,share vtv therapeutic inc vtvt free report plummet significantly company announce dismal result part phase iii trial steadfast pipeline candidate azeliragon vtv therapeutic stock have plunge last month industry decline candidate be be evaluate patient suffering alzheimer disease result show candidate do not meet co primary efficacy endpoint patient take azeliragon versus placebo do not improve cognitive functional outcome measure thealzheimer disease assessment scale cognitive subscale ada cog clinical dementia rating scale sum box cdr sb study comprise independent identical randomize double blind placebo controlled phase iii trial part part azeliragon treat group part show point decline baseline ada cog point dip baseline cdr sb compare placebo fall respectively however difference be not statistically significant azeliragon be generally well tolerate withdrawal rate month be similar placebo treatment arm consequently vtv therapeutic discontinue ongoing study involve azeliragon include open label extension study part steadfast study nevertheless substantial portion patient part steadfast have complete month treatment study protocol failure late stage study be disappointing investor successful development subsequent candidate have significantly boost growth prospect give complexity drug late have be many failure drug be develop alzheimer february merck mrk free report announce stop phase iii study apecs be evaluate verubecestat mk investigational small molecule inhibitor beta site amyloid precursor protein cleave enzyme bace patient prodromal alzheimer disease decision be take external datum monitoring committee assessed overall benefit risk recent interim safety analysis conclude be unlikely positive benefit risk be possible january pfizer pfe free report announce plan end research effort new drug alzheimer parkinson disease eli lilly lly free report be major company have suffer many failure attempt develop drug alzheimer zack rankvtv therapeutic currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2006,PFE,glaxosmithkline plc gsk free report have withdraw race buy pfizer pfe free report consumer healthcare segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain businessglaxo chief executive officer emma walmsley say management be interested deal improve company return not compromise priority capital allocation pfizer be have tough time find buyer consumer healthcare segment last week british company reckitt benckiser group also pull discussion pfizer buy latter consumer health segment reckitt benckiser backed glaxo be see frontrunner buy pfizer unit share glaxo be friday response positive news glaxo stock have rise year so far decline industry separate press release pfizer announce shingle vaccine shingrix have gain regulatory approval japan eu please note shingrix be approve unite state canada october last year also shingrix enjoy preferential recommendation center disease control prevention advisory committee immunization practice acip last year acip recommend shingrix prevention shinglesover merck mrk free report zostavax yet release glaxo announce committee medicinal product human use chmp europe have grant positive opinion recommend approval juluca drug regimen dolutegravir rilpivirine once daily single pill hiv juluca become first drug pill be approve europe final decision european commission eu be expect end second quarter juluca be approve unite state november last year juluca have be develop glaxo pfizer hiv focuse company viiv healthcare partnership johnson johnson jnj free report glaxo carry zack rank buy see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2007,PFE,pfizer inc pfe free report be repute name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be know product prevnar lyrica lipitor celebrex other pfizer share have outperformed large cap pharma industry past month stock have return timeframe compare industry gain pfizer outperformance be backed decent quarterly result positive news flow regulatory update here be reason invest stock year favorable rank earning surprise record pfizer have zack rank buy see complete list today zack rank strong buy stock here itha be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate be respectively past day strategic acquisition collaboration pfizer have be work strengthen product portfolio well pipeline acquisition licensing deal september takeover medivation strengthen pfizer cancer franchise add prostate cancer treatment xtandi portfolio xtandi be also be evaluate various other type cancer hold immense potential june anacor acquisition add eucrisa crisaborole topical ointment treat eczema pfizer pipeline pfizer estimate eucrisa peak sale potential be least hospira acquisition significantly expand sterile injectable biosimilar capability addition acquisition pfizer be look drive growth licensing deal collaborative agreement have strategic deal big name pharma sector merck co mrk free report lung cancer drug xalkori combination newly approve steglatro fix dose combination type ii diabetes bristol myer squibb company bmy free report eliquis glaxo gsk free report breast cancer drug ibrance combination deep pipeline pfizer have commit significant resource development treatment field oncology cardiology metabolic disorder neuroscience pain rare disease immunology inflammation vaccine immuno oncology most signify area company believe take lead position pfizer expect approximately drug approval next year include product have blockbuster potential include line extension xtandi ibrance xeljanz xr half potential blockbuster be expect receive approval pfizer have be work streamline effort have several late stage candidate pipeline include many immuno oncology candidate key candidate immuno oncology pipeline be bavencio avelumab be be evaluate different type cancer collaboration merck kgaa bavencio be already metastatic merkel cell carcinoma mcc advanced bladder cancer bavencio be be consider key long term growth driver pfizer explore world biosimilar pfizer market biosimilar version merck blockbuster medicine remicade unite state inflectra ixifi inflectra be first biosimilar monoclonal antibody available unite state other biosimilar late stage development include biosimilar version roche cancer drug rituxan avastin abbvie humira biosimilar version herceptin be review unite state eu meanwhile pfizer be evaluate biosimilar molecule various stage development aggressive cost cut initiative several product face slate face generic competition pfizer be look cost cut initiative drive bottom line growth company have be undertaking massive restructure cost cut measure past several year management be also look focus effort area have high potential oncology geographic region asia pfizer achieve cost reduction goal be announce end year earlier expect continue generate cost saving company also achieve target bring significant reduction annual spend end face share challenge form genericization key drug supply challenge legacy hospira portfolio pricing pressure rise competition however believe pfizer be able overcome headwind wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2008,PFE,merck co inc mrk free report report first quarter result market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck co inc price ep surprise merck co inc price ep surprise merck co inc quote merck share have rise year so far decrease industry let see thing be shape announcement factor considermerck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale keytruda sale be be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve set keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher second half momentum be expect be maintain well strong demand most market continue drive sale bridion sugammadex injection however rise competitive pressure have begin hurt sale relatively newer drug zepatier fourth quarter zepatier sale decline sequentially due reduction share volume due increase competition call merck have warn negative trend continue most market outside unite state start come pressure older product continue pricing pressure be hurt sale januvia lower demand due competition be hurt sale isentress vaccine zostavax sale continue be hurt strong competition glaxo gsk free report newly approve shingle vaccine shingrix gardasil gardasil sale be soft fourth quarter due lower sale unite state nonetheless fourth quarter call company have mentioned underlie growth increase coverage rate be still strong unite state remain be see gardasil sale improve soon be report quarter zack consensus estimate total sale vaccine segment be peg animal health franchise sale be likely remain strong zack consensus estimate animal health segment sale be earning whispersour proven model do not conclusively show merck beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate most accurate estimate be peg cent share uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2009,PFE,clovis oncology inc clvs free report recently announce fda have grant approval label expansion parp inhibitor rubraca rucaparib drug be now approve maintenance treatment recurrent ovarian cancer patient have receive prior platinum base chemotherapy drug now also be prescribe irrespective brca mutation second line set fda approval be base datum confirmatory phase iii study ariel show rubraca lead significant improvement progression free survival such patient please note rubraca have receive accelerate approval treatment advanced brca mutant ovarian cancer third later line set december latest approval accelerate approval be converted regular indication drug be review europe indication decision expect quarter share clovis be mar news surface however stock have lose so far year underperform industry decline latest approval rubraca come par other approve parp inhibitor treatment ovarian cancer astrazeneca azn free report lynparza tesaro tsro free report zejula drug be now approve patient irrespective brca mutation status create level play field player pfizer pfe free report be also evaluate parp inhibitor talazoparib phase study several advanced recurrent solid tumor moreover earlier february national comprehensive cancer network nccn add rubraca maintenance therapy third later line ovarian cancer patient clinical practice guideline oncology ovarian cancer year have start well clovis positive recommendation rubraca approval europe third later line ovarian cancer patient addition nccn guideline latest label expansion unite state moreover potential approval europe clovis seek further approval drug maintenance therapy expand patient population positive development be expect boost company top line however remain be see parp inhibitor perform equally compete field meanwhile phase iii confirmatory study ariel be evaluate rubraca compare chemotherapy patient have fail prior line therapy clovis be also look expand rubraca label additional indication prostrate breast pancreatic cancer other monotherapy combination other agent clovis oncology inc price clovis oncology inc price clovis oncology inc quotezack rankclovis currently carry zack rank sell seethe complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2010,PFE,biogen inc biib free report partner samsung bioepis have announce resolution ongoing patent dispute abbvie abbv free report regard biogen biosimilar version imraldi abbvie blockbuster arthritis drug humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan share biogen have underperform industry year so far stock have lose compare industry decrease remind investor biogen have joint venture samsung biologic biosimilar call samsung bioepis already market couple biosimilar eu namely flixabi biosimilar reference merck mrk free report remicade benepali biosimilar reference amgen pfizer pfe free report enbrel development turn make imraldi third tnf biosimilar biogen receive marketing authorization eu biogen be also work samsung biologic introduce new biosimilar market importantly biogen gross biosimilar revenue month period end december compare logged upside be primarily drive benepali record revenue compare year figure increase market share biogen inc price biogen inc price biogen inc quote zack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2011,PFE,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2012,PFE,pfizer pfe free report have announce regulatory application pipeline candidate dacomitinib have be accept review unite state eu company be look get drug approve first line treatment locally advanced metastatic small cell lung cancer nsclc patient egfr activate mutation notably fda grant priority review dacomitinib response expect september regulatory submission dacomitinib be base positive datum global head head phase iii study evaluate dacomitinib versus astrazeneca azn free report lung cancer drug iressa gefitinib patient nsclc datum study demonstrated median progression free survival pfs month treatment dacomitinib compare month iressa reflect reduction risk disease progression however patient treat dacomitinib discontinue study due adverse event compare treat iressa company state final assessment overall survival study be present medical meeting later share pfizer be almost follow news however stock have gain past year underperform industry increase importantly pfizer regulatory application candidate have recently receive acceptance unite state be lorlatinib second line treatment patient nsclc response fda be await august small cell lung cancer occur patient lung cancer condition lead cause cancer death worldwide notably egfr mutation lead growth cancer cell occur nsclc tumor globally moreover significant progress make space disease be associate low survival rate hence approval candidate provide company access huge patient population base need additional treatment apprehend disease remind investor merck mrk free report pd therapy keytruda be approve first line lung cancer set also note last month roche rhhby free report have present datum tecentriq novel combination broad range tumor include lung cancer blockbuster drug bristol myer opdivo be approve treat nsclc other pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2013,PFE,rise last year large cap pharmaceutical industry have rise year so far have however underperform gain same time frame sector be strong start struggle little thereafter probably broader market correction also mention high drug price president donald trump state union address hurt investor sentiment however sector be largely expect rebound year progress be good year pharma biotech stock sector witness positive development lead much await recovery nyse arca pharmaceutical index gain sharp contrast decline witness be tough year pharma stock give furor rise drug price key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy remain headline risk investor appear more comfortable issue moreover significantly higher number fda approval restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector come back believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit possibility more merger acquisition be also high now tax reform be place big player be lookout company innovative pipeline technology have already be quite bit buzz year potential deal sanofi sny free report celgene celg free report have already announce deal meanwhile large cap pharma industry be top zack rank industry make sense look buy rank stock space investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well look well poise earn higher profit here be look large cap pharma company sport favorable zack rank strong buy buy lundbeck hluyy free report denmark base lundbeck specialize psychiatric neurological disorder company key area focus include depression schizophrenia parkinson disease alzheimer disease accord lundbeck person world suffer psychiatric neurological disorder many receive inadequate treatment ytd lundbeck have outperformed large cap pharmaceutical industry share gain addition deliver revenue growth local currency lundbeck issue upbeat outlook estimate earning growth current year be meanwhile earning estimate be past day abbvie inc abbv free report abbvie beat estimate earning sale fourth quarter also raise earning expectation base continue strong operational performance abbvie key drug humira have be perform well base strong demand trend new competition abbvie share have outperformed industry past year support series positive news include promising datum several pivotal study regulatory nod include approval competitive hcv medicine mavyret approval imbruvica settlement humira patent dispute biotech major amgen amgn free report abbvie share be impressive year so far outperform industry estimate earning growth current year be meanwhile estimate be respectively past day pfizer inc pfe free report new york base pfizer be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product pfizer report better expect fourth quarter result beat estimate earning well sale provide upbeat outlook believe pfizer snew product ibrance contribution acquisition cost cut share buyback help company earn profit future quarters pfizer share have rise year so far estimate earning growth current year be meanwhile estimate be respectively past day nordisk nvo free report year be eventful denmark base pharma giant gain regulatory approval key pipeline drug candidate include fast act insulin aspart fiasp once daily pre filled pen ozempic hemophilia treatment rebinyn meanwhile strong performance victoza be drive top line growth believe new product solid pipeline pave way growth year company past day earning estimate have rise respectively estimate earning growth current year be pfizer abbvie nordisk be zack rank buy stock lundbeck be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2014,PFE,eli lilly company lly free report announce new advanced breast cancer treatment verzenio abemaciclib have gain fda approval first line set latest approval verzenio be approve combination inhibitor ai anastrozole letrozole initial endocrine base therapy postmenopausal woman hr advanced metastatic breast cancer have have prior systemic treatment advanced disease lilly share have decline year so far industry record increase approval be base positive interim result monarch study study compare verzenio cdk inhibitor ai versus ai placebo mentioned patient datum study show verzenio ai substantially reduce tumor size delay disease progression such be already market breast cancer indication monotherapy treatment hr advanced breast cancer have prior endocrine therapy chemotherapy metastatic disease combination therapy astrazeneca azn free report faslodex fulvestrant hr advanced breast cancer patient have disease progression follow endocrine therapy verzenio be launch unite state fourth quarter generate sale first quarter launch believe verzenio label expansion previously untreated breast cancer population drive sale higher future quarters verzenio be review eu other available cdk inhibitor market include pfizer inc pfe free report ibrance novartis nvs free report kisqali lilly carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2015,PFE,pfizer inc pfe free report announce committee medicinal product human use chmp european medicine agency ema have recommend hematology medicine be grant marketing authorization eu however committee give negative opinion recommend label expansion pfizer kidney cancer medication sutent chmp recommend approval mylotarg combination standard chemotherapy treatment patient age year newly diagnosed cd positive acute myeloid leukemia aml acute promyelocytic leukemia apl mylotarg be approve unite state september last year chmp also grant positive opinion label expansion leukemia drug bosulif first line treatment patient suffering chronic phase philadelphia chromosome positive ph chronic myelogenous leukemia cml bosulif be approve first line set ph cml unite state december last year however chmp recommend approve label expansion sutent adjuvant treatment patient high risk recurrent advanced renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney please note sutent be approve use same patient population unite state november last year be only adjuvant therapy approve recurrent rcc most common type kidney cancer european commission ec be not bound follow chmp opinion usually do so bosulif record sale develop europe region record growth year year sutent sale same region decline share pfizer be so far year compare favorably increase industry zack rank other stock considerpfizer carry zack rank buy see complete list today zack rank strong buy stock here other large cap pharma stock worth consider be lundbeck hluyy free report abbvie abbv free report nordisk nvo free report lundbeck sport zack rank strong buy abbvie nordisk have same zack rank pfizer share lundbeck be year so far estimate be past day abbvie share be year so far past day earning estimate have rise respectively nordisk share be year so far past day earning estimate have rise respectively zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2016,PFE,last week have be eventful pharma stock novartis nvs free report announce be acquire gene therapy company avexis merck mrk free report abbvie abbv free report announce successful study result other news pfizer pfe free report kidney cancer drug inlyta miss primary endpoint phase iii study recap week most important storiesnovartis buy avexis big news early week be novartis deal buy avexis lead product candidate avxs be time gene replacement therapy spinal muscular atrophy sma regulatory filing avxs unite state be expect second half year avxs have potential generate million dollar novartis approve company agree pay share avexis represent whooping premium avexis close price friday board company have approve deal buyout be anticipate close second half year read more novartis inks gene therapy deal buy avexis merck keytruda succeed key lung cancer study pivotal lung cancer study keynote merck blockbuster pd inhibitor keytruda meet primary endpoint keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base chemotherapy notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market read more merck keytruda offer survival benefit lung cancer study abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint phase iii study select program phase iii study select compare evaluate candidate moderate severe rheumatoid arthritis patient be stable background methotrexate elicit inadequate response week treatment acr response first primary endpoint be achieve patient receive mg dose upadacitinib versus placebo second primary endpoint clinical remission be achieve patient upadacitinib arm versus only placebo arm read more abbvie ra candidate meet primary endpoint phase iii meanwhile fda have extend review period abbvie pipeline candidate elagolix month fda decision previously expect second quarter now come third quarter read more fda prolong review date abbvie endometriosis candidate pfizer inlyta miss primary endpoint phase iii study pfizer kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs compare placebo phase iii atla study accordingly independent datum monitoring committee recommend study be stop plan interim analysis read more pfizer kidney cancer drug miss endpoint phase iii pfizer also announce initiation dose early stage study evaluate mini gene therapy candidate pf treatment boy duchenne muscular dystrophy dmd most common type muscular dystrophy early datum study be expect first half pacira exparel get fda nod expand label pacira pharmaceutical inc pcrx free report supplemental new drug application snda label expansion exparel nerve block set patient undergo upper extremity surgery get fda nod fda approval come surprise fda committee vote approval expand indication february read more fda okay label expansion pacira exparel stock exparel generate sale represent increase latest label expansion sale be expect go glaxo divest rare disease gene therapy drug private biotech glaxo gsk free report be divest rare disease gene therapy portfolio private biotech orchard therapeutic exchange stake company well seat board divesture be part strategic review glaxo announce july last year divest preclinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation read more glaxo sell rare disease gene therapy private biotech nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report merck astrazeneca be biggest gainer rise respectively bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup lly cyramza shine cancer study pfe azn focus next pharma world watch novartis first quarter earning result other pipeline regulatory update make fortune shift electric carshere stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2017,PFE,stock not only suffer worst week more year be also brink logging worst march trump china trade war rhetoric be threaten global economic growth tighter monetary policy be hinder bull run begin almost decade third party firm improperly keep facebook inc fb free report user datum also raise fear restrictive regulation technology sector turn disrupt tech growth trajectory long help broader market scale north market go rough patch investing stock provide excellent risk adjust return seem judicious stock face worst marchit have be rough month broader market dow jone be verge see worst march have tank almost year back wsj market datum group fact blue chip gauge lose more point last trading session mark index steepest weekly percentage loss broader be also brink ugliest march year have slump benchmark index turn negative year be time high hit earlier year addition tech laden nasdaq witness excruciating march decline meanwhile wall street so call fear gauge cboe volatility index soar last week well long term average invariably show bearish bet continue outdo bullish counterpart index so far month have trigger such selloff lead stock end worst week year restrictive trade policy rise interest ratessel stock intensified trump administration announce levy tariff ten billion dollar chinese import top impose duty foreign steel aluminum response trump tariff beij say target product import value product mostly include pork fresh fruit dry fruit steel pipe modify ethanol ginseng wine such heated trade rhetoric doesn bode well american economy full fledge trade war take place unite state slip recession future jobless rate more double current level tariff lead rise inflation uptick import price provoke fed hike rate know easy monetary policy so far have help stock market celebrate year bull run investor have pile stock notion quantitative ease help domestic economy grow better rate emerge economy china fed way have tighten monetary policy conclusion fomc meeting mar jerome powell lead federal reserve hike interest rate quarter percentage point project steeper path rate hike vote lift benchmark lend rate be unanimous thus broader market keep fall long fed continue remain hawkish facebook fiascoadd downbeat tone be sharp selloff technology sector investor remain concern tighter regulation large tech company forget tech share have gain most so far year however sector take beating follow backlash facebook handle user datum everyone raise question cambridge analytica work trump election campaign have gain access personal datum roughly facebook user knowledge facebook share see weekly decline biggest other tech behemoth include apple google parent alphabet lose more week time buy ultra safe stocksas march be plague fear trade war rise rate datum mining scandal investing low risk asset combination parameter lead better return seem judicious best way go do be create portfolio low beta stock be inherently less volatile market trade case low beta range stock be also dividend payer boast immense financial strength be immune market vagary such stock reflect solid financial structure healthy underlie fundamental better quality business further boast zack rank strong buy buy centerpoint energy inc cnp free report operate public utility hold company unite state company have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day company be expect return year higher industry estimate return dine brand global inc din free report own franchise operate rent full service restaurant unite state internationally stock have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day company be expect return year higher industry project return pfizer inc pfe free report discover develop manufacture sell healthcare product worldwide stock have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be likely return year higher industry estimate return see complete list today zack rank stock here inc jwn free report be fashion retailer provide apparel shoe cosmetic accessory woman man young adult child unite state canada company have zack rank beta have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day company be expect return year higher industry estimate return southside bancshare inc sbsi free report operate bank hold company southside bank provide range financial service individual business municipal entity nonprofit organization stock have zack rank beta company have dividend yield year average dividend yield be zack consensus estimate current year earning rise last day stock be expect return year higher industry project return medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2018,PFE,novartis ag nvs free report announce committee medicinal product human use chmp european medicine agency ema adopt positive opinion marketing authorization propose biosimilar johnson johnson jnj free report remicade infliximab chmp recommend approval biosimilar indication brand drug rheumatology dermatology note remicade be approve treat crohn disease adult child ulcerative colitis rheumatoid arthritis psoriatic arthritis ankylose spondylitis plaque psoriasis positive opinion be base comprehensive datum package be expect confirm biosimilarity infliximab original drug analytical preclinical clinical datum match quality efficacy safety earlier phase iii confirmatory study rheumatoid arthritis reflection meet primary endpoint demonstrate equivalent efficacy propose sandoz biosimilar infliximab reference medicine measure american college rheumatology acr response week novartis share have decline year compare industry fall novartis generic arm sandoz be leader biosimilar market product market biosimilar include omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report ema be due review chmp opinion note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form eea term pfizer retain manufacturing right infliximab pf country outside eea meanwhile sandoz have quite number biosimilar pipeline tentative approval further boost company generic division company have also file approval biosimilar adalimumab pegfilgrastim eu apart froma strong generic portfolio novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2019,PFE,healthcare industry be enter period significant change software new technology be gradually begin revolutionize industry drug biotech company constantly strive bring differentiate high quality medicine vaccine consumer healthcare product many person possible bring successful drug market company spend million dollar several year research development activity however many candidate fail study never reach patient biotech medical research drug discovery involve significant expenditure be thus very important research landscape change major advance science technology be transform way scientist conduct research disease be likely improve diagnosis treatment future here discuss emerge technology pharma biotech industry have start adopt slowly be poise transform sector save time cost artificial intelligence machine intelligence ai be simulation human intelligence process machine especially computer system drug biotech company be analyze huge amount datum database apply artificial intelligence machine learn identify pattern way human artificial intelligence drive solution be enable pharma biotech company identify appropriate patient population reduce eliminate need study case even predict outcome virtual patient several collaboration have be form past couple year big pharma biotech player ai drive company primarily startup novel biological target molecule pharma player used ai example last year glaxo gsk free report collaborate external company exscientia uk specialist machine learn insilico medicine leader ai lead drug discovery harness ai also last year roche rhhby free report pharma arm genentech form research partnership gn healthcare power cancer drug development latter ref causal machine learn simulation ai platform astrazeneca azn free report also collaborate boston base berg last year use artificial intelligence discover novel target therapeutic treat neurological disorder such parkinson disease jnj free report pfizer pfe free report novartis nvs free report have collaboration ibm ibm free report watson health unit leverage latter ai solution application drug discovery accelerate primarily cancer research effort company pfizer glaxo carry zack rank buy see complete list today zack rank strong buy stock here artificial intelligence have be tout next big emerge technology biotech industry drastically reduce time cost take develop new life save drug significant amount time be invest identify potential disease target testing drug candidate hit target use ai be estimate drug design timeframe be cut year year also drastically reduce cost ai be relatively early stage be used biotech drug discovery other purpose broad scale adoption be expect bio printingthree dimensional printing printing be prototyp technology different material be fuse computer control create dimensional object add biology cell process become new technique bioprinting printer be used manufacture human tissue muscle well organ bone be implanted live human printing technology also know additive manufacturing be lead major innovation medicine manufacturing particularly personalize medicine compare conventional manufacturing system bioprinter offer benefit high production rate better precision accuracy reduce material wastage save cost still new pharmaceutical drug research development printing have be use medical device sector many year be mainly used make dental implant custom prosthetic first print prescription drug spritam treat epilepsy be approve fda launch unite state be make private company aprecia pharmaceutical used zip dose technology be expect printing have great potential revolutionize field drug manufacturing be used printing drug tablet personalize dosage drug different release rate printing live tissue texas base nano bioscience develop novel assay vasoactivity used core cell culture platform magnetic bioprinting partnership astrazeneca glaxo be work project decide invest printing drug internet medical thing iomt internet medical thing bring together medical device application technology procure vital datum real time chronic disease require frequent monitoring be track effectively so patient receive timely proper treatment wearable device apple watch fitbit samsung health help user achieve fitness health target well be future healthcare pharma medical device company look innovate keep technology help patient physician better monitor track disease accord report ally market research iot healthcare market reach worldwide register cagr be have potential transform healthcare industry term delivery affordability reliability pharma tech company be now take thing step further collaborate make device track chronic lifestyle associate disease diabetes be become rampant fact scope innovation area contact lense detect glucose level device monitor caloric intake bioelectronic medicine treat wide range chronic disease robotic assist surgery be seemingly endless conclusionwhile healthcare space be grow leap bound emerge technology mount concern privacy datum protection governance prevail also many ai bioprinting research company overestimate achievement something drug biotech company be wary nonetheless nascent technology hold ample promise proper execution definitely prove be trump card space today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2020,PFE,stock market mostly see saw pre midterm election period rally once uncertainty fade say analyst goldman sachs group inc gs free report scenario be not expect be different time investor brace increase turbulence divide government be highly expect election last several month fact have see extreme level volatility investor remain concern more protectionist trade policy spike bond yield price essential commodity continue move north give such uncertainty investing stock provide excellent risk adjust return seem judicious brace month brace neck snap volatility midterm election approach goldman broader market have be roller coaster ride past few month thank trade tax polic geopolitical tension controversy surround special counsel robert mueller probe trump collude russia initiative impede presidential election have aggravate concern thus corporate profit economic report have be crucial factor stock political development have continue determine direction market last midterm election year manage eke gain april mostly trade flat september only rally once political uncertainty wane goldman fact year stock market volatility averaged compare median year year be likely be same democrat be poise regain control house representative even republican be expect maintain upper hand senate base recent poll goldman forecast democrat have nearly chance repossess house be less chance regain majority senate goldman add such divide government doesn bode well investor volatility make dramatic have already see several day sharp move so far year cboe volatility index vix so call wall street fear index have see jump less least trading session year accord wsj market datum group volatility index have experience session so far year end least highest fact volatility double feb inflation concern drag broader market such earth shatter volatility follow relatively calm last year stock market shrug political economic uncertainty demonstrated almost nothing way market pullback bond yield spike equity bond yield way have trigger market gyration benchmark year treasury note hit highest level january early european trade year yield increase treasury come pressure treasury sell higher commodity price diminish value bond fix interest payment rise oil price business house say cost steel several other raw material be increase unite state have induced inflation fear rise bond yield affected buy appetite stock uptick bond yield increase opportunity cost investing equity therefore equity become less alluring selling pressure equity benchmark intensified apr major bourse retrace negative territory top stock counter market gyrationsgiven aforesaid factor seem wall street be poise face month volatility midterm just corner take consideration investor build strategy low risk asset combination parameter lead better return best way go do be create portfolio low beta stock be inherently less volatile market trade case low beta range stock be also dividend payer boast immense financial strength be immune market vagary such stock reflect solid financial structure healthy underlie fundamental better quality business further boast zack rank strong buy buy aflac incorporate afl free report subsidiary american family life assurance company columbus provide voluntary supplemental health life insurance product company have zack rank beta stock have dividend yield zack consensus estimate current year earning rise last day company be expect return year higher industry estimate return centerpoint energy inc cnp free report operate public utility hold company unite state company have zack rank beta stock have dividend yield zack consensus estimate current year earning increase last day company be expect return year higher industry project return guess inc ge free report design market distribute license lifestyle collection apparel accessory man woman child company have zack rank beta stock have dividend yield zack consensus estimate current year earning rise last day company be expect return year higher industry estimate return see complete list today zack rank stock here inc jwn free report fashion retailer provide apparel shoe cosmetic accessory woman man young adult child unite state canada company have zack rank beta stock have dividend yield zack consensus estimate current year earning rise last day company be expect return year compare industry estimate return pfizer inc pfe free report discover develop manufacture sell healthcare product worldwide company have zack rank beta stock have dividend yield zack consensus estimate current year earning rise last day company be expect return year better industry estimate return today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2021,PFE,smart investment become buzzword today investment world millennial be frequently incline hybrid investment pattern rather traditional pure play theory value growth logic be effectiveness mixed investment strategy value growth investing approach come own share pitfall pure play value investor miss chance bet stock have bright long term prospect same way growth investor often end investing expensive stock other word make long term investment more effective principle value growth strategy need be combine quest mixed investment strategy lead introduction garp growth reasonable price approach garper look be stock be somewhat undervalue have solid sustainable growth potential investopedium fundamental metric find garp be price earning growth ratio peg be categorize value investing strategy follow principle growth value investing peg ratio be defined price earning earning growth rateit relate stock ratio future earning growth rate alone only give idea stock be trading discount peg add growth element help find stock have solid future potential lower peg ratio preferably less be always better garp investor say example stock ratio be expect long term growth rate be company peg come ratio indicate undervaluation future growth potential unfortunately ratio be often neglected due investor limitation calculate future earning growth rate stock be drawback used peg ratio doesn consider very common situation change growth rate such forecast first year very high growth rate follow sustainable lower growth rate long term hence peg base investing turn be even more reward other relevant parameter be also take consideration here be screening criterium winning strategy peg ratio less industry medianp ratio used less industry median more accurate valuation purpose zack rank strong buy buy good market condition bad stock zack rank have proven history success market capitalization greater help focus company have strong liquidity average day volume greater substantial trading volume ensure stock be easily tradable percentage change earning estimate revision week greater upward estimate revision add optimism suggest further bullishness value score less equal research show stock style score combine zack rank hold offer best upside potential here be stock qualify screening pfizer inc pfe free report company focus development wide range product include human animal biologic well small molecule medicine vaccine consumer health care product apart zack rank value score company also have impressive expect year growth rate laboratory corporation america holding lh free report be lead healthcare diagnostic company provide comprehensive clinical laboratory service end end drug development support apart discount peg stock have value score hold zack rank hill holding inc hrc free report renown medical device company partner health care provider focuse patient care solution improve clinical economic outcome core area advance mobility wound care prevention clinical surgical safety efficiency respiratory health company have impressive current year growth rate stock currently have value score zack rank see complete list today zack rank stock here hca healthcare inc hca free report be largest governmental operator acute care hospital unite state headquarter nashville tn operate hospital related health care entity operate geographically organized group national american group apart discount peg stock have value score sport zack rank terex corporation tex free report company be global equipment manufacturer cater construction infrastructure surface mining industry company manufacturing facility be locate unite state canada europe australia asia south america stock currently sport zack rank have value score also have impressive long term historical earning growth rate get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2022,PFE,fearless girl face manhattan financial district famous charge bull wall street get new permanent home end year front new york stock exchange several criticism statue have become tourist destination global symbol female business prowess installation more year fearless be ponytailed young foot tall bronze monument fist hip chin hold high symbol empowerment state street global advisor bowling green park broadway street originally install sculpture eve international woman day fearless girl be grow symbol gender equality power woman leadership spread message encourage company recruit woman board plaque statue foot read know power woman leadership make difference fearless girl be part campaign state street encourage company add more woman board advertise spdr ssga gender diversity index etf free report comprise gender diverse company have relatively high percentage woman senior leadership etf offer exposure company demonstrate greater gender diversity senior leadership other firm sector tracking ssga gender diversity index hold stock be moderately concentrated top firm account less asset pfizer pfe free report coca cola ko free report mastercard inc free report be top holding sector look information technology take largest share follow healthcare consumer staple consumer discretionary have return past year versus gain broad market fund spy free report impact woman leadershipout company unite state britain australia have woman serve board more company have add female director board placement bronze girl statue pledge do so currently woman make ceo fortune company corporate board member fortune company today record number woman be power year unite state fortune ceo be woman woman be supreme court last secretary state be woman last year world leader be woman serve country first female leader famous woman leader include angela merkel dilma rousseff corporate world indra nooyi ceo pepsico pep free report sheryl sandberg coo facebook fb free report mary barra ceo general motor gm free report angela ahrendts senior vice president apple aapl free report denise morrison ceo campbell soup company cpb free report michele buck ceo hsy free report be leader own right several research company lead woman have long history outperformance bottom lineplace fearless girl right next nyse be perfect metaphor promote more company hire woman board accord state street global advisor move fearless girl be more powerful standing alone outside nyse current home turf share charge bull hopefully continue stimulate power have woman leadership today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2023,PFE,glaxosmithkline plc gsk free report be schedule report first quarter result apr market open last quarter company deliver positive surprise share glaxo share have outperformed industry so far year stock have gain industry decline glaxo earning performance have be pretty impressive so far company bottom line surpass estimate thrice trail quarters meeting same remain overall company come average beat let see thing be shape quarter factor consider glaxo continue see strong sale pharmaceutical vaccine business segment company pharmaceutical segment be expect be drive solid sale new hiv product tivicay triumeq sale lately launch respiratory drug ellipta product nucala be likely offset decline sale older respiratory product namely seretide advair avodart fourth quarter conference call glaxo state inhaled respiratory product particularly older one be grapple persistent competitive pricing pressure expect continue meanwhile many glaxo key drug lovaza avodart be face sale decline due generic competition trend expect carry well be important note pricing dynamic rivalry wo be hurt sale company top selling drug advair unite state generic competition be hamper same europe vaccine segment be likely consistently benefit sustain uptake meningitis vaccine bexsero menveo acquire novartis ag nvs free report moreover glaxo shingrix vaccine prevention shingle approve unite state last october generate better expect initial sale previous quarter upcoming quarter expect significant contribution drug company sale sale gain favorable recommendation center disease control prevention advisory committee immunization practice merck zostavax moreover shingrix be approve eu well japan last month give indication fetch additional sale additionally glaxo receive approval other key new drug namely trelegy ellipta provide medicine single inhaler treat copd juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv be also expect drive company top line last month glaxo announce have enter agreement novartis buy latter stake consumer healthcare joint venture acquisition glaxo now stake ownership claim consumer healthcare unit include product such sensodyne flonase expect management further discuss deal be report quarter importantly sale growth be wane consumer healthcare segment due generic competition transderm scop divestment well impact general sale tax india consumer healthcare segment be anticipate remain stress first quarter be not much predict push sale meanwhile cost saving restructure continue efficiency boost operate profit earning whispersour proven model do not conclusively show glaxo be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp glaxo have earning esp most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report ourearning esp filter zack rank glaxo carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quote stock considerhere be couple health care stock worth consider right combination element surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report be schedule report earning company have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2024,PFE,eli lilly company lly free report report first quarter result apr market open last quarter company deliver positive earning surprise lilly share have decline year so far underperform industry decrease lilly performance have be pretty impressive earning beating expectation last quarters bring average positive surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotelet see thing be shape quarter factor considerlike previous couple quarters strong uptake trend new product trulicity taltz basaglar cyramza jardiance lartruvo make decline sale establish product zyprexa alimta ciali strattera effient trulicity sale be be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class positive trend be expect continue first quarter zack consensus estimate trulicity first quarter revenue be continue strong uptake outside unite state be likely drive sale cyramza strong launch uptake be expect drive sale taltz lartruvo loss exclusivity country cymbalta strattera effient axiron zyprexa evista continue hurt volume also lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country trend believe persist first quarter zack consensus estimate alimta sale first quarter be peg olumiant baricitinib be launch select european country japan generate sale year support strong launch uptake germany drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january verzenio be launch unite state fourth quarter generate sale expect new cancer drug generate higher sale first quarter also advanced breast cancer treatment gain fda approval first line set february have lead additional sale first quarter older product humulin forteo be expect do well other ciali be likely see weak sale due lower demand elanco animal health segment sale be hurt global competitive pressure trend have continue first quarter fourth quarter conference call management have say be slightly negative first half animal health revenue be expect improve second half support new product launch zack consensus estimate sale animal health segment be lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business investor look update first quarter conference call earning whispersour proven model do not conclusively show lilly beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate earning be share uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time merck co inc mrk free report have earning esp zack rank company be schedule report first quarter earning see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2025,PFE,amgen inc amgn free report announce fda have grant accelerate approval new indication leukemia drug blincyto fda approve latest supplemental biologic license application sbla blincyto label be expand include treatment patient minimal residual disease mrd positive cell precursor acute lymphoblastic leukemia approval blincyto become first fda approve drug treatment mrd patient however continue approval indication be subject clinical benefit datum confirmatory study drug be already approve treatment philadelphia chromosome negative ph relapse refractory cell precursor unite state europe amgen share be so far year compare industry loss period approval be base datum phase ii blast study evaluate blincyto mrd positive patient have achieve complete hematologic remission receive more cycle intensive chemotherapy datum show drug achieve complete mrd response detectable mrd patient median hematological relapse free survival rate drug be month note mrd refer detectable cancer cell patient have achieve complete remission conventional treatment method hence treatment mrd help achieve better possible clinical outcome patient delay stopping relapse destroy remain detectable trace leukemia blincyto have show impressive growth rate sale reach sale be expect improve further year due continue demand however impact expansion label include treatment mrd remain be see remind investor pfizer inc pfe free report besponsa have receive approval treatment relapse refractory cell precursor august unite state increase competition blincyto amgen inc price amgen inc price amgen inc quotezack rank stock consideramgen currently have zack rank hold better rank stock health care sector include horizon pharma public limit company hznp free report ligand pharmaceutical incorporate lgnd free report stock carry zack rank buy see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have increase so far year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2026,PFE,aerie pharmaceutical inc aeri free report be expect report fourth quarter result feb market close last quarter company report wider expect loss aerie performance last quarters have be mixed company incur narrower expect loss trail quarters report wider expect loss remain average negative surprise aerie pharmaceutical inc price consensus aerie pharmaceutical inc price consensus aerie pharmaceutical inc quote aerie share have return year compare industry gain likely positive surprise proven model indicate aerie be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate stand loss zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank aerie have zack rank be favorable combination zack rank positive esp indicate likely positive surprise conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor playaerie stock receive major boost fda approval lead candidate rhopressa drug lower elevated intraocular pressure patient open angle glaucoma ocular hypertension aerie do not have approve glaucoma product portfolio give potential market hold news come major breather stock glaucoma be largest segment global ophthalmic market accord national eye institute have be estimate more individual unite state suffer glaucoma number be expect reach fda approval come month ahead schedule prescription drug user fee act goal date feb aerie plan employ representative first quarter plan launch drug mid expect management throw more light drug launch fourth quarter call meanwhile aerie second product candidate roclatan netarsudil latanoprost ophthalmic solution be fix dose combination rhopressa pfizer pfe free report xalatan achieve primary efficacy endpoint phase iii registration trial name mercury mercury candidate also achieve successful month safety efficacy result mercury company expect submit nda roclatan second quarter cash burn year be project due further pipeline development other stock considerhere be few other health care stock want consider model show too have right combination element post earning beat quarter gemphire therapeutic gemp free report be expect release fourth quarter result mar company have earning esp zack rank see complete list today zack rank stock here puma biotechnology pbyi free report be schedule release fourth quarter result mar company have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2027,PFE,follow announcement fourth quarter result share momenta pharmaceutical inc mnta free report moved company report earning share cent quarter beating zack consensus estimate cent figure however be cent earn year quarter momenta pharmaceutical inc price consensus momenta pharmaceutical inc price consensus momenta pharmaceutical inc quote revenue quarter come top zack consensus estimate be year quarter momenta stock have gain last month industry decline quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due inventory price adjustment owing mylan myl free report entry copaxone market deduction reimburse company share glatopa related legal expense sandoz collaborative research development revenue come year quarter increase be due revenue recognition upfront payment csl fourth quarter research development expense be year quarter general administrative expense decrease outlookmomenta expect operate expense exclude stock base compensation net collaborative revenue range operate expense first quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesmomenta announce fda have finally approve sandoz abbreviated new drug application glatopa mg company suffer setback fda issue warning letter pfizer pfe free report february be sandoz contract fill finish manufacturing partner glatopa meanwhile momenta continue progress other pipeline candidate january momenta mylan announce plan initiate patient clinical trial propose biosimilar eylea first half investigational new drug ind application have be accept regulatory body biologic license application bla momenta biosimilar version humira be also ready be file fda company be look collaboration partner same momenta suffer setback company partner mylan announce propose biosimilar orencia do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan continue evaluate next course action momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer january momenta report positive top line datum phase single ascend dose sad multiple ascend dose mad study normal human volunteer phase randomize double blind placebo controlled study evaluate safety tolerability pharmacokinetic pharmacodynamic candidate do not exhibit adverse event be well tolerate decrease circulate igg level mean reduction day mad study addition sad portion study enrolled cohort total healthy adult volunteer show single dose achieve reduction circulate igg antibody takemomenta fourth quarter result be better expect drive receipt upfront payment be challenge company face approval delay glatopa mg report disappointing result biosimilar candidate fda approval glatopa mg relieve momenta competition limit market share gain note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity hence expect company face challenge market meanwhile progress biosimilar pipeline be encourage zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2028,PFE,key highlight week include regeneron announce positive datum praluent sarepta seek rapid approval second dmd drug orexigen filing bankruptcy recap week most important sanofi announce positive datum praluent cut price regeneron pharmaceutical regn free report partner sanofi sny free report announce positive result odyssey outcome trial praluent late breaker session american college cardiology annual scientific session orlando fl trial meet primary endpoint result show praluent significantly reduce risk major adverse cardiovascular event mace patient recent acute coronary syndrome acs event such heart attack june regeneron sanofi announce phase iiib iv odyssey dm trial patient diabetes meet primary endpoint uptake drug hasn be encourage cholesterol management market hold huge commercial potential company also announce reduction net price praluent alignment new value assessment high risk patient institute clinical economic review meanwhile phase iii study evaluate praluent homozygous familial be initiate fourth quarter read more regeneron sanofi announce positive datum praluent regeneron be zack rank strong buy stock see complete list today zack rank stock here sarepta seek rapid approval second dmd drug sarepta therapeutic srpt free report stock scale fresh week high company announce accelerate approval second drug golodirsen treat duchenne muscular dystrophy dmd most common type muscular dystrophy sarepta have meet fda division neurology product february obtain guidance regulatory pathway golodirsen sarepta file roll new drug application nda fda seek accelerate approval golodirsen dmd patient have confirm mutation dmd gene susceptible exon skip sarepta intend complete roll nda submission golodirsen year end sarepta only approve drug exondys be approve unite state once weekly intravenous infusion specifically target patient have confirm mutation dmd gene susceptible exon skip read more sarepta seek rapid approval second dmd drug stock orexigen file bankruptcy orexigen therapeutic announce have decide file voluntary petition chapter bankruptcy code bankruptcy court district delaware company also plan file motion seek authorization pursue auction sale process section bankruptcy code bidding process be expect conclude news come wake unimpressive performance weight loss drug contrave be market mysimba european union orexigen have file series motion court thereby seek ensure continuation normal operation tenure read more orexigen plummet filing chapter bankruptcy code biogen buy cognitive impairment asset pfizer biogen biib free report announce acquire phase iib ready ampa receptor potentiator cognitive impairment associate schizophrenia pfizer pfe free report upfront payment milestone payment well tiered royalty low mid percentage company be look diversify portfolio core therapeutic area multiple sclerosis disorder biogen initiate phase iib study pf determine ampa receptor potentiator be safe effective treatment cognitive dysfunction schizophrenia patient second half read more biogen buy mid stage neuropsychiatry asset pfizer biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock vertex gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round regeneron submit sbla biogen withdraw zinbryta next biotech world stay tune more regulatory pipeline update ongoing cowen healthcare conference breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2029,PFE,cancer oncology space have always be keenly watch investor interested pharma biotech sector be disease be lead cause morbidity mortality world precede only heart disease major player field include pfizer pfe free report bristol myer bmy free report novartis nvs free report astrazeneca azn free report merck mrk free report roche rhhby free report cancer drug be most important revenue driver bigwig well smaller counterpart clovis oncology tesaro puma biotechnology othersevolution cancer spacea lot progress have be make area last few year company be aim bring newer better treatment immunotherapy gene therapy target therapy other novel therapy fact focus area have increase fda approval car therapy novartis kymriah gilead gild free report yescarta last year path breaking immunocellular therapy be time treatment used patient own cell fight cancer acquisition kite gilead juno celgene have lead renew interest area interest parp inhibitor have also increase considerably well be next major class therapeutic oncology accord imsquintile new cancer drug be approve indication worldwide cost cancer therapeutic supportive care drug shot unite state accounting cost more molecule be late stage development majority be target therapy attack specific feature target cancer cell new cancer drugsnew oncology brand include bristol myer opdivo merck keytruda pfizer ibrance abbvie imbruvica be fast catch give tough competition category stalwart such avastin herceptin rituxan new cancer drug approve last year include pfizer merck kgaa bavencio bladder cancer eli lilly verzenio novartis kisqali puma biotechnology nerlynx breast cancer tesaro zejula ovarian cancer most common indication new drug be small cell lung cancer nsclc hodgkin lymphoma melanoma breast cancer be patient population benefit go say new drug bring million buck company be sell huge amount money however be do enough cure patient help live longer better be relieve pain fatigue consider fact come premium fda have approve number oncology drug recent year also lower bar clinical study goal cancer candidate disease still remain top cause death many population here probably few drug have be successful allow patient limit life expectancy live year however efficacy several other be be question have lead only marginal benefit not much improvement survival quality life many drug be be approve base progression free survival amount time patient live tumor grow larger evidence benefit survival quality life be specially case drug aim treat terminal cancer few treatment option however overall survival os datum once available sometimes show drug do not help person live longer also drug do offer survival benefit gain be often marginal risk long term side effect drug have also be underestimated overall cancer survival have barely change past decade raise concern push get more drug approve instead get effective drug approve large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2030,PFE,share johnson johnson jnj free report decrease market close apr beating zack consensus estimate earning revenue be primarily due fact top selling drug remicade witness decline sale owing recent competition unite state company revenue increase year year basis first quarter come ahead consensus mark increase sale be drive primarily strong sale cancer drug favorable foreign exchange trend recent acquisition activity june jnj biggest ever acquisition buy swiss company actelion johnson johnson report gaap earning share ep first quarter year year sequential basis beat zack consensus estimate segment sale company report increase sale geographical segment sale increase year quarter international sale increase moreover business segment basis company report improvement segment consumer pharmaceutical medical device revenue increase respectively company be face headwind related sale key drug remicade zytiga certain new drug be expect make loss blood cancer drug darzalex imbruvica deliver strong sale growth quarter however company high dependence pharma segment be concern consumer medical device segment fail register attractive growth still expect adjust earning share range increase revenue guidance range expect earlier current scenario believe be prudent discuss follow etfs have relatively high exposure johnson johnson see health care etfs here health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical health care equipment supply health care provider service exposure respectively fund top holding be johnson johnson unitedhealth unh free report pfizer pfe free report allocation respectively fund have return year lose year date xlv currently have zack etf rank hold medium risk outlook read healthy earning unitedhealth etfs watch vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively fund top holding be johnson johnson pfizer unitedhealth allocation respectively fund have return year year date vht currently have zack etf rank medium risk outlook ishare healthcare etf iyh free report fund seek provide exposure healthcare stock track dow jone health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively fund top holding be johnson johnson unitedhealth pfizer allocation respectively fund have return year year date iyh currently have zack etf rank medium risk outlook be year chart compare performance etfs discuss jnj source yahoo financewant key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2031,PFE,discourage result phase ii study evaluate abbvie abbv free report promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc grab headline week other news include purchase offer jnj free report diabetes device unit successful study result announce heron therapeutic hrtx free report roche rhhby free report recap week most important storiesabbvie rova fall short key lung cancer study abbvie promising cancer candidate rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line set consult fda rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential failure trinity have raise skepticism rova potential have bring question viability stemcentrx deal read more abbvie stock fall weak lung cancer study outcome get offer lifescan unit say have receive bound offer private equity firm platinum equity lifescan diabetes device unit have time jun offer fail expire have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year read more get offer lifescan diabetes device unit pfizer get fda priority review expand label xtandi pfizer pfe free report japanese partner astella gain fda priority review regulatory filing be look expand label prostate cancer drug xtandi include early stage patient population regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result prosper study xtandi fda grant priority review decision be expect july read more pfizer xtandi label expansion filing get priority review meanwhile british company reckitt benckiser group pull discussion pfizer buy latter consumer health segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business glaxo also say have withdraw race buy pfizer unit heron htx succeed phase iii heron therapeutic pipeline candidate htx meet primary endpoint pivotal phase iii study evaluate post operative pain control follow bunionectomy hernia repair respectively top line datum study show treatment htx lead statistically significant reduction pain intensity opoid use hour follow surgery candidate be also superior bupivacaine solution be current standard care local anesthetic postoperative pain control read more heron pain candidate meet endpoint pivotal studiesroche tecentriq succeed lung cancer combo study roche tecentriq meet co primary endpoint progression free survival phase iii study evaluate pd inhibitor combination chemotherapy carboplatin abraxane first line treatment advanced squamous small cell lung cancer nsclc tecentriq be already market treatment second line metastatic nsclc label expansion first line set boost drug sale further however roche await overall survival datum study continue read more roche tecentriq phase iii combo study meet primary endpoint novartis tasigna get fda nod label expansion novartis nvs free report leukemia drug tasigna be grant fda approval use pediatric year age older population first second line treatment philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp glaxo begin new combo study benlysta glaxo gsk free report have initiate late stage study bliss believe evaluate systemic lupus erythematosus medicine benlysta combination roche rituxan benlysta previous late stage study have demonstrated consistent efficacy reduce disease activity sle aim new combination study be achieve clinical remission sle patient apart demonstrate low disease activity read more glaxosmithkline initiate phase iii combo study nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform week astrazeneca azn free report be only stock record gain last trading session decline bristol myer bmy free report be last month astrazeneca be biggest gainer merck mrk free report be biggest loser decline see last pharma stock roundup here abbv elagolix meet study goal mrk keytruda focus next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2032,PFE,cancer space see label expansion major drug week seattle genetic inc sgen free report adcetris label be expand include treatment naive patient advanced hodgkin lymphoma chl novartis nvs free report tasigna receive approval use pediatric patient year age older meanwhile fda grant priority review pfizer pfe free report regulatory application seek label expansion xtandi include early stage patient population roche hold ag rhhby free report pd inhibitor tecentriq meet primary endpoint phase iii lung cancer combination study however abbvie abbv free report announce disappointing result mid stage study evaluate lung cancer candidate rovalpituzumab tesirine rova let see news detail seattle genetic adcetris label expansion fda approve supplemental biologic license application sbla seek label expansion seattle genetic adcetris treatment naive stage iii iv chl patient drug be approve combination chemotherapy regimen avd adriamycin vinblastine dacarbazine base statistically significant improvement progression free survival datum phase iii echelon study study compare adcetris combination regimen current standard care read more seattle genetic adcetris get fda nod label expansion seattle genetic inc price seattle genetic inc price seattle genetic inc quotenovartis tasigna label expand pediatric patient novartis announce fda have approve line extension leukemia drug tasigna pediatric patient year age older philadelphia chromosome positive chronic myeloid leukemia chronic phase drug receive approval first second line set patient population drug be already available adult indication approval be base datum study evaluate tasigna patient age group year year datum show major molecular response mmr rate be newly diagnosed patient patient resistant prior therapy respectively novartis ag price novartis ag price novartis ag quotepfizer sbla xtandi get priority review fda grant priority review sbla pfizer prostate cancer drug xtandi pfizer be look include metastatic castration resistant prostate cancer indication drug label regulatory status be grant base datum phase iii prosper study decision fda be expect july year read more pfizer xtandi label expansion filing get priority review pfizer inc price pfizer inc price pfizer inc quoteroche tecentriq meet primary endpoint roche subsidiary genentech announce tecentriq combination chemotherapy carboplatin abraxane reduce risk disease worsening death compare chemotherapy alone phase iii impower study study be evaluate combo regimen patient advanced squamous small cell lung cancer however study be continue statistically significant overall survival benefit be not achieve read more roche tecentriq phase iii combo study meet primary endpoint roche hold ag price roche hold ag price roche hold ag quoteabbvie rova fail phase ii study abbvie share crash thursday follow announcement disappointing result pivotal phase ii study evaluate rova third line later small cell lung cancer study evaluate candidate sclc patient high expression protein dll have receive least previous treatment regimen include least platinum base regimen result do not meet expectation be not significant enough candidate be prioritize accelerate approval however phase iii study evaluate rova first second line setting sclc be ongoing read more abbvie stock fall weak lung cancer study outcome week abbvie collaborate international myeloma foundation conduct landmark retrospective chart review study study evaluate overall survival patient multiple myeloma abbvie inc price abbvie inc price abbvie inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2033,PFE,pfizer inc pfe free report announce phase iii study evaluate pipeline candidate tafamidis treatment transthyretin cardiomyopathy ttr cm meet primary endpoint top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month safety datum also demonstrated tafamidis be generally well tolerate patient pfizer reveal strong late stage result tafamidis study share alnylam pharmaceutical alny free report ionis pharmaceutical ion free report decline more respectively friday biotechs have make compete drug tafamidis ttr cm be rare disease associate progressive heart failure be universally fatal presently treatment be approve treat fatal disease accord pfizer press release less person disease be diagnosed life expectancy average year diagnosis be type ttr cm hereditary form wild type form disease be not hereditary attr act study include type patient however alnylam ionis have develop candidate patisiran inotersen respectively hereditary ttr amyloidosis hattr patisiran inotersen be review eu unite state be launch year tafamidis have be grant fast track status fda ttr cm meanwhile tafamidis also enjoy orphan drug designation ttr cm eu unite state tafamidis be already approve treatment transthyretin familial amyloid polyneuropathy ttr fap country unite state unite state pfizer receive complete response letter crl fda ttr fap share pfizer have decline so far year compare favorably decrease industry zack rank key pickpfizer carry zack rank buy see complete list today zack rank strong buy stock here top rank large cap pharma stock be lundbeck hluyy free report same zack rank pfizer share lundbeck have return year so far estimate increase past day hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2034,PFE,equity market be go rough patch be lot uncertainty trade negotiation recent concern facebook datum breach be weigh tech sector have increase appeal dividend investing read stock etfs juicy dividend yield bother market tech freefalla day record massive gain talk negotiation china unite state relate trade market suffer huge loss lead tech stock dow jone industrial average fall moreover standard poor fall technology heavy nasdaq slide investor flocked safety social medium company be major loser recent datum debacle introduce fresh concern activity sector participant twitter inc twtr free report slump end trading mar citron research say be shorting stock owing company reliance licensing user datum moreover facebook fb free report slump further mark zuckerberg prepare testify front congress facebook have be fall follow report datum mining firm cambridge analytica firm work president trump campaign unethically obtain datum facebook user permission not be pleasant experience zuckerberg team go front congress be necessary smart strategic step facebook head beltway public fury continue grow cambridge datum leak cnbc article cite daniel ife head technology research gbh insight trade uncertainty tension washington beij be ease sign negotiation china unite state relate trade be naive sit back relax hope negotiation win have major impact global financial market owing recent volatility market allocate portion portfolio safe dividend fund seem appeal option read etfs buy trade war fear abate moreover investor expect unite state withdraw iran nuclear deal john bolton be appoint national security adviser bring back sanction iran weigh capability export crude oil market result rise geopolitical risk increase appeal dividend investing such scenario dividend pay security provide consistent income investor uniqueness security be increase return political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively fund top holding be boee co ba free report pfizer inc pfe free report apple inc aapl free report allocation respectively fund have return year have lose year date have dividend yield quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology industrial health care allocation respectively fund top holding be exxon mobil corp xom free report johnson johnson jnj free report microsoft corporation msft free report allocation respectively fund have return year have lose year date have dividend yield schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively fund top holding be intel corp intc free report exxon mobil corp procter gamble pg free report allocation fund have return year have lose year date have dividend yield have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2035,PFE,big recession year be trigger sub prime lend unite state be worst economic slowdown great depression span year begin great depression end financial crisis have be small big recession have hit economy nearly decade go last recession analyst expect recession be round corner last recession be pretty costly government spending nearly bail big bank also announce economic stimulus package government pump money directly economy housing market be most affected price crash more unemployment rate high single digit base historic pattern few economic factor low unemployment rate hike rate fed analyst believe recession hit market however predict recession be difficult depend several factor housing price have moderate several key area job growth unite state remain decent give mixed picture economy article publish wtop com december last year indicated yield short term bond be close long term bond be term flatten yield curve indicate investor be wary long term economic growth however suggest recent rate hike have cause short term yield rise continue demand long term bond due lower bond rate europe japan be keep yield lower view equity market be also mixed equity market be grow buoy solid earning same time volatility be rise too earning be expect increase back tax cut announce last year instead rise revenue mean actual growth economy be lesser portray market performance meanwhile international monetary fund have predict economy be head recession soon publish blog express co uk however expect mild recession moreover blog publish fortune com bill gate fame investor warren buffett also believe recession be certain however be unsure timeline conclude economy be go mixed phase hence be uncertain start slip recession however impact recession be hard deal historically have be see consumer staple pharmaceutical industry be recession proof industry manufacture necessary item hence believe investor pick stock industry avoid potential setback portfolio financial crisis here present best stock industry stock sport zack rank strong buy buy hold vgm score here stand value growth momentum score be weight combination score style score system have identify stock have potential beat market score allow streamline search select winner eliminate negative aspect however be important keep mind style score carry different weight arrive vgm score research show stock impressive vgm score combine zack rank offer best upside potential see complete list today zack rank stock here further stock have be witness positive interest analyst lately industry rank roughly top half zack industry rank system way ensure pick be poise benefit bullish outlook respective industry picksguess inc ge free report perform well fiscal beating earning estimate quarters company belong textile apparel industry rank top zack industry past couple month analyst have become increasingly bullish stock upward estimate revision fiscal earning lead sharp spike zack consensus estimate fiscal be peg cent nearly cent day zack consensus estimate fiscal increase penny last day stock have gain so far year company hold zack rank have vgm score read more guess look strong go here food hold corp usfd free report cater foodservice distribution industry national footprint company belong miscellaneous food industry rank top zack industry stock have be witness solid activity estimate revision front zack consensus estimate earning have trend sharply past couple month share zack consensus estimate increase same period stock have gain so far year company sport zack rank have vgm score pfizer inc pfe free report boast strong pipeline expect approximately drug approval next year product have blockbuster potential company belong large cap pharmaceutical industry rank top zack industry analyst have great expectation company year have be revise earning estimate upward past day pfizer have see positive revision past day result estimate climb zack consensus estimate increase same period company hold zack rank have vgm score horizon pharma public limit company hznp free report nephrology drug krystexxa record impressive growth be expect continue year company belong biomedical genetic industry rank top zack industry moreover analyst have become increasingly bullish company past couple month upward estimate revision earning lead spike zack consensus estimate be peg day zack consensus estimate increase same period stock have gain past month company have zack rank vgm score read more be horizon pharma public great stock value investor right now investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2036,PFE,market close mostly higher friday dow eke gain post sixth straight session gain nasdaq slump end negative territory however major benchmark post biggest weekly close however gain be curb special counsel robert mueller indict group russian national few entity country regard involvement presidential election meanwhile housing start surge highest level financial crisis also build permit rise month high market remain close monday due observance president day dow jone industrial average dji increase close however rise little more point close tech laden nasdaq composite index close lose fear gauge cboe volatility index vix increase close total share be trade friday lower last session average share advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue do benchmark perform add meager point close green extend streak gain sixth straight session moreover broader index post biggest weekly increase last year major segment end green utility healthcare lead advancer utility select sector spdr etf xlu health care select sector spdr etf xlv increase respectively dow amassed point finish positive territory sixth straight session blue chip index rally much point mark highest level session gain dow be also support increase share pfizer inc pfe free report gain friday meanwhile dow be currently time high see complete list today zack rank strong buy stock here however nasdaq decline point finish negative territory end day streak gain tech heavy index have surge earlier session nasdaq be currently trading time record russian indict meddle electionsu special counsel robert mueller charge russian national entity country meddle presidential election russian company internet research agency be identify entity involved scam report also mentioned indict support president trump campaign denigrate candidate hillary clinton campaign run election such development weigh heavily market economic datahousing start month january come surpass estimate such increase have be highest financial crisis meanwhile build permit month january rise half year high consensus estimate period be majority new permit come north south west weekly week dow nasdaq gain respectively be biggest weekly gain dow november marked best weekly advance january meanwhile nasdaq post biggest weekly gain december president trump sign law bipartisan budget deal provide massive spending boost pentagon infrastructure turn have positive impact key index dow be year be way post biggest weekly increase november additionally nasdaq have increase more year market manage rebound decline initially follow better expect consumer price report key inflation metric strong earning season steady economy lead key index shrug yearly decline close positive territory stock make headlineshome depot keep earning beat trend guide fy home depot inc hd free report report upbeat fourth quarter fiscal continue year long trend beating earning estimate read more food deflation hurt companhia brasileira brasileira distribuicao cbd free report grupo pao acucar report fourth quarter result adjust net income continue operation come year period read more sysco buy doerle food service widen distribution ussysco corporation syy free report have acquire doerle food service louisiana base food service distributor widen distribution network buyout be expect capitalize sysco growth opportunity thus strengthen core business maximize customer value read more walmart earning miss hurt stock comp againwalmart inc wmt free report post fourth quarter fiscal result earning revenue improve year year latter also exceed zack consensus estimate read more hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2037,PFE,bristol myer squibb company bmy free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session stock picked sharply flat trend past month time frame move come report company have inked multibillion dollar global strategic collaboration agreement nektar therapeutic company have see positive estimate revision past few week zack consensus estimate current quarter have also moved higher past few week suggest more solid trading be ahead bristol myer squibb so make sure keep eye stock go forward see recent jump turn more strength road bristol myer squibb currently have zack rank hold earning esp be bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotea better rank stock large cap pharmaceutical industry be pfizer inc pfe free report hold zack rank buy see complete list today zack rank strong buy stock here be bmy go predict see other think downwall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2038,PFE,fda have propose new guideline be aim lower clinical study goal alzheimer disease drug treat earlier stage patient have not yet display functional disability clinical abnormality strategy part fda ongoing effort expand access safe effective treatment option many serious condition suggest agency be open accelerate approval process such drug fda propose guideline come week major disappointment field be announce company develop drug treat deadly brain disease earlier week merck mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely biogen biib free report also announce have decide increase number patient enrolment study be conduct crucial alzheimer disease candidate aducanumab raise concern regard chance success treatment december biogen alzheimer disease study candidate ban fail show early positive result raise investor concern candidate chance success alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function already be lose make develop drug treat disease difficult note several company have fail regard last month pfizer pfe free report reportedly announce termination effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch fda latest effort reinvigorate research effort alzheimer drug repeat failure wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2039,PFE,exelixis inc exel free report announce encourage result phase ii investigator sponsored trial cabozantinib first line treatment metastatic radioiodine rai refractory differentiate thyroid carcinoma dtc trial be be conduct center rare cancer personalize therapy abramson cancer center university pennsylvania enrollment trial be complete august patient be enrolled single arm open label trial be administer oral cabozantinib mg once daily trial enrolled metastatic rai refractory dtc patient primary endpoint trial be objective response rate partial response be achieve patient stable disease be report patient recist however evaluate patient experience decrease tumor target lesion secondary endpoint trial include progression free survival pfs time progression ttp duration response clinical benefit rate cbr defined number patient achieve objective response stable disease least month cbr month be median follow study week median pfs have not be reach median ttp patient progressed be week exelixis plan initiate pivotal phase iii study cabozantinib patient advanced dtc later base abovemention result datum other study cabozantinib previously treat dtc exelixis stock have rally year industry decline note exelixis lead product cometriq capsule form cabozantinib be approve unite state treatment progressive metastatic medullary thyroid cancer mtc april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand drug demonstrated statistically significant clinically meaningful improvement pfs versus current standard care pfizer pfe free report sutent meanwhile exelixis be develop cabozantinib broad development program comprise clinical study multiple indication celestial study advanced hepatocellular carcinoma be also ongoing exelixis also announce collaboration agreement bristol myer squibb bmy free report roche rhhby free report development cabozantinib combination immunotherapy agent early zack rankexelixis carry zack rank buy see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2040,PFE,pfizer inc pfe free report announce positive outcome fda drug advisory committee gidac meeting discuss company supplemental new drug application snda look label expansion xeljanz tofacitinib pfizer be seek get xeljanz approve treatment adult patient moderately severely active ulcerative colitis uc xeljanz janus kinase jak inhibitor be already approve treat rheumatoid arthritis active psoriatic arthritis supplemental new drug application snda xeljanz be currently review fda share pfizer be past year compare increase industry belong gidac give vote voting question related use mg twice daily bid dose week induction period snda include propose dose regimen xeljanz mg twice daily bid week induction follow dose mg bid maintenance also propose extension use tofacitinib mg bid week induction adult patient have not achieve adequate therapeutic benefit week also mg bid maintenance therapy patient inadequate response loss response intolerance tnf blocker therapy mg bid vote unanimously proposal however committee vote conduct post marketing efficacy study compare tofacitinib mg bid continuous dose regimen regimen tofacitinib mg bid induction mg bid maintenance uc population recommendation give gidac be not bound fda decision not approve tofacitinib uc be expect june pfizer inc price pfizer inc price pfizer inc quotezack rank other stock considerpfizer carry zack rank buy other top rank stock same space be regeneron regn free report ligand pharmaceutical lgnd free report enanta pharma enta free report regeneron ligand sport zack rank strong buy enanta pharma carry zack rank see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year enanta pharma deliver positive earning surprise last quarters average beat company share surge year don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2041,PFE,merck co inc mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely apecs be phase iii study evaluate efficacy safety verubecestat oral amyloid precursor protein site cleave enzyme bace inhibitor versus placebo study be stop recommendation external datum monitoring committee assessed study overall benefit risk recent interim safety analysis committee say chance observe positive risk benefit profile study continue be slim share merck decline almost tuesday past year merck share have underperform industry merck share have decline period increase industry february last year merck have discontinue study epoch phase ii iii verubecestat be evaluate mild moderate alzheimer disease due lack efficacy time committee have recommend apecs study continue unchanged alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge note several company have fail regard last month pfizer pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study december biogen biib free report announce alzheimer disease study ban fail show early positive result raise investor concern candidate chance success november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch merck carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2042,PFE,market have be extremely volatile lately owing multitude factor include rate hike fear risk potential trade war particular segment market have be attract investor attention last few year be socially responsible investing segment etfs allow invest line principle contribute make world better place own small way read etfs be impact potential trade war china investing separate stock feel be commensurate principle be difficult also maintain diversify portfolio here etfs come rescue offer diversify portfolio stock focuse particular screen environmental social governance esg related issue gender equality have be top trend so far increase focus disparity pay man woman investing company have better standing regard gender equity have be gain popularity instance hsbc reveal gender pay gap even hsbc uk workforce comprise woman moreover mere occupy senior role bank area attract investor attention be clean energy president donald trump decide leave paris climate accord last year multiple critic have argue need shift cleaner energy reduce fossil fuel consumption be multiple way gain exposure principle investing directly fund have portfolio stock involved clean energy investing fund have portfolio stock try save energy reduce carbon emission day day operation latest trend sustainable investing enthusiast be need steer clear weapon company school shooting stoneman dougla high school february incident la vegas music festival argument gun law impose stricter rule regard gun sale have pan therefore fund refrain investing company involved weapon have catch investor attention current scenario believe be prudent discuss follow etfs focus provide exposure sustainable investing theme ishare msci kld social etf dsi free report etf offer exposure stock exhibit positive esg characteristic refrain investing company involved weapon tobacco alcohol fund have aum charge fee basis point year sector look information technology health care consumer discretionary have highest exposure fund allocation respectively fund have exposure microsoft corp msft free report facebook inc fb free report alphabet inc class googl free report fund have return year year date spdr ssga gender diversity index etf etf offer exposure company have better structure term woman occupy senior role compare peer fund have aum charge fee basis point year sector look information technology health care consumer staple have highest exposure fund allocation respectively fund have exposure pfizer inc pfe free report coca cola company ko free report mastercard incorporate class fund have return year year date first trust nasdaq clean edge green energy index fund qcln free report fund be most popular bet clean energy segment have aum charge fee basis point year sector look semiconductor renewable energy equipment electrical component equipment have highest exposure fund allocation respectively fund have exposure semiconductor corporation albemarle corporation alb free report tesla inc tsla free report fund have return year year date spdr msci acwi low carbon target etf lowc free report fund bet company try save energy reduce carbon emission operation have aum charge fee basis point year sector look financial information technology industrial have highest exposure fund allocation respectively fund have exposure apple inc aapl free report microsoft corp amazon com inc amzn free report fund have return year year date want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2043,PFE,merck co inc mrk free report announce committee medicinal product veterinary use cvmp have recommend marketing authorization europe bravecto spot combination topical solution fluralaner moxidectin cat bravecto be part company animal health unit company share be so far year industry gain period veterinary medicinal product approval be used treatment internal external parasite infestation tick flea heartworm roundworm hookworm cat drug start kill activity tick flea immediately continue week prevent heartworm disease week bravecto be first approve chewable tablet formulation dog spot version be launch topical solution dog cat unite state bravecto be major growth driver animal health unit due rise demand formulation bravecto be ultimately approve eu sale product increase further however product company animal health unit face competition product other company zoetis inc zts free report eli lilly company lly free report elanco generic product merck co inc price merck co inc price merck co inc quotezack rank stock considermerck currently carry zack rank hold pfizer inc pfe free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here pfizer earning estimate increase last day company deliver positive earning surprise trail quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2044,PFE,glaxosmithkline plc gsk free report focus core business pharmaceutical vaccine consumer healthcare glaxo enjoy strong fundamental form diversify base presence different geographical area uk base company reshape business follow completion part conditional transaction novartis nvs free report march deal glaxo sell oncology asset novartis acquire novartis vaccine business exclude influenza vaccine here be reason invest stock year good rank solid vgm score glaxo carry zack rank buy favorable vgm score back test result show stock vgm score combine zack rank strong buy offer best upside potential see complete list today zack rank stock here rise share price estimate underperform broader industry glaxo share have picked year glaxo stock have rise year so far compare favorably flat trajectory industry meanwhile estimate rise respectively past day pharma giant have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise new drug vaccine do well glaxo newer respiratory hiv drug vaccine be do well continue boost revenue new product generate glaxo pharmaceutical vaccine sale continue boost revenue significantly glaxo have expect new pharmaceutical vaccine product include contribution shingrix deliver sale annum however product almost reach target significant progress pipeline glaxo have make significant progress late stage pipeline glaxo receive approval key new drug shingrix vaccine shingle enjoy preferential recommendation acip trelegy ellipta provide medicine single inhaler treat copd juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv back back approval new product have strengthen glaxo competitive position juluca have be develop glaxo partner pfizer inc pfe free report hiv focuse company viiv healthcare partnership johnson johnson jnj free report glaxo be also work expand label market product nucala additional face share challenge stiff competition genericization pricing pressure slow growth emerge market meanwhile top selling respiratory product advair be also expect face generic competition unite state year hurt sale however look glaxo strong pipeline consistent outperformance new hiv drug vaccine new product cost cut bring back track year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2045,PFE,pfizer inc pfe free report japanese partner astella announce fda have grant priority review supplemental new drug application snda prostate cancer drug xtandi pfizer be look expand label xtandi include early stage patient population fda grant priority review decision be expect july pfizer also say european medicine agency ema have validate similar label expansion application europe share pfizer have return so far year almost line increase industry regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result theprosper study xtandi detailed datum phase iii prosper study xtandi show treatment combination xtandi enzalutamide androgen deprivation therapy adt reduce risk metastase death compare adt alone man metastatic crpc double blind study median metastasis free survival mfs primary endpoint be month xtandi adt versus month adt alone remind investor top line datum prosper study be present pfizer astella september many prostate cancer patient metastatic crpc earlier stage prostate cancer experience disease progression adt however presently fda approve treatment option be available cater patient develop metastatic disease cancer spread other part body xtandi be presently approve treatment metastatic crpc patient have previously receive docetaxel approve metastatic patient population label xtandi be expand cover patient crpc xtandi be add pfizer portfolio acquisition medivation september pfizer sell xtandi unite state partnership astella latter own marketing right outside market pfizer record xtandi alliance revenue zack rank other stock considerpfizer carry zack rank buy see complete list today zack rank strong buy stock here other large cap pharma stock worth consider be lundbeck hluyy free report glaxo gsk free report roche rhhby free report same zack rank pfizer share lundbeck have return year so far estimate have increase past day glaxo share be year so far past day earning estimate have rise respectively past day roche earning estimate have rise respectively today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2046,PFE,johnson johnson jnj free report announce have receive bound offer approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year stock have decline year so far compare unfavorably gain record industry have time jun offer fail expire accept offer transaction be expect close end year sale diabetes care franchise decline due price decline competitive pressure have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year fact october announce close operation corporation diabetes care unit exit insulin pump business stop manufacturing vibe onetouch ping insulin pump say deal medical device maker medtronic inc mdt free report patient used insulin pump be offer option transfer medtronic pump carry zack rank hold better rank large cap pharma stock include abbvie inc abbv free report pfizer inc pfe free report zack rank buy see complete list today zack rank strong buy stock here abbvie earning share estimate have moved almost last day share company have shot year pfizer earning share estimate have moved last day share price company have increase past year more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2047,PFE,astrazeneca azn free report announce have secure fda approval label expansion market drug tagrisso osimertinib first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation notably tagrisso be approve unite state european union japan china second line treatment patient advanced nsclc show progress follow treatment egfr tki due egfr resistance mutation share astrazeneca have outperformed industry year date stock have gain versus industry decline remind investor last december fda accept grant priority review company supplemental new drug application snda tagrisso aforementioned indication fda nod be base positive datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum trial show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience importantly similar application tagrisso label expansion be review eu well japan decision expect second half tagrisso register sale reflect growth year period accounting total sale potential approval first line set further boost drug prospect however lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug dacomitinib phase iii study first line treatment indication moreover bristol myer squibb bmy free report be develop opdivo treatment nsclc astrazeneca too have iressa approve treat nsclc be also develop imfinzi same indication astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here note be reissue article correct inaccuracy original version publish april longer be rely hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2048,PFE,equity market be face widespread volatility thank trade negotiation recent geopolitical risk owing strike syrian chemical facility market shrug fear stem syrium attack propose sanction russia earning season be underway long term impact such factor increase appeal dividend investing read stock etfs juicy dividend yield headline market turbulence have bring portfolio reallocation back play tension washington beij have be bother market quite time now talk negotiation have be do round nothing be say certain sail market volatility allocate portion portfolio safe dividend fund seem judicious option read etfs buy trade war fear abate moreover recent chemical attack syrium have increase tension pertain russia relation recent missile strike syrian chemical plant lead coalition france have complicate situation anatoly antonov russia ambassador unite state tell wall street journal warn such action not be left consequence responsibility rest washington london paris insult president russia be unacceptable inadmissible event response russia iran syrium market take hit actual war concern instead only trade war odd happen be low be advisable safeguard portfolio such severe event be such volatile time be difficult beat algorithmic trading outlet be programme start selling merely read news headline indicate adverse event move interest rate cme fed watch tool currently forecast more rate hike many analyst believe have already be price wall street such scenario dividend pay security provide consistent income investor uniqueness security be increase return political uncertainty weigh market more so apart high dividend security exhibit low volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield vanguard dividend appreciation etf vig free report fund seek provide exposure company offer high dividend have aum charge fee basis point year sector look fund have high exposure industrial consumer service health care allocation respectively fund top holding be walmart wmt free report johnson johnson jnj free report microsoft corp msft free report allocation respectively fund have return year year date have dividend yield have garner inflow first week april etf com datum vanguard high dividend yield etf vym free report fund seek provide exposure large establish company provide high dividend have aum charge fee basis point year sector look fund have high exposure information technology financial health care allocation respectively fund top holding be microsoft corp jp morgan chase co jpm free report johnson johnson allocation respectively have return year have lose year date have dividend yield have garner inflow first week april etf com datum schwab dividend equity etf schd free report fund seek provide cheap exposure company pay high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively fund top holding be exxon mobil corp xom free report intel corp intc free report pfizer inc pfe free report allocation respectively fund have return year have lose year date have dividend yield have garner inflow first week april etf com datum want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2049,PFE,first quarter earning season have just kick latest earning preview bottom line company be expect increase highly impressive rate year year basis prospective upside mark maximum quarterly earning growth pace year report further predict zack sector be project exhibit double digit earning growth be report quarter total revenue same set company be project grow however focuse attention large cap pharma medical drug sector note sector have decrease respectively february year due broader market pressure further index have register decline second month remind investor stock market be face severe volatility last couple month strong start year downside mainly be attributable potentially damage trade war world largest economy unite state china february president donald trump announce plan impose tariff annual chinese import china retaliate notify intention levy tariff product such aggressive exchange have trigger tension possible trade dispute country moreover sluggish large cap tech stock be cite reason plummet market recent market unrest optimistic sentiment revolve remain year notably biotech sector be likely improve year advance expect new product sale thrive tandem rise demand apart successful innovation host product launch strong clinical study outcome more frequent fda nod solid performance key product grow demand drug especially deal rare treat disease agee population escalate healthcare expenditure be factor keep sector stable see complete list today zack rank stock here be important note outlook upcoming first quarter result look bright earning preview broader medical sector inclusive drug biotech well medical device company be expect record year year growth revenue rise earning pick potential winnersgiven enormity healthcare space task select stock possibility beat estimate appear quite daunting zack proprietary methodology make job fairly simple way carve top choice report cycle be look stock combination favorable zack rank zack rank strong buy buy hold positive earning esp be observed positive earning surprise deliver company mostly lead stock price appreciation well research quantitative model earning esp be used identify stock higher chance pull positive surprise impending earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter proven methodology cull stock large cap pharma medical drug sector poise surpass estimate be report quarter large cap stock be follow first pick be abbvie inc abbv free report north chicago il base company have earning esp zack rank stock have see zack consensus estimate first quarter earning be peg share company boast encourage earning track record exceed expectation last quarters average beat abbvie be schedule report earning number apr next choice be eli lilly company lly free report stock have earning esp zack rank consensus mark first quarter earning stand share headquarter indianapoli lilly have excellent positive earning surprise history company average beat trail quarters be lilly be slate announce result apr pfizer inc pfe free report too have please earning profile company have consistently outpaced expectation last quarters average beat look perfectly poise repeat winning streak time well new york base player be zack rank have earning esp consensus mark first quarter bottom line be peg cent share pfizer be schedule release financial figure give be medical drug stock first pick medical drug sector be catalent inc ctlt free report new jersey base company have earning esp zack rank zack consensus estimate first quarter earning be peg cent share company flaunt positive earning surprise record outshine expectation last quarters average beat catalent be expect report earning next choice be aratana therapeutic inc petx free report stock have earning esp be rank player consensus mark first quarter loss stand cent share base kansa aratana have outstanding earning history consecutive estimate beat trail quarters average be company be slate announce result investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2050,PFE,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2051,PFE,pass new tax bill corporate tax rate have come be likely boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location time tax rate leave company extra spending power most big pharma company discuss plan use extra cash save new tax bill fourth quarter conference call extra cash mostly be invest capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback however majority company do not mention effort regard lower prescription drug cost last week senator tina letter big pharma company expressed concern big pharma company plan used billion dollar save tax cut offer tax bill pass december be concern fact company be favore investor instead used saving bring prescription drug cost major life save drug be protected patent be steeply price thus make drug affordable help consumer lower medical cost senator have send letter ceo pfizer inc pfe free report merck co inc mrk free report johnson johnson jnj free report abbvie inc abbv free report abbott laboratory free report provide detail intend utilize major saving tax overhaul price major prescription drug have sky-rocket past year pinch hard citizen medical bill have soar moreover government also have pay higher cost drug be cover medicare concern senator be thus justified move restrict use tax saving boost shareholder be welcome move consumer moreover large player other industry have similar plan have undercut president donald trump plan create job boost wage senator be also work make cheaper generic drug available market faster introduce new legislation report kdal large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returndon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2052,PFE,combine ignorance leverage get pretty interesting result warren buffettindeed complex world investment understand amount financial leverage company bear be crucial theory cost capital company capital structure reflect mix debt equity be used finance capital project now comparative analysis same theory reveal most company prefer debt financing equity debt be cheaper especially period low interest rate moreover company opt equity financing shareholder not only become partial owner company develop direct claim company future profit well perk debt financing be interest debt be tax deductible however give uncertainty surround economy recent time be fully sure company perform next day company bearing large amount debt be more prone financial crisis especially time high interest rate federal reserve set raise interest rate unite state thrice market scenario do not seem be much favor company opt debt financing say investor real challenge be determine stock be investing have sustainable debt level debt free corporation be rare find be concept leverage come leverage simply indicate level debt corporation carry present historically several leverage ratio have emerge efficient tool evaluate company credit level support prudent equity investment most popular be debt equity ratio analyze debt equitydebt equity ratio total liability shareholder metric be liquidity ratio indicate amount financial risk company bear company lower debt equity ratio imply have more less financially stable business thereby make better investment pick company reflect high earning growth be ideal investment choice high leverage not generate satisfactory return so company low leverage instead high earning be perfect choice valentine day winning aforementioned factor be wise choose stock low debt equity ratio ensure safe return however investment strategy base solely debt equity ratio not fetch desire outcome choose stock have potential give steady return have expand screening criterium include other factor here be other parameter debt equity less industry median stock be less leverage industry peer current price greater equal stock be trading minimum average day volume greater equal substantial trading volume ensure stock be easily tradable percentage change ep greater industry median earning growth add optimism lead stock price appreciation estimate year ep growth greater show earning growth expectation zack rank strong buy buy irrespective market condition stock zack rank have proven history success vgm score research show stock vgm score combine zack rank offer best upside potential exclude stock have negative debt equity ratio here be stock make screen mgic investment mtg free report company be lead provider private mortgage insurance coverage unite state home mortgage lend industry pull average positive earning surprise trail quarters carry zack rank hancock hold company operate banking office automate teller machine state mississippi louisiana company carry zack rank have deliver average positive earning surprise trail quarters pfizer pfe free report be research base global pharmaceutical company discover develop manufacture market medicine human animal company pull positive earning surprise trail quarters carry zack rank see complete list today zack rank stock here universal health service uhs free report be nation largest most respect healthcare management company company carry zack rank boast solid long term earning growth rate dmc global boom free report be diversify technology company company sport zack rank have deliver average positive earning surprise trail quarters get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2053,PFE,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse joint venture company viiv healthcare have initiate phase iii program evaluate drug hiv regimen dolutegravir tivicay lamivudine epivir study evaluate drug regimen maintenance viral suppression achieve hiv infected patient drug regimen tenofovir alafenamide fumarate taf base regimen remind investor glaxo be also evaluate drug base regimen cabotegravir johnson johnson jnj free report rilpivirine phase iii study treat adult virally suppress hiv infection moreover company be also evaluate cabotegravir monotherapy prevention hiv infection sexually active woman hiv treatment generally be drug base regimen latest entrant market be gilead science inc gild free report once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide approve earlier month however glaxo be try reduce number medicine hic treatment regimen compromise efficacy conventional drug regimenshare glaxosmithkline have underperform industry so far year stock have lose industry rally period phase iii tango study investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week compare continuation taf base regimen study also evaluate long term antiviral activity tolerability safety combination therapy week glaxo be also evaluate combination regimen gemini study patient hiv have receive prior treatment datum gemini tango study be anticipate note glaxo newest hiv medicine juluca be single tablet contain dolutegravir rilpivirine juluca be first drug regimen approve fda meanwhile several company interested develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2054,PFE,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put pfizer inc pfe free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front pfizer have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend pfizer current pe level put almost line midpoint past year further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point pfizer have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead pfizer stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now pfizer have ratio be higher average come right now also see chart be just slightly high stock particular past few year anything pfizer be higher end range time period metric suggest company stock price have already appreciate degree relative sale broad value outlookin aggregate pfizer currently have zack value style score putt top stock cover look make pfizer solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be better industry average ratio be generally apply find company stock be overpriced underpriced reference cash flow generation potential compare competitor stock overall pfizer be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give pfe zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be quite encourage current year have see estimate go higher past day compare none lower next year estimate have see upward downward revision same time period result current year consensus estimate have rise past month next year estimate have increase see consensus estimate trend recent price action stock chart pfizer inc price consensus pfizer inc price consensus pfizer inc bullish trend be stock have zack rank buy be expect outperformance company term bottom linepfizer be inspire choice value investor be hard beat incredible lineup statistic front furthermore robust industry rank top solid zack rank instill investor confidence however be hard get too excited company overall past year industry have underperform broader market see poor past performance industry good industry rank signal stock be likely benefit favorable broader factor immediate future add positive estimate revision robust value metric believe have strong value contender pfizer more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2055,PFE,dow traverse difficult week decline consecutive trading session investor remain concern prospect trade war follow president trump decision impose tariff steel aluminum import trump decision dismiss secretary state rex tillerson add investor jitter ultimately investor look pick blue chip stock dip help index finish green thursday last week dow increase last friday move past mark first time feb upbeat job datum lower wage growth subdue inflationary concern curb rate hike fear economy add job february exceed consensus estimate job addition however average hourly wage rise only february lower january increase index gain last week president trump sign tariff plan law fresh levy steel import aluminum import be impose however plan exclude country canada mexico offer trump chance renegotiate term nafta country also unite state want discuss national security issue country dow index decline monday investor remain concern prospect trade war follow trump decision impose tariff steel aluminum fear nature drag industrial lower session decline weigh broader market dow component sector unite technology corporation utx free report company mmm free report boee company ba free report decline respectively index lose tuesday trump administration dismiss secretary state rex tillerson additionally trump order broadcom inc avgo free report abandon plan takeover qualcomm incorporate qcom free report follow share qualcomm decline weigh broader market meanwhile consumer price index cpi increase february line consensus estimate figure be lower january increase development significantly reduce rate hike fear index decrease wednesday end red third consecutive trading day follow concern possible trade war china hostile move china jeopardize boee performance be share fall weigh dow register day decline point share decline index rebound thursday increase special counsel robert mueller reportedly subpoena trump organization trump business related document factor trade war fear weigh investor sentiment however dow manage post day rise point investor indulge bargain hunting seek blue chip stock dip dow component unitedhealth group incorporate unh free report increase be biggest contributor blue chip index gain day component move index apple inc aapl free report be likely come new version io maco annual worldwide developer conference wwdc set begin jun company announce session involve technical design focuse session present zack rank hold apple engineer help build next generation apps used newly announce apple technology apart software announcement company well make big announcement related hardware apple keep sale be now rumore launch variant iphone notably company be also rumore be work new high end noise cancele ear headphone upgrade version airpod advanced siri integration next generation smart speaker homepod face id technology read apple announce wwdc date expectation rise boee lockheed martin corp lmt free report joint venture unite launch alliance ula subsidiary have secure contract satellite launch service term unite launch service llc ul subsidiary deliver afspc afspc satellite intend orbit award contract division launch system enterprise directorate space missile system center los angele air force base be value modification contract ul carry launch vehicle production mission integration launch operation spaceflight certification afspc afspc mission operation be complete march deliver afspc satellite afspc satellite be deliver post completion operation june stock have zack rank strong buy see complete list today zack rank strong buy stock here chevron corporation cvx free report phillip psx free report joint venture jv chevron phillip chemical company lp recently announce be ready put new ethane cracker locate cedar facility baytown tx work get delay due hurricane harvey chevron have zack rank company launch feedstock start operation new cracker be primarily schedule come online end company new facility most energy efficient cracker have production capacity metric ton annum new ethane cracker construction be start completion mark finishing final phase company gulf coast petrochemical project facility be expect increase company ethylene polyethylene production capacity read chevron phillip bring new ethane cracker texas online merck co inc mrk free report announce supplemental biologic license application sbla pd therapy keytruda have be accept priority review fda latest application zack rank merck be look expand label keytruda treatment advanced cervical cancer disease progression chemotherapy fda grant priority review decision be expect jun be first time fda have accept filing pd therapy cervical cancer meanwhile be fourteenth regulatory submission keytruda accept fda sbla be base part datum phase ii keynote study read merck keytruda get priority review cervical cancer pfizer inc pfe free report announce positive outcome fda drug advisory committee gidac meeting discuss company supplemental new drug application snda look label expansion xeljanz tofacitinib zack rank buy pfizer be seek get xeljanz approve treatment adult patient moderately severely active ulcerative colitis uc xeljanz janus kinase jak inhibitor be already approve treat rheumatoid arthritis active psoriatic arthritis supplemental new drug application snda xeljanz be currently review fda read pfizer get fda panel back new indication xeljanz walmart inc wmt have expand online grocery delivery service more metro region unite state announcement follow recent launch various kitchen product meal kit expansion strategy enable zack rank walmart reach nearly nation household end year currently service be available market initiative be expect provide consumer more accessibility walmart flourishing online grocery delivery service read walmart strengthen grocery delivery plan expansion performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlookmarket be pass difficult time primarily due development related trump administration president trump have fire several key official recently add atmosphere uncertainty instability meanwhile decision impose tariff pronouncement china have weigh big industrial name give backdrop investor look likely look key economic release such gdp report comfort next week more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2056,PFE,novartis ag nvs free report be schedule report first quarter result apr swiss pharmaceutical company stock have rally last month compare industry gain novartis have excellent track record last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent result novartis provide guidance novartis expect net sale grow low mid single digit novartis operate segment innovative medicine pharmaceutical alcon sandoz generic innovative medicine be project grow mid single digit revenue sandoz be expect be broadly line decline slightly alcon sale be estimate grow low mid single digit innovative medicine division record sale combat generic pricing pressure novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya continue drive top line psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio launch rixathon biosimilar version roche rhhby free report rituxan rituximab erelzi biosimilar amgen amgn free report enbrel eu have boost company portfolio however sale division be project decline due continue industry wide pricing pressure unite state meanwhile loss exclusivity key drug novartis portfolio continue hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu further oncology drug be face new competition form immuno oncology therapy ophthalmology division alcon be struggle consequently novartis take few step revive business turnaround have be encourage management believe create standalone company capital market exit create additional shareholder value decision be expect first half depend alcon performance future earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price consensus ep surprise novartis ag price consensus ep surprise novartis ag quote stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter pfizer inc pfe free report have earning esp zack rank company be schedule release first quarter result see complete list today zack rank stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2057,PFE,bond yield be scaling record high expectation hike interest rate year budget deal declare top senator strengthen economy give federal reserve enough reason raise rate pick wage spark fear inflation bolster expectation fed take more aggressive stance hike rate forget soft treasury auction feb drag bond price help yield move rise bond yield rattle equity market result lot gyration not bond yield rise increase opportunity cost investing other asset class such equity thus make less attractive give such uncertain time investor select safest stock particularly be sound enough withstand intensify volatility market stock finish lower bond yield stock market be roller coaster week major bourse largely finished red feb current level stand nearly last month record high dow shed point broader slide point cboe volatility index vix wall street so call fear gauge meantime remain read mark indicate bearish outlook equity market be sharp contrast fear gauge read last year vix fall low stock struggle direction marked comeback once dormant volatility treasury yield continue scale record high year treasury note yield be basis point follow decline earlier week year treasury note rise basis point register largest day gain oct similarly year rate jump basis point highest level march drive treasurys treasury yield moved north congressional leader strike year bipartisan budget deal boost expectation stronger economy turn bolster possibility imminent rate hike eventually lead higher bond yield fact record rise wage growth spark fear inflation lead investor believe fed hike rate more time anticipate bipartisan budget dealu senate leader reach deal raise federal spending almost address kind fiscal issue have be plague washington year have agree lift cap defense funding domestic government outlay defense budget be raise funding domestic program be hike congress have time again vote raise budget cap earlier have be bipartisan deal uplift cap billion dollar first be forge paulryan patty murray second be sign however deal have extend fiscal have expire wage see fastest growth labor market have come long way great recession wage grow fastest pace january more half year average hourly wage increase cent help average year year hourly earning rise highest june needless say several state have raise wage minimum wage have be raise state january have positive impact worker economic policy institute spike bond yield halter market rally major selling point equity financial crisis have be rise bond yield investor always compare yield equity fix income case equity earning be largely consider yield share stock thus current rise bond yield have make more alluring compelling investor pull money stock moreover value future earning go interest rate go higher interest rate affect almost everything mortgage auto loan purchasing house become expensive credit card bite become harder turn lead recession end year old bull market best screening parameter widespread uncertaintyas equity market fret rise yield make sure pick safe investment general look company be unperturbed wavering market condition best way go do be create portfolio low beta stock be inherently less volatile market trade case low beta range stock also have good position market pay part earning shareholder dividend dividend payer boast solid financial structure be immune market vagary further be position grow term be economically price top safe stock buywe have thus select stock flaunt aforesaid virtue solid zack rank buy see complete list today zack rank strong buy stock here inc free report provide software solution help organization plan develop manage secure application enterprise environment unite state internationally have beta company have dividend yield year average dividend yield be forward price earning ratio current financial year be lower industry average stock be part transportation air freight cargo industry be expect give solid return almost current quarter year respectively quest diagnostic incorporate dgx free report provide diagnostic testing information service unite state internationally have beta company have dividend yield year average dividend yield be forward price earning ratio current financial year be lower industry average stock be part medical outpatient home healthcare industry be expect give steady return current quarter year respectively pfizer inc pfe free report discover develop manufacture sell healthcare product worldwide company have beta have dividend yield year average dividend yield be forward price earning ratio current financial year be lower industry average stock be part large cap pharmaceutical industry be expect give positive return unite parcel service inc up free report package delivery company provide transportation logistic financial service unite state internationally have beta company have dividend yield year average dividend yield be forward price earning ratio current financial year be lower industry average stock be part transportation air freight cargo industry be expect give solid return nearly current quarter year respectively bancorp usb free report financial service hold company provide range financial service unite state company have beta jt have dividend yield year average dividend yield be forward price earning ratio current financial year be slightly lower industry average stock be part bank major regional industry be expect give steady return current quarter year respectively make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2058,PFE,pfizer inc pfe free report japanese partnerastella pharma inc announce detailed result late stage study expand label prostate cancer drug xtandi include early stage patient detailed datum phase iii prosper study xtandi show treatment combination xtandi enzalutamide androgen deprivation therapy adt reduce risk metastase death compare adt alone man castration resistant metastatic prostate cancer crpc double blind study median metastasis free survival mfs primary endpoint be month xtandi adt versus month adt alone remind investor top line datum prosper study be present pfizer astella september base result study company make regulatory filing unite state eu prosper study also investigate time prostate specific antigen psa progression time first use new antineoplastic therapy overall survival key secondary endpoint be reduction risk psa progression xtandi arm compare adt alone median time psa progression xtandi group be month compare month adt alone many prostate cancer patient metastatic crpc earlier stage prostate cancer experience disease progression adt however presently fda approve treatment option be available cater patient develop metastatic disease xtandi be presently approve treatment metastatic crpc patient have previously receive docetaxel approve metastatic patient population label xtandi be expand cover patient crpc pfizer share have underperform industry year stock have return period compare unfavorably increase industry xtandi be add pfizer portfolio acquisition medivation september pfizer sell xtandi unite state partnership astella latter own marketing right outside market pfizer record xtandi alliance revenue pfizer inc price pfizer inc price pfizer inc quote zack rank other stock considerpfizer carry zack rank buy other top rank stock health care space be xoma corp xoma free report exelixis exel free report sucampo carry zack rank see complete list today zack rank strong buy stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company surge year xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company sky-rocket year sucampo deliver positive earning surprise last quarters average beat share price company surge year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2059,PFE,be approach end first quarter let ass quarter unfold drug biotech sector year begin strong note drug biotech sector particularly expectation increase activity sanofi sny free report celgene celg free report have already announce deal also pfizer pfe free report be aggressively lookout buyer consumer healthcare unit british firm glaxo gsk free report reckitt benckiser group pull discussion solid run first month first quarter drug biotech sector struggle march probably broader market pressure few negative update pipeline regulatory front large cap pharma industry have decline year so far biotech industry have decline same time frame have underperform fall same time frame however please note first month year sector record gain so do however decline month march put break momentum abbvie rova fall short expectation key lung cancer study dermira acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint study celgene be issue refusal file letter fda ozanimod multiple sclerosis nda biogen partner abbvie announce voluntary decision withdraw multiple sclerosis drug zinbryta worldwide market due risk liver injury orexigen therapeutic meanwhile file bankruptcy solid bioscience mid stage study lead duchenne muscular dystrophy candidate sgt be put clinical hold protagonist therapeutic announce discontinuation mid stage study key ulcerative colitis treatment be recovery card be widely expect biotech drug sector rebound year progress believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit outlook optimistic rest year here highlight stock prove be good buy stock carry zack rank strong buy buy have see share price earning estimate rise year see complete list today zack rank stock here glaxoafter underperform broader industry glaxo share have picked year glaxo stock have rise year so far meanwhile estimate rise respectively past day zack rank buy stock be expect record sale growth year next yearadverum biotechnology advm free report adverum biotechnology carry zack rank buy loss estimate company narrow last day sale growth year biotech stock be expect be adverum share have return year so far ligand pharmaceutical lgnd free report rank stock have rise year earning estimate rise respectively past day company be expect record sale growth year next year lundbeck hluyy free report year date basis lundbeck share have gain meanwhile earning estimate increase past day rank stock today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2060,PFE,new drug application nda pfizer pfe free report anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki candidate lorlatinib have be accept fda nda seek approval lorlatinib treatment patient alk positive metastatic small cell lung cancer nsclc have receive prior treatment more alk tkis nda have also be grant priority review decision be expect august similar application seek marketing authorization europe japan have also be accept regulatory agency respective country share pfizer be almost follow news stock have return past year underperform industry gain period pfizer submit regulatory application base positive datum phase ii portion phase ii study evaluate lorlatinib several cohort base prior therapy small cell lung cancer occur patient have lung cancer lead cause cancer death worldwide lung cancer be attractive avenue pharmaceutical company due widespread occurrence disease however be also most competitive space due presence large number player several large small company be develop have approve therapy treatment various form lung cancer remind investor last month merck mrk free report announce encourage result phase iii study evaluate pd therapy keytruda combination eli lilly lly free report alimta carboplatin nsclc also note roche rhhby free report recently present datum tecentriq novel combination broad range tumor include lung cancer blockbuster drug bristol myer opdivo be approve treat nsclc other pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2061,PFE,johnson johnson jnj free report subsidiary janssen announce fda have grant approval prostate cancer drug zytiga abiraterone acetate combination prednisone treat early stage prostate cancer notably zytiga be earlier approve unite state eu treat metastatic castration resistant prostate cancer mcrpc treatment experience patient chemotherapy contain docetaxel latest nod regulatory body drug label have be expand treat newly diagnosed patient metastatic high risk castration sensitive prostate cancer cspc zytiga be approve treatment newly diagnosed cspc patient eu november company also submit regulatory filing combination therapy japan canada mexico switzerland singapore philippine give indication share have outperformed industry year time stock have increase compare favorably industry rally fda approval expand patient population be support encourage datum pivotal phase iii latitude study evaluate zytiga prednisone combination cspc patient prior experience cytotoxic chemotherapy datum trial demonstrated statistically significant improvement overall survival give patient population combination regimen show reduction death risk compare placebo be important note zytiga be most important successful product company oncology portfolio drug sale surge fourth quarter owing improve share grow metastatic castration resistant prostate cancer market be highest prescribe oral medication unite state patient metastatic crpc approval combination therapy cspc patient population increase zytiga sale future quarters incidentally market drug cspc patient have receive docetaxel therapy be pfizer pfe free report japanese company astella pharma combine xtandi enzalutamide zytiga be face patent challenge unite state company anticipate impact generic competition drug year also be confident absorb effect potential zytiga headwind be earlier expect generic launch johnson johnson price johnson johnson price johnson johnson quote zack rank key picksj carry zack rank hold better rank stock health care sector be exelixis inc exel free report xoma corporation xoma free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have soar year time xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2062,PFE,total earning total healthcare market capitalization be revenue growth not only be growth rate impressive earning revenue beat ratio respectively be great too robust number have push healthcare stock higher average gain response earning announcement most notable player johnson johnson jnj free report be first major drug company report earning jan follow pfizer pfe free report eli lilly company lly free report jan jan respectively other major drug company merck mrk free report bristol myer squibb company bmy free report report feb feb respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson issue outlook earning share revenue read healthcare etfs focus post jnj result pfizer earning drug giant come earning revenue beat earning share cent come cent zack consensus estimate revenue be also ahead estimate annual basis earning share revenue rise respectively pfizer guide revenue range earning share merck earning focusmerck beat earning estimate miss revenue earning share come cent surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck issue revenue guidance earning share guidance bristol myer earning focusbristol myer top estimate front report earning share cent penny zack consensus estimate year earning cent revenue grow edge past zack consensus estimate company provide earning share guidance see healthcare etfs here eli lilly earning focuseli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly raise earning guidance maintain revenue outlook range etf pharma etfs see terrible trading past month latest global market rout string earning beat bolster confidence space compelling investor cash beaten price have highlighted detail fund have zack etf rank hold suggest room upside day ahead read inverse equity etfs bet historic selloff powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest more share bmy pfe jnj lly etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account least share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month read new pharma etf pill investor need know first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly makeup more ftxh have lower level aum share averaged daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2063,PFE,allergan plc agn free report announce fda have approve label expansion infective drug avycaz ceftazidime avibactam nod drug be now approve treatment patient hospital acquire bacterial pneumonia ventilator associate bacterial pneumonia habp vabp due gram negative bacterium approval mark third therapeutic indication drug unite state notably avycaz be market treatment complicate urinary tract infection cuti include pyelonephritis cause designate susceptible pathogen consist certain pseudomona aeruginosa avycaz be also indicated cure adult patient complicate intra abdominal infection ciai combination metronidazole remind investor company supplemental new drug application snda avycaz be accept fda priority review october base precede qualify infectious disease product designation aforementioned indication importantly avycaz be first gram negative antibiotic approve unite state treat habp vabp year allergan share have lose year time outperform industry decline approval be base inferiority datum pivotal phase iii reprove study evaluate safety efficacy avycaz adult patient habp vabp trial meet primary endpoint show drug be inferior meropenem broad spectrum antibiotic reduce death risk irrespective cause drug also show study controlled environment outside human body activity certain gram negative bacterium cause habp vabp significantly avycaz be jointly market allergan pfizer pfe free report allergan have right avycaz north america right rest world be own pfizer avycaz rake sale month end sep year figure fda approval expand patient population improve commercial potential company press release habp vabp be second most common type nosocomial hospital originated infection unite state mainly intensive care unit hence potential market opportunity avycaz be huge country apart avycaz allergan infective portfolio comprise antibiotic namely teflaro allergan plc price allergan plc price allergan plc quote zack rank key picksallergan carry zack rank sell better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company deliver positive surprise trail quarters average beat share price company have soar year time breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2064,PFE,dow experience mixed week lose momentum first few day rebound next bond yield spiked follow improve inflation rate hike prospect lead investor switch equity bond such expectation be heighten fed indicated rate hike march be more less certain financial blue chip gain result bullish earning number help index gain latter half week last week dow increase last friday follow better expect earning intel corporation intc additionally dow post rise more point meanwhile gdp increase seasonally adjust annual rate fourth quarter follow gain more previous quarters mark economy strongest stretch growth expansion start mid additionally week treasury secretary steven mnuchin say weakness dollar be beneficial trade ice dollar index fall week settle follow mnuchin comment index gain last week benchmark register fourth straight weekly increase senate give consent pass bill end recent government shutdown additionally encourage earning result traveler company inc trv free report company mmm free report caterpillar inc cat free report boost market dow index decrease monday suffering biggest day drop monday sep loss come follow shift investment equity bond treasury yield reach best level april expectation increase growth inflation boost yield year treasury note follow sector real estate utility be consider alternative bond decline share apple inc aapl free report fall news tech behemoth have decide halve production target iphone first month year index lose tuesday follow slump healthcare energy stock blue chip amazon com amzn free report berkshire hathaway inc brk free report jpmorgan chase co jpm free report announce together form healthcare company order cut related cost employee announcement weigh healthcare sector oil price fall tuesday shale production come barrel day highest level jan eia separately higher rate environment optimism steady economic growth higher inflation weigh bond price index increase wednesday straight day decline share boee company ba free report rise settle best level ever aircraft manufacturer post fourth quarter earning share revenue beat expectation turn boost key index meanwhile federal reserve opted leave benchmark rate unchanged range market lose gain fed state inflation be likely reach desire level medium term project gradual increase key rate index gain thursday even investor switch equity bond treasury bond yield continue hover best level april however rise rate hike prospect help financial blue chip goldman sachs group inc gs free report jpmorgan gain respectively turn boost dow component move index boee report adjust earning share fourth quarter beating zack consensus estimate bottom line reflect improvement year quarter upside be drive record delivery strong performance well favorable tax reform share company fourth quarter revenue amount beating zack consensus estimate top line also improve year year zack rank strong buy boee adjust core earning share expectation be range gaap earning be project range share company currently expect revenue range read boee top earning estimate issue guidance intel corp intc report fourth quarter gaap earning share beat zack consensus estimate cent figure surge year quarter sequentially adjust time tax expense result corporate tax reform gaap loss come cent share quarter revenue totale reflect increase year year quarter quarter figure beat zack consensus estimate adjust mcafee formerly intel security group transaction revenue increase stock have zack rank see complete list today zack rank stock here mcdonald corp mcd free report post robust result fourth quarter adjust earning share ep surpass consensus mark improve year quarter constant currency mcdonald have zack rank buy upside reflect stronger operate performance saving meanwhile foreign currency translation have positive impact cent share earning quarter notably adjust earning exclude impact net tax cost associate tax cut job act revenue beat consensus mark decline year year decline reflect impact company strategic refranchise initiative read mcdonald earning beat solid comp growth pfizer inc pfe free report report fourth quarter adjust earning share cent beat zack consensus estimate cent pharma heavyweight deliver revenue also beat zack consensus estimate pfizer have zack rank full year sale be flat year year operational basis sale marginally beat zack consensus estimate be line guidance range adjust earning share full year exceed zack consensus estimate well guide range read pfizer stock fall earning sale beat microsoft corp msft free report deliver second quarter fiscal earning cent share beat zack consensus estimate cent figure rally year year basis revenue increase almost year quarter constant currency cc further figure marginally exceed zack consensus estimate revenue be positively impact primarily due strategic growth investment cloud business artificial intelligence ai robust sale implementation third quarter fiscal zack rank hold microsoft expect foreign exchange increase revenue growth point cog growth point operate expense growth also point read microsoft surpass earning revenue apple report first quarter fiscal earning share beat zack consensus estimate cent increase almost year year sequentially earning jump net sale increase year year almost sequentially comfortably surpass zack consensus estimate zack rank apple benefit robust iphone service segment revenue growth however iphone unit sale miss zack consensus estimate apple service sale revenue also miss consensus estimate second quarter fiscal revenue be project zack consensus estimate be gross margin be expect operate expense be project read apple earning beat iphone unit sale visa inc post earning share soar past zack consensus estimate cent share adjust net income come quarter company see consolidated revenue figure just beating zack consensus estimate grow year year zack rank visa reaffirm financial outlook fiscal full year company expect net revenue growth high single digit annual operate margin high read visa post strong first quarter profit payment volume performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlooka strong fourth quarter performance have help market survive initial hiccup week loss be cause surge bond yield phenomenon be likely investor day ahead well however fed delineate plan fairly clearly market be likely price march rate hike term give such backdrop bullish earning strong economy market be likely notch fresh milestone day ahead wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2065,PFE,benchmark finished negative territory tuesday follow slump healthcare energy stock blue chip amazon berkshire jpmorgan announce together form healthcare company order cut related cost employee turn weigh healthcare sector additionally recent increase shale production lead energy stock downward moreover rise bond yield have broad base negative impact key index experience worst day performance august dow witness biggest day drop last benchmark fared dow jone industrial average dji decrease point close fall close tech laden nasdaq composite index close lose fear gauge cboe volatility index vix increase close highest level august total share be trade tuesday higher last session average share decliner outnumber advancer nyse ratio nasdaq ratio favore decline issue moved benchmark tuesday commerce giant amazon com amzn free report make announcement together berkshire hathaway inc brk free report jpmorgan chase jpm free report healthcare company be build order cut cost employee improve worker satisfaction goal partnership be create company sole intention provide healthcare workforce future entity not aim make profit read more follow development health care select sector spdr xlv fall become worst perform sector session sector witness highest day drop last october dow component unitedhealth group incorporate unh free report merck co inc mrk free report decrease respectively additionally earning front pfizer inc pfe free report report fourth quarter adjust earning share revenue beat respective zack consensus estimate however share pfizer fall pharma heavyweight expect adjust tax rate be higher investor anticipate read more oil price dip weigh energy stocksoil price fall tuesday shale production recently come barrel day highest level jan eia wti brent crude price decrease settle barrel barrel respectively decrease oil price have adverse impact energy select sector spdr xle slump become second worst perform sector key component include chevron corporation cvx free report exxon mobil corporation xom free report decline respectively energy giant possess zack rank hold see complete list today zack rank strong buy stock here separately higher rate environment optimism steady economic growth higher inflation weigh bond price lower bond price support year treasury yield increase tuesday reach highest settlement almost year higher treasury yield also weigh broader equity market stock make headlinesc robinson surpass earning revenue robinson worldwide inc chrw free report fourth quarter earning share revenue beat respective zack consensus estimate read more robert half earning sale top estimate yrobert half international inc rhi free report come solid fourth quarter result top bottom line come ahead zack consensus estimate read more hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2066,PFE,pfizer inc pfe free report zack rank buy be research base global pharmaceutical company discover develop manufacture market medicine human company diversify global healthcare portfolio include human animal biologic small molecule medicine vaccine well nutritional product consumer healthcare product sell product wholesaler distributor retailer hospital clinic government agency pharmacy individual provider office grocery convenience store most recent report quarter company easily beat zack consensus earning revenue estimate pfizer post year year gain revenue adjust income adjust diluted ep report also show company tax rate fall management approve share repurchase program further conference call management allude future consolidation segment several partnership company innovative business segment brand drug vaccine consumer health grow yoy direct sale revenue improve yoy big driver success innovative segment be eliquis oral anticoagulant prescribe cardiologist xeljanz used moderately severely active rheumatoid arthritis prevnar pneumonia vaccine look ahead legacy brand drug company have strong pipeline new product focuse oncology biosimilar generic drug most exciting new drug be ibrance new treatment breast cancer be expect generate almost annual sale end management approve increase quarterly dividend make new annual dividend annual yield pfizer have paid annual dividend have increase past consecutive year moreover company be expect use tax saving further increase share repurchase program boost dividend payment next several year strong earning report positive future outlook have cause analyst increase earning estimate next quarters next fiscal year see table delta air line inc dal free report zack rank strong buy be major american airline headquarters northern boundary hartsfield jackson atlanta international airport city limit atlanta delta start operation crop dust fly mail then introduce passenger service delta business be focuse make global connection fly person cargo unite state world delta air line offer customer service more destination global airline delta delta connection carrier service delta air line delta connection carrier offer service nearly destination continent delta have add more international capacity other airline combine be leader atlantic company most recent quarter beat zack consensus earning revenue estimate second consecutive quarter report show revenue be overall domestic total passenger improve cargo rise other revenue gain yoy earning share improve yoy big jump other revenue be due several key area club board sale administrative fee loyalty program ancillary business baggage fee refinery tailwind company be co brand partnership american express delta get interchange fee delta amex card portfolio realize charge ebit go delta be expect increase due contractual increase price mile delta get amex further whole partnership deal amex generate revenue be expect increase contract go look forward management guide ep range well previous guidance boost be mostly due tax reform plan be expect benefit ep management guide ep increase revenue available seat rasm expectation yoy rise rasm be due improvement leisure business travel increase ep guidance upgrade rasm expectation cause analyst positively revise estimate fy fy further stock price have continue move upwards begin see improvement price earning consensus graph price consensus price consensus quotedure december quarter company repurchase worth stock part share repurchase program announce march company also pay solid annual dividend yield hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2067,PFE,gilead science inc gild free report receive major boost fda approve company once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval come ahead pdufa date feb provide major boost gilead hiv franchise company top earning revenue estimate fourth quarter magnitude decline hcv sale be wider expect hcv franchise have be pressure due lower patient start increase competition form abbvie abbv free report company guidance also lack lustre expect sale same decline further such scenario approval latest triple hiv therapy be likely provide impetus stock gilead be now banking hiv franchise newer avenue car therapy post kite acquisition promising nash candidate growth follow news approval share company moved gilead stock have gain last month industry decline biktarvy gilead latest triple therapy be approve complete regimen treatment hiv infection adult have antiretroviral treatment history replace current antiretroviral regimen be virologically suppress hiv rna ml stable antiretroviral regimen least month history treatment failure know substitution associate resistance individual component biktarvy meanwhile hiv franchise continue gain traction back rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval biktarvy be support encourage datum ongoing study study treatment nave hiv infected adult study virologically suppress adult biktarvy meet primary objective inferiority week study however biktarvy have box warning product label regard risk post treatment acute exacerbation hepatitis approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq other hand report reuter viiv healthcare joint venture majority own glaxosmith pfizer pfe free report shionogi ltd have file lawsuit gilead allege patent infringement viiv dolutegravir component venture triple drug hiv treatment triumeq zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2068,PFE,momenta pharmaceutical inc mnta free report announce fda classify outcome fourth quarter reinspection pfizer inc pfe free report mcpherson facility voluntary action indicated vai glatopa mg ml be approve fda glatopa mg ml be first ap rate substitutable generic equivalent once daily copaxone generic be develop be be commercialize collaboration sandoz ag sandoz generic arm novartis pharma ag nvs free report collaboration agreement sandoz be responsible glatopa mg ml momenta earn contractually defined profit drug sale sandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer february be sandoz contract fill finish manufacturing partner glatopa anda glatopa remain regulatory review momenta believe application review be complete time connection change vai status news bring breath fresh air investor company share go momenta stock have lose year underperform industry rally nevertheless announce change compliance status mcpherson kansa facility amend vai momenta expect gain marketing approval subsequently launch glatopa mg first half momenta have have rough time mylan nv myl free report obtain fda approval generic version copaxone mg make first generic be approve be huge setback momenta mylan launch copaxone mg copaxone mg product company expect revenue glatopa be adversely impact due decline price volume moreover be additional pressure market customer switch mg product mg product company also suffer blow regard development biosimilar candidate candidate do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity reference drug orencia normal healthy volunteer hence momenta partner mylan evaluate next course action zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2069,PFE,stock market future be pretty deeply red morning average close main index roughly half percentage point however blame be place earning season continue bring robust result company spectrum industry asian market be slightly overnight later evening await president trump initial state union address later week begin tomorrow start see new datum january job number keep earning result here be leader respective space well have perform relative expectation particularly zack consensus estimate mcdonald mcd free report post strong quarterly number top bottom line ahead open bell today earning share easily outpaced expect revenue reach company ahead zack consensus beating estimate be nothing new mcdonald previous average positive earning surprise past quarters be quarter just report mcdonald benefit stronger comp year year more mcd earning click here big pharma player pfizer pfe free report also beat estimate earning revenue cent share sale top cent expect respectively earning growth year year be nice revenue be revenue guidance full year remain range current zack consensus estimate earning guidance share be ahead have earlier expect more pfe earning click here health insurance major aetna aet free report other hand post mixed result share surpass be look revenue lower expect further year enrollment be congress continue chip away affordable care act be good aetna previous quarters generate average positive earning surprise more aet earning click here global asset management firm rowe price trow free report zack rank buy stock also post earning revenue beat report share outperformed zack consensus cent revenue do better estimate year quarter bottom line earning provide bigger surprise previous quarters average more trow earning click here
2070,PFE,dow endure volatile week index hit fresh record high fall bank share lead loss index monday index slip tuesday follow positive news major component surge treasury yield lead loss index wednesday ultimately index surge record high thursday follow investor optimism economic growth last week dow gain last friday due optimism build implementation gop tax bill such broad base gain ensure improvement major benchmark negating effect dismal economic datum nonfarm payroll month december come lower consensus estimate job addition further trade deficit increase november settle be highest deficit january ism service index december decline point index add impressive point friday finish session milestone second straight day marked third straight record close last trading session best open week gain blue chip index be rather broad base last week index gain marked dow best weekly run dec period dow touch psychological level first time be index fastest point rise inception optimism strong market performance contribute gain favorable economic datum include upbeat manufacturing report record construction spending boost market dow index lose almost nearly point monday due fall bank share snap winning run marked end day streak gain blue chip index hit intraday record earlier session suffer broad base loss finish negative territory share major bank such goldman sachs group inc gs free report jpmorgan chase co jpm free report decline respectively weigh dow bank share decline analyst estimate be time charge fourth quarter earning bank suffer due implementation tax reform index increase tuesday follow report boee company ba free report have deliver record number airplane push dow record territory such event lead share boee gain contribute much point dow blue chip index amassed point finish record also contribute dow gain be increase share johnson johnson jnj free report gain add point dow index lose wednesday yield year benchmark note surge follow report china be consider halter purchase treasury market also suffer loss report canada surface government expect trump pull nafta soon meanwhile cost import good unite state surge year high index gain point thursday hit time high follow investor optimism economic growth share boee gain emerge largest contributor dow aircraft manufacturer likely be major beneficiary higher economic growth meanwhile ppi index decline move lower first time more year component move indexboee delivery show rise commercial shipment decline defense shipment year year basis company report commercial delivery jet higher delivery figure be company delivery guidance zack rank hold boee deliver model airplane follow delivery model boee deliver unit model compare unit year other delivery include compare unit respectively defense space business boee delivery be year total delivery consist apache helicopter new remanufacture chinook helicopter new renew read boee commercial defense jet delivery meanwhile boee defense space security unit recently secure modification contract worth production increment lot small diameter bomb sdb term deal company purchase additional quantity sdbs read boee win fms deal build small diameter bomb apple inc aapl free report announce be work feature provide increase parental control smartphone usage child announcement be make follow apprehension apple shareholder jana partner llc california state teacher retirement system regard role company shape child future bloomberg zack rank apple response criticism also mentioned iphone other apple product run io have be offer parent tool enable control child access company also offer ask buy feature require consent parent buy good service add bloomberg company be focuse make vigilance stricter new tool read apple develop tool increase parental control merck co inc mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen zack rank merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible read merck keytruda combo get breakthrough therapy status meanwhile merck announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs read merck keytruda succeed high risk melanoma study chevron corporation cvx free report effort divest stake south africa business china petroleum chemical corporation snp free report better know sinopec have be approve country competition commission notably sinopec acquire stake asset subsidiary soihl hong kong hold limit completion deal soihl manufacturer supplier petroleum petrochemical product enter south african petroleum market stock have zack rank strong buy see complete list today zack rank strong buy stock here pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct zack rank pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program read pfizer stall alzheimer parkinson cut job coca cola co ko free report affiliate chile local bottler brand enter agreement buy novaverde sa move be line strategy invest newer revenue generate platform company specialize juice canned fruit vegetable mainly brand guallarauco coca cola have zack rank embotelladora andina coca cola del valle new venture coca cola chile enter stock purchase agreement ownership novaverde share be transfer completion deal coca cola del valle new venture own share coca cola chile embotelladora andina own share respectively gain ownership share embotelladora andina direct indirect ownership novaverde be approximately be already shareholder coca cola del valle new venture deal be value accord reuter report read coca cola chilean arm buy novaverde diversify portfolio performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookdespite recent hiccup market continue be fuel expectation strong economic growth bullish fourth quarter earning recently release datum manufacturing construction have also bear such sentiment several economic report be line release next few day release reveal critical insight retail sale industrial production housing most report be encourage nature market be likely maintain upward trajectory week ahead zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2071,PFE,rise demand immuno oncology drug combination merck co inc mrk free report pd therapy keytruda be fast become key top line driver pharma giant keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer have crossed mark sale third quarter keytruda become second largest product merck portfolio treatment fetch sale first month year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer therapy be only pd approve first line set keytruda development program also significantly advanced regulatory approval secure new indication unite state europe japan key approval indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo first line lung cancer new approval expand patient population drive sale third quarter momentum be maintain fourth quarter well meanwhile keytruda be be study more type cancer study include excess combination trial merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen datum several program keytruda be present medical conference expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april conclusionmerck do witness setback regard keytruda pipeline program october company announce delay readout important lung cancer study postpone be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer turn raise investor concern delay readout give competitor chance gain traction lung cancer market also combination study keytruda multiple myeloma be put clinical hold follow report death keytruda group last july also merck top line have be lately hurt generic competition several drug pricing pressure believe keytruda have immense commercial potential couple other newer drug ease impact genericization rivalry immuno oncology market have rise follow fda approval newer oncology treatment pfizer bavencio avelumab merkel cell carcinoma mcc bladder cancer indication astrazeneca imfinzi durvalumab bladder cancer believe keytruda give drug tough run money be ample scope growth immuno oncology space merck carry zack rank hold see complete list today zack rank strong buy stock here share merck have decline year industry rally zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2072,PFE,focus week be annual jpmorgan healthcare conference several biotech pharma company provide preliminary look result also provide pipeline update well outlook recap week most important storieskey takeaway jpmorgan healthcare conference several pharma company be present annual jpmorgan healthcare conference largest most informative healthcare investment symposium industry key update pfizer pfe free report say expect be rich datum delivery year bristol myer squibb company bmy free report also provide look pipeline include opportunity opdivo company also say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially merck mrk free report be also lookout business development deal exercise financial discipline company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need read more key takeaway pfizer other drug stock healthcare conference allergan be also present conference preliminary financial outlook read more allergan sale guidance lower expect glaxosmithkline gsk free report meanwhile be look strengthen pharma pipeline prioritize development capital focus core respiratory hiv infectious disease potential therapy immuno inflammation oncology area glaxo be zack rank buy stock see complete list today zack rank strong buy stock here nordisk go public ablynx proposal nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity currently be rumor additional bidder eu approval caplacizumab well change scenario far nordisk be concern acquisition make sense caplacizumab be good fit company hematology portfolio deal also give boost nordisk pipeline especially give continue pricing pressure diabetes care particularly unite state read more nordisk confirm bid ablynx face rejection sanofi regeneron boost investment dupixent cemiplimab sanofi sny free report partner regeneron have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential atopic dermatitis asthma chronic obstructive pulmonary disease development update merck merck provide late stage datum pd therapy keytruda monotherapy surgically resect high risk melanoma keytruda meet primary endpoint recurrence free survival rfs merck also announce fda have accept regulatory application doravirine investigational nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection adult response agency be expect oct fda also grant breakthrough therapy designation eisai lenvima lenvatinib combination keytruda treatment patient advanced metastatic renal cell carcinoma rcc breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint read more merck keytruda combo get breakthrough therapy status merck stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock johnson johnson jnj free report be pfizer decline last month bristol myer be glaxo decline see last pharma stock roundup here allergan announce job cut pfizer inks deal next pharma world watch usual pipeline regulatory update zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2073,PFE,bristol myer squibb company bmy free report fourth quarter earning cent share beat zack consensus estimate cent come ahead year quarter earning cent moreover total revenue surpass zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading presumably better expect earning bristol myer share have increase past year compare favorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year november fda approve label expansion drug include treatment pediatric patient ph chronic myeloid leukemia chronic phase rheumatoid arthritis drug orencia be fourth quarter melanoma drug yervoy contribute top line report quarter january label expansion drug pediatric patient advanced melanoma be approve europe opdivo be approve multiple cancer indication generate revenue year period drug receive approval intravenous administration melanoma patient adjuvant treatment however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively sale eliquis be report quarter year year multiple myeloma drug empliciti record sale year year research development expense quarter increase mainly due charge related license asset acquisition marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix december bristol myer privately hold taris biomedical llc announce clinical collaboration evaluate combination bristol myer opdivo taris investigational product tar patient muscle invasive bladder cancer moreover bristol myer also enter agreement japan base ono pharmaceutical same month agreement grant bristol myer right develop commercialize ono selective prostaglandin receptor antagonist ono sale increase primarily drive strong sale opdico follow several line extension opdivo sale rise eliquis sale increase adjust earning share full year come pipeline updatein february bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy moreover january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc december fda lift partial clinical hold phase study phase ii study evaluate opdivo combination regimen relapse refractory multiple myeloma november phase iii study checkmate be stop early opdivo achieve superior overall survival previously treat patient nsclc compare docetaxel earning guidancebristol myer provide adjust earning expectation company project earning range share zack consensus estimate earning be peg company expect revenue increase low mid single digit takebristol myer beat earning expectation primarily robust sale drug opdivo eliquis yervoy quarter guidance be also encourage meanwhile be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval prospect drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here better rank company large cap pharma industry be abbvie inc abbv free report pfizer inc pfe free report lundbeck hluyy free report carry zack rank buy share abbvie have gain past year earning estimate have go past day share pfizer have return past year earning estimate have go past day share lundbeck have gain past year earning estimate have go past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2074,PFE,spotlight be again parkinson disease pd space week have turn be important focus area pharmaceutical adms free report launch pd drug gocovri pfizer pfe free report drop plan develop treatment indication pharmaceutical have late announce full commercial launch lead product gocovri unite state treat dyskinesia patient parkinson disease pd be levodopa base therapy drug be approve fda last august base positive datum phase iii study significantly be first only drug receive approval indication unite state pfizer reportedly announce abandon plan develop treatment parkinson alzheimer disease news source pfizer expect decision lead eliminate position neuroscience discovery early development program let take look be happen difficult treat disease space be parkinson disease parkinson disease pd be progressive degenerative neurological movement disorder result loss dopamine produce brain cell disease mainly progress age be second most common disorder alzheimer nearly person worldwide be live parkinson disease person unite state be suffering indication approximately person diagnosed disease annually almost case prove fatal year additionally disease be expect claim patient multiply more double combine direct indirect cost parkinson include treatment social security payment lose income inability work be estimate nearly annum unite state alone gbi research parkinson disease market be estimate touch cagr incidence disease rise globally give rapid increase grey populace research innovative therapy parkinson space have grow last decade present drug show side effectsit have be observed pd patient traditional medication levodopa often suffer side effect however drawback pd be predominantly treat levodopa dopamine agonist key medicine dominate pd market include israeli teva pharmaceutical teva free report azilect belgium base ucb sa neupro swiss giant novartis nvs free report stalevo most be levodopa base however loss patent exclusivity product be hurt drug sale pipelinemany company be try develop introduce parkinson disease treatment market include acorda therapeutic inbrija prothena corporation prx astrazeneca medi edison pharma vatiquinone prexton therapeutic foliglurax prana biotechnology pbt notably acorda inbrija be likely first hit market fda expect respond company resubmission new drug application nda december day also permit full review february be diagnosed parkinson disease be life change affair apart costly treatment disease substantially degrade quality life capacity carry daily activity severity parkinson stretch such extent patient disorder be force retire earlier unaffected moreover lack curative therapy particular area be increase need better treatment option therefore market opportunity bring innovative product space be huge attract more player process come improve treatment choice cater widely gape unmet need many company be implement latest knowhow technology improve treatment option parkinson therefore space be project vital platform lot update await term medical sector yr return medical sector yr returnwall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2075,PFE,be eventful year pharma biotech stock industry face challenge drug pricing scrutiny pricing pressure increase competition concern regard amazon interest enter healthcare arena fewer expect acquisition deal major pipeline setback be positive development well be significant surge fda approval investor appear more comfortable drug pricing controversy innovation win day fda grant approval gene therapy cancer well rare form blindness tax reform be also expect work sector favor merger acquisition expect pick come quarters keep mind here be look key takeaway presentation make major pharma biotech stock annual morgan healthcare conference largest most informative healthcare investment symposium industry pfizer inc pfe free report pharmaceutical giant pfizer expect be rich datum delivery year company focus be therapeutic area include oncology inflammation immunology vaccine rare disease internal medicine immuno oncology portfolio focus remain mainly drug combination bavencio variety pfizer target agent first half year company present late stage datum bavencio second line small cell lung cancer vyndaqel cardiomyopathy regulatory submission be expect xtandi metastatic castration resistant prostate cancer parp inhibitor talazoparib breast cancer second half year see company present phase iii datum rivipansel sickle cell tanezumab pain company also have couple pdufa date xeljanz ulcerative colitis first indication outside rheumatology lorlatinib second line small cell lung cancer pfizer be zack rank hold stock company share be last year compare gain record industry belong celgene corporation celg free report biotech company celgene announce preliminary result well outlook healthcare conference celgene also be present significant amount datum year include revlimid rituxan relapse refractory follicular lymphoma otezla scalp psoriasis several study initiation be also expect year moreover company expect submit supplemental new drug application snda fda revlimid combination bortezomib dexamethasone rvd patient newly diagnosed multiple myeloma ndmm new drug application nda fedratinib myelofibrosis snda otezla behet disease meanwhile fda decision be expect year ozanimod relapse multiple sclerosis rm once daily formulation otezla company say continue invest business development celgene be zack rank stock company share be last year compare gain record industry belong bristol myer squibb company bmy free report bristol myer pipeline represent several opportunity long term growth company provide update blockbuster drug opdivo be expect drive mid term growth small cell lung cancer renal cell carcinoma rcc hepatocellular carcinoma gastric cancer be area represent commercial potential excess be disease area high prevalence high unmet medical need low survival rate bristol myer have several datum readout opdivo plan company immuno oncology portfolio have several early stage candidate late stage asset relatlimab lag bms bms ido company say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially bristol myer be zack rank hold stock company share be last year merck mrk free report merck too business development remain key priority company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need merck provide outlook february company say headwind remain form competitive pressure drug zostavax zepatier zetia vytorin still feel impact generic competition however keytruda represent significant growth opportunity drug be several study label expansion combination use moreover company pipeline oncology asset novel vaccine select hospital specialty product also provide scope long term growth merck be also zack rank stock see complete list today zack rank strong buy stock here company share be last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2076,PFE,dog dow strategy have history outperform dow jone industrial average long term lag return just compare gain blue chip index dog have generate outsized return previous year miss only dog dow represent highest yielding blue chip company dow jone industrial average be favor market thus have higher dividend yield due depress stock price high dividend yield suggest stock be oversold territory rebound faster other stock fundamental change such strategy combine element dividend value investing give hone stock be cheaper peer unlikely cut dividend generate market return lead juicy yield fact new tax legislation act biggest catalyst stock lead dividend hike thereby result higher shareholder return read sector etfs stock set explode higher tax cut let meet year dog dow dog dog dow verizon vz free report international business machine ibm free report pfizer pfe free report exxon mobil xom chevron cvx merck mrk free report coca cola ko free report cisco system csco free report be list astounding performance boee ba free report caterpillar cat lead departure have be replace procter gamble pg general electric ge free report investor note ge be unusual inclusion dog give cut dividend late read steer clear ge bet industrial etfs instead dog dow lead year give recovery oil natural gas price spur outperformance integrate oil giant xom cvx be respectively start year additionally general electric biggest laggard last year have turn hottest stock start year stock logged biggest weekly percentage gain nov first week new year however performance dow dog differ bull bear market great caution need be exercise investing company still look invest stock do so basket form etfs lower risk have highlighted etfs heavy exposure dog dow look exciting etf betselement dj high yield select etn dod free report be etn option provide investor pure play highest dividend yielding security dow jone industrial average equal proportion track dow jone high yield select total return index charge bps annual fee note have only aum trade light volume share average daily basis dod shed start new year alp sector dividend dog etf sdog free report fund apply dog dow theory sector sector basis used be easily do select highest yielding security gic sector equally weigh higher yielding stock appreciate order bring yield line market potentially lead outsized gain approach result portfolio stock security accounting more total asset fund have accumulate asset base trade good volume more share charge bps annual fee have gain first few trading session guggenheim dow jone industrial average dividend etf fund offer alternative strategic beta approach dow jone industrial average weighting security dividend yield rather price follow dow jone industrial average yield weight index hold dow stock basket dog account portfolio product charge bps annual fee investor have amassed asset base trade paltry volume share day average have add so far year read dow etfs more upside ahead ishare core high dividend etf hdv free report product provide exposure dividend stock tracking morningstar dividend yield focus index dog dow account portfolio suggest dog dominate return fund hdv be largest most popular etfs large cap space aum average trading volume share charge bps fee year have add first few trading session first trust morningstar dividend leader index fund fdl free report aum fund follow morningstar dividend leader index total hold stock have show dividend consistency sustainability dog dow collectively accounting asset volume be good exchange nearly share day average expense ratio come fund be so far year read dividend etfs least yield gain want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2077,PFE,merck mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible merck share have decrease past year underperform industry gain period fda grant btd combination regimen base datum rcc arm open label phase ib ii study study be currently evaluate keytruda lenvima cancer indication keytruda be merck blockbuster immunotherapy drug approve several cancer indication easai lenvima be approve single agent treat differentiate thyroid cancer combination novartis nvs free report chemo drug afinitor everolimus advanced rcc follow prior angiogenic therapy apart lenvima merck have collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotemerck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2078,PFE,johnson johnson jnj free report announce fda have grant breakthrough therapy designation late stage pipeline candidate erdafitinib treatment urothelial cancer type bladder cancer designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation erdafitinib be primarily base efficacy finding phase ii study evaluate advanced urothelial cancer indication show overall response rate stock decline year so far compare unfavorably gain record industry urothelial cancer start urothelial cell line bladder be usually characterize serious outcome due often rapid progression tumor lack efficacious treatment be sixth most common form cancer unite state be estimate more new case bladder cancer be diagnosed year press release have robust pipeline company expect launch file approval more new blockbuster product company be target more line extension exist new drug well help lessen impact genericization key product pharma portfolio key late stage candidate company pipeline include esketamine treatment resistant depression niraparib prostate cancer imetelstat myelofibrosis other regulatory filing unite state esketamine be expect niraparibis expect next year please note imetelstat be be develop partnership geron corporation gern free report important new drug guselkumab tremfya be approve last year plaque psoriasis also first dual treatment hiv juluca dolutegravir rilpivirine receive approval unite state november last year candidate be review eu juluca have be develop partnership viiv healthcare hiv company majorly own glaxo gsk free report pfizer pfe free report meanwhile symtuza darunavir base once daily single tablet regimen treatment hiv be review unite state symtuza be approve eu september last year carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2079,PFE,tuesday january stock market future be pretty deeply red morning average close main index roughly half percentage point however blame be place earning season continue bring robust result company spectrum industry asian market be slightly overnight later evening await president trump initial state union address later week begin tomorrow start see new datum january job number keep earning result here be leader respective space well have perform relative expectation particularly zack consensus estimate mcdonald mcd free report post strong quarterly number top bottom line ahead open bell today earning share easily outpaced expect revenue reach company ahead zack consensus beating estimate be nothing new mcdonald previous average positive earning surprise past quarters be quarter just report mcdonald benefit stronger comp year year more mcd earning click here big pharma player pfizer pfe free report also beat estimate earning revenue cent share sale top cent expect respectively earning growth year year be nice revenue be revenue guidance full year remain range current zack consensus estimate earning guidance share be ahead have earlier expect more pfe earning click here health insurance major aetna aet free report other hand post mixed result share surpass be look revenue lower expect further year enrollment be congress continue chip away affordable care act be good aetna previous quarters generate average positive earning surprise more aet earning click here global asset management firm rowe price trow free report zack rank buy stock also post earning revenue beat report share outperformed zack consensus cent revenue do better estimate year quarter bottom line earning provide bigger surprise previous quarters average more trow earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2080,PFE,pfizer inc pfe free report report fourth quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive higher international sale lower cost share count pharma heavyweight deliver revenue also beat zack consensus estimate revenue rise year quarter report basis operational basis revenue be flat year year sale detailcurrency movement benefit pfizer fourth quarter revenue february pfizer divest hospira infusion system business icu medical exclude currency headwind revenue prior year quarter sale rise operationally strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis somewhat offset lower sale enbrel viagra loss exclusivity product supply shortage legacy hospira product international revenue rise operational basis meanwhile revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period pfizer ih revenue be drive persistently strong momentum eliquis globally xeljanz lyrica ibrance chantix champix primarily unite state ibrance revenue rise quarter drive strong revenue however ibrance sale be softer prior quarter time price adjustment hurt international sale xeljanz sale rise lyrica sale rise eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare third quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline due generic competition begin december global prevnar prevenar revenue rise higher international sale make decline unite state prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market pediatric indication consumer healthcare revenue decline global oncology revenue increase global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect year also be retain business pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense also decline resultsfull year sale be flat year year operational basis sale marginally beat zack consensus estimate be line guidance range adjust earning share full year exceed zack consensus estimate well guide range earning rise year year guidancerevenue be expect range zack consensus estimate be peg adjust earning share be expect range zack consensus estimate share mid point adjust ep be expect increase revenue be expect increase research development expense be expect range si spending be project range adjust tax rate be expect be takepfizer fourth quarter result be expectation beat estimate earning revenue meanwhile issue upbeat guidance also pfizer say plan invest approximately capital project unite state next year increase access foreign cash follow tax reform however initial gain share pfizer fall premarket trading believe lower sale unite state sequentially softer performance ibrance quarter hurt investor sentiment past year pfizer share have increase compare unfavorably increase industry top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition pfizer achieve adjust earning growth new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance meanwhile pfizer look well poise record profit growth pfizer carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2081,PFE,merck co inc mrk free report announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer interim datum keynote study show treatment keytruda adjuvant therapy surgically resect high risk melanoma patient lead significantly improve rfs compare placebo other word keytruda show potential extend duration disease recur high risk melanoma patient study continue evaluate other key endpoint include overall survival result study be submit regulatory authority also be present future medical meeting merck be conduct study collaboration european organisation research treatment cancer eortc share merck have decline past year industry surge keytruda second largest product merck portfolio be key top line driver merck fact keytruda be continuously grow expand new indication market globally keytruda development program also significantly advanced several key regulatory approval further drive sale keytruda be be study more type cancer more study include combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo gsk free report pfizer inc pfe free report separately evaluation keytruda combination other regimen press release merck announce fda have accept new drug application nda investigational candidate doravirine nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection merck be look get doravirine approve once daily single tablet combination other antiretroviral agent also once daily fix dose combination regimen contain doravirine lamivudine tc tenofovir disoproxil fumarate tdf dor tc tdf fda be expect give decision application oct merck carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2082,PFE,regeneron pharmaceutical inc regn free report partner sanofi sny free report announce expand investment development programme cell death protein pd antibody cemiplimab oncology label expansion il il pathway block antibody dupilumab type ii allergic disease term expansion investment cemiplimab be increase increase initial agreement meanwhile sanofi regeneron continue equally fund cemiplimab development currently company be develop cemiplimab monotherapy combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas more study other indication plan begin first quarter sanofi regeneron expect submit regulatory filing unite state europe cemiplimab advanced cutaneous squamous cell carcinoma increase investment label expansion dupilumab development program enable company speed plan new study chronic obstructive pulmonary disease copd peanut allergy grass allergy well patient have multiple allergic condition new funding also support acceleration expansion development regn il antibody atopic dermatitis asthma copd share regeneron have increase industry decline past year regeneron have agree limit waiver lock clause sanofi thereby enable latter sell small percentage regeneroncommon stock own fund portion increase investment specifically sanofi be allow sell share regeneroncommon stock latter end represent share regeneron sanofi currently own regeneron opt deal sanofi sell open market separate release company also announce collaboration abbvie alnylam pharmaceutical alny free report astrazeneca biogen pfizer inc pfe free report speed effort collect genetic information person uk biobank database project help speed new drug discovery improve approval success rate collaborator commit enable speeding sequence timeline additional company be consider join consortium be originally plan sequence sample uk biobank be complete inclusion company be possible complete sequence participant end datum make broadly available uk biobank researcher end consortium effort thus largely accelerate delivery global scientific community largest big datum resource link human sequence datum other health related information sequence uk biobank sample continue be perform regeneron genetic center rgc facility world largest most sophisticated human genetic sequence center regeneron pharmaceutical inc price regeneron pharmaceutical inc price regeneron pharmaceutical inc quotezack rank regeneron carry zack rank hold see complete list today zack rank strong buy stock herezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2083,PFE,alzheimer disease ad area be focus once again pfizer inc pfe free report say be drop plan develop treatment alzheimer parkinson disease accord news source pfizer expect decision result elimination position neuroscience discovery early development program expect additional detail be available company presentation annual jpmorgan healthcare conference today pfizer have have long association alzheimer disease research area company become part dementia discovery fund be form speed development new treatment neurological disease bring together major pharma company uk government alzheimer research uk fund be involved financing new early stage drug development project however alzheimer have always be highly challenge area not much progress be make investment lot fund resource fact pfizer have face major setback way back development effort alzheimer disease treatment company partner johnson johnson jnj free report decide discontinue development bapineuzumab iv follow late stage failure other company eli lilly company lly free report merck mrk free report have also stumble effort develop treatment alzheimer lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer meanwhile evaluation merck investigational alzheimer disease treatment verubecestat be halter phase ii iii study epoch february base interim analysis external datum monitoring committee edmc study fail study be ongoing result expect february biogen also suffer setback recently independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study failure show early positive result come major disappointment biogen be develop candidate association eisai clinical stage company axovant science axon free report suffer major setback september investigational alzheimer disease candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment alzheimer disease last year company share be compare decline industry belong accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval road setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale company be currently work alzheimer disease treatment include biogen novartis nvs free report astrazeneca eisai amgen amgn free report biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment company pfizer lilly merck be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2084,PFE,merck co inc mrk free report announce datum phase ii keynote study evaluate use pd therapy keytruda patient advanced hepatocellular carcinoma hcc form liver cancer be previously treat systemic therapy sorafenib datum show treatment keytruda monotherapy lead overall response rate orr datum also show complete response rate partial response rate treatment datum also include month overall survival os progression free survival pfs rate median pfs keytruda arm be month month pfs rate percent however datum show median os be not reach time analysis month os rate be datum be present present american society clinical oncology asco gi cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer last week merck announce keytruda combination lilly lly free report alimta pemetrexed acisplatin carboplatin meet dual primary endpoint phase iii keynote study combination be evaluate first line treatment patient metastatic squamous nsclc study meet primary endpoint progression free survival pfs os co primary endpoint remind investor third quarter call merck have mentioned be include overall survival os co primary endpoint keynote study defer readout study be then estimate study complete february therefore year earlier expect positive read keynote study be big boost company share merck have lose past year compare unfavorably industry increase remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer meanwhile keytruda development program also significantly advanced regulatory approval new indication unite state additional disease europe keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2085,PFE,gilead science gild free report subsidiary kite announce have enter collaboration pfizer inc pfe free report evaluate combination newly approve car therapy yescarta axicabtagene ciloleucel pfizer utomilumab bb agonist refractory large cell lymphoma phase ii study be expect begin be sponsored kite result study be used find option further development combination similar combination kite engineer cell product utomilumab gilead stock have increase year so far compare industry gain yescarta be approve october second car cell therapy get fda approval first car therapy novartis nvs free report kymriah receive approval fda august yescarta be first car therapy indicated treatment adult patient relapse refractory large cell lymphoma more line systemic therapy pfizer be develop utomilumab also know pf hematologic cancer solid tumor single agent combination other cancer therapy remind investor kite be acquire gilead october kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio position company dominant position cellular therapy space car therapy space have remain investor focus courtesy immense potential car cell therapy be expect be revolutionary cancer treatment company also develop car therapy be juno therapeutic inc most advanced pipeline candidate include jcar jcar juno be also news recently report surface be acquire celgene corporation clinical stage company commit develop car therapy be bluebird bio inc lead oncology program bb bb be bcma car program be be develop collaboration celgene gilead science inc price gilead science inc price gilead science inc quotezack rank gilead have zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2086,PFE,week company novartis nvs free report merck mrk free report johnson johnson jnj free report be news merck provide datum keytruda novartis be news gain priority review status label expansion car therapy kymriah recap week most important storiesmerck keytruda shine st line lung cancer study merck score week pd therapy keytruda combination alimta pemetrexed cisplatin carboplatin meeting primary endpoint overall survival os progression free survival pfs late stage study first line treatment patient metastatic squamous small cell lung cancer nsclc interim analysis conduct independent datum monitoring committee show keytruda combination result significantly longer os pfs compare alimta platinum chemotherapy alone read more merck strong confirmatory phase iii lung cancer study priority review label expansion novartis kymriah novartis first company gain fda approval car therapy kymriah say agency have grant priority review company regulatory application seek expand label product novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct kymriah also get accelerate assessment status european medicine agency ema treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct read more novartis sbla car therapy kymriah accept fda unfavorable ipr decision suffer setback week patent trademark office pto issue final written decision parte review ipr related sole unexpired patent list cover company prostate cancer therapy zytiga abiraterone acetate fda orange book generic drug company argentum pharmaceutical have challenged claim patent be due expire aug issue statement regard pto decision say be evaluate option rehearing appeal court appeal federal circuit zytiga bring sale first month novartis sandoz global partnership biocon biosimilar sandoz novartis division be enter global partnership biocon development manufacture multiple biosimilar immunology oncology company share responsibility end end development manufacturing global regulatory approval number product have cost profit share arrangement responsibility be divide partnership allow company address next wave biosimilar opportunity globally sandoz biocon have have success biosimilar space sandoz portfolio include biosimilar market various country world company be currently seek fda approval biosimilar version abbvie blockbuster immunology drug humira regulatory application biosimilar be recently accept review fda pfizer gilead clinical trial collaboration pfizer pfe free report have enter clinical trial collaboration kite gilead gild free report company safety efficacy kite car cell therapy yescarta axicabtagene ciloleucel be evaluate combination pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large cell lymphoma phase ii study be expect commence year pfizer be zack rank buy stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock merck be bristol myer squibb bmy free report decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here nordisk reveal bid acquire ablynx pfizer other healthcare conference next pharma world watch usual pipeline regulatory update well fourth quarter earning announcement january make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2087,PFE,pfizer inc pfe free report be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be well know product prevnar lyrica lipitor celebrex other however many peer pfe be face generic competition pricing pressure several product other lose alliance revenue supply shortage legacy hospira product pricing pressure rise competition be hurt top line scenario investor focus remain late stage pipeline candidate commercial potential performance new product apart usual top bottom line number pharma giant have fairly decent record earning surprise company earning surpass expectation last quarters miss result average positive surprise pfizer inc price consensus pfizer inc price consensus pfizer inc quotecurrently pfe have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earn beat pfe beat fourth quarter earning come cent consensus call ep cent earning rise year year revenue beat revenue also expectation pfizer post revenue beat zack consensus estimate revenue rise year quarter report basis operational basis revenue be flat year year guidance revenue be expect range zack consensus estimate be peg adjust earning share be expect range be zack consensus estimate share pre market trading share rise more pre market trading check back later full pfe earning report later don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2088,PFE,johnson johnson jnj free report healthcare bellwether report fourth quarter result jan open bell last quarter company report positive earning surprise share have gain past year outperform increase witness industry belong earning beat expectation last quarters average positive surprise let see thing be shape announcement factor considerwe believe strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line fourth quarter however higher investment product launch put pressure profit third quarter domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably believe new product segment label expansion drug imbruvica xarelto darzalex meaningful contribution swiss biotech actelion buy june support top line however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call medical device segment sale continue gain mainly inclusion abbott medical optic acquisition diabetes care unit be however expect remain weak hurricane texas florida puerto rico hurt sale growth last report quarter due lose surgery day third quarter call company have say supply disruption be not anticipate be not clear time surgical procedure miss third quarter be re-cover fourth pricing issue india system outage europe also hurt sale extent remain be see issue be resolve time consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product be likely provide support model proven model do not conclusively show be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considera couple stock large cap pharma sector have positive earning esp favorable zack rank be merck co inc mrk free report earning esp zack rank company be schedule release result feb pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2089,PFE,exelixis inc exel free report announce amendment protocol phase ib trial cabozantinib combine roche holding rhhby free report tecentriq patient locally advanced metastatic solid tumor amendment be new expansion cohort trial cohort include include patient nsclc crpc addition previously include patient renal cell carcinoma rcc urothelial carcinoma uc primary objective expansion stage trial be determine objective response rate cohort cohort now include follow patient advanced squamous nsclc defined tumor genetic alteration egfr alk ro braf have not receive prior therapy immune checkpoint inhibitor patient nsclc defined tumor genetic alteration have progressed follow treatment immune checkpoint inhibitor patient uc have progressed follow treatment immune checkpoint inhibitor patient crpc have previously receive enzalutamide abiraterone acetate experience radiographic disease progression soft tissue multicentre phase ib open label study be divide part dose escalation phase expansion cohort phase main objective be calculate optimal dose schedule daily oral administration cabozantinib trial begin enrolment expansion cohort once recommend dose schedule be determine anticipate occur first half exelixis stock have rally massive last year compare industry gain april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy cabometyx deliver strong sale first month underlie increase demand drug new patient market share second line set increase recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand drug demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent apart roche exelixis also inked agreement bristol myer squibb bmy free report jointly develop cabozantinib collaboration immunotherapy agent exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate july evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc competition stiffen bit fda accept bristol myer supplemental biologic license application application include priority review opdivo yervoy treat intermediate poor risk patient advanced rcc action date apr expect exelixis ride high performance cabometyx zack rankexelixis flaunt zack rank strong buy see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2090,PFE,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2091,PFE,week have be pretty slow key announcement include allergan agn free report job cut announcement pfizer pfe free report collaboration agreement company sangamo arvina recap week most important storiesallergan announce job cut time announce third quarter result november allergan have say have look cost reduction order deal impact loss exclusivity loe key product include restasis week company announce cost cut restructure program lead elimination more currently filled position primarily commercial other function open position also be eliminate restructure cost primarily due severance be record mostly fourth quarter overall operate expense saving expect range compare company expect achieve additional cost reduction headcount spending rationalization read more allergan cut job loss exclusivity key drug pfizer protein degradation deal arvina pfizer have agree shell private biotech company arvina be focuse create new class drug base protein degradation company announce research collaboration license agreement discovery development drug candidate used arvina proprietary protac proteolysis target chimera platform novel technology be used creation small molecule therapeutic aim degrading disease cause cellular protein multus year agreement cover different therapeutic area see arvina drive discovery effort pfizer be responsible clinical development product result collaboration cover upfront milestone payment depend achievement specify preclinical clinical commercial milestone deal term include tiered royalty well protein degradation be area have be attract interest large cap company arvina have agreement roche rhhby free report well pfizer sangamo sign collaboration agreement pfizer have sign collaboration agreement sangamo development potential gene therapy used zinc finger protein transcription factor zfp tfs treatment amyotrophic lateral sclerosis al frontotemporal lobar degeneration ftld link mutation orf gene agreement see pfizer shell upfront payment well milestone payment worth tiered royalty net sale sangamo be responsible development zfp tf candidate pfizer be operationally financially responsible subsequent research development manufacturing orf zfp tf program other result product sangamo pfizer already have collaboration agreement be announce last year development gene therapy product hemophilia include sb read more pfizer collaborate sangamo gene therapy pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong roche macrogenic ink deal roche clinical stage biopharma company macrogenic be collaborate discovery development innovative monoclonal antibody base therapeutic treatment cancer well several autoimmune disorder infectious disease company respective platform include macrogenic dart platform roche crossmab dutafab technology be used selection bispecific format lead pipeline candidate roche be responsible further development such pipeline candidate deal see roche make upfront payment achievement milestone royalty future sale mylan partner start eylea biosimilar study mylan myl free report partner momenta announce intend start pivotal study propose biosimilar regeneron blockbuster eye drug eylea vascular endothelial growth factor vegf inhibitor eylea be indicated treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema study be schedule commence first half patient diabetic macular edema eylea be flagship product regeneron global sale come first month read more momenta mylan initiate trial biosimilar eylea cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be last month pfizer be glaxosmithkline gsk free report decline see last pharma stock roundup here roche mnk announce acquisition agreement regulatory update novartis next pharma world watch update outlook be provide several company next week annual morgan healthcare conference zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2092,PFE,abbvie abbv free report share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret imbruvica continue witness strong uptake chronic lymphocytic leukemia cll indication humira performance be drive robust demand introduction new mechanism action competition indirect biosimilar meanwhile mavyret hepatitis virus hcv have be witness strong uptake unite state international market mavyret exit market share unite state be expect become major growth driver company rosy outlook company provide upbeat outlook reflect mavyret strong uptake continue robust underlie performance other product lower tax rate thank passage tax reform abbvie expect earning share range revenue almost mid point earning guidance range reflect year year growth improvement company previously provide guidance growth mid point provide third quarter result humira sale be expect grow approximately unite state ex sale be expect be company expect record imbruvica revenue more mavyret sale be expect cross other product venclexta androgel duodopa be expect record sale respectively creon sale be expect grow synagis lupron synthroid sale be expect remain flat zinbryta sale be expect come reflect impact competition label change cash repatriation capital deployment tax reform allow abbvie more efficient access foreign cash ability use unite state company intend invest capital unite state next year be currently evaluate additional expansion facility abbvie also intend accelerate pension funding enhance executive employee compensation company be also plan time shareable contribution select not profit organization support initiative such puerto rico rebuild effort child healthcare access program certain charity abbvie also say be increase shareholder return be combination acceleration dividend growth more share buyback detail be provide later company deal far deal be concern company key focus be opportunity drive growth timeframe abbvie say be look early stage asset catalyst rich abbvie spend be expect be sale reflect higher spending support late stage pipeline mid stage program addition work expand label approve product imbruvica venclexta abbvie late stage pipeline include candidate upadacitinib rheumatoid arthritis ra crohn disease risankizumab psoriasis crohn disease abbvie be look file regulatory approval risankizumab psoriasis indication first half year regulatory filing upadacitinib ra indication be expect second half meanwhile elagolix be priority review endometriosis response fda expect second quarter abbvie share be last year compare rally industry belong abbvie be zack rank buy stock see complete list today zack rank strong buy stock here week pharma company pfizer pfe free report eli lilly company lly free report nordisk nvo free report be report fourth quarter result pfizer have earning esp fourth quarter lilly nordisk have earning esp respectively earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time pfizer lilly be zack rank hold stock nordisk be zack rank stock uncover best stock buy sell re report earning esp filter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2093,PFE,expect pfizer inc pfe free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise pharma giant have fairly decent record earning surprise company earning surpass expectation last quarters miss result average positive surprise pfizer share have rise past year compare unfavorably increase industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be likely contribute meaningfully top line however loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica develop europe supply shortage legacy hospira product divesture hospira infusion system unit continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be likely see lower sale lower demand be expect hurt sale viagra third quarter call pfizer say be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira september pfizer have estimate take couple year integrate manufacturing plant resolve majority supply chain issue company also state remediation business have take longer expect expect supply shortage hurt sale fourth quarter meanwhile bottom line be likely be drive cost saving share buyback leukemia treatment besponsa inotuzumab ozogamicin approve eu june unite state august relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be approve third quarter xeljanz sutent bosulif be approve line extension fourth quarter ixifi pfizer second biosimilar version johnson johnson jnj free report blockbuster drug remicade be also launch december new product line extension bring additional sale fourth quarter also expect management update plan new approve oral sglt inhibitor steglatro ertugliflozin tablet conference call apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other health care stock worth consider model have right combination element beat earning time abbvie inc abbv free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning feb pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2094,PFE,pfizer inc pfe free report announce collaboration sangamo therapeutic inc sgmo free report develop gene therapy used latter zinc finger protein transcription factor zfp tfs platform gene therapy be develop treat disorder amyotrophic lateral sclerosis al frontotemporal lobar degeneration ftld cause mutation orf agreement sangamo receive upfront payment pfizer be responsible development zfp tf candidate additionally sangamo also receive milestone payment well tiered royalty net sale meanwhile pfizer be responsible operationally financially development result product pfizer sangamo already have global collaboration license agreement development potential gene therapy product treat hemophilia include sb enter clinic august share pfizer increase compare industry gain also sangamo sky-rocket compare industry gain same time frame pfizer also inked deal private biotechnology company arvina discovery development drug candidate used arvina proprietary protac proteolysis target chimera platform candidate be design degrade several key disease cause protein multiple therapeutic area accord latestdeal arvina receive upfront payment achieve specify preclinical clinical commercial milestone pfizer be responsible clinical development product result deal arvina be entitle receive tiered royalty base global product sale product result collaboration pfizer inc price pfizer inc price pfizer inc quotezack rank stock considerpfizer carry zack rank hold better rank health care stock be exelixis inc exel free report xoma corporation xoma free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent cent cent last day company deliver positive earning surprise last quarters average beat share price company have surge xoma loss share estimate have narrow cent cent last day company deliver positive earning surprise last quarters average beat share price company have surge wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2095,PFE,achaogen inc akao free report announce fda have accept new drug application nda urinary tract infection candidate plazomicin fda have also grant priority review nda expedite review process decision be expect jun share company rise tuesday however achaogen stock have underperform industry past year have decline industry gain period nda be seek approval plazomicin treatment complicate urinary tract infection cuti include pyelonephritis inflammation kidney due bacterial infection also bloodstream infection bsi patient have none few treatment option available due multus drug resistant bacterium nda include datum phase iii study epic care evaluate candidate serious infection cause gram negative bacterium be resistant multiple antibiotic datum epic study show plazomicin achieve superior microbiological eradication rate cuti acute pyelonephritis patient compare pfizer pfe free report merrem care study evaluate plazomicin versus colistin patient bsi demonstrate lower rate mortality serious disease related complication press release least patient be infected antibiotic resistant infection annually unite state figure be expect double next year represent significant potential plazomicin approve separate press release company announce top line datum dose range phase efficacy study evaluate antibacterial candidate scape datum show candidate combination pernix therapeutic holding inc antibiotic cedax ceftibuten clavulanate be well tolerate dose regimen achaogen inc price achaogen inc price achaogen inc quotezack rank stock carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2096,PFE,exelixis inc exel free report ipsen announce positive detailed result pivotal phase iii celestial study cabometyx cabozantinib demonstrate significant overall survival benefit patient previously treat advanced hepatocellular carcinoma hcc celestial study meet primary endpoint cabozantinib provide statistically significant clinically meaningful improvement versus placebo overall survival os median os be month cabometyx compare month placebo median progression free survival pfs more double month cabometyx compare month placebo trial show disease control partial response stable disease be achieve cabometyx group compare placebo group company plan present result symposium san francisco later week remind investor cabometyx be already approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy december fda approve label expansion cabometyx treatment previously untreated rcc approval come back positive result randomize phase ii trial cabosun first line kidney cancer result demonstrated statistically significant clinically meaningful improvement pfs versus pfizer inc pfe free report sutent exelixis share price have increase year compare industry gain hcc be most common form liver cancer accounting more case unite state hence be dire need bring new treatment option exelixis plan submit supplemental new drug application fda first quarter cabometyx rake strong sale first month courtesy increase demand drug potential approval further boost sale drug exelixis have also initiate phase ib study investigator sponsored cabometyx combination bristol myer squibb company bmy free report opdivo nivolumab opdivo yervoy patient suffering genitourinary tumor include bladder cancer rcc exelixis have also inked agreement bristol myer squibb roche hold ag rhhby free report develop cabozantinib combination immunotherapy agent exelixis inc price exelixis inc price exelixis inc quote zack rankexelixis sport zack rank strong buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2097,PFE,amgen inc amgn free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well backed stock rally few new product be approve last year fda approve mvasi amgen allergan agn free report biosimilar version roche rhhby free report cancer drug avastin parsabiv secondary shpt eu approve amgevita amgen biosimilar version humira amgen also gain approval several line extension fda approval include new indication risk reduction major cardiovascular event datum repatha overall survival tower study leukemia drug blincyto label approval arefined indication metastatic colorectal cancerdrug vectibix eu approval pediatric formulation secondary shpt line extension expand eligible patient population drug drive sale higher future quarters amgen make several datum presentation study evaluate line extension key market product repatha kyproli blockbuster potential other study pipeline candidate tezepelumab asthma evenity osteoporosis factor likely support stock several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year amgen expect regulatory approval pipeline candidate aimovig erenumab prevention episodic chronic migraine evenity label expansion prolium kyproli month amgen already receive fda approval expand patient population xgeva multiple myeloma patient biosimilar portfolio amgen expect eu approval mvasi fda eu approval biosimilar version roche other cancer drug herceptin also amgen newer drug prolium xgeva vectibix nplate sensipar be perform well trend expect continue next year drive sale sale other newer product kyproli repatha blincyto be expect pick be approve forlabel expansion last year amgen restructure plan be make leaner more cost efficient lend support bottom line amgen face challenge give presenceof biosimilar competition slowdown sale mature drug mainly blockbuster drug enbrel positive be expect outweigh headwind amgen market enbrel partnership pfizer inc pfe free report amgen carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2098,PFE,pfizer inc pfe free report announce positive top line result phase iii comparative study evaluate pf company biosimilar version roche rhhby free report blockbuster leukemia drug rituxan mabthera rituximab notably rituxan be approve treat blood cancer include hodgkin lymphoma follicular lymphoma diffuse large cell lymphoma chronic lymphocytic leukemia well immunological disease rheumatoid arthritis share pfizer have gain year time underperform industry rally phase iii reflection study be design compare efficacy safety pharmacokinetic immunogenicity pf compare rituxan study meet primary endpoint demonstrate equivalence overall response rate first line treatment patient cd positive low tumor burden follicular lymphoma mark pfizer fifth propose biosimilar monoclonal antibody mab show positive trial result significantly pfizer biosimilar capability be substantially boost acquisition hospira december company launch ixifi second biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster drug remicade unite state remind investor pfizer be evaluate biosimilar molecule various developmental stage incidentally biosimilar product late stage development include biosimilar version roche avastin abbvie humira also herceptin biosimilar version be review unite state well eu importantly novartis teva file regulatory application last year unite state biosimilar version rituxan september june respectively pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2099,PFE,pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program share pfizer have rise past year compare unfavorably increase industry successful development therapy treatment alzheimer disease be challenge note several company have fail regard fact pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lillyalso suffer major setback august have halt development phase iii alzheimer candidate semagacestat last month biogen inc biib free report announce alzheimer disease study ban fail show early positive raise investor concern candidate chance success pfizer plan use saving terminate program re allocate spend potentially more fruitful pipeline project pfizer expect approximately drug approval next year product have blockbuster potential include line extension cancer drug xtandi ibrance well rheumatoid arthritis drug xeljanz half potential blockbuster be expect receive approval pfizer carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2100,PFE,protalix biotherapeutic inc plx free report announce european commission ec have grant orphan drug designation pipeline candidate prx pegunigalsidase alfa small biotech company be develop prx patient fabry disease rare inherited genetic lysosomal disorder orphan status prx be expect committee orphan medicinal product europe have recommend grant nov share company rise almost dec include hour movement fact protalix share be so far year outperform industry gain period intravenous administration candidate be currently be evaluate phase iii study patient have receive shire plc shpg free report replagal datum study be expect second half phase iii study be evaluate prx patient fabry disease patient have impair renal function have be treat sanofi sny free report fabrazyme phase iii study be evaluate candidate moderate severe symptom treatment nave fabry disease patient replagal fabrazyme be approve treat fabry disease replagal record sale first month fabrazyme generate sale more period represent significant prospect prx potential approval orphan drug status valid approval give prx exclusivity year protalix have market drug elelyso be approve treat gaucher disease have generate sale first month drug be market pfizer inc pfe free report unite state part exclusive license supply agreement company be also develop prx treat cystic fibrosis oprx orally deliver inflammatory treatment protalix biotherapeutic inc price protalix biotherapeutic inc price protalix biotherapeutic inc quoteprotalix currently have zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2101,PFE,expect abbvie inc abbv free report beat expectation report fourth quarter result jan market open last quarter company deliver positive earning surprise abbvie share have soar year time ahead industry rally notably abbvie earning history be quite impressive pharmaceutical company outpace estimate last quarters meeting same overall abbvie have average beat let see thing be shape company quarter factor considerabbvie expect fourth quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be anticipate have favorable impact sale period be report company key drug humira be likely remain growth driver fourth quarter backed strong demand trend drug abbvie expect humira full year sale growth mid high teen range internationally metric be project mid single digit range operational basis zack consensus estimate humira be be report quarter significantly fourth quarter conference call investor focus also be performance label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica be period other drug duopa creon be also likely continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret gain approval unite state eu canada japan third quarter mavyret record global sale quarter initial uptake drug have be impressive expect higher sale fourth quarter earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp represent difference most accurate estimate share zack consensus estimate moreover positive esp indicate likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvie have zack rank increase predictive power esp together positive esp chance beating estimate stock upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote other stock warrant lookhere be other health care stock worth consider model comprise right combination element beat earning time pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning number feb astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank player hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2102,PFE,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2103,PFE,ligand pharmaceutical incorporate lgnd free report announce have inked worldwide license agreement global innovative pharmaceutical company glenmark pharmaceutical agreement glenmark be able use full omniab platform produce mono bispecific human therapeutic antibody ligand be entitle receive receive annual platform access payment development regulatory milestone payment tiered royalty product incorporating omniab antibody meanwhile glenmark be responsible cost related program latest deal glenmark also be able access technology include separate species single license notably be first new omniab deal include omnichicken addition omnirat omnimouse omniflic omniab include transgenic animal platform consist different technology omnirat omnimouse omniflic omnichicken produce mono bispecific human therapeutic antibody ligand share have gain year time compare industry growth remind investor omniab antibody generate platform become part ligand technology portfolio follow omt inc acquisition january ligand be focuse development licensing asset fact captisol formulation technology have allow company enter several licensing deal generate royalty captisol be well validate chemically modify cyclodextrin be design improve safety solubility stability bioavailability lessen volatility irritation smell taste drug other technology platform ligand include ltp technology selexis technology technology captisol omniab have create strong platform company seek new license partnership also ligand have partnership agreement lead healthcare company novartis nvs free report amgen merck mrk free report pfizer pfe free report celgene gilead lilly other ligand pharmaceutical incorporate price ligand pharmaceutical incorporate price ligand pharmaceutical incorporate quotezack rank ligand have zack rank strong sell see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2104,PFE,share exelixis inc exel free report have rally massive year date compare industry gain exelixis lead product cometriq capsule form cabozantinib be approve unite state treatment progressive metastatic medullary thyroid cancer april tablet formulation cabozantinib cabometyx be approve unite state treatment patient advanced renal cell carcinoma rcc have receive prior angiogenic therapy cabometyx post strong sale first month thereby underlie increase demand drug new patient market share second line set increase recent fda approval cabometyx treatment previously untreated advanced rcc further boost demand approval come month ahead schedule note cabometyx cabozantinib tyrosine kinase inhibitor tki be already approve treatment rcc patient have already receive angiogenic therapy cabozantinib inhibit activity tyrosine kinase include meet axl vegf receptor ret approval come back result randomize phase ii trial cabosun result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent importantly cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median pfs cabometyx be month versus month sutent corresponding month improvement rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state sutent be widely used first line treatment rcc hence expect cabometyx challenge sutent market share first line rcc addition drug be also be evaluate advanced hepatocellular carcinoma hcc celestial study october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter hcc be most common form primary liver cancer accounting more case unite state reflect demand therapy hence potential approval drug liver cancer further boost growth potential drug early exelixis inked agreement bristol myer squibb bmy free report roche holding rhhby free report jointly develop cabozantinib combination immunotherapy agent exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate july evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc exelixis have also collaborate roche evaluate cabometyx combination tecentriq pd antibody patient advanced rcc bladder cancer june exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma rcc competition stiffen bit fda accept bristol myer supplemental biologic license application priority review opdivo yervoy treat intermediate poor risk patient advanced rcc action date apr expect exelixis ride high performance cabometyx hence be have stock investor biotech portfolio zack rankexelixis carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2105,PFE,just few day left year end be say turn be pretty good year biotech sector sector have be struggle due several issue include drug pricing controversy mixed result slower expect new product launch increase competition pipeline setback however investor be more comfortable drug pricing controversy year focus be now more fundamental sector new product sale ramp success innovation continue strong performance key product be factor help sector rebound nasdaq biotechnology index be impressive year date year also turn be pretty good fda approval be concern date regulatory agency have give nod novel drug well drug approve last year immuno oncology be key focus area be do scientific conference clinical trial collaboration acquisition fda approval approval novartis kymriah gene cell therapy gilead gild free report yescarta car chimeric antigen receptor cell cell treatment ensure highly lucrative immuno oncology market remain limelight acquisition immuno oncology focuse kite gilead also increase interest category investor expect more acquisition announcement area course be not good news sector company celgene biogen be hit pipeline setback gilead continue struggle due dwindle sale hepatitis virus hcv franchise nevertheless be quite few company fared extremely well share outperform sector well overall market back factor deal pipeline progress fda approval here be look such company xoma corporation xoma free report xoma be focuse discovery development licensing therapeutic antibody company have several licensing agreement other biotech pharma company provide xoma fund form upfront milestone payment potential royalty payment xoma share have be upward trajectory august follow signing licensing agreement novartis gevokizumab intellectual property cover use il beta target antibody treatment cardiovascular disease deal result xoma receive upfront payment worth include equity investment worth agreement term also result reduction xoma outstanding debt repayment obligation laboratoire servier extension company maturity date debt novartis couple year xoma also stand earn significant milestone payment tiered royalty sale gevokizumab year date xoma share be significantly outperform rally industry belong xoma be zack rank strong buy stock see complete list today zack rank stock here dynavax technology corporation dvax free report commercial stage biopharma company dynavax be focuse discovery development novel vaccine immuno oncology therapeutic company share shot july follow favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult heplisav have previously receive complete response letter november other february fda gain fda approval year november regulatory action make heplisav first new hepatitis vaccine unite state more year only dose hepatitis vaccine adult heplisav be first fda approve product zack rank hold stock expect launch vaccine first quarter dynavax share be whopping year date sangamo therapeutic inc sgmo free report clinical stage biotech company sangamo be focuse translate ground breaking science genomic therapy used platform technology genome editing gene therapy gene regulation cell therapy company get shot arm earlier year enter agreement pfizer pfe free report development gene therapy program hemophilia agreement see sangamo get upfront payment potential earn significant milestone payment well tiered double digit royalty net sale deal bode well long term prospect company zack rank buy company share be year date early next year sangamo expect preliminary proof concept datum sb hemophilia sb fix hemophilia sb mps sb mps ii other value driver be signing partnership deal company central nervous system tau oncology asset alnylam pharmaceutical inc alny free report rnai therapeutic company alnylam be focuse rare genetic cardio metabolic hepatic infectious disease zack rank company have strong discovery platform deep pipeline include pipeline candidate be late stage development alnylam have agreement company sanofi vir biotechnology alnylam share be year date back pipeline progress year bluebird bio inc blue free report bluebird be clinical stage company work develop lentiviral base gene therapy serious genetic disease cell base immunotherapy cancer company pipeline include lenti currently phase ii iii study treatment cerebral lentiglobin currently study treatment transfusion dependent thalassemia severe sickle cell disease company lead oncology program bb bb be bcma car program be be develop collaboration celgene bluebird share have be gain follow presentation datum annual meeting american society clinical oncology asco earlier year june share shot further august gilead announce intention acquire immuno oncology focuse kite pharma gilead kite deal have raise hope additional acquisition deal immuno oncology therapeutic area bluebird consider be attractive acquisition target bluebird be also zack rank stock share be year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2106,PFE,share therapeutic incorporate cort free report have soar so far year massively outperform growth register industry here analyze factor lead rally only market drug korlym mifepristone be approve treatment patient cush syndrome company be strive commercialize korlym successfully deploy medical liaison sale representative person be newly diagnosed cush syndrome year translate more new patient annually unite state increase awareness physician patient drug expand sale effort be likely bolster sale meanwhile be currently work develop drug additional indication be conduct phase ii safety efficacy study korlym combination eisai co ltd cancer drug halaven treatment triple negative breast cancer tnbc enrolment study be complete company announce encourage datum december anticipate successful label expansion korlym boost top line significantly disease represent huge potential many woman unite state be diagnosed year university chicago be conduct phase ii study korlym combination pfizer pfe free report xtandi treatment metastatic castration resistant prostate cancer institution also plan conduct phase ii study korlym combination celgene celg free report abraxane treatment patient tnbc importantly apart korlym be also evaluate cort cush syndrome range solid tumor early datum candidate cush syndrome have be quite promising company have begin dose patient phase ii study cort combination abraxane treatment range solid tumor cancer possible target indication include triple negative breast cancer ovarian cancer pancreatic cancer sarcoma company also have selective cortisol modulator cort phase study result be expect second quarter compound be very potent animal model fatty liver disease prevention reversal weight gain cause antipsychotic medication such zyprexa olanzapine company expect begin phase ii trial indication third quarter also third quarter earning release company raise revenue guidance company now project revenue be range higher prior expectation therapeutic incorporate price therapeutic incorporate price therapeutic incorporate quotezack rank other stock have zack rank buy top rank health care stock include sucampo pharmaceutical sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2107,PFE,merck mrk free report pfizer inc pfe free report announce fda have approve investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin adjunct diet exercise improve glycemic control patient type diabetes mellitus steglujan be fix combination steglatro januvia sitagliptin be approve patient be eligible treatment combination apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin so far year share merck have lose compare industry growth fda approve drug base datum phase iii study evaluate steglatro monotherapy combination januvia bristol myer squibb company bmy free report glucophage study also evaluate steglatro combination insulin sulfonylurea datum study show steglatro single agent combination januvia significantly reduce level measure blood glucose compare placebo steglatro also significantly reduce body weight patient be already receive combination januvia glucophage versus placebo drug also achieve significant reduction systolic blood pressure approval new drug boost merck diabetes portfolio comprise januvia janumet market drug have see volume growth first month have generate sale however merck receive complete response letter fda supplemental new drug application crl seek label expansion januvia janumet janumet xr april company be discussion fda resolve issue crl moreover merck also receive setback earlier month key immune oncology drug keytruda fail phase iii gastric cancer study merck company inc price merck company inc price merck company inc quotezack rank stock considermerck carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2108,PFE,pfizer inc pfe free report announce fda have approve ixifi second biosimilar version johnson johnson jnj free report blockbuster rheumatoid arthritis ra drug remicade infliximab notably ixifi be chimeric human murine monoclonal antibody tumor necrosis factor ixifi receive nod approve indication remicade include ra ulcerative colitis plaque psoriasis psoriatic arthritis ankylose spondylitis crohn disease share pfizer have rise so far year underperform industry rally approval be base encourage datum phase iii study reflection biologic license application be file fda april notably february pfizer have divest right development manufacturing ixifi european economic area eea novartis generic arm sandoz however pfizer retain manufacturing right ixifi country outside eea remind investor pfizer first biosimilar product remicade inflectra be launch last november unite state company have exclusive right inflectra unite state certain other territory september pfizer file lawsuit district court allege be resort unfair practice prevent sale inflectra available wholesale acquisition cost be lower reference product pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract boost insurer not cover inflectra thus make difficult access patient protect reference product pfizer also claim anticompetitive contract discount be offer hospital purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product key revenue generator latter pfizer be evaluate biosimilar molecule various stage development biosimilar product late stage development include biosimilar version roche rhhby free report rituxan avastin abbvie abbv free report humira biosimilar version herceptin be review unite state eu europe pfizer market nivestim biosimilar version amgen neupogen retacrit well biosimilar version amgen epogen pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2109,PFE,spark therapeutic once free report share plunge dec investor be disappoint datum phase ii study evaluate gene therapy candidate spk treat hemophilia datum spk look less competitive biomarin pharmaceutical inc bmrn free report hemophilia candidate valoctocogene roxaparvovec formerly bmn achieve better factor viii level biomarin have announce datum candidate last week share spark therapeutic have lose so far year underperform industry rise period dose range phase ii study evaluate dose vector genome kg vg kg body weight vg kg vg kg spk datum announce form phase ii study show impressive reduction overall annualize bleed rate abr overall annualize infusion rate air abr be reduce week annualize bleed initiate administration spk similarly air be reduce annualize infusion spk administration reduction however factor viii level achieve be not impressive also not consistent patient infuse vg kg achieve mean factor viii activity level week moreover patient infuse dose vg kg spk achieve mean factor viii activity level week patient achieve week biomarin valoctocogene roxaparvovec achieve mean factor viii activity level test dose candidate however biomarin test higher dose candidate vg kg vg kg separate press release spark therapeutic pfizer inc pfe free report announce datum phase ii study evaluate spk treatment patient hemophilia datum study show impressive reduction abr air moreover patient be administer spk have discontinue regular factor ix concentrate infusion also show sustain steady state factor ix activity level hemophilia be rare genetic disorder characterize mutation factor viii gene be responsible clot blood human body deficiency factor viii increase risk bleed become potentially life threaten even case modest injury spark therapeutic inc price spark therapeutic inc price spark therapeutic inc quotezack rank stock considerspark therapeutic carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2110,PFE,dow experience holiday shorten eventful week notch gain successive day market be close monday christmas day holiday decline share key tech component push dow downward tuesday tech stock snap day lose streak wednesday boost index upward gain continue thursday index close yet record high last week dow decline last friday investor be reluctant participate intraday trading ahead christmas holiday lead unusually low volume day whole meanwhile trump sign tax bill well legislation pass senate keep government funded jan come economic datum new home sale november come unit more consensus estimate unit order durable good november come consensus estimate increase meanwhile personal saving rate november decline decade low index gain last week post fifth straight week gain senate republican finally pass tax overhaul bill development permanently slash corporate tax rate follow tax cut major bank telecom company pledge provide better pay employee turn boost investor sentiment moreover gdp increase third quarter post best growth pace more year dow weekmarket be close christmas day holiday monday index decrease point follow decline share apple inc aapl free report share iphone maker plummet worst decline august taiwan economic daily report tech giant be plan cut current quarter sale forecast new iphone unit initial unit meanwhile retail holiday sale unite state surge year high push sector stock higher further energy share rally crude future surge tuesday however benchmark end negative territory loss incur due apple not be offset encourage development index increase advance major tech player offset decline energy stock technology sector snap straight session lose streak end green buoy gain facebook inc fb free report microsoft corporation msft free report broader market largely continue winning run republican pass first tax reform year overall investor find few catalyst lowest volume week year trading volume fact remain lowest level year only average share be trade day year last year share be trade day index gain thursday register st record close year dow fail register intraday high fail achieve milestone only index advanced point largest contribution come unitedhealth group incorporate unh international business machine corp ibm free report financial emerge strongest gainer day technology select sector spdr xlk add second successive day gain share apple gain meanwhile material select sector spdr xlb gain follow increase price copper component move boee company ba free report business division defense space security recently secure foreign military sale fms contract worth term deal company procure new qa aircraft be provide qatar emiri air force contract be award air force life cycle management center patterson air force base be schedule be dec fms fund be utilize partially finance work be execute st loui mi read boee win deal supply jet qatar air force separate development zack rank hold boee recently secure modification contract manufacture delivery full rate production aircraft lot jet be provide navy government contract also offer lot segregable effort include unknown obsolescence class change assessment obsolescence monitoring value contract be award naval air system command patuxent river md majority work be carry seattle wa rest be execute various other location unite state cambridge boee utilize fiscal aircraft procurement navy foreign military sale fms fund complete task work related deal be schedule be december read boee secure deal manufacturing aircraft merck co inc mrk free report pfizer inc pfe free report announce fda have approve investigational oral sglt inhibitor steglatro ertugliflozin tablet steglujan ertugliflozin sitagliptin adjunct diet exercise improve glycemic control patient type diabetes mellitus merck have zack rank steglujan be fix combination steglatro januvia sitagliptin be approve patient be eligible treatment combination apart drug fda also approve segluromet ertugliflozin metformin same indication patient already treat steglatro glucophage metformin inadequately controlled type diabetes mellitus patient be already treat combination ertugliflozin metformin read merck diabetes drug get fda nod adjunct therapy unitedhealth recently announce wholly own subsidiary have sign definitive purchase agreement be set launch tender offer empresas banmdica initial step acquire chilean company deal value nearly enhance unitedhealth footprint south america transaction be expect close first quarter subject customary term condition zack rank unitedhealth already have presence south america backed acquisition amil participacoe sa make former operator hospital clinic brazil deal likely be beneficial unitedhealth give banmedica year expertise latin america largest private health group chile colombia peru further acquisition boost unitedhealth international operation stock have zack rank see complete list today zack rank strong buy stock here verizon communication inc vz free report ericsson eric free report qualcomm technology inc subsidiary qualcomm inc qcom free report have recently complete first successful fdd frequency division duplexing massive mimo multiple input multiple output trial fully compatible customer device verizon have zack rank trial be complete used ericsson latest massive mimo software hardware verizon wireless network mobile test device test device be power qualcomm snapdragon chipset be equip lte modem modem support transmission mode tm technology be compatible massive mimo test be conduct irvine read verizon qualcomm ericsson complete massive mimo trial general electric company ge free report recently land locomotive manufacturing order canadian national railway company cni free report undisclosed amount class railroad buy new locomotive manufacture ge transportation operate segment ge zack rank strong sell ge manufacture tier et tier es tier certify locomotive evolution series part order evolution series be best selling most successful freight locomotive history most class railroad north america have order tier locomotive company be well know produce significantly less particulate matter oxide nitrogen meet stringent environmental protection agency emission standard manufacturing locomotive be do fort worth tx facility ge manufacturing solution production delivery locomotive be expect be do next year begin read ge secure locomotive deal canadian national railway performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week have be year remember bourse dow nearly respectively year date even close thursday dow be course weekly gain do indeed occur index have post weekly gain last week year first time be little suggest gain not continue occur go forward projection fourth quarter earning remain strong fuel mainly recently conclude tax reform further economy continue remain robust international pressure be mostly absent give backdrop dow be likely go strength strength even herald more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2111,PFE,wall street be already hot start new year dow surge new height tech giant amazon amzn free report nvidia nvda free report pick right left tempting be try find next hot tech stock best place start search top pick be massive institutional investor put money term institutional investor cover large spectrum company firm include mutual pension fund endowment private foundation insurance company large investment firm more institutional investor many case have power move market investment institution pour hundred million dollar different stock often employ team analyst perform expensive highly detailed research make large stock purchase once position be take institution have ability resource pump stock favorable medium coverage investor conference used nasdaq detailed institutional holding page be base filing sec september actually find exactly percentage company outstanding share be hold institution say let take look stock high institutional ownershipthat investor want consider pfizer inc pfe free report institutional owner hold pharmaceutical powerhouse share be institutional level holder own total share blackrock blk be largest single holder share vanguard state street corp own respectively pfizer be currently zack rank buy sport grade growth value style score system help earn overall vgm score company be currently trading earning come large cap pharmaceutical industry average top pfizer present solid value investor ratio mark discount compare industry average look ahead pfizer fourth quarter company earning be expect surge year year base current zack consensus estimate pfizer be set report result jan bank america bac free report share bank america experience marginal dip wednesday company report result be subdue time charge related new gop tax law company report quarterly revenue rise year year term large backer banking giant boast substantial institutional ownership rate total institutional holder claim share warren buffett berkshire hathaway brka be biggest bank america institutional holder claim share blackrock come second own bac share vanguard claim share bank america be currently zack rank strong buy rock grade momentum more bank be currently trading earning present discount industry also look ahead bank america have experience upward earning estimate revision upcoming full year last day microsoft corporation msft free report microsoft be also currently zack rank buy institutional investor own technology powerhouse current share total firm hold msft share vanguard blackrock capital world investor be currently largest institutional holder last week share microsoft have pop currently rest just week high microsoft also boat current cash flow growth rate crush industry average help company invest new technology ai base current zack consensus estimate microsoft be project see current quarter earning gain year year company quarterly revenue be project reach mark nearly surge year period microsoft be set report fiscal year second quarter result jan more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2112,PFE,glaxosmithkline plc gsk free report receive approval fda center biologic evaluation research label expansion influenza vaccine vaccine have be approve infant month older vaccine present be approve active immunization influenza subtype type viruse person year age older glaxo share decline year rally witness industry belong approval same dose influenza vaccine be used person age month company submit supplemental biologic license application sbla fda seek approval expand label fluarix quadrivalent march sbla be base positive datum phase iii pivotal study evaluate efficacy fluarix quadrivalent child month month age also basis supportive study vaccine be lead therapeutic area glaxo overall vaccine sale rise first month glaxo vaccine business be strengthen acquisition novartis ag nvs free report influenza vaccine business meningitis vaccine menveo bexsero have be perform well be key contributor sale glaxo latest vaccine product pipeline be shingle vaccine shingrix october glaxo divest quadrivalent meningitis acwy vaccine nimenrix mencevax pfizer inc pfe free report zack rank other key pickglaxocarry zack rank buy top rank health care stock be exelixis inc exel free report sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company surge wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2113,PFE,third quarter report cycle be draw close quarterly result have be strong overall beat percentage be line recent quarters growth rate have be particularly impressive also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week generic maker mylan myl free report miss estimate earning sale due lower epipen sale one report last week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have small biotech pharma company be set report third quarter result nov let see thing be shape quarter puma biotechnology inc pbyi free report puma biotech be schedule release earning market close deliver positive surprise last quarter company earning track record have be good so far have deliver average positive surprise last quarters quarter puma have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg loss share uncover best stock buy sell re report earning esp filter puma biotechnology only market product nerlynx neratinib be launch treatment positive breast cancer august so be first quarter puma record sale nerlynx read more puma earning surpass estimate again intrexon corporation xon free report intrexon be also schedule announce result market close last quarter company deliver positive earning surprise trail quarters miss expectation twice surpass estimate once meeting same other result average negative surprise company have earning esp zack rank sell zack consensus estimate be peg loss cent share investor focus be expect be intrexon pipeline conference call company be develop several candidate partnership other company read more store intrexon earning season ligand pharmaceutical inc lgnd free report ligand be expect report market close ligand earning history have be mixed bag company surpass estimate last quarters miss same other also deliver trail quarter average positive surprise last quarter company come positive earning surprise company have earning esp zack rank strong buy see complete list today zack rank stock here zack consensus estimate earning be peg cent share expect investor focus remain company update regard partnership major pipeline asset third quarter conference call read more store ligand earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2114,PFE,have be banner year stock market trend be likely continue next year tax reform act major drive factor stock couple strong corporate earning accelerate economic growth many part world christmas tree symbolize good tiding let build similar tree stock loving investor rake big gain start base most valuable portion tree technology sector seem be perfect fit here be place top broad zack sector industry classification semiconductor general be expect outperform be cyclical sector tend move higher market rally new area such autonomous car cloud compute gaming wearable vr headset drone virtual reality device internet thing iot artificial intelligence continue fuel exceptional growth intel intc have zack rank strong buy seem excellent pick stock see solid earning estimate revision cent next year past day fall industry have zack rank top see complete list today zack rank stock here stock form leave tree be westlake chemical corporation wlk free report basic material sector acco brand corporation acco industrial product sector sector be expect benefit trump pro growth policy especially big spending infrastructure thus carry sector rank top westlake chemical have zack rank be part industry rank top have see solid earning estimate revision next year past day expect growth rate other hand acco brand see positive earning estimate cent next year past day expect earning estimate have zack rank buy industry rank top look best stock be first see top stock portfolio here top layer have select energy sector be expect be largest contributor earning growth hollyfrontier corporation hfc seem intriguing pick sector have rank top stock see solid earning estimate revision cent next year past day expect earning growth rate have zack rank industry rank top very top be star stock zack rank xoma corporation xoma have soar nearly year so far room more upside next year zack consensus estimate have moved loss loss cent rise earning estimate indicate analyst optimistic view earning indicate higher chance outperformance additionally stock boast solid industry rank top now be do tree structure time decorate bell candy light chocolate concentrate area expect benefit most tax reform bell candy be company be poise benefit tax policy bring offshore cash home reduce tax top hoarder be tech sector apple aapl microsoft msft free report cisco csco free report alphabet googl free report oracle orcl free report hold money overseas accord moody drug maker amgen inc amgn gilead science gild pfizer pfe free report merck co mrk free report also stash huge cash offshore be likely gain tax repatriation policy stock have zack rank hold banking stock be fairy light tree light dual tailwind rise rate tax cut accord keefe bruyette wood tax cut add median bank earning ab bernstein see earning share jump large bank mid cap bank be several choice bank new york mellon corporation bk free report currently have zack rank industry rank top company be expect generate double digit earning growth next year small cap stock pay highest effective tax rate be sweet treat be biggest beneficiary corporate tax cut accord thompson reuter datum company russell pay median effective tax rate larger multinational pay mega cap stock dow jone industrial average pay additionally tend outperform rise rate environment give spread top rank stock double digit earning growth potential include upland software inc upld free report farmer merchant bancorp inc fmao free report geopark ltd gprk petm express inc pet free report stock double year voila tree be bring bountiful return investor jingle santa bell look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2115,PFE,busy last week filled clinical trial datum presentation annual meeting american society hematology cancer space see regulatory approval label expansion drug week roche hold ag rhhby free report breast cancer drug perjeta receive fda nod label expansion post surgery breast cancer high risk recurrence bristol myer squibb company bmy free report blockbuster pd inhibitor drug opdivo receive approval intravenous administration patient completely resect melanoma lymph node involvement metastatic disease unite state meanwhile pfizer inc pfe free report bosulif have be approve treat philadelphia chromosome positive ph chronic myelogenous leukemia cml first line set exelixis inc exel free report also announce approval cabometyx label expansion previously untreated advanced renal cell carcinoma rcc however celgene corporation celg free report suffer setback key drug revlimid fail phase iii study evaluate maintenance therapy treatment nave follicular lymphoma patient meanwhile astrazeneca azn free report announce acceptance supplemental new drug application snda fda seek label expansion tagrisso include first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation snda be also grant priority review suggest speedy review decision next month let see major news detail roche perjeta get approval post surgery breast cancer fda approve perjeta combination herceptin chemotherapy adjuvant therapy positive early breast cancer high risk recurrence drug regimen significantly reduce risk disease recurrence death compare herceptin chemotherapy alone read more roche perjeta get fda nod post surgery breast cancer also week roche enter agreement acquire base biotech company ignyta boost oncology portfolio ignyta be focuse develop therapy cancer rare mutation ignyta lead candidate entrectinib be currently phase ii study patient nsclc roche hold ag price roche hold ag price roche hold ag quotepfizer bosulif approve first line therapy leukemia bosulif label expansion first line set patient chronic phase ph cml be approve fda drug be already approve second later setting indication read more pfizer leukemia drug get fda nod first line set fda have also grant breakthrough therapy designation combination therapy bavencio inlyta be be investigate patient advanced rcc first line treatment combination therapy be currently be evaluate phase ib study pfizer inc price pfizer inc price pfizer inc quoteexelixis cabometyx approve first line kidney cancer exelixis rcc drug cabometyx be grant label expansion first line set fda approve label expansion base datum phase ii cabosun study demonstrated cabometyx be superior pfizer sutent treat first line kidney cancer read more exelixis cabometyx get fda nod first line kidney cancer exelixis carry zack rank hold see complete list today zack rank strong buy stock here exelixis inc price exelixis inc price exelixis inc quotecelgene revlimid fail phase iii lymphoma study celgene be follow news failure phase iii revlimid study study evaluate revlimid combination roche rituxan maintenance therapy treatment nave patient follicular lymphoma combination fail achieve superiority complete response progression free survival standard care rituxan chemotherapy revlimid be primary growth driver celgene label expansion lymphoma have further boost potential celgene corporation price celgene corporation price celgene corporation quotebristol myer opdivo approve intravenous use metastatic melanoma fda approve intravenous administration pd inhibitor opdivo adjuvant treatment post surgery patient melanoma involve lymph node be metatstatic approval be base datum phase iii checkmate study datum study have demonstrated opdivo have significantly improve recurrence free survival compare yervoy opdivo be first drug receive approval adjuvant treatment indication bristol myer have also announce committee medicinal product human use have recommend approval yervoy europe treat pediatric patient year older unresectable metastatic melanoma read more bristol myer yervoy get positive chmp opinion melanoma bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotemeanwhile biolinerx initiate phase iii genesis study evaluate lead pipeline candidate bl study investigate mobilization stem cell patient undergo autologous transplant multiple myeloma juno therapeutic announce partnership thermo fisher scientific use latter cell therapy system activation reagent develop car therapy pipeline look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2116,PFE,dow traverse choppy week marked gain loss even much vaunted tax legislation finally gain legislative approval index increase monday tax cut hope dip tuesday follow concern change adversely impact future monetary stimulus decline come wednesday follow pullback occur investor have already price impact tax cut ultimately index notch gain thursday bank telecom company pledge provide better pay employee last week dow increase last friday hit new time high follow optimism much await republican tax bill have garner sufficient support policymaker enable be pass follow week support senator bob corker marco rubio raise expectation tax related legislation not face further obstacle passage index gain last week follow optimism passage tax cut bill higher rate environment federal reserve finally increase benchmark interest rate quarter percentage point new rate interest hover further central bank official reiterate earlier projection possible rate hike dow index gain monday follow rise optimism much await republican tax bill be likely be pass week development be expect reduce corporate tax rate dow notch record close advanced more point first time year additionally number corporate deal also help boost investor sentiment index lose tuesday optimism passage republican tax bill be outweighed likely impact future monetary stimulus further investor widely expect much await tax cut legislation be pass week turn result stock sell however house fail comply senate rule tuesday follow house re vote tax bill again wednesday housing start rise november upwardly revise october well analyst estimate moreover build permit increase year year settle index decline wednesday investor remain indifferent even congress pass much await republican tax bill day key index reach record high level initially finished lower follow pullback market have already trade higher previous session optimism passage tax cut bill witness sell house actually pass bill index gain thursday follow gain bank energy stock follow passage legislation related tax cut major bank telecom company pledge provide better pay employee turn boost investor sentiment additionally energy sector rally upward wti oil price hit second highest level so far moreover gdp increase third quarter post best growth pace more year further support yesterday gain component move indexnike inc nke free report post second quarter fiscal earning share beat zack consensus estimate revenue come also exceed zack consensus estimate nike have zack rank hold total revenue be year year basis revenue nike brand be revenue converse be earning be year period nike cite decline gross margin higher selling administrative expense reason earning slump read nike post earning beat praise direct consumer effort pfizer inc pfe free report board director announce hike pharma giant quarterly dividend also authorize new share repurchase program quarterly dividend be raise cent cent add annual dividend share amount annual dividend yield increase dividend first quarter be payable mar shareholder record close business feb read pfizer hike dividend announce share buyback plan separate development zack rank pfizer announce fda have approve leukemia drug bosulif first line set drug be now approve first line treatment patient suffering chronic phase ph cml please note pfizer have partnership avillion bosulif read pfizer leukemia drug get fda nod first line set wal mart store inc wmt free report soon be brand walmart officially seem be leave stone unturned counter amazon amzn free report rise dominance supermarket giant have forayed meal kit space card already play earlier year amazon well source reveal wal mart start selling meal kit online begin month give competition other meal kit player blue apron aprn free report hellofresh plait big box retailer be offer kit alliance home chef takeout kit be responsible fulfillment delivery order takeout kit offer wide range global option home chef offering be more classic side takeout kit home chef conduct entire selling process walmart receive small commission well referral fee company meal kit price range kit serve roughly person medium source wal mart begin new venture approximately kit already have option sell stock have zack rank buy see complete list today zack rank strong buy stock here merck co inc mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however zack rank merck say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej read merck keytruda miss primary end point gastric cancer procter gamble company pg free report have appoint activist investor co founder trian fund management nelson peltz board effective mar prolong proxy battle latest announcement come procter gamble reveal last month peltz be lead ernesto zedillo share company nearly diluted share outstanding however latest sec filing company say result ernesto zedillo nelson peltz be extremely close peltz receive almost share vote zack rank procter gamble announce zedillo other be re elect company agree add peltz board director have garner so much shareholder support election result be so close large number shareholder vote nelson peltz be director board have engage numerous discussion mr peltz regard board seat company say read procter gamble appoint peltz board proxy battle exxonmobil corporation xom free report be likely end decade old marketing joint venture bhp billiton ltd bhp free report due concern raise australian competition consumer commission accc relate gas supply rise price accc expressed alarm company market gippsland basin biggest producer country southern state joint venture be biggest producer gippsland basin be rumore zack rank exxonmobil bhp billiton be compel end joint venture sell gas separately company argue joint venture bolster economy termination make new investment supply gippsland basin more complex primary concern be big gas buyer be receive not more offer multus year deal be possible only exxonmobil bhp billiton start marketing gas separately consequently accc announce company sell gas separately gippsland basin legal action be take partner fail comply decision read exxonmobil bhp billiton terminate marketing jv performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookinvestor have heaved sigh relief tax cut legislation finally gain approval house senate bring end long run political struggle be likely boost market day ahead evidence such trend be visible thursday promise higher pay major company boost stock moreover gdp datum have exceed expectation wide margin most other economic indicator have also be largely bullish be little stop market notch further record day ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2117,PFE,share biogen inc biib free report decline almost company alzheimer candidate ban fail meet criterium success base month interim analysis primary endpoint mid stage trial company be develop candidate collaboration eisai co ltd so far year share biogen have gain compare industry growth phase ii study study involve patient prodromal mild alzheimer disease positive biomarker brain amyloid pathology study used bayesian adaptive randomization design allow automatic change design study early success study explore efficacy dose response ban interim analysis month evaluation base eisai house develop alzheimer disease composite score adcom month comprehensive assessment treatment placebo active arm bayesian analysis month indicated success be judge higher probability achieve least reduction rate decline adcom versus placebo interim analysis assessed potential futility stopping safety neither condition be meet study continue full analysis month biogen state month blind study continue further analysis follow predefined study protocol comprehensive final analysis be conduct month look demonstrate clinically significant result datum study be expect second half biogen be look strengthen ad other disorder pipeline notably company alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study consequently lilly decide drop development candidate meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen inc price biogen inc price biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2118,PFE,key announcement week include fda approval eye disease drug well diabetes treatment label expansion exist product regulatory pipeline update be also provide company astrazeneca azn free report johnson johnson jnj free report recap week most important storiesaerie rhopressa gain fda approval aerie pharmaceutical aeri free report get boost earlier expect fda approval rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval be expect consider favorable advisory panel vote october approval come couple month ahead feb pdufa prescription drug user fee act goal date rhopressa be first product aerie portfolio company expect launch product mid second quarter read more aerie get early fda approval lead drug rhopressa merck pfizer diabetes drug get fda nod sglt inhibitor steglatro ertugliflozin have be develop merck mrk free report pfizer pfe free report gain fda approval treatment type ii diabetes steglatro be enter highly crowd diabetes market already have other sglt inhibitor form invokana farxiga jardiance steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan priority review astrazeneca tagrisso label expansion astrazeneca supplemental new drug application snda use tagrisso osimertinib first line treatment patient metastatic small cell lung cancer nsclc tumor have egfr mutation have be grant priority review fda approval indication expand patient population significantly read more astrazeneca tagrisso label expansion filing accept fda janssen car deal priority review apalutamide janssen biotech have inked worldwide collaboration license agreement legend biotech usa inc legend biotech ireland limit subsidiary genscript biotech corporation development manufacture chimeric antigen receptor car cell drug candidate lcar lcar specifically target cell maturation antigen bcma be currently regulatory review china multiple myeloma mm meanwhile clinical study be be plan unite state term deal global net trade sale exclude greater china area be record janssen company split cost profit equally greater china janssen legend have cost sharing profit split arrangement deal term also include upfront payment janssen additional payment achievement development regulatory sale milestone be latest agreement field car have be attract lot interest recent quarters janssen also announce get priority review status fda new drug application nda apalutamide company investigational next generation oral androgen receptor ar inhibitor treatment man metastatic castration resistant prostate cancer crpc fda grant priority review response be april give be fda approve treatment currently available patient population timely approval be boost company cancer portfolio have gain year date compare rally industry belong allergan provide update vraylar seysara allergan agn free report provide couple update pipeline front company partner gedeon richter say vraylar cariprazine meet primary endpoint late stage adult major depressive episode associate bipolar disorder bipolar depression company plan seek label expansion indication second half read more allergan vraylar positive bipolar disease phase iii allergan also announce nda seysara have be accept review allergan partner paratek pharmaceutical be look get antibiotic approve treatment moderate severe acne vulgaris patient year age older approval come second half fda expand label pfizer bosulif grant btd bavencio fda have give nod label expansion pfizer bosulif use newly diagnosed chronic phase ph chronic myelogenous leukemia ph cml patient bosulif initial approval be use patient chronic accelerate blast phase ph cml resistance intolerance prior therapy expand indication increase addressable patient population significantly accord american cancer society new cml case be diagnosed unite state pfizer also announce fda have grant breakthrough therapy designation btd bavencio avelumab use combination inlyta treatment nave patient advanced renal cell carcinoma rcc avelumab be partner merck kgaa breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint be second time bavencio have receive btd hard treat cancer first time be treatment patient metastatic merkel cell carcinoma mmcc disease have progressed least previous chemotherapy regimen label expansion clinical trial collaboration bmy opdivo bristol myer squibb bmy free report pd immune checkpoint inhibitor opdivo gain fda approval yet indication regulatory agency grant approval opdivo intravenous use adjuvant treatment patient completely resect melanoma lymph node involvement metastatic disease opdivo be already approve wide range indication alone well combination other agent be currently several study well fact company also announce clinical trial collaboration taris biomedical evaluation safety tolerability preliminary efficacy taris tar gemris combination opdivo phase ib study evaluate combination patient muscle invasive bladder cancer mibc be schedule radical cystectomy opdivo be prioritize brand bristol myer portfolio product bring sale first month bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock merck be lilly bristol myer decline last month bristol myer be glaxo decline see last pharma stock roundup here teva announce major job cut lilly provide outlook next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2119,PFE,recent fda approval exelixis inc exel free report cabometyx treatment previously untreated advanced renal cell carcinoma have put spotlight space rcc be most common form kidney cancer adult statistic approximately patient unite state world need first line treatment advanced kidney cancer many patient need same annually unite state approval come month ahead schedule note cabometyx cabozantinib tyrosine kinase inhibitor tki be already approve treatment rcc patient have already receive angiogenic therapy cabozantinib inhibit activity tyrosine kinase include meet axl vegf receptor ret approval come back result randomize phase ii trial cabosun result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus current standard care pfizer inc pfe free report sutent importantly cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median pfs cabometyx be month versus month sutent corresponding month improvement sutent be widely used first line treatment rcc novartis ag nvs free report votrient however fda approval cabometyx excellent rate pfs weigh sutent go forward pfizer too be strive hard retain drug leadership november fda approve label expansion sutent drug be approve adjuvant treatment adult patient high risk recurrent rcc follow nephrectomy surgical removal cancerous kidney approval be base result trac trial demonstrated significant reduction risk disease free survival event defined interval randomization tumor recurrence secondary primary cancer death cause patient high risk rcc recurrence receive sutent compare placebo adjuvant set meanwhile pfizer drug inlyta tki be also approve rcc bavencio avelumab monoclonal antibody inhibit pd combination inlyta be be develop first line treatment advanced rcc collaboration merck kgaa sector total return sector total return quoteon other hand immunotherapy be gear too place space september bristol myer squibb company bmy free report announce phase iii study be evaluate opdivo yervoy combination patient previously untreated advanced metastatic rcc meet co primary endpoint combination demonstrated superior overall survival os compare sutent intermediate poor risk patient combination also meet secondary endpoint improve os versus sutent randomize patient consequently independent datum monitoring committee have recommend trial be stop early base plan interim analysis last week fda accept bristol myer supplemental biologic license application priority review opdivo yervoy ipilimumab treat intermediate poor risk patient advanced rcc action date april fda have previously grant breakthrough therapy designation application expedite review additionally variety combination therapy be develop rcc include roche rhhby free report avastin tecentriq earlier month roche announce phase iii immotion study meet co primary endpoint investigator assessed pfs demonstrated combination tecentriq avastin provide statistically significant clinically meaningful reduction risk disease worsening death patient disease expressed pd programme death ligand expression protein compare sutent first line treatment person have advanced metastatic renal cell carcinoma mrcc top line result co primary endpoint os be not mature eisai inc merck mrk free report be also evaluate combination former lenvima multiple receptor tyrosine kinase inhibitor include fibroblast growth factor receptor fgfr combination latter pd therapy keytruda treatment nave previously treat patient metastatic clear cell rcc combination be be evaluate first line use combination ongoing phase iii study clear combination report encourage interim result september hence expect investor keep focus space give stiff competition brewing zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2120,PFE,pfizer inc pfe free report announce superiority breast cancer candidate talazoparib chemotherapy improve progression free survival pfs phase iii study embraca talazoparib be investigation dual mechanism poly adp ribose polymerase parp inhibitor company present datum study san antonio breast cancer symposium share pfizer have gain past month outperform industry rise period embraca study evaluate talazoparib single agent patient germline brca positive breast cancer have receive prior chemotherapy treatment candidate achieve significant reduction risk disease progression median pfs be month talazoparib arm versus month chemotherapy arm moreover patient talazoparib arm achieve complete partial response patient receive chemotherapy parp inhibition be new target therapy inhibit repair dna cell thus destroy cell label expansion application astrazeneca azn free report parp inhibitor lynparza be review unite state meanwhile clovis oncology inc clvs free report have collaborate bristol myer squibb company bmy free report develop parp inhibitor combination latter pd immune checkpoint inhibitor opdivo breast cancer apart talazoparib pfizer be also develop key drug ibrance treat advanced high risk early breast cancer ibrance be currently approve negative advanced metastatic breast cancer pfizer inc price pfizer inc price pfizer inc quotepfizer carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2121,PFE,last week issue article mentioned merger acquisition be quite lean pick significantly propose tax reform be finally approve reform aim cut corporate tax rate boost profit large drug biotech company change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company also focus drug pricing take backseat large drug biotech company struggle organic growth be lot chatter possible increase large give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline article discuss mid large cap name be logical acquisition target next year company pfizer pfe free report merck mrk free report johnson johnson jnj free report other matter buy drug biotech stock be current sale performance drug product prospect future sale growth quality pipeline company discuss have most factor go favor acquisition small cap drug biotech company be very difficult predict quite frequent hence have be exclude discussion biomarin pharmaceutical inc bmrn free report company product pipeline portfolio include rare disease drug be great demand be less competitive space expensive treatment bring huge profit biomarin be such drug developer market cap be biomarin key orphan disease drug vimizim kuvan continue do well backed strong underlie patient demand trend biomarin expect sustain growth drug brineura earlier expect approval year treatment child cln disease form batten disease be also huge boost biomarin impressive rare disease pipeline be also progress well approval pegvaliase treatment expect pipeline believe late stage candidate vosoritide achondroplasia most common form dwarfism bmn hemophilia have blockbuster potential biomarin have already be target takeover speculation company gilead gild amgen amgn roche be interested buy biomarin vertex pharmaceutical inc vrtx free report vertex so far have be tremendous year positive datum read out regulatory approval lead increase eligible patient population approve cystic fibrosis cf kalydeco orkambi cf be vertex main area focus consistent expansion patient population vertex cf product revenue have increase quarter quarter company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine meanwhile company have also make decent clinical progress multiple cf study year have meaningful pipeline catalyst market cap vertex be incyte corporation incy free report incyte strong oncology portfolio make lucrative target company gilead amgen bristol myer market cap incyte be more primary reason incyte be ripe buyout be product market jakafi iclusig jakafi jak inhibitor be first only product be approve polycythemia vera pv myelofibrosis mf rare blood cancer jakafi be see strong sale performance drive strong patient demand indication order expand patient population increase commercial potential drug company be work expand label further iclusig be approve chronic myeloid leukemia acute lymphoblastic leukemia meanwhile incyte pipeline boast candidate immune therapy epacadostat be study combination pd agent merck bristol myer other olumiant rheumatoid arthritis approve europe regulatory application be file unite state january alexion pharmaceutical inc alxn free report biomarin alexion be also focuse development life transform drug treatment patient ultra rare disorder key drug be soliris approve severe ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus have be consistently do well meanwhile alexion be work expand drug label include additional indication approve boost further sale growth have other drug rare disease call strensiq kanuma be emerge growth driver alexion also have robust pipeline several candidate development include soliris follow candidate alxn roche pfizer novartis be interested buy alexion market cap alexion be more today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2122,PFE,pfizer inc pfe free report announce encourage new datum post analysis phase iii study evaluate combination breast cancer drug ibrance palbociclib novartis nvs free report femara letrozole first line treatment metastatic breast cancer notably datum study be present san antonio breast cancer symposium sabcs dec ibrance be approve unite state treat hr advanced metastatic breast cancer combination inhibitor initial endocrine base therapy postmenopausal woman be also approve be used astrazeneca azn free report faslodex woman disease progression follow endocrine therapy presently ibrance be approve more country pfizer share be so far year compare unfavorably industry return paloma study be see combination ibrance femara lead improvement progression free survival pfs time recurrence tumor growth more year compare femara placebo other word study show median pfs woman treat ibrance femara be month compare month femara placebo combination arm thereby indicate reduction risk disease progression paloma have enrolled woman global site country update result safety profile post analysis be consistent primary datum paloma study report last november remind investor ibrance combination femara be clear unite state accelerate approval february treatment hr advanced metastatic breast cancer april pfizer receive regular approval drug base datum paloma trial also same time ibrance label be expand cover few more indication be used combination inhibitor not just femara pfizer be explore possibility expand ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer ibrance have be generate strong sale key driver company top line drug logged sale first month year year successful label expansion drug reap more revenue however breast cancer market competition ibrance have increase recent launch eli lilly lly free report verzenio novartis kisqali pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2123,PFE,pfizer inc pfe free report announce fda have approve leukemia drug bosulif first line set remind investor bosulif be currently approve treatment chronic accelerate blast phase philadelphia chromosome positive ph chronic myelogenous leukemia cml adult be resistant intolerant prior therapy drug be now approve first line treatment patient suffering chronic phase ph cml please note pfizer have partnership avillion bosulifshare pfizer have rise year so far compare unfavorably increase industry supplemental new drug application snda file pfizer label expansion be grant priority review fda august snda filing be base datum phase iii study bfore december last year pfizer avillion announce study have meet primary endpoint demonstrate superiority bosulif bosutinib novartis nvs free report gleevec additionally european medicine agency ema accept similar regulatory application review bosulif record revenue year year approval treat newly diagnosed patient expand eligible patient population drug sale improve further bosulif label expansion make third approval hematology indication month leukemia treatment besponsa relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be approve third quarter zack rank stock considerpfizer carry zack rank hold better rank stock pharma biotech sector include lundbeck hluyy free report xoma corp xoma free report xoma carry zack rank strong buy lundbeck have zack rank buy see complete list today zack rank stock here share lundbeck have rise so far year earning estimate have go past day xoma share have sky-rocket year date loss estimate have narrow almost past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2124,PFE,quite few pharmaceutical industry merger be card propose tax reform be finally approve senate pass amend tax reform bill last week thereby successfully pass second stage bill now be present conference committee representative house senate come together draft final bill tax reform propose cut tax rate corporate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare contrary expectation increase pharma biotech merger acquisition focus be mostly small bolt acquisition licensing deal agreement gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal year rise investor expectation trump action drug price not be onerous previously fear be lot chatter possible increase meanwhile major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buy asset strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace drug biotech company have regularly try merge acquire competitor mega merger deal achieve critical mass sale marketing meanwhile smaller biotech research firm investigate new therapy interesting pipeline candidate have also attract attention larger counterpart last few year focus drug pricing take backseat possibility repatriation fund hope be high activity pick company pfizer pfe free report merck mrk free report be expect take lead support robust cash flow balance sheet wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2125,PFE,pharma biotech sector have make nice comeback year nyse arca pharmaceutical index gain nasdaq biotechnology index be year date be sharp contrast see pharma biotech stock lot pressure sector face intense criticism rise drug price drug pricing be not only reason sector last year fewer number drug approval high profile pipeline failure slower expect new product launch increase competition be other factor weigh sector however factor ramp new product sale success innovation strong result higher number fda approval continue strong performance key product have contribute sustain recovery sector importantly investor now seem more comfortable drug pricing scenario be focuse more fundamental sector so be factor drive sector performance first foremost be industry continue witness demand product give age population increase prevalence wide variety disease strong pipeline innovative treatment impressive result increase health care spending support growth faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit sector receive additional boost more merger acquisition be announce come quarters drug pricing remain headline risk be more clarity situation other challenge sector include grow presence biosimilar generic competition slowdown growth legacy product major pipeline setback pick winnersanyone interested biotech pharma stock know be challenge pick winner high risk high return industry be constantly grow change company hit bull eye become overnight success story share double even triple positive news however negative outcome have equally strong effect share failure very well spell doom company such scenario let take look stock prefer analyst have deep knowledge understand industry company have zero stock help zack stock screener stock have be give strong buy buy rating more broker sport favorable zack rank strong buy buy sangamo therapeutic inc sgmo free report california base sangamo be clinical stage biotech company be focuse translate ground breaking science genomic therapy used platform technology genome editing gene therapy gene regulation cell therapy company have partnership agreement big player pfizer hemophilia shire huntington disease bioverativ beta thalassemia sickle cell disease next month sangamo expect proof concept datum sb hemophilia sb fix hemophilia sb mps sb mps ii other value driver be signing partnership deal company central nervous system tau oncology asset sangamo be zack rank stock strong buy buy broker rating share sangamo be year date significantly outperform industry rally see complete list today zack rank stock here sarepta therapeutic inc srpt free report cambridge base sarepta be commercial stage company focuse discovery development precision genetic medicine treat rare neuromuscular disease company key focus area be duchenne muscular dystrophy dmd sarepta dmd drug exondys be perform well company raise revenue outlook follow release third quarter result company be also progress pipeline sarepta be zack rank stock strong buy buy broker rating share sarepta be year date significantly outperform industry rally akebia therapeutic inc akba free report akebia company headquarter cambridge be focuse deliver treatment patient kidney disease hypoxia inducible factor biology company lead pipeline candidate vadadustat be development treatment anemia related chronic kidney disease dialysis dialysis patient vadadustat be currently late stage development akebia have collaboration license agreement unite state vadadustat otsuka share akebia be year date significantly outperform industry rally akebia be zack rank stock strong buy buy broker rating calithera bioscience inc cala free report south san francisco base clinical stage pharmaceutical company calithera be focuse discovery development novel small molecule drug direct tumor metabolism tumor immunology target treatment cancer lead pipeline candidate cb be be study combination standard care agent company also have collaboration license agreement incyte incy free report small molecule inhibitor hematology oncology indication calithera share be year date significantly outperform industry rally calithera be zack rank stock strong buy buy broker rating glycomimetic inc glyc free report rockville md base clinical stage biotech company glycomimetic be focuse discovery development novel glycomimetic drug address unmet medical need result disease carbohydrate biology play key role company most advanced pipeline candidate be rivipansel pan selectin antagonist be develop treatment vaso occlusive crisis sickle cell disease rivipansel be phase iii study be conduct partner pfizer pfe free report study expect complete second half glycomimetic wholly own pipeline candidate gmi be phase ii study acute myeloid leukemia aml phase study multiple myeloma glycomimetic share be year date significantly outperform industry rally glycomimetic be zack rank stock strong buy buy broker rating look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2126,PFE,merck kgaa be schedule report third quarter earning result nov merck kgaa share price have increase year date industry gain company report result business sector healthcare life science performance material merck revenue be drive sale growth healthcare life science segment first half year expect positive trend continue quarter meanwhile company be streamline healthcare business focus pipeline innovative medicine first half company receive approval bavencio metastatic merkel cell carcinoma mmcc advanced bladder cancer unite state moreover drug be approve eu japan treat mmcc late september however bavencio hasn generate meaningful sale report merck partner pfizer inc pfe free report merck multiple sclerosis drug mavenclad be also approve europe quarter company continue develop bavencio partnership pfizer several cancer indication however expect sale key drug rebif erbitux gonal be lower quarter due continue competitive pressure price reduction however favorable currency movement be expect positively impact top line third quarter moreover operate expense increase first half due new launch higher pipeline development cost company focuse development innovative pipeline launch bavencio new indication geography cost be expect be higher third quarter september merck complete divestment biosimilar business fresenius part strategy become lead science technology company company be plan focus develop pipeline oncology immuno oncology immunology meanwhile merck announce be also plan partial full sale consumer health business include number lead product counter otc category expect management shed light progress plan bavencio earning call also provide update strategic plan merck kgaa price consensus merck kgaa price consensus merck kgaa quotestock warrant lookhere be couple health care stock want consider model show have right combination element positive earning esp zack rank strong buy buy hold post earning beat quarter uncover best stock buy sell re report earning esp filter inovio pharmaceutical inc ino free report be schedule release result nov company have earning esp carry zack rank see complete list today zack rank stock here pieris pharmaceutical inc pir free report be schedule release result nov zack rank company have earning esp zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2127,PFE,exelixis inc exel free report recently announce fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma rcc approval come back positive result randomize phase ii trial cabosun first line kidney cancer result demonstrated statistically significant clinically meaningful improvement progression free survival pfs versus pfizer inc pfe free report sutent remind investor company receive significant boost april fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx treatment rcc patient have already receive angiogenic therapy cabometyx be also approve eu september treatment advanced rcc adult have earlier receive vascular endothelial growth factor vegf target therapy cabometyx rake strong sale first month reflect rise demand drug new patient market share second line set rise hence label expansion drug first line treatment kidney cancer increase target market boost sale exelixis share price have increase year date compare industry gain meanwhile celestial study advanced hepatocellular carcinoma hcc be progress top line result be expect shortly company obtain orphan drug designation same unite state hcc be most common form primary liver cancer accounting more case unite state october exelixis announce celestial trial meet primary endpoint overall survival os cabozantinib provide statistically significant clinically meaningful improvement os compare placebo patient advanced hcc independent datum monitoring committee study recommend trial be stop efficacy follow review second plan interim analysis exelixis plan submit snda fda first quarter exelixis have also inked agreement bristol myer squibb company bmy free report roche hold ag rhhby free report develop cabozantinib combination immunotherapy agent zack rankexelixis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2128,PFE,board director pfizer inc pfe free report announce hike pharma giant quarterly dividend also authorize new share repurchase program quarterly dividend be raise cent cent add annual dividend share amount annual dividend yield increase dividend first quarter be payable mar shareholder record close business feb share pfizer have rise year so far compare unfavorably increase industry pfizer regularly reward shareholder share buyback dividend company return shareholder form dividend share buyback include completion accelerate share repurchase agreement so far company have buy back share worth have remain company current buyback plan pfizer be explore strategic alternative consumer healthcare segment proceed plan use return value shareholder form share buyback dividend consumer healthcare segment pfizer be consider partial full separation spin sale other transaction decision regard same be expect be make next year even choose retain business divestment consumer healthcare business help pfizer focus innovative health segmentzack rank stock considerpfizer carry zack rank hold better rank stock pharma biotech sector include lundbeck hluyy free report ani pharmaceutical inc anip free report xoma corporation xoma free report xoma carry zack rank strong buy lundbeck ani pharmaceutical have zack rank buy see complete list today zack rank stock here ani pharmaceutical earning estimate have moved last day share price company have rise year date xoma share have sky-rocket year date loss estimate have narrow almost past day share lundbeck have rise so far year earning estimate have go past day zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2129,PFE,astrazeneca azn free report announce fda have accept grant priority review supplemental new drug application snda label expansion tagrisso osimertinib astrazeneca snda seek expand tagrisso label include first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation fda grant priority review decision be expect month drug also enjoy breakthrough therapy designation indication be grant october similar application tagrisso label expansion be review eu japan tagrisso be already market second line treatment patient egfr mutation positive nsclc unite state european union japan china astrazeneca share have outperformed industry year date stock have rally compare industry gain period snda be base datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor tki therapy first line lung cancer set datum study show risk progression death be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival pfs be month patient tagrisso compare month comparator arm tagrisso be well tolerate trial safety profile consistent previous experience tagrisso register sale first month reflect growth year period accounting total sale potential approval first line set further boost prospect drug lung cancer market be crowd several company develop marketing treatment roche hold ag rhhby free report astella tarceva be approve treat nsclc pfizer inc pfe free report be develop drug xalkori phase iii study first line treatment nsclc bristol myer squibb bmy free report be also develop opdivo treatment nsclc astrazeneca also have iressa approve treat nsclc be develop imfinzi same indication meanwhile lung cancer be most common cause death cancer indication variation mutation different gene give opportunity different therapy gain market share astrazeneca plc price astrazeneca plc price astrazeneca plc carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2130,PFE,pfizer inc pfe free report announce have buy exclusive right develop commercialize swiss company basilea pharmaceutica fungal treatment cresemba isavuconazole china other country asia pacific region notably cresemba be intravenous iv oral azole antifungal therapy presently market unite state well eu treat serious infection invasive aspergillosis invasive mucormycosis deal pfizer be exclusively entitle distribute commercialize cresemba asia pacific country china include hong kong macao significantly financial term agreement be not disclose company however pfizer do not own marketing right japan too lie asia pacific belt share company have rise so far year underperform industry rally remind investor july pfizer buy exclusive right cresemba europe include austria france germany italy unite kingdom treatment be already available last month company launch drug spain have plan introduce medicine additional european country however pfizer have marketing right nordic country namely denmark finland norway sweden iceland unite state cresemba be market basilea pharmaceutica license partner astella pharma unite state be important note company already enjoy strong position infective space market many antifungal vfend zithromax zavicefta last be add pfizer portfolio december acquisition astrazeneca plc azn free report infective business latest collaboration basilea pharmaceutica strengthen pfizer position therapeutic market pfizer inc price pfizer inc price pfizer inc quotezack rank key pickspfizer carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2131,PFE,busy earning season almost come end impressive run be again focuse latest cancer update happen week week go see cancer drug receive fda approval new indication roche hold ag rhhby free report gazyva pfizer inc pfe free report sutent astrazeneca plc azn free report faslodex however interesting product development be cancer vaccine moderna therapeutic merck mrk free report be work merck have provide fund develop vaccine combination pd therapy keytruda return right half potential sale vaccine be personalize moderna have just develop first enrolled patient top line datum be expect september aveo pharmaceutical inc aveo free report also announce launch first drug fotivda be approve europe treat kidney cancer august recap week most important faslodex approve combination use fda approve new indication breast cancer drug faslodex nov label faslodex now be expand include combination use eli lilly lly new cdk inhibitor verzenio treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy read more astrazeneca faslodex get fda nod use verzenio astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotepfizer sutent approve adjuvant treatment kidney cancer fda approve label expansion cancer drug sutent sunitinib malate latest fda approval sutent label have be expand include adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc approval mark first only adjuvant treatment recurrent rcc sutent be presently market first line treatment advanced rcc have be standard care indication approval decade application use same patient population be also review eu pfizer inc price consensus pfizer inc price consensus pfizer inc quoteroche gazyva approve first line set blood cancer roche obtain fda approval gazyva combination chemotherapy previously untreated advanced follicular lymphoma stage ii bulky iii iv patient respond combination therapy continue be treat gazyva alone approval be base superior progression free survival achieve drug compare rituxan phase iii gallium study drug be already approve use combination chlorambucil treat chronic lymphocytic leukemia cll adult have not have previous cll treatment roche hold ag price consensus roche hold ag price consensus roche hold ag quoteaveo add first drug commercial portfolio aveo partner eusa pharma announce launch kidney cancer drug fotivda european union company expect initiate selling europe start germany drug receive approval august first line treatment advanced rcc adult patient drug be also approve patient be not treat vegfr mtor pathway inhibitor therapy follow disease progression cytokine base therapy approval launch be major milestone aveo fotivda be first only market drug company portfolio acceptance drug be yet be see cut aveo dependence fund collaboration extent aveo pharmaceutical inc price consensus aveo pharmaceutical inc price consensus aveo pharmaceutical inc quoteapart label expansion drug launch buzzword immuno oncology segment car therapy grab headline major boost celgene corporation celg free report bluebird bio inc blue free report fda grant breakthrough therapy designation car therapy candidate bb candidate also receive access priority medicine europe bb be be develop previously treat patient multiple myeloma regulatory designation development be expect expedite meanwhile bayer sign collaboration agreement small base company loxo oncology give access latter pipeline candidate loxo bayer get entry field cancer treatment drug attack cancer base genetic rather attack organ origin moreover celsion submit phase ii clinical study protocol fda evaluate dna base immunotherapy gen localize treatment ovarian cancer look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2132,PFE,astrazeneca plc azn free report announce fda have grant approval new indication breast cancer drug faslodex label faslodex now be expand include combination use eli lilly lly free report new cdk inhibitor verzenio abemaciclib treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy fda approval be base monarch study datum show faslodex improve progression free survival month compare faslodex placebo share london unite kingdom base pharma giant have gain so far year compare favorably industry growth august faslodex have receive fda approval label extension first line monotherapy set treatment postmenopausal woman hr advanced breast cancer approval faslodex be only approve advanced breast cancer later line treatment believe fda approval new indication faslodex month improve sale drug future quarters drug have generate sale so far year year also please note be second time faslodex have be approve use combination cdk inhibitor be already market combination pfizer pfe free report ibrance astrazeneca carry zack rank hold better rank stock large cap pharma sector be johnson johnson jnj free report zack rank buy see complete list today zack rank strong buy stock here share be so far year earning estimate have go past day zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2133,PFE,world diabetes day be celebrate year november theme year be woman diabetes right healthy future focus be emphasize importance provide woman diabetic well risk be diagnosed diabetes affordable equitable access essential diabetes drug technology self management education information need achieve optimal diabetes outcome strengthen capacity prevent type ii diabetes ninth lead cause death woman world diabetes account death year accord information provide international diabetes foundation idf more woman have diabetes figure expect rise more woman be reproductive age birth be affected gestational diabetes gestational diabetes be associate higher risk type ii diabetes mother well child moreover many person type ii diabetes remain unaware condition long period time lead diabetes related complication time disease be diagnosed woman type ii diabetes be consider be time more likely suffer heart disease compare woman condition other diabetes related complication include blindness lower limb amputation kidney failure give statistic complication be not surprising several healthcare company devote significant amount dollar develop treatment device diabetes diabetes management diabetes market be highly crowd company come innovative treatment promising higher efficacy lower side effect currently available diabetes drug include different class treatment dpp inhibitor januvia onglyza trajenta glp receptor agonist victoza sglt invokana farxiga apart metformin insulin addition drug diabetes care market include glucose monitoring system insulin delivery system well insulin pump stock watch world diabetes world diabetes day here be look key pharma company diabetes market denmark base nordisk nvo free report be key player global diabetes market company diabetes portfolio comprise product tresiba once daily new generation insulin xultophy once daily single injection combination tresiba victoza ryzodeg soluble formulation tresiba novolog fiasp fast act mealtime insulin new formulation novolog victoza glp recent development include victoza tresiba label update victoza label now reflect prevention cardiovascular event tresiba eu label reflect significant reduction risk severe hypoglycemia well positive fda advisory panel vote semaglutide approval come later quarter however pricing pressure unite state remain major challenge diabetes care market intense competition globe also remain headwind share nordisk have gain year date significantly outperform industry rally nordisk be zack rank hold stock see complete list today zack strong buy rank stock here french drugmaker sanofi sny free report be key player diabetes market however company diabetes franchise be pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market toujeo apidra amaryl lyxumia soliqua be other diabetes product company portfolio sanofi expect global diabetes sale decline annually constant exchange rate timeframe pricing pressure increase competition formulary exclusion continue impact segment challenge diabetes market sanofi continue work expand strengthen diabetes portfolio currently have diabetes candidate pipeline include sar glp gipr dual agonist phase type ii diabetes sar glp gcgr dual agonist phase ii type ii diabetes sotagliflozin oral sglt inhibitor phase iii type type ii diabetes sar rapid act insulin phase iii type ii diabetes efpeglenatide long act glp receptor agonist phase iii type ii diabetes schedule commence quarter late stage combination study sotagliflozin type ii diabetes be schedule commence quarter share sanofi be year date compare industry rally diabetes new cardiovascular metabolic disease be growth platform astrazeneca plc azn free report key product astrazeneca diabetes portfolio include farxiga onglyza bydureon other recent approval include improve device bydureon bydureon bcise combination farxiga bydureon type ii diabetes astrazeneca diabetes franchise sale unite state be also feel impact intense pricing pressure competition share astrazeneca zack rank stock be year date compare industry rally eli lilly company lly free report be well know player diabetes market lilly have strong portfolio diabetes treatment include trulicity glp jardiance sglt trajenta humulin basaglar humalog glyxambi company have diabetes alliance boehringer ingelheim several product lilly also have strong diabetes pipeline company expect pricing pressure continue diabetes market exclusion jardiance cvs health formulary also impact company diabetes franchise sale share lilly be year date compare industry rally lilly be also zack rank stock merck co inc mrk free report diabetes franchise account third quarter pharma segment sale consist product januvia janumet however peer merck diabetes segment sale continue be affected pricing pressure merck partner pfizer pfe free report be currently seek fda approval ertugliflozin fix dose combination product ertugliflozin januvia ertugliflozin metformin response fda expect december merck be also zack rank stock company share have decline year date compare industry rally diabetes market be currently face intense pricing pressure competition market remain lucrative consider grow prevalence disease demand new better treatment today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2134,PFE,merck mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma notably keytruda be already approve unite state monotherapy third line treatment advanced gastric gej additionally be approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer share merck have lose year so far compare unfavorably industry increase phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however company say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer drug sale be primarily drive melanoma outside unite state meanwhile keytruda development program also significantly advanced year regulatory approval new indication unite state additional disease europe important approval include nod advanced bladder cancer unite state eu advanced microsatellite instability high cancer first sanction combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2135,PFE,pfizer inc pfe free report announce fda have approve label expansion janus kinase jak inhibitor xeljanz tofacitinib dose mg twice daily mg once daily extend release xr formulation latest approval xeljanz now be administer treat adult patient active psoriatic arthritis psa have inadequate response conventional synthetic disease modify antirheumatic drug csdmard tumor necrosis factor inhibitor respectively notably xeljanz mg twice daily be approve unite state second line treatment option patient moderate severely active rheumatoid arthritis ra have have inadequate response tolerate methotrexate mtx drug be approve europe china march ra significantly be first only jak inhibitor approve unite state moderate severe ra active psa share pfizer have gain so far year underperform industry rally supplemental new drug application snda xeljanz be file fda year aforementioned indication approval be base encourage datum phase iii opal oral psoriatic arthritis trial study broaden xeljanz opal broaden opal trial evaluate efficacy safety xeljanz adult patient psa program achieve primary efficacy endpoint statistically significant improvement twice daily xeljanz mg compare placebo month measurement american college rheumatology response change baseline health assessment questionnaire disability index score overall safety result study be find be consistent observed broader rheumatology development program xeljanz remind investor company be also look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis response fda be expect march next year additionally pfizer be conduct phase iiib iv head head study compare xeljanz abbvie abbv free report humira february company announce top line result assessment outcome trial demonstrated inferiority combo therapy comprise xeljanz mtx compare other combo agent humira mtx thus meeting primary endpoint be encourage pfizer label expansion effort xeljanz sale surge year year first month drug label expansion boost further sale blockbuster drug approve treat psa ra include johnson johnson jnj free report remicade amgen inc amgn free report enbrel pfizer market outside unite state canada pfizer press release company announce have start phase iii study evaluate efficacy safety once daily janus kinase jak inhibitor pf treatment moderate severe atopic dermatitis initiation surface first trial jak atopic dermatitis efficacy safety global development program pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2136,PFE,major pharma company pfizer pfe free report teva pharmaceutical industry limit teva free report sanofi read more sanofi earning line sale lag diabetes weak allergan read more allergan top earning estimate tweak view nordisk read more nordisk top earning estimate lag sale report third quarter result last week recap week most important storieswhy do teva share plunge earning teva share plunge follow release third quarter result company miss earning revenue be line expectation however key reason stock poor performance be lower outlook company face huge revenue erosion key brand drug copaxone face generic competition mg formulation well development alone be expect hit earning cent share meanwhile generic business continue face headwind price erosion remain major challenge read more teva stock plunge earning miss view cut key takeaway pfizer conference call pfizer third quarter earning surpass expectation result company raise earning outlook year read more pfizer beat earning raise ep view company say key brand include ibrance eliquis globally xtandi lyrica xeljanz chantix unite state continue perform well however company be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira complete september pfizer have expect take couple year integrate manufacturing plant resolve majority supply chain issue third quarter call company say expect make substantial progress cut sterile injectable shortage regard inflectra pfizer biosimilar version remicade company say penetration unite state continue be slower expect due exclusionary contract remicade remind investor pfizer have file lawsuit district court related provide patient physician access lower cost biosimilar read more pfizer sue accuse prevent inflectra uptake pfizer also provide insight expect impact loss exclusivity loe next few year loe be expect affect revenue next year go approximately not be more far term pipeline regulatory update be concern pfizer expect decision fda type ii diabetes drug ertugliflozin december meanwhile top line result parp inhibitor talazoparib phase iii embraca study read year end study be evaluate talazoparib versus standard care chemotherapy patient germline brca positive metastatic breast cancer datum pd inhibitor bavencio pfizer bb agent patient have not be previously treat immune checkpoint inhibitor be also due later year pfizer be also look submit application fda lorlatinib next generation alk inhibitor treatment alk positive metastatic small cell lung cancer year end pfizer have gain year date compare rally industry belong novartis seek label expansion kymriah novartis nvs free report be look expand label kymriah first car therapy gain fda approval company be seek fda approval use kymriah treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct novartis have breakthrough therapy designation dlbcl dlbcl be most common form hodgkin lymphoma nhl dlbcl be highly aggressive difficult treat hodgkin lymphoma be fatal almost patient due relapse refractory disease kymriah be currently approve patient year age cell precursor acute lymphoblastic leukemia be refractory have relapse least twice approval dlbcl indication expand patient population kymriah gilead already have presence area car therapy yescarta be approve treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment novartis also announce intention acquire advanced accelerator application strengthen presence oncology read more novartis buy french company fda approve astrazeneca blood cancer drug astrazeneca azn free report gain accelerate fda approval btk inhibitor calquence acalabrutinib adult patient previously treat mantle cell lymphoma aggressive type blood cancer be usually diagnosed advanced stage associate high relapse rate note abbvie imbruvica be also approve patient population astrazeneca also expand clinical trial collaboration incyte company evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone early lung cancer meanwhile astrazeneca say il human monoclonal antibody tralokinumab fail achieve primary endpoint late stage study severe uncontrolled asthma top line result late stage study show tralokinumab fail achieve statistically significant reduction oral corticosteroid ocs use primary endpoint add standard care patient dependent ocs fda nod drug label expansion fda also grant approval new dosage mg once daily johnson johnson xarelto mg formulation be approve use reduce continue risk recurrent venous thromboembolism vte completion least month initial anticoagulation therapy johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here valeant get fda nod vyzulta pdufa date idp valeant pharmaceutical international inc vrx free report vyzulta latanoprostene bunod ophthalmic solution also gain fda approval reduction intraocular pressure iop patient open angle glaucoma ocular hypertension company also announce fda have accept regulatory application idp halobetasol propionate tazarotene lotion investigational topical treatment plaque psoriasis response fda regard approval status treatment be expect jun cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock bristol myer squibb bmy free report be merck mrk free report be last month be merck decline see last pharma stock roundup here lilly top front mixed result bristol myer next pharma world quite few small mid cap pharma company be yet report result moreover bristol myer get response fda regard label expansion blockbuster drug sprycel use treatment child ph chronic phase cp chronic myeloid leukemia cml company be also seek approval powder oral suspension pfos formulation sprycel response agency be expect november wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2137,PFE,week be marked flurry datum presentation several company annual meeting american society hematology hold dec dec presentation also include new update datum ongoing clinical study different cancer candidate major announcement include regeneron pharmaceutical inc regn free report top line datum phase ii skin cancer candidate roche hold ag rhhby free report datum tecentriq phase iii study kidney cancer venclexta phase iii study chronic lymphocytic leukemia cll gilead science inc gild free report present update datum car therapy yescarta novartis ag nvs free report also announce update result phase iii study car therapy kymriah moreover pfizer inc pfe free report parp inhibitor demonstrated superiority chemotherapy phase iii study breast cancer let see news detail regeneron cemiplimab positive mid stage study regeneron partner sanofi sny free report announce checkpoint inhibitor target pd cemiplimab show overall response rate orr advanced cutaneous squamous cell carcinoma candidate be evaluate phase ii study empower cscc however median duration response hasn be reach datum cut date company plan file roll biologic license application bla base datum study read more regeneron sanofi report positive top line skin cancer datum regeneron pharmaceutical inc price regeneron pharmaceutical inc price regeneron pharmaceutical inc quoteroche announce datum tecentriq venclexta roche announce positive result phase iii immotion study evaluate immuno oncology drug tecentriq combination chemotherapy avastin pfizer sutent first line treatment advanced metastatic renal cell carcinoma combination therapy achieve statistically significant clinically meaningful increase progression free survival pfs compare sutent datum announce phase iii study murano evaluate venclexta rituxan compare bendamustine rituxan patient relapse refractory cll demonstrated significant reduction risk disease progression death venclexta arm murano study be be conduct aim convert current accelerate approval venclexta full approval read more roche abbvie report positive phase iii result venclexta roche hold ag price roche hold ag price roche hold ag quoteupdate approve car therapy gilead announce long term follow datum phase ii study evaluate chimeric antigen receptor cell car therapy yescarta phase ii zuma study be evaluate therapy refractory large cell lymphoma datum show single infusion yescarta achieve overall response rate orr median follow month novartis be evaluate car therapy kymriah phase iii juliet study adult patient difficult treat cancer relapse refractory diffuse large cell lymphoma datum show month patient treat kymriah show complete response relapse free probability month first response be median overall survival be not achieve median time infusion datum cutoff be month read more novartis report update result kymriah juliet study apart bluebird bio inc blue free report juno therapeutic announce additional follow datum car therapy be phase study bluebird candidate bb achieve objective response complete response juno candidate jcar show orr complete response cr rate monthspfizer parp inhibitor superior breast cancer study pfizer be develop parp inhibitor talazaporib phase iii embraca study patient germline brca positive breast cancer chemotherapy candidate achieve significant reduction risk disease progression median pfs be month talazoparib arm versus month chemotherapy arm read more pfizer talazoparib emerge superior embraca study pfizer inc price pfizer inc price pfizer inc quoteapart news bristol myer announce datum sprycel be be evaluate phase ii study philadelphia chromosome positive acute lymphoblastic leukemia sprycel follow addition chemotherapy regimen achieve event free survival rate orr year moreover fda grant priority review merck supplemental bla look label expansion keytruda include refractory primary mediastinal cell lymphoma type hodgkin lymphoma investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2138,PFE,merck co inc mrk free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion recommend marketing approval prevymis letermovir merck be look get prevymis approve eu prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct merck expect decision european commission month remind investor only last week prevymis receive approval fda prevention cmv infection common potentially serious viral infection allogeneic hsct recipient cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug unite state next month list price day tablet injection merck share have decline year increase industry other key pipeline candidate merck include doravirine hiv new drug application nda filing expect end year mk be be develop phase ii study refractory chronic cough idiopathic pulmonary fibrosis ipf cough merck pfizer pfe free report have develop diabetes candidate ertugliflozin regulatory application be review unite state eu company have file separate ndas ertugliflozin monotherapy twoforfixed dose combination metformin januvia sitagliptin respectively decision fda be expect next month merck carry zack rank hold see complete list today zack rank strong buy stock here better rank stock industry be johnson johnson jnj free report ligand pharmaceutical incorporate lgnd free report zack rank buy share be earning estimate have go past day share ligand pharmaceutical have rise year so far earning estimate have increase past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2139,PFE,arena pharmaceutical inc arna free report announce have complete full enrollment patient phase ii study evaluate pipeline candidate etrasimod ulcerative colitis uc etrasimod apd be orally available next generation sphingosine phosphate receptor modulator primary endpoint study be improvement uc symptom measure mayo clinic score week compare placebo top line result be expect be available first quarter meanwhile arena continue progress pipeline target different therapeutic area include ralinepag pulmonary arterial hypertension apd pain fibrotic disease company report positive result phase ii study ralinepag july be prepare initiate phase iii study discussion fdaarena share have outperformed industry so far year share company have soar industry have register increase several other company be also evaluate candidate uc include pfizer pfe free report be conduct study expand label rheumatoid arthritis drug xeljanz include uc indication company abbvie inc abbv free report be also look get flagship product humira approve uc company have candidate upadacitinib be be evaluate uc zack rank stock considerarena carry zack rank hold better rank health care stock same space be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2140,PFE,merck kgaa report third quarter earning american depositary share lower year figure net sale report quarter come mere organic sale growth be drive healthcare life science segment however unfavorable foreign exchange impact sale portfolio change have slight negative impact share company have perform almost line industry so far year company rise industry increase same period segment sale company report result segment healthcare life science performance material healthcare division record sale year year due negative impact foreign exchange rate negative impact portfolio change however organically sale segment be part strategy focus discovery development innovative pharmaceutical company divest biosimilar business fresenius company be also look divest consumer health business have register higher sale compare year period erbitux sale be year period due increase competition negative currency movement rebif sale come due organic decline negative currency impact gonal sale be due continue competitive pressure north america europe unfavorable currency impact sale life science segment amount primarily due growth business segment partially offset unfavorable foreign exchange effect moreover witness positive portfolio effect organic basis too segment witness sale growth process solution apply solution business record organic sale growth research solution business register organic growth performance material sale be however organically segment witness decline sale other updatein august company receive approval mavenclad europe treatment relapse multiple sclerosis ms meanwhile nice recommend approval erbitux squamous cell carcinoma head neck be follow recommendation approval mavenclad unite kingdom ms november merck kgaa be evaluate lead immuno oncology candidate avelumab number phase iii study several cancer indication partnership pfizer inc pfe free report september candidate receive approval treatment metastatic merkel cell carcinoma mmcc europe japan tradename bavencio first half bavencio receive approval mmcc advanced bladder cancer unite state however bristol myer squibb company bmy free report opdivo roche hold ag rhhby free report tecentriq be available market treatment bladder cancer outlook maintainedmerck kgaa have maintain guidance company expect net sale lower end range due appreciation euro dollar merck kgaa price consensus ep surprise merck kgaa price consensus ep surprise merck kgaa quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2141,PFE,dow continue notch gain week marked key legislative development initially investor be concern news house be consider gradual phase corporate tax rate however market receive boost fed choose not hike interest rate month investor sentiment be buoy further house republican finally reveal detailed framework new tax policy subsequently dow hit record close year last week dow increase last friday such gain be power surge tech stock share microsoft corporation msft free report intel corporation intc free report contribute most gain however blue chip index pare gain due loss chevron corp cvx free report merck co mrk free report share decline respectively broader market be also boost third quarter gdp estimate economy come consensus estimate index increase last week register seventh straight weekly gain be also longest streak weekly gain dow december last year broader market gain market watcher remain hopeful new tax code be sign policy soon moreover house representative clear budget blueprint majority republican voting favor move further ecb announce plan extend quantitative ease program dow index lose monday follow report bloomberg house be consider gradual phase corporate tax rate hurt investor sentiment cause broad base loss market investor also eagerly await announcement next fed chief name president trump be expect reveal thursday meanwhile market also suffer paul manafort be convict russian meddle case index increase tuesday follow gain share apple inc aapl free report meanwhile consumer confidence index logged best read many year last month dow gain post seventh straight month gain moreover be also dow longest streak gain april index gain wednesday fed choose not hike interest rate month moreover fed offer positive view economy say have be improve solid rate such comment boost gain broader market meanwhile investor eagerly wait president trump announce name next fed chief ism manufacturing index come october september meanwhile construction spending increase september august index increase thursday house republican finally reveal detailed framework new tax policy subsequently dow hit record close year meanwhile president trump nominated jerome powell post fed chief lead broad base gain market component move index chevron report third quarter earning share higher zack consensus estimate cent year profit cent quarterly revenue surpass zack consensus estimate be year year zack rank hold chevron total production crude oil natural gas increase compare last year corresponding period oil equivalent barrel day mboe chevron downstream segment achieve earning massive higher profit last year read refine higher oil power chevron earning beat exxonmobil corporation xom free report post third quarter report earning cent share surpass zack consensus estimate cent also bottom line improve year quarter level cent total revenue quarter increase year quarter moreover top line surpass zack consensus estimate quarterly earning upstream segment be show improvement year quarter downstream segment record profit report figure be higher july september quarter stock have zack rank strong buy see complete list today zack rank stock here apple report fiscal fourth quarter result earning share revenue easily beat zack consensus estimate respectively year year basis metric grow respectively apple have zack rank steady iphone sale higher average selling price be big factor spurt service segment resurgent macs ipad business backed impressive result fiscal first quarter gross margin be expect operate expense be project other income expense be likely be tax rate be expect be read apple earning impress iphone service lead merck report third quarter adjust earning share beat zack consensus estimate earning rise year year other item adjust earning exclude charge related new oncology collaboration britain astrazeneca azn revenue quarter decline year year sale also miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale decline year year zack rank merck raise previously issue adjust earning guidance raise sale guidance marginally second time year company expect adjust earning range compare expect earlier revenue be expect range compare earlier forecast include negative currency impact less versus approximately previously read merck earning top sale lag keytruda stay strong pfizer inc pfe free report report third quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive slightly higher sale lower cost share count pharma heavyweight deliver revenue be line zack consensus estimate revenue rise year quarter report well operational basis zack rank pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range compare expect previously zack consensus estimate be peg adjust earning share be expect range compare expect previously zack consensus estimate be peg share read pfizer beat earning raise ep view performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookin recent week market have be buoy record third quarter earning season encourage news legislative front most economic datum release last month have also be encourage nature have few worry front early day ongoing month be likely be only aberration give current state affair market continue notch new record week ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2142,PFE,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2143,PFE,be major news cancer space week failure pfizer inc pfe free report bavencio gastric cancer study setback eisai co ltd esaly free report national institute health care excellence nice do not recommend approval breast cancer drug halaven use second line set uk meanwhile astrazeneca azn free report filing label expansion tagrisso first line set treat lung cancer be accept european medicine agency ema apart bristol myer bmy free report blockbuster drug opdivo again prove worth achieve superior overall survival os phase iii lung cancer study moreover celldex therapeutic inc cldx free report also announce initiation phase study new oncology candidate cdx solid tumor recap week most important storiespfizer bavencio fail gastric cancer study pfizer germany base partner merck kgaa announce failure phase iii study evaluate key pipeline candidate bavencio avelumab treatment gastric cancer third line set study javelin gastric evaluate bavencio monotherapy patient unresectable recurrent metastatic gastric junction adenocarcinoma disease have progressed follow prior therapeutic regimen however study javelin gastric continue evaluate drug first line switch maintenance set read more pfizer merck kgaa bavencio fail gastric cancer study pfizer inc price pfizer inc price pfizer inc quoteeisai halaven suffer setback uk eisai announce nice do not recommend approval halaven uk second line set treat locally advanced metastatic breast cancer have receive chemotherapy approval have give competitive advantage drug drug be already approve uk third later line set same indication eisai co price eisai co price eisai co quotebristol myer opdivo superior lung cancer study bristol myer pd immune checkpoint inhibitor opdivo achieve superior os compare docetaxel phase iii study study checkmate evaluate drug previously treat advanced metastatic small cell lung cancer study be conduct mainly chinese patient achieve primary endpoint os earlier expect company biologic license application file basis positive result study have be accept china food drug administration bristol myer squibb company price bristol myer squibb company price bristol myer squibb company week ema accept mylan myl free report marketing authorization application biosimilar roche rhhby free report breast gastric cancer drug herceptin amgen neutropenia drug neulasta medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2144,PFE,world aids day take place year december person world come together fight hiv support live hiv commemorate have die aids related disease everybody slogan world aids day be everybody count goal be ensure access affordable high quality care service person hiv strong health care system well integration hiv tuberculosis hepatitis service accord information provide world health organization more person have lose life due hiv so far person die last year hiv related cause end approximately person be live hiv number newly infected hiv patient be currently available treatmentswhile be cure hiv present virus be controlled use effective antiretroviral arv drug accord adult child hiv be currently lifelong arv person live hiv be receive antiretroviral therapy art combination art combine more atv drug have be find be effective suppress viral replication person body thereby allow immune system strengthen regain capacity fight infection hiv drug landscape have evolved year drug vary mechanism action be approve year include multus class combination product atripla complera stribild nucleoside reverse transcriptase inhibitor nrtis combivir epivir truvada viread nucleoside reverse transcriptase inhibitor nnrtis edurant sustiva protease inhibitor pis prezista reyataz norvir hiv integrase strand transfer inhibitor insti isentress tivicay well fusion inhibitor entry inhibitor ccr co receptor antagonist accord new hiv infection fall hiv related death decline third art save life however only hiv infected person be aware status remain significant need spread awareness disease availability rapid diagnostic test rdts detect presence absence hiv antibody accord globaldata hiv market unite state france germany italy spain uk japan brazil china be expect grow be significant need new alternative arv treatment option come better tolerability higher efficacy lower rate treatment discontinuation here be look few key player hiv market drug stock focusjohnson johnson jnj free report be key player hiv market company introduce several medicine therapeutic area last year company partner glaxosmithkline plc gsk free report recently gain fda approval juluca first complete single pill drug regimen treatment hiv infection certain adult live disease be virologically suppress once daily antiretroviral be combination tivicay insti edurant nnrti maintain safety efficacy traditional drug regimen nrti simpler treatment regimen make compliance easier hiv patient need stay consistent treatment regimen order keep viral count low company be currently seek fda approval partner gilead science inc gild free report darunavir base single tablet regimen str once daily regimen comprise darunavir mg cobicistat mg emtricitabine mg tenofovir alafenamide mg taf be also work hiv vaccine company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong gilead science inc hiv be primary area focus gilead company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver gilead be currently seek fda approval investigational fix dose combination bic ftc taf fda expect respond feb meanwhile company expect complete mg cohort phase study gs tlr agonist hiv cure year end late stage study evaluate descovy pre exposure prophylaxis prep be schedule complete third quarter company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hcv product be expect generate sale however competition market be intense moreover company be face competition generic product well gilead be zack rank hold stock stock have gain year date compare rally industry belong glaxosmithkline glaxo be majority stakeholder viiv healthcare global specialist hiv company be set partnership pfizer inc pfe free report now have shionogi shareholder well key product hiv portfolio include triumeq tivicay glaxo be work bring new growth driver hiv business juluca be recent addition glaxo be explore new treatment paradigm drug regimen new modality long act injectable new mechanism action include maturation inhibitor broadly neutralising antibody company be work dolutegravir lamivudine combination also be naive patient long act cabotegravir rilpivirine combination viiv have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate glaxo zack rank stock have decline year date compare rally industry belong merck mrk free report merck have presence hiv market form isentress isentress hd hiv integrase inhibitor use combination other antiretroviral agent company hiv franchise bring sale first month year period mainly due lower demand unite state due competitive pressure merck hiv pipeline have couple late stage candidate mk doravirine nnrti mk doravirine lamivudine tenofovir disoproxil fumarate dor tc tdf company expect file regulatory approval doravirine single entity tablet fix dose combination tablet dor tc tdf year end merck zack rank stock have decline year date compare rally industry belong medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2145,PFE,glaxosmithkline plc gsk free report have announce start large late stage african study experimental long act injection prevention hiv viiv healthcare hiv company majorly own glaxo pfizer pfe free report say phase iii study hptn evaluate long act cabotegravir monotherapy prevention hiv infection sexually active woman viiv healthcare be conduct study public private funding collaboration national institute allergy infectious disease niaid bill melinda gate foundation niaid part national institutes health nih be sponsor study viiv healthcare gilead gild free report be provide medicine study enrol more woman age sub saharan african country order prevent hiv infection uninfected person present use oral retroviral medication need be take day compare cabotegravir injection be administer month approvedglaxo share have decline year so far underperform increase witness industry viiv healthcare be already conduct hptn study cabotegravir hiv uninfected man transgender woman have sex man also co funding niaid meanwhile cabotegravir be also be evaluate late stage study drug regimen johnson johnson jnj free report edurant rilpivirine third study initiation announce earlier week last week glaxo partner announce fda approval first dual treatment hiv juluca tivicay dolutegravir edurant rilpivirine juluca have be develop partnership viiv healthcare janssen hiv have be key therapeutic area glaxo new hiv drug tivicay triumeq have be record consistently strong sale gain market share glaxo hiv sale rise constant exchange rate first month meanwhile significant portion expenditure go develop hiv medicine treat prevent hiv glaxoha zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2146,PFE,share momenta pharmaceutical inc mnta free report be company report disappointing result phase study be conduct partner mylan myl free report propose biosimilar orencia company also report loss cent share third quarter narrower zack consensus estimate cent report loss be however wider year loss cent mylan price ep surprise mylan price ep surprise mylan quoterevenue quarter come top zack consensus estimate loss however revenue be year quarter momenta stock have decrease year date compare industry rally quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due higher sale deduction inventory price adjustment owing mylan entry copaxone market deduction reimburse company share glatopa related legal expense sandoz collaborative research development revenue come year quarter increase be due commercial milestone payment earn connection glatopa mg ml however upside sale be partially offset less revenue due termination baxalta collaboration agreement effective dec research development expense be general administrative expense increase outlook updatedmomenta now expect operate expense exclude stock base compensation net collaborative revenue range compare previous guidance guidance also include approximately capital expenditure operate expense third quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer inc pfe free report february be sandoz contract fill finish manufacturing partner glatopa pfizer have submit comprehensive response observation cite warning letter anda approval be now contingent satisfactory resolution compliance observation state warning letter issue pfizer meanwhile momenta continue progress other pipeline candidate currently momenta biosimilar version abbvie inc abbv humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis move ahead company plan submit candidate approval regulatory body however momenta announce do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan evaluate next course action furthermore momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer multiple ascend dose portion study be initiate january complete august top line datum be expect fourth quarter takemomenta third quarter result be overshadowed disappointing result phase study propose biosimilar verison orencia momenta have already suffer blow note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity other hand momenta anda approval glatopa be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2147,PFE,report tech giant amazon meeting generic drugmaker make round company pfizer pfe free report teva pharmaceutical industry ltd teva free report be news former report late stage datum latter announce leadership organizational change recap week most important storiesis amazon talk generic drugmaker accord cnbc report tech giant amazon be preliminary discussion generic drugmaker include mylan myl free report novartis generic arm sandoz enter pharmacy market not much information be available be lot speculation discussion industry watcher way tech giant be plan enter market drug wholesaler retailer pfizer merck kgaa bavencio fail late stage study pfizer merck kgaa suffer setback effort expand label checkpoint inhibitor bavencio avelumab therapy fail meet primary endpoint superior overall survival os compare physician choice chemotherapy late stage study be be conduct evaluate bavencio third line treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression company continue evaluate bavencio first line switch maintenance set gastric cancer accord information provide company gastric cancer be fifth most common cancer world third most common cause cancer death survival advanced disease be poor usually less year third line set be difficult treat population read more pfizer merck kgaa bavencio fail gastric cancer study leadership organizational change teva teva new ceo have announce change organization well leadership structure company key change be generic specialty medicine segment now operate single segment region north america europe growth market generic specialty organization also be merged global group newly form marketing portfolio function be set change dr michael hayden dr rob koreman dipankar bhattacharjee be exit teva effective dec several new appointment be also announce detailed restructure plan be unveil mid december teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track generic competition copaxone mg be major setback stock teva have lose value year date versus decline record industry mylan biosimilar eu review mylan partner biocon say european medicine agency ema have accept marketing application biosimilar version roche herceptin trastuzumab amgen neulasta pegfilgrastim herceptin be used treatment certain positive breast gastric cancer neulasta be used reduction duration neutropenia low count neutrophil type white blood cell incidence fever associate neutropenia adult patient treat chemotherapy certain type cancer marketing application have be withdraw earlier follow audit be conduct european inspect authority biocon drug product facility biocon say have complete corrective preventive action capas base audit be verify inspection part regulatory review process meanwhile company get response fda regulatory application biosimilar version herceptin december earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel partner commence hiv vaccine efficacy study focus world aids day today johnson johnson jnj free report bill melinda gate foundation national institutes health have initiate first efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine efficacy safety reduce incidence hiv infection woman sub saharan africa be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle note efficacy study evaluate different vaccine candidate be be conduct south africa be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong viiv start late stage study hiv prevention viiv healthcare global specialist hiv company majority own glaxosmithkline gsk free report pfizer shionogi limit shareholder have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock bristol myer bmy free report be astrazeneca decline last month bristol myer be glaxo decline see last pharma stock roundup here fda approve glaxo hiv drug roche present datum next pharma world watch regulatory pipeline news pharma stock response fda regard approval status mylan biocon biosimilar version roche blockbuster cancer drug herceptin trastuzumab be december nordisk nvo free report key player diabetes market also get know approval status latest type ii diabetes product offer semaglutide month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2148,PFE,be approach tail end third quarter report cycle result have be strong overall accelerate revenue growth have be particularly impressive number company come positive surprise have be significantly higher revenue surprise trend historical average also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning outlook total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue meanwhile earning growth be currently expect be please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have biotech pharma company be set report third quarter result nov let see thing be shape quarter mylan myl free report mylan be schedule release earning market open deliver negative earning surprise last quarter mylan earning have be mixed so far company top earning estimate trail quarters miss same other company deliver average negative earning surprise trail quarters quarter mylan have earning esp zack rank buy indicate likely positive surprise zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter newly launch product acquisition meda renaissance topical business be likely aid top line however sale epipen auto injector be anticipate decline current quarter result increase competition impact authorize generic launch read more be beat card mylan earning season horizon pharma public limit company hznp free report horizon pharma be also schedule announce result open bell earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank sell zack consensus estimate be peg cent share company expect continue double digit net sale growth ravicti meanwhile horizon pharma primary care business be pressure due implementation new commercial model read more horizon pharma earning disappointment store keryx inc kerx free report keryx be expect report market close last quarter company deliver negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise company have earning esp zack rank see complete list today zack rank strong buy stock here zack consensus estimate be peg loss cent share apart license fee keryx top line comprise revenue generate only market product auryxia be approve treat patient suffering chronic kidney disease ckd dialysis company believe recent formulary addition major part provider boost aurexia sale read more expect keryx earning season look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2149,PFE,earning revenue beatshare johnson johnson jnj free report increase market close oct beating zack consensus estimate earning revenue company revenue increase third quarter year year basis sequential basis come ahead consensus mark increase sale be drive primarily strong sale cancer drug recent acquisition activity earlier year june jnj biggest ever acquisition buy swiss company actelion johnson johnson report gaap earning share ep third quarter year year sequential basis beat zack consensus estimate segment sale company report increase sale geographical segment sale increase international sale increase moreover business segment basis company report improvement segment consumer pharmaceutical medical device revenue increase respectively company increase revenue guidance full year range update adjust ep guidance industry factorsin latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense moreover trump take dig drug pricing accuse company get away murder charge sky high drug price uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy however change deal be card have be pass congress sign trump first current scenario believe be prudent discuss follow etfs have relatively high exposure johnson johnson see health care etfs here health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year read keep portfolio healthy biotech etfs sector look fund have high exposure pharmaceutical biotech health care provider service exposure respectively sep fund top holding be johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively oct fund have return year year date oct xlv currently have zack etf rank buy medium risk outlook vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively sep fund top holding be johnson johnson pfizer unitedhealth allocation respectively sep fund have return year year date oct vht currently have zack etf rank medium risk outlook ishare healthcare etf iyh free report fund seek provide exposure healthcare stock track dow jone health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively oct fund top holding be johnson johnson pfizer unitedhealth allocation respectively oct fund have return year year date oct iyh currently have zack etf rank medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2150,PFE,conatus pharmaceutical inc cnat free report announce appointment marshall executive vice president chief operate officer chief financial officer notably marshall have year experience finance operation business advisory role also be agent private placement private biotechnology company advisor buyer seller biotechnology well pharmaceutical company transaction therefore company be banking marshall contribution aim complete ongoing phase iib study lead candidate emricasan expand pipeline meanwhile conatus be focuse effort develop emricasan january company start encore nf study encore program potential improvement fibrosis steatohepatitis patient fibrosis cause nonalcoholic steatohepatitis nash top line datum be expect first half conatus also initiate study encore lf be phase iib trial study emri monotherapy patient decompensate nash cirrhosis top line datum study be expect go forward company plan initiate new study encore xt plan extension study patient complete encore ph encore lf study continue monitoring efficacy safety clinical outcome health related quality life fact encore study be be conduct provide clinically relevant efficacy dose safety datum support initial registration emricasan chronic administration patient nash cirrhosis potentially support future label expansion december conatus sign exclusive option collaboration license agreement novartis nvs free report worldwide development emricasan be positive strategic agreement novartis not only lend expertise conatus also provide company much need fund development emricasan yet conatus have have share pipeline setback fda have place clinical hold emricasan be be develop pfizer pfe free report due preclinical observation however clinical hold be lift currently several study emricasan be ongoing datum readout schedule next couple year also stiff competition remain threat fact several company allergan agn free report intercept pharmaceutical galectin therapeutic enanta pharmaceutical be work develop treatment nash today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2151,PFE,glaxosmithkline plc gsk free report share have decline year so far underperform increase witness industry british pharma consumer giant stock be rise trajectory announcement third quarter result oct call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter earning release share glaxo have decline earning estimate also witness decline past day meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale mylan myl free report hikma pharmaceutical be look bring generic version advair unite staressale advair be already be adversely impact pricing competitive pressure unite state generic competition europe slowdown sale consumer healthcare segment year due slowdown global growth key consumer category be also concern however not everything be go wrong glaxo newer respiratory hiv drug vaccine be do well continue boost revenue new product generate glaxo pharmaceutical vaccine sale first month go ahead glaxo expect new pharmaceutical vaccine product include contribution shingrix deliver sale annum meanwhile glaxo have make significant progress late stage pipeline think glaxo possess stronger late stage pipeline large cap pharma company be focuse oncology immuno inflammation hiv respiratory therapeutic area company plan terminate partner divest pre clinical clinical program instead allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation recent back back approval new product trelegy ellipta only once daily single inhaler triple therapy copd shingrix vaccine prevention shingle juluca first dual treatment hiv have strengthen glaxo competitive position see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product cost cut bring back track next year glaxo have zack rank hold see complete list today zack rank strong buy stock here large cap pharma stock have decline year be merck co inc mrk free report due several notable pipeline setback year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2152,PFE,pfizer inc pfe free report germany base partner merck kgaa announce phase iii study evaluate key pipeline candidate avelumab treatment gastric cancer third line set fail meet primary endpoint javelin gastric trial study evaluate avelumab monotherapy treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression study fail demonstrate superior overall survival primary endpoint avelumab treatment chemotherapy study evaluate avelumab use hard treat patient population fail other gastric cancer study javelin gastric continue be evaluate avelumab first line switch maintenance set share pfizer have rise year compare increase large cap pharma industry avelumub human pd antibody receive fda approval metastatic merkel cell carcinoma mcc rare form skin cancer march advanced bladder cancer be market trade name bavencio bavencio be also approve eu japan september mcc meanwhile avelumab be be evaluate different type cancer monotherapy combination other portfolio asset pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development currently avelumab be be develop more type tumor include gastric junction head neck hodgkin lymphoma small cell lung ovarian renal cell carcinoma other study be part javelin development program bavencio be consider be key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock heresome better rank large cap pharma stock include johnson johnson jnj free report lundbeck hluyy free report carry zack rank buy share have rise year so far earning estimate have go past day share lundbeck have rise so far year earning estimate have go past day investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2153,PFE,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse company viiv healthcare have initiate phase iii program evaluate combination long act injectable cabotegravir johnson johnson jnj free report rilpivirine treat adult virally suppress hiv infection share glaxosmithkline have underperform industry so far year stock have lose compare unfavorably industry rally period atla trial comprise third phase iii study undertake viiv healthcare investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week administer week versus week study also evaluate pharmacokinetic safety tolerability combination therapy preliminary datum study be anticipate notably viiv healthcare be form november glaxosmithkline pfizer partner be later joined shionogi october remind investor phase iii atla study be already evaluate monthly dose combination regimen virally suppress patient flair study be evaluate combination first line set outcome study be expect notably last week glaxosmithkline partner jnj free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treat hiv infection most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen meanwhile several company be work develop regimen treat hiv gilead gild free report bictegravir single table regimen str be priority review unite state fda be expect announce decision february next year uninitiated mylan have receive tentative approval treat hiv fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate company increasingly develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2154,PFE,drug pricing issue cripple performance last year drug biotech industry small correction recently have witness turnaround year stock large market cap have do particularly well decline last year large cap pharma industry have rise year so far number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring large cap drug sector back track year most drug company larger market cap have see share price rise year astrazeneca azn free report nordisk nvo free report novartis nvs free report johnson johnson jnj free report have even outperformed industry however couple large cap pharma company have witness downside year discuss merck co inc mrk free report merck be very few company share be last year notwithstanding industry decline other way round year share merck have decline year so far merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here glaxosmithkline plc gsk free report share glaxo be year so far stock be rise trajectory announcement third quarter resultson oct third quarter conference call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale slowdown sale consumer healthcare segment year be also concern see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product trelegy ellipta shingrix juluca have boost portfolio lately cost cut bring back track next year merck glaxo have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2155,PFE,expect biogen inc biib free report well know name multiple sclerosis ms market beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise biogen share have rise year better industry growth same time frame biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be let see thing be shape announcement factor considerglobal patient growth be drive prescription trend sale biogen ms drug expect trend continue third quarter however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly second quarter zack consensus estimate key ms drug tysabri tecfidera be respectively meanwhile combine number patient used avonex plegridy continue decline patient transition other oral ms therapy well due higher discount allowance spinraza approve spinal muscular atrophy december witness faster anticipate adoption unite state first half backed robust underlie demand june july spinraza be approve eu canada japan boost sale however call management have mentioned spinraza sale slow second half more difficult treat patient be come patient transition intensive spinraza treatment induction less intensive maintenance schedule biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment investor focus remain tecfidera scrip trend sale rampup spinraza pipeline progress acquisition plan earning whispersour proven model show biogen be likely beat estimate have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise biogen have right mix zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank biogen have zack rank combination biogen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quoteother stock considersome other stock biotech pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2156,PFE,pfizer inc pfe free report japanese partner astella announce prostate cancer drug xtandi meet primary endpoint late stage study expand label drug include early stage patient top line datum phase iii prosper study show treatment xtandi androgen deprivation therapy adt lead statistically significant improvement metastasis free survival mfs primary endpoint man castration resistant metastatic prostate cancer crpc compare adt alone many prostate cancer patient metastatic crpc earlier stage prostate cancer experience disease progression adt however presently fda approve treatment option be available cater condition patient develop metastatic disease xtandi be presently approve treatment metastatic crpc patient have previously receive docetaxel approve metastatic patient population label xtandi be expand cover patient crpc share pfizer be almost response positive news however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer plan discuss prosper study datum fda other regulatory authority also present detailed datum future medical meeting xtandi be add pfizer portfolio acquisition medivation september pfizer sell xtandi unite state partnership astella latter own marketing right outside market pfizer record xtandi alliance revenue second quarter first december pfizer astella have announce phase iv study plato evaluate efficacy safety continue treatment xtandi do not meet primary endpoint plato study evaluate xtandi johnson johnson jnj free report zytiga prednisone compare zytiga prednisone alone xtandi be key drug prizer oncology portfolio pipeline new york base pharma giant be aggressively work expand label market cancer drug xtandi ibrance xalkori xtandi be several study include late stage study hormone sensitive prostate cancer be also mid stage development treatment advanced breast cancer hepatocellular carcinoma pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank drug biotech stock include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report zack rank share alexion be year date zack consensus estimate have climb respectively past day regeneron share year so far estimate have moved have increase past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2157,PFE,company pfizer pfe free report merck mrk free report eli lilly lly free report be news week pfizer be mull strategic option consumer healthcare business merck say not file cetp inhibitor recap week most important storiespfizer divest consumer healthcare segment pfizer be currently review different strategic option consumer healthcare business include full partial separation spin sale company also ultimately decide retain business be not first time pfizer have decide spin sell core business segment strategic step take pfizer include sale hospira infusion system business icu medical february spin animal health business lead creation zoetis well divestment nutrition business nestle pfizer have sell capsugel business affiliate kohlberg kravis robert co divestment consumer healthcare business help pfizer focus innovative health segment also bring fund company use return value shareholder form share buyback dividend read more pfizer consider sale spin consumer healthcare unit pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company have gain year date compare rally industry belong merck collaborate kalvista clinical stage pharma company kalvista pharmaceutical see share shoot collaboration agreement merck kvd future oral diabetic macular edema dme compound base plasma kallikrein inhibition kvd investigational intravitreal ivt injection be schedule move phase ii proof concept study later year merck have option acquire right candidate follow completion study merck have similar option certain other dme candidate kalvista receive refundable upfront payment well payment associate exercise option merck achievement milestone program add company also stand receive tiered royalty net sale candidate commercialize deal merck also acquire ownership stake kalvista worth pipeline setback lilly lilly suffer setback recently approve breast cancer drug verzenio fail meet primary endpoint late stage study kra mutate advanced small cell lung cancer cdk inhibitor fail meet primary endpoint overall survival os analysis secondary endpoint progression free survival pfs overall response rate orr show evidence monotherapy activity read more lilly verzenio fail phase iii lung cancer study meanwhile verzenio have be grant priority review fda use initial treatment advanced breast cancer mean response agency be month receive regulatory application instead usual timeframe month seek fda nod new prostate cancer treatment johnson johnson janssen biotech be seek fda approval apalutamide investigational next generation oral androgen receptor ar inhibitor man metastatic castration resistant prostate cancer crpc be significant unmet need patient population give absence fda approve treatment patient prostate cancer most common cancer american man be expect be diagnosed more man american cancer society apalutamide become part pipeline follow acquisition privately hold aragon pharmaceutical apalutamide approval strengthen expand presence prostate cancer market company currently sell zytiga be approve use combination prednisone treatment patient metastatic castration resistant prostate cancer mcrpc be look expand zytiga label earlier stage metastatic prostate cancer allergan settle restasis litigation innopharma allergan agn free report enter settlement agreement innopharma related litigation regard restasis patent challenged patent be list orange book be schedule expire aug settlement agreement innopharma start selling generic version eye drug unite state feb earlier certain circumstance moreover certain circumstance innopharma be allow launch authorize generic version restasis aug allergan be adopt different way protect restasis generic competition company recently come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect blockbuster eye drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct merck not file anacetrapib merck have decide not seek regulatory approval investigational cetp inhibitor anacetrapib company decision be base thorough review clinical profile drug note merck be not first company drop cetp inhibitor plan company lilly roche pfizer have have high profile setback cetp inhibitor class be more less written read more merck not seek approval cetp inhibitor anacetrapib crl acelrx acelrx pharmaceutical acrx free report share plunge company get complete response letter crl fda sufentanil sublingual tablet fda say approve regulatory application current form have ask additional safety datum agency have also ask company make certain change direction use ensure proper administration tablet acelrx have be ask validate same human factor study acelrx be look get approve reduction moderate severe acute pain dose error associate iv administration invasive single dose applicator sda medically supervised setting cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain week major stock be lilly decline last month bristol myer squibb bmy free report be see last pharma stock roundup here mylan teva copaxone news lawmaker question allergan deal next pharma world aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension october company share be favorable briefing document be report earning october read more kickstart pharma earning store stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2158,PFE,several important development be report week key highlight include termination hepatitis virus deal approval first cancer biosimilar unite state presentation datum company pfizer pfe free report bristol myer squibb bmy free report other recap week most important hcv deal termination achillion pharmaceutical achn free report share fall termination company partnership agreement johnson johnson janssen pharmaceutical hepatitis virus hcv janssen say not continue development jnj combination direct act antiviral al odalasvir simeprevir decision discontinue development do not come big surprise give intense competition pricing dynamic hcv market achillion intend focus development advanced multiple small molecule factor inhibitor complement alternative pathway read more achillion hcv partnership terminate stock fall first cancer biosimilar get fda nod fda approve allergan agn free report amgen mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu pfizer xtandi prosper late stage study pfizer partner astella pharma well be path boost sale prostate cancer drug xtandi company announce positive top line datum late stage study prosper patient metastatic castration resistant prostate cancer crpc company plan discuss datum regulatory authority expansion drug label xtandi sale have be pressure receive boost approval patient population bristol myer sign deal present cancer datum bristol myer squibb present datum european society medical oncology esmo congress show treatment opdivo lead superior recurrence free survival compare yervoy patient resect high risk melanoma read more bristol myer report positive result melanoma study meanwhile company have sign deal halozyme latter enhanze technology global collaboration license agreement be focuse use halozyme technology subcutaneous administration bristol myer immuno oncology drug thereby provide patient more flexible convenient treatment delivery option bristol myer shell upfront make future milestone royalty payment dilutive transaction be expect hit bristol myer earning penny earning cent lilly baricitinib fare well mid stage eczema study eli lilly company lly free report incyte present new safety efficacy datum mid stage study baricitinib eczema annual meeting european academy dermatology venereology eadv baricitinib combine mid potency topical corticosteroid tcs significantly improve sign symptom eczema compare tcs alone company intend commence phase iii program eczema indication later year baricitinib be currently approve eu trade name olumiant moderate severe active rheumatoid arthritis however approval be yet come unite state regulatory filing be resubmit jan lilly stock have gain year date compare rally industry belong teva appoint new ceo teva teva free report have finally end search chief executive officer ceo company announce appointment kare schultz company president ceo seasoned veteran healthcare industry schulz bring almost year experience segment schulz be recently serve president ceo lundbeck be responsible implement significant restructure initiative launch robust turnaround strategy schulz have daunting task ahead consider challenge be face teva include generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track read more teva hire kare schultz ceo be recovery card positive fda panel vote glaxo shingle vaccine glaxosmithkline gsk free report get positive vote fda vaccine related biological product advisory committee vrbpac shingrix prevention herpes zoster shingle adult age give positive vote chance gain approval look pretty high note merck zostavax live attenuate virus vaccine be currently available prevention shingle same patient population read more glaxo shingle candidate get positive fda committee vote glaxo be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session almost major stock record gain pfizer gain bristol myer slip last month bristol myer be glaxo decline see last pharma stock roundup here lilly cut job streamline operation nvs ceo step next pharma world watch usual pipeline regulatory update fda advisory panel be meeting sep discuss supplemental new drug application snda submit pfizer cancer drug sutent adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney moreover fda decision regard label expansion merck pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma be sep look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2159,PFE,very few option be available treat ovarian cancer primarily include chemotherapy radiation surgery effective treatment have many side effect chemotherapy destroy patient immune system radiation kill normal cell cancerous cell surgical process be ineffective cancer spread approval astrazeneca azn free report merck mrk free report lynparza december new target therapy treat ovarian cancer come market drug inhibit enzyme cell parp help repair dna cell thus destroy cell other parp inhibitor be approve fda tesaro inc tsro free report zejula clovis oncology inc clvs free report rubraca parp inhibitor have show more tolerability effectiveness clinical study however none market parp inhibitor rubraca zejula lynparza have be approve first line set date be many other company develop parp inhibitor include pfizer inc pfe free report abbvie inc abbv free report other let see market drug be perform have better prospect lynparza recent label expansion august be indicated maintenance treatment patient suffering platinum sensitive recurrent psr ovarian cancer regardless brca mutation status be also approve brca mutate ovarian cancer third line set drug be available capsule tablet formulation drug record sale first month grow annually drug be also be develop first line maintenance treatment brca mutate ovarian cancer astrazeneca merck expect file label expansion mid however lynparza sale have fall lately unite state launch zejula april year label expansion august include ovarian cancer patient regardless brca mutation have bring par zejula moreover potential approval first line set next year give edge other drug also astrazeneca have collaborate merck co develop lynparza combination immunotherapy successful development be boon patient rubraca receive accelerate approval fda late last year monotherapy advanced ovarian cancer patient deleterious brca mutation treat more chemotherapy clovis be conduct confirmatory study convert approval full approval meanwhile company file supplemental new drug application last month seek label expansion maintenance treatment patient psr ovarian cancer rubraca be review eu drug report sale first month however drug lag other drug be approve treat ovarian cancer irrespective brca mutation meanwhile clovis be evaluate drug phase iii study combination bristol myer bmy free report opdivo first line maintenance therapy stage iii iv high grade ovarian cancer patient be treat platinum base chemotherapy zejula be first parp inhibitor be approve maintenance treatment recurrent ovarian cancer regardless brca mutation be launch april drug be used patient do not have brca mutation be prescribe broader patient population moreover also remove requirement diagnosis brca mutation thereby reduce treatment cost time due competitive advantage zejula have register impressive growth launch have also encroach lynparza rubraca market share drug have generate sale launch company have also claim be most frequently prescribe parp inhibitor ovarian cancer further boost prospect drug european commission grant marketing authorization earlier week tesaro be also develop zejula combination merck pd drug keytruda patient platinum resistant ovarian cancer discussion be evident zejula have edge due requirement brca mutation status have fared better thus far however expand label lynparza be set get back lose share believe rubraca be relatively weaker position drug be uncertainty perform europe lynparza zejula be already approve however have end see actual performance drug few label expansion be expect next year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2160,PFE,benchmark finished green tuesday follow gain technology healthcare sector increase apple share boost broader tech sector healthcare stock rally upward medtronic post strong quarterly performance reiterate fiscal revenue ep guidance key index reach time high tuesday move level intra day trade dow jone industrial average djia increase point close index inx rise close tech laden nasdaq composite index ixic close gain total share be trade tuesday lower last session average share advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue cboe vix decrease close technology healthcare boost marketsshare apple inc aapl free report increase yesterday other tech giant facebook inc fb free report alphabet inc googl free report gain respectively gain major tech company have broad base positive impact technology select sector spdr xlk increase emerge best performer key sector technology sector reach best level share medtronic plc mdt free report advanced company report fiscal second quarter adjust earning share ep beating zack consensus estimate moreover company maintain full year fiscal revenue growth projection range cer also still expect adjust earning share growth be range cer read more medtronic be best perform stock healthcare sector health care select sector spdr xlv rise be second biggest gain sector key holding include unitedhealth group incorporate unh free report pfizer inc pfe free report advanced respectively healthcare company have zack rank hold see complete list today zack rank strong buy stock here follow gain technology healthcare stock key index moved northward small cap index russell advanced tuesday close settle best level ever exist home sale datum upbeatin economic news exist home sale rise october september seasonally adjust rate accord national association realtor sale previously own home also come higher consensus estimate follow steady increase last month exist home sale rise best pace june stock make loss widen earning view trimmedkirkland inc kirk free report post third quarter fiscal result company report wider anticipate loss read more gamestop earning top raise comp view stock upgamestop corp gme free report report robust third quarter fiscal result top bottom line surpass zack consensus estimate read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2161,PFE,johnson johnson jnj free report partner glaxosmithkline gsk free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treatment hiv infection tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant other hand be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen year so far share price be compare favorably increase witness industry come back latest news juluca approval be base datum phase iii sword study datum study publish february year show combination dolutegravir rilpivirine antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen remind investor gilead gild free report bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february next year str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2162,PFE,amgen inc amgn free report announce launch enbrel mini autotouch new auto injector device enbrel unite state enbrel mini single dose prefil cartridge used autotouch reusable autoinjector device provide additional administration option rheumatoid arthritis drug enbrel enbrel mini autotouch device be approve fda september amgen share have rally year so far better industry growth sale amgen largest product enbrel have be soft quite time now pricing pressure stiff competition be hurt sale enbrel main driver amgen revenue enbrel have record sale so far decline year year ra market be extremity crowd give presence treatment abbvie abbv free report humira pfizer pfe free report xeljanz other remain be see new device enbrel lead improvement sale however conference call amgen have say decline trend price market share continue europe biosimilar version enbrel be available unite state sandoz generic arm novartis nvs free report have receive fda approval biosimilar version enbrel erelzi notably erelzi be yet be launch unite state currently amgen have zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2163,PFE,pfizer inc pfe free report announce fda have approve label expansion cancer drug sutent sunitinib malate latest approval sutent label have be expand adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow surgery approval make first only adjuvant therapy recurrent rcc most common type kidney cancer sutent be market first line treatment advanced renal cell carcinoma rcc remind investor supplemental new drug application snda drug be accept fda earlier subsequently september drug label expand indication get mixed response fda oncologic drug advisory committee odac committee vote favor benefit risk profile sutent expand indication however drug label expansion be approve earlier target action date january pfizer share have underperform industry so far year stock have gain compare unfavorably industry rally period notably fda approval be base positive datum phase iii study trac evaluate sutent adjuvant treatment patient high risk recurrent rcc follow nephrectomy surgical removal cancer contain kidney full datum present october last year show trial meet primary endpoint improve disease free survival dfs determine blind independent central review such patient datum demonstrated sutent extend dfs year compare year placebo arm result overall risk reduction application use same patient population be also review eu significantly kidney cancer market be already pretty crowd drug face stiff competition bristol myer squibb bmy free report opdivo novartis nvs free report afinitor votrient bayer amgen nexavar roche rhhby free report avastin tecentriq other sutent generate sale year date year year due competitive pressure however approval expand patient population sale drug improve information provide company rcc account kidney cancer also high risk recurrence represent approximately patient be estimate high risk patient have rcc recurrence year hence potential market opportunity drug be huge additional indication pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2164,PFE,corporation abc free report post adjust earning share fourth quarter fiscal beating zack consensus estimate penny increase year year basis upside be primarily drive strong growth company consult service mwi animal health world courier business revenue improve almost report quarter however revenue lag zack consensus estimate fy glancein fiscal report adjust earning share year year revenue increase year year basis major highlightsin fourth quarter collaborate blue cross blue shield association pfizer pfe free report prime therapeutic walgreen boot alliance wba free report combat opioid abuse crisis unite state company aim expand availability safe medication disposal kiosk walgreen store particularly area opioid epidemic have hit community report quarter initiate product shipment walgreen retail pharmacy add launch online interactive cell gene therapy resource provide insight patient face challenge pertain treatment procedure corporation hold co price consensus corporation hold co price consensus corporation hold co quote segmental distribution segment pharmaceutical distribution service segment historically include drug corporation abdc specialty group absg report quarter revenue segment be year year basis abdc revenue be primarily back solid organic sale growth absg unit perform impressively quarter revenue rise year year increase be attribute strong oncology product sale solid performance third party logistic business other segment segment include consult service abcs world courier mwi veterinary supply revenue segment come year year basis margin detailsin fourth quarter register gross profit year year basis percentage revenue gross margin fourth quarter be flat year year operate expense fourth quarter be reflect increase year year percentage revenue operate margin expand basis point bps quarter issue guidance fiscal company expect adjust earning share fiscal band revenue growth fiscal be expect range expect adjust operate expense increase range adjust operate income growth be estimate band meanwhile operate income growth pharmaceutical distribution service segment be anticipate range peer releasepetm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2165,PFE,share pfizer pfe free report astella pharma moved higher morning trading thursday company say new prostate cancer drug xtandi meet main goal important clinical trial xtandi be actually already approve treat metastatic castration resistant prostate cancer crpc today result show statistically significant improvement survival rate man metastatic crpc many prostate cancer patient initiate androgen deprivation therapy experience disease progression illustrated rise psa level currently be fda approve treatment option patient metastatic crpc develop confirm radiographic metastatic disease say carolina urologic research center director neal shore xtandi be approve treat metastatic crpc create brand new revenue channel pfizer drug be add pharma giant portfolio company acquisition medivation last year current approval xtandi witness sale pfizer most recent quarter astella pharma be base japan own right distribute drug outside unite state pfizer share surge more early morning trading hit intraday high share process share astella gain much touch intraday high pfe have now gain more past week have help stock earn grade momentum style score system want more stock market analysis author make sure follow ryan_mcqueeney twitter new report investor guide cybersecurity cyberattack have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
2166,PFE,bristol myer squibb company bmy free report announce encourage result phase iii study checkmate opdivo checkmate be ongoing phase iii randomize double blind study opdivo versus yervoy patient have undergo complete resection stage iiib stage iv melanoma result study show opdivo mg kg lead significant improvement recurrence free survival rfs compare yervoy ipilimumab mg kg patient stage iiib stage iv melanoma follow complete surgical resection result plan interim analysis show opdivo meet primary endpoint statistically significant improvement rfs compare yervoy july company report positive result same study last week company report positive result phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival compare current standard care pfizer inc pfe free report sutent intermediate poor risk patient base plan interim analysis independent datum monitoring committee recommend study be stop early note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy label expansion additional indication give product access higher patient population increase commercial potential drug however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck co mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share meanwhile fda put partial clinical hold clinical trial checkmate checkmate trial be investigate opdivo base combination patient relapse refractory multiple myeloma bristol myer stock have gain year date industry gain fda put study hold due risk identify keytruda pd agent patient multiple myeloma addition concern astrazeneca plc azn free report fail study lung cancer drug imfinzi loom large company checkmate study opdivo zack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2167,PFE,merck co inc mrk free report announce be not go ahead filing regulatory application seek approval anacetrapib cholesteryl ester transfer protein cetp inhibitor have develop cholesterol management stock be more wednesday merck share have rise year so far compare increase industry detailed datum large phase iii cardiovascular outcome study reveal announce august show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke top line datum study be announce june company say study have meet primary endpoint be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug merck have clearly say then be not sure datum be strong enough seek approval merck say consider file regulatory application fda other agency review result external expert be apprehend investor accumulation anacetrapib fat tissue get way regulatory approval follow thorough evaluation datum discussion external expert merck decide not seek approval anacetrapib clinical profile do not support regulatory filing remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer pfe free report suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy merck carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2168,PFE,series setback continue eli lilly company lly free report company announce phase iii juniper study fail meet primary endpoint study be evaluate verzenio advanced small lung cancer nsclc kra mutation share fall tuesday announcement verzenio receive approval treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy lilly share be so far year slightly underperform industry gain period juniper study compare verzenio roche astella pharma tarceva stage iv lung cancer patient have progressed platinum base chemotherapy have receive additional systemic therapy study do not meet primary endpoint overall survival however show improvement secondary endpoint progression free survival patient overall response rate successful completion study have give verzenio edge pfizer inc pfe free report ibrance novartis ag nvs free report kisqali be only approve breast cancer lilly be currently evaluate verzenio multiple study nsclc include combination therapy merck mrk free report keytruda pd therapy remind investor lilly face major setback past year include complete response letter fda rheumatoid arthritis candidate baricitinib april fail study alzheimer candidate solanezumab november last year meanwhile lilly be also face generic competition due loss exclusivity several key drug include zyprexa cymbalta moreover alimta be face competition immuno oncology agent unite state give recent setback generic competition absence drug near approval lilly struggle maintain growth pace have show so far year eli lilly company price consensus eli lilly company price consensus eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2169,PFE,share pfizer inc pfe free report fall post third quarter revenue zack consensus estimate millionshare armour inc plummet almost post third quarter earning share lower share year quartershare aetna inc aet free report dip post third quarter revenue zack consensus estimate millionshare acorda therapeutic inc acor free report decline post third quarter revenue zack consensus estimate
2170,PFE,pfizer inc pfe free report report third quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive slightly higher sale lower cost share count pharma heavyweight deliver revenue be line zack consensus estimate revenue rise year quarter report well operational basis sale detailcurrency movement hurt pfizer third quarter revenue slightly divestiture hospira infusion system business hurt sale quarter february pfizer divest hospira infusion system business icu medical inc icui free report exclude currency headwind revenue sale rise strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis offset lower sale enbrel viagra prevnar prevenar vaccine franchise loss exclusivity product international revenue rise operational basis meanwhile revenue be flat segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report operational basis year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily unite state ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare second quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline lower demand wholesaler destock ahead potential generic competition december hurt sale viagra global prevnar prevenar revenue decline prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect next year pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market emerge market revenue grow operationally adjust selling informational administrative si expense decline operationally quarter adjust expense also decline guidance pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range compare expect previously zack consensus estimate be peg adjust earning share be expect range compare expect previously zack consensus estimate be peg share mid point adjust ep be expect increase previously research development expense be expect range previously si spending be project range previously takepfizer third quarter result be mixed beat earning estimate deliver line sale however company raise adjust earning guidance year share be pre market trading so far year pfizer share be compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect multiyear wave potential new product launch product line extension bavencio be be consider key long term growth driver pfizer bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march year advanced bladder cancer bavencio be also approve eu japan september mcc other leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approvedby fda third quarter besponsa be also approve eu june pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2171,PFE,yesterday open bell first indictment first conviction russia collusion scandal presidential election help pump brake extend bull market rally trump former campaign manager long time aide face grand jury charge low level trump campaign operative have already pled guilty lie fbi stock market index close lower monday follow straight week not become albatross stock market depend greatly perspective zack exec vp kevin matra latest profit pro column morning see paul manafort indictment little more temporary distraction believe special prosecutor robert mueller be likely end investigation soon have already exhaust finding likely feel same way nothing more blip market breather do seem be greater risk hover mueller investigation be not wrapping just begin unfold such be case market participant be more trepidatious move forward not today future dow nasdaq be halloween tuesday pre market far be spook fear trick trader investor be apparently look plenty treat good reason well case shiller august home sale report be expect bring growth home sale be trail indicator be consider be most sound housing datum economist see regularly paychex small business report morning demonstrate most stable quarter history small business index job growth have begin slow wage increase look be keep pace economic growth minneapoli seattle be city see strongest small business growth job datum be expect be strong tomorrow private sector adp adp free report payroll report friday encompass farm payroll report bureau labor statistic bls even hurricane affected quarter job growth be expect remain robust unemployment remain low mid range indicative very strong domestic labor market earning roundupafter bell expect hear steel free report electronic art ea free report ahead open bell see plenty strength performance mastercard free report outperformed earning revenue estimate post share revenue top share expect quarterly sale rise year year higher switch transaction quarter cross border volume share be hour pre market bp bp free report also trounce expectation report cent share quarterly sale easily beat zack consensus estimate oil production year year be share bp rise initially quarterly news other earning beat morning include pharma giant pfizer pfe free report consumer staple major kellogg beat earning expectation pfizer be line top line kellogg outperformed consensus stock be trading today pre market armour however be much different story earning cent share beat estimate cent quarterly sale post miss more importantly revenue sale guidance be point lower lower north american demand other operational challenge ua stock have already fall more year date be lower ahead open bell
2172,PFE,tuesday october yesterday open bell first indictment first conviction russia collusion scandal presidential election help pump brake extend bull market rally trump former campaign manager long time aide face grand jury charge low level trump campaign operative have already pled guilty lie fbi stock market index close lower monday follow straight week not become albatross stock market depend greatly perspective zack exec vp kevin matra latest profit pro column morning see paul manafort indictment little more temporary distraction believe special prosecutor robert mueller be likely end investigation soon have already exhaust finding likely feel same way nothing more blip market breather do seem be greater risk hover mueller investigation be not wrapping just begin unfold such be case market participant be more trepidatious move forward not today future dow nasdaq be halloween tuesday pre market far be spook fear trick trader investor be apparently look plenty treat good reason well case shiller august home sale report be expect bring growth home sale be trail indicator be consider be most sound housing datum economist see regularly paychex small business report morning demonstrate most stable quarter history small business index job growth have begin slow wage increase look be keep pace economic growth minneapoli seattle be city see strongest small business growth job datum be expect be strong tomorrow private sector adp adp free report payroll report friday encompass farm payroll report bureau labor statistic bls even hurricane affected quarter job growth be expect remain robust unemployment remain low mid range indicative very strong domestic labor market earning roundupafter bell expect hear steel free report electronic art ea free report ahead open bell see plenty strength performance mastercard free report outperformed earning revenue estimate post share revenue top share expect quarterly sale rise year year higher switch transaction quarter cross border volume share be hour pre market bp bp free report also trounce expectation report cent share quarterly sale easily beat zack consensus estimate oil production year year be share bp rise initially quarterly news other earning beat morning include pharma giant pfizer pfe free report consumer staple major kellogg beat earning expectation pfizer be line top line kellogg outperformed consensus stock be trading today pre market armour however be much different story earning cent share beat estimate cent quarterly sale post miss more importantly revenue sale guidance be point lower lower north american demand other operational challenge ua stock have already fall more year date be lower ahead open bell mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2173,PFE,pfizer inc pfe free report say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make next year ultimately opt retain business pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry consumer healthcare segment include several counter otc healthcare medicine vitamin personal care product be sell prescription important product be advil pain relief tablet centrum multivitamin be top selling consumer healthcare brand globally segment record sale almost first half represent growth year year chief executive officer ceo ian reed say consumer unit be not core prescription drug business potential value be more fully realize outside company regard core pharmaceutical business august pfizer say expect approximately drug approval next year include product have blockbuster potential include line extension xtandi ibrance xeljanz xr half potential blockbuster be expect receive approval fund potential spin pharmaceutical consumer healthcare business make easier company achieve goal be be apprehend consumer health biggy nestle reckitt benckiser procter gamble pg free report glaxosmithkline gsk free report johnson johnson jnj free report be interested buy unit pfizer put sale pfizer carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2174,PFE,dow notch record close tuesday follow surge share wal mart departmental store reaffirm guidance fiscal also share repurchase such announcement company send consumer staple sector higher meanwhile broad base market gain traction ahead begin third quarter earning season investor remain hopeful streak strong earning dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close increase advance issue outnumber decliner nyse nasdaq advancer outnumber decliner cboe vix decrease close dow post yet record dow amassed point notch record close tuesday register record so far year blue chip index get biggest boost surge share wal mart wmt free report increase follow announcement company investor conference departmental store state continue focus domestic exist store also strengthen commerce growth rev sale next quarter company also announce share buyback worth bid retire current plan devise oct company state new plan be used next year apart official wal mart also announce guidance fiscal state company expect adjust earning share be moreover wal mart also reveal plan open online grocery pick location store unite state meanwhile share pfizer pfe free report gain also boost dow such gain be incur follow announcement pharmaceutical company plan spin customer health care business reportedly generate annual revenue see complete list today zack rank strong buy stock here nasdaq post add almost point close positive territory major sector end green utility consumer staple stock lead advancer consumer staple select sector spdr etf xlp utility select sector spdr etf xlu gain almost gain be also boost surge share wal mart meanwhile nasdaq gather point pare loss incur earlier session end green post gain last session nasdaq rise last session economist state market gain traction ahead third quarter earning season investor remain bullish strong earning moreover investor be eyee release fomc minute september meeting unwinding balance sheet new tax code keep market much anticipate unwinding humungous balance sheet fed be announce federal reserve open market committee last month fed be slate begin gradual unwinding process month plan trim asset month read more announcement last month trump administration unveil new reform tax policy effectively lower taxe business individual proposal seek decrease corporate tax rate moreover pass business taxe currently categorize individual tax code be slash read more stock make headlineswal mart surge buyback plan upbeat guidanceon tuesday market wake news wal mart store stock repurchase program staggering be carry next year read more unite continental september traffic view bullishunite continental holding inc ual free report wholly own subsidiary unite airline report traffic number september read more statoil make discovery well turn dry britainstatoil asa have hit discovery well north uk sea drill campaign verbier well read more micron plan public offer common stockmicron technology inc mu free report semiconductor company plan offer underwriting public offer common share enhance liquidity read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2175,PFE,pharma biotech stock start strong note part market remain favor year progress so far year nasdaq biotechnology index nyse arca pharmaceutical index be respectively investor be more comfortable drug pricing scenario focus have shift fundamental sector drug pricing issue remain headwind expectation be step take trump administration drive drug price not be draconian previously expect deregulation increase competition seem be way be used control drug price fda be work lower healthcare cost speeding development next generation treatment especially rare disease target cancer therapy be also work clear backlog orphan drug application fda have approve far more drug year do whole key approval year include novartis nvs free report kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead gild free report vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product accord zack earning trend report medical sector have be better perform sector last several quarters be expect record earning growth revenue growth third quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation drug stock keep eye earning help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product company have surpass earning expectation first quarters key revenue driver include ibrance eliquis xeljanz pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential company be report third quarter result october have earning esp eli lilly company lly free report lilly have strong presence pharmaceutical well animal health segment be slate report third quarter result october zack rank stock have earning esp third quarter lilly surpass earning expectation first quarters company be face challenge include generic competition new product drive result lilly have several important pipeline catalyst line come quarters well estimate earning growth current year be lilly have gain year date compare rally industry belong vertex pharmaceutical vrtx free report vertex key player cystic fibrosis cf market surpass earning expectation last quarters average surprise company hold strong position cf market product orkambi kalydeco portfolio early august vertex have say expect cf franchise deliver revenue include orkambi revenue company be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong company be expect report third quarter result october have earning esp quarter biogen inc biib free report biogen be key name multiple sclerosis ms market several approve product tecfidera tysabri avonex portfolio company also have spinal muscular atrophy product spinraza portfolio be work develop treatment disease alzheimer parkinson amyotrophic lateral sclerosis biogen earning track record be good company surpass earning expectation last quarters average surprise company be schedule report third quarter result october have earning esp last day stock have see zack consensus estimate third quarter current year earning be revise respectively biogen zack rank stock have gain year date outperform rally industry belong merck mrk free report merck zack rank stock have consistently surpass earning expectation last quarters average surprise company be report earning october earning esp be company do have challenge form generic competition well safety issue related study be conduct keytruda new product keytruda strong performance base business provide support merck also have deep pipeline bode well long term growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2176,PFE,abbvie abbv free report share increase almost company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment patient rheumatoid arthritis ra fact abbvie share have rally outperform industry rise so far year phase iii select study be multus center randomize double blind placebo controlled parallel group study be design evaluate efficacy safety dose mg mg upadacitinib compare placebo week patient moderate severe ra be stable dose conventional synthetic dmard have have show inadequate response dosage study meet primary endpoint highly statistically significant clinically meaningful result dose compare placebo trial primary endpoint be acr response low disease activity lda result show patient receive mg patient administer mg dose once daily upadacitinib achieve acr response week treatment comparison patient receive placebo lda be achieve patient mg mg dose arm respectively compare patient receive placebo additionally study meet secondary endpoint too notably select be second ongoing phase iii study select ra clinical trial program conduct upadacitinib other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis remind investor last week company announce upadacitinib have meet primary endpoint phase iib study atopic dermatitis company plan advance candidate phase iii study next year give indication note abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be recently approve eu pfizer pfe free report xeljanz be market unite state treat ra strong competition upadacitinib approval also amgen amgn free report have already receive approval market humira biosimilar drug have not be launch yet due ongoing litigation upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2177,PFE,pfizer inc pfe free report be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be well know product prevnar lyrica lipitor celebrex other however many peer pfe be face generic competition pricing pressure several product lipitor norvasc protonix camptosar celebrex zoloft other lose alliance revenue pricing pressure rise competition be hurt top line scenario investor focus remain late stage pipeline candidate commercial potential performance new product apart usual top bottom line number pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise currently pfe have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earn beat pfe beat third quarter earning come cent consensus call ep cent earning rise year year revenue line revenue be line expectation pfizer post revenue be line zack consensus estimate revenue rise year quarter report operational basis guidance pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range versus previously zack consensus estimate stand adjust earning share be expect range compare expect previously zack consensus estimate stand share pre market trading share rise more pre market trading check back later full pfe earning report later pfizer inc price consensus pfizer inc price consensus pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2178,PFE,pfizer inc pfe free report announce final overall survival datum phase iii study profile evaluate cancer drug xalkori first line treatment alk positive small cell lung cancer nsclc xalkori be currently approve treatment alk ro positive locally advanced metastatic nsclc product generate sale first half year year profile study statistically significant improvement overall survival os rate be not observed patient treat xalkori median follow month median os patient treat xalkori be month be month patient randomize chemotherapy please note os be secondary endpoint profile progression free survival pfs be primary endpoint datum publish past statistically significant improvement pfs be noticed xalkori arm compare chemotherapy arm datum be present european society medical oncology esmo congress madrid spain pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer boast strong oncology portfolio pipeline new york base pharma giant be aggressively work expand label market cancer drug ibrance xalkori meanwhile pfizer newly approve immunotherapy bavencio be expect contribute significantly top line bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer partner merck kgaa be focuse continuously grow expand bavencio new indication market globally pfizer other oncology candidate have also be approve fda recently include besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank biotech stock include alexion pharmaceutical inc alxn free report ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report zack rank strong buy seethe complete list today zack rank stock here share alexion be year date earning estimate have rise respectively past day share ligand have rise so far year regeneron share year so far earning estimate have rise have go past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2179,PFE,equity market be go turbulent time be lot volatility uncertainty owing rise geopolitical risk political uncertainty have increase appeal dividend investing geopolitical risksnorth korea conduct sixth nuclear test hydrogen bomb be mount continental ballistic missile sep kim jong action have create huge unrest number asian economy unite state president donald trump have be suggest kim jong threat be meet military action threaten harm territory ally ambassador nikki haley say north korea be beg war have urge impose strictest sanction rogue nation read safe haven currency etfs gain dollar lose geopolitical uncertainty political risksthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong be renew doubt capability trump administration economic growth unite state be better initially expect market commerce department economic growth be second quarter compare earlier estimate read etfs watch oil price rise debt limit deal however latest show bipartisanship trump side democrat increase debt ceiling fund government mid december come disappointment fellow republican be push longer extension hour deal be pass paul ryan state shorter debt limit extension give democrat immense leverage republican once debate start again mid december such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield vanguard dividend appreciation etf vig free report fund be low cost etf seek provide exposure large establish company provide high dividend have aum charge fee basis point year sector look fund have high exposure industrial consumer service consumer good allocation respectively jul fund top holding be microsoft corporation msft free report johnson johnson jnj free report pepsico inc pep free report allocation respectively jul fund have return year year date sep currently have zack etf rank buy medium risk outlook quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively sep fund top holding be johnson johnson apple inc aapl free report microsoft corporation allocation respectively sep fund have return year year date sep currently have zack etf rank medium risk outlook ishare core dividend growth etf dgro free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure information technology health care financial allocation respectively sep fund top holding be pfizer inc pfe free report apple inc microsoft corporation allocation respectively sep fund have return year year date sep currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2180,PFE,share bristol myer squibb company bmy free report gain company end phase iii combination study checkmate earlier expect meet co primary endpoint phase iii study evaluate opdivo yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc meet co primary endpoint study show superior overall survival os compare current standard care sunitinib market sutent pfizer pfe free report intermediate poor risk patient fact combination opdivo yervoy also meet secondary endpoint improve overall survival randomize patient base plan interim analysis independent datum monitoring committee dmc recommend study be stop early safety tolerability combination treatment observed study be consistent previous report dose schedule similar subgroup august bristol myer announce top line result checkmate study study meet co primary endpoint objective response rate orr markedly co primary endpoint progression free survival favore combination opdivo yervoy versus sunitinib do not reach statistical significance bristol myer share have underperform industry year date stock have be compare industry gain same time frame note opdivo become first pd inhibitor be approve hematological malignancy classic hodgkin lymphoma unite state eu november november opdivo gain fda approval treatment patient recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy fact renal cell carcinoma be most common type kidney cancer adult have huge unmet medical need thus label expansion additional indication give product access higher patient population increase commercial potential drug additionally company enter collaboration agreement seattle genetic inc sgen free report june deal bristol myer evaluate combination opdivo seattle genetic antibody drug conjugate adc adcetris phase iii trial potential treatment option patient relapse refractory transplant ineligible advanced classical hodgkin lymphoma hl however bristol myer suffer setback january decide not pursue accelerate regulatory pathway regimen opdivo yervoy first line lung cancer unite state base review available datum currently opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc company be expect suffer further loss market share bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rankbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2181,PFE,aerie pharmaceutical inc aeri free report be expect report third quarter result nov last quarter company report narrow expect loss fact aerie performance last quarters have be decent company report narrower expect loss trail quarters post wider expect loss remain average positive surprise aerie share price have increase year date industry decline earlier month aerie stock price surge positive news lead drug rhopressa likely positive surprise proven model indicate aerie beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate stand loss cent zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aerie have zack rank be favorable combination zack rank positive esp indicate likely positive surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan hence expect investor focus pipeline update aerie lead candidate rhopressa once daily formulation lower intraocular pressure iop be be evaluate patient suffering open angle glaucoma ocular hypertension oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug apart rhopressa aerie be also evaluate roclatan aerie initiate phase iii study mercury europe other pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan be be evaluate lower iop patient glaucoma ocular hypertension company plan submit nda same first half trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe expect investor focus further pipeline update call cash burn year be project due further pipeline development aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc quotestock considerhere be health care stock want consider model show too have right combination element post earning beat quarter clovis oncology inc clvs free report have earning esp zack rank company be schedule release result nov see complete list today zack rank stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2182,PFE,third quarter report cycle be witness revenue acceleration positive revision trend result half member be already oct total earning member be same period last year higher revenue surpass earning revenue estimate respectively accord earning preview company account index total market capitalization report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig merck co inc mrk free report celgene corporation celg free report abbvie inc bristol myer squibb company bmy free report gilead science inc gild free report report third quarter result last week merck celgene abbvie outpaced zack consensus estimate earning lag same revenue however bristol myer gilead surpass expectation earning revenue notably bristol myer gilead raise earning outlook well merck raise previously issue adjust earning guidance up sale guidance marginally abbvie celgene also tighten earning guidance here have biotech pharma company be set report third quarter result oct let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning market open deliver positive earning surprise last quarter company earning performance have be mixed bottom line miss last quarters beating same other bring average surprise negative quarter pfizer have earning esp zack rank hold zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully meanwhile sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue well sale viagra be expect be affected lower demand read more be beat likely pfizer earning season previous article show pfizer be likely beat earning quarter however estimate change thereafter be not certain beat earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteincyte corporation incy free report incyte be schedule release earning market open witness negative earning surprise last quarter company earning performance have be mixed so far have deliver positive surprise last quarters miss estimate unavailable average earning surprise last quarters be negative company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here company key growth driver jakafi have be perform well expect trend continue be report quarter well incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quoteacorda therapeutic inc acor free report acorda be schedule release earning market open witness negative earning surprise last quarter company earning performance have be disappointing so far company have incur negative surprise last quarters average earning surprise last quarters be negative company have earning esp zack rank strong sell make surprise prediction difficult zack consensus estimate be peg cent share be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision expect investor focus refusal file rtf relief late stage pipeline candidate inbrija be develop treatment patient be suffering parkinson disease acorda therapeutic inc price ep surprise acorda therapeutic inc price ep surprise acorda therapeutic inc quotezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor
2183,PFE,israel base generic drug maker teva pharmaceutical industry limit teva free report see share decline last week company suffering fresh setback form fda approval generic version company top selling brand drug copaxone multiple sclerosis mylan nv myl free report gain fda approval generic version mg thrice weekly dosage well once daily mg formulation copaxone mylan be first applicant challenge mg patent company enjoy day exclusivity mylan have launch product mylan also gain approval mg dose eu fda approval generic copaxone be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug copaxone bring total sale first half end second quarter copaxone mg account more total copaxone prescription unite state entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva generic pricing erosion remain huge issue generic company teva sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor consolidation industry have increase ability negotiate lower price generic drug lead increase price erosion decrease volume moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track company have be work address issue recently announce appointment new ceo read more do teva pharmaceutical stock soar today teva have also make significant progress divestment core business however entry copaxone mg be major setback company well be teva be able get back track teva be zack rank sell stock company have see zack consensus estimate current year earning be revise downward last day zack consensus estimate have be revise downward last day teva have lose value year date versus decline industry teva deal challenge here be look drug company sport strong zack rank look well position celgene corporation celg free report celgene be focuse discovery development innovative therapy treatment cancer inflammatory disease company have several blockbuster product portfolio include revlimid pomalyst otezla celgene have rich promising pipeline well key datum readout line next year celgene zack rank buy stock have gain year date outperform rally industry belong company also have vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank strong buy stock here pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product first half year company paid dividend share buyback shareholder include accelerate share repurchase program pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score amgen amgn free report amgen most well know name biotech industry have presence oncology hematology inflammation nephrology bone health cardiovascular disease market key product include enbrel neulasta aranesp prolium xgeva epogen kyproli repatha blincyto other most product be blockbuster have blockbuster potential amgen have deep pipeline company work bring new product market combat impact potential biosimilar competition mature product franchise company have be return value shareholder form share buyback dividend amgen be also zack rank stock vgm score stock have gain year date outperform rally industry belong vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market company hold strong position market market product orkambi kalydeco vertex be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong ligand pharmaceutical incorporate lgnd free report ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen novartis other ligand also have licensing deal base omniab technology ligand recent decision acquire crystal bioscience leader avian genetic generation fully human therapeutic antibody be expect boost company revenue least earning least cent share ligand zack rank stock have gain year date substantially outperform rally industry belong look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2184,PFE,total earning total healthcare market capitalization be revenue growth earning growth appear solid compare many other sector earning revenue beat ratio respectively look disappointing most notable player johnson johnson jnj free report be first major drug company report earning oct follow eli lilly company lly free report bristol myer squibb company bmy free report oct oct respectively other major drug company merck mrk free report pfizer pfe free report report oct oct respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance read healthcare etfs focus johnson johnson earning pfizer earning drug giant come earning beat line revenue earning share cent come couple cent zack consensus estimate revenue be line estimate year year basis earning share revenue rise respectively pfizer narrow revenue guidance range raise earning share guidance range merck earning focusmerck beat earning estimate miss revenue earning share come surpass zack consensus estimate improve year quarter revenue decline year year be zack consensus estimate merck raise revenue guidance earning share guidance year bristol myer earning focusbristol myer miss earning beat revenue report earning share cent couple cent estimate revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lilly earning focuseli lilly top zack consensus estimate front earning outpaced zack consensus estimate couple cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously etf string earning beat fail boost pharma etfs see rough trading past month have highlighted detail fund have zack etf rank hold high risk outlook powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month read lie store pharma etfs spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take nearly share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket johnson johnson pfizer bristol myer eli lilly account least share merck make asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose month want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2185,PFE,astrazeneca azn announce fda have grant breakthrough therapy designation btd tagrisso osimertinib first line treatment patient metastatic epidermal growth factor receptor egfr mutation positive small cell lung cancer nsclc tagrisso be currently approve unite state european union japan china second line treatment patient advanced nsclc progress follow treatment egfr tki due egfr resistance mutation astrazeneca share have outperformed industry year date stock have surge compare industry gain btd be base phase iii flaura study evaluate tagrisso versus standard care egfr tyrosine kinase inhibitor tki therapy first line lung cancer set datum show treatment tagrisso reduce risk progression death more half compare other commonly used egfr inhibitor first line treatment patient egfr mutation positive nsclc median progression free survival pfs be month patient tagrisso compare month comparator arm tagrisso be well tolerate safety profile consistent previous experience btd fda expedite development review drug be intend treat serious disease provide access drug patient soon possible separate release company also announce european medicine agency ema have accept marketing authorisation application maa imfinzi durvalumab treatment patient locally advanced stage iii unresectable nsclc disease have not progressed follow platinum base chemoradiation therapy maa submission be base encourage datum phase iii pacific study imfinzi have already receive accelerate approval unite state treatment patient locally advanced metastatic urothelial carcinoma have disease progression follow platinum contain chemotherapy disease have progressed month receive platinum contain chemotherapy neoadjuvant adjuvant surgery potential label expansion drug boost sale company june pharmaceutical giant roche holding rhhby free report announce global randomize phase iii study alex lung cancer drug alecensa meet primary endpoint initial first line treatment alecensa significantly reduce risk disease worsening death progression free survival pfs compare pfizer pfe free report xalkori patient suffering anaplastic lymphoma kinase alk positive advanced small cell lung cancer nsclc astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rank stock carry zack rank hold better rank stock health care sector include acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat share price company have climb year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2186,PFE,dow endure significant loss holiday shorten trading week market be close monday labor day holiday index endure worst day loss several week tuesday follow rise tension north korea index rebound wednesday president donald trump conclude agreement congress debt ceiling issue however loss key component drag index lower thursday last week index gain last friday market watcher play chance possible rate hike fed follow desultory nonfarm payroll datum august total job be add economy august significantly lower consensus estimate job addition payroll addition be lower expect unemployment rate increase reach meanwhile ism manufacturing index hit year high month august index gain last week period hurricane harvey pummeled houston force major oil refinery area shut moreover north korea test fire ballistic missile japan raise geopolitical tension unite state meanwhile speaking cnbc secretary state steven mnuchin say trump administration have present detailed tax plan congress expect sign law year end dow weekmarket be close monday labor day holiday dow suffer loss more point tuesday register worst day drop aug end day winning streak such loss be incur investor rotate relatively riskier asset due escalate tension pyongyang washington likelihood fallout hurricane name irma coast florida send home insurer lower index gain wednesday president trump reach agreement key member congress extend debt ceiling deadline be do aid relief funding victim hurricane harvey however category hurricane irma gain momentum be slate land fall coast florida weekend news irma come send timeshare vacation stock lower meanwhile fed vice chairman announce plan retire mid october cite personal reason index lose thursday drag share walt disney company free report goldman sachs group inc gs free report disney share lose ceo bob iger announce company earning guidance full year be be revise downward share goldman sachs also decline weigh heavily dow broader market close marginally lower investor rotate financial seek telecom consumer discretionary stock component move index unite technology corporation utx free report recently inked definitive agreement acquire iowa base avionic firm rockwell collin inc col free report strategic transaction be likely create industry behemoth unrivaled competitive advantage be largest aircraft equipment manufacturer world individual capacity zack rank hold unite technology acquire rockwell collin share combination cash stock term agreement rockwell collin shareholder be entitle receive share cash balance amount unite technology share equate purchase price include rockwell collin net debt company expect fund transaction secondary debt offer available cash maintain solid investment grade credit rating transaction be likely close third quarter subject mandatory approval other customary close condition read unite technology inks accretive rockwell merger deal boee co ba free report recently announce be company receive aerospace system air platform technology research program contract unite state air force have ceiling value notably boee be final company receive award pentagon contract company be responsible provide quality research affordable revolutionary capability warfighter be award air force research laboratory patterson air force base boee expect complete task aug work be carry company hazelwood ms facility utilize fiscal research development fund finish task stock have zack rank buy see complete list today zack rank stock here johnson johnson jnj free report announce fda have approve label expansion oral pulmonary arterial hypertension pah medicine tracleer johnson johnson have zack rank consequently mg tablet tracleer be now approve use pediatric patient age year older idiopathic congenital pah improve pulmonary vascular resistance pvr be expect result improvement exercise ability approval tracleer have become first medicine unite state be approve use pediatric patient mg oral suspension formulation pediatric use be expect be available fourth quarter year presently tracleer be market mg dosage adult patient still be available read pah drug label expand pediatric use merck co inc mrk free report announce pd therapy keytruda have receive approval european commission first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain chemotherapy read merck keytruda get eu approval bladder cancer separate development zack rank merck announce acquire germany base rigontec privately hold immuno oncology focuse biotech upfront cash payment almost euro rigontec be leader retinoic acid inducible gene rig target therapeutic be novel immuno oncology treatment approach deal completion date be not yet disclose subject certain close condition apart upfront payment base achievement certain milestone merck also make additional contingent payment worth approximately euro read merck opt buy german immuno oncology biotech pfizer inc pfe free report announce fda have grant approval mylotarg adult patient newly diagnosed cd positive acute myeloid leukemia aml drug also receive approval treat relapse refractory cd positive aml adult well child year older pfizer have zack rank approval be expect fda oncologic drug advisory committee have vote favor mylotarg approval july however be note label drug include box warning hepatotoxicity include severe fatal hepatic veno occlusive disease approval be grant base datum multiple investigator lead clinical trial include alfa aml mylofrance alfa phase iii study evaluate mylotarg combination chemotherapy newly diagnosed aml patient drug show significant improvement event free survival ef achieve month compare month chemotherapy read pfizer acute leukemia drug mylotarg approve fda performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week investor seem be weigh several concern domestic foreign origin tension north korea continue simmer hurricane be likely make landfall weekend such crisis occur even texas recover effect hurricane harvey give such backdrop only encourage economic datum help market return winning way week ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2187,PFE,johnson johnson jnj free report healthcare bellwether announce fda have approve label expansion oral pulmonary arterial hypertension pah medicine tracleer consequently mg tablet tracleer be now approve use pediatric patient age year older idiopathic congenital pah improve pulmonary vascular resistance pvr be expect result improvement exercise ability approval tracleer have become first medicine be approve use pediatric patient mg oral suspension formulation pediatric use be expect be available fourth quarter year presently tracleer be market mg dosage adult patient still be available remind investor tracleer other pah drug include opsumit ventavis veletri uptravi be add portfolio acquisition swiss biotech actelion acquire actelion june year diversify former revenue pah category actelion newer drug opsumit uptravi have be well receive be poise become blockbuster drug however tracleer older medicine be face competitive pressure believe label expansion pediatric use improve sale tracleer go forward pah be chronic life threaten disease characterize increase blood pressure pulmonary artery pah market be highly attractive give low diagnosis rate low penetration exist therapy significant unmet medical need other actelion unite therapeutic corporation uthr free report hold strong position pah market many approve product remodulin adcirca tyvaso orenitram pfizer pfe free report revatio be used same indication well arena pharmaceutical inc arna free report have ralinepag pipeline be also be develop pah so far year share price have increase compare favorably gain record industry belong carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today
2188,PFE,aerie pharmaceutical inc aeri free report post third quarter loss cent share include stock base compensation wider zack consensus estimate loss cent year loss cent be development stage company aerie have not generate revenue product sale yet aerie share price have increase last month industry decline last month aerie stock price have surge positive news lead drug rhopressa quarter detailin report quarter research development expense decline general administrative expense surge higher operate expense quarter be attribute expansion employee base support operation preparatory activity include commercial manufacturing cost rhopressa aerie pharmaceutical inc price consensus aerie pharmaceutical inc price consensus aerie pharmaceutical inc quote pipeline updatesaerie resubmit new drug application nda lead candidate rhopressa feb expect review period month withdraw nda file september third party manufacturing facility tampa fl be not ready pre approval inspection fda company initiate preparation bring second contract manufacturer online oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug apart rhopressa aerie be evaluate roclatan once daily quadruple action fix dose combination rhopressa pfizer inc pfe free report xalatan nda roclatan be expect be file second quarter company also initiate mercury support filing europe trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe narrower expect loss third quarter be encourage be encourage company effort develop pipeline candidate potential approval rhopressa early significantly boost growth prospect zack rank key pick aerie currently carry zack rank hold better rank stock health care sector worth consider be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share have moved so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2189,PFE,pharmaceutical sector have be grab investor attention late nyse arca pharmaceutical index gain large cap pharmaceutical industry year date outpace gain new drug approval tax reform be expect provide further impetus stock however factor drug pricing competition biosimilar continue act major deterrent other hand company eli lilly company lly free report be resort workforce reduction leaner cost structure front apart johnson johnson jnj free report acquisition actelion ltd june nothing much have happened space merck co mrk free report recently announce acquire germany base rigontec privately hold immuno oncology focuse biotech boost immune oncology pipeline nevertheless propose tax reform be expect boost cash balance company turn be used merger acquisition here have picked largest drug company look well poise growth be prudent choice add portfolio base switzerland novartis ag nvs free report be leader health care solution wide array drug service novartis have presence field oncology neuroscience ophthalmology generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade recent fda approval kisqali advanced metastatic breast cancer breakthrough gene transfer treatment kymriah suspension acute lymphoblastic leukemia have further boost portfolio approval be major boost novartis give potential car therapy space growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx achieve blockbuster status believe approval new drug label expansion exist one boost top line go forward novartis currently carry zack rank buy see complete list today zack rank strong buy stock here novartis stock have gain year date strength oncology drug approval first car therapy continue boost performance pfizer inc pfe free report lead pharmaceutical company unite state focus development wide range product include human animal biologic well small molecule medicine vaccine consumer health care product pfizer be look drive growth licensing deal collaborative agreement company be look expand label approve drug ibrance xeljanz xalkori eliquis pfizer also boast strong pipeline moreover pfizer be evaluate various biosimilar molecule several stage development give potential market share company have moved last month compare favorably industry gain pfizer presently carry zack rank earning estimate company have be static past day bagsvrd denmark base nordisk nvo free report be global leader diabetes market company be also key player hemophilia care growth hormone therapy hormone replacement therapy obesity company portfolio include drug levemir novorapid victoza novomix novomix novomix novoseven norditropin additionally obesity drug saxenda liraglutide mg be launch unite state uptake have be encourage victoza be currently market leader glp segment expect victoza continue be significant contributor company top line august fda approve new indication victoza reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease believe label expansion drug further boost top line company currently carry zack rank company share have rally year date company earning estimate have moved last day headquarter leverkusen germany bayer ag bayry free report be life science company core competency area health care agriculture bayer have be consistently make effort transform pure life science company drug launch last few quarters be expect continue drive top line bayer be look label expansion oncology drug stivarga be approve treatment metastatic colorectal cancer metastatic stromal tumor company have inked several strategic deal undertake meaningful acquisition recent past bayer be look acquire cash transaction combine business be expect boost bayer crop science business provide accretion bottom line bayer currently carry zack rank buy company share have gain year date earning estimate company have moved north last day bottom line challenge form pricing pressure competition remain healthcare sector nevertheless pick outperformer space backed solid zack rank positive price movement lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2190,PFE,major pharma company eli lilly lly free report bristol myer squibb bmy free report glaxosmithkline plc gsk free report novartis read more novartis earning sale top new drug strength report third quarter result week be beat raise quarter lilly bristol myer result be mixed recap week most important storieslilly top expectation mull option animal health segment lilly third quarter result be better expect company beating top bottom line raise outlook year reflect uptake trend new pharmaceutical product company also announce be explore strategic alternative animal health business elanco animal health update expect mid company be weigh option initial public offer merger sale retention business segment bring revenue so far read more lilly beat earning explore sale elanco lilly be zack rank buy stock see complete list today zack rank strong buy stock here mixed quarter bmy be mixed quarter bristol myer company miss earning surpass revenue expectation opdivo performance remain strong presence increase competition sale grow eliquis also perform well company say business development remain top priority expect buy back share worth additional year end read more bristol myer miss earning opdivo focus company have gain year date compare rally industry belong sanofi file patent infringement lawsuit mylan lantus french drugmaker sanofi sny free report have file patent infringement suit mylan myl free report lantus lantus solostar lawsuit file unite state district court district new jersey allege infringement patent sanofi diabetes product sale be immense pressure lantus franchise remain major contributor top line earlier year august sanofi have file patent infringement suit merck allege infringement patent related lantus product interest increase pfizer consumer healthcare business ever pfizer pfe free report announce be explore strategic option consumer healthcare business include full partial separation spin sale quite few company have be rumore be interested striking deal week british pharma major glaxo be ask third quarter call interest acquire pfizer consumer healthcare business glaxo own consumer segment have be witness material slowdown global growth key category factor pricing pressure increase competition tougher emerge market weigh performance read more glaxo earning beat revenue line share meanwhile accord reuter article pfizer expect start auction process consumer healthcare business november accord source possible bidder apart glaxo reckitt benckiser include name procter gamble sanofi johnson johnson nestle nyse arca pharmaceutical index decline week major stock glaxo decline mainly reflect concern company dividend payout especially strike deal pfizer consumer healthcare business last month be see last pharma stock roundup here beat raise quarter allergan hit restasis ruling next pharma world watch earning result company merck mrk free report pfizer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2191,PFE,glaxosmithkline plc gsk free report report core earning cent american depositary share third quarter surpass zack consensus estimate cent bottom line be however flat constant exchange rate cer glaxo share drop more hour trading third quarter conference call glaxo show interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout so far year stock have lose industry increase quarterly revenue be cer back strong performance mainly pharmaceutical segment however revenue be line zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market other hand sale europe register decrease sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala vaccine prevent meningitis bexsero menveo glaxo report result segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment hiv sale rally back growth unite state international sale europe sale be however year year otherwise encourage number come back continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market respiratory sale be flat cer unite state europe sale dip however international market same increase downside be mainly due continue transition newer product portfolio sale new respiratory product relvar breo ellipta anoro ellipta arnuity ellipta nucala be offset lower sale seretide advair sale flixotide flovent ventolin sale decrease respectively ellipta product record surge sale drive market share gain global roll continue immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical include previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter sale consumer healthcare segment go slowdown market condition power brand particularly pain relief oral health category see strong performance quarter sale vaccine segment be flat cer geographically unite state europe be international market drop meningitis vaccine bexsero unite state europe menveo unite state see higher sale same be offset weak performance establish vaccine drive increase competitive pressure infanrix pediarix unite state europe notably october glaxo announce fda have grant approval vaccine shingrix prevention shingle herpes zoster subsequently same month center disease control prevention advisory committee immunization practice acip vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax company expect face generic competition advair unite state next year affect top line however be uncertainty regard timing launch generic version drug generic version advair expect be unveil company continue expect core earning growth range cer remind investor mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda advair april thereby delay entry generic hikma pharmaceutical plc generic version advair be also deny approval fda drug generic version be therefore not likely be approve year glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quotezack rankglaxo currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2192,PFE,be relatively good year pharmaceutical stock give have catch eye investor greater part occasional comment drug pricing time president trump pharma company have be largely spare close scrutiny front such scheme thing be far cry hillary clinton comment issue run last presidential election additionally trump commitment deregulation have gladden sector leader meanwhile be other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product read pharma biotech stock be big winner earning sign sector success be more evident nyse arca pharmaceutical index nasdaq biotechnology index have gain respectively year date merck co inc mrk free report pfizer inc pfe free report schedule report oct oct respectively be good time consider be better stock stock carry zack rank hold rating see complete list today zack rank strong buy stock here other major earning schedule period include aetna inc aet free report electronic art inc ea free report price pharma sector recovery fortune be more evident price performance broader industry be year date pfizer merck be underperformer respect broader industry however pfizer be better performer count have gain year date versus merck gain most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major merck pfizer be undervalue relative broader industry have ev ebitda value however pfizer hold edge here lower ev ebitda value compare merck value dividend yieldboth pfizer merck have offer superior dividend yield last year period compare broader industry have return period however dividend yield pfizer be ahead merck count only merck have offer dividend yield same period gross marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing likely help sector maintain stiff margin gross margin ttm value merck underperform rival pfizer count other hand pfizer sport gross margin ttm value outperform merck well broader industry have gross margin ttm value earning history esp estimate more comprehensive earning history merck have deliver positive surprise prior quarters average earning surprise comparison pfizer deliver earning beat trail quarters average positive earning surprise consider earning esp merck be once again clear winner esp pfizer be disadvantage merck hold value additionally merck zack consensus estimate current year have increase last day pfizer have remain unchanged conclusionour comparative analysis show pfizer hold edge merck consider price performance ev ebitda ratio gross margin also sport marginally superior dividend yield however consider estimate revision more comprehensive look previous earning performance merck be clearly better stock clinch case favor merck point time be sport superior esp value compare pfizer dismal read be be better bet merck pfizer prepare report earning next few day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2193,PFE,aerie pharmaceutical inc aeri free report announce initiation phase iii study mercury europe pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan iis be evaluate lower intraocular pressure iop patient glaucoma ocular hypertension aerie stock have surge year date compare industry gain company be conduct mercury facilitate regulatory filing europe be not necessary approval unite state company expect patient enroll study study be arm month safety trial provide day interim efficacy readout study compare roclatan inferiority prescribe fix dose combination be ganfort combination bimatoprost timolol market allergan agn free report europe study be conduct mainly unite kingdom france germany italy spain belgium topline day efficacy datum be expect early remind investor company report positive month safety result july mercury phase iii study positive top line day efficacy safety datum second phase iii study mercury aerie expect submit new drug appication nda roclatan fda first half apart roclatan aerie be also evaluate rhopressa be design lower iop patient novel mechanism action moas treat patient glaucoma ocular hypertension feb company resubmit nda rhopressa expect standard review period month company also expect start clinical study rhopressa later address japanese market aerie pharmaceutical inc price aerie pharmaceutical inc price aerie pharmaceutical inc quotezack rank stock consideraerie currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date simple trading idea zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2194,PFE,merck co inc mrk free report announce pd therapy keytruda have receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain approval be expect july committee medicinal product human use chmp european medicine agency ema have grant positive opinion recommend approval keytruda unite state keytruda receive accelerate approval advanced bladder cancer indication year approval be base datum phase ii keynote trial phase iii keynote trial datum study have show clinically meaningful improve overall survival benefit keytruda versus chemotherapy difficult treat population keytruda be presently approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced first half regulatory approval new indication additional indication europe important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending second half keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck share have rise year so far increase industry merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2195,PFE,allergan plc agn free report announce fda have approve botox cosmetic product third indication temporary improvement moderate severe forehead line appearance associate frontali muscle activity adult so far year allergan share price have slip compare industry decline approve therapeutic aesthetic use botox be key top line driver allergan cosmetic indication include improvement appearance glabellar line frown line brow severe crow foot latest fda approval make botox cosmetic only neurotoxin treatment approve facial aesthetic treatment forehead line crow foot wrinkle outer corner eye glabellar line botox therapeutic disease include overactive bladder cervical dystonia chronic migraine strabismus other drug generate sale first half increase year year drive strong demand trend latest label expansion approval forehead line treatment enjoy pent demand drive sale further remind investor botox become part allergan portfolio follow march acquisition allergan inc have previously command strong presence generic market allergan merger have find place top list world wide pharma company base sale later allergan sell generic business well anda distribution arm teva pharmaceutical industry ltd teva free report however april pfizer inc pfe free report have terminate agreement combine allergan allergan carry zack rank hold seethe complete list today zack rank strong buy stock here stock considera better rank biotech drug stock be biogen inc biib free report zack rank buy biogen have see zack consensus estimate current year earning be revise upward past day share company have rally year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2196,PFE,pharma inc meip free report announce have inked exclusive license agreement presage bioscience oncology company develop oral selective cyclin dependent kinase cdk inhibitor voruciclib formerly treatment cell lymphoma bcl pursuant agreement pharma win exclusive right develop manufacture commercialize voruciclib globally other hand presage be entitle receive term payment achieve certain development regulatory commercial milestone also successful development product presage be entitle receive mid single digit tiered royalty net sale pharma share have increase more follow news also share company have significantly outperformed industry so far year stock have surge versus industry increase period pharma also inform agreement provide efficient development path combination roche rhhby free report bcl inhibitor venclexta venetoclax company also believe deal enable party utilize pharma civo intratumoral microdose platform advance additional candidate combination treat various type cancer remind investor voruciclib boast establish clinical safety profile candidate have be evaluate many phase study more patient additionally pre clinical study voruciclib alone demonstrated cell death multiple patient chronic lymphocytic leukemia cll notably presently pfizer pfe free report ibrance palbociclib novartis nvs free report kisqali ribociclib be cdk inhibitor approve unite state treat negative breast cancer combine hormonal therapy hence voruciclib be expect confront competition approval give presence establish product target space however agreement expand pharma oncology portfolio offer additional opportunity improve life patient suffering cancer pharma inc pricemei pharma inc price pharma inc quotezack rankmei pharma currently carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2197,PFE,pharmaceutical stock be limelight week merck mrk free report ceo ken frazier resign president donald trump manufacturing council sector be also news investigation be launch rise price multiple sclerosis ms drug recap week most important storiesbayer novartis teva other face ms drug price probe drug pricing be back news investigation skyrocket price ms drug be launch rep elijah cumming rep peter welch letter have be send company include biogen teva roche novartis nvs free report merck kgaa bayer sanofi request information pricing strategy ms drug letter have also raise issue shadow pricing expensive new drug be launch price exist drug be raise other company follow suit increase price match higher price accord american academy neurology study annual sale ms drug double almost meanwhile information provide national multiple sclerosis society show average wholesale price ms disease modify therapy be shot mylan pay doj settlement mylan myl free report announce agreement have be sign department justice doj relator regard medicaid drug rebate settlement move claim relate classification mylan epipen auto injector epipen jr auto injector purpose medicaid drug rebate program have be resolve epipen be list innovator drug be reclassify mylan say also enter corporate integrity agreement office inspector general department health human service also read do mylan stock surge today broader label astrazeneca merck parp inhibitor fda expand label astrazeneca azn free report merck parp inhibitor lynparza ovarian cancer new tablet formulation be also approve maintenance treatment woman platinum sensitive recurrent ovarian cancer regardless brca mutation status well use third line set brca mutate ovarian cancer approval tablet formulation provide patient convenient dose option take tablet twice daily instead capsule twice daily astrazeneca merck be zack rank hold stock see complete list today zack rank strong buy stock here pfizer get fda nod target cancer drug pfizer pfe free report gain fda approval besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less besponsa approval path include breakthrough therapy designation priority review label come black box warning hepatotoxicity not impact uptake give poor survival rate patient population eu approval besponsa come earlier year june bristol myer opdivo combination disappoint kidney cancer study bristol myer squibb bmy free report opdivo fail meet co primary endpoint late stage study evaluate pd immune checkpoint inhibitor yervoy versus sutent sunitinib intermediate poor risk patient previously untreated advanced metastatic renal cell cancer opdivo yervoy combination meet objective response rate co primary endpoint versus fail show statistical significance progression free survival third co primary endpoint overall survival be yet mature opdivo be approve second line renal cell carcinoma positive datum study have help support label expansion first line set study ongoing overall survival datum hit co primary endpoint support label expansion also read bristol myer opdivo fail kidney cancer trial checkmate bristol myer stock have lose value year date versus gain industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock glaxo gsk free report be lilly lose last month be merck decline see last pharma stock roundup here mylan miss perrigo top zynerba plunge study failure next pharmaceutical world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2198,PFE,exelixis inc exel free report announce have complete submission supplemental new drug application snda fda cabometyx tablet patient previously untreated advanced renal cell carcinoma rcc snda submission be base positive result phase ii trial cabosun patient previously untreated advanced rcc intermediate poor risk disease international metastatic renal cell carcinoma database consortium imdc independent radiology review committee have confirm primary efficacy endpoint result investigator assessed progression free survival pfs cabosun trial study compare cabometyx pfizer pfe free report sutent first line treatment intermediate poor risk advanced rcc patient analysis committee cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death measure pfs exelixis announce cabosun meet primary endpoint cabometyx demonstrated statistically significant clinically meaningful improvement pfs compare sutent patient advanced intermediate poor risk rcc determine investigator assessment remind investor cabometyx be approve fda apr treatment patient advanced rcc receive prior angiogenic therapy potential label expansion drug further boost result new patient start refill patient already therapy continue expansion prescriber base cabometyx be drive drug sale sequential increase cabometyx sale be drive growth prescription exelixis have collaborate bristol myer squibb co bmy free report roche holding rhhby free report development drug combination immunotherapy agent exelixis share price have increase year date compare industry gain earlier week bristol myer announce disappointing top line result checkmate trial investigate immuno oncology drug opdivo combination yervoy versus sutent intermediate poor risk patient previously untreated advanced metastatic rcc trial do not meet primary endpoint note renal cell carcinoma rcc be most common type kidney cancer adult account more death worldwide year clear cell rcc be most prevalent type rcc constitute case thereby underlie demand same hence potential approval cabometyx previously untreated advanced metastatic rcc boost sale zack rankexelixis currently carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2199,PFE,equity market be go turbulent time be lot volatility uncertainty owing rise geopolitical risk political uncertainty have increase appeal dividend investing geopolitical risk have be rise north korea conduct seventh nuclear test continental ballistic missile fly japan sep kim jong action have create huge unrest number asian economy unite state response continuous missile test president donald trump maiden general assembly speech threaten completely destroy north korea prompt north korean leader kim jong unite state highest level hard line countermeasure history moreover north korea foreign minister state trump comment indicate unite state have declare war north korea declare war country have right make countermeasure include right shoot bomber even be not yet airspace border country foreign minister ri yong say however white house have reject accusation latest development make investor flock safe haven investment lead decline tech stock read safe haven currency etfs gain latest north korea threat trump actionsthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong be renew doubt capability trump administration trump introduce new travel ban restriction citizen nation be muslim majority start oct citizen chad iran libya syrium venezuela yeman somalia north korea be ban travele unite state however person hold permanent residency visa be exempt ban renew visa once expire moreover trump administration be be highly criticize separate development adviser trump have be find be used personal email address official government purpose be ironical give trump stance investigation hillary clinton use personal server prior presidential election read trump widen north korea sanction etfs focus such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund qdf free report fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively jun fund top holding be merck co inc mrk free report well fargo co wfc free report boee co ba free report allocation respectively sep fund have return year year date sep quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively sep fund top holding be johnson johnson jnj free report apple inc aapl free report microsoft corporation msft free report allocation respectively sep fund have return year year date sep have dividend yield currently have zack etf rank buy medium risk outlook schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively jun fund top holding be verizon communication inc vz free report pfizer inc pfe free report intel corp intc free report allocation respectively sep fund have return year year date sep currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2200,PFE,expect pfizer inc pfe free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share have rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue sale viagra be also likely be affected lower demand zack consensus estimate prevnar enbrel be respectively call management say penetration inflectra pfizer biosimilar version jnj free report blockbuster rheumatoid arthritis drug remicade unite state have be slower expect be experience access challenge national commercial payer fact september pfizer file lawsuit district court allege wasresorting unfair practice prevent sale inflectra do not discuss much inflectra impact brand drug sale lawsuit call expect update pfizer upcoming investor call meanwhile bottom line be likely be drive cost saving share buyback however new product launch expense investment be expect hurt profit pfizer acute lymphoblastic leukemia candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be also approve eu japan september leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approve fda third quarter besponsa be also approve eu june expect management record sale new cancer drug quarter earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction update matter be expect investor call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteother stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be merck co inc mrk free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2201,PFE,corning inc glw free report report third quarter adjust earning cent share beating zack consensus estimate cent earning increase year year sequentially growth be drive improvement revenue core revenue increase year year comfortably surpass zack consensus estimate revenue increase sequential basis result reflect strength company optical communication specialty material business line corning recently achieve milestone selling billionth kilometer optical fiber expect sale continue benefit strong demand fiber product reflect verizon communication inc vz free report deal be sign april additionally strong gorilla glass shipment drive specialty material sale glass demand be increase consistently due increase adoption smartphone maker apple inc aapl free report moreover gorilla glass shipment automotive sector also improve significantly report quarter further valor pharmaceutical glass packaging solution be jointly develop pfizer pfe free report merck gain significant traction quarter corning share have return year date slightly outperform industry rally segment display technology segment generate total revenue adjust basis revenue decrease year quarter increase sequentially lcd glass market corning volume be slightly better expect company note lcd glass price decline moderately previous quarter optical communication generate total revenue report segment revenue increase year year sequential basis back strong demand enterprise carrier product year year growth be much better management anticipate increase environmental technology segment generate revenue report segment revenue be year year sequentially year year growth be drive strong demand corning solution automotive market additional contract win specialty material generate revenue report segment revenue surge year year sequentially backed strong shipment gorilla glass life science business account revenue report revenue be year quarter sequentially operate detailsadjust gross margin contract basis point bps year quarter bps previous quarter adjust selling general administrative expense sg percentage revenue increase bps year quarter remain almost flat previous quarter moreover research development expense percentage revenue increase bps year year basis decrease bps sequentially fourth quarter corning expect lcd glass market volume remain flat sequentially company expect sequential lcd glass price decline be moderate optical communication sale be anticipate increase high single digit percentage year year basis environmental technology sale be expect increase low teen percentage specialty material sale be anticipate increase low mid teen percentage range life science business grow mid single digit percentage year quarter zack rankcorning currently carry zack rank strong sell see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2202,PFE,cancer be second most common cause death precede only heart disease traditional cancer treatment include surgery radiation chemotherapy however immunotherapy gene therapy other new novel therapy be be develop improve supplement replace traditional cancer treatment target reduce remove cancerous growth accord report american cancer society almost new cancer case be expect be diagnosed create significant need effective cancer medication go say big pharma company be gear develop bring innovative cancer treatment market well expand label market oncology drug pharma biotech giant have significant financial resource disposal have even collaborate pool resource technology here discuss pharma giant possess industry strongest oncology pipeline portfolio astrazeneca azn free report astrazeneca be work strengthen oncology product portfolio have several candidate pipeline company target be launch least new oncology medicine include lynparza tagrisso imfinzi be already approve market interesting candidate company immuno oncology pipeline be imfinzi durvalumab be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other imfinzi be launch first indication second line advanced bladder cancer other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancer be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here so far year astrazeneca share have moved compare unfavorably increase large cap pharma industry pfizer pfe free report pfizer newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer be focuse continuously grow expand bavencio new indication market globally pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development pfizer other oncology candidate have also be approve fda recently besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer be also aggressively work expand label approve cancer drug ibrance xalkori pfizer also carry zack rank hold so far year pfizer share have moved abbvie abbv free report abbvie be work expand accelerate presence oncology build grow position hematological oncologyabbvie imbruvica currently approve several cancer indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be position imbruvica pipeline molecule treatment be several company sponsored study acquisition cancer drugmaker stemcentrx abbvie gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie also carry zack rank so far year abbvie share have moved bristol myer bmy free report bristol myer pd inhibitor opdivo have be perform impressively bristol myer be work expand label opdivo further alone combination therapy yervoy other cancer agent further bristol myer cancer portfolio include multiple myeloma drug empliciti leukemia drug sprycel contribute top line addition bristol myer be evaluate other immune system pathway treatment cancer pathway help company bring market potentially immunotherapy combination monotherapy help fight different type cancer bristol myer also carry zack rank so far year bristol myer share have moved other not far behindmerck mrk free report be also conduct numerous study evaluate highly successful pd therapy keytruda more type cancer more study include more combination study roche rhhby free report dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla apart strong breast cancer franchise roche oncology portfolio also boast lung cancer drug avastin tarceva immuno oncology drug tecentriq newly approve multiple sclerosis drug ocrevus label expansion effort be ongoing cancer drug swiss drugmaker novartis nvs free report also boast many experimental cancer drug pipeline include couple biosimilar version popular cancer drug novartis cancer pipeline be bolster deal buy most glaxo gsk free report oncology portfolio lilly lly free report also layer oncology strategy call hold july involve build key treatment cyramza lartruvo abemaciclib foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy cancer market be fierce not pipeline candidate be successful however pharma biggy have enough late stage cancer program portfolio be chance quite few rollout come year surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2203,PFE,agilent technology free report recently receive approval food drug administration fda cancer diagnostic name pd ihc pharmdx test be used case urothelial carcinoma uc squamous cell carcinoma head neck scchn be new step company effort expand grow cancer diagnostic market pdl ihc pharmdx test have already be approve melanoma well squamous small cell lung cancer nsclc now have be approve uc scchn patient too test enable physician unite state identify uc scchn patient still have disease progression platinum base chemotherapy be most likely benefit treatment opdivo opdivo be immunotherapy develop bristol myer squibb bms pd ihc pharmdx be develop collaboration opdivo maker bms currently test have lot more utility other pd assay market agilent role healthcare sector be witness revolution personalize medicine be take center stage provide improve patient care better manage cost administer most appropriate treatment individual have be find not treatment be suitable suffering specific disease require more specialize test advancement have far reach effect entire healthcare system personalize medicine considerably improve patient care reduce medical bill agilent have sign several collaborative agreement pharma biotech company include pfizer pfe free report astrazeneca azn free report bristol myerssquibb merck co mrk free report amgen eli lilly develop diagnostic used genomic base technology better treatment cancer bottom lineagilent be original equipment manufacturer oem broad base portfolio test measurement product serve multiple end market remain positive agilent broad base portfolio increase focus segment higher growth potential further company continue introduce high margin product accord report com worldwide cancer diagnostic market reach drive several technological advancement diagnostic platform moreover market have see advent hybrid imaging instrument enhance accuracy such pet ct spect ct advancement have take cancer diagnostic market new height believe new assay help agilent cash fast grow healthcare cancer diagnostic segment stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2204,PFE,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2205,PFE,pfizer inc pfe free report announce fda have grant approval mylotarg adult patient newly diagnosed cd positive acute myeloid leukemia aml drug also receive approval treat relapse refractory cd positive aml adult well child year older approval be expect fda oncologic drug advisory committee have vote favor mylotarg approval july however be note label drug include box warning hepatotoxicity include severe fatal hepatic veno occlusive disease pfizer share have gain so far year underperform industry increase approval be grant base datum multiple investigator lead clinical trial include alfa aml mylofrance alfa phase iii study evaluate mylotarg combination chemotherapy newly diagnosed aml patient drug show significant improvement event free survival ef achieve month compare month chemotherapy phase iii aml study compare mylotarg monotherapy best supportive care elderly aml patient be intolerant other therapy mylotarg achieve better median overall survival period month versus month best supportive care mylofrance phase ii study evaluate single agent mylotarg relapse aml patient study show almost patient achieve complete remission median relapse free survival achieve be month be evident study mylotarg achievement support risk benefit profile aml patient remind investor mylotarg be grant accelerate approval fda single agent treat cd positive aml patient have experience first relapse be year older however year later pfizer voluntarily remove mylotarg market datum post approval phase iii study swog show clinical benefit rate fatality due treatment related toxicity be significantly higher press release cd antigen occur nearly aml patient fact aml occur nearly acute leukemia patient moreover mylotarg be first approve therapy pediatric aml give mylotarg first mover advantage estimate patient unite state be expect be diagnosed aml include child datum publish press release chemotherapy be current prefer therapy treat aml mylotarg approval new therapy improve benefit be available patient however several other company be also develop therapy treat aml include seattle genetic inc sgen free report sgn cd intrexon corporation xon free report cd specific car therapy august fda approve celgene corporation celg free report idhifa oral treatment relapse refractory aml patient pfizer inc price consensus pfizer inc price consensus pfizer inc quotepfizer currently have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2206,PFE,fda approve novel drug last year have give approval drug so far include august key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential recent landmark approval be novartis kymriah make first gene therapy unite state mark begin new era treatment cancer other serious life threaten disease drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month september fda follow advisory panel vote mylan herceptin biosimilar mylan nv myl free report hear fda soon approval status biosimilar version roche blockbuster drug herceptin trastuzumab company partner biocon ltd get favorable vote fda oncologic drug advisory committee odac july biosimilar herceptin be approve wide range indication include breast cancer metastatic adjuvant setting earlier year mylan have enter global settlement agreement roche genentech hoffmann la roche ltd herceptin trastuzumab mylan get global license exclude japan brazil mexico trastuzumab product mylan well be first launch biosimilar version herceptin unite state approval boost investor sentiment company have lose year date versus decline industry fda advisory panel discuss glaxo pfizer ptc therapeutic few fda advisory panel meeting be schedule month fda vaccine related biological product committee vrbpac be meeting sep discuss safety effectiveness glaxosmithkline plc gsk free report shingrix glaxo be look get live recombinant vaccine approve prevention herpes zoster shingle person be year old shingle common potentially serious condition cause last pain other complication such scarring visual impairment then sep fda odac be meeting discuss supplemental new drug application snda submit pfizer pfe free report cancer drug sutent pfizer be look expand sutent label adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney fda be expect render final decision regard label expansion jan sutent bring sale first half later month sep fda peripheral central nervous system drug advisory committee discuss ptc therapeutic ptct free report new drug application nda translarna ataluren treatment patient due nonsense mutation gene translarna be already approve outside unite state fda be expect give response regard approval status drug oct fda grant approval amgen allergan avastin biosimilar amgen amgn free report allergan be also expect decision fda biosimilar version roche cancer drug avastin bevacizumab company get favorable vote fda advisory panel odac recently chance gain approval fda action date sep look good share amgen have gain year date significantly outperform industry rally merck bristol myer seek label expansionmerck mrk free report be look expand label pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma keytruda be priority review indication response expect sep keytruda bring sale first half be key product merck portfolio be be evaluate wide range indication merck have gain year date versus growth industry bristol myer squibb company bmy free report be also look expand label pd inhibitor opdivo opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep opdivo prioritize brand bristol myer portfolio bring sale first half bristol myer have gain year date versus growth industry fda approve plivensia johnson johnson investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor be fda review response expect sep however early august plivensia fail get support fda arthritis advisory committee safety concern be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person unite state fda be not require do so usually follow advice advisory panel consider safety concern raise panel quite likely agency ask additional information grant approval share have gain year date outperform industry rally neos therapeutic be also await decision month nt amphetamine xr liquid suspension product candidate attention deficit hyperactive disorder adhd approval sep allow company go ahead plan launch product jan zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2207,PFE,merck co inc mrk free report announce fda have approve pd therapy keytruda monotherapy third line treatment advanced gastric junction adenocarcinoma keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug label have now be expand include treatment heavily pre treat patient recurrent locally advanced metastatic gastric junction cancer tumor express pd determine fda approve test however approval tenth new indication keytruda come accelerate basis continue approval dependent further benefit demonstrated clinical study fda approval be base datum keynote study keytruda be key top line driver merck bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced year regulatory approval new indication additional indication europe important approval include advanced bladder cancer unite state eu advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending year keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2208,PFE,pfizer inc pfe free report german partner merck kgaa announce pd monoclonal antibody bavencio avelumab have be grant marketing authorization eu monotherapy treat adult patient metastatic merkel cell carcinoma mmcc rare aggressive skin cancer company expect make drug commercially available eu germany next month notably approval drug now be market country eu include norway liechtenstein iceland be first approve immunotherapy eu give indication bavencio receive fda approval mmcc march approval drug become first immunotherapy option say cancer treatment bavencio receive fda approval second indication drug be approve urothelial carcinoma aggressive disease high rate recurrence also earlier month drug be grant approval switzerland treatment mmcc pfizer share be so far year compare unfavorably rally industry period approval be support positive datum phase ii study javelin merkel remind investor approval follow positive opinion adopt committee medicinal product human use chmp european medicine agency ema recommend approval bavencio mmcc july pfizer focus bavencio continuously grow expand new indication market globally also bavencio be be evaluate collaboration merck kgaa different type cancer include late stage study renal cell carcinoma lung cancer ovarian cancer head neck cancer pfizer be major player immunotherapy be several other big small company look develop introduce immunotherapy treatment market matter fact merck co inc mrk free report be conduct numerous study evaluate pd therapy keytruda more type cancer more study include more combination study astrazeneca plc azn free report recently approve immuno oncology drug imfinzi durvalumab be be assessed multiple cancer alone combination other regimen have bright long term prospect smaller biotechs be also work bring innovative immuno oncology treatment market kite pharma lead drug axicabtagene ciloleucel be currently priority review unite state treat aggressive hodgkin lymphoma nhl fda decision expect nov however believe bavencio give drug tough run money be ample scope growth immuno oncology space pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2209,PFE,dow mop gain week buoy announcement federal reserve decline tension unite state north korea lead gain index monday index moved higher tuesday speculation fed declare be trimming balance sheet actual announcement lead further gain wednesday ultimately index snap day stretch gain thursday stock lose luster follow fed announcement last week dow gain last friday mark sixth consecutive session gain stock be buoy rally bank stock even investor digest missile launch japan north korea bank share surge follow strong inflation number come expectation raise speculation rate hike fed retail sale drop august biggest decline month index gain last week investor sentiment improve impact hurricane irma be weaker expect dow also post biggest day percentage gain mar speaking investment conference treasury secretary state trump administration expect tax reform materialize year end also north korea threaten raze japan unite state nuclear weapon issue fresh sanction country dow index gain hit fresh record high north korea fear ebb follow secretary treasury rex tillerson announcement unite state be look peaceful solution problem country further investor focuse federal open market committee fomc day meeting give rise speculation fed start unwinding balance sheet boost treasury yield lead broad base gain financial sector index increase tuesday day fomc meeting kick meanwhile president donald trump make debut speech unite nation general assembly urge member state combat rogue nation north korea iran index gain wednesday federal reserve announce begin trimming balance sheet october fed also decide keep benchmark interest rate unchanged indicated rate hike be likely december such statement lead gain financial share benefit bank index lose thursday bring end successive day gain period index experience average increase point stock lose luster fed hint rate hike unwinding balance sheet be offing end year share apple inc aapl free report procter gamble co pg free report lose respectively contribute primarily day loss index component move index apple little snafu stage demonstrate new facial recognition feature mega edition iphone not only result wave troll meme social medium also give competitor opportunity take potshot tech giant report facebook fb free report ad post huawei take jab used clown iphone facial recognition state fail often person real artificial intelligence ai phone come oct refer upcoming device mate apple mega event sep company suffer major embarrassment phone craig federighi be used demonstrate face id feature do not unlock software chief be force use backup work be require read apple mock huawei take iphone mate development zack rank hold apple have acknowledge latest apple watch os series have issue cellular connectivity assured engineer be work problem fix be soon available future software release apple comment come several prominent reviewer lambaste watch repeat failure connect lte apple have tout build cellular usp watch read apple say watch have connectivity issue fix offing boee co ba free report have win modification contract worth provide new preliminary design activity requirement presidential aircraft par program contract be award air force life cycle management center patterson air force base contract boee complete preliminary design work modification aircraft replace age vc boee used presidential support aircraft work be schedule be complete dec be execute seattle wa read boee win air force contract par program additionally boee announce have secure contract air force provide support service minuteman iii weapon system contract company provide operation maintenance testing technical datum delivery support minuteman iii stock have zack rank buy see complete list today zack rank strong buy stock here johnson johnson jnj free report announce european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis eu johnson johnson have zack rank sell drug be approve unite state july year be market trade name tremfya treatment immune system related skin disorder decision european commission ec be expect later year read psoriasis drug guselkumab get chmp nod eu jpmorgan chase co jpm free report recently make undisclosed investment bill com largest business business payment network unite state move be part company effort enable business client do away paper check instead make receive payment electronically bill com technology be likely be integrate zack rank jpmorgan digital system early association benefit bank customer allow have access bill com network comprise almost user read jpmorgan partner bill com eradicate paper payment pfizer inc pfe free report announce fda advisory committee give mixed opinion regard regulatory application be file expand label cancer drug sutent sutent be presently market first line treatment advanced renal cell carcinoma rcc latest supplemental new drug application snda be accept fda year pfizer be look get label extend include use patient high risk rcc recurrence read pfizer sutent label expansion get mixed fda committee view meanwhile pfizer have file lawsuit district court allege johnson johnson be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product read pfizer sue accuse prevent inflectra uptake performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookdespite gain make prior announcement fed hawkish stance have ultimately rob stock much luster have end long stretch gain such narrative be unlikely continue much longer next week feature release several crucial economic report include important gdp datum positive sign front be enough help stock return winning way trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2210,PFE,last week be eventful european society medical oncology esmo congress take place week see approval pfizer inc pfe free report bavencio europe hand tesaro inc tsro free report zejula receive positive chmp opinion eu other pfizer sutent get mixed view fda advisory committee label expansion application setback roche rhhby free report early stage study tecentriq be put partial hold smaller biotech company karyopharm therapeutic inc kpti free report announce oral selective inhibitor selinexor be superior placebo reduce risk progression death liposarcoma patient recap week most important storiestesaro zejula near approval europe ovarian cancer tesaro announce committee medicinal product human use chmp have recommend marketing approval zejula company be seek approval zejula monotherapy maintenance treatment woman suffering recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response cr pr platinum base chemotherapy drug be approve unite state march read more tesaro drug zejula get positive chmp opinion tesaro inc price consensus tesaro inc price consensus tesaro inc quotepfizer bavencio approve europe mixed view sutent pfizer bavencio receive boost approval europe treat metastatic merkel cell carcinoma approval bavencio become first immunotherapy available europe indication launch be expect october drug be already approve unite state however label expansion application sutent adjuvant treatment recurrent renal cell carcinoma rcc receive mixed opinion fda advisory committee decision fda be expect january drug be currently approve first line treatment rcc read more pfizer sutent label expansion get mixed fda committee view pfizer inc price consensus pfizer inc price consensus pfizer inc continue roche last week approval amgen biosimilar roche cancer drug avastin fda week put partial hold early stage study latter tecentriq be evaluate drug multiple myeloma follicular lymphoma patient partial hold be implement due safety issue find study evaluate merck co mrk free report keytruda combination celgene revlimid pomalyst blood cancer meanwhile datum announce phase iii murano study conduct roche show venclexta combination rituxan achieve statistically significant improvement progression free survival chronic lymphocytic leukemia patient compare teva pharmaceutical industry limit teva free report treanda rituxan read more roche announce positive datum leukemia drug roche hold ag price consensus roche hold ag price consensus roche hold ag quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2211,PFE,abbvie inc abbv free report be schedule release third quarter earning oct open bell abbvie share have soar so far year industry have record increase last quarter company deliver positive surprise notably abbvie earning history be mixed bag pharmaceutical company beat estimate last quarters record line earning other quarter average beat be abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerabbvie expect third quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be not expect impact sale third quarter company key drug humira be likely remain main growth driver third quarter backed higher demand quarter abbvie expect humira sale rise high teen range internationally sale be estimate increase mid single digit range operational basis zack consensus estimate humira be third quarter significantly cancer drug imbruvica record strong sale past few quarters trend expect continue quarter be report imbruvica be approve fda treat adult patient chronic graft versus host disease cgvhd disease failure more line systemic therapy imbruvica expand label also contribute sale growth company expect drug sale growth approach third quarter zack consensus estimate imbruvica be quarter other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada earlier july august company believe maviret have potential rejuvenate growth hcv franchisea compare competitive dynamic hcv market expect management update plan maviret conference call maviret be expect contribute considerably revenue only onward company have make significant progress pipeline quarter be focus investor keep tab abbvie partner roche rhhby free report announce positive datum phase iii murano study venclexta rituxan september expand label address broader relapse refractory cll chronic lymphocytic leukemia patient population label expansion indication increase patient population venclexta significantly boost commercial potential also same month company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra rheumatoid arthritis additionally abbvie partner neurocrine bioscience announce new drug application nda elagolix have be submit fda september abbvie be look get elagolix approve oral medicine pain management associate endometriosis earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp bullish zack rank strong buy buy hold happen be not case here see zack esp abbvie have earning esp most accurate estimate zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model have right combination element beat earning quarter merck company inc mrk free report be schedule release result oct zack rank company have earning esp see complete list today zack rank stock here pfizer inc pfe free report be schedule release result oct company have earning esp also carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2212,PFE,have be month last earning report pfizer inc pfe free report share have add time frame outperform market recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver pfizer surpass earning estimate miss salespfizer report second quarter adjust earning share beat zack consensus estimate earning also rise year year weak top line performance be offset higher gross margin lower share count revenue totale fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb sale detailcurrency movement impact pfizer second quarter revenue sale growth be flat operational basis exclude revenue currency impact sale rise operational basis lower sale enbrel prevnar prevenar vaccine franchise loss exclusivity product offset strong performance key product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis international revenue decline flat operational basis meanwhile revenue be flat segment second quarter pfizer reorganize report segment pfizer innovative health ih pfizer essential health pfizer ih sale grow operationally year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue xtandi add pfizer portfolio follow sep medivation acquisition also propel revenue xtandi record alliance revenue quarter compare first quarter be partially offset continue decline revenue prevnar lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition viagra sale decline due lower sale international market reduce demand global prevnar prevenar revenue decline prevnar revenue tank due high initial capture rate eligible adult patient population follow successful launch result smaller remain catch opportunity second quarter compare year quarter unfavorable timing government purchase pediatric indication also hurt sale eucrisa crisaborole topical ointment treatment atopic dermatitis eczema be buy part jun anacor acquisition be launch first quarter ointment record sale second quarter consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue decline internal medicine rise inflammation immunology franchise decline additionally portfolio rare disease decline pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product pristiq generic version launch mar vfend zyvox celebrex lyrica lower revenue legacy hospira product divesture however business biosimilar emerge market do well quarter inflectra record sale globally other biosimilar bring sale outside market emerge market revenue grow operationally call company say inflectra penetration have be slower expect be experience access challenge national commercial payer adjust selling informational administrative si expense be flat operationally quarter adjust expense rise guidancewhile pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook mid point revenue be expect be slightly level adjust ep be expect increase previously research development expense be still expect range si spending be project range have estimate be move then follow release investor have witness upward trend fresh estimate have be revision higher current quarter compare lower pfizer inc price consensus pfizer inc price consensus pfizer inc quotevgm scoresat time stock have average growth score however momentum be do lot better charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable momentum investor also be suitable look value lesser degree growth outlookestimate have be trend upward stock magnitude revision also look promising interestingly stock have zack rank hold be expect inline return stock next few month
2213,PFE,medicine company mdco free report announce fda have grant accelerate approval experimental antibiotic vabomere combination meropenem vaborbactam treat complicate urinary tract infection cuti include pyelonephritis company expect make vabomere available market fourth quarter file new drug application nda antibiotic february currently review eu share medicine company have outperformed industry year date stock have rally compare industry gain period nda be support positive datum phase iii tango multus center randomize double blind double dummy study study be design evaluate efficacy safety tolerability vabomere patient cutis acute pyelonephritis compare pfizer inc pfe free report zosyn piperacillin tazobactam datum trial show vabomere achieve statistical superiority zosyn successful result obtain patient treat vabomere compare administer zosyn remind investor july independent datum safety monitoring board stop phase iii tango study vabomere base interim analysis interim result study show vabomere improve clinical cure rate infection type reduce rate renal adverse event comparison best available therapy vabomere have be designate qualify infectious disease product fda antibiotic resistance especially carbapenem be rapidly grow problem medicine sector fact carbapenem resistant cre infection be deadliest disease give mortality rate result be urgent need antimicrobial vabomere effectively treat cre other resistant organism successful vabomere be expect boost company top line consider lucrative market target medicine company medicine company price medicine company quotezack rank stock medicine company currently carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat acadium loss share estimate narrow last day company come positive earning surprise last quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2214,PFE,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2215,PFE,demand immuno oncology drug combination rise pfizer inc pfe free report newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant pfizer share be so far year compare unfavorably increase industry bavencio previously avelumab receive fda approval metastatic merkel cell carcinoma mcc rare aggressive skin cancer mar fda approval bavencio become first immunotherapy option treatment metastatic mcc bavencio receive fda approval second indication drug be approve urothelial carcinoma aggressive disease high rate recurrence meanwhile bavencio be review eu mcc decision expect third quarter last month committee medicinal product human use chmp european medicine agency ema grant positive opinion recommend approval bavencio mcc pfizer focus continuously grow expand bavencio new indication market globally meanwhile bavencio be be study different type cancer include late stage study renal cell carcinoma lung cancer ovarian cancer head neck cancer collaboration merck kgaa pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development immuno oncology immunotherapy be new class cancer therapy utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology drug combination be great pfizer be major player immunotherapy be several other company big well small look develop bring immunotherapy treatment market merck co inc mrk free report be conduct numerous study evaluate pd therapy keytruda more type cancer more study include more combination study astrazeneca plc azn free report recently approve immuno oncology drug imfinzi durvalumab be be evaluate multiple cancer alone combination other regimen have bright long term prospect meanwhile smaller biotechs be also work bring innovative immuno oncology treatment market kite pharma lead drug axicabtagene ciloleucel be currently priority review treat aggressive hodgkin lymphoma nhl fda decision expect nov juno therapeutic novartis ag nvs free report be develop jcar ctl respectively utilize car cell technology however believe bavencio give drug tough run be ample scope growth immuno oncology space pfizer carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2216,PFE,pfizer inc pfe free report partner avillion announce supplemental new drug application snda bosulif have be accept grant priority review fda remind investor bosulif be currently approve treatment chronic accelerate blast phase philadelphia chromosome positive ph chronic myelogenous leukemia cml adult be resistant intolerant prior therapy company be look get drug approve first line treatment patient suffering chronic phase ph cml decision fda be expect december additionally european medicine agency ema have also accept similar regulatory application review pfizer share have gain so far year underperform industry gain same period application also include patient be not eligible treatment novartis ag nvs free report gleevec tasigna bristol myer squibb company bmy free report sprycel regulatory application eu base datum phase iii bfore study evaluate mg dose bosulif newly diagnosed ph cml patient result show bosulif achieve major molecular response month significantly higher number patient compare gleevec press release be patient cml new case be expect be diagnosed represent opportunity bosulif approve first line treatment ph cml pfizer be expect decision fda label expansion leukemia drug mylotarg first line set treat acute myeloid leukemia september july fda advisory panel have vote favor approval snda mylotarg pfizer inc price consensus pfizer inc price consensus pfizer inc quotezack rank stock considerpfizer have zack rank hold better rank stock pharma sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning estimate increase cent cent cent cent last day company deliver average earning beat trail quarters stock be so far year surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2217,PFE,merck co inc mrk free report announce detailed datum large phase iii cardiovascular outcome study reveal evaluate anacetrapib cholesteryl ester transfer protein cetp inhibitor patient cardiovascular disease datum phase iii study show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke detailed datum be publish new england journal medicine present european society cardiology congress merck share have rise year so far compare unfavorably increase industry top line datum study be announce june company say study have meet primary endpoint also say cetp inhibitorled significant reduction major coronary eventsversus placebo patient high risk cardiovascular event be already receive effective cholesterol treatment however detail have only be mentioned now company funded reveal study be conduct more patient be take atorvastatin common medicine lower bad cholesterol ldl median duration least year be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug announce june merck be not sure datum be strong enough seek approval plan review result external expert company then consider file regulatory application fda other agency remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly company lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer inc pfe free report have suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy however uncertainty regard not company actually file datum regulator remain be apprehend accumulation anacetrapib fat tissue get way regulatory approval merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2218,PFE,key highlight week include lawsuit file pfizer pfe free report accuse johnson johnson jnj free report adopt exclusionary contract other anticompetitive practice prevent biosimilar uptake meanwhile company glaxosmithkline gsk free report supernus pharmaceutical supn free report be news regulatory pipeline update recap week most important storiessupernus study update supernus provide update first phase iii study spn be be evaluate treatment impulsive aggression ia patient age year have attention deficit hyperactivity disorder adhd base plan interim analysis company have decide drop lower dose mg study patient be randomize receive mg dose placebo investor be disappoint update share be read more supernus drop spn lower dose test phase iii trial chmp positive psoriasis drug tremfya guselkumab get positive opinion eu committee medicinal product human use chmp recommend marketing authorization treatment adult moderate severe plaque psoriasis be candidate systemic therapy timely approval make tremfya first biologic selectively block interleukin il cytokine play key role plaque psoriasis accord information press release person europe be estimate suffer psoriasis tremfya gain fda approval earlier year july pfizer file suit biosimilar pfizer have file lawsuit district court eastern district pennsylvania related provide patient physician access lower cost biosimilar accord lawsuit have adopt exclusionary contract other anticompetitive practice deny access undermine benefit price competition biologic market order maintain monopoly connection remicade infliximab be accuse lawsuit inappropriately exclude biosimilar competitor pfizer have launch inflectra biosimilar version remicade late biosimilar available eu many year be relatively recent entrant unite state be yet have significant impact reference product sale read more pfizer sue accuse prevent inflectra uptake glaxo innoviva copd treatment get fda nod glaxo partner innoviva get boost fda approval once daily single inhaler triple therapy trelegy ellipta treatment appropriate patient chronic obstructive pulmonary disease copd combination inhaled corticosteroid ics long act muscarinic antagonist lama long act beta adrenergic agonist laba trelegy ellipta provide patient convenient dose option be expect bring blockbuster sale read more glaxo innoviva triple combo therapy get fda nod copd glaxo stock have gain year date compare rally industry belong teva divest woman health business teva teva free report recently get new chief executive officer ceo be take step get performance back track company announce sale remain asset specialty global woman health portfolio plan divestiture segment bring total proceed be used teva pay debt decision sell woman health business be part teva effort divest core segment focus key strategic area company also announce amendment usd jpy term loan revolve credit facility teva be currently go tough time company be hit generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track roche abbvie cancer drug positive late stage study roche rhhby free report partner abbvie be look expand label cancer therapy venclexta venclyxto result late stage study murano show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug roche be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index slip last trading session major stock bristol myer squibb bmy free report gain slip last month bristol myer be glaxo decline see last pharma stock roundup here achillion slump end hcv deal teva get new ceo next pharma world watch usual pipeline regulatory update bristol myer pd inhibitor opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep meanwhile be expect response fda investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor however plivensia fail get support fda arthritis advisory committee safety concern quite likely agency ask additional information grant approval trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2219,PFE,expect merck co inc mrk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck share have rise year so far compare unfavorably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population be expect drive sale third quarter however call management warn zepatier uptake be impact ongoing decline overall patient volume many market increase competition previously strong underlie demand trend unite state europe japan have support zepatier sale company also face headwind form genericization well increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april be likely decline quarter sluggish growth integrase class continue competitor dynamic unite state europe continue affect isentress sale zack consensus estimate isentress sale be third quarter investor also be focuse performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first half vaccine animal health franchise be expect boost sale quarter zack consensus estimate vaccine total animal health segment be respectively call merck mentioned network cyber attack june disrupt global operation include manufacturing research sale time merck have say full recovery cyber attack take time result temporary delay fulfill order product not keytruda zepatier januvia certain market expect update upcoming conference call remediation expense related cyber attack increase investment ongoing launch additional cost associate new oncology collaboration astrazeneca be expect result higher operate cost quarter earning whispersour proven model show merck be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank merck have zack rank combination merck zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank include bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2220,PFE,investor seek momentum have vanguard healthcare etf vht free report radar now fund recently hit new week high share vht be approximately week low share be more gain ahead etf let take look fund term outlook get better idea be head vht focusvht focus provide exposure healthcare stock equity market charge basis point fee year have top holding johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively sep see health care etfs here move earning season be strong start company sector beating estimate latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense however uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy turn lead rally healthcare stock more gain ahead currently vht have zack etf rank buy medium risk outlook moreover etf have weight alpha so be promising outlook ahead want ride surge etf shade further want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2221,PFE,expect glaxosmithkline plc gsk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise glaxo share be year so far underperform increase witness industry glaxo performance have be pretty good so far company earning beat expectation thrice trail quarters meeting estimate remain quarter overall company have deliver average positive earning surprise let see thing be shape quarter factor considerglaxo continue see strong performance pharmaceutical vaccine business segment glaxo pharmaceutical segment be expect be drive strong sale new hiv product tivicay triumeq sale newly launch respiratory drug ellipta product nucala be expect offset decline seretide advair avodart many glaxo key drug lovaza avodart be face decline sale due generic competition importantly pricing dynamic competitive pressure be hurt sale top selling drug advair unite state generic competition be hurt advair sale europe generic version advair unite state be unlikely be approve year vaccine segment continue benefit continue uptake meningitis vaccine bexsero menveo acquire novartis ag nvs free report importantly sale growth be slow consumer healthcare segment due slowdown market condition impact divesture consumer healthcare segment be expect remain pressure third fourth quarters be not expect contribute much sale growth year meanwhile cost saving restructure continue efficiency boost operate profit september glaxo partner innoviva gain fda approval once daily single inhaler triple therapy trelegy ellipta copd combination inhaled corticosteroid ics long act muscarinic antagonist lama long act beta adrenergic agonist laba trelegy ellipta provide patient convenient dose option be expect bring blockbuster sale expect management comment plan newly approve product conference call earning whispersour proven model show glaxo be likely beat estimate have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise glaxo have right mix zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be uncover best stock buy sell re report earning esp filter zack rank glaxo have zack rank combination glaxo zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2222,PFE,healthcare sector have be spotlight lately president donald trump target drug company accuse charge extremely high price read etfs focus imf up global growth forecast market mover prescription drug price be control drug price have go roof trump say meeting add drug company frankly be get away murder want bring price other country be pay latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy however change deal be card have be pass congress sign trump first solution be year year ll get intermediate hump trump say let now discuss etfs focuse provide exposure healthcare sector health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year have holding bear significant concentration risk almost asset be allocate top holding read keep portfolio healthy biotech etfs sector look fund have high exposure pharmaceutical biotech health care provider service exposure respectively sep fund top holding be johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively sep fund have return year year date oct xlv currently have zack etf rank buy medium risk outlook vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year have holding bear significant concentration risk almost asset be allocate top holding sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively sep fund top holding be johnson johnson pfizer unitedhealth allocation respectively sep fund have return year year date oct vht currently have zack etf rank medium risk outlook bottom linexlv be more popular vht be evident higher aum however vht be more appeal investor owing cheaper expense ratio vht also have more diversify exposure term number holding moreover vht outperformed xlv year date basis year vht return more xlv so far year year return more xlv want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2223,PFE,pfizer inc pfe free report partner bristol myer squibb company bmy free report present finding phase iv study eliquis demonstrated oral anticoagulation potential achieve maintain normal heart rhythm cardioversion study emanate compare eliquis standard care heparin reduce occurrence acute stroke systemic embolism major bleed clinically relevant major bleed cause death valvular atrial fibrillation nvaf patient undergo cardioversion remind investor eliquis be already approve reduction risk stroke systemic embolism patient nvaf treatment deep vein thrombosis dvt pulmonary embolism pe reduction risk recurrent dvt pe follow initial therapy prophylaxis dvt lead pe patient have undergo hip knee replacement surgery however drug be not approve reduction stroke nvaf patient undergo cardioversion pfizer have underperform industry so far year stock have gain period industry gain come back latest news cardioversion procedure be associate concern clot blood heart travel brain stroke other body part systemic embolism emanate study show be stroke eliquis group compare stroke heparin arm however systemic embolism be observed drug group eliquis also reduce number major bleed event clinically relevant major bleed event compare heparin current standard care heparin coumadin require monitoring potential dose adjustment administer reduce risk stroke however eliquis be administer fix dose mg twice daily note eliquis be anticoagulant increase risk bleed become serious potentially fatal company also announce datum real world analysis eliquis nvaf patient separate press release analysis eliquis show lower risk stroke lower rate major bleed compare coumadin nvaf patient well select high risk patient sub population eliquis face competition anticoagulant segment johnson johnson jnj free report xarelto boehringer ingelheim pradaxa approval portola pharmaceutical inc ptla free report bevyxxa june competition be expect intensify stroke event be major concern nvaf patient finding show eliquis become prefer treatment same boost potential drug pfizer bristol myer try get label eliquis expand include finding give drug edge other market blood thinner pfizer inc price consensus pfizer inc price consensus pfizer inc quotecurrently pfizer carry zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2224,PFE,pfizer inc pfe free report have file lawsuit district court allege johnson johnson jnj free report be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product pfizer share be wednesday share be however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract encourage insurer not cover inflectra thereby make easily accessible patient protect reference product pfizer also claim anticompetitive contract be be offer hospital encourage discount purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product be key revenue generator latter remind investor second quarter conference call hold august pfizer have say inflectra penetration unite state have be slower expect be experience access challenge national commercial payer other hand have say second quarter conference call hold july rate penetration inflectramay be modest latest lawsuit suggest be responsible slow sale inflectra please note april year samsung bioepis biosimilar version remicade also receive fda approval pfizer have launch inflectra unite state november last year biosimilar be also market ex market inflectra generate sale unite state globally second quarter biosimilar be essentially cheaper version expensive biologic drug be complex make traditional generic drug biosimilar have be available eu quite be regulatory pathway biosimilar unite state long time however change pass biologic price competition innovation act bpci act part affordable care act president obama sign law march several pharma well biotech company be involved development biosimilar first biosimilar gain approval unite state be sandoz zarxio biosimilar version amgen inc amgn free report neupogen zarxio be launch unite state september inflectra be second biosimilar gain approval other approve biosimilar country include sandoz erelzi biosimilar amgen enbrel amgen amjevita biosimilar version abbvie humira however have not be launch yet due ongoing litigation earlier month fda approve first cancer biosimilar amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin biosimilar be expect reduce health care cost provide large number patient access much need biologic treatment however so far biosimilar have not see much commercial success be yet make significant dent reference product sale unite state fight drug giant be likely aid effort lower drug price increase biosimilar availability pfizer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2225,PFE,market close mostly higher wednesday federal reserve announce trimming balance sheet october fed also decide keep benchmark interest rate unchanged indicated possible rate hike december such statement lead gain financial share also bode well bank dow hit fresh record wednesday rise point buoy gain mcdonald mcd free report pfizer pfe free report gain respectively meanwhile also end level yet again briefly hit intraday high major sector end green financial lead advancer company possess zack rank hold see complete list today zack rank strong buy stock here dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close decrease total share be trade wednesday higher last session average share advance issue outnumber decliner nyse ratio nasdaq advancer outnumber decliner ratio cboe vix decrease almost close fed begin unwinding balance sheet fed announce much anticipate unwinding balance sheet federal reserve open market committee meeting culminate wednesday fed plan begin gradual unwinding process october also announce plan trim asset month fed also state rate be increase further month gradually reach maximum month such asset consist primarily treasurys mortgage backed security fed accumulate wake financial crisis quantitative ease program be do bid keep mortgage rate low provide liquidity economy fed indicate possible rate hike fed keep interest rate unchanged expect currently peg central bank announce expect hike interest rate year end moreover maintain initial forecast expect hike benchmark interest rate however fed decrease outlook initial forecast june fed state anticipate interest rate hover end lower initial forecast fed interest rate projection know dot plot indicated be rate hike december more further rate hike cme fedwatch now estimate possibility rate hike december such hawkish statement fed lead surge year treasury yield year treasury note yield surge highest level november boost financial share bode well bank spdr bank etf kbe rise financial select sector spdr etf xlf surge almost share bank also rise follow fed announcement share goldman sachs gs free report jpmorgan jpm free report pnc financial service pnc free report bank america bac free report citibank free report gain respectively exist home sale hit worst level monthsexist home sale month august come lower consensus estimate hit worst level last month figure be also lower unit month july exist home sale have drop fourth time last month economist comment be paucity available home be buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2226,PFE,issue update report catalyst pharmaceutical inc cprx free report aug fact catalyst pharma be development stage company focuse development therapy target rare neurological disease disorder such lambert eaton myasthenic syndrome lem epilepsy initially infantile spasm tourette syndrome present coral gable fl base company have candidate development firdapse cpp company expect report top line result second phase iii study firdapse treatment lambert eaton myasthenic syndrome lem second half resubmit new drug application nda end earlier receive refusal file letter fda connection nda firdapse notably agency have determine company nda be insufficient preliminary review consequently catalyst pharma be require conduct additional study agency requirement addition result previously submit phase iii datum oct reach agreement fda special protocol assessment spa protocol design clinical endpoint statistical analysis approach be take second phase iii study evaluate firdapse meanwhile company be work develop firdapse additional indication catalyst initiate investigator sponsored phase ii iii study firdapse symptomatic treatment musk antibody positive mg feb mar company report top line datum phase ii iii trial potential approval firdapse label expansion help generate revenue company additionally catalyst pharma be explore possibility develop cpp gaba inhibitor treatment epilepsy initially infantile spasm treatment other select neurological indication such complex partial seizure tourette disorder however market epilepsy treatment be highly competitive crowd give presence product pfizer pfe free report neurontin lyrica johnson johnson jnj free report topamax novartis nvs free report trileptal zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2227,PFE,week company pfizer pfe free report allergan agn free report teva teva free report report second quarter result pfizer report mixed quarter allergan top expectation teva however have tough quarter meanwhile bristol myer bmy free report announce immune oncology io focuse deal include acquisition recap week most important storiesa look earning result big company pfizer allergan teva report second quarter result week pfizer surpass earning estimate miss revenue raise concern company top line growth prospect prevnar enbrel sale decline quarter pfizer be face key loss exclusivity loe viagra later year lyrica end read more pfizer surpass earning estimate miss sale meanwhile allergan top earning sale estimate raise outlook well read more allergan earning sale top restasis sale teva share fall dismal quarter company miss earning sale reflect performance generic business continue deterioration venezuela generic business be hit accelerate price erosion lower volume mainly due customer consolidation higher competition delay new product launch teva lower outlook year slash dividend well company also expect exit market globe year end be cut headcount close actavis generic business deal teva have lose value year date versus decline industry abbvie drug get fda nod cgvhd johnson johnson jnj free report abbvie btk inhibitor imbruvica gain fda approval first cancer indication chronic graft versus host disease cgvhd adult failure more systemic line therapy make imbruvica first only approve treatment patient population mark sixth indication imbruvica stock have gain year date outperform rally industry belong bristol myer acquisition deal worth bristol myer announce be acquire ifm therapeutic venture backed biotech company work treatment modulate novel target innate immune system treat cancer autoimmunity inflammatory disorder acquisition bristol myer gain full right ifm preclinical sting stimulator interferon gene nlrp agonist program be focuse cancer sting agonist program include lead asset nlrp agonist program include potential first class pipeline candidate acquisition schedule close third quarter strengthen bristol myer immune oncology io pipeline deal see bristol myer shell upfront additional payment be make first product program achievement certain milestone additional milestone payment be make further product result program bristol myer sign io focuse deal week company sign clinical collaboration agreement clovis oncology immunotherapy opdivo be evaluate combination clovis parp inhibitor rubraca mid late stage study different type tumor meanwhile opdivo label be expand week treatment adult pediatric year older patient microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan accelerate approval be grant basis overall response rate orr duration response however note merck keytruda gain approval earlier year patient msi dmmr wider patient population merck label include patient solid tumor have progressed follow prior treatment have satisfactory alternative treatment option well colorectal cancer patient disease have progressed follow treatment certain chemotherapy drug ra drug fail get fda advisory panel support investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor fail get support fda arthritis advisory committee safety concern company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person fda be not require do so usually follow advice advisory panel consider safety concern raise panel agency well ask additional information grant approval pfizer drug get advisory panel support pfizer supplemental new drug application snda jak inhibitor xeljanz mg twice daily xeljanz xr mg once daily treatment adult patient active psoriatic arthritis psa get support fda arthritis advisory committee advisory panel vote favor approve propose dose xeljanz psa indication decision fda be dec xeljanz currently approve ra bring sale first half priority review astrazeneca btk inhibitor astrazeneca azn free report investigational btk inhibitor acalabrutinib be grant priority review fda company be look get drug approve use patient relapse refractory mantle cell lymphoma mcl have receive least prior therapy response agency be expect first quarter acalabrutinib be also give breakthrough therapy designation btd indication astrazeneca imfinzi also get btd week treatment patient locally advanced unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemoradiation therapy positive datum lilly migraine drug lilly lly free report present late stage datum investigational migraine drug lasmiditan say meet primary endpoint well key secondary endpoint result be consistent result present earlier late stage study lilly expect file fda approval second half lilly be zack rank buy stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock pfizer be lilly lose last month be astrazeneca gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch usual pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2228,PFE,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put pfizer inc pfe free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front pfizer have trail month pe ratio level compare pretty favorably market large pe ratio come focus long term trend stock current level put pfizer current pe median observed period stand hence infer stock be slightly overvalue respect especially light historical trend nevertheless stock pe compare favorably industry trail month pe ratio stand very least indicate stock be relatively overvalue right now compare peer ps ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now pfizer have ratio be lower industry average come right now pfe be actually higher zone trading range time period metric suggest company stock price have already appreciate degree relative sale broad value outlookin aggregate pfizer currently have value score putt top stock cover look make pfizer apt choice value investor other key metric make pretty clear too example company ratio used compare stock market value book value stand lower industry average additionally cf ratio great indicator value come be far better industry average clearly pfe be solid choice value front multiple angle stock overall pfizer be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give pfe zack vgm score overarch fundamental grade read more zack style score here meanwhile company earning estimate have be mixed best current quarter have see estimate go higher past day compare lower full year estimate have see upward revision downward revision same time period have have small impact consensus estimate current quarter consensus estimate have remain constant past month full year estimate have inched see consensus estimate trend recent price action stock chart pfizer inc price consensus pfizer inc price consensus pfizer inc quotepfizer have just zack rank hold indicate analyst have apprehension stock immediate future stock growth story be good long term thus be look line performance company term bottom linepfizer be inspire choice value investor be hard beat incredible lineup statistic front moreover strong industry rank top more industry further support growth potential stock fact year date industry have clearly outperformed broader market see notably pfizer have be work strengthen product portfolio acquisition licensing deal however pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line pfizer grow immuno oncology portfolio offer strong potential many asset be early stage development nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential so zack rank believe bullish analyst sentiment long term favorable industry factor make value stock compelling pick make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2229,PFE,johnson johnson jnj free report be first large cap pharma stock report earning result season oct beat zack consensus estimate earning revenue third quarter also raise sale profit outlook share be more tuesday sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter acquire swiss biotech actelion june year overall pharma sector have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise year so far outpace gain same time frame new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug better expect result especially strong performance pharmaceutical segment have raise optimism strong quarterly performance pharma sector mainly large cap company let have closer look expect big pharma stock report month early next month company be expect deliver earning beat quarter pfizer inc pfe free report pfizer be schedule announce third quarter result oct market open zack rank hold earning esp chance stock beating zack consensus estimate third quarter be high uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be expect contribute pfizer top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue be soft quarter due biosimilar competition pfizer surpass zack consensus estimate trail quarters show chart pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotebristol myer squibb company bmy free report bristol myer be schedule release result oct market open similar pfizer quantitative model indicate earning beat bristol myer zack rank stock have earning esp see complete list today zack rank strong buy stock here bristol myer high profile immuno oncology drug opdivo be likely drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication also boost drug sale bristol myer outpaced zack consensus estimate trail quarters reflect chart bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemerck company inc mrk free report merck be schedule release result oct market open zack rank earning esp chance stock beating zack consensus estimate third quarter be high merck new product keytruda cancer zepatier hcv bridion sugammadex injection likely drive revenue quarter well keytruda sale unite state be gain particularly strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe new approval expand patient population be expect drive sale further however genericization increase competition likely remain overhang merck outpaced zack consensus estimate trail quarters reflect chart merck company inc price ep surprise merck company inc price ep surprise merck company inc plc gsk free report brentford uk base glaxosmithkline be expect report result oct glaxosmithkline be also expect outperform third quarter due zack rank buy earning esp glaxo pharmaceutical vaccine business segment be expect perform well glaxo pharmaceutical segment be expect continue be drive strong sale new hiv product tivicay triumeq however many glaxo key drug lovaza avodart be face decline sale due generic competition moreover sluggish sale growth consumer healthcare segment due slowdown market condition impact divesture negatively impact top line third quarter notably company surpass zack consensus estimate trail quarters show chart glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteeli lilly company lly free report eli lillyis slate announce third quarter result oct market open zack rank earning esp chance earning beat be report quarter be high continue trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line report quarter however sluggish performance alimta cymbalta zyprexa be expect continue third quarter due loss exclusivity notably eli lilly surpass zack consensus estimate trail quarters show chart eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotenovartis ag nvs free report swiss company novartis be schedule report result oct market open novartis be not expect beat estimate third quarter due zack rank earning esp recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space moreover new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie humira amgen enbrel cosentyx achieve blockbuster status however weak alcon business generic competition several key drug be expect hurt revenue quarter notably novartis outpaced zack consensus estimate trail quarters reflect chart novartis ag price ep surprise novartis ag price ep surprise novartis ag hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2230,PFE,share mylan myl free report have decline last month compare industry loss here analyze factor lead mylan be global pharmaceutical company well establish generic business well presence specialty pharmaceutical however company continue face challenge due volatility uncertainty world largest pharmaceutical market unite state due pressure accelerate new approval company exist generic product continue consolidation customer base contribution new product launch unite state be lowest second quarter sale epipen continue decline due increase competition impact launch authorize generic recently meridian medical technology pfizer inc pfe free report company manufacture epipen auto injector epipen jr auto injector authorize generic epipen auto injector epipen jr auto injector receive warning letter fda mylan be also explore world biosimilar market have potential grow partnership biocon collaboration momenta mabion have help mylan develop wide portfolio biosimilar insulin analog generic product represent total brand market value more worldwide sale biocon partnership include biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog however fda recently notified mylan partner biocon target action date biosimilar version roche holding rhhby free report herceptin trastuzumab have be extend dec decision fda be expect sep fda extend period due review clarificatory information submit agency part application review process meanwhile company effort get advair generic approve suffer blow fda issue complete response letter crl anda generic advair diskus advair record sale thereby represent great potential company do not mention content crl such setback be likely weigh company share moreover fda recently accept novartis ag nvs free report sandoz anda advair potential approval give sandoz edge mylan moreover company believe approval delay persist thereby impact business further company believe increase competition result fda focus accelerate approval third fourth fifth generic impact sale hence expect company face challenge condition ahead zack rankmylan currently carry zack rank strong sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2231,PFE,pfizer inc pfe free report announce fda advisory committee give mixed opinion regard regulatory application be file expand label cancer drug sutent sutent be presently market first line treatment advanced renal cell carcinoma rcc latest supplemental new drug application snda be accept fda year pfizer be look get label extend include use patient high risk rcc recurrence fda oncologic drug advisory committee odac vote favor benefit risk profile sutent expand indication fda be expect give response january snda unite state be file basis iii study trac evaluate sutent adjuvant treatment patient high risk recurrent rcc follow nephrectomy surgical removal cancer contain kidney full datum present october last year show sutent extend disease free survival dfs more year compare placebo result overall risk reduction application use same patient population be also review eu sutent generate sale first half year year due competitive pressure unite state eu approve expand patient population sale drug improve be estimate high risk patient have rcc recurrence pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank large cap drug stock include novartis nvs free report nordisk nvo free report bayer bayry free report zack rank buy share novartis be year date zack consensus estimate climb respectively past day nordisk share year so far estimate have moved have increase past day bayer stock be year estimate have moved have increase almost past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2232,PFE,biogen inc biib free report announce datum long term study alzheimer disease ad candidate aducanumab datum study show continue benefit rate amyloid decline year period patient prodromal mild alzheimer disease treat aducanumab share be monday response promise show amyloid candidate company say result recently conduct analysis long term extension lte ongoing phase ib study prime aducanumab be consistent previously report datum prime prime be randomize double blind placebo controlled multiple dose phase ib study be conduct evaluate safety tolerability pharmacokinetic pharmacodynamic aducanumab patient suffering prodromal mild ad so far year biogen share have rise industry record increase biogen be conduct other phase iii study engage emerge aducanumab treatment early ad result lte study support design engage emerge study biogen be look strengthen ad other disorder pipeline biogen ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november last year eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly suffer major setback aug have halt development phase iii alzheimer candidate semagacestat meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2233,PFE,issue update research report boulder co base clovis oncology inc clvs free report aug rubraca have show impressive growth trend back company effort rubraca sale double sequentially second quarter rubraca sale be quarter however general administrative expense increase year year due effort rubraca be only approve drug company portfolio be first only oral parp inhibitor receive approval monotherapy drug be approve patient have be treat more chemotherapy select therapy base fda approve companion diagnostic rubraca clovis be conduct confirmatory study ariel ariel convert accelerate approval continue approval rubraca rubraca be license pfizer inc pfe free report jun company announce promising progression free survival pfs safety result pivotal maintenance confirmatory study ariel study demonstrated rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis intend submit supplemental new drug application snda label expansion rubraca second line later maintenance indication advanced ovarian cancer october year company believe label increase patient population least time meanwhile second phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy meanwhile rubraca be also review eu comparable ovarian cancer indication approval be expect eu first quarter clovis be establish commercial infrastructure same rubraca have immense commercial potential target market be tremendous demand parp inhibitor american cancer society ovarian cancer rank fifth death cancer woman case ovarian cancer be estimate be diagnosed be huge unmet need new treatment option give woman ovarian cancer have germline somatic brca mutation clovis be also develop rubraca additional cancer indication monotherapy combination other agent include tecentriq rubraca combination gynecologic cancer combination study be sponsored roche moreover company collaborate bristol myer squibb company bmy free report jul evaluate rubraca combination latter opdivo ovarian breast prostate cancer ovarian cancer market be already crowd presence major player launch tesaro inc tsro free report zejula apr competition have intensified further zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2234,PFE,sangamo therapeutic inc sgmo free report partner pfizer inc pfe free report announce dose first patient phase ii study gene therapy candidate sb treat hemophilia fact sb be consider be sangamo lead product candidate candidate also receive fast track designation fda currently enjoy orphan drug status unite state consequently share company have sky-rocket year date outperform industry gain present open label phase ii alta study be evaluate safety tolerability sb adult subject severe hemophilia also be expect find suitable dose range candidate fact sb be be develop part global collaboration company develop commercialize gene therapy program hemophilia datum study be expect late early hemophilia be monogenic rare bleed disorder blood do not clot normally press release number hemophilia patient unite state be estimate be globally other company be also develop gene therapy indication july roche holding ag rhhby free report announce positive datum phase iii study haven hemophilia candidate emicizumab again alnylam pharmaceutical inc alny free report be develop fitusiran phase ii study treatment patient hemophilia sangamo therapeutic inc price consensus sangamo therapeutic inc price consensus sangamo therapeutic inc quotecurrently company carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2235,PFE,issue update report catalyst pharmaceutical inc cprx free report sep catalyst pharma be development stage company focuse development therapy target rare neurological disease disorder such lambert eaton myasthenic syndrome lem epilepsy initially infantile spasm tourette syndrome present coral gable fl base company have candidate development firdapse cpp catalyst pharma share have outperformed industry year date stock have surge compare industry gain same time frame company expect report top line result second phase iii study firdapse treatment lambert eaton myasthenic syndrome lem second half resubmit new drug application nda end earlier receive refusal file letter fda connection nda firdapse notably agency determine company nda be insufficient preliminary review consequently catalyst pharma be require conduct additional study agency requirement addition result previously submit phase iii datum october reach agreement fda special protocol assessment spa protocol design clinical endpoint statistical analysis approach be take second phase iii study evaluate firdapse meanwhile company be work develop firdapse additional indication february catalyst initiate investigator sponsored phase ii iii study firdapse symptomatic treatment musk antibody positive mg march company report top line datum phase ii iii trial potential approval firdapse label expansion help generate revenue company additionally catalyst pharma be explore possibility develop cpp gaba inhibitor treatment epilepsy initially infantile spasm treatment other select neurological indication such complex partial seizure tourette disorder however market epilepsy treatment be highly competitive crowd give presence product pfizer pfe free report neurontin lyrica johnson johnson jnj free report topamax novartis nvs free report trileptal catalyst pharmaceutical inc price consensus catalyst pharmaceutical inc price consensus catalyst pharmaceutical inc quotezack rankcatalyst pharma currently carry zack rank hold see complete list today zack rank strong buy stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
2236,PFE,neos therapeutic inc neos free report announce fda have approve third attention deficit hyperactivity disorder adhd drug adzenys extend release oral suspension patient year older drug be approve once daily treatment company share be friday announcement news stock have outperformed industry so far year neos therapeutic share have rise industry rise same period fda approval give adhd patient option different dosage form other product adhd portfolio include adzenys xr odt orally disintegrate tablet cotempla xr odt adzenys xr odt adzenys be prescription drug stimulate central nervous system cns treat adhd patient year older cotempla xr odt be also cns stimulant treat adhs pediatric patient year company say adzenys xr odt be approve january be fastest grow alternative dosage form product treatment adhd company expect launch drug first half note dosage form adzenys be bioequivalent form shire plc shpg free report adderall xr remind investor shire be market leader adhd segment receive approval new adhd drug mydayis june adzenys xr odt record sale first half register sequential growth second quarter adhd space be largest fastest grow segment market be many drug available indication include johnson johnson jnj free report concerta pfizer inc pfe free report quillivant neos therapeutic inc price consensus neos therapeutic inc price consensus neos therapeutic inc quoteneo therapeutic have zack rank hold see complete list today zack rank strong buy stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
2237,PFE,glaxosmithkline plc gsk free report be schedule report second quarter result jul market open last quarter company deliver line earning glaxo share be year so far underperform increase witness zack classify large cap pharma industry glaxo performance have be pretty good so far company earning beating expectation thrice trail quarters meeting estimate remain quarter overall company have deliver average positive earning surprise let see thing be shape quarter factor considerall business segment pharmaceutical vaccine consumer healthcare be expect do well be report quarter glaxo pharmaceutical segment be expect be drive strong sale new hiv product tivicay triumeq sale newly launch respiratory drug ellipta product nucala be expect offset decline seretide advair avodart many glaxo key drug lovaza avodart be face decline sale due generic competition importantly pricing dynamic competitive pressure be hurt sale top selling drug advair generic competition be hurt advair sale europe first quarter call company have mentioned lot uncertainty surround timing advair generic launch however mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda apr thereby delay entry generic hikma pharmaceutical generic version advair be also deny approval fda generic version advair be therefore not likely be approve year vaccine segment continue benefit uptake meningitis vaccine bexsero menveo acquire novartis importantly growth consumer healthcare segment have slow first quarter conference call management have mentioned impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment be expect hurt consumer healthcare segment sale year factor impact second quarter result however cost saving restructure continue efficiency be likely boost operate profit earning whispersour proven model do not conclusively show glaxo be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand cent zack consensus estimate be peg higher cent uncover best stock buy sell re report earning esp filter zack rank glaxo zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotestock considera couple stock large cap pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
2238,PFE,horizon pharma plc hznp free report top earning sale estimate second quarter company also raise sale guidance company share moved better expect second quarter result increase guidance however horizon pharma stock be year date industry gain company report second quarter earning cent share beat zack consensus estimate cent include stock base compensation expense exclude time item be cent year quarter exclude stock base compensation expense company report ep cent sale second quarter be year year fuel solid growth orphan rheumatology business unit report sale also beat zack consensus estimate horizon pharma plc price consensus ep surprise horizon pharma plc price consensus ep surprise horizon pharma plc quotequarter orphan unit record revenue year period strong performance be backed solid net sale ravicti generate sale quarter year year drive continue conversion older generation nitrogen scavenger therapy well addition treatment nave patient due recent label expansion apr fda approve supplemental new drug application ravicti expand age range chronic management urea cycle disorder patient month older year older additionally procysbi contribute performance net sale actimmune sale report quarter be year year rheumatology unit generate sale year year also krystexxa sale quarter be strong come year year drive continue strong year year vial demand primary care garner revenue year year decline net sale be due implementation new contract model order secure broader inclusion company primary care medicine formulary net sale pennsaid duexix vimovo be respectively report quarter company raise outlook now expect sale range compare earlier estimate horizon pharma be significantly increase investment key growth driver krystexxa expect net sale krystexxa drive higher demand guidance include assumption lower net average net realize price begin second half primarily result government health resource service administration final rule drug ceiling price implementation schedule oct company expect continue double digit net sale growth ravicti room additional uptake due recent label expansion drug be also expect be launch europe second half sale procysbi decline divestiture european right sale actimmune be project grow low single digit drive year year growth second half other updatesdure quarter company acquire river vision thereby add biologic candidate teprotumumab late stage development thyroid eye disease confirmatory phase iii trial be slate be year end company expect annual net sale teprotumumab exceed jun horizon pharma sell marketing right procysbi quinsair europe middle east africa region chiesi farmaceutici company focus higher return business meanwhile company be work expand actimmune label company have collaborate fox chase cancer center evaluate actimmune combination bristol myer squibb company bmy free report opdivo phase dose study treatment kidney bladder cancer national cancer institute have plan evaluate actimmune combination merck co mrk free report keytruda treat cutaneous cell lymphoma patient phase ii study remain track begin later year takehorizon pharma second quarter result be impressive company beating top bottom line estimate moreover increase sale guidance be encourage well net sale rare disease drug increase expect krystexxa ravicti actimmune drive growth second half acquisition teprotumumab have further diversify company portfolio however key drug duexis vimovo face competition pfizer inc pfe free report celebrex generic other brand steroidal inflammatory drug nsaid cheaper generic version nsaid zack rankhorizon pharma currently have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2239,PFE,total earning total healthcare market capitalization be revenue growth earning growth be weak compare many other sector earning revenue beat ratio respectively be particularly encourage fact healthcare be fourth sector surprised investor most earning trail aerospace technology material most notable player johnson johnson jnj free report be first major drug company report earning july follow eli lilly company lly free report bristol myer squibb company bmy free report july july respectively other major drug company merck mrk free report pfizer pfe free report report july august respectively industry prime post solid result earning beat few lag revenue front johnson johnson earning world biggest maker healthcare product continue long streak earning beat narrowly miss top line estimate earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance zack consensus estimate be peg earning share revenue time earning release jnj have gain date earning announcement read brighten outlook healthcare etfs focus pfizer earning drug giant beat earning miss revenue earning share cent come couple cent zack consensus estimate revenue fall shy estimate annual basis earning share rise revenue decline pfizer expect revenue range raise lower end earning share guidance zack consensus estimate be correctly peg revenue earning share share pfe be earning announcement merck earning focusearning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck raise revenue guidance reiterate earning share projection year zack consensus estimate be currently peg revenue earning share stock have lose follow earning announcement bristol myer earning focusbristol myer report earning share cent penny ahead estimate increase year quarter revenue grow edge past zack consensus estimate company raise low end earning share guidance year zack consensus estimate time earning announcement be peg share bmy be date earning announcement see healthcare etfs here eli lilly earning focusearning eli lilly outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously zack consensus estimate time earning release be peg revenue earning share share lly have lose earning release etf string earning beat fail boost pharma etfs see rough trading past day have highlighted detail powershare dynamic pharmaceutical fund pjp be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see moderate volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose past day have zack etf rank hold rating high risk outlook read lie ahead pharma etfs second half ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top hold basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed past day have zack etf rank buy rating high risk outlook spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period have zack etf rank high risk outlook vaneck vector pharmaceutical etf etf follow mvis list pharmaceutical index hold stock basket johnson johnson take top spot basket asset pfizer bristol myer merck eli lilly collectively account asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose past day have zack etf rank medium risk outlook read etfs buy avoid healthcare bill failure want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2240,PFE,eli lilly company lly free report report third quarter result oct market open last quarter company deliver positive earning surprise lilly share have rise year so far industry record increase lilly performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise let see thing be shape quarter factor considernew product trulicity taltz jardiance have support top line past few quarters expect trend continue third quarter well trulicity sale be expect be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class newer product basaglar lartruvo taltz continue witness better sequential sale backed strong launch uptake however sale alimta cymbalta zyprexa be expect decline due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country outside unite state meanwhile lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country consensus estimate alimta third quarter be new drug olumiant baricitinib have be launch select european country july drug be approve japan be likely add top line third quarter however unite state drug be review august lilly partner incyte corporation incy free report announce re submit nda baricitinib much faster previously expect nda be expect be re submit january next year meanwhile older product humulin trajenta forteo continue do well animal health segment sale past quarters have be hurt global competitive pressure conference call management have say global competitive pressure continue hurt revenue segment rest year lesser extent consensus estimate animal health segment third quarter be earning whispersour proven model do not conclusively show lilly be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2241,PFE,share aerie pharmaceutical inc aeri free report have moved last week positive news lead drug rhopressa fact aerie stock have surge year date compare industry gain oct dermatologic ophthalmic drug advisory committee fda vote favor rhopressa approval member committee unanimously agree trial support efficacy netarsudil ophthalmic solution reduce elevated intraocular pressure patient open angle glaucoma ocular hypertension addition majority member agree rhopressa efficacy outweigh safety risk fda have set prescription drug user fee act date feb note fda be not bound advisory committee guidance take advice consideration review drug rhopressa be design lower intraocular pressure iop patient novel mechanism action moas company believe rhopressa represent first new moas lower iop patient glaucoma year potential approval drug significantly boost aerie growth prospect however rhopressa be expect face tough competion establish brand generic drug such novartis ag nvs free report simbrinza travtan allergan plc agn free report lumigan well other smaller biotechnology pharmaceutical company meanwhile aerie initiate phase iii study mercury europe other pipeline candidate roclatan roclatan be once daily quadruple action fix dose combination rhopressa pfizer pfe free report xalatan be be evaluate lower iop patient glaucoma ocular hypertension company plan submit nda same first half zack rank aerie currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2242,PFE,johnson johnson jnj free report report better expect third quarter result beating zack consensus estimate earning sale drug consumer product giant raise sale profit outlook send share pre market trading fact year so far share price be be almost line increase witness industry earning beatj third quarter earning come share beating zack consensus estimate increase year period include amortization expense special item report third quarter earning share year period sale beatsale come beating zack consensus estimate sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis third quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow organically exclude impact acquisition divestiture sale increase operational basis new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara invega sustenna sale concerta zytiga improve quarter quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june diversify revenue pah category however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report file lawsuit district court recently lawsuit pfizer allege resort unfair practice prevent sale inflectra pfizer biosimilar version remicade be launch unite state november last year pharma segment achieve clinical milestone quarter include label expansion unite state pulmonary arterial hypertension pah drug tracleer pediatric use imbruvica chronic graft versus host disease gvhd drug first indication outside cancer market imbruvica partnership abbvie inc abbv free report call company also mentioned not file global regulatory application rheumatoid arthritis candidate sirukumab remind investor last month receive complete response letter crl fda sirukumab want additional safety datum medical device segment sale come year period include operational increase positive currency movement sale gain mainly inclusion abbott medical optic acquisition add operational sale growth exclude impact acquisition divestiture operational basis worldwide sale increase domestic market sale rise year year international market sale increase operational increase year year operational growth be drive wound closure product general surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period slower growth baby care product due competitive pressure be partially offset growth beauty counter product international smoking cessation aids meanwhile international segment record increase reflect operational increase positive currency impact guidance raisedj raise adjust earning sale outlook year expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previouslyour takea indicated last quarter sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter actelion acquisition add impressive operational sale growth quarter quite few key product portfolio remicade concerta be face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend go forward carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2243,PFE,cancer capable striking fear even strongest heart be malignancy characterize uncontrolled growth abnormal cell not treat lead death accord american cancer society be more type cancer deadliest be breast cancer skin cancer lung cancer colon cancer prostate cancer blood cancer presentation european society medical oncology esmo congress hold sep madrid spain dominate headline cancer space week major presentation include bristol myer squibb company bmy free report astrazeneca plc azn free report positive result ongoing phase iii study melanoma lung cancer patient respectively pfizer inc pfe free report disappointing datum lung cancer candidate recap week most important imfinzi positive phase iii lung cancer study astrazeneca announce promising lung cancer datum late stage study new cancer drug imfinzi interim datum phase iii study pacific demonstrated imfinzi achieve improvement month progression free survival standard care patient locally advanced unresectable small cell lung cancer nsclc have not progressed follow chemoradiation datum separate phase iii flaura study lung cancer drug tagrisso show drug reduce risk progression death more half compare other commonly used egfr inhibitor read more astrazeneca lung cancer study datum promising bristol myer opdivo superior yervoy melanoma patient bristol myer announce datum phase iii study checkmate compare opdivo yervoy treat patient stage iiib stage iv melanoma have undergo complete resection interim datum study show opdivo be superior yervoy opdivo achieve statistically significant improvement recurrence free survival compare yervoy read more bristol myer report positive result melanoma study pfizer xalkori fail lung cancer study xtandi positive prostate cancer study pfizer ongoing phase iii study profile evaluate xalkori first line treatment alk positive nsclc do not meet secondary endpoint significant improvement overall survival os rate median follow month median os patient treat xalkori be month be month patient randomize chemotherapy however pfizer prostate cancer candidate xtandi achieve statistically significant improvement metastasis free survival drug be be evaluate combination androgen deprivation therapy phase iii study prosper potential label expansion include early stage prostate cancer patient read more pfizer lung cancer drug overall survival datum unfavorable disappointing week roche fda accept sandoz generic arm novartis biologic license application biosimilar version roche rhhby free report leukemia treatment rituxan rituximab novartis have receive approval rituxan biosimilar europe june rituxan have record sale almost first half setback fda approve amgen allergan biosimilar version key drug avastin treat multiple cancer indication include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi read more novartis bla biosimilar rituxan accept fda other updatesapart abovemention news be few other update cancer space fda accept new drug application ndas array biopharma seek approval combination binimetinib encorafenib treat patient braf mutant advanced unresectable metastatic melanoma regulatory body also accept supplemental nda teva pharmaceutical industry ltd teva free report trisenox seek label expansion drug include treatment nave acute promyelocytic leukemia patient nektar therapeutic announce initiation dose phase ii study evaluate efficacy safety lead immuno oncology candidate nktr combination roche tecentriq merck mrk free report keytruda look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2244,PFE,momenta pharmaceutical inc mnta free report report loss cent share second quarter line zack consensus estimate report loss be however wider year loss cent momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc quoterevenue quarter improve top zack consensus estimate momenta stock have rally year date compare industry rally quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due lower sale deduction second quarter well legal reimbursement second quarter collaborative research development revenue come year quarter decline revenue be mainly due termination baxalta collaboration agreement effective dec research development expense be general administrative expense increase outlook updatedmomenta now expect operate expense exclude stock base compensation net collaborative revenue range compare previous guidance guidance also include approximately capital expenditure operate expense third quarter be project momenta expect generate revenue mylan myl free report upfront payment quarterly basis jul momenta earn milestone payment sandoz glatopa mg continue be sole fda approve generic copaxone mg pipeline updatesandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer inc pfe free report feb be sandoz contract fill finish manufacturing partner glatopa pfizer have submit comprehensive response observation cite warning letter anda approval be now contingent satisfactory resolution compliance observation state warning letter issue pfizer meanwhile momenta continue progress other pipeline candidate currently momenta biosimilar version abbvie inc abbv free report humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis move ahead company plan submit candidate approval regulatory body fourth quarter also expect first commercial launch be early timeframe company complete enrolment phase study biosimilar version orencia apr collaboration mylan top line datum study be expect second half furthermore momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody jan company enter research collaboration license agreement csl potential future fc multimer program candidate be expect enter clinic momenta successfully complete phase single ascend dose study healthy volunteer multiple ascend dose portion study be initiate jan expect be complete aug datum single multiple ascend dose portion study be project second half takemomenta loss share come line estimate second quarter sale beat estimate anda approval glatopa be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval expect warning letter remain drag company share issue be solve nevertheless sale glatopa mg continue do well glatopa mg have capture approximately market addition potential approval boost investor confidence zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2245,PFE,janssen subsidiary johnson johnson jnj free report announce fda have approve label expansion plaque psoriasis drug stelara use adolescent year age older drug be approve adult indication company believe label expansion be significant achievement plaque psoriasis develop age year approximately third patient moreover number treatment available adolescent be limit patient be administer only dose year starter dose stelara have become lead therapeutic option share company be so far year almost line industry performance industry have gain same time frame latest approval stelara be base datum phase iii study evaluate subcutaneous administration drug adolescent patient datum show drug achieve minimal psoriasis clear skin least third patient safety datum be also consistent be achieve adult patient be almost person suffering psoriasis unite state american academy dermatology moreover national center biotechnology information state majority psoriasis patient suffer plaque psoriasis number represent huge opportunity drug follow label expansion moreover approval stelara have gain edge compete drug abbvie inc abbv free report humira novartis ag cosentyx celgene corporation celg free report otezla be only approve adult plaque psoriasis patient however pfizer inc pfe free report enbrel compete stelara adolescent segment johnson johnson price consensus johnson johnson price consensus johnson johnson quotejohnson johnson carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2246,PFE,universal health service inc uhs free report be set report second quarter result jul market close last quarter company pull positive earning surprise let see thing be shape announcement factor be consider health be likely have witness rise revenue adjust patient day behavioral health division continue previous quarter trend company acute care division be expect have deliver decent performance back adjust admission growth universal health service inc price ep surprise universal health service inc price ep surprise universal health service inc quoteuniversal health effort enhance shareholder value share repurchase have boost bottom line limit share count nevertheless increase cost related interest payment reserve settlement legal judgment lawsuit impairment long live asset have put pressure margin earning whispersour proven model do not conclusively show universal health be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp universal health have earning esp be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank universal health carry zack rank favorable zack rank increase predictive power esp need positive earning esp be confident earning beat conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be company medical sector want consider have right combination element post earning beat quarter align technology inc algn free report be set report second quarter earning jul have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be set report second quarter earning aug humana inc hum free report have earning esp zack rank company be set report second quarter earning aug more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2247,PFE,dow breach psychological barrier week strong gain strong earning performance be primarily responsible index record run index also receive boost fall sovereign bond yield monday tuesday index achieve st record finish year ultimately index breach barrier wednesday index gain again thursday suffering minor loss earlier session russia investigation lead robert mueller intensified last week dow gain friday close record level blue chip index be boost splendid earning chevron corp cvx free report enabled dow recover point decline suffer earlier session other hand exxon mobil corp xom free report post dismal earning performance lose amazon com inc amzn free report disappointing second quarter result weigh other benchmark index gain last week dow great run be support excellent earning week index component report better expect earning period be mcdonald corp mcd boee company ba free report verizon communication inc vz free report caterpillar inc cat free report dow index gain monday finish yet time high buoy rally share goldman sachs group inc gs free report home depot inc hd free report boee fall sovereign bond yield also help index touch record level trading session last month dow gain power excellent earning result release period tuesday index increase once again dow register yet record high tuesday stopping just short attain psychological milestone be st record close blue chip index breach year marked dow sixth straight session gain second straight record finish company mmm free report goldman sachs contribute most gain occasion rise bank share splendid earning jpmorgan chase co jpm free report have also be instrumental dow stellar show ultimately index breach barrier wednesday index gain mark seventh consecutive daily increase historic benchmark be achieve trading day dow hit mark stellar show be result surge share apple inc aapl free report tech behemoth post outstanding earning result broadly encourage economic condition also drive index past psychological milestone index gain thursday index register rd record index close threshold yet again day marked loss other benchmark further blue chip index notch eighth straight daily rise buoy increase share pfizer inc pfe free report early session blue chip index have suffer minor loss russia investigation lead robert mueller intensified component move index apple report spectacular result third quarter fiscal drive impressive service segment performance earning share revenue surpass zack consensus estimate respectively year year basis earning grow revenue increase apple have zack rank total iphone unit sale come year year revenue iphone grow year quarter total revenue service include revenue internet service app store apple music applecare apple pay licensing other service surge year year nearly fourth quarter fiscal company forecast revenue range compare report year quarter release iphone zack consensus estimate be peg billon read apple earning revenue beat estimate stock pfizer inc pfe free report report second quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year however pharma heavyweight deliver revenue fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb zack rank rate pfizer divest hospira infusion system business icu medical pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook read pfizer surpass earning estimate miss sale intel corp intc report second quarter gaap earning cent share surge year quarter decline sequentially earning share ep beat zack consensus estimate cent strong year year earning growth be drive increase revenue totale beat zack consensus estimate revenue be almost flat sequentially adjust intel security group isecg transaction revenue grow intel guide third quarter revenue almost flat sequentially year year exclude intel security group business project figure be better zack consensus estimate fiscal management expect revenue almost better zack consensus estimate previous expectation stock have zack rank buy see complete list today zack rank strong buy stock here chevron report strong second quarter result recovery commodity price production gain success cost saving initiative company report earning share exclude special item cent higher zack consensus estimate cent year profit cent quarterly revenue surpass zack consensus estimate increase year year zack rank rate chevron total production crude oil natural gas increase compare last year corresponding period oil equivalent barrel day mboe chevron downstream segment achieve earning less profit last year fall primarily underline absence net gain asset sale read chevron earning beat oil rally output rise exxon mobil post earning miss second quarter owing decline liquid volume lower margin chemical business company report earning cent share miss zack consensus estimate cent bottom line improve year quarter level cent exxon mobil have zack rank sell total revenue quarter increase year quarter moreover top line surpass zack consensus estimate quarterly earning upstream segment be april june quarter downstream segment record profit report figure be higher april june quarter read exxon mobil earning miss lower volume performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week week dow have manage register strong gain loss broader market index have emerge unscathed primarily due strong earning performance bulk component dow earning release come end focus shift economic datum political development investor now increasingly focus report such friday job datum release determine direction market day ahead today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2248,PFE,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise so far year outpace gain same time frame nasdaq biotechnology index be almost year date slide nyse arca pharmaceutical index have rise year date ytd decline almost last year pharma biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last meanwhile outlook upcoming third quarter result look bright earning trend article broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pick likely winnersgiven enormity healthcare space select stock have potential beat estimate appear be quite daunting proprietary methodology make fairly simple way narrow list choice earning season be look stock have combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation earning esp be proprietary methodology identify stock have high chance deliver positive surprise upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high uncover best stock buy sell re report earning esp filter here be large cap pharma stock be poise beat estimate third quarter accord methodology investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well first pick be eli lilly company lly free report indianapoli base company have earning esp zack rank hold see complete list today zack rank strong buy stock here zack consensus estimate third quarter be share company have mixed earning surprise record fact lilly earning surpass expectation last quarters average negative surprise lilly be schedule report result oct next choice be pfizer inc pfe free report carry zack rank stock have earning esp zack consensus estimate third quarter be peg cent share new york base pfizer have mixed earning surprise track record average negative earning surprise trail quarters be pfizer be schedule announce result oct astrazeneca plc azn free report too have impressive track record company consistently beating earning expectation company earning surpass estimate last quarters average positive surprise look poise beat expectation third quarter well london uk base company carry zack rank have earning esp zack consensus estimate be peg cent share astrazeneca be schedule report result nov bristol myer squibb company bmy free report be solid bet zack rank stock have earning esp new york base company deliver average positive earning surprise trail quarters bristol myer be schedule release result oct zack consensus estimate third quarter peg cent share brentford uk base glaxosmithkline plc gsk free report make list likely outperformer third quarter virtue zack rank earning esp zack consensus estimate be peg cent share glaxo be expect report result oct bottom line challenge form competitive pricing pressure remain however number company healthcare space have fared well pick outperformer space backed solid zack rank positive earning esp lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2249,PFE,spin activity have step lately biggy honeywell international hon free report pfizer pfe free report be most active one lately industrial giant honeywell announce plan spin home global distribution unit transportation system unit publicly trade company end read etfs buy year high manufacturing activity other hand pfizer be explore strategic alternative possibly bid good bye consumer healthcare segment sale spin consumer health unit be expect next year pfizer consumer sale have be essentially flat past year clearly explain pfizer intend concentrate more promising innovative pharmaceutical unit separate consumer healthcare move also signify likely introduction more deal make wall street journal however company also keep open chance retain business spin offssometime business form autonomous entity exist business division believe separated line add more value independent company such situation parent focus core business management new entity focus relative different goal profitable spin off be investor accord cantor fitzgerald spinoff complete outperformed first year trading average more percent article publish benzinga spun entity have be perform better parent company lately paypal pypl free report generate higher gain parent ebay ebay free report last year post spin whitewave food co gain last year decline dean food co df free report whitewave food be spun abbot laboratory free report cut ty part business form new company call abbvie abbv free report jan abbv be gain last year oct recent surge spin offa chicago base partner boston consult group recently comment bull market be witness currently equity be overvalue make materialization merger acquisition difficult instead high valuation better justify spin asset divest asset logic hold good be likely see more such action come day read bargain etfs pricey market notably unite state see complete spinoff fall dot com bubble burst number further decline number action again rise slide financial crisis kick datum provide dealogic quote cnbc momentum again gain momentum value have be subdue etfs play be always way play such corporate action highlight spin etfs detail etfs get further boost honeywell pfizer announcement guggenheim spin etf csd free report stock fund look track spin index paypal holding hewlett packard enterprise synchrony financial be top holding fund csd charge bps fee read paypal strong result put etfs focus vaneck vector global spin etf spun free report stock fund follow horizon kinetic global spin index be rule base equal weight index intend track performance list publicly hold spin off be domicile trade develop market western europe asia net expense ratio fund be unite state account fund gannett co time inc timkensteel be top stock fund want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2250,PFE,astrazeneca plc azn free report announce faslodex have receive fda approval label extension first line monotherapy set treatment advanced breast cancer faslodex have be approve monotherapy treatment previously untreated post menopausal woman hormone receptor positive hr human epidermal growth factor receptor negative advanced breast cancer so far year astrazeneca share have moved compare unfavorably increase industry come back latest news fda approval be base datum phase iii falcon study falcon study evaluate tumor effect tolerability profile faslodex mg placebo comparison anastrozole mg placebo datum study show treatment faslodex lead reduction disease progression death versus anastrozole current standard care treatment note faslodex be currently approve unite state treatment postmenopausal woman estrogen receptor positive locally advanced metastatic breast cancer cancer have progressed follow estrogen therapy drug be also approve unite state combination pfizer inc pfe free report ibrance palbociclib treatment hr human epidermal growth factor receptor negative advanced metastatic breast cancer woman cancer have progressed endocrine therapy remind investor faslodex be approve same first line indication eu july japan june latest approval first line set be expect improve sale drug first half faslodex generate sale year year astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here stock considersome better rank pharma biotech stock be gilead science inc gild free report regeneron pharmaceutical inc regn free report regeneron sport zack rank gilead carry zack rank buy regeneron share have moved year so far estimate have rise have go last day share gilead have rally so far year estimate have inched almost respectively last day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2251,PFE,share clovis oncology inc clvs free report have witness continuous upside year share small biotech company be so far year outperform increase register industry period let analyze factor have drive rally so far company only approve drug rubraca have show impressive growth trend drug receive accelerate approval dec company effort have help ovarian cancer drug register almost growth sale sequentially second quarter rubraca sale be first half company have new patient therapy period rubraca be parp inhibitor be approve monotherapy treatment advanced ovarian cancer patient have be treat more chemotherapy patient be select therapy base fda approve companion diagnostic rubraca drug be license pfizer inc pfe free report confirmatory study ariel ariel be be conduct clovis convert accelerate approval continue approval rubraca company share get boost announce positive top line result ariel june promising progression free survival pfs safety result pivotal maintenance confirmatory study demonstrated rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis be plan file supplemental new drug application snda fda october year base ariel datum include second line later maintenance indication advanced ovarian cancer label rubraca company expect label expansion increase patient population least time meanwhile other phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy rubraca be also review eu comparable ovarian cancer indication approval be expect eu first quarter clovis be establish commercial infrastructure same be immense commercial potential rubraca target market due increase demand parp inhibitor american cancer society ovarian cancer rank fifth death cancer woman case ovarian cancer be estimate be diagnosed be huge unmet need new treatment option give woman ovarian cancer have germline somatic brca mutation rubraca be also be develop additional cancer indication monotherapy combination other agent include tecentriq rubraca combination gynecologic cancer combination study be sponsored roche moreover jul company collaborate bristol myer squibb company bmy free report evaluate rubraca combination latter opdivo ovarian breast prostate cancer be important note ovarian cancer market be already crowd presence major player launch tesaro inc tsro free report zejula apr competition have intensified further clovis oncology inc price consensus clovis oncology inc price consensus clovis oncology inc quoteclovis currently have zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2252,PFE,pfizer inc pfe free report international cancer research group be collaborate combination study explore use ibrance first line treatment advanced breast cancer patina phase iii study evaluate ibrance cdk inhibitor combination therapy endocrine therapy versus standard therapy first line treatment hr metastatic breast cancer first patient study be randomize last month patient be expect be recruit worldwide study ibrance be presently market treatment hr disease combination inhibitor initial endocrine base therapy postmenopausal woman astrazeneca plc azn free report faslodex fulvestrant woman disease have progressed follow endocrine therapy drug be presently not approve use hr patient population pfizer share have underperform industry year so far pfizer share be period compare unfavorably increase industry ibrance play instrumental role drive pfizer revenue drug record sale first half year year pfizer be also explore possibility expand label breast cancer drug ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer meanwhile pfizer boast strong oncology pipeline key cancer candidate bavencio avelumab get fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer bavencio be review eu mcc decision expect third quarter bavencio be be tout significant top line driver new york base pharma giant cancer drug besponsa inotuzumab ozogamicin receive fda approval earlier month monotherapy treatment relapse refractory cd positive cell precursor acute lymphoblastic leukemia drug be approve eu last month meanwhile other cancer candidate include talazoparib advanced breast cancer dacomitinib advanced lung cancer egfr activate mutation conference call pfizer have mentioned approximately drug approval be expect next year include product have blockbuster potential pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank pharma biotech stock include gilead science inc gild free report regeneron pharmaceutical inc regn free report regeneron sport zack rank gilead have zack rank buy regeneron share year so far estimate have rise have go past day share gilead have rise so far year estimate have rise almost respectively past day surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2253,PFE,immunomedic inc immu free report announce encourage interim result phase ii study antibody drug conjugate adc labetuzumab govitecan immu candidate be be evaluate single agent heavily pretreat patient metastatic colorectal cancer mcrc company share close higher aug announcement news fact share company have return so far year outperform industry gain period come back news study be evaluate once weekly mg mg dose immu patient have already receive pfizer inc pfe free report camptosar therapy median progression free survival pfs achieve be month mg month mg dosage also median overall survival os demonstrated candidate be month mg month mg moreover subset patient have also receive prior treatment bayer ag bayry free report stivarga subset median pfs os achieve candidate be month month respectively better stivarga pfs os company be also develop adc sacituzumab govitecan immu patient relapse refractive metastatic triple negative breast cancer remind investor immu enjoy breakthrough therapy designation company be plan file biologic license application accelerate approval fda same indication immu be also be develop treat other metastatic solid tumor adc candidate immu be be evaluate solid liquid cancer immunomedic inc price consensus immunomedic inc price consensus immunomedic inc quotezack rank stock currently carry zack rank hold better rank stock pharmaceutical sector be alexion pharmaceutical inc alxn free report sporting zack rank strong buy see complete list today zack rank stock here alexion earning estimate increase last day company deliver positive earning surprise trail quarters average beat share price have increase year date zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2254,PFE,blue chip index register rd record finish threshold yet again day marked loss other benchmark further dow notch eighth straight daily rise buoy increase share pfizer end red energy sector slump due steep fall share concho resource apache corp nasdaq continue lackluster performance end red again have primarily be due tech overvaluation issue moreover broader market incur loss russia investigation lead robert mueller intensified
2255,PFE,look issue currently face market make sure read today ahead wall street article
2256,PFE,dow jone industrial average djia blue chip index close time high rise point process index inx decline decrease point close meanwhile nasdaq composite index ixic close decline point total share be trade thursday last session average share advance issue outnumber decliner nyse nasdaq decliner outnumber advancer dow continue winning streak
2257,PFE,blue chip index continue winning streak thursday cross psychological milestone second time trot performance be attribute rise share pfizer pfe free report however decline decline share goldman sachs gs free report weigh dow meanwhile apple aapl free report share fall identical amount follow spectacular gain iphone maker aftermath strong third quarter result
2258,PFE,early session blue chip index have suffer minor loss russia investigation lead robert mueller intensified index re-cover later close record high yet again investor have not be too happy trump administration follow series failure course implement much vaunted reform however broader market have gain encourage economic condition exceptional calendar second quarter earning energy share dip drag lower
2259,PFE,end negative territory thursday slump energy sector energy select spdr decline major industry sector close red energy sector lead decliner tumble energy sector be trigger steep decline share concho resource cxo free report apache corp apa free report decline respectively
2260,PFE,meanwhile west texas intermediate future trade new york mercantile exchange barrel decline decline occur investor decide refrain investing commodity prefer much anticipate opec meeting slate next week unfold crude price also take hit follow news oil trader andy hall be close energy centric hedge fund prediction oil price climb faster go wrong result loss further trump party legislative straight jacket market watcher be increasingly lose faith have lead broader loss economic datum
2261,PFE,institute supply management announce index have fall july june represent weakest rate growth month further report state gauge production new order employment delivery inventory order backlog new export order have decelerate employment index also reduce july june
2262,PFE,business activity index show growth consecutive month decline percentage point july june also new order index report lower july compare june stock make energy eye chemical industry alkali unit buyout
2263,PFE,oil gas transportation refine partnership genesis energy gel free report recently announce enter chemical industry acquisition alkali business stamford ct base tronox limit read more kraft heinz earning beat estimate revenue lag
2264,PFE,kraft heinz company khc free report post second quarter result earning surpass zack consensus estimate miss same revenue read more activision earning beat estimate view raise
2265,PFE,activision blizzard inc atvi free report post second quarter adjust earning revenue easily beating respective zack consensus estimate read more today stock zack hottest strategy
2266,PFE,hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2267,PFE,merck mrk free report announce fda have grant tentative approval lusduna nexvue company biosimilar version sanofi sny free report lantus insulin glargine treatment person type type ii diabetes lusduna nexvue deliver insulin pre filled dose device note candidate be formerly know mk fda have grant provisional approval trade name lusduna nexvue be used once product be make available merck share have underperform industry so far year stock have gain compare broader industry increase lusduna meet regulatory safety efficacy standard approval be tentative due ongoing litigation sanofi final approval lusduna be subject resolution sanofi litigation september last year sanofi sue merck patent infringement lantus litigation automatically invoked stay final fda approval lusduna month event court rule favor merck be sooner notably lantus have be major contributor sanofi top line have account total sale however company consider conditional approval significant milestone be advance candidate step closer market remind investor merck be develop lusduna collaboration samsung bioepis agreement term merck be responsible clinical development manufacturing bioepis be partially funding development currently application regulatory approval lusduna treatment patient type type ii diabetes be review eu remind investor eli lilly company lly free report be already marketing follow insulin glargine product basalgar dec separate press release merck announce collaboration pfizer pfe free report modernization pharmaceutical packaging introduction corning valor glass enhance storage delivery drug formulation merck company inc pricemerck company inc price merck company inc quotezack rankmerck currently carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2268,PFE,biogen inc biib free report well know name multiple sclerosis ms market report second quarter result jul market open last quarter company deliver positive earning surprise biogen share have decline year so far zack classify biom genetic industry record increase biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be let see thing be shape announcement factor considerat first quarter call company have say expect relatively stable demand tecfidera tysabri multiple sclerosis drug patient growth ex market offset modest decline due rise competition drug roche ocrevus remain be see second quarter performance reflect trend meanwhile combine number patient used avonex plegridy be decline patient transition other oral multiple sclerosis therapy other high efficacy product zinbryta launch collaboration abbvie inc abbv free report aug be expect continue contribute revenue eu drug benefit increase use high efficacy product spinraza approve spinal muscular atrophy dec be promising start backed robust underlie demand notably spinraza add top line first quarter contribute further sale conference call company have say be work expand access spinraza patient however call company have warn possible logistic coverage restriction drug well other market expect management provide update issue second quarter conference call biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment second quarter call investor focus remain tecfidera scrip trend sale ramp spinraza pipeline progress acquisition plan earning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includeeli lilly company lly free report schedule release result jul earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2269,PFE,expect eli lilly company lly free report beat expectation report second quarter result jul market open last quarter company deliver positive earning surprise so far year lilly share price have rise compare increase zack classify large cap pharma industry lilly earning performance have be mixed earning miss expectation last quarters beating other bring average negative surprise let see thing be shape quarter factor playcontinu trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line second quarter trulicity sale be be drive growth glp market market share gain jardiance sale continue be drive increase market share grow sglt class dec fda approve jardiance cv indication launch jan american diabetes association ada update diabetes treatment guideline first quarter call management have say launch cv indication ada addition jardiance treatment guideline jardiance new therapy volume have increase be expect translate higher sale however sale alimta cymbalta zyprexa be expect continue decline due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country outside also lower demand due competitive pressure mainly immuno oncology agent be hurt alimta sale nevertheless older product humalog trajenta forteo continue do well newly launch drug basaglar lartruvo add top line basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch mid dec lartruvo olaratumab be launch eu soft tissue sarcoma fourth quarter new drug be expect generate decent revenue be report quarter new drug olumiant have be launch select european country add top line second quarter drug be review apr lilly receive complete response letter crl fda baricitinib fda require additional clinical datum delay approval drug update same be expect conference call animal health segment sale suffer last quarter due global competitive pressure remain be see trend improve quarter model proven model show lilly be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank lilly have zack rank combination lilly favorable zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quoteother stock considera couple stock large cap pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2270,PFE,abbvie inc abbv free report be schedule release second quarter earning open bell jul abbvie share have rally so far year industry have record increase last quarter company deliver positive surprise note abbvie earning history be mixed bag pharmaceutical company deliver positive surprise last quarters record line earning other average earning beat last quarters be abbvie inc price ep surpriseabbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerat first quarter conference call management reveal expect second quarter earning range share revenue be expect grow report basis currency headwind be expect hurt revenue company key drug humira be likely remain main growth driver second quarter increase awareness favorable clinical datum additional indication expansion new market be expect help product continue make significant contribution top line quarter abbvie also expect humira sale growth mid high teen range internationally humira sale be expect rise mid single digit range operational basis humira be do well company be concern product long term prospect owing potential biosimilar competition area focus be performance imbruvica add abbvie portfolio follow acquisition pharmacyclic drug record strong sale past few quarters trend expect continue imbruvica have multus dollar potential company be look expand drug label solid tumor autoimmune disease company expect imbruvica sale growth approach second quarter imbruvica have huge commercial potential investor know revenue be share johnson johnson jnj free report have collaboration agreement pharmacyclic other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably last month company announce committee medicinal product human use chmp recommend marketing approval investigational hepatitis virus hcv combo regimen glecaprevir pibrentasvir candidate be market trade name maviret decision european commission be expect third quarter approval definitely provide company stronger presence competitive dynamic hcv market earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp abbvie be most accurate estimate be peg share zack consensus estimate stand higher uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be better rank health care stock want consider model show have right combination element post earning beat quarter nordisk nvo free report be schedule release result aug company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report schedule release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2271,PFE,hca healthcare inc hca free report be schedule report second quarter result jul market open last quarter hospital company post line result have however surpass earning estimate last quarters average positive surprise let see thing be shape announcement company commercial volume have be stress past few quarters have take effort build local network create greater patient access outpatient facility standpoint digital medium standpoint address issue however don expect see major improvement business second quarter last quarter company report consecutive quarter equivalent admission growth hca expect trend continue second quarter hca healthcare consistently make capital expenditure expansion service capacity large fast grow urban market incur regard expect invest company have also make number acquisition past many year expedite growth believe investment generate top line growth increase business volume share buy back company be report cushion bottom line company have not paid regular dividend ipo prefer share buyback dividend payment allocate capital maintain current policy dividend payout hca holding inc price ep surprise hca holding inc price ep surprise hca holding inc quoteearning whispersour proven model do not conclusively show hca healthcare be likely beat earning quarter be stock need have positive earning esp zack rank happen be not case here see zack esp hca holding have earning esp be most accurate estimate stand share zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank hca holding carry zack rank hold increase predictive power esp however negative earning esp make surprise prediction difficult caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock warrant lookhere be company healthcare sector consider model show have right combination element post earning beat quarter gilead science inc gild free report be expect report second quarter earning result jul company have earning esp zack rank see complete list today zack rank strong buy stock here celgene corporation celg free report have earning esp zack rank company be expect report second quarter earning result jul pfizer inc pfe free report have earning esp zack rank company be expect report second quarter earning result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2272,PFE,pfizer inc pfe free report announce leukemia candidate besponsa inotuzumab ozogamicin have be approve fda box warning label pfizer share be more thursday so far year pfizer share be compare unfavorably increase industry besponsa have be approve monotherapy treatment relapse refractory cd positive cell precursor acute lymphoblastic leukemia drug be approve eu last month approval be base datum pivotal study ino vate demonstrated patient treat besponsa show significant improvement complete response besponsa arm versus chemotherapy thereby meeting primary endpoint study however fail reach statistical significance analysis overall survival os median os besponsa arm be month versus month patient treat chemotherapy importantly label drug include box warning hepatotoxicity liver damage include hepatic veno occlusive disease vod label also have warning related increase risk relapse mortality patient take medicine post hematopoietic stem cell transplantation hsct remind investor inotuzumab ozogamicin be grant breakthrough therapy designation meanwhile pfizer boast strong oncology pipeline key cancer candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer bavencio be review eu mcc decision expect third quarter bavencio be be tout significant top line driver new york base pharma giant meanwhile pfizer be explore possibility expand label breast cancer drug ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer other cancer candidate include talazoparib advanced breast cancer dacomitinib advanced lung cancer egfr activate mutation conference call pfizer have mentioned approximately drug approval be expect next year include product have blockbuster potential pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank stock pharma biotech space include regeneron pharmaceutical inc regn free report sanofi sny free report gilead science inc gild free report regeneron sport zack rank strong buy sanofi gilead have zack rank buy regeneron share year so far estimate have rise have go past day share sanofi be year date estimate have rise respectively past day share gilead have rise so far year estimate have rise almost respectively past day surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2273,PFE,past week several wall street most talk company have post report earning season be far indeed investor still have latest report several tech giant major market mover look forward mean more important ever stay tune say massive amount earning report come be overwhelming investor luckily zack reader utilize zack earning calendar order keep track specific earning release dividend announcement other vital news have large impact portfolio used earning calendar be look ahead next week target most important upcoming report check company be expect release earning report week july pfizer inc pfe free report tuesday august market openpharma giant pfizer be set report second quarter result bell tuesday so far company large cap pharma peer be perfect earning beat industry share price have slump weak outlook drug stock soar promise regulatory reform market have see bit pullback thank administration relative inaction analyst sentiment have be mixed pfizer ve see positive negative revision second quarter earning past day current consensus estimate be call company post ep growth revenue dip quarter pfizer have strong pipeline genericization key drug lose alliance revenue pricing pressure rise competition be challenge year apple inc aapl free report tuesday august market closetech behemoth apple be schedule release fiscal third quarter earning report close bell tuesday earning consumer tech space have be strong so far apple have face new question related supply chain user desperately wait detail iphone company be poise report device sale weakness quarter nevertheless handful new gadget include company wireless earpod do debut recently help lift sale slightly accord current zack consensus estimate apple be expect record ep growth revenue growth quarter stock also sport earning esp zack rank hold make investor feel more optimistic company chance beat earning estimate time warner inc wednesday august market opencable tv leader time warner be set announce second quarter earning result market open wednesday due company pending merger free report time warner not hold earning conference call report give investor important update state business join accord latest zack consensus estimate time warner be poise post revenue growth earning be expect slip however sentiment have improve recently stock currently have earning esp top positive estimate revision have moved company zack rank buy give investor more confidence head earning report date kraft heinz company khc free report thursday august market closefood giant kraft heinz be schedule report second quarter result market close thursday biggest food company world kraft heinz report give fresh look latest consumer trend recently shift consumer preference natural organic ingredient package processed food have hurt company key segment head report just kraft heinz industry peer have surpass earning estimate season underscore challenge industry have face year so far industry share price have slip more nevertheless current zack consensus estimate be call ep growth give earning esp look most recent sentiment have be positive want more stock market analysis author make sure follow ryan_mcqueeney twitter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2274,PFE,aerie pharmaceutical inc aeri free report post second quarter loss cent share include stock base compensation narrower zack consensus estimate loss cent year loss cent be development stage company aerie have not generate revenue product sale yet note share aerie have rally year so far outperform industry rally quarter detailin report quarter research development expense decline company complete trial general administrative expense increase higher operate expense quarter be attribute expansion employee base support operation preparatory activity include commercial manufacturing cost rhopressa aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc quotepipeline updateson feb company resubmit new drug application nda lead candidate rhopressa expect review period month note aerie withdraw rhopressa nda file september third party manufacturing facility tampa fl be not ready pre approval inspection fda company initiate preparation bring second contract manufacturer online apart rhopressa aerie be evaluate roclatan once daily quadruple action fix dose combination rhopressa pfizer inc pfe free report xalatan company report positive top line day efficacy safety datum second phase iii clinical trial mercury datum mercury be expect third quarter mercury mercury be successful nda roclatan be expect be file early company also expect commence trial mercury third quarter europe support filing trial be inferiority trial compare roclatan prescribe fix dose combination ganfort combination bimatoprost timolol market allergan plc agn free report europe meanwhile company recently inked acollaboration agreement dsm primary focus potential aerie compound treat retinal disease narrower expect loss second quarter be encourage be encourage company effort develop pipeline candidate potential approval rhopressa early significantly boost growth prospect zack rank other key pickaerie currently carry zack rank buy top rank stock healthcare sector be gilead science inc gild free report currently carry zack rank see complete list today zack rank strong buy stock here gilead earning share estimate increase last sevenday follow strong result second quarter company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2275,PFE,share xerox corp xrx free report surge report adjust second quarter earning share beat zack consensus estimate share daniel co adm free report increase report second quarter adjust earning share soar year year surpass zack consensus estimate share royal caribbean cruise ltd rcl free report rise report second quarter adjust earning share be ahead zack consensus estimate share pfizer inc pfe free report fall report second quarter revenue fall short zack consensus estimate
2276,PFE,york pa base dentsply sirona inc xray free report dental solution company be expect report second quarter result aug dentsply sirona track record have be quite impressive company beating estimate trail quarters last quarter deliver negative earning surprise take quarter average positive let see thing be shape prior quarter likely positive surprise proven model show dentsply be likely beat earning have right combination key component zack esp dentsply currently have earning esp be most accurate estimate be cent zack consensus estimate come be peg cent favorable earning esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank dentsply currently carry zack rank hold be note stock zack rank strong buy buy have significantly higher chance beating earning conversely stock zack rank sell rate never be consider go earning announcement combination dentsply zack rank positive esp make reasonably confident earning beat dentsply sirona inc price ep surprise dentsply sirona inc price ep surprise dentsply sirona inc quotefactor playdentsply dental healthcare consumable segment hold considerable promise notably segment provide broad spectrum product include preventive restorative instrument endodontic laboratory dental product well consumable medical device product furthermore dentsply dental implant cad cam system imaging system treatment center orthodontic product technology segment be likely drive sale be also upbeat gradual recovery market emerge market provide significant opportunity company area be vastly untapped low dental product penetration company anticipate adjust ep range stock warrant lookhere be other company want consider model show also have right combination element post earning beat halyard health inc have earning esp carry zack rank see complete list today zack rank stock here genomic health inc ghdx free report have earning esp carry zack rank pfizer inc pfe free report have earning esp carry zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2277,PFE,merck co inc mrk free report be report second quarter earning jul market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation consistently average positive earning surprise last quarters be merck share rise year so far compare unfavourably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter believe keytruda sale likely be drive strong uptake launch new country expansion additional indication especially first line nsclc mar apr keytruda receive fda eu approval refractory classical hodgkin lymphoma chl first keytruda approval hematologic malignancy indication keytruda be approve first line combination therapy lung cancer first fda approval combination therapy expand indication especially combination therapy add keytruda sale quarter apart continue strength melanoma indication rapid penetration head neck cancer indication boost keytruda sale last couple month be series regulatory approval label expansion keytruda advanced bladder cancer expect update management plan same conference call first quarter conference call management have say be work secure reimbursement keytruda first well second line nsclc indication outside lung cancer sale become much larger contributor outside country year progress expect update conference call meanwhile ongoing launch globally be likely support zepatier sale however company continue face headwind form genericization increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region nasonex generic version launch mar cubicin lose patent protection jun zetia lose market exclusivity dec likely decline quarter sluggish growth integrase class continue competitor dynamic europe continue affect isentress sale investor focus remain performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first quarter remain be see trend improve second quarter vaccine animal health franchise also boost sale quarter earning whispersour proven model do not conclusively show merck be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate well zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quotestock considerstock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2278,PFE,johnson johnson jnj free report report mixed second quarter result earning beat expectation sale miss same however drug consumer product giant raise sale profit outlook send share more pre market trading year so far share price be compare favorably increase witness zack classify large cap pharma industry earning beatj second quarter earning come share beating zack consensus estimate increase year period include time item report second quarter earning share year period sale miss againsale come miss zack consensus estimate sale increase year quarter reflect operational increase negative currency impact organically exclude impact acquisition divestiture sale increase operational basis second quarter sale grow domestic market international market reflect operational growth partially offset negative currency impact sale segment sale decline year year reflect operational growth negative currency impact higher sale international market offset weaker performance sale domestic market decline international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be xarelto stelara invega sustenna however sale invokana invokamet decline also concerta decline zytiga sale fall importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report launch inflectra injection biosimilar version remicade late last november do not have significant impact remicade sale past quarters management be expect comment impact biosimilar second quarter sale conference call pharma segment achieve clinical milestone quarter include fda approval darzalex be used combination celgene corporation celg free report pomalyst pomalidomide dexamethasone third line treatment multiple myeloma importantly last week announce fda approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya meanwhile last month complete previously announce acquisition swiss biotech actelion diversify revenuesto pulmonary arterial hypertension pah category actelion pah drug add top line quarter medical device segment sale come year period include operational increase negative currency movement sale gain mainly inclusion abbott medical optic acquisition exclude impact acquisition divestiture operational basis worldwide sale increase sale domestic market rise year year international market sale increase operational increase year year operational growth be drive advanced surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement negatively impact sale segment sale domestic market grow year period slower growth baby care product be partially offset growth counter product meanwhile international segment record decline reflect operational decline negative currency impact guidance raisedj raise earning guidance increase lower end sale outlook expect adjust earning share range include currency impact compare expect previously revenue guidance be range compare expect previouslyour takedespite third consecutive sale miss look optimistic better sale performance second half chief executive officer alex gorsky say sale growth accelerate second half year importantly sale medical device segment be pick make lower sale international consumer pharmaceutical segment quarter sale domestic pharma segment have decelerate year key growth driver have slow due competition quite few product portfolio remicade concerta be face generic competition however believe new product tremfya label expansion drug imbruvica darzalex contribution actelion lead better sale trend remain half year carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2279,PFE,paratek pharmaceutical inc prtk free report announce positive result phase iii study oasis compare antibiotic candidate omadacycline pfizer inc pfe free report zyvox treatment acute bacterial skin skin structure infection absssi study meet key primary secondary endpoint paratek pharma look set file new drug application nda fda first half share be more hour trading oasis study evaluate efficacy safety oral once daily dose omadacycline twice daily dose zyvox study meet fda specify primary efficacy endpoint statistical inferiority ni early clinical response ecr hour first dose drug study ecr omadacycline be find be compare zyvox additionally study meet statistical ni european medicine agency specify co primary endpoint post treatment evaluation pte clinical success rate modify intent treat population omadacycline zyvox arm be respectively rate be omadacycline versus zyvox arm clinically evaluable population remind investor omadacycline have now show positive result phase iii study namely oasis oasis optic study oasis study datum show omadacycline be prescribe oral only dose regimen outpatient set be expect reduce need hospital admission treatment absssi datum oasis announce last year show candidate meet fda specify primary efficacy endpoint ecr ecr omadacycline be find be compare zyvox arm datum optic study announce apr demonstrated statistical inferiority omadacycline bayer ag bayry free report avelox treatment adult community acquire bacterial pneumonia cabp ecr hour initiation therapy be also find be statistically inferior avelox post treatment evaluation paratek intend present result study datum secondary endpoint upcoming scientific congress nda omadacycline be treatment absssi cabp include datum study note omadacycline enjoy fast track status company also intend file fda approval pipeline candidate sarecycline treatment acne second half year paratek be develop candidate allergan plc agn free report announce positive result first quarter study meet primary endpoint positive development have push paratek share price so far year outperformed zack classify medical generic drug industry increase same period zack rankparatek currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2280,PFE,pfizer inc pfe free report supplemental new drug application snda xeljanz have be accept review fda xeljanz mg twice daily jak inhibitor be presently approve second line treatment moderate severely active rheumatoid arthritis ra patient have have inadequate response tolerate methotrexate drug be approve europe china march year ra latest application company be look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis uc response fda be expect march next year pfizer share be so far year compare unfavorably zack classify large cap pharma industry gain acceptance snda be base datum pivotal study octave global clinical development program constitute octave induction octave induction octave sustain also include datum open label extension study xeljanz evaluate long term effect patient have complete treatment have failure octave sustain do not respond treatment octave datum study demonstrated xeljanz be more effective placebo induce maintain remission patient datum show patient be remission compare placebo octave patient be remission versus placebo octave week octave sustain evaluate different administration achieve remission mg mg patient compare placebo week octave induction study evaluate induction remission twice daily mg oral administration drug patient uc octave sustain evaluate xeljanz mg mg maintenance therapy patient include achieve least clinical response octave induction be encourage pfizer label expansion effort xeljanz sale be year year first quarter label expansion drug boost sale further meanwhile snda xeljanz be review psoriatic arthritis be file year response agency be expect dec pfizer inc price consensus pfizer inc price consensus pfizer inc quotezack rank stock considerpfizer currently have zack rank hold better rank stock healthcare sector include astrazeneca plc azn free report sanofi sny free report merck company inc mrk free report astrazeneca sport zack rank strong buy sanofi merck carry zack rank buy see complete list today zack rank stock here astrazeneca earning estimate have increase last day company come positive earning surprise last quarters average beat share price company be so far year merck earning estimate have moved last day company come positive earning surprise last quarters average beat share price company be so far year sanofi earning estimate have moved last day company come positive earning surprise last quarters average beat share price company be so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2281,PFE,ve see plenty marquee name put quarterly earning report already calendar apple aapl free report due close bell afternoon be still large amount well know firm have report tuesday pre market underarmour uaa free report pfizer pfe free report daniel adm free report other hit tape morning also see new econ data morning horizon include personal income spending read precede tomorrow adp private sector job report precede friday full farm payroll result other word full plate datum help move needle investor hour day ahead june read personal income spending be disappointment unchanged previous month be bump initial report number analyst have expect income growth spending come expect june figure continue show lag production wage growth continue keep price lower longer include employee salary spending remain constant specialty retailer underarmour outperformed expectation post loss much narrower bottom line expect cent share compare cent quarterly sale also beat expectation however zack rank hold company lower full year guidance current zack consensus uaa share fall stone ve rebound company restructure initiative worth look make notable improvement longer term plan pfizer report mixed morning beating estimate bottom line cent cent share once again come short revenue side compare zack consensus however earning guidance be raise morning sale guidance stay pat daniel outperformed expectation bottom line post cent share opposed cent analyst be look break fairly woeful previous year earning fail meet consensus say quarterly sale come almost dollar light expectation year year compare estimate london base bp bp free report bring solid earning surprise ahead open bell today report cent share full dime higher zack consensus estimate however revenue also fall short expectation bring quarter compare estimate oil equivalent production be year year price realization improve nicely year year
2282,PFE,pfizer inc pfe free report report second quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year other hand revenue miss expectation pharma heavyweight deliver revenue fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb pfizer divest hospira infusion system business icu medical sale detailcurrency movement impact pfizer second quarter revenue sale growth be flat operational basis exclude revenue sale rise operational basis lower sale enbrel prevnar prevenar vaccine franchise loss exclusivity product offset strong performance key product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis international revenue decline flat operational basis meanwhile revenue be flat segment second quarter pfizer reorganize report segment pfizer innovative health ih pfizer essential health pfizer ih sale grow operationally year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition also propel revenue xtandi record alliance revenue quarter compare first quarter be partially offset continue decline revenue prevnar lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside canada viagra sale decline due lower sale international market due reduce demand global prevnar prevenar revenue decline prevnar revenue tank due high initial capture rate eligible adult patient population follow successful launch result smaller remain catch opportunity second quarter compare year quarter unfavorable timing government purchase pediatric indication also hurt sale eucrisa crisaborole topical ointment treatment atopic dermatitis eczema be buy part jun anacor acquisition be launch first quarter ointment record sale second quarter consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue decline internal medicine rise inflammation immunology franchise decline additionally portfolio rare disease decline pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product pristiq generic version launch mar vfend zyvox celebrex lyrica lower revenue legacy hospira product divesture however business biosimilar do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster ra drug remicade november last year inflectra record sale globally other biosimilar bring sale outside market adjust selling informational administrative si expense be flat operationally quarter adjust expense rise guidance pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook mid point revenue be expect be slightly level adjust ep be expect increase previously research development expense be still expect range si spending be project range key drug key pipeline candidate bavencio avelumab receive accelerate fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer candidate be be study different type cancer include several combination therapy other immuno oncology agent pipeline candidate besponsa inotuzumab ozogamicin be approve eu june monotherapy relapse refractory cd positive cell precursor acute lymphoblastic leukemia candidate be review fda decision expect later month takepfizer second quarter result be mixed beat earning estimate miss same sale share decline slightly pre market trading company continue struggle sale performance pfizer share be so far year compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line product viagra lyrica chantix lose exclusivity couple year nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential bavencio be be consider key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2283,PFE,tuesday august st ve see plenty marquee name put quarterly earning report already calendar apple aapl free report due close bell afternoon be still large amount well know firm have report tuesday pre market underarmour uaa free report pfizer pfe free report daniel adm free report other hit tape morning also see new econ data morning horizon include personal income spending read precede tomorrow adp private sector job report precede friday full farm payroll result other word full plate datum help move needle investor hour day ahead june read personal income spending be disappointment unchanged previous month be bump initial report number analyst have expect income growth spending come expect june figure continue show lag production wage growth continue keep price lower longer include employee salary spending remain constant specialty retailer underarmour outperformed expectation post loss much narrower bottom line expect cent share compare cent quarterly sale also beat expectation however zack rank hold company lower full year guidance current zack consensus uaa share fall stone ve rebound company restructure initiative worth look make notable improvement longer term plan pfizer report mixed morning beating estimate bottom line cent cent share once again come short revenue side compare zack consensus however earning guidance be raise morning sale guidance stay pat daniel outperformed expectation bottom line post cent share opposed cent analyst be look break fairly woeful previous year earning fail meet consensus say quarterly sale come almost dollar light expectation year year compare estimate london base bp bp free report bring solid earning surprise ahead open bell today report cent share full dime higher zack consensus estimate however revenue also fall short expectation bring quarter compare estimate oil equivalent production be year year price realization improve nicely year year mark vickerysenior editorquestion comment article author click here
2284,PFE,becton dickinson company bdx free report be set report second quarter fiscal result aug becton dickinson have impressive track comfortably beating estimate trail quarters last report quarter deliver positive earning surprise bring quarter average let take look thing be shape prior second quarter earning announcement factor playbecton dickinson innovative product pipeline be key catalyst view plethora regulatory approval international market be help company rapidly expand product portfolio management becton dickinson expect strong demand pyxis es platform infusion pump be growth driver fiscal second quarter overall fiscal revenue be anticipate increase approximately additionally partnership collaboration be provide company competitive edge however unfavorable foreign exchange rate be anticipate remain headwind rest year furthermore uncertainty associate possibility repeal affordable care act president trump add company concern company estimate revision trend lack luster current quarter analyst moved south compare upward revision last month last month current quarter estimate decline share add concern overall fiscal adjust earning currency neutral basis be expect range reflect year year growth however include estimate unfavorable impact foreign currency company expect adjust diluted earning share represent increase approximately becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quoteearning whisper proven model do not conclusively show becton dickinson be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp becton dickinson currently have earning esp be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank becton dickinson have zack rank increase predictive power esp however negative esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter genomic health inc ghdx free report have earning esp zack rank see complete list today zack rank stock here halyard health inc have earning esp zack rank pfizer inc pfe free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2285,PFE,pfizer inc pfe free report be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product new york base company be well know product prevnar lyrica lipitor celebrex other however many peer pfe be face generic competition pricing pressure several product lipitor norvasc protonix camptosar celebrex zoloft other lose alliance revenue pricing pressure rise competition be hurt top line scenario investor focus remain late stage pipeline candidate commercial potential performance new product apart usual top bottom line number pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise currently pfe have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earn beat pfe beat second quarter earning come cent consensus call ep cent earning rise year year revenue miss revenue once again miss expectation pfizer post revenue compare consensus estimate unfavorable currency movement cut pfizer first quarter revenue guidance pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range versus expect previously pre market trading share rise pre market trading check back later full pfe earning report later pfizer inc price consensus pfizer inc price consensus pfizer inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2286,PFE,fda approve treatment last year have give approval drug so far include july key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month august new indication bristol myer opdivo bristol myer squibb bmy free report be look get label pd inhibitor expand use patient mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer crc prior oxaliplatin irinotecan base chemotherapy regulatory application be currently priority review response expect aug opidivo be currently approve wide range indication bring sale first half bristol myer have lose value year date ytd versus growth industry ra drug support fda panel fda arthritis advisory committee be meeting tomorrow discuss bla johnson johnson jnj free report investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person new treatment option have enter market last couple decade ra patient be still not adequately manage many left fewer therapeutic option due loss response available agent poor compliance due inconvenient dose earlier week fda have release briefing document meeting indicate lot emphasis be place safety profile drug especially imbalance cause death plivensia placebo approve plivensia enter pretty crowd market give presence drug humira actemra kevzara other once monthly dose schedule give advantage share have gain ytd outperform industry rally fda follow eu path give green signal abbvie maviret abbvie abbv free report also have important regulatory event come fda expect respond approval status company latest hepatitis virus hcv offer month maviret investigational pan genotypic regimen glecaprevir pibrentasvir be once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch note maviret gain eu approval just last week share abbvie have gain ytd outperform industry rally third time lucky dynavax heplisav be great week clinical stage immunology company dynavax technology corp dvax free report get favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote be third time lucky company have previously receive complete response letter heplisav nov other feb fda decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share shot positive panel vote be whopping ytd significantly outperform industry rally pfizer xeljanz be review fda advisory panelpfizer pfe free report have regulatory event month first be fda advisory panel meeting other pdufa date fda arthritis advisory committee be meeting aug discuss supplemental new drug application snda submit company jak inhibitor xeljanz xeljanz xr treatment adult patient active psoriatic arthritis efficacy safety datum benefit risk consideration be discuss panel xeljanz currently approve ra bring sale meanwhile fda be expect give response regard approval status pfizer besponsa recently gain approval eu approve besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less pfizer stock have gain ytd lag industry belong pfizer be zack rank hold stock see complete list today zack rank strong buy stock here other fda decision schedule month include response regard agio pharmaceutical inc agio free report partner celgene celg free report idhifa priority review relapse refractory acute myeloid leukemia aml idh mutation aug meanwhile fda be expect decide approval status valeant eye drug vesneo latanoprostene bunod ad treatment levodopa induced dyskinesia person parkinson disease aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2287,PFE,be busy week fda oncologic drug advisory committee odac review several experimental treatment week include novartis nvs free report car cell drug meanwhile french pharma giant sanofi sny free report announce be acquire vaccine company recap week most important storiesfda panel support novartis car drug novartis get huge boost fda advisory panel voting unanimously favor company experimental car cell therapy ctl novartis be look get treatment approve pediatric young adult relapse refractory cell acute lymphoblastic leukemia positive vote be major milestone company become first launch car cell therapy fda follow advisory panel advice ctl be currently priority review advisory panel issue positive recommendation believe chance gain approval be high read more novartis car therapy drug recommend fda panel so far novartis have outperformed zack categorize large cap pharmaceutical industry share gain industry be fda nod psoriasis treatment jnj free report tremfya gain fda approval treatment moderate severe plaque psoriasis make drug first only biologic approve selectively block only il cytokine play key role plaque psoriasis psoriasis market be pretty crowd tremfya demonstrated superior result skin clearance compare humira head head analysis week tremfya be currently late stage study treatment active psoriatic arthritis phase iii program evaluate efficacy compare cosentyx treatment moderate severe plaque psoriasis mar pdufa date pfizer xeljanz label expansion pfizer pfe free report snda xeljanz have be accept review fda response expect mar timely approval make xeljanz first oral janus kinase jak inhibitor be available person live moderately severely active ulcerative colitis uc pfizer also get favorable vote fda advisory panel acute myeloid leukemia aml drug mylotarg newly diagnosed patient final decision fda be sep mylotarg be initially approve be subsequently withdraw market late stage study fail show clinical benefit moreover higher rate fatality result treatment related toxicity be observed mylotarg arm priority review lilly advanced breast cancer drug lilly lly free report get priority review fda cdk inhibitor abemaciclib company be look get abemaciclib approve monotherapy combination therapy fulvestrant patient advanced breast cancer give priority review status lilly get response fda first quarter currently approve cdk inhibitor include pfizer ibrance novartis kisqali read more lilly breast cancer drug get priority review status fda lilly also enter settlement agreement generic player settle patent infringement lawsuit related ciali tadalafil unit dose patent settlement agreement patent be previously set expire apr now end sep ciali be approve treatment erectile dysfunction ed frustrate urinary symptom benign prostatic hyperplasia bph ciali sale be lilly say adcirca tadalafil patent remain protected nov pediatric exclusivity be grant adcirca be approve pulmonary arterial hypertension read more lilly settle patent litigation ciali generic firm sanofi buy vaccine company sanofi fail effort acquire medivation actelion announce be acquire protein science base privately hold vaccine biotech company include upfront payment achievement certain milestone acquisition sanofi be look expand flu portfolio addition egg base vaccine protein science flublok quadrivalent influenza vaccine qiv be approve fda oct be only recombinant protein base flu vaccine approve agency acquisition be schedule close third quarter sanofi be zack rank buy stock see complete list today zack rank strong buy stock here mylan herceptin biosimilar get favorable panel vote mylan myl free report get boost biosimilar version herceptin trastuzumab get favorable recommendation fda advisory panel panel vote support eligible indication reference product include breast cancer metastatic adjuvant setting biosimilar version have be develop collaboration biocon cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca azn free report be lilly gain almost last month astrazeneca be bristol myer be see last pharma stock roundup here mrk keytruda mm combo study clinical hold bayer revise outlook next pharma world watch second quarter earning result company be report jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2288,PFE,share exelixis inc exel free report have gain almost aug company share have rally whopping year so far outperform increase register zack categorize medical biomedical genetic industry period here analyze factor lead rally exelixis be company focuse develop commercialize small molecule therapy treatment cancer exelixis lead product cometriq capsule form cabozantinib be approve treatment progressive metastatic medullary thyroid cancer mtc exelixis be develop cabozantinib broad development program comprise clinical study multiple indication company receive major impetus apr fda approve tablet formulation cabozantinib distinct capsule form brand name cabometyx treatment rcc patient have receive prior angiogenic therapy cabometyx be also approve eu treatment advanced rcc adult have receive prior vascular endothelial growth factor vegf target therapy result phase ii cabosun study cabozantinib versus pfizer pfe free report sutentin formerly untreated advanced rcc be positive base cabosun result company have plan submit supplemental new drug application snda cabozantinib treat first line advanced rcc third quarter company present further positive analysis trial jun potential label expansion drug further boost result datum american cancer society kidney cancer be most commonly diagnosed form cancer man woman hence believe exelixis be poise capture major chunk market approve first line kidney cancer meanwhile early exelixis inkedagreement bristol myer squibb bmy free report roche holding ag rhhby free report develop cabozantinib combination immunotherapy exelixis collaborate bristol myer evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer company have initiate phase iii trial checkmate jul evaluate opdivo combination cabometyx opdivo yervoy combination cabometyx versus sutent patient previously untreated advanced metastatic rcc exelixis have also collaborate roche evaluate cabozantinib combination tecentriq pd antibody patient advanced rcc bladder cancer jun exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc label expansion additional indication give product access higher patient population increase commercial potential drug zack rankexelixis currently sport zack rank strong buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2289,PFE,issue update research report therapeutic inc cort free report jul share have surge year date compare favorably zack classify medical drug industry gain currently company be strive commercialize korlym mifepristone successfully deploy medical liaison sale representative fact korlym be only market drug be approve treatment patient cush syndrome notably person be newly diagnosed cush syndrome year result more new patient annually therefore believe increase awareness physician patient drug expand sale effort boost sale go forward be currently work develop drug additional indication be conduct phase ii safety efficacy study korlym combination eisai co ltd cancer drug halaven treatment triple negative breast cancer tnbc enrolment study be complete company announce encourage datum dec expect successful label expansion korlym boost top line significantly disease represent huge potential many woman be diagnosed year moreover university chicago be conduct phase ii study korlym combination pfizer pfe free report xtandi treatment metastatic castration resistant prostate cancer institution also plan conduct phase ii study korlym combination celgene celg free report abraxane treatment patient tnbc importantly apart korlym be also evaluate cort cush syndrome range solid tumor early datum candidate cush syndrome have be quite promising company have begin dose patient phase ii study cort combination abraxane treatment range solid tumor cancer possible target indication include triple negative breast cancer ovarian cancer pancreatic cancer sarcoma company expect open expansion cohort end additionally company have promising preclinical candidate cort metabolic disorder cort alcohol withdrawal cort castration resistant prostate cancer triple negative breast cancer ovarian cancer be expect enter clinic also first quarter earning release company raise revenue guidance now project revenue be range more prior expectation therapeutic incorporate price consensus therapeutic incorporate price consensus therapeutic incorporate quotezack rank stock currently carry zack rank hold better rank health care stock same space be enzo inc sporting zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2290,PFE,merck co inc mrk free report report second quarter earning share easily beat zack consensus estimate cent earning also rise year period revenue quarter increase year year beating zack consensus estimate currency movement negatively impact revenue exclude currency impact sale rise year year quarter pharmaceutical segment post revenue exclude fx impact year year mainly backed strong sale pd inhibitor keytruda keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer approve oct last month be series regulatory approval label expansion keytruda drive sale go forward important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer however earlier month pivotal phase iii study keytruda head neck squamous cell carcinoma fail meet primary endpoint overall survival also combination study keytruda multiple myeloma be place clinical hold month follow report death keytruda group meanwhile competition immuno oncology market be rise follow recent fda approval pfizer inc pfe free report bavencio avelumab merkel cell carcinoma mcc bladder cancer astrazeneca plc azn free report imfinzi durvalumab bladder cancer zepatier bring sale previous quarter attributable ongoing launch globally bridion sugammadex injection generate sale quarter year year drive strong uptake launch meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection jun zetia lose market exclusivity dec vytorin lose exclusivity apr decline quarter sale isentress januvia janumet diabetes franchise also decline quarter remicade sale decline quarter merck market brand version remicade outside johnson johnson jnj market rheumatoid arthritis drug week merck launch renflexis biosimilar version remicade cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin januvia janumet franchise record sale quarter year quarter due lower sale due pricing pressure lower customer inventory level isentress sale decline quarter lower volume demand due competitive pressure be hurt sale isentress vaccine sale be primarily drive increase gardasil pneumovax vaccine vaccine sale be also boost addition approximately gardasil sale terminate vaccine joint venture sanofi gardasil gardasil sale climb drive strong demand asia pacific favorable timing sale brazil merck animal health segment post revenue exclude fx impact year quarter primarily drive higher sale companion animal product margin gross margin come basis point bps quarter attributable favorable effect product mix lower inventory offsmarketing administrative expense increase report quarter research development spend increase quarter guidancedespite lower expectation negative impact currency exchange rate company maintain previously adjust earning guidance raise sale guidance marginally company expect adjust earning range include approximately negative foreign exchange impact versus previously revenue be expect range compare earlier forecast include negative currency impact approximately versus previously operate expense be expect increase year year mid single digit rate compare low single digit rate expect previously takemerck second quarter earning be encourage company beat sale earning strong performance new product keytruda bridion zepatier higher sale vaccine animal health franchise offset lower sale diabetes franchise loss market exclusivity many drug merck share have rise year so far compare unfavorably increase industry merck also announce cancer collaboration astrazeneca jointly commercialize develop latter parp inhibitor lynparza monotherapy combination study multiple cancer type lynparzais presently market advanced ovarian cancer meanwhile merck independently develop combination medicine lynpraza keytruda deal merck pay total consideration include upfront payment merck also say network cyber attack june disrupt global operation result temporary delay fulfill order product merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quotemerck carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2291,PFE,investor be always look stock be poise beat earning season pfizer inc pfe free report be such company firm have earning come pretty soon event be shape quite nicely report be pfizer be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface pfe report fact most accurate estimate current quarter be currently cent share pfe compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate pfe give stock zack earning esp head earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give pfe have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead pfizer beat be card upcoming report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2292,PFE,issue update research report boulder co base clovis oncology inc clvs free report jul clovis get huge boost dec fda grant accelerate approval parp inhibitor rubraca rucaparib treatment advanced ovarian cancer month earlier expect approval be base encourage objective response rate duration response study ariel clovis have license rubraca pfizer inc pfe free report company have raise public offer common stock company plan use part net proceed commercial plan sale marketing expense related launch rubraca europe approval general administrative expense increase year year first quarter reflect cost rubraca launch apr clovis announce agreement myriad genetic use latter fda approve bracanalysis cdx test identify patient germline brca mutation eligible treatment rubraca have previous agreement foundation medicine use foundationfocus cdxbrca companion diagnostic test identification eligible patient so far year clovis share price have significantly outperformed zack categorize medical biom genetic industry stock have surge compare increase broader industry rubraca be only approve drug company portfolio be first only oral parp inhibitor receive approval monotherapy drug be approve patient have be treat more chemotherapy select therapy base fda approve companion diagnostic rubraca further approval rubraca indication depend clinical benefit confirmatory study ariel ariel promising progression free survival pfs safety result ariel study be present jun show rubraca have meaningful impact delay disease recurrence advanced ovarian cancer patient clovis be plan file regulatory application label expansion include second line later maintenance treatment ovarian cancer base ariel study second half meanwhile second phase iii confirmatory study ariel be evaluate rubraca versus chemotherapy patient have fail prior line therapy meanwhile rubraca be also review eu comparable ovarian cancer indication approval be expect eu late early clovis be establish commercial infrastructure same rubraca prospect be bright be immense commercial potential target market tremendous demand parp inhibitor american cancer society ovarian cancer rank fifth death cancer woman case ovarian cancer be estimate be diagnosed be huge unmet need new treatment option give woman ovarian cancer have germline somatic brca mutation rubraca record sale first quarter company mentioned first quarter different healthcare practitioner have prescribe rubraca new patient start therapy successful significantly boost clovis top line go forward moreover clovis be develop rubraca additional indication prostrate breast pancreatic cancer other monotherapy combination other agent include tecentriq rubraca combination gynecologic cancer combination study be sponsored roche company be expect face competition currently market drug ovarian cancer include astrazeneca plc azn free report lynparza launch tesaro inc tsro free report zejula apr gain market share rubraca be challenge clovis clovis oncology inc price consensus ep surprise clovis oncology inc price consensus ep surprise clovis oncology inc quotezack rankclovis currently have zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2293,PFE,allergan plc agn free report be report second quarter earning aug market open last quarter company deliver positive earning surprise allergan share price be year so far outperform increase witness industry allergan earning performance have be mixed so far company beating expectation past quarters miss occasion average negative earning surprise last quarters be let see thing be shape announcement factor considerwhile revenue be likely be drive new product launch international growth growth key establish product botox linzess restasis earning growth likely be drive revenue operate expense management performance new product avycaz treatment adult patient complicate intra abdominal urinary tract infection vraylar bipolar disorder schizophrenia kybella double chin reduction viberzi adult suffering irritable bowel syndrome diarrhea also be focus viberzi vraylar do well past quarters expect trend continue soon be report quarter well viberzi be approve canada year be likely contribute sale however namenda ir be face generic competition continue hurt sale drug namenda xr sale also decline previous quarters due lower demand shift promotional effort namzaric be once daily fix dose combination namenda xr investor be interested hear namzaric performance quarter first quarter conference call management have mentioned namzaric sale be benefitting increase use combination therapy patient be transition monotherapy namzaric asacol delzicol sale also continue be hurt reduction demand ascaol hd follow launch authorize generic aug minastrin revenue be also likely be hurt loss exclusivity mar meanwhile recent acquisition lifecell close feb zeltiq aesthetic close apr support top line quarter first quarter call company have hint operate margin improve remain quarters year revenue grow second quarter company expect revenue approximately sg expense be expect be highest second quarter due continue strong promotion key brand addition zeltiq launch rhofade cream rosacea earning whispersour proven model do not conclusively show allergan be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate stand zack consensus estimate be peg higher result earning esp uncover best stock buy sell re report earning esp filter zack rank allergan zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision allergan plc price ep surprise allergan plc price ep surprise allergan plc quotestock considersome stock pharmaceutical sector have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug mallinckrodt public limit company mnk free report be schedule release result aug company have earning esp zack rank more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2294,PFE,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2295,PFE,immune design corp imdz free report be schedule report second quarter result aug last quarter immune design pull positive earning surprise tin fact company have post positive surprise trail quarters bring average surprise let see thing be shape announcement notably immune design share have sky-rocket outperform zack classify industry gain factor playbee development stage company immune design have not generate product revenue yet earn revenue collaboration licensing agreement product sale moreover investor remain focuse company progress pipeline candidate immune design be develop multiple candidate used discovery platform zvex glaas treatment various type cancer key pipeline candidate include cmb solid tumor merkel cell carcinoma mcc cmb have be design prime boost approach involve sequential dose complementary agent lv candidate be be evaluate soft tissue sarcoma st patient monotherapy phase combination roche hold rhhby free report tecentriq phase ii be be note early datum monotherapy phase study be positive safety profile monotherapy phase study remain favorable consistent rate ny eso trigger cell response appear stronger cmb addition randomize phase ii study cmb combination tecentriq comparison tecentriq alone locally advanced relapse metastatic soft tissue sarcoma be currently underway datum study be expect meanwhile develop glaas platform complete enrolment phase study patient mcc combination radiation immune design be collaborate merck evaluate combination pd agent keytruda treatment patient hodgkin lymphoma nhl february fda grant orphan drug designation treatment nhl company complete phase study patient mcc addition have initiate randomize phase ii study evaluate safety efficacy combination low dose local radiation keytruda patient follicular hodgkin lymphoma nhl datum evaluation be expect earning call expect immune design shed light progress ongoing trialswhat model proven model do not conclusively show earning beat immune design quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate however be not case here see zack esp immune design have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank immune design have zack rank increase predictive power esp however esp make surprise prediction difficult quarter note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision immune design corp price ep surprise immune design corp price ep surprise immune design corp quotestock considerhere be healthcare company consider instead model show have right combination element post earning beat quarter pfizer inc pfe free report have earning esp zack rank company be expect release result aug see complete list today zack rank strong buy stock here tesaro inc tsro free report have earning esp zack rank company be expect release result aug more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2296,PFE,bristol myer squibb company bmy free report second quarter earning cent share beat zack consensus estimate cent increase year period bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotetotal revenue increase year year surpass zack consensus estimate strong sale opdivo eliquis drive top line report quarter note bristol myer share have decline so far year compare unfavorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase increase outside ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year melanoma drug yervoy contribute top line report quarter opdivo be approve multiple cancer indication generate revenue year period however performance key drug virology unit be disappointing sale baraclude decline reyataz sustiva franchise deteriorate year year respectively nevertheless sale eliquis be report quarter year year bristol myer have partnership pfizer inc pfe free report eliquis bristol myer hcv franchise contribute top line orencia revenue be multiple myeloma drug empliciti record sale year year research development expense quarter increase due charge related license asset acquisition marketing selling administrative expense fall gross margin be quarter compare year quarter due change product mix recognition impairment charge related expect sale manufacturing operation sword ireland feb company repurchase common stock worth accelerate share repurchase asr agreement asr funding be do combination debt cash part company exist share repurchase authorization pipeline updatebristol myer key drug opdivo receive approval label expansion locally advanced unresectable metastatic urothelial carcinoma adult failure prior platinum contain therapy squamous cell cancer head neck adult progress platinum base therapy eu quarter supplemental biologic license application sbla label extension opdivo include hepatocellular carcinoma hcc prior sorafenib therapy update dose currently approve monotherapy indication be review earning guidance revisedbristol myer have raise lower end earning expectation company now project earning range share old guidance zack consensus estimate earning be peg takebristol myer deliver yet strong quarter top bottom line beating expectation robust sale drug opdivo eliquis yervoy quarter drive top line revise guidance be also encourage meanwhile be positive bristol myer effort develop pipeline bristol myer carry zack rank hold couple better rank stock health care sector be enzo inc sanofi sny free report enzo sport zack rank strong buy sanofi carry zack rank buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day earning estimate sanofi have decrease cent share second quarter increase full year last day more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2297,PFE,corning inc glw free report report second quarter adjust earning cent share beating zack consensus estimate couple cent earning surge year year basis sequentially report quarter year year growth be drive improvement revenue adjust revenue increase year year comfortably surpass zack consensus estimate revenue increase sequential basis result reflect strength company optical communication specialty material business line moreover corning strategy capital allocation framework continue boost shareholder value company return almost shareholder combination dividend share buyback report quarter quarter apple aapl free report announce be investing corning help create better product also note recently launch valor glass new pharmaceutical glass packaging solution have be develop collaboration pfizer pfe free report merck corning incorporate price consensus ep surprise corning incorporate price consensus ep surprise corning incorporate quoteshare corning have gain year date significantly outperform industry rally believe consistent result profitable collaboration help stock continue outperform broader market rest segment display technology segment generate total revenue adjust basis revenue decrease year quarter sequentially lcd glass market corning volume be low single digit percentage sequential basis company note lcd glass price decline moderately substantially less previous quarter optical communication generate total revenue report segment revenue grow year year sequential basis back strong demand fiber home market solution north america year year growth be much better management anticipate increase note deal verizon vz free report reflect strength base service provider overhaul network improve coverage accelerate deployment environmental technology segment generate revenue report segment revenue be year year decline sequentially year year growth be drive strong demand corning solution auto market additional contract win specialty material generate revenue report segment revenue surge year year sequentially backed consistent strong shipment gorilla glass life science business account revenue report revenue be year quarter sequentially operate detailsadjust gross margin contract basis point bps year quarter expand bps previous quarter adjust selling general administrative expense sg percentage revenue decrease bps year quarter bps previous quarter moreover research development expense percentage revenue increase bps year year basis decrease bps sequentially operate margin exclude amortization purchase intangible restructure impairment other charge contract bps year year basis bps previous quarter third quarter corning expect glass volume increase low single digit percentage sequentially company expect sequential lcd glass price decline be similar sequential decline report second quarter optical communication sale be anticipate increase more year period third quarter environmental technology sale be expect increase low single digit percentage specialty material sale be anticipate increase low mid percentage range life science business grow low single digit percentage year quarter full year corning still expect mid single digit percentage growth glass volume line overall lcd glass market price be now anticipate decline approximately lower zack rankcorning currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2298,PFE,dublin base cardinal health cah free report global player healthcare service product space be set report fourth quarter fiscal result aug bell company report adjust earning share last report quarter beat zack consensus estimate increase year year basis stock have deliver positive earning surprise past quarters average let take look thing be shape prior fourth quarter earning announcement factor playstrong outlook management cardinal health be bullish significant cash generation fourth quarter furthermore company cordis business be expect generate accretive return quarter note solid commercial momentum global basis cordis segment generate sluggish return last report quarter however fourth quarter cardinal health be expect leverage patient recovery business cordis profile meanwhile cardinal health reaffirm fiscal guidance range adjust earning share continue operation outlook represent growth approximately prior fiscal pricing pressure generic portfolio cardinal health have be grapple pricing deflation generic segment long management reimbursement pressure be likely affect company customer base also impede generic launch term incremental expense specifically pharma segment dent profit fourth quarter cutthroat competition niche space cardinal health face tough competition business segment example pharmaceutical supply chain business face competition mckesson well several smaller medical surgical distributor such henry schein owen minor intensify competition global market be likely mar cardinal health top line fourth quarter estimate revision trend company estimate revision trend lack luster current quarter analyst moved south compare upward revision last month last month current quarter estimate decline almost share add concern cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quoteearning whispersour proven model do not conclusively show cardinal health be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold beat estimate be not case here see zack esp earning esp cardinal health be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank cardinal health currently carry zack rank favorable zack rank increase predictive power esp company unfavorable esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter genomic health inc ghdx free report have earning esp zack rank see complete list today zack rank stock here halyard health inc have earning esp zack rank pfizer inc pfe free report have earning esp zack rank more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2299,PFE,last week several pharma major report second quarter result meanwhile important study datum be release merck mrk free report astrazeneca azn free report recap week most important storiesa look earning result big pharma company merck lilly lly free report glaxo roche bristol myer bmy free report astrazeneca report second quarter result last week bristol myer lilly merck beat expectation merck maintain outlook year read more merck beat earning sale keep view bristol myer update same read more bristol myer beat earning tweak view lilly be hit baricitinib update report beat raise quarter read more key takeaway lilly call baricitinib cancer pipeline meanwhile astrazeneca result be shadow disappointing mystic datum imfinzi treatment nave small cell lung cancer nsclc patient company share fall read more astrazeneca beat earning fall fail study british drugmaker glaxo set new priority company company decide allocate capital priority asset current respiratory hiv infectious disease potential oncology immuno inflammation therapy area glaxo also say more pre clinical clinical program be stop read more glaxosmithkline beat earning lower guidance lilly merck be zack rank buy stock see complete list today zack rank strong buy stock here merck keytruda miss endpoint hnscc study be lot update merck last week addition earning result company be hit disappointing result late stage study evaluate pd therapy keytruda monotherapy patient previously treat recurrent metastatic head neck squamous cell carcinoma hnscc study fail meet pre specify primary endpoint overall survival os be latest keytruda related setback merck earlier month company have announce fda have place clinical hold combination study keynote keynote keynote be conduct keytruda multiple myeloma mm meanwhile look merck second quarter result show keytruda remain strong lung cancer set keytruda be currently more study include more combination study merck astrazeneca sign oncology collaboration merck astrazeneca be collaborate global development merck keytruda astrazeneca parp inhibitor lynparza different type cancer lynparza currently approve brca mutate ovarian cancer multiple line treatment be different study range tumor type include breast prostate pancreatic cancer deal cover evaluation parp mek inhibitor pd pd inhibitor astrazeneca stand receive include upfront payment certain license option additional achievement regulatory sale milestone merck stock have gain year date ytd lag rally industry belong astrazeneca have gain ytd janssen inks deal bavarian nordic johnson johnson janssen pharmaceutical company denmark base biotech company bavarian nordic enter additional worldwide exclusive license collaboration agreement janssen get exclusive right bavarian nordic mva bn technology additional program target vaccine hepatitis virus hbv hiv make upfront payment equity investment worth bavarian nordic also be eligible receive milestone payment worth tiered royalty future sale deal company be now collaborate program combine bavarian nordic mva bn technology janssen advac technology platform pfizer astella xtandi breast cancer program drop astella report result last week provide update pipeline show company partner pfizer pfe free report have decide drop development xtandi breast cancer development program include phase iii study triple negative breast cancer phase ii study pr positive positive breast cancer astella say decision be base discussion pfizer change competitive landscape need further diagnostic development new phase ii datum ongoing program xtandi include metastatic castration resistant prostate cancer phase iii prostate cancer patient metastatic biochemical recurrence phase iii metastatic hormone sensitive prostate cancer phase iii hepatocellular cancer phase ii cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock merck be astrazeneca lose last month be bristol myer gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch second quarter earning result company pfizer shire shpg free report allergan agn free report other moreover fda arthritis advisory committee be meeting aug discuss regulatory application investigational rheumatoid arthritis treatment plivensia sirukumab more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2300,PFE,expect pfizer inc pfe free report beat expectation report second quarter result aug market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully xeljanz mg take twice daily be approve eu mar boost drug sale be report quarter also revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition be likely propel revenue hospira acquisition be expect be important growth driver well also pfizer launch inflectra biosimilar version johnson johnson jnj free report blockbuster drug remicade nov inflectra record sale globally first quarter biosimilar generate more sale soon be report quarter however pfizer continue face headwind form loss exclusivity key product pristiq zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be expect continue see lower sale lower demand continue hurt sale viagra meanwhile bottom line be drive cost saving share buyback however new product launch expense investment be expect hurt profit second quarter call investor focus be expect remain performance new product pipeline progress include biosimilar immuno oncology importantly key cancer candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer drug bring revenue second quarter management be expect shed light launch be progress conference call acute lymphoblastic leukemia candidate besponsa be also approve eu late jun expect management comment plan conference call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report earning esp zack rank company be schedule release result jul hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2301,PFE,yesterday big pharma player eli lilly company lly free report report better expect second quarter result raise outlook year however share be investor focuse company update regard investigational rheumatoid arthritis ra treatment baricitinib here be look few key takeaway lilly conference call do key drug perform lilly second quarter revenue increase year quarter top zack consensus estimate new product trulicity taltz basaglar jardiance lartruvo cyramza perform well drive volume growth late life cycle product ciali forteo drive price growth alimta continue face significant competitive headwind zyprexa cymbalta evista strattera axiron be impact loss exclusivity ciali be also affected lower volume reflect decline overall erectile disorder ed market well presence generic animal health revenue decline quarter reflect market access pressure competitive pressure cattle swine read more lilly earning top baricitinib re filing delay baricitinib face significant delaylilly announce be delay least month resubmission regulatory application baricitinib be be develop collaboration incyte incy free report mean resubmission not take place year fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm lilly disagree fda conclusion believe comprehensive clinical datum support positive benefit risk profile company enter discussion fda determine kind study need better define benefit risk profile baricitinib meanwhile lilly incyte have plan explore baricitinib other indication late stage study psoriatic arthritis slate commence next year study atopic dermatitis lupus continue phase ii atopic dermatitis datum be present scientific forum year end note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe oncology strategylilly provide depth look oncology strategy company strategy involve build key treatment cyramza lartruvo abemaciclib foundational agent focus develop new standard care change therapy clear very high bar span variety mechanism include immune oncology now lilly focus candidate priority internal development additional candidate mab csf mab merestinib study datum pending rest molecule pipeline be partner molecule have make lilly priority development list include abemaciclib be already fda review tim mab pd mab erk inhibitor tgfb ri ki pi mtor inhibitor prexasertib molecule be earmark external partner development asset be own third party lilly be look partner remain fgfr adc ralimetinib fgfr inhibitor notch inhibitor galunisertib cxcr peptide antagonist emibetuzumab bottom lilly deliver beat raise quarter company result get overshadowed baricitinib update investor be disappoint delay resubmission baricitinib regulatory filing company say be minimum delay month several product face generic competition competitive pressure increase lilly need focus bring new product market company decision prioritize oncology pipeline make sense lilly be zack rank buy stock see complete list today zack rank strong buy stock here year date lilly share have gain just top industry rally watch earning report other large cap pharma company merck co inc mrk free report pfizer inc pfe free report merck zack rank stock have pretty good earning track record have surpass expectation last quarters average surprise merck be report result jul pfizer track record be mixed company top expectation last quarters pfizer be report aug have positive earning esp second quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2302,PFE,merck kgaa be schedule report second quarter earning result aug merck kgaa share price have increase year date industry gain company report result business sector healthcare life science performance material strong performance life science be catalyst sale growth last few quarters be anticipate continue soon be report quarter however sale healthcare division be disappointing last quarter only cancer drug erbitux register sale growth mar recommendation national institute health care excellence erbitux use combination folfiri folfox first line treatment patient ra wild type metastatic colorectal cancer uk be expect boost sale however competitive pressure price reduction be expect hurt sale infertility drug gonal meanwhile year year weaken euro dollar be expect positively impact total sale company mar company receive approval bavencio treatment metastatic merkel cell carcinoma mmcc follow approval advanced bladder cancer drug bring sale quarter moreover company be develop drug partnership pfizer inc pfe free report several cancer indication subsequent quarter company receive positive opinion committee medicinal product human use chmp bavencio july monotherapy adult mmcc patient expect management shed light plan bavencio earning call merck kgaa apr announce agreement divest biosimilar business fresenius part company strategy focus pipeline innovative medicine deal be expect close second half stock warrant lookhere be couple health care stock want consider model show have right combination element positive zack earning esp zack rank strong buy buy hold post earning beat quarter uncover best stock buy sell re report earning esp filter zoetis inc zts free report have earning esp zack rank company be schedule release result aug see complete list today zack rank stock here clovis oncology inc clvs free report have earning esp zack rank company be schedule release result aug more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2303,PFE,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2304,PFE,anthem inc antm free report release second quarter result jul market open last quarter company pull positive earning surprise let see thing be shape announcement factor be consider be likely witness increase overall enrollment primarily backed substantial medical enrollment growth solid revenue growth be expect government business commercial business backed strong enrollment growth iowa medicaid contract be likely have boost company top line significantly medicare advantage product offering have support medicare enrollment growth again boost company top line however anthem expect witness higher medical cost individual aca compliant product be case last quarter addition company be also likely have experience higher benefit expense ratio medicaid business due higher claim administrative cost have rise second quarter continue previous quarter trend earning whispersour proven model do not conclusively show anthem be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp anthem have earning esp be most accurate estimate be zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank anthem currently sport zack rank favorable zack rank increase predictive power esp need positive earning esp be confident earning beat anthem inc price ep surprise anthem inc price ep surprise anthem inc quoteconversely sell rate stock never be consider go earning announcement stock considerhere be company medical sector want consider have right combination element post earning beat quarter align technology inc algn free report be set report second quarter earning jul have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be set report second quarter earning aug humana inc hum free report have earning esp zack rank company be set report second quarter earning aug more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2305,PFE,centene corporation cnc free report release second quarter result jul market open last quarter company deliver positive earning surprise let see thing be shape announcement factor be consider buyout health net be expect have boost company growth potential significantly increase revenue company missouri medicaid contract active be likely have increase membership thereby boost revenue growth second quarter medicare advantage plan operational new state jan be expect have continue contribute company revenue growth company government sponsored health insurance business be anticipate have perform well add top line company share repurchase program intend enhance shareholder value have impact margin positively reduce outstanding share count nevertheless health net high selling general administrative expense be expect have increase overall cost thereby limit bottom line growth increase cost related interest payment reserve settlement legal judgment lawsuit impairment long live asset have affected earning earning whispersour proven model do not conclusively show centene be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp centene have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter centene corporation price ep surprise centene corporation price ep surprise centene corporation quotezack rank centene carry zack rank favorable zack rank increase predictive power esp need positive earning esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be company medical sector want consider have right combination element post earning beat quarter align technology inc algn free report be set report second quarter earning jul have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be set report second quarter earning aug humana inc hum free report have earning esp zack rank company be set report second quarter earning aug more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
